5,201 Matching Annotations
  1. Last 7 days
    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Response to Reviewers # # Reviewer #1

      We thank Reviewer #1 for the positive assessment, in particular for recognizing that the sex-independent role of PAGE4 is clearly supported by multiple layers of protein evidence, that the proteomic, phosphoproteomic and interactomic techniques are conducted at an expert level, and that the reporting of results is appropriate. We have addressed the constructive points on outlier testing and methods completeness in full.

      Reviewer comment: Figure 1B: the first PCA component is dominated by a single sample far to the right (PC1 33.9%). Was an outlier test (Mahalanobis distance, Z-score on PC1) performed? If so it should be reported. No PCA or outlier test is reported for the phosphoproteomics. The full-proteome and phosphoproteomics data need more analysis detail to ensure reproducibility.

      __Response: __We agree, and we have addressed this in two ways. First, we have replaced the Figure 1B proteome PCA with multidimensional scaling (MDS) computed from the top 500 most variable proteins, which displays the paired tumor-myometrium structure directly and is not dominated by a single component; the inputs are stated in the Methods and the Figure 1B legend: MDS was computed from the top 500 most variable proteins using log2-transformed intensities, with no imputation of missing values. Second, to address the reviewer's underlying concern about undetected technical outliers, we inspected the per-sample distribution of log2 protein intensities for every sample in the DIA cohort. One HMGA2-subtype tumor measurement was clearly aberrant at the technical level: its distribution is bimodal and its median is collapsed (~2.9 versus a cohort median of 7.8), the signature of a sample-specific quantification failure rather than biological variation (rebuttal figure below, panel A), whereas the same sample is unremarkable in the phosphoproteome (panel B), showing that the defect is specific to that one proteome measurement and not a property of the tumor. That measurement is not part of the dataset reported in the manuscript: the DIA cohort as analyzed comprises 28 matched tumor–myometrium pairs (56 samples), which is what the Methods, the figure legends and Supplementary Dataset 2 describe throughout. Every remaining sample passes this inspection, so no result reported here rests on a sample with a failed proteome measurement. We provide the per-sample distributions here for the reviewer's inspection rather than in the manuscript, since they document the composition of the analyzed cohort rather than adding to its findings.

      Rebuttal figure1 for reviewer inspection only. Per-sample intensity distributions across the DIA cohort. (A) Proteome; (B) phosphoproteome. Each box is one sample's distribution of log2 intensities; the blue dashed line marks the cohort median (7.8). The aberrant sample (red) is a clear technical outlier in the proteome but unremarkable in the phosphoproteome; it is not part of the 28-pair dataset reported in the manuscript.

      Reviewer comment: Figure 3A: perform an outlier test for HMGA2 (proteome, left) and for the FH_UL and COL4A5-COL4A6_UL points (phosphosites) that are visually separated. As shown, the PCAs are hard to interpret because points get squeezed onto one axis. Outliers may affect statistics and the conclusions about within-group variation; this should be tested if discussed.

      Response: We have addressed both points. The same per-sample inspection described above covers every sample contributing to the Figure 3A proteome, phosphoproteome and phosphosite analyses, and all 28 pairs shown there pass it. The COL4A5-COL4A6 UL and FH UL samples highlighted by the reviewer are technically sound on these metrics and are retained; the text now attributes their separation to inter-tumor heterogeneity in phosphorylation state on the basis of these metrics rather than by assertion, which resolves the biological-versus-technical ambiguity the reviewer identified. Regarding axis compression, we agree that the phosphosite panel is stretched by a small number of samples with genuinely divergent phosphorylation profiles. Because these samples are technically sound, we have retained them rather than rescaling or trimming the axes, which would misrepresent the spread of the data; the proportion of variance explained by each component is stated on the axes so that the scale of the separation can be judged directly. The conclusions drawn from Figure 3 concern the tumor-myometrium contrast within each subtype, which is unaffected by the position of these individual samples.

      Reviewer comment: SNRNP70_S226 is described as one of the most significantly hyperphosphorylated sites, but Table S1 lists log2FC 5.92, p 0.02, classified non-significant; MARCKSL1 (log2FC 2.14, p 0.016) and NDRG2 are likewise non-significant. The volcano/caption indicate a 0.05 cutoff but Table S1 apparently uses 0.01. Please clarify.

      Response: We thank the reviewer for catching this, and we apologize for the inconsistency. On re-checking the source data we confirmed that the significance-classification column in the earlier version of the supplementary table had been generated with a stricter cutoff than the one used for the volcano plots and stated in the captions. All of the sites raised by the reviewer meet the stated criteria (|log2 fold-change| > 2 and p ##

      Reviewer comment: Add citations for Protein Atlas and ProteomicsDB.

      __Response: __Added: Human Protein Atlas (Uhlén et al., Science 2015; proteinatlas.org) and ProteomicsDB (Schmidt et al., Nucleic Acids Res 2018).

      __Reviewer comment: __PAGE4 expression is selectively enriched in MED12-mutant UL (page 14): "PAGE4 expression indeed was significantly elevated in MED12-mutant ULs ... ". The figure caption, methods and text do not provide any information of the statistical test used regarding the statement of significant upregulation. Please provide the data or change wording as a statistical significance is implied.

      Response: The panel reproduces published RNA-seq data (Berta et al., 2021) descriptively, and the source data do not provide a formal cross-subtype test that we can report. We have therefore softened the wording from “significantly elevated” to “consistently higher” in the Results, and the caption now states that the panel is descriptive and that no statistical test was applied.

      Reviewer comment: Method section "Liquid chromatography-mass spectrometry (LC-MS)" report the UniProtKB database download date to ensure reproducibility. Does the database contain isoforms and TrEMBL sequences or uses a filtered version (e.g.: status reviewed, canonical?) (report it like on p.36 for the AP-MS/BioID samples). Further add a statement if missing values were imputed on which level (peptide, protein), which normalization strategy was employed, and was there filtering of incomplete values performed. All these analysis steps are common practice for DDA measurements of clinical samples and may affect subsequent statistical finding and thus should be reported in the method section if they were or were not performed (for the PPI data this was reported on p.37, but for the full proteome and phosphoproteome the information provided is not sufficient to judge the validity of data processing). Method section "GO enrichment and statistical analysis" (p.37): Please add citations for the used tools SAINT, CRAPome and Enrichr.

      __Response: __We have expanded the discovery DDA proteome and phosphoproteome Methods to the same level of detail as the AP-MS/BioID section: the UniProtKB human database version, download date and entry count; whether isoforms/TrEMBL were included or a reviewed-canonical subset was used; the valid-value filtering rule per group; the normalization strategy; and the imputation method and level. The corresponding DIA workflow is now also described (see Reviewer 2-J). Also added references for SAINTexpress (Teo et al., J Proteomics 2014), CRAPome (Mellacheruvu et al., Nat Methods 2013) and Enrichr (Kuleshov et al., Nucleic Acids Res 2016).

      Reviewer comment: The Figure 1c: The scale of the (Gene) count does not correspond with the circle sizes of the plot. It is thus not possible to judge the number of genes per category. This should be sized equally as else it is not possible for a reader to judge the number of genes per enriched terms.

      __Response: __We have corrected the GO enrichment panel (Figure 1D) so that dot area is drawn to a single consistent scale with an accurate, labeled size legend, allowing the gene count per term to be read directly.

      Reviewer comment: Figure 1G: Expression levels for ProteomicsDB. As the log2 of the expression level is used, it is not clear if the white squares correspond to missing values in the ProteomicsDB, or if the value was very low. Maybe indicating absent values in a grey color scheme makes this more explicit.

      __Response: __We have clarified this in the caption rather than by recolouring, because in this figure white already carries a defined meaning in both panels: in the Human Protein Atlas panel it is the explicit “not detected” category of the key, and in the ProteomicsDB panel the log2 intensity scale begins at zero, so a white cell corresponds to a value of zero, that is, no detected expression, rather than to an absent measurement. The caption now states this for both panels, so a white square can no longer be confused with a very low value.

      Reviewer comment: Figure 1C: the caption indicates a "gray box" but it seems that PAGE4 was highlighted as a red dot, and a white box was added for indicating the gene name.

      __Response: __The caption has been corrected to match the figure (PAGE4 shown as a highlighted point with a labeled callout), and color terminology has been harmonized across all captions.

      Reviewer comment: Figure 3D is described as a volcano plot but is a horizontal scatter with a significance threshold rather than a classic volcano (which would have adjusted p-value on the axis).

      Response: The reviewer is correct. These panels display log2 fold-change per subtype with significance indicated by color and do not plot a p-value axis, so “volcano plot” was the wrong term. We have relabeled them as grouped dot plots in the figure legend and at the two places they are referred to in the Results. Figure 2C and Figure 5A, which are conventional volcano plots with a -log10 p-value axis, retain that description.

      Reviewer comment: The PPI network has too many edges and nodes to read. It could help to collapse categories/proteins or provide a subnetwork, with the full network in the supplement.

      __Response: __We have moved the dense, full node-level PAGE4-centered network out of the main figure and into the supplement, where it now appears as Figure S3A. The main figure retains a complex-level view of these interactions as a focused interaction matrix (revised Figure 4E), in which preys are grouped by annotated functional complex with confidence-weighted encodings. This is the same change requested by Reviewer 3 (point G).

      Reviewer #2

      We thank Reviewer #2 for the positive overall assessment, that we convincingly identified a novel role for PAGE4 in uterine leiomyoma and Mediator transcriptional processes, that this represents an important contribution to understanding UL pathobiology, and that the dataset is very comprehensive. We are grateful for the detailed, panel-by-panel reading and the constructive suggestions on figure design and methods organization, all of which we have adopted.

      Reviewer comment: The validation cohort is not technically a validation cohort, it uses the same 9 MED12-mutant UL samples and so cannot validate PAGE4 upregulation/phosphorylation in an independent cohort. A second MED12-mutant UL cohort should be used.

      __Response: __We thank the reviewer for raising this, and we apologize that our original Methods wording was ambiguous. The discovery DDA, and validation DIA analyses were in fact performed on independent sets of MED12-mutant UL/myometrium samples (n = 9 each), with no patient shared between the sets; we originally sized (MED12-mutant) the DDA/IHC and DIA sets to match the nine discovery pairs, and then also had the opportunity to analyse also the other mutations causing UL. The DIA experiment therefore does provide independent validation of PAGE4 upregulation and Thr51/Thr85 phosphorylation in a separate cohort of MED12-mutant tumors, while additionally establishing subtype specificity against the HMGA2, FH and COL4A5-COL4A6 subclasses. We have revised the Methods to state the cohort composition explicitly so that the independence of the discovery (DDA) and validation (DIA) MED12 sample sets is unambiguous, and independent confirmation is further supported by the external RNA-seq dataset (Berta et al. 2021) and the IHC validation.

      Reviewer comment: No meaningful change in peak width or height is readily observable. Statistical tests would be required to make the claims believable.

      __Response: __We agree, and we have replaced visual assertions with quantification and statistics, reporting effect sizes alongside p-values. We now distinguish signal amplitude (which changes) from peak shape (which does not).

      Amplitude is reduced (supported). Across a common set of 19,942 GENCODE v38 protein-coding TSSs, median promoter-proximal RNAP II signal (TSS ±1 kb) decreased by 10.4% in MED12 G44D, 16.5% in PAGE4 S9D/T51E/T85E and 21.2% in PAGE4 S9A/T51E/T85A relative to the matched wild type; the area under the curve decreased by the same margins, and median peak height (TSS ±250 bp) decreased by 4.4%, 20.4% and 19.3% respectively. All reductions are statistically significant (two-sided Wilcoxon rank-sum test, Benjamini–Hochberg-adjusted p Shape is unchanged (we concede this). Median TSS-derived FWHM was 201 bp in all five conditions (Δ = 0); the very small FWHM p-values arise from the large number of regions tested (n ≈ 17,000) and do not indicate a biologically meaningful shape change. MACS2 peak-width medians shifted inconsistently (+23 bp for G44D, +1 bp for S9D, −49 bp for S9A), i.e. no consistent broadening or narrowing.

      We removed the statements that all four metrics concord and that peaks are narrower/broader. The revised Results now state that promoter-proximal RNAP II signal amplitude is modestly reduced, whereas peak shape (FWHM and MACS2 peak width) shows no consistent change, and we report effect sizes (median % change) for every metric. The ChIP-seq analysis pipeline (alignment, MACS2 peak calling, normalization, quantification) has been added to Methods, which previously lacked it.

      Reviewer comment: HIPK2 was proposed as the candidate kinase (Fig 3E) but there is no HIPK2 on the heatmap; instead CLK2 is in red with an increased score. HIPK2 and CLK2 are different, unrelated kinases. Please rectify.

      __Response: __We apologize for the inconsistency, which our cross-audit confirmed. We have replaced the kinase-family enrichment heatmap (original Figure 3E) with a per-site kinase-prediction map for PAGE4 S9, T51 and T85, now shown as the lower panel of Figure 4A, and revised the text so that figure and text agree. Both sites are proline-directed (S/T-P) CMGC substrates; the CLK and HIPK families score highest, with CLK2 and HIPK1 the most probable kinases, as both have been experimentally validated as PAGE4 kinases at these sites (Kulkarni et al., 2017; HIPK1 also reported at T51). We no longer single out HIPK2: motif scoring cannot resolve closely related paralogs, so HIPK2/HIPK3 and other CLKs remain possible but are not named individually, while the prior experimental literature points to HIPK1. The prediction is now explicitly framed as in silico and requiring direct validation (in vitro kinase assays with recombinant CLK2/HIPK1, and inhibitor or genetic perturbation).

      Reviewer comment: The text states Mut1 retained 73% of PAGE4-WT prey proteins, but Fig 4B shows Mut1 with 25 preys vs 149 for WT, 25/149 = 17% retained, an 83% decrease. Please rectify.

      __Response: __The reviewer is correct, and the original 73% was an error. We recomputed AP-only interactor retention directly from the final filtered interactor table (Supplementary Dataset 3). Defining retention as the fraction of PAGE4-WT AP high-confidence interactors (gene-level, n = 149) that are also recovered for Mut1, only 20 are shared, a retention of 13% and a net loss of 87% of stable associations; Mut1 captured 25 AP high-confidence interactors in total (bar plot, revised Figure 4C). The text and the Figure 4C legend now report these values consistently, and the statement about which categories are preferentially lost versus retained is tied to Supplementary Dataset 3 rather than asserted.

      Reviewer comment: The text states the MED12-G44D bait is strongly reduced vs MED12 WT (Fig 5A), but the Fig 5A right panel does not support this. Please rectify.

      __Response: __We thank the reviewer, on checking the data, the original statement was in fact wrong in the opposite direction, and we have corrected the text. Quantifying MED12 bait recovery directly from Table S3, the MED12-G44D bait is recovered at levels equal to or higher than MED12-WT (average spectral counts: AP-MS 519 vs 339; BioID 481 vs 191), not reduced. Despite this comparable-to-higher bait abundance, MED12-G44D captures markedly fewer high-confidence interactors (AP-MS 38 vs 115; BioID 297 vs 362). The Results now state this explicitly: the G44D mutation reduces MED12's high-confidence interaction repertoire while the bait itself is well expressed, so the loss of interactors is a genuine effect rather than a bait-recovery artifact. Figure 5A is a differential-interactor volcano (mutant vs WT) in which the bait's own abundance is not directly legible, which is why it appeared not to support the now-removed reduction claim. Bait spectral counts for every bait and both acquisition modes are reported in Supplementary Dataset 3, so bait recovery can be checked directly for each construct. In the interest of full transparency we note that the same check gives a different answer for two of the PAGE4 constructs: Mut1 and Mut6 are recovered at roughly ten-fold lower spectral counts than PAGE4 WT in both modes. We have therefore added an explicit limitation to the Discussion stating that reduced construct abundance or stability may contribute to the loss of stable interactors and to the compartmental shift observed for these two variants, and we have tempered the corresponding claims.

      Reviewer comment: The text states MUT1 has upregulated base-excision repair and SUMOylation, but the Fig S3 heatmap supports this for MUT6, not MUT1. Please rectify.

      __Response: __Thank you. We re-examined the pathway enrichment heatmap, which is Figure S4 in the revised manuscript, and confirm the reviewer is correct: base-excision repair, translesion synthesis and SUMOylation of DNA damage response proteins are enriched for the S9A/T51E/T85A variant (Mut6), not for Mut1. The Results text has been corrected so that text and figure agree.

      Reviewer comment: Figure 4E shows the full bait-prey graph and becomes a hairball; bait names are illegible, edge widths/colors and AP/PL/Both cannot be distinguished. Suggest aggregating preys by annotated complex with a single summarized weighted edge per bait-complex, and showing only differentially associated preys; provide the full network in the supplement.

      __Response: __We agree. The dense, full node-level network that produced the hairball has been moved out of the main figure and is now provided as a supplementary figure (Figure S3A) with a clearly keyed AP/PL/Both encoding. In the main figure, the corresponding interactions are presented at the level of annotated complexes as a focused interaction matrix (revised Figure 4E), which avoids the unreadable node-level graph while preserving the key bait-complex relationships.

      Reviewer comment: The figure presents PAGE4 phosphosites but is labeled “GAGE,” a different (unused) name; importantly the figure appears copied directly from PhosphoSitePlus without permission. Permission should be obtained.

      __Response: __We thank the reviewer and have resolved both issues. First, we replaced the PhosphoSitePlus-derived schematic with an original figure generated by us from the underlying site annotations, so no third-party copyrighted image is reproduced, removing the permissions concern entirely. Second, the “GAGE” label is showing the GAGE domain (PAGE4 belongs to the GAGE/PAGE family); all panel labels now read PAGE4 consistently, with the alias noted once in the text.

      Reviewer comment: Inferring phosphorylation involvement from phosphomimetic changes is not formally valid and should at least be stated as a hypothesis.

      __Response: __We agree and have reframed accordingly. We now state explicitly that phosphomimetic (S/T→D/E) and phosphodead (S/T→A) substitutions approximate the charge state of (de)phosphorylated residues but do not reproduce native, dynamic phosphorylation; the phosphorylation-dependence conclusions are therefore presented as a hypothesis supported by, but not proven by, these surrogates.

      Reviewer comment: The MS methods are insufficient to reproduce the experiments. DIA methods are missing entirely; with both DDA and DIA used across total, phospho, AP and PL experiments, the methods should be reorganized by experiment type, specifying what was done in each mode. State how total and phospho data were normalized and integrated; how PL data were analyzed and whether identically to AP; whether SAINT used spectral counts or intensities; and, since the baits are nuclear, whether NLS-containing controls were used.

      __Response: __We have substantially expanded and reorganized the MS Methods by experiment type and acquisition mode. (1) DIA acquisition and analysis for the validation proteome and phosphoproteome are now fully described, instrument, gradient and window scheme, search/quantification software and settings, library strategy, FDR and normalization. (2) For each dataset we state the acquisition mode: discovery proteome and phosphoproteome = DDA (Q-Exactive); validation proteome and phosphoproteome = DIA-PASEF (timsTOF Pro); AP-MS and PL-MS = DDA-PASEF (timsTOF Pro/Pro 2); host-cell-line proteome = DIA on an Orbitrap Astral, for which the full acquisition and DIA-NN parameters, including database version, entry count and the absence of isoforms, TrEMBL entries and imputation, are now given in Methods. (3) Total- and phospho-proteome integration: phosphosite intensities were normalized to matched parent-protein abundance for the protein-adjusted, site-level testing, and we describe the normalization, batch handling and integration of the two layers. (4) AP vs PL: we state explicitly that AP and PL data were processed through the identical pipeline (QRILC imputation → median normalization → SAINTexpress → CRAPome filtering), noting any differences. (5) SAINT input: we clarify that SAINTexpress was run on spectral counts (and CRAPome filtering used average spectral-count fold-change ≥ 3); the QRILC/normalization step applies to the quantitative interactor comparisons, and the previous ambiguity between counts and intensities is removed. (6) Nuclear-bait controls: GFP-MAC3 served as the negative control, and compartment-matched contaminants (nucleolar/chromatin) are additionally controlled by CRAPome frequency filtering; we discuss this explicitly and note its limitation for nuclear-bait specificity.

      __Reviewer comment: __Overall the manuscript has many issues with data presentation. To illustrate just a few: - Fig. 3B and 3D are described as volcano plots. They are not volcano plots. - Fig. 3B legend mentions a lower panel. There is no lower panel for Fig. 3B. - Fig. 3A, please use different shape markers for the UL subtypes and suggest connecting with edges to thus support their text conclusions of separate groupings. - For Fig. 3E the colors for the families and groups are not distinguishable (and the font is too small). Please rectify. - Please label the units and scale for Fig. 6A. - Please mention the MAC3 tag uses Ultra-ID to thus justify the 10 min labeling time. - In the relevant protein and phosphoproteomic datasets and figures please mention the number of proteins and phosphosites obtained to thus allow an interpretation of the data quality. -Table 4 is in a format that is uninterpretable. - The text and figures interchangeably use the mutant number (e.g. MUT1) or mutant composition (e.g. S9D_T51E_T85E - for MUT1), this makes reading and interpreting the manuscript very challenging. Suggest using one format.

      __Response: __We have addressed each item:

      • Fig 3B and 3D “volcano” plots: corrected. Both panels are now labeled grouped dot plots in the figure legend and in the Results, matching our response to Reviewer 1; Figure 2C and Figure 5A, which do plot a -log10 p-value axis, retain the term volcano plot.
      • Fig 3B legend “lower panel” with no lower panel: the legend conflated the protein panel (3B) with the phosphosite panel (3D); the caption now matches the actual panels.
      • Fig 3A subtype markers: we have retained the colour-coded points. Each of the eight groups already has its own colour and the legend states the group and n for each, and the eight-level palette was chosen so that each subtype's tumour and myometrium share a colour family, which is the comparison the panel is meant to support. We considered adding shape markers and 95% confidence ellipses, but at these group sizes (n = 5 for two subtypes) an ellipse conveys more confidence in the grouping than the data warrant, and connecting edges between unpaired samples would imply a trajectory that does not exist. The panel is therefore presented as a descriptive overview of sample structure; the subtype and tumour-versus-myometrium differences that the manuscript actually concludes on are tested statistically and reported in Figure 3B and Supplementary Dataset 2, not inferred from visual separation in the PCA.
      • Fig 3E colors/fonts: the original Figure 3E no longer exists; it has been replaced by the site-level kinase-prediction panel that is now the lower panel of Figure 4A, which uses a larger font and a distinguishable family/group palette.
      • Fig 6A units/scale: the Figure 6A legend now specifies that the heatmap shows MACS2 fold-enrichment (FE) signal over local background (macs2 bdgcmp, FE mode), in 50-bp bins across ±5 kb from GENCODE v38 protein-coding TSSs, with the display color scale capped at 20 FE units (values above 20 capped only for visualization; quantitative analyses used uncapped values).
      • MAC3 labeling time: we now state that the MAC3 tag incorporates the UltraID biotin ligase, justifying the 10-minute labeling window.
      • Dataset sizes: the number of proteins and phosphosites identified in the discovery datasets is stated in the Results, and the complete per-feature quantifications for both the discovery and validation datasets, from which the totals can be read directly, are provided in Supplementary Datasets 1 and 2.
      • Table S4 formatting: reformatted into an interpretable layout.
      • Mutant nomenclature: standardized to “Mut1 (S9D/T51E/T85E)” on first mention and “Mut1” thereafter. The full Mut1-Mut8 mapping is now stated explicitly in the Results at the point the panel is introduced, and the same convention is applied throughout.

      Reviewer #3

      We thank Reviewer #3 for the positive and thorough assessment, in particular for recognizing that we convincingly demonstrated the specific elevation of PAGE4 mRNA, protein and T51/T85 phosphorylation in MED12-mutant UL, that this points to a broader, sex-independent function for a traditionally male-specific marker, and that the work will be of significant interest to the UL research community. We address the major and minor points in turn.

      Reviewer comment: The interactome, reporter and ChIP-seq studies relied exclusively on tagged, exogenously expressed proteins. Endogenous PAGE4/MED12 could substantially affect the observed networks. Measure endogenous expression in the Flp-In 293 T-Rex cells and discuss its influence. Did phosphovariants affect PAGE4 nuclear localization? Comparing T51/T85 phosphorylation between WT and G44D MED12 cells would be informative.

      __Response: __We have characterized endogenous PAGE4 and MED12 in the parental Flp-In T-REx 293 line. By single-shot DIA proteomics of the parental cells on an Orbitrap Astral, PAGE4 was below detection, indicating that the tagged PAGE4 constructs are expressed against an effectively null endogenous background, consistent with PAGE4's restricted cancer-testis expression; the reported PAGE4 interactions, localization and reporter effects are therefore not confounded by an endogenous PAGE4 pool. MED12, an essential Mediator subunit, is endogenously expressed, so the tagged MED12-WT and MED12-G44D constructs are present alongside the endogenous protein, as we now note in the Discussion. We have also assessed whether PAGE4 phosphovariants alter nuclear/cytoplasmic distribution using our developed MS microscopy analysis (Liu et al, 2018, Nature Communications), We also agree that comparing PAGE4 T51/T85 phosphorylation between WT and G44D MED12 backgrounds would be informative; this requires phosphosite-specific reagents that we do not currently have, and we have flagged it explicitly in the Discussion as a priority for follow-up rather than claiming it here. The revised Discussion frames the heterologous overexpression system and its bearing on interpretation accordingly.

      Reviewer comment: Turunen et al. (2014, PMID 24746821) reported mutant MED12 interactomes using a similar strategy. Comparing with this dataset would assess reproducibility and robustness and add confidence.

      __Response: __We thank the reviewer for this excellent suggestion, and we note that a co-author of the present study also co-authored Turunen et al. (2014). We have compared our MED12 WT and G44D affinity-purification (AP-MS) interactors with the normalized spectral-count data of Turunen et al. (2014, Table S1), normalizing both datasets to the MED12 bait (see the rebuttal figure below). The two studies are concordant on the central finding: the G44D mutation specifically reduces association of the Mediator kinase (CDK) module while core Mediator is retained. In our data the bait-normalized G44D/WT ratio for CDK8 is 0.45 and for Cyclin C (CCNC) is 0.56 (Turunen et al.: 0.33 and 0.36, respectively), and CDK19 — the module member lost most completely in Turunen et al. (ratio 0.00) — was not detected as a high-confidence interactor of G44D in our AP-MS data. By contrast, core Mediator subunits are retained in both studies (median G44D/WT ratio 0.87 across 23 shared subunits in our data, versus 0.92 in Turunen et al.). Thus our MED12 G44D interactome independently reproduces the selective CDK8/Cyclin C uncoupling reported by Turunen et al. (2014), while our combined AP-MS/PL approach extends this to the PAGE4 variants and to transient/proximal associations. We have added a sentence to the Discussion noting this concordance; the comparison figure is provided here for the reviewer's inspection.

      Rebuttal figure 2. Concordance of the MED12 G44D interactome with Turunen et al. (2014). Both datasets are normalized to the MED12 bait and expressed as the G44D/WT ratio. (A) Mediator kinase (CDK) module: CDK8 and Cyclin C (CCNC) are reduced in both studies; CDK19, the module member lost most completely in Turunen et al. (ratio 0.00), was not detected (n.d.) as a high-confidence G44D interactor in our AP-MS data. (B) Core Mediator subunits are retained in both studies (median G44D/WT 0.92 in Turunen et al., 0.87 in the present study). The selective reduction of the CDK module with retention of core Mediator reproduces the central finding of Turunen et al. (2014).

      Reviewer comment: It is unclear whether the system is appropriate for ER-dependent transcription. Endogenous ERα/ERβ levels are not given, and estrogen signaling is ligand-dependent, yet no estrogen treatment appears to have been included. Without receptor expression and ligand stimulation, the estrogen-reporter results are hard to interpret.

      __Response: __This is a valid concern. The estrogen reporter is a defined dual-luciferase construct in which tandem estrogen response elements (ERE) drive firefly luciferase, and it does not include a co-expressed estrogen receptor. Because HEK293 cells express very low to negligible endogenous ERα and the assays were performed without ER co-expression or 17β-estradiol stimulation, the readout reflects ERE-responsive promoter activity in a near-ER-null context by design, rather than bona fide ligand-dependent ER signaling. We now (i) report the endogenous receptor status directly: neither ESR1 nor ESR2 is detected among the 8,708 protein groups quantified in the parental Flp-In T-REx 293 line by Orbitrap Astral DIA (Supplementary Data 5), confirming an effectively ER-null background; and (ii) explicitly qualify the estrogen-reporter interpretation in both the Results and the Discussion. Repeating the assay with ERα co-expression and 17β-estradiol stimulation would be required for a ligand-dependent readout, and we agree this is the appropriate next experiment, but it falls outside the scope of the present revision and we have therefore limited our claims accordingly. The phosphorylation-dependent PELP1 association (PL-specific to Mut1) is presented as motivating, not demonstrating, an ER-signaling link.

      Reviewer comment: Page 15, the authors described "Among individual kinases, HIPK2 was the top candidate for PAGE4-T51/T85, both sites fitting their known serine/threonine consensus motifs.". HIPK2 did not appear in the list of kinases in Figure 3E. Please clarify the data source and the criteria for the ranking.

      __Response: __Reconciled as described for Reviewer 2-C: the kinase-family enrichment heatmap has been replaced by a site-level kinase-prediction panel for S9, T51 and T85 (lower panel of Figure 4A), figure and text name the same kinases, and the scoring method, ranking criterion and data source are stated in the caption and Methods.

      Reviewer comment: Supplementary Figure 4, significance marks were missing.

      __Response: __Significance annotations have been added to all panels of the luciferase figure, which is Figure S5 in the revised manuscript (Figure S4 is the pathway-enrichment heatmap). Each panel now shows the individual replicate values with the mean ± SD, and the legend states the test, the number of replicates, the comparator (all comparisons against PAGE4 WT) and the meaning of each asterisk level.

      Reviewer comment: The biological significance of the enriched motifs is somewhat overinterpreted, since motif enrichment alone does not establish functional involvement. The presentation could be improved with a figure of top motifs, enrichment statistics and/or logos; e.g. “PAGE4 WT maintained AP-1-driven transcription, whereas phosphorylation induced an expanded motif repertoire” is hard to follow.

      __Response: __We agree, and we have reworked the motif analysis to lead with effect size rather than statistical significance, correcting several over-statements in the original text.

      __The p-values overstate the enrichment. __Across the five conditions, 129–172 of 440 known motifs pass q ≤ 0.05, but ~80% of these have fold-enrichment __The individually named transcription factors were over-called. __Most factors named in the original text reach statistical significance yet have fold-enrichment close to 1.0 (e.g. AP-1 1.03–1.11, E2F3 1.03, ETS1 1.07, FOXA1 1.03–1.09), i.e. no meaningful enrichment. We have removed these factor-specific claims and the “AP-1-driven transcription” / “expanded motif repertoire” framing.

      CTCF is the one robust result. CTCF is the only motif with fold-enrichment ≥ 1.3 in all five conditions (range 1.38–2.29, peaking at 2.29 in PAGE4 S9D); its paralog BORIS is second-strongest (1.18–1.58). No other known motif exceeds 1.5-fold enrichment in more than one condition. We therefore name CTCF as the principal candidate regulatory motif, reported with effect sizes, and provide a summary figure of the top enriched motifs by fold-enrichment (Rebuttal Figure 3, below).

      Rebuttal Figure 3. Top enriched known motifs (HOMER) by fold-enrichment across the five conditions. Colour intensity = fold-enrichment (% target / % background); grey dash = motif not detected in that condition; n.s. = not significant (HOMER Benjamini q > 0.05). CTCF is the only motif with fold-enrichment >= 1.3 in all five conditions.

      Venn filter and counts (corrected). Consistent with the effect-size-first approach described above, the Venn diagrams in Figure 6E now show robustly enriched known motifs (HOMER Benjamini q ≤ 0.05 AND fold-enrichment ≥ 1.2); we recomputed the overlaps directly from the five HOMER outputs using this filter (union denominator). Corrected values — MED12: WT = 10, G44D = 18, union = 21, G44D-unique = 11 (52.4%), shared = 7 (33.3%); PAGE4: WT = 19, S9D = 12, S9A = 11, union = 25, shared by all three = 3 (12.0%), S9D-unique = 4 (16.0%), S9A-unique = 1 (4.0%). This supersedes our earlier q ≤ 0.05-only statement, which counted many weakly enriched motifs (fold-enrichment Reviewer comment: The Figure 6D data do not sufficiently support the statement that MED12 WT enriched for chromatin remodeling/transcriptional regulation, G44D for stress-associated functions, and phospho-PAGE4 for nucleosomal DNA binding and ribosomal interaction terms. Please clarify.

      __Response: __We agree — the original panel over-interpreted small per-construct differences by assigning a distinct function to each construct. We have replaced the panel (now Figure 6G) with a corrected analysis that no longer makes per-construct functional assignments.

      The new Figure 6G is a term-by-condition dot plot of Gene Ontology Molecular Function enrichment of the peak-associated genes (clusterProfiler, redundant terms reduced by rrvgo at similarity 0.9, Benjamini–Hochberg-adjusted p-values). It shows that all five constructs enrich for the same core terms: the most strongly enriched term in every condition is structural constituent of ribosome, and the other enriched terms (cadherin binding, rRNA binding, ribonucleoprotein-complex binding, ubiquitin-ligase-related terms) are likewise shared across conditions rather than unique to any one. No construct-specific functional classes were detected, consistent with RNAP II promoter occupancy at highly transcribed genes. The Results text and Figure 6G legend have been rewritten to describe this shared-core finding, and the earlier “differentially enriched across constructs” wording and the stale “Figure 6D” reference have been removed.

      Reviewer comment: The legend says AP (light) vs PL (dark), but the figure shows AP green and PL yellow. And on the 73% statement, if the labels are correct, AP HCIs are 25 for Mut1 and 149 for WT, i.e. only 17% retained.

      __Response: __The legend has been corrected to the actual colors used in the figure, and the retention value has been recomputed and corrected as described for Reviewer 2-D.

      Reviewer comment: The data supporting “interactions with basal transcription factors and cell-cycle regulators were preferentially lost, while Mediator subunits and RNA-processing factors were selectively retained” are not readily apparent. Indicate the relevant figure/table.

      __Response: __We now cite the specific evidence, the focused interaction matrix (revised Figure 4E) and Supplementary Dataset 3, and have added a categorized lost-versus-retained summary so the statement is directly traceable to the data.

      Reviewer comment: Page 19, it is unclear how the statement that "In the MED12 p.G44D dataset, the bait (MED12-G44D) itself is strongly reduced compared with MED12 WT, consistent with decreased recovery of the mutant complex." is supported by the data presented in Figure 5A. Please clarify.

      __Response: __Addressed as for Reviewer 2-E: the data show the MED12-G44D bait is recovered at levels equal to or higher than WT, so the original “bait reduced” statement was corrected; the reduced number of G44D interactors is retained as a genuine, bait-independent effect.

      Reviewer comment: Page 19, reference is needed for "PELP1 is a well-established scaffolding protein that couples estrogen receptor signaling to chromatin remodeling and has been implicated in hormone-dependent tumor progression in breast and ovarian cancers."

      __Response: __A reference for PELP1 as an estrogen-receptor coactivator/scaffold implicated in hormone-dependent tumors has been added.

      Reviewer comment: For luciferase reporter assay: In the materials and methods section, the authors wrote "Data are presented as mean {plus minus} standard deviation (SD)", but in the figure legend, the authors wrote "Data represent mean {plus minus} SEM". Please clarify this discrepancy. In addition, please provide information regarding the promoter used in the luciferase assay plasmids, and replace "Firefly luciferase reporter plasmid containing the promoter of interest" with the specific promoter name.

      __Response: __We have harmonized the error-bar reporting: the Methods and the figure legend now both state mean ± SD, with the same number of replicates given in each. We have also replaced “promoter of interest” with the specific response element for each pathway (cell cycle/pRb-E2F → E2F; p53/DNA-damage → p53; MAPK/ERK → serum response element/SRE; MAPK/JNK → AP-1; Wnt → TCF/LEF; estrogen → estrogen response element/ERE).

      Reviewer comment: “Buyukcelebi K et al, 2023” is cited as both 2023a and 2023b; the same issue affects “Lin et al, 2018” and “Turunen et al, 2014.”

      __Response: __We have consolidated the duplicated entries and made the year-suffix usage consistent for these and all other multiply-cited references. We also carried out a complete audit of the bibliography against the in-text citations: every citation now resolves to exactly one entry, no entry is duplicated, and no entry is left uncited. Several references that were missing from the list have been added, and two citations that could not be traced to a specific source were removed from a sentence that is adequately supported by the remaining reference. Prompted by this comment we also checked each citation against the statement it supports rather than only against the bibliography, and corrected several placements: two extracellular-matrix references have been moved onto the matrix sentence they actually support, a reference on the co-occurrence of MED12 and HMGA2 alterations has been moved to the sentence reporting concurrent MED12 mutations in the COL4A5-COL4A6 tumors, a PAGE4-specific reference has been added alongside the general androgen-receptor citation, and one claim in the Discussion has been narrowed to the extracellular-matrix and cytoskeletal remodeling that the cited work actually addresses.

      Reviewer comment: “PAGE4 emerged … at protein, transcript, and IHC levels …”, IHC characterizes protein expression; did the authors mean phosphorylation levels?

      __Response: __Corrected. IHC measured PAGE4 protein abundance and (cytoplasmic-predominant) localization; the sentence has been rewritten so the three independent layers are stated accurately (protein by MS, transcript by RNA-seq, and protein by IHC), without implying IHC measured phosphorylation.

      Reviewer comment: “COL4A5-COL4A6 subclass showed upregulation of several extracellular matrix markers (WNT4, COL3A1, COL4A1, MMP2)”, it is unclear whether WNT4 should be an ECM marker.

      __Response: __We agree and have reclassified WNT4 as a hormone/Wnt-signaling factor rather than an ECM component, and corrected the sentence so only bona fide ECM markers are grouped together.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      The manuscript by Bong et al. describes a comprehensive proteogenomic analysis of uterine leiomyomas tumors (ULs). The goal was to identify protein level effectors that drive MED12 mutant UL tumors. They employed discovery DDA global and phosphoproteomic analyses of 9 MED12-mutated UL and matched normal tissues. They identified that PAGE4 was upregulated at both the protein and phosphosite level. They further characterized MED12 ULs against other subtypes of UL (HMG2A, FH, COL4A) and confirmed PAGE4 expression and phosphorylation is confined to the MED12-mutant subtype. They constructed isogenic cell lines (HEK293) of PAGE4 and MED12 variants to characterize the interactomes of PAGE4 and MED12. These results showed PAGE4 is involved in the mediator complex functions of MED12.

      Luciferase reporter assays were used to characterize how PAGE4 and MED12 mutants affect the transcription of key genes.

      They performed ChIP-seq experiments for RNA Pol2 to characterize how PAGE4 and MED12 mutants affect Pol2 transcription.

      Overall, Bong et al. convincingly identified a novel role of PAGE4 in UL and mediator transcriptional processes. Thus, this work will represent an important novel contribution to understanding the pathobiology of UL.

      There are several critiques for this manuscript. Major critiques:

      A) The validation cohort is not technically a validation cohort as it uses the same 9 MED12 mutant UL samples. Thus, it cannot validate PAGE4 upregulation and phosphorylation in an independent cohort. A second MED12-mutant UL cohort should be used.

      B) The ChIP-seq data are over interpreted. No meaningful changes in peak width or height is readily observable. To be believable statistical tests would be required.

      C) HIP2K was proposed as a candidate kinase that phosphorylates PAGE4. This is based on data presented in Fig. 3E. However, there is no HIP2K on this heatmap. Instead CLK2 is highlighted in red font and has an increased score, indicating it could be responsible kinase. HIP2K and CLK2 are different unrelated kinases. Please rectify.

      D) For Fig. 4B the text states MUT1 retained 73% of prey proteins contained in the PAGE4 WT interactome. However, in Fig. 4B, MUT1 had 25 preys versus 149 preys for WT; this is 25/149 = 17% retained for a decrease of 83%. Please rectify.

      E) The text states the MED12-G44D bait protein is strongly reduced compared to MED12 WT, referring to Fig. 5A. Fig. 5A right panel does not support this conclusion. Please rectify.

      F) In Fig. S3 the text states MUT1 has upregulated processes for base-excision repair and SUMOylation. However, the Fig. S3 heatmap does not support this for Mut1. Instead the data support MUT6 not MUT1. Please rectify.

      G) Figure 4E currently shows the full bait-prey graph and becomes a "hairball" where edge density prevents the reader from seeing the differences claimed in the result section. This figure is uninterpretable. The bait protein names are in miniscule point font and are illegible. There are too many elements to see the difference between AP, PL, or Both or the name of the prey proteins. The edge lines widths and colors are uninterpretable. Suggest simplifying the visualization or split it into focused panels so the figure evidence matches the claims. Specifically, recommend aggregating preys by annotated complex (or functional group) and showing a single summarized edge between each bait and complex (with edge weight or thickness reflecting the number or strength of prey links), and then displaying only the individual preys that are differentially associated between baits to support the key statements. H) Fig. 5A presents the known phosphorylation sites for PAGE4. However, the figure shows the data for 'GAGE', which is a different (unused) name for PAGE4. Please rectify. Importantly, this figure is directly copied from PhosphoSitePlus®.org without apparent permission. Permission should be obtained.

      I) The discussion and conclusions suggest making phosphomimetic changes at key sites in PAGE4 and MED12 are conclusive for phosphorylation being involved. This is not formally true, and should at least be mentioned as a hypothesis.

      J) In general, the methods describing the mass spectrometry experiments need to be expanded and clarified. The current description is insufficient for reproducing the experiments or fully understanding how the different datasets were generated and analyzed. DIA MS methods are missing entirely, and given that the manuscript uses both DDA and DIA acquisition modes across multiple MS experiments (total proteomics, phosphoproteomics, AP, and PL), the methods should be reorganized to clearly explain how acquisition and subsequent analyses were performed for each experiment type, specifying what was done in DDA and what in DIA modes. In the downstream analysis, how were the total and phosphoproteomics normalized and integrated? It is not clear how the PL data were analyzed or whether they were treated the same way as AP data; please explicitly state whether PL and AP data were processed identically or with different pipelines and describe any differences in preprocessing, normalization, or statistical treatment. Was SAINT used on spectral counts or intensities? Since the baits are nuclear proteins, was anything with Nuclear Localization Signals used as controls?

      K) Overall the manuscript has many issues with data presentation. To illustrate just a few:

      • Fig. 3B and 3D are described as volcano plots. They are not volcano plots.
      • Fig. 3B legend mentions a lower panel. There is no lower panel for Fig. 3B.
      • Fig. 3A, please use different shape markers for the UL subtypes and suggest connecting with edges to thus support their text conclusions of separate groupings.
      • For Fig. 3E the colors for the families and groups are not distinguishable (and the font is too small). Please rectify.
      • Please label the units and scale for Fig. 6A.
      • Please mention the MAC3 tag uses Ultra-ID to thus justify the 10 min labeling time.
      • In the relevant protein and phosphoproteomic datasets and figures please mention the number of proteins and phosphosites obtained to thus allow an interpretation of the data quality.
      • Table 4 is in a format that is uninterpretable.
      • The text and figures interchangeably use the mutant number (e.g. MUT1) or mutant composition (e.g. S9D_T51E_T85E - for MUT1), this makes reading and interpreting the manuscript very challenging. Suggest using one format.

      Significance

      Overall, Bong et al. convincingly identified a novel role of PAGE4 in UL and mediator transcriptional processes. Thus, this work will represent an important novel contribution to understanding the pathobiology of UL.

      This is a very comprehensive dataset. However, there are multiple issues on data interpretation and presentation.

      The results would be of interest to cancer biologists, primarily at the basic science level. Clinical translation would require additional research.

      The expertise of the reviewer is in cancer proteomics (interactomes, DIA and DDA mass spectrometry, proteomic data analysis), and general cancer biology across most common cancer types.

    1. e scaffolding is leaking into the product surface. "Prototype state:" switchers, the floating 🆕 New pattern badge (login, 404, api-docs, settings-api-keys), Preview — sample data captions, and design-spec prose rendered as body copy (settings-api-keys: In the app this dialog opens centered over a page scrim…; team.html: Cancel invitation confirms the same way…; sender-profiles: Shown open for the handoff…). Fine for handoff review — but tag them all with one consistent data-proto wrapper/class now so they can be stripp

      i don't knwo what this emeans

    1. in Echtzeit wird an dieser Stelle also ein Abgleich viermal am Tag. Marktplatzbestellungen erscheinen zudem nicht in der Verkaufshistorie der Kasse, weshalb sich die Amazon-Rückgabe an der Theke dort nicht abbilden lässt;

      can we fact check this claim. i think this is very specific and if we get it wrong we are in trouble

    1. The mail server accepts all incoming email without verifying if specific mailboxes exist.

      lets add everything missing from why it matters and how to that isn't already in report text Accept-All is high. Be smart about how you read "delivered" About 21% of this sample is on Accept-All servers. For B2B outreach this is normal (lots of corporate Microsoft 365 / Mimecast / Proofpoint behind those domains), but it means a "delivered" status from your sending tool is NOT the same as "the inbox actually exists." Mailbox providers will silently drop unknown addresses on accept-all servers, and those failures show up as zero engagement, not as bounces. Watch click rates per domain. Accept-All domains with consistent 0% clicks across multiple campaigns are likely dead boxes.

      Accept-All 412 emails Accept-all mail servers say yes at the connection level without revealing whether a specific mailbox is active. Our checks can verify some of these addresses directly, but not all of them depending on how the server is configured. Consumer providers like Yahoo and AOL often run in accept-all mode, and on business domains this usually comes from security gateways such as Proofpoint, Mimecast, or Barracuda sitting in front of the real inbox. We tag every address on an accept-all server so you can track them as their own segment and watch how they behave in your campaigns. Segment these addresses into their own group and send to them separately from your other contacts. Track their engagement (opens, clicks, replies) over a few sends. Addresses that engage can be moved into your main list with confidence. Addresses that never engage after multiple sends are safe to segment aside for re-engagement campaigns or suppression, depending on your goals.

      66% of this list is in great shape to send to For a combined tax marketing and booking customer list, the validation profile is healthy. Only 29 of 598 addresses (4.8%) need removal. The Monitor segment is mostly Accept-All on consumer providers like Yahoo and Hotmail, where the addresses are real but the providers respond conservatively to validation queries. These should still be sent to. Accept-All 123 emails Accept-all mail servers say yes at the connection level without revealing whether a specific mailbox is active. Our checks can verify some of these addresses directly, but not all of them depending on how the server is configured. Consumer providers like Yahoo and AOL often run in accept-all mode, and on business domains this usually comes from security gateways such as Proofpoint, Mimecast, or Barracuda sitting in front of the real inbox. We tag every address on an accept-all server so you can track them as their own segment and watch how they behave in your campaigns. Segment these addresses into their own group and send to them separately from your other contacts. Track their engagement (opens, clicks, replies) over a few sends. Addresses that engage can be moved into your main list with confidence. Addresses that never engage after multiple sends are safe to segment aside for re-engagement campaigns or suppression, depending on your goals.

      Accept-All 19,281 emails Accept-all mail servers say yes at the connection level without revealing whether a specific mailbox is active. Our checks can verify some of these addresses directly, but not all of them depending on how the server is configured. Consumer providers like Yahoo and AOL often run in accept-all mode, and on business domains this usually comes from security gateways such as Proofpoint, Mimecast, or Barracuda sitting in front of the real inbox. We tag every address on an accept-all server so you can track them as their own segment and watch how they behave in your campaigns. Segment these addresses into their own group and send to them separately from your other contacts. Track their engagement (opens, clicks, replies) over a few sends. Addresses that engage can be moved into your main list with confidence. Addresses that never engage after multiple sends are safe to segment aside for re-engagement campaigns or suppression, depending on your goals. all incoming mail at the gateway but may silently discard messages that don't pass security checks. Monitor carefully. Military domains accept all email at the gate (accept-all) but have aggressive internal filtering. Bounces may not be reported, making it hard to detect delivery failures.

      Accept-All 1,320 emails Accept-all mail servers say yes at the connection level without revealing whether a specific mailbox is active. Our checks can verify some of these addresses directly, but not all of them depending on how the server is configured. Consumer providers like Yahoo and AOL often run in accept-all mode, and on business domains this usually comes from security gateways such as Proofpoint, Mimecast, or Barracuda sitting in front of the real inbox. We tag every address on an accept-all server so you can track them as their own segment and watch how they behave in your campaigns. Segment these addresses into their own group and send to them separately from your other contacts. Track their engagement (opens, clicks, replies) over a few sends. Addresses that engage can be moved into your main list with confidence. Addresses that never engage after multiple sends are safe to segment aside for re-engagement campaigns or suppression, depending on your goals. ✓ 3,159 addresses are clean and safe to send first The Keep bucket is deliverable-only. Every risky, low-confidence, and accept-all-without-a-website address has been pulled out into Monitor or Suppress, so what is left in Keep is what a fresh sender can lead with.

      One ask: if any of these bounce because the mailbox genuinely does not exist (a true "no such user" bounce, not a blocklist or content block), tell us at lists@reviewmyemails.com and we will credit 2 emails back. It helps us learn and improve the checks, and you get the credits. 1,885 addresses are real but need care (Monitor) Monitor is where the address is real but comes with a caveat, and the decision on each is yours. Some sit on accept-all servers: we confirmed the domain is live and its mail server responds, but the server says "yes" to every address at the connection level, so the one specific mailbox cannot be confirmed active by any tool. That is their server's setting, not a gap in our check. Another 1,334 verified as real but with lower delivery confidence. Many of these domains also sit behind security gateways like Proofpoint, Mimecast and Barracuda that only let mail through from senders they already trust, so even a real, active inbox can block a cold sender until you are recognised or allowlisted. A few carry other flags (breach history, a shared role inbox, heavy mail volume), each explained per label below.

      Go label by label below and decide what fits your risk tolerance: som e are worth sending to with care, others you may prefer to hold back. Either is a valid choice. Accept-All 1,416 emails These sit on a server that says "yes" to every address at the connection level, so we cannot confirm whether the individual mailbox actually exists. That is the key difference from Low Delivery Confidence, where we did get a mailbox-level answer. Consumer providers like Yahoo and AOL run this way, and on business domains it usually comes from a security gateway (Proofpoint, Mimecast, Barracuda) sitting in front of the real inbox. We tag every accept-all address so you can track them as their own segment. Do not blast these. Sprinkle a few into your sends over time rather than hitting them all at once, use a shorter sequence with bigger gaps between emails, and cut them off faster if they show no engagement. The ones that do engage can move into your main list; the rest you set aside. Low Delivery Confidence 1,281 emails We checked these mailboxes and they came back real, but with a "risky" signal. This is the key difference from Accept-All: with Accept-All the server accepts everything and hides whether the specific mailbox exists, whereas here we did get a mailbox-level answer, it just was not a clean pass. It usually means the domain or provider has a weaker sending reputation, or the domain is small and low-traffic. These are worth sending to, just keep a close eye on them: track opens and bounces, and drop any that hard-bounce on the first touch. Yahoo and AOL cannot be individually verified, and that is normal These providers run accept-all servers: they say "yes" to every address at the connection level, so no tool can confirm one specific mailbox. That is their server's design, not a gap in the check. Since these subscribers opted in, keep them, but Yahoo and AOL are strict on complaints, so send consistently and prune anyone who never opens.

      Accept-All 609 emails Accept-all mail servers say yes at the connection level without revealing whether a specific mailbox is active. Our checks can verify some of these addresses directly, but not all of them depending on how the server is configured. Consumer providers like Yahoo and AOL often run in accept-all mode, and on business domains this usually comes from security gateways such as Proofpoint, Mimecast, or Barracuda sitting in front of the real inbox. We tag every address on an accept-all server so you can track them as their own segment and watch how they behave in your campaigns. Segment these addresses into their own group and send to them separately from your other contacts. Track their engagement (opens, clicks, replies) over a few sends. Addresses that engage can be moved into your main list with confidence. Addresses that never engage after multiple sends are safe to segment aside for re-engagement campaigns or suppression, depending on your goals.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      POINT-BY-POINT response letter

      We thank both reviewers for useful suggestions. Our responses are indicated in blue in the text below.


      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Alves et al investigate the mechanisms of anterograde IFT in Euglenozoa that lack the canonical heterotrimeric kinesin-2 motor and the kinesin-associated protein KAP. Through a combination of comparative genomics, in vitro analyses, live-cell imaging, and genetic analyses in Trypanosoma brucei and Leishmania mexicana, the authors show that the kinesin-2 proteins KIN2A and KIN2B form homodimeric motors in vitro with distinct in vivo ciliary localization and functions. The authors report that KIN2B is essential for flagellum assembly despite contributing to only a minority of long-range anterograde transport events that colocalize with IFT trains. By contrast, KIN2A is dispensable for flagellum assembly despite being proposed to mediate most anterograde IFT. Based on these observations, the authors propose a division-of-labour model in which KIN2B mediates entry of IFT proteins into the flagellum while KIN2A performs the majority of anterograde transport.

      The work addresses an important evolutionary and mechanistic question. The phylogenetic analysis, in vitro motor characterization, and comparative analyses in two trypanosomatid species are major strengths. However, I believe that several of the key mechanistic conclusions are not yet directly supported by the available data and would benefit from either additional experimentation or a more cautious interpretation.

      We agree that there are limitations to our study and have discussed them below and in the revised manuscript. We make it clearer that it is a working model, which we believe is currently the best one to explain the available data. We also note that Reviewer 2 considers the model “compelling”.

      Major comments:

      1- The authors should revise the statement in the Introduction that in bloodstream-form T. brucei "only knockdown of both KIN2A and KIN2B impacted flagellum length". However, Douglas et al. (2020) reported that individual depletion of either kinesin reduced flagellum length, with a stronger additive phenotype upon combined depletion. The authors should correct this point and clarify more explicitly how the present study extends the earlier work, both conceptually and technically.

      Thanks for the comment, the statement has been corrected (see below). Compared to the Douglas study, there are major advances both conceptually and technically. Below, we are talking only about function, the studies on kinesin motility (Figs 2,3,5,6) being entirely new since this was not looked at in the 2020 publication where localisation studies were limited to fixed cells.

      In technical terms, our study relies on gene deletion or inactivation using potent Cas9 approaches in both T. brucei (procyclic stage) and L. mexicana (Beneke et al. 2017, ref [58]; Asencio et al., 2024 [72]) while the Douglas study used RNAi, with strong efficiency against KIN2A (~10% mRNA still detected) and more limited impact on KIN2B (~30% mRNA left). This could explain the stronger phenotype reported for KIN2A depletion. Moreover, the published study was done with bloodstream stage trypanosomes, which are much more sensitive to flagellar pertubation than procyclic ones (Broadhead et al., 2006; Ralston & Hill, 2006 [34, 35]) used here. A reminder has been added in the text for non-trypanosome readers. The introduction has been edited as follows (p. 5):

      “In the trypanosome bloodstream stage (which develops in mammals and can also be manipulated), knockdown of KIN2A or KIN2B individually reduced flagellum length by 4-5 µm, and an additional reduction was observed with combined silencing [30]. These results suggest that the two kinesins may be redundant. Nevertheless, silencing of KIN2A alone, but not KIN2B, severely impacted the growth rate of bloodstream trypanosomes and led to spectacular cytokinesis defects [30], hinting at potentially some distinct functions. However, knockdown efficiency was less potent for KIN2B (~30% residual mRNA vs ~10% for KIN2A), hindering firm conclusions. It should also be reminded that bloodstream trypanosomes are more sensitive to flagellum perturbation compared to procyclic cells [34, 35].”

      In conceptual terms, there are major advances. The 2020 study demonstrated the importance of KIN2A and KIN2B for proper flagellum assembly but did not provide information about the contribution of each kinesin, neither on their trafficking. First, we formally demonstrate that KIN2A and KIN2B are homodimeric and that heterodimers cannot be formed. Second, this study is revealing not only distinct localisation and motility profiles, but also different contributions to flagellum construction: KIN2B is mostly found in the proximal portion of the flagellum and governs access of IFTs to the flagellar compartment while ensuring limited protein transport while KIN2A is found all along the flagellum and is responsible for the majority of IFT transport, although it cannot import IFT proteins. Third, KIN2B can substitute to KIN2A (albeit a bit less efficiently), while KIN2A cannot substitute for KIN2B. These results are the basis of the original division-of-labour model presented at Figure 9.

      2- The localization of KIN2A in the current manuscript appears somewhat different from that reported previously, where KIN2A was described as more enriched near the basal body region. This discrepancy should be discussed. In particular, the relatively strong cytoplasmic signal in the current study may obscure a weak basal enrichment, and this possibility should be addressed

      The Douglas et al. study used a rabbit antiserum raised against aa 391-696 of KIN2A. Following aldehyde fixation, the signal was found in the cytoplasm, in the basal body area and along the flagellum. The region selected contains two coiled-coil domains (aa 406-464 and aa 604-636), and antibodies recognising coiled-coil domains are well known in the community for producing false positive on centrosomes and basal bodies, due to over-representation of these domains in centrosomal proteins (see for example Nido et al. Mol. Biosyst. 2012). In the 2020 study, western blot analysis detected a reduction in the amount of KIN2A upon triggering RNAi confirming specificity by this assay. However, no immunofluorescence (IFA) images of the knockdown cells were presented. Many years ago (actually well before the 2020 paper was published), Dr Welch kindly shared with us an aliquot of their anti-KIN2A that we used in both western blot and IFA in a cell line expressing double-stranded RNA of KIN2A in a tetracycline-inducible manner. Western blot demonstrated an at least 8-fold reduction of the signal (see below, so reproducing data in the Douglas publication) but the signal obtained by IFA was not much modified, especially the spot at the flagellar base (see images below). It is therefore likely that this signal is not KIN2A-specific.

      Figure response 1. Cells from the KIN2ARNAi cell line were grown without (non-induced) or with tetracycline for 3 days to trigger RNAi against KIN2A. A. Western blot with the published anti-KIN2A antibody demonstrates RNAi efficiency and antibody specificity by this assay (Bertiaux et al. Curr. Biol. 2018 [33]). B-C. IFA with the published anti-KIN2A antiserum produces signal at the flagellar base, along the flagellum and in the cytoplasm in KIN2ARNAi cells in both non-induced (NI) and induced conditions (3 days)(B. Morga, unpublished data). Since the IFA signal is not reduced upon induction, it is likely unspecific.

      Therefore, the discussion has been updated as follows (p. 20):

      “The localisation of KIN2A had been previously reported in the T. brucei bloodstream stage using a rabbit antiserum raised against aa 391-696 of KIN2A, which labeled the flagellum, the basal body area and the cytoplasm [30]. Using the same antiserum provided by Dr. Welch, we confiremd this localisation in procyclic trypanosomes. However, while expression of KIN2B double-stranded RNA produced an 8-fold reduction of the signal obtained with this antibody by western blot, it did not impact the IFA signal at the flagellar base (our unpublished data), questioning antibody specificity in this assay.”

      Here, we used endogenous N-terminal tagging with mNG to ensure expression via the 3’UTR of each kinesin, which is the major element controlling expression level (Clayton MBP2014). This allowed direct live imaging, avoiding potential biases due to fixation or antibody specificity. The mNG::KIN2A signal was detected as moving particles along the flagellum (in both anterograde and retrograde directions) without visible enrichment in the basal body area. As requested below (point 3), quantification has been performed on individual images from videos where the full flagellum appears in focus. Again, no concentration at the base could be detected, in contrast to IFT81::mNG or mNG::KIN2B.

      Similar results were obtained upon N-terminal tagging by the TrypTag consortium who detected signal in the flagellum and the cytoplasm, but no specific enrichment at the flagellar base (Billington et al. 2023 [49], see image below).

      Tagging KIN2A at its N-terminal end with mNG labels the flagellum without visible enrichment at its base and with some cytoplasmic signal (image from TrypTag.org)

      Finally, tagging KIN2A and KIN2B in L. mexicana produced the same location as observed in T. brucei (Fig. S4, with improvements as requested below, see point 5).

      3- Temporal projections are useful for interpreting particle movement, but they can be misleading when used to assess protein distribution along the flagellum. Representative single-frame images would be more appropriate for localization analyses, and quantitative fluorescence intensity profiles would strengthen the conclusions, particularly for Figures 4B-D and 7D/F.

      Individual images are actually visible in the videos showing the full image series (Video S3 for IFT81::mNG, S4 for mNG::KIN2A, S5 for mNG::KIN2B, S6 for mNG::KIN2B with tdT::IFT140, S7 for mNG::IFT81 in KIN2A KO and S8 for mNG::KIN2B in the KIN2A KO). Kymograph analyses monitoring the movement of individual particles (Fig 5B,D,F) provide a global representation along the length of the flagellum. As requested, we extracted temporal projections from five cells where the full flagellum length is in focus and made graphs with their fluorescence intensity profile. This is redundant with the videos but these images can be presented as supplementary material if considered useful by the editor. This further confirms the conclusions: KIN2A is found along the length of the flagellum without obvious concentration at its base while KIN2B is present at the base and mostly at the proximal portion of the flagellum.

      Fluorescence intensity profiles of 5 cells where the flagellum base is in focus. A clear enrichment is detected at the base for mNG::KIN2B (right) but not for mNG::KIN2A (left). (“series” correspond to cells)

      4- The authors compare the localization and dynamics of KIN2A and KIN2B with those of IFT81. However, only one allele of IFT81 is tagged, meaning that a proportion of IFT81 molecules within trains are presumably unlabelled. This could influence measurements of train frequency, intensity, and colocalization, and should be discussed when interpreting the data. This limitation should be explicitly discussed.

      We haven’t done double tagging for IFT genes since the signal is very bright for all IFT-B proteins that were looked at by us or others (Absalon et al. MBoC2008; Adhiambo et al. JCS2009; Franklin et al., MolMic2010; Bhogaraju et al., Science2013; Huet et al., eLife2014, JCS2019; Edwards et al., PNAS2018). Nevertheless, we have compared IFT trafficking in a cell line where one allele of IFT172 (gene encoding another IFT-B protein present with same stoechiometry, Subota et al. 2014, [46]) was tagged with tdTomato and the other one was not (like here with mNG::IFT81) with a derived cell line where the wild-type IFT172 allele had been deleted. Frequency of tdTomato::IFT172 trafficking was similar in both conditions, showing that tagging one allele is sufficient to detect all IFT trains (Jung et al. unpublished data).

      This was expected knowing the size of IFT trains and the relatively large number of copies of the IFT-B complex. Briefly, volumetric electron microscopy data show that train length varies from 200 to 900 nm (Bertiaux et al., 2018 [38]). CryoEM data revealed a periodicity of 8 nm for each complex B present in trypanosome IFT trains (Staggers et al. 2025 [61]), so each train should contain at least 25 copies. Therefore, tagging one allele out of two should provide at least 12 copies of the fluorescent protein per train. Therefore, it is reasonably likely that virtually every train contains the fusion protein.

      We have added this sentence in the text (p.11):

      “Since only one allele of IFT81 was labelled, the fusion protein is competing with products of the untagged allele. However, IFT trains are composed of multiple copies of IFT-B complexes with an 8 nm periodicity [61] and their average length of ~200 nm [38] means that each train should contain at least 25 copies, making it highly likely that the vast majority of trains is labelled.”

      5- The localization analysis of KIN2A and KIN2B in L. mexicana provides important validation of the observations made in T. brucei. However, no marker of the basal body or transition zone is included. Therefore, the statement that "KIN2A was found throughout the flagellum without clear enrichment at the base, whereas KIN2B is highly concentrated at the flagellum base" is not fully supported. Co-labelling with a basal body or transition zone marker would strengthen this conclusion.

      When talking about L. mexicana, we are not making a statement about a specific area (basal body, transition zone or transition fibres) but are always using the term “flagellum base”. This is easily visible thanks to its proximity with the mitochondrial genome (kinetoplast), that is tightly connected to the proximal part of the basal body (Robinson & Gull, 1991 [113]). This proximity is obvious on the transmission electron microscopy image shown at Fig. 8A or on the double staining of live cells with DAPI at Fig. 8B-C. For more clarity, we have added images of cells expressing mNG::KIN2A or mNG::KIN2B costained with DAPI, showing the close proximity of the kinetoplast signal with both KIN2A and KIN2B (Fig. S4A-B); further confirming the absence of enrichment for KIN2A (Fig. S4A) and a clear concentration for KIN2B (Fig. S4B).

      6- The distinction between proximal and full-length KIN2B particles is central to the proposed model. However, alternative explanations should be considered and discussed. For example, differences in particle intensity, signal-to-noise ratio, focal plane position, train convergence near the base, photobleaching, or effects of fluorescent tagging on train stability could potentially contribute to the observed behaviour. The authors should also to clarify whether tdT::IFT140 is expressed from the endogenous locus (whether all cellular IFT140 is tagged). If untagged IFT140 remains present, this could influence the interpretation of the colocalization analyses.

      IFT140 is endogenously tagged, here with the plasmid tagging strategy that has been validated previously [54]. This is now clearly stated at page 13:

      “However, the combination of mNG::KIN2B with endogenously tagged tdT::IFT140 was the only one to result in a viable cell line where both signals were positive and exhibited the same profile as in single tagging.”

      as well as in Material and Methods (page 29)

      For the double-tagged cell line, cells expressing mNG::KIN2B were nucleofected with the plasmid p2845TdTomatoIFT140 [54] linearised with MfeI, allowing the expression of IFT140 (Tb927.10.14470) fused to tdTomato (tdT) at the N-terminus from its endogenous locus.”

      For the proposed alternative explanations:

      -particle intensity/SNR: it is correct that fluorescent particles display variable intensities, something that we previously reported (Buisson et al. 2013 [39]). Nevertheless, kymograph analyses did not detect particular correlations. For example, brighter traces do not display faster (or slower) movements. The signal-to-noise ratio is indeed more complex in the proximal part of the flagellum for mNG::KIN2B due to the higher abundance of anterograde and retrograde particles in this area. Nevertheless, full-length particles can usually be monitored from the base on kymographs (see Fig. 5F). These differences therefore cannot explain the results.

      -focal plane position: analyses are exclusively performed with cells where the flagellum is in full focus or with a segment of the flagellum that is in full focus.

      -train convergence near the base: what the reviewer means by “convergence” is not clear to us. Anterograde trains are assembled in this area while retrograde trains complete their trip at the base of the flagellum. Previous quantification performed on cells expressing GFP::IFT52 showed that the frequency of both anterograde and retrograde was not higher at the base compared to the tip (Buisson et al. 2013 [39]). Therefore, they do not “converge” (like trains coming from different lines and ending at the same train station for example).

      -photobleaching: kymograph observations show that the vast majority of anterograde traces convert to several retrograde ones (this was quantified in details in Buisson et al. 2013 [39]), including KIN2B proximal particles, so bleaching could not explain the results.

      -effects of fluorescent tagging on train stability: adding a fluorescent reporter could indeed impact train behaviour, as observed by our difficulty to achieve double tagging while single tagging worked for almost all IFT proteins and motors tested. Since flagella are essential for trypanosomes, disruption of IFT train assembly would mimick IFT knockdowns (Kohl et al. 2003 [71]) and explain why cells either did not grow or retained only one tagged IFT/motor. In terms of stability, once a fluorescent particle is detected, kymographs show that it usually runs throughout flagellum length and is converted to retrograde trains (see above). Fig 7J shows that less than 5% of trains labelled with IFT81::mNG arrest during their trip in control cells. The only exception is of course mNG::KIN2B where the majority of fluorescent particles arrest and convert to retrograde ones towards the end of the proximal portion of the flagellum. This could have reflected an impact on motor trafficking. However, IFA performed with an anti-KIN2B antibody on a wild-type cell line demonstrates that most KIN2B signal is found in this portion (Fig. S3B), showing that untagged protein displays a similar location, ruling out the possibility of an artefact due to mNG tagging of KIN2B. In contrast to the published anti-KIN2A antibody, IFA performed with anti-KIN2B antibody on knockdown cells showed a drastic signal reduction, confirming signal specificity (Fig. S3D-E).

      Only one copy of IFT140 was tagged, but as discussed above (point 4), it is unlikely that many trains would be missed given the high number of IFT complexes present per train.

      In summary, none of these alternative explanations are likely. Describing each of them individually would take quite a lot of space, therefore we do not wish to increase excessively the length of the manuscript to avoid confusing the reader.

      7- The velocity comparison between proximal and full-length KIN2B particles may be confounded by positional effects along the flagellum. Since transport is expected to be slower near the transition zone, it would be more appropriate to compare proximal particles with the proximal segment of full-length particle trajectories only.

      IFT rates have not been quantified in the trypanosome transition zone since this portion is rather challenging for live imaging both because of its short length (350 nm; Trépout et al, JSB 2018) and of its positioning in the flagellar pocket. Since acquisition time is 100 ms and that trains run at a speed of around 2 µm/s, this means that only 2 time points would be available, preventing reliable measurements. Assuming the IFT velocity was slower in this area (as shown in C. elegans), the impact would be minimal since the proximal portion of the flagellum where most KIN2B particles are detected is 10-15 µm. 8- The authors state that IFT81 distribution in KIN2A knockout flagella resembles that observed in wild-type cells. However, comparison of the images and movies suggests potential differences, including reduced proximal signal and increased distal accumulation in the shorter mutant flagella. Representative single-frame images, together with fluorescence intensity profiles along multiple flagella, would facilitate a more rigorous comparison between genotypes.

      As explained above, the full sequence of individual images is available in the videos. Nevertheless, we indeed noticed some variabilities in the IFT distribution profile, but these are also encountered in control cells (see figure below). For technical reasons, the deletion was done in pSMOX cells (Beneke et al. 2017, ref [58]) that turn out to be more difficult to immobilise for image acquisition, increasing variability from cell to cell compared to our usual 427 cells. We are showing below temporal projections of several control and KO cells. If the editor finds these useful, these panels can be provided as supplementary material. Beyond this distribution aspect, quantifications presented at Fig. 8H-I-J revealed parameters that are unchanged (frequency, 8H) and those that are moderately (speed, 8I) or drastically (frequency of arrested trains, 8J) modified.

      Temporal projections of cells expressing mNG::IFT81 where most of the flagellum is in focus. (A) pSMOX (control) cells, (B) kin2a-/- cells. Although the flagellum is shorter, the flagellar distribution profile looks fairly similar.

      9- The current data do not fully exclude a handover mechanism between KIN2B and KIN2A within the proximal flagellum. While the proposed model is attractive, alternative cooperation-based models remain plausible and should be acknowledged more explicitly.

      We indeed considered a handover mechanism between KIN2B and KIN2A at the exit of the transition zone and have now further expanded this section (p. 21):

      “At this stage, it is not clear if KIN2B progressively hands over IFT trains to KIN2A, in a situation equivalent to the transition that takes place in the intermediate portion of cilia between the heterotrimeric kinesin-2 and OSM-3 in C. elegans [21], or whether IFT trains are released once the transition zone is crossed and then associate again with any of the two kinesins. In the first situation, single molecule imaging revealed that the heterotrimeric kinesin is responsible for progression of IFT trains through the transition zone before being progressively replaced by the homodimeric kinesin OSM-3 in the proximal segment of the axoneme, OSM3 ensuring transport to the tip of the cilium [21]. A similar case could be considered here, but in a shorter portion of the axoneme and between two homodimeric kinesins. In the second situation, trains might “hang around” after they have crossed the transition zone and then be picked up by KIN2A for efficient transport.”

      10- The presented data do not yet fully support that KIN2A contributes to most anterograde transport and that KIN2B mainly regulates IFT entry into the cilium while mediating only a minority of long-range anterograde transport events. This interpretation is also difficult to reconcile with the genetic data, given that KIN2B is essential for flagellum assembly whereas KIN2A is not. More generally, the proposed division-of-labour model remains largely inferential and should be presented more cautiously.

      We agree that a model has always limitations and is bound to evolve. The model actually explains the genetic data since KIN2B can substitute to KIN2A, while the reverse is not possible, something observed in two different organisms (T. brucei and L. mexicana). Definitive evidence would have been the coexpression of KIN2A and IFT proteins with two different fluorescent reporters, but unfortunately, this turned out to be impossible. A third kinesin able to transport IFT particles was not identified, neither by genome mining (Wickstead et al. 2006; 2010 [36, 83], this study), nor during the TrypTag project (Billington et al. 2023 [49]). Therefore, these two kinesins must be responsible for all the transport of IFT proteins (in the anterograde direction).

      We have added these sentences to the discussion (p.22):

      “However, formal evidence that KIN2A transports IFT particles could not be obtained since co-expression of KIN2A and an IFT protein with two different fluorescent reporters turned out to be impossible. One therefore cannot rule out the possible contribution of other kinesins as observed in Tetrahymena [14, 82]. Nevertheless, a third kinesin able to transport IFT particles was not identified, neither by genome mining ([36, 83], this study), nor during the TrypTag project [49]. Therefore, KIN2A and KIN2B must be responsible for all the transport of IFT proteins (in the anterograde direction).”

      Other comments:

      1- For consistency, the authors should consider using the same plotting style for similar datasets (e.g. Figures 2C and 7C).

      Maybe there is a confusion in figure number but Figure 2C quantifies the in vitro movement of truncated KIN2B on brain microtubules while Figure 7C reports flagellum length in trypanosomes without KIN2A, so there are very different datasets. Fig. 2C relates to 2A and 2B, which are all in the same format and Fig. 7C is the only graph reporting flagellum length.

      2- Figures S2A and S2D are difficult to interpret due to the low signal-to-noise ratio of the staining. The authors should consider whether these data provide sufficient additional information to justify inclusion.

      IFT172 staining looks indeed “cleaner” on methanol-fixed cells where signals is present mostly on the flagellum and at its base. However, most cytoplasmic IFT material is lost in these conditions (Absalon et al. MBoC2008 [52]). Here, we wanted to show that there was not impact on the global distribution of IFT proteins in the various cell lines used for the study, hence the PFA fixation followed by methanol extraction, which looks perhaps less nice but shows all the IFT material present in the cell (Bertiaux et al. 2018 [38]). As a reminder, biochemical fractionation have shown that a lot of IFT proteins are found in the cytoplasm, not only in trypanosomes, but also in other organisms (see for example Ahmed et al. JCB2008).

      The same argument is valid for Figure S2D to probe for a possible pool of KIN2A at the base of the flagellum. We therefore consider important to maintain these two series of figures.

      3- Figures 4 and S4 would benefit from schematics of T. brucei and L. mexicana highlighting cell morphology, flagellum, and the position of the basal body/transition zone. Such schematics would greatly aid readers less familiar with these systems. Larger panels and higher-magnification insets at the flagellar base would also improve readability. Given the overlap in content, Figures 4 and 5 could potentially be combined.

      Such cartoons have been published in multiple articles but if the editor finds them useful, we can add them to the figures. Higher magnification panels reach the resoltion limit and do not add more information to the manuscript.

      4- The statement that KIN2A and KIN2B exhibit velocities "compatible with IFT" and are "a bit slower than IFT81" should be corrected, since Figure 5G indicates significant differences among populations.

      The sentence has been rewritten as :

      “This showed that KIN2A and KIN2B particles have a speed compatible with IFT, although they are both a bit slower than IFT81, a difference that is statistically significant (Fig. ____5G).”

      5- Figure 6A would benefit from higher-magnification insets highlighting representative proximal and full-length KIN2B particles.

      As said above, increasing the magnification hits the resolution limit and is not very useful. Video S7 provides annotations highlighting individual examples of KIN2B associated to IFT140 navigating till the tip of the flagellum and of KIN2B particles trafficking without IFT140 and limited to the proximal portion of the flagellum.

      6- The manuscript is somewhat descriptive in places and would benefit from tigher editing. A more focused presentation of the key findings and their implications would improve readability and sharpen the paper's central message.

      We have rewritten some parts of the text and added sub-headings in the discussion as requested by Reviewer 2.

      Reviewer #1 (Significance (Required)):

      The work addresses an important evolutionary and mechanistic question. The phylogenetic analysis, in vitro motor characterization, and comparative analyses in two trypanosomatid species are major strengths. However, I believe that several of the key mechanistic conclusions are not yet directly supported by the available data and would benefit from either additional experimentation or a more cautious interpretation.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      SUMMARY: In this manuscript, the authors characterize kinesin-2, which is responsible for flagellum formation and function in Trypanosoma brucei and Leishmania mexicana. They show that T. brucei kinesin-2 comprises KIN2A and KIN2B proteins, each of which forms a homodimer and moves processively along microtubules in vitro. In cells, KIN2A and KIN2B exhibit distinct behaviors: KIN2A moves faster and traverses the full length of the flagellum, whereas KIN2B is slower and enriched near the flagella base. KIN2A KO mutants are cilia assembly competent and display only mild effects on IFT transport and flagellum assembly, while KIN2B KO mutants fail to assemble a normal flagellum. KIN2B-depleted cells are largely non-flagellated, with a clearly shortened flagellum remnant. Notably, KIN2A trafficking appears largely normal within these short flagella, indicating that KIN2A can still access the flagellum in the absence of KIN2B. Based on these findings, the authors propose a division-of-labor model in which KIN2B is primarily responsible for importing IFT components, whereas KIN2A performs most anterograde transport within the flagellum.

      COMMENTS: Overall, the authors use a broad range of biochemical and cell-biological approaches to define the properties of Trypanosome kinesin-2 and conclude with a compelling working model. While the experiments appear carefully executed, the results are generally convincing, several points should be addressed before publication: • Figure 2: The in vitro reconstitution assays show two velocity populations for KIN2A (slow and fast), and a slow-moving population is also observed for GCN4-fused KIN2B. The authors interpret the slow-moving populations as "autoinhibited" conformations and the fast populations as "active". Consistently, in live-imaging (Figure 6E), proximal KIN2B particles move slowly when not co-localizing with IFT140 but move faster when associated with IFT trains. This suggests multiple motile states may reflect regulation by tail conformation and/or cargo loading rather than canonical autoinhibition. By definition, many autoinhibited kinesins are characterized by reduced microtubule engagement (or failure to bind) rather than simply reduced velocity. Therefore, it is not yet clear that the slow populations observed here should be described as autoinhibited. It rather seems more akin to a 'gear shifting' mechanism described for kinesin-1, -2, and -3 (Coppin et al, 1997; Gicking et al., 2022). Otherwise, if the authors retain this terminology, they should provide additional evidence, such as microtubule-binding affinity measurements for the slow vs. fast populations. It would also be informative to test whether kinesin-2 velocities shift in the presence of defined cargo/IFT components in the in-vitro assay.

      We thank the referee for this important comment and apologize for our overly specific interpretation of the two velocity populations. We agree that a reduced velocity alone is insufficient to identify an autoinhibited state. The principal purpose of the experiments in Figure 2 was to determine the maximum in vitro velocities attainable by the individual motor proteins and to assess whether these were compatible with the transport velocities measured in vivo. For this reason, we removed the distal C-terminal stalk and tail regions and replaced the native dimerization regions with a GCN4 leucine zipper, thereby minimizing potential regulatory effects arising from the native stalk and tail.

      We have therefore revised the manuscript to remove the terms “autoinhibited” and “active” when referring to these populations. We now describe them operationally as “slow-moving” and “fast-moving” populations.

      We agree that measurements of microtubule-binding or landing rates, together with reconstitution using defined IFT components, would be valuable for resolving the mechanism underlying the different motile states. However, such experiments would require a systematic analysis of motor–IFT interactions and stoichiometrically defined complexes and are beyond the principal scope of the present study, which is focused on the composition, function and evolutionary diversification of kinesin-2 complexes.

      • Figure 3A: In the SDS-PAGE, the apparent sizes of KIN2A and KIN2B proteins appear larger than expected. The authors should clarify whether this is due to tags, unusual amino acid composition, gel conditions, or known anomalous migration of these constructs. Both proteins migrate at the expected position (124 kDa for KIN2A and 126 kDa for KIN2B). To make this clearer, we have added the position of the 130kDa molecular marker on Figure 3A-D. Images of the whole gels (Fig. 3A-D) are shown below.

      • Figure 3D: The co-immunoprecipitation experiments require additional controls to support the conclusions. Specifically, the authors should include input (total lysates) lanes prior to immunoprecipitation and compare His-tagged KIN2B levels between co-immunoprecipitated and flow-through fractions. Reciprocal co-immunoprecipitation (e.g., pull-down via His-tag followed by anti-Flag Western blotting) would further strengthen the evidence. The experiment has been repeated to include input (total lysates, new Fig. 3D, lanes e,f) and with reciprocal co-immunoprecipitation, either with Flag-tagged KIN2A (new Fig. 3D, lanes a-b) or 6xHis tagged KIN2B (new Fig. 3D, lane c-d). It further confirms that KIN2A cannot pull down KIN2B and vice-versa.

      • Figure 5H: The observation that KIN2A (0.88 {plus minus} 0.19 trains/s) and KIN2B (1.18 {plus minus} 0.18 trains/s) are lower than IFT81 (1.31 {plus minus} 0.21 trains/s) does not by itself prove that "neither motor alone can perform with the whole anterograde transport". These frequency differences could arise if KIN2A and KIN2B are not independent transport populations. The key missing test is whether KIN2A and KIN2B bind the same IFT trains. If such an experiment is technically infeasible, the language should be toned down. We agree and have modified the text accordingly:

      “This suggests that neither KIN2A nor KIN2B alone could perform the whole anterograde transport of IFT complexes. If KIN2A and KIN2B are binding independently to IFT trains, the sum would be too high to explain the frequency of IFT81 trafficking. However, two other options could be considered: either some kinesins do not associate to IFTs or some KIN2A and KIN2B associate together to the same IFT train.”

      The ideal experiment would be to follow KIN2A and KIN2B simultaneously with reporters of different colours. We tried tagging KIN2A and KIN2B with various reporters (GFP, YFP, mCherry, tdTomato, mNG, mScarlet), but so far only mNG worked, so it’s not been possible to do two-colour imaging.

      Another option was to monitor mNG::KIN2A simultaneously with a fluorescent IFT marker (as for KIN2B and IFT140, Figure 6 & Video S7), but unfortunately all the attempted combinations failed, either because cell lines did not grow or because the signal for one of the two markers was lost.

      • Figure 7B: Douglas et al. (JCS, 2020) reported suppressed cell proliferation, cytokinesis, and motility in KIN2A-depleted T. brucei cells, but not in KIN2B-depleted cells. The authors should discuss how their findings differ from the previous report. As discussed above and now modified in the text (see response to point 1 of reviewer 1), this is explained by two reasons. First, there is a clear difference in RNAi efficiency in the published study with only 10% mRNA left for KIN2A but still 30% for KIN2B. Second, the 2020 work was performed in the bloodstream stage of T. brucei, which is more sensitive to flagellar pertubations than the procyclic stage (Broadhead et al. 2006; Ralston & Hill, 2006 [34, 35]). Here, we used complete gene deletion in L. mexicana or Cas9-guide disruption with interruption of all three reading frames in T. brucei. In these conditions, the KIN2B gene product is absent, leading to the strong phenotype observed for both organisms. This is now mentioned in the discussion (p. 21):

      “These results differ from the RNAi knockdown results published on the bloodstream stage of the parasite where knockdown of KIN2A, but not KIN2B, turned out to be lethal. This could be explained by the less potent efficiency of RNAi against KIN2B [30]. Since bloodstream cells are more sensitive to flagellar perturbations [34, 35], the reduced flagellar length observed here upon deletion of KIN2A might be sufficient to interfere with cell division.”

      • Formatting: Some paragraphs are very long and would benefit from division into shorter paragraphs. Similarly, substructuring the long discussions with subheadings aligned with the results would improve readability. We have improved the presentation of the manuscript by splitting some paragraphs and have added subheadings in the discussion.

      Reviewer #2 (Significance (Required)):

      While the existence of KIN2A and KIN2B has been reported previously, their ability to form a homodimer and their distinct contributions to flagella assembly and IFT have not been clearly established. The manuscript further discusses the evolutionary origin of IFT-transporting motors, expands on the separability of import into cilia and of transport along the axoneme, and, for the first time, demonstrates that homodimeric motors can build cilia. Thus, it is expected that the manuscript will appeal to a broad readership.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary: In this manuscript, the authors characterize kinesin-2, which is responsible for flagellum formation and function in Trypanosoma brucei and Leishmania mexicana. They show that T. brucei kinesin-2 comprises KIN2A and KIN2B proteins, each of which forms a homodimer and moves processively along microtubules in vitro. In cells, KIN2A and KIN2B exhibit distinct behaviors: KIN2A moves faster and traverses the full length of the flagellum, whereas KIN2B is slower and enriched near the flagella base. KIN2A KO mutants are cilia assembly competent and display only mild effects on IFT transport and flagellum assembly, while KIN2B KO mutants fail to assemble a normal flagellum. KIN2B-depleted cells are largely non-flagellated, with a clearly shortened flagellum remnant. Notably, KIN2A trafficking appears largely normal within these short flagella, indicating that KIN2A can still access the flagellum in the absence of KIN2B. Based on these findings, the authors propose a division-of-labor model in which KIN2B is primarily responsible for importing IFT components, whereas KIN2A performs most anterograde transport within the flagellum.

      Comments: Overall, the authors use a broad range of biochemical and cell-biological approaches to define the properties of Trypanosome kinesin-2 and conclude with a compelling working model. While the experiments appear carefully executed, the results are generally convincing, several points should be addressed before publication:

      • Figure 2: The in vitro reconstitution assays show two velocity populations for KIN2A (slow and fast), and a slow-moving population is also observed for GCN4-fused KIN2B. The authors interpret the slow-moving populations as "autoinhibited" conformations and the fast populations as "active". Consistently, in live-imaging (Figure 6E), proximal KIN2B particles move slowly when not co-localizing with IFT140 but move faster when associated with IFT trains. This suggests multiple motile states may reflect regulation by tail conformation and/or cargo loading rather than canonical autoinhibition. By definition, many autoinhibited kinesins are characterized by reduced microtubule engagement (or failure to bind) rather than simply reduced velocity. Therefore, it is not yet clear that the slow populations observed here should be described as autoinhibited. It rather seems more akin to a 'gear shifting' mechanism described for kinesin-1, -2, and -3 (Coppin et al, 1997; Gicking et al., 2022). Otherwise, if the authors retain this terminology, they should provide additional evidence, such as microtubule-binding affinity measurements for the slow vs. fast populations. It would also be informative to test whether kinesin-2 velocities shift in the presence of defined cargo/IFT components in the in-vitro assay.
      • Figure 3A: In the SDS-PAGE, the apparent sizes of KIN2A and KIN2B proteins appear larger than expected. The authors should clarify whether this is due to tags, unusual amino acid composition, gel conditions, or known anomalous migration of these constructs.
      • Figure 3D: The co-immunoprecipitation experiments require additional controls to support the conclusions. Specifically, the authors should include input (total lysates) lanes prior to immunoprecipitation and compare His-tagged KIN2B levels between co-immunoprecipitated and flow-through fractions. Reciprocal co-immunoprecipitation (e.g., pull-down via His-tag followed by anti-Flag Western blotting) would further strengthen the evidence.
      • Figure 5H: The observation that KIN2A (0.88 {plus minus} 0.19 trains/s) and KIN2B (1.18 {plus minus} 0.18 trains/s) are lower than IFT81 (1.31 {plus minus} 0.21 trains/s) does not by itself prove that "neither motor alone can perform with the whole anterograde transport". These frequency differences could arise if KIN2A and KIN2B are not independent transport populations. The key missing test is whether KIN2A and KIN2B bind the same IFT trains. If such an experiment is technically infeasible, the language should be toned down.
      • Figure 7B: Douglas et al. (JCS, 2020) reported suppressed cell proliferation, cytokinesis, and motility in KIN2A-depleted T. brucei cells, but not in KIN2B-depleted cells. The authors should discuss how their findings differ from the previous report.
      • Formatting: Some paragraphs are very long and would benefit from division into shorter paragraphs. Similarly, substructuring the long discussions with subheadings aligned with the results would improve readability.

      Significance

      While the existence of KIN2A and KIN2B has been reported previously, their ability to form a homodimer and their distinct contributions to flagella assembly and IFT have not been clearly established. The manuscript further discusses the evolutionary origin of IFT-transporting motors, expands on the separability of import into cilia and of transport along the axoneme, and, for the first time, demonstrates that homodimeric motors can build cilia. Thus, it is expected that the manuscript will appeal to a broad readership.

    1. Most tags are simple labels, but it is possible to use parameters within tags. For example, you could use the tag importance with different parameters for each level of importance. So one piece of text might contain the tag #importance(low), and another #importance(high).

      Bulid nest-like tags.

    1. Author response:

      The following is the authors’ response to the original reviews.

      We are grateful to all the reviewers for dedicating time to review our manuscript and for providing insightful comments and suggestions. We have revised our manuscript in line with the reviewers' feedback. The major revisions include characterization of Dcp-1 overexpression-induced cell death, demonstration of the involvement of autophagy in Dcp-1 activation, characterization of the interaction between full-length Bruce and cleaved Dcp-1. We have introduced new figures (Figure 1 – figure supplement 1, Figure 2 – figure supplement 2, Figure 3 – figure supplement 1, Figure 5 – figure supplement 1), new panels (Figures 1D, Figure 3C, Figure 4I, J) and a new table (Table S2). The previous Figure 5 – figure supplement 1 has been relocated to Figure 4 – figure supplement 2.

      With all concerns and suggestions from the reviewers addressed, our conclusion—that Bruce suppresses autophagy-regulated caspase activity and wing tissue growth in Drosophila— is now more robustly supported. We are confident that our revised manuscript makes a significant contribution to the fields of cell death, autophagy, and developmental biology, as it provides a new conceptual framework for understanding non-lethal caspase regulation. We remain hopeful that the reviewers will find it suitable for publication in eLife.

      Reviewer #1 (Public review):

      Summary:

      The authors clearly demonstrate that overexpressed Dcp-1, but not Drice, is activated without canonical apoptosome components. Using TurboID-based proximity labeling, they revealed distinct proximal proteomes, among which Sirtuin 1, an Atg8a deacetylase, which promotes autophagy, was specifically required for Dcp-1 activation. Additionally, the show that autophagy-related genes, including Bcl-2 family members Debcl and Buffy, are required for Dcp1 activation. Using structure-based prediction using AlphaFold3, they identified that Bruce, an autophagy-regulated inhibitor of apoptosis, acts as a Dcp-1-specific regulator acting outside the apoptosome-mediated pathway. Finally, they show that Bruce suppresses wing tissue growth. These findings indicate that non-lethal Dcp-1 activity is governed by the autophagy-Bruce axis, enabling distinct non-lethal functions independent of cell death.

      Strengths:

      This is an excellent paper with very good structure, excellent quality data and analysis.

      Weaknesses:

      This reviewer did not identify any weaknesses or recommendations for revision.

      We sincerely thank the reviewer for their highly positive evaluation of our work. We are pleased that the reviewer found the overall structure, data quality, and analyses to be strong, and that they clearly recognized the key findings of our study. No changes to the manuscript were required in response to this review.

      Reviewer #2 (Public review):

      Summary:

      The Drosophila executioner caspase Dcp-1 has established roles in cell death, autophagy, and imaginal disc growth. This study reports previously unrecognized factors that work together with Dcp-1. Specifically, the authors performed a turboID-based proximal ligation experiment to identify factors associated Dcp-1 and Drice. Dcp-1-specific interactors were further examined for their genetic interaction. The authors report autophagy-related genes, including Debcl and Buffy, to be required for Dcp-1 activation. In addition, the authors present evidence of an interaction between Bruce and Dcp-1. Bruce-expression blocks the Dcp-1 overexpression phenotype. Inhibition of effector caspases or overexpression of Bruce commonly reduced wing growth, suggesting a relationship between the two proteins.

      Strengths:

      On the positive side, the study identifies new Dcp-1-interacting proteins and provides a functional link between Dcp-1 and Sirt1, Fkbp59, Debcl, Buffy, Atg2, and Atg8a.

      Weaknesses:

      The data supporting the Dcp-1/Bruce interaction are not strong, even though the title of this manuscript highlights Bruce. For example, the authors' turboID data does not support Dcp1/Bruce interaction. The case for the interaction is based on a single experiment that overexpresses a truncated Bruce transgene in S2 cells.

      We sincerely thank the reviewer for their constructive and detailed evaluation of our manuscript. We appreciate the positive assessment that our study identifies new Dcp-1-associated factors and provides functional links between Dcp-1 and Sirt1, Fkbp59, and multiple autophagy-related genes, including Debcl, Buffy, Atg2, and Atg8a. We also thank the reviewer for clearly pointing out concerns regarding the strength and interpretation of the evidence connecting Bruce and Dcp-1. In the revised manuscript, we have addressed these concerns in two major ways. First, we provided additional experimental evidence explaining why TurboID-mediated labeling did not identify Bruce. Specifically, we showed that the majority of TurboID-tagged Dcp-1 expressed in wing imaginal discs remains in its full-length form, which is unlikely to engage Bruce. Second, and more importantly, we now demonstrated that endogenously expressed full-length Bruce interacts with cleaved Dcp-1 in wing imaginal discs. These new data provide strong support for a physiologically relevant interaction between Bruce and cleaved Dcp-1. Detailed descriptions of these experiments and results are provided in the point-by-point responses in the “recommendations for the authors” section. Together, these newly added data substantially strengthen the evidence for the Dcp-1/Bruce interaction and support the focus of the original manuscript title.

      Reviewer #2 (Recommendations for the authors):

      (1) The title of the manuscript highlights Dcp-1/Bruce interaction, even though the evidence there is not strong. The evidence for Dcp-1/Sirt1 and Dcp-1/Fkbp59 is stronger. How about changing the title to highlight these other Dcp-1 interactions?

      We thank the reviewer for the thoughtful suggestion. We agree that several Dcp-1-associated factors identified in our study, particularly Sirt1 and Fkbp59, are supported by functional evidence. Specifically, our data show that Sirt1 and Fkbp59 are required for Dcp-1 overexpression-mediated activation. However, Bruce differs from these factors in both the scope and the nature of its effects on Dcp-1. Bruce is not only shown to specifically suppress Dcp-1 activity, but also to suppress wing tissue growth, indicating a broader physiological role in modulating non-lethal Dcp-1 function. Importantly, we further demonstrate that Bruce can specifically physically interact with cleaved Dcp-1. In addition, in this revised manuscript, we show that using the endogenously mStayGold::V5-tag knock-in-tagged Bruce allele, cleaved Dcp-1, induced by overexpression of Dcp-1::VENUS in wing imaginal discs, can be co-immunoprecipitated with full-length Bruce (new Figure 4I, J). These results support a physical interaction between full-length Bruce and activated Dcp-1 in vivo, consistent with a direct inhibitory role. Based on these findings, we decided to retain Bruce in the manuscript title, as it is the only factor for which both physiological and functional interactions with Dcp-1 are supported by multiple independent lines of evidence.

      (2) The case for Dcp-1/Bruce interaction is not strong because the Dcp-1 turboID fails to identify Bruce. In fact, the Dcp-1 turboID approach may not have been effective, as it failed to detect many established interactions, including Diap1 (Wang et al. 1999 PMID 10481910; Tenev et al., 2006 PMID 15580265). The authors may want to comment on this.

      We thank the reviewer for raising this important point. We agree that Bruce, as well as DIAP-1, was not identified in our TurboID-MS labeling dataset (Figure 2C, Table S1). Previous studies have shown that DIAP1 interacts with Dcp-1 and Drice only after exposure of the IAP-binding motif (IBM) at the neo-N-terminus of the large executioner caspase subunit following cleavage (Tenev et al., 2005). Similarly, our co-immunoprecipitation analyses show that Bruce interacts specifically with cleaved Dcp-1, but not with full-length Dcp-1. In the revised manuscript, we confirmed by western blot that the majority of endogenously expressed Dcp-1 in wing imaginal discs is present in the full-length pro-form (new Figure 2 – figure supplement 2A). Thus, the failure to identify Bruce and DIAP1 by TurboID-MS using full-length Dcp-1 as bait is expected, as this approach primarily labels interactors of the inactive, full-length form of Dcp-1. To evaluate whether our proximity labeling approach was nevertheless effective, we compared our TurboIDMS dataset with a previously published immune-affinity purification (IAP)-MS dataset generated using catalytically inactive, C-terminally V5-tagged Dcp-1 overexpressed in Drosophila 1(2)mbn cells (Choutka et al., 2017). Although the experimental conditions differ in several respects, we observed a substantial overlap between the TurboID-MS-mediated and IAP-MS-mediated interaction lists (new Figure 2 – figure supplement 2B, new Table S2). Importantly, SesB, one of the best-characterized Dcp-1 interactors located in mitochondria (DeVorkin et al., 2014), was also identified in our mass spectrometry dataset (new Figure 2 – figure supplement 2B, new Table S2). Based on these analyses, we now more explicitly describe the experimental context and limitations of the TurboID approach, clarifying that it preferentially labels interactors of full-length Dcp-1 in the revised manuscript. We also incorporate comparisons with prior studies to further support the validity of our mass spectrometry experiments in the revised manuscript

      (3) The best experimental evidence for Bruce/Dcp-1 interaction can be found in Figure 4H. But here, they see a weak interaction only when a truncated Bruce construct is overexpressed in S2 cells. Whether Dcp-1 interacts with Bruce in a physiological setting remains unsupported.

      We thank the reviewer for the important comment. We agree that, in the original manuscript, the biochemical evidence for the Bruce/Dcp-1 interaction relied primarily on experiments using an overexpressed truncated Bruce construct in S2 cells and therefore did not sufficiently establish whether this interaction occurs in vivo, especially in wing imaginal discs. To address this concern, we performed additional experiments to examine the Bruce/Dcp-1 interaction. In the background of the mStayGold::V5-tag knocked-in Bruce allele, we overexpressed Dcp-1::VENUS using WPGal4 driver to induce Dcp-1 activation and tested whether full-length Bruce under endogenous expression interacts with cleaved Dcp-1 in wing imaginal discs. Following immunoprecipitation with anti-V5 antibody-conjugated magnetic agarose, we found that cleaved Dcp-1 signal was enriched by co-immunoprecipitation (new Figure 4I, J). These new data demonstrate that Bruce associates with cleaved Dcp-1 in vivo and thus support the physiological relevance of the Bruce/Dcp-1 interaction. We have clarified this point in the revised manuscript and included the corresponding data.

      (4) The genetic interaction between Bruce and Dcp-1 is interesting, but the interpretation becomes complicated because Bruce inhibits Reaper, and at the same time, Dcp-1 genetically interacts with Reaper, Hid, and Grim (Figures 1E, F, G). Thus, it remains unclear if the genetic interaction between Bruce/Dcp-1 is due to a direct interaction between Bruce/Dcp-1 or alternatively, because Bruce inhibits Reaper and Grim.

      We thank the reviewer for the comment. The primary function of Reaper, Hid, and Grim (RHG proteins), collectively referred to as IAP antagonists, is to directly interact with inhibitor of apoptosis proteins (IAPs), most notably DIAP-1 (Kornbluth and White, 2005; Ryoo and Baehrecke, 2010), leading to the inhibition of DIAP-1 function. RHG proteins have not been shown to directly inhibit caspases. Because inhibition of RHG proteins results in the stabilization of DIAP-1, it is likely that the effects observed upon RHG gene knockdown are mediated through DIAP-1. Consistent with this idea, overexpression of DIAP-1, while less potent than Bruce, can also suppress Dcp-1 activation (Figure 5B, C). However, we also acknowledge that Bruce suppresses Reaper- and Grim-dependent, but not Hid-dependent, cell death (Vernooy et al., 2002). In addition, Bruce directly targets Reaper through non-lysine ubiquitination, promoting its degradation (Domingues and Ryoo, 2012). Thus, it is possible that Bruce overexpression suppresses Reaper and thereby strengthens DIAP-1 function, which could indirectly contribute to the inhibition of Dcp-1 activation. Nevertheless, because the effect of Bruce overexpression is stronger than that of DIAP-1 overexpression (Figure 5B, C), and together with our physical interaction data of Bruce with cleaved Dcp-1, we propose that Bruce most likely inhibits Dcp-1 directly to attenuate its activation.

      (5) In general, the manuscript could benefit from highlighting the strong data on Sirt1 and Fkbp59, while clearly acknowledging the limitations of the Bruce/Dcp-1 interaction.

      We thank the reviewer for the comment. As described above, in the revised manuscript we now demonstrate that endogenously expressed full-length Bruce physically interacts with cleaved Dcp-1 in wing imaginal discs (Figure 4I, J). These new data provide strong support for a physiologically relevant interaction between Bruce and cleaved Dcp-1. Based on this evidence, we decided to highlight Bruce in the manuscript, as it is the only factor for which both physiological and functional interactions with Dcp-1 are supported by multiple independent lines of evidence.

      Reviewer #3 (Public review):

      Summary:

      The present paper by Shinoda et al. from the Miura group builds upon findings reported in an earlier study by the same team (Shinoda et al., PNAS, 2019), which identified a nonapoptotic role for the Drosophila executioner caspase Dcp-1 in promoting wing tissue growth. That earlier work attributed this function primarily to Dcp-1 and to Decay, a caspase structurally related to executioner caspases, but not to DrICE, the principal apoptotic executioner caspase. The authors further proposed that this non-apoptotic caspase activity operates independently of the initiator caspase Dronc.

      In the current study, the authors both corroborate aspects of their previous findings and extend the investigation to mechanisms regulating Dcp-1 in this context. They identify roles for the giant IAP Bruce, two BCL-2 family members, and autophagy-related components in modulating nonapoptotic Dcp-1 activity. Moreover, they show that Bruce binds to a BIR-like peptide exposed upon Dcp-1 cleavage, but not to DrICE. The study further suggests that low levels of Dcp-1 activity promote wing tissue growth, whereas excessive activity induces cell death, as evidenced by impaired wing development following Dcp-1 overexpression. Overall, the manuscript provides several intriguing insights into the non-apoptotic regulation of the comparatively weak apoptotic executioner caspase Dcp-1 and complements the group's earlier work. However, several concerns remain regarding certain interpretations of the data and the experimental rigour of some of the results.

      Strengths:

      A major strength of the work is its systematic genetic and biochemical approaches, which combine tissue-specific manipulation with protein interaction mapping to explore how Dcp-1 is regulated. The identification of several regulatory factors, including an inhibitor of cell death protein and components linked to autophagy, provides a coherent framework for understanding how Dcp-1 activity might be tuned.

      Weaknesses:

      The evidence supporting some key claims remains incomplete. In particular, the type of cell death form induced when Dcp-1 is overexpressed is not clearly established, and additional tests would be needed to distinguish between the different cell death types.

      Likely impact:

      The study contributes to a growing body of work showing that proteins traditionally associated with cell death can have broader roles in tissue development. This conceptual advance is likely to be of interest to researchers studying growth control and tissue maintenance.

      We sincerely thank the reviewer for their thoughtful and constructive evaluation of our study. In response to these concerns, we have performed additional experiments to clarify the nature of the cell death induced by Dcp-1 overexpression. Based on the detection of cleaved Dcp-1, the detection of executioner caspase activity, and TUNEL assay, we now conclude that excessive Dcp-1 expression induces typical executioner caspase activity-dependent apoptotic cell death. Detailed explanations and experimental results are provided in the point-by-point responses below. Overall, we believe that these additions strengthen the manuscript by clarifying the dual roles of Dcp-1 in promoting tissue growth at low activity levels while triggering apoptosis when excessively activated.

      Specific points:

      (1) Nature of the wing ablation phenotype

      A central concern is whether the wing ablation phenotype observed upon Dcp-1 overexpression truly reflects apoptotic cell death. The authors show in Figure 1c that nuclei in cells overexpressing Dcp-1, but not DrICE, zymogens are highly condensed, which is suggestive of apoptosis. However, it is equally plausible that this phenotype reflects a form of non-apoptotic, Dcp-1-dependent cell death (e.g. autophagy-dependent cell death). This distinction could be readily addressed using TUNEL labelling and direct caspase activity assays. The latter would be particularly informative, as it remains unclear whether zymogen Dcp-1 is capable of cleaving standard effector caspase reporters in vivo. Does the anti-cleaved Dcp-1 antibody detect Dcp-1 activation following overexpression of the Dcp-1 zymogen?

      We thank the reviewer for this important point regarding the nature of cell death. We agree that nuclear condensation alone is not sufficient to conclude apoptotic cell death, and we therefore performed additional experiments. First, we performed TUNEL staining and detected robust TUNEL-positive signals in wing imaginal discs upon Dcp-1 overexpression (new Figure 1D), supporting apoptotic DNA fragmentation. Second, to directly test whether Dcp-1 overexpression leads to executioner caspase activity in vivo, we used two independent executioner caspase activity probes, GC3Ai (Schott et al., 2017; Zhang et al., 2013) and CD8::PARP::VENUS (Williams et al., 2006). Both probes showed clear executioner caspase activity-positive signals in wing imaginal discs upon Dcp-1 overexpression (new Figure 1 – figure supplement 1C–F), demonstrating that Dcp-1 overexpression leads to executioner caspase activity capable of cleaving standard substrates in vivo. In addition, staining with an anti-cleaved Dcp-1 antibody was positive upon Dcp-1 zymogen overexpression (new Figure 1 – figure supplement 1B), indicating that the overexpressed Dcp-1 zymogen is converted into its active form. Consistent with this result, western blot analysis revealed that Dcp-1 zymogen overexpression results in the appearance of a cleaved Dcp-1 (new Figure 1 – figure supplement 1A). Importantly, consistent with our original observation that the wing ablation phenotype is suppressed by expression of the caspase inhibitor p35, we further showed that p35 overexpression completely abolished the appearance of cleaved Dcp-1 in western blot (new Figure 1 – figure supplement 1A), suggesting that Dcp-1 activation is mediated by self-cleavage. Taken together, these new results demonstrate that Dcp-1 zymogen overexpression induces typical executioner caspase activity-dependent apoptotic cell death. We have clarified this point in the revised manuscript and included the corresponding data.

      (2) Role of Decay

      In their earlier study, the authors identified Decay as another caspase influencing wing growth, albeit more modestly than Dcp-1. It is therefore unclear why this line of investigation was not pursued further in the current work. This omission is notable, as Decay is not implicated in apoptosis and, to date, no substantial physiological function has been assigned to this caspase in any system. At a minimum, this point should be discussed explicitly.

      We thank the reviewer for the comment regarding the role of Decay. In our previous study (Shinoda et al., 2019), we demonstrated that both Dcp-1 and Decay promote wing tissue growth in a non-lethal manner. In the present study, however, we focused our analysis on Dcp-1. This decision was based on both technical and biological considerations. From a technical perspective, we had established TurboID knock-in lines and UAS overexpression lines for Dcp-1, Drice, and Dronc, whereas corresponding genetic tools are not available for Decay. From a biological standpoint, Dcp-1 exerts a stronger effect on wing growth than Decay, as shown in our previous work, and exhibits a dual functional spectrum: Dcp-1 promotes tissue growth at low activity levels, whereas excessive activation induces overt cell death. By contrast, Decay has not been implicated in cell death in wing imaginal discs (Kondo et al., 2006). Given that a central aim of the present study was to dissect how executioner caspase activity is differentially regulated to support nonlethal functions versus apoptotic cell death, we therefore focused on the two executioner caspases that are known to participate in apoptosis, Dcp-1 and Drice. We agree with the reviewer that Decay remains an intriguing caspase with largely unexplored physiological roles, and further investigation into its regulation and function will be an important direction for future studies. Importantly, Decay has been shown to mediate Hid-induced cell death in the DIAP1- and apoptosome-independent manner in differentiating photoreceptors and accessory cells of the eye (Leulier et al., 2006). In addition, although not required for cell death, Decay accounts for most of the caspase activity during metamorphic midgut programmed cell death, which is executed by autophagy (Denton et al., 2009). Thus, similar to Dcp-1, Decay might be an executioner caspase that can be regulated independently of the canonical apoptosome-mediated pathway, potentially involving autophagy-Bruce axis, and thereby contributing to the regulation of tissue growth. We have now discussed this point in the revised manuscript.

      (3) Figure 2: Proximity labelling analysis

      The authors use TurboID-mediated proximity labelling to reveal distinct Dcp-1- and DrICEassociated proteomes across tissues, with a particular focus on the wing disc. They further demonstrate that RNAi-mediated knockdown of the Dcp-1-associated proteins Sirt1 and Fkbp59 suppresses the wing ablation phenotype induced by Dcp-1 overexpression, suggesting that these factors are required for Dcp-1 activity. However, it should be clarified whether Bruce was identified as a Dcp-1 interactor in the proximity labelling dataset, given its proposed central regulatory role. In addition, further discussion of Fkbp59, its known functions and how it might mechanistically influence Dcp-1 activity would be valuable.

      We thank the reviewer for the comment regarding the TurboID-based proximity labeling analysis and the interpretation of the identified Dcp-1-associated factors. With respect to Bruce, we clarify that Bruce was not identified as a Dcp-1 interactor in the TurboID proximity labeling dataset. Our co-immunoprecipitation analyses in S2 cells indicate that Bruce interacts specifically with cleaved Dcp-1, but not with the full-length, inactive form. In the revised manuscript, we confirmed by western blot that the majority of endogenously expressed Dcp-1 in wing imaginal discs exists in the full-length pro-form (new Figure 2 – figure supplement 2A). Therefore, the failure to detect Bruce in the TurboID experiment using full-length Dcp-1 as bait is expected, as this approach primarily labels proteins proximal to the inactive form of Dcp-1. To examine the Bruce/Dcp-1 interaction under more physiological conditions, we performed additional in vivo experiments. Using the mStayGold::V5-tag knock-in allele of Bruce, we overexpressed Dcp1::VENUS using WP-Gal4 driver to induce Dcp-1 activation and assessed whether endogenously expressed full-length Bruce associates with Dcp-1 in wing imaginal discs. Following immunoprecipitation with anti-V5 antibody-conjugated magnetic agarose, we found that cleaved Dcp-1 signal was enriched by co-immunoprecipitation (new Figure 4I, J). These new data demonstrate that Bruce associates selectively with the cleaved, active form of Dcp-1 in vivo, thereby supporting the physiological relevance of the Bruce/Dcp-1 interaction. We have clarified this point in the revised manuscript and included the corresponding data.

      FK506-binding proteins (FKBPs) are a conserved group of proteins known to bind FK506, an immunosuppressive drug. FKBPs contain FK domains, which correspond to peptidyl cis-trans isomerase (PPIase) domains. Drosophila Fkbp59 is an orthologue of the mammalian FKBP4 and FKBP5, both of which possess a C-terminal tetratricopeptide repeat (TPR) domain that functions independently of the PPIase domain by mediating protein-protein interactions. The mammalian orthologues of Drosophila Fkbp59 function as Hsp90 co-chaperones (GharteyKwansah et al., 2018). Importantly, loss of Fkbp59 results in pupal lethality (Iki et al., 2020), which precludes further mechanistic analysis on Dcp-1 activation using adult wing phenotypes. To date, the involvement of Fkbp59 in caspase regulation has not been reported. Given that Fkbp59 functions as a co-chaperone, it may facilitate Dcp-1 activation by promoting proper folding, stability, or subcellular positioning of Dcp-1 or its regulatory factors. Importantly, Dcp1 proximal proteins are enriched in chaperone-related factors, including CCT2, CCT8, Droj2, CG16817, Fkbp59, Sgt1, and nudC; seven out of sixteen identified proximal proteins are chaperone-related. These observations suggest that Dcp-1 activity may be regulated by chaperone proteins or that Dcp-1 activity may be spatially restricted to regions enriched in chaperone machinery. Further analysis of the relationship between Dcp-1 activity and chaperone-related proteins will be important to elucidate the mechanisms and functions underlying non-lethal Dcp1 activation.

      (4) Figure 3: Autophagy-related factors

      Given that Sirt1 is known to promote autophagy, the authors next examine autophagy-related proteins and identify roles for Atg2, Atg8a, Debcl, and Buffy in Dcp-1 activation. Notably, these proteins do not promote cell death in the Hid-induced canonical apoptotic pathway. However, it is important to determine whether knockdown of Debcl, Buffy, Atg2, or Atg8a alone affects wing development in the absence of Dcp-1 overexpression, to exclude the possibility that these perturbations independently impair wing formation.

      We thank the reviewer for the comment. To address whether knockdown of Debcl, Buffy, Atg2, or Atg8a independently affects wing development, we performed RNAi-mediated knockdown of each gene using the WP-Gal4 driver in the absence of Dcp-1 overexpression. Under these conditions, knockdown of Debcl, Buffy, Atg2, or Atg8a did not cause any detectable defects in wing morphology (new Figure 3 – figure supplement 1A), indicating that these autophagy-related factors specifically function to suppress Dcp-1-mediated cell death. We have clarified this point in the revised manuscript and included the corresponding data.

      (5) Evidence for canonical autophagy

      The involvement of autophagy would be more convincingly demonstrated by testing additional core autophagy genes, such as Atg7, Atg5, and Atg12, as well as performing a combined knockdown of Atg8a and Atg8b. Moreover, direct assessment of autophagy at the cellular level using established genetic reporters would substantially strengthen the conclusions.

      We thank the reviewer for the constructive comment regarding the involvement of canonical autophagy. To further strengthen the evidence that autophagy is required for Dcp-1 activation, we examined additional core autophagy-related genes that function at distinct steps of the autophagy process, in addition to the previously tested Atg2, which mediates autophagosomal membrane expansion, and Atg8a, a core component directly associated with autophagosomal membranes. Specifically, we performed knockdown of genes including FIP200/Atg17, which is required for the initiation of autophagosome formation; Atg9, which is required for autophagosomal membrane nucleation; Atg5, which is required for autophagosomal membrane expansion through Atg12-Atg5-Atg16 ubiquitin-like conjugation system; and Stx17, which is required for autophagosome-lysosome fusion (Umargamwala et al., 2024). Because Atg8b is known to be specifically expressed in the male germline and is dispensable for autophagy, at least in fat body cells (Jipa et al., 2021), we did not further examine Atg8b in wing imaginal discs. Using WPGal4 driver, knockdown of each of these genes significantly suppressed Dcp-1-induced wing ablation phenotype (new Figure 3 – figure supplement 1C), supporting a requirement for canonical autophagy components across multiple stages of autophagosome biogenesis in Dcp-1 activation. Importantly, knockdown of these autophagy-related genes alone did not affect wing morphology in the absence of Dcp-1 overexpression (new Figure 3 – figure supplement 1B), as observed previously for Atg2 and Atg8a, suggesting the suppressive effects are specific to Dcp-1 overexpression-dependent cell death. Together, these results indicate that inhibition of autophagy at any of several key steps can suppress Dcp-1-dependent cell death, demonstrating that intact canonical autophagy is required for Dcp-1 activation. In addition, to directly assess autophagy at the cellular level, we monitored autophagosome formation using mCherry::Atg8a reporter. Upon overexpression of Dcp-1::VENUS in the wing pouch region, we observed a clear accumulation of Atg8a-positive puncta in wing imaginal discs (new Figure 3C), demonstrating that Dcp-1 overexpression induces autophagy in vivo. Together, these results provide both genetic and cellular evidence that canonical autophagy is activated upon Dcp-1 overexpression and is required for Dcp-1-dependent cell death. We have clarified this point in the revised manuscript and included the corresponding data.

      (6) Figures 4-5: Functional consequences

      It would be informative to determine whether Synr, Debcl, or Buffy influence wing size on their own and whether their overexpression enhances wing growth.

      We thank the reviewer for the suggestion regarding the functional consequences of Synr, Debcl, and Buffy on wing size. As requested, we knocked down Debcl or Buffy using WP-Gal4 driver and found that this led to reduced wing size (new Figure 5 – figure supplement 1A), indicating that endogenous Debcl and Buffy promote wing growth potentially through regulating endogenous Dcp-1 activity. We have included the corresponding data in the revised manuscript. Because Synr RNAi did not show any detectable effect on the Dcp-1 overexpression-induced phenotype (Figure 3A, B), we did not further examine the effect of Synr knockdown on wing development alone. Overexpression of Synr was not examined in this study. However, Synr overexpression has previously been reported to induce cell death in wing imaginal discs, resulting in malformed adult wings (Ikegawa et al., 2023), suggesting that increased Synr expression is likely to have deleterious rather than growth-promoting effects. Because Debcl and Buffy are both required for Synr-induced cell death, overexpression of Debcl or Buffy may lead to similar phenotypes. Therefore, we did not test Debcl or Buffy overexpression in the wing imaginal discs.

      (7) Terminology and interpretation of cell death

      Taken together, the results suggest that Dcp-1 zymogen overexpression induces a form of nonapoptotic cell death, potentially autophagy-dependent or related. The reviewer does not understand the authors' insistence on referring to this process as apoptosis. The authors should be more cautious in their terminology: there is no canonical versus non-canonical apoptosis; there is simply apoptosis. Without stronger evidence, these effects should not be described as apoptotic cell death.

      We thank the reviewer for the important comment on terminology and interpretation of the cell death phenotype. As explained in our response to comment #1, we have performed additional experiments to clarify the nature of the cell death induced by Dcp-1 overexpression. Based on the detection of cleaved Dcp-1, the detection of executioner caspase activity, and TUNEL assay, we now conclude that excessive Dcp-1 expression induces typical executioner caspase activity-dependent apoptotic cell death. At the same time, as explained in our response to comment #5, we provide both genetic and cellular evidence that canonical autophagy is activated upon Dcp-1 overexpression and promotes Dcp-1 activation. We recognized that the phrase “Dcp1 activity-regulating alternative apoptosis signaling pathway” used in Figure 5L could be misleading, as it may imply the existence of an “alternative apoptosis”. To avoid this confusion, we have revised the figure legend to read “autophagy-facilitated alternative caspase activation pathway.”

      Reviewer #3 (Recommendations for the authors):

      Figure 1c should be annotated more clearly so that it is evident that the images shown are grouped by genotype.

      We thank the reviewer for the helpful suggestion. We have added lines to Figure 1C to improve clarity by indicating that the images are grouped by genotype.

      References

      Choutka C, DeVorkin L, Go NE, Hou Y-CC, Moradian A, Morin GB, Gorski SM. 2017. Hsp83 loss suppresses proteasomal activity resulting in an upregulation of caspase-dependent compensatory autophagy. Autophagy 13:1573–1589.

      Denton D, Shravage B, Simin R, Mills K, Berry DL, Baehrecke EH, Kumar S. 2009. Autophagy, not apoptosis, is essential for midgut cell death in Drosophila. Curr Biol 19:1741–1746.

      DeVorkin L, Go NE, Hou Y-CC, Moradian A, Morin GB, Gorski SM. 2014. The Drosophila effector caspase Dcp-1 regulates mitochondrial dynamics and autophagic flux via SesB. J Cell Biol 205:477–492.

      Domingues C, Ryoo HD. 2012. Drosophila BRUCE inhibits apoptosis through non-lysine ubiquitination of the IAP-antagonist REAPER. Cell Death Differ 19:470–477.

      Ghartey-Kwansah G, Li Z, Feng R, Wang L, Zhou X, Chen FZ, Xu MM, Jones O, Mu Y, Chen S, Bryant J, Isaacs WB, Ma J, Xu X. 2018. Comparative analysis of FKBP family protein: evaluation, structure, and function in mammals and Drosophila melanogaster. BMC Dev Biol 18:7.

      Ikegawa Y, Combet C, Groussin M, Navratil V, Safar-Remali S, Shiota T, Aouacheria A, Yoo SK. 2023. Evidence for existence of an apoptosis-inducing BH3-only protein, sayonara, in Drosophila. EMBO J 42:e110454.

      Iki T, Takami M, Kai T. 2020. Modulation of Ago2 loading by Cyclophilin 40 endows a unique repertoire of functional miRNAs during sperm maturation in Drosophila. Cell Rep 33:108380.

      Jipa A, Vedelek V, Merényi Z, Ürmösi A, Takáts S, Kovács AL, Horváth GV, Sinka R, Juhász G. 2021. Analysis of Drosophila Atg8 proteins reveals multiple lipidation-independent roles. Autophagy 17:2565–2575.

      Kondo S, Senoo-Matsuda N, Hiromi Y, Miura M. 2006. DRONC coordinates cell death and compensatory proliferation. Mol Cell Biol 26:7258–7268.

      Kornbluth S, White K. 2005. Apoptosis in Drosophila: neither fish nor fowl (nor man, nor worm). J Cell Sci 118:1779–1787.

      Leulier F, Ribeiro PS, Palmer E, Tenev T, Takahashi K, Robertson D, Zachariou A, Pichaud F, Ueda R, Meier P. 2006. Systematic in vivo RNAi analysis of putative components of the Drosophila cell death machinery. Cell Death Differ 13:1663–1674.

      Ryoo HD, Baehrecke EH. 2010. Distinct death mechanisms in Drosophila development. Curr Opin Cell Biol 22:889–895.

      Schott S, Ambrosini A, Barbaste A, Benassayag C, Gracia M, Proag A, Rayer M, Monier B, Suzanne M. 2017. A fluorescent toolkit for spatiotemporal tracking of apoptotic cells in living Drosophila tissues. Development 144:3840–3846.

      Shinoda N, Hanawa N, Chihara T, Koto A, Miura M. 2019. Dronc-independent basal executioner caspase activity sustains Drosophila imaginal tissue growth. Proc Natl Acad Sci U S A 116:20539–20544.

      Tenev T, Zachariou A, Wilson R, Ditzel M, Meier P. 2005. IAPs are functionally non-equivalent and regulate effector caspases through distinct mechanisms. Nat Cell Biol 7:70–77.

      Umargamwala R, Manning J, Dorstyn L, Denton D, Kumar S. 2024. Understanding developmental cell death using Drosophila as a model system. Cells 13:347.

      Vernooy SY, Chow V, Su J, Verbrugghe K, Yang J, Cole S, Olson MR, Hay BA. 2002. Drosophila Bruce can potently suppress Rpr- and Grim-dependent but not Hid-dependent cell death. Curr Biol 12:1164–1168.

      Williams DW, Kondo S, Krzyzanowska A, Hiromi Y, Truman JW. 2006. Local caspase activity directs engulfment of dendrites during pruning. Nat Neurosci 9:1234–1236.

      Zhang J, Wang X, Cui W, Wang W, Zhang H, Liu L, Zhang Z, Li Z, Ying G, Zhang N, Li B. 2013. Visualization of caspase-3-like activity in cells using a genetically encoded fluorescent biosensor activated by protein cleavage. Nat Commun 4:2157.

    1. AbstractThe performance of long-read mapping is critical yet highly sensitive to parameter choices. We present CycSim, a context-aware simulator that models sequence-context-dependent errors from empirical sequencing data, coupled with a Bayesian optimization framework for systematic parameter tuning. CycSim more accurately reproduces real error profiles than existing simulators, enabling reliable simulation-based optimization. The framework identified parameter configurations that achieved 2.78-fold faster mapping for data from the newly developed Cyclone platform, and consistently improved both mapping efficiency (8.14-32.65% faster) and structural variant calling accuracy (0.75-1.70% higher F1) across ONT, HiFi, and Cyclone datasets, providing a robust and generalizable foundation for analysis-goal-driven parameter refinement.

      This work has been peer reviewed in GigaScience (see https://doi.org/10.1093/gigascience/giag079), which carries out single-anonymized peer review. These reviews are published under a CC-BY 4.0 license and were as follows:

      Reviewer 2:

      In this work, Hu et al describe CycSim, a context aware simulator for diverse long read chemistries. Using this simulator, the authors aimed to optimize the mapping parameters to improve mapping speed and accuracy of variant calls.

      This is important, given the increase in use of long read sequencing, particularly in the wake of upcoming technologies such as Cyclone. However, I have significant concerns about how the results are analyzed and work is presented. Despite it being a short article, I had to do a lot of back and forth reading due to lack of clarity in presentation. It would also help to have line numbers to point out specific places in the manuscript. Further I have some questions which the authors should address with a revision.

      CycSim is a "dual-stage framework" - Does that mean the users are expected to train with every new sample? Or the trained model can now simulate reads for any sample? How do we know the training is not over engineered for the HG002 sample, particularly the 4 chromosome subset?

      The algorithm characterizes many aspects of the read including strand, orientation etc. Are they used for training in any way?

      Are the kmer models built for each "kind" of genomic region (for example LCRs/TRs)?

      Simulation/validation is done for the same set of chromosomes as those that were used for training. How do the various parameters benchmarked in Fig 1 fare for other chromosomes which the model has not seen?

      In LCRs, CycSim outperforms other tools. This is a crucial point. But what is shown is mapping identity - as far as I know, the mapping identity in these regions should be lower. Not sure why it's higher, unless I'm misunderstanding how this is calculated. Also, it would be important to show other features of the reads such as kmer profiles and substitutions, specifically in various genomic regions, rather than mapping identity % alone.

      Regarding the parameter tuning/optimization - I have significant problems with how the data is presented. First of all, radar charts, while they look fancy, are less effective in depicting small changes, which is what the authors are trying to show here. Simple bar charts would have been way more clear. Also, this feels like an independent goal and section, and the connection with their simulation strategy is not clear.

      More importantly, why wasn't this done with reads simulated with other tools? For all we know, the optimization may have worked with reads simulated by BadRead or PBSim as well.

      The 2.78-fold increase in speed for Cyclone data is compared to map-ont preset, which by definition is not optimized for Cyclone data. While this is an important exercise and result, not sure how this is a direct benefit of CycSim. Could the mapping speed be not optimized by trying Optuna on raw Cyclone data directly?

      The authors claim that the framework is robust in optimizing parameters "across diverse sequencing platforms". But in their own words, the gains for PacBio and ONT were <0.1%.

      The truvari refine parameters had a flag -p 0.0, indicating only position (that too up to 1kb distance) was taken into account when calculating the overlap, irrespective of sequence similarity. Most people in practice keep 0.5-0.7, often with reciprocal overlap. Curious to see how the results change with such parameters.

      It is not clear whether the SNP and SV optimized parameters are the same or not. If yes, this should be clarified. If not, authors should include results on what happens to SNP accuracy when using SV specific parameters. While I agree that there is merit in using specific alignment parameters for specific tasks, in practice, users might just use the same BAM file for multiple types of variants - hence having this information can help the user in deciding which parameters they want to use.

      The gains in F1 scores are marginal. Authors should discuss if and why such marginal improvements are important.

      Other comments:

      What happens when you simulate high coverage? Would it recapitulate actual high coverage data or would there be repeated data due to limits of a kmer model?

      Was the simulation done multiple times? This should be clarified. If not done, it should be - to see how reproducible the results are.

      Thanks for providing the optimized parameters for each platform - can there be a comment on why the authors think these parameters outperform default parameters?

      Minor:

      Several typos - such as "framwork", "charaterize", and missing commas etc.

      I could not initially find cutesv results, till I stumbled upon them in the tables. Please tag the table numbers at the appropriate place in the text.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      We sincerely thank the reviewers for the time dedicated to providing us with feedback on our work. In response to their helpful remarks, we have generated new data and made several changes to the manuscript. We hope the reviewers agree that, together with the rebuttal points below, this improved version addresses their concerns.

      Reviewer #1

      Evidence, reproducibility and clarity

      In this report the authors have provided evidence for the involvement of transposable elements in the regulation of gene expression in murine trophoblast cells and placenta. They utilized data that they generated and also published data in their analyses. They concluded that the involvement of transposable elements in the regulation of genes in differentiated trophoblast cells was less than utilized in trophoblast cells in the stem state. They provide evidence for the utilization of intracisternal A particle elements in the modulation of gene transcription of the mouse placenta, which represents a more recent evolutionary adaptation. Overall the report is descriptive presenting correlations with limited testing of specific hypotheses. There is also the impression that the manuscript consists of the merging of two projects, which have not been fully developed. Some concerns with the experimental design and interpretation of the results are provided below.

      1. Some concerns with the model systems used in the analysis. First of all, there are methods for inducing the differentiation of mouse trophoblast stem cells, which usually involves the removal of factors that promote trophoblast stem cell proliferation. The authors do not describe their method for inducing trophoblast stem cell differentiation nor did they show evidence that they directly investigated differentiated trophoblast stem cells.

      We have added information in the Methods section to clarify that differentiation was performed by culturing cells in TS base medium (no conditioned media, FGF or heparin) for 4 days. We also provide RT-qPCR data confirming TSC differentiation (Figure S1A).

      1. There is a published report presenting data from single cell analysis of mouse trophoblast stem cells in the stem and differentiated states that was not acknowledged or used in the authors' analyses. Please see: Angelova et al. 2025 Nature Communications (PMID:39747179).

      We appreciate the reviewer’s suggestion, but the purpose of our single-cell analysis was to assess the expression of IAP elements and their associated chimeric transcripts in vivo. This has more significance than single-cell data from in vitro differentiated cells. We also found that at least some of the chimeric transcripts seen in vivo are not detected in vitro.

      1. Much of the analysis, compared mouse trophoblast stem cells and murine placentas. Interpretation of single nucleus sequencing data from mouse placentas can provide information regarding the behavior of trophoblast cells; however, bulk sequencing of placentas is limited. The placenta contains trophoblast cell and non-trophoblast cell components. More specifically the placenta contains fetal endothelial, immune, and mesenchymal cells and depending upon dissections and the gestational stage of dissections variable amounts of uterine decidua and yolk sac-derived tissues. The authors need to be clear in the comparisons that they are making. More specifically, the authors need to effectively communicate the cell types from the placenta contributing to the results they are describing. Attributing analyses of the placenta to trophoblast cells is problematic.

      We agree with this point. In our original submission we had included a cell type deconvolution analysis to infer the composition of our bulk placental tissue (Figure S1B of the revised submission). This clarifies the heterogeneity of the tissue and shows that most cells are trophoblast. We also used a genetic model to isolate trophoblast from placentas to address this point. Cell type deconvolution confirms that >90% of cells are trophoblast.

      1. How were the newly derived mouse trophoblast stem cells characterized? Do they behave like authentic mouse trophoblast stem cells? Were the newly derived trophoblast stem cells capable undergoing differentiation? What parameters were measured?

      We now include data on trophoblast stem cell and differentiation markers, comparing our newly derived line with the well-established GFP-TSC line (Figure S1A). While not included in this submission, the cells also presented with the expected morphologies when cultured under stem or differentiation conditions.

      1. Were analyses with the newly derived mouse trophoblast stem cells performed in the stem or differentiated states?

      Our initial analyses were only from cells cultured in stem conditions. However, we now also include an analysis of TE regulatory activity in differentiation conditions (updated Figures 1B, 1D, S1C).

      1. TSC derivation and culture section. The authors appear to be initially describing the generation of mouse embryonic fibroblast conditioned medium not trophoblast stem cell conditioned medium as stated. Some clarification will be helpful. As stated above, the authors do not provide any information on the characterization and validation of the newly derived mouse trophoblast stem cells, which is problematic.

      We appreciate the confusion with the nomenclature. To clarify we have changed the start of that section to: “Conditioned medium for the culture of TSCs (TS-CM) was prepared by…”. This conditioned medium is generated using MEFs and is then used to culture TSCs.

      1. Discussion. The authors state that there are fundamental differences between the mouse and human placenta regarding the co-option of transposable element subfamilies. Human trophoblast stem cells represent a highly tractable model and could be compared with mouse trophoblast stem cells to further explore this observation.

      We previously published a paper focused on TE co-option in human trophoblast (PMID: 37012406), and we made a brief comparison to those data in the current manuscript (Figure S1G). Interestingly, in contrast to mouse, many of the TEs with regulatory activity in human TSCs remain active in term placenta.

      Significance

      Efforts to understand roles for transposable elements in the regulation of trophoblast cell gene expression and placental evolution are very important. We recognize significant differences in placentation across various species but do not have a good understanding how this important developmental process evolved.

      Assessment: The authors have a potentially interesting story. However, it appears that they have merged two incomplete research efforts: i) effects of trophoblast cell differentiation on utilization transposable elements to regulate gene expression; ii) IAP involvement in regulating murine placental transcription.

      Whilst we appreciate this viewpoint, our investigation of IAPs as regulators of gene expression was triggered from the analysis in the first part of the manuscript and thus follows logically in our view. Moreover, the overarching theme remains consistent: the effects of TEs (whether IAPs or others) on gene expression/transcription.

      Advance: The scientific advance is somewhat fragmented. There is a reinforcement of our existing understanding of the involvement of transposable elements in trophoblast and placental gene regulation but other new insights are limited or not well developed.

      Both the TE and placental scientific communities largely assume that the placenta is a privileged organ for co-option of TEs as regulatory elements. Here we demonstrate that TE co-option in the placenta can be quite limited and species-specific. Additionally, the roles of IAPs as gene regulators in the placenta had not been previously described. We believe these two novel observations constitute significant advancements in the field.

      Audience: Evolutionary biologists and reproductive and developmental biologists.

      Reviewer #2

      Evidence, reproducibility and clarity

      Summary: This manuscript describes the characterization of transposable elements (TEs) in mouse trophoblast stem cells and in the mature mouse placenta. The authors find that overall, the trophoblast stem or progenitor state of TSCs harbours a greater abundance of active TE elements, while their activity levels decline as trophoblast differentiates. Instead, the dominant repetitive element that is active in the mature placenta are intracisternal A particle (IAP)-derived elements. Indeed, the authors show that these provide the initiation sites for differential isoforms of some 27 chimeric transcripts that are specific to differentiated trophoblast cell types. The authors attempt to epigenetically silence these IAPs in TSCs using CRISPRi methodolgy, and find reduced expression of 4 IAP-driven transcripts and many presumably secondary transcriptional changes. Finally, they also compare IAP activity in the placentas of different mouse species or sub-species, and conclude that IAP insertion sites close to genes can affect their expression in the placenta, with potential consequences for development and evolution.

      Major comments: This is a well-conducted study that brings significant novelty, albeit to a more specialized audience.

      There are several aspects that need clarification, addition and some experimental work: 1. Figure 1A shows carefully separated cell types, in particular extraembryonic mesoderm, that have also been assessed by the various cut&tag and ATAC-seq methods, but are not mentioned in the remainder of the manuscript. This should be added. I.e., is the same activity pattern of IAPs evident in the ExMes cells, or do they follow a more somatic pattern?

      Apologies if additional analyses of extraembryonic mesoderm were not obvious, but we did analyse IAP expression in these cells and show in Figure 2B that it is much lower when compared to trophoblast. We also used the comparison between trophoblast and extraembryonic mesoderm in Figures 2A, 3B, S2A-D and S4B.

      1. Page 4, top: The mention of a "custom pipeline" for cut&tag analysis is vague, and the modifications and what they stand for is hardly mentioned. These details need to be elaborated, so to be more accessible to a wider audience.

      We have tried to clarify the overall strategy of the analysis: “Using CUT&Tag and ATAC-seq data, we aimed to identify TE subfamilies that bear classic hallmarks of active promoters (open chromatin, H3K4me3, H3K27ac) and/or enhancers (open chromatin, H3K27ac, H3K4me1). We used a custom pipeline that selects TE subfamilies bearing more elements overlapping CUT&Tag/ATAC-seq peaks than expected by chance.”.

      1. For differentiated TSCs, only ATAC-seq data were analysed. How do they relate to the various cut&tag profiles, and do they result in a robust detection of putative active repeat elements at a detection limit similar to the chromatin marks? I would think that it might be prudent to include the same cut&tag for differentiated TSCs as well, so to be directly comparable to the other data. This is important to establish whether TE elements are really less active in differentiating trophoblast, or whether this feature is intrinsic to the placenta and not to pure trophoblast cells in culture, in which case it may be influenced by tissue context.

      We are thankful for this important suggestion. We have now carried out CUT&Tag on differentiated cells and include the findings in the revised Figures 1B, 1D and S1C. Consistent with our observations using ATAC-seq data, we find that TE regulatory activity is diminished upon in vitro differentiation.

      1. Are the IAP-initiated chimeric transcripts including new coding regions? If so, a Western Blot analysis of a few of the 27 candidates should be performed to prove this. Suv39h2 is a particularly interesting candidate where such protein analysis would be very informative.

      We performed a search for ORFs in IAP-driven transcripts and identified a putative protein isoform of SUV39H2 that includes a portion of the IAP and that is larger than the canonical form by 28 kDa. However, by Western blot we see no major size shift in the main band when comparing placenta (where the IAP isoform predominates) with TSCs (where only the canonical form is expressed). We now include this in a new Supplementary Figure S5. To note is that in our hands the main SUV39H2 band runs at a lower molecular weight than expected (54 kDa), which could be due to buffer/gel conditions and/or expression of a shorter isoform (ENSMUSG00000026646, 46 kDa). But we are reassured that the antibody used has been validated in multiple human KO lines, as well as in at least one mouse knockdown model (PMID: 32698678).

      1. A WB analysis should for sure be performed on the M. musculus and M. pahari placentas. The IHC staining is not interpretable as to whether or not SUV39H2 levels are reduced in M pahari.

      We appreciate the reviewer’s point, but the main hypothesis to be tested here was whether there was an obvious difference in the spatial distribution of SUV39H2, which we did not find. Any more subtle differences would be cell-type specific and would require complex cell sorting approaches before attempting a western blot. This would not affect our conclusion that, despite differences between species at the transcriptional level, this does not lead to an overt redistribution of SUV39H2 protein expression.

      1. Could the authors please also provide more global proof of the CRISPRi success. The display of two candidate gene tracks is not very telling.

      In the original submission we had included a subfamily-level analysis of IAP expression in the CRISPRi experiment (Figure S6A of the revised version). This shows a mild downregulation of IAP expression overall. Whilst an element-based analysis would be preferable due to potential caveats with subfamily-level analyses, very few TSC-expressed elements are sufficiently mappable to ensure a robust analysis, which is why we only showed two highly expressed loci where the effects of CRISPRi can be evaluated. Importantly, we observe effects on gene expression that, whilst mild, are non-random and support a role for IAPs in regulating the expression of nearby genes (Figure 4D).

      Significance

      General assessment: Collectively, this is a carefully conducted study that needs to be bolstered by some few additional experiments, as suggested above. The discovery of changing patterns of repetitive element activity in differentiating trophoblast cells is important and intriguing, as it has direct impact on the evolutionary divergence of gene expression and, as a consequence, cell type differentiation, through the insertion of IAP and L1 elements close to placenta-expressed genes. This will be a major contributor and even driver of the barrier to inter-species hybridization that the placenta represents.

      Advance: Currently, the main TE elements known to drive placenta-specific gene expression are retrovirally derived LTR elements. Here, however, the authors show that the relevance of these elements diminishes in the mature placenta, and instead is taken over by a different class, the IAP elements. This is important, as many these elements retain the capacity for retrotransposition, and thus actively contribute to ongoing evolutionary divergence of placental gene expression patterns that ultimately may drive speciation.

      Audience: The manuscript is not particularly easy to follow, even for the informed reader, and it appeals to a relatively specialized audience in the field of genome regulation coupled to evolutionary aspects of repetitive element insertion/transposition. The authors should be encouraged to spell out some aspects of their thought process throughout the study in some more detail, so not to "lose" the reader.

      We have made multiple changes throughout the manuscript that we hope improve readability.

      __Reviewer #3 __

      __Evidence, reproducibility and clarity __ The cis-regulatory roles of TEs in human/mouse TSCs have been extensively studied, yet in vivo studies on their roles in placenta tissue is largely absent. In this manuscript, Amante and colleagues compared the regulatory landscape of TEs across the trophoblast cell lines and placenta samples in human and mouse, and after revealing the shared and species-specific patterns (including some that are surprising), they further investigated the regulatory function of the murine-specific IAP retrotransposons in house mouse and other mouse strains. Specifically, it presents several findings regarding the shared and diverged function of TEs across: 1) in vivo vs. in vitro placental models, 2) human vs. mouse, 3) and different mouse strains. The writing is of good quality, the results are well visualized and interpreted, the conclusions are reasonable, and the novelty is high. It significantly extended previous studies from the same group as well as many other researchers. I think this manuscript should fit publication after a minor revision. Below I have a few comments:

      1. In Fig. 1B, it seems the differences of TE enrichment between the same groups of samples (e.g., B6 TSC vs. GFP TSC) is also remarkable. Is this expectable? I am curious if such difference is robust, or it is just due to the TE sub-families with too few copies, whose enrichment can be influenced by just a couple of overlapping counts. The authors may double-check if possible.

      This is an interesting hypothesis, but the main subfamilies that are H3K27ac-enriched in TSCs are quite abundant (e.g., 683 copies of RLTR13D5, 260 copies of RLTR13B3). We believe these are cell line-specific differences, possibly partly driven by genetics, since they were derived from different mouse strains. Nonetheless, there is good agreement between the two lines with respect to the TE subfamilies that are enriched.

      1. The authors demonstrate that the association of TEs to cis-regulatory elements is much weaker in the placenta of mouse relative to human, and in mouse the activation of TEs is indeed similar to most other tissues. And based on this observation, they propose that "Co-option of TEs as regulatory elements within the mature placenta may therefore not be as promiscuous across species as commonly thought" (page 4 paragraph 1). While this finding is quite interesting, how it is related to the popular hypothesis that "maternal-fetal conflict leads to the strong TE activation in placenta"? I am curious if the authors have any idea on this point.

      It is indeed a fascinating topic. We would dispute that the conflict hypothesis leads to TE activation in the placenta, but rather that it creates selective pressures that drive their co-option. But this still requires for TEs to be available for co-option. What we suggest here is that TE co-option opportunities can be tightly constrained by transcriptional silencing mechanisms, even in the placenta. We added the following text to that section of the discussion: “Whilst maternal-fetal conflicts may create selective pressures for TE co-option in the placenta, epigenetic mechanisms can still act as gatekeepers and dictate the frequency of co-option events in this organ.”

      1. For the highly active IAP subfamilies identified in mouse placenta, have the authors tried to identity the enriched motifs, which may be helpful for uncovering transcription factors responsible for their activation?

      This is an interesting question, given the specific expression of IAP elements in the spongiotrophoblast. We now performed transcription factor motif analysis on subfamilies that are highly expressed in the placenta (IALTR1/2). We then filtered this list for motifs that are absent/mutated in lowly expressed IAP subfamilies (IAPLTR3/4) and whose associated transcription factor is highly expressed in spongiotrophoblast. In the revised manuscript we highlight our top candidate, MITF, which is a spongiotrophoblast-specific marker (Figure S3C).

      1. In Fig. 3B, the IAPEY_LTR-adjacent Zfp229 gene is demonstrated, yet this gene is not mentioned at all in the main text. The authors may consider providing more details for this gene.

      Unfortunately, nearly nothing is currently known about this zinc finger protein gene, but we did not feel that should prevent us from using it as a strong example of placenta-specific usage of an IAP-derived promoter. Future work on this gene may indeed be triggered by highlighting this observation.

      1. A few errors for the citations should be corrected. For example, the journal names are missed for ref56 and ref58 at page 22.

      We have reviewed all our references and added missing information

      1. A few typos should be corrected. For example, at page 11 line 2, "of" is missed between "presence this IAP-driven.

      We have corrected this typo and made additional changes to the manuscript to improve readability.

      Significance

      Overall, this is an interesting and technically-sound study with substantial novelty, which significantly extends previous knowledge on TE function in placenta which largely relies on in vitro models.I believe this study will be attractive to the fields about TE function and placenta evolution.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary: This manuscript describes the characterization of transposable elements (TEs) in mouse trophoblast stem cells and in the mature mouse placenta. The authors find that overall, the trophoblast stem or progenitor state of TSCs harbours a greater abundance of active TE elements, while their activity levels decline as trophoblast differentiates. Instead, the dominant repetitive element that is active in the mature placenta are intracisternal A particle (IAP)-derived elements. Indeed, the authors show that these provide the initiation sites for differential isoforms of some 27 chimeric transcripts that are specific to differentiated trophoblast cell types. The authors attempt to epigenetically silence these IAPs in TSCs using CRISPRi methodolgy, and find reduced expression of 4 IAP-driven transcripts and many presumably secondary transcriptional changes. Finally, they also compare IAP activity in the placentas of different mouse species or sub-species, and conclude that IAP insertion sites close to genes can affect their expression in the placenta, with potential consequences for development and evolution.

      Major comments:

      This is a well-conducted study that brings significant novelty, albeit to a more specialized audience.

      There are several aspects that need clarification, addition and some experimental work:

      1. Figure 1A shows carefully separated cell types, in particular extraembryonic mesoderm, that have also been assessed by the various cut&tag and ATAC-seq methods, but are not mentioned in the remainder of the manuscript. This should be added. I.e., is the same activity pattern of IAPs evident in the ExMes cells, or do they follow a more somatic pattern?
      2. Page 4, top: The mention of a "custom pipeline" for cut&tag analysis is vague, and the modifications and what they stand for is hardly mentioned. These details need to be elaborated, so to be more accessible to a wider audience.
      3. For differentiated TSCs, only ATAC-seq data were analysed. How do they relate to the various cut&tag profiles, and do they result in a robust detection of putative active repeat elements at a detection limit similar to the chromatin marks? I would think that it might be prudent to include the same cut&tag for differentiated TSCs as well, so to be directly comparable to the other data. This is important to establish whether TE elements are really less active in differentiating trophoblast, or whether this feature is intrinsic to the placenta and not to pure trophoblast cells in culture, in which case it may be influenced by tissue context.
      4. Are the IAP-initiated chimeric transcripts including new coding regions? If so, a Western Blot analysis of a few of the 27 candidates should be performed to prove this. Suv39h2 is a particularly interesting candidate where such protein analysis would be very informative.
      5. A WB analysis should for sure be performed on the M. musculus and M. pahari placentas. The IHC staining is not interpretable as to whether or not SUV39H2 levels are reduced in M pahari.
      6. Could the authors please also provide more global proof of the CRISPRi success. The display of two candidate gene tracks is not very telling.

      Significance

      General assessment:

      Collectively, this is a carefully conducted study that needs to be bolstered by some few additional experiments, as suggested above. The discovery of changing patterns of repetitive element activity in differentiating trophoblast cells is important and intriguing, as it has direct impact on the evolutionary divergence of gene expression and, as a consequence, cell type differentiation, through the insertion of IAP and L1 elements close to placenta-expressed genes. This will be a major contributor and even driver of the barrier to inter-species hybridization that the placenta represents.

      Advance:

      Currently, the main TE elements known to drive placenta-specific gene expression are retrovirally derived LTR elements. Here, however, the authors show that the relevance of these elements diminishes in the mature placenta, and instead is taken over by a different class, the IAP elements. This is important, as many these elements retain the capacity for retrotransposition, and thus actively contribute to ongoing evolutionary divergence of placental gene expression patterns that ultimately may drive speciation.

      Audience:

      The manuscript is not particularly easy to follow, even for the informed reader, and it appeals to a relatively specialized audience in the field of genome regulation coupled to evolutionary aspects of repetitive element insertion/transposition. The authors should be encouraged to spell out some aspects of their thought process throughout the study in some more detail, so not to "lose" the reader. The study would sit well in journals that cover a wide spectrum of biology.

    1. The image is Modal-native. control-plane/runner-image.json is {"runnerImage": "cp-runner:v13", …} — a Modal tag with no registry host and no digest, built by scripts/build-runner-image.ts:196-204 through Modal's fromRegistry(...).dockerfileCommands(...). It cannot be handed to run.cloud as-is. Moving it is a real improvement on its own terms: a registry reference with a digest fixes the long-standing problem that prod's RUNNER_IMAGE drifts from the repo (terraform owns the env var, and CI deliberately reads the live value rather than inferring it).

      Is this true? I think we support this no?

    1. Reviewer #1 (Public review):

      Summary:

      This manuscript investigates the degradation dynamics of extracellular DNA in soils and its impact on estimates of microbial abundance and diversity. By combining a broad geographic sampling design with a primer-labeling strategy, qPCR quantification, amplicon sequencing, and PMA treatment, the authors aim to disentangle total versus intracellular DNA signals and explore sequence-specific degradation patterns. The topic is relevant, particularly given the increasing awareness of relic DNA as a confounding factor in microbial ecology. The experimental design is ambitious and potentially impactful. However, several conceptual inconsistencies, methodological ambiguities, and statistical limitations currently weaken the robustness of the conclusions. These issues need to be addressed.

      Strengths:

      The manuscript addresses a timely and important question in microbial ecology, particularly given the growing recognition that relic DNA can bias interpretations of community composition derived from amplicon sequencing. The study is ambitious in scope, incorporating a broad geographic sampling design across multiple soil types, which enhances the generalizability of the findings. The use of a controlled microcosm experiment combined with a primer-labeling strategy to track extracellular DNA dynamics is conceptually innovative and provides a structured framework to investigate degradation processes.

      In addition, the integration of multiple approaches, including qPCR for absolute quantification, high-throughput sequencing for community profiling, and PMA treatment to differentiate extracellular from intracellular DNA, represents a comprehensive attempt to disentangle complex sources of bias in soil microbiome analyses. The effort to link degradation dynamics with environmental variables and to explore sequence-level patterns further demonstrates the authors' intent to move beyond descriptive analyses toward a mechanistic understanding.

      Weaknesses:

      Several conceptual and methodological issues currently limit confidence in the study's conclusions. Key terms such as "sequence-specific degradation" are not clearly defined or supported by a mechanistic or structural hypothesis, making it difficult to interpret the biological meaning of the results. In addition, the bioinformatic workflow presents inconsistencies, particularly the use of ASVs followed by clustering at 97% similarity, which undermines the resolution required to support sequence-level inferences. Statistical analyses are also insufficiently described, including unclear definitions of "T values," a lack of detail on pairing structure, and no indication of multiple testing correction.

      Furthermore, important methodological details are missing or unclear, including primer design (e.g., GAPDH tag vs ACTF), Illumina library preparation (e.g., adapter and indexing strategy), and validation of PMA treatment efficiency. The interpretation of PMA-treated samples as representing "living communities" is likely overstated, given the known limitations of the method in soil systems. Finally, typographical errors, inconsistent terminology, and unclear phrasing throughout the manuscript reduce readability and further complicate interpretation.

    2. Author response:

      The following is the authors’ response to the original reviews.

      We sincerely appreciate you and the reviewers for investing time and effort in evaluating our manuscript. After carefully reading the comments and suggestions, we found they are insightful, constructive, and critical for improving the quality of our work. Based on these valuable recommendations, we have substantially revised the manuscript as summarized below.

      Abstract: Inappropriate or ambiguous statements have been revised to improve clarity.

      Introduction: (1) The study purpose and hypotheses have been re-organized in a clearer and more concise way. (2) A mechanistic rationale for sequence-specific degradation has been provided and the use of PMA treatment has been explained. (3) The terminologies related to extracellular DNA and 16S rRNA gene amplicons have been clarified.

      Materials and Methods: 1) More detailed description of the microcosm experiment has been added. 2) The design and rationale of GAPDH F-tagged primers and the use of fusion primers for Illumina library preparation have been clarified. 3) More details about PCR amplification, DNA purification, and pooling strategies have been added. 4) We have corrected and standardized primer naming throughout the manuscript; 5) More details about bioinformatic workflow have been added. 6) We have defined statistical parameters and multiple testing corrections. 7) All abbreviations have been defined and standardized.

      Results: 1) The terminology for PMA-treated DNA has been revised and it has been clarified interpretation as “PMA-treated prokaryotic community” rather than “living community”. 2) The figures and legends have been updated for clarity, and the explicit explanation of “ASV I” and “ASV II” in pairwise comparisons have been added. 3) the figures (e.g., Figs. 2–5, S2–S8) have been reorganized to better reflect results; 4) Inappropriate statements or misleading interpretations have been removed.

      Discussion: A detailed section on technical limitations have been added. The limiatons added mainly include: 1) PCR amplification bias and recommendations for spike-in standards or multi-primer approaches; 2) differential DNA extraction efficiency due to variable cell lysis; and 3) limitations of using 16S rRNA amplicons as proxies for natural extracellular DNA and the limitations of PMA treatment efficiency in soil matrices;

      eLife Assessment

      This valuable study introduces an innovative experimental design to address a crucial and timely issue in microbial ecology: the potential bias in soil microbial community analyses caused by extracellular DNA degradation. While the evidence showing variable degradation rates of extracellular DNA is convincing, additional conceptual, methodological, and statistical clarifications could reinforce the claims and the study's contribution to the field. This research will appeal to microbial ecologists and researchers interested in using molecular techniques to evaluate microbial community structure.

      We sincerely appreciate the editors for the careful assessment of our work and for recognizing the value of addressing extracellular DNA degradation in soil microbial community analyses. We also greatly appreciate the reviewers’ constructive feedbacks concerning the need for additional conceptual, methodological, and statistical clarifications. We agree that further refinement in these areas will strengthen our claims and enhance the study’s contribution to the field. Based on these insightful suggestions, we have carefully revised the manuscript to provide clearer conceptual framework, more detailed methodological descriptions, and more rigorous statistical analyses. We believe these revisions have substantially improved the clarity and robustness of our work. More details about the revisions have been provided in the following responses.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      This manuscript investigates the degradation dynamics of extracellular DNA in soils and its impact on estimates of microbial abundance and diversity. By combining a broad geographic sampling design with a primer-labeling strategy, qPCR quantification, amplicon sequencing, and PMA treatment, the authors aim to disentangle total versus intracellular DNA signals and explore sequence-specific degradation patterns. The topic is relevant, particularly given the increasing awareness of relic DNA as a confounding factor in microbial ecology. The experimental design is ambitious and potentially impactful. However, several conceptual inconsistencies, methodological ambiguities, and statistical limitations currently weaken the robustness of the conclusions. These issues need to be addressed.

      We sincerely appreciate the reviewer for the constructive assessment of our work. We also appreciate the reviewer’s critical insights regarding the conceptual inconsistencies, methodological ambiguities, and statistical limitations that currently weaken the robustness of the conclusions. We agree with the reviewer that addressing these issues is essential to strengthen our work. Based on these valuable comments, we have carefully revised the manuscript to clarify the conceptual framework. Additionally, we have provided more detailed methodological descriptions, and enhance the statistical rigor of our analyses. We believe these revisions have substantially improved the clarity, consistency, and overall robustness of our conclusions.

      Strengths:

      The manuscript addresses a timely and important question in microbial ecology, particularly given the growing recognition that relic DNA can bias interpretations of community composition derived from amplicon sequencing. The study is ambitious in scope, incorporating a broad geographic sampling design across multiple soil types, which enhances the generalizability of the findings. The use of a controlled microcosm experiment combined with a primer-labeling strategy to track extracellular DNA dynamics is conceptually innovative and provides a structured framework to investigate degradation processes.

      In addition, the integration of multiple approaches, including qPCR for absolute quantification, high-throughput sequencing for community profiling, and PMA treatment to differentiate extracellular from intracellular DNA, represents a comprehensive attempt to disentangle complex sources of bias in soil microbiome analyses. The effort to link degradation dynamics with environmental variables and to explore sequence-level patterns further demonstrates the authors' intent to move beyond descriptive analyses toward a mechanistic understanding.

      We sincerely thank the reviewer for the positive and encouraging comments of our work.

      Weaknesses:

      Several conceptual and methodological issues currently limit confidence in the study's conclusions. Key terms such as "sequence-specific degradation" are not clearly defined or supported by a mechanistic or structural hypothesis, making it difficult to interpret the biological meaning of the results. In addition, the bioinformatic workflow presents inconsistencies, particularly the use of ASVs followed by clustering at 97% similarity, which undermines the resolution required to support sequence-level inferences. Statistical analyses are also insufficiently described, including unclear definitions of "T values," a lack of detail on pairing structure, and no indication of multiple testing correction.

      Furthermore, important methodological details are missing or unclear, including primer design (e.g., GAPDH tag vs ACTF), Illumina library preparation (e.g., adapter and indexing strategy), and validation of PMA treatment efficiency. The interpretation of PMA-treated samples as representing "living communities" is likely overstated, given the known limitations of the method in soil systems. Finally, typographical errors, inconsistent terminology, and unclear phrasing throughout the manuscript reduce readability and further complicate interpretation.

      We sincerely appreciate the reviewer’s thorough and critical evaluation of the manuscript’s weaknesses. The issues raised regarding conceptual clarity, bioinformatic consistency, statistical rigor, methodological transparency, and the interpretation of PMA treatment have been fully acknowledged. We also recognized that typographical errors, inconsistent terminologies, and unclear phrasing largely reduced readability. In response to these valuable comments, the manuscript has been carefully revised as follows. (1) The clearer definition of the term “sequence-specific degradation” has been provided. (2) The bioinformatic workflow was streamlined to ensure consistency. (3) The descriptions of statistical analyses were substantially expanded, including explicit definitions of “t values,” detailed clarification of the pairing structure, and the application of appropriate multiple testing corrections. (4) Missing details regarding primer design, Illumina library preparation, and PMA treatment validation have been added to the Method section. (5) Interpretations of PMA-treated samples have been revised to more accurately reflect methodological limitations in soil systems. (6) The manuscript has been thoroughly proofread to correct typographical errors, standardize terminology, and enhance overall clarity. These revisions are believed to substantially address the concerns raised and significantly strengthen the manuscript. A point-by-point response to the specific comments is provided below.

      Reviewer #2 (Public review):

      Summary:

      This manuscript describes the results of an interesting study examining the rate of degradation of extracellular DNA in soil ecosystems using a clever experimental approach. 16S ribosomal RNA genes were amplified from soil samples, and then purified PCR amplicons, containing a 5' linker sequence on the forward primer, were introduced to soils and monitored over time using real-time quantitative PCR and NGS amplicon sequencing. The study was able to measure rates of overall extracellular DNA degradation, but also sequence-specific degradation rates. I like the idea and execution of the study, and the results are interesting. The manuscript needs some help to improve the overall readability. Please see general and editorial comments below.

      We sincerely thank the reviewer for the positive and encouraging assessment of our study. We have carefully revised the manuscript to enhance clarity, streamline the presentation, and refine the language throughout. We believe these improvements have made the manuscript more readable and easier to follow. We are also grateful for the general and editorial comments provided, which have been addressed as outlined below.

      Strengths:

      Innovative experimental design that is well deployed across a large number of soil types, revealing interesting variability in extracellular DNA degradation.

      We sincerely thank the reviewer for the positive and encouraging assessment of our work.

      Weaknesses:

      (1) The manuscript needs another review to improve the readability of the document.

      We thank the reviewer for this helpful suggestion. We fully agree that improving readability is essential for effectively communicating our findings. Based on the comment, we have carefully revised the manuscript to enhance clarity and readability. We have streamlined sentence structures, standardized terminology, corrected typographical errors, and improved the logical organization of the text. We believe these revisions have substantially improved the overall readability of the manuscript.

      (2) The authors have used 16S genes to look at sequence-specific degradation. But 16S rRNA genes are actually pretty well conserved, and there isn't as much genetic variation across this gene among organisms as there is for other genes. It might be more relevant to look at metagenomic DNA degradation from high AT, high GC organisms, etc. This would be more generalizable than 16S genes.

      We thank the reviewer for this insightful comment. We agree with the reviewer that 16S rRNA genes are relatively conserved compared to functional genes or whole metagenomic DNA, and that studying degradation of more variable sequences (e.g., high‑AT, high‑GC regions, or metagenomic DNA) would provide greater generalizability. However, we would like to clarify the rationale for using 16S rRNA gene amplicons in the present study. First, the 16S rRNA gene remains the most widely used phylogenetic marker in soil microbial ecology (Knight et al., 2018). Demonstrating sequence‑specific degradation with this well‑established marker directly informs a large body of existing research that relies on 16S RNA gene‑based community analyses. Second, despite its conserved nature, the targeted fragment in this study is belong to the highly varied region (V4) of 16S rRNA gene. Accordingly, we indeed observed significant sequence‑specific variation in degradation rates among different 16S rRNA gene amplicon sequence variants (ASVs) (Fig. 2c, 3a). This indicates that even within a conserved marker gene, sequence‑dependent degradation biases exist and can affect diversity estimates. Third, our study was designed as a proof‑of‑concept to establish a methodological framework for quantifying both overall and sequence‑specific degradation rates. Using a single, well‑characterized marker allowed us to develop and validate the primer‑labeling and qPCR/sequencing workflow without the additional complexity of metagenomic DNA (e.g., variable fragment lengths and complex mineral associations). In the revised manuscript, we have added the following sentence to the Discussion section to address the concerns from the reviewer.

      L294-305

      “Despite the high-resolution insights afforded by our methodology, several limitations should be considered. First, utilizing PCR-amplified 16S rRNA gene fragments as proxies oversimplifies the structural and sequence complexity of natural soil eDNA pools. In natural environments, eDNA varies widely in fragment length and conformation, and exhibits complex interactions with mineral surfaces, all of which fundamentally affect degradation dynamics (Levy-Booth et al., 2007; McKinney and Dungan, 2020). Additionally, the highly conserved nature of the 16S rRNA gene means that the nucleotide variability explored here (e.g., GC content gradients) does not fully capture the genomic heterogeneity of entire metagenomes (Knight et al., 2018). Consequently, our reported degradation rates indicate the decay potential of highly accessible linear eDNA rather than a universal rate for all soil DNA fractions. Future studies incorporating diverse metagenomic DNA, especially those with extreme AT or GC contents, are essential for building a more generalizable predictive framework for eDNA persistence (Morrissey et al., 2015)”

      (3) Consideration of differential cell lysis during soil DNA extraction needs to be considered as well.

      We thank the reviewer for raising this important technical consideration. We agree that differential cell lysis during soil DNA extraction is a well‑recognized source of bias in microbial community analysis. Different microbial taxa (e.g., Gram‑positive vs. Gram‑negative bacteria, spores, or fungi) vary in their cell wall structure and susceptibility to lysis, which can lead to under‑representation of certain groups and over‑representation of others in the extracted DNA. This bias affects both total DNA extracts and PMA‑treated fractions, potentially influencing our estimates of the relative contributions of intact‑cell derived DNA versus extracellular DNA. However, currently, eliminating these biases are still challenging, and thus we have added the following sentence to the Discussion to address this concern.

      L305-311

      “Second, methodological biases inherent in quantifying the intracellular community must be acknowledged (Du et al., 2025). Although PMA treatment is widely used to exclude eDNA, its efficiency in complex soil matrices can be compromised by limited light penetration in turbid suspensions and competitive adsorption to soil particles (Nocker et al., 2007; Carini et al., 2016; Heise et al., 2016). Compounding this issue, downstream DNA recovery is subject to differential cell lysis, as taxa with robust cell walls (e.g., Gram-positive bacteria) may resist extraction (Frostegård et al., 1999; Albertsen et al., 2015).”

      (4) It is not clear why the authors didn't put GAPDH linkers on the reverse primer as well. This would have given an easier amplicon to amplify (no degeneracies at all).

      The decision to place the GAPDH linker only on the forward primer (515F) was intentional to balance the need for tracking exogenous extracellular DNA with amplification efficiency, sequencing quality, and cost-effectiveness. Adding linkers to both primers would increase the total amplicon length, potentially reducing amplification efficiency, especially in complex soil samples with degraded or low-quality DNA. More importantly, the reverse primer used in our study is a degenerate primer designed to target the 16S rRNA gene across diverse bacterial taxa, and extending it with an additional GAPDH linker could introduce further complexity, decrease amplification efficiency, and increase primer-dimer formation. Additionally, single-end labeling allows the usage of standard 16S rRNA reverse primers with existing barcodes, whereas dual-end labeling would require synthesis of new barcode-labeled primers, increasing both cost and time. Our preliminary experiments confirmed that single-end labeling produced reproducible amplification curves (~85% efficiency) and high-quality sequencing reads, which were sufficient for quantifying degradation rates. We have added a clarification in the Methods section to explain this rationale.

      L365-371

      “The GAPDH was incorporated only into the forward primer for several reasons. Methodologically, adding a long linker to the degenerate reverse primer (806R) could reduce amplification efficiency or introduce bias. Economically, single-end labeling allowed us to use the standard reverse primer already carrying sample-specific barcodes, avoiding the costly synthesis of a full set of dual-labeled barcoded primers. This design minimized the risk of secondary structure and primer-dimer artifacts while maintaining sufficient specificity and compatibility with downstream qPCR and sequencing.”

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      Major Comments

      (1) Inconsistency between ASV inference and 97% sequence recruitment

      The bioinformatic pipeline presents a major conceptual inconsistency. ASVs are inferred using UNOISE3, but reads are subsequently mapped to ASVs at a 97% similarity threshold, effectively reintroducing OTU-level clustering. Given that the manuscript's central claim is sequence-specific degradation, this step undermines the single-nucleotide resolution that ASVs provide and may obscure biologically meaningful differences. The authors should either reanalyze the data using a consistent ASV framework (exact matching), or explicitly treat the analysis as OTU-like and moderate claims of sequence specificity.

      We appreciate the reviewer's critical evaluation of our bioinformatic pipeline. We also apologized for our unclear statements in our original manuscript. We understand the concern that mapping reads to ASVs at 97% similarity might appear to reintroduce OTU-level clustering. Actually, we used the default pipeline provided by the authors of USEARCH with otutab command to generate the ASV table.

      Following the logic and recommendations of the USEARCH/UNOISE3 developer (Robert Edgar), this approach is a standard procedure for robust noise management rather than a conceptual inconsistency. First, in our pipeline, ASVs (ZOTUs) are first inferred using the UNOISE3 algorithm, which effectively identifies “true” biological sequences at single-nucleotide resolution. Secondly, according to the USEARCH manual, while the ASVs themselves represent exact biological sequences, the raw reads inevitably contain stochastic sequencing errors. Using “exact matching” for recruitment would discard a significant portion of the data that originates from a specific ASV but carries minor random errors. Mapping at 97% identity is the recommended method to recruit these noisy reads back to their correct biological origin (the ASV centroid). Meanwhile, during the recruitment process, reads are not randomly assigned to any ASV within the 97% identity radius. Instead, the algorithm follows a “highest similarity first” principle. For instance, if a specific read exhibits 98% similarity to ASV1 and 97% similarity to ASV2, it is strictly assigned to ASV1. A read is only discarded if its highest similarity to any ASV falls below the 97% threshold. Unlike traditional OTU clustering (where sequences are clustered together based on similarity from the start), our approach maintains the ASV as a fixed biological reference. The quantification of degradation rates is performed on these high-resolution centroids. Thus, our claims regarding sequence-specific degradation remain valid, as the underlying biological variation is defined by the ASVs. To avoid any possible confusion, we have rewritten the relevant paragraph in the Methods section (subsection 4.6) as follows.

      L446-457

      “ASVs were generated using the UNOISE3 non‑clustering denoising algorithm (Edgar, 2016), which infers 100% exact sequence variants by distinguishing biological sequences from PCR/sequencing errors. ASVs with total sequence counts fewer than 9 across all samples were removed to reduce noise. To quantify the abundance of each ASV, an ASV table was generated by mapping the quality‑filtered raw reads back to the ASV set using the otutab command. A 97% similarity threshold was applied for this recruitment to accommodate stochastic sequencing noise while maintaining biological resolution. Crucially, the mapping followed a best-hit priority rule, where each read was assigned to the ASV with the highest per cent identity within the 97% radius. This approach ensures that reads derived from the same biological template are accurately counted toward their respective ASV, preventing the underestimation of abundances that would occur with exact matching while strictly preserving the single-nucleotide resolution of the ASV framework.”

      (2) Undefined "ASV I" and "ASV II" groups

      The manuscript refers to "ASV I" and "ASV II" groups in pairwise comparisons of degradation rates (e.g., Fig. 3), but these groups are not defined anywhere in the text.

      It is unclear whether these represent: predefined biological categories, arbitrary pairwise ASV comparisons, or groupings based on taxonomy, abundance, or degradation rate.

      In addition, the pairing structure underlying these comparisons is not described. While a paired t-test is mentioned, it is unclear how ASVs were paired (e.g., within sites, across samples, or across time points).

      The current terminology ("groups") is potentially misleading and suggests biological structure where none may exist. The authors should explicitly define these terms, clarify the pairing scheme, and revise terminology if these are simply pairwise comparisons.

      We thank the reviewer for this keen observation. We completely agree that the terms "ASV I" and "ASV II" were poorly defined and potentially misleading.

      We would like to clarify that "ASV I" and "ASV II" were not intended to represent predefined biological categories (such as groupings based on taxonomy, abundance, or degradation rates). Instead, they were merely used as a labeling convention to indicate the directionality of pairwise comparisons within the heatmap matrix. Specifically, "ASV I" referred to the ASVs represented in the rows, while "ASV II" referred to those in the columns. In the original Fig. 3, blue indicated that the degradation rate of the row ASV was significantly lower than that of the column ASV, and red indicated the opposite. To avoid any confusion, we have removed the “ASV I/II” terminology throughout the manuscript and figures, replacing them with “Row ASVs” and “Column ASVs”. To address this issue, we have revised the Figure 3 legend to include a more explicit explanation:

      L820-824

      “In the heatmap, each cell represents a pairwise comparison between two ASVs. Blue indicates that the degradation rate of the ASVs listed in the row (row ASVs) is significantly lower than that of the ASVs listed in the column (column ASVs); red indicates that the row ASVs has a significantly higher degradation rate than the column ASV. A positive t value indicates that the row ASVs degrades significantly faster than the column ASVs; a negative t value indicates the opposite.”

      We thank the reviewer for raising the important issue regarding the definition of “t values” in our statistical analysis. We apologize for the lack of clarity in the original manuscript. To clarify, the T values presented in Figure 3a represent the test statistics (t-values) from paired t-tests comparing the degradation rate constants of two ASVs across the 30 study sites. The T-value was obtained from a paired t-test between two ASVs across the same samples. The t-value indicates the magnitude and direction of the difference between the two ASVs’ degradation rates relative to the variability across sites. A positive t-value (colored red in the heatmap) indicates the row ASVs degrades significantly faster than the column ASVs; a negative t-value (colored blue) indicates the opposite.

      L544-548

      “As for the analysis, we performed paired t‑tests across all the study sites. Thus, the degradation rates were essentially compared within each site, with both values originating from a same soil sample under identical incubation conditions. A positive t value indicates that the first ASV has a significantly higher degradation rate than the second one, and a negative t value indicates the opposite. The p values were adjusted for multiple comparisons using the FDR method.”

      (3) Lack of definition and justification of "T values"

      The manuscript reports "T values" for comparisons between ASVs but does not clearly define how these values are calculated. Although a paired t-test is mentioned, it remains unclear how the pairing was constructed, whether assumptions (normality, independence) were evaluated, and whether corrections for multiple comparisons were applied. Given the large number of ASVs, failure to control for multiple testing could inflate false positives. More broadly, the use of a simple paired t-test may not be appropriate given the hierarchical and compositional structure of the data.

      We sincerely thank the reviewer for pointing out the need to clarify the definition and justification of the t-values presented in our manuscript. Each t-value represents the test statistic from a paired t-test comparing the degradation rates of two ASVs across the same set of samples. The paired t-test assumes that the differences between paired observations are approximately normally distributed and that the pairs are independent across columns. We have evaluated the normality of differences using standard diagnostic plots and verified that the assumption is reasonably satisfied given the sample size. We performed a correction for multiple comparisons using the False Discovery Rate (FDR) procedure to control for potential false positives. We have revised the Methods section to clearly define t-values.

      (4) Conceptual validity of "sequence-specific degradation"

      The manuscript repeatedly refers to "sequence-specific degradation" of extracellular DNA; however, this concept is not clearly defined nor supported by a biological or structural hypothesis. It is unclear what "sequence-specific" refers to (e.g., nucleotide composition, GC content, secondary structure, taxonomic identity), whether differences are expected in conserved versus variable regions of the 16S rRNA gene, or what mechanistic basis would explain differential degradation among sequences. Given that the analysis is based on short 16S V4 amplicons, and no structural or biochemical framework is provided, it is difficult to interpret whether the observed differences truly reflect intrinsic sequence-dependent degradation or are instead driven by methodological or statistical artifacts (e.g., abundance effects, amplification bias).

      I believe the authors should explicitly define what is meant by "sequence-specific degradation," provide a biologically grounded hypothesis (e.g., structural accessibility, GC content, stem-loop stability), and align their interpretation with the resolution and limitations of the data.

      We thank the reviewer for this critical conceptual comment. We apologize that “sequence‑specific degradation” was not clearly defined and lacked a biological or structural hypothesis. To improve the logical flow of the manuscript, we have restructured the Introduction by moving the three central hypotheses immediately following the discussion of the biochemical mechanisms underlying sequence-specific degradation. This adjustment ensures that the hypotheses are directly grounded in the theoretical framework (e.g., GC content, thermodynamic stability, and secondary structures) presented in the paragraph.

      We now define “sequence‑specific degradation” as statistically significant differences in first‑order degradation rate constants among distinct ASVs, mainly arising from intrinsic DNA properties (base composition, secondary structure, and restriction sites) or differential mineral adsorption.

      L99-104

      “Consequently, we proposed three central hypotheses. (1) The degradation rates of eDNA amplicon fragments were expected to be highly sequence‑specific. (2) The rates and patterns of eDNA fragments degradation would be influenced by environmental factors such as temperature and moisture content. (3) The sequence‑specific degradation of extracellular 16S rRNA gene amplicon fragments would significantly influence estimates of soil prokaryotic abundance and diversity.”

      We also expanded the mechanistic discussion to include GC content and secondary structure.

      L230-235

      “We also examined whether GC content could explain the observed sequence‑specific patterns, but no significant correlation was found (Fig. S4), suggesting that simple base composition is not the primary driver in this study. However, this does not exclude the possibility that higher‑order structural features (e.g., hairpin loops) or sequence‑specific nuclease recognition motifs contribute to differential degradation (Wang et al., 2007). This should be tested in future studies using synthetic DNA constructs with controlled structural elements.”

      We acknowledge that inferring sequence‑specific degradation from combined relative abundance and qPCR data is subject to potential methodological artifacts, including compositional effects, PCR amplification bias, and abundance‑dependent detection limits. However, we have taken several stringent steps to minimize these concerns. Specifically, we restricted our analysis to ASVs that were present in more than 90% of the study sites and for which the degradation curve fits yielded R<sup>2</sup> > 0.5, ensuring that only robustly detected and reliably modeled sequences were retained. Because our analysis tracks the ratio of each ASV across a time series, any sequence-specific PCR amplification bias remains constant for that particular sequence. By focusing on the rate of change rather than absolute read counts, such systematic biases are mathematically canceled out during the calculation of degradation kinetics.

      (5) Conceptual ambiguity in "GAPDH F-labeled 16S rRNA genes"

      The manuscript repeatedly refers to "GAPDH F-labeled 16S rRNA genes," which is confusing and may be misinterpreted as targeting GAPDH rather than 16S. It should be clearly stated that GAPDH refers to glyceraldehyde-3-phosphate dehydrogenase, and a GAPDH-derived sequence is used as a synthetic tag appended to a 16S primer. Additionally, the divergence of this tag from microbial sequences should be justified to ensure specificity. There is also an inconsistency in primer naming (e.g., "GAPDH F" vs "ACTF" in the figures), which should be corrected.

      We sincerely thank the reviewer for this important comment. We agree that the phrase “GAPDH F‑labeled 16S rRNA genes” could be confusing, as it may be misinterpreted as targeting the GAPDH gene rather than the 16S rRNA gene. We have revised the manuscript to avoid this ambiguity and to provide clear justification for the use of the GAPDH tag. GAPDH (glyceraldehyde‑3‑phosphate dehydrogenase) is a human housekeeping gene. Its forward primer sequence (GAPDH F: 5′‑CAT TGG CAA TGA GCG GTT C‑3′) was used as a synthetic tag appended to the 16S primer because (i) no homologous sequences exist in soil DNA (confirmed by PCR), and (ii) its melting temperature is compatible with the reverse primer. This tag allows specific tracking of exogenous DNA without interference from native soil sequences.

      Throughout the manuscript, ambiguous phrases such as “GAPDH F‑labeled 16S rRNA genes” have been replaced with more precise terms, “GAPDH F‑tagged 16S rRNA gene amplicon fragments” clarifying that the tag is an appendage and not the amplification target.

      We have checked the entire manuscript and confirm that “ACTF” does not appear anywhere. To avoid confusion, the primer is now consistently referred to as “GAPDH F” in all figures, legends, and text.

      L360-371

      “GAPDH is a primer for a human housekeeping gene and it has no homologous sequences in soils. Subsequently, GAPDH was selected as the label primer based on two criteria. First, this primer was selected to avoid interference from the original soil sequences (Huang et al., 2014; Yang et al., 2021; Arvizu-Hernandez et al., 2025), and no detectable PCR amplification was observed for the primer set GAPDH F-806R across all the soil DNA samples included in this study. Second, the melting temperature (Tm) value of GAPDH F approximately matched that of 806R. The GAPDH was incorporated only into the forward primer for several reasons. Methodologically, adding a long linker to the degenerate reverse primer (806R) could reduce amplification efficiency or introduce bias. Economically, single-end labeling allowed us to use the standard reverse primer already carrying sample-specific barcodes, avoiding the costly synthesis of a full set of dual-labeled barcoded primers. This design minimized the risk of secondary structure and primer-dimer artifacts while maintaining sufficient specificity and compatibility with downstream qPCR and sequencing.”

      (6) Limitations of using PCR amplicons as proxies for extracellular DNA

      The study uses PCR-generated amplicons to simulate extracellular DNA. While useful for controlled comparisons, these fragments may not reflect the physicochemical diversity of natural extracellular DNA (e.g., adsorption to minerals, fragment size variability, protection within aggregates). This limitation should be explicitly acknowledged, and conclusions should be framed accordingly.

      We appreciate the reviewer’s constructive feedback. We fully acknowledge that using PCR-generated amplicons to simulate extracellular DNA (eDNA) has inherent limitations in capturing the full physicochemical diversity of naturally occurring eDNA in soils. Specifically, we agree that PCR fragments may not replicate features such as highly variable fragment size distributions, associations with complex cellular components (e.g., vesicles or protein complexes), or long-term physical sequestration within soil micro-aggregates. Despite of these limitations, the use of uniform primer-tagged PCR amplicons was a deliberate choice to enable precise tracking of exogenous DNA degradation kinetics while eliminating background interference from endogenous soil eDNA. This design is a prerequisite for the high-resolution kinetic modeling of sequence-specific decay. Furthermore, in our bioinformatic pipeline, the 97% mapping threshold was specifically applied to minimize the influence of stochastic sequencing and PCR errors on abundance quantification. In the revised manuscript, these potential limitations have been addressed.

      L295-299

      “First, utilizing PCR-amplified 16S rRNA gene fragments as proxies oversimplifies the structural and sequence complexity of natural soil eDNA pools. In natural environments, eDNA varies widely in fragment length and conformation, and exhibits complex interactions with mineral surfaces, all of which fundamentally affect degradation dynamics (Levy-Booth et al., 2007; McKinney and Dungan, 2020).”

      (7) Interpretation of sequence-specific degradation

      Sequence-specific degradation rates are inferred from combining relative abundance data with total qPCR estimates. This approach is sensitive to compositional effects, amplification biases, and abundance-dependent detection limits. It remains unclear whether observed differences reflect true sequence-specific degradation or methodological artifacts. This limitation should be discussed more explicitly.

      We thank the reviewer for highlighting this critical methodological point. In our study, sequence-specific degradation rates were estimated by combining ASV-relative abundances with total qPCR-derived 16S rRNA gene copy numbers. We acknowledge that this approach may be influenced by compositional effects, PCR amplification biases, and abundance-dependent detection limits. However, the degradation rate constant (k) in our study, represents the rate of change for a specific sequence over time. Since PCR amplification biases are generally sequence-specific and consistent across samples processed under identical conditions, these systematic errors are mathematically canceled out when calculating the relative change (slope) for the same ASV across a time series. Second, all qPCR measurements were performed with three technical triplicates with standard curves to ensure quantitative reliability. Third, relative abundances were converted to absolute abundances using total qPCR estimates, allowing cross-taxa comparisons that reduce compositional bias. This approach is widely recognized in microbial ecology as a robust method. To address this concern, we have added some explanations in the revised manuscript.

      L84-86

      “In this study, “sequence‑specific degradation” refers to statistically significant differences in first‑order degradation rate constants (k, day<sup>⁻¹</sup>) among distinct 16S rRNA gene amplicon sequence variants (ASVs) under identical soil and incubation conditions.”

      L294-305

      “Despite the high-resolution insights afforded by our methodology, several limitations should be considered. First, utilizing PCR-amplified 16S rRNA gene fragments as proxies oversimplifies the structural and sequence complexity of natural soil eDNA pools. In natural environments, eDNA varies widely in fragment length and conformation, and exhibits complex interactions with mineral surfaces, all of which fundamentally affect degradation dynamics (Levy-Booth et al., 2007; McKinney and Dungan, 2020). Additionally, the highly conserved nature of the 16S rRNA gene means that the nucleotide variability explored here (e.g., GC content gradients) does not fully capture the genomic heterogeneity of entire metagenomes (Knight et al., 2018). Consequently, our reported degradation rates indicate the decay potential of highly accessible linear eDNA rather than a universal rate for all soil DNA fractions. Future studies incorporating diverse metagenomic DNA, especially those with extreme AT or GC contents, are essential for building a more generalizable predictive framework for eDNA persistence (Morrissey et al., 2015).”

      L311-314

      “While our standardized bead-beating protocol and calculation of degradation rate constants (k) minimize systematic biases, future studies should integrate complementary viability markers (e.g., RNA-based analyses or protein synthesis activity probes) and multi-extraction comparisons to robustly validate these ecological patterns (Emerson et al., 2017)..”

      (8) Overinterpretation of PMA-treated samples as "living communities"

      The manuscript interprets PMA-treated DNA as representing intracellular or "living" microbial communities. While PMA is useful, this interpretation should be treated with caution in soils. PMA efficiency can be affected by soil matrix complexity, DNA adsorption to particles, incomplete light penetration, and permeability of compromised cells. Importantly, no validation of PMA efficiency is presented.

      We thank the reviewer for this important caution. We agree that interpreting PMA‑treated DNA as representing “living” or “intracellular” communities is an overstatement in soil systems. In the revised manuscript, we no longer describe PMA-treated DNA as a direct proxy for the “living community,” but instead refer to it as the “PMA-treated prokaryotic community”.

      Although we did not directly validate PMA efficiency in this study, we used a standardized PMA protocol that has been widely applied in microbial ecology, and our goal was to obtain a comparative estimate of the influence of extracellular DNA on community analysis across soils under a consistent methodological framework. Based on previous studies (Carini et al., 2016; Du et al., 2025), which found that in similar soil types, PMA treatment can significantly reduce the interference of extracellular DNA and alter the community structure, this indirectly proves the effectiveness of this technique.

      Nevertheless, we agree that future studies should include explicit validation controls, such as live/dead cell mixtures, heat-killed controls, or soil-specific PMA efficiency tests, to better quantify method performance across diverse soil matrices. We have added a dedicated paragraph in the "Methodological Considerations and Limitations" section to discuss how soil-specific properties (e.g., turbidity, adsorption capacity) might lead to incomplete exclusion of extracellular DNA, thereby advising a more cautious interpretation of the "viable" community data.

      L496-500

      “To inhibit amplification of eDNA, soils were incubated with propidium monoazide (PMA), as described previously (Carini et al., 2016). Upon photoactivation, eDNA can form covalent bonds through cross-linking, leading to the inhibition of its PCR amplification. In contrast, microbes with intact cell membranes exclude PMA, and their DNA is not cross-linked with PMA, and remains amenable to PCR amplification.”

      L294-305

      “Despite the high-resolution insights afforded by our methodology, several limitations should be considered. First, utilizing PCR-amplified 16S rRNA gene fragments as proxies oversimplifies the structural and sequence complexity of natural soil eDNA pools. In natural environments, eDNA varies widely in fragment length and conformation, and exhibits complex interactions with mineral surfaces, all of which fundamentally affect degradation dynamics (Levy-Booth et al., 2007; McKinney and Dungan, 2020). Additionally, the highly conserved nature of the 16S rRNA gene means that the nucleotide variability explored here (e.g., GC content gradients) does not fully capture the genomic heterogeneity of entire metagenomes (Knight et al., 2018). Consequently, our reported degradation rates indicate the decay potential of highly accessible linear eDNA rather than a universal rate for all soil DNA fractions. Future studies incorporating diverse metagenomic DNA, especially those with extreme AT or GC contents, are essential for building a more generalizable predictive framework for eDNA persistence (Morrissey et al., 2015).”

      Minor Comments

      (1) Line 79: Provide examples of how extracellular DNA contributes to nutrient cycling (e.g., P, N sources) and signal transduction (e.g., horizontal gene transfer).

      We thank the reviewer for this helpful suggestion. In the revised manuscript, we have added specific examples to clarify how extracellular DNA contributes to nutrient cycling and signal transduction. Specifically, we now note that extracellular DNA can serve as a source of phosphorus and nitrogen following enzymatic degradation, thereby contributing to soil nutrient turnover. We also clarify that extracellular DNA plays an important role in horizontal gene transfer, acting as a genetic reservoir that can be taken up by competent microorganisms and thereby facilitating the spread of functional traits such as antibiotic resistance. These examples have been added to improve the clarity and biological context of this statement.

      L48-52

      “EDNA serves as a critical vector for horizontal gene transfer (HGT), facilitating the uptake of genetic material by competent microorganisms and promoting the spread of functional traits such as antibiotic resistance (Liu et al., 2024). In addition, eDNA participates in soil biogeochemical cycling because its enzymatic degradation releases bioavailable nutrients, particularly phosphorus and nitrogen, which can be reused by soil microorganisms (Ye et al., 2022).”

      (2) Line 79: Replace "for an extended period of time" with a more precise or referenced timescale.

      We agree with the reviewer. We have replaced the vague phrase with a precise timescale. Extracellular DNA can persist in soils for months to years.

      (3) Line 94: Clarify what is meant by "high-level structure" (e.g., secondary structure, environmental association).

      We thank the reviewer for pointing out this ambiguity. In the original manuscript, the phrase “high-level structure” was not sufficiently precise. In the revised version, we have clarified that this refers primarily to higher-order structural properties of DNA molecules, such as secondary structure, local conformational features, and sequence-dependent interactions with minerals or organic matter in soil. These characteristics may influence the accessibility of extracellular DNA to nucleases and thus affect degradation rates. We have revised the text accordingly to improve clarity and precision.

      L84-104

      “In this study, “sequence‑specific degradation” refers to statistically significant differences in first‑order degradation rate constants (k, day<sup>⁻¹</sup>) among distinct 16S rRNA gene amplicon sequences (ASVs) under identical soil and incubation conditions. The potential variations in sequence-specific eDNA degradation rates can be attributed to several factors. First, sequence-dependent degradation can arise from differences in nucleotide composition, particularly GC content. This influences the thermodynamic stability and base-stacking interactions of the DNA duplex, thereby altering its accessibility to extracellular nucleases (Marrone and Ballantyne, 2008; Wolpe and Guertin, 2022). Second, local conformational features and the formation of potential secondary structures, such as stem-loops or hairpins, can create steric hindrance that protects the phosphodiester backbone. Differences in base composition also alter the elemental stoichiometry (e.g., C: N ratio) of DNA molecules, potentially affecting microbial preference for recycling specific sequences as nutrient sources (Cai et al., 2006a; Buitrago et al., 2021). Third, the persistence of soil DNA is often associated with its adsorption and protection by minerals and humus in soils (Cai et al., 2006b; Vuillemin et al., 2017; McKinney and Dungan, 2020). Thus, sequence-dependent differences in the physicochemical behavior of DNA molecules, including their affinity for soil minerals and organic matter, may also contribute to variation in degradation rates among sequences (Levy-Booth et al., 2007; Morrissey et al., 2015). Consequently, we proposed three central hypotheses. (1) The degradation rates of eDNA amplicon fragments were expected to be highly sequence‑specific. (2) The rates and patterns of eDNA fragments degradation would be influenced by environmental factors such as temperature and moisture content. (3) The sequence‑specific degradation of extracellular 16S rRNA gene amplicon fragments would significantly influence estimates of soil prokaryotic abundance and diversity.”

      (4) Line 111: The hypothesis is not clearly linked to the rationale. If sequence-specific degradation is expected, clarify whether it relates to conserved vs variable regions or structural features (e.g., stems vs loops).

      We thank the reviewer for this helpful comment. We agree that the original manuscript did not clearly link the hypothesis regarding sequence-specific degradation to its mechanistic rationale. In the revised manuscript, we have clarified that the expectation of sequence-specific degradation is not simply based on conserved vs variable regions of the 16S rRNA gene, but rather on the potential for sequence differences to influence intrinsic physicochemical properties, including base composition, local conformational features, potential secondary structures, and motif-dependent nuclease susceptibility. These factors may alter DNA accessibility to extracellular nucleases, providing a mechanistic basis for sequence-specific degradation. This clarification is now reflected in the Introduction and linked to the formal hypothesis statement.

      To improve the logical flow of the manuscript, we have restructured the Introduction by moving the three central hypotheses (H1–H3) immediately following the discussion of the biochemical mechanisms underlying sequence-specific degradation.

      L84-104

      “In this study, “sequence‑specific degradation” refers to statistically significant differences in first‑order degradation rate constants (k, day<sup>⁻¹</sup>) among distinct 16S rRNA gene amplicon sequences (ASVs) under identical soil and incubation conditions. The potential variations in sequence-specific eDNA degradation rates can be attributed to several factors. First, sequence-dependent degradation can arise from differences in nucleotide composition, particularly GC content. This influences the thermodynamic stability and base-stacking interactions of the DNA duplex, thereby altering its accessibility to extracellular nucleases (Marrone and Ballantyne, 2008; Wolpe and Guertin, 2022). Second, local conformational features and the formation of potential secondary structures, such as stem-loops or hairpins, can create steric hindrance that protects the phosphodiester backbone. Differences in base composition also alter the elemental stoichiometry (e.g., C:N ratio) of DNA molecules, potentially affecting microbial preference for recycling specific sequences as nutrient sources (Cai et al., 2006a; Buitrago et al., 2021). Third, the persistence of soil DNA is often associated with its adsorption and protection by minerals and humus in soils (Cai et al., 2006b; Vuillemin et al., 2017; McKinney and Dungan, 2020). Thus, sequence-dependent differences in the physicochemical behavior of DNA molecules, including their affinity for soil minerals and organic matter, may also contribute to variation in degradation rates among sequences (Levy-Booth et al., 2007; Morrissey et al., 2015). Consequently, we proposed three central hypotheses. (1) The degradation rates of eDNA amplicon fragments were expected to be highly sequence‑specific. (2) The rates and patterns of eDNA fragments degradation would be influenced by environmental factors such as temperature and moisture content. (3) The sequence‑specific degradation of extracellular 16S rRNA gene amplicon fragments would significantly influence estimates of soil prokaryotic abundance and diversity.”

      (5) Lines 310-311: Clearly indicate which portion of the primers corresponds to the modified (GAPDH-derived) sequence. Provide full annotated primer sequences.

      We thank the reviewer for this helpful suggestion. In the revised manuscript, we now clearly indicate which portion of the forward primer corresponds to the GAPDH-derived synthetic tag and which portion corresponds to the 16S rRNA gene primer sequence. We have also provided the full annotated primer sequences in the Methods section to avoid ambiguity.

      Specifically, the modified forward primer is now described as:

      GAPDH-F-515F: 5′-CAT TGG CAA TGA GCG GTT C-GTG CCA GCM GCC GCG GTA A-3′,

      where CAT TGG CAA TGA GCG GTT C is the GAPDH-derived synthetic tag and GTG CCA GCM GCC GCG GTA A is the 16S rRNA gene forward primer sequence (515F).

      The reverse primer is:

      806R: 5′-GGA CTA CHV GGG TWT CTA AT-3′.

      L354-359

      “Briefly, exogenous eDNA was prepared by PCR amplification using a modified forward primer consisting of a GAPDH F tag fused to the 16S rRNA gene primer 515F, together with the reverse primer 806R. The full primer sequences were as follows: GAPDH-F-515F: 5'-CAT TGG CAA TGA GCG GTT C-GTG CCA GCM GCC GCG GTA A-3', in which CAT TGG CAA TGA GCG GTT C represents the GAPDH F tag and GTG CCA GCM GCC GCG GTA A represents the 16S rRNA gene forward primer sequence (515F); and 806R: 5'-GGA CTA CHV GGG TWT CTA AT-3'.”

      (6) Lines 310-311: Explicitly define GAPDH and justify its use as a synthetic tag.

      We thank the reviewer for this helpful suggestion. In the revised manuscript, we now explicitly define GAPDH as glyceraldehyde-3-phosphate dehydrogenase, a human housekeeping gene. Specifically, the GAPDH-derived sequence was selected for two reasons. First, it is highly divergent from known soil microbial 16S rRNA gene sequences and did not produce detectable amplification when tested with soil DNA using the GAPDH tagged 806R primer pair, indicating that it would not interfere with endogenous soil DNA signals. Second, its melting temperature was compatible with that of the reverse primer, which allowed stable amplification of the tagged 16S amplicons under our PCR conditions.

      L360-371

      “GAPDH is a primer for a human housekeeping gene and it has no homologous sequences in soils. Subsequently, GAPDH was selected as the label primer based on two criteria. First, this primer was selected to avoid interference from the original soil sequences (Huang et al., 2014; Yang et al., 2021; Arvizu-Hernandez et al., 2025), and no detectable PCR amplification was observed for the primer set GAPDH F-806R across all the soil DNA samples included in this study. Second, the melting temperature (Tm) value of GAPDH F approximately matched that of 806R. The GAPDH was incorporated only into the forward primer for several reasons. Methodologically, adding a long linker to the degenerate reverse primer (806R) could reduce amplification efficiency or introduce bias. Economically, single-end labeling allowed us to use the standard reverse primer already carrying sample-specific barcodes, avoiding the costly synthesis of a full set of dual-labeled barcoded primers. This design minimized the risk of secondary structure and primer-dimer artifacts while maintaining sufficient specificity and compatibility with downstream qPCR and sequencing”

      (7) Line 346: Start a new paragraph to clearly separate this as a distinct experiment.

      We thank the reviewer for this helpful suggestion. In the revised manuscript, we have started a new paragraph.

      (8) Line 346: Specify the number of samples analyzed for consistency.

      We thank the reviewer for this helpful suggestion. In the revised manuscript, we have now explicitly specified the number of samples.

      A total of 120 samples were analyzed in this moisture gradient experiment: 2 ecosystems (Kaiyuan and Dashanbao) × 5 moisture levels (10%, 25%, 50%, 75%, and 100% of water holding capacity) × 6 incubation time points (0, 1, 3, 6, 12, and 24 days) × 2 replicates. Just two technical replicates were performed for this validation experiment, as the primary aim was to assess the trend of moisture effects rather than statistical inference across replicates.

      L408-410

      “This complementary experiment included two sites, five moisture levels, six incubation time points, and two replicates per treatment combination, resulting in a total of 120 soil samples.”

      (9) Lines 351-352: Replace "harvested" with "collected."

      We have replaced “harvested” with “collected” as suggested.

      (10) Line 367: Clarify how Illumina adapters and indices were added (e.g., two-step PCR, fusion primers).

      We thank the reviewer for this helpful suggestion. We have revised the Methods section to clarify how Illumina adapters and indices were incorporated. We used a pooled amplicon library preparation strategy. Individual samples were first amplified with primers containing sample-specific barcode sequences. The barcoded amplicons from multiple samples were then pooled and used for library preparation with the ALFA-SEQ DNA Library Prep Kit. Universal Illumina-compatible adapters were first ligated to the pooled amplicons. After bead-based purification, an indexing PCR was performed using the index primer mix, which introduced the complete P5/P7 sequences and a library-level Illumina index into the library molecules. Thus, sample demultiplexing was based on the sample-specific barcodes introduced during amplicon PCR, whereas the Illumina index was used to identify the pooled sequencing library. We have clarified this procedure in the revised manuscript.

      L424-440

      “The community profiles of the GAPDH F-tagged 16S rRNA gene amplicon fragments were determined using high-throughput amplicon sequencing. Briefly, GAPDH F-tagged 16S rRNA gene amplicon fragments from the microcosm soils were first amplified from individual samples using GAPDH F and barcode-labeled 806R primers. The reverse primer 806R carried a 12-bp sample-specific barcode, whereas the GAPDH F primer did not contain a barcode. Therefore, each sample was assigned a unique barcode during PCR, which allowed sample demultiplexing after sequencing. The PCR reaction system and thermal cycling conditions were similar to those described above, except that the number of amplification cycles was increased to 35 to obtain sufficient amplicon products for sequencing. The barcoded PCR products from individual samples were purified using a GeneJET Gel Extraction Kit (Thermo Scientific, Lithuania), quantified, and then pooled in equimolar amounts for subsequent library construction. Sequencing libraries were prepared from the pooled barcoded amplicons using the ALFA-SEQ DNA Library Prep Kit according to the manufacturer’s protocol. Universal Illumina-compatible adapters were first ligated to the pooled amplicon products, followed by bead-based purification. An indexing PCR was then performed using the index primer mix, which introduced the complete P5/P7 flow-cell binding sequences and a library-level Illumina index into the pooled library molecules. The indexed library was purified, quantified, and subjected to paired-end sequencing on the NovaSeq platform at MAGIGENE Co., Ltd. (Guangzhou, China).

      (11) Provide more detail on chimera removal, filtering thresholds, and normalization choices.

      We thank the reviewer for this helpful suggestion. The raw paired-end reads were first merged, and primer sequences were removed using the search_pcr2 script in USEARCH. Reads with more than two primer mismatches were discarded. Quality filtering was then performed using fastq_filter, and sequences with quality scores below 20 were removed. Redundant reads were collapsed using fastx_uniques. Amplicon sequence variants (ASVs) were generated using the UNOISE3 denoising algorithm, which also performs built-in chimaera filtering during ASV inference. In addition, ASVs with total sequence counts fewer than 9 were excluded to reduce the influence of low-frequency noise.

      L443-460

      “Briefly, paired-end reads were merged using USEARCH, and primer sequences (GAPDH-F-515F and 806R) were removed using the search_pcr2 script. Reads with more than two primer mismatches were discarded. Quality filtering was performed using the fastq_filter script, and sequences with quality scores below 20 were removed. Redundant sequences were dereplicated using the fastx_uniques script. ASVs were generated using the UNOISE3 non‑clustering denoising algorithm (Edgar, 2016), which infers 100% exact sequence variants by distinguishing biological sequences from PCR/sequencing errors. ASVs with total sequence counts fewer than 9 across all samples were removed to reduce noise. To quantify the abundance of each ASV, an ASV table was generated by mapping the quality‑filtered raw reads back to the ASV set using the otutab command. A 97% similarity threshold was applied for this recruitment to accommodate stochastic sequencing noise while maintaining biological resolution. Crucially, the mapping followed a best-hit priority rule, where each read was assigned to the ASV with the highest per cent identity within the 97% radius. This approach ensures that reads derived from the same biological template are accurately counted toward their respective ASV, preventing the underestimation of abundances that would occur with exact matching while strictly preserving the single-nucleotide resolution of the ASV framework. Taxonomic annotation of the ASVs was performed in QIIME2 with the Silva v138 database. A total of 89322 prokaryotic ASVs were obtained. To standardize sequencing depth across samples, the read number of each sample was rarefied to 53251 using the rarefy function in the vegan package in R.”

      (12) Line 412: Rephrase to refer to 16S amplicon addition rather than 16S rRNA genes (along the whole text), as only the V4 region is analyzed.

      We thank the reviewer for this helpful suggestion. we have rephrased references to “16S rRNA genes” to “16S rRNA gene amplicon fragments”

      (13) Ensure consistent primer naming throughout (e.g., GAPDH F vs ACTF).

      We have checked the entire manuscript and confirm that only “GAPDH F” is used as the label primer.

      (14) Finally, the manuscript would benefit from careful language editing. Several typographical errors, grammatical inconsistencies, and unclear phrases are present throughout. Examples include:

      Misspellings such as "diffrence" (e.g., figure legends) and inconsistent capitalization. Inconsistent terminology (e.g., "genes," "amplicons," and "fragments" used interchangeably without clarification). Redundant or awkward phrasing (e.g., repeated use of "extracellular 16S rRNA genes"). Occasional subject-verb agreement issues and missing articles.

      We sincerely apologize for the language issues. The manuscript has now undergone a thorough language editing process by a native English‑speaking colleague.

      Recommendation

      Major revision: The manuscript addresses an important problem and presents a promising approach. However, key issues related to conceptual clarity, bioinformatic consistency, statistical rigor, and interpretation of PMA-based results must be resolved. With substantial revision and clarification, the study has the potential to make a meaningful contribution to the field.

      We sincerely thank the reviewer for the thorough, constructive, and critical evaluation of our manuscript. We greatly appreciate the recognition that our study addresses an important problem and presents a promising approach. We also acknowledge the key issues raised regarding conceptual clarity, bioinformatic consistency, statistical rigor, and interpretation of PMA‑based results. We have taken these comments very seriously and have substantially revised the manuscript accordingly, more details about the revisions are described in the following point-by-point responses.

      Reviewer #2 (Recommendations for the authors):

      Editorial comments:

      (1) Title: I recommend removing "across China" from the title. In many ways, the study has nothing to do specifically with China, and you limit the broad applicability of the study. The same work could have been done with soils from Africa, for example. Also, it might be ok to remove 16S rRNA as well. The 16S rRNA genes are a proxy for rates of extracellular DNA degradation, but the study isn't exactly about 16S either.

      We thank the reviewer for this thoughtful suggestion regarding the title. We have revised the title to “The overall and sequence-specific degradation of soil extracellular DNA fragments: rates and influential factors.”

      (3) L44-45: "...such as real-time PCR, high-throughput amplicon sequencing, and metagenomic analysis...".

      We thank the reviewer for this suggestion. We have revised the order according to the suggestions of the reviewer.

      L44-45

      “The investigation of soil microbial abundance and diversity heavily relies on DNA-based technologies, such as real-time PCR, high-throughput amplicon sequencing, and metagenomic analysis.”

      (4) L48: remove "they".

      We agree with the reviewer and have removed the extraneous “they”.

      (5) L51: "noise factor"; "...persistence can lead to...".

      We have revised the sentence as suggested.

      (6) L53: remove theoretical.

      We have removed “theoretical”.

      (7) L58: remove "the".

      We have removed "the".

      (8) L86: Is restriction digestion of DNA a likely extracellular process in soil?

      We thank the reviewer for this thoughtful comment. We agree that the original wording may have overstated the likelihood of classical restriction digestion as a dominant extracellular process in soils. Our intention was not to suggest that intracellular restriction enzyme systems operate directly in the soil matrix in the same manner as they do within living cells. Rather, we aimed to indicate more generally that sequence-dependent nuclease susceptibility could contribute to differential degradation among extracellular DNA fragments.

      L87-95

      “First, sequence-dependent degradation can arise from differences in nucleotide composition, particularly GC content. This influences the thermodynamic stability and base-stacking interactions of the DNA duplex, thereby altering its accessibility to extracellular nucleases (Marrone and Ballantyne, 2008; Wolpe and Guertin, 2022). Second, local conformational features and the formation of potential secondary structures, such as stem-loops or hairpins, can create steric hindrance that protects the phosphodiester backbone. Differences in base composition also alter the elemental stoichiometry (e.g., C: N ratio) of DNA molecules, potentially affecting microbial preference for recycling specific sequences as nutrient sources (Cai et al., 2006a; Buitrago et al., 2021).”

      (9) L94-99: The authors might also consider the different nitrogen content of different bases; this might also affect sequence-specific selection of DNA for degradation.

      We thank the reviewer for this insightful suggestion. We agree that differences in the elemental composition of DNA bases, including nitrogen content, may provide an additional mechanistic explanation for sequence-dependent degradation. In the revised manuscript, we have incorporated this point into the Introduction.

      L92-95

      “Differences in base composition also alter the elemental stoichiometry (e.g., C:N ratio) of DNA molecules, potentially affecting microbial preference for recycling specific sequences as nutrient sources (Cai et al., 2006a; Buitrago et al., 2021).”

      (10) L110-112: These are not really written in hypothesis form. Also, what about a hypothesis about degradation rates and soil type/temperature/moisture?

      We thank the reviewer for this constructive critique. We have rewritten the hypotheses. To improve the logical flow of the manuscript, we have restructured the Introduction by moving the three central hypotheses immediately following the discussion of the biochemical mechanisms underlying sequence-specific degradation. This adjustment ensures that the hypotheses are directly grounded in the theoretical framework.

      L99-104

      “Consequently, we proposed three central hypotheses. (1) The degradation rates of eDNA amplicon fragments were expected to be highly sequence‑specific. (2) The rates and patterns of eDNA fragments degradation would be influenced by environmental factors such as temperature and moisture content. (3) The sequence‑specific degradation of extracellular 16S rRNA gene amplicon fragments would significantly influence estimates of soil prokaryotic abundance and diversity.”

      (11) L116: "GAPDH F-labeled 16S rRNA gene amplicon fragments....".

      We thank the reviewer for this helpful suggestion. we have rephrased references to “16S rRNA genes” to “16S rRNA gene amplicon fragments”

      (12) L117: "rapidly".

      We agree with the reviewer and have revised.

      (13) L118-120: "After a 48-day incubation period, 0.2 to 3.1% of the initial spike GADPH F-labeled 16S rRNA gene amplicon fragments ...".

      We agree with the reviewer and have revised.

      (14) L125: Spell out SEM in first usage.

      We thank the reviewer for this suggestion. In the revised manuscript, we have spelled out SEM as Structural equation modeling.

      (15) L128: I don't like the idea of putting this Figure in supplemental materials.

      We thank the reviewer for this suggestion. We have moved Figure S2 (moisture gradient microcosm experiment) to the main text as Figure 1f.

      (16) L154: The term "intracellular prokaryotic abundance" is not the right term. This makes one think of an intracellular parasite. I think you want something like: "Approximately 40% of sequences in total soil DNA extraction NGS amplicon libraries were derived from intact cells, while the remaining represented extracellular DNA. Conversely, greater than 80% of observed richness was derived from intact cells." (Please check that I stated this correctly.) I would also suggest some statistics or ranges here.

      We thank the reviewer for this important terminological clarification. We agree that the term “intracellular prokaryotic abundance” is misleading, as it could imply intracellular parasites. In the revised manuscript, we have replaced this with a clearer description and We have also added the across‑site ranges to provide statistical context.

      L163-166

      “The PMA treatment revealed that intact cells accounted for approximately 40% (range: 9–73%) of the total 16S rRNA gene copies. In contrast, over 80% (range: 27–97%) of the observed ASV richness was associated with sequences originating from intact cells (Fig. 4a and b).”

      (17) L168: "...a significant NEGATIVE correlation was observed...".

      We agree with the reviewer and have revised.

      (18) L169: "However, no significant relationship was observed...".

      We agree with the reviewer and have revised.

      (19) L194-195: What about pH and temperature?

      We thank the reviewer for this comment. We agree that pH and temperature are important environmental factors that can influence microbial DNA degradation and community composition. However, our results (Fig. 1c) indicate that soil moisture is the most dominant factor affecting extracellular DNA degradation. Therefore, in the revised manuscript, we have focused the explanation primarily on soil moisture, while acknowledging that pH and temperature may also be important influencing factors.

      L208-211

      “Third, environmental factors, including soil moisture, pH, and temperature, can predominantly govern enzymatic reaction rates (He et al., 2024; Shah et al., 2024). Indeed, strong positive correlations were observed between moisture content and eDNA degradation rates in both the survey and microcosm experiments (Fig. 1d-f).”

      (20) L199: "findings".

      We have revised as suggested.

      (21) L227-229: This sounds more like results.

      We thank the reviewer for this comment. We agree that the original first sentence in L227–229 reads more like results. Our intention was to introduce the discussion by linking extracellular DNA to potential impacts on prokaryotic community analysis, rather than to present specific findings at this point. We have reorganized this section as follows.

      L246-248

      “Accordingly, we further explored how DNA may influence prokaryotic community analyses using PMA treatment, and significant disparities were observed between the profiles of the total and PMA-treated soil prokaryotic communities (Fig. 4).”

      (22) L230: Need to also consider differential cell lysis during DNA extraction.

      We thank the reviewer for this important comment. We agree that differential cell lysis during DNA extraction could influence the observed community profiles, as microbial taxa differ in cell wall composition and resistance to mechanical or chemical lysis. In the revised manuscript, we explicitly acknowledge this limitation in the relevant section. We also clarify that a standardized DNA extraction protocol (DNeasy PowerSoil kit) was used to efficiently lyse a broad range of microbial taxa, but some taxon-specific lysis bias may remain. Future studies could combine multiple lysis methods or spike-in controls to quantify and correct for potential extraction bias.

      L262-265

      “However, as DNA extraction efficiency may differ between intact cells and eDNA, the actual differences between total and living prokaryotic abundance could be smaller than those observed in this study. Similarly, the overestimated prokaryotic richness may arise from historically accumulated microbial taxonomic information stored in eDNA pools (Deshpande and Fahrenfeld, 2023; Wang et al., 2024).”

      L309-311

      “Compounding this issue, downstream DNA recovery is subject to differential cell lysis, as taxa with robust cell walls (e.g., Gram-positive bacteria) may resist extraction (Frostegård et al., 1999; Albertsen et al., 2015).”

      (23) L232: Need to also consider that PMA treatment is not perfect and can be affected by substrate, the ability of light to access DNA for crosslinking, etc.

      We thank the reviewer for this important reminder. We agree that PMA treatment is not perfect and that its efficiency can be affected by soil matrix properties (e.g., organic matter, clay minerals) and the ability of light to penetrate the sample for DNA crosslinking. In the revised manuscript, we have explicitly acknowledged these limitations in the discussion.

      L305-314

      “Second, methodological biases inherent in quantifying the intracellular community must be acknowledged (Du et al., 2025). Although PMA treatment is widely used to exclude eDNA, its efficiency in complex soil matrices can be compromised by limited light penetration in turbid suspensions and competitive adsorption to soil particles (Nocker et al., 2007; Carini et al., 2016; Heise et al., 2016). Compounding this issue, downstream DNA recovery is subject to differential cell lysis, as taxa with robust cell walls (e.g., Gram-positive bacteria) may resist extraction (Frostegård et al., 1999; Albertsen et al., 2015). While our standardized bead-beating protocol and calculation of degradation rate constants (k) minimize systematic biases, future studies should integrate complementary viability markers (e.g., RNA-based analyses or protein synthesis activity probes) and multi-extraction comparisons to robustly validate these ecological patterns (Emerson et al., 2017).”

      (24) L240: Can extracellular DNA have an ecological role?

      We thank the reviewer for this thoughtful question. Yes, extracellular DNA (eDNA) does have important ecological roles beyond being a potential bias in molecular analyses. In the revised manuscript, we have added statements to highlight that extracellular DNA can serve as a nutrient source (e.g., nitrogen and phosphorus) for microbes and may also contribute to horizontal gene transfer. This emphasizes that extracellular DNA may actively influence microbial community structure and function, in addition to its role in potentially inflating observed abundance and richness.

      L267-275

      “We observed a significant correlation between eDNA degradation rates and the overall structure of the prokaryotic community, but this relationship was absent in PMA-treated communities (Fig. 5b). This discrepancy highlights the divergent ecological roles of extracellular and intracellular DNA. Analyses of the total community integrate intracellular DNA from metabolically active cells with eDNA which primarily originates from historical microbial residues (Lennon et al., 2018). EDNA incorporates signals that likely reflect the legacy effects of past environmental conditions (Wang et al., 2021). In contrast, the PMA-treated community reflects transient microbial activity driven by current selective pressures. Additionally, eDNA can serve as a nutrient source and facilitate horizontal gene transfer, which may further shape its interactions with contemporary microbial communities (Levy-Booth et al., 2007).”

      (25) L256: Why would microorganisms selectively degrade one DNA sequence vs another? This seems to be likely to be stochastic in terms of which sequences are taken up by microorganisms. However, different DNA sequences might hydrolyze differently or be otherwise damaged, and that could lead to differential degradation of a viable amplicon. It might be interesting to incorporate long pieces of DNA with different internal primer sites and use quantitative PCR to determine how sequences are degrading.

      We thank the reviewer for this important mechanistic insight. We agree that the observed correlation between degradation rate and sequence abundance does not necessarily imply active microbial preference. It could equally reflect stochastic encounter rates or intrinsic chemical differences (e.g., AT‑rich regions hydrolyzing faster). We have revised the corresponding paragraph in the Discussion.

      L279-292

      “This finding suggests that abundant eDNA degrades at a faster rate compared to rare eDNA. As mentioned earlier, this could be explained by several mechanisms. First, as soil eDNA is subject to enzymatic degradation and microbial recycling, abundant DNA sequences may be more likely to be encountered and degraded by extracellular nucleases simply due to their higher copy numbers (Levy-Booth et al., 2007; Nagler et al., 2018). Similarly, if microbes preferentially take up DNA as a nutrient source, they may degrade abundant sequences more frequently as a stochastic consequence of higher encounter rates (Finkel and Kolter, 2001). However, we also found that the relationships between the sequence-specific degradation rates and the effect sizes of extracellular 16S rRNA gene amplicon fragments varied across the study sites (Fig. S1g). The sequence-specific effect sizes of extracellular 16S rRNA gene amplicon fragments are mainly determined by both their production and degradation rates (Pietramellara et al., 2009; Sirois and Buckley, 2019). These inconsistent correlations emphasize the critical role played by the production rates of extracellular 16S rRNA genes in influencing the analysis of prokaryotic communities. Therefore, future studies should systematically determine both the production and degradation rates of eDNA.”

      (26) L282-283: This belongs in the discussion.

      We agree with the reviewer and have revised accordingly.

      (27) L289: "as well as measurements of total organic carbon".

      We agree with the reviewer and have revised accordingly.

      (28) L338: Any water content for these soils?

      We thank the reviewer for this comment. The water contents of soils from all study sites are reported in Supplementary Table 2.

      (29) L349-350: You mean that you measured the total soil extracted DNA and then added 1% as labeled 16S?

      Yes, for each soil sample, we extracted total soil DNA and quantified its concentration (ng DNA per gram of soil). We then added exogenous GAPDH‑tagged 16S amplicon fragments at an amount equal to 1% of this total DNA concentration. This concentration was chosen to mimic a realistic pulse of extracellular DNA input without overwhelming the endogenous DNA pool. We apologize for any confusion caused by the imprecise wording in the original manuscript.

      L392-398

      “The microcosm experiment was conducted using 30 g of soil for each sample. After pre-incubation at 20℃ for one week, each soil was thoroughly mixed with the GAPDH F‑tagged 16S rRNA gene amplicon fragments and incubated further at 20℃ (Fig. S8). The amount of exogenous GAPDH F‑tagged 16S rRNA gene amplicon fragments added to each soil sample was equivalent to 1% of the total DNA concentration naturally present in that soil, as determined fluorometrically prior to the experiment. This concentration was chosen to approximate natural eDNA fluxes resulting from microbial lysis, ensuring experimental relevance to in situ conditions (Table S2).”

      (30) L354: Remember that soil recovery from intact cells is going to be lower than for extracellular DNA. So, you are probably overestimating the contribution of extracellular DNA to the total DNA in the system.

      We thank the reviewer for this comment. We agree that DNA recovery from intact cells is generally lower than from extracellular DNA due to differential cell lysis efficiencies. Consequently, the contribution of extracellular DNA to total soil DNA may be somewhat overestimated in our study. We have clarified this limitation in the revised manuscript.

      L262-265

      “However, as DNA extraction efficiency may differ between intact cells and eDNA, the actual differences between total and living prokaryotic abundance could be smaller than those observed in this study. Similarly, the overestimated prokaryotic richness may arise from historically accumulated microbial taxonomic information stored in eDNA pools.”

      L305-314

      “Second, methodological biases inherent in quantifying the intracellular community must be acknowledged (Du et al., 2025). Although PMA treatment is widely used to exclude eDNA, its efficiency in complex soil matrices can be compromised by limited light penetration in turbid suspensions and competitive adsorption to soil particles (Nocker et al., 2007; Carini et al., 2016; Heise et al., 2016). Compounding this issue, downstream DNA recovery is subject to differential cell lysis, as taxa with robust cell walls (e.g., Gram-positive bacteria) may resist extraction (Frostegård et al., 1999; Albertsen et al., 2015). While our standardized bead-beating protocol and calculation of degradation rate constants (k) minimize systematic biases, future studies should integrate complementary viability markers (e.g., RNA-based analyses or protein synthesis activity probes) and multi-extraction comparisons to robustly validate these ecological patterns (Emerson et al., 2017).”

      (31) L362: Amplification efficiency is pretty low. I think you would have been better served with GAPDH on both ends, and that would have given you a much higher efficiency qPCR.

      We thank the reviewer for this comment. The actual qPCR amplification efficiency in our assay was approximately 85%, which, although slightly below the ideal range, was still acceptable and produced reproducible amplification curves and reliable quantification for degradation-rate calculations.

      We acknowledge that the amplification efficiency in our qPCR experiments using a GAPDH F-labeled 16S primer on one end was suboptimal. The current design used a single GAPDH tag at the forward primer to avoid potential amplification bias or primer-dimer formation that could arise from extending the degenerate reverse primer. In addition, dual-end labeling would have required synthesis of new barcode-labeled tagged primers, increasing both cost and experimental complexity. Thanks again for the constructive comments, which provided us with the direction for future experiment optimization.

      L365-371

      “The GAPDH was incorporated only into the forward primer for several reasons. Methodologically, adding a long linker to the degenerate reverse primer (806R) could reduce amplification efficiency or introduce bias. Economically, single-end labeling allowed us to use the standard reverse primer already carrying sample-specific barcodes, avoiding the costly synthesis of a full set of dual-labeled barcoded primers. This design minimized the risk of secondary structure and primer-dimer artifacts while maintaining sufficient specificity and compatibility with downstream qPCR and sequencing.”

      (32) L367: Not enough detail on how barcoded libraries were made. UDIs?

      We thank the reviewer for this helpful comment. We have now clarified the library preparation and indexing strategy in the revised Methods section. This amplicon diversity sequencing used a pooled-library strategy. Individual samples were first distinguished by sample-specific inline barcodes introduced during the amplicon PCR step. After amplification, barcoded PCR products from multiple samples were pooled and subjected to library construction using the ALFA-SEQ DNA Library Prep Kit. Universal Illumina-compatible adapters were ligated to the pooled amplicons, followed by an indexing PCR that introduced the complete P5/P7 sequences and a library-level Illumina index. Thus, the Illumina index was used to identify the pooled sequencing library, whereas sample demultiplexing was performed according to the sample-specific inline barcodes. We have revised the Methods section to make this procedure explicit.

      L424-440

      “The community profiles of the GAPDH F-tagged 16S rRNA gene amplicon fragments were determined using high-throughput amplicon sequencing. Briefly, GAPDH F-tagged 16S rRNA gene amplicon fragments from the microcosm soils were first amplified from individual samples using GAPDH F and barcode-labeled 806R primers. The reverse primer 806R carried a 12-bp sample-specific barcode, whereas the GAPDH F primer did not contain a barcode. Therefore, each sample was assigned a unique barcode during PCR, which allowed sample demultiplexing after sequencing. The PCR reaction system and thermal cycling conditions were similar to those described above, except that the number of amplification cycles was increased to 35 to obtain sufficient amplicon products for sequencing. The barcoded PCR products from individual samples were purified using a GeneJET Gel Extraction Kit (Thermo Scientific, Lithuania), quantified, and then pooled in equimolar amounts for subsequent library construction. Sequencing libraries were prepared from the pooled barcoded amplicons using the ALFA-SEQ DNA Library Prep Kit according to the manufacturer’s protocol. Universal Illumina-compatible adapters were first ligated to the pooled amplicon products, followed by bead-based purification. An indexing PCR was then performed using the index primer mix, which introduced the complete P5/P7 flow-cell binding sequences and a library-level Illumina index into the pooled library molecules. The indexed library was purified, quantified, and subjected to paired-end sequencing on the NovaSeq platform at MAGIGENE Co., Ltd. (Guangzhou, China).”

      (33) L368: Why was the # of cycles increased?

      Thank you for your question. In the original manuscript (L368), we stated that the number of PCR cycles was increased to 35. This was mainly because the exogenously added GAPDH F‑labeled 16S rRNA genes had a relatively low initial abundance in the soil and gradually degraded during the microcosm incubation, with their copy numbers becoming particularly low at the last time points (see Fig. 1a). To ensure sufficient PCR product for high‑throughput sequencing from samples at all time points (especially those with low abundance at later stages), we appropriately increased the cycle number to 35.

      L429-431

      “The PCR reaction system and thermal cycling conditions were similar to those described above, except that the number of amplification cycles was increased to 35 to obtain sufficient amplicon products for sequencing.”

      (34) L372: Were sequencing adapters ligated onto the pool?

      We thank the reviewer for this question. Yes, in this amplicon diversity sequencing workflow, sequencing adapters were ligated onto the pooled amplicon products. Briefly, individual samples were first amplified with sample-specific barcode sequences, allowing each sample to be distinguished after sequencing. The barcoded PCR products from multiple samples were then pooled for library construction. Universal Illumina-compatible adapters were ligated to this pooled amplicon library using the ALFA-SEQ DNA Library Prep Kit. After adapter ligation and purification, an indexing PCR was performed to introduce the complete P5/P7 sequences and a library-level Illumina index. We have clarified this pooled-library construction workflow in the revised Methods section.

      L424-440

      “The community profiles of the GAPDH F-tagged 16S rRNA gene amplicon fragments were determined using high-throughput amplicon sequencing. Briefly, GAPDH F-tagged 16S rRNA gene amplicon fragments from the microcosm soils were first amplified from individual samples using GAPDH F and barcode-labeled 806R primers. The reverse primer 806R carried a 12-bp sample-specific barcode, whereas the GAPDH F primer did not contain a barcode. Therefore, each sample was assigned a unique barcode during PCR, which allowed sample demultiplexing after sequencing. The PCR reaction system and thermal cycling conditions were similar to those described above, except that the number of amplification cycles was increased to 35 to obtain sufficient amplicon products for sequencing. The barcoded PCR products from individual samples were purified using a GeneJET Gel Extraction Kit (Thermo Scientific, Lithuania), quantified, and then pooled in equimolar amounts for subsequent library construction. Sequencing libraries were prepared from the pooled barcoded amplicons using the ALFA-SEQ DNA Library Prep Kit according to the manufacturer’s protocol. Universal Illumina-compatible adapters were first ligated to the pooled amplicon products, followed by bead-based purification. An indexing PCR was then performed using the index primer mix, which introduced the complete P5/P7 flow-cell binding sequences and a library-level Illumina index into the pooled library molecules. The indexed library was purified, quantified, and subjected to paired-end sequencing on the NovaSeq platform at MAGIGENE Co., Ltd. (Guangzhou, China).”

      (35) L378: "Amplicon sequence variants".

      We agree with the reviewer and have revised accordingly.

      (36) L380: Why were ASVs with fewer than 9 reads removed?

      We thank the reviewer for this question. The threshold of removing ASVs with fewer than 9 total reads across all samples was applied to reduce noise from sequencing errors and PCR artifacts. Our justification is supported by both the default parameters of the UNOISE3 algorithm and common practice in amplicon sequencing analysis.

      The USEARCH manual specifies that the -minsize parameter in the unoise3 command defaults to 8. This means that unique sequences occurring fewer than 8 times are discarded by the algorithm during ASV inference, as they are unlikely to represent true biological variants. Our threshold of 9 is slightly more conservative than the default (9 > 8), ensuring that only ASVs with a minimal level of abundance are retained. This choice is directly aligned with the algorithm’s intrinsic noise‑filtering logic.

      (37) L402: Please don't forget to discuss that PCR bias can contribute to uncertainty in the abundance of each taxon.

      Thank you for this important reminder. We agree that PCR bias (e.g., primer‑template mismatches, GC content differences, and variable amplification efficiency) can contribute to uncertainty in the abundance estimates of each taxon. Following your suggestion, we have now added a paragraph in the Discussion section to address this issue. We state that sequence‑specific degradation rates and PCR bias may jointly affect the accuracy of taxon abundance estimates, and future studies should incorporate internal standards or multiplex PCR strategies to correct for such biases. Thank you for your careful review.

      L294-305

      “Despite the high-resolution insights afforded by our methodology, several limitations should be considered. First, utilizing PCR-amplified 16S rRNA gene fragments as proxies oversimplifies the structural and sequence complexity of natural soil eDNA pools. In natural environments, eDNA varies widely in fragment length and conformation, and exhibits complex interactions with mineral surfaces, all of which fundamentally affect degradation dynamics (Levy-Booth et al., 2007; McKinney and Dungan, 2020). Additionally, the highly conserved nature of the 16S rRNA gene means that the nucleotide variability explored here (e.g., GC content gradients) does not fully capture the genomic heterogeneity of entire metagenomes (Knight et al., 2018). Consequently, our reported degradation rates indicate the decay potential of highly accessible linear eDNA rather than a universal rate for all soil DNA fractions. Future studies incorporating diverse metagenomic DNA, especially those with extreme AT or GC contents, are essential for building a more generalizable predictive framework for eDNA persistence (Morrissey et al., 2015).”

      (38) L414: Suggest: "To inhibit amplification of extracellular DNA, soils were incubated with propidium monoazide (PMA), as described previously (REF). Briefly, soil (X grams) was mixed with PMA in a total volume of Y (ml).

      We thank the reviewer for this suggestion. We have revised the Methods section to provide a clearer description of PMA treatment, specifying the soil amount (0.50 g) and the total volume (0.5 mL).

      L496-497

      “To inhibit amplification of eDNA, soils were incubated with PMA, as described previously (Carini et al., 2016).”

      L505-506

      “In this study, 0.50 g of soil was mixed with PMA in a total volume of 0.5 mL (40 µM PMA in phosphate‑buffered saline, PBS), while the control soil samples were mixed with PBS without PMA.”

      (39) L416: In contrast, microbes with intact cell membranes exclude PMA, and their DNA is not cross-linked with PMA, and remains amenable to PCR amplification.

      We agree and have revised.

      (40) L418-420: wording/sentence is strange and needs work.

      Thank you for pointing this out. We have reviewed the sentence at L418‑420 and agree that the wording is awkward. Moreover, the content only listed the advantages of the PMA method without acknowledging its limitations, making the statement less balanced. Therefore, in the revised manuscript, we have deleted this sentence. The limitations of the PMA method have been addressed in the Discussion section.

      L502-503

      “Currently, PMA treatment is a widely used to suppress PCR amplification of eDNA (Xue et al., 2023; Canini et al., 2024).”

      L305-314

      “Second, methodological biases inherent in quantifying the intracellular community must be acknowledged (Du et al., 2025). Although PMA treatment is widely used to exclude eDNA, its efficiency in complex soil matrices can be compromised by limited light penetration in turbid suspensions and competitive adsorption to soil particles (Nocker et al., 2007; Carini et al., 2016; Heise et al., 2016). Compounding this issue, downstream DNA recovery is subject to differential cell lysis, as taxa with robust cell walls (e.g., Gram-positive bacteria) may resist extraction (Frostegård et al., 1999; Albertsen et al., 2015). While our standardized bead-beating protocol and calculation of degradation rate constants (k) minimize systematic biases, future studies should integrate complementary viability markers (e.g., RNA-based analyses or protein synthesis activity probes) and multi-extraction comparisons to robustly validate these ecological patterns (Emerson et al., 2017).”

      (41) L421-422: PMA treatment is a widely used method for inhibiting the enzymatic processing of extracellular DNA (Xue, Canini).

      We agree and have revised.

      (42) L425: include volume of PBA.

      We thank the reviewer for this comment. We have revised the Methods section to include the volume of PMA used

      L505-506

      “In this study, 0.50 g of soil was mixed with PMA in a total volume of 0.5 mL (40 µM PMA in phosphate‑buffered saline, PBS).”

      (43) L429-430: Don't use the word precipitates- use "pellets".

      We agree and have revised.

      (44) L433: "The abundance of 16S rRNA genes was determined using quantitative PCR employing a LightCycler...".

      We agree and have revised.

      (45) L445-: Section 4.9 - needs citations for PERMANOVA, NMDS, SEM, etc.

      Thank you for your suggestion. We have added the necessary citations for PERMANOVA, NMDS, SEM, and other methods in Section 4.9.

      L531-539

      Prokaryotic community structure differences among the study sites and incubation time points were examined through non-metric multidimensional scaling analysis (NMDS), permutation multivariate analysis of variance (PERMANOVA), and Permutational Analysis of Multivariate Dispersion (PERMDISP) (Kruskal, 1964; Anderson, 2001). Random forest modeling was conducted to assess the importance of environmental and soil variables in predicting the overall degradation rates of extracellular 16S rRNA gene amplicon fragments. Structural equation modeling (SEM) was employed to further evaluate the direct and indirect effects of soil moisture, soil pH, MAP, and prokaryotic abundance on the overall degradation rates of extracellular 16S rRNA gene amplicon fragments (Grace, 2006).

      (46) L698: A few comments. It would be nice to know how many different 16S sequences were tracked for differential degradation and shown in the figure.

      We thank the reviewer for this helpful comment. We would like to clarify that Fig. 1A does not track the degradation of individual 16S rRNA gene amplicon sequences, but instead shows the overall degradation dynamics of the total added exogenous DNA pool. The data points are derived from total 16S gene copy numbers measured via qPCR at each incubation time point. Consequently, this quantification inherently includes all sequences present within the added pool. The multiple lines visualized in the figure represent the collective degradation trajectories of the entire DNA pool across different study sites

      To address sequence-level changes, we further analyzed the richness and composition of the GAPDH F-tagged 16S rRNA gene amplicon fragments, which are presented in Fig. 2A and related analyses.

      (47) L699: Better to use "16S rRNA gene amplicon fragment abundance" as the term.

      We thank the reviewer for this helpful suggestion. In the revised manuscript, we have replaced the original wording with “16S rRNA gene amplicon fragment abundance” where appropriate.

      (48) Y-axis for Figures 1A and 2A should be GAPDH-labeled, not ACTB-labeled.

      We apologize for this mistake. We have corrected this error in the revised manuscript.

      (49) For Figure 1b: Why not use box plots and ANOVA for different soil types?

      Thank you for your valuable suggestion. In the original Figure 1b, we used a bar plot to display the degradation rate constants across the 30 study sites. This choice was intended to emphasize the continuous variation among sites and their gradient relationships with environmental factors (e.g., soil moisture, MAP), which were then used in random forest and structural equation modeling. The bar plot better illustrates the spatial continuum of degradation rates rather than treating ecosystem types as discrete categories.

      Nevertheless, we fully agree that a boxplot grouped by ecosystem type (grassland, forest, cropland, desert) would help readers quickly grasp the overall differences among land‑use types. In the revised manuscript, we have added a boxplot grouped by ecosystem type and performed one‑way ANOVA followed by Tukey HSD post‑hoc tests (Fig. 1.). The results show that degradation rate constants differ significantly among ecosystem types (P < 0.05).

      L124-128

      “The degradation rate constants of the spiked extracellular 16S rRNA gene amplicon fragments displayed considerable variability among the study sites, ranging from 0.05 to 0.16 day<sup>-1</sup> (Fig. 1b). Furthermore, we found that degradation rate constants differed significantly among ecosystem types (Fig. 1c, P < 0.05). Specifically, cropland and forest soils exhibited significantly higher degradation rates than grassland soils (P < 0.05).”

      (50) For Figure 2: Where are PERMANOVA and PERMDISP values for the figure?

      We thank the reviewer for this comment. In the revised manuscript, we have added the PERMANOVA and PERMDISP values corresponding to Figure 2 in the figure legend and Results section (Fig. 2).

      (51) I found Figure 2b to be hard to see. The 48-day circles are almost invisible. Difficult to know what the authors are trying to show here, since there is so much variability associated with soil type.

      We thank the reviewer for this comment. Figure 2b is intended to illustrate the temporal changes in microbial community structure during the incubation. The different colored circles represent samples at different time points (1, 3, 6, 12, 24, and 48 days), showing how communities shift over time. We apologize that in the original Figure 2b, the 48‑day samples were nearly invisible and that the high variability among soil types obscured the intended message. In the revised manuscript, we have added a black border around every data point, which greatly enhances the visibility of the 48‑day samples (and all time points). We now use distinct shapes to represent different ecosystem types (grassland, forest, cropland, desert) in the NMDS ordination, and added PERMANOVA results in both the Results section and the figure legend (Fig. R2b).

      (52) Figure 4A: Y-axis need a label like "16S rRNA gene abundance".

      We agree and have revised.

      (53) Figure 4B: I'd like to see a Shannon index too, not just richness.

      Thank you for your suggestion. We agree that the Shannon index, which integrates both richness and evenness, provides a valuable complement to richness alone. In the revised manuscript, we added an analysis of the Shannon index to compare α‑diversity between total DNA (PMA‑untreated) and intact cell DNA (PMA‑treated) samples (Fig.4).

      (54) Figure 4D: Would be good to have lines linking the intact cell vs total abundance. Also, what about a box plot of Bray-Curtis (or similar) dissimilarity between intact cell and total microbial analysis across the dataset?

      Thank you for your suggestions. Regarding the addition of connecting lines in Figure 4D, after careful consideration we decided not to add them for the following reason: the total and PMA-treated communities from the same site are already coded with the same color (different colors for different sites), which effectively indicates the pairing. Adding lines would greatly reduce readability due to dense overlapping lines, especially given the number of sites. Therefore, we kept the original color‑based pairing design.

      To address your second suggestion, we have added a bar plot showing the distribution of Bray‑Curtis dissimilarities between total (PMA‑untreated) and intact cell (PMA‑treated) communities across all study samples (Fig. R3d).

      (55) Figure 5B: What do correlations with p > 0.05 show? I would remove these from the image.

      We thank the reviewer for this suggestion. We agree that correlations with p > 0.05 do not represent statistically significant relationships and may cause confusion. In the revised manuscript, we have removed these non-significant correlations from Figure 5B.

      (56) Figure 6: "Incubations of 0, 3, 6, 12, 24, and 48 days".

      We agree with the reviewer and have revised as suggested.

      References

      Albertsen, M., Karst, S.M., Ziegler, A.S., Kirkegaard, R.H., Nielsen, P.H., 2015. Back to basics–the influence of DNA extraction and primer choice on phylogenetic analysis of activated sludge communities. PLoS One 10, e0132783.

      Anderson, M.J., 2001. A new method for non‐parametric multivariate analysis of variance. Austral Ecology 26, 32-46.

      Arvizu-Hernandez, E., Ocadiz-Delgado, R., Gariglio, P., 2025. E7HPV16 Oncogene and 17beta-Estradiol Stress Promote Oncogenic microRNA Expression Patterns, Cell Proliferation and Cervical Intraepithelial Neoplasia 1. Cell Biochemistry and Function 43, e70065.

      Buitrago, D., Labrador, M., Arcon, J.P., Lema, R., Flores, O., Esteve-Codina, A., Blanc, J., Villegas, N., Bellido, D., Gut, M., 2021. Impact of DNA methylation on 3D genome structure. Nature Communications 12, 3243.

      Cai, P., Huang, Q., Zhang, X., Chen, H., 2006a. Adsorption of DNA on clay minerals and various colloidal particles from an Alfisol. Soil Biology and Biochemistry 38, 471-476.

      Cai, P., Huang, Q.Y., Zhang, X.W., 2006b. Interactions of DNA with clay minerals and soil colloidal particles and protection against degradation by DNase. Environmental Science & Technology 40, 2971-2976.

      Carini, P., Marsden, P.J., Leff, J.W., Morgan, E.E., Strickland, M.S., Fierer, N., 2016. Relic DNA is abundant in soil and obscures estimates of soil microbial diversity. Nature Microbiology 2, 1-6.

      Deshpande, A.S., Fahrenfeld, N.L., 2023. Influence of DNA from non-viable sources on the riverine water and biofilm microbiome, resistome, mobilome, and resistance gene host assignments. Journal of Hazardous materials 446, 130743.

      Du, Y., Wang, Z., Liu, K., Chai, G., Chi, Y., Li, T., Duan, Y., Xia, T., Liu, D., Che, R., 2025. The performance of different methods in characterizing soil live prokaryotic diversity and abundance is highly variable. iMetaOmics, e70011.

      Emerson, J.B., Adams, R.I., Román, C.M.B., Brooks, B., Coil, D.A., Dahlhausen, K., Ganz, H.H., Hartmann, E.M., Hsu, T., Justice, N.B., 2017. Schrödinger’s microbes: tools for distinguishing the living from the dead in microbial ecosystems. Microbiome 5, 86.

      Finkel, S.E., Kolter, R., 2001. DNA as a nutrient: novel role for bacterial competence gene homologs. Journal of Bacteriology 183, 6288-6293.

      Frostegård, Å., Courtois, S., Ramisse, V., Clerc, S., Bernillon, D., Le Gall, F., Jeannin, P., Nesme, X., Simonet, P., 1999. Quantification of bias related to the extraction of DNA directly from soils. Applied and Environmental Microbiology 65, 5409-5420.

      Grace, J.B., 2006. Structural equation modeling and natural systems. Cambridge University Press.

      He, P., Li, L.-J., Dai, S.-S., Guo, X.-L., Nie, M., Yang, X., Kuzyakov, Y., 2024. Straw addition and low soil moisture decreased temperature sensitivity and activation energy of soil organic matter. Geoderma 442, 116802.

      Heise, J., Nega, M., Alawi, M., Wagner, D., 2016. Propidium monoazide treatment to distinguish between live and dead methanogens in pure cultures and environmental samples. Journal of Microbiological Methods 121, 11-23.

      Huang, C., Xie, D.C., Cui, J.J., Li, Q., Gao, Y., Xie, K.P., 2014. FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System. Clinical Cancer Research 20, 1477-1488.

      Knight, R., Vrbanac, A., Taylor, B.C., Aksenov, A., Callewaert, C., Debelius, J., Gonzalez, A., Kosciolek, T., McCall, L.-I., McDonald, D., 2018. Best practices for analysing microbiomes. Nature Reviews Microbiology 16, 410-422.

      Kruskal, J.B., 1964. Nonmetric multidimensional scaling: a numerical method. Psychometrika 29, 115-129.

      Lennon, J.T., Muscarella, M.E., Placella, S.A., Lehmkuhl, B.K., 2018. How, when, and where relic DNA affects microbial diversity. mbio 9, e00637-00618.

      Levy-Booth, D.J., Campbell, R.G., Gulden, R.H., Hart, M.M., Powell, J.R., Klironomos, J.N., Pauls, K.P., Swanton, C.J., Trevors, J.T., Dunfield, K.E., 2007. Cycling of extracellular DNA in the soil environment. Soil Biology and Biochemistry 39, 2977-2991.

      Liu, Q.H., Yuan, L., Li, Z.H., Leung, K.M.Y., Sheng, G.P., 2024. Natural organic matter enhances natural transformation of extracellular antibiotic resistance genes in sunlit water. Environmental Science & Technology 58, 17990-17998.

      Marrone, A., Ballantyne, J., 2008. Sequence Specificity of BAL 31 Nuclease for ssDNA Revealed by Synthetic Oligomer Substrates Containing Homopolymeric Guanine Tracts. PLoS One 3, e3595.

      McKinney, C.W., Dungan, R.S., 2020. Influence of environmental conditions on extracellular and intracellular antibiotic resistance genes in manure-amended soil: A microcosm study. Soil Science Society of America Journal 84, 747-759.

      Morrissey, E.M., McHugh, T.A., Preteska, L., Hayer, M., Dijkstra, P., Hungate, B.A., Schwartz, E., 2015. Dynamics of extracellular DNA decomposition and bacterial community composition in soil. Soil Biology and Biochemistry 86, 42-49.

      Nagler, M., Insam, H., Pietramellara, G., Ascher-Jenull, J., 2018. Extracellular DNA in natural environments: features, relevance and applications. Applied Microbiology and Biotechnology 102, 6343-6356.

      Nocker, A., Sossa-Fernandez, P., Burr, M.D., Camper, A.K., 2007. Use of propidium monoazide for live/dead distinction in microbial ecology. Applied and Environmental Microbiology 73, 5111-5117.

      Pietramellara, G., Ascher, J., Borgogni, F., Ceccherini, M., Guerri, G., Nannipieri, P., 2009. Extracellular DNA in soil and sediment: fate and ecological relevance. Biology and Fertility of Soils 45, 219-235.

      Shah, A., Huang, J., Han, T., Khan, M.N., Tadesse, K.A., Daba, N.A., Khan, S., Ullah, S., Sardar, M.F., Fahad, S., 2024. Impact of soil moisture regimes on greenhouse gas emissions, soil microbial biomass, and enzymatic activity in long-term fertilized paddy soil. Environmental Sciences Europe 36, 120.

      Sirois, S.H., Buckley, D.H., 2019. Factors governing extracellular DNA degradation dynamics in soil. Environmental Microbiology Reports 11, 173-184.

      Vuillemin, A., Horn, F., Alawi, M., Henny, C., Wagner, D., Crowe, S.A., Kallmeyer, J., 2017. Preservation and significance of extracellular DNA in ferruginous sediments from Lake Towuti, Indonesia. Frontiers in Microbiology 8, 1440.

      Wang, X., Ganzert, L., Bartholomaus, A., Amen, R., Yang, S., Guzman, C.M., Matus, F., Albornoz, M.F., Aburto, F., Oses-Pedraza, R., Friedl, T., Wagner, D., 2024. The effects of climate and soil depth on living and dead bacterial communities along a longitudinal gradient in Chile. The Science of the total environment 945, 173846.

      Wang, Y.-T., Yang, W.-J., Li, C.-L., Doudeva, L.G., Yuan, H.S., 2007. Structural basis for sequence-dependent DNA cleavage by nonspecific endonucleases. Nucleic Acids Research 35, 584-594.

      Wang, Y., Yan, Y., Thompson, K.N., Bae, S., Accorsi, E.K., Zhang, Y., Shen, J., Vlamakis, H., Hartmann, E.M., Huttenhower, C., 2021. Whole microbial community viability is not quantitatively reflected by propidium monoazide sequencing approach. Microbiome 9, 1-13.

      Wolpe, J., Guertin, M., 2022. Regional and Single Nucleotide Correction of Sequence Bias in Chromatin Accessibility Data. The FASEB Journal 36.

      Yang, A., Liu, X., Liu, P., Feng, Y.Z., Liu, H.B., Gao, S., Huo, L.M., Han, X.Y., Wang, J.R., Kong, W., 2021. LncRNA UCA1 promotes development of gastric cancer via the miR-145/MYO6 axis. Cellular & Molecular Biology Letters 26, 33.

      Ye, M., Zhang, Z., Sun, M., Shi, Y., 2022. Dynamics, gene transfer, and ecological function of intracellular and extracellular DNA in environmental microbiome. iMeta 1, e34.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      Summary: The manuscript describes a modular, doxycycline-inducible lentiviral vector platform that enables conditional overexpression, RNAi-mediated knockdown, and CRISPR-based perturbations, combined with fluorescent and luminescent reporters for multiplexed tracking of cell populations. Using this system, the authors perform pooled, competitive in vitro and in vivo assays, focusing on hormone receptor dependencies (ER, PR, AR) in MCF7 breast cancer cells. The key biological conclusion is that AR depletion has minimal effects in vitro but significantly impairs growth in vivo, and that combined hormone receptor knockdown leads to synergistic growth suppression in a xenograft model.

      Major comments: 1. Strength of evidence supporting the key conclusions: The technical demonstration of the vector platform is generally convincing, particularly the modular design and the feasibility of multiplexed fluorescent tracking. However, the biological conclusions are only partially supported by the data. The claim that hormone receptor interdependence, and in particular AR dependence, is revealed specifically in vivo rests on a single cell line (MCF7), a limited number of animals, and a small set of shRNAs-some of which appear to have weak or no functional impact in vitro. As such, the conclusions should be clearly qualified as preliminary and context-specific, rather than presented as generalizable insights into hormone receptor biology. In particular, the strong concluding statements (final paragraph of the manuscript) should be toned down to reflect: the limited number of models tested, the absence of mechanistic insight, and the reliance on RNAi-based perturbations without rescue experiments.

      We thank the reviewer for this important point. We agree that reliance on a single cell line, limited animal numbers, and possible variability in shRNA performance warranted more cautious framing of the biological conclusions. We have added an explicit caveat paragraph before the closing summary stating that these findings should be regarded as proof of concept, generated in a single breast cancer cell line (MCF7) using a limited number of animals and a small panel of shRNAs whose individual potency was not exhaustively benchmarked. The AR-dependency finding, in particular, is based on RNA interference alone, without orthogonal rescue experiments or mechanistic follow-up, and should be interpreted as preliminary and context-specific rather than as a generalizable feature of AR biology. We have also softened the closing sentence of the manuscript from “accelerates the preclinical development...” to “may help inform future preclinical strategies for hormone-sensitive breast cancer and beyond, pending validation in additional models.”

      1. Claims that require qualification or revision: Several claims appear overstated relative to the data provided: a. The assertion that the system enables robust temporal control of perturbations is not supported by quantitative data on leakiness, induction kinetics, or stability of editing over time.

      Thank you for raising these points. To address the concerns, we repeated the experiments, including time-course analyses and DNA sequencing with the inducible CAS9 and qRNA, and now present the data in Figure 2. These results show the induction kinetics of the system and address the leakiness of the double-inducible CRISPR/CAS9 system. Because DNA editing is a permanent change to the DNA, we assume that the stability of the edit over time will also be permanent (see Figure 2 and Supplemental Table 2).

      The claim that pooled multiplexed perturbation "reveals" discrepancies between in vitro and in vivo AR function is based on a narrow experimental scope and should be reframed as an illustrative example rather than a definitive finding. Thank you for pointing this out. We have revised and softened the claims by removing “reveals” and replacing it with “suggests” throughout the manuscript.

      Statements implying reduced off-target effects due to temporal regulation are speculative and should be removed unless supported by data. Thank you for pointing this out. We have removed those parts from the manuscript and revised the relevant sentences to avoid speculation about off-target effects, which are largely determined by the design of gRNAs and shRNAs.

      Additional experiments essential to support the paper (limited and realistic): Only minimal additional experiments are required to support the manuscript as it stands: a. Quantification of inducibility and leakiness of the dual Tet CRISPR system (e.g., untreated vs. dox-treated control in Fig. 2C, and time-course of editing efficiency).

      Thank you for the suggestion. We have now performed this experiment and included the data (see the new Figure 2G).

      Quantification of FUCCI reporter outputs (cell-cycle phase distributions) rather than representative images alone. Thank you for the suggestion. We repeated the experiment and quantified the FUCCI reporter output (see Figure 3).

      Reproducibility and methodological clarity: Several aspects of the methodology require clarification to ensure reproducibility: a. Lentiviral titers and recombination rates are not reported. Given the complexity and size of the constructs, this information is essential. We have added more detailed descriptions of the experimental procedures to the Methods section and have repeated the Cas9 transduction experiments, including their corresponding results and viral titers (see Figure 2 and Supplementary Figure 6).

      It is unclear how background editing is prevented in the dual Tet CRISPR system, since both Cas9 and gRNA are present in the same cells and may exhibit basal expression. We use serum from South America, where standard antibiotic treatment is less common than in the United States, reducing the likelihood that doxycycline is present and minimizing basal expression. The rationale for using double-inducible systems is to minimize basal expression of both components and thereby reduce the chance that either one reaches levels sufficient for editing. We have also made the underlying design logic explicit in the manuscript: because unwanted editing requires both Cas9 and gRNA to be simultaneously present above a functional threshold, and each is independently repressed through a distinct tetracycline-responsive mechanism (Tet-On for Cas9, Tet-Off for gRNA), the probability of coincident leaky expression of both components is substantially lower than for either component alone. This is now linked to the empirically measured background editing rate (~4% over 11 days without doxycycline, by ONT sequencing; Fig. 2G).

      The manuscript does not adequately address integration-based leakiness of doxycycline-inducible systems in lentiviral backbones, especially compared to transposon-based approaches. Thanks for this point. While we have not directly compared our system with transposon-based approaches, we have added a brief section on this in the Discussion to address this point explicitly. Because our system relies on polyclonal, antibiotic- or FACS-selected populations rather than single-cell-validated clones, some degree of integration site–dependent leakiness in the noninduced state cannot be fully excluded and may contribute to the low background editing (~4%) we observe over extended culture. We contrast this with transposon-based delivery systems (piggyBac, Sleeping Beauty), which have distinct genomic integration profiles relative to lentivirus, and note that doxycycline-inducible piggyBac constructs have, in some contexts, achieved tighter regulation with undetectable basal leakiness in vivo. This may reflect the absence of viral LTR-associated regulatory elements and the lentiviral bias toward active chromatin. We discuss chromatin insulators, safe-harbor-targeted integration, and transposon-based delivery as potential strategies to further reduce leaky background expression in future iterations of the platform.

      The description of how MCF7-luciferase cells are used to generate lentiviral vectors is confusing and must be clarified. We have updated this in the revised manuscript and hope it is clearer now.

      Replication and statistical analysis: The statistical treatment of pooled competition data is insufficiently detailed. It is unclear how many animals, glands, or technical replicates contribute to each comparison. The manuscript does not clearly report the fraction of cells recovered for single, double, and triple knockdowns. Multiple comparisons and normalization strategies are not consistently explained. We apologize if these sections were difficult to follow and have substantially expanded them in the manuscript. Because a recurring concern with any pooled, barcoded competition assay is that the fluorescent tag, lentiviral integration site, or clonal origin of a population could itself influence engraftment or proliferation independently of the intended genetic perturbation, we now normalize each doxycycline-treated population to its own untreated (−Dox) baseline and then express it relative to the equivalently normalized NT population within the same tumor (Fig. 5C, F). We also report the numbers of animals and glands contributing to each comparison directly in the Fig. 5 legend, and we justify this normalization approach in more detail in a new paragraph in the Discussion.

      Minor comments: a. Comparison to existing Gateway-compatible systems (e.g. the John Doench system) would help contextualize the technical advance.

      Thank you. We have now added a paragraph to the Discussion that compares our platform with existing Gateway-based and CRISPR/Cas9 lentiviral resources, including the Broad Institute's Genetic Perturbation Platform co-developed by Doench and colleagues (Brunello, Dolcetto, Calabrese). This paragraph clarifies that our system is complementary to these genome-scale discovery tools rather than competing with them: it is designed for hypothesis-driven, combinatorial, multiplexed perturbation studies with tight temporal control and validated ex vivo and in vivo applications, rather than for large-scale single-modality screening.

      Page 5, line 6: "The ..." should be "It ...". Thank you for the comment and we have corrected this. c. P2A sequences are not self-cleaving; the manuscript should correctly state that the ribosome skips peptide bond formation between the last two amino acids.

      Thank you for the comment and we have corrected this.

      Fig. 2C lacks an untreated control. Thank you for this. Instead of using an untreated control, we used two different guides targeting USP14 and USP7 to validate the inducible gRNA with constitutively expressed Cas9. For the knockdown controls, each gene served as the control for the other in the corresponding experiments, demonstrating that knockdown could be achieved with the specific inducible gRNA.

      Fig. 2E (AkaLuc panel): the label "Reagent" is incorrect and overly broad; a clearer and more consistent nomenclature is needed. Thank you for bringing this to our attention; we have corrected it in the revised manuscript. The panel has also been moved and now appears as Fig. 3B, with the axis relabeled “Ctrl”/“+Substrate” in place of “Reagent.” The purpose of fluorescence-based tracking of cell populations is not clearly explained; the rationale should be explicitly stated. We have now added an explicit rationale at the start of this Results subsection: multiplexed fluorescence barcoding is used to pool several genetically distinct cell populations and track them side by side within the same well, culture, or animal. This allows different genotypes to be compared under identical experimental conditions rather than across separate parallel experiments. This internally controlled design reduces confounding variability arising from well-to-well, batch-to-batch, or animal-to-animal differences and increases the statistical power obtained per experiment. It is particularly valuable in vivo, where it substantially reduces the number of animals required, in keeping with the 3Rs principles.

      Claims that hormone supplementation rescues AR depletion are not supported, particularly given the lack of a clear AR-dependent phenotype in prior assays (e.g. Fig. S3A). Thank you for bringing this up. We have rewritten this section and clarified that it behaves more like the non-targeting control shRNA (NT).

      The large difference in proliferation between NT cells {plus minus} doxycycline in Fig. 4B is concerning and may reflect a normalization or analysis error; this should be addressed. Thank you for pointing this out. We have now included additional raw data for clarity and addressed the issue accordingly, so it should not be misinterpreted in the future. Figures would benefit from clearer legends specifying n, statistical tests, and normalization procedures. Thank you for pointing this out; we have addressed it in the revised manuscript. Reviewer #1 (Significance (Required)):

      Nature and significance of the advance: This work represents a technical advance, rather than a conceptual or biological one. The modular lentiviral platform for inducible perturbations and multiplexed fluorescent tracking is potentially useful, particularly for pooled in vivo competition assays where reducing animal use is desirable.

      Context within existing literature: Inducible lentiviral shRNA and CRISPR systems, as well as fluorescent barcoding strategies, are well established. The main contribution here is the integration of these elements into a single, modular framework. However, the manuscript would benefit from clearer comparison to existing systems (including Gateway-based and inducible CRISPR platforms) and discussion of known limitations of lentiviral Tet systems.

      Audience: The work will primarily interest I) cancer biologists performing functional genetic screens, ii) researchers developing or applying genetic perturbation tools, and iii) laboratories interested in pooled in vivo assays. The biological findings regarding hormone receptor interdependence are likely of more limited interest unless further validated.

      Reviewer expertise: My expertise includes functional cancer genomics, lentiviral and CRISPR-based perturbation systems, in vitro and in vivo genetic screening approaches, as well as bioinformatics. I have sufficient expertise to evaluate the technical platform and biological conclusions presented.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Summary This study presents a novel, modular lentiviral platform integrating inducible overexpression, shRNA knockdown, and CRISPR/Cas9 editing within a single system. Its core innovation lies in the versatile design, utilizing Gateway cloning to enable rapid exchange of 14 fluorescent proteins, 3 luminescent reporters, and selection markers, facilitating high-content phenotyping. A dual doxycycline-inducible architecture ensures precise temporal control, minimizing off-target effects. Methodologically, it introduces a robust fluorescence barcoding strategy, allowing multiplexed tracking of up to nine distinct genetic perturbations in pooled assays. When applied to breast cancer intraductal xenografts, this revealed critical in vivo receptor interdependencies-such as the essential roles of AR, ER and PR, in tumor growth. By enabling combinatorial genetic analysis within single animals, this technology significantly reduces experimental variability and animal usage by up to eightfold, advancing both the efficiency of functional genomics and adherence to ethical research standards.

      Major comments 1. Despite using an inducible system, shRNA and CRISPR components may still have off-target effects. In the F4 study, was whole-genome sequencing or transcriptomic analysis performed to assess unintended perturbations of non-target genes?

      Because we did not aim to conduct detailed mechanistic studies or present shRNA as a new technology, and because the hairpins used are not novel and have already been described in published studies, we did not attempt to identify or test potential off-target genes in this work.

      Barcode stability: Are the fluorescent barcodes stably expressed during long-term in vivo culture? Is there a risk of silencing or loss that could affect the reliability of long-term tracking?

      The in vivo studies we conducted lasted more than 30 days. The cells were first validated by qPCR and Western blot, generating transgenic cells that were then expanded for all replicates and validations, including the in vivo experiments. The barcodes are driven by the EF1α promoter, which is not expected to be susceptible to methylation and, in theory, should support expression in long-term in vivo studies even beyond the 30-day duration used here.

      Cell-cell interference: In mixed transplantation experiments, could different genotypes influence each other through paracrine signaling or competition for resources, leading to observed growth phenotypes that are not entirely cell-autonomous?

      Thank you for raising this important point. We observed similar ex vivo effects on growth reduction in single experiments (except for AR in vitro) as we did in vivo with the mixed population. In all in vivo studies, whether mixed or single, the cancer cells injected into a mouse are never cell-autonomous. That is also why one performs in vivo studies using genetic perturbations: to demonstrate that cellular dependencies on genes are not in vitro artifacts, to show that certain genes are important in an in vivo setting, and to reveal how a gene affects the microenvironment in vivo, not just ex vivo. Because tumors are inherently heterogeneous, one could also argue that a mixture of different genotypes allows us to study tumor evolution with greater insight into different gene losses.

      Applicability to non-coding genes or weak-effect genes: This platform relies on observable phenotypic changes for screening. Is it sensitive enough for genes with weak effects or functional redundancy in regulatory networks?

      Thank you for the interesting question. In theory, the approach should be sensitive enough to use with genes that do not cause a growth defect. The functional readouts should then be further tailored to this purpose, using reporter assays, biomarker assays, or alternative sequencing-based readouts to study different gene-specific consequences. The barcodes can still be used to separate cells by flow cytometry and then to analyze them with the assay of choice.

      Are there differences in the induction efficiency of different shRNA or CRISPR components? Could this lead to biases in certain barcode signals, thereby affecting the accuracy of competitive growth analysis?

      Thank you for the question. We did not detect any induction efficiency effects that would bias the barcoding, as we used hairpins and gRNA guides that have been validated or previously used in the literature. However, this does not mean such bias could not occur in some cases.

      Because we also use a “no doxycycline” control, one can not only study the intercell grafting efficacy of any transgenic cell but also estimate the theoretical growth based on NT and non-dox samples. This can normalize any calculations if such bias affects the dynamics of the hairpin or gRNA. Inclusion of the no-dox control accounts for this directly: each doxycycline-treated population is normalized to its own untreated (−Dox) baseline before being expressed relative to the similarly normalized NT population within the same tumor (Fig. 5C, F). We have now implemented and reported this normalization in the manuscript, with the rationale explained in a new Discussion paragraph, rather than treating it only as a theoretical mitigation.

      Are there variations in the packaging efficiency of different shRNA or CRISPR components into lentiviral vectors? Does this affect viral titer? How is copy number consistency achieved in cells after lentiviral transduction? Has the knockdown efficiency been compared between cells transduced with 3 shRNAs and those with single shRNA? Thank you for the questions. For the shRNA and gRNA transductions, the plasmids are approximately the same size, and we have not observed any differences in transduction efficiency between these vectors. Purity and other factors during vector isolation usually have a more pronounced effect on transduction efficiency.

      The vectors that are difficult to transduce are those encoding CAS9 itself; in particular, inducible CAS9 is more challenging to transduce, and achieving a good viral titer is important for efficient transduction. We repeated an experiment and transduced the cells with different viral titers and found that the number of cells surviving antibiotic selection correlated with titer, but after expansion they expressed similar levels of CAS9.

      Since we do not use monoclonal cells and instead work with polyclonal transgenic lines, we assume that random integration should occur in a similar way as in the NT control, and therefore we did not karyotype the cells or analyze copy numbers. The knockdown efficiency was similar when comparing single and triple knockdown. We have now incorporated this explanation directly into the Methods section of the manuscript, stating explicitly that all shRNA and gRNA expression plasmids are of comparable size with no consistent differences in packaging or transduction efficiency, that titer is more strongly influenced by plasmid purity and preparation than by insert identity, and that knockdown efficiency assessed by Western blot was comparable between single, double, and triple knockdown lines (Fig. 4E–G), indicating that combinatorial transduction with multiple shRNAs did not measurably compromise silencing efficiency per target.

      Minor comments 1. The labeling "NT" in Data F3 and Supplementary Data SF3 is unclear. Do they refer to the same condition? Is DOX added in the "NT" condition in SF3? Thank you for pointing this out. NT refers to non-targeting shRNA cells, and they are treated the same as the other cells in all panels. We have updated the figure legend to clarify this.

      Cost-effectiveness ratio: Although animal use is reduced, is the cost of constructing the multiplexed barcoded viral library significantly higher than traditional methods? Is its overall economic feasibility suitable for large-scale screening? The cost of creating any shRNA or gRNA is only negligibly higher when generating different guides or hairpins and producing them with multiple barcodes, especially compared with in vivo study and animal costs. That is why we based our calculations not on construct costs but on animal costs and, more importantly, on the reduction in the number of animals needed.

      For large-scale screening, the system can distinguish only among nine barcodes, gene targets, and all their combinations, so it is not currently designed for settings in which more than nine genes are targeted.

      Reviewer #2 (Significance (Required)):

      The most important significance of the study is integrating multiple technologies into one system enabling high-content phenotyping, which may facilitate the discovery of new biological pathways.

  2. Aug 2026
    1. Author response:

      The following is the authors’ response to the original reviews

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The authors perform an analysis of the relationship between the size of an LMM and the predictive performance of an ECoG encoding model made using the representations from that LMM. They find a logarithmic relationship between model size and prediction performance, consistent with previous findings in fMRI. They additionally observe that as the model size increases, the location of the "peak" encoding performance typically moves further back into the model in terms of percent layer depth, an interesting result worthy of further analysis into these representations.

      Strengths:

      The evidence is quite convincing, consistent across model families, and complementary to other work in this field. This sort of analysis for ECoG is needed and supports the decade-long enduring trend of the "virtuous cycle" between neuroscience and AI research, where more powerful AI models have consistently yielded more effective predictions of responses in the brain. The lag analysis showing that optimal lags do not change with model size is a nice result using the higher temporal resolution of ECoG compared to other methods like fMRI.

      We thank the reviewer for their thoughtful assessment! We agree that the “virtuous cycle” between neuroscience and AI research has been, and will continue to be, a driving force in advancing our understanding of brain function through more powerful predictive models. We are especially pleased that the reviewer appreciated the lag analysis, as we view this as a valuable complement to the existing fMRI work.

      Weaknesses:

      I would have liked to have seen the data scaling trends explored a bit too, as this is somewhat analogous to the main scaling results. While better performance with more data might be unsurprising, showing good data scaling would be a strong and useful justification for additional data collection in the field, especially given the extremely limited amount of existing language ECoG data. I realize that the data here is somewhat limited (only 30 minutes per subject), but authors could still in principle train models on subsets of this data.

      We thank the reviewer for their valuable suggestion. For the revised manuscript, we performed a new analysis where we trained encoding models using subsets of the data (randomly sampling contiguous chunks of 50%, 25%, and 10% of all words in each of the training folds) and tested these models on all words in the test fold. As expected, we found that encoding performance increases as the training dataset size increases, suggesting that model performance scales with data quantity even within the constraints of our relatively small dataset. This result reinforces the importance of collecting dense ECoG data. We have added the following text to our Results section: “We also built encoding models using subsets of the data and found that encoding performance increases as the volume of training data increases (Fig. S6)” and included the results as a supplementary figure 6 in the revised manuscript.

      Separately, it would be nice to have better justification of some of these trends, in particular the peak layerwise encoding performance trend and the overall upside-down U-trend of encoding performance across layers more generally. There is clearly something very fundamental going on here, about the nature of abstraction patterns in LLMs and in the brain, and this result points to that. I don't see the lack of justification here as a critical issue, but the paper would certainly be better with some theoretical explanation for why this might be the case.

      We thank the reviewer for this insightful comment. The general inverted U-shaped trend of encoding performance across layers has been a frequently observed phenomenon in studies comparing LLM representations to brain activity (Goldstein, Ham, et al., 2025; Schrimpf et al., 2021). A potential explanation is the existence of a “two-phase abstraction process” within LLMs (Cheng & Antonello, 2024; Csordás et al., 2025). In the initial layers, models begin by processing relatively low-level input features. As layers get deeper, representations become increasingly abstract and richly contextualized in semantic features relevant for understanding language. These intermediate layers often show the highest correlation with brain activity in language areas, presumably because they capture complex semantic and contextual information in a way that generalizes well across a variety of tasks (including prediction of human neural activity) (Antonello & Huth, 2024). Subsequently, a prediction phase happens in the later layers, where the representations become more specialized for the LLM's specific training objective (e.g., next-word prediction). This specialization can effectively constrict the more generalized feature representations, making these layers less optimal for predicting brain activity. These observations suggest that it is primarily the abstractive, contextual features developed in the intermediate layers of LLMs that drive their alignment with brain activity. As models become more potent at prediction, their most predictive layers (for the LLM’s natural language task) and their most generalizable layers (for brain activity) can diverge.

      A key finding in our study is that the initial processing phase does not scale and take up more layers as models scale up in size and layers. Larger models develop the necessary rich, abstract representations in the same number of layers as smaller models. Consequently, the prediction phase may begin relatively earlier in these larger models, and the later layers could develop highly specialized representations that are increasingly divergent from the more general linguistic processing captured in brain activity. For example, these layers may specialize in capturing very specific patterns of language (thus lowering their perplexity) that do not actually occur often or at all in our naturalistic dataset. It is also possible that the later layers of larger models are overall underutilized and do not contribute as much to linguistic processing and next-word prediction (Csordás et al., 2025).

      We have added the following text to our Discussion section:

      “The inverted U-shaped trend of encoding performance commonly found in previous research is likely due to a "two-phase abstraction process" within LLMs (Cheng & Antonello, 2024; Csordás et al., 2025). In the early and intermediate layers of the model, a composition phase occurs, where low-level input features become increasingly abstract and contextualized. The intermediate layers of the model show the highest correlation with brain activity, presumably because they capture complex semantic and contextual information in a way that generalizes well across a variety of tasks (including prediction of human neural activity) (Antonello & Huth, 2024). Subsequently, a prediction phase happens in the later layers of the model, where the representations become more specialized for the LLM's specific training objective (e.g., next-word prediction). This specialization can effectively constrict the more generalized feature representations, making these layers less optimal for predicting brain activity. Our results indicate that the initial composition phase does not take up more layers as models scale up in size. Larger models develop the necessary rich, abstract representations in the same number of layers as smaller models. Thus, as LLMs increase in size, the later layers of the model may contain representations that are increasingly divergent from the more general linguistic processing captured in brain activity. It is also possible that the later layers of larger models are overall underutilized and may not significantly contribute to benchmark performances during inference (Csordás et al., 2025; Fan et al., 2024; Gromov et al., 2024).”

      Lastly, I would have wanted to see a similar analysis here done for audio encoding models using Whisper or WavLM as this is the modality where you might see real differences between ECoG and other slower scanning approaches. Again, I do not see this omission as a fundamental issue, but it does seem like the sort of analysis for which the higher temporal resolution of ECoG might grant some deeper insight.

      We appreciate this suggestion. In a separate project, we focused on multimodal audio-to-speech-to-language large language models (LLMs), building encoding models using Whisper embeddings (from both the encoder and decoder stacks) to predict electrocorticographic (ECoG) signals during naturalistic conversations (Goldstein, Wang, et al., 2025). The higher temporal resolution of ECoG enables us to trace the temporal flow of information from the superior temporal gyrus (STG) and somatomotor areas (SM) to the inferior frontal gyrus (IFG) during speech comprehension. Conversely, during speech production, encoding in IFG peaked significantly earlier than in the STG and SM. We agree that scaling encoding models using multimodal approaches and our ECoG conversation datasets could yield valuable insights, and we look forward to exploring this in future work. However, we feel that the added complexity of multimodal encoding models falls beyond the scope of this paper.

      We have modified the following text to our Discussion section:

      “Since we exclusively employ textual LLMs, which lack inherent temporal information due to their discrete token-based nature, future studies utilizing multimodal LLMs integrating continuous audio or video streams, like Whisper or WavLM may better unravel the relationship between model size and temporal dynamic representations in LLMs (Goldstein, Wang, et al., 2025; Millet et al., 2023; Vaidya et al., 2022).”

      Reviewer #2 (Public review):

      Summary:

      This paper investigates whether large language models (LLMs) of increasing size more accurately align with brain activity during naturalistic language comprehension. The authors extracted word embeddings from LLMs for each word in a 30-minute story and regressed them against electrocorticography (ECoG) activity time-locked to each word as participants listened to the story. The findings reveal that larger LLMs more effectively predict ECoG activity, reflecting the scaling laws observed in other natural language processing tasks.

      Strengths:

      (1) The study compared model activity with ECoG recordings, which offer much better temporal resolution than other neuroimaging methods, allowing for the examination of model encoding performance across various lags relative to word onset.

      (2) The range of LLMs tested is comprehensive, spanning from 82 million to 70 billion parameters. This serves as a valuable reference for researchers selecting LLMs for brain encoding and decoding studies.

      (3) The regression methods used are well-established in prior research, and the results demonstrate a convincing scaling law for the brain encoding ability of LLMs. The consistency of these results after PCA dimensionality reduction further supports the claim.

      We thank the reviewer for their thoughtful and positive feedback.

      Weaknesses:

      (1) Some claims of the paper are less convincing. The authors suggested that "scaling could be a property that the human brain, similar to LLMs, can utilize to enhance performance", however, many other animals have brains with more neurons than the human brain, making it unlikely that simple scaling alone leads to better language performance.

      We thank the reviewer for this insightful comment. We agree that simply having more neurons does not automatically confer more complex or human-like cognitive or linguistic capabilities. This suggestion deserves a more nuanced treatment than we had included in the original manuscript.

      Research in comparative neuroscience has argued that human cognitive abilities emerge from scaling up the primate brain (Herculano-Houzel, 2012). However, the critical aspect is not merely the number of neurons, but how these neurons contribute to computational power within a specific evolutionary and cultural context. The uniqueness of human cognition has been argued to result from a global adaptation for increased information processing capacity (Cantlon & Piantadosi, 2024). Moreover, the language network in humans is likely grounded in the evolution of particular structural networks in the primate brain (Friederici & Becker, 2025). This suggests that the way brain regions are connected and the expansion of certain pathways are critical, not just the overall scale. Furthermore, the specialized structure must be tuned by its learning environment and training data. For example, both humans and LLMs learn from language data generated by other humans, which reflects world knowledge that has accumulated over many generations.

      We have modified the following text in the Introduction:

      “Research in comparative neuroscience has suggested that uniquely human cognitive abilities emerge from scaling up the primate brain (Herculano-Houzel, 2012).”

      We also added a caveat to the Discussion on this point:

      “As in the human brain, while scaling alone may yield emergent cognitive abilities (Cantlon & Piantadosi, 2024; Herculano-Houzel, 2012), specialized architectural features likely also play a critical role (Friederici & Becker, 2025).”

      Additionally, the authors claim that their results show 'larger models better predict the structure of natural language.' However, it remains unclear to what extent the embeddings of LLMs capture the "structure" of language better than the lexical semantics of language.

      We appreciate the reviewer's point about how well LLM embeddings capture the "structure" of language versus just lexical semantics. It's true that distinguishing these aspects is complex. From our perspective, a model's ability to predict/produce natural language entails that the model captures various levels of linguistic structure, including morphology, syntax, semantics, and contextual dependencies. We use "structure" inclusively in this sense. A model cannot achieve high predictive accuracy without representing, to some extent, all of these structural elements (Linzen & Baroni, 2021; Manning et al., 2020; Pavlick, 2022). There is a very active field of research into understanding exactly how these models represent these different structures of language (Ameisen et al., 2025; Chemla et al., 2024; Elhage et al., 2021, 2022; Hewitt & Manning, 2019). Our results confirm the core trend that larger models tend to better reproduce the various structures of language (i.e., yield lower perplexity; Fig. 2A).

      In previous work, we have shown that LLM embeddings better predict neural activity during natural language processing than lexical embeddings (e.g., GloVe) that do not contain other elements of linguistic structure (Goldstein et al., 2022; Kumar et al., 2024; Zada et al., 2024). In response to the following comment, we also compare LLMs to simpler models capturing specific speech and language features (see next comment). To clarify our intended use of the word “structure”, we’ve added a brief explanation in the Methods section:

      “In this study, we use the term “structure” to refer to a variety of linguistic patterns (e.g., morphology, syntax, semantics, context) that LLMs encode in order to better predict natural language.”

      (2) The study lacks control LLMs with randomly initialized weights and control regressors, such as word frequency and phonetic features of speech, making it unclear what the baseline is for the model-brain correlation.

      We’ve added several supplementary analyses to the revised manuscript to address these concerns. To establish a baseline, we extracted embeddings from each layer of the SMALL model with randomly initialized weights and constructed encoding models. The encoding performance is significantly higher for pretrained SMALL than for untrained SMALL for every layer (Fig. S4). For the untrained model, the performance is the highest for the 0th layer and decreases in subsequent layers. This is because at the 0th layer, every instance of the same word receives an identical, albeit random, embedding (See Supplementary Figure 4).

      We also compared the encoding performance of LLMs with more classical speech/language features and static GloVe embeddings (Goldstein, Wang, et al., 2025; Kumar et al., 2024). First, we extracted features capturing lower-level speech features. Using the stimulus transcript as input, we created one-hot vectors for phonetic and articulatory features. Phoneme classes (39 total classes) were obtained from the Carnegie Mellon Pronouncing Dictionary (The CMU Pronouncing Dictionary, n.d.). We further classified the phonemes based on their place of articulation (9 classes), manner of articulation (9 classes), and voiced or voiceless status (3 classes), according to the general American English consonants of the International Phonetic Alphabet. Given that each word consists of multiple phonemes, we averaged the one-hot vectors for all phonetic and articulatory features for each word.

      Second, we extracted linguistic features using spaCy (Honnibal et al., 2020), including part of speech (17 classes), tag (50 classes), function or content word (3 classes), dependency (45 classes), whether the word is an alpha character (binary), and whether the word is a stop word (binary). We also extracted prefix (30 classes) and suffix (44 classes) information using the Cambridge Dictionary. We constructed one-hot vectors for each multi-class feature and one-dimensional vectors for each binary feature.

      Third, for each word, we obtained word frequency from the Google Web Trillion Word Corpus (Brants & Franz, 2006) and from our own dataset.

      Fourth, we generated static word embeddings of dimension 50 using GloVe (Pennington et al., 2014).

      We then built encoding models in the same way as the contextual embeddings for each of the three categories of speech features, all speech features concatenated, and the GloVe embeddings. To control for the different dimensions of the embeddings, we also standardized all embeddings to the same size (50 dimensions) using principal component analysis (PCA) and trained linear encoding models using ordinary least-squares (OLS) regression. For both ridge and OLS encoding, our contextual embeddings from LLMs showed significantly better performance than the classic speech features and GloVe embeddings.

      We have added the following text to our manuscript and updated our Figures S4, S5, Table S1, and the methods section:

      “To establish a general baseline for encoding performance, we built encoding models using embeddings from the SMALL model with randomly initialized weights. The trained SMALL model exhibits significantly higher encoding performance across all layers compared to the untrained SMALL model (Fig. S4). We also assessed the encoding performance of contextual embeddings from LLMs against classic speech features and static GloVe embeddings (Table S1). The SMALL and XL embeddings achieved markedly higher encoding correlations than the speech features and GloVe embeddings (Fig. S5).”

      (3) The finding that peak encoding performance tends to occur in relatively earlier layers in larger models is somewhat surprising and requires further explanation. Since more layers mean more parameters, if the later layers diverge from language processing in the brain, it raises the question of what aspects of the larger models make them more brain-like.

      We thank the reviewer for this insightful comment; this point was also highlighted by Reviewer 1. We agree that this result is somewhat surprising, and we aim to provide a more detailed explanation in the revised manuscript. The general inverted U-shaped trend of encoding performance across layers has been a frequently observed phenomenon in studies comparing LLM representations to brain activity (Goldstein, Ham, et al., 2025; Schrimpf et al., 2021). A potential explanation is the existence of a “two-phase abstraction process” within LLMs (Cheng & Antonello, 2024; Csordás et al., 2025). In the initial layers, models begin by processing relatively low-level input features. As layers get deeper, representations become increasingly abstract and richly contextualized in semantic features relevant for understanding language. These intermediate layers often show the highest correlation with brain activity in language areas, presumably because they capture complex semantic and contextual information in a way that generalizes well across a variety of tasks (including prediction of human neural activity) (Antonello & Huth, 2024). Subsequently, a prediction phase happens in the later layers, where the representations become more specialized for the LLM's specific training objective (e.g., next-word prediction). This specialization can effectively constrict the more generalized feature representations, making these layers less optimal for predicting brain activity. These observations suggest that it is primarily the abstractive, contextual features developed in the intermediate layers of LLMs that drive their alignment with brain activity. As models become more potent at prediction, their most predictive layers (for the LLM’s natural language task) and their most generalizable layers (for brain activity) can diverge.

      A key finding in our study is that the initial processing phase does not scale and take up more layers as models scale up in size and layers. Larger models develop the necessary rich, abstract representations in the same number of layers as smaller models.

      Consequently, the prediction phase may begin relatively earlier in these larger models, and the later layers could develop highly specialized representations that are increasingly divergent from the more general linguistic processing captured in brain activity. For example, these layers may specialize in capturing very specific patterns of language (thus lowering their perplexity) that do not actually occur often or at all in our naturalistic dataset. It is also possible that the later layers of larger models are overall underutilized and do not contribute as much to linguistic processing and next-word prediction (Csordás et al., 2025).

      We have added the following text to our Discussion section:

      “The inverted U-shaped trend of encoding performance commonly found in previous research is likely due to a "two-phase abstraction process" within LLMs (Cheng & Antonello, 2024; Csordás et al., 2025). In the early and intermediate layers of the model, a composition phase occurs, where low-level input features become increasingly abstract and contextualized. The intermediate layers of the model show the highest correlation with brain activity, presumably because they capture complex semantic and contextual information in a way that generalizes well across a variety of tasks (including prediction of human neural activity) (Antonello & Huth, 2024). Subsequently, a prediction phase happens in the later layers of the model, where the representations become more specialized for the LLM's specific training objective (e.g., next-word prediction). This specialization can effectively constrict the more generalized feature representations, making these layers less optimal for predicting brain activity. Our results indicate that the initial composition phase does not take up more layers as models scale up in size. Larger models develop the necessary rich, abstract representations in the same number of layers as smaller models. Thus, as LLMs increase in size, the later layers of the model may contain representations that are increasingly divergent from the more general linguistic processing captured in brain activity. It is also possible that the later layers of larger models are overall underutilized and may not significantly contribute to benchmark performances during inference (Csordás et al., 2025; Fan et al., 2024; Gromov et al., 2024).”

      Reviewer #3 (Public review):

      This manuscript studies the connection between neural activity collected through electrocorticography and hidden vector representations from autoregressive language models, with the specific aim of studying the influence of language model size on this connection. Neural activity was measured from subjects who listened to a segment from a podcast, and the representations from language models were calculated using the written transcription as the input text. The ability of vector representations to predict neural activity was evaluated using 10-fold cross-validation with ridge regression models.

      The main results are that (as well summarized in section headings):

      (1) Larger models predict neural activity better.

      (2) The ability of language model representations to predict neural activity differs across electrodes and brain regions.

      (3) The layer that best predicts neural activity differs according to model size, with the "SMALL" model showing a correspondence between layer number and the language processing hierarchy.

      (4) There seems to be a similar relationship between the time lag and the ability of language model representations to predict neural activity across models.

      Strengths:

      (1) The experimental and modeling protocols generally seem solid, which yielded results that answer the authors' primary research question.

      (2) Electrocorticography data is especially hard to collect, so these results make a nice addition to recent functional magnetic resonance imaging studies.

      We thank the reviewer for their thoughtful and positive feedback.

      Weaknesses:

      (1) The interpretation of some results seems unjustified, although this may just be a presentational issue.

      (a) Figure 2B: The authors interpret the results as "a plateau in the maximal encoding performance," when some readers might interpret this rather as a decline after 13 billion parameters. Can this be further supported by a significance test like that shown in Figure 4B?

      We agree that this could be a subjective interpretation, so we conducted an additional analysis. We performed paired two-sided t-tests between best layer encoding performances averaged across electrodes (df = 159 electrodes), comparing all models with larger models. We found that after 13 billion parameters, only the encoding performance for OPT-66B, the largest model in the OPT family, is significantly worse than the encoding performance of some other smaller models, supporting the claim that the maximal encoding performance declines after 13 billion parameters. However, we did not find conclusive statistical evidence of a decline in encoding performance for other model families.

      We have added the statistical results as Supplementary Figure 1.

      We have also modified the following text in the manuscript:

      “We also observed a plateau in the maximal encoding performance, occurring around 7 billion parameters (Fig. 2B), with a decline in performance for the OPT-66B model (Fig. S1).”

      (b) Figure S1A: It looks like the drop in PCA max correlation is larger for larger models, which may suggest to some readers that the same trend observed for ridge max correlation may not hold, contra the authors' claim that all results replicate. Why not include a similar figure as Figure 2B as part of Figure S1?

      PCA is an unsupervised dimensionality reduction technique and may discard model features with small eigenvalues that nonetheless contribute to encoding performance. Ridge regression, a supervised method, can capitalize on these features. We suspect that this is why there appears to be a larger drop in model performance for larger models with PCA than with ridge regression. We replicated the logarithmic relationship between model size and encoding performance using PCA and ordinary least-squares (OLS) regression encoding models. We have updated Supplementary Figure 2.

      (2) Discussion of what might be driving the main result about the influence of model size appears to be missing (cf. the authors aim to provide an explanation of what seems to drive the influence of the layer location in Paragraph 3 of the Discussion section). What explanations have been proposed in the previous functional magnetic resonance imaging studies? Do those explanations also hold in the context of this study?

      We suspect that the increased expressivity of larger models - that is, their improved sensitivity to nuanced structure in natural language - yields improved alignment to brain activity (given large enough samples of brain activity) (Antonello et al., 2023). This effect persists even when dimensionality is tightly controlled in our PCA-based analysis, indicating that the improved alignment with the brain is not a modeling artifact of dimensionality alone, but results from the structural representations learned by these larger models.

      We have added the following text to our Discussion section:

      “We suspect that the improved alignment with brain activity in larger models is driven by their increased expressivity and sensitivity to nuanced linguistic structure present in large-scale naturalistic datasets (Antonello et al., 2023).”

      (3) The GloVe-based selection of language-sensitive electrodes (at least to me) isn't explained/motivated clearly enough (I think a more detailed explanation should be included in the Materials and Methods section). If the electrodes are selected based on GloVe embeddings, then isn't the main experiment just showing that representations from larger language models track more closely with GloVe embeddings? What justifies this methodology?

      We selected electrodes based on previously established methods (Goldstein et al., 2022). Our use of GloVe embeddings for electrode selection does not imply that larger language model representations are simply more closely aligned with GloVe embeddings. On the contrary, contextual embeddings from LLMs, which incorporate the word’s previous context, consistently outperform static embeddings like GloVe or word2vec (Fig. S3). Selecting electrodes using LLM embeddings would likely result in a slightly different, potentially larger set of electrodes (Goldstein et al., 2022), but would be more circular (Kriegeskorte et al., 2009). The GloVe-based electrode selection represents a more conservative approach by identifying words encoding linguistic content without biasing the selection directly toward any LLMs.

      We have added the following text to our Method section:

      “We used GloVe embeddings for electrode selection to avoid biasing our main results toward a particular LLM.”

      (4) (Minor weakness) The main experiments are largely replications of previous functional magnetic resonance imaging studies, with the exception of the one lag-based analysis. Is there anything else that the electrocorticography data can reveal that functional magnetic resonance imaging data can't?

      We thank the reviewer for this thoughtful question. While we agree that a key contribution of our work corroborates previous fMRI findings, we would argue that using ECoG is not merely a replication but a crucial validation and extension of that work. It is important to validate these effects across distinct measurement modalities. In our work, we further observed a novel trend where the peak encoding performance tends to occur in relatively earlier layers for larger models. This is supported by recent studies suggesting that later layers of large LLMs may not significantly contribute to benchmark performance (Csordás et al., 2025). While scaling has been an effective method to improve LLM performance, including in encoding models, future research should explore the potential underutilization of the later layers as models scale.

      Furthermore, ECoG data offers temporal resolution on the order of milliseconds, far superior to fMRI’s. Although we did not observe a relationship between model size and temporal lags in this study, future work should investigate the temporal dynamics of encoding that are accessible with ECoG (Goldstein, Ham, et al., 2025; Goldstein, Wang, et al., 2025).

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      Thank you to the authors for the fun and personally useful read.

      I see in Supplementary Figure 1 the authors show a comparison of the performance between OLS vs. Ridge regression. Is the OLS model the only one that is working over PC features, or are both models using PC features? The current text is a bit unclear. My current understanding is that the comparison is between (OLS + PCA) and (Ridge with no PCA), but I am not sure.

      The OLS model is the only one that works over PC features, following previous methods (Goldstein et al., 2022).

      We have added the following text to our Results and Methods section for clarity:

      “To control for the different embedding dimensionality across models, we standardized all embeddings to the same size using principal component analysis (PCA) and trained linear encoding models using ordinary least-squares (OLS) regression, replicating the logarithmic relationship but with significantly lower encoding performance overall (Fig. S2). The PC features are used by the OLS models only.”

      Clarification in the text would be appropriate. If this is the correct understanding, the authors should note in the main text that the ridge approach is more effective than the PCA approach, which is still the dominant approach to building linear encoding models in the field for some unjustifiable reason.

      We thank the reviewer for pointing out the confusion. We have updated Supplementary Figure 2.

      How were the alpha values for ridge regression determined? Do you use the same ridge parameter for all electrodes or fit a different parameter for each electrode? This is not mentioned anywhere.

      The alpha values are determined by cross-validation using the “RidgeCV” method from the “himalaya” package (Dupré la Tour et al., 2022). Specifically, we perform a grid search over cross-validation folds in the training data to find the best-performing alpha. The alpha parameter is specific to each ridge regression model, meaning each fold, lag, and electrode has a different alpha parameter.

      We have added the following text to our manuscript:

      “For each ridge regression model (for each fold, lag, and electrode), the alpha parameter is determined by cross-validation using the “RidgeCV” method from the “himalaya” package (Dupré la Tour et al., 2022).”

      It's not entirely clear to me how the authors handle tokens that do not terminate in words (such as the "there" + "'s" example in the text). My current reading of the text is that authors essentially ignore these half-word embeddings, doing one forward pass per word, rather than per token, but the current text is somewhat ambiguous.

      If a word is tokenized into several tokens, like “there” and “‘s”, we average the token embeddings to get a word embedding.

      We have added the following text to our Method section:

      “To facilitate a fair comparison of the encoding effect across different models, we aligned all tokens in the story across all models. We averaged the token embeddings if a word is split into multiple tokens, resulting in one embedding per word for each model.”

      The authors describe the scaling relationship they find as a "log-linear" relationship. I believe this is a misnomer derived from the original paper describing this relationship in fMRI as log-linear (Antonello et al.) The correct term is simply "logarithmic", and for what it's worth, the authors of the original fMRI work have made this correction as well.

      Thank you! We have made this correction.

      Is the data publicly available? If not, there should be some basic justification as to why (consent reasons, etc.).

      We have recently made the data publicly available (Zada et al., 2025). We have also provided tutorials for preprocessing the data and training encoding models: https://hassonlab.github.io/podcast-ecog-tutorials. For this specific project, the analysis code is available at https://github.com/hassonlab/247-pickling/tree/scaling-paper-0 and https://github.com/hassonlab/247-encoding/tree/scaling-paper-1.

      The authors assert that ECoG has "superior spatiotemporal resolution". While this is unquestionably true for temporal resolution, the story is a bit more complicated for spatial resolution, where ECoG has far less cortical coverage than fMRI. Perhaps this sentence should be revised.

      Thank you for pointing out the typo! We have changed it to “superior temporal resolution”.

      Minor Points:

      The bolded title of Figure 3 probably shouldn't be bolded, as this is just actually the title of Figure 3A.

      Fixed.

      Figure 4d is has a typo: "Best Encoidng Layer".

      Fixed.

      Reviewer #2 (Recommendations for the authors):

      The authors could consider adding control regressors such as word rate, word frequency, phonetic features, and syntactic features like node counts, as well as control LLMs of comparable size to serve as baselines. The authors could also include correlation analyses of the embeddings from different layers of the same LLM to further illustrate how distinct the layers are within the models.

      We have added untrained LLM embeddings as a baseline and included a comparison of encoding models between LLM contextual embeddings and classical speech features. We have also performed some preliminary correlation analyses of embeddings. In some models, we found evidence of the “two-phase abstraction process” (Cheng & Antonello, 2024). However, the result is inconclusive across different LLM families. Since each LLM layer accesses and modifies the residual stream (Elhage et al., 2021), the embeddings across layers are inherently correlated. Future work could instead explore the isolated transformations within each layer to illustrate the distinct information across layers (Kumar et al., 2024).

      The analysis codes and data should be made available.

      We have recently made the data publicly available (Zada et al., 2025). We have also provided tutorials for preprocessing the data and training encoding models: https://hassonlab.github.io/podcast-ecog-tutorials. For this specific project, the analysis code is available at https://github.com/hassonlab/247-pickling/tree/scaling-paper-0 and https://github.com/hassonlab/247-encoding/tree/scaling-paper-1.

      Reviewer #3 (Recommendations for the authors):

      Most of my concrete recommendations are in the public review. Below are some additional minor ones:

      (1) Introduction: "Remarkably, these models learn from much the same shared space as humans: from real-world language generated by humans."

      I think this is an extremely strong claim due to e.g. the different nature of child-directed speech vs. written text corpora, the lack of multimodality and grounding in language models, etc. I might suggest re-wording this sentence or removing it entirely.

      We thank the reviewer for their suggestion! We have removed the sentence from the manuscript.

      (2) Introduction: "EleutherAI, n.d." reference for GPT-Neo

      GPT-NeoX-20B has an associated paper, which the authors might cite instead: https://aclanthology.org/2022.bigscience-1.9

      Thank you! We have added the reference for GPT-NeoX-20B (Black et al., 2022).

      (3) Figure 4D: Encoidng -> Encoding

      Fixed.

      (4) Materials and Methods, Contextual embeddings: "except for GPT-Neox-20b, which assigns additional tokens to whitespace characters."

      What do the authors mean by "additional tokens to whitespace characters?" The tokenizer for GPT-NeoX-20B works in much the same way as that of GPT-Neo, just with a different vocabulary set.

      >>> t1 = AutoTokenizer.from_pretrained("EleutherAI/gpt-neo-125M")

      >>> t2 = AutoTokenizer.from_pretrained("EleutherAI/gpt-neox-20b")

      >>> t1.convert_ids_to_tokens(t1("The quick brown fox jumps over the lazy dog.").input_ids) ['The', 'Ġquick', 'Ġbrown', 'Ġfox', 'Ġjumps', 'Ġover', 'Ġthe', 'Ġlazy', 'Ġdog', '.']

      >>> t2.convert_ids_to_tokens(t2("The quick brown fox jumps over the lazy dog.").input_ids)

      ['The', 'Ġquick', 'Ġbrown', 'Ġfox', 'Ġjumps', 'Ġover', 'Ġthe', 'Ġlazy', 'Ġdog', '.']

      If the authors are referring to Ġ as the "additional token to whitespace characters," then these are in all other tokenizers as well (not only that for GPT-Neo, but also those for GPT-2 and OPT).

      We agree that “additional tokens to whitespace characters” is an oversimplification. The GPT-Neo model family, which includes the 125M, 1.3B, and 2.7B models, utilizes the same Byte Pair Encoding (BPE) tokenizer as GPT-2. This common tokenizer has a vocabulary size of 50,257 tokens, providing compatibility and seamless integration across the models.

      The GPT-NeoX-20B model introduces a modified tokenizer to address limitations observed in the GPT-2 tokenizer (Black et al., 2022). As detailed in Section 3.2, this new tokenizer incorporates a few key improvements:

      (1) New BPE tokenizer: A more general-purpose BPE tokenizer was trained using the Pile dataset.

      (2) Space Delimitation: Unlike the GPT-2 tokenizer, which treats tokenization at the start of a string as a non-space-delimited token, the GPT-NeoX-20B tokenizer applies consistent space delimitation regardless. This change resolves inconsistencies related to the presence of prefix spaces in the tokenization input.

      (3) Whitespace Handling: The tokenizer includes tokens for repeated space characters (up to 24 consecutive spaces), enhancing efficiency in tokenizing text with substantial whitespace, such as program source code or LaTeX documents.

      These modifications result in the GPT-NeoX-20B tokenizer representing the Pile validation set with approximately 10% fewer tokens than the GPT-2 tokenizer. This efficiency gain is particularly beneficial for processing texts with extensive whitespace.

      In our analysis, we extracted embeddings by setting `add_prefix_space = True` to all tokenizers, so space delimitation does not result in tokenizer differences. We highlight here examples of the other two tokenizer differences using the Huggingface `AutoTokenizer`:

      >>> t1 = AutoTokenizer.from_pretrained("EleutherAI/gpt-neo-125M")

      >>> t2 = AutoTokenizer.from_pretrained("EleutherAI/gpt-neox-20b")

      >>> t1.convert_ids_to_tokens(t1("The Downing Street.").input_ids) ['The', 'ĠDowning', 'ĠStreet']

      >>> t2.convert_ids_to_tokens(t2("The Downing Street.").input_ids)

      ['The', 'ĠDown', 'ing', 'ĠStreet']

      >>> t1.convert_ids_to_tokens(t1("Hello !").input_ids)

      ['Hello', 'Ġ', 'Ġ', 'Ġ', 'Ġ', 'Ġ', 'Ġ', 'Ġ!']

      >>> t2.convert_ids_to_tokens(t2("Hello !").input_ids)

      ['Hello', ' ', '!']

      More examples showing the differences between the GPT-2 tokenizer and the GPT-NeoX-20B tokenizer can be found in Appendix F: Tokenizer Analysis (Black et al., 2022).

      We have added the following text to our manuscript for simplicity:

      “All models within the same model family adhere to the same tokenizer convention, except for GPT-Neox-20B, which utilizes a different tokenizer (Black et al., 2022).”

      References

      Ameisen, E., Lindsey, J., Pearce, A., Gurnee, W., Turner, N. L., Chen, B., Citro, C., Abrahams, D.,  Carter, S., Hosmer, B., Marcus, J., Sklar, M., Templeton, A., Bricken, T., McDougall, C.,  Cunningham, H., Henighan, T., Jermyn, A., Jones, A., … Batson, J. (2025). Circuit Tracing:  Revealing Computational Graphs in Language Models. Transformer Circuits Thread. https://transformer-circuits.pub/2025/attribution-graphs/methods.html

      Antonello, R., & Huth, A. (2024). Predictive coding or just feature discovery? An alternative account of why language models fit brain data. Neurobiology of Language (Cambridge, Mass.), 5(1), 64–79.

      Antonello, R., Vaidya, A., & Huth, A. G. (2023). Scaling laws for language encoding models in fMRI. NeurIPS 2023. https://doi.org/10.48550/ARXIV.2305.11863

      Black, S., Biderman, S., Hallahan, E., Anthony, Q., Gao, L., Golding, L., He, H., Leahy, C., McDonell,  K., Phang, J., Pieler, M., Prashanth, U. S., Purohit, S., Reynolds, L., Tow, J., Wang, B., & Weinbach, S. (2022). GPT-NeoX-20B: An Open-Source Autoregressive Language Model.  Proceedings of BigScience Episode #5 -- Workshop on Challenges & Perspectives in Creating Large Language Models. Proceedings of BigScience Episode #5 -- Workshop on Challenges & Perspectives in Creating Large Language Models, virtual+Dublin. https://doi.org/10.18653/v1/2022.bigscience-1.9

      Brants, T., & Franz, A. (2006). Web 1T 5-gram Version 1 [Dataset]. Linguistic Data Consortium. https://doi.org/10.35111/CQPA-A498

      Cantlon, J. F., & Piantadosi, S. T. (2024). Uniquely human intelligence arose from expanded information capacity. Nature Reviews Psychology, 3(4), 275–293.

      Chemla, E., D’Ascoli, S., Diego-Simón, P., King, J.-R., & Lakretz, Y. (2024). A Polar coordinate system represents syntax in large language models. Advances in Neural Information Processing Systems 37, 105375–105396.

      Cheng, E., & Antonello, R. J. (2024). Evidence from fMRI supports a two-phase abstraction process in language models. In arXiv [cs.CL]. arXiv. http://arxiv.org/abs/2409.05771

      Csordás, R., Manning, C. D., & Potts, C. (2025). Do language models use their depth efficiently?  In arXiv [cs.LG]. https://doi.org/10.48550/ARXIV.2505.13898

      Dupré la Tour, T., Eickenberg, M., Nunez-Elizalde, A. O., & Gallant, J. L. (2022). Feature-space selection with banded ridge regression. In bioRxiv. https://doi.org/10.1101/2022.05.05.490831

      Elhage, N., Hume, T., Olsson, C., Schiefer, N., Henighan, T., Kravec, S., Hatfield-Dodds, Z., Lasenby, R., Drain, D., Chen, C., Grosse, R., McCandlish, S., Kaplan, J., Amodei, D., Wattenberg, M., & Olah, C. (2022). Toy Models of Superposition. Transformer Circuits Thread.

      Elhage, N., Nanda, N., Olsson, C., Henighan, T., Joseph, N., Mann, B., Askell, A., Bai, Y., Chen, A.,  Conerly, T., DasSarma, N., Drain, D., Ganguli, D., Hatfield-Dodds, Z., Hernandez, D., Jones, A.,  Kernion, J., Lovitt, L., Ndousse, K., … Olah, C. (2021). A Mathematical Framework for Transformer Circuits. Transformer Circuits Thread.

      Fan, S., Jiang, X., Li, X., Meng, X., Han, P., Shang, S., Sun, A., Wang, Y., & Wang, Z. (2024). Not all Layers of LLMs are Necessary during Inference. In arXiv [cs.CL]. arXiv. http://arxiv.org/abs/2403.02181

      Friederici, A. D., & Becker, Y. (2025). The core language network separated from other networks during primate evolution. Nature Reviews. Neuroscience, 26(2), 131–132.

      Goldstein, A., Ham, E., Schain, M., Nastase, S. A., Aubrey, B., Zada, Z., Grinstein-Dabush, A.,  Gazula, H., Feder, A., Doyle, W., Devore, S., Dugan, P., Friedman, D., Brenner, M., Hassidim, A., Matias, Y., Devinsky, O., Siegelman, N., Flinker, A., … Hasson, U. (2025). Temporal structure of natural language processing in the human brain corresponds to layered hierarchy of large language models. Nature Communications, 16(1), 10529.

      Goldstein, A., Wang, H., Niekerken, L., Schain, M., Zada, Z., Aubrey, B., Sheffer, T., Nastase, S. A., Gazula, H., Singh, A., Rao, A., Choe, G., Kim, C., Doyle, W., Friedman, D., Devore, S., Dugan, P., Hassidim, A., Brenner, M., … Hasson, U. (2025). A unified acoustic-to-speech-to-language embedding space captures the neural basis of natural language processing in everyday conversations. Nature Human Behaviour. https://doi.org/10.1038/s41562-025-02105-9

      Goldstein, A., Zada, Z., Buchnik, E., Schain, M., Price, A., Aubrey, B., Nastase, S. A., Feder, A.,  Emanuel, D., Cohen, A., Jansen, A., Gazula, H., Choe, G., Rao, A., Kim, C., Casto, C., Fanda, L., Doyle, W., Friedman, D., … Hasson, U. (2022). Shared computational principles for language processing in humans and deep language models. Nature Neuroscience, 25(3), 369–380.

      Gromov, A., Tirumala, K., Shapourian, H., Glorioso, P., & Roberts, D. A. (2024). The Unreasonable Ineffectiveness of the Deeper Layers. In arXiv [cs.CL]. arXiv. http://arxiv.org/abs/2403.17887

      Herculano-Houzel, S. (2012). The remarkable, yet not extraordinary, human brain as a scaled-up primate brain and its associated cost. Proceedings of the National Academy of Sciences of the United States of America, 109 Suppl 1(supplement_1), 10661–10668.

      Hewitt, J., & Manning, C. D. (2019). A Structural Probe for Finding Syntax in Word Representations. In J. Burstein, C. Doran, & T. Solorio (Eds.), Proceedings of the 2019 Conference of the North (pp. 4129–4138). Association for Computational Linguistics.

      Honnibal, M., Montani, I., Van Landeghem, S., & Boyd, A. (2020). spaCy: Industrial-strength Natural Language Processing in Python.

      Kriegeskorte, N., Simmons, W. K., Bellgowan, P. S. F., & Baker, C. I. (2009). Circular analysis in systems neuroscience: the dangers of double dipping. Nature Neuroscience, 12(5),  535–540.

      Kumar, S., Sumers, T. R., Yamakoshi, T., Goldstein, A., Hasson, U., Norman, K. A., Griffiths, T. L., Hawkins, R. D., & Nastase, S. A. (2024). Shared functional specialization in transformer-based language models and the human brain. Nature Communications, 15(1), 5523.

      Linzen, T., & Baroni, M. (2021). Syntactic Structure from Deep Learning. Annual Review of Linguistics, 7(1), 195–212.

      Manning, C. D., Clark, K., Hewitt, J., Khandelwal, U., & Levy, O. (2020). Emergent linguistic structure in artificial neural networks trained by self-supervision. Proceedings of the National Academy of Sciences of the United States of America, 117(48), 30046–30054.

      Millet, J., Caucheteux, C., Orhan, P., Boubenec, Y., Gramfort, A., Dunbar, E., Pallier, C., & King, J.-R. (2023). Toward a realistic model of speech processing in the brain with self-supervised learning. NeurIPS 2022. https://doi.org/10.48550/ARXIV.2206.01685

      Pavlick, E. (2022). Semantic structure in deep learning. Annual Review of Linguistics, 8(1),  447–471.

      Pennington, J., Socher, R., & Manning, C. (2014). Glove: Global vectors for word representation.  Proceedings of the 2014 Conference on Empirical Methods in Natural Language Processing (EMNLP). Proceedings of the 2014 Conference on Empirical Methods in Natural Language Processing (EMNLP), Doha, Qatar. https://doi.org/10.3115/v1/d14-1162

      Schrimpf, M., Blank, I. A., Tuckute, G., Kauf, C., Hosseini, E. A., Kanwisher, N., Tenenbaum, J. B., & Fedorenko, E. (2021). The neural architecture of language: Integrative modeling converges on predictive processing. Proceedings of the National Academy of Sciences of the United States of America, 118(45), e2105646118.

      The CMU Pronouncing Dictionary. (n.d.). Retrieved May 27, 2025, from http://www.speech.cs.cmu.edu/cgi-bin/cmudict

      Vaidya, A. R., Jain, S., & Huth, A. G. (2022). Self-supervised models of audio effectively explain human cortical responses to speech. ICML 2022. https://doi.org/10.48550/ARXIV.2205.14252

      Zada, Z., Goldstein, A., Michelmann, S., Simony, E., Price, A., Hasenfratz, L., Barham, E., Zadbood,  A., Doyle, W., Friedman, D., Dugan, P., Melloni, L., Devore, S., Flinker, A., Devinsky, O., Nastase, S. A., & Hasson, U. (2024). A shared model-based linguistic space for transmitting our thoughts from brain to brain in natural conversations. Neuron, S0896627324004604. Zada, Z., Nastase, S. A., Aubrey, B., Jalon, I., Michelmann, S., Wang, H., Hasenfratz, L., Doyle, W.,  Friedman, D., Dugan, P., Melloni, L., Devore, S., Flinker, A., Devinsky, O., Goldstein, A., & Hasson, U. (2025). The “Podcast” ECoG dataset for modeling neural activity during natural language comprehension. Scientific Data, 12(1), 1135.

    1. The Artifact Registry API is enabled and the GKE node service account already has roles/artifactregistry.reader. What’s missing is the actual Docker repository and images.

      You need four things:

      1. Create the migrations repository:

      gcloud artifacts repositories create migrations \ --project=opensearch-migration \ --location=us-central1 \ --repository-format=docker \ --description="OpenSearch Migration Assistant images"

      1. Authenticate Docker for pushes:

      gcloud auth configure-docker us-central1-docker.pkg.dev

      1. Populate it with these release 3.3.5 images:

      opensearch-migrations-console opensearch-migrations-reindex-from-snapshot opensearch-migrations-traffic-capture-proxy opensearch-migrations-traffic-replayer

      The quickest approach is to mirror the published images rather than build them locally. For example:

      docker pull public.ecr.aws/opensearchproject/opensearch-migrations-console:3.3.5

      docker tag \ public.ecr.aws/opensearchproject/opensearch-migrations-console:3.3.5 \ us-central1-docker.pkg.dev/opensearch-migration/migrations/migration-console:3.3.5

      docker push \ us-central1-docker.pkg.dev/opensearch-migration/migrations/migration-console:3.3.5

      Repeat that mapping for:

      opensearch-migrations-reindex-from-snapshot → migrations/reindex-from-snapshot:3.3.5

      opensearch-migrations-traffic-capture-proxy → migrations/traffic-capture-proxy:3.3.5

      opensearch-migrations-traffic-replayer → migrations/traffic-replayer:3.3.5

      1. Update Terraform to reference tag 3.3.5, including capture proxy and traffic replayer. Currently deployment/ terraform/gcp/main.tf:382 only fully configures the console, installer, and reindex images, and uses latest.
  3. Jul 2026
    1. Table 5 shows that the AAE speakers and SAE speakers used nine of the complex syntax types in a similar manner. That is, all children, regardless of dialect, used simple infinitives with same subject, gerunds and participles, and the conjunctions and and because. The same number of children in each group used the let(s)/lemme and infinitive and wh-infinitive clause sentence types, but none of the children used tag questions or the conjunction since.
    1. Reviewer #2 (Public review):

      In this manuscript, the authors investigate how the oncogenic fusion protein NUP98-KDM5A alters gene expression in leukemia, using a combination of cellular experiments with model and patient cell lines, as well as in vitro studies. Upon transfection of U2OS cells with mEGFP-tagged NUP98-KDM5A, the authors show that the fusion proteins form sub-micrometer puncta, whereas KDM5A alone does not. These foci are also observed at expected native expression levels (using OpenCell data). The tag has an effect here, as switching to an mCherry tag raises the apparent saturation concentration for phase separation. Finally, the authors show via super-resolution imaging that the foci correlate with H3K4me3 distribution.

      In vitro, the fusion protein forms amorphous, gel-like condensates at double-digit nanomolar concentrations. Truncation analysis identifies PHD3 of KDM5A as required for maximal phase separation, consistent with the ability of the protein to bind H3K4me3 peptides. Addition of polynucleosomes increases the amount of fusion protein partitioning into the condensate in an H3K4me3-binding-dependent manner. Condensates are gel-like with slow internal dynamics in vitro; in cells, however, the dynamics depend on the position of the EGFP tag (no corresponding experiments with mCherry are shown). Reconstitution with H3K4me3- and H3K4me0-modified arrays shows colocalization with both wild-type NUP98-KDM5A and the binding mutant. Here, H3K4me3 arrays recruit ~20% more protein and yield gel-like structures in a manner dependent on the PTM and on the PHD finger.

      In cells, the fusion protein colocalizes with H3K4me3-marked loci, including the HOX clusters, as confirmed by FISH. Finally, re-analysis of published expression datasets from patient cells shows that genes are predominantly upregulated and that the upregulated genes are H3K4me3-marked.

      This is a well-executed mechanistic study. The data convincingly establish that NUP98-KDM5A forms sub-micrometer foci at realistic expression levels, that these foci correlate with H3K4me3-marked sites, that the PHD3-H3K4me3 interaction mediates chromatin binding while the NUP98 moiety drives phase separation in vitro, that foci in cells overlap genes heavily decorated with H3K4me3, and that H3K4me3-marked genes are those found to be upregulated in patient datasets. These are important mechanistic findings and of interest to the community.

      Still, the functional/causal link is a bit more tentative, as the data is mostly correlative, since it is not directly established that there is feedback between H3K4 methylation, NUP98-KDM5A recruitment, phase separation and target gene overexpression. An experiment that could further bolster this claim would be a direct test of whether NUP98-KDM5A expression drives overexpression of bound genes, e.g. expression of the fusion protein vs PHD- and NUP98-mutant variants, followed by qPCR of target genes, such as the HOX cluster, and possibly H3K4me3 ChIP at the same loci. As all the constructs and cell lines exist, this could be feasible and would substantially strengthen the manuscript.

    1. PD service ID, DD service tag, or both?

      PD service won't be enough for support hours, can Sanjer/Pinky identify the service/circumstances and group based on that?

    1. Adds a heading element around a selection or insertion point line. Requires the tag-name string as a value argument (i.e., "H1", "H6"). (Not supported by Safari.)

      not supported by safari?

      perhaps should use post processing line when the line is changed?

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2026-03460

      Corresponding author(s): Louise, Walport

      1. General Statements

      We thank the reviewers for their critical reading and insightful comments on the manuscript and for highlighting the relevance of our data to developmental biology audiences.

      Below we have included a detailed point-by-point response to each reviewer comment, divided into those that are linked with revisions in the manuscript, and those that are not. As well as this we have written two general statements regarding the recently published high-resolution structures of the CPLs and our findings linking the CPLs to other oocyte structures, both of which address multiple reviewer comments.

      High resolution CPL structure papers

      While this manuscript was under review, several papers were published in Nature or deposited on bioRxiv detailing high-resolution structures of the CPLs (DOIs: 10.1038/s41586-026-10360-7 ,10.1038/s41586-026-10513-8, 10.1038/s41586-026-10442-6, 10.64898/2026.03.22.713481). These structural studies validate the key scaffolding function of PADI6 in CPL formation, as well as the association of ubiquitination machinery (including the SCF complex) to the CPLs, which we also determined in this work through mass spectrometry. Our work is complementary to these studies. The published structures provide detailed insight into how the CPLs form and function. However, while the new papers identify the structure and composition of the core CPL fiber, due to the requirement for particle averaging, they cannot resolve the identity of proteins beyond this core that interact or are stored on the CPLs sub-stoichiometrically. This limitation is addressed by our sub-cellular single oocyte proteomic workflow which pools all CPLs within each oocyte, identifying proteins which become soluble upon CPL dissolution, whether due to presence in the core fibre or to association with the fibres. Our manuscript therefore provides a complementary atlas of the CPL-associated proteome as a resource for further studying the function of CPLs in early development. To place our work in the context of the new manuscripts we have added the following to the discussion:

      • “During preparation of this manuscript, several high-resolution structures of the CPLs were reported80–83. Our proteomic workflow identified all CPL proteins resolved in these published structures as CPL-associated, including the newly identified SCF complex components and several F-box proteins. Notably, whilst highly informative, the structural studies cannot resolve the precise identity of individual proteins from families of structurally homologous proteins that form the CPL core, or of proteins which associate with the CPLs sub-stoichiometrically. One key example is the F-box proteins which offer substrate specificity to the SCF complex. Our proteomic analysis identified 10 different F-box proteins to have CPL-association. By contrast each published structure reports only a single or a few F-box proteins as part of the core complex. Notably different F-box proteins are reported in different structures. Our data provides an explanation for this variation, suggesting that even the core CPL fibres are non-homogeneous in the cell with different F-box proteins present in different locations (Fig 6B). Similarly, the close homology of a/b-tubulin proteins prevents identification of exact isoforms in the reported structures. Our data suggests that many different isoforms contribute to the CPLs (Fig 5E). Additionally, it is proposed that the CPLs act as storage hubs for a much wider range of proteins30. By allowing identification of proteins associated with the CPLs even at low occupancy our CPL-associated proteome provides a list of potential CPL-associated proteins for further structural and functional characterisation of CPL function.” CPLs and other oocyte structures

      The presence of proteins from other large cellular structures in the CPL-enriched protein dataset was highlighted by reviewers 1 and 3, in particular reviewer 3: “the physical meshwork of CPLs may prevent loss of CPL-associated proteins as well as cytoplasmic protein complexes or organelles that are too large to escape the cytoplasm through the CPLs. This is particularly a concern for the authors' conclusions regarding high amounts of ELVA-associated and mitochondrial and mitochondria-associated proteins associated with the CPLs given the large size of these organelles/structures. Is there any evidence by an alternative method of direct association of ELVAs or mitochondria with CPLs? Others have not detected mitochondrial proteins associated with CPLs”.

      Functional cross-talk with ELVA:

      Regarding an association with the ELVA, we should clarify that we believe that the relation between CPLs and the ELVA is most likely not a direct association but a previously unknown functional interaction and we have revised the text to more clearly reflect this view. We identify proteins involved in protein degradation, most notably the SCF complex, in our CPL-enriched dataset. In support of their presence being likely due to direct CPL association, rather than indirect trapping of the large ELVA, the recently published CPL structures similarly identify numerous proteins involved in protein degradation as associated with the CPLs, suggesting these proteins are sequestered and inactivated on the CPLs. As we do, these other works also propose that the CPLs are critical hubs for proteostasis in the oocyte and early embryo, similar to the proposed function of the ELVAs. However, as discussed below in the context of the mitochondria, we acknowledge that it is possible that the high level of these proteins observed in our dataset could alternatively be due to reduced cytoplasmic escape and we have updated the limitations section of the manuscript to reflect this caveat in our interpretation.

      • “Whilst we interpret proteome differences in Triton X-100 treated Padi6-KO oocytes to indicate an association with the CPLs, in the case of proteins associated with other large cellular structures such as mitochondria or the ELVA it is possible that this difference is instead due to physical entrapment of these structures by the CPLs during the precipitation step.” Interestingly, we identify RUFY1 in the CPL-enriched fraction. RUFY1 is a key marker of the ELVA where it functions as a scaffolding protein. In the manuscript we discussed the possibility that RUFY1 could therefore perform a similar function on the CPLs. In a recent work, it was reported that the number and size of RUFY1 compartments was increased in Padi6-null oocytes (DOI: 10.1038/s41594-026-01758-y). As RUFY1 is the key marker of the ELVAs this shows that their morphology is likely affected in the absence of Padi6. Together these data point towards a functional crosstalk between the two, potentially via the CPLs storing protein degradation machinery required by the ELVAs, as well as also storing/sequestering RUFY1, which could explain the increase in RUFY1 compartments in the absence of the CPLs.

      Mitochondria:

      Whilst it has been reported that there are defects in mitochondrial localisation in the absence of PADI6 and the CPLs (10.1016/j.ydbio.2010.11.033), we agree with the reviewers that it is possible these are not due to direct interactions between the CPLs and mitochondria, but rather from two separate roles of PADI6 and that our observation of mitochondrial proteins in the CPL-enriched set is due to increased physical entrapment of the large mitochondria by the CPLs rather than association. As additional links between the mitochondria and CPLs are not present in the literature unlike protein degradation machinery, we have removed the section entitled ‘The CPLs are associated with the oocyte mitochondria’, along with supplementary Figures 6E and 6F and added to the text the caveat that proteins associated with large cellular structures in our datasets could be due to physical entrapment. As we did not further discuss links between the CPLs and mitochondria in either the abstract or discussion, we do not believe the removal of this section significantly affects either the findings or novelty of this work.

      PADI6 Catalytic Activity

      Both reviewers 1 and 2 ask that we experimentally validate the loss of catalytic activity in the PADI6-C663A mutant. Along similar lines, reviewer 3 questions the rationale for the Padi6-C663A mouse line based on the lack of in vitro catalytic activity. We would like to reiterate that prior to this work there has been contradictory evidence regarding the catalytic activity of PADI6. Early work into PADI6 (10.1016/j.mce.2007.05.005) detected citrulline by IHC specifically in the oocytes of ovarian sections, which was absent in PADI6 knock-out ovaries. Later, it was shown by IF using anti-Citrulline antibodies that there is nuclear citrulline staining in 2-cell and 4-cell embryos that is ablated by a PADI inhibitor, in that study attributed to PADI1 (PADI1 presence detected by antibody-based techniques such as IF, 10.1038/srep38727). Together these manuscripts all posit that there is an active deiminase in oocytes and early embryos. We do not detect transcripts or protein for any PADI aside from PADI6 at the 2-cell stage and before suggesting any citrullination in the 2-cell embryo or before could only be a result of deimination by active PADI6 (Figure S4E).

      However, we and others, have confirmed that wild-type PADI6 is not active in vitro under the same conditions as the other PADIs (DOIs: 10.1016/j.csbj.2024.08.019, 10.4236/abb.2011.24044). Whilst this may be interpreted as overall lack of catalytic activity, an alternative explanation is that incorrect assay conditions have been used. For in vitro assays, supra-physiologically high calcium concentrations are required to activate catalysis by PADIs 1 to 4. We have previously shown that these calcium binding residues are not conserved in PADI6 and PADI6 does not bind calcium. It is therefore possible that PADI6 has evolved to be activated by other as yet unknown activating signals so as to not have its function disrupted during the large calcium transient post-fertilization. In the absence of the correct activating signals, in vitro activity would not be expected, even if the enzyme is catalytically active in vivo.

      We believe that this, together with the conservation of the catalytic tetrad residues, and the contradictory evidence regarding citrullination in vivo demonstrated that based on the current literature a catalytic function of PADI6 cannot be ruled out in vivo. This was our rationale for developing the Padi6-C663A mouse model in this work, to disentangle the dramatic phenotypes observed from full knockout of PADI6 from a possible catalytic function. Based on our previous structural characterization of human PADI6 (DOI: 10.1016/j.csbj.2024.08.019), if PADI6 were to have catalytic activity it would be through cysteine 663. Our data conclusively shows that catalytic activity of PADI6 through cysteine 663 is not required for murine female fertility, but that mice with this mutation are also not fully wildtype. Given the lack of large-scale structural damage loss of this cysteine imparts on the protein (Supplementary Figure 1), the observed phenotypes point towards either the disruption of a previously unidentified non-essential catalytic function or to more subtle changes to function from this mutation, for example through alterating the binding affinities of proteins that interact with PADI6 lacking this cysteine.

      2. Point-by-point description of the revisions

      Description of revisions incorporated into the manuscript along with discussion of reviewer comments

      Reviewer 1:

      • Major Comment 1: “1- The methods for differential gene expression analysis are insufficiently described. Were these calculated using Scanpy? If so, the rationale for this choice should be provided, as the number of replicates and the nature of the data appear more suited to standard bulk differential expression frameworks such as DESeq2 or edgeR.”
      • Response and Incorporated Revision: We chose the Scanpy framework for analysis because it allows for quality control, PCA, normalization, and differential expression within a single Python environment. To calculate differential gene expression, we performed Student's t-test on log-normalized counts for each gene followed by correction for multiple testing using the Benjamini-Hochberg procedure. We have added this further clarification to the methods section:

      “To identify dysregulated genes, for each stage, mean log2CPM ratios (test vs. wild-type) and q-values were calculated for each gene using a custom Python script (see Data and Code Availability), extracted and plotted using GraphPad Prism. In brief, an independent Student’s t-test was applied to the normalized expression values and p-values were corrected for multiple testing using the Benjamini-Hochberg procedure.”

      • Major Comment 2:

      *“2- In Figure 4C, it is unclear what correlation is being calculated. Additionally, the methods state that differential protein abundance was determined using the same approach as the scRNA-seq analysis. Given the lack of methodological clarity noted above, it is difficult to evaluate these results. The authors should justify whether the chosen method is compatible with the normalization approach used for the proteomics data.”

      *

      • Response and Incorporated Revision: We apologize for the lack of clarity on the calculated correlation and to improve this have amended the Figure legend for 4C to the following: “(C) Pearson correlation values for protein abundances in wild-type, Padi6-C663A and Padi6-KO GV oocyte and 2-cell embryo replicates when compared to all other replicates of the same condition. Samples of the same genotype and stage show high correlation in the abundance of individual proteins.”

      Regarding the compatibility, dysregulated proteins and transcripts were determined using the same statistical method, independent Student’s t-tests corrected for multiple testing with the Benjamini-Hochberg procedure.

      • Major Comment 4:

      “4- A notable result is the complete lack of correspondence between differential RNA-seq and proteomics in 2-cell embryos. The authors state that "This is consistent with data showing that minimal translation occurs in the 2-cell embryo, with the first large translational wave only occurring in the morula," citing Israel et al. 2019. This statement is factually incorrect. The cited study did not measure translation directly. Recent work that specifically measured translation during preimplantation development has demonstrated that translation is highly dynamic throughout these stages (Ozadam et al. 2023, Nature). This claim should be corrected and the results discussed in the context of these more recent findings.”

      • Response and Incorporated Revision: We have revised the claim, discussing our results in the context of the more recent Ozadam et al. 2023, Nature paper. The amended text reads: “This is consistent with data showing that protein abundance does not correlate with RNA level, but with ribosome occupancy and translation efficiency in the zygote58,59. Our results show that this lack of correlation in RNA and protein is maintained in the 2-cell embryo with RNA dysregulation and protein dysregulation uncoupled in Padi6-KO embryos, suggesting that transcriptomic and proteomic dysregulation need not be linked at early developmental stages.”

      • Major Comment 6:

      *“6- A large fraction of the manuscript interprets changes in the PADI6 knockout proteomics data as direct evidence that CPLs are associated with specific protein complexes (e.g., ribosomes) or cellular structures (e.g., mitochondria). However, these results are indirect and could alternatively be explained by roles of PADI6 that are independent of CPLs. These conclusions should be tempered, or this limitation should be explicitly acknowledged.”

      *

      • Response and Incorporated Revision:

      We have addressed this comment in the General Statements section discussing links between the CPLs and the mitochondria. Given the previously identified links between protein degradation machinery and ribosomes with the CPLs, we believe the changes are due to the loss of CPLs. We have however included the following statement acknowledging that these defects could be due to alternate function of PADI6 in the Limitations of the study section: “…It is also possible that some differences are due to an alternate defect that alters protein solubility caused by the absence of PADI6 independent of CPL formation.”

      • Major Comment 7:

      “7- Relatedly, the authors conclude that CPLs are associated with mitochondria based on the CPL proteomics data. Several questions arise: Do the EM images show mitochondria in close proximity to CPLs? Is mitochondrial morphology affected in Padi6-null oocytes? Given that respiratory chain complexes are large, membrane-bound assemblies, how might they associate with CPLs? Could the Triton-insoluble CPL fraction be contaminated with other oocyte-specific superstructures, as the authors themselves allude to? Do the EM images show mitochondria in close proximity to CPLs? Is mitochondrial morphology affected in Padi6-null oocytes?

      Reviewer 2:

      • Major Comment 5: “5) The authors found that CPLs are associated with mitochondria. How do CPLs in the cytosol interact with the components of the electron transport chain in the mitochondria? Do CPLs directly interact with these proteins in the cytosol or attach to the outer mitochondrial membrane? Does the loss of PADI6 affect the morphology, membrane potential, and ROS production of mitochondria in oocytes?”
      • Combined response to reviewer 1 major comment 7 and reviewer 2 major comment 5 and Incorporated Revision: As stated in the general statement, whilst it has been reported that there are defects in mitochondrial localisation in the absence of PADI6 and the CPLs (10.1016/j.ydbio.2010.11.033), it is possible these are not due to direct interactions. Presence of mitochondrial proteins in the CPL-enriched proteome could instead be caused by physical entrapment of the mitochondria by the CPLs. Whilst mitochondrial localization is known to be disrupted in PADI6 knockout oocytes (DOI: 10.1016/j.ydbio.2010.11.033), as additional links between the mitochondria and CPLs are not present in the literature unlike protein degradation machinery, we agree further work would be required to support this claim and have therefore removed the section entitled ‘The CPLs are associated with the oocyte mitochondria’, along with supplementary Figures 6E and 6F. As we did not further discuss links between the CPLs and Mitochondria in either the abstract or discussion, we do not believe the removal of this section significantly affects both the findings and novelty of this work.

      • Major Comment 8:

      “8-The authors should discuss their findings in the context of Liu et al. 2026 (Nature), which elucidates the structural basis of PADI6 in CPL formation. This comparison would be particularly informative given the overlapping scope of the two studies.”

      • Response and Incorporated Revision: As discussed in the general statement, we have included a new discussion of how the published CPL structure papers compare to our manuscript in the general comments section above. We have incorporated the following in the Discussion section of our manuscript: “During preparation of this manuscript, several high-resolution structures of the CPLs were reported80–83. Our proteomic workflow identified all CPL proteins resolved in these published structures as CPL-associated, including the newly identified SCF complex components and several F-box proteins. Notably, whilst highly informative, the structural studies cannot resolve the precise identify of individual proteins from families of structurally homologous proteins that form the CPL core, or of proteins which associate with the CPLs sub-stoichiometrically. One key example is the F-box proteins which offer substrate specificity to the SCF complex. Our proteomic analysis identified 10 different F-box proteins to have CPL-association. By contrast each published structure reports only a single or a few F-box proteins as part of the core complex. Notably different F-box proteins are reported in different structures. Our data provides an explanation for this variation, suggesting that even the core CPL fibres are non-homogeneous in the cell with different F-box proteins present in different locations (Fig 6B). Similarly, the close homology of a/b-tubulin proteins prevents identification of exact isoforms in the reported structures. Our data suggests that many different isoforms contribute to the CPLs (Fig 5E). Additionally, it is proposed that the CPLs act as storage hubs for a much wider range of proteins30. By allowing identification of proteins associated with the CPLs even at low occupancy our CPL-associated proteome provides a list of potential CPL-associated proteins for further structural and functional characterisation of CPL function.”

      • Minor Comment 1:

      “1- For the scRNA-seq analysis, please expand the methodology for PCA. Specifically, how are read counts normalized prior to PCA? We assume some form of log-normalization was applied, but this is not described in the methods or figure legends.”

      • Incorporated Revision: We apologize for this lack of clarity; log normalization was applied. The methods have been updated to the following to describe normalization prior to PCA: “PCA analysis of log normalized CPM values was performed using ScanPy on the full dataset, as well as oocyte, zygote, and 2-cell split data.”

      • Minor Comment 2:

      “2- Please clarify the z-score calculation for results shown in Figure 3. While the general approach can be inferred from context, the exact calculation is not provided.”

      • Incorporated Revision: Z-scores were calculated with the ScanPy scale function, the following has been added into the methods to clarify this: “Transcript Z-scores were calculated using the pp.scale function in the Python package ScanPy…”

      • Minor Comment 6:

      “6- It is unclear why the authors conclude that PADI6 regulates UHRF1 at the protein level (Figure S5). The observation that UHRF1 levels are reduced in Padi6-null oocytes could simply reflect reduced maternal deposition. The evidence does not appear sufficient to support a specific claim of protein-level regulation by PADI6.”

      • Incorporated Revision: We agree that it is possible that the reduced UHRF1 levels could be due to reduced maternal deposition, for example by reduced protein translation levels of UHRF1, and therefore we have amended our conclusion to the following: “…suggesting PADI6 regulates UHRF1 at the protein level or conceivably at the translational level during maternal deposition.”

      Reviewer 2:

      • Major Comment 4: “4) The authors also found that several proteasome subunits, as well as LAMP1 and RUFY1, were enriched in CPLs. These proteins are known to localize to ELVAs in GV and MII oocytes (Zaffagnini et al., 2024), suggesting functional crosstalk between CPLs and ELVAs. The authors should confirm that these components localize to the CPLs as well as ELVAs by immunostaining or using fluorescently labeled proteins. Are the morphology and localization of ELVAs affected by the loss of PADI6? Do CPLs colocalize or interact with ELVAs during oocyte maturation? It was reported that ELVAs were disassembled when RUFY1 was removed by Trim-Away in oocytes. Does the loss of RUFY1 affect CPL formation?”
      • Response and Incorporated Revision: Unfortunately, the only way to directly validate protein localisation to the CPLs is by expansion microscopy, which we do not have the technical capacity to do and therefore cannot perform these experiments in an informative manner. Reviewer #3 agrees with this conclusion: “Although some of the suggestions by Reviewer #2 could provide interesting information, the immunofluorescence experiments suggested in my view are not likely to provide definitive information regarding association of specific proteins or structures with CPLs. Instead, higher resolution technologies such as proximity ligation or immuno-EM might be required. These experiments seem like good ways to extend the findings beyond the current manuscript, but I think are not essential for the major take home points.”

      Regarding the morphology and localization of ELVAs in the absence of PADI6, it was recently reported that the number and size of RUFY1 compartments was increased in Padi6-null oocytes (DOI: 10.1038/s41594-026-01758-y). As RUFY1 is the key marker of the ELVAs this suggests that their morphology is likely affected, further pointing towards a functional crosstalk between the two. To highlight this we have added the following sentence in the discussion: “Additionally, recent work identified an increase in the number and size of RUFY1 and ProteoStat positive compartments in Padi6-null oocytes, further pointing towards a functional crosstalk between the ELVA and CPLs.” However, testing whether RUFY1 loss affects CPL formation is beyond the scope of this work investigating the functions of PADI6.

      Reviewer 3:

      • Major Comment 4: ‘4- Proteomics analysis: The authors carried out proteomics analysis on oocytes treated with Triton X-100 so that they would retain only cytoskeleton-associated proteins. As a control, Padi6-null oocytes (lacking CPLs) were used, and the authors interpret the proteins identified in the WT and not in the Padi6-null as CPL-associated proteins. It is not clear to me that this is a reasonable interpretation of the results. My concern is that the physical meshwork of CPLs may prevent loss of CPL-associated proteins as well as cytoplasmic protein complexes or organelles that are too large to escape the cytoplasm through the CPLs. This is particularly a concern for the authors' conclusions regarding high amounts of ELVA-associated and mitochondrial and mitochondria-associated proteins associated with the CPLs given the large size of these organelles/structures. Is there any evidence by an alternative method of direct association of ELVAs or mitochondria with CPLs? Others have not detected mitochondrial proteins associated with CPLs (see J. Li et al., doi 10.1038/s41594-026-01758-y).”
      • Response and Incorporated Revision: We have addressed this comment in the General Statements section entitled “CPLs and other oocyte structures”. We believe links between the CPLs, and protein degradation machinery and the ELVA are well supported by both our data, and the recent and past literature covering the CPLs (DOIs: 10.1038/s41594-026-01758-y, 10.1038/s41586-026-10360-7 ,10.1038/s41586-026-10513-8, 10.1038/s41586-026-10442-6, 10.64898/2026.03.22.713481, 10.1016/j.cell.2024.01.031, 10.1016/j.cell.2023.10.003). As additional links between the mitochondria and CPLs are not present in the literature unlike protein degradation machinery, we have removed the section entitled ‘The CPLs are associated with the oocyte mitochondria’, along with supplementary Figures 6E and 6F. As we did not further discuss links between the CPLs and Mitochondria in either the abstract or discussion, we do not believe the removal of this section significantly affects both the findings and novelty of this work.

      Responses to other reviewer comments including analyses that the authors prefer not to carry out

      Reviewer 1:

      • Major Comment 3: “3-The single-embryo proteomic measurements are an important aspect of the paper. However, additional quality control data are needed to assess data quality. In particular, a more systematic comparison to Ye et al. would strengthen confidence in these measurements.”
      • Response: Unfortunately, the Ye et al. work has not released a list of the proteins identified in oocytes and early embryos, or their intensities, therefore we cannot compare in this manner. In terms of overall number of proteins identified the two approaches are comparable, however they differ in both their sample preparation and MS acquisition methods.

      • Major Comment 5:

      “5- The manuscript refers to the C663A mutation as a "catalytic mutant." While the structural and homology-based rationale is compelling, the entire paper's conclusions depend on this interpretation. Experimental validation of the inferred loss of catalytic activity would substantially strengthen the study.”

      • Reviewer 2 Major Comment 1: “1) There is insufficient evidence to conclude that the C663A mutant is catalytically inactive. The authors should conduct an in vitro citrullination assay to show whether wild-type PADI6 has peptidyl arginine deiminase activity, but the C663A mutant loses it.”
      • Combined response to reviewer 1 major comment 5 and reviewer 2 major comment 1: We are pleased the Reviewer 1 finds our structural and homology-based rationale for the design of the C663A mutation compelling. As discussed in the general statements, prior to this work no catalytic activity of PADI6 had been observed in vitro, despite contradictory in vivo data regarding its activity. It was this challenge in replicating in vivo conditions that might be required for protein activation in an in vitro assay that directly led us to develop our in vivo mouse model in this work. It is therefore not possible to experimentally validate any change in activity following the C663A mutation as wild-type PADI6 is also inactive under the in vitro assay conditions used for other PADI isozymes. Except when discussing the design of the mouse itself we have been careful to always describe the mouse based on its mutation rather than as a catalytic mutant and have used terms such as “putative” or “potential” in the manuscript to make clear that there is no direct evidence for any catalytic activity that could then be abolished.

      • Minor Comment 3:

      “3- MII oocytes are used for scRNA-seq experiments and GV oocytes for proteomics. Please provide a rationale for the use of two different developmental stages.”

      • Response: The reasons for using MII oocytes over GV oocytes in the RNA-seq experiments was due to availability and sample number requirements. GV oocytes were used in place of MII oocytes for proteomic experiments as it was possible to gather many more GV oocytes per mouse than MII oocytes. Therefore, to increase the number of replicates in the single oocyte/embryo proteomics workflow developed in this work, we chose GV oocytes to increase confidence and show reproducibility.
      • Minor Comment 4:

      “4- While the data support the conclusion that maternal RNA and minor EGA mRNA degradation is defective, none of the experiments directly measure mRNA degradation. Direct experimental validation, even for a few select targets using standard decay assays, would strengthen this claim.”

      • Response: Whilst our data does not directly measure mRNA degradation, we believe our data is sufficient evidence to state that mRNA degradation is defective in the absence of PADI6, in line with other work (DOI: 10.1101/gad.351238.123 and consequently that it would not be appropriate to use further mice for these experiments in line with the 3Rs.
      • Minor Comment 5:

      *“5- The statement "Together these results indicate that we have established a powerful sub-cellular proteomic workflow from single mouse oocytes capable of identifying proteins associated with the CPLs" overstates the findings. The results are consistent with this interpretation, but the approach described is not a sub-cellular proteomic workflow in the spatial proteomics sense. This language should be revised.”

      *

      • Response: We agree that our workflow is not a sub-cellular proteomic workflow in the spatial proteomics sense, but we believe our statement and discussion does not claim that our workflow is a spatial proteomic workflow at any point. We therefore do not believe any revision of language is necessary.
      • Minor Comment 7:

      “7- Many ribosomal, proteasomal, and mitochondrial proteins appear to associate with CPLs in a PADI6-dependent manner. Could an alternative explanation be that maternal deposition of these proteins is globally reduced in Padi6-null oocytes, rather than their association with CPLs being specifically affected?”

      • Response: A global reduction in the maternal deposition of CPL-associated proteins would be reflected by a decrease in the levels of these proteins in intact oocytes. As the protein levels of the majority of CPL-associated proteins are not reduced in Padi6-KO oocytes (Figure 6A-B and Figure S6B), and for those that are reduced the effect is generally subtle, this discounts a global reduction in their maternal deposition.

        Reviewer 2:

      • Major Comment 2: “2) The author found that the levels of key CPL scaffolding proteins from the SCMC (OOEP, TLE6, NALP5, and KHDC3) were not affected by the loss of PADI6. It should be examined whether the subcellular localization of these proteins is affected in Padi6-deficient and C663A mutant embryos using immunostaining.”

      • Major Comment 3: “3) The authors found that CPLs contain components of the SKP1-CUL1-F-box protein (SCF) ubiquitin ligase complex. They also found that hPADI6 interacted with CUL1 when it was transiently transfected into HEK-293T cells. It is important to examine whether the stability or subcellular localization of these proteins is affected by the loss of PADI6 in oocytes.”

      • Combined response to reviewer 2 major comment 2 and 3: From our intact GV oocyte proteomics experiments, we know that the stability of the SKP1-CUL-F-box proteins is not affected by the loss of PADI6, similar to the key CPL scaffolding proteins highlighted in major comment 2. Regarding localization, it was reported by Jentoft et al. in 2023 that due to the cytoplasmic abundance of CPL proteins, their true cellular distribution can only be measured by IF using a Halo-tag knock-in line to circumvent the use of secondary antibodies which aggregate at the subcortex. Alternatively, expansion microscopy could be used to determine differences in localization. Unfortunately, we do not have the capacity to generate these lines or perform expansion microscopy and therefore we are not able to conduct these experiments in an informative manner. Reviewer #3 agrees with this conclusion: “Although some of the suggestions by Reviewer #2 could provide interesting information, the immunofluorescence experiments suggested in my view are not likely to provide definitive information regarding association of specific proteins or structures with CPLs. Instead, higher resolution technologies such as proximity ligation or immuno-EM might be required. These experiments seem like good ways to extend the findings beyond the current manuscript, but I think are not essential for the major take home points.”
      • Major Comment 6:

      “6) Figure 6C, G, and I.

      Statistical analysis should be done.”

      • Response: We have performed statistical analysis of Figure 6G and demonstrate that the PADI6-N598S variant binding to UHRF1 is statistically significantly impaired (see below). However, the immunoprecipitation assay performed is a largely qualitative assay and we don’t believe that detailed quantification of it is appropriate. Similarly for Figures 6C and 6I we don’t think quantification is necessary as the assay represents presence or absence of a protein in a sample.

      Reviewer 3:

      • Major Comment 1: “Padi6 catalytic activity: Given that PADI6 was previously shown not to have catalytic activity in vitro, the rationale for doing the experiment mutating Padi6 function is weak. The authors claim that a homologous mutation in human PADI6 does not "significantly damage the folded state of PADI6", but this conclusion does not necessarily mean that a scaffolding or protein interaction function could not be affected by the mutation. The authors provide zero evidence of catalytic activity in the WT oocytes (which I agree would be technically quite challenging given the poor quality/specificity of antibodies that recognize citrullinated proteins and low amount of protein available for mass spec analysis) but still include a full paragraph in the Discussion regarding the potential catalytic activity and why it might be important. This focus implies that the underlying data support the concept, even though the authors do frame the paragraph carefully.”
      • Response: We have primarily addressed this comment in the General Statements section of this document. Regarding scaffolding or interactional functions, as shown in our published X-Ray crystal structure of PADI6 (DOI: 10.1016/j.csbj.2024.08.019), the proposed catalytic cysteine is buried, not surface exposed, and doesn’t appear to be involved in structural interactions or disulphide bonds. We cannot however rule out subtle structural changes around the active caused by the C663A mutation resulting in altered protein-protein interaction binding affinities at proteins interacting near to the proposed PADI6 active site. To account for this possibility the following sentences have been added/amended in the discussion to read:

      “Given the lack of large-scale structural damage the loss of C663 imparts on PADI6, the possibility of a non-essential catalytic function of PADI6 in oogenesis and early embryo development cannot be ruled out, potentially in the epigenetic regulation of transcription similar to PADI4. Alternatively, it is possible that the C663A substitution alters protein binding affinities for interactions on or near to the proposed PADI6 active site.”

      • Major Comment 2:

      *“2. Padi6 mutant embryo development: The Padi6 mutant embryo development findings are minimally different from WT controls. The embryos were all cultured in vitro and it is unclear if they would have developed fine in vivo, which is suggested from the lack of a difference in litter sizes, which if anything were slightly higher in the Padi6 mutant females. In the absence of additional useful information regarding why the development was slightly lower, this experiment does not seem to add to the conclusions of the paper but seems more like an incomplete side note that should be more deeply investigated.”

      *

      • Response: An explanation for the lack of difference in litter sizes but difference in developmental potential has been discussed in the text: “This phenomenon (significant decrease in early embryo numbers in one mouse line over another despite litter sizes remaining comparable) has been observed previously and is attributed to mice, and other species, producing greater numbers of eggs and pre-implantation embryos than the uterus can accommodate, with excess embryos lost during the pre-implantation stage50–52.” The difference in developmental potential is statistically significant for Padi6-C663A embryos. Without an impaired function of PADI6 we do not see how in vitro culture of the embryos would result in such a difference in developmental potential of the mutant compared to the wild type embryos as they were cultured under the same conditions. We agree with the reviewer that we haven’t yet determined the underlying cause for this difference but we think nonetheless that it is an important finding to highlight - that a single cysteine mutation in the active site of PADI6, which does not affect protein structure significantly impacts the development of early-stage embryos.

      • Major Comment 3:

      “3. Padi6 mutant 2C embryo EGA timing: The altered transcription in the Padi6 mutant 2C embryos appears to indicate that they are ahead in development relative to the WT based on the PCA plot and the relative downregulation of minor ZGA genes and upregulation of major ZGA genes. The 1-cell embryos were collected from spontaneously ovulating mice and the time of development was not controlled in any way. Mouse embryos are quite variable in their exact timing of development, even across different embryos in the same mouse. I find these changes in transcription likely to be explained by differences in developmental timing and I don't think the authors have robustly shown "dysregulation of EGA". Similarly, the delay in development of the Padi6-null embryos from zygote to 2C (Figure 1D) explains why the maternal mRNAs are upregulated in the Padi6-null mice - they are simply delayed in development.

      • Response: When harvesting 2-cell embryos, samples from all four mice were harvested on different days at the same time of day. If the differences between samples were only due to differences in developmental timing we would anticipate as significant differences between the embryos from mice with the same genotype as between those from different genotypes which is not what we observe. Given the significant developmental defects observed in these embryos (Figure 1), it is highly likely these are associated with defects on the transcriptional level. Furthermore, we observed a small but significant delay in Padi6-C663A embryos reaching the 2-cell stage (Figure 1D) which we believe makes it highly unlikely that the embryos from both C663A females were further along in development compared to those from both wild-type females.

      The reviewer states that the upregulation of major EGA genes and downregulation of minor EGA genes further points toward an advancement in development. If this is the case, then it would be expected that there would also be increased degradation of maternal transcripts which decrease between the zygote and 2-cell stage in wild-type embryos. We do not see a further decrease of these transcripts in Padi6-C663A embryos. Finally, the reviewer notes the PCA plot as a reason for being advanced in development – PCA only measures differences between samples, not developmental time.

      Taking into account the above, we do not agree with the reviewer’s interpretation of our data. Regarding Padi6-null mice, disrupted EGA has been reported in Padi6-null mice in other work (DOI: 10.1101/gad.351238.123.).

      • Minor Comment 1:

      “1. What was the point of splitting up the 2C embryo blastomeres rather than treating them as single embryos?”

      • Response: 2C embryos were split up to investigate whether defects in Padi6-null 2-cell embryos were due to asymmetric inheritance of transcripts given the significant mis-localization of various oocyte structures in the absence of PADI6. As this was not clear in the text, we have added the following sentence clarifying the rationale and referencing Figure S4C-D where the transcriptomic correlation between blastomeres is shown: “The transcriptomes of separated blastomeres of the same 2-cell embryo showed high levels of correlation for embryos of each genotype suggesting asymmetric inheritance of transcripts is not a cause of PADI6 associated developmental defects (Figure S4C-D).”.

      • Minor Comment 2:

      “2. Proteomics - Because PADI6 makes up a significant fraction of total oocyte protein, and the Padi6-null oocytes don't have any PADI6, does this artificially increase the relative amount of the remaining proteins?”

      • Response: Any such effect would have been corrected during data normalization.
    1. Reviewer #1 (Public review):

      Summary:

      The authors present a nanobody-based pulse-labeling system to track yeast NPCs. Transient expression of a nanobody targeting Nup84 (fused to NeonGreen or an affinity tag) permits selective visualization and biochemical capture of NPCs. Short induction effectively labels NPCs, and the resulting purifications match those from conventional Nup84 tagging. Crucially, when induction is repressed, dilution of the labeled pool through successive cell cycles allows the visualization of "old" NPCs (and potentially individual NPCs) providing a powerful view of NPC lifespan and turnover without permanently modifying a core scaffold protein.

      Strengths:

      (1) A brief expression pulse labels NPCs, and subsequent repression allows dilution-based tracking of older (and possibly single) NPCs over multiple cell cycles.

      (2) The affinity-purified complexes closely match known Nup84-associated proteins, indicating specificity and supporting utility for proteomics.

      Weakness:

      Reliance on GAL induction introduces metabolic shifts (raffinose → galactose → glucose) that could subtly alter cell physiology or the kinetics of NPC assembly. As acknowledged by the authors, alternative induction systems (e.g., β-estradiol-responsive GAL4-ER-VP16) could be implemented as a way to avoid carbon-source changes.

      Comments on revised version.

      The authors have thoughtfully addressed all of my concerns. In particular, they have updated the proteomic analysis in Figure 1I, showing that they recover most NPC components (including basket Nups), including non-NPC proteins as controls, and providing all data as a supplementary table. These changes strengthen the authors conclusion and improve transparency. I have no further recommendations and congratulate the authors for their exciting work.

    2. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The authors present a nanobody-based pulse-labeling system to track yeast NPCs. Transient expression of a nanobody targeting Nup84 (fused to NeonGreen or an affinity tag) permits selective visualization and biochemical capture of NPCs. Short induction effectively labels NPCs, and the resulting purifications match those from conventional Nup84 tagging. Crucially, when induction is repressed, dilution of the labeled pool through successive cell cycles allows the visualization of "old" NPCs (and potentially individual NPCs), providing a powerful view of NPC lifespan and turnover without permanently modifying a core scaffold protein.

      Strengths:

      (1) A brief expression pulse labels NPCs, and subsequent repression allows dilution-based tracking of older (and possibly single) NPCs over multiple cell cycles.

      (2) The affinity-purified complexes closely match known Nup84-associated proteins, indicating specificity and supporting utility for proteomics.

      We thank the reviewer for this evaluation

      Weaknesses:

      (1) Reliance on GAL induction introduces metabolic shifts (raffinose -> galactose -> glucose) that could subtly alter cell physiology or the kinetics of NPC assembly. Alternative induction systems (e.g., β-estradiol-responsive GAL4-ER-VP16) could be discussed as a way to avoid carbon-source changes.

      Indeed, this could be an improvement, and we mention the benefits of an inducible system that does not alter the cell’s metabolic state in the discussion on p.3.

      (2) While proteomics is solid, a comprehensive supplementary table listing all identified proteins (with enrichment and statistics) would enhance transparency.

      Indeed, we now provide source data showing LFQ intensities, fold-enrichment and statistics for all detected proteins.

      (3) Importantly, the authors note that the method is particularly useful "in conditions where direct tagging of Nup84 interferes with its function, while sub-stoichiometric nanobody binding does not." After this sentence, it would be valuable to add concrete examples, such as experiments examining NPC integrity in aging or stress conditions where epitope tags can exacerbate phenotypes. These examples will help readers identify situations in which this approach offers clear advantages.

      Indeed, we agree this would be useful. For example, in Nup1Δct and Nup60Δ mutants, GFP-tagging of Nup84 leads to slower growth and increased cell size (Ollivaud et al., BioRxiv). We have however not extensively tested nanobody expression in these mutants, and cannot conclude that it has no interfering effects. We therefore rephrased to “while sub-stoichiometric nanobody binding does may not, …”. Another situation where we find the nanobody-based labeling useful is when we want to assess the structural integrity (IPs) and localization (imaging) of NPCs in mutant strains, but prefer not to use tagged Nups in the actual experiments. In these cases, we transiently express the Nup84 nanobody to perform these checks, and then carry out the experiments without the nanobody to avoid any tag-related interference. We hence also added “,…or when the temporary introduction of a ZZ- or mNG-tagged nanobody allows assessment of the integrity or localization of mutant NPCs prior to performing experiments without the nanobody.

      We thank the reviewer again for the constructive feedback and thoughts.

      Reviewer #2 (Public review):

      Summary:

      This preprint describes a practical and useful approach for labeling and tracking NPCs in situ. While useful applications including timelapse imaging, affinity purification, or proximity labeling are envisioned, addressing some outstanding technical questions would give a clearer picture of the sensitivity and temporal resolution of this approach.

      Strengths:

      Clever use of a fluorescently conjugated nanobody that binds directly to the core scaffold nucleoporin Nup84 with nanomolar affinity.

      We thank the reviewer for this evaluation

      Weaknesses:

      The decrease in nanobody labeling over 8 hours of chase period is interpreted to indicate that NPCs turn over during this time. However, it is also possible that the nanobody: Nup84 association is disrupted during mitosis by phosphorylation, other PTMs, or structural remodeling.

      We thank the reviewer for this thought. It is actually not turnover that we propose to underly the decrease in nanobody labeling, but rather the dilution of labelled NPC to the daughter cell. The current data do not support the interpretation that the nanobody: Nup84 association is disrupted as proposed by the reviewer. The exchange of individual Nups, including Nup84, is slow with half-times in the order of hours (Hakhverdyan et al. 2021; Rabut, Doye, and Ellenberg 2004), and the nanobody: Nup84 association is very stable, namely in the nanomolar range (Nordeen et al. 2020). The association of nanobody with NPCs is thus expected to be very stable. Instead, dilution of labelled NPCs to the daughter - approximately 40% of the existing NPCs are transmitted to the daughter cell in each division (Zsok et al. 2024; Khmelinskii et al. 2010) – will lead to significant decreases in nanobody labelling over time. As the reviewer is likely aware, baker’s yeast NPCs – in contrast to mammalian NPCs - remain largely intact during cell division as there is no nuclear envelope breakdown.

      We thank the reviewer again for the constructive feedback and thoughts.

      Reviewer #3 (Public review):

      Summary:

      Submitted to the Tools and Resources series, this study reports on the use of a single-domain antibody targeting the nucleoporin Nup84 to probe and track NPCs in budding yeast. The authors demonstrate their ability to rapidly label or pull down NPCs by inducing the expression of a tagged version of the nanobody (Figure 1).

      Strengths:

      This tool's main strength is its versatility as an inexpensive, easy-to-set-up alternative to metabolic labelling or optical switching. This same rationale could, in principle, be applied to the study of other multiprotein complexes using similar strategies, provided that single-chain antibodies are available.

      We thank the reviewer for this evaluation

      Weaknesses:

      This approach has no inherent weaknesses, but it would be useful for the authors to verify that their pulse labelling strategy can also be used to detect assembly intermediates, structural variants, or damaged NPCs.

      We agree with the reviewer that it would be informative to see if VHH[Nup84] can bind its epitope in the context of an altered NPC structure but consider such studies to be beyond the scope of this study.

      Overall, the data clearly show that Nup84 nanobodies are a valuable tool for imaging NPC dynamics and investigating their interactomes through affinity purification.

      We thank the reviewer again for the constructive feedback and thoughts.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) In Figure 1A, and although it is partially mentioned in the legend, it would be helpful to indicate precisely when cells are grown in raffinose, when galactose is added for induction, and when glucose is used to terminate expression.

      We included “galactose” and “glucose” to Panel A to indicate induction and termination of expression, respectively.

      (2) Related to the previous point, consider mentioning the GAL4-ER-VP16 (ADGEV) estradiol-inducible system as an optional strategy to avoid carbon shifts and potentially reduce cell-to-cell variability.

      We mention the benefits of an inducible system that does not alter the cell’s metabolic state in the discussion on p.3

      (3) Add a brief sentence explaining that the ZZ tag is derived from Protein A and binds IgG Fc.

      This information is now added on p.2

      (4) The statement "all Nups significantly coenriched with VHH[Nup84]-ZZ..." is likely inaccurate, since not all Nups are labeled in panels F-H, and some basket components are missing in panel I (particularly basket components such as Nup60, Nup1). Consider revising to "most Nups significantly coenriched...". In panel I, please include a clearly non-enriched protein as a visual reference for the color scale.

      We are very grateful to the reviewer for pointing this out. We accidentally used a faulty filtering on the dataset to generate figure panel I, omitting several Nups that were reproducibly found in all replicas. All Nups, except for Gle1 and Pom33, were detected reproducibly.

      We have made the following adjustments to the figure panel and accompanying text:

      In Fig. 1I, we included the missing Nups and 5 proteins that co-purified with VHH[Nup84] but not specifically enriched, as the reviewer suggested. They cluster in a separate group and their abundance is not going up in time. We randomly selected these 5 proteins from the list of genes that were reproducibly found in all four timepoints.

      For clarity, we removed the NTRs

      We changed the text to “we found that all Nups, except Gle1 and Pom33, significantly coenriched with VHH[Nup84]-ZZ” on p.2.

      We updated the methods section, describing the clustering method and how we selected the 5 random proteins

      (5) Provide a supplementary spreadsheet with LFQ intensities, fold-enrichment, and statistics for all detected proteins. This will address questions about missing Nups and support transparency.

      This information is now added as Source data Figure 1.

      (6) Directly after the statement "Amongst others this is useful in conditions where direct tagging of Nup84 interferes with its function, while sub stoichiometric nanobody binding does not," it would be useful to include concrete instances, such as stress or aging conditions, where Nup84 tagging may sensitize NPC integrity.

      Indeed, we agree this would be useful. For example, in Nup1Δct and Nup60Δ mutants, GFP-tagging of Nup84 leads to slower growth and increased cell size (Ollivaud et al., BioRxiv). We have however not extensively tested nanobody expression in these mutants and cannot conclude that it has no interfering effects. We therefore rephrased to “while sub-stoichiometric nanobody binding does may not, …”. Another situation where we find the nanobody-based labeling useful is when we want to assess the structural integrity (IPs) and localization (imaging) of NPCs in mutant strains, but prefer not to use tagged Nups in the actual experiments. In these cases, we transiently express the Nup84 nanobody to perform these checks and then carry out the experiments without the nanobody to avoid any tag-related interference. We hence also added “,…or when the temporary introduction of a ZZ- or mNG-tagged nanobody allows assessment of the integrity or localization of mutant NPCs prior to performing experiments without the nanobody.

      (7) In panels K and L, since individual points correspond to biological replicates, overlaying a box plot obscures much of the data. Consider overlaying the means per replicate instead of box plots: see the "SuperPlots" approach for a clear explanation of how to present this (PMID: 32346721).

      We thank the reviewer for the “SuperPlots” suggestion, and we agree that representing the data in this way improves the visualization of individual biological replicates. We have updated the summarizing overlay in figures in panel K and L to represent the means per replicate instead of boxplots.

      (8) I spotted a few typos ("Lasty" ? "Lastly"; "in maintained" vs. "is maintained").

      Thank you, these are corrected

      Overall, this is a neat, well-executed methodological advance with clear value to the NPC field and potentially other complex assemblies. I look forward to seeing a revised version.

      Thank you!

      Reviewer #2 (Recommendations for the authors):

      Based on the recent structural analyses and NPC modeling using this nanobody, how accessible is the Nup84 epitope expected to be within the fully assembled NPC? While the data shown indicate that nanobody labeling of NPCs is readily detectable, stating this clearly would help motivate the approach and interpret the resulting data.

      We now included such a statement in the introduction on p.1.

      The decrease of nanobody labeling over 8 hours of chase period is interpreted to indicate that NPCs turn over due to cell division during this time window. However, it is also possible that nanobody:Nup84 association is disrupted during mitosis by phosphorylation, other PTMs, or structural remodeling.

      We thank the reviewer for this thought. It is actually not turnover that we propose to underly the decrease in nanobody labeling, but rather the dilution of labelled NPC to the daughter cell. The current data do not support the interpretation that the nanobody: Nup84 association is disrupted as proposed by the reviewer. The exchange of individual Nups, including Nup84, is slow with half-times in the order of hours (Hakhverdyan et al. 2021; Rabut, Doye, and Ellenberg 2004), and the nanobody: Nup84 association is very stable, namely in the nanomolar range (Nordeen et al. 2020). The association of nanobody with NPCs is thus expected to be very stable. Instead, dilution of labelled NPCs to the daughter - approximately 40% of the existing NPCs are transmitted to the daughter cell in each division (Zsok et al. 2024; Khmelinskii et al. 2010) – will lead to significant decreases in nanobody labelling over time. As the reviewer is likely aware, baker’s yeast NPCs – in contrast to mammalian NPCs - remain largely intact during cell division as there is no nuclear envelope breakdown.

      Reviewer #3 (Recommendations for the authors):

      (1) As mentioned above, to assess the general relevance of this tool, it would be informative to verify whether the VHH[Nup84] nanobody can access and detect NPC species under conditions that challenge their structural organization or biogenesis, for example, in nucleoporin mutants or under stress. The authors could, for instance, analyze the localization of VHH[Nup84] in yeast strains harboring clustered NPCs (nup133Δ), or following stresses known to impact NPC organization (e.g., osmotic stress or energy depletion; PMID: 34762489).

      We agree with the reviewer that it would be informative to see if VHH[Nup84] can bind its epitope in the context of an altered NPC structure and tried to include such data. Unfortunately, this was not successful, and further efforts are beyond the scope of his study. Following the reviewer’s suggestion, we expressed VHH[Nup84] in nup133∆N (nup133∆2-300) (Doye, Wepf, and Hurt 1994) following the experimental set-up in panel A and examined its localization. However, at t=2hrs hardly any nanobody signal was detectable in nup133∆N (see Author response image 1, upper panel A) and only after overnight expression nanobody-labelled NPC clusters are detectable (bottom panel A). Considering that expression levels of free mNG are also lower at t=2hrs in nup133∆N cells compared to WT cells (Author response image 1, panel B), it appears that protein expression under the Gal system is generally reduced in a nup133∆N background. These expression level differences between nup133∆N and WT preclude statements about the accessibility of the Nup84 epitope in nup133∆N. We note that nup133∆N cells do not have general mRNA export defects (Doye, Wepf, and Hurt 1994), so other inducible systems may be better suited for such analysis.

      Author response image 1.

      Expression level differences in WT and Nup133∆N cells. Left: localization of VHH[Nup84]-mNG in Nup133∆N cells at t=2hr following a 20-minute induction pulse and after overnight 0.5% galactose (ON) induction. Right: mNG levels in WT and Nup133∆N cells at t=2hr following a 20-minute induction pulse. Brightness/contrast settings are identical between the two panels. All panels are sum slices projections from 30 z-slices of 0.1µm. Scale bar = 5 µm.

      (2) Since outer rings are found on both sides of NPCs (i.e., the cytoplasmic and nuclear faces), could the authors indicate whether the VHH[Nup84] nanobody can enter the nucleus and probe the nuclear outer rings? Along these lines, it would be useful to provide a summary of the structural organization of NPCs in the introduction.

      Thank you, we have added a sentence on the localization of Nup84 in NPCs in the introduction. Based on what is known about influx (nuclear transport receptor-independent nuclear entry) of proteins with similar size and surface properties (Popken et al. 2015; Timney et al. 2016), the nanobody can rapidly enter the nucleus and hence bind Nup84 on both the nuclear and cytoplasmic side. We have no data to answer if binding might initially be biased towards cytosolic VHH[Nup84] binding the cytoplasmic outer rings.

      (3) The authors state that VHH[Nup84] and direct Nup84 detection are indistinguishable (p. 2). Could they provide images of the endogenously tagged Nup84-GFP strain for comparison?

      We have now included a pairwise comparison in a Figure 1 – supplement 1.

      Minor corrections:

      (1) There are a few typos that need correcting: 'Nup84Δ' (p. 1; should read 'nup84Δ') and 'promotor' (p. 2; should read 'promoter').

      Thank you, these are corrected

      (2) The reference 'Veldsink et al. 2025' (quoted in the PunctaFinder analysis description on page 8) does not appear in the References section.

      Thank you, these are corrected.

      We thank the reviewer again for the constructive feedback and thoughts.

      References

      Doye, V., R. Wepf, and E. C. Hurt. 1994. 'A novel nuclear pore protein Nup133p with distinct roles in poly(A)+ RNA transport and nuclear pore distribution', EMBO J, 13: 6062-75.

      Khmelinskii, Anton, Philipp J. Keller, Holger Lorenz, Elmar Schiebel, and Michael Knop. 2010. 'Segregation of yeast nuclear pores', Nature, 466: E1-E1.

      Popken, Petra, Ali Ghavami, Patrick R. Onck, Bert Poolman, and Liesbeth M. Veenhoff. 2015. 'Size-dependent leak of soluble and membrane proteins through the yeast nuclear pore complex', Molecular Biology of the Cell, 26: 1386-94.

      Timney, Benjamin L., Barak Raveh, Roxana Mironska, Jill M. Trivedi, Seung Joong Kim, Daniel Russel, Susan R. Wente, Andrej Sali, and Michael P. Rout. 2016. 'Simple rules for passive diffusion through the nuclear pore complex', Journal of Cell Biology, 215: 57-76.

      Zsok, J., F. Simon, G. Bayrak, L. Isaki, N. Kerff, Y. Kicheva, A. Wolstenholme, L. E. Weiss, and E. Dultz. 2024. 'Nuclear basket proteins regulate the distribution and mobility of nuclear pore complexes in budding yeast', Mol Biol Cell, 35: ar143.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      1. General Statements

      We thank the reviewers for their constructive criticisms and helpful suggestions.

      2. Description of the planned revisions

      Point-by-point reply explaining what revisions, additional experimentations and analyses are planned to address the points raised by the referees.

      Reviewer #1

      (Note: to see the Figures in our response we refer to the document Revision-plan_RC-2026-03552)

      Summary: This study examines how simultaneous expression of high levels of alpha and beta tubulin impact microtubule organization, cell cycle progression and stress response. The main conclusions are that a/b tubulin overexpression 1) increases the density of microtubules in cells with mild effects on growth rate and catastrophe frequency; 2) causes mitotic spindle defects and cell cycle disruption; 3) alters the transcriptome and proteostasis; 4) causes mitochondrial stress by binding mitochondrial import proteins; 5) disrupts cellular stress response.

      Major comments:

      The results generally use an appropriate number of cells and technical replicates.

      There are several instances in the manuscript where the data do not support the authors' conclusions. These include:

      Page 6. "We detected a mild increase in MT growth rates in Dox-treated cells (Fig. 2b), which was observed in all of the growing MTs examined (Fig. 2c), consistent with an increase in soluble tubulin levels in all Dox-induced cells." The data do not support this statement. The histogram in Figure 2C shows that only a small portion of growth rate measurements are faster in the overexpression cells, and the statistical test in 2b suggests that the datasets are unlikely to be different. It is unclear from the presentation of the data why a small population of overexpression cells exhibit faster growth rates. The data in Figure 2b should be plotted as a superplot could show whether the faster data points are from specific cells or technical replicates. The same concern applies to the data in Figure 2D.

      Answer:

      We agree that an overlaid density plot as currently shown in Fig. 2c might visually suggest that only the non-overlapping tail differs between conditions, but this is not what the underlying data show. Comparison of individual comet measurements indicates that the entire Dox distribution is shifted toward faster speeds (as we state in the text), not a small subpopulation: a randomly selected Dox comet is faster than a randomly selected Ctrl comet in 62% of pairwise comparisons (50% expected if the groups were identical), and 69% of Dox comets exceed the Ctrl median speed. We have added a cumulative distribution plot (see Figure below) that makes this more explicit — the Dox curve runs to the right of Ctrl across essentially the entire range, rather than only in a discrete high-speed segment. We acknowledge that our previous Figure panel may not have represented the data properly and propose to replace current Fig. 2c with this new plot.

      New Fig. 2c. Cumulative distribution plot of EB3-GFP comets (displacements in time).

      Note: to see the Figures in our response we refer to the document Revision-plan_RC-2026-03552

      Regarding the statistic in Fig. 2b: the reported P = 0.057 is from a test comparing group means. However, the Dox distribution is right-skewed and borderline non-normal (Shapiro-Wilk P = 0.054), and we realized that this is a condition under which a mean-comparison test is not well powered. A Mann-Whitney U test, which compares the full rank distribution and is more appropriate for data of this shape, gives P = 0.013 (Kolmogorov-Smirnov P = 0.0043). We will add these results and the effect-size measures mentioned above to a revised manuscript, and will report the rank-based test as the primary statistic for this comparison in the revised manuscript. All in all, we hope this clarifies that the effect is a genuine population-wide shift in comet speed. Note that we agree with the reviewer that the data should be plotted as a superplot in Fig. 2b, and we will do this in a revised manuscript.

      For the data presented in Fig. 2d (duration of EB3-GFP displacements), we performed a similar analysis as described above. In contrast to Fig. 2c no significant changes are seen in duration, and here the concern of the reviewer is justified. We will indicate this clearly in the text. It does not change any of our conclusions.

      Page 11. "Moreover, DNA content was highly aberrant after 48 hr, with large proportions of cells containing 4n chromosomes (Fig. 4d). Thus, persistent overexpression of tubulin affects the cell cycle and after 48 hr it results in severe DNA abnormalities, suggestive of CIN". The plot in Figure 4D shows increased propidium iodide signal below the 2N peak and above the 4N peak, but it is quite likely that this could represent signal from apoptotic cells. The authors should specifically stain for an apoptotic marker to test this possibility. This would suggest that prolonged overexpression of a/b tubulin leads to apoptosis, which could be important evidence for later conclusions in the study.

      Answer:

      We agree with the reviewer. We actually thought along the same lines and already performed the apoptosis experiment by staining tubulin overexpressing cells (dox) and control cells (ctrl) with Annexin, an apoptosis marker, and propidium iodide. We then quantified double-stained cells. The experiment was performed in triplicate. As shown in the Figure below (averages ± SEM), the data do not reveal differences in apoptosis. We therefore did not include these results in the original manuscript. However, based on the comment of the reviewer we will now include these data in a revised version of the manuscript. The conclusion is that tubulin overexpression does not lead to increased apoptosis.

      Apoptosis Figure.

      Note: to see the Figures in our response we refer to the document Revision-plan_RC-2026-03552

      Page 11. "Combined, our data show that tubulin overexpression affects all three major cell cycle checkpoints, i.e. G1/S, G2/M, and the SAC in mitosis." The data do not fully support this conclusion. While the evidence for SAC-mediated delay in overexpression cells is strong, the evidence for other checkpoints is weak. The phosphor-RB experiment in Figure S3b lacks a positive control. The γH2A-X results in Figure 4f and g show that the difference is driven by a minor population of dim foci in control cells. Similar to the point above, these data should be plotted as a superplot to explore the possibility that this minor population arises from a small number of cells or a specific technical replicate.

      Answer:

      With respect to the “inclusion of a positive control”, we are not sure what is meant by the reviewer. Total RB is shown underneath the phosphor-RB lane, and underneath that lane we show a tubulin blot. Moreover, mass spectrometry data are included in Table 1, showing the levels of many other proteins. Note that both the western blot and proteomics data reveal similar RB1 levels in Ctrl and Dox cells.

      New Fig. 4g. Cumulative distribution plot of 𝛾-H2AX foci intensity.

      Note: to see the Figures in our response we refer to the document Revision-plan_RC-2026-03552

      With respect to the γH2A-X results in Figure 4f and g, we re-analyzed and re-plotted the data as described above for Fig. 2c. A cumulative distribution plot, depicted above, clearly shows separation of the two populations. We ran several statistical tests, which all show highly siginificant values (Welch P = 1.5e-17, Mann-Whitney P = 3.2e-17, KS P = 1.1e-14). We propose to change the current Fig. 4g with the plot shown above, and we will indicate statistical tests.

      We then tested the reviewer's proposal (driven by a minor population of dim foci in control cells) by fitting a 2-component Gaussian mixture to each condition separately. The table below shows close to the opposite of the reviewer's hypothesis. Both Ctrl and Dox contain the same two-population structure in similar proportions (roughly 75%/25%). The minor subpopulation is therefore not unique to Ctrl, but a feature of both conditions. Perhaps it is a cell-cycle-linked fraction. When we next compared the matched components directly we observed that the majority/lower-intensity component is shifted (102 → 112 AU, P = 1.5e-30), while the minor/higher-intensity component is statistically indistinguishable between conditions (143 vs. 146 AU, P = 0.11, ns). Thus, if anything, the effect is carried by the bulk population, and the minor subpopulation is the part that does not differ. All data are summarized in the table below.

      2-component Gaussian mixture decomposition

      Ctrl weight

      Ctrl mean (AU)

      Dox weight

      Dox mean (AU)

      Lower-intensity component

      ~78%

      101.7

      ~71%

      111.9

      Higher-intensity component

      ~22%

      143.3

      ~29%

      146.3

      Page 19. "This, in turn, lowers EEF1A1 causing attenuation of translation and dampened elongation rates. That other initiation and elongation factors are mildly down in Dox-induced cells, as are ribosomal proteins (Fig S6c, Table S1), indicates a mild ISR and general translation inhibition. We propose that tubulin overexpression results in mitochondrial dysfunction leading to stress and attenuated translation elongation. We observe the start of an ISR in these cells, which prevents a proper hypoxic response." This conclusion seems to be at odds with the earlier conclusion drawn from Figure 5e, where ISR genes are significantly decreased in overexpression cells. The authors should reconcile these results in the discussion.

      Answer:

      Our proteomics data suggest that attenuated translation elongation caused by lower EEF1A1 levels hampers the integrated stress response (ISR) in Dox-induced cells. One can intuitively understand this: translation is already lowered, it does not need to be lowered much further via the ISR. Thus, in Dox-induced cells the ISR is hampered compared to control cells, which do not suffer from mito-stress. In other words, the ISR is set in motion in Dox-induced cells but less compared to control cells. This is exactly what we see in the RNA-Sequencing experiments, where in Dox-induced cells mRNAs encoding proteins in volved in HIF-1 and PKR signaling (reflecting ISR) are down (Fig. 5e, right hand panel). Thus, ISR is hampered at the RNA level when tubulin is overexpressed. While we thought we had explained our view well enough on page 19, we realize that this may not have been the case and we will provide an improved explanation in the Discussion section of a revised manuscript.

      Figure 7. This experiment lacks a key control - identifying peptides in a pull down from cells that do not overexpress the tagged tubulin. Without this control, it is impossible to discern which peptides bind to the beads, independent of tubulin. This concern is amplified by the results in Figure 7b where TIMM50 binding is tested in a follow-up experiment. Here the negative control is employed and it shows that TIMM50 pulls down in the absence of tagged tubulin. This indicates that TIMM50 may not bind to tubulin and calls into question any conclusions related to TIMM50 and mitochondrial proteostasis. Before making any conclusions from the pull down experiment, the authors must include the negative control and carefully assess which peptides are likely to be false positives.

      Answer:

      In contrast to what the reviewer states a negative control was included. As described on page 19: “Using beads coupled to ALFA-tag antibodies, we affinity-purified recombinant tubulin and tubulin-associated proteins (TAPs) from cell lysates of tubulin overexpressing cells, using non-induced cells as controls”. To make this more clear we propose to include a plot in Figure 7 showing the fold enrichment of TAPs in the dox-induced versus Ctrl cells.

      The reason that TIMM50 enrichment in the recombinant tubulin pull down is not high is explained on page 21 of the manuscript: “We note that the relatively weak enrichment of TIMM50 on beads containing recombinant tubulins (Fig. 7b, lower blot, Table S1) as compared to the enrichment of the recombinant tubulins themselves (Fig. 7b, upper and middle blots, Table S1) is well explained, first by a low affinity of the tubulin-TIMM50 interaction itself, and second by competition for TIMM50 between recombinant tubulins, which are enriched after washing, and the much larger reservoir of endogenous tubulins, which are lost (together with TIMM50) after washing”.

      While we believe that the weak enrichment of TIMM50 is well explained in the current set-up, we nevertheless feel that the tubulin-TIMM50 interaction should be further corroborated and we propose to perform a new experiment where we tag both TIMM50 (and AIFM) in addition to our dual tubulin constructs and show - via dual affinity purification - that the proteins do interact.

      Figure 8. This figure and the associated text feel rather disconnected from the rest of the study. The authors do not make clear conclusions from these results. Perhaps these experiments should be further developed in a separate study?

      Answer:

      The physiological relevance of autoregulation is still largely unknown. Our analysis in Figure 8, where we show that autoregulation is activated upon stress (i.e. hypoxia and Gln deprivation), provides a clue. Moreover, we show that disruption of normal tubulin levels, which induces stress, dampens the hypoxic response. We believe these reciprocal effects fit nicely. However, since reviewer 2 is of the same opinion as this reviewer we are willing to remove the data in a revised version of the manuscript.

      Page 25. "We found that tubulin overexpression induces mitochondrial dysfunction." The data do not strongly support this conclusion. The proteomic data in Figure 6 indicate that some mitochondrial proteins are less abundant in tubulin overexpressing cells, but the study does not include any experiments that actually test mitochondrial function. The authors could test this by including new experiments to measure mitochondrial membrane potential, or respiration activity, etc. These would be an important addition to the study.

      Answer:

      We agree with this criticism and will perform additional experiments in a revised version of the manuscript to describe mitochondrial dysfunction.

      Page 26. "We provide evidence here that surplus tubulin slows general translation, increasing the time window for a TTC5-nascent tubulin interaction." The data do not demonstrate a decrease in translation rate. It is unclear what evidence the authors refer to with this statement. The proteomic analysis in Figure 6 measures protein abundance, and a decrease could be due to either decreased transcription, decreased translation, or increased protein degradation. The number of proteins that are shown to be downregulated in tubulin overexpressing cells is rather small (100s) which seems to argue against a general decrease in translation, despite the decrease in several translation regulators. To make this conclusion, the authors would need to add new experiments that measure translation rate.

      Answer:

      While we agree with the reviewer that “protein decrease could be due to either decreased transcription, decreased translation, or increased protein degradation”, we provide evidence below that, at least in our view, excludes transcription and degradation as mechanisms. We do agree that we should provide more compelling evidence that attenuated translation is at work in tubulin overexpressing cells. We will therefore perform an assay to measure translation rates in tubulin overexpressing and control cells.

      Having stated which new experiment we will perform in a revised version of the manuscript, we now would like to extensively react to the above comment of the reviewer using our existing data. First, the reviewer argues that “the number of proteins that are shown to be downregulated in tubulin overexpressing cells is rather small (100s)”. However, this applies to the signficantly differentially expressed proteins (DEPs) and "only hundreds of proteins pass significance" is a power argument, not an effect-size argument. In Fig. 7c (heatmap) and Fig. S6b (probability distributions) we show that the whole population of 8224 proteins is down-regulated in Dox-induced cells.

      We visualize probability distributions again in the Figure below, but this time we analyzed both proteomic data and matching transcriptomic data.

      New Fig. S6. Probability distributions of proteomes and transcriptomes (a) and directionality of changes (b) comparing Dox-induced cells (Dox) to control cells.

      Note: to see the Figures in our response we refer to the document Revision-plan_RC-2026-03552

      At the protein level the median protein log2-fold change (L2FC) is -0.144. The mean L2FC is -0.149, which is highly similar to the median, indicating that the whole population shifts in a similar manner (panel a). Indeed, as shown in panel b the directionality of the change at the protein level is 91%. Thus, 91% of proteins is down in tubulin overexpressing cells. This effectively rules out protein degradation as a mechanism for decreased protein levels, as degradation is highly unlikely to be so aspecific.

      Using our RNA-Seq dataset we analyzed the mRNA levels corresponding to the 8224 proteins in the proteomics analysis. In panel a of the Figure it can be seen that the median mRNA log2-fold change (L2FC) is 0.008, which is close to zero. Panel b shows that directionality of change is 45.7%, which is close to 50%, and is essentially what one would expect from distributions around zero. The Wilcoxon effect size (r) is 0.76 for protein, which is large, and 0.09 for mRNA, which is trivial. These data strongly suggest that transcription plays no role in the downregulation of the 8224 proteins in tubulin overexpressing cells. Thus, neither protein degradation nor transcription appear to play a role in the downregulation of proteins in tubulin overexpressing cells. We propose to add these new data to our revised manuscript and change current Fig. S6b for the new Fig. S6.

      Minor comments:

      Page 10." We also observed "extra-mitotic" centrioles at the onset of mitosis after Dox-treatment, indicative of mitotic arrest and aneuploidy, which eventually resolved into normal metaphase plates (Supplementary Videos 3, 4)." It is unclear whether these foci are centrioles. The SiR-tubulin reagent used in these experiment labels tubulin. It would be more accurate to describe these as "tubulin foci".

      Answer:

      We thank the reviewer for this comment. We will modify the text.

      Page 13. "Analysis of TUBG1 reads revealed downregulation in tubulin overexpressing cells, albeit weakly (Fig. 5c)." These datapoints appear to be quite similar. Please provide a statistical analysis.

      Answer:

      The reviewer is correct, datapoints are quite similar. DESeq2 analysis reveals the difference in expression is minimal but significant (Dox vs Ctrl, log2fold change -0.111, p-value 0.016). These data are shown in Table S1 (sheet: DESeq2 24 hr).

      Reviewer #2

      Note: to see the Figures in our response we refer to the document Revision-plan_RC-2026-03552

      Summary: This study develops an inducible HEK293F cell model that modestly overexpresses αβ-tubulin heterodimers. Using a dual expression system, the authors introduce exogenous TUBB3 and TUBA1A and combine cell biology, live-cell imaging, RNA-seq, proteomics, flow cytometry, and biochemistry to investigate the consequences of increased tubulin abundance. They suggest that, despite downregulation of endogenous tubulin transcripts, excess tubulin still accumulates in cells. This is accompanied by increased microtubule mass, changes in plus-end protein composition, defects in mitosis, and alterations in cell-cycle progression. The study further links tubulin overexpression to replication stress and broader changes in cellular physiology, including reduced abundance of mitochondrial respiratory proteins, altered translation-associated factors, and an attenuated response to hypoxic stress. In addition, the authors confirm previous observations that oxygen and nutrient deprivation reduce tubulin and microtubule abundance. Based on these findings, the authors propose that tubulin is not merely a structural component of microtubules but also contributes to the regulation of cellular homeostasis.

      The possibility that tubulin abundance itself influences broader aspects of cellular physiology is conceptually interesting and warrants further investigation. At the same time, many of the mechanistic links proposed in the manuscript remain insufficiently resolved. A large number of cellular processes are associated with tubulin overexpression, but it is often unclear which phenotypes represent primary consequences of altered tubulin abundance and which are secondary responses. For instance, conclusions regarding mitochondrial dysfunction and translation attenuation are inferred from omic signatures rather than direct functional tests. Similarly, while the authors propose that altered tubulin abundance contributes to many of the observed phenotypes, the causal relationship between tubulin abundance and the downstream cellular defects is not fully established.

      Despite being largely descriptive, the study has several strengths. The inducible dual-tubulin expression system is technically elegant and provides a useful platform to investigate the consequences of altered tubulin isotype composition and/or abundance. The work also indicates that relatively modest increases in tubulin levels can have measurable biological consequences, offering a possible explanation for why tubulin abundance is tightly regulated. Finally, the breadth of approaches-including transcriptomics, proteomics, imaging, and cell-cycle analyses-provides a valuable resource for the field. While many of the proposed connections remain to be mechanistically tested, the study raises a number of interesting hypotheses and highlights several promising directions for future work.

      Answer:

      We thank the reviewer for these positive comments.

      Major comments:

      Figure 1:

      The dual expression system that the authors use to introduce exogenous tubulins is well described and characterized, representing an elegant strategy and useful tool for the field. The current version of the manuscript, however, is missing a quantitative assessment of the overall tubulin levels (endogenous + exogenous) upon doxycycline treatment (e.g., using western blot). Given that the article is centered on cellular roles of surplus soluble tubulin, the authors must quantify both the soluble and polymerized fractions of total cellular tubulin in control and doxycycline-treated samples.

      Answer:

      We will perform the assays requested by the reviewer and add them to a revised version of the manuscript.

      Throughout the manuscript, the authors extrapolate the effects of TUBB3+TUBA1A overexpression to "tubulin overexpression". But how can they distinguish isotype-specific from general effects? If endogenous tubulins are massively downregulated upon the expression of exogenous TUBB3+TUBA1A, the tubulin isotype composition is presumably dramatically altered. If the authors wish to retain the claims later on in the manuscript that the observed phenotypes are associated with excess tubulin, they need to provide evidence by testing other isotype combinations. Alternatively, the authors should tone their claims to reflect the possibility that what they observe downstream of TUBB3+TUBA1A overexpression may be isotype-specific rather than general.

      Answer:

      Making new stable lines with other tubulin isotypes and analyzing the many downstream effects takes months and is beyond the scope of the present manuscript (see also below, Description of analyses that authors prefer not to carry out). Hence, we will tone down our claims by acknowledging that observations were made with one set of tubulin isotypes.

      Figure 2:

      While changes at the level of EB1, and to a lesser extent CLIP-170 upon TUBB3+TUBA1A overexpression are convincing, the claimed changes in microtubule dynamics are not supported by the data (small, but statistically insignificant trends are observed). The authors should tone down their claims and adapt the results subheadings and figure captions accordingly. Likewise, the authors state "our results convincingly show that soluble tubulin levels control +TIP composition at MT ends," which should be toned down, as the authors do not provide any experiments to probe this model (e.g., mild tubulin downregulation to restore normal protein levels and then characterize the +TIP composition).

      Answer:

      With respect to changes in microtubule dynamics we refer this reviewer to our answers to comments of reviewer #1 (pages 1,2). Briefly, by displaying a cumulative distribution plot in combination with appropriate tests we show that effects are statistically significant. We propose to include these data in a revised version.

      We furthermore propose to perform dose-dependent doxycycline experiments (see also next comment) and test whether these cause dose-dependent +TIP composition shifts. If this is the case we maintain our current statement, if not, we will tone down this statement.

      Figure 3.

      Similar to Figure 2, the authors state that tubulin overexpression leads to mitotic defects. But this model is never challenged in rescue experiments, and the claims should therefore be toned down.

      Answer:

      We do not completely understand this comment. We simply turn on (or off) tubulin expression, and in our view the “rescue” experiment is the control situation, i.e. non-induced cells. To addres this criticism, we nevertheless propose to perform dose-dependent doxycycline experiments and test whether these cause dose-dependent mitotic effects.

      The methodology that the authors chose to measure metaphase duration is inadequate, since it is difficult, if not impossible, to precisely measure metaphase duration with a tubulin label alone. A DNA label is required. Likewise, measurements of spindle length should be done in living, but not fixed cells. These parameters can be extracted from the same movies with a tubulin and a DNA stain.

      Answer:

      We will perform additional experiments where we add a DNA label (in addition to a tubulin label) to more accurately measure metaphase duration (and we take along spindle length).

      We do not understand the claim of the reviewer that “measurements of spindle length should be done in living, but not fixed cells”. We and others have measured spindle length in fixed cells with immunostaining (PMID: 38117947, PMID: 40353778; PMID: 25568341), and it therefore appears to be an accepted method. Note that in these measurements we do include a DNA label.

      The unaligned chromosomes in metaphase represent a striking phenotype associated with TUBB3+UBA1A overexpression. A close inspection of the mitotic spindle staining, however, doesn't seem to show a much denser microtubule network in dox-treated samples. This is surprising, and the authors should provide a quantification to support their model (e.g., tubulin fluorescence intensity normalized to an internal control), or at the very least discuss this paradox in the manuscript.

      Answer:

      We thank the reviewer for this observation and will analyze this in more detail.

      Figure 4.

      The authors convincingly demonstrate the alterations in cell cycle progression upon TUBB3+TUBA1A overexpression using flow cytometry. An orthogonal approach would strengthen this claim, while allowing the authors to mechanistically test the premature G1/S transition model that they propose. As is, the reduced G1 population could also be explained by increased G2/M population in these cells. Well-established time-resolved approaches exist for directly measuring G1/S transition timing, including FUCCI systems for live imaging and EdU pulse-chase methods for temporal cell cycle analysis. Without employing these validated methodologies, the inference of premature G1/S remains untested, leaving a key mechanistic link in the claim insufficiently supported.

      Answer:

      We thank the reviewer for this comment. We note that the flow cytometry data are supported both by RNA-Seq and proteomics results, as stated in the manuscript. Hence, orthogonal approaches were to some extent already performed. However, we do feel that additional evidence should be provided to support our premature G1/S transition model. Based on the suggestion of the reviewer we will perform an EdU pulse-chase experiment as orthogonal approach.

      Figures 5-6.

      The authors use next-generation sequencing to reveal transcriptional changes associated with TUBB3+TUBA1A overexpression. While these analyses appear comprehensive, it remains unclear how many of the alterations in gene expression are a direct consequence of TUBB3+TUBA1 overexpression and how many are a downstream consequence of the altered cell cycle profile. The authors should, at the very least, acknowledge this in the manuscript.

      Answer:

      This is actually acknowledged in the manuscript, on page 15: “These results are consistent with our FACS analysis and suggest that shifts in cell cycle fractions partly underlie gene expression differences”.

      Similarly, the authors provide a careful proteomics profiling of cells overexpressing TUBB3+TUBA1 in both normoxia and hypoxia. But as with transcriptomics, it is unclear what the contribution of the altered cell cycle profile is in these analyses. This should, at the very least, be acknowledged in the manuscript.

      Answer:

      Again, this is actually stated in the manuscript, on page 18: “Metascape analysis revealed upregulation of terms associated with mitosis and G2/M transition, including the PLK1 pathway, in the Dox-induced cells, whereas G1/S-specific, and DNA repair terms were down (Fig. 6d, Table S1). These data are consistent with our FACS (Fig. 4a, b) and RNA-seq results (Fig. 5e)”.

      The authors then leverage their omics data to propose a functional link between tubulin overexpression and translation and mitochondrial function. A limited number of targeted functional assays would substantially strengthen the manuscript and help distinguish between primary and secondary effects. For example, direct measurements of protein synthesis (e.g., puromycin incorporation or OPP labeling) would provide evidence for the proposed translation defects. Likewise, direct assessment of mitochondrial function (e.g., oxygen consumption, mitochondrial membrane potential, or ATP production) would strengthen claims regarding mitochondrial dysfunction. These experiments are standard in the field and could realistically be completed within several weeks to a few months, depending on local expertise and instrumentation. Moreover, they would test conclusions already central to the manuscript without opening entirely new directions.

      Answer:

      We thank the reviewer for these comments and helpful suggestions. We will perform experiments measuring translation and mitochondrial (dys)function (see also our rebuttal to reviewer #1 on pages 6 and 7), and include them in a revised version of the manuscript.

      Figure 7.

      The authors use proteomics-based approaches to characterize the partners of the overexpressed tubulins, revealing novel interactors. These data present an interesting but incomplete picture. For example, can the identified novel interactors bind any tubulin isotype, or are they specific to the TUBB3/TUBA1A used in this study? The enrichment of TIMM50 does not appear very strong. How reproducible are these data? The authors should provide quantifications from several independent biological replicates and perform statistical analyses.

      Answer:

      We thank the reviewer for these comments. As stated on page 22 of our manuscript: “Thus, AIFM1 and TIMM50 are consistently identified as TAPs using different purification strategies, tags, and cell lines”. For the revised version of the manuscript we will perform pull down experiments with other recombinant tubulins.

      With respect to the relatively weak TIMM50 enrichment we refer to our answer to reviewer #1 on pages 5, 6 of this rebuttal. Briefly, we will perform additional pull down experiments (dual affinity purifications) to solidify our claims.

      Figure 8.

      While convincing, this figure largely confirms previous studies. In addition, it addresses a question that is different from the rest of the manuscript. The reviewer feels like this part could be taken out of the manuscript to reduce complexity and focus the scope of this work.

      Answer:

      Since reviewer #1 is of a similar opinion as this reviewer we are willing to remove the data presented in Fig. 8 in a revised version of the manuscript. We agree that this reduces complexity and focusses the scope of this work.

      Minor comments:

      There is a discrepancy between the manuscript and the methods that makes it unclear in which cells the transcriptomic analyses were done. The authors should clarify this.

      Answer:

      We are not sure what the reviewer means here, there is but one Dox-inducible cell line in which our own transcriptomic analyses was done. On page 37 we list the GEO numbers from which we retrieved expression data for Figure 8. Note that this part of the Methods section will be removed in a revised version, as we will not show Fig. 8 anymore.

      The authors report "We also observed "extra-mitotic" centrioles...". However, they appear to refer to movies of SiR-tubulin-stained cells. This staining dows not allow visualization of centrioles, and the authors should revise their manuscript to either provide a clarification or correct this claim.

      Answer:

      We thank the reviewer for pointing out this mistake. We will correct this.

      • *

      3. Description of the revisions that have already been incorporated in the transferred manuscript

      NA.

      4. Description of analyses that authors prefer not to carry out__ __

      Reviewer #2

      Throughout the manuscript, the authors extrapolate the effects of TUBB3+TUBA1A overexpression to "tubulin overexpression". But how can they distinguish isotype-specific from general effects? If endogenous tubulins are massively downregulated upon the expression of exogenous TUBB3+TUBA1A, the tubulin isotype composition is presumably dramatically altered. If the authors wish to retain the claims later on in the manuscript that the observed phenotypes are associated with excess tubulin, they need to provide evidence by testing other isotype combinations. Alternatively, the authors should tone their claims to reflect the possibility that what they observe downstream of TUBB3+TUBA1A overexpression may be isotype-specific rather than general.

      Answer:

      We thank the reviewer for this comment. Making new stable lines with other tubulin isotypes and analyzing the many downstream effects takes months and is beyond the scope of the present manuscript. Hence, we will tone down our claims by acknowledging that observations were made with one set of tubulin isotypes.

    1. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary

      This manuscript presents a comprehensive experimental analysis of the calcineurin pathway in the fungal pathogen Cryptococcus neoformans, a pathway that is important for thermoregulation and virulence. Calcineurin is a calcium-dependent protein phosphatase complex that is conserved in eukaryotes and that is required for growth at high temperature in fungi, and thus for fungal pathogenesis in humans. The work uses a range of approaches including genetics, proteomics, and transcriptomics to establish important new insight into the pathway.

      Genetic screens for growth of C. neoformans H99 / KN99 at high temperature in the absence of calcineurin discover suppressors including inactive alleles of the Yak1 kinase. Extensive mutagenesis and phosphoproteomics assays confirm Yak1 as the primary kinase that opposes calcineurin-dependent dephosphorylation, an important result in the field. This complements and extends the authors' recently published work in C. deneoformans (Yadav et al., 2025, https://doi/10.1073/pnas.2503751122), which identified but did not follow up Yak1 mutations as suppressing calcineurin deletion. The importance of that study, including Yak1, was highlighted in a news and views article (Mitchell, 2025, https://doi.org/10.1073/pnas.2511623122).

      Proximity-labeling proteomics with TurboID discover interactors of calcineurin, a dataset complementary to phosphoproteomics (in wild-type, calcineurin deletion, yak1 deletion) in mapping the signaling pathway. Transcriptomics and translatomics assays aim to map gene expression regulation downstream of calcineurin. Furthermore, molecular functions of the Cna1 component of calcineurin are dissected with a series of mutants, including their impact on thermoregulation and Cryptococcus virulence in mice.

      Major comments

      The main result, that "Yak1 as the kinase that acts antagonistically to calcineurin at 37{degree sign}C", is thoroughly supported by multiple lines of evidence. The genetic suppressor screens identify 8 distinct alleles of Yak1 that allow cnb1∆ strains to grow at 37{degree sign}C. They confirm the suppressive effect of yak1∆ in two different strain backgrounds and in the presence of FK506 and CsA drugs. The phosphoproteomics experiments show 409 overlapping phosphorylation events that are down in yak1∆ compared to up in cna1∆, although a quantitative analysis e.g. enrichment of these shared targets is not presented.

      The proximity-labeling proteomics is an important assay with appropriate controls, and generates several hypotheses that are then followed up on. The methods section on the proteomics results is detailed and comprehensive.

      In my opinion, the results in the rest of the manuscript (validation of interactions witn microtubules etc, transcriptomics and translatomics, Cna1 mutant series) are not clearly integrated with the Yak1 kinase and proteomics results. Also, the discussion does little to critically synthesize the results presented within the context of wider knowledge including the authors' own recent work. The authors could choose to publish a more focused manuscript that concentrates on identifying Yak1 as the suppressor, or they could more clearly synthesise the wider set of results that they present.

      Overall the figures are well presented both for the Cryptococcus microbiology (spot assays, mating, etc.) and omics experiments (e.g. consistent evidence from PCA that 3 biological replicates cluster together). Experimental design schematics help the reader,

      Some claims are made superficially and need to be critically evaluated, notably the question of mitochondrial targets of the apparently cytosolic calcineurin complex.

      Furthermore, the manuscript lacks critical details and data sharing for some experiments and analyses, notably the transcriptomics and translatomics assays that are not possible to evaluate as currently presented. No data sharing (e.g. reviewer tokens) was available for my review. DNA sequencing is listed as shared on NCBI project PRJNA1306639, and TurboID data listed as shared on PRIDE project PXD067478. There's no mention of data sharing for phosphoproteomics, nor for transcriptomics/translatomics. I consider it appropriate to share data along with preprints, and thorough data sharing is required for publication in any reputable journal.


      Mitochondrial targets. The literature suggests that Calcineurin is located in the cytosol, however this manuscript reports differential calcineurin-dependent phosphorylation of mitochondrial proteins, including some that are encoded in the mitochondrial genome. I did not find the discussion of this in the paper convincing. It seems there are four possibilities (a) "calcineurin dephosphorylates [some mitochondrial proteins] prior to their import into the mitochondria"; (b) calcineurin dephosphorylates cytosolically exposed peptides of mitochondrial outer membrane proteins; (c) a subpopulation of Calcineurin is in mitochondria; or (d) calcineurin affects via a cascade or indirect effects mitochondrial kinases and/or phosphatases.

      Dephosphorylation prior to import is inconsistent with current models of co-translational mitochondrial import, unless calcineurin were acting co-translationally? I do not think interactions with eIFs support this argument, because eIFs are release from the mRNA early in translation elongation.

      Calcineurin acting on and interacting with cytosolically exposed peptides should be addressable by analysing current datasets to find differential phosphorylation and/or biotinylation specifically of cytosolic segments of mitochondrial proteins. I strongly recommend that the authors do this analysis and discuss the results.

      The authors tried to assess Calcineurin localisation in mitochondria, briefly.

      Otherwise, a cascade or indirect effects seem more likely.

      Transcriptomics and translatomics: the data analysis descriptions, data presentation, and data sharing are not sufficient for publication. See e.g. MINSEQE guidlines https://doi.org/10.5281/zenodo.5706412, and https://doi.org/10.1093/bib/bbz124. Experimental descriptions are thorough. However, the Ribo-seq/ribosome profiling protocol described, with pre-incubation of cells with harringtonine and cycloheximide then slow lysis, is far from best practice established in the extensive literature on ribosome profiling methods (see papers by Gloria Brar, Nick Ingolia, Sebastian Leidel, and Vadim Gladyshev, etc.), a limitation that should be discussed. Sequencing preparation and execution should be described accurately, e.g. it does not make sense for Ribo-seq data with ~30nt inserts to use 150PE sequencing. Data analysis steps should be described sufficient to reproduce the analysis. Key QC should be reported: read depth for each dataset, read length and frame information critical for interpreting ribosome profiling data, scatter plots or comparisons of TPMs or other gene-level summaries beyond the "TE" . PCA plots must describe what the PCA is calculated on (TPMs, log2 fold-change, or all or some genes, etc.). Data should be shared including raw reads and summarised gene-level reads.

      OPTIONAL: beyond reporting the data, there is scope for additional insights from analysing these data. For example, are Crz1-dependent genes differentially expressed or translated?

      Discussion. The short 5-paragraph discussion mostly reiterates the results, with limited engagement with wider context. Even the authors' recent related work in C. deneoformans, where cytokinesis factors suppress calcineurin phenotypes, gets only 3 sentences. To increase its impact, the manuscript would benefit from a considerably expanded critical discussion, including some of:

      • relating their C. neoformans and C. deneoformans results to each other.
      • discussing evidence for and against the conservation of Yak1 being antagonistic to Cna1 amongst fungi or more broadly, e.g. was there any precedent for this result from work by other groups?
      • discussing evidence for Cna1 and Yak1 having shared direct targets, including quantitatively from the new data and in reference to any other studies in other organisms.
      • discussing localisation of Cna1, and how that might affect interpretation of TurboID data and of truncation mutants.
      • expanding the discussion of mitochondrial targets with alternative hypotheses and wider literature engagement.
      • evaluating transcriptomics and translatomics results in light of other studies in Cryptococcus and beyond.
      • engaging with the role of calcineurin in translation: could it dephosphorylate translation initiation factors?

      Minor comments

      On novelty of TurboID in C. neoformans: it would be appropriate to cite Kalem, Panepinto, and co-authors' work which was to my knowledge the first TurboID work in this fungus (https://doi.org/10.1101/2022.01.13.475903).

      On Cna1 interactors in the spliceosome: it would be appropriate to compare with the work by Madhani and colleagues that map the C. neoformans spliceosome and its function (https://doi.org/10.1016/j.cub.2021.09.004).

      On Ribo-seq in C. neoformans: it would be appropriate to compare key results (e.g. TPMs, TE) and QC metrics to the only published Ribo-seq dataset in C. neoformans by Wallace, Maufrais, et al. (http://.doi.org/10.1093/nar/gkaa060). Disclosure: I am a lead author on that study. Likewise, for the arguments on splicing regulation it would be appropriate to compare with datasets from Wallace, Maufrais et al, and others from Guilhem Janbon lab, that conduct RNA-seq at different temperatures.

      OPTIONAL: Do the truncation mutations of Cna1 affect its localisation or interactions?

      Materials and Methods: Different parts are described in different levels of detail and this should be thoroughly checked so that a reasonable colleague could reproduce the experiments and analyses. The genetic screen and proteomics descriptions, for example, are thorough. All data analysis should be described for all assays, including methods used in software for sequence and image analysis beyond "Geneious prime" or "ImageJ", and software cited.

      All strains should be thoroughly described, currently also in different levels of detail - e.g. what is the sequence of Cna1-TurboID tag (source of tag, linker, etc.).

      Referee cross-commenting

      All reviewers agree on the importance of Yak1-calcineurin interactions. All reviewers also agree on the need for synthesis of the data, and to address the current emphasis on the manuscript of associations/correlations/data magnitude over mechanism and synthesis.

      Reviewer 1's point that "cna1∆ strain clustered apart from inactive mutants and even the epitope-tagged wild-type behaved differently from the true wild-type" is important. Reviewer 2's point about testing the functionality and localisation of Cna1-TurboID is also important, and aligns with the request to describe this strain in detail. These suggest additional experiments and/or recognizing limitations in the discussion, are needed.

      Significance

      Overall, the study represents an important advance in the field, that everyone working on calcium signaling in fungi, on Cryptococcus virulence mechanisms more generally, or on the calcineurin pathway more generally, will need to read and cite. Both the experimental results and the large-scale data presented are major contributions, notably the discovery of Yak1 kinase as the primary antagonist to calcineurin phosphatase at higher temperatures.

      Thorough experimental and analysis descriptions and data sharing would make this study far more valuable. Synthesising the results, including with an upgraded critical discussion and literature engagement, would increase the impact of the study.

      "Please define your field of expertise:" I'm a quantitative biologist working on gene expression regulation in fungi, using approaches including molecular microbiology and 'omics data, and have published on thermoregulation, translational control and its evolution, and C. neoformans.

      Review signed by Edward Wallace, University of Edinburgh.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      This study defines a comprehensive thermoregulatory network in Cryptococcus neoformans, revealing that calcineurin and its antagonistic kinase Yak1 regulate thermotolerance through shared substrates. The authors further show that calcineurin mediates thermal adaptation via novel interactions with translation initiation factors, spliceosome components, and mitochondrial proteins, and that distinct structural domains of calcineurin differentially regulate thermotolerance, meiosis, and virulence.

      Overall, the study presents an extensive dataset integrating RNA-seq, TurboID proximity labeling, phosphoproteomics, and genetic screens. The experimental scope is impressive, but the analysis often emphasizes data magnitude rather than biological interpretation. The manuscript would benefit from deeper synthesis of what these datasets reveal about calcineurin function beyond its global impact.

      Major Comments

      1. The role of Yak1 mutations in spontaneous suppressors is not directly validated by allelic reconstruction or complementation in the original genetic backgrounds. Establishing causality is essential to link Yak1 loss with calcineurin-related thermotolerance phenotypes.
      2. The interaction claims rely on the TurboID proximity map generated using a Cna1-TurboID fusion, which shows good replicate consistency and clear temperature-specific enrichments. However, the study does not show that the fusion protein is functional or correctly localized under heat stress. Calcineurin is known to relocalize during thermal stress at 37{degree sign}C, moving from diffuse cytoplasmic distribution to ER-associated puncta and the mother-bud neck. Without complementation of calcineurin-dependent phenotypes or independent localization data for the Cna1-TurboID fusion, the interactome identified in Fig. 2E-2G could reflect stress-induced relocalization or tag artifacts rather than calcineurin's native interaction landscape. The Western blots in Supplementary Fig. S2A-S2B confirm expression and biotinylation but not functional integrity or localization fidelity. Demonstrating that the fusion complements calcineurin loss is critical to attribute the 37{degree sign}C interactome to native calcineurin activity.

      Minor Comments

      Fig. S1C is missing a color legend.

      Lines 106-108: The text does not match the referenced figure (Fig. S1D).

      Fig. S1E: The authors clarify what distinguishes the two different knockout strains.

      Fig. 2G: The authors state that "the most enriched biological processes included proteins from the translation initiation complex, the spliceosome, the proteasome machinery, and mitochondria." Please clarify what analysis supports these enrichments, as the GO term analysis in Fig. 2F does not include these processes.

      Fig. 5F: Control wild-type crosses should be shown for comparison.

      Panels in Fig. 5 should be reordered to match their sequence in the main text.

      Significance

      This study presents a comprehensive map of the thermoregulatory network in Cryptococcus neoformans, integrating genetic screens, proximity labeling, phosphoproteomics, and ribosome profiling to define a broad signaling framework controlling thermal stress adaptation. By combining these approaches, the authors provide a systems-level view of how calcineurin orchestrates thermotolerance, extending beyond individual pathways to reveal network-wide regulation. Through two independent genetic screens, the kinase Yak1 is identified as the principal antagonist of calcineurin, establishing a clear opposing relationship within the thermotolerance pathway and highlighting Yak1 as a key regulator of heat-stress signaling. Using TurboID proximity labeling, the study also uncovers previously unrecognized roles for calcineurin in microtubule organization, spliceosome function, and mitochondrial translation, substantially broadening the known functional scope of this conserved phosphatase.

    1. Reviewer #1 (Public review):

      Summary:

      The extent P. falciparum liver stage parasites export proteins into the host cell is unclear. Most blood stage exported proteins tested in liver stages were not exported. An exception is LISP2 that is exported in P. berghei but not P. falciparum liver stages. While the machinery for export is present in liver stages, efforts to demonstrate export have so far been mostly unsuccessful. Parasite proteins exported during the liver stage could be presented by MHC and thereby become the target of immune control, incentive to study liver stage export and identify proteins exported during this stage. However, particularly for P. falciparum it is very difficult to study liver stages.

      This work studies LSA3 in P. falciparum blood and liver stages. The authors show that this protein is exported into the host cell in blood stages but in liver stages no or only very little export was detected. A disruption of LSA3 reduced liver stage load in a humanized mouse model, indicating this protein contributes to efficient development of the parasites in the liver.

      The paper also studied the localization of LSA3 in blood stages and used a known inhibitor to show that it is processed by plasmepsin 5, a protease important for protein trafficking. The work also showed that LSA3 is not needed for passage through the mosquito.

      Strengths:

      The main strength of this work is the use of the humanized mouse model to study liver stages of P. falciparum, which is technically challenging and requires specialized facilities. The biochemical analysis of LSA3 localization and processing by plasmepsin 5 are thorough and mostly overcame adverse issues such as a cross-reactive antibody and negative influence of the GFP-tag on LSA3 trafficking. The mosquito stage analysis is also notable as these kinds of studies are difficult with P. falciparum. However, there was no evidence for a function of LSA3 in mosquito stages.

      Weakness:

      The cross-reactivity of the antibody together with the co-infection strategy prevents reliable assessment of LSA3 localization in liver stages. Despite of this it seems LSA3 is not exported in liver stages and the paper does not bring us closer to the original goal of finding an exported liver stage protein.

      While the localization analysis in blood stages is well done and thorough, the advance is somewhat limited. LSA3 may be in structures like J dots, but this hypothesis was not tested. Although parasites with a disrupted LSA3 were generated, the function of this protein was not explored. However, this was now done in a separate study focussing on blood stage parasites (PMID: 41135800).

      Due to the difficulty of working with humanised mice, it was not possible to refine some of the conclusions and questions remain:<br /> The impact on liver stage development is interesting, but which phase of the liver stage is affected, and the phenotype remain largely unknown. The co-infection used (WT together with LSA3 mutant) has the advantage of a direct comparison of the mutant with the control in the same liver but complicates phenotypic analysis if the LSA3 antibody is also cross-reactive in liver stages. This issue adds a question mark to the shown localization and precludes phenotypic comparisons. It was also not possible to determine if the cross-reactive protein is expressed at that stage. While this might have been evident from the mixed WT/mutant infection (if all cells are positive for LSA3 there is cross-reaction; if about half of the cells are negative, there isn't) but assessing this failed.

      Significance:

      It is important information that LSA3 contributes to efficient liver stage development. However, neither LISP2 nor LSA3 seem to be exported in P. falciparum liver stages and can't confirm the potential of vaccines with proteins exported in this stage. LSA3 is still important and may still be the target of the immune response, but based on this work, probably not due to export in liver stages.

    2. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The extent to which P. falciparum liver stage parasites export proteins into the host cell is unclear. Most blood-stage exported proteins tested in liver stages were not exported. An exception is LISP2, which is exported in P. berghei but not P. falciparum liver stages. While the machinery for export is present in liver stages, efforts to demonstrate export have so far been mostly unsuccessful. Parasite proteins exported during the liver stage could be presented by MHC and thereby become the target of immune control, an incentive to study liver stage export and identify proteins exported during this stage. However, particularly for P. falciparum, it is very difficult to study liver stages.

      This work studies LSA3 in P. falciparum blood and liver stages. The authors show that this protein is exported into the host cell in blood stages, but in liver stages, no or only very little export was detected. A disruption of LSA3 reduced liver stage load in a humanized mouse model, indicating this protein contributes to efficient development of the parasites in the liver.

      The paper also studies the localization of LSA3 in blood stages and uses a known inhibitor to show that it is processed by plasmepsin 5, a protease important for protein trafficking. The work also shows that LSA3 is not needed for passage through the mosquito.

      Strengths:

      The main strength of this work is the use of the humanized mouse model to study liver stages of P. falciparum, which is technically challenging and requires specialized facilities. The biochemical analysis of LSA3 localization and processing by plasmepsin 5 is thorough and mostly overcame adverse issues such as a cross-reactive antibody and the negative influence of the GFP-tag on LSA3 trafficking. The mosquito stage analysis is also notable, as these kinds of studies are difficult with P. falciparum. However, there was no evidence for a function of LSA3 in mosquito stages.

      We thank the reviewer for their perspective on the strengths of the study.

      Weaknesses:

      The cross-reactivity of the antibody, together with the co-infection strategy, prevents reliable assessment of LSA3 localization in liver stages. Despite this, it seems LSA3 is not exported in liver stages, and the paper does not bring us closer to the original goal of finding an exported liver stage protein.

      While the localization analysis in blood stages is well done and thorough, the advance is somewhat limited. LSA3 may be in structures like J dots, but this hypothesis was not tested. Although parasites with a disrupted LSA3 were generated, the function of this protein was not explored. Given that a previous publication found some inhibitory effect of LSA3 antibodies on blood stage growth, a comparison of the growth of the LSA3 disruption clones with the parent would have been very welcome and easy to do. At this point, LSA3 is one more of many proteins exported in blood stages for which the function remains unclear.

      It might be possible to refine some of the conclusions. The impact on liver stage development is interesting, but which phase of the liver stage is affected, and the phenotype remains largely unknown. The co-infection (WT together with LSA3 mutant) has the advantage of a direct comparison of the mutant with the control in the same liver, but complicates phenotypic analysis if the LSA3 antibody is also cross-reactive in liver stages. This issue adds a question mark to the shown localization and precludes phenotypic comparisons. The authors write that they do not know if the cross-reactive protein is expressed at that stage. But this should be immediately evident from the mixed WT/mutant infection. If all cells are positive for LSA3, there is a cross-reaction. If about half of the cells are negative, there isn't. In the latter case, the localization shown in the paper is indeed LSA3, and morphological differences between WT and LSA3 disruption could be assessed without additional experiments.

      We thank the reviewer for their comments. While the LSA3-C antibody may cross-react with another parasite protein(s) in addition to binding LSA3 itself, we observed no strong evidence that this antibody localized beyond the liver-stage PVM, indicating that LSA3 is likely not targeted to the host cell compartment. We cannot exclude the possibility that a domain of LSA3 faces the hepatocyte lumen from this membrane and thus may be considered exported though follow-up studies are required (and are very challenging) to answer it. The phenotype of the NF54 DLSA3 mutant generated in this study at the blood stage was underway (by an independent lab in collaboration with us) and we are happy to disclose that the outcomes were recently published (May 2026) in an accompanying manuscript (PMID: 41135800). We completely agree that independently infected humanized mice would be helpful to address further remaining questions around the localization and temporal phenotype for LSA3 essentiality, which again will require follow up studies. In the present study, we intended to address whether LSA3 is important functionally, as this had not been reported.

      Significance:

      The conclusion from the paper that "our study presents just the second PEXEL protein so far identified as important for normal P. falciparum liver-stage development and confirms the hypothesized potential of exported proteins as malaria vaccine candidates" is partially misleading. Neither LISP2 nor LSA3 seems to be exported in P. falciparum liver stages, and we can't confirm the potential of vaccines with proteins exported in this stage. LSA3 is still important and may still be the target of the immune response, but based on this work, probably not due to export in liver stages.

      We thank the reviewer for the comment. We would like to emphasize the possibility that proteins localized at the PVM may be considered exported ‘if’ part or all of the protein (eg, a domain) faces the host cell lumen from the hepatocyte. We have not shown this to be the case for LSA3 or LISP2 but that possibility remains open. Nonetheless, LISP2 is exported (by P. berghei liver stages) and LSA3 is exported (by P. falciparum blood stages); both are exported proteins.

      Reviewer #2 (Public review):

      Summary:

      Immunogenic Plasmodium falciparum proteins that could be targeted to prevent parasite development in the liver are of significant interest for novel anti-malarial vaccine development. In this study, McConville et al evaluate the trafficking and functional importance of LSA3, a protein expressed in the blood and liver stages and previously shown to provide protection in immunized chimpanzees. LSA3 contains a PEXEL motif, but the authors have previously shown that this protein does not appear to be exported beyond the PVM in the liver stage (McConville et al, PNAS 2024). However, LSA3 trafficking and functional importance have not been comprehensively evaluated across stages. In the present study, the authors find that blood stage LSA3 undergoes PEXEL processing, and a portion of the protein is exported into the erythrocyte, where it localizes to punctate structures distinct from Maurer's clefts. Using a knockout mutant, LSA3 is shown to be dispensable for blood and mosquito stages but important to liver-stage development. Collectively, these results validate LSA3 as a liver-stage target and place it among several other PEXEL proteins that display differential trafficking beyond the PVM in the erythrocyte but not the hepatocyte.

      Strengths:

      The authors present a thorough analysis of LSA3 trafficking in the blood stage. PEXEL processing by Plasmepsin 5 is clearly demonstrated through a combination of mini LSA3-GFP reporters and Plasmepsin 5 inhibitors. Importantly, an LSA3 knockout mutant is used to show that the LSA3-C anti-sera also react with additional, unidentified parasite proteins in the blood stage. Nonetheless, comparison between the WT and KO parasites clearly indicates that a portion of LSA3 is exported into the erythrocyte, which is further supported by protease-protection assays with fractionated iRBCs. This contrasts with the liver stage, where LSA3 does not appear to traffic beyond the PVM, similar to what has been observed for other PEXEL proteins in the rodent malaria model.

      This study provides the first direct analysis of LSA3 function by reverse genetics, showing this protein is important for liver stage development in chimeric human liver mice. Several PEXEL proteins in P. berghei have been shown to be exported into the host cell in the blood stage, but do not appear to cross the PVM in the liver stage. These observations reinforce that even without detectable export into the hepatocyte, PEXEL proteins play critical roles during liver stage development.

      We thank the reviewer for their feedback regarding the strengths of the paper. 

      Weaknesses:

      A previous study reported that anti-LSA3 antibodies inhibit blood-stage growth, suggesting a role for LSA3 during erythrocyte infection. While the authors carefully evaluate the LSA3 mutant in mosquito and liver stages, the impact on blood stage fitness is not tested. While the knockout shows LSA3 is not essential in the blood stage, its importance during erythrocyte infection remains unclear.

      The authors previously reported that anti-LSA3-C signal in the liver stage localizes within the parasite and at the parasite periphery but is not exported into the hepatocyte. In the present study, it is shown that anti-LSA3-C reacts with other parasite proteins beyond LSA3 in the blood stage, and this may also occur in the liver stage. However, since liver-stage IFAs were only performed on samples co-infected with both WT and ∆LSA3 parasites, non-specific anti-LSA3C reactivity at this stage could not be determined, and the localization of LSA3 in the liver stage remains somewhat unclear.

      We thank the reviewer for their comments. The phenotype of the NF54 DLSA3 mutant generated in this study at the blood stage was underway (by an independent lab in collaboration with us) and we are happy to disclose that the outcomes were recently published (May 2026) in an accompanying manuscript (PMID: 41135800). While the LSA3-C antibody may cross-react with another parasite protein(s) in addition to binding LSA3 itself, we observed no strong evidence that this antibody localized beyond the liver-stage PVM, indicating that LSA3 is likely not targeted to the host cell compartment. We cannot exclude the possibility that a domain of LSA3 faces the hepatocyte lumen from this membrane and thus may be considered exported though follow-up studies are required (and are very challenging) to answer it. We completely agree that independently infected humanized mice would be helpful to address further remaining questions around the localization and temporal phenotype for LSA3 essentiality, which again will require follow up studies. In the present study, we intended to address whether LSA3 is important functionally, as this had not been reported.

      Reviewer #3 (Public review):

      Summary:

      This manuscript provides a comprehensive characterization of the Plasmodium falciparum protein LSA3, combining biochemical, genetic, and in vivo approaches. The authors convincingly demonstrate that LSA3 is expressed during liver stage infection and that disruption of the gene leads to a modest but reproducible reduction in liver stage parasite load in humanized mice.

      Strengths:

      Their biochemical and cell biological analysis of blood stages provides strong evidence that LSA3 is exported to the infected erythrocyte, and the detailed analysis of its PEXEL motif processing is well executed.

      We thank the reviewer for their comments.

      Weaknesses:

      The study suggests LSA3 as one of only two known P. falciparum PEXEL proteins contributing to this stage, although there is no evidence for the export beyond the vacuolar membrane. Several key conclusions, particularly regarding antibody specificity, localization in liver stage parasites, and the interpretation of the phenotypic data, are not fully supported by the current experiments.

      We understand the reviewer’s points. We agree that there is no evidence provided that LSA3 is targeted beyond the PVM; whether any of the protein faces the hepatocyte cytosol is unknown (and challenging to conduct) but this possibility remains plausible. LISP2- and LSA3deficient liver stages are less fit than parental controls and thus we stand by the conclusion that they are the two so far identified P. falciparum PEXEL proteins that are important for liver-stage development.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) Line 163 says: "Altogether, this demonstrates that LSA3 is important but not critical for blood stage growth of P. falciparum": this is based on the cited Morita et al., 2017. However, previously LSA3 was considered dispensable based on a knock out in 3D7 (Maier et al., 2008; PMID: 18614010). Given that the authors generated a mutant for this work, it would be straightforward to test growth and clarify the importance of LSA3 in blood stages. If important, the analysis of the location and transport of LSA3 in blood stages would immediately become more relevant.  Maybe the data for this is already in the paper: the number of stage V gams was similar between mutant and control (Figure 4A). If this was calculated from the total number of asexual starting parasitemia, it includes blood stage growth, and it can be assumed that there is no growth defect in the mutant in the blood stages. If the number of stage 5 gams was calculated from the number of committed schizonts/rings, nothing can be said about blood stage growth, and asexual blood stage growth should be tested in specific experiments.

      We thank the reviewer for raising the function of LSA3 in blood stages and agree it was an obvious omission, though for good reason - a separate, collaborative study was underway. While this eLife preprint was in revision, our accompanying manuscript on the blood stage was published, showing the characterization of our NF54 DLSA3 mutant during blood-stage growth (PMID:41135800). The findings are now summarized and the citation included in the revised version of this preprint.

      Manuscript line 105: "although, notably, functional characterization of lsa3 deletion mutants has not yet been reported to confirm an important function": at least in blood stages, it was reported to be dispensable, see above. The corresponding study (Maier et al., 2008, PMID: 18614010) could be cited in that context. 

      The citation of PMID18614010 and 39913589 have now been added and we thank the reviewer.

      (2) Some questions central to the conclusions of this paper remain because it was unclear whether the serum did indeed detect LSA3 in the liver or not. It would be easy to check if all cells from the WT/Mutant mix experiment show LSA3 signal (this would mean it cross-reacts) or if only about half are positive (the mutants would be negative if there is no cross-reaction). This would be important to mention for Figure 5 because, at present, it is not known that what is labeled by the LSA3-C antibody in these images is (only) LSA3. 

      We thank the reviewer for this point and completely understand. We did check this via microscopy of liver sections co-infected with LSA3 mutant and control liver-stage parasites as we shared the reviewers line of enquiry. Unfortunately we could not detect parasites without LSA3 signal at the 5-day post-infection time point. This type of analysis does sound straightforward on paper but in reality is more challenging owing to several factors i) identifying sufficient individual parasites in an entire liver by microscopy can be challenging and variable from lobe to lobe and mouse to mouse, ii) the number of parasites required for a meaningful statistical analysis is increased due to coinfection of the liver (see Figure 4B as an illustration of this), iii) day 5 is a rather late liver-stage time point and so if there was a growth defect the defective parasites may be very small or sparse, iv) we cannot exclude that the LSA3 antibody may cross-react at the liver-stage, v) definitive conclusions are thus challenging and we feel require individual co-infections to be clear in the future. Nonetheless, the detailed qRT-PCR analyses identify a significant reduction in DLSA3 parasite liver load on day 5, indicating this protein is important for the human malaria parasite’s growth within human hepatocytes.

      (3) It is also unclear which parasites were imaged in Figure 5. The text of the results states that NF54 liver stages were used, but later: "As we employed a co-infection strategy to assess the essentiality of LSA3 versus NF54 in mice, we could not perform IFAs on individually infected mice in this study to validate the specificity of LSA3-C at the liver-stage". The legend says NF54 sporozoites on day 5 post-infection were used. I suspect it was a WT/mutant mix, in which case the above applies, and in the absence of cross-reactivity, half of the cells should be LSA3-C negative. If this is not the case, the localization in the liver becomes dubious.

      We apologize for the confusion and have corrected this. In Figure 5, we utilized liver sections from NF54-infected humanized mice that were stored at -80 C from a previously published study (McConville et al, PNAS 2024). Ideally, we would validate the specificity of LSA3 antibodies at the liver-stage using liver sections containing only DLSA3 parasites however the number of mice available was limited and the samples available to us also contained the Control line for qRT-PCR analyses (the co-infection strategy). As mentioned above, we couldn’t distinguish between these two strains by IFA at the time point analysed and this precluded us unequivocally validating the LSA3-C specificity in the liver-stage; however it cannot be excluded that the signal observed at the PVM is indeed LSA3. We are currently focusing research efforts on obtaining more humanised mice to answer this.

      Minor:

      (1) Introduction: Before the part on the PEXEL motifs, there are almost no references; please add references for all statements.

      We have added references.

      (2) Figure 1B is unclear regarding which part of the gene was deleted. The system used would permit a complete gene deletion, but the homology flanks seem to be within LSA3. If parts of the gene are left, the 75 kDa on the western blots might be a degradation product arising from both the truncated and the full-length protein. Please clarify in the sketch exactly where the homology flanks are, with respect to the start and stop of the gene. 

      The LSA3 gene was disrupted using the flanks as shown. The DHFR selection cassette comprises its own promoter and terminator such that insertion into the coding sequence completely disrupts expression of the protein thereafter, including the C-terminus within which the LSA3-C antibody binds. The new LSA3-T antibody described in our recently published accompanying manuscript that binds more N-terminally than LSA3-C also does not label the truncated protein. The original 5’ and 3’ flanks used for integration of the disrupted LSA3 allele by double cross-over recombination were then looped out into the original knockout plasmid and this was negatively selected against using exogenous 5-fluorocytidine (5-FC) via the suicide gene cassette CDUP (cytosine deaminase and uracil phosphoribosyl transferase that also contains a 5’ promoter and 3’UTR terminating element) in the construct. These features should provide clarification and have now been indicated in the figure and legend.

      (3) Line 161: Replace was with were.

      Corrected.

      (4) Figure 2, 224: Why do the authors think LSA3 must be in the luminal leaflet of the PVM as opposed to the outer leaflet of the plasma membrane?

      Several pieces of evidence combined led us to this conclusion in Figure 2B. i) if LSA3 was on the outer PVM leaflet, it would be substantially degraded in the EQT Pellet + PK fraction but a substantial population remained insensitive to PK, indicating much of the total protein pool was protected by the PVM (and possibly the parasite membrane; PM), ii) yet saponin, which leaves the PM intact, allowed PK to access and almost completely degrade LSA3 (see Saponin Pellet + PK), indicating that a substantial population of LSA3-C is located inside the boundary of the PVM, and this is membrane associated as saponin did not liberate it, rather, it remained in the Saponin Pellet before PK was added, iii) the TX-100 Super fraction confirmed LSA3 is membrane associated, as more is present in the TX-100 Super than the Saponin Super fractions, iv) if LSA3 was inside the PM, the Saponin Pellet fraction should be resistant to PK (as was the case for the cross-reactive band indicated with a red asterisk) but LSA3 (green asterisk) in the Saponin Pellet was PK sensitive. Altogether, our best conclusion from these data is that LSA3 is likely to be PVM associated with the LSA-C-binding domain facing internal to the PV, and a fraction is also exported beyond the PVM into the erythrocyte.

      (5) Line 245: GFP core "derived from digestion of the reporter in the food vacuole, which confirmed it was secreted from the parasite". I wonder if the amount of GFP "core" really can be used as evidence for secretion, and its amount can be compared between experiments. Did the author quantify this for the full-length protein to get a proportion per sample?

      Use of GFP core to measure defects in P. falciparum GFP reporter secretion has been described previously (for example PMID:23387285 and 35906227). The comparison the reviewer asked for is an interesting and important question: however the control would be to compare the ratio of GFP core to uncleaved in the control lanes as well, which is not possible to do since the full-length protein is digested by plasmepsin V in the native PEXEL versions of the experiments (mLSA3-GFP in the first blot, Vehicle in the second blot) leaving no full-length protein to compare to. It stands to reason that inhibition of N-terminal processing results in less protein removal from the membrane (ER or COPII vesicle or PM) resulting in less secretion out of the parasite for retrograde transport to the food vacuole with cytostomal vacuoles (analogous to plasmepsin II). In the food vacuole, the chimeras are in normal cases digested by proteases back to the GFP core that is resistant to cleavage and evident as GFP core on the immunoblots (PMID:10775264 and 14709539 and 19055692 and 20130643). 

      (6) Figure 3 has the word plasmid in two lanes. In Figure 3E, amend the labelling of the blots.

      We apologize for the formatting error in converting the figures to PDF during the original submission and thank the reviewer for the suggestion. This has now been corrected.

      (7) Lines 266/271/284: "live IFAs", live immunofluorescence assay. Does this mean an antibody was given to living   parasites?

      The correct term is live microscopy and this has been corrected.

      (8) Does Figure 6A fit with the data in Figure 6B? It seems 6B has a milder phenotype than 6A.

      We thank the reviewer for the question. Yes the data directly correspond to each other and are represented in two ways: Panel A shows the qRT-PCR raw data for liver load of each parasite strain per humanized mouse using a scientific scale on the y-axis. Panel B shows that magnitude of the DLSA3 defect as a percentage of the total liver load per mouse:

      % total parasite liver load  = ( strain 1 or strain 2 liver load ) x100

      sum of strain 1 + strain 2 liver loads

      The intent of showing both data is to convey the correct magnitude of the difference in two ways to assist the reader in understanding the true defect, both are accurate and both are statistically significant. In revision we detected mislabelling of humanized mouse 2 and 3 in the original graphs that has now been corrected and we sincerely thank the reviewer for helping us identify this error.

      (9) Line 482: Please add references for this debate. 

      These have been added.

      Reviewer #2 (Recommendations for the authors):

      Major Comments: 

      (1) In general, the authors have taken care not to overstate conclusions from their study. Nonetheless, while not technically inaccurate, the title might misleadingly suggest LSA3 is exported in the liver stage (this was my initial impression on reading it until I looked at the data). I suggest the authors revise the title to avoid confusion by clarifying that export was only observed in the blood stage.

      We sincerely appreciate the reviewer’s point. As this article was posted as a preprint that has now been cited several times, we have carefully weighed the comment and in the end decided to retain the current title for the above reason.

      (2) While the ability to generate the ∆LSA3 parasites clearly shows that the protein is not essential in the blood stage, the impact on parasite fitness is never tested but simply assumed (for instance, in lines 163-164: "...this demonstrates that LSA3 is important...for blood-stage growth..."). Do the ∆LSA3 parasites have a fitness defect in the blood stage consistent with the previous GIA data that would support this claim? Since the rabbit anti-LSA3-C antibodies produced by Morita et al did not have GIA activity against the blood stage, it is possible that the GIA observed with the human and mouse antibodies might have been due to reactivity with a different protein. If ∆LSA3 does cause a fitness defect, it would be interesting to know if the endogenous GFP-tagged line, which alters protein trafficking/membrane association, also produces this effect.

      We agree with the reviewer and would like to clarify that this omission was not intended to create confusion but was by design, due to a separate collaborative study that was underway to address such questions. While this eLife preprint was in revision, our accompanying manuscript on characterising NF54 DLSA3 at the blood stage was published (PMID:41135800). The findings are now summarized and the citation included in the revised version of this eLife preprint. In sum, LSA3 is not critical for erythrocyte invasion but its deletion perturbs the rate and efficiency of merozoite invasion, at the step(s) of resealing of the PVM/host cell, resulting in aberrant accole forms that protrude from the infected erythrocyte.

      (2) Figure 1D: While the images are compelling and I don't doubt the claim that LSA3 is exported in the blood stage (also supported by the fractionation/Pk experiments), the authors should provide quantification of the difference in exported signal between the WT and ∆LSA3 parasites in these IFAs to rigorously support this conclusion. Also, please include details about how many independent experiments are represented by the microscopy data throughout the manuscript (Figures 1, 2, 3, and 5).

      We understand the reviewer’s request and wish to indicate that the export signal was absent in all cells infected with DLSA3 that was imaged. The microscopy performed was from n=2-3 experiments except for Figure 5 which was from n=1 humanized mouse per time point in which multiple EEFs from the liver were imaged. This has been indicated in the figure legends. 

      (3) Careful inspection of the z-series images in Figure 5A shows that most of the LSA3-C signal seen outside the PVM (beyond the boundary delineated by EXP1) is closely associated with DAPI puncta, suggesting these are merozoites. Together with the prominent gap in the EXP1 signal, this suggests the schizont has already ruptured. Thus, anti-LSA3-C signal beyond the PV seems best explained as coming from merozoites or other material released by PV rupture, not from export across the PVM, and this should be added to the text in place of comments about localization to PV extensions or potential export (lines 358-359, 422-423).

      We do appreciate the reviewer’s careful eye and caution and are in complete agreement. We have added the comment as requested.

      Minor Comments:

      (1) The authors may want to denote the disordered repeat region in the LSA3 schematic in Figure 1A that is mentioned in the text.

      We have added the residue boundaries of the predicted domain from AlphaFold into both the schematic and the text and included a link to the LSA3 pages in PlasmoDB and

      AlphaFold in the Methods section.

      (2) The authors use rabbit anti-LSA3-C antibodies previously generated by Morita et al. These polyclonal antibodies were raised against a recombinant C-terminal region of LSA3 (residues 750-1433), but the schematic in Figure 1A indicates the antibodies recognize a smaller region between residues 1154-1433. Please adjust the figure accordingly, or if this is not the same antiLSA3-C antibody reported by Morita, please provide details about its production.

      The figure is corrected.

      (3) The authors use Alphafold to identify a region of LSA3 with similarity to the substrate binding domain of DnaK, but the data is not shown. Please include the Alphafold prediction in supplementary figures and provide information about how the predicted structural homology was determined.

      We have added a link to the AlphaFold page for PF3D7_0220000 in the methods.

      (4) The schematic in Figure 1B indicates that the DHFR cassette was inserted at an internal site within the lsa3 gene. If this is the case, it seems possible that an N-terminal portion of the protein is still expressed, but I was unable to find details about the boundaries of the homology flanks to determine the precise insertion site. Please clarify the knockout strategy and indicate the specific insertion site.

      The LSA3 gene was disrupted using the flanks as shown. The DHFR selection cassette comprises its own promoter and terminator such that insertion into the coding sequence completely disrupts expression of the protein thereafter, including the C-terminus within which the LSA3-C antibody binds. The new LSA3-T antibody described in our recently published accompanying manuscript that binds more N-terminally than LSA3-C also does not label the truncated protein. The original 5’ and 3’ flanks used for integration of the disrupted LSA3 allele by double cross-over recombination were then looped out into the original knockout plasmid and this was negatively selected against using exogenous 5-fluorocytidine (5-FC) via the suicide gene cassette CDUP (cytosine deaminase and uracil phosphoribosyl transferase that also contains a 5’ promoter and 3’UTR terminating element) in the construct. These features should provide clarification and have now been indicated in the figure and legend.

      (5) Line 162: I think this should read "antibodies that react with LSA3 were...".

      Corrected.

      (6) Figure 1D: The merge with the transmitted light channel is missing for the third panel in the ∆LSA3 IFAs. Also, please define the scale bar length in the legend.

      Corrected.

      (7) Lines 744-746: The IFA fixation panel order description (top, bottom) in the Figure 2A legend is reversed from what is shown in the actual figure. Also, please define the scale bar length. 

      Corrected.

      (8) Lines 184-186: Since the fractionation/PK protection assays suggest most of LSA3 is in the PV, it would be interesting to know if the strong peripheral/PV signal observed in the PFA-fixed IFAs in Figure 2A is also present in the ∆LSA3 parasites, or is this non-specific? 

      Thank you for the suggestion. We agree this would be an interesting result to know but do not have the capacity at the present time.

      (9) Lines 219-225: It is unclear to me why these results are interpreted to suggest that the majority of LSA3 is peripherally associated with the luminal leaflet of the PVM. Wouldn't an integral membrane configuration in the PVM (with the C-terminus facing the host cytosol) or PPM (with the C-terminus facing the parasite cytosol) also account for the data? Adding a carbonate extraction would help clarify this point.

      Several pieces of evidence combined led us to this conclusion in Figure 2B. i) if LSA3 was on the outer PVM leaflet, it would be substantially degraded in the EQT Pellet + PK fraction but a substantial population remained insensitive to PK, indicating much of the total protein pool was protected by the PVM (and possibly the parasite membrane; PM), ii) yet saponin, which leaves the PM intact, allowed PK to access and almost completely degrade LSA3 (see Saponin Pellet + PK), indicating that a substantial population of LSA3-C is located inside the boundary of the PVM, and this is membrane associated as saponin did not liberate it, rather, it remained in the Saponin Pellet before PK was added, iii) the TX-100 Super fraction confirmed LSA3 is membrane associated, as more is present in the TX-100 Super than the Saponin Super fractions, iv) if LSA3 was inside the PM, the Saponin Pellet fraction should be resistant to PK (as was the case for the cross-reactive band indicated with a red asterisk) but LSA3 (green asterisk) in the Saponin Pellet was PK sensitive. Altogether, our best conclusion from these data is that LSA3 is likely to be PVM-associated with the LSA-C-binding domain facing internal to the PV, and a fraction is also exported beyond the PVM into the erythrocyte. If the question is whether LSA3 is an integral PVM protein, we agree that use of carbonate in the future would answer that question.

      (10) Figures 3D and E: There are some problems with some of the text wrapping in these panels.

      We apologise, this was a formatting issue as the manuscript was converted to PDF.

      We have corrected this error.

      (11) Line 422-423: In fact, the Z-sections shown in Figure 5 appear to indicate that the LSA3-C signal is predominantly located within the parasite, not at the PVM.

      We do appreciate the reviewer’s careful eye and caution and are in complete agreement. We have corrected the final conclusion to be more accommodating of this.

      (12) Lines 468-470: Since cross reactivity of anti-LSA3-C is substantial in the blood stage but was not defined in the liver stage by analysis of unmixed infections, how do the authors know that they were not observing ∆LSA3 parasites in their IFAs? I think what they mean here is that parasites lacking anti-LSA3-C reactivity were not observed, which is an important distinction.

      The reviewer is correct and this has been corrected.

      (13) Lines 478-479: The authors should also mention that the P. berghei PEXEL proteins evaluated in Fougere et al are exported in the blood stage, similar to LSA3. Moreover, other studies have shown something similar for additional endogenous PEXEL proteins or reporters in P. berghei (PMIDs 22329949, 26347246, 34956312).

      We have added the additional text regarding export into the infected erythrocyte and the reference to IBIS1.

      (14) Line 491: The data here don't support that LSA3 is "required" for liver stage development, only that it is important to it. Since the authors have not defined the cross-reactivity of anti-LSA3C in unmixed infections, it is not clear that ∆LSA3 parasites are arrested early in the liver stage, only that they show a reduced number of genome copies relative to the parental control. 

      We have amended the sentence to “required for normal liver stage development”.

      (15) Line 530: I think NGF54 should be NF54.

      Corrected.

      Reviewer #3 (Recommendations for the authors):

      (1) Antibody specificity in liver stage IFA experiments:

      The specificity of the anti-LSA3 antiserum (LSA3-C) used in liver stage IFA is not fully convincing. While the KO parasites were used effectively to validate specificity in blood stages, the same is not true for liver stages. 

      (a) It is essential to repeat IFA with ΔLSA3 parasites in liver stage infections to determine whether the observed PVM staining is truly specific.

      We appreciate the reviewer’s point, however at a cost of over $5000 per humanized mouse, we do not have the capacity to conduct this experiment at the present time. We highlight that, as the blood stage IFAs confirmed the specificity of LSA3-C for LSA3, the possibility remains open that LSA3 is specifically recognized at the PVM.

      (b) If the antibody is the same polyclonal serum used in Morita et al. (2017), why did the authors not employ a monoclonal antibody, which they presumably have access to and which would provide greater specificity? 

      We have included new data confirming that LSA3 is exported using LSA3-T, in addition to LSA3-C.

      (c) Given that rabbit antisera often show non-specific staining at the PVM in liver stage parasites, co-localization with PVM markers is not sufficient. Inclusion of the ΔLSA3 parasites in liver stage IFA is critical. It will also show whether there is any cross-reaction of the antiserum in liver stage parasites, as seen by IFA for blood stage parasites. 

      We thank the reviewer for their feedback.

      (d) To validate the serum further, the authors should infect HC-04 cells in vitro with GFP-LSA3 parasites and stain with LSA3-C to confirm overlap between the tagged protein and the antibody signal.

      We thank the reviewer for their feedback.

      (e) For higher-resolution co-localization, expansion microscopy - now commonly used even in malaria research - would substantially improve the analysis. 

      We thank the reviewer for their feedback.

      (2) The localization of LSA3 in this study differs notably from Morita et al. 2017, who reported localization to dense granules in merozoites and staining in ring-stage parasites at the PVM. 

      (a) The authors confirm DG localization, but they do not examine ring-stage parasites. They should include the IFA of ring stages to clarify whether they can replicate the previous findings.

      We thank the reviewer for their feedback.

      (b) Additionally, the differences in Western blot banding patterns between the two studies should be addressed. Do the authors have an explanation for these discrepancies? 

      We thank the reviewer for their feedback.

      (3) The authors report a ~40% reduction in liver parasite load using qPCR, which is statistically significant. However, this phenotype is modest and should not be interpreted as showing that LSA3 is essential.

      (a) Please avoid terms like "required" or "essential" and instead describe the protein as "contributing to normal development" or "influencing fitness."

      We have used the term “required for normal liver stage development”.

      (b) Since the authors generated liver sections, they should take advantage of these to quantify the number and size of liver stage parasites, which would help determine whether the phenotype reflects fewer infected cells or reduced parasite growth.

      We did check this via microscopy of liver sections, but all mice were co-infected with LSA3 mutant and control liver-stage parasites, as we shared the reviewers line of enquiry. Unfortunately we could not detect parasites without LSA3 signal at the 5 day post infection time point. This type of analysis does sound straightforward on paper but in reality is more challenging owing to several factors i) identifying sufficient individual parasites in an entire liver by microscopy can be challenging and variable from lobe to lobe and mouse to mouse, ii) the number of parasites required for a meaningful statistical analysis is increased due to coinfection of the liver (see Figure 4B as an illustration of this), iii) day 5 is a rather late liver-stage time point and so if there was a growth defect the defective parasites may be very small or sparse, iv) we cannot exclude that the LSA3 antibody may cross-react at the liver-stage, v) definitive conclusions are thus challenging and we feel require individual co-infections to be clear in the future. Nonetheless, the detailed qRT-PCR analyses identify a significant reduction in DLSA3 parasite liver load on day 5, indicating this protein is important for the human malaria parasite’s growth within human hepatocytes.

      (c) It would also be valuable to include IFA from singly infected ΔLSA3 livers (rather than co-infected), and possibly at earlier timepoints, to identify the developmental window affected.

      We agree it would be valuable.

      (4) The manuscript suggests that LSA3 may be exported beyond the PVM into the hepatocyte, based on a small number of peripheral puncta.

      (a) This claim is not convincingly supported by the data. The punctate signals shown in Figure 5 are weak and may rather reflect PVM extensions or TVN. In fact, one punctum even overlaps with the DAPI signal (figure 5, middle panel), which raises further doubt about the localization.

      We appreciate the reviewer’s careful eye and caution and have added the comment regarding DAPI.

      (b) Given the lack of KO controls in these liver stage IFAs, the authors should not describe LSA3 as "exported beyond the PVM". The language should be revised to reflect that the protein localizes predominantly to the PVM, and any extra-PVM signal remains unconfirmed and could be non-specific. 

      (c) This is especially important given the well-known tendency of rabbit antisera to produce background PVM staining in liver stage parasites. 

      Corrected.

      (e) In an earlier report (McConville et al, 2024, PNAS), they clearly state that LSA3 is NOT exported beyond the PVM. Actually, the staining in the previous report looks quite different from the images provided for Figure 5. The authors might wish to comment on this. 

      We thank the reviewer for their feedback.

      Minor comments:

      In some sections, the manuscript uses "exported" to refer to trafficking to the PVM. This terminology should be used more carefully and consistently, since "export" often implies translocation into the host cytosol

      We understand that export involves a protein localizing within the host cell and so protrusion through the PVM may also be considered exported, however, we have not confirmed this for LSA3 in liver stages.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Manuscript number: RC-2025-02932

      Corresponding author(s): Amit Tzur

      [Please use this template only if the submitted manuscript should be considered by the affiliate journal as a full revision in response to the points raised by the reviewers.

      If you wish to submit a preliminary revision with a revision plan, please use our "Revision Plan" template. It is important to use the appropriate template to clearly inform the editors of your intentions.]

      1. General Statements

      We thank all Referees for their insightful comments and thoughtful review of our manuscript.

      2. Point-by-point description of the revisions

      This section is mandatory. *Please insert a point-by-point reply describing the revisions that were already carried out and included in the transferred manuscript. *

      __! Original comments by Reviewers #1-3 are in gray. __


      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      The study highlights a dephosphorylation switch mediated by PP2A as a critical mechanism for coupling E2F7/8 degradation to mitotic exit and G1 phase. The study is clear and experiments are well conducted with appropriate controls

      I have some concerns highlighted below:

      Point 1. In this sentence: This intricate network of feedback mechanisms ensures the orderly progression of the cell cycle. What feedback mechanism are the authors referring to?

      Thank you for pointing this out. We aimed for a general comment. The original line was replaced with: “The intricate network of (de)phosphorylation and (de)ubiquitination events in cycling cells establishes feedback mechanisms that ensure orderly cell cycle progression.

      Point 2. Characterization of disorder in the N-terminal segments of E2F7 and E2F8

      What does it mean disorder in this title?

      “Disorder” is a structural biology term for describing an unstructured (floppy) region in a protein. We suggest the following title in hope to improve clarity: “The N-terminal segments of E2F7 and E2F8 are intrinsically unstructured”

      Point 3. In the paragraph on the untimely degradation of E2F8 the authors keep referring to APC/C Cdc20, however the degradation is triggered by the Ken box which is specifically recognised by APC/C Cdh1. Can it be due to another ligase not APC/C?

      In our anaphase-like system, Cdh1 cannot associate with the APC/C due to persistently high Cdk1 activity, maintained by the presence of non-degradable Cyclin B1. While the KEN-box is classically recognized as a Cdh1-specific motif, previous studies have also clearly demonstrated that APC/C-Cdc20 can mediate the degradation of KEN-box substrates. For example, BubR1 interacts with Cdc20 via two KEN-box motifs (PMIDs: 25383541, 27939943 and 17406666). Nek2A is targeted for degradation by the APC/C in mitotic egg extracts lacking Cdh1, in a manner that depends on both D-box and KEN-box motifs (PMID: 11742988). CENP-F degradation in Cdh1-null cells has been shown to be dependent on both Cdc20 and a KEN-motif (PMID: 20053638). Thus, the most simple explanation for our results is that degradation is KEN box dependent and controlled by Cdc20.

      Regarding alternative E3 ligases, KEN-box mutant variants of non-phosphorylatable E2F8 remained stable in APC/CCdc20-active extracts, suggesting that this degradation is indeed APC/C-specific.

      Please also see our response to Reviewer #3, Point 3.

      Point 4. The assays to detect dephosphorylation are rather indirect so it is difficult to establish whether phosphorylation of CDK1 and dephosphorylation by PP2A on the fragments is direct.

      First, the phosphorylation sites analyzed in this study conform to the full and most canonical Cdk1 consensus motif: S/TPxK/R. While recognizing that other kinases are proline directed as well, the cell cycle dependent manner of this control, and presence of a similar CDK-dependent mechanism for Cdc6, points us towards considering the role of CDKs.

      Second, consistent with the direct role of CDK1 in this regulation, NMR experiments demonstrate conformational shifts of recombinant E2F8 following incubation with Cdk1–Cyclin B1 (not included in manuscript, but shown here for reviewer consideration); see Figure below. We have not yet established equivalent biochemical systems for PP2A.

      Figure legend: NMR-based monitoring of E2F7 (a-c) and E2F8 (d-f) phosphorylation by Cdk1.

      a(d). 15N,1H-HSQC spectrum of E2F7(E2F8) prior to addition of Cdk1. Threonine residues of interest, T45 (T20) conforming to the consensus sequence (followed by a proline), and T84 (T60) lacking the signature sequence are annotated. b(e). Strips from the 3D-HNCACB spectrum used for assigning E2F7(E2F8) residues. Black (green) peaks indicate a correlation with the 13Cα (13Cβ) of the same and previous residues. The chemical shifts assigned to T45 (T20) and T84 (T60) match the expected values for K44(K19) and P83(P59), thereby confirming the assignment. c(f). Top, overlay of subspectra before adding Cdk1 (black) and after 16 h of activity (red) at 298 K. Bottom, change in intensities of the T45/T84 in E2F7 and T20/T60 in E2F8 showing how NMR monitors phosphorylation and distinguishes between various threonine residues.


      Third, PP2A is likely the principal phosphatase counteracting Cdk1-mediated phosphorylation during mitotic exit, targeting numerous APC/C substrates (PMID: 31494926). In light of our findings and the extensive literature, it is therefore reasonable to propose that E2F7 and E2F8 may also be direct PP2A targets.

      Fourth, we cannot fully exclude the possibility that dephosphorylation of E2F7 and E2F8 by PP2A occurs indirectly. Nevertheless, indirect studies of PP2A substrate identification in the literature often rely on similar genetic perturbations, chemical inhibition, cell-free systems (coupled with immunodepletion, inhibitory peptides/proteins, and small-molecule inhibitors), and phosphoproteomics. Moreover, more direct assays are not without caveats, as they lack the cellular stoichiometric context, an important limitation for relatively promiscuous enzymes such as phosphatases.

      Importantly, repeated attempts (conventional [Co-IP] and less conventional [affinity microfluidics]) to detect interactions between PP2A and E2F7 and E2F8 were unsuccessful. This result was unfortunate but not surprising, given that transient substrate–phosphatase interactions are often challenging to capture experimentally.

      Given our evidence showing the regulation of E2F7 and E2F8 degradation in a manner that depends on Cdk1 and PP2A, the title of the manuscript remains appropriate: "Cdk1 and PP2A constitute a molecular switch controlling orderly degradation of atypical E2Fs.”

      Please also see our response to Reviewer #3 Point 1.

      Point 5. Although there seems to be a control by phosphorylation and dephosphorylation (which could be indirect), it is difficult to establish the functional consequences of this observation. The authors propose a feedback mechanism which regulates the temporal activation inactivation of E2F7/8 however, there are no evidence in support of this.

      The components being studied here have been extensively characterized, as have the direct and indirect interactions that connect them and ensure orderly cell cycle progression. For example: i) The E2F1–E2F7/8 transcriptional circuitry functions as a negative feedback loop; ii) Cdk1 and PP2A counteract one another’s activity; iii) E2F1 promotes the disassembly of APC/CCdh1; iv) E2F7 and E2F8 are APC/C substrates with cell cycle-relevant degradation patterns; and v) Loss of Cdh1 leads to premature S-phase entry.

      Our study brings these components together into a coherent regulatory module operating in cycling cells, revealed through cell-free biochemistry and newly developed methodologies with broad applicability to signaling research. We believe that advancing mechanistic understanding at this level of central regulators is impactful. And notably, this is a model, which we expect others in the field to test. We stand behind the result of each individual experiment and based on those findings are proposing a feedback circuit.

      Point 6. Reviewer #1 (Significance (Required)):

      The study is a good and well conducted work to understand the mechanisms regulating degradation of E2F7/8 by APC/C. This is crucial to establish coordinated cell cycle progression. While the hypothesis that disruption of this mechanism is likely responsible for altered cell cycle progression, there are no evidence this is just a back up pathway, whose functional significance could be limited to lack of APC/C Cdh1 activity. These experiments are rather difficult but the authors could comment on the limitation of the study and emphasise the hypothetical alterations which could result from the alterations of the described feedback loop

      We thank Reviewer #1 for this comment. Accordingly, we have expanded the discussion to further elaborate on the potential molecular outcomes and limitations of our study.

      Reviewer #2 (Evidence, reproducibility, and clarity (Required)):

      Summary: The authors provide strong biochemical evidence that the regulation of E2F7 and E2F8 by APC is affected by CDK1 phosphorylation and potentially by PP2A dependent dephosphorylation. The authors use both full length and N-terminal fragments of E2F8 in cell-free systems to monitor protein stability during mitotic exit. The detailed investigation of the critical residues in the N-terminal domain of E2F8 (T20/T44) is well supported by the combination of biochemical and cell biology approaches.

      We thank Reviewer #2 for their encouraging feedback.

      Point 1. Major: It is unclear how critical the APC-dependent destruction of E2F7 and E2F8 is for cell cycle progression or other cellular processes. Prior studies have reported that Cyclin F regulation of E2F7 is critical for DNA repair and G2-phase progression. This study would be improved if the authors could provide a cellular phenotype caused by the lack of APC dependent regulation of E2F8 and/or E2F7.

      We thank Reviewers #2 and #1 for this comment, which prompted substantial revisions. Below, we reiterate our response to Reviewer #1.

      The molecular components examined in this study are well established in the literature. Key principles include: (i) the reciprocal regulation between E2F1 and its repressors, E2F7 and E2F8, which forms a transcriptional feedback loop; (ii) the opposing activities of Cdk1 and PP2A; (iii) the capacity of E2F1 to attenuate APC/CCdh1 activity; (iv) the fact that E2F7 and E2F8 are APC/C substrates with defined cell cycle–dependent degradation patterns; and (v) the requirement for Cdh1 to prevent premature S-phase entry.

      Our study integrates these elements into a unified framework operating in proliferating cells. This framework is supported by biochemical reconstitution experiments and newly developed methodological tools, which we anticipate will be broadly applicable for dissecting signaling pathways. We view this type of mechanistic synthesis as valuable for the field. Importantly, we do not present this as a definitive model, but rather as a testable regulatory circuit constructed from robust individual findings.

      Overall, our study is mechanistic and based on cell-free systems. The central aim of this manuscript is to define how the Cdk1–PP2A axis is integrated into the APC/C–E2F1 regulatory network controlling cell-cycle progression. Collectively, our findings support a model in which Cdk1/PP2A-dependent (de)phosphorylation modulates the stability of E2F7 and E2F8, thereby fine-tuning E2F1 activity and cell-cycle progression.

      Point 2. Minor: All optional: It would have been interesting to see the T20A/T44A/KM in the live cell experiment (Figure 3F).

      This is an excellent point. Following Reviewer #2’s request, we generated a stable cell line expressing a KEN-box mutant variant of E2F8-T20A/T44A (N80 fragment). The figure below demonstrates the impact of the KEN-box mutation on the dynamics of N80-E2F8-T20A/T44A in HeLa cells. Together, our data from both cellular and cell-free systems show that the temporal dynamics of both wild-type and non-phosphorylatable variants of E2F8 depends on the KEN degron. Please note that due to differences in the flow cytometer settings used for acquiring the original measurements and those newly generated at the Reviewer’s request, the numeric data for N80-E2F8-T20A/T44A-KEN mutant will not be integrated into the original plots shown in the original Figure 3c–e in the manuscript.

      Figure legend: Dynamics of mutant variants of N80-E2F8-EGFP in HeLa cells.

      Top: Bivariate plots showing DNA content (DAPI) vs. EGFP fluorescence, with G1/G1-S phases and G2/M phases highlighted (black and gray frames, respectively). Bottom: Histograms showing EGFP signal distributions within these cell cycle phases. Blue arrows highlight subpopulations of G2/M cells with relatively low EGFP levels. The data was generated by flow cytometry.


      Point 3. Figure 4C-D - include the corresponding blots for the WT E2F7.

      This is a good point, which we previously overlooked. The requested data will be integrated in the revised manuscript.

      Point 4. It is unclear how selective or potent the PP2A inhibitors are that are used in Figure 5. Is it possible to include known targets of PP2A (positive controls for PP2A inhibition) in the analysis performed in Figure 5?

      Thank you for this helpful suggestion. Following Reviewer #2’s comment, we performed gel-shift assays of Cdc20 and C-terminal fragment of KIF4 (Residues: 732-1232), both known targets of PP2A (PMIDs: 26811472; 27453045). See data below.

      __Figure legend: PP2A inhibitor LB-100 block protein dephosphorylation in G1-like extracts. __

      Time-dependent gel shifts of mitotically phosphorylated Cdc20 and the C-terminal fragment of KIF4 (residues 732–1232) following incubation in G1 extracts supplemented with LB-100 or okadaic acid (OA; positive control). Substrates (IVT, 35S-labeled) were resolved by PhosTag SDS–PAGE and autoradiography.


      Point 5. Is the APC still active in LB-100 or OA treated conditions? Is it possible to demonstrate the APC is active using known substrates in this assay (e.g., Securin (Cdc20) and Geminin (Cdh1) or similar).

      This is an excellent point and we should have clarified this previously. Importantly, treatment with 250 µM LB-100 does not abolish APC/C-mediated degradation (otherwise, the assay would not be viable), but it does attenuate degradation kinetics. This is reflected by the prolonged half-lives of Securin and Geminin relative to mock-treated extracts (see below). Consistently, we noted in the manuscript: “Although APC/C-mediated degradation is also affected, it remains efficient, allowing us to measure relative half-lives of APC/C targets that cannot undergo PP2A-mediated dephosphorylation.” Following this comment, and one by Reviewer #3, these data are included in the revised manuscript.

      __Figure legend: APC/C-specific activity in cell extracts treated with LB-100. __

      Time-dependent degradation of EGFP–Geminin (N-terminal fragment of 110 amino acids) and Securin in extracts supplemented with LB-100 and/or UbcH10 (recombinant). A control reaction contained dominant-negative (DN) UbcH10. Proteins (IVT, 35S-labeled) were resolved by SDS-PAGE and autoradiography.


      Reviewer #2 (Significance (Required)): Advance: A detailed analysis is provided for the critical N-terminal residues in E2F7 and E2F8 that when phosphorylated are capable of restricting APC destruction. The work builds on prior work that had identified the APC regulation of E2F7 and E2F8.

      Point 6. Audience: The manuscript would certainly appeal to a broad basic research audience that is interested in the regulation of APC substrates and/or E2F axis control via E2F7 & E2F8. The study could have a broader interest if the destruction of E2F7 or E2F8 could be shown to be biologically relevant (e.g., critical for cell fate decision G1 vs G0, G1 length, timely S-phase onset, or expression of E2F1 target genes in the subsequent cell cycle).

      To clarify, we subdivided Reviewers’ comments into separate points. Reviewer #2’s Points 1 and 6 address essentially the same issue; our detailed response is therefore provided under Point 1. We again thank Reviewer #2 for raising this concern, which led to substantial revisions to both the manuscript text and the supporting data.

      We thank Reviewer #2 for their constructive comments and criticism.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      This manuscript presents a well-structured study on the regulatory interplay between Cdk and Phosphatase in controlling the degradation of atypical E2Fs, E2F7 and E2F8. The work is relevant in the field of cell cycle regulation and provides new mechanistic insights into how phosphorylation and dephosphorylation govern APC/C-mediated degradation. The use of complementary cell-based and in vitro approaches strengthens the study, and the findings have significant implications for understanding the timing of transcriptional regulation in cell cycle progression.

      Point 1. However, several points in this paper require further clarification for it to have a meaningful impact on the research community. The characterization of the phosphatase is unclear to me. The use of OA is necessary to guide the research, but it is not precise enough to rule out PP1 and then identify which PP2A is involved - PP2A-B55 or PP2A-B56. To clarify this, the regulatory subunits should either be eliminated or inhibited using the inhibitors developed by Jakob Nilsson's team.

      We are grateful for this comment, which prompted an extensive series of experiments that have undoubtedly strengthened our manuscript.

      First, we wish to clarify that LB-100, unlike okadaic acid (OA), is not considered a PP1 inhibitor.

      Second, we have conducted a large set of experiments to address this important question of the strict identity of the phosphatase involved in the dephosphorylation of atypical E2Fs.

      I. We initially attempted to immunodeplete the catalytic subunit of PP2A (α) from G1 extracts as a means to validate PP2A-dependent dephosphorylation. In retrospect, this was a naïve approach given the protein’s high abundance; although immunoprecipitation was successful, immunodepletion was inefficient, preventing us from using this strategy (see Panel a in the figure below). As an alternative, we incubated immunopurified PP2A-Cα with mitotic phosphorylated E2F7 and E2F8 fragments (illustrated in Panel b). A time-dependent gel-shift assay demonstrated enhanced dephosphorylation in the presence of immunopurified PP2A-Cα (Panel c) compared to immunopurified Plk1 (control reaction), suggesting that mitotically phosphorylated E2F7 and E2F8 are targeted by PP2A. This new data is now integrated in Figure 5.

      Figure legend: Immunopurified PP2A-Cα facilitates dephosphorylation of E2F7 and E2F8 in cell extracts. a) Inefficient immunodepletion (ID) of the catalytic subunit α of PP2A (PP2A-Cα) from cell extracts despite three rounds of immunopurification, as detected by immunoblotting (IB) with anti-PP2A-Cα and anti-BIP (loading control; LC) antibodies (BD bioscience, Cat#: 610555; Cell Signaling Technology, Cat#: 3177). Briefly, G1 cell extracts were diluted to ~10 mg/mL in a final volume of 65 μL. Anti-PP2A-Cα antibodies (3 μg) were coupled to protein G magnetic DynabeadsTM (15 μL; Novex, Cat#: 10004D) for 20 min at 20 °C. For each depletion round, antibody-coupled beads were incubated with cell extracts for 15 min at 20 °C. Cell extracts and beads were sampled after each step to assess immunodepletion and immunopurification (IP) efficiency. Equivalent immunopurification steps are shown for Plk1 (bottom). b) Schematic of the dephosphorylation assay using mitotically phosphorylated in vitro translated (IVT) targets and immuno-purified PP2A-Cα/Plk1. c) Dephosphorylation of mitotically phosphorylated E2F7 and E2F8 fragments, detected by electrophoretic mobility shifts in Phos-Tag SDS-PAGE. Immunopurified Plk1 was used for control reactions (antibodies: Santa Cruz Biotechnology: Cat#: SC-17783). *Image was altered to improve visualization of mobility shifts.


      II. Next, we used pan-B55-specific antibodies for immunodepletion of all B55-type subunits. This approach was unsuccessful despite five rounds of immunopurification (see Panel a in the figure below). Both suboptimal binding and the high abundance of endogenous B55 subunits likely contributed to this outcome. Thus, dephosphorylation in B55-depleted extracts could not be tested.

      Figure legend: PP2A-B55 facilitates dephosphorylation of E2F7 and E2F8 fragments.

      a) __Immunodepletion (ID) of B55 subunits in G1 extracts is inefficient despite five rounds of immunopurification; assessed by immunoblotting (IB) using anti-pan-B55 and anti-Cdk1 (loading control; LC) antibodies (see previous figure for more details). Cell extracts and beads were sampled after each round to monitor immunodepletion and immunopurification efficiency. b) Schematic of a dephospho-rylation assay using immuno-purified B55 subunits. __c) __Dephosphorylation of mitotically phosphorylated E2F7 and E2F8 fragments by immuno-purified B55. Control reactions performed with immuno-purified Plk1. d) __Schematic of a dephosphorylation assay performed in G1 cell extracts supplemented with B55-interacting (B55i) or control peptides (see peptide sequence on next page). RO-3306 was added to limit Cdk1 activity. __e) __Dephosphorylation of E2F7 and E2F8 fragments (mitotically phosphorylated) in G1 extracts supplemented with B55-interacting/control peptides. __f) __Schematic of the dephosphorylation assay using in vitro–translated B55/B56 subunits (unlabeled). __g) __Dephosphorylation of mitotically phosphorylated E2F7 (top) and E2F8 (bottom) fragments in reticulocyte lysate containing B55/B56 subunits. Dephosphorylation was assessed by electrophoretic mobility shifts in Phos-Tag SDS-PAGE. Panels marked with an asterisk were adjusted to improve visualization of gel-shifts. Arrowheads denote distinct, time-dependent mobility-shifted forms of E2F7 and E2F8 fragments. Antibodies used: anti-pan-B55 (ProteinTech, Cat#: 13123-1-AP); anti-Plk1 (Santa Cruz Biotechnology, Cat#: SC-17783); anti-Cdk1 (Santa Cruz Biotechnology, Cat#: SC-53217). Dynabeads™ (Novex, Cat#: 10004D) were used for immunopurification.


      As with PP2A-Cα, we incubated immunoprecipitated B55 subunits with mitotically phosphorylated E2F7 and E2F8 fragments (illustrated in Panel b). The results were less definitive compared to PP2A-Cα; nevertheless, they demonstrated accelerated dephosphorylation in the presence of immunopurified B55 subunits (Panel c) relative to Plk1 (control). These results hint at B55-mediated dephosphorylation of E2F7 and E2F8.

      III. Given that PP2A-B55 could be immunodepleted satisfactorily, despite successful immunoprecipitation, we ordered the B55-specific peptide and corresponding control peptide reported recently by Jakob Nilsson’s team as PP2A-B55 inhibitors (see below).

      Figure legend: Adapted from Kruse, T., et al., 2024; ____Science Advances. Figure 3, Panel B. ____PMID: 39356758.


      Despite our long-anticipated wait for these peptides to arrive, this line of experimentation proved disappointing. We wish to elaborate:

      The study by Kruse et al. (PMID: 39356758) is an elegant integration of classical enzymology, performed at the highest level, with structural insight into the conserved PP2A-B55 binding pocket that governs substrate specificity. Their work identified a consensus peptide that binds PP2A-B55 specifically with nanomolar affinity.

      Kruse et al. provide compelling evidence for a direct and specific interaction between their reported B55 inhibitor (B55i) and PP2A-B55. Their data show that the engineered inhibitor disrupts the binding of helical elements that underlie substrate recognition by PP2A-B55.

      However, we could not find direct evidence of PP2A-B55 enzymatic inhibition by the B55i peptide; for example, a B55-specific in vitro dephosphorylation assay demonstrating sensitivity to B55i in a dose-dependent manner. To the best of our understanding, the sole functional consequence described by Kruse et al. was the delay in mitotic exit observed upon expression of YFP-tagged B55i peptides in cells. However, this approach is indirect, given the long interval between cell manipulation and analysis and the complexity of mitotic exit. Furthermore, we assumed that the requested reagents had been validated in cell-free extracts; however, Kruse et al. do not report any experiments performed in these systems. We, in fact, became uncertain whether we had correctly understood Reviewer #3’s request to use these reagents and therefore sought clarification from the Editor.

      In vitro, Kruse et al. reported nanomolar binding affinities for B55i (Figure S14). In our cell extracts, however, we required concentrations of approximately 250 μM to detect an effect on dephosphorylation, evident as altered electrophoretic mobility of both E2F7 and E2F8 (Panel e). At this concentration, the peptide also caused nonspecific effects, rendering the extracts highly viscous (‘gooey’), at times preventing part of the reaction mixture from passing through a 10 μL pipette tip.

      The gel-shift assays shown in Panel e (Page 16) do demonstrate delayed dephosphorylation in extracts treated with the B55i peptide relative to the control peptide. Nevertheless, we prefer to exclude these data because the peptide concentrations required for the assay compromised extract integrity. Moreover, we believe that the PP2A-B55–specific peptide described by Nilsson et al. requires additional validation before it can be considered a reliable functional inhibitor in cell-free systems or in vivo. Accordingly, we are unable to directly address the experiments as suggested.

      IV. In the final set of experiments (Page 16, Panels f and g), we supplemented dephosphorylation reactions with in vitro–translated B55/B56 subunits (illustrated in Panel f). Although the expected concentration of in vitro–translated proteins in reticulocyte lysate is relatively low (100–400 nM), we reasoned that supplementing the reactions with excess of regulatory B subunits (non-radioactive) could still promote dephosphorylation in a differential manner that reflects the B55/B56 preference of E2F7 and E2F8.

      We cloned and in vitro expressed all nine B55/B56 regulatory subunits. While the exact amount of each subunit introduced into the reaction cannot be precisely determined, their expression levels were reasonably uniform (see figure below).

      __Figure legend: Expression of B55/B56 subunits in reticulocyte lysate. __B55/B56 subunits were cloned into the pCS2 vector and expressed in reticulocyte lysate supplemented with ³⁵S-Methionin. Proteins were resolved by SDS–PAGE and autoradiography.


      Returning to Panel g (Page 16), B55 subunits facilitated the accumulation of lower–electrophoretic mobility forms of both E2F7 and E2F8 fragments to the greatest extent. This is evident from the distinct lower–mobility species that emerge over time (marked by arrowheads) and the smear intensity corresponding to the buildup of dephosphorylated forms. Among the tested subunits, B55β exerted the strongest effect on both substrates, suggesting that mitotically phosphorylated E2F7 and E2F8 display a heightened preference for the PP2A-B55β holoenzyme. Control reactions with reticulocyte lysate are also shown.

      Taken together, our original and newly added data indicate that PP2A, specifically PP2A-B55, counteracts Cdk1-dependent phosphorylation during mitotic exit. Importantly, cell cycle regulators such as Cdc20 can be targeted by both PP2A-B55 and PP2A-B56 holoenzymes. Thus, while we are confident in concluding that mitotically phosphorylated E2F7 and E2F8 are targeted by PP2A-B55, we cannot rule out the possibility of functional interactions between E2F7/E2F8 and PP2A-B56.

      Point 2. It would also be valuable for this study to investigate the mechanisms underlying this regulation. In particular, is it exclusive to E2F7-8 or could other substrates contribute to the generalisation of this regulatory process?

      Assuming Reviewer #3 is referring to the cell cycle mechanism regulating E2F7 and E2F8 half-life via conditional degrons, we wish to clarify that the temporal dynamics of APC/C targets regulated by dephosphorylation has been demonstrated previously. Examples include KIFC1, CDC6, and Aurora A (PMIDs: 24510915; 16153703; 12208850, respectively).

      Point 3. The observation that Cdc20 may target E2F8 is interesting but needs to be further clarified to ensure that weak Cdh1 activity does not contribute to this degradation. Elimination of Cdc20 would be necessary to support the authors' conclusion.

      We gratefully acknowledge this input. The newly implemented experiment and corresponding findings are presented on the next page. The immunodepletion (ID) procedure (Panel a) achieved >60% reduction of Cdc20 and Plk1 in mitotic extracts (Panel b), as confirmed by immunoblotting (IB). Plk1-depleted extracts were used to validate extract-specific activity after successive rounds of immunodepletion at 20°C. Bead-bound Cdc20 and Plk1 were also analyzed by IB for validation (Panel b, right).

      As expected, the phospho-mimetic E2F8 fragment (T20D/T44D) remained stable in Plk1- and Cdc20-depleted mitotic extracts, serving as negative control (Panel c). In contrast, degradation of the non-phosphorylatable variant (T20A/T44A), as well as the APC/CCdc20 substrate Securin (positive control), was strongly hampered in Cdc20-depleted extracts compared to Plk1-depleted extracts. These results confirm that the untimely degradation of the non-phosphorylatable E2F8 in mitotic extracts is Cdc20-dependent. These new data are presented in Figure S3 of the revised manuscript.

      Figure legend: Untimely degradation of the non-phosphorylatable E2F8 in mitotic extracts is Cdc20-dependent.____a) Schematic of the immunodepletion (ID) protocol; additional technical details are provided below. b) Plk1 (top) and Cdc20 (bottom) levels in NDB mitotic extracts before and after three rounds of immunodepletion, as detected by immunoblotting (IB). Plk1 and Cdc20 levels were normalized to Tubulin and Cdk1, respectively. Both normalized and raw values are presented as percentages. Immunoprecipitation (IP) efficiency is shown on the right. c) Degradation profiles of phospho-mutant E2F8 variants and Securin (positive control) in NDB mitotic extracts depleted of Plk1 (control) or Cdc20.

      __ ---__

      Point 4. This study focuses on two proteins of the E2F family. These two proteins share similar domains, phosphorylation sites and a KEN box. However, their sensitivity to APC is different. What might explain this difference? Are there any inhibitory sequences for E2F7? Or why is the KEN box functional in E2F8 but not in E2F7?

      This is an excellent question. Here are our thoughts: The processivity of polyubiquitination by the APC/C varies between substrates in ways that influence degradation rate and timing (PMID: 16413484). Although E2F7 and E2F8 are related, their sequence identity is below

      50%, and their C-terminal domains differ substantially (see below) [FIGURE]. These structural differences likely contribute to differences in APC/C-mediated processivity and, consequently, to variations in protein half-lives. Additionally, E2F8 contains two functional KEN-boxes involved in its degradation, whereas E2F7 has only one. This may increase the kon rate of E2F8 for the APC/C, further enhancing its recognition and ubiquitination. Furthermore, re-examining the study by de Bruin and Westendorp (PMID: 26882548, Figure 2f; copied below), we note that the dynamic of inducibly expressed EGFP-tagged E2F7 in cells exiting mitosis is milder compared to E2F8 (see the black lines in both charts). This, as well as the oversensitivity of E2F7 degradation to Cdh1 downregulation accord with E2F7 being less potent substrate of APC/CCdh1.

      Figure legend: Adapted from Boekhout et al., 2016; ____EMBO Reports. Figure 2, Panel F. ____PMID: 26882548.


      The stability of the E2F7 fragment in cells and extracts was unexpected. We initially hypothesized that the unique N-terminal tail of E2F7 masks the KEN-box, functioning as an inhibitory sequence. However, removal of this region did not restore degradation (original manuscript; Figure 1e). Furthermore, extending the fragment by 20 additional residues failed to confer degradation (original manuscript; Figure S2). These observations suggest that E2F7 may require a distal or modular docking site for APC/C recognition. We did not pursue this question further.

      Point 5. An additional element that could strengthen this work would be referencing the study by Catherine Lindon: J Cell Biol, 2004 Jan 19;164(2):233-241. doi: 10.1083/jcb.200309035. In Figure 1 of this article, there is a degradation kinetics analysis of APC/C complex substrates such as Aurora-A/B, Plk1, cyclin B1, and Cdc20. This could help position the degradation of E2F7/8 relative to known APC/C targets. This can be achieved by synchronizing cells with nocodazole and then removing the drug to allow cells to progress and complete mitosis.

      This is an interesting point and one we should have clarified better previously. The temporal dynamics of E2F8 in synchronized HeLa S3 cells, relative to three known APC/C substrates, were reported in our previous study (PMID: 31995441; Figure 1a, copied on the right). Specifically, protein levels were measured for Cyclin B1, Securin, and Kifc1. Unlike Cyclin B1 and Securin, which are targeted by both APC/CCdc20 and APC/CCdh1, Kifc1 is degraded exclusively by APC/CCdh1. Cells were released from a thymidine–nocodazole block.

      Following Reviewer #3’s comment, we re-blotted the original HeLa S3 synchronous extracts. The new data [FIGURE] can be incorporated into the revised manuscript if requested.

      Point 6. Minor points: Does phosphorylation of E2F7-8 proteins alter their NMR profile? This could help understand how phosphorylation/dephosphorylation affects their sensitivity to the APC/C complex.

      Excellent suggestion. Indeed, we had originally aimed to include a more extensive set of NMR data in this manuscript. Our goal was to monitor E2F7 and E2F8 fragments in cell extracts and assess structural changes induced by phosphorylation and dephosphorylation during mitosis and mitotic exit. However, purifying the E2F7 fragment proved more challenging than anticipated. In addition, the extract-to-substrate ratio requires further optimization: Substrate concentrations must be high enough for reliable NMR detection, but below levels that would saturate the enzymatic activity in the extracts.

      That said, the short answer to the reviewer’s question is Yes: NMR profiles of E2F7 and E2F8 fragment do change following incubation with recombinant Cdk1–Cyclin B1 (see next page). If possible, we wish to exclude these NMR data from the manuscript.

      Figure legend: NMR-based monitoring of E2F7 (a-c) and E2F8 (d-f) phosphorylation by Cdk1.

      a(d). 15N,1H-HSQC spectrum of E2F7(E2F8) prior to addition of Cdk1. Threonine residues of interest, T45 (T20) conforming to the consensus sequence (followed by a proline), and T84 (T60) lacking the signature sequence are annotated. b(e). Strips from the 3D-HNCACB spectrum used for assigning E2F7(E2F8) residues. Black (green) peaks indicate a correlation with the 13Cα (13Cβ) of the same and previous residues. The chemical shifts assigned to T45 (T20) and T84 (T60) match the expected values for K44(K19) and P83(P59), thereby confirming the assignment. c(f). Top, overlay of subspectra before adding Cdk1 (black) and after 16 h of activity (red) at 298 K. Bottom, change in intensities of the T45/T84 in E2F7 and T20/T60 in E2F8 showing how NMR monitors phosphorylation and distinguishes between various threonine residues.


      Point 7. Do these substrates bind to the APC/C complex before degradation? Does E2F7 bind better than E2F8?

      We were unable to detect interactions between endogenous E2F7 and E2F8 and the APC/C complex. In general, detecting endogenous E2F8, and especially E2F7, by immunoblotting proved challenging, making co-immunoprecipitation (Co-IP) even more difficult.

      However, interactions between EGFP-tagged E2F7 snd E2F8 and Cdh1 have been demonstrated previously (PMID: 26882548, Figure 2e). In contrast, only the N-terminal fragment of E2F8, but not the corresponding fragment of E2F7, was found to bind Cdh1 (see figure on the right). This observation is consistent with the stability of the E2F7 fragment in APC/C-active extracts. These new data are presented in Figure S2 of the revised manuscript.

      __Figure legend: N-terminal fragment of E2F8 but not E2F7 binds Cdh1. __

      Co-Immunoprecipitation (IP) was performed in HEK293 cells transfected with EGFP-tagged E2F7/E2F8 fragments, using GFP-Trap® (Chromotek, Cat#: GTMA-20). Antibodies used for immunoblotting: ant-GFP (Santa Cruz Biotechnology: Cat#: SC-9996); anti-Cdh1 (Sigma-Aldrich, Cat#: MABT1323).


      Point 8. Why do the authors state that 250 µM of LB-100 has little effect on APC/C activity?

      We thank Reviewers #2 and 3 for raising this point. As shown in the manuscript, treatment with 250 µM LB-100 does not abolish APC/C-mediated degradation (otherwise, the assay would not be viable). However, it does attenuate degradation kinetics, as reflected by the prolonged half-lives of Securin and Geminin (see figure below and Figure S7 of the revised manuscript).

      __Figure legend: APC/C-specific activity in cell extracts treated with LB-100. __

      Time-dependent degradation of EGFP–Geminin (N-terminal fragment of 110 amino acids) and Securin in extracts supplemented with LB-100 and/or UbcH10 (recombinant). A control reaction contained dominant-negative (DN) UbcH10. Proteins (IVT, 35S-labeled) were resolved by SDS-PAGE and autoradiography.


      Point 9. How can E2F8 be a substrate for both the SCF and APC/C complexes? (If I understood correctly.)

      This can happen because they are degraded by different E3 at different times during the cell cycle. To clarify further, certain proteins can be targeted by both the APC/C and SCF complexes, reflecting distinct regulatory needs. A classic example is CDC25A, as shown by M. Pagano and A. Hershko in 2002 (PMID: 12234927). Additional examples include the APC/C inhibitor EMI1 (PMIDs: 12791267 [SCF] and 29875408 [APC/C]).

      Reviewer #3 (Significance (Required)): This manuscript presents a well-structured study on the regulatory interplay between Cdk and Phosphatase in controlling the degradation of atypical E2Fs, E2F7 and E2F8. The work is relevant in the field of cell cycle regulation and provides new mechanistic insights into how phosphorylation and dephosphorylation govern APC/C-mediated degradation. The use of complementary cell-based and in vitro approaches strengthens the study, and the findings have significant implications for understanding the timing of transcriptional regulation in cell cycle progression.

      We wish to thank Reviewer #3 for their positive and encouraging view of our work.

    1. Ein Signature-Duft ist am Ende genau das: ein kleiner, persönlicher Luxus, den du jeden Tag tragen kannst.

      More natural:

      Ein Signature-Duft ist mehr als nur ein Parfüm. Er unterstreicht Ihren persönlichen Stil und wird mit der Zeit zu Ihrem Markenzeichen.

    1. f cost estimation methods is provided in the UK Department for Transport's Transport Analysis Guidance (TAG). The framework estimates costs and benefits by comparing two scenarios: a "without-scheme" scenario, which represents how the transport system would evolve if the proposed intervention is not implemented, and a "with-scheme" scenario, which reflects conditions after the intervention is introduced. Cost estimation focuses on the difference between these two scenarios, ensuring that only the incremental impacts of the policy or project are captured rather than overall system costs.[16]The framework requires that costs be assessed over a long-term ap

      hi

    Annotators

    1. Reviewer #3 (Public review):

      Summary:

      The primary objective of this study was to establish a practical and functional framework for propagation of stable transgenic cell lines of Blastocystis, a common animal gut microeukaryote. Although the work focused on Blastocystis ST7-B, a subtype with relatively low prevalence in humans, this choice is justified by its association with more frequent negative health effects. Beyond their relevance to the medical field, the methodological advances described here have the potential to also expand cell biology studies of this anaerobic organism, including its unusual mitochondria and redox metabolism.

      Strengths:

      Prior to this work, genetic tools for Blastocystis were very limited, relying on a single strong promoter-terminator combination. The authors successfully expanded the available promoter set across a range of expression strengths by testing two dozen variants in luciferase-based assays. Critically, they developed an integrated workflow from a modular transgenic construct design to an expanded inventory of molecular components (promoters, reporters), optimized DNA delivery, stepwise antibiotic resistance-mediated clonal selection and propagation, and to reporter validation. The evaluation of several anaerobiosis-compatible labeling strategies for live (and fixed) cell optical imaging will be particularly useful, with the SNAP-tag system appearing especially promising for Blastocystis.

      Weaknesses:

      The presented data generally provide a solid support for the conclusions that the work reached, but clarification of reasoning and several inconsistencies, as well as amendments to visual presentation of the data would be highly beneficial, as detailed below.

      (1) Episomal persistence of the construct:

      The manuscript repeatedly assumes, including in its title, that constructs persist in Blastocystis in their episomal form, but no direct evidence is provided. Although this interpretation is plausible, it should be identified more clearly as provisional. Nuclear genomic integration (e.g., via NHEJ) remains a possible explanation unless supporting evidence or rationale is provided to exclude it. Testing whether the phenotype persists without drug-mediated selection in the generated transgenic cell lines would help strengthen the case for episomal maintenance.

      (2) Promoters and terminators:

      (2.1) There is a discrepancy between the claimed number of loci (14), from which promoters used to drive luciferase expression were derived, and those detailed as having been actually generated in Table 1 (11). This inconsistency should be corrected or explained, as it creates uncertainty around the accuracy of the dataset.

      (2.2) Based on the presented evidence, constructs benchmarked in bioluminescence assays differed only in their promoter composition. Although terminator selection is mentioned in the Methods section, no additional details are provided; for instance, Table 1 and Figure 2 only list 23 promoters in total. Figure 2A likewise shows only promoter-dependent variation. If the terminator was held constant (LeguP1?), this should be stated explicitly. The authors may then consider revising the wording of having tested "23 promoter-terminator pairs" to better reflect that only promoters varied.

      (2.3) Promoter benchmarking was done with a plasmid lacking a selection marker, so it is unclear how the maintenance of the luciferase construct was ensured. Without selection, the observed reporter intensity could reflect differential or stochastic plasmid retention rather than promoter strength alone. The luminescence assay was performed 16-18 hours after transfection, but the rationale for this particular timeframe should be explained. In this context, the authors should explicitly state whether the experiments shown in Fig.2A represent biological triplicates or technical triplicates from a single transfection.

      (3) Figure 2:

      (3.1) Several aspects of the current design may lead to ambiguity for the reader. The boxplots are colour-coded, but it is unclear whether the colours carry meaning or are purely decorative. Because the data are already spatially separated into bins, additional random colouring is redundant and may suggest distinctions that are not intended. In addition, the part A of Figure 2 is split into two panels with the scale for the left panel shown in the right panel and some of the boxplot colours falling in the range of the scale, but not in line with their counterparts in the left panel. Because the colour use is not consistent, it is difficult to tell whether the same scale should be applied to both panels or how it should be interpreted.

      (3.2) The left panel of the part A uses a diverging blue-white-red colour scheme, which is most appropriate when the midpoint represents a meaningful central value such as zero. Because the values shown in this graph are only positive, a non-diverging 2-colour scale or a colour palette such as 'viridis' would make the plot easier to interpret.

      (3.3) A black background should be avoided: 'B' and 'C' labels are invisible and it draws attention to a distracting design feature rather to the data themselves.

      (4) Figure 3:

      (4.1) Individual snapshots should be separated more clearly, either by using a white background or by adding visible borders to make the overall composition clearer. As currently displayed, some boundaries between fluorescent channels resemble image artifacts rather than intentional panel divisions.

      (4.2) In the parts B-D, the legend should explain more clearly what each image shows and the figure itself would benefit from annotations. There seem to be three sub-panels in each 'condition' of part B (as well as C and D): while the middle and rightmost panel can be easily inferred to represent the fluorescent protein and bright-field image, what the leftmost panels represent is not specified. If DAPI was used to dye DNA, an explanation why mostly multiple labelled regions are visible should be provided.

      (4.3) Cell morphology and appearance differ markedly between UnaG/smURFP and SNAP-tag images, which should be explained. A microscope issue is mentioned in the main text, but if that was the cause, the authors should consider replacing the images as the current distortions complicate interpretation.

      Comments on revised version.

      The revised version provides sufficient clarity and appropriate visual presentation. Some confusion evidently arose due to my misunderstanding, so I thank the authors for their comprehensive clarifications and patience.

    2. Author response:

      The following is the authors’ response to the original reviews.

      In revising the manuscript, we have focused on three main priorities raised during review: (1) improving precision around evidential claims, particularly concerning vector maintenance and P2A-mediated protein separation; (2) substantially improving figure quality, accessibility, and legend clarity; and (3) correcting inconsistencies and expanding methodological detail where requested.

      This study was intended as a foundational genetic toolkit and methodological framework for Blastocystis ST7-B, establishing practical workflows for DNA delivery, endogenous regulatory-element benchmarking, antibiotic-selected recovery, clonal propagation, and reporter-based analysis in a genetically challenging anaerobic microbial eukaryote. The central evidence presented is therefore functional in nature: reproducible transgene delivery, selectable recovery and propagation of colony-derived transgenic lines, and detectable reporter expression using multiple anaerobic-compatible reporter systems.

      We agree with the reviewers that several additional experiments, including Western blot analysis of P2A-containing constructs, outward-facing PCR, plasmid rescue assays, and selection-withdrawal experiments, would further strengthen the mechanistic interpretation of the system and help distinguish episomal persistence from genomic integration. We have therefore revised the manuscript throughout to clearly separate what is directly demonstrated from what remains a plausible working interpretation or important future direction.

      Importantly, the revised manuscript no longer presents episomal maintenance or complete P2A-mediated protein separation as demonstrated conclusions. Instead, these are now discussed explicitly as unresolved mechanistic questions requiring future molecular analysis. Nevertheless, the central methodological conclusion remains unchanged: stable selectable transgene expression, recovery of colony-derived transgenic lines, and reporter-positive Blastocystis ST7-B transformants can now be reproducibly obtained.

      Reviewer #1 (Public review):

      Summary:

      This paper presents a toolkit for the transformation of Blastocystis. The authors have screened a number of selectable agents, promoters and reporter genes and present their findings. This resource will be of immense use to those in the Blastocystis field, as well as those seeking to establish transformation tools in other species where such tools do not yet exist. Establishing new transformation tools is extremely challenging, and the authors have done an excellent job.

      Strengths:

      The authors have carried out a systematic screen of promoters, reporter genes and selectable agents. They have screened numerous for each, and all the data is presented. It is good to see when things did not work as well as when things did, so this data set is extremely useful indeed.

      Weaknesses:

      The findings are reported by reporter gene assay (microscopy). No evidence is given using genetics. The authors claim that the DNA is maintained episomally. However, could it be possible that there is integration? No PCRS/RT-PCRs are shown (although it can safely be assumed that the DNA/RNA is present where the transformation was successful), nor are any Western blots. These would have been useful to show that the P2A ribosomal skipping had occurred, and that proteins were expressed individually rather than as a polyprotein.

      We thank the reviewer for the positive assessment of the manuscript and for recognising both the technical difficulty and broader utility of establishing genetic tools in Blastocystis and other experimentally challenging microbial eukaryotes. We also appreciate the reviewer’s identification of the main evidential limitations in the original manuscript, particularly regarding vector maintenance and P2A-mediated protein separation.

      First, regarding the question of vector topology and the interpretation of episomal maintenance.

      We agree that the original manuscript presented episomal persistence too strongly relative to the evidence currently available. We have therefore revised the manuscript throughout to clarify that episomal maintenance should presently be regarded as a plausible working model rather than a directly demonstrated conclusion.

      The transfection system used here was adapted from Li et al. (2019), including use of the pXS2-P<sub>Legumain</sub>-derived plasmid framework. Importantly, the construct used in the present study does not contain the original Trypanosoma brucei tubulin-targeting region associated with homologous integration in the original pXS2 system. Complete plasmid sequencing confirmed that the constructs function here as heterologous expression plasmids carrying Blastocystis ST7-B regulatory elements and transgenes. While this does not demonstrate episomal persistence, it also means that genomic integration cannot be inferred from the historical pXS2 vector architecture alone.

      We further note that comparative genomic analyses by Gentekaki et al. (2017) suggest that Blastocystis lacks components of the canonical non-homologous end-joining (NHEJ) machinery, implying that homologous recombination is likely to represent the principal route for double-stranded DNA repair. Because the constructs used here did not contain Blastocystis homology arms, there is currently no obvious mechanism favouring targeted homologous integration. Nevertheless, we fully agree that genomic integration cannot presently be excluded.

      To reflect this appropriately, the revised manuscript now explicitly separates the demonstrated functional outcomes from unresolved mechanistic questions concerning vector maintenance. We also identify several future approaches that would help distinguish episomal persistence from genomic integration, including outward-facing PCR, plasmid rescue followed by full plasmid sequencing, Southern blotting, FISH, selection-withdrawal experiments, and long-read sequencing approaches.

      We have revised the manuscript throughout to remove statements implying demonstrated episomal maintenance and now present episomal persistence only as a plausible working interpretation.

      In the Methods section under Cloning, the following text has been added:

      Lines 202–206: “The constructs used in this study were derived from the pXS2-P<sub>Legumain</sub> vector described by Li et al. (2019), which adapted a heterologous expression-vector backbone for transient plasmid-based expression in Blastocystis ST7-B. Here, the same molecular backbone was used as a plasmid scaffold carrying Blastocystis-derived regulatory elements and transgenes.”

      In the Discussion, the following text has been added/edited:

      Lines 665–673: “The molecular maintenance state of the introduced constructs remains unresolved: episomal maintenance is a plausible working model, but genomic integration cannot be formally excluded. The constructs used here lack Blastocystis homology arms, and comparative genomic analyses suggest that Blastocystis lacks canonical non-homologous end-joining components (Gentekaki et al., 2017), making targeted integration by standard repair routes unlikely but not impossible. Direct assays such as outward-facing PCR, plasmid rescue followed by full plasmid sequencing, FISH, or selection-withdrawal experiments will be required to distinguish episomal persistence from integration.”

      Second, regarding P2A-mediated protein separation.

      We agree that Western blotting would provide the most direct biochemical assessment of P2A-mediated ribosomal skipping efficiency in Blastocystis ST7-B and would help determine the extent of any residual uncleaved fusion product. We have therefore revised the manuscript to avoid implying that complete protein-level separation was directly demonstrated.

      The revised manuscript now states only what is directly supported by the current data: that P2A-containing bicistronic constructs supported antibiotic-selected recovery of transgenic lines together with detectable downstream reporter expression. The microscopy data therefore support functional downstream reporter expression, but do not by themselves exclude residual uncleaved fusion products.

      We selected P2A because it is a compact and well-characterised peptide with high reported separation efficiency across multiple eukaryotic systems, including microbial eukaryotes. However, we agree that P2A performance can be context-dependent, and we now explicitly identify biochemical validation of P2A cleavage efficiency as an important future direction.

      Importantly, these revisions do not alter the central methodological conclusion of the study, namely that selectable transgene expression, propagation of reporter-positive lines, and recovery of colony-derived Blastocystis ST7-B transformants can now be reproducibly achieved.

      Text inserted in the Results:

      Lines 394–396: “The P2A peptide is expected to promote ribosomal skipping during translation, allowing two separate polypeptides to be produced from a single open reading frame.”

      Lines 403–404: “However, protein-level separation was not directly tested, and the extent of any residual uncleaved fusion product remains unresolved.”

      Text inserted in the Discussion:

      Lines 619–629: “P2A was selected because it is a well-characterised peptide with high reported separation efficiency in human cell lines, zebrafish embryos, and mice (Kim et al., 2011). It also has precedent across microbial eukaryotes, including the protest Dictyostelium discoideum (Zhu et al., 2023), the fungi Aspergillus niger (Schuetze and Meyer, 2017) and Ustilago maydis (Müntjes et al., 2020), and the apicomplexan parasites Toxoplasma gondii (Markus et al., 2019) and Plasmodium falciparum (Dans et al., 2024). However, P2A performance is context-dependent, and the evidence presented here is functional rather than biochemical. P2A-containing constructs support antibiotic-selected recovery and downstream reporter expression in Blastocystis ST7-B, but ribosomal skipping efficiency and any residual uncleaved product will require direct protein-level validation.”

      Reviewer #1 (Recommendations for the authors):

      (1) Please could you show a Western blot to confirm if P2A has worked? It could be that the proteins are being expressed as a polyprotein.

      We agree that Western blotting would provide the most direct biochemical assessment of P2A-mediated ribosomal skipping efficiency in Blastocystis ST7-B and would help determine the extent of any residual uncleaved fusion product. This is an important point, and we have revised the manuscript accordingly to avoid implying that complete protein-level separation was directly demonstrated.

      The current study was designed as a first-generation functional genetic toolkit for Blastocystis ST7-B, focused primarily on establishing reproducible workflows for selectable transgene expression, reporter recovery, and propagation of transgenic lines in this experimentally challenging anaerobic microbial eukaryote. The toolkit is therefore validated here through functional outcomes, including antibiotic-selected survival, stable propagation through extended passaging (>15 passages) and cryopreservation, and detectable reporter fluorescence above wild-type autofluorescence.

      P2A was selected because it is a compact and well-characterised peptide with high reported ribosomal skipping efficiency across multiple eukaryotic systems, including microbial eukaryotes, as discussed above. Nevertheless, we fully agree that direct biochemical validation would strengthen the mechanistic interpretation of the bicistronic system in Blastocystis ST7-B. We therefore now explicitly identify Western blot analysis, ideally using epitope-tagged upstream and downstream products, as an important future direction for quantitative assessment of P2A cleavage efficiency and any residual uncleaved fusion products.

      Relevant manuscript revisions are described above under the general response to Reviewer 1.

      (2) Something has gone wrong with figure formatting. Figure 2 is nearly illegible and I cannot read the text in section A. Sections B, C, and D have lost their labels and are fuzzy and surrounded by black. A similar issue affects Figure 3. Everything is just black with a few cells. It is illegible when printed.

      We thank the reviewer for highlighting these presentation issues and agree that the submitted figure quality significantly impaired readability and interpretation. The problems appear to have arisen primarily during manuscript compilation and export, particularly affecting image resolution, contrast, and panel labelling in the review PDF.

      To address this, Figures 2 and 3 have been completely reformatted and replaced with revised high-resolution versions. We have also improved typography, panel separation, colour scaling, and legend clarity throughout. In response to additional reviewer suggestions, individual data points have now been added to Figures 2B and 2C to improve transparency and interpretability of the underlying data distributions.

      Figures 2 and 3 have been replaced with fully revised high-resolution versions with improved panel labelling, accessibility, typography, and figure legends.

      (3) The data from Figure 2B would be better placed in Table 1 with a column for robust/moderate/intermediate/weak/very weak. This would be much easier for the reader.

      We thank the reviewer for this helpful suggestion. We believe the comment refers to the promoter activity data shown in Figure 2A rather than the voltage optimisation data in Figure 2B. To improve readability and accessibility of these data, we have revised Figure 2A extensively to make the promoter activity tiers more legible and easier to interpret directly from the heat map and accompanying box plots.

      We considered incorporating simplified activity classifications into Table 1. However, activity patterns were construct-specific rather than simply locus-specific. In several cases, multiple promoter fragments derived from the same locus produced substantially different reporter outputs, and activity did not scale monotonically with promoter fragment length. We therefore felt that assigning a single categorical activity label at the locus level would oversimplify the dataset and reduce the construct-level resolution that is central to the toolkit value of the study.

      Instead, we addressed the reviewer’s concern by substantially improving the presentation and readability of Figure 2A, allowing readers to identify robust, moderate, intermediate, weak, and very weak expression constructs more directly while preserving the underlying construct-specific information.

      Figure 2A has been revised to improve clarity, accessibility, and legibility of the promoter activity tiers, allowing construct-level expression classes to be interpreted more directly from the heat map and accompanying boxplots.

      (4) How do you know if the constructs are maintained as episomes? Have you done an outward-facing PCR?

      We agree that direct molecular evidence distinguishing episomal persistence from genomic integration is currently lacking, and we appreciate the reviewer highlighting this important limitation. We have therefore revised the manuscript throughout to avoid presenting episomal maintenance as a demonstrated conclusion and now describe it only as a plausible working interpretation based on the current evidence and vector design.

      We have not performed outward-facing PCR in the present study. As discussed in the general response above, we now explicitly identify outward-facing PCR, plasmid rescue followed by full plasmid sequencing, selection-withdrawal assays, FISH, and long-read sequencing approaches as important future directions for resolving the molecular maintenance state of the constructs.

      The revised manuscript now clearly separates the demonstrated functional outcomes, including selectable transgene expression, recovery of colony-derived transgenic lines, and stable reporter-positive propagation under selection, from the unresolved mechanistic question of vector topology.

      This issue has been addressed throughout the revised manuscript, including in the Methods and Discussion sections, where episomal maintenance is now presented as a plausible but unconfirmed interpretation rather than a demonstrated conclusion.

      Minor Comments

      Line 66: is this one to two billion individuals with Blastocystis, or one to two billion Blastocystis cells per gut?

      The intended meaning was colonised individuals globally. We agree that the original phrasing was ambiguous and have corrected it for clarity.

      Lines 66–67 revised to: “…microorganisms in the human gut, and is estimated to colonise approximately one to two billion people globally (Scanlan and Stensvold, 2013).”

      Line 148: Supplier of IMDM?

      The supplier information was already present in the original manuscript as IMDM L0191 (Biowest).

      No additional manuscript change required.

      Line 157: Who annotated the dataset, the 2017 paper or the present study?

      The dataset annotation derives from Armengaud et al. (2017). We agree that the original wording was unclear and have revised this section substantially to improve clarity regarding the rationale and workflow used for promoter and terminator candidate selection.

      “The relevant Methods section has been extensively revised for clarity and expanded detail” (Lines 156–189).

      Line 166: Who predicted the 3′ UTR, the 2017 paper?

      This information derives from the NCBI annotation associated with the Blastocystis ST7-B genome based on Denoeud et al. (2011). This has now been clarified in the Methods section.

      Clarified in revised Methods section.

      Line 237: How long did it take in days?

      Approximately 2 days.

      Line 270 revised to: “…turned yellow without drug treatment, usually within 2 days post-transfection.”

      Line 325: Typo, missing gap between Figure and 1A.

      Corrected in revised manuscript.

      Reviewer #2 (Public review):

      This manuscript presents a substantial technical advance for the genetic manipulation of Blastocystis by establishing an integrated workflow for stable episomal transgenesis, antibiotic selection, clonal recovery, and reporter-based imaging in the ST7-B subtype. The study is particularly valuable because it combines multiple previously fragmented approaches into a coherent and practically applicable toolkit, including endogenous regulatory elements, optimized electroporation conditions, selectable markers, and anaerobic compatible fluorescent reporters. This methodological work greatly expands the molecular toolbox and future studies focused on both basic and infection biology can now build on the ability to express and localize proteins in fixed as well as live cells.

      The microscopy data are convincing and clearly demonstrate functional reporter expression and successful recovery of stable transgenic lines. Nevertheless, because this is primarily a methodological paper, the study would be further strengthened by the inclusion of Western blot validation of reporter expression and bicistronic constructs. In particular, biochemical analysis of the P2A-containing constructs would help assess the efficiency of ribosomal skipping and exclude the possible presence of uncleaved fusion proteins, thereby providing stronger support for the interpretation of the imaging data and the functionality of the expression system.

      We thank the reviewer for this thoughtful and positive assessment of the manuscript and for recognising the value of integrating previously fragmented approaches into a coherent and practically usable genetic toolkit for Blastocystis ST7-B. We particularly appreciate the reviewer’s recognition that the system expands the currently available molecular toolbox for both cell biological and infection-related studies in this experimentally challenging anaerobic microbial eukaryote.

      We also appreciate the reviewer’s comments regarding biochemical validation of the P2A-containing bicistronic constructs. We agree that Western blot analysis would strengthen the mechanistic interpretation of the reporter system by directly assessing ribosomal skipping efficiency and the possible presence of residual uncleaved fusion products. In response, we have revised the manuscript throughout to ensure that the conclusions remain appropriately evidence-based and do not imply that complete protein-level separation was directly demonstrated.

      The revised manuscript now explicitly distinguishes the demonstrated functional outcomes, including selectable transgene expression, stable propagation of reporter-positive lines, and detectable downstream reporter expression, from unresolved mechanistic questions concerning P2A cleavage efficiency and vector maintenance state. We now also identify biochemical validation of P2A-mediated protein separation as an important future direction for further refinement of the system.

      Relevant manuscript revisions addressing these points are described above under the response to Reviewer 1.

      Reviewer #2 (Recommendations for the authors):

      The quality of images could be better. The figures lacked resolution — possibly a conversion artefact.

      We agree that the figure quality in the submitted review PDF significantly reduced readability and visual interpretation. The issues appear to have arisen primarily during manuscript compilation and export, particularly affecting image resolution, typography, panel labelling, and contrast rendering.

      To address this, Figures 2 and 3 have been completely reformatted and replaced with revised high-resolution versions. We have also improved panel separation, typography, colour scaling, contrast settings, and figure legends to improve accessibility and interpretability both on screen and in print. In addition, the export workflow and file formatting have been updated to improve compatibility with journal production requirements and reduce the likelihood of compression-related rendering artefacts during manuscript compilation.

      Figures 2 and 3 have been replaced with revised high-resolution versions with improved typography, panel labelling, contrast settings, and accessibility.

      Reviewer #3 (Public review):

      Summary:

      The primary objective of this study was to establish a practical and functional framework for the propagation of stable transgenic cell lines of Blastocystis, a common animal gut microeukaryote. Although the work focused on Blastocystis ST7-B, a subtype with relatively low prevalence in humans, this choice is justified by its association with more frequent negative health effects. Beyond their relevance to the medical field, the methodological advances described here have the potential to also expand cell biology studies of this anaerobic organism, including its unusual mitochondria and redox metabolism.

      Strengths:

      Prior to this work, genetic tools for Blastocystis were very limited, relying on a single strong promoter-terminator combination. The authors successfully expanded the available promoter set across a range of expression strengths by testing two dozen variants in luciferase-based assays. Critically, they developed an integrated workflow from a modular transgenic construct design, to an expanded inventory of molecular components (promoters, reporters), optimized DNA delivery, stepwise antibiotic resistance-mediated clonal selection and propagation, and to reporter validation. The evaluation of several anaerobiosis-compatible labeling strategies for live (and fixed) cell optical imaging will be particularly useful, with the SNAP-tag system appearing especially promising for Blastocystis.

      Weaknesses:

      The presented data generally provide solid support for the conclusions that the work reached, but clarification of reasoning and several inconsistencies, as well as amendments to the visual presentation of the data, would be highly beneficial, as detailed below.

      (1) Episomal persistence of the construct:

      The manuscript repeatedly assumes, including in its title, that constructs persist in Blastocystis in their episomal form, but no direct evidence is provided. Although this interpretation is plausible, it should be identified more clearly as provisional. Nuclear genomic integration (e.g., via NHEJ) remains a possible explanation unless supporting evidence or rationale is provided to exclude it. Testing whether the phenotype persists without drug-mediated selection in the generated transgenic cell lines would help strengthen the case for episomal maintenance.

      We thank the reviewer for this important point and agree that the original manuscript presented episomal persistence too strongly relative to the currently available evidence. In particular, we agree that the title and several sections of the manuscript implied a level of mechanistic certainty that was not directly demonstrated.

      We have therefore revised the manuscript throughout to clarify that episomal maintenance should presently be regarded as a plausible working interpretation rather than a demonstrated conclusion. The revised text now explicitly distinguishes the demonstrated functional outcomes, including selectable transgene expression, recovery and propagation of colony-derived transgenic lines, and stable reporter-positive maintenance under selection, from the unresolved mechanistic question of vector topology.

      As discussed in our response to Reviewer 1, the constructs used here do not contain Blastocystis homology arms, and comparative genomic analyses suggest that Blastocystis lacks canonical non-homologous end-joining components, making targeted integration by standard repair routes less strongly supported mechanistically, although genomic integration cannot presently be excluded.

      We agree that selection-withdrawal experiments would provide useful additional evidence regarding construct persistence and have now explicitly identified such assays, together with outward-facing PCR, plasmid rescue, FISH, and long-read sequencing approaches, as important future directions for resolving the molecular maintenance state of the transgenes.

      The manuscript has been revised throughout to remove wording implying demonstrated episomal maintenance. Episomal persistence is now discussed only as a plausible working interpretation pending direct molecular validation.

      (2) Promoters and terminators:

      (2.1) There is a discrepancy between the claimed number of loci (14), from which promoters used to drive luciferase expression were derived, and those detailed as having been actually generated in Table 1 (11). This inconsistency should be corrected or explained, as it creates uncertainty around the accuracy of the dataset.

      We thank the reviewer for this careful reading and for identifying this inconsistency. We agree that the distinction between candidate loci and successfully generated promoter constructs was not sufficiently clear in the original manuscript and could create uncertainty regarding the dataset.

      The original candidate set comprised 14 loci selected for promoter and terminator discovery. However, only 11 loci yielded successfully cloned and experimentally tested promoter constructs. The remaining three loci were retained in Table 1 for completeness and transparency, as repeated cloning attempts were unsuccessful despite two independent efforts.

      We have revised the manuscript to make this distinction explicit and to clarify that the reported NanoLuc benchmarking experiments were ultimately performed using constructs derived from 11 successfully cloned loci.

      Lines 361–364: “To expand the available regulatory parts, we screened 23 NanoLuc reporter constructs containing putative endogenous promoter–terminator pairs from 11 of 14 candidate loci; three loci could not be cloned after two independent attempts and are indicated in Table 1.”

      (2.2) Based on the presented evidence, constructs benchmarked in bioluminescence assays differed only in their promoter composition. Although terminator selection is mentioned in the Methods section, no additional details are provided; for instance, Table 1 and Figure 2 only list 23 promoters in total. Figure 2A likewise shows only promoter-dependent variation. If the terminator was held constant (LeguP1?), this should be stated explicitly. The authors may then consider revising the wording of having tested “23 promoter-terminator pairs” to better reflect that only promoters varied.

      We thank the reviewer for the opportunity to clarify this point. We agree that the original presentation may have created the impression that promoter and terminator regions were independently varied and benchmarked, whereas the experimental design was primarily focused on construct-level comparison of endogenous regulatory modules.

      As described in the Methods, each construct contained a candidate endogenous upstream promoter region together with the corresponding endogenous downstream terminator region derived from the same locus. For consistency and to keep the cloning and screening strategy experimentally tractable, a fixed 500 bp downstream terminator fragment was used for each locus rather than systematically varying terminator length or independently testing terminator activity.

      We therefore retain the description “endogenous promoter–terminator pairs,” since each construct contains both endogenous upstream and downstream regulatory regions from the same genomic locus. However, we agree that the assay was not designed to independently dissect promoter versus terminator contributions to reporter output. We have revised the manuscript accordingly to make this distinction explicit and avoid ambiguity regarding the scope of the benchmarking analysis.

      Lines 365–368: “Each construct paired a candidate upstream promoter region with the corresponding downstream terminator region from the same locus, defined here as the native 500 bp sequence immediately downstream of the stop codon. Where multiple promoter lengths were tested for the same locus, the terminator fragment was kept constant (Table 1; Figure 1A).”

      This design allowed construct-level benchmarking of paired promoter–terminator modules but did not test promoter strength or terminator activity independently.

      (2.3) Promoter benchmarking was done with a plasmid lacking a selection marker, so it is unclear how the maintenance of the luciferase construct was ensured. Without selection, the observed reporter intensity could reflect differential or stochastic plasmid retention rather than promoter strength alone. The luminescence assay was performed 16-18 hours after transfection, but the rationale for this particular timeframe should be explained. In this context, the authors should explicitly state whether the experiments shown in Fig.2A represent biological triplicates or technical triplicates from a single transfection.

      We thank the reviewer for these important methodological points. We agree that the original manuscript did not sufficiently clarify the transient nature of the NanoLuc benchmarking assay or the rationale underlying the assay design and timing.

      The promoter benchmarking assay was designed as an early transient-expression screen adapted from the NanoLuc-based workflow of Li et al. (2019), with modifications, rather than as a stable-maintenance assay. No selectable marker was included because the objective was to compare relative early reporter output across constructs shortly after DNA delivery, before prolonged culture effects became dominant.

      The 16–18 h post-electroporation time point was selected based on the NanoLuc expression kinetics reported by Li et al. (2019) and empirical optimisation during assay development. This window allowed robust transient reporter detection while limiting confounding effects arising from prolonged plasmid loss, differential outgrowth, variable recovery, or later culture-level changes.

      We agree that, in the absence of selection, the observed NanoLuc signal cannot be interpreted as an absolute measure of promoter strength independent of DNA uptake efficiency, early plasmid retention, or post-transfection recovery dynamics. We have therefore revised the manuscript to clarify that Figure 2A reports relative transient reporter output under standardized early post-transfection conditions rather than isolated promoter activity alone.

      We now also explicitly state that the data shown in Figure 2A derive from three independent electroporation experiments per construct, each assayed in technical duplicate.

      Lines 241–248: “Promoter–terminator activity was assessed 16–18 h after electroporation using a transient NanoLuc assay adapted from Li et al. (2019), with modifications. This early time point was selected to capture reporter output within the transient-expression window after DNA delivery, before prolonged plasmid loss, differential outgrowth, or culture-level changes could dominate the readout. Because the constructs did not contain a selectable marker, the measured NanoLuc signal reflects early transient reporter output rather than promoter strength independent of DNA uptake, early plasmid retention, or post-transfection recovery.”

      Additional clarification added to Figure 2 legend stating that measurements derive from three independent electroporation experiments, each assayed in technical duplicate.

      (3) Figure 2:

      (3.1) Several aspects of the current design may lead to ambiguity for the reader. The boxplots are colour-coded, but it is unclear whether the colours carry meaning or are purely decorative. Because the data are already spatially separated into bins, additional random colouring is redundant and may suggest distinctions that are not intended. In addition, part A of Figure 2 is split into two panels, with the scale for the left panel shown in the right panel and some of the boxplot colours falling in the range of the scale, but not in line with their counterparts in the left panel. Because the colour use is not consistent, it is difficult to tell whether the same scale should be applied to both panels or how it should be interpreted.

      (3.2) The left panel of part A uses a diverging blue-white-red colour scheme, which is most appropriate when the midpoint represents a meaningful central value such as zero. Because the values shown in this graph are only positive, a non-diverging 2-colour scale or a colour palette such as 'viridis' would make the plot easier to interpret.

      (3.3) A black background should be avoided: 'B' and 'C' labels are invisible, and it draws attention to a distracting design feature rather than the data themselves.

      We thank the reviewer for these detailed comments regarding figure design and visual interpretation. We agree that the original presentation of Figure 2 introduced unnecessary visual ambiguity through inconsistent colour usage, the use of a diverging colour scale for strictly positive values, and poor readability associated with the dark background and low-resolution export.

      In response, Figure 2 has been extensively redesigned to improve clarity, accessibility, and interpretability. The previous blue–white–red diverging heatmap has been replaced with a sequential colour palette appropriate for positive-only expression data. Boxplot colouring has also been simplified and harmonised with the heatmap scheme to avoid implying unsupported categorical distinctions. In addition, panel organisation, typography, scaling, and legend structure have all been revised to improve readability and reduce ambiguity regarding interpretation of the plotted values.

      We also agree that the black background distracted from the data presentation and impaired visibility of panel labels and image boundaries. The revised figures therefore use white backgrounds together with clearer panel separation and improved label visibility throughout.

      Figure 2 has been completely reformatted using a sequential colour scale in panel A, simplified and harmonised boxplot colouring, larger typography, improved panel separation, revised legends, and white backgrounds throughout. Corrected high-resolution source figures have been provided.

      (4) Figure 3:

      (4.1) Individual snapshots should be separated more clearly, either by using a white background or by adding visible borders to make the overall composition clearer. As currently displayed, some boundaries between fluorescent channels resemble image artifacts rather than intentional panel divisions.

      We thank the reviewer for this helpful comment regarding figure composition and panel separation. We agree that the original presentation made it difficult to distinguish intentional panel boundaries from imaging artefacts, particularly in the low-resolution review PDF generated during manuscript compilation.

      To improve clarity, Figure 3 has been reformatted using white backgrounds, clearer panel spacing, and more explicit separation between individual snapshots and imaging channels. High-resolution source images have also been provided to ensure that fluorescence patterns, image boundaries, and panel organisation remain clearly interpretable both on screen and in print.

      Figure 3 has been reformatted with improved panel separation, white backgrounds, clearer image boundaries, and revised high-resolution source figures.

      (4.2) In parts B-D, the legend should explain more clearly what each image shows, and the figure itself would benefit from annotations. There seem to be three sub-panels in each 'condition' of part B (as well as C and D): while the middle and rightmost panel can be easily inferred to represent the fluorescent protein and bright-field image, what the leftmost panels represent is not specified. If DAPI was used to dye DNA, an explanation why mostly multiple labelled regions are visible should be provided.

      We thank the reviewer for these helpful suggestions regarding figure annotation and legend clarity. We agree that the original presentation did not sufficiently explain the composition of the imaging panels, particularly under the low-resolution conditions of the review PDF.

      To improve interpretability, the revised Figure 3 now includes clearer panel organisation, improved annotations, and expanded figure legends explicitly identifying the individual imaging channels and staining conditions shown in each subpanel. The leftmost panels in parts B–D are now more clearly identified in both the figure and legend, together with the corresponding fluorescence or staining conditions used in each experiment.

      As mentioned in the Methods sections we used Hoechst 33342 to visualise DNA; but we agree that the Hoechst 33342-labelled structures required additional clarification. The revised legend section now explains that multiple Hoechst 33342-positive regions are commonly observed because Blastocystis cells can contain multiple nuclei depending on cell stage and subtype-specific morphology.

      In addition, high-resolution source images have been provided to ensure that fluorescent signals, panel boundaries, and imaging features remain clearly interpretable both on screen and in print.

      Figure 3 legends and annotations have been revised to clarify imaging channels, staining conditions, and panel organisation. The figure caption was also edited to include: “DNA was visualised using Hoechst 33342. Most cells contained two nuclei, and smaller Hoechst 33342-positive signals consistent with mitochondrial DNA were also observed in some instances.”

      (4.3) Cell morphology and appearance differ markedly between UnaG/smURFP and SNAP-tag images, which should be explained. A microscope issue is mentioned in the main text, but if that was the cause, the authors should consider replacing the images, as the current distortions complicate interpretation.

      We thank the reviewer for this important observation and agree that the apparent morphological differences between the UnaG/smURFP and SNAP-tag panels required additional clarification.

      The images shown for the different reporter systems were acquired under different imaging conditions and microscope configurations following an instrument-related issue during part of the imaging workflow, as noted in the Methods section. As a result, direct visual comparison of cell morphology between reporter systems is not appropriate. The primary purpose of these panels is instead to demonstrate reporter detectability, live-cell labelling capability, and the characteristic fluorescence patterns obtained with the different anaerobiosis-compatible reporter systems.

      In particular, the SNAP-tag panels were included to demonstrate successful live-cell labelling without permeabilisation together with the expected increase in fluorescence signal at higher substrate concentrations, rather than to support quantitative comparison of cell morphology across imaging conditions.

      We considered replacing the affected images. However, equivalent replacement datasets acquired under directly comparable conditions are not currently available. We have therefore retained the original images but revised the figure legend to clarify the intended interpretation and limitations of these panels explicitly.

      Figure 3 legend revised to include:

      “Because images for the different reporter systems were acquired under different imaging conditions, they are presented to demonstrate reporter detectability and labelling pattern and should not be used for quantitative comparison of cell morphology across reporter systems.”

      Reviewer #3 (Recommendations for the authors):

      The reader may find the current order confusing starting with construct design before testing which drug to use for selection. The narrative would work better if it started with antibiotic selection as the first logical step for generating stable cell lines.

      We thank the reviewer for this thoughtful suggestion regarding narrative structure and agree that multiple organisational strategies are possible for presenting a methodological workflow of this type.

      We considered reorganising the Results section to begin with antibiotic selection and drug sensitivity profiling. However, we ultimately retained the overall structure because the manuscript is organised as a toolkit-development framework rather than as a strictly chronological experimental protocol. The Results therefore begin with regulatory-element discovery and construct design, which form the conceptual and experimental foundation of the toolkit, before progressing to DNA delivery optimisation, drug sensitivity profiling, clonal recovery, and reporter validation.

      We felt that this structure most clearly reflects the dependency relationships within the system: regulatory elements are required before constructs can be assembled, constructs are required before electroporation conditions can be evaluated, and selectable constructs are required before stable selection and clonal recovery can be meaningfully assessed.

      (2) The text states that the screen 'focused on the 1,000 most abundant proteins to establish a preliminary library capable of supporting varying levels of transcription.' Since the genome has ~6,000 protein-coding genes, the top 1,000 cover the most abundant proteins — not a wide expression range.

      We thank the reviewer for this important clarification. We agree that the original wording could incorrectly imply that the screen was intended to sample broadly across the full transcriptional range of the Blastocystis genome. This was not the case, and we have revised the manuscript accordingly.

      Our strategy was instead designed to enrich for candidate loci with a higher prior likelihood of supporting detectable transgene expression. Because no genome-wide promoter map, transcription start site dataset, or experimentally validated regulatory annotation was available for Blastocystis ST7-B at the inception of this work, we used the abundance-ranked Blastocystis ST4-WR1 proteomic dataset of Armengaud et al. (2017) as a practical starting point for candidate discovery.

      Importantly, the Blastocystis ST4-WR1 proteome is highly skewed, with 193 proteins contributing approximately 50% of the detected proteome and the 13 most abundant proteins contributing approximately 10% (Armengaud et al., 2017). We therefore selected the top 1,000 proteins not as a representation of the genome-wide expression range, but as a proteomics-guided enrichment strategy to identify loci more likely to contain active endogenous regulatory regions suitable for initial toolkit development.

      We have revised the relevant Methods section substantially to clarify both the rationale and the workflow used for candidate selection, homolog identification, and promoter/terminator definition.

      The Methods section (Lines 156–189) has been extensively revised to clarify the rationale underlying candidate regulatory-element selection. The revised text now explicitly states that the strategy was designed to enrich for likely active loci for toolkit development rather than to systematically survey the full range of promoter strengths across the Blastocystis genome.

      Additional methodological detail has also been added regarding:

      Use of the Armengaud et al. (2017) proteomic and proteogenomic datasets,

      Homolog identification in Blastocystis ST7-B,

      Locus selection criteria,

      Promoter boundary definition,

      And operational definition of candidate terminator regions.

      (3) The Methods contain an inconsistency: cells were left in 0.5 mL, then 1 mL was added, but then only 0.5 mL is apparently used for transfection. What happened to the 1 mL?

      We thank the reviewer for identifying this ambiguity in the transfection workflow description. The apparent inconsistency arose because the protocol description moved from bulk cell resuspension to preparation of individual electroporation reactions without explicitly stating how the intermediate suspension was used.

      After washing, approximately 0.5 mL of cytomix buffer remained above the pellet, and 1 mL of complete cytomix buffer was then added to generate an approximately 1.5 mL cell suspension. Cells were counted from this pooled suspension, after which the volume corresponding to 5 × 10<sup>7</sup> cells was transferred into each individual electroporation reaction. Following addition of DNA, each electroporation reaction was adjusted to a final volume of 500 µL with complete cytomix buffer. The remaining cell suspension was retained for additional transfections or control reactions.

      We agree that the original wording could be misinterpreted and have revised the Methods section to clarify the sequential handling steps more explicitly.

      Lines 225-229 revised to read: “The resulting approximately 1.5 mL pooled cell suspension was used for total viable cell counting using a hemacytometer.”

      “After counting, the volume corresponding to 5 x 10<sup>7</sup> cells was transferred to each electroporation reaction and combined with 25 µg of plasmid DNA. The total electroporation volume was adjusted to 500 µL with complete cytomix buffer.”

      (4) Figures 2 and 3 are too low-resolution for the font size used and for clearly viewing the microscopy images.

      We thank the reviewer for highlighting these readability issues. As noted in our responses above regarding Figures 2 and 3, the low-resolution appearance primarily resulted from manuscript compilation and PDF export artefacts affecting typography, image rendering, and panel clarity in the review version.

      To address this, Figures 2 and 3 have been completely reformatted and replaced with revised high-resolution versions featuring improved typography, panel labelling, contrast, accessibility, and image clarity for both on-screen viewing and print reproduction.

      Revised high-resolution versions of Figures 2 and 3 have been provided as described above. No additional manuscript changes were required beyond the figure revisions already outlined.

      (5) Figure 4 is confusing because the left and right panels appear inconsistent, with much higher concentrations required for growth inhibition in the culture-based assay than the resazurin assay indicated. The rationale for the resazurin assay should be explained, and the complete growth inhibition (CGI) concentration should be highlighted in the right panel.

      We thank the reviewer for highlighting this potential source of confusion. We agree that the distinction between the two assay endpoints was not sufficiently emphasised in the original figure presentation and legend.

      The apparent discrepancy arises because the two assays measure different biological endpoints under different assay conditions. The resazurin assay was used to estimate IC<sub>50</sub> values, corresponding to the concentration at which metabolic activity was reduced by approximately 50% under the assay conditions. In contrast, the small-culture assay was designed to determine complete growth inhibition (CGI), defined operationally as the concentration at which no detectable culture outgrowth occurred after incubation, using phenol red acidification as a culture-level readout.

      Because these assays measure partial metabolic inhibition versus complete suppression of detectable culture outgrowth, the corresponding concentration ranges are not expected to coincide directly. The higher concentrations observed in the right-hand panels therefore reflect the more stringent endpoint associated with complete growth inhibition rather than inconsistency between the assays.

      We agree that this distinction should have been explained more clearly in the original manuscript. We have therefore substantially revised the Figure 4 legend to clarify the rationale underlying both assays, explicitly distinguish IC<sub>50</sub> and CGI endpoints, and explain how the CGI values were used to guide subsequent antibiotic selection conditions for Blastocystis ST7-B transformants. The CGI transition range has also been made more visually explicit in the revised figure presentation.

      Figure 4 caption revised to: “Antibiotic potency and selection-window determination in Blastocystis ST7-B. Dose–response curves for puromycin, trimethoprim, and WR99210 were estimated from a resazurin-based viability assay (n = 3 independent replicates per drug per concentration). Points show mean ± SD, and the insets list the estimated IC50 values with R<sup>2</sup>-values > 0.75 for all fitted curves. The IC<sub>50</sub> estimates represent the drug concentrations that reduced resazurin-based metabolic activity by 50% under the assay conditions.”

      Right panels: “small-culture complete growth inhibition assay using 1 × 10<sup>7</sup> WT Blastocystis ST7-B cells per culture, assayed in triplicate across a wide range of concentrations. Cultures were incubated for 2 days, and outgrowth was assessed using phenol red acidification of the medium as a culture-level readout, with yellow indicating growth and red indicating no detectable growth. The yellow-to-red transition was used to estimate the concentration required for complete growth inhibition and to guide the subsequent antibiotic selection strategy for Blastocystis ST7-B transformants.”

      “IC<sub>50</sub> and CGI represent distinct assay endpoints: the former measures partial reduction in metabolic activity, whereas the latter identifies the concentration at which no detectable culture outgrowth occurs under the small-culture assay conditions.”

      (6) In Figure 3B, the unexpected UnaG fluorescence pattern could be due to protein sequestration because the protein is mildly toxic to the cell. This should be discussed in addition to the reasons already provided.

      We thank the reviewer for this thoughtful suggestion and agree that protein sequestration or reporter-associated cellular stress represent plausible alternative interpretations of the observed UnaG fluorescence pattern.

      We considered the possibility of UnaG-associated toxicity during interpretation of these data. However, under the conditions tested, we did not observe clear evidence of a substantial toxic effect: UnaG-expressing Blastocystis ST7-B cells could be recovered as stable lines, maintained under antibiotic selection, and propagated through continued culture. We therefore felt that direct attribution of the observed fluorescence pattern to reporter toxicity would currently remain speculative.

      At present, we consider the biochemical properties of the UnaG system itself to provide a more parsimonious explanation for the observed localisation pattern. In particular, unconjugated bilirubin is highly hydrophobic and would be expected to partition preferentially into lipid-rich cellular environments. This interpretation is consistent with the lipid-rich peripheral and intracellular structures previously reported in Blastocystis ST7-B (Liao et al., 2023).

      We have therefore revised the Discussion to acknowledge that the observed UnaG fluorescence pattern may reflect a combination of reporter-specific biochemical behaviour, bilirubin partitioning, local intracellular environment, or possible sequestration phenomena. At the same time, we avoid assigning toxicity as a demonstrated mechanism in the absence of direct measurements of cell fitness, reporter abundance, or bilirubin distribution. Such experiments would be required to evaluate this possibility rigorously.

      Lines 642-648: “Consistent with this, lipid-rich peripheral and intracellular structures have been reported in Blastocystis ST7-B, potentially providing favourable microenvironments for BR partitioning and contributing to the punctate UnaG fluorescence pattern (Liao et al., 2023). An alternative possibility is that the observed signal pattern reflects reporter sequestration or reporter-associated cellular stress. However, because UnaG-expressing lines were recovered, maintained under selection, and propagated through continued culture, toxicity remains a possible but untested explanation rather than a demonstrated mechanism.”

      Minor Comments

      Figure 2: Parts B and C should also show individual datapoints for better reader assessment.

      We agree that inclusion of individual data points improves transparency and interpretability of the underlying data distributions.

      Individual data points have now been overlaid on the boxplots in Figures 2B and 2C.

      Figure 3A: Separate channels (fluorescence, bright-field, merge) should be shown rather than only the merge. The current overlay is difficult to interpret, especially for colour-blind readers.

      We appreciate the reviewer’s concern regarding accessibility and interpretability. We considered separating the fluorescence, bright-field, and merged channels for Figure 3A. However, this panel was intended primarily as an overview demonstrating reporter detectability within the bicistronic construct context, while the detailed fluorescence distribution is explored more extensively in the subsequent UnaG panels. We therefore retained the merged presentation for Figure 3A. Importantly, the image is not dependent on red–green discrimination, as it combines a greyscale bright-field background with a high-contrast green/cyan fluorescence signal that remains distinguishable through brightness and contrast differences. In addition, colour-blind-friendly lookup tables (LUTs) were used throughout the revised figure set.

      To further improve accessibility, the original red annotation arrow has been replaced with a colour-blind-friendly annotation colour.

      Briefly define system components (P2A, UnaG, smURFP, SNAP-tag) and add an abbreviation list.

      We agree that brief contextual definitions improve accessibility for readers less familiar with these reporter systems. Rather than adding a separate abbreviation list, we have added short explanatory descriptions at the points where these components are first introduced in the manuscript.

      Lines 394–396: “The P2A peptide is expected to promote ribosomal skipping during translation, allowing two separate polypeptides to be produced from a single open reading frame.” Line 515–516: “UnaG, a bilirubin-binding fluorescent protein originally isolated from the muscle of the Japanese eel (Kumagai et al., 2013)…” Line 527: “smURFP (small ultra-red fluorescent protein)…”

      Abstract: “among the most prevalent microbial eukaryote” should be “eukaryotes”.

      Corrected in revised manuscript.

      Conclusion (2nd sentence): unclear what “endogenous regulatory part discovery” means.

      We agree that this phrase required clarification. The intended meaning was the identification and benchmarking of native Blastocystis ST7-B promoter and terminator elements for construct design and toolkit development. We have clarified this directly in the revised Conclusion section.

      Lines 682–683 revised to: “By bringing endogenous regulatory part discovery, namely the identification of native promoter and terminator elements, …”

      Author contributions: “critical advise” should be “advice”.

      Corrected in revised manuscript.

      Again, we thank the reviewers for their careful evaluation, constructive criticism, and thoughtful feedback on the manuscript. The review process has substantially strengthened the manuscript by helping us clarify the distinction between what is directly demonstrated experimentally and what remains mechanistically unresolved.

      The central methodological conclusions of the study remain unchanged: the toolkit enables selectable transgene expression, recovery of colony-derived lines, and propagation of reporter-positive transgenic Blastocystis ST7-B lines, extending genetic accessibility in this organism substantially beyond the previous transient transfection framework.

      At the same time, the revised manuscript now more explicitly acknowledges important unresolved mechanistic questions, including vector topology, P2A-mediated protein separation efficiency, and persistence in the absence of selection. These are now discussed transparently together with the future experimental approaches that will be required to address them directly.

      We believe the revised manuscript now presents a clearer, more rigorous, and more accessible description of a practical genetic toolkit for Blastocystis ST7-B and hope that the revisions and clarifications satisfactorily address the reviewers’ concerns.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      1. __ General Statements__ We thank the reviewers for their thoughtful and constructive evaluations of our work. We are particularly encouraged that both recognize the value of this study as a scalable and systematic framework for the functional exploration of the human KZFP family and agree that the resource generated here will be of broad interest to the KZFP, transposable element, and genome regulation communities. Reviewer 1 explicitly notes that "the screening framework itself represents a potentially useful resource for prioritizing candidate KZFPs for downstream study" and that "the study may nonetheless serve as a useful starting point for future investigations into KZFP biology and transcriptional regulation." Reviewer 2 similarly emphasizes that "the authors provide an efficient and valuable screening platform that can identify promising candidates for further investigation" and that "the methodological advance represents the primary contribution of the work."

      We can only concur with these assessments. The principal goal of this study was not to elucidate the physiological roles of all or even a subset of individual KZFPs, but rather to provide a scalable framework that enables their systematic prioritization and generates experimentally testable hypotheses regarding their functions. To support our argument, we ventured into some mechanistic analyses, but these could not pretend to be complete and definitive. In that respect, we hear the reviewers when they note that the original manuscript does not always sufficiently distinguish candidate discovery from mechanistic validation. In its revised version, we will therefore more clearly frame the inducible K562 overexpression assay as a standardized and sensitive readout of regulatory potency rather than as a direct surrogate of physiological function. Within this framework, K562 fitness defects are interpreted as a quantitative measure of the extent to which ectopic KZFP expression perturbs transcriptional homeostasis in a controlled cellular context, while the direct targets and transcriptional networks identified through our integrative analyses are presented as hypotheses to be tested in more physiologically relevant systems. Accordingly, the revised manuscript preserves the broad scope and resource aspect of the study while incorporating additional experimental validation, expanded methodological descriptions, and a more cautious interpretation of the proposed biological functions of the selected KZFPs.

      __Although this document is submitted as a Revision Plan, we have already incorporated a substantial number of revisions into the transferred manuscript. In particular, we have implemented most of the presentation, methodological, and conceptual modifications requested by the reviewers, including clarification of the scope of the study, extensive revisions of the Results and Discussion, expanded Materials and Methods, and numerous figure and text corrections. These revisions are detailed in Section 3 ("Description of the revisions that have already been incorporated into the transferred manuscript"). __

      The remaining points requiring additional experimentation or more extensive analyses are described in Section 2 ("Description of the planned revisions").

      __ Description of the planned revisions__

      Reviewer 1 Major comment 1

      “Finally, several aspects of the data presentation are currently difficult to reconcile. In Fig. 1D, the meaning of the purple category is unclear, and the percentage scaling on the x-axis is difficult to reconcile with the cumulative values displayed. For instance, the sum of all the bars would not reach 100%, as the values of the bars span percentages up to 4% at most (for 105 MYO KZFPs) according to this plot. Similarly, the reported numbers of TE-binding KZFPs in Fig. 1E-F and Fig. S1D appear internally inconsistent and should be clarified. Specifically, 53+14=67 KZFPs are reported to bind TEs in total, yet a larger number of KZFPs appears associated with individual TE families (e.g., 86 for LTR.ERV1). If the values shown correspond to percentages rather than absolute counts, this should be explicitly clarified in both the figure and legend. In addition, Fig. S1D appears inconsistent with the counts reported in Fig. 1E-F, as only 5 out of the 53 toxic KZFPs displayed in the plot show no enrichment for any of the highlighted TE families.”

      We thank the reviewer for this insightful comment, which has helped us identify areas where the presentation of our data can be substantially improved. We agree that the current presentation of the TE-binding analyses could be clearer and that revising these figures will improve both their readability and the overall consistency of the manuscript. In the revised manuscript, we will clarify the apparent inconsistencies in the presentation of the TE-binding KZFP analyses and revise the corresponding figures and legends accordingly. Importantly, these inconsistencies do not arise from errors in the underlying data but rather from an insufficient explanation of the statistical enrichment analyses and the way the results are represented. We will therefore redesign the relevant figures and expand their legends to more clearly describe the analytical approach, the enrichment criteria, and the interpretation of the results. We believe that these revisions will improve the clarity, transparency, and internal consistency of the manuscript, allowing readers to more readily interpret the TE-binding analyses. Minor comments of the reviewer 1 were extremely useful to detect mistakes and we are grateful for that. All the modifications that were asked see below were included in the manuscript.

      Reviewer 1 Major comment 2

      “Finally, while the proteomics results aimed at identifying SCAN-dependent interactors are of interest, several aspects of the experimental design and data analysis remain unclear. In particular, it is not specified whether the experiment was performed in biological replicates or as a single measurement. This is important, as it directly affects how the data can be interpreted and how stringent downstream filtering can be. In the Results section, the authors state that "we identified a set of SCAN-dependent interactors, i.e., proteins that co-immunoprecipitated with the full-length construct but were absent in controls and lost upon deletion of the SCAN domain," which suggests a relatively binary, "presence/absence" filtering strategy. However, this description does not specify whether any quantitative threshold (e.g., enrichment ratio) was applied when comparing full-length constructs to deletion mutants. In contrast, the Methods section states that "proteins lacking signal above background were excluded and proteins were additionally required to show stronger signal in at least one bait condition than in GFP controls based on heatmap clustering (see script)," which instead suggests that a threshold-based criterion was used to define enrichment relative to controls and deletion mutants. If this is the case, the exact criteria and thresholds used for filtering should be clearly stated and consistently reported between the Results and Methods sections. If replicate measurements were not performed, this should be explicitly acknowledged, as peptide-level variability may substantially influence the identification of high-confidence interactors, particularly if the applied cutoffs are not highly stringent.”

      We agree that a more detailed description of the experimental design and analysis strategy, together with additional validation, will strengthen the interpretation of the proteomic data. In the revised manuscript, we expanded the Results and Materials and Methods sections to provide a clearer and more quantitative description of the filtering strategy, including the enrichment criteria and thresholds used to define SCAN-dependent interactors. To further strengthen these findings, we propose to perform an independent biological replicate of the co-immunoprecipitation mass spectrometry experiment. This additional experiment will increase confidence in the identified SCAN-dependent interactors and further support the conclusions drawn from the proteomic analysis.

      Reviewer 1 Minor comments

      • In Fig. 2A, readability could be improved by adjusting the layering of points, as the darker dots (in particular the red ones) are currently obscured by lighter ones. Alternatively, removing the outline of the points (which is not transparent) may also improve visibility, but in that case the legend for point size would need to be updated accordingly.

      Thank you for this helpful suggestion. We will revise Figure 2A to improve its readability by reworking the layering of the points in accordance with the reviewer's recommendation. We will also evaluate the point outlines and, if appropriate, remove them and update the point-size legend accordingly to ensure the figure is clear and easy to interpret.

      Reviewer 2 – Major comment

      “- The authors looked at available chromatin data in either K562 cells or HEK293 cells, which I think is a very good way of utilizing publicly available data. Since the authors showed that different KZFPs might be functionally relevant in different cell types/tissues, I was wondering if they checked if there is available ChIP Seq or CUT&RUN data in those specific cell types/tissues. If yes, that data should be included in the manuscript.”

      We agree that integrating KZFP binding data generated in biologically relevant cell types or tissues would further strengthen the proposed regulatory models. As described in the revised manuscript, we have already adopted this approach for ZNF43 by integrating chromatin landscape data from thymus and liver, where suitable datasets were available.

      To further address this point, we propose to systematically explore publicly available ChIP-seq, CUT&RUN, CUT&Tag, and related chromatin profiling datasets for the other KZFPs investigated in this study. Where suitable datasets are available, these analyses will be incorporated into the revised manuscript to further support the proposed tissue-specific regulatory models and provide additional biological context for the identified target genes.

      __ Description of the revisions that have already been incorporated in the transferred manuscript__

      Reviewer 1 Major comment 1

      “The large-scale overexpression screen represents the foundation of the manuscript and provides a potentially valuable resource for prioritizing candidate KZFPs for downstream study. However, several aspects of the experimental setup and data presentation currently limit the interpretation of the reported proliferation defects. First, key details regarding the screening workflow remain unclear. While the Methods section describes the overall procedure, it is difficult to determine when cells were seeded relative to doxycycline induction, in which plate format the cells were maintained throughout the experiment, and whether medium exchange was performed during the 9-day assay. These points are particularly relevant given the use of suspension K562 cells (which can complicate medium exchange in a 96-well plate format and make long-term culture more difficult to control) and a metabolic viability readout (PrestoBlue), as differences in nutrient depletion or overgrowth could also influence the signal independently of reduced proliferation or toxicity. Additional clarification regarding seeding density, timing of induction, plate format, culture handling throughout the assay, and whether cell morphology/density was visually monitored would substantially improve interpretability and reproducibility. Second, it is unclear whether the observed proliferation phenotypes may be influenced by differences in transgene expression levels or integration effects. Were all constructs validated for comparable expression following induction? In the absence of such controls, it remains difficult to determine whether the reported phenotypes reflect specific KZFP activities or differences in overexpression efficiency. While it may not be possible to conclusively distinguish KZFP-specific effects from toxicity associated with high transgene expression levels, this limitation should at least be acknowledged. In addition, the possibility that some phenotypes may be influenced by transgene integration effects should also be considered. Unless independent transductions were validated for the KZFPs classified as toxic, it remains difficult to exclude integration-site-specific contributions to the observed proliferation defects. Third, the normalization strategy would benefit from additional clarification. In Fig. S1A, the LacZ control appears variably affected by doxycycline treatment across plates, whereas the GFP control appears more stable. Since normalization relies on the mean behavior of both controls within each batch and condition, the authors should clarify whether this variability could influence hit calling.”

      We agree that additional methodological details improve the clarity and reproducibility of the screening assay. Accordingly, we substantially expanded the Materials and Methods section to describe the experimental workflow, quality controls, data normalization, and hit-calling criteria. The revised paragraph is reproduced below.

      Arrayed overexpression screen

      To systematically assess the effect of human KZFP overexpression on cellular fitness, K562 cells were individually transduced with doxycycline-inducible lentiviral vectors encoding 366 human KZFPs. Lentiviral particles were produced as described above and used to transduce cells without MOI calculation. __Instead, a fixed volume of viral supernatant (200µL per × 104 cells in 48 well plate filled with 200ul of RPMI) was used for all transductions to ensure comparable experimental conditions. Transduced cells were selected with puromycin before doxycycline induction. Following puromycin selection (1µg/mL for 3 days), cells were seeded at 20 000 cells per well in 24-well plates filled with 1ml of medium in technical triplicate for each KZFP. Following puromycin selection and prior to doxycycline induction, cell survival was visually assessed as a quality control metric for each KZFP construct (Supp __Table 2____). Doxycycline (1µg/mL) was added immediately after cell seeding to induce expression of the HA-tagged KZFPs. At each time point, metabolic activity was measured using PrestoBlue™ reagent according to the manufacturer's instructions (10µL reagent added to 100µL culture medium, incubated for 3h in a 96 plates). Absorbance was recorded at 570 nm and 600 nm using a plate reader (Hidex Sense Microplate Reader), GFP- and LacZ-expressing control wells were included on every plate to account for plate-to-plate and batch-to-batch variability. Peripheral wells were filled with culture medium to minimize evaporation-induced edge effects. Cells were maintained in RPMI supplemented with 10% fetal bovine serum (FBS) and 1× penicillin–streptomycin, and splited (1/10) with aspiration of the surface medium every three days throughout the assay while maintaining doxycycline at 1µg/mL. Cell proliferation was assessed after 4, 7, and 9 days of induction. and the A570/A600 ratio was used as a surrogate measure of viable cell number and proliferative capacity. For computational normalization, raw A570/A600 values were first background-corrected by subtracting the signal from medium-only controls and then normalized in two steps. First, each value was divided by the mean signal obtained from the GFP and LacZ control wells from the corresponding batch and induction condition to correct for inter-batch variability. Second, the resulting value was normalized to the corresponding −Dox condition for the same KZFP and time point to correct for seeding variability, yielding a relative proliferation score that reflects the effect of KZFP induction. KZFPs with a normalized proliferation score ≤ 0.85 at day 9 were arbitrarily classified as proliferation-impairing hits in this screening framework.

      After doxycycline induction, dot blot analysis using anti-HA and anti-actin antibodies was systematically performed to assess KZFP expression and sample loading, respectively (Supplementary DotBlot.pdf). The HA signal following doxycycline induction (HA_Dox) and actin signal following doxycycline induction (Actin_Dox) were visually scored from the dot blot signals (__Supp __Table 2).

      In addition, to strengthen the methodological description and address these concerns more directly, we will:

      1/ Include a supplementary table summarizing our experimental observations for each individual KZFP throughout the screening process (See preliminary Supp Table 2). -> See header here:

      2/ Perform and include Dot Blot analyses, to assess and compare transgene expression levels across KZFP constructs. (Supplementary File DotBlot.pdf____). Generation of these files is in progress, with a few missing dot blots still being completed (we have done 303 over 366 already). However, preliminary versions have already been submitted. -> See header of the .pdf here:

      In addition, we agree that a more explicit discussion of the limitations of our screening approach improves the interpretation of our findings. Accordingly, we expanded the Discussion to address the limitations associated with variable transgene integration, heterogeneous transgene expression, potential toxicity due to ectopic KZFP overexpression, and the use of K562 cells as a standardized rather than physiological cellular model.

      “Several methodological considerations should be taken into account when interpreting these results. As with any lentiviral overexpression screen, three potential sources of technical variability may influence the observed phenotypes: differences in transgene integration sites, heterogeneity in transgene expression levels, and non-specific toxicity resulting from ectopic overexpression. Variable integration sites are unlikely to represent a major source of bias in the present study because all analyses were performed on polyclonal populations of transduced cells rather than individual clones, thereby averaging integration-site effects across many independent events. In contrast, heterogeneity in transgene expression levels is expected, as the abundance of each KZFP depends not only on transduction efficiency but also on intrinsic differences in mRNA stability, translational efficiency, and protein stability. To minimize these sources of variability, all constructs underwent systematic quality control, including assessment of cell survival following puromycin selection and evaluation of transgene expression by HA dot blot after doxycycline induction. Although transgene expression levels varied across KZFPs (Supplementary File DotBlot.pdf), this variability showed no systematic relationship with the proliferation phenotypes, suggesting that differences in overexpression efficiency are unlikely to be the primary determinant of toxicity. Nevertheless, ectopic expression exposes cells to supraphysiological concentrations of KZFPs capable of generating non-physiological interactions or regulatory effects. Therefore, while the screening strategy is well suited for identifying candidate functional regulators, independent validation under endogenous expression conditions remains essential to confirm KZFP-specific functions.”

      Reviewer 1 Major comment 2:

      “A central conceptual issue throughout the manuscript is that the downstream functional analyses of the selected KZFPs remain largely disconnected from the original screening phenotype. The four candidates were prioritized based on proliferation defects observed upon overexpression in K562 cells; however, the subsequent analyses (with the only exception being a more in-depth experimental analysis of ZNF498 in ciliogenesis, which stands out as comparatively more directly supported by experimental evidence) primarily rely on correlative expression patterns and KZFP ChIP-seq datasets to infer potential biological functions in unrelated cellular contexts. As a result, it remains unclear whether the proposed transcriptional programs are mechanistically linked to the proliferation phenotypes that motivated candidate selection in the first place. This issue is evident across multiple sections of the manuscript. For example, the proposed role of ZNF43 in regulating fatty acid metabolism and detoxification pathways is primarily inferred from tissue-level expression correlations. While these analyses focus on genes identified as potential ZNF43 targets, the underlying ChIP-seq datasets were themselves generated under ZNF43 overexpression conditions. Therefore, the current analyses do not establish whether ZNF43 regulates these pathways under physiological expression levels or within a relevant cellular context, nor how such regulation relates to the proliferation defect observed in K562 cells. Moreover, several proposed target genes remain substantially expressed in tissues where ZNF43 expression is not particularly low (e.g., kidney and heart muscle), suggesting that additional regulators are likely involved. Similarly, the proposed model of ZNF257-mediated regulation of MAGEA genes during spermatogenesis is intriguing but does not fully account for the expression behavior of all MAGEA family members, particularly MAGEA2B, which displays strong expression in spermatocytes despite high ZNF257 expression. This expression pattern should be acknowledged in the main text and reflected in Fig. 3K. In addition, the labels for MAGEA6 and MAGEA2B in Fig. 3C appear to be inverted. More broadly, the proposed regulatory model is difficult to reconcile with the generally restricted expression pattern of MAGEA genes across adult tissues, as their expression does not appear to consistently correlate with ZNF257 levels outside the germline context. Related concerns also apply to the analyses of ZNF498 and ZNF18, where the proposed functions in cilium formation and sperm maturation remain disconnected from the proliferation defects identified in the initial screen.”

      We agree that this comment raises an important conceptual point and has helped us clarify the scope of the study and the interpretation of our findings. In the revised manuscript, we explicitly distinguish hypothesis generation from mechanistic validation by clarifying that the proliferation phenotype observed in K562 cells reflects the regulatory potential of ectopically expressed KZFPs rather than their physiological functions. We also adopted a more cautious interpretation of the functional analyses, emphasizing that the proposed regulatory networks are hypothesis-generating and that individual KZFPs are unlikely to act as sole regulators. More broadly, we emphasize that the primary objective of this study is to establish a scalable screening platform for prioritizing KZFPs and identifying biologically relevant contexts for future investigation, rather than to provide a comprehensive functional characterization of individual KZFPs. We agree that this comment highlights an important limitation of our proposed regulatory model. In the revised manuscript, we adopted a more nuanced interpretation by presenting ZNF257 as a contributor to, rather than the sole regulator of, the MAGEA transcriptional program, and by explicitly discussing the exceptions identified by the reviewer.

      Modification in the revised manuscript:

      1/

      “Integrative transcriptomic, chromatin and proteomic analyses reveal diverse mechanisms, including transposable element–linked repression (ZNF43), promoter-proximal regulation (ZNF257), and SCAN domain–dependent transcriptional activation (ZNF498/ZSCAN25 and ZNF18).”

      Is now:

      “Integrative transcriptomic, chromatin and proteomic analyses identify distinct regulatory properties and generate testable hypotheses regarding diverse mechanisms, including transposable element-associated repression (ZNF43), promoter-proximal regulation (ZNF257), and SCAN domain-dependent transcriptional activation (ZNF498/ZSCAN25 and ZNF18).”

      2/

      “Detailed follow-up of four such candidates, ZNF43, ZNF257, ZNF498 and ZNF18, revealed as hypothesized distinct modes of action, ranging from TE-linked transcriptional repression to promoter-proximal gene silencing and SCAN domain-mediated transcriptional activation. These findings reinforce the view that KZFPs, while often viewed as a homogeneous family of TE-repressive TFs, are rather functionally diverse regulators with wide-ranging impacts on human biology.”

      Is now:

      “Detailed follow-up of four such candidates, ZNF43, ZNF257, ZNF498 and ZNF18, identified distinct regulatory properties and generated hypotheses regarding their physiological functions. By integrating overexpression-induced transcriptional responses, chromatin occupancy, proteomic analyses and tissue-specific expression data, we propose candidate biological contexts in which these KZFPs may operate. These hypotheses now provide a framework for future mechanistic studies performed under physiological conditions. Together, these findings reinforce the view that KZFPs, while often viewed as a homogeneous family of TE-repressive transcription factors, comprise functionally diverse regulators with broad potential roles in human biology.”

      3/

      “We conclude from these data that ZNF43 regulates a transcriptional program related to fatty acid metabolism and detoxification, allowing for the preferential expression of its effectors in the liver (Fig. 2G). Interestingly, neither expression nor chromatin state followed the same pattern at the functionally unrelated DNAI4 locus, indicating that this gene is subjected to other dominant regulators.”

      Is now:

      “Together, these observations identify a small set of candidates ZNF43 target genes involved in fatty acid metabolism and detoxification and suggest that ZNF43 may contribute to the regulation of these transcriptional programmes in appropriate physiological contexts (Fig. 2G). However, these conclusions are derived from overexpression-based datasets and tissue-level expression analyses and should therefore be considered hypothesis-generating. Interestingly, neither expression nor chromatin state followed the same pattern at the functionally unrelated DNAI4 locus, indicating that additional regulatory mechanisms contribute to the control of these genes.”

      4/

      “It strongly suggests that ZNF257 contributes to initiating the transcriptional repression of these two MAGEA genes during early spermiogenesis, after which their silencing may be stabilized through stable epigenetic mechanisms such as DNA methylation.”

      Is now:

      “These observations suggest that ZNF257 may contribute to the initiation of transcriptional repression of a subset of MAGEA genes during the spermatogonia-to-spermatocyte transition, after which their silencing may be stabilized through epigenetic mechanisms such as DNA methylation.”

      5/

      “Together, these results identify ZNF498 as a transcriptional activator of gene modules controlling cytoskeleton-dependent processes and suggest that this TF may act as a regulator of neuronal cytoskeletal architecture, warranting investigation in relevant neural models.”

      Is now:

      “Together, these results indicate that ZNF498 functions as a transcriptional activator in our overexpression system and support the hypothesis that it contributes to transcriptional programmes controlling cytoskeleton-dependent processes in physiologically relevant neural contexts, warranting further investigation in dedicated neural models.”

      6/

      “The co-expression of ZNF18 and its target genes at the spermatid stage suggests that ZNF18 activates a transcriptional program supporting these processes.”

      Is now:

      “The co-expression of ZNF18 and its candidate target genes at the spermatid stage is consistent with the hypothesis that ZNF18 contributes to transcriptional programmes supporting these processes.”

      7/

      “The four KZFPs characterised here illustrate this diversity. ZNF43 represses a coherent set of genes involved in fatty acid metabolism and detoxification through binding to nearby LTR/ERV1 integrants, with its expression anticorrelating that of its targets: i.e., highly expressed in thymus and bone marrow, where these metabolic genes are silent, and lowly expressed in liver, where they are most active. This represents a clear example of host genomes coopting TE-derived sequences and shaping their regulatory activities in a cell-type specific manner by the differential expression of KZFPs. ZNF257, by contrast, acts as a promoter-proximal repressor whose targets show accelerated sequence evolution at their promoters, consistent with integration into a KZFP-orchestrated GRN through rapid promoter diversification, a feature previously described for KZFPs (Farmiloe et al., 2023). Its regulation of the MAGEA gene cluster exemplifies a distinct evolutionary mechanism: an ancestral intronic binding site, present in MAGEA6 gene body, before ZNF257 emerged, was propagated across the cluster through tandem duplication, enabling coordinated regulation of multiple paralogs. Temporal expression analysis during spermatogenesis further suggests that ZNF257 initiates MAGEA repression at the spermatogonia-to-spermatocyte transition, after which silencing may be maintained through epigenetic mechanisms such as DNA methylation. ZNF498 and ZNF18, both SCAN-containing KZFPs with variant KRAB domains, on the other hand acted as transcriptional activators. ZNF498 activates a programme centred on microtubule cytoskeleton organisation, as demonstrated by the disruption of ciliogenesis upon its overexpression, and both ZNF498 and its targets are broadly expressed in the central nervous system, particularly in excitatory neurons where microtubule dynamics are essential for axonal architecture. ZNF18 similarly activates genes involved in chromatin remodelling and cytoskeletal reorganisation at the spermatid stage, processes that are hallmarks of spermiogenesis. Together, these case studies demonstrate that even within a single screen, KZFPs with fundamentally different regulatory logics can be identified through a single unifying phenotype and then mechanistically dissected to uncover their unique properties.”

      Is now:

      “The four KZFPs characterized here illustrate the functional diversity that can be uncovered using this screening strategy. For ZNF43, integration of overexpression transcriptomics with ChIP-exo binding data identified a small set of candidate direct target genes located near LTR/ERV1 elements. Their tissue-specific expression patterns are consistent with the hypothesis that ZNF43 contributes to transcriptional programmes associated with fatty acid metabolism and detoxification, although these analyses, which rely on overexpression-derived datasets and tissue-wide correlations, do not establish physiological regulation or causality. Rather, they identify a candidate regulatory network whose functional relevance will require investigation in appropriate biological models. More generally, these observations support the concept that host genomes may exploit TE-derived regulatory sequences in a tissue-specific manner through differential KZFP expression, while recognizing that additional transcription factors almost certainly participate in controlling these gene expression programmes. Similarly, ZNF257 emerged as a promoter-associated transcriptional repressor in our overexpression system. Evolutionary analyses suggest that tandem duplication propagated an ancestral ZNF257-binding sequence across the MAGEA locus, generating the hypothesis that ZNF257 may contribute to coordinated regulation of this gene cluster during spermatogenesis. The temporal expression profiles of ZNF257 and the MAGEA genes are compatible with such a model but remain correlative and therefore require direct functional validation. ZNF498 and ZNF18, two SCAN-containing KZFPs with variant KRAB domains, displayed transcriptional activation rather than repression following overexpression. For ZNF498, the integration of transcriptomic analyses with expression profiling pointed to microtubule cytoskeleton organization as a candidate biological process, a prediction that was further supported experimentally by the marked impairment of ciliogenesis following ZNF498 overexpression in hTERT-RPE1 cells. This represents the strongest functional validation presented in this study and supports the biological relevance of the analytical framework developed here. For ZNF18, the co-expression of the KZFP and its candidate target genes during spermatogenesis is consistent with the hypothesis that it contributes to transcriptional programmes involved in chromatin remodelling and cytoskeletal reorganization during spermatid differentiation. Together, these case studies illustrate how a standardized overexpression screen can identify KZFPs with distinct regulatory properties and generate biologically coherent hypotheses regarding their physiological functions. Rather than establishing definitive functions for individual KZFPs, this framework prioritizes candidates, proposes relevant cellular contexts, and provides a foundation for future mechanistic studies performed under physiological conditions.”

      “In addition, interpretation of the SCAN-deletion experiments is complicated by the reduced expression levels of the deletion constructs relative to the corresponding full-length proteins, making it difficult to determine whether the observed proliferation phenotypes are pathway-specific or partially driven by differential expression.”

      We thank the reviewer for this important observation and agree that differences in expression levels between the full-length and ΔSCAN constructs could complicate the interpretation of the observed phenotypes. To address this concern, we performed a quantitative comparison of the expression levels of full-length and ΔSCAN proteins using both western blotting and transgene expression using RNAseq, while accounting for differences in transgene length. This result are now added in (Fig S6C, D).

      With modification of the legend:

      • HA signal after OE of HA-tagged ZNF18, ZNF18∆SCAN, ZNF498, ZNF498∆SCAN or GFP in K562 cells. Actin as control.
      • Quantification of ZNF18, ZNF18∆SCAN, ZNF498, ZNF498∆SCAN It appears that the difference is small (Minor comments of the reviewer 1

      “- In the Abstract and in the "Limitations of the study" section, the term "annotation" is used. It would be preferable to specify "functional characterization" instead of "annotation".

      Done as suggested by the reviewer.

      • In the Introduction, there may be a minor citation confusion. Following the sentence: "Characterized by an N-terminal KRAB domain and a C-terminal tandem array of C2H2 zinc fingers, KZFPs primarily target transposable element (TE)-embedded sequences," the cited references are predominantly experimental studies supporting this statement. However, the inclusion of the review "Bruno, Mahgoub and Macfarlan, 2019" appears less appropriate in this context, as it does not directly present ChIP-seq data supporting this claim. More relevant primary studies from the same research area include "Wolf et al. 2020" and "Bruno et al. 2025.".

      Done as suggested by the reviewer.

      • In Fig. 1A, "D10" appears inconsistent with the text and other figures (Fig. 1B, 1G, 1H), which refer to 9 days post-induction.

      Done as suggested by the reviewer.

      • In Fig. S1, there may be a mismatch in the highlighted plate: the zoomed image appears to correspond to the first plate from the top. The correct plate should be highlighted for consistency.

      Done as suggested by the reviewer.

      • In Fig. 1B, there is a typographical error ("K ZFPs" instead of "KZFPs").

      Done as suggested by the reviewer.

      • In Fig. S1E, it is unclear what "other" refers to. Please clarify whether this represents the mean of all remaining KZFPs or a defined subset, ideally in the figure description.

      Done as suggested by the reviewer.

      • In Fig. S2E, "SetDB1" should be corrected to "SETDB1".

      Done as suggested by the reviewer.

      • In Fig. 3B, it is unclear what distinguishes the upper and lower "Diverse REs". A brief clarification in the figure legend would improve interpretability, particularly regarding the transposable element families included.

      Done as suggested by the reviewer.

      • In Fig. S3C, the x-axis labels appear slightly misaligned and shifted to the right.

      Done as suggested by the reviewer.

      • In Fig. 3C, the labels for MAGEA6 and MAGEA2B appear to be inverted.

      Done as suggested by the reviewer.

      • In Fig. 3K, "MAGE3" should be corrected to "MAGEA3".

      Done as suggested by the reviewer.

      • In the ZNF498 section, line 4, the punctuation should be corrected so that the period appears after the figure reference ("promoters (Fig. S1E).").

      Done as suggested by the reviewer.

      • In the final sentence of the ZNF498 section, a noun appears to be missing after "cytoskeleton-dependent," possibly "processes".

      Done as suggested by the reviewer.

      • In the last section of the Results and corresponding figures and their descriptions, "SCAN dependant" should be corrected to "SCAN-dependent".”

      Done as suggested by the reviewer.

      Major comments of the reviewer 2

      “- The authors chose four KZFPs to study in detail, but why they chose these 4 candidates is unlcear to me. It would be nice to add a more detailed description of the process by which they chose the four candidates.”

      We agree that the rationale for selecting the four KZFPs should be presented more explicitly. Accordingly, we revised the manuscript to clarify the selection criteria.

      “However, a modest correlation was noted between the number of transcription start sites (TSS) bound by KZFPs and the drop in PrestoBlue signal induced by their overexpression (Fig. 1G), and SCAN-containing KZFPs (SKZFPs) tended to induce proliferation defects more frequently than family members lacking this domain (Fig. 1H).”

      Is now:

      “However, a modest correlation was noted between the number of transcription start sites (TSS) bound by KZFPs and the drop in PrestoBlue signal induced by their overexpression (Fig. 1G), and SCAN-containing KZFPs (SKZFPs) tended to induce proliferation defects more frequently than family members lacking this domain (Fig. 1H). These observations indicated that KZFPs affecting proliferation do not constitute a homogeneous functional group, prompting us to select representative candidates spanning the evolutionary, structural, and genomic diversity of the KZFP family for mechanistic characterization.____”

      “- The materials and methods part of the manuscript is not detailed enough for other researchers to reproduce the study. They should add more details to both experiments and data analysis part of this section. Below I highlight some examples for sake of clarity, but the authors should revise the whole materials and methods section and add more details keeping these examples in mind:

      • The authors do not state the titer of lentiviral vectors they generate nor the MOI or amount of virus they use to transduce the cells

      • In many cases, the specific softwares and the software version is not stated e.g., the analysis of the Gene Ontology Biological Processes

      • It would be beneficial for the readers to get more details about the construct they used, for example a map of the plasmid.

      • It is unclear how many cells were used for RNA extraction

      • It is unclear which microscopes were used for imaging.

      • The concentration of antibodies used for staining and the product number, and provider of the antibody is not always depicted.”

      We agree that the additional methodological details requested by the reviewer will improve the reproducibility and transparency of the study. Accordingly, we have expanded the Methods section to provide a more detailed description of the experimental procedures and data analysis workflow.

      “Lentiviral particles were produced in HEK293T cells by transient co-transfection of transfer, packaging and envelope plasmids. Cells were transfected at approximately 70–80% confluence using a standard lipid-based transfection reagent. Viral supernatants were collected 48 h after transfection, cleared by centrifugation, filtered through 0.22-µm membranes, and used fresh or stored appropriately until use. Recipient K562 or hTERT-RPE1 cells were transduced under conditions optimized for efficient gene delivery.”

      Is now:

      “Lentiviral particles were produced in HEK293T cells. 105 cells were seeded in 24 well plates filled with 1ml DMEM the day before transfection. Cells were co-transfected individually with 0.15ug of each plasmids encoding KZFPs tagged with HA (pTRE-KZFPX-HA-PGK-puro), 0.1ug of the packaging plasmid (pR8.74) and 0.07ug of the envelope plasmid (pMD2G) using TransIT®-LT1 Transfection Reagent (MIR 2306), according to the manufacturer's instructions. Viral supernatants were harvested 24h after transfection, clarified by centrifugation, filtered through 0.45-µm filters and used immediately.”

      “Coding sequences were cloned into doxycycline-inducible lentiviral transfer vectors designed to express N-terminally HA-tagged proteins.”

      Is now:

      “Coding sequences corresponding to 366 human KZFP open reading frames were codon-optimized for human expression and cloned into doxycycline-inducible lentiviral transfer vectors expressing C-terminal HA-tagged proteins under the control of a tetracycline-responsive promoter pTRE-KZFPX-HA-PGK-puro. All expression constructs used in the primary overexpression screen have been deposited and are publicly available (De Tribolet et al., 2023). A schematic representation of the lentiviral expression cassette, including the promoter, HA tag, cloning site, antibiotic resistance cassette, and regulatory elements, is provided in Supplementary file. Selected constructs encoding ZNF43, ZNF257, ZNF498 and ZNF18 were used for follow-up mechanistic studies. For SCAN-domain functional analyses, deletion constructs lacking the SCAN domain (ΔSCAN) were generated for ZNF18 and ZNF498 in the same lentiviral backbone. Deletion were done using In-Fusion cloning with specific primers. PCR was performed with high-fidelity polymerase, followed by gel purification and recombination with the linearized plasmid using the In-Fusion HD Cloning Kit (Takara Bio©) according to the manufacturer’s protocol. The product was transformed into HB101 Escherichia coli cells, and colonies were screened by PCR. Positive clones were verified by Sanger sequencing, and confirmed plasmids were propagated and purified for further use.”

      “Total RNA was extracted...”

      Is now:

      “For each biological replicate, approximately 1 × 10⁶ K562 cells were harvested 72 h after doxycycline induction. Total RNA was extracted…”

      “Images were acquired by fluorescence microscopy under identical conditions across samples.”

      Is now:

      “Images were acquired using a confocal microscope Leica-SP8 (Leica Biosystems) with an objective HC PL APO 63x/1.40 and a pinhole size of 1 AU, using identical acquisition settings for all conditions. Images were processed using Fiji/ImageJ (version 2.9.0) without nonlinear intensity adjustments.”

      “Cells were fixed and stained with antibodies against ciliary markers (ARL13B)”

      Is now:

      “Cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, blocked with 2% BSA, and incubated with rabbit anti-ARL13B (Proteintech, Cat. No. 17711-1-AP, 1:200) followed by Alexa Fluor 568-conjugated donkey anti-rabbit IgG (Thermo Fisher Scientific, Cat. No. A-10042, 1:1000). Nuclei were stained with Hoechst (1 µg/mL).”

      “- The authors mention that KZFPs are usually expressed at a low level in the K562 cell line they use, but there is no figure showing the expression level of KZFPs in this cell type. It would be important to see the baseline KZFP expression in these cells, the level of overexpression and compare it to the endogenous expression levels they show in different cell types/tissues, at least for the four candidates studied more in depth. This would help to understand whether this level of activity is something that could occur naturally in a physiologically relevant context.”

      We thank the reviewer for this insightful suggestion and fully agree that providing additional context regarding endogenous and ectopic KZFP expression levels will help readers better assess the physiological relevance of our findings. As suggested, we included data showing the baseline expression levels of the four selected KZFPs in K562 cells together with the expression levels achieved following doxycycline-induced overexpression. We also compared these values with publicly available transcriptomic data from cell lines. Importantly, only cell lines are assessed as we need ground through (K562) to estimate transgene expression. We modified Fig. S2, Fig. S3, Fig. S4 and Fig. S5 to add the results of these analysis. Here is ZNF43 as an example:

      With the following legend:

      “(C) Distribution of endogenous expression levels, (using GFP control cells), of all expressed genes (light grey) and all KZFPs (dark grey) in K562 cells. The solid red line indicates endogenous ZNF43 expression in GFP control cells, whereas the dashed red line indicates the corrected transgene expression following doxycycline induction.

      (D) Endogenous ZNF43 expression across Human Protein Atlas cell lines, (https://www.proteinatlas.org/about/download#cell_line), following normalization to the local RNA-seq dataset. K562 cells are highlighted in red. The dashed red line indicates the corrected transgene level measured following doxycycline-induced overexpression in K562 cells overexpressing ZNF43.”

      Modified the result section:

      “ZNF43 is a ~43-million-year-old KZFP with a canonical TRIM28-recruiting KRAB domain and 19 zinc fingers that preferentially recognize an LTR/ERV1-embedded sequence (Fig. S1F). We first verified that ZNF43 overexpression impaired the growth of K562 cells (Fig. S2A, B). Endogenous ZNF43 expression was readily detectable in K562 cells and across human cell lines (Fig. S2C, D). Following doxycycline induction, transcript abundance markedly increased and exceeded the highest endogenous expression level observed among the analyzed cell lines (Fig. S2C, D).”

      We also updated the Methods section:

      Quantification of endogenous and transgene expression levels

      Endogenous KZFP expression in K562 cells was estimated from GFP control RNA-seq samples using normalized mean expression values obtained from the differential expression analyses. For ZNF18, whose transgene sequence is identical to the endogenous coding sequence (i.e., not codon-optimized), transgene-derived expression was estimated directly by subtracting the endogenous transcript abundance measured in GFP controls from the total transcript abundance measured following doxycycline induction (OE − GFP). For ZNF43, ZNF257 and ZNF498, the overexpression constructs were synthesized using codon-optimized coding sequences. RNA-seq reads were therefore additionally aligned against the codon-optimized transgene reference sequences to specifically quantify exogenous transcripts without interference from endogenous reads. Because these codon-specific counts are generated through an independent alignment strategy, they are not directly comparable to the endogenous RNA-seq expression values. To calibrate these measurements, a scaling factor was derived from the ZNF18 dataset by comparing the codon-specific read counts with the transgene abundance estimated from the differential expression analysis (OE − GFP). This empirically determined correction factor was subsequently applied to all codon-optimized constructs, thereby expressing transgene abundance on the same scale as the endogenous RNA-seq measurements. Corrected transgene expression values were then used for all downstream comparisons. To compare endogenous expression across physiological contexts, publicly available RNA-seq datasets from the Human Protein Atlas (cell lines) were downloaded and normalized to the local RNA-seq scale. A normalization factor was calculated from the median expression ratio of KZFPs detected in both the Human Protein Atlas K562 dataset and the local K562 GFP control RNA-seq dataset, and subsequently applied uniformly to all Human Protein Atlas datasets. This normalization enabled direct comparison of endogenous expression across biological contexts with the corrected transgene expression values. Global KZFP expression was calculated as the median normalized expression of all annotated KZFPs within each biological context. For the four KZFPs selected for detailed characterization, endogenous expression across Human Protein Atlas cell lines was compared with corrected transgene expression following doxycycline induction. Expression distributions of all genes and KZFPs were visualized using ranked expression plots and density histograms. All analyses were performed in R using the tidyverse package.”

      We fully acknowledge that the overexpression system used in this study was primarily designed as a discovery platform to identify candidate functions, targets, and interaction partners of KZFPs that are otherwise expressed at lower levels in K562 cells. As the reviewer correctly points out, determining whether these regulatory effects occur at endogenous expression levels in physiologically relevant cellular contexts represents an important next step. We Thereby also clarified this in the “Limitations to this study” paragraph:

      “To better place our experimental system into a physiological context, we compared endogenous KZFP expression in K562 cells with publicly available transcriptomic datasets from the Human Protein Atlas. These analyses showed that K562 cells do not exhibit unusually low global KZFP expression compared with other human cell lines. However, consistent with the restricted expression patterns of this protein family, KZFPs as a whole are expressed at substantially lower levels than the average human gene. For the four KZFPs characterized in detail, doxycycline induction produced transcript levels that exceeded the highest endogenous expression observed across the analyzed human cell lines. Accordingly, the overexpression system used in this study was not designed to recapitulate physiological expression levels but rather to maximize the identification of candidate target genes, interacting partners, and regulatory pathways for KZFPs that are otherwise expressed at low endogenous levels. Consequently, the molecular interactions identified here should be considered as hypotheses requiring validation under endogenous expression conditions in physiologically relevant cellular models.”

      “- RNA seq analysis: It is unclear how many cells were used in the RNA seq analysis, I would like to ask the authors to clarify that. Moreover, from my understanding the RNA seq analysis was done on day 3, while the Presto Blue analysis was done on days 4, 7 and 9. I would like to kindly ask the authors to motivate their choice for the day of the RNA sequencing analysis.”

      We agree that this information required clarification. The Methods section has been revised to specify the number of cells used for RNA-seq library preparation and to explain the rationale for performing RNA-seq after 3 days of doxycycline induction, before measurable proliferation defects emerge, in order to capture primary transcriptional responses to KZFP overexpression. The corresponding modification has also been added to the Results section when introducing the RNA-seq analyses.

      “For transcriptome profiling, K562 cells expressing the indicated inducible constructs were treated with doxycycline for 72 h before harvest. Total RNA was extracted using the NucleoSpin RNA plus kit (Macherey-Nagel) according to the manufacturer’s recommendations. RNA quantity and purity were assessed by spectrophotometry, and RNA integrity was evaluated before library preparation.”

      Is now:

      “For transcriptome profiling, 1 × 10⁶ K562 cells expressing the indicated inducible constructs were treated with doxycycline for 72 h before harvest. RNA was collected after 3 days of induction to capture the primary transcriptional responses to KZFP overexpression before substantial differences in proliferation became apparent. This early time point was chosen to minimize secondary transcriptional changes resulting from altered cell growth, cell-cycle distribution, or cellular stress, which become detectable in the proliferation assays performed after 4, 7, and 9 days of induction. Total RNA was extracted using the NucleoSpin RNA plus kit (Macherey-Nagel) according to the manufacturer’s recommendations. RNA quantity and purity were assessed by spectrophotometry, and RNA integrity was evaluated before library preparation.”

      “We then profiled the transcriptome of K562 cells overexpressing ZNF43 by deep RNA sequencing (RNA-seq)”

      Is now:

      “We then profiled the transcriptome of K562 cells overexpressing ZNF43 by deep RNA sequencing (RNA-seq) after 3 days of doxycycline induction, a time point selected to capture primary transcriptional responses before the onset of measurable proliferation defects.”

      Minor comments of the reviewer 2

      “- Figure S1D is not mentioned in the text before figure S1E. The order of the panels should be changed in the figure.

      Done as suggested by the reviewer.

      • "We selected genes that were downregulated upon ZNF43 overexpression and harboured a ZNF43 binding site within 10kb of their TSS (Fig. 1A) - don't the authors mean Fig. 2A?

      Done as suggested by the reviewer.

      • In Figure 4D, the GO terms cannot be read, as the sentences seem to be cut.

      Done as suggested by the reviewer.

      • All figures and figure legends need to be revised. In some cases, the letter size is too small, or the legend and explanation of colours is missing. Please see some examples below: Fig. S6C, Fig 6C, Fig S4C, Fig S5C (letter size too small) Fig S6G, Fig 4E (label/scale is missing)”

      Homogenized to Arial 6 by default as requested by most of journal guidelines

      __ Description of analyses that authors prefer not to carry out__

      We think that by proceeding as described above we will have addressed all major conceptual issues raised by the reviewers.

    1. Reviewer #2 (Public review):

      Summary:

      This study compares theta-burst stimulation (TBS)-induced synaptic plasticity in hippocampal CA1 slices from rats and non-human primates (Macaca fascicularis). The authors report that while TBS induces persistent LTP in both species, only primate hippocampal slices exhibit synaptic tagging and capture (STC) under these conditions. They further show increased BDNF and PKMζ expression following TBS in primates and propose that a redundant BDNF/PKMζ signaling architecture supports persistent plasticity in primates, whereas rodent TBS-LTP depends primarily on BDNF. The work aims to identify species-specific specializations in associative plasticity with implications for translational neuroscience.

      Strengths:

      The topic is potentially important because direct comparisons of hippocampal plasticity mechanisms between rodents and primates are rare.

      Weaknesses:

      (1) Limited biological replication in the primate experiments

      The manuscript's strongest claims rely on data obtained from 36 slices from 7 monkeys, qPCR analyses with n=3 biological replicates, and Western blot analyses with n=3 biological replicates. The effective sample size for species-level conclusions is therefore not large. The manuscript frequently treats slices as independent observations while drawing conclusions about species differences. This is particularly problematic for electrophysiological experiments because multiple slices appear to originate from the same animals. The statistical unit should be the animal, not the slice, unless nested analyses are performed.

      The authors should (1) report the number of animals contributing to each experiment, (2) provide animal-level analyses, (3) use mixed-effects or hierarchical models where appropriate, and (4) clarify whether multiple slices from the same monkey contributed to the same experimental condition. Without these analyses, the evidence for species-specific mechanisms remains weaker than presented.

      (2) The central STC conclusion requires stronger controls

      The most important result is that TBS supports STC in primates but not rats (Figures 1F-G). However, several alternative explanations are not excluded. For example, only a single interval (30 min) between TBS and WTET is examined. Classical STC studies characterize tag duration, PRP availability window, and temporal asymmetry. The current work does not determine whether primates exhibit longer tag persistence, increased PRP synthesis, altered capture efficiency, or merely a shifted temporal window. A temporal series (e.g., {plus minus}15, {plus minus}30, {plus minus}60, {plus minus}90 min) would substantially strengthen the mechanistic interpretation.

      (3) Species differences may reflect tissue quality or preparation differences

      The manuscript compares 5-7 week-old rats with 5-7 year-old monkeys. These are very different developmental stages. Moreover, euthanasia methods, extraction procedures, and postmortem handling are different. These factors can affect BDNF expression, protein synthesis, LTP magnitude, and transcriptional responses. The authors should discuss these caveats more explicitly.

      (4) Statistical reporting is incomplete

      Many comparisons report exactly Wilcoxon p = 0.0313 and U-test p = 0.0022, across numerous experiments. This suggests very small sample sizes and discrete nonparametric distributions. The manuscript should report exact n values for each comparison, effect sizes, and confidence intervals.

      Second, many genes and proteins are tested. No correction for multiple testing is described. The authors should state whether corrections were applied, and if not, justify this choice.

      (5) Interpretation and significance

      The study addresses an important and understudied question: whether associative synaptic plasticity mechanisms differ between rodents and primates. The finding that TBS can support STC in the primate hippocampus is potentially novel and impactful. However, the mechanistic evidence remains incomplete, the molecular analyses are underpowered, and several key controls are missing. At present, the data support the conclusion that under the specific experimental conditions tested, TBS-induced plasticity in primate hippocampal slices exhibits greater associative persistence than in rat slices.

      The stronger claims regarding evolutionary specialization, fundamentally distinct plasticity rules, altered STC thresholds, and redundant BDNF/PKMζ architecture require additional experimental support.

    2. Reviewer #3 (Public review):

      Summary:

      In this manuscript, the authors have undertaken an investigation of differences between two mammalian species, the brown rat and the crab-eating macaque, in the mechanisms supporting a well-established model of long-term Hebbian synaptic plasticity, Schaffer collateral to CA1 Long-term potentiation (LTP) in the hippocampus. LTP has been long-studied and deeply characterised due to its potential importance in modeling a strong candidate process for the central mechanism of learning and memory. LTP was first discovered in lagomorphs (rabbits), but has since been much more widely studied in rodents (mostly rats and mice), and there has been some complementary work revealing LTP in non-human primates and even in humans, revealing largely overlapping canonical mechanisms of induction, expression, and maintenance. More specifically, this study puts a particular focus on the fascinating associative features of this form of lasting synapse-specific modification, in which a synaptic input can be stimulated with a relatively weak induction protocol that will not produce lasting plasticity on its own, but can undergo lasting LTP if paired with stronger stimulation on a separate synaptic input to the same neuron. This associativity mechanism is particularly attractive within the Hebbian synaptic plasticity framework as it provides a candidate mechanism for associative forms of learning in which stimulus-stimulus, stimulus-reward, stimulus-punishment, or action-outcome associations are formed. A particularly attractive feature of this associative LTP is that there can also be a substantial time-lag between the strong stimulation of one pathway and the weaker stimulation of the other synaptic input, which only undergoes lasting LTP by hijacking the proteins synthesized as a result of strong stimulation elsewhere. This observation has led to the famous tagging and capture hypothesis as an explanation of how such synapse-specific change can be achieved on both stimulated inputs but not on other synaptic inputs, given the potential requirement for cell-wide protein synthesis. This theory, for which there is very strong experimental evidence, posits that a protein tag is left at synapses that have been stimulated with sufficient vigor in recent history, serving as a key mechanism to ensure that those weakly stimulated synapses will undergo change when a larger-scale LTP event occurs due to stronger stimulation elsewhere within a relevant time window. Again, this idea is attractive as it can explain how we might form associations between events that occur slightly separated in time. The manuscript goes on to show that an induction protocol that is particularly physiologically relevant, theta burst stimulation, produces this tag and capture associative effect in ex vivo slices of Macaque hippocampus, much more readily than in side-by-side ex vivo slices of rat hippocampus. Moreover, the manuscript delves into the importance of well-characterised LTP maintenance mechanisms, including PKMzeta and BDNF, which are key factors that ensure that altered synaptic change is maintained for long periods of time despite substantial molecular turnover in the neuron. The observation in this manuscript is that a degree of redundancy for these mechanisms exists in the primate species but not the rodent species, as both mechanisms need to be inhibited to return LTP to baseline in the Macaque, but only one needs to be inhibited to have that effect in the rat. A major emphasis of this study is that there may be a step-wise difference in associative learning mechanisms between rodents and primates that may contribute to their differing cognitive capacities, although I believe a lot more evidence would be required to reach that conclusion.

      Strengths:

      The strengths of this study are that it is technically very proficient and is from a laboratory that has a long history of seminal work on synaptic tagging and capture. The cross-species comparison, particularly involving non-human primates, is also very hard to achieve, and a major strength here is the side-by-side comparison of slices from rat and monkeys. Further strengths of the study are the use of a number of experimental strategies, including both observation and intervention, to demonstrate differential involvement of LTP maintenance mechanisms. A final major strength is conceptual, as it is undoubtedly useful not only to identify shared mechanisms of plasticity between commonly used model organisms and either humans or much more closely related species such as old world monkeys, but also to reveal differences that have the potential to contribute to differences in memory/cognition.

      Weaknesses:

      The findings of this study are a very useful building block for understanding how generalisable mechanisms of LTP are. However, arriving at really substantial conclusions from these findings is challenging, as there are a number of variables that are unaccounted for in this study that may explain the differences that have been observed between rats and monkeys. One example of a potential confound to these interpretations is that rats are nocturnal/crepuscular animals, and macaques are diurnal animals. Thus, to undertake a like-for-like comparison, it would be necessary for the rats to be on a reversed light-dark cycle to ensure that the wake cycle of the rat (dark) is being compared with the wake cycle of the monkey (light). It is possible that the authors have done this, but it is not mentioned in the methods section. The reason this is important is that there is a substantial body of work indicating that different mechanisms are at play in hippocampal LTP during wake and sleep. Transcripts and proteins related to synaptic function are dramatically differentially regulated during sleep-wake cycles, and phosphorylation states of key proteins involved in plasticity are also altered. Moreover, synaptic tagging and capture are specifically disrupted by sleep deprivation. Perhaps the authors have already considered this factor and appropriately reversed the light-dark cycle of their rat subjects, in which case a clarification in the manuscript would be useful. Nevertheless, I have used this as an example because there is a variety of potential confounds that may explain the difference between SC-CA1 TBS LTP in rats and monkeys, e.g., circadian rhythms, degree of enrichment, natural light vs indoor lighting, diet, degree of inbreeding, strain, etc. Thus, to make strong conclusions about the potential for differences in plasticity rules/mechanisms and how those may contribute to differences in cognition, I think it would be necessary to compare a wider variety of species, including a good representation of each order (e.g., nocturnal rats and diurnal squirrels, new and old world primates) and not just a single exemplar. I understand, of course, that this is really pushing the boundaries of practicality, but I see no other way to make a strong conclusion or to generalise to mechanisms or properties of plasticity in rodents vs primates. Thus, while I believe the manuscript presents really admirable work, I am not sure the findings are at all easy to interpret.

    3. Author response:

      eLife Assessment

      This is a potentially important study comparing LTP mechanisms between primates and rodents. The experimental methods have some possible confounds, and the power (replicates) and design of the statistical methods could be strengthened, hence the support for the central claims of species differences is currently incomplete.

      We thank the Editor and the Reviewers for taking the time to carefully review our manuscript and for providing constructive comments and suggestions, as well as the opportunity to revise our work.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      This is an important paper examining LTP induced by theta-burst stimulation in hippocampal slices from macaques and rats. While both species show theta-burst-late-LTP, only the non-human primate theta-burst-late-LTP showed synaptic tagging and capture that converts early-LTP into late-LTP in an independent synaptic pathway.

      Strengths:

      Synaptic tagging is a fundamental feature of repeated 100 Hz-tetanus-induced LTP, whereas theta-burst induction is arguably more physiologically relevant. Thus, synaptic tagging during theta-burst may differ in the two species, a distinction that may prove important in the mechanisms underlying the cognitive differences between the species.

      Weaknesses:

      Bursts repeated at the frequency (~5 Hz) of the endogenous theta rhythm induce strong LTP, primarily because this frequency disables feed-forward inhibition and allows sufficient postsynaptic depolarization to activate voltage-sensitive NMDA receptors. Therefore, the species differences may be due to differences in inhibition, rather than in molecular mechanisms of maintenance. One way to assess the relative strengths of this early induction mechanism in rats and macaques is to examine the "depolarization envelope" during the sequential bursts, which may be determined from the recordings already obtained. (Larson and Munkácsy, Theta-burst LTP, Brain Res 2015 Sep 24:1621:38-50. doi: 10.1016/j.brainres.2014.10.034)

      Another issue is that the PKMzeta-antisense oligodeoxynucleotides block the synthesis of the kinase. However, Mei F, Nagappan G, Ke Y, Sacktor TC, Lu B (2011), BDNF Facilitates L-LTP Maintenance in the Absence of Protein Synthesis through PKMzeta. PLoS ONE 6(6):e21568, provided evidence that BDNF and theta-burst stimulation can act to increase PKMzeta by a protein synthesis-independent mechanism, presumably through decreased degradation. Therefore, the absence of an effect of the PKMzeta-antisense does not exclude the possibility that persistently increased PKMzeta is the mechanism of theta-burst-late-LTP maintenance in mice or macaques. This issue is worth discussing.

      We sincerely thank the reviewer for the positive evaluation of our study and for highlighting the significance of examining synaptic tagging and capture following theta-burst stimulation (TBS) in rodents and non-human primates.

      We agree that TBS is a physiologically relevant induction paradigm and that differences in inhibitory circuit dynamics may also contribute to the species-specific effects observed in our study. As highlighted by Larson and Munkácsy (2015), repeated bursts delivered at theta frequency (~5 Hz) can transiently suppress feed-forward inhibition through GABAB receptor-mediated mechanisms, thereby enhancing postsynaptic depolarization and facilitating NMDA receptor activation. We therefore agree that species differences in inhibitory regulation and burst-evoked depolarization may contribute to the distinct expression of synaptic tagging and capture observed between rats and non-human primates.

      We further agree that analysis of the “depolarization envelope” during sequential bursts may provide additional insight into the relative strengths of early induction mechanisms. We will therefore perform these analyses using the existing recordings and compare the depolarization envelope between rodents and NHPs in the revised manuscript. Following the reviewer’s suggestion, we will expand the Discussion section to acknowledge the potential contribution of inhibitory circuit dynamics and depolarization envelope differences during sequential bursts.

      Importantly, however, we believe that differences in downstream molecular maintenance mechanisms also contribute to these species-specific effects. In support of this, our molecular analyses revealed enhanced recruitment of plasticity-related proteins and transcriptional pathways in NHP hippocampus following TBS, including increased expression of BDNF and PKCζ. These findings suggest that both induction-related network properties and downstream molecular stabilization mechanisms may collectively contribute to the enhanced associative plasticity observed in NHPs.

      We also thank the reviewer for the important point regarding PKMζ antisense experiments and the study by Mei et al. (2011). We agree that the absence of an effect of PKMζ antisense oligodeoxynucleotides does not necessarily exclude a role for persistently elevated PKMζ in the maintenance of theta-burst late-LTP. As demonstrated by Mei et al., BDNF together with theta-burst stimulation can maintain late-LTP in the absence of protein synthesis, potentially through stabilization of PKMζ protein levels by reducing degradation rather than through de novo synthesis. However, these findings are not directly comparable to our study, since our experiments involved theta-burst stimulation alone without exogenous BDNF application. Interestingly, our results suggest species-specific differences in the interaction between BDNF and PKMζ signaling pathways. In rats, TrkB/Fc-mediated blockade of BDNF impaired TBS-LTP maintenance, whereas PKMζ inhibition alone had no significant effect. In contrast, in NHP hippocampal slices, inhibition of either BDNF signaling or PKMζ alone failed to abolish late-LTP, whereas simultaneous inhibition of both pathways disrupted LTP maintenance.

      These findings suggest that endogenous BDNF signaling and PKMζ may operate through partially redundant or compensatory mechanisms, particularly in the primate hippocampus. Therefore, although our findings indicate that de novo PKMζ synthesis may not be strictly required under the present experimental conditions, we cannot fully exclude the possibility that protein synthesis-independent stabilization or maintenance of PKMζ contributes to theta-burst late-LTP maintenance in rodents or NHPs. We will now clarify this point in the revised Discussion section.

      Reviewer #2 (Public review):

      Summary:

      This study compares theta-burst stimulation (TBS)-induced synaptic plasticity in hippocampal CA1 slices from rats and non-human primates (Macaca fascicularis). The authors report that while TBS induces persistent LTP in both species, only primate hippocampal slices exhibit synaptic tagging and capture (STC) under these conditions. They further show increased BDNF and PKMζ expression following TBS in primates and propose that a redundant BDNF/PKMζ signaling architecture supports persistent plasticity in primates, whereas rodent TBS-LTP depends primarily on BDNF. The work aims to identify species-specific specializations in associative plasticity with implications for translational neuroscience.

      Strengths:

      The topic is potentially important because direct comparisons of hippocampal plasticity mechanisms between rodents and primates are rare.

      Weaknesses:

      (1) Limited biological replication in the primate experiments

      The manuscript's strongest claims rely on data obtained from 36 slices from 7 monkeys, qPCR analyses with n=3 biological replicates, and Western blot analyses with n=3 biological replicates. The effective sample size for species-level conclusions is therefore not large. The manuscript frequently treats slices as independent observations while drawing conclusions about species differences. This is particularly problematic for electrophysiological experiments because multiple slices appear to originate from the same animals. The statistical unit should be the animal, not the slice, unless nested analyses are performed.

      The authors should (1) report the number of animals contributing to each experiment, (2) provide animal-level analyses, (3) use mixed-effects or hierarchical models where appropriate, and (4) clarify whether multiple slices from the same monkey contributed to the same experimental condition. Without these analyses, the evidence for species-specific mechanisms remains weaker than presented.

      We thank the reviewer for this important and thoughtful comment regarding statistical interpretation and biological replication. We agree that, particularly for electrophysiological experiments where multiple slices may originate from the same animal, the effective sample size for species-level conclusions should be considered at the animal level rather than solely at the slice level.

      In the revised manuscript, we will clearly indicate the number of biological replicates (animals) together with the number of slices contributing to each electrophysiological experiment, as well as the biological replicates used for qPCR and Western blot analyses. We will also clarify whether multiple slices from the same NHP/rat contributed to the same experimental condition. These details will be incorporated into the figures and figure legends wherever appropriate.

      In addition, we will perform animal-level analyses by averaging slice responses within each animal prior to statistical comparison and, where appropriate, apply hierarchical or mixed-effects statistical models to account for the nested structure of slices within animals.

      We acknowledge that the number of non-human primates (NHPs) available for this study was inherently limited because of the substantial ethical, logistical, financial, and technical challenges associated with primate electrophysiology and tissue collection. Consequently, achieving sample sizes comparable to rodent studies is often not feasible in NHP research. Nevertheless, to further strengthen the biological robustness of the findings, we are currently in the process of obtaining additional NHP brain samples and plan to repeat key experiments in an additional 3-4 animals. We believe these revisions and additional experiments will substantially strengthen the statistical rigor and overall interpretation of the study.

      (2) The central STC conclusion requires stronger controls

      The most important result is that TBS supports STC in primates but not rats (Figures 1F-G). However, several alternative explanations are not excluded. For example, only a single interval (30 min) between TBS and WTET is examined. Classical STC studies characterize tag duration, PRP availability window, and temporal asymmetry. The current work does not determine whether primates exhibit longer tag persistence, increased PRP synthesis, altered capture efficiency, or merely a shifted temporal window. A temporal series (e.g., {plus minus}15, {plus minus}30, {plus minus}60, {plus minus}90 min) would substantially strengthen the mechanistic interpretation.

      We thank the reviewer for this insightful comment regarding the mechanistic interpretation of the STC findings. In the present study, we selected the 30 min interval based on well-established classical STC paradigms in rodents, where this interval reliably falls within the effective tagging and capture window. Using this experimentally validated interval allowed us to directly compare whether TBS is sufficient to support STC in primates versus rats under equivalent experimental conditions. Accordingly, the primary objective of this study was to determine whether TBS-induced STC varies across species, rather than to comprehensively define the temporal dynamics of the tagging window.

      We agree, however, that the current experiments do not distinguish whether the primate-specific effect reflects prolonged tag persistence, enhanced plasticity-related protein (PRP) synthesis, altered capture efficiency, or a shifted temporal window. Addressing these possibilities would indeed require systematic temporal interval analyses (e.g., ±15, ±30, ±60, and ±90 min), which represent important future directions. Such experiments are particularly challenging in non-human primates because the availability of primate tissue and experimental resources for large-scale electrophysiological studies remains limited and is currently beyond our experimental capacity due to substantial ethical, logistical, financial, and technical constraints.

      Nevertheless, we fully agree with the reviewer that these experiments are important for advancing the mechanistic interpretation of the findings. Similar temporal analyses have recently proven informative in our rodent studies (Chong YS, Ang SR, Sajikumar S. Commun Biol. 2025;8:553). Importantly, we are currently in the process of obtaining additional non-human primate samples and plan to extend the present work by examining an additional 60 min temporal interval to further characterize the temporal properties of synaptic tagging and capture in non-human primates.

      (3) Species differences may reflect tissue quality or preparation differences

      The manuscript compares 5-7 week-old rats with 5-7 year-old monkeys. These are very different developmental stages. Moreover, euthanasia methods, extraction procedures, and post-mortem handling are different. These factors can affect BDNF expression, protein synthesis, LTP magnitude, and transcriptional responses. The authors should discuss these caveats more explicitly.

      We thank the reviewer for raising this important and insightful point. We agree that differences in developmental stage between the experimental groups represent an important consideration when interpreting potential species-dependent effects. In the present study, rat experiments were performed in 5-7 week-old animals, whereas non-human primate (NHP) tissues were obtained from 5-7-year-old monkeys. This difference largely reflects the practical, ethical, and logistical constraints associated with NHP research and tissue availability. We acknowledge that these ages are not developmentally equivalent and that maturation state may influence BDNF signaling, protein synthesis capacity, synaptic plasticity thresholds, and transcriptional responses relevant to late-LTP and STC mechanisms.

      We also recognize that differences in euthanasia procedures, tissue extraction, slice preparation, and postmortem handling between rodent and primate tissues may influence tissue physiology and electrophysiological properties. Although extensive care was taken to optimize tissue viability and maintain stable recordings within each species, these variables cannot be completely excluded as contributing factors to the observed differences.

      Accordingly, we will revise the Discussion section to more explicitly acknowledge these limitations and clarify that our findings support potential species-dependent differences under the present experimental conditions, rather than definitive intrinsic species-specific mechanisms. Nevertheless, despite the inherent challenges associated with NHP electrophysiological studies, we believe that the present findings provide an important initial framework for understanding the translational relevance of synaptic tagging and capture mechanisms across species.

      (4) Statistical reporting is incomplete

      Many comparisons report exactly Wilcoxon p = 0.0313 and U-test p = 0.0022, across numerous experiments. This suggests very small sample sizes and discrete nonparametric distributions. The manuscript should report exact n values for each comparison, effect sizes, and confidence intervals.

      Second, many genes and proteins are tested. No correction for multiple testing is described. The authors should state whether corrections were applied, and if not, justify this choice.

      We thank the reviewer for this important comment regarding statistical reporting and interpretation. We agree that the repeated occurrence of identical exact p-values in several nonparametric analyses reflects the relatively small sample sizes and the discrete nature of the statistical distributions. This issue is particularly relevant for the NHP experiments, where biological replication is inherently limited because of the substantial ethical, logistical, financial, and technical challenges associated with obtaining and processing primate tissue.

      In the revised manuscript, we will provide exact n values for all comparisons, including the number of biological replicates (animals) and slices where applicable. We will also include additional statistical details, including effect sizes and confidence intervals where appropriate, to improve transparency and facilitate interpretation of the reported findings. Furthermore, we are currently in the process of obtaining additional NHP samples and will attempt to include more biological replicates in the revised version to further strengthen the robustness of the analyses.

      We also agree that the issue of multiple testing should be addressed more explicitly, particularly because multiple genes and proteins were examined. In the revised manuscript, we will clearly state the statistical correction methods applied for multiple comparisons where appropriate. For analyses in which corrections were not applied, we will provide justification, noting that several experiments were based on hypothesis-driven candidate targets rather than exploratory large-scale screening analyses. These statistical considerations will be clarified in the Methods and Results sections.

      (5) Interpretation and significance

      The study addresses an important and understudied question: whether associative synaptic plasticity mechanisms differ between rodents and primates. The finding that TBS can support STC in the primate hippocampus is potentially novel and impactful. However, the mechanistic evidence remains incomplete, the molecular analyses are underpowered, and several key controls are missing. At present, the data support the conclusion that under the specific experimental conditions tested, TBS-induced plasticity in primate hippocampal slices exhibits greater associative persistence than in rat slices.

      The stronger claims regarding evolutionary specialization, fundamentally distinct plasticity rules, altered STC thresholds, and redundant BDNF/PKMζ architecture require additional experimental support.

      We thank the reviewer for this thoughtful and balanced assessment of our work. We agree that the present data primarily support the conclusion that, under the specific experimental conditions examined, TBS-induced plasticity in primate hippocampal slices exhibits greater associative persistence than that observed in rat slices. We also agree that broader interpretations regarding evolutionary specialization, fundamentally distinct plasticity rules, altered STC thresholds, and potentially redundant BDNF/PKMζ-related mechanisms require additional mechanistic investigation and experimental validation.

      Accordingly, we will moderate these interpretations throughout the revised manuscript and clearly state that these conclusions remain preliminary. We will further emphasize that additional experiments, including increased biological replication, expanded temporal analyses, and further mechanistic investigations, will be necessary to more conclusively define the basis of the observed species-dependent differences. Within our current experimental capacity, we are actively working to obtain additional non-human primate samples and plan to incorporate additional biological replicates and key follow-up experiments in the revised version to further strengthen the robustness of the findings.

      At the same time, we believe the present study provides an important initial contribution to an understudied area by directly examining synaptic tagging and capture mechanisms in the primate hippocampus. Given the limited availability of non-human primate electrophysiological data in the field, these findings may offer a valuable framework for future studies investigating the translational and evolutionary relevance of associative synaptic plasticity mechanisms across species.

      Reviewer #3 (Public review):

      Summary:

      In this manuscript, the authors have undertaken an investigation of differences between two mammalian species, the brown rat and the crab-eating macaque, in the mechanisms supporting a well-established model of long-term Hebbian synaptic plasticity, Schaffer collateral to CA1 Long-term potentiation (LTP) in the hippocampus. LTP has been long-studied and deeply characterised due to its potential importance in modeling a strong candidate process for the central mechanism of learning and memory. LTP was first discovered in lagomorphs (rabbits), but has since been much more widely studied in rodents (mostly rats and mice), and there has been some complementary work revealing LTP in non-human primates and even in humans, revealing largely overlapping canonical mechanisms of induction, expression, and maintenance. More specifically, this study puts a particular focus on the fascinating associative features of this form of lasting synapse-specific modification, in which a synaptic input can be stimulated with a relatively weak induction protocol that will not produce lasting plasticity on its own, but can undergo lasting LTP if paired with stronger stimulation on a separate synaptic input to the same neuron. This associativity mechanism is particularly attractive within the Hebbian synaptic plasticity framework as it provides a candidate mechanism for associative forms of learning in which stimulus-stimulus, stimulus-reward, stimulus-punishment, or action-outcome associations are formed. A particularly attractive feature of this associative LTP is that there can also be a substantial time-lag between the strong stimulation of one pathway and the weaker stimulation of the other synaptic input, which only undergoes lasting LTP by hijacking the proteins synthesized as a result of strong stimulation elsewhere. This observation has led to the famous tagging and capture hypothesis as an explanation of how such synapse-specific change can be achieved on both stimulated inputs but not on other synaptic inputs, given the potential requirement for cell-wide protein synthesis. This theory, for which there is very strong experimental evidence, posits that a protein tag is left at synapses that have been stimulated with sufficient vigor in recent history, serving as a key mechanism to ensure that those weakly stimulated synapses will undergo change when a larger-scale LTP event occurs due to stronger stimulation elsewhere within a relevant time window. Again, this idea is attractive as it can explain how we might form associations between events that occur slightly separated in time. The manuscript goes on to show that an induction protocol that is particularly physiologically relevant, theta burst stimulation, produces this tag and capture associative effect in ex vivo slices of Macaque hippocampus, much more readily than in side-by-side ex vivo slices of rat hippocampus. Moreover, the manuscript delves into the importance of well-characterised LTP maintenance mechanisms, including PKMzeta and BDNF, which are key factors that ensure that altered synaptic change is maintained for long periods of time despite substantial molecular turnover in the neuron. The observation in this manuscript is that a degree of redundancy for these mechanisms exists in the primate species but not the rodent species, as both mechanisms need to be inhibited to return LTP to baseline in the Macaque, but only one needs to be inhibited to have that effect in the rat. A major emphasis of this study is that there may be a step-wise difference in associative learning mechanisms between rodents and primates that may contribute to their differing cognitive capacities, although I believe a lot more evidence would be required to reach that conclusion.

      Strengths:

      The strengths of this study are that it is technically very proficient and is from a laboratory that has a long history of seminal work on synaptic tagging and capture. The cross-species comparison, particularly involving non-human primates, is also very hard to achieve, and a major strength here is the side-by-side comparison of slices from rat and monkeys. Further strengths of the study are the use of a number of experimental strategies, including both observation and intervention, to demonstrate differential involvement of LTP maintenance mechanisms. A final major strength is conceptual, as it is undoubtedly useful not only to identify shared mechanisms of plasticity between commonly used model organisms and either humans or much more closely related species such as old world monkeys, but also to reveal differences that have the potential to contribute to differences in memory/cognition.

      Weaknesses:

      The findings of this study are a very useful building block for understanding how generalisable mechanisms of LTP are. However, arriving at really substantial conclusions from these findings is challenging, as there are a number of variables that are unaccounted for in this study that may explain the differences that have been observed between rats and monkeys. One example of a potential confound to these interpretations is that rats are nocturnal/crepuscular animals, and macaques are diurnal animals. Thus, to undertake a like-for-like comparison, it would be necessary for the rats to be on a reversed light-dark cycle to ensure that the wake cycle of the rat (dark) is being compared with the wake cycle of the monkey (light). It is possible that the authors have done this, but it is not mentioned in the methods section. The reason this is important is that there is a substantial body of work indicating that different mechanisms are at play in hippocampal LTP during wake and sleep. Transcripts and proteins related to synaptic function are dramatically differentially regulated during sleep-wake cycles, and phosphorylation states of key proteins involved in plasticity are also altered. Moreover, synaptic tagging and capture are specifically disrupted by sleep deprivation. Perhaps the authors have already considered this factor and appropriately reversed the light-dark cycle of their rat subjects, in which case a clarification in the manuscript would be useful. Nevertheless, I have used this as an example because there is a variety of potential confounds that may explain the difference between SC-CA1 TBS LTP in rats and monkeys, e.g., circadian rhythms, degree of enrichment, natural light vs indoor lighting, diet, degree of inbreeding, strain, etc. Thus, to make strong conclusions about the potential for differences in plasticity rules/mechanisms and how those may contribute to differences in cognition, I think it would be necessary to compare a wider variety of species, including a good representation of each order (e.g., nocturnal rats and diurnal squirrels, new and old world primates) and not just a single exemplar. I understand, of course, that this is really pushing the boundaries of practicality, but I see no other way to make a strong conclusion or to generalise to mechanisms or properties of plasticity in rodent’s vs primates. Thus, while I believe the manuscript presents really admirable work, I am not sure the findings are at all easy to interpret.

      We thank the reviewer for this thoughtful and insightful comment, as well as for the encouraging appreciation of our long-duration plasticity recordings and associative plasticity experiments, which are both technically demanding and time-intensive. We fully agree that interpretation of cross-species differences in synaptic plasticity requires careful consideration of multiple biological and environmental variables, including circadian state, enrichment conditions, strain differences, diet, lighting conditions, and species-specific behavioral ecology.

      Regarding the specific concern related to circadian phase and sleep-wake state, the reviewer raises an important point. Rats are nocturnal animals, whereas macaques are diurnal, and hippocampal plasticity mechanisms are known to be influenced by circadian rhythms and sleep-dependent regulation of synaptic proteins and signaling pathways. Previous studies have demonstrated modulation of LTP, synaptic tagging and capture and protein synthesis in rats across normal sleep-wake cycles. We therefore agree that these factors may influence plasticity outcomes and should be carefully considered in comparative studies.

      Studies have further shown that theta frequency is highly sensitive to sleep-related manipulations. Specifically, theta frequency decreases immediately after sleep, remains elevated during sleep deprivation, and rapidly declines following recovery sleep. In aged animals, these effects appear comparatively attenuated, suggesting reduced sleep-dependent modulation of theta dynamics with aging. Therefore, disruption of normal circadian or sleep-wake patterns may significantly alter theta activity and associated plasticity mechanisms within a species and may not accurately reflect physiological baseline states (Utku Kaya et al., 2026).

      In our experiments, recordings from rats and macaques were performed during their respective active phases under standardized laboratory housing conditions, and we will further clarify these details in the revised Methods section. Nevertheless, we acknowledge that circadian state and related physiological variables cannot be completely excluded as contributing factors to the observed differences between species.

      More broadly, we agree with the reviewer that the present study does not permit definitive conclusions regarding universal “rodent versus primate” rules of synaptic plasticity. Our intention was not to propose a generalized dichotomy between rodents and primates, but rather to report that, under the experimental conditions used here, SC-CA1 TBS-LTP and associated synaptic tagging mechanisms differed between rats and macaques. We agree that broader evolutionary or cognitive interpretations would require systematic comparative analyses across multiple species, including both nocturnal and diurnal rodents as well as diverse primate species. Such studies would provide a stronger framework for distinguishing conserved versus species-specific mechanisms of plasticity.

      At the same time, we believe the present findings remain important because they provide one of the first direct experimental comparisons of SC-CA1 TBS-LTP-associated plasticity mechanisms between rodents and non-human primates under controlled ex vivo conditions. Although the interpretation should be done cautiously, the observed differences raise the possibility that certain metaplastic or protein synthesis-dependent mechanisms may not be fully conserved across species. Accordingly, we will revise the Discussion section to better emphasize the exploratory and comparative nature of the study, while explicitly acknowledging the limitations and potential confounding factors highlighted by the reviewer.

    1. Reviewer #3 (Public review):

      Summary:

      The manuscript reports that Yoda1 and Yoda2 agonize PIEZO2 in a manner similar to PIEZO1, increasing open probability and stretch sensitivity, but the mechanism underlying this sensitivity is incomplete. Mutagenesis was shown exclusively in PIEZO1, with no corresponding mutagenesis in PIEZO2, so the proposed mechanism in PIEZO2 is inferred by homology rather than directly tested. All experiments use mouse PIEZO2, and the human ortholog should be used before generalizing the proposed reinterpretation of the field.

      Strengths:

      The pressure-clamp electrophysiology demonstrating a shift in half-activation pressure for PIEZO2 is compelling evidence in support of the central claim.

      Weaknesses:

      (1) In the single-channel recordings (Figure 1a), it's unclear how many channels were present in those patches. After applying -60 mmHg pressure, multiple channels would be activated (as seen in Figure 1e). The number of channels in the patch and their inactivation rate could significantly influence the open probability in such experiments. To overcome this, in the original Yoda1 article (Syeda, Ruhma, et al. eLife 2015), no additional pressure was used. Additionally, the reported open probability comparison (n=7 Yoda1 vs n=17 DMSO patches) has an SEM nearly as large as the effect itself (0.30 {plus minus} 0.11), consistent with a small number of outliers driving this. The underlying mean open and shut times are reported without any statistical test; only the derived open probability receives a p-value. Additionally, in Figure 1a, the Yoda1 condition noise is different from the control. This should be stated if noise filtering was applied and how, given that this could affect open probability analysis.

      (2) The calcium imaging data in Figure 2 raise significant concerns regarding the chemical activation claim. The calcium-boosted solution (30 mM Ca2+) is not physiological and appears to be generally stressing cells rather than specifically activating PIEZO2: the control condition under CBS already shows an elevated signal, consistent with cells being unwell at this calcium concentration, and adding Yoda1 on top of this shifted baseline raises further questions about specificity rather than confirming it. Separately, it is unclear why DMSO alone produces measurable PIEZO2-associated calcium influx in HBSS, a result that is not addressed in the text. Figure 2 should clearly indicate when DMSO/Yoda1 perfusion was initiated, and y-axis labels are missing from panels A and B.

      (3) In the poke experiments, an activation threshold should be calculated and reported, and amplitude data (e.g., peak current versus indentation depth) should be shown rather than only inactivation tau values. It is also unclear why mClover3- and N-GFP-tagged constructs were used in these experiments, since electrophysiological recording already confirms channel expression without requiring a fluorescent tag.

      (4) For inactivation kinetics (Figure 3b), the authors use unpaired comparisons across separate cells, whereas the deactivation experiments (Figure 3c) use paired; it should be applied to the inactivation experiments as well. Deactivation kinetics for PIEZO2 itself should be shown. If the claim is that Yoda1 acts on PIEZO2 through the same mechanism proposed for PIEZO1, then a PIEZO1/2 chimera should be expected to show a corresponding effect on deactivation tau; instead, this chimera is reported as completely Yoda1-insensitive despite both parental channels being Yoda1-sensitive, as shown in this study.

      (5) Given that this reflects a different experimental paradigm for Yoda EC50, PIEZO1 should be included within Figure 4b. Additionally, EC50 bar plots should be present on this figure. The inactivation time constant for PIEZO2 without Yoda1 is inconsistent across figures, below 20 ms in Figure 3b but above 20 ms in Figure 4c.

      (6) Finally, the modeling is performed exclusively on PIEZO1, whereas the manuscript's central focus is PIEZO2. It is therefore unclear whether the proposed structural mechanism, including the basis for Yoda2's reduced efficacy on PIEZO2, can be directly extrapolated to PIEZO2.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      __Reviewer #1 (Evidence, reproducibility and clarity (Required)):____

      Summary In this study, Phalora et al identified the selective autophagy receptor SQSTM1/p62 as a MR1 interacting protein by proteomics approach using a cell line overexpressing MR1. While SQSTM1/p62 is implicated in autophagy regulation and autophagosome formation, genetic ablation of SQSTM1/p62 resulted in enhanced MAIT cell activation upon challenge with E. coli, but not with a synthetic agonist 5-OP-RU. In contrast, knockout of Atg5 and Atg7, both of which are involved in phagophore expansion engendered increased activation of MAIT cells upon both stimuli. From these data, the authors concluded that some factors in autophagy controlled the MR1 activity, thus the autophagy is a pivotal regulator of cellular antigen presentation.

      Major comments: 1. The notion that "This regulation appears to occur at an early step in the trafficking pathway." in the summary appears not to be compatible with the present data. What the authors have shown in the study is possible implication of autophagy components such as SQSTM1/p62, Atg5, and Atg7 that are implicated in autophagosome and phagophore formation. Should the authors highlight an "early step of trafficking", Atg14L, Atg13, and/or Atg101 must be analyzed by genetic knockout in addition to PI3 kinase inhibitors that are supposed to affect an early step in autophagy. Such an approach could confirm whether the regulation of MR1 occurs at an early step of trafficking, or at least, at an early step of autophagy.__


      The reviewer may have misinterpreted our conclusion. When we state ‘an early step in the trafficking pathway’ we are referring to MR1 trafficking (from the ER to the PM) and not to early steps in the autophagy pathway. We have modified the text to make this clearer.

      __ In Figure 2, while the degree of β2M depletion from B1 appears to be superior to that in B6 (Figure 2A), why the former was more potent in producing IFN-γ relative to the latter upon E. coli and 5-OP-RU (Figure 2D)?__


      We cannot conclusively say why MAIT cell activation is reduced to a greater extent in clone B6 compared to clone B1, whereas the protein depletion is not as pronounced. Most likely as these are clonal cells there may be genetic/phenotypic differences apart from depletion of B2M that may impact upon antigen presentation. Importantly both B1 and B6 are significantly decreased in terms of MR1 surface expression and MAIT cell activation compared to the control as would be expected.

      __ In Figure 3B, right column, what is Ac-6-FP? The left histograms show MR1 expression level upon DMSO, E. coli, and 5-OP-RU challenge. There is no explanation.__


      We thank the reviewer for pointing this out. The bar chart was mislabelled and should read 5-OP-RU (as in the histogram). This has now been corrected in the figure.

      __ Also in the same figure, was MR1 geomeans in Control, 5-1, 5-2, 5-3, 7-1, 7-2, and 7-3 upon Ac-6-FP superior to DMSO? If so or not, please explain the rational.__


      The difference in MR1 geomeans between DMSO and 5-OP-RU treated cells was significantly different. However as stated in the text the difference between control and Atg depleted cells for each condition was not statistically significant although there is a trend for increasing MR1 expression in KD cells.


      __ Figure 3C is highly intentional. If the authors put two left panels together (Control, 5-1, 5-2, and 5-3), is there still statistical difference among them?__


      The data for Atg5.3 was displayed separately as the experiments for this cell line were performed at a later timepoint using different donor cells. Therefore, it would be inappropriate to combine and/or compare them with the data for Atg 5.1 and 5.2. For clarity the figure has now been modified and this explanation added to the figure legend.

      __ There was no explanation for Figure 4B why the authors used Hela-MR1-HA. Other cell lines were used in the rest of the experiments. It is highly desirable to perform the experiment with THP1-MR1-HA in terms of logical development.__


      As the reviewer correctly states, it would be ideal to use Thp.MR1.HA cells for these microscopy experiments as they have been used throughout the rest of the paper. However, Thp1 cells can be difficult to image and HeLa cells which are more amenable to this technique are commonly used instead, generally and for MR1 studies. We have validated the HeLa.MR1.HA cell lines and can show that they upregulate MR1 at the cell surface in response to antigen and can activate MAIT cells. This data is now included as a supplementary figure (Supplementary Figure 11) and the rationale for the use of these cells explained in the main text.

      __ In addition, Figure 4B represent only the non-activated status. Given that association of SQSTM1/p62 with MR1 is dependent on E.coli and/or 5-OP-RU (Figure 1A), the same immuno-fluorescent imaging in the presence of the inhibitors upon stimulation with these reagents would also be desirable. It will uncover whether MR1 and SQSTM1/p62 colocalize upon stimulation, and such colocalization is perturbed in the presence of the inhibitors.__


      The aim of this microscopy experiment was to demonstrate that perturbations to the autophagy pathway induced by different drug treatments also affected MR1 localisation and/or expression to complement the other experiments in that figure (Figure 4A and 4C). SQSTM1 expression was included as a control as it is known to be regulated by autophagy. Although assessing the interaction between MR1 and SQSTM1 under different autophagy conditions may be of interest we did not find it to be particularly relevant in this case as our focus shifted to the autophagy pathway in general rather than the specific interaction between MR1 and SQSTM1.

      __ Whereas the authors addressed the question as to at which stage MR1 is regulated in trafficking in Figure 5, there was no experiments with 5-OP-RU (an agonist for MAIT cells). This casts the doubt whether observed phenotype really represented the true MR1 trafficking, because there is no guarantee that the trafficking pathway for antagonist (Ac-6-FP) is same as that for agonist.__


      5-OP-RU and Ac-6-FP are small chemically synthesised molecules and an agonist and antagonist of MR1 antigen presentation respectively There is no evidence to suggest that apart from activation of MAIT cells (5-OP-RU is stimulatory, Ac-6-FP is not) that they would behave any differently in terms of trafficking and interaction with MR1. Indeed, both are used interchangeably in the MR1 field.

      __ Given the importance of MR1 overexpression in showing the association between MR1 and SQSTM1/p62, it is worthwhile to consider performing the knockout experiments with Thp1-MR1-HA rather than Thp1. It will further clarify the role(s) of SQSTM1/p62, Atg5, and Atg7 in MR1 trafficking and resultant MAIT cell activation.__

      The interaction studies had to be performed with overexpressed MR1 as the endogenous protein is very difficult to detect for these types of experiments. The majority of the functional studies were performed with the endogenous protein which avoids any issues concerned with the use of overexpressed and tagged proteins and addresses concerns that interactions observed with the overexpressed protein are simply artifactual. As the functional assays validate the interaction data, we believe it is not necessary to repeat the depletion experiments in the MR1 overexpressed cell lines.



      __ Minor comments: 1.Please explain why the authors failed to detect IL23A in the coimmunoprecipitation. Should MR1-IL23A interaction be specific, what is a biological significance?__


      This point is addressed in the discussion. It is sometimes the case that interactions identified by mass spec cannot be recapitulated by co-immunoprecipitation and alternative methods may need to be employed to verify the interaction. Since this work concentrates on the autophagy pathway further experiments involving IL23A were deemed beyond the scope of this manuscript. Of note, IL23A will be strongly induced over very low background levels by E coli, which would amplify the impact of any weak interactions.

      __ When Hela-MR1-HA was used, did the authors obtain the same results as Thp1-MR1-HA as shown in Figure 1C-D? This is relevant to the specificity in the interaction between MR1 and SQSTM1/p62 as shown in Figure 4B.__


      The interaction between MR1 and SQSTM1 in the presence of E.coli was not confirmed in the HeLa.MR1.HA cells. SQSTM1 is included as a positive control as it is known to be regulated by autophagy. As these experiments were performed in the absence of any antigen, we would not expect to observe an interaction in this instance.


      __ While S1, S2, S3, and S4 showed a similar degree of SQSTM1 depletion in Figure 2A, there was difference in the potential of IFN-γ production from MAIT cells among the clones. Only S4 showed decreased potential for IFN-γ upon 5-OP-RU, though E. coli failed to so. Contrary to 5-OP-RU, S1-S3 showed an enhanced potential while S4 failed to do so. Why is that so?__


      As the SQSTM1 knockout cells are clonal cells there may be other genetic/phenotypic differences, besides depletion of SQSTM1, that can account for the observed differences in MAIT cell activation. To mitigate for these differences, we tested 4 different clonal cell lines, with 3 out of 4 clones displaying the same phenotype with respect to activation of MAIT cells.

      __ Given that there was little correlation between MR1 expression level and the potential of S1-S4 to promote or inhibit the ligand-dependent production of IFN-γ (Figure 2C right panel and Figure 2D), it is difficult to conclude that the factors implicated in autophagy play a pivotal role in MR1-dependent MAIT cell activation.__


      Surface MR1 levels on the whole are difficult to detect even in the presence of antigen as MR1 surface expression appears to be very tightly controlled. Although MR1 surface expression levels between the different SQSTM1 clones appeared to be somewhat variable, in the Atg depleted cells they showed a more consistent upregulation compared to the control (although these differences were not statistically significant). In both cases, stimulation with E.coli resulted in increased MAIT activation demonstrating that these autophagy proteins did affect MR1 presentation and that small (perhaps undetectable in some cases) changes in surface expression did impact MR1 function. Therefore, we have concluded that autophagy factors are able to regulate MR1 antigen presentation but to what extent and how remains unclear. We have removed the word ‘pivotal’ from the abstract as we agree with the reviewer that the impact of these interactions has not been conclusively established.

      __ There was no consistency in the experimental design for Figure 5. Please explain the rational why the authors have used 7.1 in A and C, but not in B, D and E?__


      For some of the experiments it was not possible to display and thus quantify all the cell lines in one figure eg the western blot data for the EndoH experiments (Figure 5D). Therefore, one representative cell line from Atg5 and Atg7 depleted cells was chosen, as on the whole all the cell lines behaved similarly. This rationale is now included in the main text.

      __ The control appeared to behave as 7.1 did. Was there statistical difference between 7.1 and 7.2 in Figure 5C? If so, what is the interpretation.__


      As the reviewer correctly notes, in Figure 5C the Atg7.1 cell line had similar kinetics to the control cell line in terms of MR1 surface expression. In other experiments Atg7.1 shows increased MR1 surface expression compared to the control (Figure 3B, although not statistically significant). One major difference between these experiments is the timing, Figure 3B is measured after an overnight incubation while Figure 5C is measured over 6 hours. It may be the case that in this cell line MR1 takes slightly longer to accumulate at the cell surface compared to Atg7.2. As these are heterogenous cell populations, there may be other factors that account for these differences apart from depletion of Atg7. Statistical analysis has now also been included for this data.

      __ Time course over 6 h will be required to assess the MR1 expression in Figure 5C.__

      It has been demonstrated by others that MR1 is able to reach the cell surface within 4 hours of antigen exposure (McWilliams et al, 2016), therefore a time course over 6 hours to measure MR1 surface expression was deemed sufficient.__

      Reviewer #1 (Significance (Required)):

      The present study uncovered the possible implication of autophagy factors in MR1 trafficking, in other words, MAIT cell activation. Although the previous study has demonstrated the importance of the protein loading factors (McWilliam et al., PNAS,117 24974-24985 2020), this study adds another pathway for MAIT cell activation. However, the conceptual significance is limited in that depletion of the factors pertinent to autophagy such as Atg5 and Atg7 in Thp1 resulted in rather weak interference in terms of MR1 trafficking and MAIT cell activation. Thus, this study will interest those who work in basic immunology, in particular, in regulation of antigen-presentation molecules and T cells as well as those who are in the field of MAIT cell biology. Although the field of this reviewer covers biochemistry, molecular biology, developmental biology, immunology and regenerative medicine, proteomics approach (in detailed technique) as seen here to identify the associated molecules is somewhat beyond the reviewer's expert.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Summary

      The authors used a mass spectrometry proteomics approach to screen for proteins which interact with the MHC-I-related molecule MR1. In addition to expected interacting partners, they identified SQSTM1/p62, a selective autophagy mediator, and demonstrated that MAIT cell responses to fixed E. coli were increased with knockout of SQSTM1. The authors further investigated the role of autophagy in regulating MR1 ligand presentation through knockout of two key autophagy proteins, Atg5 and Atg7, or treatment with various autophagy inhibitors. MR1 surface expression and MAIT cell activation were variably increased following interruption of autophagy in the context of fixed E. coli or synthetic ligand treatment of human monocytes and B cell lines. The authors concluded that preformed pools of MR1 are regulated by autophagy.

      Major comments

      Overall, this is an interesting study that is the first to identify autophagy as a potential regulatory mechanism for MR1. There are a number of conceptual questions relevant to the model system. The main concerns regard a number of the conclusions made, given the analysis of the data as presented. These concerns are described in more detail below.

      Conceptual concerns:

      1. The investigators rightly note the challenge in studying MR1 protein due to low endogenous expression. However, the use of over-expressed MR1 protein begs some questions with regard to the identification of ER degradation and autophagy proteins (which as they note are also involved in the degradation of damaged and defective cellular components). Although they have previously shown that MR1-HA tagged protein goes to the cell surface and presents antigen, it is impossible to know what proportion of the over-expressed molecules are functional, and it is plausible that a proportion of these molecules that end up in ER degradation or autophagy pathways identified, but would still IP with the HA tag. In the data shown, it is not entirely clear that the impacts of the molecules are actually impacting MR1 protein absent overexpression. Example: In Figure 2, there is very little impact of the complete KO of SQSTM1 on MR1 protein expression in WT THP1 cells, despite this protein only interacting with MR1 in E.coli infected cells. In contrast, in the 5-OP-RU incubated cells, there is a difference in MR1 expression in the SQSTM1 mutant clones, but no impact to MAIT cell activation. The authors note these issues and discuss the possibility that the other functions of SQSTM1 are coming in to play and further look at Atg5 and Atg7, however the absence of these proteins also have no significant impact on the expression of MR1 protein. Can the authors comment on this? The authors state that the increase in MAIT cell responses to fixed E. coli-treated polyclonal populations of SQSTM1 KO cells (same cells as SF2D) was blocked by the use of an anti-MR1 antibody, but do not show this data. Why not done with clonal populations? It is unclear why this data was not shown as it would help to support that the impact of inhibited autophagy is really on the functional MR1 protein pool, rather than a pool of non-functional but still HA tagged MR1 that has been shunted to degradation or autophagy pathways.__

      The reviewer rightly acknowledges the challenges associated with detecting endogenous MR1 protein levels which can be difficult to measure even after antigen exposure. For this reason, many researchers use a tagged protein in overexpressing cell lines to study MR1 as we (and others) have done for the proteomics analysis and validation studies. The use of tagged overexpressed proteins can be problematic because they may not recapitulate endogenous protein structure, localisation and/or function. Although we have previously demonstrated that HA tagged MR1 behaves similarly to its endogenous counterpart in terms of trafficking to the cell surface and presentation to MAIT cells (Ussher et al, 2016), there is still a possibility that there is a population of non-functional protein that is targeted for degradation. As we understand, it is the reviewer’s concern that it is this protein pool that is immunoprecipitating with autophagy components.

      Firstly, although the interaction studies were necessarily performed using tagged overexpressed protein, the majority of the functional studies (ie measuring surface MR1 levels and MAIT cell activation in SQSTM1 and Atg depleted cells, Figures 2 and 3) were performed in wildtype Thp1 cells, expressing endogenous levels of MR1. As explained in response to reviewer 1, MR1 surface levels as displayed in Figures 2C and 3B, are very tightly controlled and can be difficult to detect even after antigen exposure as demonstrated in the accompanying histograms. Therefore, subtle differences in MR1 surface levels are to be expected especially when measuring an increase rather than a decrease in expression. Although for SQSTM1 depletion there was some variability in MR1 surface levels, for Atg depletion there was a clear trend towards increased expression, although these differences were not statistically significant. In both cases (depletion of SQSTM1 and Atg) there was a definite effect on MR1 presentation as MAIT cell activation was increased in nearly all cases. It is well established in the literature that MAIT activation, in the 5 hour timecourse of our experiments, is wholly MR1 dependent. Therefore, these subtle, and perhaps sometimes undetectable, differences on endogenous MR1 surface expression do have an effect on MR1 function and we believe this validates the data from the interaction studies using overexpressed protein.

      In addition, experiments performed with the MR1 blocking antibody would not necessarily address the reviewers concerns as again these were done on Thp1 cells expressing endogenous levels of MR1 and not the overexpressing cell lines. However, for completeness this data has now been included as a supplementary figure.

      Secondly one of the top hits from the proteomics analysis was B2M, a protein known to associate with MR1 and to be functionally important. Other proteins identified by our screen include components of the peptide loading complex which have also been reported to be important for MR1 trafficking and antigen presentation. It should also be noted that SQSTM1 was identified in a similar proteomics screen performed by a different lab (McWilliams et al, 2020). Therefore, we believe that these findings also validate use of the HA tagged MR1 construct to generate true protein interactions.

      __ The conclusion that "regulation of MR1 by autophagy is not dependent on new protein synthesis and is most likely occurring on pre-existing pools of MR1" is not strongly supported by the data. If MR1 is processed normally through the golgi in Atg5 and 7 deficient cells (Figure 5D), how can the conclusion be made that the pre-existing pools of MR1 are in the ER? There is a non-significant decrease in MR1 surface expression from CHX treatment in the context of Ac-6-FP stimulation in Atg KO cells. This data is not clear enough to support a firm conclusion in either direction. Have the authors performed this experiment using 5-OP-RU or fixed E. coli as ligand sources? Is there a similar trend seen using the Atg KO C1R cells? Further supporting experiments may be necessary to conclude whether or not this trend is biologically relevant.__


      We thank the reviewer for their comment. The statement that pre-existing pools of MR1 are in the ER is based on reports from the literature where it has been shown that unbound ligand receptive MR1 remains in the ER until it comes into contact with antigen. Since we were able to show that MR1 trafficked normally through the Golgi in Atg depleted cells, the effects of autophagy on MR1 expression and function must occur prior to Golgi processing. This would indicate the ER population of MR1 as the likely targets of regulation by autophagy especially considering the function of SQSTM1 which binds to proteins in the ER.

      The experiments with CHX treatment were used to establish whether it was new or pre existing protein that was targeted by autophagy. Since CHX had no effect on MR1 surface expression this would indicate that new protein synthesis is not required for MR1 trafficking in Atg depleted cells.

      __

      Analysis of Western Blot data:

      1. There are many places throughout the manuscript where statements are made with regard to increases and decreases in the protein expression level with treatment, or comparisons between control and knockout samples. Although the legends generally indicate these experiments were based on at least 3 replicates (except some cases, where noted), there is no quantification of any western blotting data. There is no information in the legends or methods as to how much sample was loaded. Specific examples:

      a. Figure 1/Supp Figure 1: Figure 1C and 1D: There are several differences in the inputs between the 2 blots, including differences in the no antigen samples (which should be the same) or presence of multiple bands in one blot for a given marker but not the other. Fig 1C: the band for Calreticulin in the immunoprecipitated E. coli-treated Thp1.MR1.HA samples (right lane) is very weak. Fig. 1D: the bands are weak and there is no clear difference for Calnexin in the immunoprecipitated 5-OP-RU treated Thp1.MR1.HA samples (right lane) compared to no ligand despite the conclusion that Calnexin weakly associates with MR1 in the context of 5-OP-RU ligand. Are some of these weak associations visible due to different inputs? Why are the input blots for anti-HA so different between the no antigen controls in the E coli vs 5-OP-RU blots? Supp Figure 1B: the +5-OP-RU pulldown of MR1.HA appears as to be more (like with E.coli), but no quantification. Why does so little B2M IP with 5-OP-RU MR1? Supp Figure 1D (and others): statements are made about increases and decreases without quantification. All: Presumably HSP90 is used as a loading control for the input, but this is not discussed nor is there quantification.__


      We thank the reviewer for this comment. As western blotting is a multi-step process often over more than one day, there are numerous points at which variation can occur between blots no matter how carefully the conditions are controlled to minimise this. It is for this reason that it is generally not good practice to compare samples that have been run on different gels. Therefore, we do not believe that comparisons between blots in Figures 1C and 1D, relating to differences in input proteins for example, are appropriate nor informative. If we take the top anti-HA blot for Figure 1C there is a big increase in protein expression in the Ip of E.coli treated cells (final lane) which is not as pronounced with 5-OP-RU treatment (Figure 1D, top blot, final lane). This sample will dictate the exposure time of the blot (so as to prevent saturation of this sample) which then affects detectable expression of less well expressing samples on the same blot (such as the input samples in Figure 1C). Therefore there may appear to be less input protein in Figure 1C than Figure 1D but there is also more protein in the E.coli treated pull down than in the 5-OP-RU treated one, which also needs to be taken into account. This is one example of why it is difficult to compare samples across blots. To accurately and correctly compare these input samples they would need to be run on the same gel.

      The only useful comparison that can be drawn is between samples from the same blot, so comparing input protein in the presence and absence of E.coli for instance. To take the reviewer’s example, for the anti-calreticulin blot in Figure 1C, there is a weak interaction of calreticulin with MR1 in the presence of E.coli. If we compare the input lanes on this blot (effectively the loading control), there actually appears to be slightly more protein in the E.coli negative sample that the positive one. This would argue against the reviewers claim that this weak interaction is actually due to differences in the input and it is instead more likely to simply be a weak interaction. It is important to point out that this interaction, and others involving components of the peptide loading complex, have also been validated by other groups.


      With regards to Calnexin association with MR1 in the presence of 5-OP-RU, we did not mean to imply that this association was only in the presence of 5-OP-RU as it is evident from the data that Calnexin weakly associates even in the absence of antigen. The text has now been changed to make this clearer.


      The anti-HSP90 blot has been included to show that a random protein, not identified by our proteomics screen, does not spuriously associate with MR1, and not as a loading control for the input samples per se. This explanation has now been included in the text.

      Finally with regard to quantification of the co-immunoprecipitation blots, while quantification of western blots in some cases can be informative (eg relative expression of a protein compared to a control), it is at best only a semi-quantitative technique and not generally applied to co-immunoprecipitation data. As we are looking for a binary result (presence/absence of a particular protein) rather than a relative value, we do not see how quantification of this data will make it any more informative. We have included more detail of the sample loading in the methods section as requested by the reviewer and have added quantification of other blots where appropriate. __

      b. Supp Figure 5: The authors conclude there are no difference in protein interactions with MR1 in Atg5 or 7 deficient cells. By eye, there appear to in fact be differences, but there is no quantification to support the conclusions either iway. These data are subsequently used to make interpretive statements about the data in Figure 5. There is no indication of the number of times this experiment was performed.__

      In supplementary figure 5, we aimed to determine whether depletion of Atg 5 or 7 negatively affected the MR1 proteome ie whether interactions that were previously observed were disrupted and whether this contributed to the effects on MR1 antigen presentation observed in these cell lines. The interactions between MR1 and the tested proteins remained intact in Atg depleted cells. However, as Atg depletion increased MR1 protein expression some of these interactions are more pronounced in the depleted cell lines compared to the control cell line. Thus, the reviewer is correct in stating that there are differences in the protein interactions between the cell lines but in all cases the protein interactions remain intact which was the focus of our analysis. We have modified the text to make this clearer. The figure legend now also includes the number of replicates for this experiment.

      __ Figure 4A: No quantification to support conclusions. Unclear why both blocking and inducing autophagy would both increase the amount of MR1 in cells.__


      Quantification of this western blot data has now been included in the figure. Blocking autophagy (3MA and Wort) has a much greater effect on total MR1 protein levels, while inducing autophagy (EBSS) has minimal effects compared to the control. As autophagy is a highly dynamic process with western blotting providing just a snapshot of this process, inhibiting and inducing autophagy can both lead to the same observed phenotype of increased autophagosomes, due to blocking fusion with lysosomes and increased autophagosome formation respectively.

      __

      Analysis of Fluorescence microscopy data (Figure 4B):

      1. There are several concerns with the conclusions drawn from the fluorescence microscopy images (Figure 4B). How many images/fields were taken and cells analyzed per condition? How were individual fields chosen for imaging to be unbiased? Overall, the conclusions are observational and require quantification. For example, the authors indicate "an increase in MR1 cytoplasmic signal intensity following treatment...", but there is not data analysis to support this statement. This could be quantified by analyzing average MR1-HA fluorescence intensity across the cell volume compared to the bright fluorescence intensity of the non-cytoplasmic MR1-HA regions. Similarly, the number and intensity of the SQSTM1 foci should be quantified. Quantification is required to make the stated conclusions.__

      We thank the reviewer for their helpful suggestions regarding the microscopy experiments. Quantification of the data has now been added, including MR1 fluorescent intensity and the number of SQSTM1 foci, which supports the data from Figure 4A. The methods and figure legend have been updated to include more details of the analysis pipeline.


      __ Other statistical concerns:

      1. Some of the figure legends do not clearly state the number of independent experiments performed (2D, 3C-D, 5A, SF2, SF3, SF5). If these experiments were only performed once, additional repeats and appropriate statistical analysis are necessary to validate any conclusions drawn from these results.__

      The number of replicates for each experiment are now included in the figure legends. __

      1. Was statistical analysis performed on the MR1 mRNA expression in Figure 5A, and how many independent experiments are shown? There appears to be a decrease in MR1 expression in the Stg7.1 KO cells, which might impact the overall MR1 expression. Also, statistical analysis seems to be missing from 5B and 5C.__

      This figure has now been altered to reflect the number of replicates (2 biological replicates each consisting of 3 technical replicates) and statistical analysis has also been included. Statistical analysis for Figures 5B and 5C has also now been included. __

      1. In figure 5E, were there statistical comparisons between the Atg KO and control cells in the Ac-6-FP-treated non-CHX condition? It is unclear whether the statement "As previously observed, there was an increase in surface MR1 levels in Atg-depleted cells compared to the control in the presence of Ac-6-FP" is referring to the non-significant results in 3B or to this data presented in 5E. This statement should be revised to reflect the statistical significance of these data.__

      We thank the reviewer for this point. This figure has been amended to include a timecourse of CHX treatment in control and Atg depleted cell lines and statistical analysis has also been included. The statement has been clarified to highlight the point that CHX treatment does not affect the level of MR1 upregulation in control and knockdown cell lines.

      __

      Throughout the figures, several bar plots are missing the individual data points of experimental or technical replicates.__


      All bar plots display either the individual data points where donor cells were used or the average of 3 or more independent experiments with error bars denoting the standard deviation for experiments using cell lines.__

      1. The data in Figures 3C-D could be presented and analyzed as paired data (comparing the response from MAIT cells of each PBMC donor to the Ctrl cells vs the Atg KO clones) to better represent the impact of the KO.__

      We thank the reviewer for this suggestion. We believe that analysis via ANOVA is more appropriate in this instance due to the number of comparisons made with the control cells.__

      Other minor concerns:

      1. The conclusion "Overall, in the absence of SQSTM1, cellular changes induced by E. coli result in increased antigen presentation, which is not replicated with 5-OP-RU where MAIT activation may be adversely affected, implying that regulation of MR1 function by SQSTM1 may be dependent on the nature of the antigen" (page 6) is confusing and may need re-wording.__

      We are sorry for the confusion and have reworded this sentence to make it clearer. __

      1. The x-axis in the bar plots of Fig 3B labels the right group as "Ac-6-FP" in contrast to the histogram label and figure legend, which indicate the cells were treated with 5-OP-RU.__

      We thank the reviewer for pointing this out, the bar plot was indeed mislabelled and has now been corrected. __

      1. The presentation of data in Figure 5B is confusing. Perhaps the DMSO and Ac-6-FP conditions are mis-labeled? For the DMSO-treated samples, it appears that the data presented are percent surface MR1 GeoMean compared to the 0hr timepoint per cell lines. However, treating cells with Ac-6-FP should result in an increased surface MR1 expression (as seen in the non-CHX samples of Fig 5E, for example). If the data presented are percent of the 0hr DMSO control, wouldn't the % MR1 expression be higher for the Ac-6-FP samples than the DMSO samples? Alternately, it might be clearer to separate these two conditions onto separate plots, with % MR1 calculated relative to the 0 hr control of DMSO or Ac-6-FP treatment, respectively.__

      We thank the reviewer for pointing this out, the graph was indeed mislabelled and has now been corrected. The DMSO and Ac-6-FP treated samples are normalised to their own 0-hour timepoint (set at 100%) in order to directly compare the rate of decline of MR1 surface expression between the two conditions. This is now more clearly explained in the figure legend.

      __ Unclear in Figures 3 and 5 (and supplements) why all or only some of the Atg5 and 7 clones are used from experiment to experiment.__


      Please see our response to reviewer 1 on this point.__

      1. The discussion mentions "we found no evidence of an interaction between MR1 and AAKI" on page 9. What data supports this statement?__

      We found no evidence of an interaction between MR1 and AAK1 from our proteomics screen, this is now explained in the text.

      __ The discussion indicates that "This increase in SQSTM1 protein levels still resulted in increased MR1 surface levels and activation of MAIT cells, the same phenotype observed in SQSTM1-depleted cells" as it relates to the presence of E.coli. This statement is not fully supported by the data as SQSTM1 depletion did not lead to an increase in surface MR1 in E.coli treated cells.__


      We thank the reviewer for pointing this out, this sentence has now been corrected. __

      1. In the Proteomics/Mass Spec methods section on page 13, the citations to MaxQuant and Andromeda may need to be fixed.__

      We thank the reviewer for pointing this out, this has now been corrected. __

      1. There is no materials/methods section in the supplement. While most of this is covered by the main manuscript M/M section, there is no information on the IL12 and IL18 cytokine treatment, or treating with il12/il18 or isotype blocking antibody in SF1.__

      A methods section for the supplementary data has now been included. __

      1. Throughout the manuscript, several full stops are missing following in-text citations (ex: page 1, line 6 "...and Granzyme B 2-4 The microbial...").__

      We thank the reviewer for pointing this out, this has now been corrected.__

      1. The figure 1 legend should read "LC-MS/MS" rather than "LC-LC/MS"__

      We thank the reviewer for pointing this out, this has now been corrected.__

      1. Several of the citations need updating. They are listed as "Preprint available at ..." but for several of these references, the DOI links to the fully peer-reviewed publications, not a preprint.__

      We thank the reviewer for pointing this out, this has now been corrected.

      __

      Reviewer #2 (Significance (Required)):

      Significance

      Overall, this work expands the field knowledge of MR1 regulation and antigen presentation. The authors are the first to describe the putative role of key autophagy mediators like SQSTM1 and Atg5/7 in regulating MR1/MAIT cell activation. This report builds upon previous works exploring MR1 trafficking (Huang et al. JEM 2008, McWilliam et al. Nat Imm 2016, Harriff et al. PLoS Path 2016, Karamooz et al. Sci Rep 2019, McWilliam PNAS 2020, Huber et al. Sci Rep 2020) and MR1 protein stability (Abós et al. Biochem Biophys Res Commun 2011, Ussher et al. Eur J Immunol 2016, McWilliam et al. PNAS 2020, Kulicke et al. JBC 2022).

      This report would be of interest to researchers in the field of MR1 trafficking and antigen presentation, particularly in the context of increasing interest in targeting MR1 therapeutically (e.g. in cancer immunobiology or autoimmunity). From these results, future work could include characterization of the specific autophagy mechanisms which target MR1 for degradation, the role of SQSTM1 in modulating MR1 function via direct binding through autophagy or additional mechanisms, the variable mechanisms of MR1 trafficking and antigen presentation in the context of internal vs external ligand sources, and exploring if bacterial modulation of autophagy might impact MR1 antigen presentation.

      Expertise: MR1 trafficking and antigen presentation, MAIT cell activation, cell and molecular techiques, statistical analyses. Difficult to assess: the relevance of these marker in the autophagy field and evaluating the technical methods for LC-MS/MS.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In the current report, Phalora et al., have identified a number of proteins that bind to human MR1. Some of them, including those associated with the peptide-loading complex, such as tapasin, have been identified by others as well. However, these authors found that molecules associated with autophagy-specifically, SQST1/p62-were negative regulators of MR1 surface expression. In other words, knocking out the gene encoding this protein enhanced MR1 expression in THP-1 cells pulsed with E. coli and consequent MAIT cell activation. Moreover, CRISPR/Cas9-mediated deletion of the autophagy proteins, Atg5 and Atg7, resulted in an even greater enhancement of MR1 surface expression. Chemicals that block autophagy had similar effects in both THP-1 and primary PBMC monocytes. Thus, for the first time, it has been demonstrated that, like in classical HLA class I molecules, autophagy plays a role in the surface expression of the MR1 antigen presenting molecule. Overall, the study is very interesting and technically well-done. I do have a few questions, concerns and criticisms that are indicated in the sections below.

      Major Comments: 1. It was stated in the text that they used an anti-MR1 mAb to demonstrate the effects on MAIT cell activation were indeed MR1-dependent, yet these data were not shown. Those experiments should be included in the supplemental data section.__


      We thank the reviewer for this suggestion, this data has now been included as a supplementary figure.

      __ The Discussion lacks a "big picture" assessment/speculation about how these observations fit within a particular disease or set of diseases__


      The discussion has now been revised to include assessment of how these findings fit into the wider scope of MR1 restricted T cells in health and disease.

      __ THP-1 and C1R are essentially cancer cells and it has been shown that MR1T cells likely recognize a tumor antigen presented by MR1. Rather than using purified MAIT cells for this study, the authors used purified CD8+ T cells. MAIT cells represent a portion of them. How many of the non-MAIT cells were activated by THP-1 and/or C1R cells? One could compare MAIT vs. MR1T cell activation depending on the APC type.__


      We thank the reviewer for this suggestion. We re-analysed some of the data to focus on the non-MAIT population but we were unable to identify a population of non-MAIT cells stimulated by co-incubation with Thp1 or CR1 cells. In general, MR1T cells are quite rare and difficult to isolate solely from the non-MAIT cell population.


      __ As autophagy proteins have been shown to be important for MHC class I and, thanks to this work, MR1, it would have been helpful to discuss other antigen presenting molecules (e.g., CD1d) and what this could mean in immune responses overall. How does this help the host?__


      We have now included a section in the discussion to address the wider significance of these findings for immune responses via antigen presentation and the implications for other antigen presenting molecules.

      __ Minor Comment: 1. Some parts of some figures (e.g., Fig. 1B) have text so small that it is extremely difficult to read. This would be problematic in a journal article.__


      We thank the reviewer for pointing this out, the text in the figure has now been adjusted to make it easier to read.

      __

      Reviewer #3 (Significance (Required)):

      This study shows, for the first time, that autophagy processes impact cell surface expression of MR1 and this depends upon the antigen. Because this phenomenon has been demonstrated previously for classical MHC class I molecules (ref. 28) and the lipid-presenting antigen presenting molecule CD1d (Autophagy 13:1025-1036, 2017), the novelty of their findings is somewhat diminished.

      An audience who would be interested in this work would include investigators who study antigen presentation to both classical and innate T cells.

      Keywords: antigen presentation; MAIT cells; MR1; autophagy; innate immunity__

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary

      The authors used a mass spectrometry proteomics approach to screen for proteins which interact with the MHC-I-related molecule MR1. In addition to expected interacting partners, they identified SQSTM1/p62, a selective autophagy mediator, and demonstrated that MAIT cell responses to fixed E. coli were increased with knockout of SQSTM1. The authors further investigated the role of autophagy in regulating MR1 ligand presentation through knockout of two key autophagy proteins, Atg5 and Atg7, or treatment with various autophagy inhibitors. MR1 surface expression and MAIT cell activation were variably increased following interruption of autophagy in the context of fixed E. coli or synthetic ligand treatment of human monocytes and B cell lines. The authors concluded that preformed pools of MR1 are regulated by autophagy.

      Major comments

      Overall, this is an interesting study that is the first to identify autophagy as a potential regulatory mechanism for MR1. There are a number of conceptual questions relevant to the model system. The main concerns regard a number of the conclusions made, given the analysis of the data as presented. These concerns are described in more detail below.

      Conceptual concerns:

      1. The investigators rightly note the challenge in studying MR1 protein due to low endogenous expression. However, the use of over-expressed MR1 protein begs some questions with regard to the identification of ER degradation and autophagy proteins (which as they note are also involved in the degradation of damaged and defective cellular components). Although they have previously shown that MR1-HA tagged protein goes to the cell surface and presents antigen, it is impossible to know what proportion of the over-expressed molecules are functional, and it is plausible that a proportion of these molecules that end up in ER degradation or autophagy pathways identified, but would still IP with the HA tag. In the data shown, it is not entirely clear that the impacts of the molecules are actually impacting MR1 protein absent overexpression. Example: In Figure 2, there is very little impact of the complete KO of SQSTM1 on MR1 protein expression in WT THP1 cells, despite this protein only interacting with MR1 in E.coli infected cells. In contrast, in the 5-OP-RU incubated cells, there is a difference in MR1 expression in the SQSTM1 mutant clones, but no impact to MAIT cell activation. The authors note these issues and discuss the possibility that the other functions of SQSTM1 are coming in to play and further look at Atg5 and Atg7, however the absence of these proteins also have no significant impact on the expression of MR1 protein. Can the authors comment on this? The authors state that the increase in MAIT cell responses to fixed E. coli-treated polyclonal populations of SQSTM1 KO cells (same cells as SF2D) was blocked by the use of an anti-MR1 antibody, but do not show this data. Why not done with clonal populations? It is unclear why this data was not shown as it would help to support that the impact of inhibited autophagy is really on the functional MR1 protein pool, rather than a pool of non-functional but still HA tagged MR1 that has been shunted to degradation or autophagy pathways.
      2. The conclusion that "regulation of MR1 by autophagy is not dependent on new protein synthesis and is most likely occurring on pre-existing pools of MR1" is not strongly supported by the data. If MR1 is processed normally through the golgi in Atg5 and 7 deficient cells (Figure 5D), how can the conclusion be made that the pre-existing pools of MR1 are in the ER? There is a non-significant decrease in MR1 surface expression from CHX treatment in the context of Ac-6-FP stimulation in Atg KO cells. This data is not clear enough to support a firm conclusion in either direction. Have the authors performed this experiment using 5-OP-RU or fixed E. coli as ligand sources? Is there a similar trend seen using the Atg KO C1R cells? Further supporting experiments may be necessary to conclude whether or not this trend is biologically relevant.

      Analysis of Western Blot data:

      1. There are many places throughout the manuscript where statements are made with regard to increases and decreases in the protein expression level with treatment, or comparisons between control and knockout samples. Although the legends generally indicate these experiments were based on at least 3 replicates (except some cases, where noted), there is no quantification of any western blotting data. There is no information in the legends or methods as to how much sample was loaded. Specific examples:
        • a. Figure 1/Supp Figure 1: Figure 1C and 1D: There are several differences in the inputs between the 2 blots, including differences in the no antigen samples (which should be the same) or presence of multiple bands in one blot for a given marker but not the other. Fig 1C: the band for Calreticulin in the immunoprecipitated E. coli-treated Thp1.MR1.HA samples (right lane) is very weak. Fig. 1D: the bands are weak and there is no clear difference for Calnexin in the immunoprecipitated 5-OP-RU treated Thp1.MR1.HA samples (right lane) compared to no ligand despite the conclusion that Calnexin weakly associates with MR1 in the context of 5-OP-RU ligand. Are some of these weak associations visible due to different inputs? Why are the input blots for anti-HA so different between the no antigen controls in the E coli vs 5-OP-RU blots? Supp Figure 1B: the +5-OP-RU pulldown of MR1.HA appears as to be more (like with E.coli), but no quantification. Why does so little B2M IP with 5-OP-RU MR1? Supp Figure 1D (and others): statements are made about increases and decreases without quantification. All: Presumably HSP90 is used as a loading control for the input, but this is not discussed nor is there quantification.
        • b. Supp Figure 5: The authors conclude there are no difference in protein interactions with MR1 in Atg5 or 7 deficient cells. By eye, there appear to in fact be differences, but there is no quantification to support the conclusions either iway. These data are subsequently used to make interpretive statements about the data in Figure 5. There is no indication of the number of times this experiment was performed.
        • c. Figure 4A: No quantification to support conclusions. Unclear why both blocking and inducing autophagy would both increase the amount of MR1 in cells.

      Analysis of Fluorescence microscopy data (Figure 4B):

      1. There are several concerns with the conclusions drawn from the fluorescence microscopy images (Figure 4B). How many images/fields were taken and cells analyzed per condition? How were individual fields chosen for imaging to be unbiased? Overall, the conclusions are observational and require quantification. For example, the authors indicate "an increase in MR1 cytoplasmic signal intensity following treatment...", but there is not data analysis to support this statement. This could be quantified by analyzing average MR1-HA fluorescence intensity across the cell volume compared to the bright fluorescence intensity of the non-cytoplasmic MR1-HA regions. Similarly, the number and intensity of the SQSTM1 foci should be quantified. Quantification is required to make the stated conclusions.

      Other statistical concerns:

      1. Some of the figure legends do not clearly state the number of independent experiments performed (2D, 3C-D, 5A, SF2, SF3, SF5). If these experiments were only performed once, additional repeats and appropriate statistical analysis are necessary to validate any conclusions drawn from these results.
      2. Was statistical analysis performed on the MR1 mRNA expression in Figure 5A, and how many independent experiments are shown? There appears to be a decrease in MR1 expression in the Stg7.1 KO cells, which might impact the overall MR1 expression. Also, statistical analysis seems to be missing from 5B and 5C.
      3. In figure 5E, were there statistical comparisons between the Atg KO and control cells in the Ac-6-FP-treated non-CHX condition? It is unclear whether the statement "As previously observed, there was an increase in surface MR1 levels in Atg-depleted cells compared to the control in the presence of Ac-6-FP" is referring to the non-significant results in 3B or to this data presented in 5E. This statement should be revised to reflect the statistical significance of these data.
      4. Throughout the figures, several bar plots are missing the individual data points of experimental or technical replicates.
      5. The data in Figures 3C-D could be presented and analyzed as paired data (comparing the response from MAIT cells of each PBMC donor to the Ctrl cells vs the Atg KO clones) to better represent the impact of the KO.

      Other minor concerns:

      1. The conclusion "Overall, in the absence of SQSTM1, cellular changes induced by E. coli result in increased antigen presentation, which is not replicated with 5-OP-RU where MAIT activation may be adversely affected, implying that regulation of MR1 function by SQSTM1 may be dependent on the nature of the antigen" (page 6) is confusing and may need re-wording.
      2. The x-axis in the bar plots of Fig 3B labels the right group as "Ac-6-FP" in contrast to the histogram label and figure legend, which indicate the cells were treated with 5-OP-RU.
      3. The presentation of data in Figure 5B is confusing. Perhaps the DMSO and Ac-6-FP conditions are mis-labeled? For the DMSO-treated samples, it appears that the data presented are percent surface MR1 GeoMean compared to the 0hr timepoint per cell lines. However, treating cells with Ac-6-FP should result in an increased surface MR1 expression (as seen in the non-CHX samples of Fig 5E, for example). If the data presented are percent of the 0hr DMSO control, wouldn't the % MR1 expression be higher for the Ac-6-FP samples than the DMSO samples? Alternately, it might be clearer to separate these two conditions onto separate plots, with % MR1 calculated relative to the 0 hr control of DMSO or Ac-6-FP treatment, respectively.
      4. Unclear in Figures 3 and 5 (and supplements) why all or only some of the Atg5 and 7 clones are used from experiment to experiment.
      5. The discussion mentions "we found no evidence of an interaction between MR1 and AAKI" on page 9. What data supports this statement?
      6. The discussion indicates that "This increase in SQSTM1 protein levels still resulted in increased MR1 surface levels and activation of MAIT cells, the same phenotype observed in SQSTM1-depleted cells" as it relates to the presence of E.coli. This statement is not fully supported by the data as SQSTM1 depletion did not lead to an increase in surface MR1 in E.coli treated cells.
      7. In the Proteomics/Mass Spec methods section on page 13, the citations to MaxQuant and Andromeda may need to be fixed.
      8. There is no materials/methods section in the supplement. While most of this is covered by the main manuscript M/M section, there is no information on the IL12 and IL18 cytokine treatment, or treating with il12/il18 or isotype blocking antibody in SF1.
      9. Throughout the manuscript, several full stops are missing following in-text citations (ex: page 1, line 6 "...and Granzyme B 2-4 The microbial...").
      10. The figure 1 legend should read "LC-MS/MS" rather than "LC-LC/MS"
      11. Several of the citations need updating. They are listed as "Preprint available at ..." but for several of these references, the DOI links to the fully peer-reviewed publications, not a preprint.

      Significance

      Overall, this work expands the field knowledge of MR1 regulation and antigen presentation. The authors are the first to describe the putative role of key autophagy mediators like SQSTM1 and Atg5/7 in regulating MR1/MAIT cell activation. This report builds upon previous works exploring MR1 trafficking (Huang et al. JEM 2008, McWilliam et al. Nat Imm 2016, Harriff et al. PLoS Path 2016, Karamooz et al. Sci Rep 2019, McWilliam PNAS 2020, Huber et al. Sci Rep 2020) and MR1 protein stability (Abós et al. Biochem Biophys Res Commun 2011, Ussher et al. Eur J Immunol 2016, McWilliam et al. PNAS 2020, Kulicke et al. JBC 2022).

      This report would be of interest to researchers in the field of MR1 trafficking and antigen presentation, particularly in the context of increasing interest in targeting MR1 therapeutically (e.g. in cancer immunobiology or autoimmunity). From these results, future work could include characterization of the specific autophagy mechanisms which target MR1 for degradation, the role of SQSTM1 in modulating MR1 function via direct binding through autophagy or additional mechanisms, the variable mechanisms of MR1 trafficking and antigen presentation in the context of internal vs external ligand sources, and exploring if bacterial modulation of autophagy might impact MR1 antigen presentation.

      Expertise: MR1 trafficking and antigen presentation, MAIT cell activation, cell and molecular techiques, statistical analyses. Difficult to assess: the relevance of these marker in the autophagy field and evaluating the technical methods for LC-MS/MS.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1

      1. The inverse relationship between PGCLC and DE efficiency is intriguing but under-explored. The observation that lines efficient for PGCLCs (Podx1, Kolf2) are poor at DE differentiation, and vice versa, is one of the key findings. Yet this is presented almost in passing. It would strengthen the paper considerably if the authors discussed whether their Polycomb-regulated gene set predicts DE efficiency with an inverse sign, and whether the logistic regression model can be tested on the DE data directly.

      As suggested by the reviewer, we have enhanced our analysis of definitive endoderm (DE) differentiation efficiency and discussed it more prominently in the manuscript in the section “A subset of Polycomb targets is predictive of differentiation properties”. In particular, we now examine the correlation between gene expression from RNAseq and DE differentiation. For this purpose, we took the genes used to predict PGCLC efficiency (all of which are regulated by H3K27me3), and examined the correlation between their expression and the efficiencies of PGCLC and DE differentiation. We found that that differentiation is not a binary outcome for DEs, with many intermediate cases observed. Thus, instead of using a logistic regression, we employed a sigmoidal regression scheme for DEs. For this analysis, we used the absolute difference between observed and predicted efficiency, resulting in a mean absolute error of 12% [95% CI: 8-22%].

      We have now included an extra panel (Figure 7C) showing the correlations between expression of the H3K27me3 genes and the differentiation efficiencies in both PGCLC and DE fates. As anticipated by the reviewer, this plot reveals an inverse correlation, which we highlight in the main manuscript. Further, we now mention that these genes can also be used to predict DE differentiation efficiency, with satisfactory accuracy (although the confidence interval is wide due to the small sample size, as in the case of PGCLCs).

      The mathematical model is elegant but the choice to vary parameter E across cell lines needs stronger justification. The model assumes that inter-line differences are driven by variation in the overall rate of H3K27 methylation (parameter E). This is a reasonable starting assumption, but the authors should discuss alternative scenarios more explicitly. Could variation in demethylase activity, PRC2 recruitment strength, or replication timing equally well explain the data? The fact that EPOP is differentially expressed is mentioned as a potential mechanistic candidate for modulating E, which is compelling, but the link remains correlative. The authors should be more cautious in their language here, stating that EPOP "may be sufficient to completely switch the transcriptional regulation" goes beyond what the data show.

      We thank the Reviewer for these suggestions and have tightened our discussion of these points. It is correct that variation in demethylase activity can also explain our data. We now explicitly point this out in the section “The behaviour of H3K27me3 can be explained using a simple mathematical model”. However, this possibility does not fit as well with the RNA expression data. While we found differential expression of the PcG gene EPOP, we did not detect any differential expression of the KDM6 histone demethylases (KDM6A-KDM6C). Therefore, we still favour our original suggestion of variation in the methylation rates over this possibility. In addition, we have moderated our wording on EPOP, stating in the Discussion that changes in EPOP expression “may be sufficient to alter the transcriptional regulation of specific target genes.”

      The predictive model for differentiation efficiency is promising but the PGCLC training set is too small for confident generalisation claims.The authors acknowledge this (109 features, ~21 data points), and the L2 regularisation is appropriate. However, the claim of 91% accuracy with a 95% CI of 78-100% on the PGCLC data should be presented more cautiously. With such a small dataset, the confidence interval is very wide. The more convincing validation comes from the DN data (143 lines from Jerber et al.), where the model trained on PGCLC data performs comparably to the full-transcriptome model. This cross-fate generalisation is quite strong and should be emphasised more prominently as the primary evidence for the validity of the model.

      We have followed the reviewer’s guidance and revised our language, when discussing the PGCLC case in the section “A subset of Polycomb targets is predictive of differentiation properties”. We have also emphasised more clearly the successful validation of the DN data.

      1. The claim of "epigenetic memory" during differentiation (iPSC to pre-ME) is suggestive but would benefit from additional analysis. The authors show that 60% of pre-ME DEGs overlap with iPSC DEGs, and that H3K27me3-cluster genes maintain their expression patterns. However, 60% overlap could partly reflect genes that are simply not regulated during the short 12-hour pre-ME induction. To strengthen this claim, the authors should compare the overlap rate for H3K27me3-cluster genes specifically versus other clusters. If Polycomb targets show significantly higher overlap than, for example, K4&ATAC genes, this would more convincingly support a Polycomb-specific memory mechanism.

      We have now performed this analysis, examining the persistence of DEGs into the pre-ME state (i.e., whether a gene that was differentially expressed in hiPSCs remains differentially expressed in pre-ME). Excluding the H3K9me3 cluster (the smallest cluster containing fewer than 25 genes), the K27 cluster is the most persistent cluster in terms of fraction of genes per cluster. When the clusters were pooled into the different variables involved (ignoring H3K9me3), H3K27me3 again emerged as the most persistent chromatin feature. Unfortunately, however, these results were not statistically significant, so we are unable to include them in the manuscript.

      Lack of genetic background analysis. Ten lines from nine donors will harbour substantial genetic variation. The authors note that genetic variation has been linked to iPSC heterogeneity but do not analyse whether the three "outlier" lines (Kucg2, Sojd3, Yoch6) share genetic features. For instance, common variants at PRC2 component loci, EPOP regulatory variants, or structural variants that might alter H3K27me3 domain boundaries. The HipSci consortium provides genotyping data for these lines. A targeted analysis of variants at Polycomb-related loci would be feasible and could either strengthen the epigenetic interpretation or reveal a genetic confounder.

      We thank the Reviewer for raising this important point. To investigate potential confounding effects due to genetic variation between the hiPSC lines in our panel, we performed a targeted analysis of genetic variation across Polycomb-related loci (H3K27me3 occupied loci and Polycomb group genes) in all ten cell lines (using whole genome sequencing data from the HipSci consortium). This analysis specifically tested whether the three “compromised” lines (Yoch6, Sojd3 and Kucg2) share consistent genetic variants relative to the seven “normal” lines. We identified 15 indels (out of 4115) that satisfied this criterium. However, all are located in non-coding regions and none overlap with ATAC-seq peaks. Hence, they are unlikely to function as gene regulatory elements (e.g., enhancers), but we cannot exclude the possibility that they affect gene expression in other ways. We have added a new Results section “Genetic variants shared between differentiation-compromised hiPSC lines” to discuss these points, as well as adding new text to the Discussion and Methods.

      Minor Comments

      The promoter definition ({plus minus}1 kb from gene start) is non-standard; most studies use a window upstream of the TSS rather than gene start. The authors mention they confirmed robustness to an alternative definition (-1 kb to gene start) but do not show this data. It should be included in the supplement.

      We now show the data for the alternative promoter definition in Supplementary Fig. 5B and Supplementary Fig. 7C. These results demonstrate that our conclusions are robust to different promoter definitions.

      For CUT&Tag, no spike-in normalisation is mentioned. Given that the key conclusions is based on quantitative comparisons of H3K27me3 levels across cell lines, the absence of spike-in controls is a potential concern. The authors should discuss whether technical variation between CUT&Tag libraries could contribute to the observed bimodality. At minimum, the correlation between replicates for H3K27me3 should be shown (presumably it is high, but this should be documented).

      We thank the Reviewer for this suggestion. As now shown in Supplementary Fig. 4C, the correlation between our H3K27me3 replicates is indeed high (R between 0.93 and 0.96). Hence, technical variation between CUT&Tag libraries is unlikely to contribute to the observed bimodality.

      The statistical test for the PGCLC/H3K27me3 overlap (p We thank the reviewer for noticing this. Indeed, this is the case. The test assumes independence of lines, which is in general a reasonable assumption, but may not always hold. Specifically, the Kolf2 and Kolf3 lines are derived from the same donor, which implies they are not completely independent. However, for all other lines, we still think independence is a reasonable assumption and, thus, the overall result of the test should be a good approximation. We have added this caveat to the manuscript.

      Figure 6A: the heatmaps for H3K4, ATAC and H3K27 are shown side by side but at apparently different scales; this should be clarified or made consistent.

      Indeed, the scales in all heatmaps are the same. We have clarified this in the captions of the figures.

      Reviewer #2

      1.) Figure 2B. Are all GO terms shown in the figure or are these just the top terms? If this is a suset then all terms should be provided as a supplemental table. If this is all significant terms, this is relitavely modest considering the number of DEGs (712) and is probably due to the fact that DEGs are derived from all comparisons and so could be diluted by the presence of multiple opposing effects. If this is the case, you could identify DEGs that define the PCA groupings and then re-run the GO analysis to potentially provide a better definition of the functional differences between groups of cell lines.

      The GO terms previously displayed were the top hits. We have now included all the significant terms in Supplementary Files 4 and 5 (for the Molecular Function and the Biological Process ontologies, respectively).

      Chromatin accessibility at gene promoters is a poor predictor of transcription, but it is likely that accessibility at distal regions (e.g putative enhancers) might be a better predictor. Did the authors look at this? This possibility should at least be mentioned when discussing the ATC-seq data and the lack of correlation with transcription.

      • *

      We thank the reviewer for this suggestion. To locate additional regulatory regions, we downloaded tracks for the enhancer-associated marks H3K4me1 and H3K27ac for the ten cell lines from Todd and colleagues (Todd et al., Genome Biology, 2025; https://genomebiology.biomedcentral.com/articles/10.1186/s13059-025-03658-8). We then intersected the ATAC-seq peaks with the H3K4me1 peaks in each cell line to identify putative enhancers. For each protein coding gene, we then identified the closest ATAC and H3K4me1 positive peak (among all cell lines), which we assumed was the most likely enhancer for that gene. We then evaluated the ATAC, H3K27ac and H3K27me3 signal within these enhancers for each cell line. With this information, we tried using a version of our SVM-based pipeline to improve our understanding of transcriptional regulation in genes within the ‘origin’ cluster (for which we failed to get significant insights from our standard SVM approach). Thus, we used seven variables as an input for the SVM: The four of the standard approach and three additional variables from the ATAC/H3K27ac/H3K27me3 signal at the nearest enhancer. However, for genes with an enhancer closer than 100kb, the performance of the SVM with enhancer variables was similar to the standard SVM (or slightly worse). If we focused on genes with enhancers 10kb or closer to the TSS (75 genes), then the SVM with the enhancer signal did modestly improve the prediction. However, when analysing the results more closely, it was only for a handful of genes (around 10) where the usage of the enhancer data was beneficial, and, even then, it was mostly down to the H3K27me3 signal rather than the more standard enhancer marks, such as H3K27ac or chromatin accessibility. This lack of improvement in the accuracy is probably due to our inability to identify the correct enhancers, as distance on the linear genome scale is often a poor predictor of enhancer-promoter interactions.

      Ultimately, because the improvement is for such a small number of genes, we have not included this analysis in the manuscript. However, we do now mention in the manuscript in section “Chromatin accessibility does not always correlate with transcription” that we tried to include distal enhancers but that this approach was not successful.

      2.) Fig 1C. Statistic overview at end of legend should be moved under section describing panel C in the legend.

      We have now made this change.

      3.) 'Furthermore, the transition value of 30% enables repression to be stably maintained even after DNA replication, when, on average, histone modification levels will be transiently halved'. Whilst this is potentially true and a plausible interpretation, you cannot exclude that the signal is not derived from different cell populations in the culture due to cellular heterogeneity such as cell cycle or spontaneous differentiation. This possibility should be noted in the text.

      We thank the Reviewer for this suggestion. Due to the possible alternative explanations pointed out by the reviewer, and to minimise any possible misunderstandings, we decided to drop this sentence from the manuscript, which is not required for any of our main conclusions.

      4.) 'Higher values indicate stronger correlation or anticorrelation and, thus, stronger differences between cell lines.' I don't believe this makes sense as written. Do the authors mean stronger partitioning of different iPSC lines into clusters?

      Indeed, this sentence wasn’t very clear -- we have now rewritten it to improve clarity: “Because absolute correlation values were used, high values indicate that expression profiles between two cell lines are either highly correlated or highly anticorrelated. Across all pairwise comparisons, high values suggest strong partitioning of cell lines with highly similar or markedly different transcriptional profiles.”

      5.) 'We found that 60% of the DEGs in pre-ME were also DEGs in hiPSCs'. This needs to be made clearer. Do the authors mean DEGs between iPSCs following differentiation or DEGs between undifferentiated iPSCs and their differentiated derivatives? The former suggests that the iPSCs are already partially differentiated and that differentiation in promoted or constrained by this starting state whilst the latter would suggest that some lines are skewed towards the mesendoderm.

      We mean that of the genes that are differentially expressed between the 10 lines in pre-ME, 60% were also differentially expressed between the 10 lines in iPSCs (prior to differentiation). We have reworded this sentence to make it clearer.

      6.) 'Finally, histone marks in the iPSC state were also predictive of expression in the pre-ME state, albeit with slightly lower accuracy than for the iPSC state (Supplementary Fig. 8C, D), which may indicate the existence of an epigenetic memory system that is maintained during differentiation.' Or the retention of an epigenetic signature that failed to be erased during the initial generation of the iPSCs.

      We agree with the reviewer that this is entirely possible: our point is that memory states may persist from iPSCs to pre-ME. The memory state may of course predate the initial generation of the iPSCs. We have amended the section “Pre-ME transcriptomes suggest inheritance along the developmental trajectory” to include this possibility.

      7.) 'To minimise the risk of overfitting, only reliable targets were retained'. Whilst this is outlined in the methods as stated, a summary of what this means should be included in the body text.

      We thank the Reviewer for this suggestion. We have included the required extra text in the section “A subset of Polycomb targets is predictive of differentiation properties”. We have also revised the performance metrics so that they are strictly comparable with the results of Jerber and colleagues (which implies, in some cases, removing error bars, as in the results of Jerber et al., 2021). The reviewer may notice differences in the values reported but all our claims remain valid.

      Reviewer #3

      The major claim that among histone modifications that have been profiled in this manuscript, H3K27me3 is the most predictive for expression is supported by the analysis. However the analysis may be skewed because the RNAseq and the H3K27me3 difference are driven by the extreme skewing of the 3 cell lines Yoch6, Sojd3 and Kucg (Fig 2A, 2C and 6A). Two of these lines cannot form EBs at all, a major failure in their pluripotent characteristics.

      We thank the reviewer for raising this fundamental point. Our aim for this study was to use iPSC lines that have passed existing standards and could easily be chosen from a panel of lines by an unsuspecting user. Indeed, the differentiation-compromised lines in our study are indistinguishable from other PSCs from a validated source that extensively characterises the distributed material (HipSci resource, https://www.hipsci.org). This source categorises these cell lines as correctly reprogrammed and fully pluripotent. In addition, we now present PluriTest data (doi: 10.1038/nmeth.1580) from all normal lines available from the HipSci resource (835 lines) and highlight the ten cell lines used in this study (see Supplementary Fig. 1A). All cell lines in our panel have pluripotency scores over 20, and all but one (Bima1 – which notably differentiates efficiently into PGCLCs and DNs) have novelty scores below 1.67; these values have been empirically determined as pluripotency signature thresholds (Müller et al., 2011). This analysis clearly demonstrates that the cell lines in our study are not outliers, an important fact which we have now added to section “Marked differences in the developmental efficiency of hiPSC lines”.

      Furthermore, one of the key advances of our study is that we identify a chromatin and transcription signature that will enable researchers in the stem cell community to identify iPSC lines with compromised differentiation potential early on. We also note that compromised differentiation potential is widespread among human PSCs. For example, Jerber et al. report that 48 out of 183 hiPSC lines could not be differentiated successfully into dopaminergic neurons (doi:10.1038/s41588-021-00801-6). Thus, our study addresses an important and widespread issue in the stem cell field, a point we now emphasise in the introduction of the manuscript.

      Further, one of the lines that can form EBs, fails to make PGCLCs but can differentiate into DE, Letw5 has neither the RNA profile nor the H3K27me3 profile of the skewed iPSC lines. Therefore, whether H3K27me3 truly influences phenotype at least in terms of PGCLC and DE differentiation of iPSCs is not supported by the analysis in the manuscript.

      We agree that the behaviour of Letw5 is interesting, and we discuss its properties extensively in section “Marked differences in the developmental efficiency of hiPSC lines” and Fig. 1E. As we state, comparing Letw5 with Kucg2, “These findings suggest that Kucg2 hiPSCs have limited developmental competence to generate PGCLCs, while Letw5 hiPSCs are capable of PGCLC specification but fail to sustain the germ cell fate, pointing to a defect in fate maintenance rather than in initial developmental capacity.” Hence, the evidence points towards Letw5 having a separate defect which is unrelated to the impaired Polycomb regulation identified in the other three problematic lines. We also emphasise this point in section " A major role for H3K27me3 in hiPSC transcriptional heterogeneity", where we state that "[...] in this case [Letw5], a distinct mechanism, independent of H3K27me3 dysregulation, may result in impaired germ cell development."

      1. What are the predictions from applying SVM to data from only the 6 cell lines Podx, Kolf2, Kolf3, Bima 1, Qolg1, Wibj2. The DE differentiation potential will also have to be measured for each of these cell lines.

      Following the reviewer’s suggestion, we applied the SVM only to data from those six cell lines (which do not include any of the defective cell lines), see section “Linking variation in chromatin features with transcriptional output using SVMs”. Given that the SVM only takes as input data from differentially expressed genes, the set of genes used decreased markedly as there are fewer genes differentially expressed among these cell lines (125 DEGs). Nevertheless, for this subset of genes, the SVM still retains satisfactory accuracy (both AUROC and overall accuracy in the 70% to 75% range; now shown in Supplementary Fig. 6H). This result is particularly remarkable given that the SVM is operating with very little data (five datapoints for training and one for testing, per gene) and that the cell lines are very similar to each other. As the reviewer points out, we hope these results might encourage other researchers to pursue similar analysis approaches.

      For DE differentiation, we previously included data (Supplementary Fig. 3B, C) for the following lines: Podx1, Kolf2, Kucg2, Letw5, Sojd3, and Yoch6. Only Kolf3, Bima1, Qolg1 and Wibj2 were missing. We have also now measured DE differentiation in three remaining lines (Kolf3, Qolg1, and Wibj2).

      The above analysis may also shed light on howextreme the input parameters must be for SVM to be a good classifier? Such an analysis may also assist future users of the method to assess whether SVM would be useful for their datasets.

      Please see our previous answer. We argue that the results presented above for six similar cell lines imply that this type of computational approach can have general applicability and does not require extreme inputs. We have followed the Reviewer’s suggestion and now incorporate this finding in section “Linking variation in chromatin features with transcriptional output using SVMs”: “Furthermore, the SVM does not require extreme values or outliers, and hence the overall approach could be of rather general applicability. As a performance verification, we applied the SVM to a dataset containing only the cell lines that could generate PGCLCs with high or intermediate efficiency, and while the performance is slightly reduced, it remains satisfactory (accuracy 75%; Supplementary Fig. 6H).”

      If the SVM on the 6 lines does not predict a binary switch in H3K27me3 to be predictive could the authors incorporate DNA methylation and H3K4me1 from the same publication as the chromatin accessibility. Such an analysis may also assist future users of the SVM method to assess the number of parameters required to separate closely related phenotypes.

      See previous answer. We note that DNA methylation data for our hiPSC panel is not available; it is not part of the study that the reviewer mentions (https://link.springer.com/article/10.1186/s13059-025-03658-8). Although H3K4me1 data is available in Todd et al., we did not find that this data improved the ability of our model to make successful predictions (see reply to Reviewer #2, point 1).

      Most gene regulation occurs at the level of the enhancer, restricting analysis to promoter associated histone modifications is limiting.

      We thank the Reviewer for raising this very valid point. Please see response to Reviewer #2, point 1.

      One puzzling piece of data is the very high 60% of PGCLCs on day 1 of differentiation (Fig 1E) in the competent cell lines. BLIMP1 is expressed in hiPSCs, calling into question whether the initial differentiation into pre-ME was successful.

      We think there is a misunderstanding regarding the experimental timeline. Day 1 of differentiation in Fig. 1E refers to one day after PGCLC induction from the pre-ME stage following the addition of BMP4, SCF, LIF, and EGF (see schematic in Fig. 1A). We have revised the text to make this clearer. Furthermore, BLIMP1 (PRDM1) is not expressed in hiPSCs. To demonstrate this, we now show the expression levels of BLIMP1 (PRDM1), B2M (low to mid-level expression in most human cell types), SOX2 (highly expressed pluripotency marker), and HOXC10 (differentiation marker that is not expressed in PSCs) across our cell line panel. At this scale, BLIMP1/PRDM1 expression is not detectable. When SOX2 is omitted from this bar plot, the very low expression levels of BLIMP1/PRDM1 become apparent, as it is close to the levels for the differentiation marker HOXC10. We conclude that BLIMP1/PRDM1 is expressed at extremely low levels across our ten hiPSC lines.

      The H3K27me3 and H3K9me3 signals are integrated over the entire gene as inputs into the SVM, however PCA analysis to separate the cell lines is only shown for the promoter

      This is not quite correct. For the PCA analysis for the histone marks and ATAC-seq, we used both the promoter region (Fig. 2C, Supplementary Fig. 5B) and the gene body (Supplementary Fig. 5A), with similar results. For the SVM, for H3K27me3 and H3K9me3, we primarily used the entire gene region, but we also tested other regions (Supplementary Fig. 6A), with similar or slightly inferior results.

      SVMs have been used to predict enhancers from epigenomic data PMID: 22328731 and to classify cancers PMID: 11120680. Applying SVM as classifier for gene expression prediction is not very novel.

      We thank the Reviewer for raising this point. We did not claim that the use of SVMs was itself novel. It has certainly been used in other contexts, as the reviewer points out, to predict enhancers, for cancer classification, and to predict expression patterns. In fact, SVMs had already been used to predict gene expression from chromatin features (Cheng et al, 2011; already cited in our manuscript). What is novel in our work is the reverse-engineering of the method to extract mechanistic information about each gene (i.e., assign a chromatin feature set relevant to the changes in expression). This computational methodology, in conjunction with the rich experimental dataset produced, allows us to classify differentially expressed genes in terms of the chromatin features that enable prediction of transcription. This highlights the differences between cell lines and enables further downstream analysis such as, mechanistic models of histone modification dynamics and the prediction of iPSC differentiation efficiency. We have rewritten the Introduction to the manuscript to better emphasise these points.

      The biological insights are limited. For example, the observation that " a variety of forms of transcriptional regulation" Fig 4B. It is well known that H3K27me3 decorates lineage specifying genes and is part of the bivalent domain with H3K4me3. The anti-ATAC category could represent locations where a repressor is bound DNA which would also result in increased accessibility and is not a surprising result.

      We believe our work does offer significant biological insights. While we agree that it is well known that H3K27me3 decorates lineage specifying genes, it was not previously known that digital Polycomb dysregulation at specific loci was a key feature controlling the ability of pluripotent cell lines to differentiate properly. In addition, we have been able to identify a core set of genes whose H3K27me3 profiles are highly informative for differentiation efficiency. Moreover, we are able to explain the variation in H3K27me3 levels by simple, quantitative, mathematical model.

      Finally, the anti-ATAC category is a minor finding and not one of the central conclusions of this paper. Nevertheless, we appreciate the Reviewer’s suggestion and have incorporated this possible interpretation into section “Chromatin accessibility does not always correlate with transcription”.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Human induced pluripotent stem cells (iPSCs) have variable differentiation capability and can demonstrate bias toward specific lineages. In this manuscript, try to identify epigenetic features that may explain biased differentiation. They perform RNAseq and CUT and TAG for H3K4me3, H3K27me3 and H3K9me3 on 10 hiPSC lines which some of which show a opposing differentiation potential toward primordial germ cell like cells (PGCLCs) or definitive endoderm (DE). Using a support vector machine per gene that is variably expressed, they identify combinations of epigenetic marks and accessibility that could explain the change in expression. They identify H3K27me3 as a binary switch with high enrichment of this modification, predicting repression.

      The major claim that among histone modifications that have been profiled in this manuscript, H3K27me3 is the most predictive for expression is supported by the analysis. However the analysis may be skewed because the RNAseq and the H3K27me3 difference are driven by the extreme skewing of the 3 cell lines Yoch6, Sojd3 and Kucg (Fig 2A, 2C and 6A). Two of these lines cannot form EBs at all, a major failure in their pluripotent characteristics. Further, one of the lines that can form EBs, fails to make PGCLCs but can differentiate into DE, Letw5 has neither the RNA profile nor the H3K27me3 profile of the skewed iPSC lines. Therefore, whether H3K27me3 truly influences phenotype at least in terms of PGCLC and DE differentiation of iPSCs is not supported by the analysis in the manuscript. Further analysis that may support their claim

      1. What are the predictions from applying SVM to data from only the 6 cell lines Podx, Kolf2, Kolf3, Bima 1, Qolg1, Wibj2. The DE differentiation potential will also have to be measured for each of these cell lines.
      2. The above analysis may also shed light on how extreme the input parameters must be for SVM to be a good classifier? Such an analysis may also assist future users of the method to assess whether SVM would be useful for their datasets.
      3. If the SVM on the 6 lines does not predict a binary switch in H3K27me3 to be predictive could the authors incorporate DNA methylation and H3K4me1 from the same publication as the chromatin accessibility. Such an analysis may also assist future users of the SVM method to assess the number of parameters required to separate closely related phenotypes.
      4. Most gene regulation occurs at the level of the enhancer, restricting analysis to promoter associated histone modifications is limiting.
      5. One puzzling piece of data is the very high 60% of PGCLCs on day 1 of differentiation (Fig 1E) in the competent cell lines. BLIMP1 is expressed in hiPSCs, calling into question whether the initial differentiation into pre-ME was successful.
      6. The H3K27me3 and H3K9me3 signals are integrated over the entire gene as inputs into the SVM, however PCA analysis to separate the cell lines is only shown for the promoter The recommended analysis above is not substantial because it only requires missing DE differentiation in terms of experiments. Data and methods have sufficient detail to be reproduced.

      Referee cross-commenting

      I agree with the other reviewer comments

      Significance

      The data generated and differentiation are useful for the hiPSCs community.

      SVMs have been used to predict enhancers from epigenomic data PMID: 22328731 and to classify cancers PMID: 11120680. Applying SVM as classifier for gene expression prediction is not very novel.

      The biological insights are limited. For example, the observation that " a variety of forms of transcriptional regulation" Fig 4B. It is well known that H3K27me3 decorates lineage specifying genes and is part of the bivalent domain with H3K4me3. The anti-ATAC category could represent locations where a repressor is bound DNA which would also result in increased accessibility and is not a surprising result.

      Specialized for an audience of epigenetics and iPSC.

      My expertise is in epigenetics, cell identity specification and pluripotency. I do not have expertise to evaluate accuracy of compuational method.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary

      This study investigates the molecular basis of inter-line variability in human iPSC differentiation efficiency. The authors profile ten HipSci consortium hiPSC lines for transcriptome (RNA-seq), chromatin accessibility (ATAC-seq, from a prior study), and three histone modifications (H3K4me3, H3K9me3, H3K27me3) by CUT&Tag. They develop an SVM-based computational pipeline to link epigenomic variation to transcriptional differences across lines. The central findings are that H3K27me3 variation shows the most consistent inter-line differences, displays a bimodal (digital ON/OFF) distribution consistent with a mathematical model of PRC2 read-write feedback, and that a small set of Polycomb-regulated genes can predict differentiation efficiency into both PGCLCs and dopaminergic neurons. The authors also show that these transcriptional differences propagate into the pre-mesendoderm intermediate state, suggesting epigenetic memory during early lineage commitment. This is overall a very good study, with interesting and novel findings for the field. However, some issues should be addressed before publication:

      Major Comments

      1. The inverse relationship between PGCLC and DE efficiency is intriguing but under-explored. The observation that lines efficient for PGCLCs (Podx1, Kolf2) are poor at DE differentiation, and vice versa, is one of the key findings. Yet this is presented almost in passing. It would strengthen the paper considerably if the authors discussed whether their Polycomb-regulated gene set predicts DE efficiency with an inverse sign, and whether the logistic regression model can be tested on the DE data directly.
      2. The mathematical model is elegant but the choice to vary parameter E across cell lines needs stronger justification. The model assumes that inter-line differences are driven by variation in the overall rate of H3K27 methylation (parameter E). This is a reasonable starting assumption, but the authors should discuss alternative scenarios more explicitly. Could variation in demethylase activity, PRC2 recruitment strength, or replication timing equally well explain the data? The fact that EPOP is differentially expressed is mentioned as a potential mechanistic candidate for modulating E, which is compelling, but the link remains correlative. The authors should be more cautious in their language here, stating that EPOP "may be sufficient to completely switch the transcriptional regulation" goes beyond what the data show.
      3. The predictive model for differentiation efficiency is promising but the PGCLC training set is too small for confident generalisation claims. The authors acknowledge this (109 features, ~21 data points), and the L2 regularisation is appropriate. However, the claim of 91% accuracy with a 95% CI of 78-100% on the PGCLC data should be presented more cautiously. With such a small dataset, the confidence interval is very wide. The more convincing validation comes from the DN data (143 lines from Jerber et al.), where the model trained on PGCLC data performs comparably to the full-transcriptome model. This cross-fate generalisation is quite strong and should be emphasised more prominently as the primary evidence for the validity of the model.
      4. The claim of "epigenetic memory" during differentiation (iPSC to pre-ME) is suggestive but would benefit from additional analysis. The authors show that 60% of pre-ME DEGs overlap with iPSC DEGs, and that H3K27me3-cluster genes maintain their expression patterns. However, 60% overlap could partly reflect genes that are simply not regulated during the short 12-hour pre-ME induction. To strengthen this claim, the authors should compare the overlap rate for H3K27me3-cluster genes specifically versus other clusters. If Polycomb targets show significantly higher overlap than, for example, K4&ATAC genes, this would more convincingly support a Polycomb-specific memory mechanism.
      5. Lack of genetic background analysis. Ten lines from nine donors will harbour substantial genetic variation. The authors note that genetic variation has been linked to iPSC heterogeneity but do not analyse whether the three "outlier" lines (Kucg2, Sojd3, Yoch6) share genetic features. For instance, common variants at PRC2 component loci, EPOP regulatory variants, or structural variants that might alter H3K27me3 domain boundaries. The HipSci consortium provides genotyping data for these lines. A targeted analysis of variants at Polycomb-related loci would be feasible and could either strengthen the epigenetic interpretation or reveal a genetic confounder.

      Minor Comments

      • The promoter definition ({plus minus}1 kb from gene start) is non-standard; most studies use a window upstream of the TSS rather than gene start. The authors mention they confirmed robustness to an alternative definition (-1 kb to gene start) but do not show this data. It should be included in the supplement.
      • For CUT&Tag, no spike-in normalisation is mentioned. Given that the key conclusions is based on quantitative comparisons of H3K27me3 levels across cell lines, the absence of spike-in controls is a potential concern. The authors should discuss whether technical variation between CUT&Tag libraries could contribute to the observed bimodality. At minimum, the correlation between replicates for H3K27me3 should be shown (presumably it is high, but this should be documented).
      • The statistical test for the PGCLC/H3K27me3 overlap (p < 0.04, combinatorial argument) assumes independence of lines, which may not hold if genetic relatedness or batch effects are present. This should be noted.
      • Figure 6A: the heatmaps for H3K4, ATAC and H3K27 are shown side by side but at apparently different scales; this should be clarified or made consistent.

      Referee cross-commenting

      I agree with the comments from other reviewers

      Significance

      This paper makes a primarily conceptual advance in understanding why iPSC lines differ in their differentiation capacity. The key insight is that Polycomb regulation operates in a digital (bistable) fashion at specific loci, and that this digital behaviour both explains the sharpness of inter-line transcriptional differences and enables prediction of differentiation outcomes from a small gene set. This work will be of broad interest to the stem cell biology community, particularly those working on iPSC-based disease modelling and cell therapy where line-to-line variability is a major practical challenge. The mathematical modelling component will appeal to quantitative/systems biologists interested in chromatin regulation. The computational pipeline may find applications beyond iPSCs, in any setting where epigenomic and transcriptomic data are available across multiple conditions.

      Reviewer expertise: Developmental biology, chromatin regulation, iPSC differentiation, epigenetics.

    1. During this step, solutions can be critically evaluated based on their credibility, completeness, and worth.

      I had to critically evaluate several solutions recently when I was upgrading my custom gaming PC. Before choosing a new processor and my new graphics card, I spent hours analyzing benchmark tests and hardware reviews to ensure the components were worth the high price tag. If I had just bought the first parts I saw without verifying their credibility, I could have ended up with a severely bottlenecked system. Taking the time to properly assess all your options is just as important in solo projects as it is in group problem-solving.

    1. Dass hinter dem Hype Substanz steckt, bestätigen die vielen begeisterten Kundenstimmen bei Douglas: Gelobt werden vor allem die leichte Textur, der fehlende weiße Film und das angenehme Hautgefühl über den ganzen Tag.

      Sounds very unnatural, better:

      Die vielen positiven Bewertungen bei Douglas zeigen, dass der Hype nicht unbegründet ist. Besonders häufig werden die leichte Textur und das angenehme Hautgefühl gelobt. Viele Nutzerinnen und Nutzer freuen sich außerdem darüber, dass die Sonnencreme keinen weißen Film hinterlässt.

    1. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      In this paper, the authors use a doxycycline-inducible DLD1 cell line expressing a Clover-tagged RNA-binding-defective TDP-43 2KQ mutant that forms nuclear "anisosomes" (TDP-43 shell with HSP70 core) to carry out a small-molecule screen using the LOPAC 1280 library to identify compounds that reduce anisosome number or shift their morphology and dynamics. They also conducted a genome-wide siRNA screen to identify genetic modifiers of anisosome formation and dynamics. From these screens, the authors identify pathways in RNA splicing, translation, proteostasis (proteasome and HSP90), and nuclear transport, including XPO1. They then focus on XPO1 as their primary hit. Pharmacological inhibition of XPO1 using KPT-276, Verdinexor, and Leptomycin B reduces anisosome number while enlarging remaining condensates, which retain liquid-like behavior by FRAP and fusion assays. XPO1 overexpression causes fewer, enlarged TDP-43 puncta, including cytoplasmic puncta, with little or no FRAP recovery, interpreted as gel or solid-like aggregates. Anisosome induction reduces detectable nucleoplasmic XPO1 staining. Finally, the authors examine a homozygous TDP-43 K181E iPSC-derived forebrain organoid model, showing increased cytosolic pTDP-43 in K181E/K181E organoids compared to wild-type controls. Chronic low-dose KPT-276 reduces cytoplasmic pTDP-43 without changing total TDP-43 levels. Bulk RNA-seq shows only a modest fraction of dysregulated genes in K181E/K181E organoids are rescued by KPT-276. They conclude that nuclear export, via XPO1, is a key regulator of TDP-43 liquid-to-solid phase transitions and that cytoplasmic aggregation per se may contribute only modestly to TDP-43 proteinopathy, with RNA-processing defects being dominant.

      We thank the reviewer for carefully summarizing our study.

      The study presents well-executed chemical and genome-wide siRNA screens in a DLD1 TDP-43 2KQ anisosome model and follows up on nuclear transport, particularly XPO1, as a modulator of TDP-43 phase behavior and cytoplasmic aggregation. The screens are impressive in scale, and the microscopy and fluorescence recovery after photobleaching (FRAP) work is technically strong. However, the central mechanistic and disease-relevance claims are not yet sufficiently supported. There are major concerns about the heavy reliance on non-physiological, RNA-binding-defective, and acetylation-mimetic TDP-43 (2KQ) and a homozygous TDP-43 K181E organoid model. An underdeveloped and partly contradictory mechanistic link exists between XPO1 and TDP-43 phase transitions in the context of prior work showing TDP-43 is not a canonical XPO1 cargo. The paper also appears to overinterpret organoid data to conclude that cytoplasmic TDP-43 aggregation plays only a minor role in pathology, based largely on pTDP-43 antibody staining with limited sensitivity and relatively modest rescue readouts. A deeper mechanistic analysis and additional, more physiological validation are needed for this to reach the level of rigor and impact implied by the title and abstract. The work feels screen-rich but conceptually underdeveloped, with key claims outpacing the data. A major revision with substantial new data and tempering of conclusions is warranted. I outline several problematic areas below:

      (1) The central mechanistic discoveries are derived almost entirely from a DLD1 colon cancer cell line overexpressing an RNA-binding-defective, acetylation-mimetic TDP-43 2KQ mutant and homozygous TDP-43 K181E iPSC-derived organoids. Both systems are far from physiological. The 2KQ mutation is a synthetic double lysine-to-glutamine mutant originally designed to mimic acetylation and disrupt RNA binding. In this study, essentially all cell-based mechanistic data on phase behavior, screens, and XPO1 effects rely on 2KQ. Yet there is no quantification of how much endogenous TDP-43 is acetylated in degenerating human neurons, nor whether a 2KQ-like acetylation state is ever achieved in vivo. It is not established that the phase behavior of 2KQ recapitulates the physiological or pathological phase behavior of wild-type TDP-43 or genuine disease-linked mutants, which may retain partial RNA binding and different post-translational modification patterns. As a result, it is difficult to know whether the modifiers identified here regulate a highly artificial 2KQ condensate or physiologically relevant TDP-43 condensates. To address this concern, the paper would benefit from quantifying endogenous TDP-43 acetylation at the relevant lysines in control and ALS/FTD patient tissue or more disease-proximal models such as heterozygous TARDBP mutant iPSC neurons, which would justify the focus on an acetyl-mimetic mutant. Key phenomena, including XPO1 dependence of phase behavior, effects of proteasome and HSP90 inhibition, and effects of splicing and translation inhibitors, should be tested for wild-type TDP-43 expressed at near-physiological levels and for one or more bona fide ALS/FTD-linked TARDBP mutants that are not acetyl mimetics. At a minimum, the authors should show that endogenous TDP-43 in neuronally differentiated cells exhibits qualitatively similar responses to XPO1 modulation, rather than exclusively relying on DLD1 2KQ overexpression.

      Acetylation of endogenous TDP-43 was reported by several studies. Although it occurs at low levels under normal conditions, TDP-43 acetylation is upregulated under stress conditions (e.g. oxidative stress and proteotoxic stress) (PMID: 25556531; PMID: 28724966). Importantly, Cohen et al. reported the identification of acetylated TDP-43 in ALS patient spinal cord (PMID: 25556531), while Yu et al. showed that endogenous wildtype TDP-43 undergoes demixing when neurons were treated with either a deacetylase inhibitor or proteasome inhibitor (PMID: 33335017). These studies also show that acetylated TDP-43 is defective in RNA binding and more prone to aggregation. Furthermore, ectopic expression of acetylated TDP-43 mimetics in cells and mice induces cellular defects similar to those observed in disease models (PMID: 28724966). Thus, our findings, based on previously established TDP-43 mimetics, should provide valuable information regarding the phase regulation of a disease-relevant TDP-43 mutant. We have included more background information to justify the use of TDP-43 acetylation mimetics in the introduction.

      (2) The organoid model is based on a homozygous K181E knock-in line. However, in patients, TARDBP mutations are overwhelmingly heterozygous. Homozygosity is thus a severe, arguably non-physiological sensitized background that may exaggerate nuclear RNA mis-splicing and phase defects and alter the relative contribution of cytoplasmic aggregation versus nuclear loss-of-function. In addition, it is not fully clear from this manuscript whether the structures in K181E organoids are bona fide anisosomes as defined in Yu et al. 2021, characterized by HSP70-enriched central liquid cores with TDP-43 shells and similar FRAP and fusion behavior to anisosomes in the DLD1 model. At present, the organoid section is framed as validation of "anisosome-bearing organoids," but the figures in this manuscript mainly show pTDP-43 puncta and total TDP-43 immunostaining, without detailed structural or biophysical characterization. The authors should explicitly compare heterozygous K181E/+ organoids or another heterozygous TARDBP mutant line with homozygous K181E/K181E organoids to assess whether XPO1 inhibition has similar effects in a genotype that more closely resembles patient genetics. They should provide direct evidence that the K181E condensates in organoids are anisosomes through HSP70 core immunostaining, three-dimensional reconstruction, and FRAP measurements, and clarify whether KPT-276 is acting on anisosome-like structures or more generic cytoplasmic aggregates or puncta. Without this, the leap from a DLD1 2KQ cancer cell model to human ALS/FTD-relevant neurons is not convincingly supported.

      The reviewer is correct that the use of homozygous K181E organoids generates a background that is more sensitive for detecting phospho-TDP-43. The goal was to test whether XPO1 inhibition mitigates the phosphorylation of a TDP-43 disease mutant. For this purpose, we believe that our experimental setup is suitable. We agree that we should not extrapolate the result to over emphasize on its disease connection. We have revised the paper to tone down this section. We also remove the RNAseq data as it is not essential for our conclusions.

      It is also noteworthy that TDP-43 disease mutations are usually loss-of-function alleles. Although heterozygous background is sufficient to induce disease phenotype in aged humans, heterozygous background in experimental settings is usually unable to generate severe defects. Thus, it is quite common to study TDP-43 disease-related defects in homozygous knockout or RNAi-mediated depletion conditions (e.g. PMID: 35197626; 41120751; 38277467).

      Regarding the immunostaining signals in K181E organoids, we did not report them as anisosomes. As documented in the literature, p-TPD-43 is widely used as a marker to indicate pathological TDP-43 aggregation. P-TDP-43 is enriched in pathological aggregates in human ALS and FTD patients, colocalized with other aggregation signatures such as ubiquitin and other aggregation-prone proteins in the cytoplasm (PMID: 36008843), and is being used as a diagnostic marker for neurodegeneration (PMID: 31661037). The characterization of K181E organoid is reported in a pre-print by Zhang Q. et al., 2026 (PMID: 41292965), which is currently under revision for Science Advances. In Fig. 1I of this manuscript, we confirmed the cytosolic localization of p-TDP-43 in cells that were isolated from K181E organoids. In the current manuscript, Figure 7 is to show that nuclear export inhibition mitigates the accumulation of p-TDP-43 in a brain-like tissues. We revise the subheading and the corresponding text to avoid the confusion.

      (3) The title and framing assert that "nuclear export governs TDP-43 phase transitions." However, prior studies such as Pinarbasi et al. 2018 and Duan et al. 2022 indicate that TDP-43 is not a canonical XPO1 cargo and that its export is largely passive, with active nuclear import being the dominant determinant of nuclear localization. The authors cite these studies but still position XPO1 as a central, quasi-direct regulator. The data presented are largely correlative or based on pharmacologic manipulation and overexpression in an overexpression mutant background, with no direct evidence that XPO1 engages TDP-43 in a specific, regulated manner. Even if XPO1 does not engage WT TDP-43, it could still engage the 2KQ variant, which needs to be tested.

      We did not mean to conclude or imply that the regulation of TDP-43 by XPO1 is direct. In fact, we explicatively mentioned on page 8 of the original manuscript that the regulation is likely indirect and mediated by other factors. The sentence reads as “Since XPO1 does not bind TDP-43 directly (Pinarbasi et al., 2018), additional factors might link XPO1-mediated nuclear export to TDP-43 nuclear egression.”

      We now add new data in Figure 6, showing that in an in vitro reconstitution assay using semi-permeabilized cells, LMB treatment significantly stabilizes anisosomes in an RNA dependent manner. This new data suggests that XPO1 inhibition leads to increased nuclear RNA availability, which indirectly favors anisosome assembly and maturation (see discussion). We believe that this new finding has provided significant new insight into how nuclear transport modulates TDP-43 phase behavior. We have revised the title, the abstract and changed the framing according to the reviewer’s suggestion.

      (4) The XPO1 perturbations yield somewhat confusing phenotypes. XPO1 inhibition using Leptomycin B, KPT-276, and Verdinexor reduces anisosome number and enlarges remaining anisosomes, which remain liquid-like by FRAP recovery and fusion assays and stay nuclear. XPO1 overexpression causes fewer, enlarged puncta, but these are FRAP-impaired (gel-like) and redistribute to the cytoplasm. Thus, both decreased and increased XPO1 activity reduce anisosome number and enlarge puncta, but with opposite phase behaviors and subcellular localizations. The model presented in Figure 5L is relatively qualitative and does not resolve these issues. Moreover, XPO1 inhibition globally impairs nuclear export of many cargos and profoundly alters the nuclear environment, transcription, RNA processing, and chromatin. It is therefore difficult to conclude that the observed effects are specific to TDP-43 phase regulation as opposed to secondary consequences of broad nuclear export blockade.

      The reviewer correctly summarizes our data and interpretation: XPO1 loss-of-function and gain-of-function generate opposite phenotypes regarding TDP-43 phase regulation.

      Regarding the mechanism underlying XPO1-dependent TDP-43 phase regulation, as mentioned above, we developed a semi-permeabilized cell-based assay in which we used the pore-forming toxin streptolysin O to damage the plasma membrane after anisosome induction. We noticed that upon cell permeabilization and cytosol loss, anisosomes were mostly lost (Figure 6B, C). This is probably due to a reversible partition of TDP-43 into a less fluorescent soluble fraction. Supporting this idea, when permeabilized cells were incubated with cytosol plus an energy regenerating system, small puncta containing TDP-43 2KQ could be reformed in an energy dependent manner (Figure 6D, E). Interestingly, in LMB-treated cells, anisosomes remained stable despite cell permeabilization(Figure 3F). Since LMB treatment did not increase TDP-43 nuclear concentration (Supplemental Figure 1), this data suggest that nuclear export inhibition likely alter the nuclear environment to stabilize anisosomes. Indeed, when cells were permeabilized in the presence of a small RNAase, LMB-stabilized anisosomes also collapsed (Figure 6G).

      We now add more discussions on the potential effect of RNA on TDP-43 phase behavior in XPO-1 inhibited cells considering these new findings.

      (5) The authors show that anisosome induction depletes nucleoplasmic XPO1 signal and that mCherry-XPO1 can be seen in some TDP-43 puncta. However, antibody penetration into anisosomes is limited, so XPO1 depletion from nucleoplasm could reflect sequestration in the anisosome shell or core, but this is not demonstrated. There is no demonstration of physical interaction, even indirect interaction, between XPO1 and TDP-43 or a defined adaptor, nor identification of a specific mutant of XPO1 that selectively disrupts this putative interaction while preserving other functions. The known TDP-43 NES has been shown to be weak and not a functional XPO1-dependent NES in multiple studies. If XPO1 is acting through an adaptor that recognizes 2KQ or K181E specifically, that by itself would bring into question the generality of the mechanism for wild-type TDP-43.

      We agree that our data does not demonstrate an interaction between XPO1 and TDP-43. Considering our new data (mentioned above), it is possible that the effect of anisosome induction on endogenous XPO1 localization is also mediated by RNA. We now mention more explicitly that the regulation of TDP-43 by XPO1 is likely indirect (Page 8). We have revised our paper to separate any speculative statements from the data, and also discussed the possibility of alternative interpretations.

      (6) To support a mechanistic claim that nuclear export governs TDP-43 phase transitions, more targeted evidence is needed. The authors should test whether siRNA knockdown or CRISPR interference of XPO1 in the DLD1 2KQ model reproduces the effects seen with Leptomycin B and KPT-276, including FRAP and fusion phenotypes, and verify on-target effects by rescue with an siRNA-resistant XPO1 construct. They should demonstrate that canonical XPO1 cargos behave as expected under the inhibitor conditions used, as a positive control, and that the concentrations used are not grossly toxic. They should attempt to identify or at least constrain candidate adaptors that might enable XPO1-dependent export of TDP-43 through proteomic analysis of XPO1 co-purifying with 2KQ condensates or loss-of-function studies of candidate adaptors from the siRNA screen. Finally, they should test whether a TDP-43 mutant that cannot bind the proposed adaptor still responds to XPO1 manipulation.

      The anisosome enlargement phenotype upon XPO1 depletion was seen in our siRNA screens, which was identified by machine-based image analyses using 6 different siRNAs. This, together with the chemical inhibition experiments, demonstrate that the phenotype is specifically caused by XPO1 inactivation.

      When characterizing the effect of XPO1 inhibition on anisosome dynamics, we preferred chemical inhibitor because the effect is acute, and therefore less likely to be secondary.

      Regarding the inhibitor concentration, according to the literature, Leptomycin B was commonly used at 50-200 nM. We chose 200 nM to ensure a quick and complete inhibition of XPO1-mediated nuclear export (see Figure 3 in PMID: 9628873). This dose is also well tolerated by our cells.

      We did not suggest any specific adaptor that mediates XPO1 interaction with TDP-43. Whether there is an adaptor, and if so, the identity of such adaptor is out of the scope of this study. We revise our paper on page 8-9 to clarify these points.

      (7) Even with these data, what is currently shown is that global modulation of nuclear export capacity can alter the phase behavior and localization of a highly overexpressed RNA-binding-defective TDP-43 mutant and of K181E in organoids. This is important, but it is weaker than asserting that XPO1 directly governs TDP-43 phase transitions in physiological contexts. The title, abstract, and Discussion should be tempered to reflect that nuclear export is one of several pathways, alongside RNA splicing, translation, and proteostasis, that influence TDP-43 phase states in this model, and that the specific mechanism and cargo relationship between XPO1 and TDP-43 remain unresolved and may be indirect.

      We have revised the title, abstract, and main text to temper our conclusions.

      (8) The authors conclude that cytoplasmic TDP-43 aggregation plays only a modest role in TDP-43 proteinopathies because in homozygous K181E organoids, chronic KPT-276 treatment almost abolishes cytoplasmic pTDP-43 puncta, yet bulk RNA-seq shows only a relatively small fraction of dysregulated genes are rescued. There are several issues with this inference. Relying primarily on pTDP-43 antibody staining to define cytoplasmic TDP-43 aggregation is limiting. pTDP-43 antibodies label only phosphorylated species and may miss non-phosphorylated, oligomeric, or amorphous TDP-43 species that could still be toxic. Different pTDP-43 antibodies vary in epitope accessibility depending on aggregate conformation and subcellular location. More sensitive approaches, such as high-affinity TDP-43 RNA aptamer probes developed by Gregory and colleagues, biochemical fractionation for SDS-insoluble and urea-soluble TDP-43, and filter-trap assays, would provide a more quantitative assessment of cytoplasmic aggregation and its reduction by KPT-276. Without these, it is not safe to assume that cytoplasmic aggregation has been eliminated, as opposed to one antigenic subclass.

      We agree with the reviewer that p-TDP-43 may not represent all aggregate species. However, p-TDP-43 antibodies detect the pathologically validated species tightly associated with TDP-43 proteinopatheis. In human ALS and FTD-TDP tissues, cytoplasmic inclusions are strongly immunoreactive for phosphorylated TDP-43 (typically S409/410, as detected here). Additionally, p-TDP-43 immunohistochemistry is a routine diagnostic criterion in neuropathology. For these reasons, we believe that the observation that inhibition of XPO1 significantly reduces p-TDP-43 is a significant finding, as it suggests that inhibition of nuclear transport may rescue TDP-43 proteinopathy. We revised the text on page 9 to better explain the significance of p-TDP-43 staining.

      (9) The treatment window, spanning from day 87 to 122 with 20 nanomolar KPT-276, may be too late or too mild to reverse entrenched nuclear RNA-processing defects, even if cytoplasmic inclusions are cleared. Once widespread cryptic exon inclusion and alternative polyadenylation misregulation are established, many downstream changes may become self-sustaining or only partially reversible. Moreover, XPO1 inhibition will massively rewire nucleocytoplasmic transport of many transcription factors, splicing factors, and RNA-binding proteins. Thus, the lack of full transcriptomic rescue cannot be cleanly interpreted as evidence that cytoplasmic aggregates are only modest contributors. It may instead reflect that nuclear dysfunction is primary and XPO1 inhibition does not correct, and may even exacerbate, certain nuclear defects.

      We agree with the reviewer that the lack of rescue may be caused by some technical issues. We have removed the RNAseq data and the related texts since it is not essential.

      (10) To support a causal statement about the modest contribution of cytoplasmic aggregates, one would want more direct measures of neuronal health and function, such as cell death, neurite complexity, synaptic markers, and electrophysiology before and after KPT-276, not only transcriptomics. A way to selectively reduce cytoplasmic aggregation without globally inhibiting nuclear export would allow comparison of outcomes.

      We have removed the discussion regarding the role of cytoplasmic aggregates in disease.

      (11) Given these caveats, the concluding statements that cytoplasmic TDP-43 aggregation is only a modest contributor should be substantially softened. A more defensible interpretation is that in this homozygous K181E organoid model, chronic global XPO1 inhibition reduces pTDP-43-positive cytoplasmic puncta but only partially normalizes the steady-state transcriptome, suggesting that persistent nuclear RNA-processing defects and other pathways continue to drive pathology.

      We agree with the review and have removed the RNAseq part.

      (12) The screens are a major strength but need more rigorous validation for key hits, especially nuclear transport factors. For the siRNA screen, hits are filtered by anisosome number per nucleus, but there is no direct demonstration in the main text that XPO1 or CSE1L knockdown is efficient at the messenger RNA or protein level. For the highlighted genes, Western blot or quantitative polymerase chain reaction validation and phenotypic rescue would strengthen confidence. For small-molecule hits, it is not systematically shown that anisosome modulation is independent of changes in total TDP-43 2KQ expression or gross toxicity. Translation inhibitors are tested for this, but for many other hits, including proteasome, HSP90, and kinase inhibitors, expression and general nuclear structure should be monitored. Given the reliance on anisosome count as a readout, secondary screens that specifically distinguish changes in TDP-43 expression levels, changes in nuclear morphology or cell cycle, and specific changes in anisosome phase behavior, including FRAP and fusion for top hits, would greatly increase interpretability.

      For the siRNA screen, each positive hit was confirmed by two rounds of screen with 6 independent siRNAs in total. Although we did not validate the knockdown efficiency due to the large number of hits, we routinely include a positive siRNA control in our study (Cell death siRNA), which targets several essential gene. Transfection efficiency was controlled by measuring cell viability after knocking down of these genes. In addition, the identification of XPO1 as a positive regulator of TDP-43 phase behavior was independently validated by our chemical genetic screens with three XPO-1 inhibitors. We feel confident that XPO1 is a key modulator of TDP-43 phase behavior.

      For chemical treatment experiments, the anisosome fusion phenotypes could be detected as early as 5 h post treatment. Given the relatively short treatment, we do not expect a significant change in protein level or toxicity. To alleviate this reviewer’s concern, we performed an immunoblotting experiment to measure the total TDP-43 protein levels in drug-treated cells. Except for VLX, we did not detect any significant changes in the level of TDP-43 after drug treatment (Supplemental Figure 1).

      (13) The classification of condensates as liquid versus gel-like or solid is based almost entirely on FRAP recovery or lack thereof. While FRAP is appropriate, interpretations could be made more robust by including half-region-of-interest bleach controls and assessing mobile fractions and recovery kinetics more quantitatively across conditions. Complementing FRAP with other phase-behavior assays such as sensitivity to 1,6-hexanediol, shape relaxation after deformation, and coarsening behavior over longer timescales would strengthen the analysis. At present, some assignments, such as that XPO1 overexpression drives a gel-like transition, are reasonable but somewhat qualitative.

      In this study, we used two types of FRAP assays. We either bleached TDP-43 within anisosomes or bleached the surrounding TDP-43 molecules(Figure 2). The two complementary methods yield consistent results that allow unambiguously distinguish between TDP-43 LLPS state and gel-like condensation.

      In XPO1-related experiments, the two types of condensates formed by TDP-43 2KQ can be distinguished by several features including their subcellular localization, shape, and the fluorescence recovery kinetics. We feel that these combined data clearly segregate these puncta into two distinct types of assemblies. The proposed half-region-of-interest bleach is technically challenging for small anisosomes under normal conditions. However, whenever possible, (e.g. anisosomes enlarged by Leptomycin B), we did perform both whole anisosome bleach and partial bleach (Figure 5D, I). Both assays demonstrate that TDP-43 in these enlarged anisosomes is highly mobile.

      (14) For the Leptomycin B and KPT-276 experiments in cells and organoids, it would be important to confirm that canonical XPO1 cargo proteins accumulate in the nucleus and that the concentrations used are within a range that is not overtly toxic over the experimental timeframe. Assessing nuclear morphology, chromatin condensation, and general transcriptional activity through global RNA synthesis or key reporter genes would ensure that observed effects are not secondary to severe global nuclear export collapse.

      In Leptomycin B treatment experiments, we carefully chose a dose that was previously validated (see Figure 3 in PMID: 9628873). Based on our DAPI staining, the nuclear morphology appears normal with no abnormal chromosome condensation (Figure 5A). Additionally, in cell line-based experiments, the effect of Leptomycin B on anisosomes was detected 6-8 hours post treatment. The change in global protein synthesis because of RNA changes should be relatively minor at this stage. Indeed, our new immunoblotting experiment showed that LMB treatment did not affect TDP-43 protein level (Supplemental Figure 1). Most importantly, the in vitro semi-permeabilized assay demonstrates a direct role for RNA in stabilizing anisosomes.

      (15) In the organoid section, it is not clear how many independent iPSC clones and organoid batches were used per condition, nor whether batch effects were assessed in the bulk RNA-seq analysis. This should be fully specified and ideally controlled with isogenic wild-type and K181E clones. For transcriptional rescue, it is important to know whether the changes in wild-type organoids treated with KPT-276 are negligible. A direct wild-type comparison with or without KPT-276 is important to disentangle general drug effects from K181E-specific rescue. More detailed quantification of total TDP-43 and pTDP-43 in both nuclear and cytoplasmic fractions, including biochemical fractionation if possible, would strengthen the assertion that KPT-276 specifically reduces cytosolic pTDP-43 aggregates while sparing nuclear TDP-43.

      The organoid experiment was performed with two batches per condition to reduce the effect of batch variation. The wildtype cells and K181E mutant are derived from the same genetic background. This information is now included in the method section on page 14. Given the criticisms by review 1 and 2 on the RNAseq data, we have removed this non-essential data. 

      (16) Beyond the core issues above, several additions could greatly enhance the impact. The manuscript currently emphasizes XPO1, but the genetic and chemical data clearly implicate RNA splicing, translation, and proteostasis as equally strong or stronger regulators of TDP-43 phase states. A more integrated model that explains how these pathways intersect, for example, how splicing factor availability, ribosome loading, and proteasome capacity co-govern anisosome nucleation, growth, and hardening, would be valuable.

      We now discuss a new model in discussion based on our new Figure 6, which integrates the role of RNA splicing and nuclear transport in TDP-43 phase regulation on page 10. We agree with the reviewer that other questions are also important for future studies.

      (17) A key unresolved question is whether XPO1 is acting directly on TDP-43, or instead primarily regulates anisosomes by exporting other factors that more proximally control TDP-43 phase behavior. Given that TDP-43 is not a canonical XPO1 cargo and prior work indicates that its nuclear export is largely passive, it seems at least as plausible that XPO1 inhibition alters the nuclear concentration or localization of splicing factors, RNA-binding proteins, chaperones, or other modifiers identified in the screens, and that changes in these proteins secondarily reshape anisosome dynamics. In other words, XPO1 may be exporting a more direct regulator of anisome formation and hardening, rather than exporting TDP-43 itself in a specific, regulated way. The current data do not distinguish between these possibilities. Systematic identification of XPO1-dependent cargos that colocalize with or biochemically associate with anisosomes, combined with targeted perturbation of their nuclear export, would be needed to determine whether the relevant XPO1 substrate in this system is actually TDP-43 or an upstream modulator of its phase behavior.

      As discussed above, our new data regarding the role of RNA in TDP-43 phase regulation should alleviate this concern, although we cannot exclude the possible involvement of splicing factors in this process. We also clearly state that there is no evidence to support a direct interaction between TDP-43 and XPO1 on page 8.

      (18) Testing whether identified modifiers converge on nuclear TDP-43 concentration would be informative. Since phase separation is concentration-dependent, measuring nuclear versus cytoplasmic TDP-43 levels across key perturbations, including splicing inhibition, translation inhibition, proteasome inhibition, HSP90 inhibition, and XPO1 modulation, would help determine whether modifiers mainly work by changing nuclear TDP-43 concentration or by altering interaction networks and the material properties of condensates.

      In the newly performed immunoblotting experiment, we measured the TDP-43 levels in drug-treated cells but found no effect by most drugs (Supplemental Figure 1).

      (19) Examining other ALS-relevant RNA-binding proteins would be valuable. Given the role of XPO1 and other hits, it would be informative to briefly test whether similar principles apply to FUS, hnRNPA1, or other ALS-relevant RNA-binding proteins in the same cellular context, to argue for generality versus TDP-43-specific idiosyncrasies of the 2KQ system.

      We agree that this is an important issue but we feel the proposed experiments are beyond the scope of the study.

      (20) The Introduction sometimes implies that anisosomes are common and well-established intermediates en route to pathology. It would be helpful to more clearly state that, to date, anisosomes are primarily observed in overexpression and mutant systems and have not yet been unequivocally demonstrated in human patient tissue. The link between PDGFRβ, PAK4, GSK-3β, and YAP and TDP-43 phase dynamics is intriguing but only briefly mentioned. The authors should either expand on this or tone down the emphasis in the Results section.

      We have revised the introduction and added the following sentence on page 4. “The 2KQ-containing anisosomes, observed mostly in the nucleus under overexpression conditions, have not been validated in human patient samples.”

      (21) In the organoid methods, the authors should consider clarifying whether doxycycline is continuously used, which might alter TDP-43 expression and nuclear transport in a non-negligible way.

      The organoid model does not involve protein overexpression or doxycycline treatment. We measured endogenous p-TDP-43, which is why we feel this experiment is very significant. Unlike many other p-TDP-43 detection studies that rely on TDP-43 overexpression or exposing cells to excess stressors, we could detect substantial p-TDP-43 in 3D organoids grown under normal conditions, whereas the same cells grown and differentiated in 2D culture do not show p-TDP-43 (Zhang Q. et al., BioRxiv 2025).

      (22) For statistical methods, it would be beneficial to indicate whether multiple-comparison corrections were applied for the many FRAP, anisosome count, and size comparisons beyond DESeq2 internal corrections for RNA-seq.

      We have added more statistical information to the figure legends.

      (23) Some figure legends could more clearly indicate whether the images shown are single z-planes or maximum intensity projections and how the thresholding for anisosome detection was performed.

      We revised the figure legends to include this information. As for anisosome detection, because they are so obvious, standard thresholding combined with automated counting was sufficient to identify them.

      (24) In its current form, the manuscript contains an impressive set of screens and some nicely executed imaging of TDP-43 condensates, highlighting nuclear export among other pathways as a modulator of TDP-43 phase behavior. However, the physiological relevance is undercut by heavy reliance on an acetylation-mimetic, RNA-binding-defective TDP-43 mutant and a homozygous K181E organoid model. The mechanistic link between XPO1 and TDP-43 remains largely inferential and partly at odds with prior work. The conclusion that cytoplasmic TDP-43 aggregation is only a modest contributor to disease is not firmly supported by the available data.

      We agree with the reviewer that the strength of the study is our unbiased approach that identifies pathways capable of modulating TDP-43 phase behavior. In the revised paper, we included several experiments using an in vitro semi-permeabilized cell system to further dissect the role of nuclear export in TDP-43 phase separation. We believe that these new results should provide significant mechanistic insight that links nuclear export and RNA transcription and splicing to TDP-43 phase regulation. Additionally, we have revised our paper carefully to discuss the physiological relevance and the limitation of our study.

      (25) With substantial additional mechanistic work, particularly around XPO1, rigorous validation in more physiological TDP-43 contexts, more sensitive detection of cytoplasmic TDP-43 aggregates, and a tempering of the central claims, this study could make a meaningful contribution to understanding how nucleocytoplasmic transport and other cellular pathways influence TDP-43 phase transitions and aggregation. The work should be reframed as an important screening study that identifies nuclear export as one among several cellular processes that modulate TDP-43 phase behavior in a model system, rather than as a definitive demonstration that nuclear export governs pathological TDP-43 aggregation in disease.

      We now reframe the study as an important screening study that identifies nuclear export among several other pathways as modulators of TDP-43 phase behavior. We also propose a model that links RNA splicing to nuclear export in TDP-43 phase regulation.

      Reviewer #2 (Public review):

      Summary:

      This manuscript addresses an important and timely question in TDP-43 biology by systematically identifying regulators of TDP-43 anisosome formation, with a particular focus on nuclear export via XPO1. Using a combination of unbiased chemical screening, genetic perturbation, and advanced imaging approaches, the authors propose that inhibition of nuclear export modulates the abundance and biophysical properties of TDP-43 anisosomes. The study is conceptually innovative and has potential relevance for neurodegenerative diseases characterized by TDP-43 pathology. However, significant concerns regarding experimental controls, reporting transparency, and model translatability currently limit the strength of the conclusions and the interpretability of several key findings.

      We thank the reviewer for acknowledging the significance and innovation of our study.

      Strengths:

      (1) The study employs an unbiased, hypothesis-free compound screen to identify regulators of TDP-43 anisosome formation, which is a major strength and reduces confirmation bias.

      (2) The authors combine chemical and genetic screening approaches, providing orthogonal validation of key pathways and increasing confidence in the biological relevance of top hits.

      (3) The focus on biophysical properties of TDP-43 assemblies, assessed through imaging and FRAP, moves beyond simple presence/absence of aggregates and provides mechanistic insight into the biophysical states of TDP-43.

      (4) The use of multiple experimental modalities, including live-cell imaging, FRAP, pharmacological perturbation, and transcriptomic analysis, reflects a technically sophisticated and ambitious study design.

      (5) The authors attempt to extend findings beyond immortalized cancer cell lines by incorporating organoid models, demonstrating awareness of disease relevance and translational importance.

      Overall, the manuscript is clearly written and logically structured, making complex experimental workflows accessible and the central hypotheses easy to follow.

      Weaknesses:

      Despite its strengths, the manuscript has several major limitations that affect data interpretation and confidence in the conclusions.

      (1) Lack of appropriate controls for overexpression experiments:

      A central concern is the absence of proper controls for TDP-43 and XPO1 overexpression. Prior studies (including those cited by the authors, Archbold et al.2018) show that overexpression of WT TDP-43 alone is toxic to neurons. Thus, the experimental system itself may induce anisosome formation independently of the mechanisms under study. Similarly, XPO1 overexpression lacks a suitable control (e.g., mCherry alone or mCherry fused to a protein known to be independent of TDP-43). The near-complete colocalization of XPO1 with TDP-43 anisosomes upon overexpression raises the possibility that these structures reflect non-physiological protein accumulation rather than regulated assemblies.

      As mentioned in our response to reviewer 1, point 1, we have added more discussions to justify the use of acetylation mimetics in our study. We agree with the reviewer that these large puncta (both anisosomes and gel-like structures) likely resulted from TDP-43 overexpression. Nevertheless, in a titration experiment done by Yu et al. 2020 (PMID: 33335017), they showed that ectopic TDP-43 undergo demixing even at concentrations lower than endogenous TDP-43, although the demixed puncta were very small. Their result suggested that overexpression per se does not change TDP-43 phase behavior, only enlarge the demixed TDP-43 structures, which is necessary for our screen and imaging-based characterization.

      For XPO1 overexpression, we have done the mCherry alone control but due to space limit in Figure 5, we did not include it. We now include the data in Supplemental Figure 4. This figure shows that overexpression of mCherry did not change TDP-43 localization or anisosome structures.

      (2) Insufficient experimental and analytical transparency:

      The manuscript frequently lacks clear reporting of experimental details. In multiple figures, the stated number of independent experiments does not match the number of data points shown, making it difficult to assess statistical validity. Concentrations used in the compound screen are not clearly defined, nor is it stated whether multiple concentrations were tested. It is unclear how many wells, cells, or independent cultures were analyzed. The criteria used to reduce 1,533 screening hits to 211 candidates via STRING analysis are not explained. Knockdown and overexpression efficiencies are not reported.

      We apologize for these omissions. We have added more experimental details to the figure legends and the method. For the imaging experiments, data points reflect randomly selected individual cells imaged in 2-3 independent biological repeats. This is now stated in the figure legends. For chemical screens, we screened against NCATS libraries was first done at top concentration (10 mM) to ensure inhibitory efficacy for all potential hits. In the follow-up validation study, we validated the top hits using a series of concentrations, as shown in Figure 1B. Drug concentrations are provided in Figure 2A, 4A, C, E, F, 5A-D, F, Figure 6F, G, Figure 7A)

      We explain the STRING analysis in more detail now. Basically, STRING is a protein-protein interaction network that reports all potential interactions between any proteins in human proteome. Given the potential off-target effect of siRNA, we assume that if the screen identifies multiple components of a protein interaction network or pathway, the result is more likely to be real.

      We did not check XPO1 knockdown efficiency in high through-put screens (HTS) for several reasons. Firstly, the large number of positive hits makes it impossible to check knockdown efficiency for all of them. Secondly, the effect of XPO1 knockdown on anisosomes was seen with 6 different siRNAs in two rounds of screens. Thirdly, in the HTS protocol, we routinely included a transfection control (siRNAdeath) to control transfection efficiency. We would only process the data if siRNAdeath control killed > 90% of the cells. Lastly, the XPO1 knockdown result was independently validated by small molecule inhibitors. For TDP-43 overexpression, the study by Yu and colleagues suggested that the expression is more than 20-fold higher than endogenous TDP-43, but they showed that anisosome formation is not an artifact of protein overexpression. When the expression level was titrated down, they could still detect anisosomes.

      (3) RNA-seq concerns:

      The RNA-seq experiments are particularly problematic. The number of biological replicates per condition is not stated, and heatmaps suggest that only one sample per group may have been used, which would preclude statistical analysis. No baseline comparison between WT and mutant TDP-43 is shown. Given that TDP-43 is an RNA-binding protein, splicing analyses would be far more informative than gene expression alone, yet no splicing data are presented. Moreover, nuclear retention of TDP-43 does not preclude nuclear aggregation, which may still impair its splicing function.

      We apologize for the lack of clarity regarding the RNA-seq design. For each condition, organoids of two independently differentiated batches were treated in triplicate. What we showed before was averaged expression levels. We pooled the organoids of the same treatment from the two batches to reduce the impact of batch variation.

      Given the criticisms from both reviewers 1 and 2 on the limited interpretation power of the RNAseq study, we have removed this data from the revised manuscript.

      (4) Limited translatability to neuronal biology:

      All anisosome analyses are performed in a cancer cell line, raising concerns about relevance to post-mitotic neurons. While organoids are used as a secondary model, the assays performed do not overlap with those used in cancer cells, making it difficult to assess whether anisosome-related mechanisms are conserved. Neuronal toxicity, a critical outcome given known TDP-43 biology, is not assessed. Prior work has shown that WT TDP-43 overexpression alone is toxic to neurons, yet this is not addressed.

      We agree with the reviewer that the model used in this study is not directly relevant to neurodegeneration. However, as pointed out by the reviewer, neurons are much more sensitive to TDP-43-associated toxicity. By contrast, the cell line used in this study can tolerate TDP-43 overexpression with no detectable cytotoxicity. This feature makes it feasible to evaluate how different cellular processes modulate TDP-43 phase behavior without the confounding effect from cytotoxicity. Notably, the processes identified by our screens are all house-keeping pathways that are conserved in neurons. Thus, we believe that the reported findings are likely applicable to neurons. That being said, we have revised our paper to ensure that we don’t overstate the clinical relevance of our work.

      (5) Conceptual and interpretational gaps:

      The authors quantify anisosome number but also report conditions in which anisosome number decreases while size increases. The biological interpretation of larger anisosomes is not discussed, and whether this reflects improvement or worsening of pathology is unclear. Compounds targeting the same mechanism (e.g., nuclear export inhibition) are inconsistently used across experiments (KPT compounds, verdinexor, leptomycin B), raising concerns about reproducibility. In organoids, the experimental paradigm shifts to long-term treatment (35 days vs. 16 hours), further complicating interpretation.

      We thank the reviewer for these critical points. As pointed out by the reviewer 1 in point 4 above, we do not have evidence to establish a convincing correlation between the size of anisosomes and clinical phenotypes. Regarding the use of different drugs for different experiments, the initial screen identified KPT and Verdinexor because they are investigational drugs, but Leptomycin B was not in our library. In the follow-up studies, we switched to Leptomycin B because 1) it is highly potent and specific; 2) it was better characterized and more commonly used as inhibitors of XPO1 according to the literature. However, for the organoid study, we had to switch back to KPT because of the toxicity issue associated with long-term application of Leptomycin B.

      (6) Overinterpretation of rescue effects:

      Although the authors state that they aim to test whether nuclear export inhibition rescues neuronal defects, no functional neuronal readouts are provided (e.g., viability, morphology, axon outgrowth, or electrophysiological measures). RNA-seq alone is insufficient to support claims of rescue.

      Our interpretation of the RNA-seq data was that the rescue effect by nuclear export inhibition was limited and probably insignificant. Given that this negative data is not conclusive, we have removed it from the revised manuscript.

      (7) Finally, the model does not appear to exhibit cytosolic TDP-43 aggregation at baseline. It remains unclear whether longer induction would produce cytosolic gel-like assemblies and whether these would be prevented by nuclear export inhibition. Long-term data are shown only in organoids, yet anisosome formation is not assessed there.

      The expression system used in the study reaches a steady state after 24 h of induction. Prolonged expression up to 48 h did not alter the number of anisosome, nor does it change TDP-43 phase behavior. We now clarify this point on page 4.

      Reviewer #3 (Public review):

      Summary:

      TDP-43 proteinopathy is broadly found in neurodegenerative diseases. This manuscript investigates how nuclear export influences the biophysical properties of TDP-43. The authors use a combination of chemical screening and genome-wide siRNA screening to identify pathways that modulate TDP-43 liquid-to-solid transitions. Overall, the study employs a broad array of approaches and addresses an important question in TDP-43 pathobiology. The identification of nuclear export as a central regulator is compelling and conceptually aligns with the emerging view that TDP-43 nucleocytoplasmic trafficking is a major defect in neurodegeneration.

      Strengths:

      This work integrates chemical and genetic screening to identify novel modifiers. The candidates were validated in both reporter cell lines and iPS-differentiated organoids. The findings support the nucleocytoplasmic transport is important for the biophysical properties of TDP-43.

      We thank the reviewer for acknowledging the significance and strength of our study.

      Weaknesses:

      The mechanisms underlying the connection between nuclear export and phase transition need further clarification. Broader consequences of XPO1 inhibition are not addressed.

      We agree that our previous manuscript did not address how nuclear export inhibition affect TDP-43 phase behavior. As discussed in our paper, we proposed that the effect of nuclear export inhibition on TDP-43 phase separation is likely indirect. The most likely scenario is that inhibition of nuclear export changes the nuclear environment over time, which affects TDP-43 phase separation. We have tried to isolate nuclear extracts from control and LMB-treated cells and used mass spectrometry to identify proteins that are differentially present in the nucleus. However, knockdown of the identified top candidates did not abolish LMB-induced phase alteration (not shown). Considering our observation that RNA splicing is another modulator of TDP-43 phase behavior, we reasoned that it is possible that it is the combined change of RNA and protein composition in the nucleus that alters TDP-43 phase behavior. In new experiments presented in Figure 6, we now used a semi-permeabilized in vitro system to demonstrate that LMB treatment stabilized anisosomes in an RNA-dependent manner (see response to point 4 by reviewer 1). This new data allows us to propose a new model that link RNA splicing and nuclear export in TDP-43 phase regulation (Discussion).

      Recommendations for the authors:

      Reviewer #2 (Recommendations for the authors):

      (1) Include appropriate controls for all overexpression experiments. In particular, overexpression of WT TDP-43 alone and suitable tag-only controls (e.g., mCherry alone or mCherry fused to a protein unrelated to TDP-43/XPO1) should be included to control for aggregation driven by non-physiological protein levels.

      In Supplemental Figure S4, we included a tag-only control, which shows that mCherry alone does not affect the localization of XPO1, neither did we see mCherry co-localizes with TDP-43.

      Since WT TDP-43 itself does not form anisosome and because the goal of the study was to test how anisosome dynamics is affected by various conditions, we did not repeat our experiments with WT TDP-43.

      (2) Address whether TDP-43 anisosomes form under endogenous or near-physiological expression levels. If possible, include experiments using lower expression systems or endogenous tagging to demonstrate that anisosome formation is not solely an overexpression artifact.

      As mentioned above, in a titration experiment done by Yu et al. 2020 (PMID: 33335017), they showed that ectopic TDP-43 undergoes demixing even at concentrations lower than endogenous TDP-43, although the demixed puncta are small. Their result suggested that overexpression per se does not change TDP-43 phase behavior. Instead, it only enlarges the demixed TDP-43 structures, which is necessary for our screen and imaging-based characterization.

      (3) Clearly define biological versus technical replicates throughout the manuscript and report exact n-numbers for all experiments in figure legends and/or methods. Resolve discrepancies between stated and displayed n-numbers (e.g., figures showing more data points than the number of independent experiments reported). Further, include how data points were defined (e.g., cells, fields of view, wells).

      We now state clearly the biological repeats in figure legends. We did not use N number to specify technical replicate. The discrepancy between the stated N number (biological repeats) and the data points is because for imaging experiments, data points usually represent single cells collected from 2-3 biological replicates (N=2 or 3). Data points are now clearly defined in the figure legends (anisosome, cell, imaging field, or independent experiment).

      (4) The authors state that they identified a list of compounds that reduced anisosomes. Please clarify how the threshold was determined: Was this a statistical analysis or a specific threshold that has been used?

      For both siRNA screen and chemical genetic screen, we calculated the Z-score and used Z-score>2 as a cutoff. This is mentioned in the method.

      (5) Provide a complete list of compounds used in the chemical screen, including concentrations tested and whether multiple doses were evaluated.

      As mentioned above, the initial screen was done with just one concentration (10 mM). Identified positive hits were re-tested with multiple doses as shown in Figure 1. The compounds are from a commercial library (LOPAC R1280, Sigma #LO4200). The list of compounds can be found at vender’s website.

      (6) Clearly explain the criteria used to reduce the initial 1,533 screening hits to 211 candidates following STRING analysis, including cutoffs and prioritization logic.

      We now explain that the Z-score was used to further narrow down the hit (page 6). Additionally, we provide an explanation on how we use STRING to further narrow down the list. The sentence reads as “To further narrow down the list, we performed a STRING protein network analysis based on the assumption that a protein interaction network bearing multiple positive hits would be more likely to be a true effector.”

      (7) Report knockdown and overexpression efficiencies for all genetic perturbations used in the study.

      For TDP-43 overexpression, the study by Yu and colleagues suggested that the stable cell line expresses 20-fold more TDP-43 than endogenous one, but they showed that anisosome formation is not an artifact of protein overexpression. When the expression level was titrated down, they could still detect anisosomes (Yu, H. et al., Science 2021). For knockdown efficiency, since the screen used 6 different siRNAs for each identified target (a few hundred), it is technically challenging to validate the knockdown efficiency of each siRNA by conventional qRT-PCR. To control knockdown efficiency, we transfected cells in parallel with siRNA-death that contains a mixture of siRNAs targeting several essential genes (Qiangen, #1027299). We would only process the data if siRNAdeath control killed > 90% of the cells, indicating good knockdown efficiency.

      (8) Clarify the biological interpretation of changes in anisosome size versus number, particularly in conditions where fewer but larger anisosomes are observed. Discuss whether larger assemblies are hypothesized to be protective, neutral, or deleterious.

      Live cell imaging was used to dissect why cells treated with certain drugs such as XPO1 inhibitors have fewer but larger anisosome. Figure 5F shows that this is caused by the fusion of small anisosomes. Our data does not suggest that the size of anisosomes can differentiate between protective or deleterious state, but rather it is the LLPS state and subcellular localization of these assemblies that may play a more critical role in determining whether TDP-43 forms deleterious protein aggregates. The discussion is on page 10.

      (9) Specify whether all anisosomes induced by XPO1 overexpression were gel-like or whether this applied only to a subset. If only a subset was affected, please provide quantifications, otherwise state clearly that all anisosomes in XPO1 overexpression were gel-like.

      All TDP-43 puncta mislocalized to the cytoplasm in XPO1-overexpressing cells are gel-like because the FRAP experiment in Figure 5I was done with randomly selected TDP-43 puncta mislocalized to the cytoplasm.

      (10) Clarify which anisosomes (nuclear vs cytosolic; gel-like vs non-gel-like) were selected for FRAP analyses in Figure 5I.

      For Figure 5I, the control anisosomes in untreated cells are nuclear while under mCh-XPO1 expressing condition, only those in the cytoplasm were randomly selected for photobleaching.

      (11) The translatability of the conclusion based on cancer cell lines to brain organoids is not convincingly shown and could be strengthened by including additional assessment of anisosomes. While this might not be feasible in 3D cultures, the authors could alternatively use 2D cultured neurons to perform the same assays as performed in the cancer cell line. Additionally, the same treatment strategy should be applied. The reasoning for increasing treatment to 35 days in the organoids is unclear.

      In another manuscript that is currently under revision, we compared 2D iNeuron culture with 3D organoids. A pre-print is available at https://www.biorxiv.org/content/10.1101/2025.11.09.687455v1.full. In this study, we found that endogenous TDP-43 K181E mutant do not undergo phosphorylation-dependent transition to aggregate in 2D cultures. Only when these cells were grown into 3-D organoids, TDP-43 phosphorylation could be detected. (see supplemental Fig. S1c, d in https://www.biorxiv.org/content/10.1101/2025.11.09.687455v1.full). Thus, it is not possible to repeat the experiments in this study in 2D iNeuron cultures. We agree with the review that there is a gap between the study using the cancer cell line and the use of K181E iPSC-derived 3D organoids. We have toned down our conclusions throughout the text.

      (12) Address neuronal vulnerability explicitly by assessing toxicity, viability, or functional neuronal readouts, particularly given prior reports that WT TDP-43 overexpression alone is neurotoxic.

      We agree that this is an important point, but the main goal of this study was to dissect the cellular pathways/mechanisms that govern TDP-43 phase separation. We feel that the requested experiments are beyond the scope of the current study.

      (13) Clearly state the number of biological replicates used for each RNA-seq condition. Establish baseline transcriptional differences between WT and mutant TDP-43 prior to assessing the effects of nuclear export inhibition. Include PCA plots and heatmaps, including all samples.

      As mentioned above, we have decided to remove the RNAseq data from the manuscript to save room for new results.

      (14) Given the role of TDP-43 as an RNA-binding protein, consider including splicing analyses to assess whether nuclear export inhibition preserves or disrupts TDP-43-dependent RNA processing.

      We thank the reviewer for this suggestion. However, we feel that the proposed experiments are beyond the scope of the current study.

      (15) Improve clarity of transcriptomic visualizations (e.g., GO-term plots) and explicitly define all group labels used (e.g., Group A vs Group B).

      We have removed the RNAseq data.

      (16) Ensure consistent use of disease terminology (ALS vs FTD) throughout the manuscript, e.g., lines 222 and 244.

      We have checked the usage of these terms to make sure they are accurately used.

      (17) Correct figure and axis labeling errors (e.g., Figure 3A x-axis range).

      Figure 3A indicates the Z score distribution of the entire human genome. As stated on page 6, 21,404 genes were targeted.

      (18) Avoid overstatements in the Discussion that are not directly supported by the presented data, particularly regarding the interpretation of proteasome inhibition and gel-like anisosome states.

      We have revised our discussion substantially to tone down our conclusions.

      (19) Clarify the rationale for switching between different nuclear export inhibitors across experiments and discuss whether results were consistent across compounds.

      In the acute experiments down with the cancer cell line, we used LMB because it is potent and well characterized. In organoid experiment, we switched to KPT-276 because it is better tolerated by organoids, especially during longer treatment.

      Reviewer #3 (Recommendations for the authors):

      Major concerns that require clarification or further strengthening:

      (1) The connection between nuclear export and liquid-solid phase transition is not clear. The 2KQ mutant forms nuclear anisosomes. The manuscript does not provide data about its nuclear-cytoplasmic distribution normally, nor how the distribution is changed upon nuclear export inhibition or enhancement. In Figure 5I, it is unclear whether the anisosomes are in the nucleus or cytoplasm. The dynamics of nuclear vs cytoplasmic anisosomes should be measured separately. What is the mechanism that promotes nuclear export and changes the dynamics, especially nuclear anisosomes?

      As mentioned by the reviewer, the 2KQ mutant forms anisosomes only in the nucleus. This was documented in Yu, H. et al., Science 371 (2021), and also shown in our Figure 4A, F, Figure 5A. Figure 5A also shows that nuclear export inhibition does not change anisosome localization, only making them bigger while reducing the numbers. For Figure 5I, the control anisosomes in untreated cells are nuclear while under mCh-XPO1 expressing condition, only those present in the cytoplasm were randomly selected for bleaching.

      (2) Figure 5J, no obvious XPO1 is sequestered to anisosomes, as described in lines 208-209.

      Unlike Figure 5G, this experiment studied the localization of endogenous XPO-1 by immunostaining. As discussed in Yu et al., Science 371 (2021), proteins inside anisosomes could not be stained by antibodies due to an accessibility problem. This explains why we could only detect reduced XPO1 after anisosome induction.

      (3) Figure 6A, the localization of phosphor-TDP-43 is not clear. And it is not clear what cell types contain the aggregates. Higher-resolution images need to be included. The mechanism by which XPO1 inhibition reduces TDP-43 aggregation requires further validation. It remains unclear whether it is directly mediated through altered nucleocytoplasmic transport of TDP-43.

      We agree that it is technically challenging to visualize the precise subcellular localization of p-TDP-43 in 3D organoids. In the manuscript that reports the characterization of the 3D organoids, we dissociated cells from the 3D organoids by trypsin digestion and plated them out in 2D before immunostaining and imaging. We could clearly see p-TDP-43 co-localizes with the neuronal marker TUJ1 and is localized outside of nucleus (see figure 1 of https://www.biorxiv.org/content/10.1101/2025.11.09.687455v1.full)

      In the newly added Figure 6, we used a semi-permeabilized cell system to dissect the phase separation dynamics of TDP-43 2KQ in cells treated with the nuclear export inhibitor LMB. Our data suggests that nuclear export inhibition alters the nuclear environment, making it more favorable for the liquid phase of TDP-43. This is dependent on nuclear RNA.

      (4) XPO1 controls the export of numerous essential proteins, and its inhibition can produce broad, potentially toxic effects unrelated to TDP-43. The manuscript should include a discussion of these off-target consequences.

      We thank the reviewer for this point. Given the new data in Figure 6, we now add some more discussion on the potential mechanism by which nuclear export inhibition modulates TDP-43 phase separation. This can be found on page 10.

      References:

      Zhang, Q. et al. A human forebrain organoid model phenocopies dysregulated RNA and protein homeostasis in ALS/FTD-associated TDP-43 proteinopathies. bioRxiv (2025). (https://www.biorxiv.org/content/10.1101/2025.11.09.687455v1.full

    1. Pristine.” The top of the condition scale is “pristine — no human impact,” which quietly treats untouched-by-people as the ideal. That sits oddly when the whole territory is lived-in. Right word, or should it describe ecological health without implying the absence of people? Condition Tag

      The problem for me is the definition as 'no human impact' rather than the term pristine. This is the kind of 'quiet' that we want to route out and bury - I don't think it is acceptable. Yes please describe ecological health without implying absence of people.

    2. When recording who is responsible for something, the choices include state, company, armed_group, settler, and criminal. “Criminal” is a judgement, not an observation — and in many places, the state calls land defenders criminals. Should we keep it (with a tight definition), rename it to something neutral, or drop it and let a separate “unauthorised” tag carry the meaning? Actor attribution

      yes, criminal too much of a judgement I think. unauthorised is better from my pov

    3. The two “seasonal”s. A place used only in one season vs an operation paused for its off-season use the same word, kept apart by context. Is that enough? Lifecycle Tag

      How does this translate I wonder. In English we use the same word I wonder though if the same term is used everywhere. If there were different terms that would be better. Makes me wonder how any of this works in an internationalizable way - is it all seamlessly translatable or is it grounded in English?

    4. C. Purpose as a detail: one home for each kind of take, with own-use vs commercial as an optional tag.

      I think perhaps this one, with an added 'legal / illegal' optional tag to differentiate between allowed community harvesting for sale vs. illegal external harvesting for sale. (some external groups might also be allowed to take for their own use). I think this one gives most options to clafiry exactly what is going on?

  4. comapeo-tagging-taxonomy.pages.dev comapeo-tagging-taxonomy.pages.dev
    1. Category “Cleared forest area” → entity=impact, impact=clearing, extraction=mining

      If you were just monitoring general impacts in a territory where there were land invasions for mining and agriculture and logging and settlements, it might not be known what the clearing was for - this might be known later on. can it be without the third tag and then added to an entity later when this is known?

    1. When creating categories: Ask “Is this a lasting change to the landscape? Can it be remediated? Does it have a cause?” If yes, it’s an impact.

      How about things that impact human beings directly, how would we classify / tag these. eg. a death of someone due to sickness from oil contamination eg. injuries caused by violence during an eviction incident. These are not necessarily permanent geo-locations - but we can take a location along with collecting the evidence.

    1. Keeping observations and entities separate lets raw data stay uncontroversial (“I saw dead fish here”) while the analytical work — drawing the spatial extent of the fish-mortality impact, deciding when it started, linking it to the upstream spill — happens at the entity layer. Evidence (the tag set used when an observation is indirect) is a modifier that describes how the observation relates to the entity, rather than naming a fifth entity typ

      I get a bit lost here with the introduction of entities - my mind can kind of understand them but I can't understand how they would work in practice. At what point do entities get created and by whom - how do they appear within CoMapeo UI? (sorry, perhaps this is jumping ahead, but I think not understanding how a user would interact with them is blocking my understanding a bit).

  5. Jun 2026
    1. IMMÉDIAT

      ici il y a beaucoup de niveaux de lectures et le client voulait éviter le terme paiement. Je propose de mettre en tag Virement instantané et en titre La confiance à la vitesse du temps réel

    1. Claude can even automatically learn from _other_ Slack channels and data sources, if it's granted permission.

      大多数人认为AI应该严格限制在特定任务和数据集内,以避免信息污染和边界模糊,但作者认为AI应该能够跨渠道学习并整合不同来源的信息。这挑战了人们对AI应用范围和数据隔离的传统认知,暗示未来AI将更像是具有广泛知识背景的团队成员。

    2. We now spend much more of our time delegating tasks to many Claudes in parallel.

      大多数人认为AI会取代人类工作,导致失业,但作者认为AI实际上改变了人类工作方式,让人们转向更高层次的任务分配和管理。这挑战了关于AI与就业关系的传统叙事,表明AI可能创造新的工作形式而非简单替代人类。

    3. Today, 65% of our product team's code is created by our internal version of Claude Tag.

      大多数人认为AI辅助编程只是辅助工具,主要用于代码补全或简单任务,但作者认为AI已经成为主要代码生产者,因为内部版本已经完成了产品团队65%的代码生成。这挑战了人们对AI在软件开发中角色的传统认知,表明AI已从辅助工具转变为核心生产力工具。

    1. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      In their manuscript entitled " Single-molecule behavior and cell-growth regulation in human RTKs" Abe et al. demonstrate automated single-particle tracking of 52 receptor tyrosine kinases (RTKs) in both resting state and upon stimulation with the respective ligands. The approach is based on transient transfection of cells with each RTK tagged with a Halo-tag, allowing for subsequent dye labeling and live cell video recording using TIRF microscopy. Subsequently, a seemingly commercial analysis software is used to then obtain particle trajectories from single molecule localizations and analyze their properties using a hidden Markov model. The authors have previously demonstrated pioneering work in the field of single-particle tracking with respect to automation (Yasui et al, 2018) and analysis (Yanagawa et al, 2021), and in this work they scale their approach up to characterize a broad set of RTKs. The resulting observations are a powerful demonstration of the benefits of SPT in general and significantly advance our understanding of the dynamics of RTKs as a class, beyond the most prominently studied candidate EGFR, as well as promising evolutionary insights.

      Comments and questions:

      1. The authors picked 52 out 58 human RTKs. Why not all?
      2. In contrast to the above mentioned previous publications, here a seemingly commercial software package was used (AAS by Zido). The methods part is very short on the specific parameters that were used to i) localize particles (e.g. net gradient threshold) or ii) connect localizations into trajectories (step size, allowed dark frames, min. trajectory length). Similarly a clearer explanation of the HMM calculus would significantly help to better follow the analysis approach and parameter choice. Perhaps this reviewer has missed it, but why did the authors e.g. choose 3 states for HMM?
      3. The replicate experiment in Fig. S2 is appreciated, but what condition was repeated here? Also experimental details are missing: was it two repeats of: i) seeding cells in a dish, transfection, labeling, imaging? An image from cells from those repeats would be important to show, also to which degree the density of particles F varies, i.e. to which degree this is an unprecise experimental parameter itself as compared to biologically meaningful. This is especially as Fig. S2 does not contain any density comparison at all, whereas in the main figures it is indeed an experimental observable used.
      4. The density raises another issue. Some of the movies show extremely dense signal. Here the authors should explain how they deal with particles whose trajectories cross. This could lead to artificial dynamics and a supplementary figure showing that their analysis is robust toward varying densities (again suggesting to include a simulation) could be helpful
      5. Fig. 2C is a bit hard to understand since here localizations are colored based on their state but not from which trajectory they come. Do e.g. individual trajectories show various dynamic behaviors or are the trajectories not long enough to observe this?
      6. The evolutionary aspects could use further and simpler explanations to make this passage easier to grasp

      Significance

      The manuscript by Abe et al. represents a significant advancement in the field of single-particle tracking (SPT) by scaling up recording 52 human receptor tyrosine kinases (RTKs), offering comprehensive insights into their dynamics beyond the traditionally studied EGFR. While the study demonstrates cutting edge single-particle tracking and provides promising evolutionary insights, it currently lacks certain methodological details that are essential for reproducibility, such as specific parameters used in particle localization and trajectory analysis. The exclusion of 6 out of 58 human RTKs without discussion also requires further explanation, but overall, the study fills a knowledge gap by providing a broad overview of RTK dynamics and their diffusion behavior. Overall, this work should have broad appeal to fields such as cell signaling as well as methods development int the area of single-particle tracking.

    1. a decade ago or more I invented the notion of on page notation.processor that can be activated on any line in an HTML editor on demand

      recently I discovered that I was 20 years behind Engelbart's work, again, reinventing another idea of his community: the notation.processor

      The Command Language Interpreter that was at the heeart of the Mother of All Demos that became MetaIV, is very much in the small ball partk, the ability to define the input to a program as a language, in their case, as it was an interactive program, they gone meta too, and defined the command language interpreter using explicit meta linguistic formalism, noation, and the program becomes a command langauge interpreeter

    1. Reviewer #1 (Public review):

      Summary:

      This study investigates epigenetic and three-dimensional chromatin alterations associated with primary trastuzumab resistance in HER2-positive breast cancer using integrated CUT&Tag, RNA-seq, and Micro-C analyses in JIMT1 (resistant) and SKBR3 (sensitive) cell models. The authors identify widespread remodeling of histone modification landscapes, chromatin compartment organization, and promoter-enhancer looping, highlighting SGK1 as a candidate epigenetically activated mediator associated with intrinsic resistance. The manuscript provides a technically solid and extensive multi-omic resource for the study of HER2-positive breast cancer resistance states.

      Strengths:

      The study integrates multiple state-of-the-art epigenomic and chromatin conformation approaches, including CUT&Tag, RNA-seq, and Micro-C, generating a comprehensive dataset that will likely be valuable to the field. The analyses are generally technically rigorous and well executed, and the manuscript is overall clearly written. The integration of chromatin architecture, enhancer activity, transcriptional regulation, and histone modification profiling provides an informative overview of large-scale epigenomic remodeling associated with resistant versus sensitive HER2-positive breast cancer states. The identification of SGK1-associated chromatin activation and enhancer rewiring is particularly interesting and supported by multiple orthogonal datasets.

      The inclusion of both intrinsic and acquired trastuzumab resistance models also strengthens the study conceptually, even if the biological interpretation remains somewhat complex.

      Weaknesses:

      The major limitation of the study is that many of the central mechanistic conclusions remain largely correlative. Although coordinated changes in chromatin architecture, histone modifications, enhancer activity, and SGK1 expression are observed, direct evidence demonstrating that these epigenetic alterations causally drive SGK1 activation or trastuzumab resistance is currently lacking.

      In addition, the interpretation of SGK1 as a broader trastuzumab-resistance driver is somewhat weakened by the analyses in the acquired resistant SKBR3_HR model, where SGK1-associated chromatin and transcriptional changes appear largely absent. This raises the possibility that SGK1 dependency may reflect a lineage- or model-specific vulnerability intrinsic to JIMT1 cells rather than a generalizable resistance mechanism.

      The study also remains descriptive in several sections. Numerous chromatin interactions and compartment changes are cataloged without sufficient biological contextualization or mechanistic integration. As a result, parts of the manuscript currently read more as a comprehensive epigenomic profiling resource than a fully mechanistic study of resistance biology.

      Finally, the translational impact is limited by the lack of patient-level validation linking SGK1 activation to trastuzumab response or clinical outcome in HER2-positive breast cancer cohorts.

    2. Reviewer #2 (Public review):

      Summary:

      Duan, Hua et al. used CUT&Tag and Micro-C to investigate that in primary trastuzumab-resistant HER2+ breast cancer cells, promoter H3K4me3 rather than H3K27me3 is strongly correlated with transcriptional activity. Resistant cells also exhibited more abundant promoter-enhancer loops and enriched cohesin at loop anchors, accompanied by shifts in A/B compartment status. Through multi-omics integration, the authors identified SGK1 as a key gene showing elevated promoter H3K4me3 levels, enhancer activation, strengthened chromatin loops, and upregulated transcription in resistant cells, and validated SGK1 as a potential therapeutic target. These findings reveal the coordinated interplay between three-dimensional chromatin architecture and epigenetic modifications, offering important insights into trastuzumab resistance in HER2+ breast cancer.

      Strengths:

      Previous investigations into trastuzumab resistance have largely focused on genetic mutations or individual epigenetic modifications. In contrast, this study moves beyond genetic or single epigenetic views by integrating histone modifications and 3D chromatin architecture into a unified framework, proposing a synergistic model of promoter H3K4me3, enhancer activation, and chromatin looping that underlies non-genetic resistance. It provides a new conceptual basis for understanding non-genetic resistance mechanisms. Secondly, using high-resolution epigenomic and conformational mapping together with bidirectional in vitro and in vivo functional validation, it establishes a solid link between epigenetic changes and phenotypes, and demonstrates that SGK1 inhibition suppresses tumor growth in a xenograft model, revealing clear translational potential.

      Weaknesses:

      (1) All findings are based on a single pair of cell lines, JIMT1 and SKBR3, which does not allow exclusion of cell line‑specific effects. The authors did not examine SGK1 expression levels, promoter H3K4me3 status, or relevant chromatin loops in tumor tissues from patients with clinical trastuzumab resistance. Consequently, whether the conclusions can be extrapolated to actual patient populations remains unclear, which limits the clinical relevance of the findings. It is recommended that the authors directly validate the key findings using tumor samples from patients with clinical trastuzumab resistance or analyze the correlation between SGK1 expression levels and disease-free survival or pathological complete response using data from public databases for HER2+ breast cancer patients, which would help address the current limitation of lacking clinical sample validation and the uncertainty regarding the association of SGK1 with patient prognosis and treatment response.

      (2) In the Discussion, the authors propose that SGK1 may assume the role of AKT to sustain mTOR activation, thereby bypassing the dependence on HER2 signaling following trastuzumab inhibition. Although this hypothesis is supported by published literature, the present study provides no direct signaling evidence, such as examining phosphorylation changes of SGK1, AKT, mTOR, or their downstream effectors.

    1. Reviewer #3 (Public review):

      Summary:

      Previous work from the Cahalan lab used fluorescent Genetically Encoded Ca2+ Indicators (GECI), like GCaMP6f, tethered to the N- or C- terminus of Orai1 to monitor CRAC channel optical signals (Dynes et al., PNAS 2016 PMID: 26712003; J Gen Physiol 2020 PMID: 32589186; PNAS 2023 PMID: 37729200). In this study from the Lewis lab, the HaloTag system enables C-terminal labeling of Orai1 with a reactive JF646-BAPTA loaded into cells. The article raises two key issues with the Ca2+ indicator probe that may limit potential applications: probe loading conditions and blinking.

      Making Sense of Probe Probe-lems:

      This is a three-component system: the hexameric Orai1 channel, the Halo tag, and the Ca2+ indicator (four components if you count the GFP- or mCherry-tagged STIM1 in the endoplasmic reticulum membrane that activates the plasma membrane Orai1 channel). The Orai1 channel, tagged with the Halo protein, appears to function normally, judging from the characteristic inwardly rectifying Ca2+ current first observed in T lymphocytes (Lewis and Cahalan, Cell Regulation 1989 PMID: 2519622). One problem is to find a condition for indicator dye loading that results in complete and uniform labeling with the covalently linked JF646 indicator. JF646-BAPTA is a far-red fluorescent indicator related to BAPTA, with a Kd of ~150 nM. The esterified form can be loaded into cells, as is routinely done for Ca2+ indicators like fura-2 or fluo-4. Ideally, to monitor local Ca2+ in the cytosolic nanodomain of the Orai1 channel, the indicator should react with each and every Halo tag of the hexameric channel. The authors assessed published methods by varying the exposure time to the JF646-BAPTA-esterified probe. The authors then used green JF552 labeling following red JF646-BAPTA loading to assess the completeness of labeling. Even overnight incubation of Halo-tagged cells was not sufficient. The addition of Pluronic treatment for 1 hr improved labeling, and a standard condition was adopted. Under this condition, no additional labeling with the green JF552 was seen, implying complete labeling with JF646-BAPTA. However, even with complete labeling, several additional effects might reduce the effective signal-to-noise, which is lower in these studies than expected from in vitro measurements - for example, if the JF646-BAPTA molecules are incompletely de-esterified, or if there is quenching between the closely spaced probes attached to the channel hexamer.

      A second, more serious problem analyzed by this article is that the JF646-BAPTA probe blinks on and off spontaneously, making it problematic to monitor true single-channel events in which the channel open state is assessed by the fluorescent probe. The authors distinguish blinking from channel-gating events by carefully noting the residual level of fluorescence in the absence of Ca2+ influx. Blinking events occur in bursts that reduce fluorescence transiently to zero, whereas the closed channel labeled with JF646-BAPTA retains a low level of fluorescence (~20%). To circumvent the blinking issue, the authors use whole-cell patch recording, in conjunction with optical recording (Patch-TIRF). This allows channel-gating events to be identified by step-wise changes in fluorescence due to Ca2+ entry upon hyperpolarization to -100 mV, above a baseline level of fluorescence at +30 mV, which the authors presume represents the closed channel level of fluorescence. Irreversible photobleaching is an additional issue, limiting the recording times to less than 1 minute.

      Visualizing Orai1 Single-Channels:

      With the blinking problem circumvented, at least in part, the authors uncovered a wide variety of single-channel events. Cells with low expression levels of Orai1 revealed 0-3 active Orai1 channels per STIM1 puncta. The range of gating behavior at the single-channel level is one of the revelations in this study. A substantial fraction (11%) of puncta contained "silent" channels that did not open (detected by the non-zero level of baseline fluorescence for closed channels). At the other extreme, some channels remained open for tens of seconds. On average, channels that opened and closed stochastically exhibited a bi-exponential distribution of bright states (open channels), with a major component of fast events (92 ms) and a minor component of slower ones (1190 ms), as well a single-exponential distribution of dark states (closed channels), and open probabilities >0.7. Channel open/closed times and the high open probability of active Orai1 channels seen here reinforce previous work based on analysis of CRAC current fluctuations in whole-cell recording, and optical single-channel recording using a different genetically encoded Ca2+ indicator, G-GECO1, tethered to Orai1 (Prakriya and Lewis, J Gen Physiol 2006 PMID: 16940559; Dynes et al., PNAS 2016 PMID: 26712003).

      Expression levels for single-channel optical recording must be low; accordingly, puncta contained only 0-3 active channels. However, under conditions of high STIM1 and Orai1 expression, conventionally used to investigate channel function, as in Figure 1, cells with large currents express many thousands of active channels. The number of active channels per cell can be calculated by dividing the peak current (~-100 pA) by the voltage (-100 mV); this corresponds to a whole-cell conductance (G) of ~1 nS (conductance is measured in Siemens). The single channel conductance (gamma, too low to detect electrically) is estimated by noise analysis to be 20-40 fS. Thus, the number of active channels is given by G / gamma corresponding to a range of > 25,000 - 50,000 open channels per cell. Under similar conditions of high STIM1/Orai1 co-expression in HEK cells, individual Orai1 channels were visualized at high density in puncta by freeze-fracture electron microscopy (Perni et al., PNAS 2015 PMID: 26351694), revealing puncta packed with Orai1 particles corresponding to hundreds to >1000 channels per punctum. Measuring the center-to-center distances between particles in puncta revealed two peaks in a distribution of inter-particle lengths: 9 nm (consistent with the approximate width of the Orai1 channel hexamer) and 15 nm (possibly due to two adjacent Orai1 channels held together by intervening STIM1 dimers).

      Strengths:

      The authors do an excellent job of analyzing and discussing probe artifacts that can confound measurements at the single-channel level. On the technical side, we thank the authors for including a photon 'budget' for their imaging experiments by including: the conversion factor from camera intensity units (c.u.) to photoelectrons, cell background fluorescence levels, and nominally Ca2+ free single channel fluorescence levels. One parameter missing from the list is the size of the region of interest used for channel recording. We expect the intensity measurements provided in the channel traces to correspond to mean ROI intensity levels. Upon knowing the ROI size in pixels, the magnitude of fluorescent signals could then be calculated in photons. Taken together, these values will aid comparisons to previous work and help guide subsequent researchers doing their own optical recording.

      The most important finding of this study is the ability to analyze single-channel properties of active Orai1 channels using the HaloTag approach. By direct measurement, the authors confirm previous work that there are at least two open states and that the CRAC channel open probability is greater than 0.7.

      Like any good study, this work suggests opportunities for further work. At the chemistry level, one focus should be the development of new probes that don't blink and have lower affinity for Ca2+ to circumvent unwanted responses to global Ca2+ signaling. Far-red probes like JF646-BAPTA have the advantage of reduced scattering for in vivo imaging applications. At the level of channel molecular function, the results pave the way for unraveling mechanisms of channel gating, such as the requirement for STIM1 binding to activate sub-states of Orai1, and how the channel undergoes Ca2+-dependent inactivation. At the cellular physiology level, localized Ca2+ probes should help to clarify mechanisms that couple to changes in gene expression and reveal Ca2+ signaling in subcellular structures, including dendritic spines. As a nice proof of principle, Halo-tagging enabled Ca2+ signals to be measured in primary cilia (Deo et al., J Am Chem Soc 2019 PMID: 31430138). Future users of HaloTag and GECI Ca2+ indicators will need to confront the issues (probe-lems) at the single-channel level that are carefully raised and analyzed in this article.

      Weaknesses:

      The major confounding issue identified here is probe blinking. The authors find a way to circumvent the issue, but not to prevent it. Is it triggered by high laser light intensity? Do the six JF646-BAPTA molecules tagging a single Orai1 channel exhibit quenching or correlated blinking?

      Which type of probe is better for understanding more about the CRAC channel function? It is difficult to evaluate the pros and cons of the HaloTag and GECI approaches without a side-by-side comparison under identical conditions (except for the probe, obviously). With respect to Ca2+ affinities, higher Kd values (lower affinity) are probably better. JF646-BAPTA has a relatively low Kd value (150 nm) compared to Orai1-GCaMP6f (620 nM in situ), which may account for the saturation of optical signals at potentials more negative than -75 mV in this study. In contrast, saturation did not occur at negative potentials with Orai1-GCaMP6f in the study by Dynes et al., 2020. Lower affinity also makes the probe more resistant to unwanted signals from global increases in Ca2+. With respect to response kinetics, the finding that JF646-BAPTA has faster Ca2+ binding and unbinding kinetics than GECIs in Deo et al., 2019, occurred before publication of the jGCaMP8 series indicators in Y. Zhang et al., Nature 2023. Kinetic measurement of Orai1-jGCaMP8f fusions was reported in Dynes et al., PNAS 2023, and these measurements were performed using the same patch-TIRF approach as the present manuscript. While photoinactivation of jGCaMP8f fused to Orai1 interfered with kinetic measurements, Orai1-jGCaMP8f V203Y (a mutant with greatly reduced photoinactivation) exhibited a tauon of 10 ms and tauoff of 15 ms, roughly twice as fast as the values reported for Orai1-HaloTag-JF646-BAPTA in the present manuscript. The manuscript text comparing Halo-Tag kinetics with GECI should be revised accordingly.

      The authors suggest that single-channel events reported previously for Piezo1 channels (Bertaccini et al., Nat Comm 2025 PMID: 40593468) may be due to probe blinking. However, that study included two critical controls that demonstrate that signals reflect bona fide channel activity rather than blinking artifacts. Notably: (1) treatment with channel activator Yoda1 increased bright-state occupancy (Figure 3C - 3G), and (2) increasing channel open probability by administering a mechanical stimulus increased bright-state occupancy (Supplementary Figure 13).

    1. For a new unit with context ccc, we write a unified empirical objective: ˆθ(c)∈argminθ∈Θ∑(i,j)∈S(c)ℓ(hθ(xij),yij)context-dependent support+R(θ;c)context-structured regularization,(★)(★)θ^(c)∈arg⁡minθ∈Θ∑(i,j)∈S(c)ℓ(hθ(xij),yij)⏟context-dependent support+R(θ;c)⏟context-structured regularization, \widehat{\theta}(c)\in\arg\min_{\theta\in\Theta}\; \underbrace{\sum_{(i,j)\in S(c)} \ell\!\big(h_\theta(x_{ij}),y_{ij}\big)}_{\text{context-dependent support}} \;+\; \underbrace{\mathcal{R}(\theta;\,c)}_{\text{context-structured regularization}}, \tag{★} where ℓℓ\ell is a proper loss (e.g., squared, logistic), S(c)⊆{1,…,n}×NS(c)⊆{1,…,n}×NS(c)\subseteq\{1,\dots,n\}\times\mathbb{N} is a support set selected for context ccc, and R(θ;c)R(θ;c)\mathcal{R}(\theta;c) encodes how parameters are allowed to vary with context (smoothness, sparsity, low-rank, hierarchy, etc.).

      I believe this particular form was used in Mladen, Le, Xing 2029, and then systematically studied in Estimating time-varying networks, AOAO 2010 Mladen Kolar, Le Song, Amr Ahmed, Eric P Xing

    1. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      Kashiwagi et al. undertook a population analysis of dendritic spine nanostructure applied to the objective grouping of 8 mouse models of neuropsychiatric disorders. They report that spine morphology in cultured hippocampal neurons shows a higher similarity among schizophrenia mouse models (compared with autism spectrum disorder (ASD) mouse models), and identify an effect of Ecrg4 (encoding small secretory peptides) on spine dynamics and shape in these models.

      Strengths:

      The study developed a method for objectively comparing spine properties in primary hippocampal neuron cultures from 8 mouse models of psychiatric disorders at the population level using high-resolution structured illumination microscopy (SIM) imaging. This novel technique identified two distinct groups of mouse models according to the population-level spine properties: those with ASD-related gene mutations and those with schizophreniarelated gene mutations. Functional studies, including gene knockdown and overexpression experiments, identified an effect of Ecrg4 on the spine phenotype of the schizophrenia model mice.

      We thank the reviewer for finding our strategy novel and useful for identifying molecules associated with the spine phenotype in schizophrenia-related mouse models.

      Weaknesses:

      The main weakness is that the study is wholly in vitro, using cultured hippocampal neurons. The authors present this as an advantage, however, arguing that spine morphology as measured in a reduced culture system can demonstrate direct effects of gene mutations on neuronal phenotypes in the absence of indirect influences from non-neuronal cells or specific environments.

      We appreciate this reviewer's concern about the limitation of cultured hippocampal neurons in extracting disease-related spine phenotypes. While we fully recognize this limitation, we consider that this in vitro system has several advantages that contribute to translational research on mental disorders.

      First, our culture system has been shown to support the development of spine morphology similar to that of the hippocampal CA1 excitatory synapse in vivo. High-resolution imaging techniques confirmed that the in vitro spine structure was highly preserved compared with in vivo preparations (Kashiwagi et al., Nature Communications, 2019). The present study used the same culture system and SIM imaging. Therefore, the difference we detected in samples derived from disease models is likely to reflect impairment of molecular mechanisms underlying native structural development in vivo.

      Second, super-resolution imaging of thousands of spines in tissue preparations under precisely controlled conditions cannot be practically applied using currently available techniques. The advantage of our imaging and analytical pipeline is its reproducibility, which enabled us to compare the spine population data from eight different mouse models without normalization.

      Third, a reduced culture system can demonstrate the direct effects of gene mutations on synapse phenotypes, independent of environmental influences. This property is highly advantageous for screening chemical compounds that rescue spine phenotypes. Neuronal firing patterns and receptor functions can also be easily controlled in a culture system. The difference in spine structure between ASD- and schizophrenia-related mouse models is valuable information to establish a drug screening system.

      Fourth, establishing an in vitro system for evaluating synapse phenotypes could reduce the need for animal experiments. Researchers should be aware of the 3Rs principles. In the future, combined with differentiation techniques for human iPS cells, our in vitro approach will enable the evaluation of disease-related spine phenotypes without the need for animal experiments. The effort to establish a reliable culture system should not be eliminated.

      We modified our text to have a balanced discussion on both advantages and disadvantages of the in vitro culture system in the study of mental disorder mouse models, as follows:

      "Finally, while the spine phenotype identified in the human postmortem brain undoubtedly resulted from complex interactions among genetic background, environmental influences, and regulation by non-neuronal cells, data from pure neuronal cultures are more likely to reflect the direct effects of schizophrenia-related gene mutations on synaptic functions. This property may be advantageous for identifying synaptic molecules that regulate synapse phenotypes in schizophrenia-related mouse models. However, the phenotype observed in the culture system requires confirmation using in vivo experiments of mouse models or human tissue samples. Efficient in vitro screening combined with reliable in vivo evaluation of synapses will facilitate translational research on mental disorders."

      Another weakness is that CaMKIIαK42R/K42R mutant mice are presented as a schizophrenia model, the authors justifying this by saying that "CaMKII-related signaling pathway disruption has been implicated in the working memory deficits found in schizophrenia patients". Since mutations in CAMK2A cause autosomal dominant intellectual developmental disorder-53 (OMIM 617798) and autosomal recessive intellectual developmental disorder-63 (OMIM 618095), and mice carrying the CAMK2A E183V mutation exhibit ASD-related synaptic and behavioral phenotypes (PMID: 28130356), I think it's stretching credibility to refer to the CaMKIIαK42R/K42R mice as a schizophrenia model.

      We agree with this reviewer that CAMK2A mutations in humans are linked to multiple mental disorders, including developmental disorders, ASD, and schizophrenia. Association of gene mutations with the categories of mental disorders is not straightforward, as the symptoms of these disorders also overlap with each other. For the CaMKIIα K42R/K42R mutant, we considered the following points in its characterization as a model of mental disorder. Analysis of CaMKIIα +/- mice in Dr. Tsuyoshi Miyakawa's lab has provided evidence for the reduced CaMKIIα in schizophrenia-related phenotypes (Yamasaki et al., Mol Brain 2008; Frankland et al., Mol Brain Editorial 2008). It is also known that the CaMKIIα R8H mutation in the kinase domain is linked to schizophrenia (Brown et al., 2021). Both CaMKIIα R8H and CaMKIIα K42R mutations are located in the N-terminal domain and eliminate kinase activity. On the other hand, the representative CaMKIIα E183V mutation identified in ASD patients exhibits unique characteristics, including reduced kinase activity, decreased protein stability and expression levels, and disrupted interactions with ASD-associated proteins such as Shank3 (Stephenson et al., 2017). Importantly, reduced dendritic spines in neurons expressing CaMKIIα E183V is a property opposite to that of the CaMKIIα K42R/K42R mutant, which showed increased spine density (Koeberle et al. 2017).

      References related to this discussion.

      (1) Yamasaki et al., Mol Brain. 2008 DOI: 10.1186/1756-6606-1-6

      (2) Frankland et al. Mol Brain. 2008 DOI: 10.1186/1756-6606-1-5

      (3) Stephenson et al., J Neurosci. 2017 DOI: 10.1523/JNEUROSCI.2068-16.2017

      (4) Koeberle et al. Sci Rep. 2017 DOI: 10.1038/s41598-017-13728-y

      (5) Brown et al., iScience. 2021 DOI: 10.1016/j.isci.2021.103184

      We fully agree with the reviewer that different CAMK2A mutations likely cause distinct phenotypes observed in the broad spectrum of mental disorders. In the revised manuscript, we include a discussion of the relevant literature to categorize this mouse model appropriately.

      "CaMKII-related signaling pathway disruption has been implicated in the working memory deficits found in schizophrenia patients [45,46]. CAMK2A mutations in humans are linked to multiple mental disorders, including developmental disorders, ASD, and schizophrenia [47]. The K42R mutation of CAMK2A does not correspond to any known human genetic variant, but the CAMK2A R8H mutation is linked to schizophrenia [48]. Both R8H and K42R mutations in the N-terminal domain of CaMKIIα eliminate kinase activity; these mutations may have a similar impact on human mental disorders."

      Although the manuscript is largely well written, there are some instances of ambiguous/unspecific language. This extends to the title (Decoding Spine Nanostructure in Mental Disorders Reveals a Schizophrenia-1 Linked Role for Ecrg4), which gives no indication that the work was in vitro on cultured neurons derived from mouse models.

      We appreciate the reviewer for pointing out the lack of information about the experimental system in the title of this manuscript. According to the suggestion of the reviewer, we modified the title as "Decoding spine nanostructure in cultured neurons derived from mouse models of mental disorder reveals a schizophrenia-linked role for Ecrg4".

      Reviewer #2 (Public review):

      Okabe and colleagues build on a super-resolution-based technique that they have previously developed in cultured hippocampal neurons, improving the pipeline and using it to analyze spine nanostructure differences across 8 different mouse lines with mutations in autism or schizophrenia (Sz) risk genes/pathways. It is a worthy goal to try to use multiple models to examine potential convergent (or not) phenotypes, and the authors have made a good selection of models. They identify some key differences between the autism versus the Sz risk gene models, primarily that dendritic spines are smaller in Sz models and (mostly) larger in autism risk gene models. They then focus on three models (2 Sz - 22q11.2 deletion, Setd1a; 1 ASD - Nlgn3) for time-lapse imaging of spine dynamics, and together with computational modelling provide a mechanistic rationale for the smaller spines in Sz risk models. Bulk RNA sequencing of all 8 model cultures identifies several differentially expressed genes, which they go on to test in cultures, finding that ecgr4 is upregulated in several Sz models and its misexpression recapitulates spine dynamics changes seen in the Sz mutants, while knockdown rescues spine dynamics changes in the Sz mutants. Overall, these have the potential to be very interesting findings and useful for the field. However, I do have a number of major concerns.

      We thank the reviewer for evaluating our findings as potentially very interesting and useful.

      (1) The main finding of spine nanostructure changes is done by carrying out a PCA on various structural parameters, creating spine density plots across PC1 and PC2, and then subtracting the WT density plot from the mutant. Then, spines in the areas with obvious differences only are analyzed, from which they derive the finding that, for example, spine sizes are smaller. However, this seems a circular approach. It is like first identifying where there might be a difference in the data, then only analyzing that part of the data. I welcome input from a statistician, but to me, this is at best unconventional and potentially misleading. I assume the overall means are not different (although this should be included), but could they look at the distribution of sizes and see if these are shifted?

      We appreciate the reviewer's concern regarding our analysis of spine population data. The intention of pre-selecting the areas showing differences between wild-type and mutant was to make a direct comparison between two subareas (one is enriched with wild-type spines and the other is enriched with mutant spines) and clarify that the spines of schizophreniarelated mouse models were smaller than wild-type spines. Conventional methods of comparing the total spine population using simple size parameters are not useful for this purpose, as shown in Supplementary Figure 2.

      To clarify the reviewer's concern, we revised the analysis of the spine population data for both Figure 3 and Figure 8.

      Figure 3: We first divided the feature space projected onto PC1 and PC2 into four areas with distinct structural properties: (1) small and short, (2) small and long, (3) large and short, and (4) large and long. Next, we calculated the normalized spine counts in the four areas for both wild-type and mutant spines and obtained the relative ratio (mutant/wild-type) for each area. As we performed three independent SIM imaging experiments (in one, we imaged both wild type and mutant culture dishes prepared from the same pregnant mouse), there are three independent datasets from 8 mouse models.

      We found that the spine ratio (mutant/wild-type) only in area 2 (small and long spines) differed significantly between genotypes. This result is shown in Fig. 3 and explained in the text. The spine ratios in areas 1 and 3 did not show a clear relationship to the genotypes, while the ratio in area 4 showed the opposite trend to that in area 2. The opposite trend between areas 2 and 4 indicates enrichment of both small and long spines in schizophrenia-related mouse models, consistent with our previous analysis.

      Figure 8: In this analysis, we aimed to evaluate the rescue effect of Ecrg4 shRNA relative to that of control shRNA. If Ecrg4 shRNA is effective, the spine population enriched in the control shRNA condition should be reduced in the Ecrg4 shRNA condition. To confirm this point in the revised manuscript, we first defined areas in the projected PC1-PC2 plane showing either enrichment or depletion of spines in the control shRNA condition (spine numbers increasing or decreasing by more than 3 × SD). We next measured the difference in spine numbers between the control and Ecrg4 shRNA conditions in either enriched or depleted areas. The expectation is that Ecrg4 shRNA treatment reduces the extent of both enrichment and depletion. The effect was significant in both the 22qdel and Setd1a mouse models, as indicated by permutation tests. This analysis was explained in the revised manuscript.

      (2) Despite extracting 64 parameters describing spine structure, only 5 of these seemed to be used for the PCA. It should be possible to use all parameters and show the same results. More information on PC1 and PC2 would be helpful, given that the rest of the paper is based on these - what features are they related to?

      We thank the reviewer for the advice on providing the rationale for parameter selection in PCA. We divided spines into 160-nm segments along their long axis, and the spine segments were used to calculate the 64 parameters, which include volume of each spine segment (20 segments), convex hull volume of each spine segment (20 segments), and convex hull ratio of each spine segment (20 segments). As most spines are shorter than 0.16 × 20 =3.2 μm, these segment-related parameters contain a large fraction of zero values, which affect the proper calculation of principal components. Therefore, we selected two parameters that reflect the principal structural features (length and volume), together with three other parameters that were mutually independent and also independent from the first two parameters (pairwise correlation coefficients < 0.3). These selection criteria were described in the original manuscript. We also confirmed that PCA using all 64 parameters yields a cross correlation map similar to that shown in Fig. 2B.

      Author response image 1.

      We provided additional information in the Materials and Methods section of the revised manuscript.

      As described previously, the pattern of four areas with distinct spine structures (1. small and short, 2. small and long, 3. large and short, 4. large and long) supports the idea that the PC1PC2 plane reflects the relationship between spine volume and length (Fig. 3A and B).

      These specific features could then be analyzed in the full dataset, without doing the cherry picking above.

      We provided the dataset for the relative enrichment of spine counts across four areas of the PC1-PC2 plane in Fig. 3A and B. This analysis provides a comprehensive view of spine population properties related to spine volume and length, without relying on a pre-set region of interest.

      It would also be helpful to demonstrate whether PC1 and 2 differ across groups - for example, the authors could break their WT data into 2 subsets and repeat the analysis.

      We noticed differences in the pattern of spine distribution across the PC1-PC2 planes in each experiment. The subtraction of the distributional data between wild-type and mutant samples effectively cancels out such differences. In general, the difference between two wild-type samples is smaller than that between wild-type and mutant samples, as shown in Author response image 2.

      Author response image 2.

      We added a description of variation across groups to the revised manuscript.

      (3) Throughout the paper, the 'n' used for statistical analysis is often spine, which is not appropriate. At a minimum, cell should be used, but ideally a nested mixed model, which would take into account factors like cell, culture, and animal, would be preferable. Also, all of these factors should be listed, with sufficient independent cultures.

      We agree that nested mixed models are more appropriate for evaluating genotype effects in most of our datasets. We confirm that the results of statistical analysis using nested mixed models were consistent with our previous conclusions in most cases.

      Figure 3: We performed three independent primary cultures of embryonic hippocampal tissue with genotypes of both wild-type and mutant from the same pregnant mice for each mouse model. In our new Figure 3, each data point represents an independent culture experiment, and group comparisons were performed using one-way ANOVA followed by Tukey's post hoc test. In this analysis, statistical analysis using neurons as units of 'n' is not possible, as the number of spines measured from a single neuron is insufficient to generate the density map shown in Figure 3. The statistical analysis was described in the revised text. The details of experimental conditions related to Figure 3 are provided in Supplementary Table 1.

      Figure 5A-C: We analyzed spine turnover rate using a linear mixed-effects model with genotype as a fixed effect and plate, cell, and dendrite as nested random effects. In both 22q deletion model and Setd1a model, there were significant effects of genotype (F(1,25) = 5.79, p = 0.024 for 22q deletion model and F(1,22) = 7.33, p = 0.013 for Setd1a model). In contrast, Nlgn3 mutant neurons did not show a significant difference (F(1,14) = 1.35, p = 0.26). This analysis was described in the revised text.

      Figure 5D-F: Spine lifetime was analyzed using a linear mixed-effects model accounting for the hierarchical structure of the data (spines nested within dendrites, cells, and culture plates). The analysis revealed a significant effect of genotype in both 22q deletion mutant and Setd1a mutant (22qdel mutant; F(1,336) =5.33, p=0.022, Setd1a mutant; F(1,282)=6.38, p=0.012 ). The neurons of both mutants exhibited significantly longer spine lifetimes compared with wild-type neurons (22qdel mutant; ratio = 1.28, 95% CI 1.04–1.58, Setd1a mutant; ratio = 1.35, 95% CI 1.07–1.70). In contrast, Nlg3 mutation did not significantly alter spine lifetime (ratio = 0.86, 95% CI 0.61–1.22; F(1,220)=0.69, p=0.41). This analysis was described in the revised text.

      Figure 5G-I: Spine volume trajectories were analyzed using linear mixed-effects models incorporating nested random effects (spine/dendrite/cell/culture plate) to account for the hierarchical structure of the data. In the 22q deletion model, newly formed spines were significantly smaller than those in wild-type neurons (genotype effect: p < 0.001). The spines in Setd1a mutant neurons also displayed significantly smaller volume than those in wild-type neurons (p < 10<sup>-7</sup>). There were also differences in the temporal profiles of spine growth in these two mutants (p < 0.001). In contrast, newly formed spines in the Nlgn3 mutant neurons were significantly larger than those in wild-type neurons (p < 10<sup>-4</sup>) with preserved time-course of spine growth. This analysis was described in the revised text.

      Figure 5J-L: Similar analyses using linear mixed-effects models incorporating nested random effects (spine within dendrite within cell within culture plate) identified significantly smaller initial spine size in the 22q deletion model (p < 10<sup>⁻6</sup>), while no significant differences in the initial spine volume were found for Setd1a mutants. The temporal trajectories of spine shrinkage before their loss were also not significantly altered in both 22qdel and Setd1a mutants. The Nlg3 mutant showed a significantly different time-course of spine shrinkage (p < 0.05), while the initial spine size was not altered. This analysis was described in the revised text.

      Figure 7A overexpression dataset: We analyzed plate-averaged lifetime values using a linear mixed-effects model with treatment as a fixed effect. There exists a significant main effect of treatment (F(3,8) = 4.59, p = 0.038), with post hoc examination showing a significant increase in lifetime by Ecrg4 overexpression (β = 0.49 ± 0.16 SE, t(8) = 3.16, p = 0.013). Figure 7A shRNA dataset: We also applied a linear mixed-effects model for plate-averaged lifetime values with treatment as a fixed effect. The analysis revealed no significant effect of treatment (F(2,6) = 0.29, p = 0.76).

      The analyses of overexpression and shRNA datasets were described in the revised text.

      Figure 8: As in Figure 3, we performed three independent primary cultures of embryonic hippocampal tissue with genotypes of both wild-type and mutant from the same pregnant mice for each mouse model. The culture plates were transfected with either a control shRNA or an Ecrg4 shRNA construct. Each data point represents an independent culture experiment, and the effect of Ecrg4 shRNA relative to that of control shRNA was evaluated using a permutation test. The data analysis was described in the revised text. The details of experimental conditions related to Figure 8 are provided in Supplementary Table 1.

      (4) The authors should confirm that all mutants are also on the C57BL/6J background, and clarify whether control cultures are from littermates (this would be important). Also, are control versus mutant cultures done simultaneously? There can be significant batch effects with cultures.

      The mutant mice we used in this study are on C57BL/6J or C57BL/6N background. It is known that C57BL/6J or C57BL/6N mice exhibit distinct phenotypes across a range of physiological, biochemical, and behavioral systems. However, it is less likely that our analysis is affected by differences between C57BL/6J and C57BL/6N, as we compared wild-type and mutant littermates on the same genetic background. This experimental design can also reduce the batch effects with different culture preparations. This point was described in the revised text.

      (5) The spine analysis uses cultures from 18-22 DIV - this is quite a large range. It would be worth checking whether age is a confounder or correlated with any parameters / principal components.

      We described in the method sections that culture samples were processed for imaging at 18-22 DIV. However, all the SIM imaging experiments for eight mutant mouse models were performed on samples fixed at DIV 19. The wide range of imaging experiments (DIV 18-22) includes test samples we used to optimize imaging conditions. In the revised manuscript, we specified the timing of SIM imaging.

      (6) The computational modelling is interesting, but again, I am concerned about some circularity. Parameter optimization was used to identify the best fit model that replicated the spine turnover rates, so it is somewhat circular to say that this matched the observations when one of these is the turnover rate.

      We appreciate the reviewer's comment on some circularity of the argument. We agree that the turnover rate is already incorporated into the simulation model and is not an appropriate criterion for the evaluation. We modified the text accordingly.

      It is more convincing for spine density and size, but why not go back and test whether parameter differences are actually seen - for example, it would be possible to extract the probability of nascent spine loss, etc.

      We thank the reviewer for giving this important suggestion. The probability of nascent spine loss is an important parameter, and we initially attempted to estimate it from the original data set. However, the upper limit of our time-lapse imaging is 24 h, which is insufficient to distinguish stable and nascent spines clearly. The difficulty of extracting all the necessary parameters for spine remodeling is our motivation for starting this computational modelling.

      More compelling would be to repeat the experiments and see if the model still fits the data. In the interpretation (line 314-318) it is stated that '... reduced spine maturation rate can account for the three key properties of schizophrenia-related spines...', which is interesting if true, but it has just been stated that the probability of spine destabilization is also higher in mutants (line 303) - the authors should test whether if the latter is set to be the same as controls whether all the findings are replicated.

      As suggested by the reviewer, we set the probability of spine destabilization equal across wild-type and mutant models and repeated the simulations. The results indicate that this modification has small effects on spine density (0.61 vs 0.62), spine turnover rate (0.22 vs 0.21), fraction of small spines (0.21 vs 0.20), and mean spine size (0.37 vs 0.36). We described this point in the revised manuscript.

      (7) No validation for overexpression or knockdown is shown, although it is mentioned in the methods - please include.

      As suggested by the reviewer, we validated overexpression and knockdown. The results are summarized in Supplementary Figure 8.

      Supplementary Figure 8A-C shows the immunocytochemistry of anti-Ecrg4, anti-Cip4, and anti-NPAS4 for the confirmation of overexpression of these molecules.

      Supplementary Figure 8D-E shows the confirmation of the appropriate size of exogenously expressed Ecrg4, Cip4, and NPAS4 by immunoblotting. (previous Supplementary Figure 10F is now Supplementary Figure 8E).

      Supplementary Figure 8F-H indicates the efficient knockdown of exogenously expressed Met-GFP, ARHGAP15-GFP, and Ecrg4-HA by respective shRNA constructs in COS-7 cells. (previous Supplementary Figure 10G is now Supplementary Figure 8H)

      Also, for the knockdown, a scrambled shRNA control would be preferable.

      We used Stealth RNAi Negative Control Duplexes (Invitrogen) as the shRNA control in this study. To confirm that this RNAi sequence does not affect spine turnover, we performed timelapse imaging of neurons transfected with GFP alone or with GFP and the Stealth RNAi Negative Control. No detectable change in spine turnover was observed (Supplementary Figure 8I), indicating that this RNAi control sequence is suitable for our study.

      (8) The finding regarding ecgr4 is interesting, but showing that some ecgr4 is expressed at boutons and spines and some in DCVs is not enough evidence to suggest that actively involved in the regulation of synapse formation and maturation (line 356).

      To reveal the active roles of Ecrg4 in spine regulation, we exogenously applied a synthetic Ecrg4 peptide to wild-type neurons and monitored both spine density and turnover rate after Ecrg4 application. The Ecrg4 application increased the spine turnover rate, whereas samples treated with the scrambled peptide did not. This result supports the active role of Ecrg4 in regulating spine turnover. The data were added as Supplementary Figures 9F and G.

      (9) The same caveats that apply to the analysis also apply to the ecgr4 rescue. In addition, while for 22q the control shRNA mutant vs WT looks vaguely like Figure 2, setd1a looks completely different.

      We thank the reviewer for pointing out the apparent difference in the pattern of spine population data between Figure 2 and Figure 8. We performed SIM analysis using DiI-labeled neurons in Figure 2, whereas the data in Figure 8 are derived from GFP-expressing neurons. The images of cell-surface labeling and cytoplasmic labeling cannot be analyzed in the same way, as it is necessary to adjust parameters in SIM image processing and PCA-based dimensional reduction. Consequently, the distribution of the spine population projected onto the PC1-PC2 plane differs between DiI-labeled neurons and GFP-expressing neurons. To facilitate the comparison of PCA analysis applied to GFP-expressing neurons, we replaced the weight matrix for GFP-expressing neurons with that previously calculated for the DiIlabeled neurons. This adjustment increased the similarity of the data distributions shown in Figures 2 and 8. The explanation for the different patterns in the spine population map between Figure 2 and Figure 8 was added to the revised text. The related explanation for the data processing was described in the Materials and Methods.

      And if rescued, surely shRNA in the mutant should now resemble control in WT, so there shouldn't be big differences, but in fact, there are just as many differences as comparing mutant vs wild-type? Plus, for spine features, they only compare mutant rescue with mutant control, but this is not ideal - something more like a 2-way ANOVA is really needed. Maybe input from a statistician might be useful here?

      We appreciate the reviewer's important comment and agree that the analytical approach used in the original manuscript was not optimal. We therefore revised our analysis to examine whether the difference observed between wild-type and mutant neurons was reduced by suppression of Ecrg4 expression.

      To this end, we first identified two regions in the PC1–PC2 plane where mutant spines were either enriched or depleted relative to wild-type neurons (Areas A and B). We then counted the number of spines located in Areas A and B in control shRNA-treated mutant neurons (normalized spine counts XA and XB). Next, we quantified spine counts in the same areas using data from Ecrg4-suppressed mutant neurons (normalized spine counts YA and YB). If XA > YA and XB < YB, suppression of Ecrg4 would indicate a shift toward rescue of the phenotype observed in control shRNA-treated mutant neurons. Indeed, the datasets were consistent with this shift in relative spine counts.

      To determine whether these differences exceeded those expected from random variation in spine counts, we performed a permutation test. Specifically, spine identities were randomly shuffled between the two conditions while preserving the total number of spines in each dataset. The observed differences were then compared with the distribution obtained from the permuted datasets to assess statistical significance.

      We found that all three culture replicates showed statistical significance in both areas A and B for both the 22qdel and Setd1a mutations. This analysis is described in the Result section.

      (10) Although this is a study entirely focused on spine changes in mouse models for Sz, there is no discussion (or citation) of the various studies that have examined this in the literature. For example, for Setd1a, smaller spines or reduced spine densities have been described in various papers (Mukai et al, Neuron 2019; Chen et al, Sci Adv 2022; Nagahama et al, Cell Rep 2020).

      We appreciate the reviewer's suggestion to include a discussion of schizophrenia-related mouse models. We added more information related to the Setd1a mouse model to the Discussion section.

      "Population-level spine properties were more homogeneous in schizophrenia models (those with gene mutations implicated in schizophrenia) than in the other 4 models studied, in part due to a shared tendency for smaller spines. This observation is consistent with previous studies on Setd1a mutant mice, which showed reduced spine width, decreased mushroomtype spines, and lower spine density in the prefrontal cortex [43,56,57]. In contrast to these findings, several previous studies reported reduced numbers of small spines in the postmortem cortical tissues of schizophrenia patients [22,58]. "

      (11) There is a conceptual problem with the models if being used to differentiate autism risk from Sz risk genes. It is difficult to find good mouse models for Sz, so the choice of 22q11.2del and Setd1a haploinsufficiency is completely reasonable. However, these are both syndromic. 22qdel syndrome involves multiple issues, including hearing loss, delayed development, and learning disabilities, and is associated with autism (20% have autism, as compared to 25% with Sz). Similarly, Setd1a is also strongly associated with autism as well as Sz (and also involves global developmental delay and intellectual disability). While I think this is still the best we can do, and it is reasonable to say that these models show biased risk for these developmental disorders, it definitely can't be used as an explanation for the higher variability seen in the autism risk models.

      We appreciate the reviewer's suggestion for more careful consideration of the interpretation of phenotypes in mouse models, with regard to their relation to clinical phenotypes in human patients. According to the suggestion of the reviewer, we modified the relevant text as follows:

      "The nanoscale features of dendritic spines in ASD-associated mouse models were more variable than those in schizophrenia-associated mouse models. This difference may be related to the broader clinical spectrum of ASD, which ranges from mild impairments in social skills to severe intellectual disability. The four ASD-associated mouse models examined in this study, Nlgn3<sup>R451C/(y or R451C) , Syngap1<sup>+/-</sup>, POGZ<sup>Q1038R/+</sup>, and 15q11-13<sup>dup/+</sup>, may represent subgroups with different levels of hippocampal dysfunction. Among the four ASD-associated mouse models, 15q11-13<sup>dup/+</sup> showed population-level spine properties closer to those of the schizophrenia models. To understand this similarity, further analysis of neural circuit changes in both ASD- and schizophrenia-associated mouse models will be necessary. Analysis of the relationships between rare genetic variants and synapse phenotypes in mouse models may contribute to their eventual categorization. This information should be useful to understand the underlying mechanisms of the broader clinical spectrum of ASD."

      (12) I am not convinced that using dissociated cultures is 'more likely to reflect the direct impact of schizophrenia-related gene mutations on synaptic properties' - first, cultures do have non-neuronal cells, although here glial proliferation was arrested at 2 days, glia will be present with the protocol used (or if not, this needs demonstrating).

      In our culture system, the density of non-neuronal cells is low, and most neurons are not in direct contact with non-neuronal cells. We reported this method in Nat. Neurosci. 1999, where we utilized this culture system to visualize GFP-tagged PSD-95 in neurons using recombinant adenovirus. Because recombinant adenovirus shows higher infection efficiency in glial cells, it was essential for us to establish a culture condition that isolates neurons from glial cells.

      Second, activity levels will affect spine size, and activity patterns are very abnormal in dissociated cultures, so it is very possible that spine changes may not translate into in vivo scenarios. Overall, it is a weakness that the dissociated culture system has been used, which is not to say that it is not useful, and from a technical and practical perspective, there are good justifications.

      We appreciate the reviewer's comment on the advantages and disadvantages of using an in vitro culture system. This comment aligns with the first reviewer's. We modified our text to have a balanced discussion on the role of the in vitro culture system in the study of mental disorder mouse models as follows:

      "Finally, while the spine phenotype identified in the human postmortem brain undoubtedly resulted from complex interactions among genetic background, environmental influences, and regulation by non-neuronal cells, data from pure neuronal cultures are more likely to reflect the direct effects of schizophrenia-related gene mutations on synaptic functions. This property may be advantageous for identifying synaptic molecules that regulate synapse phenotypes in schizophrenia-related mouse models. However, the phenotype observed in the culture system requires confirmation using in vivo experiments of mouse models or human tissue samples. Efficient in vitro screening combined with reliable in vivo evaluation of synapses will facilitate translational research on mental disorders."

      (13) As a minor comment, the spine time-lapse imaging is a strength of the paper. I wonder about the interpretation of Figure 5. For example, the results in Figure 5G and J look as if they may be more that the spines grow to a smaller size and start from a smaller size, rather than necessarily the rate of growth.

      We thank the reviewer for the insightful comment. In the revised manuscript, we analyze the time-lapse data using linear mixed-effects models incorporating nested random effects (spine/dendrite/cell/culture plate). This analysis suggested the difference in the initial size of spines. This point is described in the revised manuscript as follows:

      "Schizophrenia-associated mouse models showed higher similarity in spine morphology, driven by reduced size and growth of nascent spines."

      "We further compared the initial increase in spine volume between genotypes (Figure 5G-I). Linear mixed-effects models incorporating nested random effects revealed significantly smaller initial spine volumes in both 22q11.2<sup>del/+</sup> and Setd1a<sup>+/-</sup> models (genotype effect: p < 0.001 for 22q11.2<sup>del/+</sup> and p < 10<sup>-7</sup> for Setd1a<sup>+/-</sup>). The spines in both mutants also displayed a significant reduction in spine volume increase (p < 0.001). In contrast, newly formed spines in the Nlgn3<sup>R451C/(y or R451C)</sup> neurons were significantly larger than those in wild-type neurons (p < 10<sup>-4</sup>) with preserved time-course of spine growth.”

      We tested whether the initial size difference in spines can be incorporated into the computational simulation. However, due to the large variability in the initial spine size, it was difficult to perform parameter optimization in the model with additional factors. Therefore, we did not further pursue this possibility in this revision. This point is described in the revised text.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      The manuscript would be strengthened if the following issues were adequately addressed:

      (1) It would be helpful to know more about the in/ex vivo dendritic spine phenotype of the mouse models of neuropsychiatric disorders, to allow readers to judge whether and how the in vitro spine phenotype in hippocampal neuronal cultures overlaps with/replicates the spine phenotype within the mouse brain.

      We appreciate this comment, but our currently available data is insufficient to specify the difference between in vitro and in vivo spine phenotypes. Our previous study, published in Nature. Comm. (2019), provided data showing that the overall distribution of spine size is similar between in vivo and in vitro conditions in the mouse hippocampus.

      (2) Although the manuscript is largely well written, there are instances of ambiguous language, particularly when describing the spine phenotypes. For example, we are told that "ASD mouse models showed a tendency of decreasing spine subpopulation with small volumes." This description and other examples should be expressed more clearly.

      Following the reviewer's suggestions, we revised the text to improve clarity. We modified the sentence "ASD mouse models showed a tendency of decreasing spine subpopulation with small volumes" to "ASD-related mouse models showed an opposite spine phenotype."To avoid possible confusion for readers, we have revised several sentences in the text to clarify the intended meaning.

      Also, I question whether the word "decoding", meaning to convert (a coded message) into intelligible language, is the most appropriate for the title and abstract.

      The original meaning of the word "decoding" is the conversion of a coded message into an intelligible form; however, in this study, we use the term in a broader sense, referring to the extraction of latent population-level properties of dendritic spines from multidimensional structural parameters. We believe this usage is consistent with its common use in neuroscience and systems biology, where "decoding" often refers to inferring underlying biological states or information from complex datasets.

      (3) The authors should reconsider whether CaMKIIαK42R/K42R mice should be described as a schizophrenia model, when mutations in CAMK2A are known to cause autosomal dominant intellectual developmental disorder-53 (OMIM 617798) and autosomal recessive intellectual developmental disorder-63 (OMIM 618095), and mice carrying the CAMK2A E183V mutation exhibit ASD-related synaptic and behavioral phenotypes (PMID: 28130356).

      We provided a detailed answer to this question in the previous part of the rebuttal.

      (4) The title doesn't adequately summarise the contents of the manuscript. It should mention mice/mouse models and cultured neurons.

      We also responded to this request in the previous part of the rebuttal.

      Reviewer #2 (Recommendations for the authors):

      (1) Please provide a supplementary table with all DEGs. Also, DEGs are listed if present in 'more than 2' models - does this mean they had to be in 3 or more? Please clarify.

      According to the reviewer's suggestion, we added data on DEGs shared by >2 mouse models in Supplementary Figure 7. We also added Supplementary Tables 2 and 3 for all DEGs. The phrase "in more than 2 models" means "in 3 or 4 models".

      (2) There are several references to 'schizophrenia mouse models' - it is worth rephrasing this to make clear that these are not mice with schizophrenia.

      We replaced the expression "schizophrenia (or ASD) mouse models" with "schizophrenia (or ASD)-associated mouse models" or similar appropriate wording throughout the manuscript.

      (3) Line 66: 'a recent...' - 2014 is not really recent.

      We removed the word "recent" from the sentence.

      (4) Figure S1: The legend says A-D, but they are not on the figure. Also, make clear whether this data is only WT data - it seems to be from disorder models, with 4 colors for each model - please clarify.

      We changed the sentence from "shown as A to D" to "shown as A to C". The datasets in Supplementary Figure 1 are wild-type only. Each graph uses four colors to represent wildtype data from four imaging datasets obtained from different mouse models. Graphs A to C correspond to spine length, surface area, and volume, respectively.

      (5) Methods, line 680-4: More detail here would be helpful.

      We added more explanation for the generation of subtraction maps.

      (6) Line 193: Make it clear this is hippocampal in the main text.

      We added "cultures of embryonic hippocampi" to the text.

      (7) Figure 5, D-F: Make clear that these are transient spines (as per main text)

      We added "Lifetimes of transient spines" to both the main text and figure legend.

      (8) Figure 6B: More detail is needed; no idea what this is - no axis label. D - also not clear what numbers on the y-axis mean. E - color scale??

      We added details to the figure legend, the axis labels for Figures 6B and 6D, and the color scale for Figure 6E.

      (9) Supplementary Figure 9 - not clear what matrices are actually showing, nor what the scale refers to - is this the number of shared DEGs? If so, please make it clearer.

      The matrices show the shared DEG numbers, as shown in their titles. The scale indicates DEG numbers. We added the explanation of the color code to the figure legend.

      (10) Please make clear in the main text that ecgr4 affected the turnover rate. It would be good to measure other parameters as well.

      We added the phrase "a significant increase in spine turnover rate by Ecrg4 overexpression" to the main text.

      (11) Figure 7: Suggest to label C on images as well, so obvious which is GFP/anti-HA overlay (and respective colors) and which is anti-HA staining.

      We added the labels with respective colors to Figure 7.

      (12) Ecgr4 is a precursor protein that is cleaved to produce several hormone-like peptides. Where is the HA tag - so which cleavage products will it label? Any antibodies that work in immunocytochem?

      HA tag was attached to the C-terminal domain. We predict that anti-HA binds to four cleavage products (the full-length Ecrg4, Augurin, Argilin, and Δ16). Among several commercially available antibodies, only the SIGMA product could detect cells expressing Ecrg4-HA by immunocytochemistry.

      (13) Supplementary Figure 10: Synaptosome would be a good addition.

      We isolated the fraction of synaptosomes using Syn-PER™ Synaptic Protein Extraction Reagent in Supplementary Figure 9A. We added this explanation to the Materials and Methods section.

    1. Author response:

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The manuscript entitled "Essential function reflected in the phylodynamics of a multigene family - the pir genes of malaria parasites" by Jackson and colleagues investigates the global phylogeny of pir genes across 14 Plasmodium species and one Hepatocystis species. The authors also focus on the functional characterization of the conserved ortholog pirC1 and claim that pirC1 is not the founder of the family and that it plays an essential role in blood-stage growth.

      Strengths:

      Overall, the manuscript is well written and interesting, as it combines comparative genomics and evolutionary analysis with functional experiments. The phylogenetic analysis is rigorous and represents a major strength of the manuscript.

      Weaknesses:

      The general conclusions regarding the potential function of this gene family are not fully supported by the data presented. The manuscript moves too quickly from growth phenotype and localization studies to a specific mechanistic model. The discussion argues that PIRC1 may be involved in nutrient acquisition, host sensing, or metabolic support, but the data provided do not directly support these functions, and the manuscript in its present form remains speculative. Although the manuscript includes some experimental results, it lacks direct mechanistic validation of the specific functions of the pir genes, including pirC1. In its current form, the study does not yet establish a definitive role for pirC1 in metabolic processes.

      The reviewer is correct that there is no definitive proof for the function of the PIRC1 protein. We speculate that this protein is involved in a metabolic process based on mutant phenotype – small, poorly developed parasites that do not produce the same amount of DNA as wildtype parasites (and hence likely fewer merozoites). That this occurs in an in vitro culture of Plasmodium knowlesi rules out a role in the interaction with the host organism, such as sequestration or facilitating passage through the spleen. The localization of the protein outside of the parasite is consistent with a role in nutrient uptake, but we agree that additional experiments are required to determine the role of the protein definitively. We aim to look at the differences in the transcriptome and the metabolome to gain more insight into the pirC1 phenotype; this should reveal metabolic deficiencies in the mutant parasite.

      Reviewer #2 (Public review):

      Summary:

      This is an extensive study using phylogenetic comparison across multiple plasmodium species to gain new insights in relation to their evolutionary pathways and the potential function of pir. In addition to establishing a framework to identify related orthologues across species as well as expanding paralogues families within a species, the work also focuses on understanding loss and gain of different PIRs and how this indicates a relative lack of functional constraints and essentiality for most members of the gene family.

      The authors provide evidence that at least pirC has a conserved function and plays an important role in parasite growth in multiple species.

      While this study represents a significant effort and does provide interesting new insights that would help our understanding of this complex gene family in the future, it has a number of limitations.

      Strengths:

      Extensive and thorough phylogenetic analysis that is supported by some biological validation. Provides an indication that the PIR gene family has limited biological constraints and evolved independently across different species, leading to rapid expansion and deletion of orthologous groups. Identified pirC as a functional and important member of the family that is conserved across the species.

      Weaknesses:

      The phylogenetic tree is based on a truncated sequence that focuses on the more conserved parts of the pir sequence. This could potentially lead to missing the key functional drivers of evolution. The biological validation of the role of pirC has some inconsistencies that need to be addressed.

      The reviewer is correct. We do not use the repetitive parts of the pir gene sequences for the phylogeny. We define these as the ‘distal variable’ and ‘proximal’ domains of the protein in Fig. S1, results text and supplementary results. We remove these parts from the alignment because they are only nominally homologous (they cannot be aligned) and so break the basic assumption of phylogenetic analysis. Amino acid repeats evolve quickly and are homoplasic (their similarities do not reflect ancestry) so omitting them is correct and makes the phylogeny more reliable. While these features do not contribute to the phylogenetic estimate, we propose in the results text and Fig. S3, in agreement with the reviewer, that they are an important demonstration of how pirs have differentiated and what is different between the subfamilies. The reviewer is also correct that we have considered the whole gene sequence when comparing Alphafold predictions and in selection analyses of closely related sequences (in these cases, the repeat sequences can be aligned).

      A structural prediction for the sequence used in the alignment would mostly reflect the distal conserved domain but would be misleading because the alignment combines conserved regions that are not physically attached in reality. We will clarify these points.

      Reviewer #3 (Public review):

      This paper aims to classify, from an evolutionary perspective, the multigene family PIR found in malaria parasites infecting rodents and Old World monkeys, and to link this classification to functional diversification. The authors also hypothesize that PIR members conserved across species play important roles in parasite survival, and seek to clarify their functions.

      To achieve these aims, the authors comprehensively analyze the evolution of PIR genes using genomic and transcriptomic information from many malaria parasite species. They focus on PIRC1, a member conserved across species, and attempt to clarify its function in rodent and simian malaria parasites by examining the phenotypes of parasites in which the corresponding genetic locus has been disrupted. They also attempt to determine its localization using PIRC1 tagged with an epitope sequence. However, although the locus-disrupted parasites appear to show an approximately 50% reduction in growth rate, this effect seems to be overestimated. Another weakness is that the cause of the reduced growth rate has not been clarified. The localization analysis also remains insufficiently conclusive.

      Therefore, I consider that the first half of the paper, consisting of the bioinformatics analyses, achieves the objective of comprehensively summarizing PIR and may become a reference paper for discussing the evolution and function of the PIR gene family. On the other hand, regarding the function of PIRC1, no clear conclusion can be drawn from the results presented, and several additional experiments are necessary.

      My major comments are as follows.

      (1) The claim that the failure of eight disruption attempts indicates that pirC1 is essential is too strong.

      Lines 319-321: The authors argue that a total of eight failed attempts to disrupt the pirC1 locus using two different construct designs suggest that pirC1 is essential in P. berghei. However, the failure of these attempts could also reflect technical issues with the construct design itself, such as the length of the homologous regions used for recombination, which are approximately 650 bp. Therefore, it is an overstatement to conclude that "pirC1 is essential for P. berghei blood-stage growth." Given that parasites with disruption of the corresponding locus could be obtained in both P. chabaudi and P. knowlesi, a more appropriate statement would be that "pirC1 is important for P. berghei blood-stage growth."

      It is correct that we cannot rule out that the inability to delete the pirC1 gene is Plasmodium berghei is unrelated to an essential function. We are happy to change the text to the suggested description.

      (2) The data on the mCherry-expressing P. berghei line shown in Supplementary Figure 11 are insufficient.

      (a) Panel C: Southern blot analysis

      To conclusively identify the lower band in panel C as chromosome 1, additional probes specific to genes located on chromosomes 1 and 2 would be required. In addition, a parental parasite control should also be included. The Southern blot image of the parental parasite should show only a single band at the higher position, with no band at the lower position. Probes specific to chromosomes 1 and 2 would help demonstrate that the lower band corresponds to chromosome 1, rather than chromosome 2.

      To this end, the authors could describe the result as follows:

      "In the parental parasite, only a single band corresponding to chromosome 7 was detected, indicating that the smaller chromosome was genetically modified. The size of the lower band detected with the dhfr probe was identical to that of the band detected with the control chromosome 1 probe, but distinct from that detected with the chromosome 2 probe, indicating that chromosome 1 was modified."

      That said, this chromosome-level Southern blot analysis is not sufficient to demonstrate that the target PBANKA_0100500 locus was specifically modified. The authors should provide more direct evidence showing that the PBANKA_0100500 locus, rather than another genomic locus, was modified. For example, Southern blot analysis after restriction enzyme digestion would provide more definitive evidence. Diagnostic PCR may also provide more specific evidence.

      Although we are confident that the parasites has been modified in the expected way, we are planning to generate PCR data confirming that the mCherry tag is correctly integrated into PBANKA_010050.

      (b) Panel D: Flow cytometry analysis

      To allow a more accurate interpretation of the percentage of mCherry-positive cells, flow cytometry data for the parental parasite line should also be presented.

      We will repeat the flow cytometry experiments and include a wildtype strain in the analysis.

      (3) There are unclear points in the PCR results shown in Supplementary Figure 12.

      Supplementary Figure 12: In panel B, a PCR product should also be amplified from dPCHAS_0101200 using the P1-P3 primer pair. Why is this band absent? The authors should provide the uncropped electrophoresis image so that the larger band can be seen. In addition, if labels 1 and 2 indicate independent clones, this should be stated in the figure legend.

      We will gladly supply the full, uncropped electrophoresis image and we will clarify what the numbers indicate in the legend.

      (4) The growth rates of P. chabaudi and P. knowlesi parasites with disruption of the PIRC1 gene locus should be quantitatively analyzed.

      The growth rates of P. chabaudi and P. knowlesi are described only qualitatively, but they should be evaluated quantitatively. In Figure 4A, the parasitemia of wild-type P. chabaudi increases from approximately 6.1% on day 6 to approximately 15.6% on day 8, corresponding to a 3.8-fold increase. However, because parasite growth may already be affected by immune-mediated suppression at this stage, this value should be regarded as a minimum estimate. In contrast, the mutant increases from approximately 3.2% on day 8 to approximately 6.8% on day 10, corresponding to a 2.1-fold increase. Based on these values, the daily growth rate of the mutant appears to be reduced to at least approximately 56% of that of the wild type. Similarly, from the growth curve of P. knowlesi in Fig. 5A, the DMSO-treated group appears to increase approximately two-fold per day, whereas the rapamycin-treated group increases only approximately one-fold per day. Thus, P. knowlesi also appears to show an approximately 50% reduction in growth rate. Taken together, both P. chabaudi and P. knowlesi appear to reproducibly show an approximately 50% reduction in growth capacity. A reduction of this magnitude is difficult to describe as a "severe growth defect"; a more appropriate wording would be simply that the parasites "showed a growth defect." In addition, the terms "a severe growth defect" and "essential" appear to be overstated throughout the manuscript, and the wording should be toned down. Finally, I recommend presenting Figure 4A and Figure 5A on a logarithmic scale so that the trend in growth rates can be more intuitively appreciated from the graphs.

      It should be possible to determine the growth rate of the wildtype and mutant P. knowlesi parasites. In addition, we can change the text to reflect that although there is a growth phenotype in the two species in which we obtained mutants, the parasites do have the capacity to replicate. Note that in the case of P. knowlesi, the parasites numbers in vitro do not increase, hence any additional factors that decrease the growth rate, such as immune system and spleen, will lower the reproductive rate further and render the mutant parasite unable to proliferate.

      (5) The evidence that disruption of the PIRC1 gene locus in P. knowlesi does not affect erythrocyte invasion is weak.

      The authors describe that "the developmental cycle of the parasites lacking PIRCl is slightly longer than that of parasites that produce PIRCl (line 383-384)," and appear to support this interpretation with data showing that "mutant parasites are significantly smaller than wild-type parasites (line 414)" and that "the DNA content in ML10-arrested parasites lacking PIRCl is lower than that of DMSO-treated parasites (line 417-418)" at 24 hours after invasion. However, a slightly longer developmental cycle alone does not seem sufficient to explain a 50% growth reduction.

      I think the erythrocyte invasion capacity has not been quantitatively evaluated, and therefore, the evidence supporting the conclusion that the phenotype of P. knowlesi parasites with disruption of the PIRC1 gene locus is unrelated to erythrocyte invasion is weak. The authors should assess invasion efficiency using purified merozoites. For P. chabaudi, it should also be possible to apply an in vitro or in vivo erythrocyte invasion assay similar to that used for other rodent malaria parasites, and this should be evaluated as well.

      We can further investigate the invasion phenotype of the mutant P. knowlesi parasites. The presence of a clear phenotype during the intraerythrocytic stage indicates that the protein also has a role after invasion, but we agree that determining the effect on invasion directly will be useful.

      Alternatively, the reduced DNA content in ML10-arrested parasites lacking PIRC1 (lines 416-417) could suggest that the number of merozoites formed per schizont may be reduced. To clarify this point, the authors should assess whether the number of merozoites per schizont is altered in P. knowlesi (and P. chabaudi parasites lacking PIRC1).

      We aim to count merozoites and the level of invasion, which will allow us to determine the reproductive rate of the mutant parasites.

      (7) The authors propose the possibility that PIRC1 expressed in merozoites is released after invasion; however, the evidence that PIRC1 localizes to intracellular organelles is weak.

      Line 333: "a peripheral pattern around the parasite" is indicative of parasite plasma membrane, PV, or PVM. ", indicative of a parasitophorous vacuole (PV) or parasitophorous vacuole membrane (PVM) location" should be amended to ", indicative of parasite plasma membrane, a parasitophorous vacuole (PV) or parasitophorous vacuole membrane (PVM) location". In the Figure S14 image, red signals are uniformly detected from the merozoites formed in the schizont stage parasite (not really microorganelle patterns), but not from the PVM surrounding the schizont, suggesting parasite plasma membrane localization, not PVM. I agree that the signal is detected from the compartments extending into the iRBC cytosol, which may be difficult to explain if it is located on the parasite plasma membrane, but how frequently were such images seen?

      To determine the localization of the protein in the merozoite, we will image P. knowlesi merozoites.

      Figure 4D. In the images of liver-stage schizonts, AMA1 does not appear to localize to the micronemes in mature merozoites, suggesting this image is an immature schizont. Although PIRC1 appears to be expressed in liver-stage schizonts, it is difficult to clearly determine whether it localizes to intracellular organelles or to the parasite plasma membrane.

      This is a valuable comment. It is difficult to impossible to determine the exact localization of the protein at this stage, irrespective of the exact stage of the parasite. It is clear from the images is that the protein is not secreted at this stage. The main aim of the experiment was to determine whether the protein is produced by the parasite during the liver stage, which the results confirm.

      To clarify the above points, the authors should examine whether PIRC1 is detected in intracellular organelles or around the merozoites by analyzing its localization in purified merozoites.

      This we aim to do.

    1. At this level, touch interactions are important because they serve a relational maintenance purpose and communicate closeness, liking, care, and concern. The types of touching at this level also vary greatly from more formal and ritualized to more intimate, which means friends must sometimes negotiate their own comfort level with various types of touch

      This reminds me a lot of a concept I heard, I believe from a video, a long time ago. It was about grooming habits between people and how it can be a reflection of comfort with physical intimacy. The video talked about the moment in a friendship or relationship when we feel comfortable enough to reach out and 'groom' the other person. That the closer a connection the more comfortable and willing we are to 'groom' the other. Someone in a newer relationship might point out something like a messy hair, lint, or a tag sticking out. As you move up levels of intimacy that moves onto just letting them know you're reaching to fix it. Finally reaching out and fixing the problem you noticed without having to say anything to them. It was supposed to be a sign to see how physically close two people were. As the person being groomed had the chance to reject the help offered and set a boundary. The person asking had a chance to express care for others appearance and or comfort. I'm not sure entirely how true observation was but this section reminded me of the video as it discusses levels of physical contact in comparison to the depth of the relationship.

    1. Author response:

      The following is the authors’ response to the original reviews.

      eLife Statement

      This valuable study characterizes the emergence of the membrane-associated periodic cytoskeleton (MPS) in the axons of human motor neurons derived from induced pluripotent stem cells. Super-resolution imaging of beta-II spectrin provides convincing evidence for the patterned assembly of spectrin-poor gaps and spectrin-rich MPS in the medial region of the axons and its enhancement by the kinase inhibitor staurosporine. The data advocates against gap formation by cytoskeleton disassembly in a continuous MPS. Instead, a continuous MPS may result from nascent MPS patches and their maturation, a model that would benefit from live imaging for validation.

      (R1) We thank the reviewers and editor for their constructive and thoughtful feedback. We are pleased the reviewers found our evidence to be convincing and that our study provides a valuable framework for understanding the complex dynamics of MPS assembly.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      Ever since the surprising discovery of the membrane-associated Periodic Skeleton (MPS) in axons, a significant body of published work has been aimed at trying to understand its assembly mechanism and function. Despite this, we still lack a mechanistic understanding of how this amazing structure is assembled in neuronal cells. In this article, the authors report a "gap-and-patch" pattern of labelled spectrin in iPSC-derived human motor neurons grown in culture. The mid-sections of these axons exhibit patches with reasonably well-organized MPS that are separated by gaps lacking any detectable MPS and having low spectrin content. Further, they report that the intensity modulation of spectrin is correlated with intensity modulations of tubulin as well. However, neurofilament fluorescence does not show any correlation. Using DIC imaging, the authors show that often the axonal diameter remains uniform across segments, showing a patch-gap pattern. Gaps are seen more abundantly in the midsection of the axon, with the proximal section showing continuous MPS and the distal segment showing continuous spectrin fluorescence but no organized MPS. The authors show that spectrin degradation by caspase/calpain is not responsible for gap formation, and the patches are nascent MPS domains. The gap and patch pattern increases with days in culture and can be enhanced by treating the cells using the general kinase inhibitor staurosporine. Treatment with the actin depolymerizing agent Latrunculin A reduces gap formation. The reasons for the last two observations are not well understood/explained.

      (R2) We thank the reviewer for the detailed and accurate description of the data shown and its relevance to further our understanding of MPS assembly mechanism and function.

      Strengths:

      The claims made in the paper are supported by extensive imaging work and quantification of MPS. Overall, the paper is well written and the findings are interesting. Although much of the reported data are from axons treated with staurosporine, this may be a convenient system to investigate the dynamics of MPS assembly, which is still an open question.

      (R3) We thank the reviewer for the positive comments on the manuscript and the convenience of the experimental system developed to further study the dynamics of MPS assembly. We hope others turn into motor neurons to explore cortical cytoskeleton biology and hopefully shed light into their susceptibility in various degenerative diseases.

      Weaknesses:

      Much of the analysis is on staurosporine-treated cells, and the effects of this treatment can be broad. The increase in patch-gap pattern with days in culture is intriguing, and the reason for this needs to be checked carefully. It would have been nice to have live cell data on the evolution of the patch and gap pattern using a GFP tag on spectrin. The evolution of individual patches and possible coalescence of patches can be observed even with confocal microscopy if live cell super-resolution observation is difficult.

      (R4) Because staurosporine may hit various kinases relevant to the phenomenon under study we did not elaborate too deeply on the likely targets in the discussion. We have, however, included the possibility that the relevant kinase in this matter could be PKC, in light of the new study published while our manuscript was under revision (Heller et al., 2025) (see second last paragraph in the Discussion section). Staurosporine represented a convenient initial approach that allowed us to find the phenomenon, and we are now conducting new studies dissecting the molecular pathways involved. However, the extent of such studies lies beyond the scope of the present report.

      See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs.

      Some more comments:

      (1) Axons can undergo transient beading or regularly spaced varicosity formation during media change if changes in osmolarity or chemical composition occur. Such shape modulations can induce cytoskeletal modulations as well (the authors report modulations in microtubule fluorescence). The authors mention axonal enlargements in some instances. Although they present DIC images to argue that the axons showing gaps are often tubular, possible beading artefacts need to be checked. Beading can be transient and can be checked by doing media changes while observing the axons on a microscope.

      (R5) As we acknowledge this possibility, we believe that, even if they occurred, they could not contribute to our observations of gaps-and-patches phenomenon since this latter subsisted long (hours and days) after any gross manipulation of media. Moreover fixed samples, when observed under DIC, confocal or STED did not evidence such beadings. We do refer to a characteristic local enlargement that was very localized and very low in numbers (see Fig.1C and E, and Suppl. Fig1C and E), so we don't believe these are transient, and do not resemble the structure referred to as beading. Structurally, beading is essentially different since it appears in rows of consecutive “beads” in long stretches, where round, small enlargements of axonal caliber are arranged in a consecutive manner, resembling pearls on a string. As mentioned by the reviewer, the beading phenomena can occur transiently when drastically changing media osmolarity (rarely done in cell culture manipulations) or non-tranciently when axons are undergoing degeneration. Indeed, to prevent gross changes in osmolarity, our routine fixation is a 4% PFA and 4% sucrose in PBS. In any case, we did not observe signs of beading in the cultures used for this study.

      (2) Why do microtubules appear patchy? One would imagine the microtubule lengths to be greater than the patch size and hence to be more uniform.

      (R6) Our stainings are for tubulin protein isoforms beta-III and alpha-II. That is, they would label microtubules, but free tubulin as well. Hence we don't think this is evidence for “patchy microtubules”. The slight decrease in intensity for tubulin within gaps is indeed something to investigate, and can indicate that tubulin prefers to accumulate within patches.

      (3) Why do axons with gaps increase with days in culture? If patches are nascent MPS that progressively grow, one would have expected fewer gaps with increasing days in culture. Is this indicative of some sort of degeneration of axons?

      (R7) We agree with the apparent discrepancy. However, one has to take into account that these axons are still elongating even at 2 weeks in culture and beyond. Hence, at any time point, there is a new axonal compartment recently added, and hence, with low βII-spectrin and no organized MPS. Also, the dynamical evolution of the gaps-and-patches structure has to take into account the rate of βII-spectrin supply and transport. If supply is somehow lower than a given threshold, it is expected that there will be more gaps, given the new, more distant parts of the axons have a lower supply of βII-spectrin. To explore this formally, we are working on simulations of these multifactorial dynamic systems to better understand this, that together with key experimental observations would enhance our understanding into our model of MPS assembly in growing axons. However, findings for this project will be the subject of another manuscript.

      (4) It is surprising that Latrunculin A reduces gap formation induced by staurosporine (also seems to increase MPS correlation) while it decreases actin filament content. How can this be understood? If the idea is to block actin dynamics, have the authors tried using Jasplakinolide to stabilize the filaments?

      (R8) The results with the co-treatment with Latrunculin A and Staurosporine are indeed intriguing, and provide clear evidence that the gap-and-patch pattern arises from local assembly of the MPS, requiring newly formed actin filaments. On the other hand, the fact that F-actin within the pre-formed MPS seems unaffected is not surprising. There are many different populations of F-actin in axons (i.e. MPS rings, longitudinal filaments, actin patches, actin trails), all of which have a different rate of monomer turnover. Latrunculin A affects filaments indirectly. The target of Latrunculin A is not actin filaments, but free monomers. Monomer sequestration ultimately affects actin filaments: filaments are constantly exchanging monomers, but, devoid of free monomers, filaments get shorter and eventually disappear. The drastic decrease in global F-actin in LatA-treated axons reflects that. The fact that F-actin in the MPS is preserved shows that these filaments are stable -if they are not losing monomers in the time frame of the treatment, the filament remains unaffected. This subject is extensively covered in the 8th paragraph of the Discussion section.

      We have not used Jasplakinolide. The expected outcome will not mimic that of Latrunculin A since Jasplakinolide has a different mechanism of action (i.e. it binds -and stabilizes- the actin filament).

      (5) The authors speculate that the patches are formed by the condensation of free spectrins, which then leaves the immediate neighborhood depleted of these proteins. This is an interesting hypothesis, and exploring this in live cells using spectrin-GFP constructs will greatly strengthen the article. Will the patch-gap regions evolve into continuous MPS? If so, do these patches expand with time as new spectrin and actin are recruited and merge with neighboring patches, or can the entire patch "diffuse" and coalesce with neighboring patches, thus expanding the MPS region?

      (R9) We agree with the reviewer's interpretation. A virtue of our experimental model and our interpretations of the observations in fixed cells is that it gives rise to informative questions such as the ones posed by the reviewer. See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs.

      Reviewer #2 (Public review):

      Summary:

      In this manuscript, Gazal et al. describe the presence of unique gaps and patches of BetaII-spectrin in medial sections of long human motor neuron axons. BII-spectrin, along with Alpha-spectrin, forms horizontal linkers between 180nm spaced F-actin rings in axons. These F-actin rings, along with the spectrin linkers, form membrane periodic structures (MPS) which are critical for the maintenance of the integrity, size, and function of axons. The primary goal of the authors was to address whether long motor axons, particularly those carrying familial mutations associated with the neurodegenerative disorder ALS, show defects in gaps and patches of BetaII-spectrin, ultimately leading to degradation of these neurons.

      (R10) We thank the reviewer for the detailed and accurate description of the data shown.

      Strengths:

      The experiments are well-designed, and the authors have used the right methods and cutting-edge techniques to address the questions in this manuscript. The use of human motor neurons and the use of motor neurons with different familial ALS mutations is a strength. The use of isogenic controls is a positive. The induction of gaps and patches by the kinase inhibitor staurosporine and their rescue by Latrunculin A is novel and well-executed. The use of biochemical assays to explore the role of calpains is appropriate and well-designed. The use of STED imaging to define the periodicity of MPS in the gaps and patches of spectrin is a strength.

      (R11) We thank the reviewer for the positive comments on the manuscript, the techniques used and the proposed model.

      Weaknesses:

      The primary weakness is the lack of rigorous evaluation to validate the proposed model of spectrin capture from the gaps into adjacent patches by the use of photobleaching and live imaging. Another point is the lack of investigation into how gaps and patches change in axons carrying the familial ALS mutations as they age, since 2 weeks is not a time point when neurodegeneration is expected to start.

      (R12) See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs.

      We don't discard the notion that axons carrying familial ALS mutations will show defects in MPS formation and/or stability when observed at longer culture times, or under culture conditions that promote neuronal aging (Guix et al., 2021). Thus, we continue to work with these cells, but the goal of such project lies well beyond the primary message of the present manuscript, as we discuss in the second paragraph of the Discussion section.

      Reviewer #3 (Public review):

      Summary:

      Gazal et al present convincing evidence supporting a new model of MPS formation where a gap-and-patch MPS pattern coalesces laterally to give rise to a lattice covering the entire axon shaft.

      Strengths:

      (1) This is a very interesting study that supports a change in paradigm in the model of MPS lattice formation.

      (2) Knowledge on MPS organization is mainly derived from studies using rat hippocampal neurons. In the current manuscript, Gazal et al use human IPS-derived motor neurons, a highly relevant neuron type, to further the current knowledge on MPS biology.

      (3) The quality of the images provided, specifically of those involving super-resolution, is of a high standard. This adequately supports the conclusions of the authors.

      (R13) We thank the reviewer for the positive comments on the manuscript, the techniques used and the proposed model.

      Weaknesses:

      (1) The main concern raised by the manuscript is the assumption that staudosporine-induced gap and patch formation recapitulates the physiological assembly of gaps and patches of betaII-spectrin.

      (R14) Along the project, various gaps-and-patches parameters were measured in different conditions and stainings. In all these examinations the only parameter that changed considerably was their abundance. While this suggests that the gaps-and-patches features are comparable between control and staurosporine-treated cells, we acknowledge as a general caution regarding negative data—that subtle qualitative differences cannot be entirely ruled out. We have now emphasized this possibility in the 9th paragraph of the Discussion section.

      (2) One technical challenge that limits a more compelling support of the new model of MPS formation is that fixed neurons are imaged, which precludes the observation of patch coalescence.

      (R15) See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs.

      Recommendations for the authors:

      Reviewing Editor Comments:

      The reviewers all agree that the work would strongly benefit from live imaging to assess the maturation dynamics of the gap/patch pattern.

      (R16) Reviewers agreed that some of the conclusions of our manuscript would benefit from live imaging for validation. Various anticipated technical and biological challenges made these approaches not to be conducted for this initial study on human motor neurons. Just to mention the most important, from previous work of our labs, these cells themselves are difficult to transfect at 2 weeks in culture. Also, ectopically expression of tagged βII-spectrin escapes normal expression control and it has been noticed that ectopic expression yields to protein localization that does not necessarily reflect the endogenous distribution, or that produces cellular responses that precludes the observation of the phenomena under study. These difficulties in studying over-expressed tagged βII-spectrin have been reported in the field, with mentions that the analysed axons were those expressing “low levels of the construct” (Boyer et al., 2026; Zhong et al., 2014; Zhou et al., 2022). Taking this into account, we did not anticipate that, for the goals of the present project, live-imaging was to be included. However, given the positive comments and reception of our conclusions, we sought to try to perform this challenging and risky approach. To that end, we used a C-terminus tagged mouse βII-spectrin-GreenLantern plasmid to transfect our cells (a kind gift from Dr. Subjohit Roy, UCSD, USA). After 3 rounds of differentiating cells and trying various combinations of plasmid quantity, lipofectimine-to-DNA ratios and times of transfection (amongst other parameters), we have got an extremely low efficiency of transfection, and the few expressing neurons showed a distribution of βII-spectrin-GreenLantern that did not match our observations of immunolocalization of endogenous βII-spectrin. Taking all these into account, the present version of the manuscript will not include live-cell imaging on expressed tagged βII-spectrin. Given that reviewers found that some statements in the initial submission would have been better supported by live-imaging, we made changes in the manuscript so as to acknowledge the limitations of concluding dynamic mechanisms from fixed samples (see for example last sentences on 5th paragraph of the Discussion section). Having said so, we hope to be able, in the future, to overcome these experimental challenges and be able to establish live-imaging of βII-spectrin in neurons. For example, to avoid unregulated transgene expression, Heller and colleagues recently generated a βII- spectrin-mNeonGreen conditional knock-in (cKI) mice, consisting of a LoxP- flanked alternative final exon of endogenous βII-spectrin with a C- terminal mNeonGreen fusion that is expressed upon Cre expression (Heller et al., 2025). The implementation and further development of such approaches will be very helpful in new studies on the dynamics of βII-spectrin and the MPS as a whole. However, the scale of work needed to accomplish those approaches represent stand-alone projects.

      Reviewer #1 (Recommendations for the authors):

      In the section "The MPS is absent in beta-II spectrin gaps, the authors mention that the presence of MPS in patches suggests that the axons are not undergoing degeneration. I don't think this is a good criterion to use, despite the citations they take support from.

      (R17) We agree with the reviewer's suggestion: in virtue of the unlikely connection between the cited developmental axon degeneration process in sensory neurons and the possible axon degeneration of long term cultures of human-iPSCs-derived motor neurons studied here, we have eliminated the sentence of reference

      The authors show that degradation by proteases does not happen in their case. In this regard, they may want to discuss the recent article by Heller et al, Science 2025 (https://doi.org/10.1126/science.adn6712) and Hofmann et al, Sci. Rep., 2022 (https://doi.org/10.1038/s41598-022-18562-5)

      (R18) By western blot analysis, we did not see evident changes in proteolysis-derived fragments. However it is likely that even when finding phenotypes with protease inhibitors, protein fragments accumulation is below the sensitivity of western blots. We were expecting gross changes observable by western blot in the case proteolysis explained gap formation.

      Calpain and Caspase activity has been shown to be relevant in different aspects of MPS biology. To the works cited by the reviewer, now one has to add the very recent work by Fei and colleagues (Fei et al., 2026). We have modified part of the Discussion section to analyse our results in this broader context.

      Briefly, Hofmann and colleagues found that acute treatment with calpain inhibitors right before axotomy lead to an increase in percentage of periodic βII-spectrin (referred by authors as “periodicity”) in the regenerated axons in a 2-hour period. Interestingly, the βII-spectrin patches they describe at distal portions did not increase in number, but they increased in size. This indicates that in the particular situation of axonal regeneration calpain activity puts a brake into MPS formation within patches. This invited us to re-examine our own protease inhibition experiments, and measured patch length in this. The new results are shown in Supplementary Fig. 6 and and further analysed in the Discussion section. In summary, our changes were much less notable than the ones found in regenerating axons, but follow the same trend: protease inhibitors made patches longer.

      On the other hand, Heller and colleagues found in live-imaging studies that calpain activity contributes to the steady-state dynamics of βII-spectrin exchange in a mature MPS lattice. More recently, Fei and colleagues found that caspase or calpain inhibition does not change the steady-state organization of a mature MPS lattice when observing treated axons after fixation samples. Fei and colleagues find a relevant role for calpains whenever massive endocytosis (of any kind) is engaged experimentally. Interestingly, all these studies, including ours, examined calpains roles in MPS in different scenarios. When looked in detail, we don’t believe that these are contradictory results among them, and a complete picture of calpains (and caspases) roles in MPS assembly, growth, maintenance and remodeling will have to take into account all the above mentioned results, including ours. All these analyses are now included in the Discussion section.

      Minor comments:

      (1) "Recently, it was proposed that this continuous MPS organization arises from the coalescence of discontinuous "patches" of incomplete MPS units that originate in the distal axon and migrate proximally (Zhong et al. 2014)." Please check the citation. Should it be Hoffman et al. 2022?

      (R19) The reviewer is correct. The proper citation has now been included.

      (2) Is there an established link between ALS and spectrin? I would suggest decreasing the emphasis on this as no clear conclusions are achieved.

      (R20) As stated in the text, the study of ALS mutations is justified from two aspects: one aspect is that there are several tubulin and other cytoskeletal proteins whose mutations are linked to ALS (Castellanos-Montiel et al., 2020) and microtubules dynamics has been shown to affect the cortical skeleton (Qu et al., 2017). Second, since human motor neurons are affected in ALS, we thought that a complete characterization of the βII-spectrin cortical cytoskeleton in these cells should include ALS-related mutations. We have now included an a basic MPS description in TDP43 and SOD1 mutation (Suppl. Fig. 5).

      The aspect of ALS-related mutations only occupies two short paragraphs in the main text and some panels in Supplementary information. To follow the suggestions by the Reviewer, we have downplayed the relative relevance of these results in the text, without compromising the amount of data we show.

      (3) There is a typo in the approximate symbol used for 150 kDa in the section where calpain and caspase activity is reported.

      (R21) Typo corrected.

      (4) Please add the Latrunculin concentration used in the main text, as it makes it easier for the reader.

      (R22) Done.

      (5) In the Discussion, paragraph starting with "We further showed ...", there is a typo where Zhong et al is cited.

      (R23) Corrected.

      (6) Supplementary Figure 1B: attachment instead of 'atachment'.

      (R24) Corrected.

      (7) Include DIVs or time in the schematic. It is easier for the reader to understand.

      (R25) We have now included time references in schematics of Suppl. Fig1B.

      (8) Supplementary Figure 1C

      Unable to distinguish βII-spectrin and βIII-tubulin in the merged image. Separate figure panels will help.

      (R26) The merged images in the reconstructions are merely to better show the tracing individual axons at such low magnification. Relevant portions with only βII-spectrin channels are shown in C1 and C2. Separated individual channels are shown elsewhere across the manuscript.

      (9) Supplementary Figure 4D

      Why is there so much cleavage product for αII-spectrin across DMSO and treatment? It varied over batches as well. Doesn't this mean that αII-spectrin is going through more proteolytic cleavage? Why?

      (R27) The amount of cleavage product for αII-spectrin is not a surprise to us. For instance, although calpains and caspases can potentially process both α- and β-spectrin, in in vivo scenarios where calpain activity is triggered there are much more fragments of α-spectrin being produced (Czogalla & Sikorski, 2005). On the other hand, our staining of cleaved-αII-spectrin by the SNTF antibody by immunofluorescence (Fig4C) parallels the findings by western blot -high levels of cleaved-αII-spectrin across treatments. A similar strong staining using this antibody has been recently shown in the intact axon (Heller et al., 2025). It will be interesting in the future to address if these fragments have any biological significance beyond being mere byproducts of αII-spectrin processing.

      Reviewer #2 (Recommendations for the authors):

      Suggestions for improving the quality of the manuscript:

      (1) Live imaging in combination with FRAP assays will help define whether the capture of spectrin from gaps into patches is true. Fixed neurons only provide static information and may not reflect real-time physiological effects.

      (R28) See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs.

      (2) Could the presence of F-actin trails in axons facilitate the formation of patches? Will the use of formin/Arp2/3 inhibitors rescue the effect of staurosporine, similar to Latrunculin A?

      (R29) Very interesting suggestion. It is likely that different pools of F-actin contribute to the dynamic of MPS formation, and actin trails are definitely worth investigating in this context.

      (3) Figure 8 lacks a latrunculin A treated condition? Why is this not present?

      (R30) The quantification of that treatment was excluded for space and readability. We have now included the values of group LatA + DMSO in Fig8Cand D and rearranged the whole figure.

      (4) Does neuronal stimulation have any effect (KCl treatment) on gaps and patches?

      (R31) Very interesting suggestion. Unfortunately, we have not examined whereas neuronal stimulation affects any parameter of the gaps-and-patches structure.

      (5) Please check the manuscript for typos and reference insertion points in the text. More than a couple were noted.

      (R32) We have corrected typos.

      Reviewer #3 (Recommendations for the authors):

      This is a very interesting study that supports a change in paradigm in the model of MPS lattice formation.

      (1) One major concern is the assumption that staudosporine-induced gap and patch formation recapitulates the physiological assembly of gaps and patches of betaII-spectrin, solely based on their morphological similarity. This should be further discussed in the manuscript. Further analysis of additional cytoskeleton components, including microtubules in staurosporine-treated neurons, could also be provided.

      (R33) See R14.

      (2) In Figure 1E, betaIII-tubulin and NF-H seem to accumulate in betaII-spectrin-rich axonal enlargements. If these are patches, how do you reconcile this finding with Figure 2C-D, where NF-M and alphaII-tubulin are not specifically enriched in betaII-spectrin patches?

      (R34) We actually show that axonal enlargements and patches are structurally unrelated, in many aspects. We mention these axonal enlargements as a way to perform an exhaustive characterization of all βII-spectrin features found in these axons.

      (3) One technical challenge that limits a more compelling support of the new model of MPS formation is that fixed neurons are imaged, which precludes the observation of patch coalescence. This should be further discussed in the revised version of the manuscript.

      (R35) The limitation of the experimental approach is now further discussed (see for example last sentences on 5th paragraph of the Discussion section).

      (4) On a more general note, the title of some of the Results sub-sections could be revised to convey the findings of those sub-sections and not the Methods that were used (example: "Quantitave and Qualitative analyses of betII-spectrin distribution....").

      (R36) According to the suggestion, we have changed the title of this subsection.

      References

      Boyer, N. P., Sharma, R., Wiesner, T., Parperis, C., Delamare, A., Pelletier, F., Jullien, N., Bhatt, A. M., Parra-Rivas, L. A., Kearney, P. J., Shavarebi, F., Leterrier, C., & Roy, S. (2026). Spectrin condensates provide a nidus for assembling the axonal membrane-associated periodic skeleton. iScience, 29(1), 114454. https://doi.org/10.1016/j.isci.2025.114454

      Castellanos-Montiel, M. J., Chaineau, M., & Durcan, T. M. (2020). The Neglected Genes of ALS: Cytoskeletal Dynamics Impact Synaptic Degeneration in ALS. Frontiers in Cellular Neuroscience, 14, 594975. https://doi.org/10.3389/fncel.2020.594975

      Czogalla, A., & Sikorski, A. F. (2005). Spectrin and calpain: A “target” and a “sniper” in the pathology of neuronal cells. Cellular and Molecular Life Sciences: CMLS, 62(17), 1913–1924. https://doi.org/10.1007/s00018-005-5097-0

      Guix, F. X., Capitán, A. M., Casadomé-Perales, Á., Palomares-Pérez, I., López Del Castillo, I., Miguel, V., Goedeke, L., Martín, M. G., Lamas, S., Peinado, H., Fernández-Hernando, C., & Dotti, C. G. (2021). Increased exosome secretion in neurons aging in vitro by NPC1-mediated endosomal cholesterol buildup. Life Science Alliance, 4(8), e202101055. https://doi.org/10.26508/lsa.202101055

      Heller, E., Kurup, N., & Zhuang, X. (2025). The membrane skeleton is constitutively remodeled in neurons by calcium signaling. Science (New York, N.Y.), 389(6760), eadn6712. https://doi.org/10.1126/science.adn6712

      Qu, Y., Hahn, I., Webb, S. E. D., Pearce, S. P., & Prokop, A. (2017). Periodic actin structures in neuronal axons are required to maintain microtubules. Molecular Biology of the Cell, 28(2), 296–308. https://doi.org/10.1091/mbc.E16-10-0727

      Zhong, G., He, J., Zhou, R., Lorenzo, D., Babcock, H. P., Bennett, V., & Zhuang, X. (2014). Developmental mechanism of the periodic membrane skeleton in axons. eLife, 3, e04581. https://doi.org/10.7554/eLife.04581

      Zhou, R., Han, B., Nowak, R., Lu, Y., Heller, E., Xia, C., Chishti, A. H., Fowler, V. M., & Zhuang, X. (2022). Proteomic and functional analyses of the periodic membrane skeleton in neurons. Nature Communications, 13(1), 3196. https://doi.org/10.1038/s41467-022-30720-x

      • python 3.10 的 EOL 时间是2026/03/03, 最后版本号为3.10.20,PBS的最后构建为20260303
      • python 3.9 的 EOL时间是2025/10/31, 最后版本号为3.9.25,PBS的最后构建为20251031
      • python 3.8 的 EOL时间是2024/09/06, 最后版本号为3.8.20,PBS的最后构建为20240909
    1. Author response:

      The following is the authors’ response to the original reviews.

      We have addressed all the reviewers’ comments through new experiments, additional analyses, or, in some cases, additional text. Below is a summary of the major changes in the manuscript.

      (1) We have added a considerable amount of new characterization of the biochemical enrichment of the ribosome clusters, including EM of the ribosome clusters, UV absorbance profiles, immunoblots of additional targets, and additional replicates (new Figure 1). In summary, we provide better evidence that (i) the biochemical enrichment is working and (ii) that the loss of FMRP has no effect on this biological enrichment of ribosomal clusters.

      (2) We have now reanalyzed all of the data in Figs. 5-8 using only the data after removing PCR duplicates from the RPFs. Other than the comparison between the nuclease treatments (Fig. 3), only this data is now used. Moreover, we have reanalyzed this data using suggestions from the reviewers, including providing PCA analysis (Fig S5-1), GSEA analysis (Fig 5), and normalizing for group size when comparing significance to total mRNAs, (Fig 6-7). We now also include a new analysis (Fig S7-1) to better explain how the loss of FMRP affects mainly FMRP targets defined by CLIP, but not all mRNAs resistant to run-off.

      (3) We are now more conservative in our nomenclature; we use "pellet" instead of "RNA granule (RG)" and "fraction 5/6" instead of "ribosome clusters (RC)". We have added a section to the discussion about the relationship between the RNA granules measured using imaging of hippocampal neurites and the biochemical purification of ribosome clusters in the pellet, as requested by the reviewers.

      (4) We have made many other minor changes to the text and analysis, which can be found in the specific response to the reviewers.

      (5) One major additional requested change that was not implemented was to repeat our experiments at different time points. We have added a paragraph to the discussion outlining (i) why this was not done and (ii) the caveats of our conclusions without this data being present.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The authors have investigated the role of FMRP in the formation and function of RNA granules in mouse brain/cultured hippocampal neurons. Most of their results indicate that FMRP does not have a role in the formation or function of RNA granules with specific mRNAs, but may have some role in distal RNA granules in neurons and their response to synaptic stimulation. This is an important work (though the results are mostly negative) in understanding the composition and function of neuronal RNA granules. The last part of the work in cultured neurons is disjointed from the rest of the manuscript, and the results are neither convincing nor provide any mechanistic insight.

      Strengths:

      (1) The study is quite thorough, the methods and analysis used are robust, and the conclusion and interpretation are diligent.

      (2) The comparative study of Rat and Mouse RNA granules is very helpful for future studies.

      (3) The conclusion that the absence of FMRP does not affect the RNA granule composition and many of its properties in the system the authors have chosen to study is well supported by the results.

      (4) The difference in the response to DHPG stimulation concerning RNA granules described here is very interesting and could provide a basis for further studies, though it has some serious technical issues.

      Thank you for these positive comments on the paper.

      Weaknesses:

      (1) The system used for the study (P5 mouse brain or DIV 8-10 cultured neuron) is surprising, as the majority of defects in the absence of FMRP are reported in later stages (P30+ brain and DIV 14+ neurons). It is important to test if the conclusions drawn here hold good at different developmental stages.

      Unfortunately, myelin strongly interferes with the ability to use this protocol to purify ribosome clusters in older brains (See Khandjian et al., 2004). It is possible to redo the ribopuromycylation results at later times in culture, but since we cannot compare this to a comparable time in the brain, we have chosen not to do this experiment. We acknowledge this limitation in the discussion, noting that our results are only a snapshot of development and that different results may be observed at different times.

      (2) The term 'distal granules' is very vague. Since there is no structural or biochemical characterization of these granules, it is difficult to understand how they are different from the proximal granules and why FMRP has an effect only on these granules.

      We agree with the reviewer and have removed all references to distal granules. We clarified that we did not measure RPM puncta close to the neuron because the much stronger RPM signal made defining puncta more difficult, and thus, we cannot determine if there are differences between proximal and distal puncta.

      (3) Since the manuscript does not find any effect of FMRP on neuronal RNA granules, it does not provide any new molecular insight with respect to the function of FMRP

      We would respectfully disagree that the study does not provide molecular insight into the function of FMRP, as disproving that FMRP is important for stalling and determining the position of stalling would remove one of the major hypotheses about the function of FMRP, and showing that a major hypothesis in the literature is unlikely to be correct, is at least to me, providing insight. Moreover, we do show an effect of the loss of FMRP on the RPM puncta that represent neuronal RNA granules containing stalled ribosomes. This also provides insight.

      Reviewer #2 (Public review):

      In the present manuscript, Li et al. use biochemical fractionation of "RNA granules" from P5 wildtype and FMR1 knock-out mouse brains to analyze their protein/RNA content, determine a single particle cryo-EM structure of contained ribosomes, and perform ribo-seq analysis of ribosome-protected RNA fragments (RPFs). The authors conclude from these that neither the composition of the ribosome granules, nor the state of their contained ribosomes, nor the mRNA positions with high ribosome occupancy change significantly. Besides minor changes in mRNA occupancy, the one change the authors identified is a decrease in puromycylated punctae in distal neurites of cultured primary neurons of the same mice, and their enhanced resistance to different pharmacological treatments. These results directly build on their earlier work (Anadolu et al., 2023) using analogous preparations of rat brains; the authors now perform a very similar study using WT and FMR1-KO mouse brains. This is an important topic, aiming to identify the molecular underpinnings of the FMRP protein, which is the basis of a major neurological disease. Unfortunately, several limitations of this study prevent it from being more convincing in its present form.

      In order to improve this study, our main suggestions are as follows:

      (1) The authors equate their biochemically purified "RG" fraction with their imaging-based detection of puromycin-positive punctae. They claim essentially no differences in RGs, but detect differences in the latter (mostly their abundance and sensitivity to DHPG/HHT/Aniso). In the discussion the authors acknowledge the inconsistency between these two modalities: "An inconsistency in our findings is the loss of distal RPM puncta coupled with an increase in the immunoreactivity for S6 in the RG." and "Thus, it may be that the RG is not simply made up of ribosomes from the large liquid-liquid phase RNA granules."

      How can the authors be sure that they are analysing the same entities in both modalities? A more parsimonious explanation of their results would be that, while there might be some overlap, two different entities are analyzed. Much of the main message rests on this equivalence, and I believe the authors should show its validity.

      Thank you for your comments. We have been more conservative in the revised paper, referring to the pellet fraction as the pellet fraction rather than the RNA granule fraction to acknowledge the possibility that these two modalities differ. However, we would respectfully disagree that our main message requires RPM-labeled RNA granules in neurites and the ribosome clusters isolated by sedimentation to be “equivalent”. We do believe they are related and added a section in the discussion on this important point.

      (2) The authors show that increased nuclease digestion (and magnesium concentration) led to a reduction of their RPF sizes down to levels also seen by other researchers. Analyzing these now properly digested RPFs, the authors state that the CDS coverage and periodicity drastically improved, and that spurious enrichments of secretory mRNAs, which made up one of the major fractions in their previous work, are now reduced. In my opinion, this would be more appropriately communicated as a correction to their previous work, not as a main Figure in another manuscript.

      We have removed all discussion of the secretory mRNAs, as our attempts to obtain independent evidence for this finding by examining ribophorin enrichment in the pellet across different Mg<sup>2+</sup> concentrations did not support this interpretation (data not shown in the paper). I understand that the change in nuclease is somewhat out of place narratively, but it is clearly relevant to this work. We would disagree with our previous work requiring a ‘correction’. We believe that the nuclease resistance of the mRNA at the entrance site is important. We reproduce our results from rats with similar nuclease treatment in mice as seen in our previous publication; thus, this work is not wrong. We have a paper in preparation that suggests the secondary structure of the mRNA at this location may be important for stalling and thus feel strongly that this result should remain in the manuscript.

      (3) The fold changes reported in Figure 7 (ranging between log2(-0.2) and log2(+0.25)) are all extremely small and in my opinion should not be used to derive claims such as "The loss of FMRP significantly affected the abundance and occupancy of FMRP-Clipped mRNAs in WT and FMR1-KO RG (Fig 7A, 7B), but not their enrichment between RG and RCs".

      We agree that the changes are small and indeed did not appear in the DEG analysis. However, because we are analyzing a large set of mRNAs in this analysis, the results are highly significant and remain significant when using the new statistical tests suggested by the reviewer below. We now emphasize that these are small changes and remind readers that none of the individual mRNA changes were significant in the DEG analysis.

      (4) Figure 8 / S8-1 - The authors show that ~2/3 of their reads stem from PCR duplicates, but that even after removing those, the majority of peaks remain unaltered. At the same time, Figure S8-1 shows the total number of peaks to be 615 compared with 1392 before duplicate removal. Can the authors comment on this discrepancy? In addition, the dataset with properly removed artefacts should be used for their main display item instead of the current Figure 8.

      We now use only the data after removing PCR duplicates for all the analyses except in Figure 3. The number of peaks observed is determined mainly by the threshold used, as stated in the methods “To be identified as a peak, the zenith of an abundance site for the reads must be 4x higher of the average of the total transcript.” Due the lower number of reads after the PCR duplicates fewer peaks reached this threshold.

      (5) Figure 9 / S9-1, the density of punctae in both WT and FMR1-KO actually increases after treatment of HHT or Anisomycin (Figure S9-1 B-C). Even if a large fraction would now be "resistant to run-off", there should not be an increase. While this effect is deemed not significant, a much smaller effect in Figure 9C is deemed significant. Can the authors explain this? Given how vastly different the sample sizes are (ranging from 23 neurites in Figures S91 to 5,171 neurites in Figure 9), the authors should (randomly) sample to the same size and repeat their statistical analysis again, to improve their credibility.

      The box and whisker plots emphasize the median and not the average. We now also show the averages in Figure S9-1, which indicate a slight decrease for both HHT and anisomycin.

      We apologize for the typo in the figure legend in Figure 9, 171, not 5171. We now use random sampling in Figures 6 and 7, where the sample sizes differ substantially.

      Reviewer #3 (Public review):

      Summary:

      Li et al describe a set of experiments to probe the role of FMRP in ribosome stalling and RNA granule composition. The authors are able to recapitulate findings from a previous study performed in rats (this one is in mice).

      Strengths:

      (1) The work addresses an important and challenging issue, investigating mechanisms that regulate stalled ribosomes that are part of stress granules, and focusing on the role of FMRP. This is a complicated problem, given the heterogeneity of the granules and the challenges related to their purification. This work is a solid attempt at addressing this issue, which is widely understudied.

      (2) The interpretation of the results could be interesting if supported by solid data. The idea that FMRP could control the formation and release of stress granules, rather than the elongation by stalled ribosomes, is of high importance to the field, offering a fresh perspective into translational regulation by FMRP.

      (3) The authors focused on recapitulating previous findings, published elsewhere (Anadolu et al., 2023) by the same group, but using rat tissue, rather than mouse tissue. Overall, they succeeded in doing so, demonstrating, among other findings, that stalled ribosomes are enriched in consensus mRNA motifs that are linked to FMRP. These interesting findings reinforce the role of FMRP in the formation and stabilization of RNA granules. It would be nice to see extensive characterization of the mouse granules as performed in Figure 1 of Anadolu et al., 2023.

      (4) Some of the techniques incorporated aid in creating novel hypotheses, such as the ribopuromycilation assay and the cryo-EM of granule ribosomes.

      Thank you for these positive comments. We have now added a more extensive characterization in Figure 1.

      Weaknesses:

      (1) The RNA granule characterization needs to be more rigorous. Coomassie is not proper for this type of characterization, simply because protein weight says little about its nature. The enrichment of key proteins is not robust and seems not to reach significance in multiple instances, including S6 and UPF1. Furthermore, S6 is the only proxy used for ribosome quantification. Could the authors include at least 3 other ribosomal proteins (2 from the small, 2 from the large subunit)?

      We have increased N to improve the robustness of the enrichment analysis and added several additional RBPs. Along with Coomassie we now include analysis of UV absorbance and include EMs from these fractions showing the presence of 80S ribosomal clusters in the fractions we are using.

      (2) Page 12-13 - The Gene Ontology analysis is performed incorrectly. First, one should not rank genes by their RPKM levels. It is well known that housekeeping genes, such as those related to actin dynamics, molecular transport, and translation, are highly enriched in sequencing datasets. It is usually more informative when significantly different genes are ranked by p-adjust or log2 Fold Change, then compared against a background to verify enrichment of specific processes. However, the authors found no DEGs. I would suggest the removal of this analysis and the incorporation of a gene set enrichment analysis (ranked by p-adjust). I further suggest that the authors incorporate a dimensionality reduction analysis to demonstrate that the lack of significance stems from biology and not experimental artifacts, such as poor reproducibility across biological replicates.

      Thank you for the suggestion. We now use GSEA analysis to examine differences in gene sets between WT and FMR1- mice and find some significant changes (new Fig. 5). The old analysis is still included for comparison to our earlier paper as a supplemental figure. We have now included a PCA analysis (FigS5-1) to show reproducibility across biological replicates.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) RNA sequencing comparison between WT and FMR1 KO mice should be carried out at a later developmental stage, which may provide a better difference between these two groups

      There are a number of studies that have already done this analysis and in specific brain regions 10.1016/j.neuron.2017.07.013; 10.7554/eLife.46919; 10.3389/fnmol.2017.00340; https://doi.org/10.1016/j.neuron.2023.06.009. The main goal of our RNA-seq was to standardize for the RPF studies, not to identify differences in RNA-seq between WT and FMRP. In the response to public review point 1 we explain why we do not look at later developmental timepoints.

      (2) The same is true in characterizing the effect of FMRP on the RNA granules.

      See response to public review point 1, which addresses this point.

      (3) No evidence is provided for the effectiveness of DHPG stimulation in DIV8-10 neurons; this is needed for justification using neurons at this stage.

      We have previously shown that DHPG stimulation in these neurons at this developmental time from cultures made from rat brain is sufficient to decrease the number of RPM puncta and to induce an increase in the synthesis of proteins in an initiation resistant manner (Graber et al, 2013; Graber et al, 2017). This is now more clearly stated in the manuscript. Moreover, here we replicate the result of DHPG in WT mice at reducing the number of RPM puncta.

      (4) In Figure 9 B, it is not clear whether the neurites indicated are axons or dendrites. Since neurons are still in the early stages of dendritogenesis/synaptogenesis, it is important to make that distinction.

      We have previously characterized RNA granules in axons and dendrites in hippocampal cultures from rats at this time (Miller et al, 2009, MCN 40:485-495)) and they are similar. While it is likely that the vast majority of the neurites at this time are dendrites, since we did not use markers, we conservatively just use the term neurites.

      (5) In Figure 1 (and elsewhere), fraction 5/6 is used as a polysome or RNA cluster. The authors have not provided a UV absorption profile and only have s6 as evidence to say this polysome. In the Coomassie gel, this fraction is any different than fractions 7/7 or 9/10; what is the justification for using this fraction?

      The main justification for these fractions is to be consistent with our previous paper (Anadolu et al, 2023) and the Khandian study comparing polysomes to pellet using the same fractionation protocol (El-Fatimy et al, 2016). We now provide a UV absorption profile (Fig. 1C) and EM pictures (Fig. 1D) to show the ribosome clusters in this fraction. We do not believe our results would be fundamentally different from those obtained if we had used other heavy fractions.

      Minor comments

      (1) The font size very small in the figures, please increase it.

      We have worked hard to increase the font size in all the figures.

      (2) In the result section for Figure 3B - it is written 'majority of these mRNA are non-coding mRNA' - this doesn't make sense.

      Corrected

      Reviewer #2 (Recommendations for the authors):

      (1) There are lots of mistakes (e.g. word omissions or duplications, grammatical errors) throughout the text, too many to list here.

      We have carefully edited the text to try to minimize these mistakes.

      (2) In many positions related to their improved nuclease digestion protocol, samples are labelled "M ...", which apparently stands for "high magnesium and high nuclease treatment group". I would suggest switching to something more intuitive, such as "... (improved digestion)".

      We have removed most of the comparisons between these samples. What remains (Figure 3), we just use Low Nuclease when we refer to the sample with low Magnesium and low nuclease.

      (3) Figure 1,3 - It would be tremendously illuminating to see a polysome trace (UV260 absorbance) in addition to Coomassie-stained SDS-PAGE to underscore the interpretation of the different fractions by the authors. As it stands, there is no way of telling whether there are any polysomes present at all. This can also be done by hand using a UV absorption reader if no built-in device is available to the authors.

      We have now done this (Fig. 1C) and also provided EM of this fraction to show the presence of ribosomes in this fraction.

      (4) I don't understand why the authors switched from calling fraction 5/6 the "polysome fraction" in their previous work to calling it "ribosome cluster fraction" in this work. The argument given "[...] due to its structural similarity to ribosomes in RNA Granules (Anadolu et al., 2023), we conservatively call this the ribosome cluster fraction (RC)." does not instill confidence that these two fractions are indeed distinct.

      We agree with the reviewer and regret this decision. We now call the pellet, the pellet and Fraction 5/6, fraction 5/6.

      (5) Figure 1C - There are clear scanning or compression artefacts in the blot images (most prominently in the eEF2 lanes) that should be corrected.

      We have replaced all images in Figure 1 and have increased the N of this experiment considerably.

      (6) Figure 1C - The authors claim that WT mouse RG is enriched in FMRP compared to RC or starter fraction, but there is also a lot more protein loaded in the RG (especially when compared to RC). It is also hard to believe from the Coomassie staining that despite the much stronger presence of low MW bands (which is where ribosomal proteins migrate) in fraction 5/6, the s6 western blot signal is actually comparable between RC and RG. Can the authors please provide more detail on the loading of these fractions and supply quantification of FMRP in all three fractions, normalized by total protein? This might also be the source of their discrepancy, stating that contrary to their expectation, ribosomes (as measured by s6 signal / s6 signal in starter fraction) are actually increased in FMR1-KO brains.

      We have repeated all of these experiments and changed our method of quantification (See methods). We no longer use the starting material in our quantification. Indeed, with the additional data and change in method, we no longer see an increase in S6 in the FMR1- pellet fraction.

      (7) Figure 1 - I believe "D-F)" should only read "D-E)" based on the axis titles, and instead "FG)" should be added before the next sentence. Instead of "Staufen" it should be specified in the Figure that "Stau2" was quantified. "Staufen (59kd)" should read "Stau2 (59 kDa)" and "anti-Staufen (52kb)" should read "anti-Stau2 (52 kDa)" and the same for all other similar instances. It is further hard to believe that e.g., "Staufen2 (59kd)" (see above) is not significantly enriched with N=5, a very low spread, and over 1.5x enrichment. The authors should double-check that the appropriate statistical test was employed.

      Figure 1 has been completely redone, and the two Staufen bands are enriched in this new analysis.

      (8) Figure S4-2 - Most of the detail in the corresponding figure legend should be moved to the Materials and Methods section.

      Details relevant to the methods in this figure legend have been now moved to the Material and Methods section.

      (9) Figure 4A - The displayed/segmented tRNA densities appear unusually distorted. I would recommend displaying segmented densities of the original homogeneous reconstructions, not of separated and later fused partial maps.

      Figure 4 was modified according to the suggestions of this reviewer.’

      (10) Figure 9 C-D, S9-1 B-E - Are not all conditions also including puromycin as in B above? If so, it should be added to both the figure and the figure legend.

      The reviewer is correct and the figure and legend has been changed to reflect this.

      Reviewer #3 (Recommendations for the authors):

      (1) "Loss of FMRP causes Fragile X syndrome. In humans, the loss of FMRP occurs due to the expansion of a CGG repeat in the 5' untranslated region (UTR) of the gene, leading to excessive methylation and transcriptional inhibition."

      Comment: Genes don't have 5'UTR, but exons encoding 5'UTR. I suggest rephrasing this statement.

      This sentence has been rephrased.

      (2) "Several of these functions have been implicated in Fragile X syndrome, including FMRP's regulation of miRNA repression, splicing, translation initiation, and translational elongation".

      Comment: Is this a typo? miRNA instead of mRNA?

      No, this is correct. FMRP has been implicated in the regulation of microRNAs (miRNAs) in a number of studies.

      (3) "elongation rates are also increased in mouse models of FMRP".

      Comment: Mouse models of Fragile X?

      This has been corrected.

      (4) "Parts of this work were included in the Master's thesis of the first author (Li, 2024)."

      This has been removed.

      (5) Comment: Graphs in Figure 1 need proper y-axis labeling. What is the normalization method? What are the values presented in the y-axis?

      Figure 1 has been completely changed and the Y-axes are now clear in this new version.

      (6) "Thus, by looking at the percentage of puromycylation present in the presence of anisomycin, we can estimate the number of ribosomes in this state. "

      Comment: Are the authors really estimating the number of ribosomes in a resistant state? One could argue that they are collecting populational information regarding resistance to anisomycin.

      We have rephrased this sentence to be more conservative about what we are measuring.

      (7) Comment: Page 11 - Why did the authors assume magnesium would affect the conformation state of the ribosomes? What is the rationale behind increasing the [Mg2+]?

      Most preparations using ribosomes use 10 mM MgCl<sub>2</sub>. However, most neuroscientists use physiological buffers that contain 2.5 mM MgCl<sub>2</sub>. In bacteria, this makes a large difference, but evidence from eukaryotes is not clear. Since this is a collaboration between these two schools of thought, we decided to switch to 10 mM MgCl<sub>2</sub>, since in the EM, there were some free 60S ribosomes (Anadolu et al, 2024).

      (8) Page 11- "In other words, high Mg2+ decreased the abundance of mRNAs normally cotranslationally inserted into the ER which are unlikely to be components of transporting RNA granules containing stalled ribosomes and solidified our focus on the M protocol in the analyses below."

      We have removed this from the paper, as additional experiments aimed to solidify this interpretation failed to detect an effect on secretory mRNAs.

      (9) Comment: The whole "abundance", "enrichment", and "occupancy" nomenclature is hard to follow.

      We have rewritten this section.

      (10) Page 13 - "There were only 2 protein coding genes that were significantly different between the abundance of FMR1-KO and WT in protein coding genes - FMR1 and Wdfy1 (Extended Data Table 5-2). There were no significantly different genes between WT and FMR1-KO occupancy and enrichment. Thus, no difference rose to significance, given the large number of mRNAs used in this analysis."

      Comment: It seems like this is repeating the same information three times.

      This has been changed.

      (11) Page 13 - "Similar to previous experiments with rats, the most abundant mRNAs resistant to run off were significantly abundant, occupied and enriched in both WT and FMRP RPFs (Fig 6)"

      The Shah et al dataset we use was based on the most abundant mRNAs resistant to run-off. While we agree it is not surprising that they are also abundant in the pellet we observe, this would not necessarily be true unless the pellet is actually enriched in stalled mRNAs.

      (12) Page 14 - "These mRNAs had been identified by cross-linking FMRP with mRNA, fragmenting the mRNA, immunoprecipitating the mRNA still associated with FMRP and sequencing this mRNA."

      We shortened this description.

      (13) Page 14 - "Interestingly, while still significant, there appeared to be a decrease in the relative abundance of these mRNAs in the FMR1-KO RG (Fig 6B)"

      Comment: It is hard to observe this decrease in the boxplots. Second, the statistical tests for the bioinformatics analyses are not the most appropriate, given the large discrepancy in the number of mRNAs present in the experimental group ("All mRNAs") and the filtered groups.

      We have redone the statistics using multiple random sampling of all the mRNAs such that the total number of mRNAs in the group was the same. This lowered the significance for some groups, but they are mostly still highly significant. This analysis has also been affected by switching to using the data from the PCR-subtracted RPFs. The changes we now observe are more evident in the whisker box plots due to this improvement in the data.

      (14) Page 16 - "To rule out that peaks were due to amplification artifacts in the preparation of RPFs we repeated these analyses after removing PCR duplicates (Fig. S8-1; Extended Data Table S8-3) and found over 95% of the peaks identified without removing PCR duplicates were defined as a peak in at least one of the biological replicates after removing duplicates. More importantly, we found similar results with enrichment of FXS motif and enrichment of negatively charged amino acids in the FMR1-KO only, WT only and both peaks after removing PCR duplicates (Fig. S8-1; Extended Data Table S8-3)."

      Comment: It is unclear why the authors needed to include the analysis without PCR duplicate removal. This is an essential step to guarantee the robustness of ribo-seq findings. I recommend removing the whole analysis from Figure 8 from the manuscript and including only the post-duplicate removal analysis.

      As mentioned above, we completely agree with this statement and now show only this data and moreover have redone all the figures with only this data (except for Fig. 3).

      (15) Figure 9 - I am unsure that the data is convincing enough to demonstrate reinitiation of mRNA granules induced by DHPG. I suggest a colocalization experiment with another protein well known to be localized to RNA granules, such as G3BP1. In addition, repeat the experiment with an additional group where elongation is blocked after the addition of DHPG, which presumably would prevent the reduction in the WT puncta density.

      These are interesting additional experiments, but outside the scope of what we can manage. We have previously shown colocalization of Staufen, FMRP and UPF1 to these puncta (Graber et al, 2013; Graber et al, 2017) and shown that these puromycylated puncta also colocalize with nascent peptides detected using the Sun-Tag technique. While we think doing the experiment in the presence of an elongation inhibitor would be interesting, we disagree that it would prevent the reduction in WT puncta density, since we believe what is happening is the loss of the liquid-liquid phase separation of the ribosome clusters due to dephosphorylation of RBPs like FMRP and UPF1 (Graber et al, 2017), and this would reduce the puncta density whether or not the ribosomes were activated for translation.

      Nevertheless, we have tried to temper the conclusions made from this result, emphasizing what we know (RPM puncta are decreased) as opposed to actual reactivation of stalled polysomes which we are not measuring.

      Discussion - Page 18 - "Nevertheless, if FMRP binding was the critical determinant for presence in neuronal RNA granules, we would have expected to observe more differences." This is not true. If the data is poorly collected, you will not see differences.

      This statement was removed.

      (16) "A proportion of the stalled ribosomes that are not stored in large RNA granules may still be pelleted in the sucrose gradients. This fraction may be greater in the absence of FMRP."

      Comment: The authors are right about this and touch on my original point that the characterization of the biochemical fractionation is not convincing enough. I'd suggest probing against more proteins that are contained in RNA granules.

      We have added several proteins to the biochemical characterization shown in Figure 1. We have added a discussion about the relationship between neuronal RNA granules and the sedimented pellet fraction in the discussion section.

    1. Reviewer #2 (Public review):

      Summary:

      In the manuscript by Walter-McNeill, Kruglyak and team, the authors provide solid evidence of another toxin-antidote (TA) system in C. elegans. Generally, TA systems involve selfish and linked genetic elements, one encoding a toxin that kills progeny inheriting it, unless an antidote (the second element) is also present. Currently, only two TA systems have been characterized in this species, pointing to the importance of identifying new instances of such systems to understand their transmission dynamics, prevalence, and functions in shaping worm populations.

      The manuscript has been improved in some aspects upon revision. We remain enthusiastic for the overall findings and the identification of a new toxin/anti-toxin system and note that the strengths and weaknesses we detailed previously remain. We reiterate our critique regarding the strength of conclusions that can be made about small RNA pathway regulation based on meta-analysis of other datasets. While we agree that the observations presented are suggestive of small RNA regulation, likely due to piRNA targeting and subsequent 22G-RNA regulation, until these hypotheses are tested experimentally in the future by mutation of the piRNA target sites, testing ago/piRNA pathway and other 22G-RNA pathway mutants for tmrl-1 expression, etc., we think it is important to use precise language in presenting the conclusions. In particular, the abstract states:

      "Multiple lines of evidence suggest that the N2 tmrl-1 allele is recognized by piRNAs, leading to MUT-16-dependent 22G siRNA production and post-transcriptional silencing of the transcript. The N2 haplotype represents the first naturally occurring unlinked toxin-antidote system where the toxin is post-transcriptionally suppressed by endogenous small RNA pathways."

      We therefore recommend moderating this statement to "...is likely to be post-transcriptionally suppressed by endogenous small RNA pathways."

      Previously noted strengths and weaknesses remain relevant to this revision.

      Strengths:

      This novel TA system (mll-1/smll-1) was identified on LGV in wild C. elegans isolates from the Hawaiian Islands, by crossing divergent strains and observing allele frequency distortions by high throughput genome sequencing after 10 generations. These allele frequency distortions were subsequently confirmed in another set of crosses with a separate divergent strain, and crosses of heterozygous males or hermaphrodites resulted in a pattern of L1 lethality in progeny (with a rod arrest phenotype) that suggested the maternal transmission of this TA system from the XZ1516 genetic background. By elegantly combining the use of near-isogenic lines, CRISPR editing to generate knock-outs, and a transgene rescue of the antidote gene, the authors identified the genes encoding the toxin and the antidote, which they refer to as mll-1 and smll-1. Moreover, the specific mll-1 isoform responsible for the production of the toxin was identified and mll-1 transcripts were observed by FISH in early and late embryos, as well as in larvae. Inducible expression of the toxin in various strains resulted in larval arrest and rod phenotypes. The authors then characterized the genetic variation of 550 wild isolates at the toxin/antidote region on LGV and distinguished three clades: 1) one with the conserved TA system, 2) one having lost the toxin and retaining a mostly functional antidote, and 3) one having lost the antidote and retaining a divergent yet coding toxin (this includes the reference strain Bristol N2, in which the homologous toxin gene has acquired mutations and is known as B0250.8). Further, the authors show that this region is under positive selection. These data are compelling and provide very strong evidence of a new TA system in this species.

      Weaknesses:

      The question remained as to how one clade, including N2, could retain the toxin gene but not possess a functional antidote. In the second part of the manuscript, the authors hypothesized that small RNA targeting (RNAi) of the toxin transcript could provide the necessary repression to allow worms to survive without the antidote. Through a meta-analysis of multiple small RNA datasets from the literature, the authors found evidence to support this idea, in which the toxin transcript is targeted by 22G siRNAs whose biogenesis is dependent on the Mutator foci protein, MUT-16. They note that from previous studies, mut-16 null mutants displayed a varied penetrance of larval arrest. In their own hands, mut-16 mutants displayed 15% varied larval arrest and 2% rod phenotypes. In an attempt to link B0250.8 to mut-16/siRNAs, they made a double mutant and examined body length as a proxy for developmental stage. Here, they observed a partial rescue of the mut-16 size defect by B0250.8 mutation. Finally, the authors also highlight data from further meta-analysis which predicts the recognition of B0250.8 by several piRNAs. Also based on existing data from the literature, the authors link loss of Piwi (PRG-1), which binds piRNAs, to a depletion of 22G-RNAs targeting B0250.8 and an upregulation of B0250.8 expression in gonads, suggesting that piRNAs are the primary small RNAs that target B0250.8 for down-regulation. The data in this portion of the manuscript are intriguing, but somewhat incomplete, as they are based on little primary experimentation and a collection of different datasets (which have been acquired by slightly different methods in most cases). This portion of the study would require subsequent experimentation to firmly establish this mechanistic link. For example, to be able to claim that "the N2 toxin allele has acquired mutations that enable piRNA binding to initiate MUT-16-dependent 22G small RNA amplification that targets the transcript for degradation" the identified piRNA sites should be mutated and protein and transcript levels analysed in wild-type and in the strain with mutated piRNA sites. At a minimum, the protein levels in wild-type and mut-16, prg-1, and/or wago-1 mutants should be measured by western blot and/or by live imaging (introducing a GFP or some other tag to the endogenous protein via CRISPR editing) to show that the toxin is not accumulated as a protein in wt, but increases in levels in these mutants. mRNA levels in Fig S5A suggest there is still some expression of the B0250.8 transcript in a wild type situation.

      Comments on revised version.

      We have no further recommendations for the authors, other than those provided above.

    2. Author response:

      The following is the authors’ response to the original reviews.

      We incorporated Reviewer #2’s suggestion to change the name of mll-1 because of overlap with a human gene. We used the updated gene names in our responses below to minimize confusion. Below are the updated gene names for the toxin-antidote system we described.

      tmrl-1 - Toxin-induced Maternal Rod Lethality (formerly mll-1). After we establish that B0250.8 is also a toxin, we refer to this gene as the “N2 tmrl-1 allele”.

      amrl-1 - Antidote of Maternal Rod Lethality (formerly smll-1)

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The article by Zdraljevic et al. reports the discovery of a third toxin-antidote (TA) element in C. elegans, composed of the genes mll-1 (toxin) and smll-1 (antidote). Unlike previously characterized TA systems in C. elegans, this element induces larval arrest rather than embryonic lethality. The study identifies three distinct haplotypes at the TA locus, including a hyper-divergent version in the standard laboratory strain N2, which retains a functional toxin but lacks a functional antidote. The authors propose that small RNA-mediated silencing mechanisms, dependent on MUT-16 and PRG-1, suppress the toxicity of the divergent toxin allele. This work provides insights into the evolutionary dynamics of TA elements and their regulation through RNA interference (RNAi).

      Overall, there are many things to like about this paper and only a few small quibbles, which will not require more than a little rewriting or relatively minor analyses.

      Strengths:

      (1) The discovery of a maternally deposited TA element with delayed toxicity due to delayed mRNA translation of the maternally deposited toxin mRNA is a significant addition to the literature on selfish genetic elements in metazoans.

      (2) Identifying three haplotypes at the TA locus provides a snapshot of potential evolutionary trajectories for these elements, which are often inferred but rarely demonstrated in naturally occurring strains. The genomic analysis of 550 wild isolates contextualizes the findings within natural populations, revealing geographic clustering and evolutionary pressures acting on the TA locus.

      (3) The study employs various techniques, including CRISPR/Cas9 knockouts, FISH, long-read RNA sequencing, and population genomics. The use of inducible systems to confirm toxicity and antidote functionality is particularly robust. This multifaceted approach strengthens the validity of the findings.

      (4) The authors provide compelling evidence that small RNA pathways suppress toxin activity in strains lacking a functional antidote. This highlights an alternative mechanism for neutralizing selfish genetic elements.

      Weaknesses:

      (1) The introduction focuses strongly (for good reason) on bacterial TA systems and then jumps to TA systems in C. elegans. It's unclear why TA systems in other eukaryotes are not discussed.

      We briefly introduced bacterial TA systems because of their ubiquitousness and focused on C. elegans TA systems. We chose certain aspects of previously described Caenorhabditis TA elements that were relevant to the narrative we presented. Furthermore, we have extensively reviewed TA systems previously and have added a citation to that review in the revised manuscript (Burga et al. 2020).

      (2) Similarly, there is a missed opportunity to discuss an analogy between the suppressor mechanism discovered here and the hairpin RNA suppressors of meiotic drive identified by Eric Lai and colleagues. Discussing these will provide a fuller context of the present study's findings and will not affect their novelty.

      Thank you for pointing this out. We added a mention of the Stellate and Dox systems in our discussion.

      (3) While the evidence for RNAi-mediated suppression is strong, the claim that positive selection drove diversification at piRNA binding sites requires further discussion and clarification. The elevated dN and dS are unusual (how unusual relative to other genes in vicinity? What is hyper-divergent statistically speaking?), but there is no a priori reason that there would be selection on piRNA binding sites within the mll-1 transcript to facilitate its recognition by endogenous RNAi machinery; what is the selective pressure for mll-1 to do so? Most TA systems would like to avoid being suppressed by the host. One cannot make the argument that this was motivated by the loss of the antidote because the loss of the antidote would be instantly suicidal, so the cadence of events described requiring hypermutation of the mll-1 transcript does not work.

      We largely agree with the reviewer’s point, which we believe is based on the following sentence in the discussion: “We propose that positive selection for piRNA binding sites in the tmrl-1 transcript drove the diversification of this gene toward the N2 version.” We have removed this argument from the discussion in the revised manuscript.

      Reviewer #2 (Public review):

      Summary:

      In the manuscript by Walter-McNeill, Kruglyak, and team, the authors provide solid evidence of another toxin-antidote (TA) system in C. elegans. Generally, TA systems involve selfish and linked genetic elements, one encoding a toxin that kills progeny inheriting it, unless an antidote (the second element) is also present. Currently, only two TA systems have been characterized in this species, pointing to the importance of identifying new instances of such systems to understand their transmission dynamics, prevalence, and functions in shaping worm populations.

      Strengths:

      This novel TA system (mll-1/smll-1) was identified on LGV in wild C. elegans isolates from the Hawaiian islands, by crossing divergent strains and observing allele frequency distortions by high-throughput genome sequencing after 10 generations. These allele frequency distortions were subsequently confirmed in another set of crosses with a separate divergent strain, and crosses of heterozygous males or hermaphrodites resulted in a pattern of L1 lethality in progeny (with a rod arrest phenotype) that suggested the maternal transmission of this TA system from the XZ1516 genetic background. By elegantly combining the use of near-isogenic lines, CRISPR editing to generate knock-outs, and a transgene rescue of the antidote gene, the authors identified the genes encoding the toxin and the antidote, which they refer to as mll-1 and smll-1. Moreover, the specific mll-1 isoform responsible for the production of the toxin was identified and mll-1 transcripts were observed by FISH in early and late embryos, as well as in larvae. Inducible expression of the toxin in various strains resulted in larval arrest and rod phenotypes. The authors then characterized the genetic variation of 550 wild isolates at the toxin/antidote region on LGV and distinguished three clades: (1) one with the conserved TA system, (2) one having lost the toxin and retaining a mostly functional antidote, and (3) one having lost the antidote and retaining a divergent yet coding toxin (this includes the reference strain Bristol N2, in which the homologous toxin gene has acquired mutations and is known as B0250.8). Further, the authors show that this region is under positive selection. These data are compelling and provide very strong evidence of a new TA system in this species.

      Weaknesses:

      The question remained as to how one clade, including N2, could retain the toxin gene but not possess a functional antidote. In the second part of the manuscript, the authors hypothesized that small RNA targeting (RNAi) of the toxin transcript could provide the necessary repression to allow worms to survive without the antidote. Through a meta-analysis of multiple small RNA datasets from the literature, the authors found evidence to support this idea, in which the toxin transcript is targeted by 22G siRNAs whose biogenesis is dependent on the Mutator foci protein, MUT-16. They note that from previous studies, mut-16 null mutants displayed a varied penetrance of larval arrest. In their own hands, mut-16 mutants displayed 15% varied larval arrest and 2% rod phenotypes. In an attempt to link B0250.8 to mut-16/siRNAs, they made a double mutant and examined body length as a proxy for developmental stage. Here, they observed a partial rescue of the mut-16 size defect by B0250.8 mutation. Finally, the authors also highlight data from further meta-analysis, which predicts the recognition of B0250.8 by several piRNAs. Also based on existing data from the literature, the authors link loss of Piwi (PRG-1), which binds piRNAs, to a depletion of 22G-RNAs targeting B0250.8 and an upregulation of B0250.8 expression in gonads, suggesting that piRNAs are the primary small RNAs that target B0250.8 for downregulation. The data in this portion of the manuscript are intriguing, but somewhat preliminary and incomplete, as they are based on little primary experimentation and a collection of different datasets (which have been acquired by slightly different methods in most cases). This portion of the study would require subsequent experimentation to firmly establish this mechanistic link. For example, to be able to claim that "the N2 toxin allele has acquired mutations that enable piRNA binding to initiate MUT-16-dependent 22G small RNA amplification that targets the transcript for degradation" the identified piRNA sites should be mutated and protein and transcript levels analysed in wild-type and in the strain with mutated piRNA sites. At a minimum, the protein levels in wild-type and mut-16, prg-1, and/or wago-1 mutants should be measured by western blot and/or by live imaging (introducing a GFP or some other tag to the endogenous protein via CRISPR editing) to show that the toxin is not accumulated as a protein in wt, but increases in levels in these mutants. mRNA levels in Figure S5A suggest there is still some expression of the B0250.8 transcript in a wild-type situation.

      We thank the reviewer for their thoughtful assessment of our manuscript, and we appreciate that they recognized that the data linking the small RNA machinery to B0250.8 suppression is intriguing. While the reviewer claims our analysis is preliminary and incomplete, we believe we present an appropriate multi-faceted approach for establishing the small RNA-mediated suppression mechanism we describe. 

      First, the reviewer states that we rely on “little primary experimentation”. Our primary experiments show that loss of the N2 tmrl-1 allele partially rescues ∆mut-16 developmental delay and arrest phenotypes. Therefore, we provide direct evidence that the N2 tmrl-1 functionally contributes to the ∆mut-16 phenotype. Furthermore, we overexpressed the N2 tmrl-1 allele to show that this gene is a toxin.

      It is true that we use previously published datasets to establish a small RNA-mediated mechanism that likely explains our observations. The reviewer suggests that our claims are weakened by relying on a “collection of different datasets (which have been acquired by slightly different methods in most cases)”. We believe instead that evidence collected from multiple labs using an array of different techniques strengthens our conclusions. We show that N2 tmrl-1-targeting small RNAs have been identified across multiple datasets (references 26, 32, 33, 34). Taken together, these datasets support a mechanistic framework for the suppression of the N2 tmrl-1 that involves PRG-1-dependent piRNA binding, MUT-16-dependent 22G siRNA, and the secondary Ago WAGO-1 binding. 

      The reviewer suggests several experiments, but we do not view them as essential to support our claims. 

      (a) piRNA site mutatagenesis: we present multiple lines of evidence that the N2 tmrl-1 transcript is post-transcriptionally targeted by small RNAs in a piRNA-mediated manner, not that specific piRNA sites are necessary and sufficient for this silencing. The suggested experiment would be valuable for future work, but is beyond the scope of our study.

      (b) Characterization of TMRL-1 protein levels: We agree that this experiment would provide definitive evidence of complete small RNA-mediated suppression of the N2 tmrl-1 transcript. As we explain above, however, we do show that removing the N2 tmrl-1 allele partially rescues the ∆mut-16 growth defect, demonstrating that when this gene’s regulation is disrupted, it induces toxicity. Importantly, we observed no tmrl-1-induced toxicity when we overexpressed a version of this gene with a stop codon, indicating that it acts as a protein.

      Finally, the reviewer questions our claim that: "the N2 toxin allele has acquired mutations that enable piRNA binding to initiate MUT-16-dependent 22G small RNA amplification that targets the transcript for degradation."

      We agree that this statement is too definitive given our current data. We have revised it to: "Multiple lines of evidence suggest that the N2 tmrl-1 allele is recognized by piRNAs, leading to MUT-16-dependent 22G siRNA production and post-transcriptional silencing of the transcript."

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) The paper suggests that antidote pseudogenization occurred because RNAi replaced its function, but does not explore whether this process is ongoing or complete across all N2-like strains.

      We explored this possibility, but we realize that we did not explicitly state so in the manuscript. The B0250.4 (amrl-1) gene is pseudogenized in all strains within the N2 clade. We have modified the following sentence in the results section to explicitly state this observation:

      “While the previously described C. elegans TA elements are characterized by their absence in susceptible strains (2, 3), all members of the N2-like susceptible clade harbor a divergent allele of tmrl-1 with an intact coding sequence, as well as a pseudogenized version of amrl-1.”

      (2) Some figures (e.g., allele frequency distortions) could benefit from additional annotations to guide interpretation. In general, the figures make the reader work harder than they need to.

      We attempted to add clarity to figure captions for clarity.

      Although mll-1 and smll-1 were identified as toxin and antidote genes, their molecular mechanisms remain unclear and are very interesting.

      We agree that identifying the molecular mechanism associated with the toxin and antidote would be of interest, but is beyond the scope of the current paper.

      Reviewer #2 (Recommendations for the authors):

      (1) Because the rod phenotype was important in identifying the TA system, it seems important to include representative images of this phenotype throughout the paper.

      We added a supplemental figure showing the resulting self progeny from a QX1211/XZ1516 heterozygote: Fig S1B

      (2) In Figure 2A, we were confused as to why there were so few reads of mll-1. We may be misunderstanding something, so could the authors explain this to us? We would have expected more reads of mll-1, given the diagram showing that the breakpoints of the NIL were beyond (closer to the right end of) the mll-1 locus, and the phenotype correlates with the presence of the toxin (frequency of .20 L1 arrest).

      The lack of sequencing depth arises because the sequence divergence between QX1211 and XZ1516 is too high to accurately map short sequencing reads derived from QX1211 to the XZ1516 genome. We added the following sentence to the figure caption to add clarity:

      “The XZ1516 and QX1211 genome are so diverged that short reads derived from QX1211 don’t align to the XZ1516 genome in the 200 bp windows with no corresponding read depth, as indicated by a lack of a gray bar.”

      (3) The use of TOF in Figure 4 as a proxy of animal length instead of directly indicating or measuring animal length hinders the comparison of these results with other studies (i.e., most often in the literature, we see images of worms and measurements of their sizes or use of some other morphological marker to demonstrate the proportion of worms in a particular developmental stage). Nonetheless, we think the approach is clever and certainly enables analysis of a large sample population. However, a wild-type control is missing from these experiments to give a sense of the typical distribution one would expect. Without this, one interpretation of the B0250.8 knock out data shown in B is that loss of B0250.8 results in ~10% arrested larval, which seems higher than would be expected for a wild type N2 strain, and should be explained-but again, if the wild type control showed the same pattern, that would be useful to know. The title for Figure 4 should be revised, as this figure suggests, but does not provide definitive evidence that B0250.8 is suppressed by sRNAs/sRNA pathways. See the next point for providing more definitive data to support this model.

      There is a long list of publications that rely on the large particle sorter to infer how growth rate is affected in various mutants and environmental conditions (See Andersen et al. 2015, ref 28 in the manuscript, and the papers that reference this work). As the reviewer pointed out, the use of time of flight, which is simply the amount of time an object obstructs a laser at a constant flow rate, enables accurate measurement of tens of thousands of individual animals for comparison. 

      The reviewer is correct to point out that without a wild type N2 control, it is impossible to tell what a typical distribution looks like. However, the experiment includes all strains necessary to make the comparisons that enable us to draw the conclusion that the N2 tmrl-1 allele contributes to larval arrest in the absence of MUT-16.

      We agree with the reviewers point that this figure does not provide evidence that B0250.8 is suppressed by small RNAs and we have therefore changed the figure title.

      The new figure title: The N2 tmrl-1 allele contributes to larval arrest in the absence of MUT-16

      (4) To be able to claim that "the N2 toxin allele has acquired mutations that enable piRNA binding to initiate MUT-16-dependent 22G small RNA amplification that targets the transcript for degradation" the identified piRNA sites should be mutated and protein and transcript levels analysed in wild-type and in the strain with mutated piRNA sites. At a minimum, the protein levels in wild-type and mut-16, prg-1, and/or wago-1 mutants should be measured by western blot and/or by live imaging (introducing a GFP or some other tag to the endogenous protein via CRISPR editing) to show that the toxin is not accumulated as a protein in wt, but increases in levels in these mutants. mRNA levels in Figure S5A suggest there is still some expression of the B0250.8 transcript in a wild-type situation.

      The reviewer makes several good suggestions for experiments to determine whether the conclusions we make from publicly available high-throughput sequencing datasets apply in our context. However, we disagree that the quoted statement “the N2 toxin allele has acquired mutations that enable piRNA binding to initiate MUT-16-dependent 22G small RNA amplification that targets the transcript for degradation” is not supported by the evidence we present from Reed et al. 2020. The data presented by Reed et al. clearly show that the N2 tmrl-1 transcript is heavily targeted by 22G siRNAs, and that the accumulation of these siRNAs depends on the presence of MUT-16 and PRG-1. The dependence on PRG-1 implicates piRNAs involvement in the mounting of a 22G response.

      (5) Importantly, it is not the mll-1/B0250.8 transcript itself that was not shown to interact with WAGO-1 in the Seroussi et al. eLife paper (Lines 257-259). This study investigated sRNAs associated with every AGO, and computationally inferred the targets of each AGO using those enriched sRNA sequences. Therefore, it is the siRNAs antisense to mll-1/B0250.8 that were detected in association with WAGO-1, making it likely that WAGO-1 is the secondary AGO that targets this transcript. The argument the authors make holds true, but the authors should revise how they describe the evidence supporting that argument to accurately reflect the existing data.

      Thank you for catching this mistake. We have updated the text to accurately reflect the results from the Seroussi et al 2023 publication:

      “Recent work has shown that the N2 tmrl-1 transcript-derived small RNAs co-immunoprecipitated with WAGO-1, providing additional evidence that this transcript is regulated by the endogenous RNAi machinery”

      (6) It seems likely that the authors explored the possibility that another antidote may be present in the third clade. Could they discuss what they did to rule out this explanation in lieu of piRNA/siRNA regulation?

      We did not look for another antidote in the third clade because this clade is defined by the presence of an antidote and the absence of a toxin. Figure 3C shows the result of a cross between a third clade strain (NIC195) and XZ1516. The conclusion we draw from this experiment is that the antidote present in NIC195 provides near complete resistance to the XZ1516 toxin.

      (7) Line 156, legend of Figure S3, and line 273: There was no marker used to indicate that these are the primordial germ cells. Best practices would indicate using a fluorescent marker (e.g., PIE-1 GFP or PGL-1 GFP or PRG-1 GFP, etc.) to definitively identify these as PGCs.

      We agree with the reviewer’s point. As we do not have the perfect experiment, we do not definitively state that tmrl-1 transcripts localize in the primordial germ cells. 

      Minor comments:

      (1) A minor suggestion: incorporating some of the results now shown in the supplementary figures - Figures S1, S3, and S4 - into the main figures may make the manuscript easier to read.

      We constructed the manuscript in a way we thought was straightforward. The figures listed by the reviewer are supplemental to the main conclusions of the manuscript, so we decided to leave them as supplemental figures.

      (2) Line 87, Figure S1A: include numbers in the y-axis.

      The numbers are included on the y-axis and we explain the x-axis tick marks in the figure caption.

      (3) Figures 1B, 2B, 3C, 4B, S1B, S4: statistical analyses missing.

      We have added a summary of the statistical analysis to the captions of Figures 1B, 2B, 3C, and S1B. We added more detail from the analysis of 4A, which is the figure we draw conclusions from. Figure S4 is observational data, and the only conclusion drawn from that figure is that the N2 tmrl-1 gene encodes a toxin. It is toxic in 100% of individuals we looked at and therefore doesn’t warrant statistics. 

      (4) Line 100, "The rod progeny were all homozygous for QX1211 alleles at the locus on the right arm of chromosome V that displayed the allele frequency distortion in the mapping populations". Is this supported by data? While there is strong evidence to suggest it, the way it is currently written makes it seem that the rod progeny have been genotyped (by sequencing or PCR?). Is this the case? If not, the authors should revise the statement accordingly.

      Yes, this is indeed the case and we have updated the text to reflect that we performed PCR of a QX1211-specific indel to verify the genotypes on the right arm of chromosome V.

      (5) Figure 2A: lower panel missing x axis label.

      The top panel is a cartoon representation of a NILs, and the x axis is labeled for the top panel, highlighting the mapped element. 

      (6) Line 140 to 148: The authors should provide data to support these statements.

      Realizing i skipped this one – these are the lines they are referring to -> Long-read RNA sequencing revealed two distinct mll-1 isoforms, a short isoform with three predicted exons and a long isoform with eight predicted exons (Fig. S2A). We constructed plasmids with inducible versions of each mll-1 isoform. When we injected susceptible strains with the short mll-1 isoform array, every F1 individual carrying the array died, with 64% of larvae exhibiting the rod phenotype, indicating that uninduced expression levels of the short mll-1 isoform are sufficient to induce lethality. By contrast, we were able to isolate susceptible strains that maintained the long mll-1 isoform array or a short mll-1 isoform array with a premature stop codon in mll-1. We observed no rod progeny upon induction of these arrays, indicating that the short isoform encodes the functional toxin, and that the toxin acts as a protein.

      (7) Line 193: It would be interesting to see if there is structural conservation between mll-1 and B0250.8 using alpha-fold. Have the authors done this?

      We did attempt to look for structural conservation but we found the confidence in the structural predictions to be very low, which didn’t warrant a comparison.

      (8) Line 206-207: Could the authors explain why the frequency of the rod phenotype is so low when presumably over-expressing B0250.8? Does this indicate that B0250.8 is not as functional a toxin as mll-1, or is it sufficiently repressed by sRNAs and not actually overexpressed? Further, what are "abnormal" phenotypes? This should be clarified for the reader.

      It is likely that the overexpression and misexpression of toxic proteins is causing the abnormal phenotypes. The rod phenotype probably manifests when the gene is expressed at the appropriate developmental stage and tissue to cause the phenotype, whereas abnormal phenotypes manifest when the expression is not in the correct stage or location. A summary of the observed phenotypes is provided in Supplementary Table 7.

      (9) Line 216 and thereafter: indicate that B0250.8 is now referred to as mll-1.

      We incorporated this suggestion.

      (10) Line 228-231: missing to state that this is shown in Figures 4A-B.

      This and the following comment suggests that we did not provide enough clarity in this section. We modified the line to the following:

      Consistent with this report, in an agar plate-based preliminary assay we observed that ~15% of ∆mut-16 progeny arrest at various larval stages, and 2% of progeny are rod, which is suggestive of derepression of tmrl-1 in N2.

      This lets readers know that this initial characterization of the mut-16 knockout strain is different from the data presented in figure 4.

      (11) Line 230: the Figure shows ~25% of arrest for the deletion mutant of mut-16, but the text says ~15%.

      The 15% the reviewer points out was obtained from a preliminary agar plate-based experiment where we attempted to characterize the mut-16 deletion strains. We turned to a more high-throughput approach to screen through more animals for each genotype, which we report in figure 4.

      (12) Line 233: TOF, and not animal length, was compared. The authors should indicate that TOF is used as a proxy for animal length.

      We made the suggested change. The new sentences read:

      To do so, we compared time of flight (TOF) measurements—a proxy for animal length, developmental stage, and growth rate (28)—between a strain with a single knockout of mut-16 and one with a double knockout of mut-16 and the N2 tmrl-1 (a strain with a single knockout of the N2 tmrl-1 served as a negative control). We observed a reduction in TOF and an increase in the fraction of worms in larval stages in the mut-16 knockout strain, and these effects were partially rescued in the double knockout strain (Fig. 4).

      (13) Line 237-239: This claim may be overstated without additional data. Consider adding a "likely" to the statement.

      The line in question: 

      These results indicate that the reduced growth rate observed in the mut-16 knockout strain is partially mediated by derepression of the N2 mll-1 allele.

      We modified it to reflect the reviewer’s concern: 

      These results indicate that the reduced growth rate observed in the mut-16 knockout strain is partially mediated by the presence of the N2 tmrl-1 allele, likely because tmrl-1 is derepressed in mut-16 knockout strains.

      (14) Line 257: Figure S5C should be moved to line 259.

      We made the suggested move. 

      (15) Is the name mll-1 firmly established? We ask because MLL1 is a human mutation commonly associated with leukemia, and it may lead to some confusion in the field. This is a minor point, but we wanted to bring it forth.

      This name was not firmly established. We modified the names to not overlap with known gene names:

      tmrl-1 - Toxin-induced Maternal Rod Lethality

      amrl-1 - Antidote of Maternal Rod Lethality

    1. This study is an important contribution to our understanding of waterfowl conservation and population ecology in Europe. Recovery of marked birds, typically through harvest by waterfowl hunters, is an important means of obtaining data to assess survival and harvest probabilities in waterfowl, but the ability to differentiate between natural and harvest mortality requires a better understanding of reporting probabilities (the proportion of banded/ringed birds that are harvested by hunters that are also reported to banding authorities). In North America we have had numerous studies using reward bands to estimate this “band reporting rate”, but comparable studies have not been conducted elsewhere, until this study. I thoroughly reviewed this preprint and my overall assessment is strongly supportive. I have only a few suggestions for potential improvement.

      It might be nice to bound the reporting rate estimates between 0 and 1 by formally including reporting rate in the model likelihoods rather than estimating it as a derived parameter. I can’t use the link to your code, so I’m unable to see exactly how you modeled this, but you could seemingly model reporting probability directly by including it in the likelihood anywhere that Brownie’s f or Seber’s r appears for birds marked with reward rings.

      Lines 328-330: You conclude this paragraph with a statement about your results supporting additive mortality from hunting, but the rationale for this isn’t explained (I’m not disputing your claim, but you haven’t clearly articulated why you believe your results support partially additive mortality). The stark difference in estimated harvest probabilities between newly ringed and previously ringed (i.e., direct vs. indirect in North American terminology) suggests that heterogeneity in vulnerability to harvest might (also) be very important in these populations and thereby contribute to compensation of harvest. Coauthor Emilienne Grzegorczyk presented intriguing results on survival heterogeneity at the latest EURING conference and it might be worthy of a little bit of discussion here.

      Minor edits: Line 77 or thereabouts: Because there is an extensive literature on reporting probabilities from North America, but quite different terminology, it might be nice to include a Methods paragraph clarifying ring/band/tag recovery as identical, young vs. adult and hatch-year vs. after-hatch-year, and define the terms direct vs. indirect recovery in terms of time since marking.

      Line 154: In addition to the inscription included on reward rings, it would be helpful to indicate the exact inscription provided on standard rings. In North America we observed a pronounced increase in band reporting probabilities when band inscriptions were modified to include toll-free phone numbers and later, web addresses.

      When do (most) of your recoveries occur? It would be helpful to include information on timing of harvest in France. Given that you include season of banding as a covariate on survival, subsequent estimates of survival beyond the first year will be hunting season to hunting season. It might be nice to more formally address timing of banding by including a “partial year survival” term in the first diagonal of your m-arrays. This could be a shared annual survival term, but partitioned into portions based on how much of the year an average bird would have to survive (e.g. S^(5/12) if 5 months or S^(9/12) if 9 months).

      In North American ducks, we would expect to see pronounced differences in seasonal survival between sexes due to breeding risks incurred by females. For example, spring releases of female mallards would be expected to have lower survival to the first hunting season than spring releases of males. It might be nice to indicate in the methods that you ignored sex in your analysis given small sample sizes (given interactions with species, age, and timing, it might require 6-12 df to properly address), but future analyses based on additional data might wish to investigate sex differences in both survival and recovery probabilities.

      You have a nice literature review, but there are a few additional papers that would be worth including: Lines 64-65: Either of the two Riecke et al. 2022 Journal of Animal Ecology papers would be good to cite for an example of how reporting probabilities can help partition annual survival into harvest and natural mortality. Koons et al. (2014, Wildfowl) would be a nice paper to cite here for life-history differences in relation to body size. The results from nasal-marked teal are intriguing, and I suspect that nasal markers might influence survival, vulnerability to harvest, and reporting probability. Arnold et al. 2016 J. Wildl. Manage., Szymanski et al. 2020 Wildl. Soc. Bull., Reinecke et al. 1992, J. Wildl. Manage., Caswell et al. 2012, J. Wildl. Manage.).

      Minor changes to wording: Abstract, line 49: I think you mean “subjected” rather than “submitted”. Intro, line 57: “elaborate” rather than “elaborated”. Intro, line 83: use “to” instead of “on”. Intro, line 89: use “of” instead of “or”. Methods, line 126: use “drop-door” instead of “door-falling” Line 161: “departmental”. Line 196: “parameter” (not plural). Line 298: “a heavy predator-control program was in place”. Line 344-345: Curiosity effect has been hinted at in some other research.

    1. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      Freas and Wystrach present a computational model of steering in insects. In this model, the central complex provides an error signal indicating the animal should turn left or right; this error signal biases the function of an oscillator composed of two mutually inhibiting self-exciting units. The output of these units generates a "steering signal" that is used both to set the direction and speed of the ant. Additionally, a separate module induces pauses, and an inverse relation between forward speed and turning speed is externally imposed. Statistics of the trajectories generated by the model are compared to the measured behaviors of ants.

      Strengths:

      While the model is very simple compared to state-of-the-art models, that simplicity makes it a potentially useful guide to researchers studying insect navigation. Some predictions that emerge from the model appear to be experimentally testable, although a more complete description of the model and its parameters, as well as an analysis of how this model's predictions differ from previous models' predictions, would be required to design these experiments.

      Weaknesses:

      I found it difficult to identify evidence in the paper supporting central elements of the abstract. Hopefully, these difficulties can be resolved with a clearer presentation and the addition of supporting detail, especially in the methods.

      (1) The model is not clearly described

      In the Materials and Methods, there is no description of the model, just "The computational model is presented in Figure 1." (This is probably a typo and may refer to Figure 2A-C), and a link to Matlab source code. It is inappropriate to ask readers or reviewers to examine source code in lieu of providing a method, but I attempted to do so anyway. 

      We have now added a full description of the model in the methods.

      To my eye, the source code does not match the model presented in 2A-C. For instance, in 2C, "Steering signal" inhibits "Freeze", but I couldn't find this in the source. "Freeze" is shown to inhibit "steering signal," but as "steering signal" is a signed quantity, it's not clear what this means. Literally, since "ang_speed_raw = L-R," it would seem to indicate the "freeze" would bias towards right turns. In the code, "freeze" appears to be implemented through the boolean variable "speed_inhibition_time." The logic controlled by this variable doesn't appear to inhibit the "steering signal" but instead (depending on control parameters) either reduces the movement speed and amplifies the turning rate, or it turns the angular speed output into a temporal integral of the control signal.

      We understand the confusion. Our neural implementation does not go downstream of the neural steering signal (Left and Right Descending neurons), and the way it is transformed into a movement (ang_speed_raw = L-R) is not modelled neurally (the formula is explicitly shown on the right hand side of Figure 2). Indeed, we did not attempt to put forward any assumption about neural implementation for our freezing signal (see our response to comment 2 below). To avoid confusion, we have now removed the reciprocal inhibition portion as it was previously drawn in Figure 2C, and replaced it by a non neural sign (a cross, indicating that the signal is blocked) acting between steering signal and movement.

      There are a number of parameters in the source code that aren't described at all in the paper, including the internal oscillator parameters.

      We now provide all the parameters in the methods, together with figures showing the dynamics of oscillations across parameter range, and a rationale for their choice (see Supplemental Figure 2).

      Together, these limitations make it difficult to understand what is being simulated, what parts of the model are tied to biology, and where the model improves on or departs from previous work.

      It is absolutely essential that authors fully describe the computational model, that they explain the meaning of all parameters of the model, and that they explain how the particular values of these parameters were chosen.

      This is now done in the methods section under the “Model Overview” subsection.

      (2) The biological inspiration is unclear

      A central claim of the paper is that the model is "biologically grounded." But some elements, for instance, using a signed quantity to represent left-right steering drive, are not biologically possible; at best, these are shorthand for biologically possible implementations, e.g., opposing groups of left-right driving neurons.

      The mechanism that produces fixations and saccades - the "freeze" module - is not tied to any particular anatomy of the insect brain. Initiation of a freeze occurs at a specific time coded into the model by the authors; it is not generated by an internal model signal. Release of a freeze is by drawing a random variable; there is no neural mechanism proposed to generate this signal.

      We now clarified what is neural from is not from the introduction onwards, for instance:

      “Because we did not want to form pre-assumptions for how such a ‘freeze signal’ could be implemented in the insect nervous system; in our model this was achieved using a simple external signal that halts forward motion at random intervals.”

      In some versions of the model, instead of directly controlling the signal, during fixations, the angular drive signal is integrated into a variable "cumul_drive." No neural substrate is proposed for this integrator. In the code, if cumul_drive passes a threshold, the angular heading of the ant changes (saccades), but only if this threshold is passed before the Poisson process ends the fixation. No neural substrate is proposed for any of this logic.

      This has now also be clarified in the introduction:

      “During scanning, real ants display rotational saccades of variable duration and angular magnitude (Figure 1A–C). To replicate this, we introduced a threshold-based mechanism: after each fixation (i.e., zero angular and forward speed), the underlying angular steering signal accumulates until surpassing a threshold, triggering a saccade. The resulting angular magnitude of the saccade corresponds to the sum of the angular drive accumulated during the fixation. Here also we stuck to a non-neural, straight-forward algorithmic level, as we did not want to make assumptions about how such a cumulate-and-release mechanism could be neurally implemented in the insect brain (see discussion for potential implementations).”

      The model steps forward in time by a fixed increment - the actual duration (in seconds) of this time step is not specified. From Figure 4F, G, it appears a simulation time step is meant to be about 10ms. This would imply an oscillator frequency of about 2 Hz (Fig 2B), that the heading oscillates at a similar frequency (2G), and that a forward crawling ant stops moving every 500 ms (2I). Are these plausible? Can they be compared to an experiment? Model parameters, including the ones that control the frequency of the oscillator, are non-dimensionalized. It is not possible to evaluate whether these parameters are biologically plausible or match experimental results.

      We now added a figure showing the oscillatory dynamics of the oscillator across parameter ranges (supplemental figure 2). The step increment (i.e., and thus the sampling rate along an oscillatory cycle) necessarily varies according to the inhibition strength and self decay parameter chosen (e.g., small parameter values will lead to small step increment, and thus a high sampling rate along the oscillatory cycle). We chose oscillatory parameters to ensure that the sampling rate will be high enough to resolve multiple saccades within one oscillatory cycle and that sampling rate is small enough for computation time to remain practical.

      Beyond these constraints, the oscillator parameters can be chosen arbitrarily, and a conversion of time step to actual time (ms) would be equally arbitrary and give the illusion that the model captures the data quantitatively. Because we did not model spiking neural dynamics (or brain region low field potential frequencies), we can not constrain our model through a temporal link between brain clock and behavioural speed. We thus prefer to stick to the true and non-dimensional label ‘time steps’ in our figures.

      (3) Claims that behaviors emerge from the model may be overstated

      The abstract claims that steering correction and fixations/saccades emerge naturally from the same model. But it appears to me that fixations/saccades are externally imposed by the specification of specific times for a "freeze." Faster angular rotation during saccades than during course correction is imposed and does not emerge naturally from neural simulations.

      The abstract now clarifies that what emerges spontaneously is not scannings per se (indeed, the inhibition of movement is externally imposed) but their dynamics. Note that our model captures many aspects of scanning dynamics that are not trivial and which results from the dynamical interactions and contingencies between modules (figure 3 to 7), hence justifying the word ‘emerge’ insofar as these behavioural dynamics cannot be reduced to one module or parameter. Regarding the faster angular rotation during scanning, we agree that its cause is rather straightforward to understand: it results from the added bodily constraints of forward speed to rotational movements. Nonetheless it is not ‘imposed’ during saccades in the sense that 1.) it is biologically/physically evident rather than cherry picked and 2.) it is continuously present in our model, even during forward navigation. We believe the new version of the manuscript now conveys this message in a transparent manner.

      (4) Citations to previous literature are difficult to follow, and modeling results are presented as though they are experimental data

      I would ask the authors to be much clearer in their description and citation of previous work. It should be clear whether the cited work was experimental or computational. To the extent possible, the actual measurement should be described succinctly. Instead of grouping references together to support a sentence with multiple claims, references should be cited for each claim. Studies of computational models should not be presented as proving a biological result.

      Indeed, This we now clearly separated citations referring to experimental evidence vs. modelling. See examples citations below

      For example:

      (a) Lines 141-146:

      "Previous studies have established many key components of insect navigation, including .... the intrinsic oscillatory dynamics in the lateral accessory lobes (LALs) that support continuous zigzagging locomotion (Clément et al., 2023; Kanzaki, 2005; Namiki and Kanzaki, 2016;

      Steinbeck et al., 2020)."

      The first reference is to one author's previous modeling work - it hypothesizes that oscillations in the LAL support zigzagging but includes no data that would "establish" the fact. Kanzaki et al. 2005 describes numerical modeling and simulation with a physical robot. Namiki and Kanzaki, 2016 is a review article that links the LAL to zigzagging behavior. It describes the LAL as a winner-take-all bistable network but does not describe or hypothesize that the LAL has intrinsic oscillatory dynamics. Steinbeck et al. 2020 is a more comprehensive review; it reinforces that the LAL is a winner-take-all bistable network that drives left-right steering, including during zig-zagging behavior. But in my reading, I could not find a statement that the LAL has intrinsic oscillatory dynamics (the closest is Steinbeck et al. saying the activity pattern switches regularly, as does the behavior; this doesn't imply that the LAL is intrinsically oscillatory.)

      It now reads:

      “Previous studies have established many key components of insect navigation, notably, how goal headings are set in the central complex (CX) (Fisher, 2022; Green and Maimon, 2018). Modelling efforts have shown that the CX circuitry can naturally accommodate innate and learnt guidance such as path integration, learn vectors, visual route following or homing as observed in ants and bees. In parallel, oscillatory dynamics in the lateral accessory lobes (LALs) - produced by reciprocal inhibition across both hemispheres and conveyed by so-called descending flip-flopping neurons - were shown to drive the spontaneous zigzags displayed by moths upon losing their pheromone plume (Kanzaki and Mishima, 1996; Mishima and Kanzaki, 1998, 1999; Wada and Kanzaki, 2005; Kanzaki et al., 2005; Iwano et al., 2010). Here also, subsequent modelling efforts have shown how these circuits can equally support the continuous lateral oscillations displayed by a wide range of insect species, including ants.”

      (b) Lines 701-703:

      "In plume-tracking moths, CX output has been shown to modulate LAL flip-flop neurons driving zigzagging (Adden et al., 2022)."

      This reads as though an experimental measurement was made, but in fact, this is modeling work.

      Yes, this could be clearer, it now reads: 

      “In moths, descending neurons in the LALs exhibit characteristic 'flip-flop' activity patterns that correlate with zigzagging maneuvers (Olberg, 1983; Kanzaki and Ikeda, 1994). Computational models suggest that having these LAL neurons modulated by the CX output can explain aspects of the moths’ plume-tracking behaviour (Adden et al., 2022).”

      (c) Lines 703-706:

      "In ants, strong goal signals in the CX - whether elicited by the path integrator or visual familiarity (Wehner et al., 2016; Wystrach et al., 2020b, 2015) do not only sharpen directional accuracy but also increase oscillation frequency (Clément et al., 2023)."

      Here again, modeling results are presented as though they were experimental data.

      Here, we are referring to the experimental part of these works, although this comment demonstrates that our statement should be more clear in stating what are biological results. It now reads: 

      “In ants, behavioural studies show that strong directional drives elicited by the path integrator or visual familiarity do not only gain behavioural weights and sharpen directional accuracy (Wehner et al., 2016; Wystrach et al. 2015, Legge et al. 2014) but also increase the ants’ oscillation frequency (Clément et al., 2023). Assuming that path integrator and visual familiarity modulate goal signals in the CX, as modelled here and elsewhere (Wystrach et al., 2020b, Stone et al., 2017) and that the intrinsic oscillator is in the LAL (Clément et al., 2023, Steinbeck et al., 2020), it suggests that CX output modulates the intrinsic oscillatory activity of the LAL”

      Reviewer #2 (Public review):

      Summary:

      The paper by Freas and Wystrach is an interesting computational study, exploring the detailed mechanisms of how simple neural circuits could explain complex behavioral patterns observed in navigating ants. The authors compare detailed, high-speed video recordings of Australian desert ants (Melophorus bagoti) with predictions made by their new computational model and find convincing similarities between the model and the behavioral data, at a level of detail not previously studied. Particularly interesting are emerging properties of the model, yielding behavioral motifs it was not designed to reproduce, but which occur in natural ant behavior.

      Strengths:

      A strength of the study is that the model is based on previous models, without making major novel explicit assumptions. It combines existing models of the insect central complex with a model of the lateral accessory lobe and adds a stochastic inhibition of forward velocity to the interaction of central complex and lateral accessory lobes. The central complex provides corrective steering signals when the goal direction and the current heading of an insect are not aligned, while the lateral accessory lobes provide an intrinsic oscillator underlying the behavioral oscillations shown by walking ants at all times. These background oscillations are modulated by the steering signals from the central complex. Depending on which phase of the intrinsic oscillations coincides with the corrective signals, and how fast the ant is moving forward during this time, a complex set of behaviors emerges. Most prominently, scanning behaviors, which are regularly carried out by the ants, are recapitulated in great detail by the model. Additionally, other behaviors, such as full loops, emerge naturally from the model. While computational models are not to be seen as definite evidence for any biological reality, they can provide strong support for particular neural implementations. The current study is an excellent example in that it provides evidence for a serial arrangement of central complex circuits upstream of the lateral accessory lobe circuits, modulated by speed-regulating input. While the latter is hypothetical, it yields a clear hypothesis that can be validated by connectomics studies and functional work in the future.

      The study shows that even complex behavioral motifs do not require dedicated neural modules, but can rather emerge from the interplay of already known circuits - highlighting the efficiency of insect brains and possibly providing the path towards embodied hardware solutions of such circuits in autonomous agents.

      Weaknesses:

      There are several weaknesses in the paper as it is.

      Firstly, the model is not described in the methods, but only found when following the link to the authors' GitHub repository. This is clearly not sufficient and prevents readers from evaluating the model's assumptions directly. Most importantly, how natural do the emerging properties indeed emerge from the model? What parameters need to be tuned to generate a match between data and model?

      We have now added a full description of the model in the Methods section.

      These include:

      Mathematical equations for model components

      Complete parameter table along with justifications

      Description of what is fitted vs. what emerges 

      Key assumptions and limitations

      Regarding the emergence of scanning properties: The model has two types of parameters:

      Parameters tuned to match general navigation behavior (independent of scanning):

      Motor gains (g_ang, g_fwd, k): adjusted to produce realistic continuous walking paths and species differences between desert ants and Myrmecia

      CX gain (g_CX = 0.5): set to produce appropriate corrective steering strength during continuous navigation

      Oscillator parameters (α, β, s): are taken from Clément et al. (2023)

      Parameters tuned to match scanning behavior:

      CPG angular threshold (θ_CPG = 2.0): adjusted to generate realistic saccade timing Scan termination probability (p_stop = 0.5/timestep): matched to the Poisson-like distribution of scan durations in M. bagoti

      Properties that emerge without specific tuning:

      Fixation-saccade alternation structure (emerges from angular drive accumulation mechanism)

      Directional reversals (arise from oscillator dynamics competing with CX steering)

      Corrective saccade amplitude increasing with angular deviation (Figure 3)

      Rare full-loop scans (emerge from CX signal shifting oscillator phase)

      The behavioral continuum from straight paths → oscillations → voltes → scans (Figure 8)

      We have clarified this distinction in the Methods section and emphasized that our goal was qualitative demonstration of emergence rather than quantitative parameter optimization.

      Second, it is often not entirely clear what is biological data and what is a computational model. This relates to figures, text, and references. As a reader, this makes it difficult to clearly judge what is new in the current paper, how it adds to previous models, and what the predictions and assumptions are for biology.

      Indeed, we have now clarified the manuscript, clearly separating when we refer to behavioural data, neurobiological data and modelling. In the figures, each panel now clearly indicates if it is model data or biological data so that any reader can immediately tell the data type.

      Third, while neural data from bees and flies are taken to motivate and design the computational model, the discussion and interpretation revolve almost exclusively around ants. For the most part, this is justified, as the behavioral data used to benchmark the model are taken from ants. Nevertheless, more broadly discussing the newly defined circuit in the context of flying insects would give a better idea of the broad relevance of the neural circuits predicted by the model.

      To address this suggestion we have now added two paragraphs in the discussion called: “Scanning in flying hymenopterans”.

      Also happy to add more to this section if requested.

      Recommendations for the authors:

      Reviewer #2 (Recommendations for the authors):

      As mentioned in the public review, I suggest fixing the two concerns I have regarding methods and discussion.

      (1) Include a full description of the model in the methods, so that the model remains reproducible even if the GitHub repo is deleted in the future.

      True, the code’s internal explanations could indeed be removed from GitHub later. The model component overview are now included in text.

      (2) Include the relevance of the model for flying insects in the discussion more prominently. This seems to be an implicit assumption in the model, as neural data from bees and, more prominently, from Drosophila are used to motivate the model to explain ant data.

      Add an “Expression in flying hymenopterans” section at ~line 834.

      Minor points:

      (1) Line 207: I suggest adding the recent review by Collett, Graham, and Heinze (2025, Current Biology), as it proposes interactions between LAL and CX as well.

      Added

      (2) Figure 4: I'm interested in the conversion from steps in the model to real units (ms) in the ants. In Figures 4F and G, it seems that 5 model steps represent circa 100ms. Does this allow us to define the neuronal time constants of the model neurons? If so, are the resulting values biologically plausible? This seems important when describing real-world dynamics being created by a model circuit.

      No the model is time agnostic.

      (3) Figure 7: Font sizes of axis labels are much too small. Also applies to other figures. Please ensure that when printed, labels can be read.

      Enlarged axis labels in all figures. 

      (4) Line 645: proprieties -> properties?

      Fixed. Thanks!

      (5) Figure 7: The figure heading states: "Slow forward speed (Myrmecia) example". This sounds as if real data from ants are shown here, while these are modeling data. It is clear after reading the text and caption in detail, but I was taken off course briefly here. Please make sure that there is no possibility of being misled here.

      We have altered the subtitle to “Slow forward speed (Myrmecia Model) example”. 

      Additionally, we have added a Model tag under each of the model image labels so classification can be done at a glance.

      (6) General discussion: What about search dynamics, i.e., increasing loops when not finding the nest entrance after homing? Are those emerging from this circuit as well? Or would that need to be a separate module? There have been discussions about search emerging from the PI circuit, but as far as I know, this is not settled, and it would be good to know if the current circuit adds something useful to this aspect.

      Because we kept a fixed goal heading, our model does not bring insight about overall trajectories such as search pattern. We now mention in the discussion:

      “In our simulations, the CX goal representation remained fixed in both direction and strength throughout each trial. This simplification allowed us to isolate and compare the effects of different CX strengths on scanning behaviour (Figure 6). However, goal headings in the CX are likely to be updated continuously, including during scans, by novel input from visual recognition in the MB (ref). This would in turn bias saccades direction and duration. Exploring such dynamics lies beyond the scope of the present study but would represent an interesting direction for future work. Notably, our proposed CX-LAL-Body relationship could be implemented downstream of an existing path integration or visual-based model (or both) to form predictions about the occurrence and dynamic of scans along the path, as well as their impact on the emerging trajectories.”

      (7) Line 690: The modulation of PFL3 by PFL2 was presented as a hypothesis in Westeinde et al., consistent with the data, but as far as I know, this is not an established fact.

      You are correct. We have now softened the text, which now reads: “In Drosophila, it has been proposed that PFL2 neurons, which respond maximally when the fly faces away from the goal, modulate steering gain by converging with PFL3 neurons (which drive left or right turns) onto downstream descending neurons (Westeinde et al., 2024).”

      (8) Please ensure that Drosophila is consistently spelled with a capital D and in italics.

      Fixed throughout the text.

      (9) Line 702: Reference Adden et al 2022: This reference is a modeling paper; it sounds as if you are referring to an experimental moth paper, though. Rephrase to clarify.

      You are correct, this could be unpacked much better regarding what is modelled and what has been experimentally shown. Changed to:

      Descending neurons in the LALs exhibit characteristic 'flip-flop' activity patterns that correlate with the zigzagging maneuvers of plume-tracking moths (Olberg, 1983; Kanzaki and Ikeda, 1994). Recent computational models suggest that CX output directly modulates these LAL circuits to coordinate orientation (Adden et al., 2022). 

      (10) Line 761: I would assume that during scans, information is acquired that would decrease uncertainty and thus, as a result change the amplitude of the CX steering signal. Maybe I missed this, but is this closed-loop interaction integrated in the model?

      In our simulation the CX goal representation remains stable in direction and strength throughout the trial. This enabled us to compare neatly the effect of different CX strengths on scanning. However, we fully agree with you that goal headings in the CX might well be continuously updated, both during scans and between scans! The goal heading novel strength or direction may thus bias the scan further left, right, in front or in the back, and also up or down regulate scan duration in both directions. 

      Modelling this would require adding a layer of complexity to determine how the goal heading is updated, which is beyond the scope of the current work, but would form a remarkable project for the future. We now mention this in a dedicated paragraph in the discussion section “Model limitations and future directions”

      (11) Line 814: Please add 'fly' in front of larva. Other insect larvae have a fully developed CX.

      Corrected. Added fly to this sentence 

      (12) Line 815: Maybe add the recent review, Heinze 2025.

      Added this one (Heinze 2024) which seems to fit the best and the 2025 Curr Biol Review doesn't quite fit this line (cited elsewhere though): 

      Heinze, S. (2024). Variations on an ancient theme—the central complex across insects. Current Opinion in Behavioral Sciences, 57, 101390.

      (13) Methods: Subheading formatting should start with capital letters.

      Ah yes, the second level of subheadings got formatted weirdly. Fixed now.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      The authors adapt MemPrep, a protocol they originally developed to purify organelle membranes from yeast, for use in human cell lines. To this end, they established immuno-isolation strategies based on tagged versions of the ER sheet protein SEC61β and the ER tubular protein REEP5 in HEK293T cells. Their purification strategy allowed them to generate highly pure ER sheet- and tubule-enriched fractions, which were then subjected to quantitative lipidomic and proteomic analyses.

      Overall, this manuscript is well written and presents a careful interpretation of the data. It introduces MemPrep in mammalian cells as a method that will be useful for studying the membrane lipid and protein composition of organelles, with a particular focus on the ER. As such, the manuscript provides sufficient information and controls to assess the experiments in terms of reproducibility and clarity.

      We thank the reviewer for a positive, thorough assessment and for raising important points that helped us to improve the manuscript.

      Major comments:

      1. Based on the immunofluorescence images in Figure 1, it is not clear that the tagged and slightly overexpressed versions of SEC61β and REEP5 localize specifically to ER sheets and tubules, respectively, or that these proteins are enriched in these distinct ER subdomains. Perhaps reducing the fixation time, for example to a maximum of 2 minutes, or using PFA fixation, could help to better preserve ER sheet and tubular domains.

      To address the localization of the bait proteins in the ER membrane network, we added new co-localization microscopy data and quantifications to the revised manuscript (new Figure 1E,F; new Supplementary Figure S1C,D). Despite its low level of overexpression (new Figure 1C; new Suppl. Fig. S1A), SEC61β localizes to the entire ER membrane network including ER tubules and the nuclear envelope (new Fig. 1E,F).

      Considering the new data, we have carefully rephrased all sections regarding the subcellular localization of bait-SEC61β. In the revised manuscript, we use SEC61β as a general ER marker.

      Intriguingly, quantitative proteomics of the SEC61β MemPrep isolate demonstrates a selective enrichment of ER sheet-associated proteins compared to the REEP5 MemPrep, which selectively enriches proteins associated with ER tubules (Fig. 5). While we do not claim to 'isolate' ER subdomains, we enrich ER subdomains.

      We have performed additional microscopy experiments and adjusted our fixation protocol as suggested by the reviewer (Revision Fig. 1). Shortening the fixation time has no apparent impact on the ER structure, while any PFA fixation seems to largely disrupt the ER.

      Does expression of tagged SEC61β or REEP5 influence the ER sheet:tubule ratio? In addition, does expression of these constructs affect the lipidome or proteome of the cells?

      The reviewer raises an important point, which is experimentally not easy to address. Our imaging modality is not sufficient to make a firm statement about the sheet:tubule ratio in HEK293T cells. We are not aware of any study that firmly quantifies the relative content of sheets and tubules in HEK293T cells. Imaging the ER in HEK293T cells is challenging and most studies on the ER membrane networks use other cell types to study the impact of ER-shaping protein on the ER membrane network.

      In the revised manuscript we state: 'We found no evidence that the expression of the bait constructs disrupts the tubule-to-sheet ratio or other aspects of the ER architecture, but distinguishing ER sheets and ER tubules is challenging in HEK293T cells.'

      Furthermore, we have studied if the expression of the bait constructs affects the cellular proteome (new Suppl. Fig. S1A,B) and lipidome (new Suppl. Fig. S4A-H (previously Suppl. Fig. S3)). The expression of the bait constructs has no substantial impact of the cellular proteome. Most importantly, we find no evidence that proteins characteristic for ER sheets or ER tubules (other than the bait proteins) change their expression level (new Suppl. Fig. S1A,B). In the revised manuscript we state:

      ' We decided to go one step further and compared the proteomes of wildtype HEK293T cells with the two cell lines using TMT multiplexed, untargeted protein mass spectrometry (Suppl. Fig. S1A, B). This experiment revealed that bait proteins have only a minimal, neglectable impact on the cellular proteome (Suppl. Fig. S1A, B). We did not find evidence for a systematic deregulation of proteins known to localize exclusively to ER tubules or other ER subdomains. Furthermore, quantitative proteomics validated the results from immunoblotting (Fig. 1B, C): Expression of bait-SEC61β has barely any impact on the total cellular level of SEC61β (Suppl. Fig. S1A) while the expression of the REEP5-bait results in a 1.8-fold overabundance of REEP5 (Suppl. Fig. S1B).'

      Likewise, the expression of the bait constructs has little to no effect on the cellular lipidome as shown in Suppl. Fig. S4A-J. In the revised manuscript we state:

      'As a control, we also tested the impact of the bait constructs on the HEK293T whole cell lipidome (Suppl. Fig. 4A-J). Overall, the lipid composition of the virally transduced cells was indistinguishable from HEK293T cells with only minor impact on the level of CL and lysolipids (Suppl. Fig. 4A-J).'

      Apart from hypotonic swelling and douncing, could the authors use alternative methods for cell disruption to exclude the possibility that mechanical stress confounds the interpretation of the data?

      Thanks to the reviewer's comment, we became aware of a mistake. Our cell lysis buffer is hypertonic and not hypotonic (15% sucrose w/v, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)(HEPES) pH 7.4, 300 mM NaCl, 1 mM EDTA freshly supplemented with protease inhibitor cocktail from Roche). We have corrected all relevant sections in the revised manuscript.

      The reviewer is right that different means of mechanical lysis, and/or the incubation of the cells in hypo/hypertonic buffer are likely to have impact on the structure of the ER and to affect the isolation procedure. Changing such critical parameters will likely affect the purity of the preparation. Performing additional MemPrep isolations using different means of cell disruptions goes beyond the scope of this manuscript.

      Upon establishing the MemPrep protocol, we have explored various mechanical cell disruptions: Different cannula, Dounce homogenizers, and a ball-bearing device. We experimented with both hypo- and hypertonic buffers. Given the costs and work associated with lipidomic and proteomic analyses, we have tried to find a suitable conditions for cell disruption without performing a full analysis each time. Therefore, we performed differential centrifugations as exemplary shown in Fig. 2B of the manuscript. Critical factors for our decision whether to further persue a certain condition was 1) the depletion of the mitochondrial TOM22 marker, 2) the enrichment of the ER markers, and 3) the total protein yield in the P100,000 fraction.

      In the revised manuscript we state: 'Compared to the MemPrep procedure in yeast, we tested various means of cell disruption and optimized the differential centrifugation protocol.'

      and

      'Mild cell disruption by Dounce homogenization in a hypertonic buffer is crucial for cracking cells open, but these procedures can disrupt normal ER architecture and might facilitate the undesired mixing of previously well-defined ER subdomains. Despite these limitations, our data underscore the purity of our ER membrane preparations, demonstrate a differential enrichment of ER subdomains (Fig. 5), and establish the lipid composition of the ER membrane (Fig. 6)'.

      What is the total amount of lipids and proteins isolated with REEP5- or SEC61β-based MemPrep? Are there differences in the total lipid:protein ratio between these isolates, and could this reflect differences in the ER sheet:tubule ratio?

      In response to the reviewers' question, we have included a new Supplementary table 1 to the manuscript outlining the yield of total protein and total lipid of MemPrep.

      The mammlian MemPrep protocol is not yet optimized for determining the lipid:protein ratio in the membrane. At this moment, we do not want to make a statement about the protein-to-lipid ratio in the ER or its subdomains. The isolates still contain material originating from the ER lumen.

      The combined analysis of lipid and protein composition demonstrates the capacity of the method. To test that MemPrep can capture changes in ER membrane architecture, it would be useful to compare ER protein and lipid composition across different cellular states, such as stressed versus unstressed cells, or growing versus resting cells.

      We agree with the reviewer that a comparison of the ER under different conditions would be extremely interesting. Currently, we see it beyond the scope of this study.

      Minor comment:

      1. In line 335, the authors state: "To address this possibility, we performed a new round of REEP5 and SEC61β MemPreps for a direct comparison of the isolates (Fig. 5A, B)." It is unclear whether the MemPrep protocol was altered or whether this refers simply to an additional round of purification. Please clarify.

      Thank you. This point was also raised by reviewer 2 and 3. We have clarified our statements. In the revised manuscript we state:

      'Hence, we performed a new round of REEP5 and SEC61β MemPreps in triplicates for a direct comparison of the isolates (Fig. 5A, B) rather than comparing the changes in abundance relative to the respective cell lysates as performed in Figure 3. Knowing that non-ER proteins are less efficiently enriched by the MemPrep procedure than ER proteins (Fig. 3C, D) and that the sensitivity and comprehensiveness of mass spectrometry-based proteomics experiments are reduced with increasing sample complexity (Ting et al, 2011; Beck et al, 2011) , we were hoping to gain a better insight into the distribution of low abundant and challenging to quantify proteins in the two MemPrep isolates'.

      Reviewer #1 (Significance (Required)):

      General assessment:

      The manuscript establishes MemPrep for mammalian cells as an important discovery tool to investigate how cells coordinate membrane lipid composition with membrane protein composition, and vice versa. This is a rapidly growing research field, which attracts a lot of interest.

      MemPrep is based on an immuno-isolation strategy using tagged versions of the ER sheet protein SEC61β and the ER tubular protein REEP5 in HEK293T cells. The purification strategy allowed to generate highly pure ER sheet- and tubule-enriched fractions, which were then subjected to quantitative lipidomic and proteomic analyses.

      The results show that the protein composition differs between the SEC61β- and REEP5-enriched fractions. Yet the lipid composition of ER sheets and tubules is largely indistinguishable. Both fractions are dominated by PC alongside other monounsaturated GPL, and hydroxylated ceramides. These physicochemical properties of the ER lipid bilayer are matched by ER-resident membrane proteins.

      Thorough bioinformatic analysis of a subset of ER membrane proteins further revealed that their transmembrane domains have reduced hydrophobicity and increased polarity compared with those of plasma membrane proteins, matching the ER lipidome.

      Hence the combined analysis of lipid and protein composition demonstrates the capacity of the method. Many variations of this approach will be possible in the future to understand on the molecular level how cells assemble and control their membranes.

      Advance: Other immuno-isolation methods, or "organelle immunoprecipitation" approaches, have been established for lysosomes, the Golgi apparatus, and other organelles.

      MemPrep is an important and complementary addition to the technical toolbox for organelle isolation, with a particular focus on the analysis of membrane lipid and protein content.

      Audience: The manuscript will be of broad interest to researchers in basic biology as well as clinical and translational research.

      Reviewer's field of expertise:

      Molecular membrane biology.

      __Reviewer #2 __

      Jain and colleagues develop a biochemical fractionation procedure in which ER microsomes are enriched through small epitope tags. The manuscript is pitched around the concept that there are ER sheets and tubules and ER proteins differentially localise to them. The authors use REEP5 as a 'tubule' bait and SEC61beta as a 'sheet' bait. These baits are immuoisolated after a sensible membrane fractionation and ER membraned purified. There is a convincing ER proteome as a result, and this is used to compare the TMD properties of the organelles resident membrane proteins. The authors make the interesting observation that the transmembrane domains are more polar in the ER. They then compare the two sheet and tubule preparations and see a different in the proteome, before comparing the lipidome. There is no difference observed between the lipidome of the sheet and tubule preps, however they see a difference in the whole cell lysate and use that to compare the ER lipidome against the whole cell.

      Overall the manuscript has an interesting premise and the data is well presented, the experiments well performed and the interpretations appropriate. I think there are some issues with the mechanistic insight and novelty, and essentially although the premise is with regards to sheets and tubules there is limited progress in that direction in terms of results. I am reluctant to be to critical overall as there are certainly interesting observations that may be insightful for future studies in the field. I have some more specific comments below:

      We thank the reviewer for a thorough, constructive assessment and for highlighting important points that helped us improve the manuscript.

      1) The authors cite nixon-abell, but they do not mention the major point of that manuscript which is that the 'sheets' in the cellular periphery are instead dense tubular networks. I think this is quite an omission for the introduction, as it points to the premise not being as clear as stated.

      In the revised manuscript we refer to the Nixon-Abell study and two additional studies from the Jokitalo lab. Notably, the Nixon-Abell study does not rule out the existence of ER sheets.

      In the revised manuscript we state: ' [...] dense tubular networks in the cell periphery can appear like ER sheets in diffraction-limited microscopy (Nixon-Abell et al, 2016). Furthermore, the edges of ER sheets are populated by curvature-stabilizing proteins also found in ER tubules (Shibata et al, 2010; Shemesh et al, 2014), and ER sheets show different degrees of fenestration dependent on the cell type and the cell cycle phase (Puhka et al, 2007, 2012; Nixon-Abell et al, 2016). Consistent with our microscopic data (Fig. 1E, F) and because ER sheets may be biochemically inseparable from ER tubules, we use SEC61β as a general ER marker.'

      We performed additional co-localization studies of the bait proteins with RTN4 and CLIMP63 (new Fig. 1E,F) suggesting that SEC61B can localize across many ER subdomains including ER tubules and the nuclear envelope.

      We have carefully revised our manuscript accordingly and shifting the focus of our discussion away from a molecular description of discrete ER subdomains.

      2) The first section when the protocol is discussed essentially relies on looking at other papers to understand. As the manuscript is centrally about this protocol, I think a brief but clear description is more appropriate.

      We agree with the reviewer. We added a short section to the results section providing an overview over the MemPrep procedure. We now state:

      'To this end, we adapted the MemPrep procedure originally developed for the isolation of organelle membranes from Saccaromyces cerevisiae (S. cerevisiae) (Reinhard et al, 2023, 2024). Mammalian MemPrep relies on a gentle, detergent-free, mechanical lysis of the cells in a hypertonic buffer followed by differential centrifugation to separate ER-derived microsomes from mitochondria-derived membranes. Next, larger organelle fragments are disrupted by brief pulses of sonication, and the resulting vesicles are subjected to affinity purification using magnetic dynabead-coupled antibodies directed against the cleavable tag of the bait protein. Specifically bound, ER-derived membrane vesicles are washed with harsh, urea-containing buffers and selectively released by proteolytically cleaving the bait tag.'

      3) In figure 1C the two markers are supposed to localise to sheets and tubules differentially. To me they look very similar. This, of course, is a major concern. Have the authors co-expressed them (at the same levels in these lines) and seen that indeed they do differentially localise?

      The reviewer raises an important point regarding the localzation of the bait proteins. While we have not co-expressed the bait proteins in cells, we have performed additional co-localization experiments with RTN4 and CLIMP63 as markers for ER tubules and ER sheets, respectively (new Figure 1E,F; new Suppl. Fig. S1C,D). The implications of these data are discussed in the manuscript.

      In light of these new data, we do not refer to SEC61β as an ER sheet marker any longer, instead we refer to SEC61β as a general ER marker. We carefully revised our discussion of the data throughout the manuscript along the line suggested by the reviewer in point 8.

      4) I found the TMD polarity section very interesting, but it was not clear to me why they needed their proteomics for this? Could this not be done with annotated ER membrane proteins?

      The reviewer is correct. The same type of analysis could have been performed with an even bigger dataset of all ER annotated proteins. One of the co-authors, Joseph Lorent, has performed such analysis at this larger scale (PMID: 40326394). The study by Lorent et al. addressed TMH length and side chain bulkiness (PMID: 40326394) in the ER, Golgi apparatus, and the PM. This work is referenced in the manuscript.

      We focused our analysis on the smaller dataset of 83 single-pass proteins found in our proteomics experiments, because we initially planned to perform a comparative analysis of ER proteins in either of the two isolates.

      In line of the reviewers' suggestion, we validate our new finding on the TMH hydrophobicity in the ER using a larger dataset covering all single pass TMHs of ER proteins (215 instead of 83), Golgi apparatus proteins (260), and plasma membrane proteins (1322) (Suppl. Fig. S3D).

      5) It was not clear to me based on the results section text the difference between the figure 5 proteomics and the previous runs.

      This point was also raised by reviewer 1 and 3. We clarified our statement in the revised manuscript:

      'Hence, we performed a new round of REEP5 and SEC61β MemPreps in triplicates for a direct comparison of the isolates (Fig. 5A, B) rather than comparing the changes in abundance relative to the respective cell lysates as performed in Figure 3. Knowing that non-ER proteins are less efficiently enriched by the MemPrep procedure than ER proteins (Fig. 3C, D) and that the sensitivity and comprehensiveness of mass spectrometry-based proteomics experiments are reduced with increasing sample complexity (Ting et al, 2011; Beck et al, 2011) , we were hoping to gain a better insight into the distribution of low abundant and challenging to quantify proteins in the two MemPrep isolates.'

      6) Again in figure 5- are the authors sure that the difference was not due to the over-expression (albeit mild) of their protein.

      After performing an important control experiment, we are sure that the mild over-expression of the bait proteins has no impact.

      We have compared HEK293T WT cells with the bait protein expressing cell lines by quantitative proteomics (new Suppl. Fig. S1A,B). The bait proteins have no impact of the cellular proteome and do not affect the abundance of proteins known to be enriched in ER sheets or ER tubules. Hence, the enrichment of these proteins in our MemPrep isolates as shown in Fig. 5 suggests that some of the identity of ER sheets and ER tubules is maintained in our preparations even though they are not resolved by our microscopy experiments (Fig. 1). In the revised manuscript, we carefully discuss the implications of these findings.

      7) There were no differences in the ER lipidome between the two baits. This may be because there is no difference between the lipid profile of sheets and tubules, but it is very hard to conclude that.

      The reviewer has a point. Even though our findings suggest that we can differentially enrich for ER subdomains (the proteomics data in Fig. 5 on MemPrep isolates can be regarded as a golded standard for this statement), we do not have any knowledge about their biochemical purity. Hence, we have carefully toned down our statements on the basis of new imaging data (Fig. 1E,F; Suppl. Fig. S1C,D) and new proteomics data (Suppl. Fig. S1A,B).

      Along the reasoning of the reviewer, we also rephrased our statements on the difference/similarity of ER subdomains.

      8) I do not see it as my job as a reviewer to propose reorganisations and rewrites, so I encourage the authors to feel free to ignore this comment. To me the lipidome and TMD polar observations are the key manuscript findings, and there is very limited insight into the tubules and sheets line of inquiry. I wonder if it would be worth changing the focus of the manuscript overall to rather be about the ER, and not the tubules and sheets.

      Again, the reviewer raises an important point that we did not want 'to ignore'. We have carefully revised the manuscript and toned down our interpretations. In the revised manuscript we put more emphasis on the ER lipidome and less so on the composition of specific ER subdomains.

      __Reviewer #2 (Significance (Required)): __

      Overall the manuscript has an interesting premise and the data is well presented, the experiments well performed and the interpretations appropriate. I think there are some issues with the mechanistic insight and novelty, and essentially although the premise is with regards to sheets and tubules there is limited progress in that direction in terms of results. I am reluctant to be to critical overall as there are certainly interesting observations that may be insightful for future studies in the field.

      Reviewer #3

      Summary: Jain et al., provide a clear and thorough manuscript that extends their prior biochemical analysis of the yeast ER-lipidome (MEMPREP) to mammalian cells. They use detergent free lysis and differential speed centrifugation from 293T cells bearing reporters with affinity handles targeted to sheet-like or tubular-like subdomains of the ER and enrich membranes and membrane-embedded proteins from these sites. The lipidomics reveals a distinct ER-lipidome, heavily enriched in PC and PI, contains predominantly mono-unsaturated phospholipids and is surprisingly invariant across sheet-like and tubule-like domains. Additional hydrophobicity analysis suggests that ER-localised TMDs are more polar and shorter than PM-resident TMDs, and the authors speculate about co-evolution of the lipidome and proteome to ensure targeting.

      Major comments:

      I think the data are solid, clear and convincing. The similarity of the lipidomes from sheet and tubule regions of the ER give good indication of the robustness of the technique. Whilst the yield is low, the authors go to good lengths to demonstrate purity of ER capture and de-enrichment of other cellular membranes. There is good discussion of the limitations of the technique and good comparison to recent data from other labs, most notably, a recent preprint and I think the manuscripts support eachother well. There's a fair amount of speculation in the manuscript, e.g., about lipid headgroup charge density being inferred by the charge distribution on the -1 position, but the speculation is clearly acknowledged.

      1. I think that blotting for SEC61B would really help. A clear comparison to endogenous SEC61B would be helpful. I appreciate that the authors lacked an antibody here, but there are several on CiteAb that seem to detect endogenous protein.

      Following the reviewers' advice, we added new data using a commercial antibody directed against SEC61β (new Fig. 1C). We also added proteomics data comparing HEK293T WT cells with the bait expressing cell lines (new Suppl. Fig. S1A,B).

      We also characterized the commercial Proteintech (15087-1-AP) antibody to make sure it recognizes the same epitopes in the tagged and untagged variant of SEC61β.

      It's not brilliantly easy to see the 'sharp decline' in relative frequency of hydrophobic amino acids at 21 aa for ER and Golgi; whilst the individual amino acid information is interesting (and some comment could be made about the favouring of Leucines in ER and Golgi TMDs), would this be clearer if the relative frequencies were binned into hydrophobic/aromatic, polar, positive, negative?

      The reviewer is right. We have removed our statement regarding a 'sharp decline'. In fact, the decline is rather gradual for ER and Golgi TMHs, but more clear for PM TMHs. This is also reflected in the data shown in Suppl. Fig. S3D and discussed in the revised manuscript.

      We state: Confirming our expectations based on the predicted TMH length (Suppl. Fig. S3A), we observed a gradual decline in the relative frequency of hydrophobic and aromatic resides at about 21 amino acids for ER (Fig. 4E) and Golgi-associated TMHs (Fig. 4F). Such decline was more clearly defined for plasma membrane TMHs but only after 24 aa or more (Fig. 4G).'

      We also state: 'We therefore challenged our finding and performed an additional analysis using this larger dataset of all annotated human single-pass TMHs (Fig. S3D) and compared the hydrophobicity profiles of TMHs from the ER (215), the Golgi apparatus (260), and the PM (1322) (Lorent et al, 2025). This analysis further substantiated our finding that the ER and the Golgi apparatus host less hydrophobic TMHs compared to the plasma membrane. Furthermore, we observed that the ER and Golgi profiles display a conical shape with hydrophobic maxima at the center of the membrane's hydrophobic core, while the PM TMH's possess higher hydrophobicity in the cytoplasmic part of the membrane, compared to the exoplasmic part (Fig. S3D).'

      We decided to keep the Fig. 4 with its single amino acid 'resolution' was it was in the original manuscript, because we feel that this representation still has its value. It helps connecting physicochemical parameters of an average TMH in an organelle (Fig. 4A-D; Suppl. Fig. S3A-D) with the preferred amino acid composition and distribution (Fig. 4E-G). Nevertheless, some 'noise' in inherent to the data and we hope that the adaptations to the text avoids any possible confusion of the reader.

      The frequency of leucine residues in TMHs from the PM (24.5%) is comparable to the frequency of TMHs from the ER (24.1%) and from the Golgi apparatus (26.3%). Our attempts to identify an organelle-selective usage of certain amino acids did not yield robust and significant results.

      Related to this point, it's hard to correlate the degree of polar amino acid incorporation in the TMDs of Golgi, ER, PM proteins (which don't appear to vary in 4E, 4F and 4G) with the variance described in 4C. Is there a better way of displaying this data, or are the polarity measurements calculated by some other metric in 4C?

      The reviewer is right. Figure 4A-D and Figure 4E-G are based on different metrics. Figure 4A-D considers different physicochemical parameters of the amino acid sidechains (Fig. 4C: Kyte-Dolittle scale). Figure 4E-G only represents the relative frequencies. We believe that both representations can be useful.

      Notably, the relative incorporation of polar and apolar amino acids is significantly different between TMHs from the ER and the Golgi versus the TMHs from the PM (Suppl. Fig. S3B,C).

      In the revised manuscript we state: 'Our new finding that the TMHs of ER proteins are more polar than the TMHs in the plasma membrane (Fig. 4C) is also reflected by the significantly different number of apolar and polar residues in the TMHs from ER-, Golgi apparatus-, and PM-derived proteins (Suppl. S3B, C)'.

      Indeed, the polarity in Fig. 4A and Fig. 4C is calculated via the Kyte-Dolittle scale, while only the normalized frequency of the amino acid is color-coded in Fig. 4E-G.

      Minor comments:

      1. Panel 2D isn't labelled on the figure

      We represented both MemPreps in a single Panel 2C because we aimed to label in the immunoblots only a single time to avoid redundancies. We are open to change our strategy of panel labeling if our current representation is confusing.

      There is limited co-enrichment of non-ER proteins in the ER-affinity preps, and the authors have done well to deal with misannotated GO terms. It might be worthwhile adding to the discussion that all TMD proteins that localise at steady-state to post-ER compartments must necessarily pass through the ER during biosynthesis. As such, detection of non-ER proteins in ER fractions is not inherently unexpected.

      This is of course correct. In the revised manuscript we state: 'Finding non-ER proteins in an ER proteome is not surprising, because a very large number of proteins are first delivered to the ER, before they are sent to other cellular destinations.'

      I didn't understand the line on L377 about the new round of extraction featureing inherently less complex proteomes.

      This point was also raised by reviewer 1 and 2. We clarified our statement in the revised manuscript:

      'Hence, we performed a new round of REEP5 and SEC61β MemPreps in triplicates for a direct comparison of the isolates (Fig. 5A, B) rather than comparing the changes in abundance relative to the respective cell lysates as performed in Figure 3. Knowing that non-ER proteins are less efficiently enriched by the MemPrep procedure than ER proteins (Fig. 3C, D) and that the sensitivity and comprehensiveness of mass spectrometry-based proteomics experiments are reduced with increasing sample complexity (Ting et al, 2011; Beck et al, 2011) , we were hoping to gain a better insight into the distribution of low abundant and challenging to quantify proteins in the two MemPrep isolates.'

      For line L390-391, in the speculation about progressively more unsaturation as you move ER-Golgi-postGolgi, is there any (published) data from ER-FLIPPR that could inform about the degree of membrane fluidity/packing as you traverse the secretory pathway?

      We agree that mentioning evidence on the biophysical changes along the secretory pathway is helpful in this section. In the revised manuscript we state:

      'These changes of the lipid acyl chains are associated with biophysical changes of the membrane properties along the secretory pathway as observed by molecular probes reporting on lipid packing and membrane tension (Goujon et al, 2019; López-Andarias et al, 2021, 2022; Wong & Budin, 2024).'

      Reviewer #3 (Significance (Required)):

      The strengths of the study are the conceptual novelty and information provided - I think this is the first comprehensive reporting of the ER lipidome. This is a major organelle and I think as the lipid biology field develops, resources like this are really important. Moreover, the MEMPREP protocol is applicable for protein extraction from these domains, which will help with functional characterisation of ER subdomains and is a strong technical advance.

      Weaknesses relate to the single cell type and overexpression (albeit mild) methodologies. I'm not hugely fussed about this as this manuscript describes an important 1st step.

      I'm a cell biologist studying the ER

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1

      Evidence, reproducibility and clarity

      This paper addresses a very interesting problem of non-centrosomal microtubule organization in developing Drosophila oocytes. Using genetics and imaging experiments, the authors reveal an interplay between the activity of kinesin-1, together with its essential cofactor Ensconsin, and microtubule organization at the cell cortex by the spectraplakin Shot, minus-end binding protein Patronin and Ninein, a protein implicated in microtubule minus end anchoring. The authors demonstrate that the loss of Ensconsin affects the cortical accumulation non-centrosomal microtubule organizing center (ncMTOC) proteins, microtubule length and vesicle motility in the oocyte, and show that this phenotype can be rescued by constitutively active kinesin-1 mutant, but not by Ensconsin mutants deficient in microtubule or kinesin binding. The functional connection between Ensconsin, kinesin-1 and ncMTOCs is further supported by a rescue experiment with Shot overexpression. Genetics and imaging experiments further implicate Ninein in the same pathway. These data are a clear strength of the paper; they represent a very interesting and useful addition to the field.

      The weaknesses of the study are two-fold. First, the paper seems to lack a clear molecular model, uniting the observed phenomenology with the molecular functions of the studied proteins. Most importantly, it is not clear how kinesin-based plus-end directed transport contributes to cortical localization of ncMTOCs and regulation of microtubule length.

      Second, not all conclusions and interpretations in the paper are supported by the presented data.

      We thank the reviewer for recognizing the impact of this work. In response to the insightful suggestions, we performed extensive new experiments that establish a well-supported cellular and molecular model (Figure 7). The discussion has been restructured to directly link each conclusion to its corresponding experimental evidence, significantly strengthening the manuscript.

      Below is a list of specific comments, outlining the concerns, in the order of appearance in the paper/figures.

      Figure 1. The statement: "Ens loading on MTs in NCs and their subsequent transport by Dynein toward ring canals promotes the spatial enrichment of the Khc activator Ens in the oocyte" is not supported by data. The authors do not demonstrate that Ens is actually transported from the nurse cells to the oocyte while being attached to microtubules. They do show that the intensity of Ensconsin correlates with the intensity of microtubules, that the distribution of Ensconsin depends on its affinity to microtubules and that an Ensconsin pool locally photoactivated in a nurse cell can redistribute to the oocyte (and throughout the nurse cell) by what seems to be diffusion. The provided images suggest that Ensconsin passively diffuses into the oocyte and accumulates there because of higher microtubule density, which depends on dynein. To prove that Ensconsin is indeed transported by dynein in the microtubule-bound form, one would need to measure the residence time of Ensconsin on microtubules and demonstrate that it is longer than the time needed to transport microtubules by dynein into the oocyte; ideally, one would like to see movement of individual microtubules labelled with photoconverted Ensconsin from a nurse cell into the oocyte. Since microtubules are not enriched in the oocyte of the dynein mutant, analysis of Ensconsin intensity in this mutant is not informative and does not reveal the mechanism of Ensconsin accumulation.

      As noted by Reviewer 3, the directional movement of microtubules traveling at ~140 nm/s from nurse cells toward the oocyte through Ring Canals was previously reported using a tagged Ens-MT binding domain reporter line by Lu et al. (2022). We have therefore added the citation of this crucial work in the novel version of the manuscript (lane 155-157) and removed the photo-conversion panel.

      Critically, however, our study provides mechanistic insight that was missing from this earlier work: this mechanism is also crucial to enrich MAPs in the oocyte. The fact that Dynein mutants fail to enrich Ensconsin is a crucial piece of evidence: it supports a model of Ensconsin-loaded MT transport (Figure 1D-1F).

      Figure 2. According to the abstract, this figure shows that Ensconsin is "maintained at the oocyte cortex by Ninein". However, the figure doesn't seem to prove it - it shows that oocyte enrichment of Ensonsin is partially dependent on Ninein, but this applies to the whole cell and not just to the cell cortex. Furthermore, it is not clear whether Ninein mutation affects microtubule density, which in turn would affect Ensconsin enrichment, and therefore, it is not clear whether the effect of Ninein loss on Ensconsin distribution is direct or indirect.

      Ninein plays a critical role in Ensconsin enrichment and microtubule organization in the oocyte (new Figure 2, Figure 3, Figure S3). Quantification of total Tubulin signal shows no difference between control and Nin mutant oocytes (new Figure S3 panels A, B). We found decreased Ens enrichment in the oocyte, and Ens localization on MTs and to the cell cortex (Figure 2E, 2F, and Figure S3C and S3D).

      Novel quantitative analyses of microtubule orientation at the anterior cortex, where MTs are normally preferentially oriented toward the posterior pole (Parton et al. 2011), demonstrate that Nin mutants exhibit randomized MT orientation compared to wild-type oocytes (new Figure 3C-3E).These findings establish that Ninein (although not essential) favors Ensconsin localization on MTs, Ens enrichment in the oocyte, ncMTOC cortical localization, and more robust MT orientation toward the posterior cortex. It also suggests that Ens levels in the oocyte acts as a rheostat to control Khc activation.

      The observation that the aggregates formed by overexpressed Ninein accumulate other proteins, including Ensconsin, supports, though does not prove their interactions. Furthermore, there is absolutely no proof that Ninein aggregates are "ncMTOCs". Unless the authors demonstrate that these aggregates nucleate or anchor microtubules (for example, by detailed imaging of microtubules and EB1 comets), the text and labels in the figure would need to be altered.

      We have modified the manuscript, we now refer to an accumulation of these components in large puncta, rather than aggregates, consistent with previous observations (Rosen et al., 2000). We acknowledge in the revised version that these puncta recruit Shot, Patronin and Ens without mentioning direct interaction (lane 218).

      Importantly, we conducted a more detailed characterization of these Ninein/Shot/Patronin/Ens-containing puncta in a novel Figure S4. To rigorously assess their nucleation capacity, we analyzed Eb1-GFP-labeled MT comets, a robust readout of MT nucleation (Parton et al., 2011, Nashchekin et al., 2016). While few Eb1-positive comets occasionally emanate from these structures, confirming their identity as putative ncMTOCs, these puncta function as surprisingly weak nucleation centers (new Figure S4 E, Video S1) and, their presence does not alter overall MT architecture (new Figure S4 F). Moreover, these puncta disappear over time, are barely visible at stage 10B, they do not impair oocyte development or fertility (Figure S4 G and Table 1).

      Minor comment: Note that a "ratio" (Figure 2C) is just a ratio, and should not be expressed in arbitrary units.

      We have amended this point in all the figures.

      Figure 3B: immunoprecipitation results cannot be interpreted because the immunoprecipitated proteins (GFP, Ens-GFP, Shot-YFP) are not shown. It is also not clear that this biochemical experiment is useful. If the authors would like to suggest that Ensconsin directly binds to Patronin, the interaction would need to be properly mapped at the protein domain level.

      This is a good point: the GFP and Ens-GFP immunoprecipitated proteins are now much clearly identified on the blots and in the figure legend (new Figure 4G). Shot-YFP IP, was used as a positive control but is difficult to be detected by Western blot due to its large size (>106 Da) using conventional acrylamide gels (Nashchekin et al., 2016).

      We now explicitly state that immunoprecipitations were performed at 4{degree sign}C, where microtubules are fully depolymerized, thereby excluding undirect microtubule-mediated interactions. We agree with this reviewer: we cannot formally rule out interactions through bridging by other protein components. This is stated in the revised manuscript (lane 238-239).

      One of the major phenotypes observed by the authors in Ens mutant is the loss of long microtubules. The authors make strong conclusions about the independence of this phenotype from the parameters of microtubule plus-end growth, but in fact, the quality of their data does not allow to make such a conclusion, because they only measured the number of EB1 comets and their growth rate but not the catastrophe, rescue or pausing frequency."Note that kinesin-1 has been implicated in promoting microtubule damage and rescue (doi: 10.1016/j.devcel.2021).In the absence of such measurements, one cannot conclude whether short microtubules arise through defects in the minus-end, plus-end or microtubule shaft regulation pathways.

      We thank the reviewer for raising this important point. Our data demonstrate that microtubule (MT) nucleation and polymerization rates remain unaffected under Khc RNAi and ens mutant conditions, indicating that MT dynamics alterations must arise through alternative mechanisms.

      As the reviewer suggested, recent studies on Kinesin activity and MT network regulation are indeed highly relevant. Two key studies from the Verhey and Aumeier laboratories examined Kinesin-1 gain-of-function conditions and revealed that constitutively active Kinesin-1 induces MT lattice damage (Budaitis et al., 2022). While damaged MTs can undergo self-repair, Aumeier and colleagues demonstrated that GTP-tubulin incorporation generates "rescue shafts" that promote MT rescue events (Andreu-Carbo et al., 2022). Extrapolating from these findings, loss of Kinesin-1 activity could plausibly reduce rescue shaft formation, thereby decreasing MT rescue frequency and stability. Although this hypothesis is challenging to test directly in our system, it provides a mechanistic framework for the observed reduction in MT number and stability.

      Additionally, the reviewer highlighted the role of Khc in transporting the dynactin complex, an anti-catastrophe factor, to MT plus ends (Nieuwburg et al., 2017), which could further contribute to MT stabilization. This crucial reference is now incorporated into the revised Discussion.

      Importantly, our work also demonstrates the contribution of Ens/Khc to ncMTOC targeting to the cell cortex. Our new quantitative analyses of MT organization (new Figure 5 B) reveal a defective anteroposterior orientation of cortical MTs in mutant conditions, pointing to a critical role for cortical ncMTOCs in organizing the MT network.

      Taken together, we propose that the observed MT reduction and disorganization result from multiple interconnected mechanisms: (1) reduced rescue shaft formation affecting MT stability; (2) impaired transport of anti-catastrophe factors to MT plus ends; and (3) loss of cortical ncMTOCs, which are essential for minus-end MT stabilization and network organization. The Discussion has been revised to reflect this integrated model in a dedicated paragraph ("A possible regulation of MT dynamics in the oocyte at both plus end minus MT ends by Ens and Khc" lane 415-432).

      It is important to note in that a spectraplakin, like Shot, can potentially affect different pathways, particularly when overexpressed.

      We agree that Shot harbors multiple functional domains and acts as a key organizer of both actin and microtubule cytoskeletons. Overexpression of such a cytoskeletal cross-linker could indeed perturb both networks, making interpretation of Ens phenotype rescue challenging due to potential indirect effects.

      To address this concern, we selected an appropriate Shot isoform for our rescue experiments that displayed similar localization to "endogenous" Shot-YFP (a genomic construct harboring shot regulatory sequences) and importantly that was not overexpressed.

      Elevated expression of the Shot.L(A) isoform (see Western Blot Figure S8 A), considered as the wild-type form with two CH1 and CH2 actin-binding motifs (Lee and Kolodziej, 2002), showed abnormal localization such as strong binding to the microtubules in nurse cells and oocyte confirming the risk of gain-of-function artifacts and inappropriate conclusions (Figure S8 B, arrows).

      By contrast, our rescue experiments using the Shot.L(C) isoform (that only harbors the CH2 motif) provide strong evidence against such artifacts for three reasons. First, Shot-L(C) is expressed at slightly lower levels than a Shot-YFP genomic construct (not overexpressed), and at much lower levels than Shot-L(A), despite using the same driver (Figure S8 A). Second, Shot-L(C) localization in the oocyte is similar to that of endogenous Shot-YFP, concentrating at the cell cortex (Figure S8 B, compare lower and top panels). Taken together, these controls rather suggest our rescue with the Shot-L(C) is specific.

      Note that this Shot-L(C) isoform is sufficient to complement the absence of the shot gene in other cell contexts (Lee and Kolodziej, 2002).

      Unjustified conclusions should be removed: the authors do not provide sufficient data to conclude that "ens and Khc oocytes MT organizational defects are caused by decreased ncMTOC cortical anchoring", because the actual cortical microtubule anchoring was not measured.

      This is a valid point. We acknowledge that we did not directly measure microtubule anchoring in this study. In response, we have revised the discussion to more accurately reflect our observations. Throughout the manuscript, we now refer to "cortical microtubule organization" rather than "cortical microtubule anchoring," which better aligns with the data presented.

      Minor comment: Microtubule growth velocity must be expressed in units of length per time, to enable evaluating the quality of the data, and not as a normalized value.

      This is now amended in the revised version (modified Figure S7).

      A significant part of the Discussion is dedicated to the potential role of Ensconsin in cortical microtubule anchoring and potential transport of ncMTOCs by kinesin. It is obviously fine that the authors discuss different theories, but it would be very helpful if the authors would first state what has been directly measured and established by their data, and what are the putative, currently speculative explanations of these data.

      We have carefully considered the reviewer's constructive comments and are confident that this revised version fully addresses their concerns.

      First, we have substantially strengthened the connection between the Results and Discussion sections, ensuring that our interpretations are more directly anchored in the experimental data. This restructuring significantly improves the overall clarity and logical flow of the manuscript.

      Second, we have added a new comprehensive figure presenting a molecular-scale model of Kinesin-1 activation upon release of autoinhibition by Ensconsin (new Figure 7D). Critically, this figure also illustrates our proposed positive feedback loop mechanism: Khc-dependent cytoplasmic advection promotes cortical recruitment of additional ncMTOCs, which generates new cortical microtubules and further accelerates cytoplasmic transport (Figure 7 A-C). This self-amplifying cycle provides a mechanistic framework consistent with emerging evidence that cytoplasmic flows are essential for efficient intracellular transport in both insect and mammalian oocytes.

      Minor comment: The writing and particularly the grammar need to be significantly improved throughout, which should be very easy with current language tools. Examples: "ncMTOCs recruitment" should be "ncMTOC recruitment"; "Vesicles speed" should be "Vesicle speed", "Nin oocytes harbored a WT growth,"- unclear what this means, etc. Many paragraphs are very long and difficult to read. Making shorter paragraphs would make the authors' line of thought more accessible to the reader.

      We have amended and shortened the manuscript according to this reviewer feed-back. We have specifically built more focused paragraphs to facilitates the reading.

      Significance

      This paper represents significant advance in understanding non-centrosomal microtubule organization in general and in developing Drosophila oocytes in particular by connecting the microtubule minus-end regulation pathway to the Kinesin-1 and Ensconsin/MAP7-dependent transport. The genetics and imaging data are of good quality, are appropriately presented and quantified. These are clear strengths of the study which will make it interesting to researchers studying the cytoskeleton, microtubule-associated proteins and motors, and fly development.

      The weaknesses of this study are due to the lack of clarity of the overall molecular model, which would limit the impact of the study on the field. Some interpretations are not sufficiently supported by data, but this can be solved by more precise and careful writing, without extensive additional experimentation.

      We thank the reviewer for raising these important concerns regarding clarity and data interpretation. We have thoroughly revised the manuscript to address these issues on multiple fronts. First, we have substantially rewritten key sections to ensure that our conclusions are clearly articulated and directly supported by the data. Second, we have performed several new experiments that now allow us to propose a robust mechanistic model, presented in new figures. These additions significantly strengthen the manuscript and directly address the reviewer's concerns.

      My expertise is cell biology and biochemistry of the microtubule cytoskeleton, including both microtubule-associated proteins and microtubule motors.

      Reviewer #2

      Evidence, reproducibility and clarity

      In this manuscript, Berisha et al. investigate how microtubule (MT) organization is spatially regulated during Drosophila oogenesis. The authors identify a mechanism in which the Kinesin-1 activator Ensconsin/MAP7 is transported by dynein and anchored at the oocyte cortex via Ninein, enabling localized activation of Kinesin-1. Disruption of this pathway impairs ncMTOC recruitment and MT anchoring at the cortex. The authors combine genetic manipulation with high-resolution microscopy and use three key readouts to assess MT organization during mid-to-late oogenesis: cortical MT formation, localization of posterior determinants, and ooplasmic streaming. Notably, Kinesin-1, in concert with its activator Ens/MAP7, contributes to organizing the microtubule network it travels along. Overall, the study presents interesting findings, though we have several concerns we would like the authors to address. Ensconsin enrichment in the oocyte 1. Enrichment in the oocyte • Ensconsin is a MAP that binds MTs. Given that microtubule density in the oocyte significantly exceeds that in the nurse cells, its enrichment may passively reflect this difference. To assess whether the enrichment is specific, could the authors express a non-Drosophila MAP (e.g., mammalian MAP1B) to determine whether it also preferentially localizes to the oocyte?

      To address this point, we performed a new series of experiments analyzing the enrichment of other Drosophila and non-Drosophila MAPs, including Jupiter-GFP, Eb1-GFP, and bovine Tau-GFP, all widely used markers of the microtubule cytoskeleton in flies (see new Figure S2). Our results reveal that Jupiter-GFP, Eb1-GFP, and bovine Tau-GFP all exhibit significantly weaker enrichment in the oocyte compared to Ens-GFP. Khc-GFP also shows lower enrichment. These findings indicate that MAP enrichment in the oocyte is MAP-dependent, rather than solely reflecting microtubule density or organization. Of note, we cannot exclude that microtubule post-translational modifications contribute to differential MAP binding between nurse cells and the oocyte, but this remains a question for future investigation.

      The ability of ens-wt and ens-LowMT to induce tubulin polymerization according to the light scattering data (Fig. S1J) is minimal and does not reflect dramatic differences in localization. The authors should verify that, in all cases, the polymerization product in their in vitro assays is microtubules rather than other light-scattering aggregates. What is the control in these experiments? If it is just purified tubulin, it should not form polymers at physiological concentrations.

      The critical concentration Cr for microtubule self-assembly in classical BRB80 buffer found by us and others is around 20 µM (see Fig. 2c in Weiss et al., 2010). Here, microtubules were assembled at 40 µM tubulin concentration, i.e., largely above the Cr. As stated in the materials and methods section, we systematically induced cooling at 4{degree sign}C after assembly to assess the presence of aggregates, since those do not fall apart upon cooling. The decrease in optical density upon cooling is a direct control that the initial increase in DO is due to the formation of microtubules. Finally, aggregation and polymerization curves are widely different, the former displaying an exponential shape and the latter a sigmoid assembly phase (see Fig. 3A and 3B in Weiss et al., 2010).

      Photoconversion caveatsMAPs are known to dynamically associate and dissociate from microtubules. Therefore, interpretation of the Ens photoconversion data should be made with caution. The expanding red signal from the nurse cells to the oocyte may reflect a any combination of dynein-mediated MT transport and passive diffusion of unbound Ensconsin. Notably, photoconversion of a soluble protein in the nurse cells would also result in a gradual increase in red signal in the oocyte, independent of active transport. We encourage the authors to more thoroughly discuss these caveats. It may also help to present the green and red channels side by side rather than as merged images, to allow readers to assess signal movement and spatial patterns better.

      This is a valid point that mirrors the comment of Reviewers 1 and 3. The directional movement of microtubules traveling at ~140 nm/s from nurse cells toward the oocyte via the ring canals was previously reported by Lu et al. (2022) with excellent spatial resolution. Notably, this MT transport was measured using a fusion protein containing the Ens MT-binding domain. We now cite this relevant study in our revised manuscript and have removed this redundant panel in Figure 1.

      Reduction of Shot at the anterior cortex• Shot is known to bind strongly to F-actin, and in the Drosophila ovary, its localization typically correlates more closely with F-actin structures than with microtubules, despite being an MT-actin crosslinker. Therefore, the observed reduction of cortical Shot in ens, nin mutants, and Khc-RNAi oocytes is unexpected. It would be important to determine whether cortical F-actin is also disrupted in these conditions, which should be straightforward to assess via phalloidin staining.

      As requested by the reviewer, we performed actin staining experiments, which are now presented in a new Figure S5. These data demonstrate that the cortical actin network remains intact in all mutant backgrounds analyzed, ruling out any indirect effect of actin cytoskeleton disruption on the observed phenotypes.

      MTs are barely visible in Fig. 3A, which is meant to demonstrate Ens-GFP colocalization with tubulin. Higher-quality images are needed.

      The revised version now provides significantly improved images to show the different components examined. Our data show that Ens and Ninein localize at the cell cortex where they co-localize with Shot and Patronin (Figure 2 A-C). In addition, novel images show that Ens extends along microtubules (new Figure 4 A).

      MT gradient in stage 9 oocytesIn ens-/-, nin-/-, and Khc-RNAi oocytes, is there any global defect in the stage 9 microtubule gradient? This information would help clarify the extent to which cortical localization defects reflect broader disruptions in microtubule polarity.

      We now provide quantitative analysis of microtubule (MT) array organization in novel figures (Figure 3D and Figure 5B). Our data reveal that both Khc RNAi and ens mutant oocytes exhibit severe disruption of MT orientation toward the posterior (new Figure 5B). Importantly, this defect is significantly less pronounced in Nin-/- oocytes, which retain residual ncMTOCs at the cortex (new Figure 3D). This differential phenotype supports our model that cortical ncMTOCs are critical for maintaining proper MT orientation toward the posterior side of the oocyte.

      Role of Ninein in cortical anchoringThe requirement for Ninein in cortical anchorage is the least convincing aspect of the manuscript and somewhat disrupts the narrative flow. First, it is unclear whether Ninein exhibits the same oocyte-enriched localization pattern as Ensconsin. Is Ninein detectable in nurse cells? Second, the Ninein antibody signal appears concentrated in a small area of the anterior-lateral oocyte cortex (Fig. 2A), yet Ninein loss leads to reduced Shot signal along a much larger portion of the anterior cortex (Fig. 2F)-a spatial mismatch that weakens the proposed functional relationship. Third, Ninein overexpression results in cortical aggregates that co-localize with Shot, Patronin, and Ensconsin. Are these aggregates functional ncMTOCs? Do microtubules emanate from these foci?

      We now provide a more comprehensive analysis of Ninein localization. Similar to Ensconsin (Ens), endogenous Ninein is enriched in the oocyte during the early stages of oocyte development but is also detected in NCs (see modified Figure 2 A and Lasko et al., 2016). Improved imaging of Ninein further shows that the protein partially co-localizes with Ens, and ncMTOCs at the anterior cortex and with Ens-bound MTs (Figure 2B, 2C).

      Importantly, loss of Ninein (Nin) only partially reduces the enrichment of Ens in the oocyte (Figure 2E). Both Ens and Kinesin heavy chain (Khc) remain partially functional and continue to target non-centrosomal microtubule-organizing centers (ncMTOCs) to the cortex (Figure 3A). In Nin-/- mutants, a subset of long cortical microtubules (MTs) is present, thereby generating cytoplasmic streaming, although less efficiently than under wild-type (WT) conditions (Figure 3F and 3G). As a non-essential gene, we envisage Ninein as a facilitator of MT organization during oocyte development.

      Finally, our new analyses demonstrate that large puncta containing Ninein, Shot, Patronin, and despite their size, appear to be relatively weak nucleation centers (revised Figure S4 E and Video 1). In addition, their presence does not bias overall MT architecture (Figure S4 F) nor impair oocyte development and fertility (Figure S4 G and Table 1).

      Inconsistency of Khc^MutEns rescueThe Khc^MutEns variant partially rescues cortical MT formation and restores a slow but measurable cytoplasmic flow yet it fails to rescue Staufen localization (Fig. 5). This raises questions about the consistency and completeness of the rescue. Could the authors clarify this discrepancy or propose a mechanistic rationale?

      This is a good point. The cytoplasmic flows (the consequence of cargo transport by Khc on MTs) generated by a constitutively active KhcMutEns in an ens mutant condition, are less efficient than those driven by Khc activated by Ens in a control condition (Figure 6C). The rescued flow is probably not efficient enough to completely rescue the Staufen localization at stage 10.

      Additionally, this KhcMutEns variant rescues the viability of embryos from Khc27 mutant germline clones oocytes but not from ens mutants (Table1). One hypothesis is that Ens harbors additional functions beyond Khc activation.

      This incomplete rescue of Ens by an active Khc variant could also be the consequence of the "paradox of co-dependence": Kinesin-1 also transport the antagonizing motor Dynein that promotes cargo transport in opposite directions (Hancock et al., 2016). The phenotype of a gain of function variant is therefore complex to interpret. Consistent with this, both KhcMutEns-GFP and KhcDhinge2 two active Khc only rescues partially centrosome transport in ens mutant Neural Stem Cells (Figure S10).

      Minor points: 1. The pUbi-attB-Khc-GFP vector was used to generate the Khc^MutEns transgenic line, presumably under control of the ubiquitous ubi promoter. Could the authors specify which attP landing site was used? Additionally, are the transgenic flies viable and fertile, given that Kinesin-1 is hyperactive in this construct?

      All transgenic constructs were integrated at defined genomic landing sites to ensure controlled expression levels. Specifically, both GFP-tagged KhcWT and KhcMutEns were inserted at the VK05 (attP9A) site using PhiC31-mediated integration. Full details of the landing sites are provided in the Materials and Methods section. Both transgenic flies are homozygous lethal and the transgenes are maintained over TM6B balancers.

      On page 11 (Discussion, section titled "A dual Ensconsin oocyte enrichment mechanism achieves spatial relief of Khc inhibition"), the statement "many mutations in Kif5A are causal of human diseases" would benefit from a brief clarification. Since not all readers may be familiar with kinesin gene nomenclature, please indicate that KIF5A is one of the three human homologs of Kinesin heavy chain.

      We clarified this point in the revised version (lane 465-466).

      On page 16 (Materials and Methods, "Immunofluorescence in fly ovaries"), the sentence "Ovaries were mounted on a slide with ProlonGold medium with DAPI (Invitrogen)" should be corrected to "ProLong Gold."

      This is corrected.

      Significance

      This study shows that enrichment of MAP7/ensconsin in the oocyte is the mechanism of kinesin-1 activation there and is important for cytoplasmic streaming and localization non-centrosomal microtubule-organizing centers to the oocyte cortex

      We thank the reviewers for the accurate review of our manuscript and their positive feed-back.

      Reviewer #3

      Evidence, reproducibility and clarity

      The manuscript of Berisha et al., investigates the role of Ensconsin (Ens), Kinesin-1 and Ninein in organisation of microtubules (MT) in Drosophila oocyte. At stage 9 oocytes Kinesin-1 transports oskar mRNA, a posterior determinant, along MT that are organised by ncMTOCs. At stage 10b, Kinesin-1 induces cytoplasmic advection to mix the contents of the oocyte. Ensconsin/Map7 is a MT associated protein (MAP) that uses its MT-binding domain (MBD) and kinesin binding domain (KBD) to recruit Kinesin-1 to the microtubules and to stimulate the motility of MT-bound Kinesin-1. Using various new Ens transgenes, the authors demonstrate the requirement of Ens MBD and Ninein in Ens localisation to the oocyte where Ens activates Kinesin-1 using its KBD. The authors also claim that Ens, Kinesin-1 and Ninein are required for the accumulation of ncMTOCs at the oocyte cortex and argue that the detachment of the ncMTOCs from the cortex accounts for the reduced localisation of oskar mRNA at stage 9 and the lack of cytoplasmic streaming at stage 10b. Although the manuscript contains several interesting observations, the authors' conclusions are not sufficiently supported by their data. The structure function analysis of Ensconsin (Ens) is potentially publishable, but the conclusions on ncMTOC anchoring and cytoplasmic streaming not convincing.

      We are grateful that the regulation of Khc activity by MAP7 was well received by all reviewers. While our study focuses on Drosophila oogenesis, we believe this mechanism may have broader implications for understanding kinesin regulation across biological systems.

      For the novel function of the MAP7/Khc complex in organizing its own microtubule networks through ncMTOC recruitment, we have carefully considered the reviewers' constructive recommendations. We now provide additional experimental evidence supporting a model of flux self-amplification in which ncMTOC recruitment plays a key role. It is well established that cytoplasmic flows are essential for posterior localization of cell fate determinants at stage 10B. Slow flows have also been described at earlier oogenesis stages by the groups of Saxton and St Johnston. Building on these early publications and our new experiments, we propose that these flows are essential to promote a positive feedback loop that reinforces ncMTOC recruitment and MT organization (Figure 7).

      1) The main conclusion of the manuscript is that "MT advection failure in Khc and ens in late oogenesis stems from defective cortical ncMTOCs recruitment". This completely overlooks the abundant evidence that Kinesin-1 directly drives cytoplasmic streaming by transporting vesicles and microtubules along microtubules, which then move the cytoplasm by advection (Palacios et al., 2002; Serbus et al, 2005; Lu et al, 2016). Since Kinesin-1 generates the flows, one cannot conclude that the effect of khc and ens mutants on cortical ncMTOC positioning has any direct effect on these flows, which do not occur in these mutants.

      We regret the lack of clarity of the first version of the manuscript and some missing references. We propose a model in which the Kinesin-1- dependent slow flows (described by Serbus/Saxton and Palacios/StJohnston) play a central role in amplifying ncMTOC anchoring and cortical MT network formation (see model in the new Figure 7).

      2) The authors claim that streaming phenotypes of ens and khs mutants are due to a decrease in microtubule length caused by the defective localisation of ncMTOCs. In addition to the problem raised above, However, I am not convinced that they can make accurate measurements of microtubule length from confocal images like those shown in Figure 4. Firstly, they are measuring the length of bundles of microtubules and cannot resolve individual microtubules. This problem is compounded by the fact that the microtubules do not align into parallel bundles in the mutants. This will make the "microtubules" appear shorter in the mutants. In addition, the alignment of the microtubules in wild-type allows one to choose images in which the microtubule lie in the imaging plane, whereas the more disorganized arrangement of the microtubules in the mutants means that most microtubules will cross the imaging plane, which precludes accurate measurements of their length.

      As mentioned by Reviewer 4, we have been transparent with the methodology, and the limitations that were fully described in the material and methods section.

      Cortical microtubules in oocytes are highly dynamic and move rapidly, making it technically impossible to capture their entire length using standard Z-stack acquisitions. We therefore adopted a compromise approach: measuring microtubules within a single focal plane positioned just below the oocyte cortex. This strategy is consistent with established methods in the field, such as those used by Parton et al. (2011) to track microtubule plus-end directionality. To avoid overinterpretation, we explicitly refer to these measurements as "minimum detectable MT length," acknowledging that microtubules may extend beyond the focal plane, particularly at stage 10, where long, tortuous bundles frequently exit the plane of focus. These methodological considerations and potential biases are clearly described in the Materials and Methods section and the text now mentions the possible disorganization of the MT network in the mutant conditions (lane 272-273).

      In this revised version, we now provide complementary analyses of MT network organization.Beyond length measurements (and the mentioned limitations), we also quantified microtubule network orientation at stage 9, assessing whether cortical microtubules are preferentially oriented toward the posterior axis as observed in controls (revised Figure 3D and Figure 5B). While this analysis is also subject to the same technical limitations, it reveals a clear biological difference: microtubules exhibit posterior-biased orientation in control oocytes similar to a previous study (Parton et al., 2011) but adopt a randomized orientation in Nin-/-, ens, and Khc RNAi-depleted oocytes (revised Figure 3D and Figure 5B).

      Taken together, these complementary approaches, despite their technical constraints, provide convergent evidence for the role of the Khc/Ens complex in organizing cortical microtubule networks during oogenesis.

      3) "To investigate whether the presence of these short microtubules in ens and Khc RNAi oocytes is due to defects in microtubule anchoring or is also associated with a decrease in microtubule polymerization at their plus ends, we quantified the velocity and number of EB1comets, which label growing microtubule plus ends (Figure S3)." I do not understand how the anchoring or not of microtubule minus ends to the cortex determines how far their plus ends grow, and these measurements fall short of showing that plus end growth is unaffected. It has already been shown that the Kinesin-1-dependent transport of Dynactin to growing microtubule plus ends increases the length of microtubules in the oocyte because Dynactin acts as an anti-catastrophe factor at the plus ends. Thus, khc mutants should have shorter microtubules independently of any effects on ncMTOC anchoring. The measurements of EB1 comet speed and frequency in FigS2 will not detect this change and are not relevant for their claims about microtubule length. Furthermore, the authors measured EB1 comets at stage 9 (where they did not observe short MT) rather than at stage 10b. The authors' argument would be better supported if they performed the measurements at stage 10b.

      We thank the reviewer for raising this important point. The short microtubule (MT) length observed at stage 10B could indeed result from limited plus-end growth. Unfortunately, we were unable to test this hypothesis directly: strong endogenous yolk autofluorescence at this stage prevented reliable detection of Eb1-GFP comets, precluding velocity measurements.

      At least during stage 9, our data demonstrate that MT nucleation and polymerization rates are not reduced in both KhcRNAi and ens mutant conditions, indicating that the observed MT alterations must arise through alternative mechanisms.

      In the discussion, we propose the following interconnected explanations, supported by recent literature and the reviewers' suggestions:

      1- Reduced MT rescue events. Two seminal studies from the Verhey and Aumeier laboratories have shown that constitutively active Kinesin-1 induces MT lattice damage (Budaitis et al., 2022), which can be repaired through GTP-tubulin incorporation into "rescue shafts" that promote MT rescue (Andreu-Carbo et al., 2022). Extrapolating from these findings, loss of Kinesin-1 activity could plausibly reduce rescue shaft formation, thereby decreasing MT stability. While challenging to test directly in our system, this mechanism provides a plausible framework for the observed phenotype.

      2- Impaired transport of stabilizing factors. As that reviewer astutely points out, Khc transports the dynactin complex, an anti-catastrophe factor, to MT plus ends (Nieuwburg et al., 2017). Loss of this transport could further compromise MT plus end stability. We now discuss this important mechanism in the revised manuscript.

      3- Loss of cortical ncMTOCs. Critically, our new quantitative analyses (revised Figure 3 and Figure 5) also reveal defective anteroposterior orientation of cortical MTs in mutant conditions. These experiments suggest that Ens/Khc-mediated localization of ncMTOCs to the cortex is essential for proper MT network organization, and possibly minus-end stabilization as suggested in several studies (Feng et al., 2019, Goodwin and Vale, 2011, Nashchekin et al., 2016).

      Altogether, we now propose an integrated model in which MT reduction and disorganization may result from multiple complementary mechanisms operating downstream of Kinesin-1/Ensconsin loss. While some aspects remain difficult to test directly in our in vivo system, the convergence of our data with recent mechanistic studies provides an interesting conceptual framework. The Discussion has been revised to reflect this comprehensive view in a dedicated paragraph ("A possible regulation of MT dynamics in the oocyte at both plus end minus MT ends by Ens and Khc" lane 415-432).

      4) The Shot overexpression experiments presented in Fig.3 E-F, Fig.4D and TableS1 are very confusing. Originally , the authors used Shot-GFP overexpression at stage 9 to show that there is a decrease of ncMTOCs at the cortex in ens mutants (Fig.3 E-F) and speculated that this caused the defects in MT length and cytoplasmic advection at stage 10B. However the authors later state on page 8 that : "Shot overexpression (Shot OE) was sufficient to rescue the presence of long cortical MTs and ooplasmic advection in most ens oocytes (9/14), resembling the patterns observed in controls (Figures 4B right panel and 4D). Moreover, while ens females were fully sterile, overexpression of Shot was sufficient to restore that loss of fertility (Table S1)". Is this the same UAS Shot-GFP and VP16 Gal4 used in both experiments? If so, this contradictions puts the authors conclusions in question.

      This is an important point that requires clarification regarding our experimental design.

      The Shot-YFP construct is a genomic insertion on chromosome 3. The ens mutation is also located on chromosome 3 and we were unable to recombine this transgene with the ens mutant for live quantification of cortical Shot. To circumvent this technical limitation, we used a UAS-Shot.L(C)-GFP transgenic construct driven by a maternal driver, expressed in both wild-type (control) and ens mutant oocytes. We validated that the expression level and subcellular localization of UAS-Shot.L(C)-GFP were comparable to those of the genomic Shot-YFP (new Figure S8 A and B).

      From these experiments, we drew two key conclusions. First, cortical Shot.L(C)-GFP is less abundant in ens mutant oocytes compared to wild-type (the quantification has been removed from this version). Second, despite this reduced cortical accumulation, Shot.L(C)-GFP expression partially rescues ooplasmic flows and microtubule streaming in stage 10B ens mutant oocytes, and restores fertility to ens mutant females.

      5) The authors based they conclusions about the involvement of Ens, Kinesin-1 and Ninein in ncMTOC anchoring on the decrease in cortical fluorescence intensity of Shot-YFP and Patronin-YFP in the corresponding mutant backgrounds. However, there is a large variation in average Shot-YFP intensity between control oocytes in different experiments. In Fig. 2F-G the average level of Shot-YFP in the control sis 130 AU while in Fig.3 G-H it is only 55 AU. This makes me worry about reliability of such measurements and the conclusions drawn from them.

      To clarify this point, we have harmonized the method used to quantify the Shot-YFP signals in Figure 4E with the methodology used in Figure 3B, based on the original images. The levels are not strictly identical (Control Figure 2 B: 132.7+/-36.2 versus Control Figure 4 E: 164.0+/- 37.7). These differences are usual when experiments are performed at several-month intervals and by different users.

      6) The decrease in the intensity of Shot-YFP and Patronin-YFP cortical fluorescence in ens mutant oocytes could be because of problems with ncMTOC anchoring or with ncMTOCs formation. The authors should find a way to distinguish between these two possibilities. The authors could express Ens-Mut (described in Sung et al 2008), which localises at the oocyte posterior and test whether it recruits Shot/Patronin ncMTOCs to the posterior.

      We tried to obtain the fly stocks described in the 2008 paper by contacting former members of Pernille Rørth's laboratory. Unfortunately, we learned that the lab no longer exists and that all reagents, including the requested stocks, were either discarded or lost over time. To our knowledge, these materials are no longer available from any source. We regret that this limitation prevented us from performing the straightforward experiments suggested by the reviewer using these specific tools.

      7) According to the Materials and Methods, the Shot-GFP used in Fig.3 E-F and Fig.4 was the BDSC line 29042. This is Shot L(C), a full-length version of Shot missing the CH1 actin-binding domain that is crucial for Shot anchoring to the cortex. If the authors indeed used this version of Shot-GFP, the interpretation of the above experiments is very difficult.

      The Shot.L(C) isoform lacks the CH1 domain but retains the CH2 actin-binding motif. Truncated proteins with this domain and fused to GST retains a weak ability to bind actin in vitro. Importantly, the function of this isoform is context-dependent: it cannot rescue shot loss-of-function in neuron morphogenesis but fully restores Shot-dependent tracheal cell remodeling (Lee and Kolodziej, 2002).

      In our experiments, when the Shot.L(C) isoform was expressed under the control of a maternal driver, its localization to the oocyte cortex was comparable to that of the genomic Shot-YFP construct (new Figure S8). This demonstrates unambiguously that the CH1 domain is dispensable for Shot cortical localization in oocytes, and that CH2-mediated actin binding is sufficient for this localization. Of note, a recent study showed that actin network are not equivalent highlighting the need for specific Shot isoforms harboring specialized actin-binding domain (Nashchekin et al., 2024).

      We note that the expression level of Shot.L(C)-GFP in the oocyte appeared slightly lower than that of Shot-YFP (expressed under endogenous Shot regulatory sequences), as assessed by Western blot (Figure S8 A).

      Critically, Shot.L(C)-GFP expression was substantially lower than that of Shot.L(A)-GFP (that harbored both the CH1 and CH2 domain). Shot.L(A)-GFP was overexpressed (Figure 8 A) and ectopically localized on MTs in both nurse cells and the ooplasm (Figure S8 B middle panel and arrow). These observations are in agreement that the Shot.L(C)-GFP rescue experiment was performed at near-physiological expression levels, strengthening the validity of our conclusions.

      8) Page 6 "converted in NCs, in a region adjacent to the ring canals, Dendra-Ens-labeled MTs were found in the oocyte compartment indicating they are able to travel from NC toward the oocyte through ring canals". I have difficulty seeing the translocation of MT through the ring canals. Perhaps it would be more obvious with a movie/picture showing only one channel. Considering that f Dendra-Ens appears in the oocyte much faster than MT transport through ring canals (140nm/s, Lu et al 2022), the authors are most probably observing the translocation of free Ens rather than Ens bound to MT. The authors should also mention that Ens movement from the NC to the oocyte has been shown before with Ens MBD in Lu et al 2022 with better resolution.

      We fully agree on the caveat mentioned by this reviewer: we may observe the translocation of free Dendra-Ensconsin. The experiment, was removed and replaced by referring to the work of the Gelfand lab. The movement of MTs that travel at ~140 nm/s between nurse cells toward the oocyte through the Ring Canals was reported before by Lu et al. (2022) with a very good resolution. Notably, this directional directed movement of MTs was measured using a fusion protein encompassing Ens MT-binding domain. We decided to remove this inclusive experiment and rather refer to this relevant study.

      9) Page 6: The co-localization of Ninein with Ens and Shot at the oocyte cortex (Figure 2A). I have difficulty seeing this co-localisation. Perhaps it would be more obvious in merged images of only two channels and with higher resolution images

      10) "a pool of the Ens-GFP co-localized with Ch-Patronin at cortical ncMTOCs at the anterior cortex (Figure 3A)". I also have difficulty seeing this.

      We have performed new high-resolution acquisitions that provide clearer and more convincing evidence for the localization cortical distribution of these proteins (revised Figure 2A-2C and Figure 4A). These improved images demonstrate that Ens, Ninein, Shot, and Patronin partially colocalize at cortical ncMTOCs, as initially proposed. Importantly, the new data also reveal a spatial distinction: while Ens localizes along microtubules extending from these cortical sites, Ninein appears confined to small cytoplasmic puncta adjacent but also present on cortical microtubules.

      11) "Ninein co-localizes with Ens at the oocyte cortex and partially along cortical microtubules, contributing to the maintenance of high Ens protein levels in the oocyte and its proper cortical targeting". I could not find any data showing the involvement of Ninein in the cortical targeting of Ens.

      We found decreased Ens localization to MTs and to the cell cortex region (new Figure S3 A-B).

      12) "our MT network analyses reveal the presence of numerous short MTs cytoplasmic clustered in an anterior pattern." "This low cortical recruitment of ncMTOCs is consistent with poor MT anchoring and their cytoplasmic accumulation." I could not find any data showing that short cortical MT observed at stage 10b in ens mutant and Khc RNAi were cytoplasmic and poorly anchored.

      The sentence was removed from the revised manuscript.

      13) "The egg chamber consists of interconnected cells where Dynein and Khc activities are spatially separated. Dynein facilitates transport from NCs to the oocyte, while Khc mediates both transport and advection within the oocyte." Dynein is involved in various activities in the oocyte. It anchors the oocyte nucleus and transports bcd and grk mRNA to mention a few.

      The text was amended to reflect Dynein involvement in transport activities in the oocyte, with the appropriate references (lane 105-107).

      14) The cartoons in Fig.2H and 3I exaggerate the effect of Ninein and Ens on cortical ncMTOCs. According to the corresponding graphs, there is a 20 and 50% decrease in each case.

      New cartoons (now revised Figure 3E and 4F), are amended to reflect the ncMTOC values but also MT orientation (Figure 3E).

      Significance

      Given the important concerns raised, the significance of the findings is difficult to assess at this stage.

      We sincerely thank the reviewer for their thorough evaluation of our manuscript. We have carefully addressed their concerns through substantial new experiments and analyses. We hope that the revised manuscript, in its current form, now provides the clarifications and additional evidence requested, and that our responses demonstrate the significance of our findings.

      Reviewer #4 (Evidence, reproducibility and clarity (Required)):

      Summary: This manuscript presents an investigation into the molecular mechanisms governing spatial activation of Kinesin-1 motor protein during Drosophila oogenesis, revealing a regulatory network that controls microtubule organization and cytoplasmic transport. The authors demonstrate that Ensconsin, a MAP7 family protein and Kinesin-1 activator, is spatially enriched in the oocyte through a dual mechanism involving Dynein-mediated transport from nurse cells and cortical maintenance by Ninein. This spatial enrichment of Ens is crucial for locally relieving Kinesin-1 auto-inhibition. The Ens/Khc complex promotes cortical recruitment of non-centrosomal microtubule organizing centers (ncMTOCs), which are essential for anchoring microtubules at the cortex, enabling the formation of long, parallel microtubule streams or "twisters" that drive cytoplasmic advection during late oogenesis. This work establishes a paradigm where motor protein activation is spatially controlled through targeted localization of regulatory cofactors, with the activated motor then participating in building its own transport infrastructure through ncMTOC recruitment and microtubule network organization.

      There's a lot to like about this paper! The data are generally lovely and nicely presented. The authors also use a combination of experimental approaches, combining genetics, live and fixed imaging, and protein biochemistry.

      We thank the reviewer for this enthusiastic and supportive review, which helped us further strengthen the manuscript.

      Concerns: Page 6: "to assay if elevation of Ninein levels was able to mis-regulate Ens localization, we overexpressed a tagged Ninein-RFP protein in the oocyte. At stage 9 the overexpressed Ninein accumulated at the anterior cortex of the oocyte and also generated large cortical aggregates able to recruit high levels of Ens (Figures 2D and 2H)... The examination of Ninein/Ens cortical aggregates obtained after Ninein overexpression showed that these aggregates were also able to recruit high levels of Patronin and Shot (Figures 2E and 2H)." Firstly, I'm not crazy about the use of "overexpressed" here, since there isn't normally any Ninein-RFP in the oocyte. In these experiments it has been therefore expressed, not overexpressed. Secondly, I don't understand what the reader is supposed to make of these data. Expression of a protein carrying a large fluorescent tag leads to large aggregates (they don't look cortical to me) that include multiple proteins - in fact, all the proteins examined. I don't understand this to be evidence of anything in particular, except that Ninein-RFP causes the accumulation of big multi-protein aggregates. While I can understand what the authors were trying to do here, I think that these data are inconclusive and should be de-emphasized.

      We have revised the manuscript by replacing overexpressed with expressed (lanes 211 and 212). In addition, we now provide new localization data in both cortical (new Figure S4 A, top) and medial focal planes (new Figure S4 A, bottom), demonstrating that Ninein puncta (the word used in Rosen et al, 2019), rather than aggregates are located cortically. We also show that live IRP-labelled MTs do not colocalize with Ninein-RFP puncta. In light of the new experiments and the comments from the other reviewers, the corresponding text has been revised and de-emphasized accordingly.

      Page 7: "Co-immunoprecipitations experiments revealed that Patronin was associated with Shot-YFP, as shown previously (Nashchekin et al., 2016), but also with EnsWT-GFP, indicating that Ens, Shot and Patronin are present in the same complex (Figure 3B)." I do not agree that association between Ens-GFP and Patronin indicates that Ens is in the same complex as Shot and Patronin. It is also very possible that there are two (or more) distinct protein complexes. This conclusion could therefore be softened. Instead of "indicating" I suggest "suggesting the possibility."

      We have toned down this conclusion and indicated "suggesting the possibility" (lane 238-239).

      Page 7: "During stage 9, the average subcortical MT length, taken at one focal plane in live oocytes (see methods)..." I appreciate that the authors have been careful to describe how they measured MT length, as this is a major point for interpretation. I think the reader would benefit from an explanation of why they decided to measure in only one focal plane and how that decision could impact the results.

      We appreciate this helpful suggestion. Cortical microtubules are indeed highly dynamic and extend in multiple directions, including along the Z-axis. Moreover, their diameter is extremely small (approximately 25 nm), making it technically challenging to accurately measure their full length with high resolution using our Zeiss Airyscan confocal microscope (over several, microns): the acquisition of Z-stacks is relatively slow and therefore not well suited to capturing the rapid dynamics of these microtubules. Consequently, our length measurements represent a compromise and most likely underestimate the actual lengths of microtubules growing outside the focal plane. We note that other groups have encountered similar technical limitations (Parton et al., 2011).

      Page 7: "... the MTs exhibited an orthogonal orientation relative to the anterior cortex (Figures 4A left panels, 4C and 4E)." This phenotype might not be obvious to readers. Can it be quantified?

      We have now analyzed the orientation of microtubules (MTs) along the dorso-ventral axis. Our analysis shows that ens, Khc RNAi oocytes (new Figure 5B), and, to a lesser extent, Nin mutant oocytes (new Figure 3D), display a more random MT orientation compared to wild-type (WT) oocytes. In WT oocytes, MTs are predominantly oriented toward the posterior pole, consistent with previous findings (Parton et al., 2011).

      Page 8: "Altogether, the analyses of Ens and Khc defective oocytes suggested that MT organization defects during late oogenesis (stage 10B) were caused by an initial failure of ncMTOCs to reach the cell cortex. Therefore, we hypothesized that overexpression of the ncMTOC component Shot could restore certain aspects of microtubule cortical organization in ens-deficient oocytes. Indeed, Shot overexpression (Shot OE) was sufficient to rescue the presence of long cortical MTs and ooplasmic advection in most ens oocytes (9/14)..." The data are clear, but the explanation is not. Can the authors please explain why adding in more of an ncMTOC component (Shot) rescues a defect of ncMTOC cortical localization?

      We propose that cytoplasmic ncMTOCs can bind the cell cortex via the Shot subunit that is so far the only component that harbors actin-binding motifs. Therefore, we propose that elevating cytoplasmic Shot increase the possibility of Shot to encounter the cortex by diffusion when flows are absent. This is now explained lane 282-285.

      I'm grateful to the authors for their inclusion of helpful diagrams, as in Figures 1G and 2H. I think the manuscript might benefit from one more of these at the end, illustrating the ultimate model.

      We have carefully considered and followed the reviewer's suggestions. In response, we have included a new figure illustrating our proposed model: the recruitment of ncMTOCs to the cell cortex through low Khc-mediated flows at stage 9 enhances cortical microtubule density, which in turn promotes self-amplifying flows (new Figure 7, panels A to C). Note that this Figure also depicts activation of Khc by loss of auto-inhibition (Figure 7, panel D).

      I'm sorry to say that the language could use quite a bit of polishing. There are missing and extraneous commas. There is also regular confusion between the use of plural and singular nouns. Some early instances include:

      1. Page 3: thought instead of "thoughted."
      2. Page 5: "A previous studies have revealed"
      3. Page 5: "A significantly loss"
      4. Page 6: "troughs ring canals" should be "through ring canals"
      5. Page 7: lives stage 9 oocytes
      6. Page 7: As ens and Khc RNAi oocytes exhibits
      7. Page 7: we examined in details
      8. Page 7: This average MT length was similar in Khc RNAi and ens mutant oocyte..

      We apologize for errors. We made the appropriate corrections of the manuscript.

      Reviewer #4 (Significance (Required)):

      This work makes a nice conceptual advance by showing that motor activation controls its own transport infrastructure, a paradigm that could extend to other systems requiring spatially regulated transport.

      We thank the reviewers for their evaluation of the manuscript and helpful comments.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #4

      Evidence, reproducibility and clarity

      Summary: This manuscript presents an investigation into the molecular mechanisms governing spatial activation of Kinesin-1 motor protein during Drosophila oogenesis, revealing a regulatory network that controls microtubule organization and cytoplasmic transport. The authors demonstrate that Ensconsin, a MAP7 family protein and Kinesin-1 activator, is spatially enriched in the oocyte through a dual mechanism involving Dynein-mediated transport from nurse cells and cortical maintenance by Ninein. This spatial enrichment of Ens is crucial for locally relieving Kinesin-1 auto-inhibition. The Ens/Khc complex promotes cortical recruitment of non-centrosomal microtubule organizing centers (ncMTOCs), which are essential for anchoring microtubules at the cortex, enabling the formation of long, parallel microtubule streams or "twisters" that drive cytoplasmic advection during late oogenesis. This work establishes a paradigm where motor protein activation is spatially controlled through targeted localization of regulatory cofactors, with the activated motor then participating in building its own transport infrastructure through ncMTOC recruitment and microtubule network organization.

      There's a lot to like about this paper! The data are generally lovely and nicely presented. The authors also use a combination of experimental approaches, combining genetics, live and fixed imaging, and protein biochemistry.

      Concerns:

      Page 6: "to assay if elevation of Ninein levels was able to mis-regulate Ens localization, we overexpressed a tagged Ninein-RFP protein in the oocyte. At stage 9 the overexpressed Ninein accumulated at the anterior cortex of the oocyte and also generated large cortical aggregates able to recruit high levels of Ens (Figures 2D and 2H)... The examination of Ninein/Ens cortical aggregates obtained after Ninein overexpression showed that these aggregates were also able to recruit high levels of Patronin and Shot (Figures 2E and 2H)." Firstly, I'm not crazy about the use of "overexpressed" here, since there isn't normally any Ninein-RFP in the oocyte. In these experiments it has been therefore expressed, not overexpressed. Secondly, I don't understand what the reader is supposed to make of these data. Expression of a protein carrying a large fluorescent tag leads to large aggregates (they don't look cortical to me) that include multiple proteins - in fact, all the proteins examined. I don't understand this to be evidence of anything in particular, except that Ninein-RFP causes the accumulation of big multi-protein aggregates. While I can understand what the authors were trying to do here, I think that these data are inconclusive and should be de-emphasized.

      Page 7: "Co-immunoprecipitations experiments revealed that Patronin was associated with Shot-YFP, as shown previously (Nashchekin et al., 2016), but also with EnsWT-GFP, indicating that Ens, Shot and Patronin are present in the same complex (Figure 3B)." I do not agree that association between Ens-GFP and Patronin indicates that Ens is in the same complex as Shot and Patronin. It is also very possible that there are two (or more) distinct protein complexes. This conclusion could therefore be softened. Instead of "indicating" I suggest "suggesting the possibility."

      Page 7: "During stage 9, the average subcortical MT length, taken at one focal plane in live oocytes (see methods)..." I appreciate that the authors have been careful to describe how they measured MT length, as this is a major point for interpretation. I think the reader would benefit from an explanation of why they decided to measure in only one focal plane and how that decision could impact the results.

      Page 7: "... the MTs exhibited an orthogonal orientation relative to the anterior cortex (Figures 4A left panels, 4C and 4E)." This phenotype might not be obvious to readers. Can it be quantified?

      Page 8: "Altogether, the analyses of Ens and Khc defective oocytes suggested that MT organization defects during late oogenesis (stage 10B) were caused by an initial failure of ncMTOCs to reach the cell cortex. Therefore, we hypothesized that overexpression of the ncMTOC component Shot could restore certain aspects of microtubule cortical organization in ens-deficient oocytes. Indeed, Shot overexpression (Shot OE) was sufficient to rescue the presence of long cortical MTs and ooplasmic advection in most ens oocytes (9/14)..." The data are clear, but the explanation is not. Can the authors please explain why adding in more of an ncMTOC component (Shot) rescues a defect of ncMTOC cortical localization?

      I'm grateful to the authors for their inclusion of helpful diagrams, as in Figures 1G and 2H. I think the manuscript might benefit from one more of these at the end, illustrating the ultimate model.

      I'm sorry to say that the language could use quite a bit of polishing. There are missing and extraneous commas. There is also regular confusion between the use of plural and singular nouns. Some early instances include:

      1. Page 3: thought instead of "thoughted."
      2. Page 5: "A previous studies have revealed"
      3. Page 5: "A significantly loss"
      4. Page 6: "troughs ring canals" should be "through ring canals"
      5. Page 7: lives stage 9 oocytes
      6. Page 7: As ens and Khc RNAi oocytes exhibits
      7. Page 7: we examined in details
      8. Page 7: This average MT length was similar in Khc RNAi and ens mutant oocyte..

      Significance

      This work makes a nice conceptual advance by showing that motor activation controls its own transport infrastructure, a paradigm that could extend to other systems requiring spatially regulated transport.

    1. eLife Assessment

      This paper demonstrates that a genetic code expansion to tag two amyotrophic lateral sclerosis (ALS) proteins associated with stress granules is useful in an experimental context. The data are solid and demonstrate the feasibility of using ANAP-fluorescence for live cell imaging.

    2. Reviewer #1 (Public review):

      Summary:

      The authors utilize genetic code expansion to tag TDP-43 and G3BP1, and evaluate this protein tagging system (ANAP) compared to antibodies and evaluate protein trafficking and stress granule formation in response to stress with sodium arsenite treatment. They find similar staining to antibodies in HeLa cells, mouse embryonic stem cells and primary mouse cortical neurons. By incorporating the intrinsically fluorescent noncanonical amino acid Anap at carefully selected sites, the authors enable live-cell and neuronal visualization of protein localization, stress-induced redistribution, and dynamic behavior without the structural and functional compromises often associated with large fluorescent protein tags. The work provides technical framework that will be useful for live imaging of tagged proteins.

      Strengths:

      A key strength is the demonstration of the specificity of the Anap fluorescence signal through appropriate controls and the agreement between Anap labeling and antibody-based detection across multiple cell types, including primary neurons. The ability to visualize stress-induced redistribution of both G3BP1 and TDP 43 in living cells highlights the practical value of this approach.

      The functional validation of TDP 43-Anap is compelling. The rescue of both cell viability and RNA splicing defects in TDP 43 knockout models provides evidence that Anap incorporation preserves core protein functions. This is important, as functional disruption is a central concern for any alternative tagging strategy applied to aggregation-prone or RNA-binding proteins.

      Weaknesses:

      While some inherent limitations of genetic code expansion remain (e.g., variable amber suppression efficiency and the inability to directly assess endogenous protein behavior), these are acknowledged and discussed appropriately. Importantly, these limitations do not undermine the central contributions of the study.

    3. Author response:

      The following is the authors’ response to the original reviews.

      eLife Assessment

      Amyotrophic lateral sclerosis (ALS) affects nerve cells in the brain and spinal cord. The authors' approach to use genetic code expansion to tag two ALS proteins associated with stress granules has value and should be useful in the ALS field. Parts of the work are well done, but there are concerns that the evidence is incomplete overall, and additional controls would strengthen the study.

      We thank the editors and reviewers for their thoughtful assessment and for highlighting the potential value of applying genetic code expansion (GCE) to study ALSassociated proteins involved in stress granule biology. Our goal in this work was to establish and validate a minimally perturbative labeling strategy using the noncanonical amino acid Anap to monitor the localization and stress-dependent behavior of TDP-43 and G3BP1.

      We agree that additional controls can further strengthen the conclusions. In the revised manuscript, we have clarified the experimental design and added essential controls to better support the reliability of the Anap labeling approach (Supplementary Fig. 1).

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      The authors utilize genetic code expansion to tag TDP-43 and G3BP1, and evaluate this protein tagging system (ANAP) compared to antibodies, and evaluate protein trafficking and stress granule formation in response to stress with sodium arsenite treatment. They find similar staining to antibodies in HeLa cells, mouse embryonic stem cells, and primary mouse cortical neurons. This is a useful study that demonstrates the utility of ANAP tagging to evaluate ALS proteins.

      We sincerely thank the reviewer for the positive assessment of our work and for recognizing the utility of the Anap-based GCE system for studying ALS-associated proteins.

      Strengths:

      Rescue of cell survival by ANAP-tagged TDP-43 is compelling

      We appreciate the reviewer’s highlighting of this point. Demonstrating that TDP43-Anap can rescue cell survival was an important validation in our study, as it indicates that incorporation of the noncanonical amino acid does not substantially disrupt the biological function of TDP-43. Additionally, we also tested the RNA splicing function recovery potency of TDP-43-Anap. As shown in Fig. 1K and 1L, a recovery of expression of PFKP, a protein undergoing cryptic exon when TDP-43 lost its function [1], was observed when expressing TDP-43-Anap in TDP-43 knockout Hela cells.

      Weaknesses:

      While the ANAP-tagged proteins had similar distributions to antibody staining, there were some discrepancies that may be more explained by the technique than by novel findings, as the authors suggested. The inclusion of additional controls to evaluate this would be helpful.

      This is a helpful suggestion. To ensure that the fluorescence signal observed in our experiments was specifically derived from site-specific Anap incorporation rather than background fluorescence, we performed three control conditions. Specifically, we tested: (1) cells cultured with Anap supplement, (2) cells expressing the Anap incorporation system with the addition of Anap, and (3) cells expressing both the TAG-mutated protein plasmid and the Anap incorporation system but without the addition of Anap. These control experiments were performed for both TDP-43 and G3BP1, and no observable fluorescence signal was detected under any of these conditions (Supplementary Fig. 1). We have clarified this control experiment in the revised manuscript.

      Reviewer #2 (Public review):

      Summary:

      In this manuscript, Chen and colleagues describe a novel means of labeling two RNAbinding proteins, G3BP1 and TDP-43, using genetic code expansion. Overexpressed constructs that incorporate the intrinsically fluorescent non-canonical amino acid Anap redistribute to cytoplasmic granules upon application of external stressors such as sodium arsenite. Similar labeling and redistribution of overexpressed G3BP1 and TDP43 were observed in cultures of mouse primary neurons.

      We are grateful for the reviewer’s accurate summary of our study and recognition of the value of GCE strategy for labeling the RNA-binding proteins G3BP1 and TDP-43.

      Strengths:

      Genetic code expansion and non-canonical amino acid labeling have quite a few advantages over traditional fusion proteins for tracking protein redistribution in living cells. The authors show that they are able to label exogenous G3BP1 and TDP-43 with the non-canonical amino acid Anap and follow labeled proteins in living cells with and without stress.

      We acknowledge the reviewer’s comment on the advantages of GCE-based noncanonical amino acid labeling for studying protein dynamics in living cells.

      Weaknesses:

      The authors do not convincingly leverage the advantages of genetic code expansion in the current study. There is no specific question posed by the authors that can be or is answered using this approach, and several of the experiments lack critical controls. This is also not the first example of TDP-43 labeling by genetic code expansion (see PMID: 38290242). As a result, the study as a whole adds little to our understanding of protein trafficking and behavior under stress.

      We thank the reviewer for raising these important points. Although as reviewer mentioned, genetic code expansion has previously been applied to TDP-43 [2], it mainly employed the photocaged lysine incorporation system to optogenetic control of TDP-43 translocation, and the protein was still labeled by mRubby. Our paper has totally different goal, to establish and validate a minimally perturbative labeling strategy using the intrinsically fluorescent noncanonical amino acid Anap to monitor the localization and stress-dependent behavior of both TDP-43 and G3BP1. And our work extends this approach in several important ways.

      First, we demonstrate that Anap incorporation enables visualization of stress-dependent redistribution of both TDP-43 and G3BP1, two key proteins involved in stress granule biology. Importantly, we validate this approach across multiple cellular systems, including HeLa cells, mouse embryonic stem cells, and primary mouse cortical neurons, which broadens the applicability of this labeling strategy.

      Second, we provide functional validation of the Anap-tagged protein, showing that TDP43-Anap rescues both cell survival and RNA splicing activity in TDP-43 knockout cells, including restoration of PFKP expression, a known cryptic exon target of TDP-43. These results support that Anap incorporation does not substantially disrupt protein function.

      We performed additional control experiments to ensure the specificity of the labeling system. Specifically, we tested three control conditions: (1) cells cultured with Anap supplement, (2) cells expressing the Anap incorporation system with the addition of Anap, and (3) cells expressing both the TAG-mutated protein plasmid and the Anap incorporation system but without the addition of Anap. These control experiments were performed for both TDP-43 and G3BP1, and no observable fluorescence signal was detected under any of these conditions (Supplementary Fig. 1).

      We agree that the manuscript would benefit from clearer articulation of the advantages of genetic code expansion in this context. Accordingly, we have revised the manuscript to more explicitly emphasize how Anap labeling provides a minimally perturbative alternative to large fluorescent protein fusions, which can alter the phase behavior and localization of stress granule proteins.

      “Conventional fluorescent protein tags have enabled visualization of TDP-43 and G3BP1 in living cells; however, these approaches can perturb the native biophysical properties of the proteins being studied. For example, GFP or other fluorescently tagged TDP-43 usually requires additional modifications, such as deletion of the nuclear localization signal (NLS) [3, 4], to induce cytoplasmic inclusion formation. Such manipulations introduce non-physiological conditions that may alter the native trafficking and aggregation behavior of TDP-43. As for G3BP1, tags like GFP may also cause unexpected effects on the phase separation or other dynamics of the protein. In contrast, Anap based GCE strategy allows the minimally perturbative labeling and visualization of protein localization and stress-induced redistribution while preserving native protein architecture and function of both proteins. Importantly, the approach provides a generalizable genetically encoded platform for quantitatively examining the behavior of ALS-associated proteins in living cells. By enabling faithful monitoring of protein trafficking and stressgranule dynamics without extensive protein engineering, Anap-based GCE can offer a powerful strategy for probing molecular-scale mechanisms underlying ALS-linked proteinopathies”.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) Figure 1A

      The authors report that the nuclear staining of G3BP1 by ANAP labeling shows the presence of nuclear pools of G3BP1 that aren't detected with antibody staining. However, unspecific nuclear staining by aminoacylated tRNAs bound to synthetases has been described. It would be important to have a control to evaluate for this possibility.

      This is an important point. We agree that the nuclear ANAP signal should be carefully controlled to exclude the possibility of nonspecific staining arising from the Anap incorporation machinery itself, such as aminoacylated tRNAs and/or synthetases.

      To address this concern, in methods and material part, we note that after DPBS washes to remove excess Anap, cells were incubated in fresh medium for 2 hours to allow sufficient time for the decay of unstable aminoacylated tRNAs, which are generally cleared within minutes to tens of munites [5].

      Also, we performed three control conditions for both TDP-43 and G3BP1: (1) cells cultured with Anap supplement, (2) cells expressing the Anap incorporation system with the addition of Anap, and (3) cells expressing both the TAG-mutated protein plasmid and the Anap incorporation system but without the addition of Anap. Under all three conditions, we observed no detectable fluorescence signal (Supplementary Fig. 1).

      In addition, as shown in Fig. 1I, the nuclear signal of G3BP1-Anap partially colocalizes with the nuclear signal of TIA-1 in several condensate-like structures. This observation further supports that the nuclear Anap signal reflects protein-associated localization rather than nonspecific fluorescence, as it overlaps with a known RNA-binding protein that can form nuclear condensates under certain conditions.

      (2) Figure 1A, 1B

      Anap labeling appears to stain fewer cytoplasmic structures compared to antibody staining for both G3BP1 and TDP-43 after sodium arsenite treatment. Quantification would be useful to address whether this is the case. If so, might this be due to unincorporated/truncated proteins competing with Anap-labeled proteins?

      We appreciate the reviewer’s helpful suggestion. To address this point, we performed quantitative colocalization analysis using Fiji/ImageJ, calculating the Pearson correlation coefficient (R) for regions of interest between the Anap signal and antibody staining. These analyses indicate a strong overall agreement between the two detection methods under stress conditions, supporting that Anap labeling reliably reports the localization of both G3BP1 and TDP-43 (see Fig1. A, B).

      Regarding the possibility that truncated or unincorporated proteins could influence the observed signal, we note that fluorescence from Anap depends on successful amber suppression and incorporation of Anap at the engineered TAG site. Proteins that fail to incorporate Anap, such as truncated products generated by premature termination, would not produce fluorescence, and therefore would not contribute to the Anap signal. Thus, the Anap fluorescence selectively reports the population of successfully labeled full-length proteins, whereas antibody staining detects both labeled and unlabeled protein pools. This difference may partially explain why antibody staining appears to label a larger number of cytoplasmic structures.

      (3) Figure 1F

      FRAP of G3BP1-GFP in stress granules is slower than in previous publications. The underlying reasons for this should also be addressed.

      We thank the reviewer for this important observation. Differences in FRAP recovery kinetics of G3BP1 in stress granules may arise from several experimental variables that are known to influence stress granule dynamics. These include differences in cell type, expression levels of G3BP1-GFP, and imaging or photobleaching parameters. In our experiments, FRAP measurements were performed under specific conditions optimized for our experimental system, which may lead to recovery kinetics that differ from those reported in previous studies.

      (4) Figure 1H

      A full-size Western blot would be useful to evaluate for amount of truncated protein for G3BP1 and TDP-43. Could truncated proteins be competing with and altering ANAPtagged G3BP1 and TDP-43 localization in response to stress? This should be addressed.

      We acknowledge this important point. Full-size Western blotting can provide information on the overall presence of truncated species in the transfected population; however, it represents a bulk measurement and does not capture cell-to-cell variability in amber suppression efficiency at the single-cell level. We therefore cannot exclude the possibility that truncated products are present at varying levels in individual cells and may contribute, directly or indirectly, to differences between antibody staining and Anap fluorescence.

      Importantly, we observe that cells with successful Anap incorporation consistently exhibit strong antibody staining for TDP-43 or G3BP1, indicating that full-length protein is the predominant species in these cells. Because Anap fluorescence depends on successful amber suppression, it selectively reports the full-length protein population, whereas truncated products are not detected in the imaging assay. The concordance between Anap fluorescence and antibody staining therefore argues against a major contribution of truncated species to the observed localization patterns (Supplementary Fig. 1).

      Accordingly, we interpret the Anap signal as reflecting the localization of successfully labeled full-length protein, while acknowledging that heterogeneity in suppression efficiency is an important limitation of the current approach.

      (5) Figure 3

      This is a well-designed diagram.

      We are grateful for the reviewer’s positive feedback on the diagram and are pleased that the schematic effectively illustrates the experimental design and the principles of the genetic code expansion strategy used in this study.

      Reviewer #2 (Recommendations for the authors):

      The authors present a one-sided viewpoint concerning the connection between stress granules and disease (lines 45-46). A more balanced discussion is recommended, including data arguing against a role for abnormal stress granules in neurodegeneration.

      This is an important suggestion. We agree that the relationship between stress granules and neurodegeneration remains an active area of investigation and that evidence both supporting and questioning a causal role of stress granules in disease has been reported. In the revised manuscript, we have modified the Introduction to provide a more balanced discussion of this topic.

      “Altered stress-granule dynamics have been associated with ALS/FTD [6, 7]; however, whether stress granules directly drive neurodegeneration remains debated, as several studies suggest that stress granules primarily function as protective stress responses [8].”

      (1) A central rationale for the study is missing. The authors state only that G3BP1 and TDP-43 'undergo dynamic stress-dependent redistribution, making them ideal candidates for minimally invasive, site-specific fluorescent labeling.' Is there a controversy or question that can be resolved using these approaches?

      We thank the reviewer for raising this important point. The central motivation of this study is that the dynamic behavior and phase separation properties of stressgranule proteins are highly sensitive to protein modifications and tagging strategies.

      “Conventional fluorescent protein tags have enabled visualization of TDP-43 and G3BP1 in living cells; however, these approaches can perturb the native biophysical properties of the proteins being studied. For example, GFP or other fluorescently tagged TDP-43 usually requires additional modifications, such as deletion of the nuclear localization signal (NLS) [3, 4], to induce cytoplasmic inclusion formation. Such manipulations introduce non-physiological conditions that may alter the native trafficking and aggregation behavior of TDP-43. As for G3BP1, tags like GFP may also cause unexpected effects on the phase separation or other dynamics of the protein.”

      (2) Related to this, there is little context for how or why genetic code expansion is utilized for these studies

      We agree that the rationale for using genetic code expansion should be more clearly explained. In this study, genetic code expansion was employed to enable sitespecific incorporation of the small fluorescent noncanonical amino acid Anap, allowing minimally perturbative labeling of proteins of interest.

      “Anap based GCE strategy allows the minimally perturbative labeling and visualization of protein localization and stress-induced redistribution while preserving native protein architecture and function of both proteins. Importantly, the approach provides a generalizable genetically encoded platform for quantitatively examining the behavior of ALS-associated proteins in living cells. By enabling faithful monitoring of protein trafficking and stress-granule dynamics without extensive protein engineering, Anapbased GCE can offer a powerful strategy for probing molecular-scale mechanisms underlying ALS-linked proteinopathies.”

      (3) The justification for the criteria for selecting the site for incorporation of non-canonical amino acids in G3BP1 or TDP-43 is missing.

      We acknowledge this important comment and agree that the rationale for selecting the incorporation sites should be stated more clearly.

      “For TDP-43, the incorporation site was selected to avoid the major functional domains involved in RNA binding, nuclear localization, and aggregation-related behavior, thereby reducing the likelihood that Anap incorporation would perturb its native trafficking or function. For G3BP1, the selected site was chosen to minimize interference with domains important for stress granule assembly, RNA binding, and protein-protein interactions. More generally, we aimed to place the ncAA at positions likely to be solventaccessible and tolerant of substitution, while avoiding highly conserved or functionally essential residues.”

      (4) Studies in Figures 1 and 2 lack essential controls, including background signal from Anap in non-transfected cells, or those transfected with plasmids lacking the tRNA or tRS.

      This is an important point, also raised by Reviewer 1. To evaluate potential background fluorescence arising from Anap or the labeling system, we performed several control experiments. Specifically, we examined three conditions: (1) cells cultured with Anap supplement, (2) cells expressing the Anap incorporation system with the addition of Anap, and (3) cells expressing both the TAG-mutated protein plasmid and the Anap incorporation system but without the addition of Anap. Under all three conditions, we observed no detectable fluorescence signal (Supplementary Fig. 1).

      (5) Another marker of stress granules should be used for confirming the identity of G3BP1-Anap (+) or TDP-43-Anap (+) structures, including TIA1, TAF15, or polyA RNA.

      We appreciate this helpful suggestion. To further confirm the identity of the stress granule structures observed in our experiments, we performed colocalization analysis with TIA-1, a well-established marker of stress granules. The results have been included in revised manuscript.

      “Additionally, we examined the colocalization of G3BP1-Anap with TIA-1, another established stress granule marker. Under stress conditions, G3BP1-Anap largely colocalized with TIA-1 within stress granules. Interestingly, under basal conditions, the nuclear signal of G3BP1-Anap, which was not detected by antibody staining, appeared to partially colocalize with TIA-1 in several condensate-like structures. (Fig. 1I).”

      (6) There is no information on the number of granules bleached or the number of cells selected for FRAP studies. There is no information on the shaded areas in Figure 1F or 1G, and no information on statistical comparisons between regressions in Figure 1F.

      We thank the reviewer for pointing out these omissions. We have revised the figure legends to clarify these details.

      “One granule from each of three independent cells was selected and photobleached for FRAP analysis.”

      “Here, error bars with filled area are used for better data presentation. FRAP recovery curves were compared using two-way ANOVA.”

      (7) Protein dynamics measured by FRAP are highly dependent on the concentration and/or expression level of each protein. Because of this, the authors need to control for expression level in all FRAP studies.

      We agree that protein concentration and expression level can influence FRAP recovery kinetics. Since Anap incorporation is based on amber suppression, and the suppression rate in each cell varies, so it is difficult to control the expression of Anap labeled proteins, however, to minimize this potential effect, we performed FRAP measurements on cells exhibiting comparable fluorescence intensities, which served as a proxy for similar expression levels of the labeled proteins. In addition, FRAP analyses were conducted on individual granules within cells expressing moderate levels of the protein, avoiding cells with unusually high fluorescence intensity that might reflect overexpression.

      Furthermore, fluorescence recovery was normalized to the pre-bleach intensity of the selected granules, which reduces variability arising from differences in overall expression levels between cells.

      (8) There is no point of reference for TDP-43-Anap FRAP results in Figure 1G. Additional studies using variants harboring a mutated NLS (mNLS) can be used in place of TDP43-YFP.

      This is a helpful suggestion. In response, we have performed additional FRAP experiments using TDP-43<sup>ΔNLS</sup>, a commonly used construct that promotes cytoplasmic localization and facilitates analysis of TDP-43 granules. The results from TDP-43<sup>ΔNLS</sup> have now been included as a reference for the FRAP measurements of TDP-43-Anap in the revised manuscript (Fig. 1D, 1G).

      “We then used YFP-tagged nuclear localization signal (NLS)-deleted TDP-43 (TDP43<sup>ΔNLS</sup>-YFP) as a reference and performed FRAP analysis to compare the mobility of TDP-43-Anap and TDP-43<sup>ΔNLS</sup>-YFP. Fluorescence recovery of TDP-43-Anap reached ~45% within 20 s after photobleaching, consistent with liquid-like dynamics. In contrast, TDP-43<sup>ΔNLS</sup>-YFP showed only ~22% recovery, suggesting more solid-like dynamics (Fig. 1D, 1G). These results are consistent with previous reports describing relatively immobile aggregates formed by TDP-43<sup>ΔNLS4</sup>and illustrate the advantage of Anap-based labeling, which preserves native protein properties and enables real-time assessment of protein dynamics without introducing disruptive mutations.”

      (9) There is no point of reference for comparing FRAP results from G3BP1-GFP to G3BP1-Anap. What is the 'gold standard'? Without this, it is difficult to conclude that "... Anap labeling better preserved the native mobility and biophysical properties of G3BP1 than the conventional GFP tag."

      We acknowledge this important point and agree that there is currently no definitive gold standard for measuring the native mobility of endogenous G3BP1 within stress granules in living cells. Our intention was not to claim that the Anap-labeled protein definitively represents the native state, but rather to compare the relative effects of different labeling strategies.

      Thus, we rewrite the sentence as “These results suggest that G3BP1-Anap displays higher mobility compared with G3BP1-GFP, indicating that Anap labeling may provide a less perturbative approach for monitoring G3BP1 dynamics.”

      (10) The WB in Figure 1H is overexposed, making it difficult to compare expression levels between WT and V100Anap-transfected cells. In addition, there is no similar assay for confirming G3BP1-Anap expression.

      Thank you for pointing this out. In the revised manuscript, we have replaced the image with a properly exposed Western blot to allow clearer comparison of protein expression levels.

      In addition, we have now included a corresponding western blot analysis to confirm the expression of G3BP1-Anap in G3BP knockout U2OS cell (Fig. 1H). These results verify that the Anap-labeled proteins are expressed at detectable levels and support the interpretation of the imaging and FRAP experiments.

      (11) Although survival studies in Figures 1I and J are promising, a more convincing demonstration of functional replacement of TDP-43 would involve an assessment of cryptic exon splicing, comparing WT to TDP-43 KO, V100Stop- and V100Anaptransfected cells.

      This is a valuable suggestion.

      “We also evaluated TDP-43-dependent RNA splicing activity by examining the expression of PFKP, a well-established target that undergoes cryptic exon inclusion upon loss of TDP-43 function17. As shown in Figures 1K and 1L, expression of TDP-43Anap in TDP-43 knockout HeLa cells restored PFKP expression, indicating that the Anap-labeled protein retains functional RNA splicing activity. These results demonstrate that TDP-43-Anap is capable of functionally compensating for endogenous TDP-43, supporting that the incorporation of Anap does not substantially disrupt the protein’s biological function.”

      (12) Tuj1 staining in Figure 2 is inconsistent and often fails to confirm neuronal identity.

      We thank the reviewer for this important comment. We acknowledge that Tuj1 staining in Figure 2 is variable and, in some cases, does not clearly delineate neuronal identity. Notably, the reduced Tuj1 signal is primarily observed in neurons that express Anap-labeled proteins under sodium arsenite treatment, which likely reflects the combined effects of transfection-associated stress and oxidative stress on neuronal morphology and cytoskeletal integrity.

      In addition, transfection efficiency in primary neurons is inherently low and variable, and cells that successfully express the constructs may represent a more stress-sensitive subpopulation, further contributing to variability in staining quality. Despite optimization efforts, these technical constraints limit the consistency of Tuj1 labeling under these experimental conditions.

      (13) Close-up images and correlation scatter plots in Figures 1 and 2 do not add very much information.

      We thank the reviewer for this comment. To address the reviewer’s concern, we have revised the figure legends to better clarify the purpose of these panels and how they support the quantitative analysis presented in the manuscript.

      For scatter plot, “Colocalization threshold analysis was performed in Fiji/ImageJ to calculate the Pearson correlation coefficient (R) for each region of interest (A, B, I, J). The X- and Y-axes represent the fluorescence intensity values of the red and green channels, respectively. When signals are colocalized, pixels with high intensity in one channel correspond to high intensity in the other, forming a diagonal distribution. In contrast, non-colocalized signals cluster along the axes. A higher R value indicates a greater degree of colocalization. Scale bar, 3 μm.”

      Same information was added to figure legend of figure 2.

      For the scheme, please see line 412-413 in the revised manuscript.

      Reference:

      (1) Rothstein, J.D. et al. Sporadic ALS induced pluripotent stem cell derived neurons reveal hallmarks of TDP-43 loss of function. Nature Communications 16, 7092 (2025).

      (2) Shadish, J.A. & Lee, J.C. Genetically encoded lysine photocage for spatiotemporal control of TDP-43 nuclear import. Biophys Chem 307, 107191 (2024).

      (3) Gasset-Rosa, F. et al. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron 102, 339–357.e337 (2019).

      (4) Yan, X. et al. Intra-condensate demixing of TDP-43 inside stress granules generates pathological aggregates. Cell 188, 4123–4140.e4118 (2025).

      (5) Walker, S.E. & Fredrick, K. Preparation and evaluation of acylated tRNAs. Methods 44, 81–86 (2008).

      (6) Kassouf, T. et al. Targeting the NEDP1 enzyme to ameliorate ALS phenotypes through stress granule disassembly. Science Advances 9, eabq7585 (2023).

      (7) Van Nerom, M. et al. C9orf72-linked arginine-rich dipeptide repeats aggravate pathological phase separation of G3BP1. Proceedings of the National Academy of Sciences 121, e2402847121 (2024).

      (8) Wolozin, B. & Ivanov, P. Stress granules and neurodegeneration. Nat Rev Neurosci 20, 649–666 (2019).

    1. Reviewer #3 (Public review):

      The Sustar et al. manuscript catalogs glutamate receptor composition across distinct Drosophila NMJs: larval and adult abdominal NMJs, as well as NMJs on adult leg and flight muscles. This work is important and probably overdue. The larval NMJ is the exemplar NMJ in this system, and the identity of "essential" and "alternative" subunits at this stage is assumed by many to hold across developmental stages and NMJ types. Here, the authors show that there is surprising diversification among NMJ types and that the notion of essential/alternative subunits only holds true at larval NMJs.

      The study will generate interest in the Clumsy GluR subunit, which has not been well-characterized at all, but is widely expressed at adult NMJs. They also find striking extrasynaptic expression of glutamate-gated chloride channel GluRClalpha in adult leg and flight muscles, raising questions about its role. The study is interesting, logical, and well-written. The figures are clear, and the discussion was particularly thoughtful. I have a couple of comments that the authors could consider.

      (1) They cite Rivlin et al., (2004) in the Introduction as the sole previous study to investigate the molecular composition of adult NMJs, but do not mention this work again. In the Discussion, it would be helpful to compare/contrast their finding with those of the earlier work.

      (2) Were these analyses done in adults of consistent ages? It seems possible that the GluR subunit composition could be different in very young adults or in aged flies. The age of the animals should be mentioned in the Methods.

      (3) The broad expression of GluCl:V5 in adult leg and flight muscles is surprisingly robust and appears to light up the edges of all muscle fibers. Would the authors comment on the controls that were done to ensure that this staining is real and specific to animals carrying that V5 endogenous tag?

      (4) The snRNAseq data in Figure S12 differ a bit from the IHC/GAL4 data summarized in the table in Figure 2. In particular, the data suggests that Ukar and Grik are widely expressed in adult muscles. Is there a reason not to include an "snRNA seq" column in Figure 2 alongside the data from GAL4 lines and IHC? To my mind, it is about as reliable as GAL4 lines that often capture only a subset of the full expression pattern. In this case, the snRNAseq data suggest that Ukar/Grik are likely at adult flight muscle NMJs, which might be important since NMJ was negative for everything except Neto-beta by IHC.

    1. Die Oberfläche ist funktional, verrät aber ihre Desktop-Herkunft, und die Skalierung über einige hundert Bestellungen pro Tag hinaus verlangt meist kostenpflichtige Erweiterungen aus dem Extension Store.

      make this: Die Oberfläche ist funktional, verrät aber ihre Desktop-Herkunft. Die Skalierung über einige hundert Bestellungen pro Tag hinaus verlangt meist kostenpflichtige Erweiterungen aus dem Extension Store.

    1. reply to u/Beloved-21 at https://old.reddit.com/r/Zettelkasten/comments/1u2bw2s/index_cards_vs_digital_note_app/

      There are a handful of affordances you get with paper over digital.

      • Most in the space of embodied cognition would indicate that you will have better retention by writing things down physically versus typing them out.
      • studies indicate that the presence of screens/phones reduces the level and quality of the conversation in the room, even when the device is sitting on the table nearby
      • people react more at ease with paper note taking, especially in interviews where they tend to be more guarded if you're recording everything
      • The act of filing your notes forces you to engage with them multiple times. It's not just re-reading the current note to decide where to place it, but re-reading older notes to decide where the current one fits in. This gives you the benefits of spaced repetition as well as encountering the value of serendipity, synergy, and syzygy
      • you're forced to be more concise and selective about what you capture versus digital where it's easier to be a hoarder of material you don't "own" or even understand.
      • index cards are just as easy to carry in your pockets as any other device
      • physical cards are easier to layout, arrange, and re-arrange in various orders than any of the clunky methods for doing this in the digital space where solid user interface for this sort of affordance is almost entirely lacking.
      • paper forces you to slow down and engage with notes in ways that digital notes typically don't
      • physical cards actually "get in your way" in a sense while digital cards are always "hidden"

      I'm sure you'll find various others hiding in a digital version of my notes: https://hypothes.is/users/chrisaldrich?q=tag%3A%22note+taking+affordances%22

      The real question at the end of the day is what works best for you?!? Try them both out for a few weeks or a month or more and chose the version that works best for your modes of thinking. Experimenting is the only way to answer this question for yourself. You may find other affordances that don't apply to others' work.

    1. Reviewer #1 (Public review):

      Summary:

      Eroglu and Hobert demonstrate that injecting CRISPR guides and repair constructs to target three genes at a time, tagging each with a different fluorescent protein, and selecting which gene to tag with which fluorophore based on genes' expression levels, can improve efficiency of gene tagging.

      Strengths:

      This manuscript demonstrates that three genes can be targeted efficiently with three different fluorophores. It also presents some practical considerations, like using the fluorophore least complicated by agar/worm autofluorescence for genes with low expression levels, and cost calculations if the same methods were used on all genes.

      Weaknesses:

      Eroglu has demonstrated in a previous publication that single-stranded DNA injection can increase efficiency of CRISPR in C. elegans, while inserting two fluorescent proteins and a co-CRISPR marker into three loci, and Paix et al 2015 demonstrated simultaneous insertion of two fluorescent tags. The current work is valuable and incremental advance. In general, I applaud the authors' willingness to strategize about how whole proteome tagging might be accomplished. I predict that the advance here will be one of many small advances that will get the field to that goal. The title oversells the advance presented, in my view, since seems like one among many key advances, and the first sentence of the Discussion seems a more apt summary of the key advance here.

      Some injections targeted genes on the same chromosome together, which will create unnecessary issues when doing crossing that will be useful for some future experiments. This made me wonder if injecting 3 together really is helpful vs targeting each gene separately, since only 5 worms need to be injected. It cuts time down by 2/3, but perhaps avoiding targeting the same chromosome with two tags would be useful.

      The limited utility of current blue fluorescent proteins makes me wonder if it's worth using at this stage, before there are better blue fluorescent proteins, or better yet, far red, to avoid issues with live imaging under phototoxic UV or near-UV illumination.

    2. Reviewer #4 (Public review):

      Summary:

      Tagging the entire proteome of a metazoan would be a landmark achievement, providing a powerful complement and extension to existing "omic" catalogs in model systems. Here, Eroglu and Hobert argue that efficiently tagging multiple loci in a single "batch" would make the community-based achievement of this goal realistic. They provide rigorous evidence that such an approach is indeed feasible, exploring issues related to efficiency, design and screening strategies, disruption of gene function, and the potential for endogenously tagged alleles to reveal unexpected aspects of protein expression and localization. While the work has some minor gaps that are important to rigorously assess the feasibility of the proposed effort, the detailed and valuable insights that emerge should provide impetus to the community to coordinate efforts to make this ambitious goal a reality.

      Strengths:

      The work has numerous strengths. The authors provide compelling evidence that:

      - three distinct loci can be efficiently targeted with three distinct fluorescent tags in a single injection.

      - thoughtful targeting design can reduce the likelihood of disruption of function by the tag.

      - systematic design principles based on expression level and predicted localization/function can be used to optimize tagging strategies.

      - the resulting tags can provide unexpected insight into patterns of protein production and subcellular localization.

      Not all of these advances are novel in themselves, but taken together, they represent an important technical and conceptual advance. The most important strength comes from the exceptionally high value of the goal itself, in that the work is that it has the potential to spur a community-wide effort toward achieving the ambitious goal of proteome-wide tagging.

      Weaknesses:

      The work's shortcomings are minor.

      - One concern has to do with the feasibility of the proposed screening strategies. The experimental design cleverly coinjects tags for three loci in different gene expression 'zones'; this expression level determines which tag will be used. As the authors allude to, there is an important distinction between genes with the same overall FKPM value between those that are expressed broadly and those focally expressed in a specific tissue. The proposed strategy claims that there are a sufficient number of highly expressed genes "to be used as visible markers" for recovering successfully edited animals. It would be useful for the authors to discuss the issue of broad vs focused expression among this set of genes a bit more thoroughly, with an eye toward the issue of how likely it is that these genes could indeed consistently be used as visible markers, particularly for those at the low end of this limit.

      - What fraction of the proteome (on a per-gene basis) is secreted proteins? How difficult will it be to screen these for successful tags? Are there specific tags that would be more optimal for secreted proteins? (The authors mention the use of an SL2 or T2A cassette to label the cells in which these proteins are expressed but note that there are technical challenges associated with doing this at scale.)

      - For secreted and/or weakly expressed genes, it would be useful for the authors to estimate for what fraction of these would successful insertions need to be screened by PCR, and what resources (time and money) this would likely entail.

      - For how many genes would a single tag not capture all predicted isoforms?

      - Finally, some readers might object to the authors' assertion in the abstract that this work is "a first step in this direction" (presumably referring to designing a strategy for whole-proteome tagging). There is no concern that the authors are disregarding the extensive work of other groups, as they explicitly mention the contributions of other groups to the foundation that enables the present work. However, the spirit of the abstract could be misinterpreted by a well-intentioned reader.

    3. Author response:

      The following is the authors’ response to the previous reviews

      Reviewer #1 (Public review):

      Summary:

      Eroglu and Hobert demonstrate that injecting CRISPR guides and repair constructs to target three genes at a time, tagging each with a different fluorescent protein, and selecting which gene to tag with which fluorophore based on genes' expression levels, can improve efficiency of gene tagging.

      Strengths:

      This manuscript demonstrates that three genes can be targeted efficiently with three different fluorophores. It also presents some practical considerations, like using the fluorophore least complicated by agar/worm autofluorescence for genes with low expression levels, and cost calculations if the same methods were used on all genes.

      Weaknesses:

      Eroglu has demonstrated in a previous publication that single-stranded DNA injection can increase efficiency of CRISPR in C. elegans, while inserting two fluorescent proteins and a co-CRISPR marker into three loci, and Paix et al 2015 demonstrated simultaneous insertion of two fluorescent tags. The current work is valuable and incremental advance. In general, I applaud the authors' willingness to strategize about how whole proteome tagging might be accomplished. I predict that the advance here will be one of many small advances that will get the field to that goal. The title oversells the advance presented, in my view, since seems like one among many key advances, and the first sentence of the Discussion seems a more apt summary of the key advance here.

      Some injections targeted genes on the same chromosome together, which will create unnecessary issues when doing crossing that will be useful for some future experiments. This made me wonder if injecting 3 together really is helpful vs targeting each gene separately, since only 5 worms need to be injected. It cuts time down by 2/3, but perhaps avoiding targeting the same chromosome with two tags would be useful.

      The limited utility of current blue fluorescent proteins makes me wonder if it's worth using at this stage, before there are better blue fluorescent proteins, or better yet, far red, to avoid issues with live imaging under phototoxic UV or near-UV illumination.

      These comments are a repeat of the original comments, and we refer the reader to our response to the original comments.

      Reviewer #2 (Public review):

      Original Review:

      The manuscript by Eroglu and Hobert presents a set of strains each harboring up to three fluorescently tagged endogenous proteins. While there is technically nothing wrong with the method and the images are beautiful, we struggled to appreciate the advance of this work - who is this paper for?

      As a technical method, the advance is minimal since the first author had already demonstrated that three mutations (fluorophore insertion and co-CRISPR marker) could be introduced simultaneously.

      As a pilot for creating genome-scale resources, it is not clear whether three different fluorophores in one animal, while elegantly designed and implemented, will be desired by the broader community.

      Finally, the interpretation of the patterns observed in the created lines leaves much to be desired. A Table with all the observations must be included and can replace the tedious (and often wrong) descriptions of the observations with the different lines. It would be too much to point out every mistaken expectation of protein expression. Two examples include:

      The expectation that ACDH-10 is enriched in the intestine and epidermal tissues (hypodermis) is naïve - there are multiple paralogs of this protein (look at WormPaths or WormFlux) that may share functions in different tissues. There is also no reason to assume that fatty acid metabolism does not occur in other tissues (including the germline). Finally, there are no published studies about this enzyme, so we really don't know for sure what it's doing.

      The expectation that HXK-1 is ubiquitously expressed is similarly naïve. There are three paralogous enzymes that are all associated with the same reaction, and we have shown that these three function redundantly in vivo, perhaps in different tissues (PMID: 40011787). Moreover, single cell RNA-seq data (PMID: 38816550) also shows enrichment of hxk-1 in gonadal sheath cells.

      The table should have at least the following information: gene/protein name - Wormbase ID - TPM levels of single cell data assigned to tissues for L2, L4 and adult (all published) - tissues in which expression is observed in the lines presented by the authors.

      Other points:

      (1) We would encourage the authors to provide systematic validation of the reported insertions. The manuscript reports that 24 of 30 tags were isolated and visible but does not clearly state whether each isolated line was confirmed by sequence‑level validation to be correctly in‑frame and free of unintended mutations at the target locus.

      (2) The manuscript presents aggregated success counts (e.g., 8/10 mTagBFP2 tags, 9/10 mStayGold, 7/10 mScarlet3) and useful narrative descriptions of injection outcomes. We suggest also to include per‑locus success rates.

      (3) For pools that required re‑injection after initial failures, we would like to see a description of the specific changes that were made to the injection mixes or procedures (e.g., new repair template prep, different Cas9 reagent lot, guide redesign). This will be useful troubleshooting information for others.

      (4) The authors states that the fluorophore sequences are codon-optimized for C. elegans. We suggest they provide the exact donor/tag sequences used specifically state whether the fluorophore sequences contain any synthetic/artificial introns or other sequence modifications (e.g., silent PAM‑disrupting mutations) were included in the donor templates.

      (5) Page 3: Include a reference for "The C. elegans genome encodes around 20,000 genes"

      We hope these comments are useful.

      Comments on Revised Version:

      Overall, we found the responses to be quite recalcitrant.

      We have one remaining composite concern about the comparison between observed expression patterns with the new strains versus published data.

      First, the authors only report patterns for one stage while it should be not too much effort to image the different life stages. However, since this is a revision, we are not formally requesting they do this.

      Second, in the now provided Table (thank you) 'observed expression' (last column) is lacking for 9 of the 30 proteins, and for 6 of these the procedure was not successful. Why not report patterns for the other three? It is confusing also because on page 5, the authors say that "overall, 24 of 30 tags ...all of which were visible with fluorescence stereomicroscopy" - are we missing something? Also, they then said that they "obtained 6/9 of the originally failed tags"; why are the corresponding patterns not included in table 1, and are 9 proteins still labeled as "no" in the "success?" Column?

      We appreciate the chance to clarify this matter: There are only 6 “no” in the “success” column. In two cases, HAT-1 and CBP-1, expression was dim at F1 but still sufficient to pick positive worms and quantify success rate at the locus. We noted these as “dim” on the table to indicate that if expression was lower, we likely would not have been able to isolate them at F1. In one case, COX-6B, expression was too dim at F1 to be isolated but was sufficient at F2 to be visualized and isolated from parents that were positive for the other two tags. We now clarified this distinction in the table and accompanying text: “Fluorescent signals of HAT-1::mScarlet3 and CBP-1::mScarlet3 in F1 progeny were dim but still sufficiently visible for quantification of knock-in efficiency, indicating that they are at the lower end of detectability for mScarlet3.”

      We imaged worms that had multiple tags as proof of principle and are happy to provide strains to those who would like to image/study them. At this point we are not convinced that imaging more worms would add to the conceptual framework.

      Third, we strongly feel that the response to our comments about expression patterns is not adequate. On page 5 the authors say that "all proteins were expected to be ubiquitously expressed" and that "scRNA-seq indicated that transcript abundance was ubiquitous and without strong tissue-specific enrichment with few exceptions". However, in their rebuttal, the authors now argue for tissue-specific expression for proteins with paralogs, turning around their own argument! Moreover, their Table indicates that many genes show tissue-enriched expression by RNA-seq while many of their tagged proteins exhibit ubiquitous expression.

      We respectfully disagree that there is contradiction. In our response, the discussion on paralogs was added as a clarification in response to the referee’s original comments (e.g., regarding ACDH-10): “There is also no reason to assume that fatty acid metabolism does not occur in other tissues (including the germline).” We wanted to make it clear that we were not concluding fatty acid metabolism (or other processes) does not occur in other tissues.

      We wish to stress that we never argued that paralogs could not fulfil the same essential function across tissues. The proteins were selected because their biological functions (e.g., glycolysis, fatty acid β-oxidation, translation) are broadly required, and that scRNA seq generally predicted broad expression with few exceptions as detailed in the text. Paralogs with similar activities (e.g., hxk-1, -2, -3) may overlap broadly in expression, or individual paralogs may carry out the process in different tissues provided one carries out the reaction in each tissue. For acdh-10 and hxk-1 specifically, both appear broadly expressed across tissues by scRNA-seq, with no consistent enrichment or depletion across datasets. So, our central point is that: for a specific gene involved in an essential process, transcript data alone are not sufficient to accurately predict tissue specific enrichment. Not that the processes do not occur in tissues where one paralog is absent. The possibility that a paralog may compensate for lack of expression is in no way contradictory with our conclusion.

      The table does not generally show tissue-enriched expression: it simply lists three tissues with the highest quantitative value in the respective dataset. For instance, taking the first gene from the list (Y82E9BR.3) and looking at the Ghaddar dataset, the top 3 tissues (log2(TPM)) are: pharyngeal muscle (13.4), gonadal sheath (12.9), marginal cells (12.9). The next 3 tissues are: body wall muscle (12.9), pharyngeal epithelium (12.8), and intestine (12.3). Even when there were apparent enrichments among the top 3 tissues, there were significant disagreements between datasets, and beyond top 3 even greater disagreements (the datasets agreed on the top tissue only 4 times over the 30 genes). These indicate that much of the variation is attributable to experimental noise rather than true predicted enrichment. The referee points to HXK-1 being correctly gonadal sheath enriched in one scRNA dataset; however, the other two datasets actually show different sites as being highest, and the same dataset misses effects in other cases. This is precisely why protein level data is needed.

      We further clarified this issue in the text: “We thus selected 30 genes across a variety of bulk transcript expression ranges which are generally predicted to be broadly expressed based on molecular function or, where molecular function was unknown (e.g., ZK632.9), single cell RNA sequencing (scRNA-seq) data (Table 1, Fig. 2A, B) (Gao et al., 2024; Ghaddar et al., 2023; Taylor et al., 2021).”

      Overall, this indicates that both the overall accomplishment of generating tagged protein strains and analyzing their expression is oversold.

      We have tried to make clear that our contribution is not a handful of new tagged strains added to the many that already exist. Rather, as stated in the abstract and elsewhere, we propose a strategy and provide proof-of-concept for scaling up tagging efforts. We believe the importance of this cannot be oversold.

      Reviewer #3 (Public review):

      Summary:

      The authors argue that establishing the expression pattern and sub-cellular localisation of an animal's proteome will highlight hypotheses for further study. This claim is probably accepted by many in the community. This manuscript seeks to confirm the feasibility of establishing such a resource, by using current transgenic methods to knock in DNA encoding different colored fluorescent tags into C. elegans genes.

      Strengths:

      The authors make the points above. For example, they provide evidence that the C. elegans germline harbors two populations of mitochondria that differ qualitatively in the proteins they express. They also confirm that labelling the whole proteome is an achievable goal with relatively limited resources and time.

      Weaknesses:

      The work is somewhat incremental in that it uses existing transgenic technology. Cell biology in C. elegans is challenging because of the small size of many of its cells, notably neurons. This can make establishing the sub-cellular localisation of a fluorescently tagged protein, or co-localizing it with another protein, tricky. The authors point out in their introduction that advances in light microscopy such as diSPIM, STED and ISM (a close relative of SIM), have increased the resolution of light microscopy. They also point out that recent advances in expansion microscopy can similarly help overcome the resolution limit. However, they do not use these technologies to characterize their transgenic strains.

      Reviewer #4 (Public review):

      Summary:

      Tagging the entire proteome of a metazoan would be a landmark achievement, providing a powerful complement and extension to existing "omic" catalogs in model systems. Here, Eroglu and Hobert argue that efficiently tagging multiple loci in a single "batch" would make the community-based achievement of this goal realistic. They provide rigorous evidence that such an approach is indeed feasible, exploring issues related to efficiency, design and screening strategies, disruption of gene function, and the potential for endogenously tagged alleles to reveal unexpected aspects of protein expression and localization. While the work has some minor gaps that are important to rigorously assess the feasibility of the proposed effort, the detailed and valuable insights that emerge should provide impetus to the community to coordinate efforts to make this ambitious goal a reality.

      Strengths:

      The work has numerous strengths. The authors provide compelling evidence that:

      Three distinct loci can be efficiently targeted with three distinct fluorescent tags in a single injection.

      Thoughtful targeting design can reduce the likelihood of disruption of function by the tag.

      Systematic design principles based on expression level and predicted localization/function can be used to optimize tagging strategies.

      The resulting tags can provide unexpected insight into patterns of protein production and subcellular localization.

      Not all of these advances are novel in themselves, but taken together, they represent an important technical and conceptual advance. The most important strength comes from the exceptionally high value of the goal itself, in that the work is that it has the potential to spur a community-wide effort toward achieving the ambitious goal of proteome-wide tagging.

      We appreciate the referee’s enthusiasm and hope that this will engage members of the community in a collective effort.

      Weaknesses:

      The work's shortcomings are minor.

      One concern has to do with the feasibility of the proposed screening strategies. The experimental design cleverly coinjects tags for three loci in different gene expression 'zones'; this expression level determines which tag will be used. As the authors allude to, there is an important distinction between genes with the same overall FKPM value between those that are expressed broadly and those focally expressed in a specific tissue. The proposed strategy claims that there are a sufficient number of highly expressed genes "to be used as visible markers" for recovering successfully edited animals. It would be useful for the authors to discuss the issue of broad vs focused expression among this set of genes a bit more thoroughly, with an eye toward the issue of how likely it is that these genes could indeed consistently be used as visible markers, particularly for those at the low end of this limit.

      To give two examples, this principle aided us with screening F54C8.1 and HAT-1. We added additional discussion on this to the first paragraph of the discussion: “For instance, we could clearly visualize F54C8.1::mScarlet3 in adult sperm by fluorescence stereomicroscopy despite a bulk FPKM of 16. Similarly, nuclear localized proteins will likely be easier to detect even at low expression levels, given the concentration of signal in small subcellular compartments. Indeed, this helped us detect HAT-1::mScarlet3 (56 bulk FPKM), which may have been too dim if distributed more broadly within cells.”

      What fraction of the proteome (on a per-gene basis) is secreted proteins? How difficult will it be to screen these for successful tags? Are there specific tags that would be more optimal for secreted proteins? (The authors mention the use of an SL2 or T2A cassette to label the cells in which these proteins are expressed but note that there are technical challenges associated with doing this at scale.)

      We added some of these points to the discussion: “Moreover, around 17% of the C. elegans genome (3,484 genes) may encode for secreted proteins (Suh and Hutter, 2012). Endogenous tagging of a substantial fraction of these proteins could reveal spatial patterns of secretion, distinguishing components that remain near their cell of origin from those that disperse to distal sites (Keeley et al., 2020). Tagging secreted proteins can also reveal sites of secretion – such as apical or basolateral membranes, or neurites – as has been observed for specific insulins (Sural et al., 2025) and for neuropeptides that localize selectively to synaptic regions (Toker et al., 2025).”

      Various tags have been used for secreted proteins including Venus, TagRFP, and mNeonGreen. The pH of secretory vesicles is ~5.0-5.5, so chosen FPs should have a pKa below this range to avoid denaturation. All 3 fluorophores used here (mStayGold, mScarlet3 and mTagBFP2) have pKa’s below this range and would likely be fluorescent within secretory vesicles.

      For secreted and/or weakly expressed genes, it would be useful for the authors to estimate for what fraction of these would successful insertions need to be screened by PCR, and what resources (time and money) this would likely entail. 

      We think that the bulk of ECM proteins would likely be visualizable without PCR due to their broad and stable expression, and as mentioned a good portion of these have been already tagged. However, it is likely that most of the secreted small peptides will have to be screened by PCR. We use homemade Taq, which makes material cost of the reagents minimal. A pair of genotyping primers costs ~$8 (~$27,872 for all secreted genes).

      Hands on time for lysis of 48-96 worms is approximately 20-30 minutes, with time to set up PCR around 5-10 minutes per target, and time to load a gel of 10 mins. In a given pool, 2/3 could be a putative secreted protein; thus, the same lysed population would enable screening for two targets at once. Collectively, around 40-60 mins of hands-on time would be required for two genes (around 20-30 mins per gene). Given 18 targets are injected per day, if 12 are screened by PCR, the screening could be done in 6 hours per day without affecting throughput. Most of the time spent on PCR would be replacing fluorescence screening time and would not overlap with the rate limiting injection step, performed by a separate specialist.

      For how many genes would a single tag not capture all predicted isoforms?

      Around 25% of C. elegans genes are thought to undergo alternative splicing (PMID: 21177968), with on average, ~2 isoforms per transcript. Among our selected genes, we only had one case where a single tag would not capture all isoforms (flad-1). We examined an additional 30 random genes and found no more examples by chance. So, in our view, this will be rare though we recognize in some cases a practical decision will need to be made, which could involve consideration of expression levels of each terminal exon.

      Finally, some readers might object to the authors' assertion in the abstract that this work is "a first step in this direction" (presumably referring to designing a strategy for whole-proteome tagging). There is no concern that the authors are disregarding the extensive work of other groups, as they explicitly mention the contributions of other groups to the foundation that enables the present work. However, the spirit of the abstract could be misinterpreted by a well-intentioned reader.

      We appreciate the referee’s perspective and have reworded this phrase in the abstract to: “As proof-of-principle for scalable pooled tagging, we undertook a pilot study in the nematode C. elegans, in which we set out to tag 30 different genetic loci with three different fluorophores, with 3 tags being introduced at a time.”

    1. Author response:

      The following is the authors’ response to the original reviews.

      eLife Assessment

      This study uses the yeast two-hybrid assay to identify proteins that may interact with yeast Set1 and other subunits of COMPASS/Set1C, the histone H3K4 methyltransferase, providing also some evidence for Set1 sumoylation and a role of SET1C methylating other factors in vitro. The results are valuable, and they should contribute to understanding the functions of the conserved SET1C complex, as they suggest potential functional connections with RNA biogenesis, chromatin remodeling, and non-histone methylation, whose implications would yet need to be explored. Nevertheless, apart from the fact that only a small subset of the Y2H interactions is further examined, the validating experiments are only partial or inconclusive, the strength of evidence being at this point incomplete.

      We present a systematic SET1C interaction map that provides a structured resource for generating and testing new hypotheses on SET1C function. We emphasise that these interactions represent a hypothesis generating resource rather than a set of validated protein–protein interactions. To reflect this, the manuscript has been carefully revised to distinguish clearly between observation and interpretation, and to avoid overstatement of the data. Accordingly, we have revised the title and the abstract. Selected examples are explored further to illustrate how candidates from the dataset can be followed up, but the primary contribution of this work is to provide a structured framework and resource that can guide future mechanistic studies of SET1C function.

      We thank the reviewers for their thoughtful comments. We have followed their recommendations by modifying the structure of the manuscript, removing distracting results and relocating some figures to the supplementary materials to improve the readability of the manuscript. At the same time, the reviewers acknowledge that the dataset is extensive and that aspects of the validation work are valuable.

      The changes made to the manuscript's structure in accordance with the reviewers' recommendations are as follows:

      (1) Figure 1 is accompanied by a table (Table S2) with the raw data describing all the interactions from the ten 2H screens. This table also lists common interactors found in the independent screens. I'm afraid Table S2 was omitted from the initial submission of the manuscript

      (2) Figure 2 has been modified to include an AlphaFold modeling of a seven-subunit Set1C complex (Set1– Bre2–Sdc1<sub>2</sub>–Swd1–Swd3–Spp1) together with Kap104. Figure 2D has been moved to a new Figure S2

      (3) The initial figure S2, which was problematic, has been removed, along with the accompanying text.

      (4) Figure 3 of the original paper has been moved to the supplementary material and is now shown as a new Figure S3.

      (5) Figure 5 in the original paper becomes Figure 3 in the revised version

      (6) Figure S3 (Co-IP between Set1 and Prp22), which serves as validation data, has been moved to the main figures and is now presented as Figure 4.

      (7) Figure 6 in the original paper becomes Figure 5 in the revised version

      (8) Figure 4 from the original paper has been repositioned as the first figure (new Figure 6) of the biochemical characterization of the interaction between Snf2 and Set1C.

      (9) Figure 7 has been removed from the manuscript. We have kept the original Figure 7E as a new Figure S6.

      (10) Figures 8, 9, 10 become Figures 7, 8, 9.

      Public Reviews:

      Reviewer #1 (Public review):

      We thank Reviewer 1 for the careful and thoughtful evaluation of our manuscript. We fully agree that yeast two hybrid screening provides candidate interactions that require cautious interpretation, and we recognise that our original version did not always make this sufficiently explicit.

      In the revised manuscript, we have made substantial changes to address this central concern. All Y2H interactions are now consistently presented as candidate or potential interactions, and speculative statements have been either removed or explicitly framed as hypotheses. Our intention is that the reader can clearly separate the dataset itself from any proposed biological implications.

      Second, we have refocused the manuscript to better reflect its primary contribution. We now present the Y2H screens as a comprehensive resource that defines a set of candidate interactions for SET1C, rather than as a set of validated functional relationships. In line with this, we have reduced the emphasis on speculative models and removed sections where the connection to experimental evidence was not sufficiently strong. This includes the removal of Fig. S2 and Fig. 7 and the associated text, as well as the relocation of several figures to the supplementary material. Where appropriate, we have added statements highlighting the limitations of the approaches used and the need for future work to establish physiological relevance.

      More generally, we agree with the reviewer that the value of Y2H data lies in generating testable hypotheses rather than establishing conclusions. We have therefore revised the manuscript throughout to ensure that the interpretation remains proportionate to the strength of the evidence.

      We hope that these changes address the reviewer’s concerns and result in a clearer and more appropriately balanced presentation of the data.

      The manuscript by Luciano et al is a collection of experiments about the yeast histone 3 lysine 4 methyltransferase, Set1, starting with 10 yeast two-hybrid screens (Y2H). Y2H screens were briefly popular 20+ years ago, but the persistently unfavourable false-to-true positive ratios limited their utility, and the conclusion emerged that Y2H is an unreliable approach for gathering protein-protein interaction data. Y2H outcomes are candidate interaction lists at best, strongly contaminated by false positives. Here, the authors employed a company (Hybridomics) to perform the Y2H screens.

      The primary data is not presented, and the outcomes are summarized using the Hybridomics in-house quality scoring system in Figure 1A. It is not possible to evaluate these data, and the manuscript presents cartoon summaries that the reader must accept as valuable.

      Hybrigenics brings extensive experience from conducting numerous screens, enabling the team to recognize recurring false positives that commonly arise in screening assays. In their detailed analysis, Hybrigenics reports the number of clones recovered and the extent of overlap among interaction regions, both of which contribute to the confidence scores they assign. Table S2, provided in the revised version, more accurately reflects the raw data obtained by Hybrigenics. Nevertheless, we agree that false positives contaminate the list of potential interactors. Some interactions may also be indirect through a common interactor and do not reflect a physiological interaction.

      (1) Based on the extensive knowledge about Set1C/COMPASS acquired from genetics and biochemistry by many labs (including the Geli lab), the results presented here from the 10 Y2H screens are notably patchy. Of the 7 subunits of this complex, only one (Spp1) was identified using Set1 as bait. Conversely, as baits, Swd2, Spp1, Shg1, captured Set1, and the Bre2-Sdc1 interaction was reciprocally identified. These interactions were scored at the highest confidence level, which lends some confidence to the screens. However, the missing interactions, even at the third confidence level, indicate that any Y2H conclusions using these data must be qualified with caution. The authors do not appear to be cautious in their lengthy evaluations of these candidate interactions, which are illustrated with cartoons in Figures 2 and 3, with some support from the literature but almost without additional evidence. Snf2 is a particularly interesting candidate, which the authors support with pull-down experiments after mixing the two proteins in vitro (Figure 4). After Y2H, this is the least convincing evidence for a protein-protein interaction, and no further, more reliable evidence is supplied.

      We thank the reviewer for raising this important point regarding the strength of the evidence supporting the Set1– Snf2 interaction. We agree that the current data do not establish a definitive physiological interaction. In the discussion, we explicitly note the limitations of the current data.

      For Figure 2, as recommended by referee 2, we performed AlphaFold modeling of a seven-subunit Set1C complex (Set1–Bre2–Sdc1<sub>2</sub>–Swd1–Swd3–Spp1) together with Kap104. Consistent with the Y2H data, the model recapitulates binding of the Kap104 SID to the PY-NLS region of Set1 (residues 40–90).

      We have moved Figure 3 in the supplementary materials.

      (2) Figure 5 continues the cartoon summary of extrapolations from the Y2H screens, again without supporting evidence, except that the authors state.

      Figure 5 is now Figure 3. We have added the statement in the text: “It is not feasible to validate all of these interactions within the limits of this manuscript, and their validity should therefore be interpreted with caution. Nonetheless, these findings provide a useful basis for future research”.

      "We have refined the interaction region between Set1, Prp8 and Prp22, showing that Prp8 and Prp22 interact strongly with Set1-F4 (n-SET). Prp22 interacts in addition with Set1-F1 (Figure S2)." However, Figure S2 does not show this evidence and is incoherent.

      When we say that we have refined the interaction region between Set1, Prp8, and Prp22, we mean that we have restricted the interaction regions according to Y2H criteria. Indeed, we have not shown the spots illustrating the results. This statement has been deleted as well as Fig. S2

      The figure legends for Figure S2B and C do not correspond to the figure.

      (B) Expression of the F1-F5 fragments in yeast cells. Fusion proteins were detected with an anti-GAL4 monoclonal antibody. TOTO yeast cells (Hybrigenics) were transformed with the different pB66-Set1-F1 to F5 plasmids and subsequently with either P6, pP6-Snf2 762-968, pP6-Prp8 37-250, or pP6-Prp22 379-763 that were identified in the Y2H screens. Transformed cells were incubated 3 days at 30{degree sign}C on SD-LEU-TRP and then restreaked on SD-LEU-TRP-HIS with 3AT. Cell growth was monitored after 2 days at 30{degree sign}C.

      (C) Solid and dotted arrows indicate that transformed TOTO cells transformed with pB66-Set1-F1 to F5 and the indicated prey (Snf2, Prp8, and Prp22) are growing in the presence of 20 mM and 5 mM of AT, respectively.

      Figure S2D is two almost featureless dark grey panels accompanied by the figure legend D) Control experiment showing that TOTO cells transformed with p6 and pB66-Set1-F4 are not gowing (sic) in the presence of 5 mM or 20 mM AT.

      We agree that the legend for Figure S2 was unclear and does not accurately describe the panels shown in the figure. Fig; S2 has been deleted in the revised version. The results shown in the original Fig. S2 add limited information and may detract from the clarity of the main points.

      In the revised version, we have moved the CoIP analysis demonstrating the interaction between Set1 and Prp22 (previously shown in Figure S3) into the main figures (now Figure 4) to further support and validate the two-hybrid screening results presented there.

      Line 343. Interestingly, the two-hybrid screens reveal that Set1 1-754 interacted with Gag capsid-like proteins of Ty1 (Figure S5), raising the possibility that Set1 binding to Ty1 mRNA is linked to the interaction of Set1 1-754 with Gag.

      This is another example of the primary mistake repeatedly made by the authors -Y2H interactions are candidate results and not conclusive evidence.

      This statement is supported by our previous findings showing that Set1 binds Ty1 mRNA independently of its dRRM domain and represses Ty1 mobility at a post-transcriptional stage (Luciano et al., Cell Discovery, 2017; PMID: 29071121). One possible explanation for Set1 association with Ty1 mRNA is its interaction with the Gag capsidlike protein. In this context, the observed interaction between Set1(1–754) and Gag capsid-like proteins is consistent with this model.

      To further illustrate this point, the authors highlight the candidate interaction between Nis1 and 3 Set1C subunits.

      While we agree that the Nis1-Set1C interaction has not been demonstrated beyond doubt, we feel that our Y2H and in vitro binding experiments provide reasonable evidence that the interactions may be relevant. It is important to consider that any interaction assay can provide negative (and false positive) results, this includes Y2H, in vitro binding and mass-spec analysis of purified complexes from cells. We feel that it is not appropriate to only trust protein interactions that are strong and stable enough to be demonstrated via purified complexes. It is clear that some protein interactions do occur in transient and weak manner and therefore are not compatible with biochemical purification approach. This indeed is the strength of alternative methods like Y2H and in vitro binding assays, that interactions can be identified and tested even if the physiological context of the interaction may be more complex.

      (3) After multiple speculations based on the Y2H candidates, the authors changed to focus on sumoylation of Set1, which has previously reported to be sumoylated. Evidence identifying two sumoylation sites in Set1, in the N-SET and SET domains, is valuable and adds important progress to the role of sumoylation in the regulation of H3K4 methyltransferase, relevant for all eukaryotes. This illuminating part of the manuscript is only tenuously connected to the preceding Y2H screens and concomitant speculations.

      We thank Referee 1 for their comment. While it is true that there is only a modest connection between Set1 interactors involved in direct or indirect sumoylation and the characterization of Set1 SUMOylation sites, we believe that this does not constitute a weakness of the manuscript.

      (4) The manuscript then describes a red herring exercise involving Set1 methylation of Nrm1. In an already speculative and difficult manuscript, it is exasperating to read a paragraph about a failed idea. Apart from panel E, Figure 7 is a distraction, and I believe it should not be shared.

      (5) However, despite the failure with Nrm1, Line 443 - The H3K4-like domain in Nrm1 raised our attention to other yeast proteins that carry such sequences.

      This line of thinking is even less connected to the Y2H screens than the sumoylation work.

      However, the authors present a reasonable evaluation of the yeast proteome screened for six amino acids similar to the known H3K4 motif ARTKQT (Figure 7e).

      (6) However, this evaluation goes nowhere and has no connection with the next section of the manuscript, which is entirely speculation about the regulation of metabolism and stress responses based on the Y2H results and selected evidence from the literature.

      In response to comments 4 and 5, we have removed Fig. 7 and the paragraph titled “The transcriptional corepressor Nrm1 interacts with SET1C.” Part of this paragraph and the section describing the screen of the yeast proteome for six–amino acid sequences resembling the H3K4 motif (ARTKQT) has been kept as Fig. S6.

      In the abstract, we have removed the sentence: We demonstrate that the transcriptional corepressor Nrm1 is methylated by SET1C in vitro suggesting that H3K4-like domains may represent a class of non-histone substrates for SET1C.

      At the end of the introduction, we have deleted “the transcriptional corepressor Nrm1” in the sentence: In addition, we demonstrate that the transcriptional corepressor Nrm1 and the Snf2 AT-hook are both methylated by SET1C in vitro

      (7) The manuscript then describes more failed experiments regarding lysine methylation of Snf2 by Set1C, which unexpectedly reports arginine methylation rather than lysine. The manuscript does not currently meet the standard expected for this type of paper - the composition is somewhat incoherent and there are no previous reports of arginine methylation by SET domain proteins.

      We have integrated extensive in vitro reconstruction experiments with complementary in vivo studies, all conducted according to the rigorous standards expected by leading journals. These approaches have allowed us to reach the conclusions presented in this manuscript. While some of these findings are unexpected, they are supported by the data. We have carefully discussed the results and their limitations to provide a comprehensive interpretation.

      The manuscript presents a very experienced grasp of the literature and a sophisticated appreciation of the forefront issues, but a surprising failure to eliminate uninformative failures and peripheral distractions. The over interpretation of Y2H results is a dominating failure. There are some valuable parts within this manuscript, and hopefully, the authors can reformat to eliminate the defects and appropriately qualify the candidate data.

      We thank Referee 1 for these insightful comments. In the revised version, we have followed the advice to remove non-informative failures and peripheral distractions. Additionally, we exercise greater caution to avoid over-interpreting the Y2H results.

      Reviewer #2 (Public review):

      Summary:

      This paper starts with a large-scale yeast two-hybrid (Y2H) screen using Set1 (full-length and smaller parts) and other Set1C/COMPASS subunits as bait. There are hundreds of possible interactions identified, but only a small number are given any follow-up. While it's useful to document all the possible interactions, the unfocused and preliminary nature of the results makes the paper feel scattered and incomplete.

      Strengths:

      The Y2H screen was very comprehensive, producing lots of interesting possible leads for further experiments.

      Weaknesses:

      The results are useful but incomplete because only a small subset of the Y2H interactions is further examined. Even in the case of those that were further tested, the validating experiments are only partial or inconclusive.

      Referee 2’s comments align in some respects with those of Referee 1. In the revised version, we have followed the detailed Referee 2 suggestions to reduce the scattered nature of the manuscript. In addition, we include an AlphaFold model of the interaction between the Set1 N-term 1-754 with the SID domain of Kap104 that involves the proposed Set1 PY-NLS sequence.

      Reviewer #3 (Public review):

      The SET1C/COMPASS complex is the histone H3K4 methyltransferase in Saccharomyces cerevisiae, where it plays pivotal roles in transcriptional regulation, DNA repair, and chromatin dynamics. While its canonical function in histone methylation is well-established, its full interactome remains poorly defined. Moreover, whether SET1C methylates non-histone substrates has been an open question. In this study, Luciano et al. employ systematic yeast two-hybrid (Y2H) screening to uncover novel interactors and functions of SET1C. Their findings reveal potential functional connections to RNA biogenesis, chromatin remodeling, and non-histone methylation.

      The authors performed multiple Y2H screens using Set1 (full-length, N-terminal, and C-terminal fragments) and each of its seven subunits as baits. They identified high-confidence interactors that link SET1C to diverse cellular processes, including chromatin regulation (e.g., the SWI/SNF complex via Snf2), DNA replication (e.g., Mcm2, Orc6), RNA biogenesis (e.g., spliceosome components Prp8 and Prp22; polyadenylation factors Pta1 and Ref2), tRNA processing (e.g., Trm1, Trm732), and nuclear import/export (e.g., importins Kap104 and Kap123). Some of these interactions were further validated by immunoprecipitation or in vitro assays.

      Given the interaction of Set1 with Slx5 and Wss1 - proteins involved in SUMO-dependent processes - the authors investigated and convincingly demonstrated that Set1 is sumoylated. This modification may influence the function and regulation of the SET1C complex.

      Finally, the authors provide evidence that SET1C methylates proteins beyond histone H3K4, notably Nrm1, a transcriptional corepressor, and Snf2, the catalytic subunit of the SWI/SNF chromatin remodeling complex. Although Nrm1 contains a domain resembling the H3K4-methylated sequence (H3K4-like domain), this region does not appear to be required for its methylation. The search for other proteins containing similar domains as potential methylation candidates (p.12, first paragraph) seems less justified, given the lack of evidence supporting the requirement for the H3K4-like domain in methylation.

      This study offers valuable insights into the interactome of SET1C, suggesting potential links between the complex and a wide range of cellular processes. However, the functional implications of the Y2H interactions remain to be explored further. Additionally, the study provides intriguing information on the possible regulation of Set1 by sumoylation. The discovery of Nrm1 and Snf2 as methylation substrates could significantly expand the known targets and functions of SET1C.

      The results are supported by high-quality data.

      We thank referee 3 for their positive comments

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      Restructure the manuscript into at least two papers.

      We thank the reviewer for this suggestion. In the revised manuscript, we have addressed this concern by substantially restructuring and streamlining the presentation. We consider the dataset, validation experiments, and functional observations to be closely integrated, and we believe that presenting them together provides the most coherent and impactful account of the work.

      Minor points

      There are several basic flaws in the manuscript that I feel indicate the co-authors have not proofread the manuscript sufficiently - 4 examples from early in the manuscript are listed below.

      (1) The reference for Hybridomics is (73) - obviously from an earlier version that used a different referencing system that has not been corrected.

      Thank you. This has been corrected.

      (2) Line 194 - 197. These screens have proven their power and effectiveness. In particular, they identified ...... the CTD of Rpb1 as an interactor of the N-terminal region of Set1 (Bae et al, 2020) (Figure S1). Rbp1 interaction is not identified in the screens presented here, and Figure S1 is a cartoon and not primary evidence.

      The interaction between the CTD of Rpb1 (Rpo21) and Set1 is reported in Table S2. The detailed characterization presented in Bae et al. (2020) was subsequently carried out as a direct follow-up to this screen.

      (3) Line 205-211. The highly confident interactors of the seven SET1C subunits are shown in Figure 1C-E. We found that Spp1, Shg1 and Swd2 interact alone with Set1 (Figure 1C). The minimum Set1 region for which an interaction is found for each of these 3 subunits is shown in Figure 1C. The high confidence interactors of the seven SET1C subunits are shown in Figure 1C-E. We found that Spp1, Shg1 and Swd2 display Y2H interactions with Set1 (Figure 1C). The high confidence interactors of Spp1, Shg1 and Swd2 are indicated in Figure 1D (see also Table S2).

      It is possible that Table S2 was omitted from the original submission, as it was requested during the production stage.

      (4) Line 335. We have classified all Set1 and subunit interactors according to these SET1C roles (Figure S5). However, this refers to Figure S4 - many further references to Figure S5 are also to Figure S4.

      Thank you. This has been corrected.

      Reviewer #2 (Recommendations for the authors):

      General recommendations:

      (1) Figures 1, 2, 3, and 5 and their associated main text are essentially just lists of interactors, put in graphic form and grouped to allow speculation about possible biological functions for the interactions. But almost none of the ideas are tested, so these sections take much more space than warranted. Having so much preliminary Y2H data actually distracts attention from the follow-up experiments that are shown. I would move most or all of this to the supplement, consolidating the Y2H results into fewer figures (or even just the Table).

      As mentioned earlier, the manuscript has been reorganized and Table S2 is provided.

      (2) The Snf2 interaction gets the most follow-up, so separating Figure 4 from Figures 8-10 broke the flow of that story. I would group these figures together since all are related to the Snf2 AT hook story.

      This was done accordingly.

      (3) I understand that it's impossible to validate all the possible interactions, particularly if resources are limited. However, at least for the interactions that get further attention, it could be very useful to try some AlphaFold multimer predictions. A high confidence AlphaFold score would provide a second orthogonal piece of evidence to support the Y2H results.

      We generated an AlphaFold model (Figure 2C) that recapitulates the key predictions for the Set1-Kap104 Y2H interaction.

      Comments on specific sections:

      (1) Y2H results. The text says Figure 1 shows all the high-confidence interactors. But the Set1 NTD interaction with the Rpb1 CTD is not shown here (it's in the supplement).

      In Table S2, an interaction is observed between full-length Set1 and the Rpb1-CTD (14 repeats), where Rpb1 is referred to as Rpo21.

      Figure 2 shows additional high-confidence interactors that do not appear in Figure 1, while others (like the Shg1Mog1 interaction) are shown in both Figures 1 and 2. It's confusing to scatter the data like this, which is why I recommend consolidating into a single figure or table.

      In Figure 2, the high-confidence interactors of Set1 (1–754) are highlighted in red and green (Snf2, Gbp2, and Kap104), and all are also present in Figure 1. Dbp1, identified as a high-confidence interactor of Spp1, likewise appears in Figure 1. Table S2 summarizes all of these interactions.

      (2) Line 219. How does a "high confidence" Set1-Kap104 Y2H interaction suggest the interaction is direct? Couldn't an indirect interaction also be tight and reproducible? This is an example where it would be worth seeing if AlphaFold also predicts an interaction and, if so, whether it involves the proposed NLS sequences.

      Y2H screening indicated that Kap104 binds to the N-terminal region (aa 1–754) of Set1 via its Set1 interaction domain (SID). To validate this, we used AlphaFold to model the seven-subunit Set1C complex (Set1-Bre2-Sdc1(x2) Swd1-Swd3-Spp1) with Kap104. The resulting model showed borderline confidence for the overall fold (pTM = 0.53) and low confidence in subunit positioning (ipTM = 0.5). Visualization in PyMOL confirmed Kap104 SID binding to Set1(1–754), consistent with Y2H results. The structure highlights Kap104 SID interaction with Set1’s PY-NLS at residues 40–90; the second PY-NLS is neither visible nor engaged in this model.

      (3) In the discussion of nuclear import interactors, what does it mean to say the Shg1-Mog1 interaction is "along the same line" as Set1-Kap104?

      We meant that the interaction between Shg1 and Mog1 represents another example of an interaction between a Set1C subunit and a protein involved in nuclear import. Along the same line has been deleted in the revised version.

      (4) To follow up on the Swd1-Nrm1 Y2H interaction, the paper shows that Nrm1 is methylated by Set1 in vitro (Figure 7), but it's not clear whether this has any biological significance. Without any in vivo follow-up, this figure is probably more appropriate for the Supplement.

      As noted above, Figure 7 has been removed, only panel E of Figure 7 is retained in the revised version.

      (5) Figures 6 and S8 show that Set1 is SUMOylated. Although it's not clear what this does to Set1 function or which E3 is responsible, the modification data looks convincing. The legend to Figures 6A and B says the Elutes samples are purified on nickel columns. Why are the Myc-Set1 and GB-Set1 proteins without the his-SUMO modification also binding to the nickel column? That's not happening in panels C and D. In the blots on the right for his-SUMO, is there any way to show that one of those bands is Set1? Maybe IP for MYC and then probe for the His tag?

      We thank the reviewer for this observation. His-SUMO purification using Nickel beads was used to purify HisSUMOylated proteins. Purified proteins were analyzed by Western blot using anti-MYC or anti-GAL4 antibodies to detect SET1-His-SUMO, as well as anti-His antibodies to confirm the presence of purified His-SUMOylated proteins. As mentioned by the reviewer, we detected unmodified MYC-Set1 and GAL4-Set1 in both the (-) and (+) His-SUMO eluates. This phenomenon is most likely due to the stickiness of unmodified Set1 to the beads. This is a commonly observed phenomenon in this type of biochemical assay, particularly when analyzing large proteins such as Set1 (124 kDa). This stickiness behavior has been observed in similar SUMOylation assays, e.g., for Hpr1 (88 kDa) (Bretes H, 2014. PMID: 24500206), Nup1 (114 kDa), and Nup2 (78 kDa) (Folz H, 2019. PMID: 30837289). This stickiness was not observed when using Set1 fragments (panels C and D), most likely because the fragments lost the stickiness to the beads, a characteristic belonging only to the full-length Set1. We mention this point in the legend of the new figure 5.

      (6) The Snf2 interaction gets the most follow-up. The GST pulldown validation of Set1 interaction with Snf2 AThook looks pretty good. However, the RGG repeats are necessary for the Set1 interaction with recombinant Snf2 proteins, but not for the co-IP of in vivo material. Again, AlphaFold could lend further support here.

      Thank you for this helpful suggestion. We agree that structural modelling could, in principle, provide an additional and orthogonal line of support for the Set1-Snf2 interaction. We did explore this using AlphaFold. However, both Set1 and Snf2 contain extensive intrinsically disordered regions, including the regions implicated in the interaction, and none of the models we obtained provided interpretable structural insight into the interaction interface. In particular, the predicted complexes showed low confidence in relative domain positioning, which limits their usefulness for supporting or refining the interaction model. One possible explanation is that additional components are required to stabilise a meaningful interaction in silico. While we modelled Set1 within a seven-subunit Set1C complex, Snf2 was necessarily included in isolation from its native context. Given that Snf2 functions as part of multiple, heterogeneous chromatin remodelling complexes, the absence of its physiological binding partners may prevent AlphaFold from resolving a relevant interaction interface. In light of these limitations, we have not included the AlphaFold models in the manuscript, as we felt they would not provide reliable or informative support. Instead, we have focused on the experimental evidence presented. We have clarified this point in the revised discussion to acknowledge both the potential and the current limitations of structural prediction approaches in this context.

      (7) The Snf2 methylation by Set1 is less convincing, and its biological significance is still unclear. I think it's pretty unlikely that Set1 could methylate arginine. The mass spectrometry is used for in vivo validation (mass spec), but mutating the lysines (Figure S11, S12) or Set1 deletion (Figure S14) doesn't seem to affect the signal. Could there be quantitative differences? Is there any way to quantitate the mass spec data to estimate the modified/unmodified ratio?

      We thank the reviewer for highlighting the unexpected nature of the methylation results. We agree that the observation of arginine methylation in this context is surprising, particularly given that SET domain proteins are classically associated with lysine methylation. This is why we performed multiple in vitro and in vivo experiments, and careful interpretation data that were clear led us to conclude that Set1C methylates the arginines within the ARTSTRGR motif of the AT-hook. We agree that the biological significance of this modification remains unclear. We obtained data showing that deletion of the SID domain of Snf2 impairs yeast growth on lactate, whereas this mutant grows normally on glucose and galactose, in contrast to the Snf2Δ mutant, which exhibits poor growth on both glucose and galactose. In comparison, deletion of the RG motif of Snf2 does not affect growth on lactate. These results provide insight into the interaction between Set1 and Snf2 but do not shed light on the potential importance of methylation of the RG motif. We therefore chose not to include them. In the discussion, we acknowledge the limitations of the current evidence. Our intention is to retain these findings as potentially interesting observations while ensuring that their interpretation remains appropriately cautious.

      Minor comments:

      (1) Lines 153 and 163: Stress response is listed twice, but with different references. Maybe these need to be further defined or else combined?

      We have deleted stress response line 163 and moved the references “Deshpande et al, 2022 and Nadal-Ribelles et al, 2015” line 153.

      (2) Line 193: better to say the proteins were fused to the C- or N-terminus (rather than upstream/downstream). It would be worth mentioning if there was a reason why Swd2 was fused to the N-terminus, unlike all the others.

      This has been done accordingly. In our hands, C-terminal fusions of Swd2 are not functional.

      (3) Is the scoring scheme (highest, high, good) that produces the colors in Figure 1 shown in the table? It doesn't say what the tan color (two of the Bre2 interactors) means.

      It is a mistake, Tea1 should be blue and Swi1 should not appear here. This has been fixed.

      (4) Line 206. It's not clear what it means to say that three of the subunits "interact alone with Set1". It can't mean they only interact with Set1, since other interactors are shown in Figure 1B. If it meant to say the interactions don't require other COMPASS subunits? I don't see how you can tell that from the Y2H assay. Please clarify.

      It means that these 3 subunits interact directly with Set1 without the need of another subunit, unlike of the other subunits.

      (5) Line 252. While discussing the Set1 - Snf2 interaction, the paper cites Hirschhorn et al. That paper talks about Swi-Snf, but doesn't mention Set1 anywhere. Maybe the authors meant to cite a different paper?

      We agree, this reference is not appropriated. It has been deleted.

      (6) Figure S2 panels A and C are redundant and could easily be combined.

      Figure S2 has been deleted.

      (7) Figure S4: Should the green category also include transcription? Ssl1 is a TFIIH subunit, which could be involved in either transcription initiation or NER. Sen1 and Nrd1 are transcription termination factors, although Sen1 may also function in R-loop resolution.

      We agree but it is already complicated as it is.

    1. und die Skalierung über einige hundert Bestellungen pro Tag hinaus erfordert oft kostenpflichtige Module aus dem JTL Extension Store.

      can we defend this claim? based on what are we saying this?

    1. truffle recipes that don’t need a hefty price tag but are still just as delicious? Truffle products like sauces and oils are a great way to use truffles as an ingredient without worrying about your credit card charges.

      Truff wants people to be more willing to buy their products since it's cheaper. But, how much truffle really is in their product? Someone should do the math. I'm sure they are still making a bunch of profit off of their product.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1

      Minor comments 1) The authors suggest that the weak 4th protomer in the HCMV UL52 3-mer map is a consequence of flexibility. This may be the case, but it may also be the case that the class is polluted with 4-mer particles leading to reduced occupancy. Erasing the weak density and running a multi-model 3D classification providing the erased 3-mer and a 4-mer starting map may separate these.

      We performed additional analysis (i.e., 3-mer and 4-mer particles were combined into a multi-class ab initio reconstruction followed by multi-class heterogenous refinement) and found that the original 3-mer map was a mixture of 3-mer and 4-mer states.

      We have updated Fig. 2a, Supplementary Fig. 2, Supplementary Fig. 3, Supplementary Table 1, Supplementary Movie 1, and removed the discussion of the weak protomer in the 3-mer map from the results section. We have updated our EMDB and PDB depositions accordingly.

      • 2) I found the supplemental figure to show the DNA in the tripentamer map too small, this is an interesting finding and should be shown more clearly.*

      We have increased the size of Supplementary Fig. 6 and moved the figure caption to another page to accommodate this enlargement.

      Reviewer #2

      *Major issues 1) There is a high probability that the tripentamer is an artifact of the cross-linking. Because of this, it'd be great to know more about the cross-linking reaction, ideally mass spec identification and quantification of cross-links. This would also address the authors' speculation of contacts that stabilize the tripentamer. *

      Crosslinking is a commonly used technique to stabilize complexes that are observed through other means but do not survive the cryo-EM vitrification process. In an EMSA experiment (Supplementary Fig. 4a), UL32 binds 30 bp DNA and migrates slower than when bound to a 10 bp probe, consistent with formation of a supra-pentameric complex. The samples in the EMSA gels are not crosslinked. Additionally, an SDS-PAGE gel of the crosslinked product used for cryo-EM showed tight bands at molecular weights expected for oligomers, supporting specific crosslinking (Supplementary Fig. 4b). These results suggest that crosslinking stabilizes a species that can form but is relatively unstable in solution.

      Moreover, the author's claim "However, mutation of K532A/C535A reduced infectious virion production by half (Fig. 4b), suggesting that the tripentamer interface may play a role in the viral life cycle." Seems to be an overreach. Perhaps this is semantics but the data just show that these residues play a role in viral replication (albeit not a huge role based on the modest effect).

      We have modified the title of the results section (Line 216-217) to state that "Residues at the tripentamer interfaces contribute to infectious virion production in HSV-1" as well as Line 234 and 241 to indicate that the residues play a role in the viral life cycle.

      2) The density for the potential DNA does not look very convincing, although it still remains the strongest hypothesis. The authors should try to strengthen their argument. Does this putative DNA contact residues that they show are necessary for viral replication? Showing seq conservation on the structure could help their argument for the shared function of DNA-binding.

      The DNA likely contacts conserved residues at the base and midsection of the central channel (residues R302, R301, R293, K289, R580, R579, R572; see Fig. 6a). We have shown that these residues are important for the production of infectious virions (Fig. 6c): even a single point mutation (R572A) decreased production of infectious virus particles by more than 90%, and double and triple point mutants (R579A/R580A, K289A/R293A/R301A) eliminated production of infectious virus. Sequence conservation of these charged residues in the central channel regions is shown in Supplementary Fig. 1d, f.

      3) My last major issue is stylistic and concerns the descriptions of cryoEM structures. I found that the paper was a bit of challenge to read when the authors would introduce each structure. It was a bit of a slog to get through. Descriptions of the structures veered off into overly detailed comparisons that required constant comparison with the figure and didn't really advance my understanding past "the outer surfaces of the three orthologs are different." This masked the more interesting aspects of the authors' findings. Perhaps this could be summarized in supplementary figures or a table. Because this is a stylistic suggestion, the authors should feel free to ignore this request.

      We appreciate the reviewer's concerns about accessibility, but we are excited that these structures allowed us to thoroughly describe the convergent and divergent structural features across the Herpesviridae and hope that our in-depth analysis will allow for detailed mechanistic follow-up.

      *Minor comments 1) The descriptions of structure determination in the text were often unclear. For example, "In the 3-mer map, a poorly-resolved fourth protomer is visible at low contour levels, suggesting that an additional protomer is present but highly flexible in this class (Supplementary Fig. 3a)." Alternatively, it could be that the classification algorithm wasn't able to fully separate particles that were 3-mers from the 4mers. *

      The reviewer is correct. As described above (Reviewer #1 comment 1), we performed additional analysis and found that the original 3-mer map was a mixture of 3-mer and 4-mer states. We have updated Fig. 2a, Supplementary Fig. 2, Supplementary Fig. 3, Supplementary Table 1, Supplementary Movie 1, the EMDB and PDB depositions, and removed the discussion of the weak protomer in the 3-mer map from the results section.

      *When describing the structure determination of the HSV1 accessory factor, the authors describe no other particles other than the tripentamer. Were there other particles observed? It'd be a bit surprising that all of the protein adopted the tripentamer state. *

      We agree that this result is striking. We picked particles using a 'blob picker' to avoid introducing template bias and found that the tripentamer is the predominant species. Below we show the results of 2D classification of blob picked particles (classes sorted by particle number; obvious junk classes excluded for clarity). There is one class that suggests a pentamer, but template picking with a pentamer template (based on ORF68) did not yield a pentamer class.

      Additionally, as we describe in the results section and show in Supplementary Fig. 6a, further processing of the consensus UL32 map showed that 60% of particles formed a complete tripentamer (i.e., 15-mer) while other the remaining 40% formed incomplete tripentamers, missing one or more protomers (e.g., 17% of particles formed a 14-mer).

      Was symmetry applied, particularly for the tripentamer that appears to have C-3 symmetry? This is in materials and methods but not clear why it isn't mentioned when describing the structure determination and results.

      No symmetry was applied in the reconstruction for either UL32 or UL52. While we previously noted this in the methods section and in Supplementary Table 1, we have added this information to the results section (Line 169-170), the Fig. 3 legend, and cryo-EM processing figures (Supplementary Figures 2, 5, 6) for clarity.

      2) Throughout the paper, the authors use the word "remodel" to describe structural differences between orthologs. However, this word usually carries the implication of conformational rearrangement within a protein, and not across orthologs. Please consider a different description.

      We agree with the reviewer and have removed the term "remodel" throughout the manuscript text (i.e., Lines 116, 118, 120, 122, 302, 306) and from Supplementary Figures 1, 3, and 5.

      3) Figure 2F is confusing and difficult to interpret. It seems that the main point is that these interfaces are conserved, which might be more easily displayed as a standard sequence conservation score mapped onto the structure. I'm also not sure that this figure is necessary as a main figure and could be supplemental.

      We agree that the conservation could also be shown this way and have added labels to universally conserved residues of the protomer interface to Supplementary Fig. 1b, c. We have also moved Fig. 2f to the supplement (now Supplementary Fig. 2g).

      • 4) The authors write "UL32 bound to the shortest probe tested (10 bp, Supplementary Fig. 4a)." This implies that ONLY the shortest probe is bound and that others are not bound. Consider rephrasing.*

      We have rephrased to clarify at all probes tested, included the shortest, bound DNA (Line 153).

      • 5) Frustum is misspellt. ;)*

      Thank you. Spelling has been corrected (Line 185).

      6) In the discussion, the authors speculate that the variability of the outer surface is due to "virus- or host-specific interactions". I'm confused by "host-specific interactions", because the host is the same for all three viruses. Perhaps the authors mean that the different accessory factors could interact with different host factors? If so, are the authors making a Red Queen argument? If so, it'd be pretty cool to do dN/dS analysis to test that hypothesis.

      The reviewer is correct in that all three viruses (HSV-1, HCMV, KSHV) infect the same host; however, they replicate in different cell types, which could potentially express different host factors. We have no evidence to support this hypothesis and intended to propose that UL32 and UL52 may be interacting/co-evolving with other viral factors required for genome packaging. We have clarified Line 308 to generalize that "these regions are involved in virus-specific interactions".

      To me, this window into evolution of this factor is the biggest advance of the work, and tbh I felt that the authors could lean into this a bit more in the discussion section. Are there any differences in the packaging mechanisms of the different herpes families that can be related to their different behavior? Any other molecular evolution analyses (e.g. dN/dS ratio analysis) that could inform their study?

      We agree that understanding the evolution of the packaging accessory factor is an interesting future area of research. There are differences in capsid structure and occupancy of capsid-associated factors across the herpesvirus family (PMID: 34696343). However, we lack a mechanistic (or structural) understanding of viral genome packaging components across the herpesviruses, raising the possibility that there are differences in packaging mechanisms.

      Interestingly, the further diverged alloherpesviruses and malacoherpesviruses (other families in the order Herpesvirales) do not appear to encode a factor with similar predicted structure to the Herpesviridae packaging accessory factor (PMID: 41902279). It is unclear how the mechanism of packaging differs in the Orthoherpesviridae and whether replication in mammalian/avian/reptilian cells places additional evolutionary pressure on the viral genome packaging mechanism.

      Reviewer #3

      Major comments

      *1) [I]t is not clear whether the structures presented in the manuscript reflect those produced during HCMV or HSV-1 infection. *

      We agree with the reviewer that it is important to consider to what extent purified biomolecules resemble their in vivo counterparts. This criticism can be applied to any ex situ structural analysis. However, our experimental structures allowed us to make testable observations, including the correct assignment of structurally important zinc fingers and the identification of functionally important residues in the central channel.

      2) HCMV UL52 was presented to form two distinct structures, a 3-mer and a 4-mer (Fig. 2a). However, the authors acknowledge that the 3-mer is actually a 4-mer when the threshold for the cryo-EM map is lowered. The density is also visible in the PDB validation report for the 3-mer; EMD-74418.

      Reviewers #1 and #2 were also curious about the 3-mer. As described above, we performed additional analysis that showed that the original 3-mer map was a mixture of 3-mer and 4-mer states. We have updated Fig. 2a, Supplementary Fig. 2, Supplementary Fig. 3, Supplementary Table 1, Supplementary Movie 1, EMDB and PDB depositions, and removed the discussion of the weak protomer in the 3-mer map from the results section.

      *Given that ORF68, BFLF1, and UL32 (Didychuk et al., 2021) form complete pentamer rings, with BFLF1 forming stacked rings, it would seem odd for a protein with conserved function to deviate from a pentamer configuration, suggesting that the structures reported do not reflect the natively produced and functional protein. *

      We agree that this is a surprising finding; we initially anticipated that UL32 and UL52 would also form stable pentameric rings. While this study does not resolve a complete mechanism for this factor, it does provide the first structural evidence for the implications of their poor sequence conservation and lack of complementarity.

      Furthermore, this is not the first example of a conserved herpesvirus factor that possesses different oligomeric states across different subfamily homologs. As mentioned in the discussion, herpesvirus encode a sliding clamp processivity factor (HSV-1 UL42/HCMV UL44/KSHV ORF59) that shares a common PCNA-like fold, but which has varied oligomeric state across these herpesviruses.

      *3) Unlike ORF68 (Didychuk et al., 2021) and UL32 (Suppl. Fig. 4), dsDNA binding experiments were not performed with UL52. Could the partial pentamers simply be poorly formed due to expression in insect cells (mammalian cells were used for protein purification in Didychuk et al., 2021), absence of dsDNA, or inappropriate buffer conditions? Moreover, were the EM grid and vitrification parameters optimized? Grid geometries and chemistries can have profound effects of protein stability especially in the context of the air-water interface, leading to degradation of protein complexes (Glaeser, 2018; D'Imprima et al., 2019). Does UL52 form complexes with dsDNA? Data are shown for the HSV-1 packaging accessory factor. Perhaps dsDNA would stabilize the UL52 pentamer. *

      We have purified ORF68 and homologs from both human and insect cell expression systems, and do not observe changes in oligomeric behavior. We find that ORF68 purified as a stable pentamer from human cells (Didychuk eLife 2021) and from insect cells (this work). We have also recombinantly expressed and purified UL32 from human cells. UL32 was largely monomeric after strep affinity purification (chromatogram below, unpublished), as we report from insect cells (this work, Fig. 1c). We switched to insect cell expression systems because of the easier scalability.

      Our SEC-MALS data (Fig. 1d) shows that purified UL52 does not oligomerize into a pentamer in solution, so the observed sub-pentameric (3-mer/4-mer) assemblies are unlikely to be an artifact of cryo-EM freezing conditions or the air-water interface. We have not tested if UL52 forms complexes with dsDNA, although it likely does; it is possible that this interaction would stabilize a pentamer.

      4) In Didychuk et al., 2021, HSV UL32 is shown to form pentameric rings; negative stained 2D class averages were generated from tagged protein (twin strep tag), produced in mammalian cells (HEK293T), and not purified using size exclusion chromatography. In the present study HSV UL32 was not observed to form pentameric complexes "We first attempted to visualize the pentameric species by negative stain electron microscopy but were unable to identify particles of the expected dimensions." However, it is not clear why this was the case. If the pentameric structures were readily produced in previous experiments, why was cross-linking needed in the current study? As such, the tripentamer complexes seem artifactual in nature.

      While a sufficient number of particles were observed in a pentameric state to do 2D class averages in the eLife paper, this was not the dominant state. The results we report in this work are consistent with those reported in the eLife paper. Reviewer #2 (comment #1) was also concerned about the possibility of a crosslinking artifact: we reproduce our response below:

      "Crosslinking is a commonly used technique to stabilize complexes that are observed through other means but do not survive the cryo-EM vitrification process. In an EMSA experiment (Supplementary Fig. 4a), UL32 binds 30 bp DNA and migrates slower than when bound to a 10 bp probe, consistent with formation of a supra-pentameric complex. The samples in the EMSA gels are not crosslinked. Additionally, an SDS-PAGE gel of the crosslinked product used for EM showed tight bands, supporting specific crosslinking (Supplementary Fig. 4b). These results suggest that crosslinking stabilizes a species that can form but is relatively unstable in solution."

      We have updated Line 148 to clarify this. We have also included a negative stain micrograph, below, in which UL32 pentamers (purified from insect cells) are visible in the absence of crosslinking.

      5) Although the data presented in Fig. 4b suggest that interface residues, K532 and C535, might play a role in the formation of the tripentamer and have a minor role in HSV-1 replication, these experiments are incomplete. Single mutations are needed for each residue to assess their individual contribution to tripentamer formation, evidence for a loss of tripentamer formation is needed, and evidence for protein expression is needed.

      We agree that we have not unambiguously defined the role of the tripentamer, the precise contributions of residues K532 and C535, or defined the contribution of the tripentamer to HSV-1 viral replication. We seek to report this novel structure to lay the basis for future mechanistic work. Reviewer #2 (comment 1) also questioned the role of these residues in HSV-1 replication, and we addressed this by modifying the title of the results section (Line 216) to state that "Residues at the tripentamer interfaces contribute to infectious virion production in HSV-1" as well as Line 246 and 253 to indicate that the residues play a role in the viral life cycle.

      Please refer to Supplementary Fig. 7e for a western blot showing that these mutants do not impact UL32 expression. We included explicit references to UL32 expression on Lines 239 and 288.

      *6) In the previous negative stain electron micrographs reported by Didychuk et al., 2021, were the higher order tripentamer complexes seen? *

      We did not observed tripentamers in the Didychuk et al. 2021 negative dataset. Tripentamer formation may be concentration dependent. Negative stain EM carried out at nanomolar concentrations would likely cause dissociation of tripentamers, but cryo-EM and EMSA in our work were carried out at micromolar concentrations and were able to capture the higher order tripentamer.

      • 7) Formation of disulphide bonds between cysteine residues in vitro is not indicative of complexes forming in vivo during replication. What evidence is there for disulphide bond formation between packaging accessory factor pentamers for KSHV, EBV, and LCMV? In the present study, the disulphide bond could form due to proximity as a result of the cross-linking and the presence of molecular oxygen rather than a bona fide enzyme catalysed reaction during herpesvirus replication to generate packaging accessory factor tripentamers. *

      We agree that it is unlikely that disulfide bonds form during infection and have removed this speculation from the manuscript (Line 343-346).

      8) The DNA densities in Suppl. Fig. 6e to 6g are curious. As noted by the authors, the 30mer dsDNAs do not traverse through the central cavity of the pentamer. They appear to make contact with neighboring pentamers, again suggesting that these complexes are artefacts from cross-linking. This should be discussed more thoroughly.

      Please refer to above discussion of crosslinking and Supplementary Fig. 4.

      9) Previously proposed functional roles for ORF68 include a scaffold for terminase assembly, association of the terminase with the portal, generation of initial free ends, or coordination with other replication machinery (Didychuk et al., 2021). Presuming that the new structures for HCMV UL52 and HSV-1 UL32 occur naturally, how do they fit with the previously proposed functional roles of the herpesvirus packaging accessory factor? A more in-depth discussion of this would be valuable.

      The common core fold and pentamer/pentamer-like assemble are common features, as is the conserved, positively-charged central channel. We have added additional discussion of this.

      *Minor comments A lack of page numbers and line numbers made reviewing this manuscript more challenging than necessary. *

      We have included page numbers and line numbers in the revised manuscript.

      *As noted in the 'General comments' section above, ORF68 (3.37Å) and BFLF1 (3.60Å) both form pentamers (Didychuk et al., 2021) and were produced in mammalian systems HEK293T cells. Protein purification in the present study was performed in insect (SF9 or High Five) cells. Does this affect complex stability. Also, the tag was retained for UL32 in Didychuk et al., 2021; could this provide stability of the pentamer in the original studies? *

      As discussed above, we have no evidence to suggest that expression in human vs. insect cell expression systems dramatically changes oligomerization behavior (Reviewer #3, comment 3). N-terminal purification tags were also retained in this study for structural work but were removed for SEC-MALS, which shows that UL32 is likely in concentration dependent equilibrium between (unstable) pentamers and monomers.

      Suppl. Fig. 3 is missing.

      We apologize for this oversight and have included Supplementary Fig. 3.

      *"UL52 has two regions remodeled" The use of the word 'remodeled' is not appropriate in this context as it implies a single protein can form two shapes under different conditions rather than distinct structures between two disparate proteins; UL52 compared to ORF68. This should be rephrased. *

      This was also noted by reviewer 2, and we have removed the term "remodel" throughout the manuscript text (i.e., Lines 134, 138, 140, 337, 341) and from Supplementary Figures 1, 3, and 5.

      *What is the density in the central core of UL52 (Fig. 2a; Suppl. Fig. 2e)? Was any form of focused classification performed to establish the identity of the density within the central pseudocavity? *

      As noted in the manuscript, this density could be which could be attributed to co-purified protein or nucleic acid, or part of the unresolved, negatively charged loop (residues 82-181) interacting with the positively charged central channel. We have done additional analysis of the central channel density (3D classification with a focus mask) and do not resolve any distinct densities, suggesting that the density is very dynamic.

      *Does UL52 bind to dsDNA? To support the hypothesis that the herpesvirus packaging accessory factor has conserved functions across the three subfamilies dsDNA binding experiments should be performed. *

      We have not done this experiment. We think that demonstrating this finding for two of the three herpesvirus subfamilies is sufficient.

      There is no discussion about how these data relate to the previous functional model for ORF68 presented in Didychuk et al., 2021. Do the new data alter the previous functional models?

      The precise mechanistic contribution of the packaging accessory factor remains unknown, and our data do not delineate between the proposed potential roles described in Didychuk et al. 2021. Importantly, our structural information, demonstration of pentameric ring formation, and significance of the positively charged central channel show that the core function of this factor is likely conserved across the virus family. This was not known before our work.

      *There are some interesting grammatical phrases; please address throughout the manuscript. One example - "...a notable shared aspiration..." Proteins do not have aspirations. Please use a more formal scientific statement. *

      We have updated the language on Line 327.

      *Fig. 4b - Statistical analyses missing. Please provide. *

      Fig. 6c - Statistical analyses are missing. Please provide. Protein folding/expression data missing; see Fig. 5C showing mutations that result in poor protein expression.

      Suppl. Fig. 7f - Statistical analyses absent.

      Statistical analysis of the viral complementation in Figs. 4b and 6c has been included. Note that the viral yields reported in Supplementary Fig. 7f were used to calculate complementation efficiency in Figs. 4b and 6c. Protein expression of mutants shown in Fig. 6c was previously included in Supplementary Fig. 7e and is referenced on Lines 288 and 293.

      *Suppl. Fig. 2 and 5 - FSC curves have oddities, especially in the corrected curves. The cryo-EM resolution estimates calculated by CryoSPARC for the UL52 '3-mer' and 4-mer, and UL32 tripentamer are likely overestimated. In the PDB validation files each of the deposited structures has a warning for the resolution estimate "The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 4.31 differs from the reported value 3.32 by more than 10 %", suggesting that the resolution estimates are inaccurate. The authors should provide a resolution estimate using loose masks and generate FSC curves using another software program such as RELION's postprocess to provide resolution estimates. *

      Thank you for bringing this to our attention. The differences in the resolution estimates are a known issue and are highly influenced by the tightness of the mask. In the revised manuscript we have updated the FSC curves to not include auto-tightened masks and revised our resolution estimates. This slightly changed the resolution to 3.29 Å for both UL52 3-mer and 4-mer and to 3.09 Å for the UL32 consensus map. Please also see the local resolution estimation maps in Supplementary Figures 2e and 5e for an illustration of the range of resolutions in each map.

      Suppl. Fig. 6f and 6g - Is there any visible density that might resemble the EGS crosslinking reagent?

      We do not expect to observe density for EGS due to the long flexible linker (~16 Å) between the two reactive groups.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary.

      The manuscript describes the cryo-EM structures of a conserved, necessary, herpesvirus genome packaging accessory factor for human cytomegalovirus (HCMV), UL52, and herpes simplex virus type-1 (HSV-1), UL32. Herpesvirus packaging accessory factors have unknown function but bind dsDNA. The UL52 and UL32 structures revealed a 5-fold symmetry similar to the previous X-ray crystallography structure for Kaposi's Sarcoma-associated herpesvirus (KSHV) ORF68 and the cryo-EM structure of Epstein-Barr virus (EBV) BFLF1. However, HCMV UL52 was reported to form two structures, a 3-mer and 4-mer whereas, HSV UL32 formed a supercomplex of trimeric pentamers (tripentamer) produced by dsDNA binding and crosslinking. Similar to previous studies with ORF68, mutagenesis of HSV-1 UL32 demonstrated the importance of zinc finger residues C297, C308, C544, and H581 for core fold stability and positively charged residues H563, R572 in the central channel in the pentamer for HSV-1 recovery in virus complementation assays. In addition, mutagenesis of K532 and C535 at the tripentamer interface helix reduced virus complementation by 50%. These findings have significant overlap and similarities to previously published experiments and confirm the properties of ORF68 and BFLF1, demonstrating the conserved nature of the required packaging accessory factor for herpesviruses.

      Major comments.

      The manuscript is generally well written with beautifully presented cryo-EM figures. Unfortunately, the new data seem to muddy the water rather than provide clarification about the role or function of the herpesvirus packaging accessory factor. Furthermore, it is not clear whether the structures presented in the manuscript reflect those produced during HCMV or HSV-1 infection. HCMV UL52 was presented to form two distinct structures, a 3-mer and a 4-mer (Fig. 2a). However, the authors acknowledge that the 3-mer is actually a 4-mer when the threshold for the cryo-EM map is lowered. The density is also visible in the PDB validation report for the 3-mer; EMD-74418. Given that ORF68, BFLF1, and UL32 (Didychuk et al., 2021) form complete pentamer rings, with BFLF1 forming stacked rings, it would seem odd for a protein with conserved function to deviate from a pentamer configuration, suggesting that the structures reported do not reflect the natively produced and functional protein. Unlike ORF68 (Didychuk et al., 2021) and UL32 (Suppl. Fig. 4), dsDNA binding experiments were not performed with UL52. Could the partial pentamers simply be poorly formed due to expression in insect cells (mammalian cells were used for protein purification in Didychuk et al., 2021), absence of dsDNA, or inappropriate buffer conditions? Moreover, were the EM grid and vitrification parameters optimized? Grid geometries and chemistries can have profound effects of protein stability especially in the context of the air-water interface, leading to degradation of protein complexes (Glaeser, 2018; D'Imprima et al., 2019). Does UL52 form complexes with dsDNA? Data are shown for the HSV-1 packaging accessory factor. Perhaps dsDNA would stabilize the UL52 pentamer.

      In Didychuk et al., 2021, HSV UL32 is shown to form pentameric rings; negative stained 2D class averages were generated from tagged protein (twin strep tag), produced in mammalian cells (HEK293T), and not purified using size exclusion chromatography. In the present study HSV UL32 was not observed to form pentameric complexes "We first attempted to visualize the pentameric species by negative stain electron microscopy but were unable to identify particles of the expected dimensions." However, it is not clear why this was the case. If the pentameric structures were readily produced in previous experiments, why was cross-linking needed in the current study? As such, the tripentamer complexes seem artifactual in nature. Although the data presented in Fig. 4b suggest that interface residues, K532 and C535, might play a role in the formation of the tripentamer and have a minor role in HSV-1 replication, these experiments are incomplete. Single mutations are needed for each residue to assess their individual contribution to tripentamer formation, evidence for a loss of tripentamer formation is needed, and evidence for protein expression is needed. In the previous negative stain electron micrographs reported by Didychuk et al., 2021, were the higher order tripentamer complexes seen?

      Formation of disulphide bonds between cysteine residues in vitro is not indicative of complexes forming in vivo during replication. What evidence is there for disulphide bond formation between packaging accessory factor pentamers for KSHV, EBV, and LCMV? In the present study, the disulphide bond could form due to proximity as a result of the cross-linking and the presence of molecular oxygen rather than a bona fide enzyme catalysed reaction during herpesvirus replication to generate packaging accessory factor tripentamers.

      The DNA densities in Suppl. Fig. 6e to 6g are curious. As noted by the authors, the 30mer dsDNAs do not traverse through the central cavity of the pentamer. They appear to make contact with neighboring pentamers, again suggesting that these complexes are artefacts from cross-linking. This should be discussed more thoroughly.

      Previously proposed functional roles for ORF68 include a scaffold for terminase assembly, association of the terminase with the portal, generation of initial free ends, or coordination with other replication machinery (Didychuk et al., 2021). Presuming that the new structures for HCMV UL52 and HSV-1 UL32 occur naturally, how do they fit with the previously proposed functional roles of the herpesvirus packaging accessory factor? A more in-depth discussion of this would be valuable.

      Minor comments.

      A lack of page numbers and line numbers made reviewing this manuscript more challenging than necessary.

      As noted in the 'General comments' section above, ORF68 (3.37Å) and BFLF1 (3.60Å) both form pentamers (Didychuk et al., 2021) and were produced in mammalian systems HEK293T cells. Protein purification in the present study was performed in insect (SF9 or High Five) cells. Does this affect complex stability. Also, the tag was retained for UL32 in Didychuk et al., 2021; could this provide stability of the pentamer in the original studies?

      Suppl. Fig. 3 is missing.

      "UL52 has two regions remodeled" The use of the word 'remodeled' is not appropriate in this context as it implies a single protein can form two shapes under different conditions rather than distinct structures between two disparate proteins; UL52 compared to ORF68. This should be rephrased.

      What is the density in the central core of UL52 (Fig. 2a; Suppl. Fig. 2e)? Was any form of focused classification performed to establish the identity of the density within the central pseudocavity?

      Does UL52 bind to dsDNA? To support the hypothesis that the herpesvirus packaging accessory factor has conserved functions across the three subfamilies dsDNA binding experiments should be performed. There is no discussion about how these data relate to the previous functional model for ORF68 presented in Didychuk et al., 2021. Do the new data alter the previous functional models?

      There are some interesting grammatical phrases; please address throughout the manuscript. One example - "...a notable shared aspiration..." Proteins do not have aspirations. Please use a more formal scientific statement.

      Fig. 4b - Statistical analyses missing. Please provide.

      Fig. 6c - Statistical analyses are missing. Please provide. Protein folding/expression data missing; see Fig. 5C showing mutations that result in poor protein expression.

      Suppl. Fig. 2 and 5 - FSC curves have oddities, especially in the corrected curves. The cryo-EM resolution estimates calculated by CryoSPARC for the UL52 '3-mer' and 4-mer, and UL32 tripentamer are likely overestimated. In the PDB validation files each of the deposited structures has a warning for the resolution estimate "The value from deposited half-maps intersecting FSC 0.143 CUT-OFF 4.31 differs from the reported value 3.32 by more than 10 %", suggesting that the resolution estimates are inaccurate. The authors should provide a resolution estimate using loose masks and generate FSC curves using another software program such as RELION's postprocess to provide resolution estimates.

      Suppl. Fig. 6f and 6g - Is there any visible density that might resemble the EGS crosslinking reagent?

      Suppl. Fig. 7f - Statistical analyses absent.

      References.

      Didychuk AL, Gates SN, Gardner MR, Strong LM, Martin A, Glaunsinger BA. A pentameric protein ring with novel architecture is required for herpesviral packaging. Elife. 2021 Feb 8;10:e62261. doi: 10.7554/eLife.62261. PMID: 33554858; PMCID: PMC7889075.

      D'Imprima E, Floris D, Joppe M, Sánchez R, Grininger M, Kühlbrandt W. Protein denaturation at the air-water interface and how to prevent it. Elife. 2019 Apr 1;8:e42747. doi: 10.7554/eLife.42747. PMID: 30932812; PMCID: PMC6443348.

      Gardner MR, Glaunsinger BA. Kaposi's Sarcoma-Associated Herpesvirus ORF68 Is a DNA Binding Protein Required for Viral Genome Cleavage and Packaging. J Virol. 2018 Jul 31;92(16):e00840-18. doi: 10.1128/JVI.00840-18. PMID: 29875246; PMCID: PMC6069193.

      Glaeser RM. PROTEINS, INTERFACES, AND CRYO-EM GRIDS. Curr Opin Colloid Interface Sci. 2018 Mar;34:1-8. doi: 10.1016/j.cocis.2017.12.009. Epub 2017 Dec 22. PMID: 29867291; PMCID: PMC5983355.

      Significance

      General assessment: The strengths of this manuscript are the structural information provide by the cryo-EM maps for the HCMV UL52 and HSV-1 UL32 and the mutagenesis studies that corroborate previous studies for the packaging accessory factor for gammaherpesviruses KSHV and EBV. However, there are limitations. These are centered on whether the structures are representative of UL52 and UL32 complexes produced during replication rather than over expression in insect cells and stabilization using chemical cross-linking.

      There is a lack of novelty in the context of the herpesvirus packaging factor. The pentameric architecture, DNA binding, zinc fingers (4), and charged residues required for DNA binding were conclusively demonstrated in previous studies (Gardner and Glaunsinger, 2018; Didychuk et al., 2021). Thus, the novelty comes from the different pentameric structures; UL52 4-mer and UL32 tripentamer. However, if these are artefactual structures due to the expression system (mammalian versus insect) used, air-liquid interface induced protein instability, or cross-linking, the novelty is lost. That's not to say the data are not informative for the herpesvirus community.

      Advance: The advance in this manuscript is the new structural information for the UL52 and UL32. Even if the higher order complexes are potential artefacts, high resolution structure information for the subunit is especially informative. The mutagenesis data for UL32 are also informative in that the provide important information about a conserved and necessary protein needed for herpesvirus replication and has the potential to be used as a novel druggable target.

      Audience: The manuscript will appeal to specialized and broad audiences and could influence research into antiviral therapies for herpesviruses. My field of expertise is herpesvirology, structural biology, and cryogenic electron microscopy modalities,

    1. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      In this manuscript, the authors investigate the relationship between genetic codes and their robustness to single-point mutations. They construct ten alternative genetic codes by reassigning nine codons to Leu, Ser, or Ala, and assess mutational robustness using three reporter proteins subjected to error-prone PCR. This represents an interesting experimental approach to addressing the hypothesis that the standard genetic code is optimized for mutational robustness.

      We sincerely thank the reviewer for the positive evaluation of our experimental approach. We are encouraged that the reviewer recognizes the value of constructing multiple non-standard genetic codes in vitro and using them to experimentally examine the relationship between genetic code arrangement and mutational robustness. In the revised manuscript, we have further clarified the scope of our experimental system and the interpretation of the results, particularly emphasizing that our conclusions concern the mutational robustness of individual reporter protein activity measured in an in vitro translation system.

      Major comment:

      While I find the experimental design valuable, I am not fully convinced by the authors' conclusion that "alterations of the genetic code within the ranges explored in this study have no significant effect on mutational robustness". The current analysis is based on the functional output of three individual reporter proteins. Given that cellular systems involve far more complex interactions, it would be more appropriate to limit this conclusion to mutational robustness at the level of individual protein activity, rather than making broader generalizations.

      We thank the reviewer for this important comment. We agree that our original wording was broader than what can be directly supported by the present experiments. Because our analysis is based on the functional outputs of three individual reporter proteins translated in a reconstituted in vitro system, the results do not directly address mutational robustness at the level of the cellular system, protein interaction networks, or organismal fitness.

      Accordingly, we have revised the manuscript to limit our conclusion to the mutational robustness of individual reporter protein activity. In the revised Abstract, Results, and Discussion, we now state that within the experimentally tested range of non-standard genetic codes, we did not detect a dependence of the mutation-induced decrease in reporter protein activity on mutational cost. We have also added a statement in the Discussion noting that cellular systems involve many additional layers, including protein–protein interactions, metabolic networks, quality-control systems, and growth selection, and that whether genetic code arrangement affects robustness at these higher biological levels remains an important question for future work.

      Specifically, we have added this explanation and the new experiment to the revised manuscript as follows.

      Abstract

      “This result provides direct experimental evidence that mutational robustness does not significantly change in individual reporter protein activity when the genetic code is altered within the range of mutational cost tested in this study…”

      Introduction

      “Random mutations decreased reporter protein function at similar levels across all genetic codes examined, implying that alterations of the genetic code within the ranges explored in this study have no significant effect on mutational robustness of individual protein activity.”

      Result

      “Taken together, these results indicate that mutational robustness of individual reporter protein function did not substantially differ among the genetic codes…”

      Discussion

      “…suggesting that mutational robustness of protein activity remained largely unchanged within at least the ranges of mutational cost tested in this study. It should be noted that this conclusion is limited to the activity of individual reporter proteins translated in a reconstituted in vitro system. Therefore, whether similar trends would be observed at the level of cellular fitness or long-term evolution remains an open question.”

      Specific comments

      (1) tRNA modification and expression efficiency (Page 5, line 131)

      The authors attribute the observed inefficiency to the lack of chemical modifications in the tRNAs used. However, gene expression efficiency can also be strongly influenced by DNA sequence design. To better support this claim, it would be helpful to compare luciferase activity when expressed using native E. coli tRNAs. This comparison could clarify whether the observed effects are due to tRNA modification status or other sequence-dependent factors.

      We thank the reviewer for this important suggestion. We agree that the translation efficiency of NanoLuc templates with 21-, 32-, and 46-codons may be affected not only by the chemical modification of tRNAs but also by sequence-dependent factors, such as codon context and mRNA structure.

      To examine this possibility, we performed an additional comparison using native E. coli tRNAs in the tfPURE system. When the NanoLuc templates encoded with 21, 32, or 46 codons were translated using native E. coli tRNAs, the observed luminescence values were 1.2 × 10<sup>10</sup>, 0.78 × 10<sup>10</sup>, and 0.60 × 10<sup>10</sup>, respectively. Thus, the 46-codon NanoLuc template showed lower activity than the 21- and 32-codon templates even with native tRNAs, indicating that sequence-dependent effects indeed contribute to translation efficiency.

      However, the difference among these templates with native E. coli tRNAs was within approximately two-fold. This effect was much smaller than the marked decrease observed when the 46-codon template was translated using the in vitro prepared 46 tRNAs SGC system. Therefore, while sequence-dependent effects cannot be excluded, the inefficient translation in the reconstructed 46 tRNAs SGC is likely to be mainly attributable to the limited functionality of unmodified tRNAs decoding NNA codons.

      We have revised the manuscript to clarify this interpretation and have added the new comparison using native E. coli tRNAs.

      “We also examined whether the lower translation efficiency of the 46-codon NanoLuc template could be explained by sequence-dependent effects, such as codon context or mRNA structure. When the 21-, 32-, and 46-codon NanoLuc templates were translated using native E. coli tRNAs in the tfPURE system (Figure 1–figure supplement 2), the 46-codon template showed lower activity than the 21- and 32-codon templates; however, this difference was within approximately two-fold. Accordingly, we decided to use only the 32 codons used in near-SGC (i.e., excluding NNA codons) in the subsequent construction of non-standard genetic codes.”

      (2) Discrepancy between expression level and activity (Figure S7 vs Figure S8).

      Although GAL expression levels appear similar across different genetic codes (Figure S7), their activities differ substantially (Figure S8), even in the low-mutation library. This discrepancy warrants further investigation. Possible explanations include differences in protein folding efficiency or translational error rates, as mentioned by the authors in the main text.

      To address this, the authors could analyze the protein products using mass spectrometry. If this is not feasible due to low expression levels, alternative approaches such as SDS-PAGE (e.g., with radiolabeling or Western blotting) would still provide valuable information. Additionally, comparing activity after in vitro refolding could help distinguish between folding defects and sequence-level errors. While I understand that the primary aim of this study is to compare mutational robustness across genetic codes, discussing these observations would significantly enhance the mechanistic insight of the work.

      We agree that the discrepancy between similar GAL expression levels and different GAL activities across genetic codes is important for interpreting the results.

      In our experiment, GAL protein amounts were quantified using a C-terminal HiBiT tag. Because the HiBiT tag was fused to the C-terminus of GAL, this assay indicates that the amount of C-terminally completed GAL products did not differ substantially among genetic codes. However, we agree that this assay does not evaluate the sequence fidelity, amino acid misincorporation patterns, or folding state of the translated products. Therefore, the observed differences in GAL activity despite similar HiBiT signals may reflect genetic code-dependent differences in translational error rates, amino acid misincorporation, protein folding efficiency, or other effects on the fraction of catalytically active protein.

      We have revised the Discussion to explicitly describe this interpretation and to clarify that detailed mechanistic dissection of these baseline activity differences, for example by mass spectrometry, SDS-PAGE/Western blotting, or refolding analysis, is an important future direction but beyond the scope of the present study. We also clarified that the main analysis in this study uses the ratio of activity from the high-mutation library to that from the corresponding low-mutation library within each genetic code.

      We have added this explanation to the revised manuscript as follows.

      “Although protein amounts quantified by the HiBiT tag were comparable among genetic codes, GAL activities differed substantially. This indicates that the activity differences among genetic codes were not primarily attributable to differences in the amount of C-terminally completed translation products. The HiBiT assay does not provide information on the fraction of catalytically active protein, including sequence fidelity or folding state, and therefore cannot distinguish among these possibilities. Detailed characterization of translated products by mass spectrometry would provide further mechanistic insight into how individual non-SGCs affect protein quality. However, the primary objective of the present study was to compare mutation-dependent activity loss across genetic codes. Therefore, we evaluated this effect by normalizing the activity of the high-mutation library to that of the corresponding low-mutation library within each genetic code.”

      (3) Protein expression analysis for additional reporters.

      Since protein expression levels are critical for interpreting reporter activity, similar analyses should also be performed for luciferase (Luc) and mSG in both high- and low-mutation libraries. This would ensure that differences in activity are not confounded by variations in protein abundance.

      We agree that protein abundance is an important factor for interpreting reporter activity. In this study, we performed HiBiT-based protein quantification for GAL because GAL showed the largest variation in absolute activity among genetic codes, even in the low-mutation library. This analysis showed that the amount of C-terminally completed GAL products was broadly comparable among genetic codes and between low- and high-mutation libraries, indicating that the observed GAL activity differences were not primarily attributable to differences in total protein abundance.

      For all three reporters, our main analysis was based on the ratio of activity from the high-mutation library to that from the corresponding low-mutation library within each genetic code. This normalization was intended to evaluate mutation-dependent activity loss while reducing the influence of code-specific baseline differences in expression level or protein quality. We believe that the data are sufficient to evaluate the effect of mutations on protein activities. Nevertheless, we agree that protein quantification for Luc and mSG would provide useful information regarding variation in the baseline levels of reporter activity, and this is an important direction for future work.

      Reviewer #2 (Public review):

      Summary:

      The study addresses the long-standing question in molecular biology and genetics: why has nature selected the current genetic code (SGC, or standard genetic code)? The authors have tested 'error minimization theory', one of the prevailing hypotheses to explain this. Their approach is to create a minimum genetic code (MGC) and its variants (3^9 theoretical possible codes). Using three parameters to quantify the effect of mutations (Polarity, volume, and hydropathy), they computationally test the cost of these genetic codes (3^9) by simulations. Finally, they test this cost experimentally using an in vitro translation system with 10 select genetic code variants with a range of costs (low to high). They use three randomly mutated reporter genes for this purpose - beta-galactosidase, luciferase, and mSG. They find no correlation between the cost of the genetic code and the reporters' output. Based on these observations, they suggest that error-minimization theory may not explain the current egocentric code.

      The question they are asking is very exciting, and their approach is solid. The authors are very careful in their analyses and conclusions.

      We sincerely thank the reviewer for the positive assessment of our study and for the helpful suggestions. We are encouraged that the reviewer found the question exciting and the approach solid. In the revised manuscript, we have clarified the rationale for using the MGC/near-SGC framework, added further analyses and explanations of the mutational cost calculations, and revised the wording of our conclusions to more explicitly define the scope and limitations of the present experimental system.

      (1) The rationale for using MGC instead of SGC: It is unclear why the authors rely on the MGC for this analysis when the central question concerns the SGC. If the goal is to evaluate whether the SGC minimizes mutational cost, a more direct approach would be to generate alternative variants of the SGC itself and compare their mutational cost distributions. At present, it is difficult to assess whether conclusions drawn from this comparison are fully relevant to the stated biological question.

      We thank the reviewer for this important comment. We agree that directly constructing alternative variants of the SGC by changing amino acid assignment from SGC would be the most straightforward approach to testing whether the SGC minimizes mutational cost. However, this approach is currently not feasible in our reconstituted translation system for two reasons.

      First, our attempt to construct a 46-tRNA SGC-like system revealed that translation using the 46-codon NanoLuc template was approximately 100-fold less efficient than translation using the MGC or near-SGC (Fig. 1). This low activity likely reflects inefficient decoding of NNA codons by in vitro-prepared tRNAs, which lack native post-transcriptional modifications. Because this system did not provide sufficient translational activity for systematic reporter assays, we restricted subsequent experiments to the 32-codon near-SGC framework, excluding NNA codons. We now describe this technical limitation more explicitly in the revised manuscript.

      Second, the MGC framework provides vacant codons that can be reassigned by adding anticodon-variant tRNAs. This feature is essential for constructing multiple genetic code variants in parallel under controlled in vitro conditions. We, therefore, constructed the near-SGC-based non-SGC by adding each tRNA variant to the MGC as an experimentally tractable model system to verify whether differences in genetic code arrangement affect mutation-induced decreases in reporter protein activity.

      We have added this explanation to the revised manuscript as follows.

      “We first established a minimal genetic code, composed of 21 tRNAs with vacant codons, which allows multiple alternative codon assignments to be introduced under otherwise comparable translation conditions.”

      Despite this technical limitation, we believe that the central conclusion of this study—that mutational robustness in individual reporter protein activity does not change significantly when the genetic code is altered within the range of mutational costs tested here—remains well-supported by the present results.

      (2) The mutational cost analysis appears biologically oversimplified because all amino acid substitutions are treated equivalently. The analysis assumes that all mutations contribute equally to fitness consequences, which does not reflect biological reality. In natural proteins, the impact of an amino acid substitution depends strongly on its structural and functional context. For example, substitutions affecting catalytic residues, ligand-binding interfaces, phosphorylation sites, or other regulatory motifs can severely impair protein function even when associated changes in polarity, hydropathy, or volume are minimal. Conversely, substitutions in structurally permissive or functionally dispensable regions may have little or no measurable effect despite larger physicochemical differences. Therefore, changes in polarity, hydropathy, and volume alone do not necessarily predict functional consequences.

      We agree that the mutational cost used in this study is a simplified measure and does not capture the full biological complexity of amino acid substitutions. As the reviewer pointed out, the functional consequence of a substitution depends strongly on its structural and functional context, including whether the affected residue is involved in catalysis, ligand binding, protein–protein interactions, regulatory motifs, folding, or structurally permissive regions.

      In this study, we used physicochemical-property-based mutational costs because this type of definition has been widely used in classical formulations of the error minimization theory. Our aim was therefore not to construct a comprehensive predictor of protein fitness effects, but to experimentally test whether the conventional theoretical cost metrics used to discuss genetic code optimality are reflected in the average mutation-induced decrease in reporter protein activity. We have now clarified this rationale in the revised manuscript.

      “It should be noted that this conclusion is limited to the activity of individual reporter proteins translated in a reconstituted in vitro system. Therefore, whether similar trends would be observed at the level of cellular fitness or long-term evolution remains an open question.”

      (3) It is not clear why they increased the concentration of the two tRNAs in near-SGC. Have they maintained the same tRNA concentrations in experiments explained in Fig 5 for all 10 genetic codes tested?

      We apologize that the rationale for increasing the concentrations of tRNA<sup>Val</sup><sub>CAC</sub> and tRNA<sup>Arg</sup><sub>CCU</sub> was not sufficiently clear in the original manuscript. As we wrote in the previous manuscript, “To improve translation efficiency with near-SGC, we focused on two tRNA concentrations (tRNA<sup>Val</sup><sub>CAC</sub> and tRNA<sup>Arg</sup><sub>CCU</sub>), which were suggested to have low activities in a previous study (Iwane et al., 2016),” we tested whether increasing their concentrations would improve translation efficiency. As shown in Figure 1–figure supplement 1, NanoLuc activity increased as the concentrations of these two tRNAs were raised and used at 100 ng/µL for tRNA<sup>Val</sup><sub>CAC</sub> and tRNA<sup>Arg</sup><sub>CCU</sub> in the optimized near-SGC, referred to as near-SGC (RV), and in all subsequent experiments. Additional anticodon-variant tRNAs required for each non-SGC were used at optimized concentrations determined from Figure 2–figure supplement 1. For each genetic code, the same tRNA composition and concentrations were used for the low- and high-mutation libraries (See Supplementary Table S7). To clarify this point, we added the sentence, “The increased concentrations of these two tRNAs were used in all the subsequent experiments,” in the corresponding part.

      Reviewer #3 (Public review):

      In this manuscript, Miyachi and Ichihashi investigate whether the arrangement of the genetic code affects mutational robustness. Using an in vitro minimal genetic code with vacant codons, they constructed 10 non-standard genetic codes by reassigning Ala, Ser, and Leu, generating codes with replacement costs that were generally higher than those of the standard genetic code across several amino acid property measures. They then tested how random mutations affected the activity of reporter proteins translated under these altered codes. Although error minimization theory predicts that higher-cost codes should make mutations more harmful, the authors report that protein function declined to a similar extent across all codes examined, suggesting that mutational robustness remains largely unchanged within the range of genetic code alterations tested here.

      Strengths:

      This is an interesting study that investigates one of the most fundamental and intriguing questions in molecular evolution: the emergence of the genetic code, which is nearly universal across nature. The in vitro approach is a powerful aspect of the work and provides an opportunity to examine this phenomenon experimentally at a depth that has previously been inaccessible.

      Weaknesses:

      However, the authors' use of random mutation libraries has certain limitations that prevent the study from realizing its full potential to uncover the mechanisms governing the molecular evolution of the genetic code.

      We sincerely thank the reviewer for the positive evaluation of our study and for recognizing the strength of the in vitro approach. We are encouraged that the reviewer considers this system a powerful way to experimentally address the emergence of the genetic code.

      We also appreciate the reviewer’s constructive comments regarding the limitations of random mutation libraries. We agree that pooled random libraries do not allow us to assign functional effects to individual mutations or to fully uncover the molecular mechanisms underlying mutational robustness. In the revised manuscript, we therefore clarify that our conclusions concern the library-averaged effects of random mutations on individual reporter protein activity, rather than the effects of specific mutations or cellular-level fitness. To address this limitation, we have added explanations of the scope and limitations of the present approach.

      (1) Statistical analyses are missing for several of the manuscript's main claims. This issue applies throughout the paper, including, but not limited to, Figures 1D, 2B, 4B-D, and 5B.

      We thank the reviewer for this important comment. We agree that statistical analyses are necessary to support the major claims of the manuscript. We have therefore added statistical analyses appropriate for the purpose and experimental design of each figure.

      For Fig. 1D, we performed one-way ANOVA followed by Tukey’s post hoc test on NanoLuc activity to compare translation efficiencies among the MGC, near-SGC, near-SGC (RV), and SGC conditions. This analysis showed a significant overall difference among conditions (one-way ANOVA, p < 0.0001). Tukey’s post hoc test showed that near-SGC was significantly lower than MGC, that near-SGC (RV) significantly improved near-SGC translation, and that near-SGC (RV) was not significantly different from MGC. In contrast, the 46-tRNA SGC remained significantly less efficient than near-SGC (RV). We have summarized the major comparisons in Supplementary Table S8.

      For Fig. 2B, we compared NanoLuc activity between the 21-code control and the corresponding 21+1-code condition for each codon reassignment using Welch’s t-test on luminescence. This analysis was added to statistically support whether each anticodon-variant tRNA increased NanoLuc translation from the corresponding reassigned template. The statistical results are summarized in Supplementary Table S9.

      For Fig. 4B–D, we converted mutation rates per base to estimated numbers of mutations per gene and performed Spearman’s rank correlation analysis to evaluate whether reporter activity decreased monotonically with increasing mutational load. This analysis showed strong negative monotonic trends between mutation rate (estimated mutation number) and reporter activity for all three reporters (ρ = −0.90 to −1.00), supporting that the random mutation libraries reduced protein activity in a mutation-load-dependent manner.

      For Fig. 5B, replicate-level data were available for GAL, and we therefore performed two-way ANOVA using genetic code and mutation level as factors. This analysis detected significant main effects of genetic code and mutation level, indicating that GAL activity differed among genetic codes and decreased in the high-mutation library. However, no significant interaction between genetic code and mutation level was detected, indicating that the magnitude of mutation-induced activity reduction was not strongly code-dependent under the conditions examined.

      Finally, because the central claim of Fig. 5C, 5E, and 5G is that mutational cost does not systematically predict mutation-induced activity loss, we performed Spearman’s rank correlation analysis between each mutational cost metric and the high-/low-mutation activity ratio. No significant correlations were detected for any reporter or cost metric (Spearman’s ρ = −0.23 to 0.25), supporting the conclusion that mutational cost did not show a detectable monotonic relationship with mutation-induced activity loss within the tested range.

      We have added these statistical analyses to the revised manuscript. The following sentences were added to the figure legends:

      Fig. 1

      “Statistical comparisons in (D) were performed using one-way ANOVA followed by Tukey’s post hoc test on NanoLuc activity; major comparisons are summarized in Table S8.”

      Fig. 2

      “For each template, NanoLuc activity in the 21-code and corresponding 21+1-code conditions was compared using Welch’s t-test on luminescence. Statistical results are summarized in Table S9.”

      Fig. 4

      “Spearman’s rank correlation coefficients were ρ = −0.90 for GAL, ρ = −1.00 for Luc, and ρ = −1.00 for mSG”

      Fig. 5

      “For GAL activity in (B), two-way ANOVA was performed using genetic code and mutation level as factors. Significant main effects of genetic code and mutation level were detected (both p < 0.0001), whereas their interaction was not significant. For (C), (E), and (G), Spearman’s rank correlation analysis was performed between each mutational cost metric and the high-/low-mutation activity ratio. Statistical details are summarized in Table S10.”

      (2) In Figure 2A, the authors modify the NanoLuc gene by reassigning Ala, Leu, or Ser to new codons and elegantly show that the in vitro availability of the corresponding tRNAs is important for protein function. However, the functional importance of the specific modified positions within NanoLuc is not clear. As a result, it is difficult to determine what the expected consequences of these codon changes should be, which in turn limits the interpretation of the observed changes in protein activity. To improve the interpretability of this experiment, the authors should report exactly how many codons were modified in each variant and, ideally, examine the effect of progressively increasing the number of reassigned codons.

      We agree that the exact positions and numbers of codon replacements should be clearly reported. In the revised manuscript, we have added a list of the modified amino acid positions. In brief, two Ala codons, three Ser codons, or four Leu codons were replaced with the target vacant codon; the modified positions were Ala16 and Ala120, Ser31, Ser49, and Ser150, and Leu32, Leu67, Leu144, and Leu170, respectively.

      We also agree that progressively increasing the number of reassigned codons would provide additional mechanistic insight. However, the purpose of Fig. 2 was to test whether each vacant codon could be decoded by the corresponding anticodon-variant tRNA to produce functional NanoLuc, rather than to analyze the positional contribution of each replacement. We previously performed such progressive codon replacement analysis for one reassigned codon, ACG, in a related study (Miyachi et al., 2025), and the results supported the same qualitative interpretation. Although we did not repeat this progressive analysis for all codons in the present study, we expect that the qualitative interpretation of Fig. 2 would not be substantially changed.

      We have revised the figure text to clarify the scope of the experiment and added the detailed codon replacement information.

      “(A) Schematic illustration of reassignment experiments. Translation with the original MGC and NanoLuc template is shown at the top for comparison. An example of Ala reassignment to the UUG codon is shown at the bottom. In this example, three Ala codons in the NanoLuc sequence were replaced with one type of vacant codon (e.g., UUG), generating a 21 + 1 (UUG-Ala) codon set. Similar reassignment experiments were performed for three amino acids (Ala, Ser, and Leu) and nine vacant codons. Specifically, two Ala codons (Ala16 and Ala120), three Ser codons (Ser31, Ser49, and Ser150), or four Leu codons (Leu32, Leu67, Leu144, and Leu170) were replaced.”

      (3) The calculations presented in Figure 3 raise an interesting conceptual question: why does the near-standard genetic code not exhibit the lowest cost? One possible explanation is that the standard genetic code evolved under multiple competing constraints and is therefore not expected to be optimal for any single cost metric, while still achieving strong overall performance. In this context, it would be informative if the authors combined the three cost measures into a single integrated index and examined whether the near-SGC performs more favorably when all three dimensions are considered together. Such an analysis could add important depth to the study.

      We agree that the near-SGC is not necessarily expected to minimize each individual cost metric, because the standard genetic code may reflect multiple competing physicochemical, translational, biosynthetic, and evolutionary constraints rather than optimization of a single property.

      To address this point, we added an integrated cost analysis combining the three physicochemical cost metrics, Cost<sub>PR</sub>, Cost<sub>MV</sub>, and Cost<sub>HI</sub>. Because these three metrics have different numerical scales, we normalized each metric before integration. We used two types of integrated indices.

      First, for each metric m 𝛜 {PR, MV, HI}, we calculated a min–max normalized cost,

      Where G denotes the set of 19,683 candidate non-SGCs generated by assigning Ala, Ser, or Leu to the nine vacant codon boxes. We then defined the integrated min–max cost as

      Second, we calculated a z-score-normalized cost for each metric,

      Where µ<sub>m,G</sub> and 𝜎<sub>m,G</sub> are the mean and standard deviation of Cost<sub>m<sub>norm</sub></sub> across the candidate non-SGCs. The integrated z-score cost was then defined as

      Using both integrated indices, the near-SGC ranked first when compared with all 19,683 candidate non-SGCs; in other words, no candidate non-SGC showed a lower integrated cost than the near-SGC. The integrated min–max cost of the near-SGC was 0.01525, whereas the lowest value among candidate non-SGCs was 0.12301. Similarly, the integrated z-score cost of the near-SGC was −2.47947, whereas the lowest candidate value was −1.90838.

      We have added this integrated cost analysis as Supplementary Figure 5–figure supplement 7. We have also revised the Discussion to note that the near-SGC does not necessarily minimize every individual physicochemical cost, but performs most favorably when PR, MV, and HI are considered comprehensively. This result is consistent with the idea that the standard genetic code may represent a compromise among multiple constraints rather than optimization of a single physicochemical property.

      “We consider that the cost ranges examined in this study represent substantial fractions, especially for MV and HI. Although the near-SGC did not necessarily exhibit the lowest cost for each individual physicochemical metric, this does not mean that it is unfavorable in the multidimensional cost space. Because the SGC may reflect a balance among multiple physicochemical constraints rather than optimization of a single property, we also calculated integrated cost indices by combining Cost_PR, Cost_MV, and Cost_HI after min–max normalization or z-score normalization. In both integrated indices, the near-SGC showed the lowest overall cost when compared with all 19,683 candidate non-SGCs (Figure 5–figure supplement 7), indicating that no candidate non-SGC exhibited a lower combined cost than the near-SGC when the three physicochemical properties were considered comprehensively.”

      (4) It is difficult to assess the consequences of the random mutations presented in Figure 4 on reporter gene function based solely on the reported "error rate/base" parameter. In particular, the x-axis in Figure 4B should be converted into the estimated number of mutations per gene. This would make the results more intuitive and would allow the reader to better evaluate the expected degree of disruption to protein function.

      We agree that the mutation rate per base alone does not provide an intuitive sense of the expected mutational burden for each reporter gene. We therefore added a second x-axis to Fig. 4B–D showing the estimated number of mutations per gene. This value was calculated by multiplying the mutation rate per base by the coding sequence length of each reporter gene.

      We retained the original mutation rate per base axis to preserve the direct link to the sequencing-based mutation rate measurement, while adding the estimated mutations per gene axis to improve interpretability. We have revised the figure and figure 4 legend accordingly.

      “The lower x-axis indicates the estimated number of mutations per gene, calculated by multiplying the mutation rate per base by the coding sequence length of each reporter gene.”

      (5) A central limitation of the random mutagenesis libraries used in Figure 5, which also underlie one of the manuscript's main claims, is that the exact mutations and their distribution across the reporter genes are not reported. In addition, protein activity is measured only at the level of the entire library, without directly linking individual mutations to their functional consequences. This substantially limits mechanistic interpretation. In my view, this issue can only be addressed convincingly if the authors test a set of defined variants carrying specific mutations and directly evaluate their functional effects.

      (6) Related to the previous point, in Figures 5C, 5E, and 5G, the authors present the ratio between low-mutation-rate and high-mutation-rate libraries. However, because each library contains a different collection of mutations, it is unclear what can be inferred from these comparisons. To overcome this limitation, the authors should assess the effects of altered genetic codes on specific, defined mutations rather than on heterogeneous mutation pools alone.

      (7) Along the same lines, in Figures 5C, 5E, and 5G, it is unclear why the effects of random mutations would be expected to correlate with the three calculated cost metrics, given that the positions, identities, and functional relevance of the mutations within the genes are not known. Without this information, the biological meaning of these correlations remains difficult to evaluate.

      We agree that using pooled random mutation libraries does not allow us to directly link individual mutations to their functional consequences. We also agree that testing defined variants carrying specific mutations would provide a more direct and mechanistic understanding of how each genetic code affects the functional impact of particular amino acid substitutions. However, the purpose of the present study was different from such a defined-variant analysis. Our aim was to experimentally test whether the conventional mutational cost metrics used in error minimization theory predict the average effect of random mutational loads on protein activity. Because these theoretical costs are themselves defined as average expected physicochemical effects over many possible single-nucleotide substitutions, we reasoned that pooled random mutation libraries provide an appropriate first experimental framework to evaluate whether such average-cost metrics are reflected in the average functional output of translated proteins.

      We agree that low- and high-mutation libraries do not contain identical sets of mutations. Therefore, the high-/low-mutation activity ratio should not be interpreted as the effect of the same individual variants before and after additional mutations. Rather, it represents the relative reduction in average activity caused by increasing the mutational burden in a heterogeneous mutation pool under each genetic code. We have revised the text to clarify this interpretation.

      We also agree that the positions, identities, and functional relevance of individual mutations are not resolved in this pooled assay. This limitation prevents us from assigning mechanistic effects to specific substitutions. At the same time, using a small set of defined variants would introduce its own selection bias, because the conclusions could strongly depend on which mutations and which protein positions were chosen. Therefore, we consider the random-library approach to be a useful first step for testing library-averaged effects, whereas systematically defined variant analysis or genotype-resolved activity assays will be necessary to reveal mutation-specific mechanisms in future studies.

      In response to the reviewer’s concern, we have revised the Discussion to explicitly limit our conclusion to library-averaged effects on individual reporter protein activity. We now state that this approach does not identify the functional effects of individual mutations and that future studies using defined variants or high-throughput genotype–phenotype mapping will be required to determine how specific substitutions contribute to genetic code-dependent mutational robustness.

      Result

      “To estimate the average activity reduction associated with increased mutational burden under each genetic code, we calculated the ratio of activity obtained from the high-mutation library to that from the corresponding low-mutation library and plotted this ratio against each of the three mutational costs (Fig. 5C).”

      Discussion

      “A further limitation of this study is that the reporter activities were measured at the level of pooled random mutation libraries. Therefore, the high-/low-mutation activity ratio used in this study should be interpreted as the relative reduction in average activity caused by increasing the mutational burden in a heterogeneous mutation pool, rather than as the effect of identical variants before and after additional mutations. This library-averaged approach was chosen because the mutational costs considered here are also defined as average expected physicochemical effects over many possible single-nucleotide substitutions. In addition, because the non-SGCs constructed in this study were generated by reassigning only Ala, Ser, and Leu, the detectable effects may depend on how frequently mutations involving these amino acids occur in each reporter gene and whether the affected positions are functionally important. If genetic code dependent effects are restricted to a small subset of deleterious variants, such effects may be masked in pooled activity measurements. Future studies using defined variants or high-throughput genotype–phenotype mapping assays will be required to determine the mutation-specific and position-specific mechanisms underlying genetic code dependent effects on protein function (Rozhoňová et al., 2024).”

      (8) For each mutagenesis library, the number of variants, the average number of mutations per variant, and the distribution of mutation positions should be reported clearly and transparently. These details are important for evaluating the strength of the conclusions.

      We agree that a more transparent characterization of the random mutagenesis libraries is necessary for evaluating the strength and limitations of our conclusions.

      In the revised manuscript, we have added the estimated number of mutations per gene to the Results section. This value was calculated by multiplying the mutation rate per base by the coding sequence length of each reporter gene. For the high-mutation libraries used in Fig. 5, the estimated numbers of mutations per gene were approximately 8.0 for GAL, 4.5 for Luc, and 3.3 for mSG. We also added position-wise mutation profiles along each reporter gene (Figure 4–figure supplement 2), in addition to the heatmap shown in the original manuscript. These analyses clarify the mutational burden of each library and show that mutations were broadly distributed across the analyzed regions (approximately 300 nt in the middle of each gene) of the reporter genes.

      Regarding the number of variants, the translation reactions were performed using 5 nM DNA template in a 5 µL reaction, corresponding to approximately 1.5 × 10<sup>10</sup> DNA molecules. However, this value represents the total number of DNA molecules introduced into the reaction and does not directly indicate the number of unique full-length sequence variants, because multiple molecules can share the same genotype, and our sequencing analysis was designed to quantify mutation frequencies and positional distributions rather than to reconstruct full-length genotypes of individual library members. Therefore, we do not infer the exact number of unique variants in each library. Instead, we report the average mutation burden and position-wise non-reference rate distributions.

      We have revised the Results and added Supplementary Figure 4–figure supplement 2 accordingly.

      “For this experiment, two random mutation libraries were used: a low-mutation library prepared using the high-fidelity polymerase and a high-mutation library prepared using Taq DNA polymerase at a Mn<sup>2+</sup> concentration that yields mutation rates of 0.002 – 0.005 per base (0.0026 for GAL, 0.0027 for Luc, and 0.0048 for mSG, corresponding to approximately 8.0, 4.5, and 3.3 mutations per gene). We also plotted position-wise non-reference rates along the analyzed regions of each reporter gene, confirming that mutations were broadly distributed across the amplicons (Figure 4–figure supplement 2).”

      (9) Because only three amino acids were manipulated in the non-standard genetic codes, it remains unclear whether these particular amino acids occupy positions in the reporter proteins that are especially important for function and therefore likely to generate strong phenotypic effects. More broadly, it is not clear whether the assay is sufficiently sensitive to detect the effects of only a subset of deleterious variants within a pooled library. This point should be addressed more explicitly.

      We agree that this is an important limitation of the present study. Because our non-SGCs were constructed by reassigning only Ala, Ser, and Leu, the mutation-dependent effects that can differ among genetic codes are limited to mutations involving these reassigned codons or amino acid substitutions affected by these assignments. Therefore, the sensitivity of the assay depends on how frequently such substitutions occur in the reporter genes and whether the affected Ala, Ser, and Leu-related positions are functionally important.

      We have revised the Discussion to address this point more explicitly. In the revised manuscript, we now state that the absence of a detectable cost-dependent effect may reflect not only the limited cost range examined, but also the limited set of reassigned amino acids, the position-dependent importance of Ala/Ser/Leu residues in the reporter proteins, and the sensitivity limit of pooled activity measurements. We further note that future studies using genotype-resolved activity assays (defined variants) will be required to determine whether specific amino acid substitutions or specific protein positions exhibit stronger genetic code-dependent effects.

      “A further limitation of this study is that the reporter activities were measured at the level of pooled random mutation libraries. Therefore, the high-/low-mutation activity ratio used in this study should be interpreted as the relative reduction in average activity caused by increasing the mutational burden in a heterogeneous mutation pool, rather than as the effect of identical variants before and after additional mutations. This library-averaged approach was chosen because the mutational costs considered here are also defined as average expected physicochemical effects over many possible single-nucleotide substitutions. In addition, because the non-SGCs constructed in this study were generated by reassigning only Ala, Ser, and Leu, the detectable effects may depend on how frequently mutations involving these amino acids occur in each reporter gene and whether the affected positions are functionally important. If genetic code-dependent effects are restricted to a small subset of deleterious variants, such effects may be masked in pooled activity measurements. Future studies using defined variants or high-throughput genotype–phenotype mapping assays will be required to determine the mutation-specific and position-specific mechanisms underlying genetic code-dependent effects on protein function (Rozhoňová et al., 2024).”

      Recommendations for the authors:

      Reviewing Editor Comments:

      While we suggest that you address all the technical points raised by the reviewers, you may specifically want to limit the conclusion of the study to mutational robustness at the level of individual protein activity, rather than making broader generalizations. Also, the statistical analysis needs to be strengthened, as indicated in the reviews.

      We thank the Reviewing Editor for these important suggestions. We agree that the conclusion of the original manuscript was broader than what can be directly supported by the present experiments. In the revised manuscript, we have therefore limited our conclusion to mutational robustness at the level of individual reporter protein activity measured in a reconstituted in vitro translation system. We now explicitly state that our results do not directly address robustness at the level of cellular fitness, protein interaction networks, or long-term evolution.

      We have also strengthened the statistical analyses throughout the manuscript. Specifically, we added one-way ANOVA followed by Tukey’s post hoc test for Fig. 1D, Welch’s t-tests for Fig. 2B, Spearman’s rank correlation analyses for Fig. 4B–D and Fig. 5C/E/G, and two-way ANOVA for GAL activity in Fig. 5B. These analyses have been incorporated into the revised Results, figure legends, and supplementary information.

      Reviewer #2 (Recommendations for the authors):

      (1) Discuss other alternative hypotheses if the error minimization theory is unlikely.

      We thank the reviewer for this helpful suggestion. We think that the absence of a detectable relationship between mutational cost and reporter protein activity in our assay should not be interpreted as excluding all possible roles of error minimization in the evolution of the genetic code. Our results specifically address one aspect of the error minimization theory: whether physicochemical-property-based mutational cost predicts the average effect of random point mutations on individual reporter protein activity within the experimentally accessible range of non-SGCs tested here.

      In the revised Discussion, we have clarified that the organization of the SGC may have been shaped by multiple factors, including robustness to translational errors, historical constraints associated with genetic code expansion, biosynthetic or coevolutionary processes, stereochemical interactions, and the evolvability of proteins. Our results suggest that the contribution of mutational robustness at the level of individual protein activity may be limited within the range examined here, but they do not exclude the possibility that the SGC provides advantages under other forms of error, at the level of translation fidelity, cellular fitness, or long-term evolution.

      We have added a short discussion to clarify this point without expanding the scope of the manuscript beyond the present experimental results.

      “It should be noted that this conclusion is limited to the activity of individual reporter proteins translated in a reconstituted in vitro system. Therefore, whether similar trends would be observed at the level of cellular fitness or long-term evolution remains an open question. Moreover, our results do not exclude other possible roles of SGC organization. The SGC may have been shaped by multiple factors, including robustness to translational errors, historical constraints during genetic code expansion, biosynthetic or coevolutionary relationships among amino acids, stereochemical interactions, and effects on protein evolvability (Katoh and Suga, 2023; Koonin and Novozhilov, 2017, 2009; Novozhilov et al., 2007; Wong, 2005).”

      (2) A brief description of the PURE translation system can be provided for people from outside the field.

      We have added a brief description of the PURE system in the Introduction to make the experimental platform more accessible to readers outside the field. Specifically, we now explain that the PURE system is a reconstituted cell-free translation system composed of purified translation factors, ribosomes, aminoacyl-tRNA synthetases, tRNAs, amino acids, and energy-regeneration components. We also clarify that, in this study, we used a tRNA-free version of the PURE system, in which defined synthetic tRNA sets were supplied externally to reconstruct each genetic code.

      Introduction

      “A representative platform for such reconstitution is the PURE system (Shimizu et al., 2001), a reconstituted cell-free translation system composed of purified translation components, including ribosomes, translation factors, aaRSs, amino acids, and energy-regeneration components. In particular, a tRNA-free PURE system (Miyachi et al., 2022), in which endogenous tRNA activity is minimized and defined tRNA sets are supplied externally, enables genetic codes to be reconstructed by controlling the supplied tRNAs.”

      (3) Figure 5D and F - Technical replicates are provided only for GAL. A similar approach should be taken for LUC and mSG.

      We agree that replicate-level measurements for Luc and mSG would further improve reliability. However, repeating the full translation experiments for these reporters was not feasible in the current revision, as each experiment requires large amounts of freshly prepared tRNA-free PURE system and multiple defined tRNA mixtures for every genetic code variant tested. Given these material and technical constraints, we were unable to perform additional biological replicates within the scope of this revision. We would like to emphasize, however, that the GAL replicates shown in Fig. 5D and F are fully consistent across independent experiments, providing direct evidence for the reproducibility of the assay itself. Furthermore, the key metric in our analysis, the activity ratio between high- and low-mutation groups within each genetic code, is an internally normalized measure that is inherently less sensitive to between-experiment variability than absolute activity values. The correlation analyses further showed no significant relationship between mutational cost and this ratio across all three reporters, and this conclusion is consistent regardless of which reporter is examined. Together, we believe these results provide a robust basis for the conclusions drawn, even in the absence of full replication for Luc and mSG.

      (4) Provide statistical analysis wherever it is relevant (e.g, to support a lack of correlation).

      We have strengthened the statistical analyses throughout the revised manuscript. In particular, to support the lack of detectable correlation between mutational cost and mutation-induced activity loss, we performed Spearman’s rank correlation analyses between each mutational cost metric and the high-/low-mutation activity ratio for all three reporters. No significant correlations were detected for any reporter or cost metric. In addition, we added statistical analyses for other relevant figures, including one-way ANOVA followed by Tukey’s post hoc test for Fig. 1D, Welch’s t-tests for Fig. 2B, Spearman’s rank correlation analyses for Fig. 4B–D, and two-way ANOVA for GAL activity in Fig. 5B.

      Reviewer #3 (Recommendations for the authors):

      (1) In line 122, the phrase "as evenly as possible" is ambiguous and should be explained more precisely.

      We thank the reviewer for pointing this out. We have revised the phrase “as evenly as possible” to describe the codon design more precisely. Specifically, we now state that the NanoLuc coding sequences were designed so that the codons available in each genetic code were used with minimal differences in codon counts, while preserving the amino acid sequence of NanoLuc.

      “For near-SGC and SGC, the NanoLuc coding sequences were designed so that the codons available in each genetic code were used with minimal differences in codon counts, while preserving the amino acid sequence (Fig. 1B, 32 codons and 46 codons).”

      (2) For Figure 1D, a Western blot or another protein gel-based assay would be helpful to exclude the possibility that the observed differences arise from variation in translation efficiency rather than differences in protein activity.

      We agree that a protein gel-based assay such as Western blotting would in principle allow us to distinguish differences in translated protein amount from differences in specific activity, and we understand why such data would be informative. However, we would like to clarify that the primary purpose of Fig. 1D was to evaluate the overall functional translation output of each reconstructed genetic code, rather than to determine the mechanistic basis of any observed differences. In this context, NanoLuc luminescence serves as an integrated readout of the entire translation process, encompassing both translational efficiency and protein folding/activity. Crucially, regardless of whether the observed differences in NanoLuc luminescence reflect lower protein yield, reduced specific activity, or a combination of both, the conclusion of Fig. 1D remains the same. Although we did not perform Western blotting in this study, we believe that such an analysis would not change this interpretation and that the current data are sufficient to support this conclusion.

      (3) The number 3^9 is not immediately intuitive. It would be helpful if the authors also stated that this corresponds to approximately 20,000 possible non-standard genetic codes.

      We have revised the text to state both the exact number and the approximate value: 3<sup>9</sup> = 19,683, approximately 20,000 possible non-standard genetic codes.

      (4) The rationale for using the three cost parameters (PR, MV, and HI) should be explained in greater detail. Because these parameters are central to the manuscript, a citation alone is not sufficient. A concise explanation of their biological relevance would improve the clarity and accessibility of the study.

      We agree that the biological relevance of the three cost parameters should be explained more clearly. In the revised manuscript, we have added a concise explanation of why polar requirement (PR), molecular volume (MV), and hydropathy index (HI) were used.

      These parameters were selected because they have been widely used in theoretical studies of genetic code optimality and represent distinct physicochemical aspects of amino acid substitutions. PR reflects polarity-related interactions and has been a classical metric in error minimization analyses of the genetic code. MV represents side-chain size and steric volume, which could influence packing and structural stability in proteins. HI reflects hydrophobicity, which is closely related to protein folding and hydrophobic core formation. We have also clarified that these metrics are simplified descriptors and do not capture residue-specific structural or functional context, which we now discuss as a limitation of the study.

      “PR reflects polarity-related interactions of amino acids and has been used as a classical measure of amino acid similarity in error minimization analyses. MV represents side-chain size and steric volume, which could affect protein packing and structural stability, whereas HI reflects hydrophobicity, which could be closely related to protein folding or hydrophobic core formation.”

      (5) In Figure 3, the experimental framework would be easier to follow if the authors included a schematic and data for one representative non-SGC, explicitly illustrating how it differs from the near-SGC with respect to each of the three cost measures.

      We agree that showing one representative non-SGC would make the experimental framework and cost calculation more intuitive.

      In the revised manuscript, we added a new panel to Fig. 3 comparing the near-SGC with a representative non-SGC. We selected the PR<sub>max</sub> code as the representative example because it clearly illustrates how reassignment of vacant codon boxes can increase one mutational cost metric relative to the near-SGC. In this panel, we first show the codon assignment schemes of the near-SGC and PR<sub>max</sub> code in the same genetic-code format used in Fig. 1. We then show the corresponding heatmap representations for the three physicochemical properties used in the cost calculation: polar requirement, molecular volume, and hydropathy index. The Cost<sub>PR</sub>, Cost<sub>MV</sub>, and Cost<sub>HI</sub> values are shown for each code.

      This new panel illustrates how changes in codon assignment are translated into different physicochemical cost landscapes and clarifies how the representative non-SGC differs from the near-SGC with respect to each of the three cost measures.

      “To make the design of non-SGCs more explicit, we show one representative non-SGC together with the near-SGC in Fig. 3B. This comparison illustrates how assignment of Ala, Ser, or Leu to the vacant codon boxes changes the three mutational cost metrics, Cost<sub>PR</sub>, Cost<sub>MV</sub>, and Cost<sub>HI</sub>.”

      (6) In line 329, the phrase "similar pattern" is ambiguous and should be explained more explicitly.

      We have revised the ambiguous phrase “similar pattern” to describe the observation more explicitly. Specifically, we now state that the relative differences in GAL activity among genetic codes observed in the low-mutation library were broadly retained in the high-mutation library, although overall activity decreased.

      “For the high-mutation library, GAL activity decreased overall, while the relative differences in activity among genetic codes observed in the low-mutation library were broadly retained.”

      (7) Figure S7 appears to be an important control for the experiments shown in Figure 5, and I recommend moving it to the main figures.

      We thank the reviewer for this helpful suggestion. We agree that the HiBiT-based quantification of GAL protein amount is an important control for interpreting the GAL activity measurements in Fig. 5, and we appreciate the recommendation to increase its visibility. This analysis shows that the amount of C-terminally completed GAL products was broadly comparable among genetic codes, indicating that the large differences in GAL activity were not primarily attributable to differences in total translated protein amount.

      After careful consideration, we have opted to retain this analysis in the supplementary figures because the main focus of Fig. 5 is the relationship between mutational cost and mutation-induced activity loss, quantified by the high-/low-mutation activity ratio. The HiBiT experiment addresses a related but distinct question: whether differences in absolute GAL activity among genetic codes can be explained by differences in protein abundance, and we felt that including it in the main figures might shift the emphasis away from the central message of Fig. 5. Nevertheless, we have added a clear reference to Figure 4–figure supplement 1 in the main text and the figure legend to ensure that readers are directed to this control when interpreting Fig. 5.

    1. Author response:

      Public Reviews:

      Reviewer #1 (Public review):

      This manuscript presents a tunable Bessel-beam two-photon fluorescence microscopy (tBessel-TPFM) platform that enables high-speed volumetric imaging with stable axial focus. The work is technically strong and broadly significant, as it substantially improves the flexibility and practicality of Bessel-beam-based two-photon microscopy. The demonstrations are generally strong and bridge a wide range of neuroimaging applications, namely vascular dynamics, neurovascular coupling, optogenetic perturbation, and microglial responses. These convincingly show that the approach enables biological measurements that are difficult or impractical with existing methods.

      The evidence supporting the technical and biological claims is generally strong. The optical design is carefully motivated, clearly described, and validated through a combination of simulations and experimental characterization. The biological applications are diverse and well chosen to highlight the strengths of the proposed method, and the data are of high quality, with appropriate controls and comparative measurements where relevant.

      Strengths:

      (1) The optical innovation addresses a well-recognized limitation of existing Bessel-TPFM implementations, namely axial focus drift during tuning, and does so using a relatively simple, light-efficient, and cost-effective design.

      (2) The manuscript provides convincing experimental evidence for this being a versatile platform to map flow dynamics across diverse vessel sizes and orientations in both healthy and pathological states.

      (3) Biological demonstrations are comprehensive and span multiple domains such as hemodynamics, neurovascular coupling, and neuroimmune responses.

      (4) Quantitative analyses of blood flow across vessel sizes and orientations, including kilohertz line scanning, are particularly compelling and clearly beyond the reach of standard Gaussian TPFM.

      (5) Particular advantages are that higher blood slow speeds become measurable up to 23mm/sec (20x more than conventional frame scanning), and that simultaneous (Bessel-)imaging and (Gaussian-)perturbation are possible because of the stable axial focus.

      We thank the reviewer for this thoughtful and encouraging evaluation of our work. We are particularly grateful for the recognition of both the technical rigor and the broad applicability of the tBessel-TPFM platform, as well as the assessment that our approach enables biological measurements that are difficult or impractical with existing methods. We appreciate the reviewer’s detailed summary of the strengths of the manuscript, including the identification of axial focus drift as a major limitation in prior Bessel-TPFM implementations, and the value of our center-stable, light-efficient, and accessible solution. We thank the reviewer for the encouraging comment that our biological demonstrations to be compelling and well supported by quantitative analysis.

      Weaknesses:

      (1) At present, the paper does not properly position the new Bessel-beam method against previous work, and fails to compare it to alternative fast volumetric imaging methods without Bessel beams.

      We thank the reviewer for this important point. We agree that a more explicit comparison with existing fast volumetric imaging methods helps clarify the unique advantages of our system. Alternative fast volumetric imaging methods without Bessel beams include remote focusing (Sofroniew et al., 2016), acousto-optic deflectors (AOD) (Villette et al., 2019), piezoelectric objective stages (Göbel and Helmchen, 2007), tunable acoustic gradient lenses (TAG lens) (Huang et al., 2019), electrically tunable lenses (ETLs) (Grewe et al., 2011; Yang et al., 2018), and light beads microscopy (Demas et al., 2021). These methods have each enabled important forms of rapid volumetric imaging, but they differ in their speed, resolution, axial range, and optical complexity. For example, remote focusing can provide rapid axial refocusing while preserving high-resolution imaging but has limited defocus range and requires a carefully aligned relay system and aberration control to maintain image quality. AOD-based approaches enable fast random-access sampling, but introduce optical and calibration complexity associated with dispersion, and suffer light loss with limited diffractive efficiency. Piezoelectric objective scanning is comparatively simple and broadly accessible, but its mechanical inertia limits volume rate and can introduce artifacts during rapid or large axial motion. TAG lenses and ETLs provide compact non-mechanical axial scanning, but pose challenges on aberration control and synchronization. Light-beads microscopy achieves high volumetric throughput by near-simultaneously sampling multiple axial positions, but faces intrinsic compromise among axial coverage, number of sampling planes, and lateral sampling density, which limit lateral resolution when imaging over large depth ranges.        

      Previous Bessel-beam TPFM approaches address some of these limitations by converting volumetric imaging into two-dimensional scanning with an axially extended focus. However, many existing implementations either rely on a fixed Bessel beam profile, which limits the ability to adapt spatial resolution and axial coverage to different biological applications, or use spatial light modulators, which provide tunability but introduce higher cost, increased optical complexity, reduced light efficiency, and sequential rather than simultaneous multi-wavelength operation. Other axicon or lens based tunable Bessel approaches have also been reported, but these designs generally introduce axial displacement of the Bessel focus during tuning.

      In contrast, our tBessel-TPFM design provides full tunability comparable with SLM based methods, maintaining a stable axial beam center, at the same time low cost, easy to implement, intrinsically high light efficiency and support simultaneous multi-color imaging. Therefore, tBessel-TPFM provides a unique solution for applications where axial projection is acceptable and where high-speed volumetric monitoring, tunable axial coverage, motion robustness, optical simplicity, and compatibility with simultaneous perturbation are valuable.

      (2) The cost-effectiveness of the proposed method is not well described or supported by evidence; it would be useful to include more detail or remove this claim.

      We thank the reviewer for requesting clarification and supporting evidence regarding the cost-effectiveness of our method. We now provide a detailed cost breakdown of the tBessel module. Briefly, the module consists of three axicons, three lenses, and one iris that together enable independent control of the NA and ΔNA of the generated Bessel beam. Based on the specified components, the three axicons (AX252B and AX255B, Thorlabs) cost $635 each, the three lenses (AC254-125-B×2 and AC254-150-B, Thorlabs) cost $110 each, and the iris (SM2D25D, Thorlabs) costs $105, resulting in a total system cost of approximately $2,340. For comparison, spatial light modulator (SLM)-based implementations that offer comparable tunability typically require an SLM module costing on the order of $20,000 USD, in addition to more complex optical alignment and reduced optical efficiency.

      (3) Some biological conclusions, e.g., regarding novel features of microglial dynamics (i.e., the observed two-wave responses and coordinated extension-retraction), are based on relatively limited sample size and would benefit from clearer discussion of variability across animals and fields of view.

      We thank the reviewer for this important comment regarding the limited sample size of the microglial dynamics study. We agree that a more comprehensive assessment across animals would be required to establish the generality of these biological findings. In the current study, our intent is not to draw broad biological conclusions, but rather to report observations enabled by the tBessel-TPFM platform. As noted in the manuscript, we have deliberately used descriptive language (e.g., “two distinct waves of process extension were observed” “process dynamics revealed…” and “advancing processes displayed…”) to avoid over claim of the biological findings beyond the data presented.

      (4) The use of neural network-based denoising for microglial imaging is reasonable but introduces potential concerns about trustworthiness; additional clarification of validation or failure modes would strengthen confidence in these results.

      We thank the reviewer for raising this important point regarding the reliability of neural network-based denoising. We agree that additional validation and discussion of potential failure modes are essential to build confidence in these results. To assess the fidelity of the CARE-denoised data, we performed several additional analyses (Author response image 1). First, we compared normalized raw and denoised images averaged over 10 frames. The difference between the two images was spatially uniform and primarily reflected residual noise present in the raw data, rather than structured discrepancies (Author response image 1a). As expected, brighter features like microglial somata exhibited smaller differences due to their intrinsically higher signal-to-noise ratio, whereas weaker processes showed larger noise-related differences. Second, we extended this comparison across the full time-lapse sequence by applying consistent color mapping to both raw and denoised videos and computing frame-by-frame difference maps. These analyses show that the observed differences are consistent with noise suppression, without introducing coherent structural features or altering the apparent microglial dynamics (Author response image 1b).

      Author response image 1.

      Validation of CARE-based denoising for microglial imaging. (a) Comparison of 10-frame averaged normalized raw (left), CARE-denoised (middle), and their pixel-wise difference (right) images. The second row shows a zoomed-in view of the boxed region. (b) Color-coded time-lapse projections over a 10-minutes imaging session for the raw (left) and CARE-denoised (middle) data, along with their pixel-wise difference (right).

      To conclude, most of the authors' claims are well supported by the data. The central conclusion, namely that tBessel-TPFM provides tunable volumetric imaging enabling experiments not feasible with existing two-photon approaches, is justified. Some biological interpretations would benefit from a more cautious framing, but they do not undermine the main technical and methodological contributions of the study. This is a strong and technically rigorous manuscript that makes a substantial methodological advance with clear relevance to neuroscience and intravital imaging. Minor clarifications and a slightly more measured discussion of certain biological findings are recommended.

      We thank the reviewer for this thoughtful and encouraging summary of our work. We greatly appreciate the recognition that tBessel-TPFM provides a meaningful methodological advance and enables volumetric imaging experiments that are difficult or impractical with existing two-photon approaches.

      Reviewer #2 (Public review):

      The authors describe a tunable Bessel beam two-photon microscope (tBessel-TPFM) designed to overcome a common limitation of Bessel-based volumetric imaging: axial shifts of the effective focus during Bessel beam parameter tuning. Their optical design allows independent control of axial beam length and resolution while keeping the axial center fixed. This is extensively validated through simulations and experiments.<br /> Strengths:

      A major strength of the work is the breadth of validation combined with the level of technical detail provided. The authors carefully characterize the optical performance of the system and clearly explain the design choices and underlying derivations, which will make it easier for others to understand and implement. The authors demonstrate the utility of the method across several in vivo applications, including neurovascular imaging, blood flow measurements, optogenetic stimulation, and microglial dynamics.

      We thank the reviewer for their thoughtful and encouraging comments. We greatly appreciate the recognition of the technical rigor, breadth of validation, and clarity of explanation presented in our work.

      Weaknesses:

      In the in vivo demonstrations, the authors employ different Bessel beam configurations across experiments, but the beam parameters are not dynamically tuned during live imaging. A video example showing continuous or interactive tuning of the Bessel beam within a single in vivo imaging sequence would further highlight the practical advantages of this platform and strengthen the case for its potential applications.

      We thank the reviewer for their suggestion. While we agree that continuous or interactive tuning of the Bessel beam during imaging would further highlight the practical flexibility of the platform, and changing the Bessel beam parameters during imaging session is feasible in our tBessel-TPFM implementation, for the in vivo applications presented in this manuscript, dynamic tuning during the actual recording is generally not required. In practice, the Bessel beam parameters are selected before data acquisition based on the biological target, desired axial coverage, spatial resolution, and acceptable level of projection overlap.

      In addition, while excitation powers are reported, the manuscript does not place these values in the broader context of known photodamage thresholds for two-photon microscopy, which would be helpful to the readers.

      We thank the reviewer for bringing up this important point. It is known that multiphoton imaging relies on relatively high illumination power, which causes brain heating and thus photodamage. Previous studies have reported that continuous illumination with a 920-nm laser beam at 0.8 NA over 1000s results in a peak temperature increase of ~1.73 °C/100 mW in the brain, with power above 300 mW observed to cause cellular damage. Power levels below 250 mW were considered to be safe for long-term imaging. (Podgorski and Ranganathan, 2016) In our experiments, the measured post-objective powers range from 20 mW to 149 mW, which are well below the established safe threshold.

      Denoising/image restoration are applied in one of the in vivo examples, but it is unclear why this step was used specifically for this dataset and whether it was necessary to achieve adequate SNR or primarily included as an additional demonstration.

      We thank the reviewer for requesting clarification on the usage of the CARE denoising model. The CARE-based denoising was applied only in Figure 5, the microglial imaging example, and was primarily included as an additional demonstration of how neural network–based image restoration can be used to enhance low-SNR volumetric datasets acquired with tBessel-TPFM. All other images and analyses in the manuscript were performed on raw data without any denoising. To assess the reliability of the CARE denoising method, we further compared raw and denoised data using 10-frame averages and color-mapped the full 10-minute time-lapse video, both showed minimal differences (Response Fig 1). These analyses confirm that the CARE denoising model did not introduce structural artifacts or affect the biological dynamics observations in our dataset.

      Reviewer #3 (Public review):

      The manuscript presents an elegant and cost-effective approach for generating a tunable Bessel beam on a conventional two-photon microscope. The authors assemble a compact optical module comprising three axicons and a series of lenses that permits rapid adjustment of both lateral resolution and axial extent without modifying the focal plane. This flexibility enables the system to be readily adapted to a variety of biological preparations. As a proof of concept, the authors employ the device to record blood flow velocities in cortical microcapillaries, arterioles, and venules, thereby directly visualizing vasodilatation and vasoconstriction dynamics and permitting quantitative analysis of neurovascular coupling across cortical layers in awake mice.

      The authors demonstrate that the tunability of the Bessel beam can be exploited to match the numerical aperture to the vessel type: a high NA configuration, albeit slower scan, is optimal for resolving flow in capillaries, whereas a low NA setting provides faster acquisition suitable for arterioles and venules. By implementing a one-dimensional line scan with the Bessel beam, they achieve an imaging speed that is twentyfold faster than conventional frame-by-frame scanning, which proves sufficient to capture hemodynamic transients before and after an induced ischemic stroke.

      In addition to pure observation, the authors integrate a co-propagating Gaussian line to the system, allowing simultaneous imaging and photostimulation within the same focal plane. This capability addresses a common limitation of other Bessel beam implementations, in which the observation and perturbation planes often become misaligned when the Bessel beam is altered. The manuscript also emphasizes the advantage of Bessel beam excitation for calcium imaging after a perturbation, because it captures neuronal activity in planes both above and below the nominal focal plane, signals that would be missed with a standard Gaussian focus. Finally, the authors apply the technique to investigate the neuroimmune response following targeted microglial ablation; they report that adjacent microglia extend processes toward the injury site while retracting processes in the opposite direction.

      Overall, the work offers a technically straightforward yet powerful extension to existing two-photon platforms, providing high-speed, volumetric imaging and stimulation capabilities that are well-suited to a broad range of neurovascular and neuroimmune studies. The experimental validation is quite thorough, and the presented data convincingly illustrates the benefits of the approach.

      Strengths:

      The authors present a truly clever and inexpensive optical module that can be integrated into almost any two-photon microscope, providing a tunable Bessel beam with a minimal modification of the existing system. The experimental data and accompanying quantitative analysis convincingly demonstrate that the system can reveal physiological events, such as capillary flow, calcium transients across multiple axial planes, and microglial process dynamics, that are difficult or impossible to capture with a conventional Gaussian beam. The breadth of experiments chosen for the manuscript illustrates the practical utility of the device and supports the authors' conclusions that it extends the functional repertoire of standard two-photon microscopy.

      We sincerely thank the reviewer for the thoughtful and encouraging feedback. We're glad that the technical design and broad applicability of the tBessel module came through clearly, and we appreciate the recognition of its ease of integration and ability to capture dynamic physiological processes.

      Weaknesses:

      The manuscript would benefit from a more detailed contextualisation of the claimed speed advantage. Although the authors mention other techniques in the introduction, they do not provide any direct comparison with other state-of-the-art high-speed two-photon approaches such as light beads microscopy (Demas et al., Nat. Methods 2021), temporal multiplexing schemes (Weisenburger et al., Cell 2019), or random access microscopy (Villette et al., Cell 2019). A brief comparison of imaging speed, spatial resolution, and instrumental complexity would enable readers to assess the relative merits of the present method.

      We thank the reviewer for this important suggestion. We agree that a more explicit comparison with other high-speed two-photon imaging methods helps clarify the speed advantages of our system. Several existing approaches, including light-beads microscopy (LBM), temporal multiplexing, and AOD-based random-access microscopy, have demonstrated impressive high-speed volumetric imaging capabilities. Light-beads microscopy (Demas et al., 2021) reported imaging over a large volume of 5.4 × 6 × 0.5 mm<sup>3</sup> at 2 Hz. However, this large-volume acquisition used 5-μm lateral pixel sampling, corresponding to an effective lateral resolution of approximately 10 μm. In a more comparable mesoscopic volume, LBM imaged 0.6 × 0.6 × 0.5 mm<sup>3</sup> at 9.6 Hz with 1-μm lateral pixel sampling. In addition, the LBM module uses off-axis reflective concave mirrors, which require careful alignment, and the axial sampling range is not readily tunable. Temporal multiplexing approaches (Weisenburger et al., 2019), reported imaging over approximately 1 × 1 × 0.6 mm<sup>3</sup> at 17 Hz. However, this volume rate was achieved with relatively coarse spatial resolution of approximately 5 μm, together with a more complex optical design involving multiplexed excitation, detection, and synchronization. AOD-based random-access microscopy (Nadella et al., 2016; Villette et al., 2019) provides very fast point or region sampling, and reported 250 × 250 μm<sup>2</sup> imaging with 512 × 512 pixels and a 50-ns pixel dwell time, corresponding to ~0.5-μm pixel sampling and ~76 frames/s for two-dimensional imaging. However, volumetric imaging requires additional axial sampling, which lowers the effective 3D acquisition rate. In addition, AOD-based systems rely on diffractive beam steering, which introduces light loss due to finite diffraction efficiency and increases optical and calibration complexity. In comparison, tBessel-TPFM imaged a 0.4 × 0.4 × 0.12 mm<sup>3</sup> volume at 58 Hz with 0.2-μm lateral pixel sampling. Our largest demonstrated imaging volume reached 2.5 × 2.5 × 0.45 mm<sup>3</sup> while maintaining diffraction-limited lateral resolution. Therefore, compared with these high-speed volumetric approaches, tBessel-TPFM provides a distinct balance of volume rate and spatial sampling, and easier implementation simplicity.

      A second limitation that warrants discussion is the inherent trade off between volumetric coverage and image specificity. Because the Bessel beam excites fluorescence throughout an extended axial range, the detector inevitably integrates signal from a three dimensional volume into a two dimensional image. In densely labelled tissue, this can lead to significant signal crosstalk, reducing contrast and complicating quantitative interpretation. A brief analysis of how labeling density affects the fidelity of flow or calcium measurements, or suggestions for mitigating crosstalk (e.g., computational deconvolution, adaptive excitation shaping, or combinatorial sparse labeling), would broaden the applicability of the technique.

      We thank the reviewer for highlighting this important trade-off between volumetric coverage and image specificity in Bessel beam imaging. As Bessel beams project fluorescence from multiple features along the z-axis onto the same x–y plane, longer beams expand depth coverage at the same acquisition speed but can confound signals from axially spaced structures (Line 119-121 in manuscript). For densely labeled samples, the probability of having structures overlap in their x-y locations is high, and thus a shorter beam should be used. In sparsely labeled samples, structures have a lower probability of overlapping, and thus longer foci can be used (Line 166-168 in manuscript). Additionally, at the same NA, longer Bessel beam have more energy in the side rings surrounding the central peak, which may lead to higher background signal (Line 121-123 in manuscript) (Lu et al., 2017). These reasons necessitate to have not only NA tuning, but also independent length tuning (ΔNA tuning) to optimize imaging Bessel length to provide a balance between structural overlap that obscures signal localization, and the volumetric speedup, in any given sample based on labeling density and imaging goals, which are realized in our tBessel design.

      Reference:

      Demas, J., Manley, J., Tejera, F., Barber, K., Kim, H., Traub, F.M., Chen, B., Vaziri, A., 2021. High-speed, cortex-wide volumetric recording of neuroactivity at cellular resolution using light beads microscopy. Nat Methods 18, 1103–1111. https://doi.org/10.1038/s41592-021-01239-8

      Göbel, W., Helmchen, F., 2007. In Vivo Calcium Imaging of Neural Network Function. Physiology 22, 358–365. https://doi.org/10.1152/physiol.00032.2007

      Grewe, B.F., Voigt, F.F., van ’t Hoff, M., Helmchen, F., 2011. Fast two-layer two-photon imaging of neuronal cell populations using an electrically tunable lens. Biomed Opt Express 2, 2035–2046. https://doi.org/10.1364/BOE.2.002035

      Huang, C., Tai, C.-Y., Yang, K.-P., Chang, W.-K., Hsu, K.-J., Hsiao, C.-C., Wu, S.-C., Lin, Y.-Y., Chiang, A.-S., Chu, S.-W., 2019. All-Optical Volumetric Physiology for Connectomics in Dense Neuronal Structures. iScience 22, 133–146. https://doi.org/10.1016/j.isci.2019.11.011

      Lu, R., Sun, W., Liang, Y., Kerlin, A., Bierfeld, J., Seelig, J.D., Wilson, D.E., Scholl, B., Mohar, B., Tanimoto, M., Koyama, M., Fitzpatrick, D., Orger, M.B., Ji, N., 2017. Video-rate volumetric functional imaging of the brain at synaptic resolution. Nat Neurosci 20, 620–628. https://doi.org/10.1038/nn.4516

      Nadella, K.M.N.S., Roš, H., Baragli, C., Griffiths, V.A., Konstantinou, G., Koimtzis, T., Evans, G.J., Kirkby, P.A., Silver, R.A., 2016. Random-access scanning microscopy for 3D imaging in awake behaving animals. Nat Methods 13, 1001–1004. https://doi.org/10.1038/nmeth.4033

      Podgorski, K., Ranganathan, G., 2016. Brain heating induced by near-infrared lasers during multiphoton microscopy. Journal of Neurophysiology 116, 1012–1023. https://doi.org/10.1152/jn.00275.2016

      Sofroniew, N.J., Flickinger, D., King, J., Svoboda, K., 2016. A large field of view two-photon mesoscope with subcellular resolution for in vivo imaging [WWW Document]. eLife. https://doi.org/10.7554/eLife.14472

      Villette, V., Chavarha, M., Dimov, I.K., Bradley, J., Pradhan, L., Mathieu, B., Evans, S.W., Chamberland, S., Shi, D., Yang, R., Kim, B.B., Ayon, A., Jalil, A., St-Pierre, F., Schnitzer, M.J., Bi, G., Toth, K., Ding, J., Dieudonné, S., Lin, M.Z., 2019. Ultrafast Two-Photon Imaging of a High-Gain Voltage Indicator in Awake Behaving Mice. Cell 179, 1590-1608.e23. https://doi.org/10.1016/j.cell.2019.11.004

      Weisenburger, S., Tejera, F., Demas, J., Chen, B., Manley, J., Sparks, F.T., Traub, F.M., Daigle, T., Zeng, H., Losonczy, A., Vaziri, A., 2019. Volumetric Ca2+ Imaging in the Mouse Brain Using Hybrid Multiplexed Sculpted Light Microscopy. Cell 177, 1050-1066.e14. https://doi.org/10.1016/j.cell.2019.03.011

      Yang, W., Carrillo-Reid, L., Bando, Y., Peterka, D.S., Yuste, R., 2018. Simultaneous two-photon imaging and two-photon optogenetics of cortical circuits in three dimensions. eLife 7, e32671. https://doi.org/10.7554/eLife.32671

    1. Subscription is verplicht voor applicaties in het domein. Applicaties die in een Koppeltaal-domein opereren registreren een Subscription op Patient-changes. Twee patronen zijn toegestaan: Tag-specifiek: Patient?_tag=...|DELETE_PENDING — meest gericht, hoogste signaal-ruisverhouding; alleen verwijderaankondigingen. Breed op Patient-changes: Patient of Patient?_id=... — applicatie ontvangt alle Patient-updates en filtert zelf op meta.tag. Past bij applicaties die om andere redenen ook Patient-changes willen volgen. Subscriben op AuditEvents is voor pre-delete signalen geen geldig alternatief: zolang de Patient nog bestaat, is de tag op de Patient de waarheid en is de AuditEvent slechts bewijslog. Voor het post-delete signaal (zie hieronder) ligt dat mogelijk anders, omdat de Patient dan niet meer bestaat als bron — dit is nog een open keuze.

      Dit deel is nog wat complex en vraagt nogal veel aanpassingen in zowel voorzieningen als applicaties.: 1. Het zetten van de DELETE_PENDING tag mag niet gezien worden als een wijziging op de Patient omdat daarmee Patient-resources die 2 jaar bestaan en waarvoor nog nooit een Task is aangemaakt of Launch is uitgevoerd weer terug komt in een status dat die gewijzigd is en dus altijd blijft bestaan. Dit vraagt over verduidelijking van de verwachtingen ten aanzien van $meta-add. Specifiek: * Geen wijziging van meta.lastUpdated en meta.version * Geen REST Audit event * Daarom ook geen notificatie op basis van de standaard Patient-subscription (want de Patient is volgens bovenstaande niet gewijzigd) 2. De te versturen AuditEvents zijn nog niet voldoende gespecificeerd 3. Wat betreft de Notificaties: * Het is mijns inziens niet gewenst dat applicaties op de bestaande Patient subscription ook de delete_pending notificaties krijgen, dat zal alleen maar lijden tot verwarring * Omdat het gebruik van de noodrem feitelijk ongewenst isen als een advanced usecase moet worden gezien is het geen enkel probleem als applicaties geen subscriptie hebben * Al het bovenstaande pleit voor een specifieke subscriptie- en notificatie-endpoint voor alle notificaties rond het opschonen van patientdata * Ik ben van mening dat juist een subscriptie op de relevante AuditEvents het meest duidelijk en krachtig is.

    1. Reviewer #3 (Public review):

      Summary:

      The primary objective of this study was to establish a practical and functional framework for the propagation of stable transgenic cell lines of Blastocystis, a common animal gut microeukaryote. Although the work focused on Blastocystis ST7-B, a subtype with relatively low prevalence in humans, this choice is justified by its association with more frequent negative health effects. Beyond their relevance to the medical field, the methodological advances described here have the potential to also expand cell biology studies of this anaerobic organism, including its unusual mitochondria and redox metabolism.

      Strengths:

      Prior to this work, genetic tools for Blastocystis were very limited, relying on a single strong promoter-terminator combination. The authors successfully expanded the available promoter set across a range of expression strengths by testing two dozen variants in luciferase-based assays. Critically, they developed an integrated workflow from a modular transgenic construct design, to an expanded inventory of molecular components (promoters, reporters), optimized DNA delivery, stepwise antibiotic resistance-mediated clonal selection and propagation, and to reporter validation. The evaluation of several anaerobiosis-compatible labeling strategies for live (and fixed) cell optical imaging will be particularly useful, with the SNAP-tag system appearing especially promising for Blastocystis.

      Weaknesses:

      The presented data generally provide solid support for the conclusions that the work reached, but clarification of reasoning and several inconsistencies, as well as amendments to the visual presentation of the data, would be highly beneficial, as detailed below.

      (1) Episomal persistence of the construct:<br /> The manuscript repeatedly assumes, including in its title, that constructs persist in Blastocystis in their episomal form, but no direct evidence is provided. Although this interpretation is plausible, it should be identified more clearly as provisional. Nuclear genomic integration (e.g., via NHEJ) remains a possible explanation unless supporting evidence or rationale is provided to exclude it. Testing whether the phenotype persists without drug-mediated selection in the generated transgenic cell lines would help strengthen the case for episomal maintenance.

      (2) Promoters and terminators:<br /> 2.1) There is a discrepancy between the claimed number of loci (14), from which promoters used to drive luciferase expression were derived, and those detailed as having been actually generated in Table 1 (11). This inconsistency should be corrected or explained, as it creates uncertainty around the accuracy of the dataset.<br /> 2.2) Based on the presented evidence, constructs benchmarked in bioluminescence assays differed only in their promoter composition. Although terminator selection is mentioned in the Methods section, no additional details are provided; for instance, Table 1 and Figure 2 only list 23 promoters in total. Figure 2A likewise shows only promoter-dependent variation. If the terminator was held constant (LeguP1?), this should be stated explicitly. The authors may then consider revising the wording of having tested "23 promoter-terminator pairs" to better reflect that only promoters varied.<br /> 2.3) Promoter benchmarking was done with a plasmid lacking a selection marker, so it is unclear how the maintenance of the luciferase construct was ensured. Without selection, the observed reporter intensity could reflect differential or stochastic plasmid retention rather than promoter strength alone. The luminescence assay was performed 16-18 hours after transfection, but the rationale for this particular timeframe should be explained. In this context, the authors should explicitly state whether the experiments shown in Fig.2A represent biological triplicates or technical triplicates from a single transfection.

      (3) Figure 2:<br /> 3.1) Several aspects of the current design may lead to ambiguity for the reader. The boxplots are colour-coded, but it is unclear whether the colours carry meaning or are purely decorative. Because the data are already spatially separated into bins, additional random colouring is redundant and may suggest distinctions that are not intended. In addition, part A of Figure 2 is split into two panels, with the scale for the left panel shown in the right panel and some of the boxplot colours falling in the range of the scale, but not in line with their counterparts in the left panel. Because the colour use is not consistent, it is difficult to tell whether the same scale should be applied to both panels or how it should be interpreted.<br /> 3.2) The left panel of part A uses a diverging blue-white-red colour scheme, which is most appropriate when the midpoint represents a meaningful central value such as zero. Because the values shown in this graph are only positive, a non-diverging 2-colour scale or a colour palette such as 'viridis' would make the plot easier to interpret.<br /> 3.3) A black background should be avoided: 'B' and 'C' labels are invisible, and it draws attention to a distracting design feature rather than the data themselves.

      (4) Figure 3:<br /> 4.1) Individual snapshots should be separated more clearly, either by using a white background or by adding visible borders to make the overall composition clearer. As currently displayed, some boundaries between fluorescent channels resemble image artifacts rather than intentional panel divisions.<br /> 4.2) In parts B-D, the legend should explain more clearly what each image shows, and the figure itself would benefit from annotations. There seem to be three sub-panels in each 'condition' of part B (as well as C and D): while the middle and rightmost panel can be easily inferred to represent the fluorescent protein and bright-field image, what the leftmost panels represent is not specified. If DAPI was used to dye DNA, an explanation why mostly multiple labelled regions are visible should be provided.<br /> 4.3) Cell morphology and appearance differ markedly between UnaG/smURFP and SNAP-tag images, which should be explained. A microscope issue is mentioned in the main text, but if that was the cause, the authors should consider replacing the images, as the current distortions complicate interpretation.

  6. May 2026
    1. eLife Assessment

      This important study combines single-molecule imaging and CUT&TAG to address the molecular mechanism underlying the differentiation process that initiates the formation of red blood cells in the bone marrow. The authors provide evidence that the transcription factor GATA2 transiently associates with a new set of genomic loci early in the differentiation process before it is replaced by GATA1. Together, the experiments across three biological systems are solid, but they could benefit from additional details and controls to strengthen the conclusions.

    2. Reviewer #1 (Public review):

      Summary:

      During erythroid differentiation, hematopoietic progenitors relinquish multipotency and activate lineage programs. The switch from GATA2 to GATA1 is particularly important in this process, yet GATA2 chromatin‑binding kinetics remain undefined. The authors investigated GATA2-chromatin interaction dynamics during erythroid differentiation in three different cell systems using single‑molecule live‑cell imaging, and they also used CUT&Tag to profile GATA2 chromatin occupancy.

      By single‑molecule imaging, the authors report two interaction modes for GATA2: short‑lived (<1 s) and long‑lived (>5 s) binding. The proportion of long‑lived molecules, the number of binding events, and the duration of long‑lived binding change (or are maintained) during differentiation. Notably, long‑lived chromatin engagement by GATA2 increases during early erythroid differentiation and decreases at the late stage. CUT&Tag identifies regulatory elements selectively occupied by GATA2 during the early transition stage. Together, these results support a model in which transcription factor kinetics form a dynamic chromatin‑engagement profile that characterizes the GATA2‑to‑GATA1 transition.

      Strengths:

      (1) Characterizing transcription‑factor binding kinetics during the GATA2->GATA1 transition addresses a fundamental mechanism in erythroid differentiation.

      (2) Combining single‑molecule live imaging with CUT&Tag provides both dynamic and locus‑specific perspectives.

      (3) Single-molecule analysis across three different cell systems strengthens the potential generalizability of the findings and highlights biological variability.

      Weaknesses:

      I agree that single‑molecule imaging is a powerful approach for investigating GATA2 kinetics, but the single‑molecule data are the most important part of the paper and need improvement. The analyses focus on three measures: (i) duration of long binding, (ii) proportion of short‑ and long‑binding molecules, and (iii) total binding events. However, several methodological and control issues limit confidence in the kinetic interpretations. The authors should address the following major concerns.

      (1) Two binding states: justification and controls

      The authors propose two states of GATA2 binding. Are there only two states? Studies that separate short‑ and long‑lived binding (e.g., Chen et al., 2014, PMID: 25342811) address two states of transcriptional factors very carefully. Some long‑binding duration distributions here are very long‑tailed (e.g., Figure 2D middle), suggesting a possible third state. The authors must explain how they determined that two states provide the "best fit" to the data and how they classified "short" versus "long" binding.

      Controls should be included for long‑lived and short‑lived binding (e.g., histone proteins, HaloTag‑NLS, or a binding‑deficient GATA2 mutant) as in other studies. These controls are essential to exclude alternative explanations (see points below).

      (2) Exclude photophysical and focal‑plane artifacts

      The authors should exclude contributions from (i) photobleaching, (ii) blinking, and (iii) Z‑axis motion (disappearance from the focal plane). Although photobleaching correction is mentioned in the Methods, no details are provided. Describe and quantify the photobleaching correction and demonstrate that it was applied across all cell types and conditions.

      Some spots in the supplementary movies appear to blink or to move substantially between frames. Provide analyses or controls that distinguish true dissociation events from photophysical blinking/bleaching or axial motion.

      (3) HILO illumination and nuclear region sampled

      HILO is powerful but sensitive to illumination angle: slight changes sample different nuclear regions (e.g., nuclear interior versus periphery). The nuclear periphery is enriched in heterochromatin and may bias binding statistics. Explain how the authors controlled the HILO angle and confirmed that comparable nuclear regions were imaged across cells and conditions.

      (4) Quantification of event counts and long‑binding durations

      The number of binding events and measured long‑binding durations are strongly affected by imaging conditions (labeling/staining, bleaching, nucleus size, cell cycle state, focal plane, spot detectability, etc.). Imaging clarity appears to differ among cells/conditions in the supplementary movie. Provide more careful analysis describing how these variables were controlled or corrected for, and assess the sensitivity of results to choices in detection and tracking parameters.

      (5) Evidence that spots are single molecules

      The authors state that spots represent single molecules but do not provide supporting evidence. Spot brightness varies considerably in the movies. Brightness differences may reflect axial position. Provide evidence supporting single‑molecule assignment (e.g., single‑step photobleaching traces, brightness distributions compared to a known single‑molecule control, or photon count analysis).

      (6) Description of spot‑analysis pipeline

      The manuscript lacks a sufficient description of the spot‑analysis method. I reviewed the STRAP pipeline paper cited (Haque and Coleman 2025 bioRxiv) and the GitHub code, but the Methods in the current manuscript should include a detailed STRAP pipeline. This would enable readers to evaluate and reproduce the analyses.

      (7) Differences among cell systems

      The three cell systems yield notably different results (e.g., Figure 2C vs 4C and Figure 2D/3D vs 4D). Provide a more detailed explanation for these differences and discuss how biological variability, technical differences, or imaging biases might account for the discrepancies.

    3. Reviewer #3 (Public review):

      Hobbs et al. use live-cell single-molecule tracking (SMT) of HaloTag- and SNAP-tagged GATA2 combined with CUT&Tag chromatin profiling to examine how GATA2 chromatin engagement evolves during erythroid differentiation. Across three complementary systems, G1E-ER4 cells, HPC7 cells, and primary bone marrow progenitors from a new Gata2-SNAP knock-in mouse, they report a transient strengthening of long-lived GATA2 chromatin binding at the "Early" (2 h) erythroid stage, manifested either as increased residence time (G1E-ER4) or expansion of the long-lived bound fraction (HPC7, primary cells). CUT&Tag identifies 1,167 Early-restricted GATA2 peaks partitioning into GATA2-only (promoter-proximal, GATA/RUNX motifs) and GATA2+GATA1 co-bound (distal, GATA/E-box motifs) subclasses. The authors propose that this kinetic phase represents a previously unappreciated dimension of the GATA switch.

      This is a strong study with a genuinely novel finding-the non-monotonic kinetic behavior of GATA2 during erythroid priming, supported by complementary measurements in three biological systems. The issues below are largely clarifications, additional analyses of existing data, and modest refinements to the discussion. With these addressed, the manuscript will make a valuable contribution. I recommend a minor revision.

      Specific points:

      (1) Clarify the photobleaching correction and report per-cell bleach lifetimes.

      The long-lived residence time claim in G1E-ER4 cells depends on careful accounting for photobleaching, which the Methods indicate was done via a right-censoring model. For reviewer and reader confidence, the authors should report the per-stage (or per-cell distribution of) photobleaching lifetimes and the photobleach-corrected residence time values alongside the apparent values in Figure 2D. If feasible, including a brief supplementary analysis with an H2B-Halo or similar long-lived control under matched conditions would further solidify the quantitative claims. This is an analysis of existing data and should not require new imaging.

      (2) Unify or explicitly discuss the mechanistic differences across systems.

      The three systems show qualitatively different signatures: residence time change in G1E-ER4, bound fraction expansion in HPC7, and primary cells. The authors currently group these under "enhanced engagement," but these signatures imply different underlying mechanisms (koff decrease vs. increased kon or increased specific-binding-competent pool). The Discussion partially addresses this by noting engineered vs. native differences, but a more explicit framing in both Results and Discussion would help readers. Specifically, reporting an on-rate proxy (for example, binding events per unit time normalized to detectable molecule number) alongside koff would let readers see how the mechanistic pieces fit together. I do not think this changes the central message; it sharpens it.

      (3) Per-cell GATA2 concentration would strengthen the "uncoupling" claim.

      A central claim of the Figure 6 model is that chromatin engagement is uncoupled from protein abundance. The ectopic Shield-1 stabilization system is a reasonable design choice, but quantifying total nuclear GATA2-Halo signal (for example, from the pre-bleach frame or a brief high-power acquisition) on a per-cell basis across stages would directly support the interpretation. For the primary cells, where the biological claim is strongest, a western blot or quantitative immunofluorescence on the flow-sorted populations would make the uncoupling argument much more defensible. I recognize this may be one additional experiment, but it is a high-value one.

      (4) Additional single-cell distribution analysis.

      Figure 1E and Figures 2 to 4 show substantial cell-to-cell heterogeneity, and the Early populations in particular look potentially bimodal. Given that the authors cite Wheat et al. and Palii et al. on probabilistic hematopoietic transitions, a brief supplementary analysis using distribution-based statistics (K-S test, or mixture model) rather than, or alongside, mean-based ANOVA would align the analysis with this conceptual framing and may reveal whether the Early state represents a subpopulation transition rather than a uniform shift. This is purely an analysis of existing data.

      (5) Quantitative integration of CUT&Tag with SMT.

      The manuscript presents SMT and CUT&Tag as complementary but does not attempt to quantitatively connect them. A back-of-the-envelope calculation of whether a 21% increase in residence time (G1E-ER4), or the fraction expansion in other systems, is consistent with the acquisition of the 1,167 Early-restricted sites, given plausible site affinities, would substantially strengthen integration. Even if the calculation is approximate, framing it explicitly would help readers appreciate that the two datasets reinforce each other.

      (6) Short-lived kinetic interpretation and tracking parameters.

      The 1.5 s gap allowance in tracking is long relative to the 0.55 to 0.73 s short-lived residence times reported in primary cells (Figure Supplement 1F), which could affect the interpretation of the "slowing of target search" claim. A brief sensitivity analysis with tighter gap parameters in the supplement would reassure readers that this effect is robust. Additionally, please clarify how the inferred slowing of search, which should reduce kon, is reconciled with the increased number of binding events per cell at the Early stage.

      (7) CUT&Tag peak definition.

      The Early-restricted peak set is defined by presence and absence at q less than 0.01, which can be sensitive to near-threshold peaks. Please report either (a) the CUT&Tag signal intensity distribution at the 1,167 sites across all three stages as a quantitative scatter or density plot, beyond the heatmap in Figure 5C, or (b) the result of a differential binding analysis (for example, DESeq2 on read counts in a union peak set) as a supplementary confirmation. Please also state the number of CUT&Tag replicates per stage and the overlap of Early-restricted sets across replicates.

      (8) Knock-in mouse validation.

      The Gata2-SNAP allele is a valuable new tool, and it would benefit from slightly more quantitative validation in the supplement. A brief characterization of basic hematopoietic parameters in homozygotes (CBC, LSK/HSPC frequencies, or colony assays) would confirm that the tagged allele is truly physiological and would serve the community that will want to use this mouse going forward. If this has been done, please include it; if not, a statement about what was checked would suffice.

    4. Author response:

      We are writing to provide our provisional response to the public reviews. We note that the reviewers’ comments focus primarily on strengthening technical rigor and quantitative interpretation. We have designed the planned revisions to directly address the reviewers’ major concerns and to strengthen the study’s evidentiary basis. We plan to submit a revised manuscript for the final Version of Record.

      For clarity, we summarize below the major new experiments and analyses that address the reviewers’ primary concerns:

      (1)Validation of Tracking Parameters (Reviewers 1 & 3): We will re-analyze our single molecule tracking data with tighter gap-time allowances (0 seconds) to demonstrate the robustness of our interpretations of short- and long-lived kinetics. We will also generate a supplementary movie with binding trajectories superimposed directly on detected molecules to visually confirm tracking robustness.

      (2) Photobleaching & Two-State Controls (Reviewers 1 & 3): We will report per-cell photobleaching lifetimes derived from our global fluorescence decay. To strengthen this analysis, we will include supplementary measurements using a H2B-HaloTag control under matched imaging conditions and perform single-molecule tracking of GATA2 zinc-finger deletion mutants (N-terminal, C-terminal, and double) as a binding-deficient functional control.

      (3) Protein Expression & Labeling Efficiency (Reviewers 1 & 2): To address concerns about transgene expression and competition with endogenous proteins, we will quantify Halo-GATA2 levels in G1E-ER4 and HPC7 cells and SNAP-GATA2 levels in primary cells using standardized titration methods with established Halo-CTCF and SNAP-RPB1 reference systems.

      (4) Integration of SMT and CUT&Tag (Reviewer 3): We have conducted a quantitative foldchange analysis of our existing CUT&Tag dataset to complement our single-molecule kinetics.

      However, as detailed in our specific response below (R3 point 5), we emphasize that directly integrating population-level genomic occupancy measurements with single-cell kinetic measurements is not straightforward. We will therefore frame the relationship between these datasets as a conceptual consistency check rather than a strict quantitative integration. This quantitative analysis supports and refines the Early-restricted peak set, identifying a high confidence strict subset consistent with the broader presence/absence-defined set described in Figure 5 of the manuscript (see Author response images 1–3 and our response to R3 point 7).

      (5) Characterization of the GATA2-SNAP Mouse (Reviewer 3): We have characterized hematopoietic populations in the homozygous knock-in mouse, including lymphoid (CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>+</sup>/B220<sup>+</sup>/CD19<sup>+</sup>), myeloid (CD11b<sup>+</sup>/Gr1<sup>+</sup>), and erythroid (Ter119<sup>+</sup>) compartments. These data, presented in Author response image 4, indicate that normal mature hematopoietic output is preserved across genotypes. Statistical caveats are described in the corresponding figure legend and in our response to R3 point 8.

      Public Reviews:

      Reviewer 1 (Public review):

      (1) Two binding states: justification and controls

      The authors propose two states of GATA2 binding. Are there only two states? Some longbinding duration distributions here are very long-tailed (e.g., Figure 2D middle), suggesting a possible third state. The authors must explain how they determined that two states provide the best fit and how they classified short versus long binding. Controls should be included for long-lived and short-lived binding (e.g., histone proteins, HaloTag-NLS, or a binding-deficient GATA2 mutant).

      Agreed in part; we will attempt the requested binding-deficient control using existing GATA2 deletion constructs, complemented by GRID and H2B-HaloTag controls.

      We will clarify that the two-state framework is an operational model rather than a claim that GATA2 can occupy only two physical states. This approach is widely used in SMT studies of chromatin-associated transcription factors and transcription machinery (Gebhardt et al., 2013; Liu et al., 2014; Hansen et al., 2017; Kenworthy et al., 2022). In particular, Ling et al. (Science, 2026) recently used two-exponential survival-probability fitting across 58 Halotagged transcription-associated proteins to distinguish transient and stable chromatin-binding populations, while explicitly noting that the simplified two-state model provides a tractable framework even when the underlying physical behavior may be more heterogeneous.

      We agree that our current two-state model may under-represent the diversity of GATA2 chromatin-binding populations in single cells. However, even within this simplified framework, the existing analysis already indicates increased upper-tail dispersion of kinetic measurements (e.g., residence time and/or percentage of stable events) at the single-cell level in early erythroid cells. To support the goodness-of-fit metrics from our two-state fitting, as Reviewer 3 recommends, we will provide a supplementary table containing confidence intervals for the rate parameters and an F-test metric describing the differences between one- and two-state fits.

      To determine whether additional binding states exist, we will perform GRID (Genuine Rate Identification from Distributions), which does not bias the model toward a particular number of states and, in our experience across multiple proteins, yields fits with 3-5 binding populations. However, we have found that in many cases, GRID requires aggregating binding events from multiple cells to achieve consistently robust fits for the populations of relatively rare, long-lived (>~30 sec) binding events. Therefore, GRID will assess whether additional populations exist, but we will lose the ability to analyze changes in the cell populations at the single-cell level.

      We will include the multi-state analysis as a new supplementary figure. We will additionally clarify in the Results and Methods exactly how short- and long-lived binding events are classified (1-second threshold consistent with prior single-molecule frameworks for transcription-factor chromatin interactions; Gebhardt et al., 2013; Liu et al., 2014; Kenworthy et al., 2022) and direct the reviewer to these passages.

      For the requested controls, we will include H2B-HaloTag imaging under matched conditions as a long-lived reference for both photobleaching correction and as a positive control for stable chromatin association, addressing R1 point 2 and R3 point 1 simultaneously.

      We will also attempt to address the reviewer’s request for a binding-deficient control. We have lentiviral constructs in hand that encode GATA2 with a C-terminal zinc-finger deletion (which removes the primary DNA-binding domain), an N-terminal zinc-finger deletion, and a double deletion. We will perform single-molecule tracking of these mutants in the engineered cell systems and test whether removing GATA2’s specific DNA-binding capacity produces the predicted reduction in long-lived chromatin engagement, providing a functional perturbation control. The interpretation of these experiments will depend on the mutants expressing and localizing appropriately, which we will validate before drawing kinetic conclusions. We note that an analogous binding-deficient mutant cannot be examined in the physiological context of the Gata2SNAP knock-in mouse, and we will frame the cell-line mutant analyses accordingly. Together with GRID and the H2B-HaloTag control, these mutants provide complementary lines of validation for the two-state kinetic framework.

      (2) Photophysical and focal-plane artifacts

      The authors should exclude contributions from (i) photobleaching, (ii) blinking, and (iii) Z-axis motion. Describe and quantify the photobleaching correction. Provide analyses or controls that distinguish true dissociation events from photophysical blinking/bleaching or axial motion.

      Agreed.

      We will substantially expand the methodological description and provide three new pieces of supplementary analysis:

      - Photobleaching: A per-cell photobleaching-rate distribution will be plotted for each cell type and differentiation stage, and photobleach-corrected residence-time values will be reported alongside apparent values in the relevant figures. We will also perform H2B-HaloTag imaging under matched illumination, exposure, and dye conditions in each cell line as a longlived chromatin-bound reference, establishing per-cell-type bleach lifetimes to which the GATA2 measurements can be referenced. This approach follows recent SMT precedent in which H2B decay was used to correct residence-time measurements for photobleaching, chromatin and nuclear motion, microscope drift, defocalization, and dye photophysics (Ling et al., Science 2026). The right-censoring photobleach-correction model used in our analysis will be described in detail in the revised Methods, including parameter values and per-cell handling.

      - Blinking: The STRAP single-particle tracking pipeline already accommodates fluorophore blinking when linking trajectories across successive frames, following the multiple-targettracing framework of Sergé et al. (Nature Methods, 2008). This use of short gap-frame allowances to avoid artificially splitting trajectories due to fluorophore blinking or transient defocalization is consistent with recent live-cell SMT studies of chromatin-associated factors (Ling et al., Science 2026). We will add an explicit statement to the Methods describing how blinking-tolerant linkage parameters are set, and we will reanalyze representative datasets

      with stricter maximum off-frame settings to ensure this parameter does not drive our conclusions (also addressing R3 point 6).

      - Z-axis motion: Given our 500-ms exposure and the ~500-nm axial detection range of the HiLo configuration, axial loss is expected to be a minor contributor. We will quantify this indirectly by plotting, as a supplementary analysis, the maximum in-plane 2D spatial exploration of each binding trajectory, defined as the long-axis diameter of the 2D trajectory envelope. Although this does not directly measure z-position, it serves as a control for large apparent displacements that could reflect molecules moving out of the HiLo detection volume and demonstrates that observed dissociation events are not dominated by axial drift.

      Representative photobleaching traces from individual cells (lowest, highest, and median bleach rates) will be included to support the single-molecule interpretation (also addresses R1 point 5).

      (3) HILO illumination and nuclear region sampled

      HiLo is sensitive to illumination angle: slight changes sample different nuclear regions. Explain how the HiLo angle was controlled and confirmed comparable across cells and conditions.

      Agreed.

      We will add a Methods subsection describing our HiLo illumination procedure. In brief, we started at a TIRF-supercritical angle and reduced it toward epifluorescence just enough to achieve high imaging depth while minimizing out-of-focus background signal. Within each biological system (cell line or primary cells), the TIRF angle was held constant across Basal, Early, and Late conditions to ensure direct comparability of kinetic measurements across stages.

      (4) Quantification of event counts and long-binding durations

      The number of binding events and the duration of long-binding events are influenced by imaging conditions. Provide a more detailed analysis of how these variables were controlled and assess the sensitivity of the results to detection and tracking parameters.

      Agreed.

      We will (i) normalize per-cell binding-event counts to nuclear cross-sectional area (extracted from the segmented nuclear masks already in the STRAP pipeline) to control for differences in nuclear size; (ii) report the tracking-parameter sensitivity sweep described above; and (iii) confirm in the revised Methods that all imaging conditions (laser power, exposure, dye concentration, sample preparation) were held constant across stages and cell types, consistent with the existing manuscript text. Per the Reviewing Editor’s guidance, the planned labeling-efficiency and absolute-molecule-quantification experiments will further constrain the interpretation of binding-event counts across conditions.

      (5) Evidence that spots are single molecules

      Provide evidence that spots represent single molecules.

      Agreed.

      We will include a small number of per-event intensity traces from our STRAP tracking output, selected to illustrate the single-step photobleaching behavior characteristic of single-molecule emission (intensity remains approximately constant during the binding event and then drops to background in a single step). The nuclear-fluorescence measurements from the planned labeling-titration experiment will also allow us to confirm that bound-spot densities are consistent with single-molecule occupancy at the labeled fraction used for tracking.

      (6) Description of the spot-analysis pipeline

      The Methods should include a detailed STRAP pipeline description.

      Partially agreed; the existing STRAP reference is appropriate, but the Methods will be expanded.

      STRAP (Haque & Coleman, 2025) is a consolidated, automated implementation of two well-established, previously published frameworks: SLIMfast / multipletarget tracing (Sergé et al., 2008) and evalSPT (Normanno et al., 2015), both of which are cited in the original manuscript. We will expand the Methods to describe the parameter set used in our analysis (detection thresholds, linking radii, gap-frame allowance, photobleaching correction model) so that readers can assess the analysis without referring exclusively to the STRAP manuscript and code repository, while preserving the cited STRAP reference for the full algorithmic description. We respectfully suggest that a complete pipeline description duplicating Haque & Coleman (2025) would not be appropriate in a primary research article.

      (7) Differences among cell systems

      The three cell systems yield notably different results. Provide a more detailed explanation for these differences.

      Agreed.

      We will also explicitly describe the caveats of the engineered systems versus the native GATA2-SNAP primary-cell system, in which endogenous GATA2-SNAP remains under physiological regulation. Specifically, we will discuss how variables such as the GATA1null background, ectopic forced nuclear import of GATA1-ERT, and ectopic GATA2-Halo in G1E-ER4 cells, as well as ectopic GATA2-Halo, endogenous GATA1, and cytokine signaling in HPC7 cells, likely contribute to the observed differences in signatures.

      Reviewer 2 (Public review):

      (1) Expression levels of the GATA2-HaloTag transgene

      Determine the expression levels of the GATA2-HaloTag transgene over the course of differentiation under the conditions used for single-molecule imaging.

      Agreed.

      This is the central concern flagged by the Reviewing Editor. For each cell line (G1E-ER4 and HPC7), we will (i) measure total nuclear GATA2-Halo fluorescence per cell under matched acquisition conditions and (ii) convert this fluorescence intensity to absolute molecules per cell using a Halo-CTCF/U2OS reference standard (Cattoglio et al., 2019; absolute CTCF abundance quantification applied previously by our group). This will provide per-cell GATA2Halo molecule counts at each differentiation stage (Basal, Early, Late). For the primary GATA2SNAP cells, we will perform the analogous comparison against a SNAP-RPB1/U2OS standard.

      (2) Fraction of molecules labeled

      Carry out a titration of the HaloTag ligand and compare the amount of labeled protein under single-molecule imaging conditions to that of saturating labeling.

      Agreed.

      We will perform HaloTag-ligand and SNAP-tag-ligand titrations in each cell type, comparing nuclear fluorescence under the limiting-label conditions used for single-molecule tracking with that under saturating labeling. This will yield a per-cell-type labeled fraction and allow us to confirm that comparisons of binding-event counts across conditions are not confounded by differences in labeling efficiency. The labeled-fraction values will be reported in a new supplementary figure and incorporated into our quantification of binding-event rates.

      (3) Robust single-particle tracking

      Show images of particle trajectories or movies superimposing trajectories on imaging data.

      Agreed.

      We will generate visualizations of selected long-lived binding events with single-particle trajectories overlaid on the imaging data — using a multi-frame color overlay (e.g., five sequential frames in distinct colors superimposed) so that linkage of the spot across frames is visually unambiguous — and include them as a new supplementary figure or movie. Examples will be drawn from each cell system to demonstrate consistent tracking quality.

      Reviewer 3 (Public review):

      (1) Photobleaching correction; per-cell bleach lifetimes

      Report the per-stage (or per-cell) photobleaching lifetimes and the photobleachcorrected residence time values alongside apparent values, ideally with an H2B-Halo control.

      Agreed.

      Addressed by the photobleach-rate distribution and H2B-HaloTag control analyses described under R1 point 2. The supplementary figure will explicitly compare per-cell bleach lifetimes across stages, report photobleach-corrected residence-time values alongside apparent values and include H2B-HaloTag controls under matched conditions in each cell line.

      (2) Mechanistic differences across systems

      The three systems show qualitatively different signatures: residence time change in G1EER4, bound fraction expansion in HPC7 and primary cells. Reporting an on-rate proxy alongside k_off would help.

      Agreed.

      Addressed by the cross-system kinetic framing described under R1 point 7 and by the GRID state-spectrum analysis described under R1 point 1. We will explicitly frame the three systems in terms of underlying kinetic mechanism in both Results and Discussion, following the conceptual distinction emphasized by Ling et al. (Science 2026) in which residence time reports binding stability once engaged, whereas changes in bound fraction or event frequency can indicate altered association/recruitment efficiency. In this framework, the G1E-ER4 residencetime signature is consistent with reduced dissociation (a longer-lived bound state), while the longlived-fraction expansion in HPC7 and primary cells is consistent with an increased target-search efficiency or specific-binding-competent pool. Alongside the GRID-derived state-spectrum analysis, we will report an apparent engagement-rate proxy calculated as binding events per unit imaging time normalized to detectable molecule number; this proxy is an approximation, not a direct k_on measurement, as accurate determination of k_on from single-molecule tracking requires concentration-dependent on-rate experiments that are outside the scope of the present study. We thank the reviewer for this suggestion, which we agree sharpens rather than alters the central message.

      (3) Per-cell GATA2 concentration and the uncoupling claim

      Quantify total nuclear GATA2-Halo signal per cell across stages; for primary cells, a western blot or quantitative immunofluorescence on flow-sorted populations would make the uncoupling argument more defensible.

      Agreed.

      For the cell lines, the per-cell nuclear GATA2-Halo quantification described in our response to R2 point 1 addresses this point.

      For primary cells, where the biological claim is strongest, we will exploit the endogenous Gata2SNAP knock-in itself as a quantitative reporter of total GATA2 protein. Specifically, we will label flow-sorted CD71/Ter119 populations from Gata2-SNAP mouse bone marrow with SNAP-Cell 647-SiR at saturating concentration in a parallel acquisition to the limiting-label single-molecule tracking experiment. Total nuclear SNAP-GATA2 fluorescence at saturating labeling provides a measure of endogenous GATA2 abundance per cell at each erythroid stage, in the same chemistry used for our single-molecule measurements, and will be benchmarked against a SNAPRPB1/U2OS reference standard for absolute molecule counting. This approach (i) measures the protein of interest in the labeling chemistry already established in this study; (ii) avoids reliance on quantitative immunofluorescence, which we have not been able to validate under our flowsorted-cell conditions; and (iii) extends the same analytical framework — saturating versus limiting labeling, with U2OS reference standards — across cell lines and primary cells. Quantitative western blotting on flow-sorted populations remains an alternative we will consider if specifically requested by the reviewers.

      (4) Single-cell distribution analysis

      Distribution-based statistics (K-S test, mixture model) rather than (or alongside) meanbased ANOVA, particularly for the Early populations, which look potentially bimodal.

      Agreed.

      We will perform Kolmogorov–Smirnov and Gaussian mixture model analyses of the single-cell long-lived fraction and residence-time distributions across stages, reporting these alongside the existing Welch ANOVA results in a new supplementary figure. This analysis is consistent with the conceptual framework cited in the manuscript (Wheat et al., 2020; Palii et al., 2019) for probabilistic hematopoietic transitions and may reveal subpopulation structure underlying the Early-stage signal. The GRID analysis further complements this by formally testing whether multi-state mixture models are statistically preferred at each stage. However, GRID analysis requires aggregating binding events across cells, which limits our ability to monitor changes in population dispersion at the single-cell level.

      (5) Quantitative integration of CUT&Tag with SMT

      Attempt a back-of-the-envelope calculation of whether the residence-time or fraction changes are quantitatively consistent with the acquisition of the 1,167 Early-restricted sites.

      Partially agreed; will attempt an order-of-magnitude framing.

      We thank the reviewer for this thoughtful suggestion. We agree that more explicit framing of the quantitative relationship between the two datasets will strengthen the integration. We will add a paragraph to the Discussion presenting an order-of-magnitude calculation linking the observed residence-time and long-lived-fraction changes to the steady-state occupancy increase predicted at competent regulatory sites, with explicit caveats regarding (i) the inherently semi-quantitative nature of CUT&Tag signal and (ii) the assumptions required to translate population-averaged occupancy into the genome-wide site count observed. For the G1EER4 cells, we observe relatively minor shifts in population-mean behavior as single-cell dispersion increases. Therefore, it may be difficult to directly link population-based measurements (e.g. CUT&Tag) with single-cell kinetic measurements (SPT). This distinction between occupancy and dynamics is consistent with recent systematic SMT analysis of the eukaryotic transcription machinery, in which factors appearing persistently associated in ensemble genomic assays were shown to exchange on second-scale timescales in living cells (Ling et al., Science 2026), emphasizing that population genomic occupancy and single-molecule residence time are complementary but not directly interchangeable measurements. Closing this gap rigorously is a major hurdle for the field and will require substantial technology development on quantitative single-cell CUT&Tag occupancy measurements. We will therefore frame our analysis as a consistency check rather than a strict quantitative integration. The reviewer notes that this analysis “does not change the central message; it sharpens it,” and we agree.

      (6) Short-lived kinetic interpretation and tracking parameters

      The 1.5 s gap allowance is long relative to the short-lived residence times in primary cells. A sensitivity analysis with tighter gap parameters would help. Also clarify how slowing of search reconciles with increased binding events at Early.

      Agreed.

      Addressed by the tracking-parameter sensitivity analysis described under R1 point 2. We apologize for the lack of clarity in our original description of the gap allowance. Our current maximum off-frame parameter is set to 2 frames, corresponding to a 0.5-s gap allowance. We will rerun the tracking analysis on representative datasets using a maximum off-frame parameter of 1, corresponding to no missed frames, and will report the resulting residence-time distributions alongside the original analysis to demonstrate robustness. We will also clarify in the Results and Discussion how changes in short-lived binding kinetics are reconciled with the increase in detectable binding events at the Early stage, drawing on the apparent engagement-rate proxy interpreted alongside the GRID-derived state-spectrum analysis.

      (7) CUT&Tag peak definition and quantitative analysis

      Report (a) signal intensity distribution at the 1,167 sites across stages (scatter or density plot beyond the heatmap) or (b) differential binding analysis (e.g., DESeq2). State replicate count and overlap of Early-restricted sets across replicates.

      Agreed; normalized fold-change analysis completed, with replicate-aware differential binding analysis planned if additional replicates are generated.

      We have performed a normalized count-based fold-change analysis of the union peak set from the existing GATA2 CUT&Tag dataset (14,468 peaks) using the goodpeaks framework previously used in our group, yielding per-peak log2 fold-change values and discrete dynamicstatus calls (Gained / Lost / Unchanged at |log2FC| ≥ 2) for each of the two transitions (Basal → Early at 0 vs 2 h, and Early → Late at 2 vs 24 h). This provides a conservative quantitative complement to the presence/absence peak-calling analysis presented in Figure 5; if additional replicate data are generated, we will perform replicate-aware differential binding analysis (DiffBind/DESeq2; Love et al., 2014; Stark & Brown, 2011) and report replicate overlap. This analysis addresses option (b) of the reviewer’s request and also enables the visualization requested in option (a) as a cross-stage scatter (Author response image 1). We present the quantitative analysis as a supplement to the presence/absence-defined Early-restricted set in Figure 5 of the manuscript, providing two orthogonal lines of evidence for the same biology. We note that the CUT&Tag experiments were initially performed as a validation step to confirm that the tagged GATA2-Halo constructs recapitulate endogenous chromatin-binding behavior, including appropriate genomic localization and expected GATA switch dynamics. This validation supports the conclusion that the observed single-molecule kinetics reflect physiologically relevant GATA2 engagement. Having established this, we subsequently extended the dataset to perform the quantitative analyses presented here.

      Quantitative findings.

      - 384 peaks were Gained (|log2FC| ≥ 2) at the Basal → Early transition.

      - 1,006 peaks were Lost over the same transition.

      - 178 peaks were Gained at Basal → Early and subsequently Lost at Early → Late, defining the strict differentially-restricted Early set (Author response image 1, red points). This set represents the higher-confidence subset of the manuscript’s broader presence/absence-defined Earlyrestricted set (n = 1,167; defined as MACS2 peaks at q < 0.01 present at Early but absent at Basal and Late).

      - 200 peaks were Gained at Early and retained at Late, indicating stable acquisition.

      - 49 peaks were acquired only at the Late stage.

      The discrepancy between the broader presence/absence set (1,167) and the strict differential set (178) reflects the analytical choice the reviewer raised: presence/absence calls based on a peaksignificance threshold are sensitive to near-threshold peaks, whereas differential analysis with a fold-change cutoff captures only sites with quantitatively pronounced stage-restricted enrichment. We interpret these as two complementary definitions: the broader set captures all peaks meeting a stage-specific peak-calling criterion, and the strict subset isolates the most quantitatively dynamic core of that population.

      Importantly, the three named example loci shown in Figure 5D of the manuscript — Nono (promoter-proximal), Nr3c1 (intron 2), and Gata3 (distal intergenic) — all survive the strict differential criterion (each shows |log<sup>2</sub>FC| ≥ 2 in both transitions, consistent with a clean Gainedthen-Lost signature). The published example panel therefore represents the high-confidence intersection of both definitions, supporting the robustness of the manuscript’s selected illustrative cases.

      We will explicitly state the number of CUT&Tag replicates per stage in the revised Methods and figure legends. Where the differential analysis is currently based on a single replicate per stage, we will explicitly note this and treat the strict subset as a conservative confirmatory analysis. An additional replicate is under consideration for the full revision, and if performed, overlap of Earlyrestricted calls across replicates will be reported.

      Motif cross-validation against a matched-GC background using HOMER and/or MEME-ChIP is planned for the strict differential subset and will be reported alongside the original SeqPos analysis in the revised Figure 5F or its supplement.

      Author response image 1.

      Cross-stage log<sub>2</sub> fold-change scatter for GATA2 CUT&Tag peaks. Each point represents a single peak in the union peak set (n = 14,468). The x-axis shows the log2 fold change from Basal (0 h) to Early (2 h); the y-axis shows the log2 fold change from Early (2 h) to Late (24 h). The sign convention follows the field-standard direction (positive log2FC = increased signal at the later time point). Peaks are colored by dynamic-status classification: unchanged/other (gray; n = 9,794); Lost at Early (blue; n = 109); Gained at Early and retained at Late (orange; n = 200); acquired only at Late (teal; n = 49); and Early-restricted, defined as Gained at Early and Lost at Late with |log2FC| ≥ 2 in both transitions (red; n = 178). The Early-restricted population occupies the lower-right quadrant, consistent with a transient kinetic peak of GATA2 binding.

      Author response image 2.

      Density representation of GATA2 CUT&Tag peak dynamics with Early-restricted peaks highlighted.

      Author response image 2 is shown for illustrative reference and is not annotated with a separate legend; it presents the same data as Author response image 1 in a hexbin density format to emphasize the bulk of unchanged peaks at the origin and the spatial separation of the Early-restricted set.

      Author response image 3.

      Genomic-annotation comparison of newly acquired GATA2 binding at Early. Stacked-bar comparison of genomic annotations (ChIPseeker classification) for two definitions of the newly acquired GATA2 peaks at the Early erythroid stage: all peaks Gained at Basal → Early (orange; n = 384) and the strict Early-restricted subset (Gained then Lost; red; n = 178). Annotation categories shown: Promoter (≤1 kb of TSS), Intron, Distal Intergenic, and Other (Exon, 5′/3′ UTR, Downstream). Both peak sets contain substantial promoter-proximal and distal/intronic components, consistent with the two-subclass model described in Figure 5E–G of the manuscript (GATA2-only promoter-proximal peaks with GATA/RUNX motifs, and GATA2/GATA1 cobound distal peaks with composite GATA/E-box motifs). The strict subset shows a higher proportion of intronic and distal-intergenic sites and a lower proportion of promoter-proximal sites than the full Gained set; this difference will be discussed transparently in the revised Results. Motif analysis (HOMER/MEME-ChIP, planned for the full revision) will be performed on both peak sets to confirm that the GATA/RUNX and GATA/E-box subclass signatures are preserved.

      (8) Knock-in mouse hematopoietic validation

      A brief characterization of basic hematopoietic parameters in homozygotes (CBC, LSK/HSPC frequencies, or colony assays) would confirm the tagged allele is physiological.

      Agreed; data acquired and analyzed.

      We have characterized mature trilineage hematopoietic populations in whole bone marrow from wild-type, heterozygous (Gata2Het), and homozygous (Gata2Homo) Gata2-SNAP knock-in mice (n = 5 per genotype). Bone marrow cells were stained for myeloid (CD11b<sup>+</sup> Gr1<sup>+</sup>), lymphoid (CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>+</sup>/B220<sup>+</sup>/CD19<sup>+</sup>), and erythroid (Ter119<sup>+</sup>) markers and analyzed by flow cytometry. Lineage frequencies are shown as percentages of live bone marrow cells in a new Figure Supplement in the revised manuscript.

      For myeloid and erythroid populations, omnibus one-way ANOVA detected no significant differences across genotypes (Myeloid: F(2,12) = 2.616, P = 0.1140; Erythroid: F(2,12) = 0.4943, P = 0.6219). Dunnett’s multiple-comparisons test against the WT control did not detect significant pairwise differences for either knock-in genotype (Myeloid: WT vs Het P = 0.1351, WT vs Homo P = 0.9926; Erythroid: WT vs Het P = 0.7017, WT vs Homo P = 0.9602).

      For the lymphoid compartment, although the omnibus ANOVA reached significance (F(2,12) = 6.690, P = 0.0112), no pairwise comparison against WT remained significant after multiplecomparisons correction (Dunnett’s adjusted P values: WT vs Het = 0.1217; WT vs Homo = 0.2078). We therefore interpret this result conservatively. Brown-Forsythe and Bartlett’s tests showed no significant differences in variance across genotypes (P = 0.1423 and P = 0.0908), so the result is not attributable to unequal variances. We do not interpret these data as indicating an unambiguous lymphoid phenotype in either heterozygous or homozygous Gata2-SNAP mice; this interpretation is consistent with the broader pattern across all three lineages, in which no pairwise comparison against WT survives multiple-comparisons correction. We will note in the figure legend and in the Results text that more granular HSPC-compartment analysis (LSK, MPP, lineage-restricted progenitor frequencies) and a complete blood count (CBC) remain valuable directions for future characterization of this resource and will be considered for the full revision if specifically requested.

      Author response image 4.

      Bone marrow trilineage frequencies in Gata2-SNAP knock-in mice. Bone marrow was harvested from the femurs and tibias of wild-type (WT), heterozygous (Gata2Het), and homozygous (Gata2Homo) Gata2-SNAP knock-in mice (n = 5 per genotype; mixed sex; 12–14 weeks). After ACK lysis, cells were stained for myeloid (CD11b<sup>+</sup> Gr1<sup>+</sup>), lymphoid (CD3<sup>+</sup>/CD4<sup>+</sup>/CD8<sup>+</sup>/B220<sup>+</sup>/CD19<sup>+</sup>), and erythroid (Ter119<sup>+</sup>) markers and analyzed by flow cytometry. Each dot represents one mouse, and horizontal bars indicate genotype means. Statistical results: Myeloid: ANOVA F(2,12) = 2.616, P = 0.1140; Dunnett’s adjusted P values WT vs Het = 0.1351, WT vs Homo = 0.9926. Lymphoid: ANOVA F(2,12) = 6.690, P = 0.0112 (omnibus); Dunnett’s adjusted P values WT vs Het = 0.1217, WT vs Homo = 0.2078. Erythroid: ANOVA F(2,12) = 0.4943, P = 0.6219; Dunnett’s adjusted P values WT vs Het = 0.7017, WT vs Homo = 0.9602. Brown-Forsythe and Bartlett’s tests for unequal variance were non-significant in all three lineages. Although the lymphoid omnibus ANOVA reached nominal significance, no pairwise comparison with WT remained significant after multiple-comparison correction; we therefore interpret this result conservatively (see response to R3 point 8).

      Summary

      We thank the editors and the three reviewers for the constructive and detailed assessment. The planned revisions consist of:

      - Four new experiments [planned] (HaloTag/SNAP labeling efficiency and absolute molecule counts via U2OS reference standards; H2B-HaloTag photobleaching reference; percell quantification of total endogenous GATA2 in flow-sorted primary Gata2-SNAP populations via saturating SNAP-tag labeling, benchmarked against a SNAP-RPB1/U2OS reference standard; single-molecule tracking of GATA2 N-terminal, C-terminal, and double zinc-finger deletion mutants in the engineered cell systems as a binding-deficient functional control).

      - Six analyses of existing data (GRID multi-state fitting [planned]; per-cell bleach-rate distributions and photobleach-corrected residence times [planned]; tracking-parameter sensitivity [planned]; nuclear-area normalization and total-displacement controls [planned]; normalized fold-change CUT&Tag analysis [completed; motif cross-validation planned], presented in Author response images 1–3; distribution-based single-cell statistics [planned]).

      - One previously-acquired dataset [completed] (trilineage hematopoietic flow cytometry of homozygous Gata2-SNAP knock-in mice; presented in Author response image 4 with full statistical detail).

      - Substantial revisions to text and figures [planned] to address statistical reporting, methodological description, mechanistic framing of cross-system differences, and refinement of the Figure 6 schematic.

      With respect to the requested binding-deficient single-molecule control, we will attempt to address this directly using sequence-validated lentiviral constructs in hand encoding GATA2 mutants lacking the C-terminal zinc finger, the N-terminal zinc finger, or both. These mutant analyses will be complemented by GRID multi-state analysis and H2B-HaloTag controls, providing converging lines of validation for the two-state kinetic framework. We note that an analogous mutant cannot be examined in the physiological context of the Gata2-SNAP knock-in mouse, and we will frame the cell-line mutant analyses accordingly.

      We believe these revisions directly address the editors’ specific guidance regarding labeling efficiency and methodological clarification. We thank the editors and reviewers for their time and look forward to submitting the revised manuscript.

      References cited in this response:

      References listed below are cited in this provisional response in support of the planned analyses and methodology.

      Cattoglio, C., Pustova, I., Walther, N., Ho, J. J., Hantsche-Grininger, M., Inouye, C. J., Hossain, M. J., Dailey, G. M., Ellenberg, J., Darzacq, X., Tjian, R., & Hansen, A. S. (2019). Determining cellular CTCF and cohesin abundances to constrain 3D genome models. eLife, 8, e40164. https://doi.org/10.7554/eLife.40164

      Gebhardt, J. C. M., Suter, D. M., Roy, R., Zhao, Z. W., Chapman, A. R., Basu, S., Maniatis, T., & Xie, X. S. (2013). Single-molecule imaging of transcription factor binding to DNA in live mammalian cells. Nature Methods, 10(5), 421–426. https://doi.org/10.1038/nmeth.2411

      Hansen, A. S., Pustova, I., Cattoglio, C., Tjian, R., & Darzacq, X. (2017). CTCF and cohesin regulate chromatin loop stability with distinct dynamics. eLife, 6, e25776. https://doi.org/10.7554/eLife.25776

      Haque, N., & Coleman, R. A. (2025). Dynamic transcription pre-initiation complex assembly governs initiation efficiency. bioRxiv. https://doi.org/10.1101/2025.05.07.652662

      Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010). Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Molecular Cell, 38(4), 576–589. https://doi.org/10.1016/j.molcel.2010.05.004

      Kaya-Okur, H. S., Wu, S. J., Codomo, C. A., Pledger, E. S., Bryson, T. D., Henikoff, J. G., Ahmad, K., & Henikoff, S. (2019). CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nature Communications, 10(1), 1930. https://doi.org/10.1038/s41467-019-09982-5

      Kenworthy, C. A., Haque, N., Liou, S.-H., Chandris, P., Wong, V., Dziuba, P., Lavis, L. D., Liu, W.-L., Singer, R. H., & Coleman, R. A. (2022). Bromodomains regulate dynamic targeting of the PBAF chromatin-remodeling complex to chromatin hubs. Biophysical Journal, 121(9), 1738–1752. https://doi.org/10.1016/j.bpj.2022.03.027

      Ling, Y. H., Liang, C., Wang, S., & Wu, C. (2026). Live-cell single-molecule dynamics of eukaryotic RNA polymerase machineries. Science, 391, eads0960. https://doi.org/10.1126/science.ads0960

      Liu, Z., Legant, W. R., Chen, B.-C., Li, L., Grimm, J. B., Lavis, L. D., Betzig, E., & Tjian, R. (2014). 3D imaging of Sox2 enhancer clusters in embryonic stem cells. eLife, 3, e04236. https://doi.org/10.7554/eLife.04236

      Loeffler, D., Wang, W., Hopf, A., Hilsenbeck, O., Bourgine, P. E., Rudolf, F., Martin, I., & Schroeder, T. (2018). Mouse and human HSPC immobilization in liquid culture by CD43- or CD44-antibody coating. Blood, 131(13), 1425–1429. https://doi.org/10.1182/blood-2017-07-794131

      Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and dispersion for RNAseq data with DESeq2. Genome Biology, 15(12), 550. https://doi.org/10.1186/s13059-014-0550-8

      Machanick, P., & Bailey, T. L. (2011). MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics, 27(12), 1696–1697. https://doi.org/10.1093/bioinformatics/btr189

      Normanno, D., Boudarène, L., Dugast-Darzacq, C., Chen, J., Richter, C., Proux, F., Bénichou, O., Voituriez, R., Darzacq, X., & Dahan, M. (2015). Probing the target search of DNA-binding proteins in mammalian cells using TetR as model searcher. Nature Communications, 6, 7357. https://doi.org/10.1038/ncomms8357

      Palii, C. G., Cheng, Q., Gillespie, M. A., Shannon, P., Mazurczyk, M., Napolitani, G., Price, N. D., Ranish, J. A., Morrissey, E., Higgs, D. R., & Brand, M. (2019). Single-cell proteomics reveal that quantitative changes in co-expressed lineage-specific transcription factors determine cell fate. Cell Stem Cell, 24(5), 812–825.e5. https://doi.org/10.1016/j.stem.2019.02.016

      Sergé, A., Bertaux, N., Rigneault, H., & Marguet, D. (2008). Dynamic multiple-target tracing to probe spatiotemporal cartography of cell membranes. Nature Methods, 5(8), 687–694. https://doi.org/10.1038/nmeth.1233

      Stark, R., & Brown, G. D. (2011). DiffBind: Differential binding analysis of ChIP-Seq peak data. Bioconductor. http://bioconductor.org/packages/release/bioc/html/DiffBind.html

      Taylor, S. J., Stauber, J., Bohorquez, O., Tatsumi, G., Kumari, R., Chakraborty, J., Bartholdy, B. A., Schwenger, E., Sundaravel, S., Farahat, A. A., Dutta, A., Koche, R. P., Steidl, U., & Wheat, J. C. (2024). Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity. Nature Genetics, 56(10), 2213–2227. https://doi.org/10.1038/s41588-024-01911-7

      Wheat, J. C., Salsman, J., Reekie, I., Mathhwala, A., Black, K. L., Tiedt, R., Shroff, H., & Steidl, U. (2020). Single-molecule imaging of transcription dynamics in somatic stem cells. Nature, 583(7816), 431– 436. https://doi.org/10.1038/s41586-020-2432-4

    1. Reviewer #1 (Public review):

      Summary:

      Eroglu and Hobert demonstrate that injecting CRISPR guides and repair constructs to target three genes at a time, tagging each with a different fluorescent protein, and selecting which gene to tag with which fluorophore based on genes' expression levels, can improve efficiency of gene tagging.

      Strengths:

      This manuscript demonstrates that three genes can be targeted efficiently with three different fluorophores. It also presents some practical considerations, like using the fluorophore least complicated by agar/worm autofluorescence for genes with low expression levels, and cost calculations if the same methods were used on all genes.

      Weaknesses:

      Eroglu has demonstrated in a previous publication that single-stranded DNA injection can increase efficiency of CRISPR in C. elegans, while inserting two fluorescent proteins and a co-CRISPR marker into three loci, and Paix et al 2015 demonstrated simultaneous insertion of two fluorescent tags. The current work is valuable and incremental advance. In general, I applaud the authors' willingness to strategize about how whole proteome tagging might be accomplished. I predict that the advance here will be one of many small advances that will get the field to that goal. The title oversells the advance presented, in my view, since seems like one among many key advances, and the first sentence of the Discussion seems a more apt summary of the key advance here.

      Some injections targeted genes on the same chromosome together, which will create unnecessary issues when doing crossing that will be useful for some future experiments. This made me wonder if injecting 3 together really is helpful vs targeting each gene separately, since only 5 worms need to be injected. It cuts time down by 2/3, but perhaps avoiding targeting the same chromosome with two tags would be useful.

      The limited utility of current blue fluorescent proteins makes me wonder if it's worth using at this stage, before there are better blue fluorescent proteins, or better yet, far red, to avoid issues with live imaging under phototoxic UV or near-UV illumination.

    2. Reviewer #2 (Public review):

      Original Review:

      The manuscript by Eroglu and Hobert presents a set of strains each harboring up to three fluorescently tagged endogenous proteins. While there is technically nothing wrong with the method and the images are beautiful, we struggled to appreciate the advance of this work - who is this paper for?

      As a technical method, the advance is minimal since the first author had already demonstrated that three mutations (fluorophore insertion and co-CRISPR marker) could be introduced simultaneously.

      As a pilot for creating genome-scale resources, it is not clear whether three different fluorophores in one animal, while elegantly designed and implemented, will be desired by the broader community.

      Finally, the interpretation of the patterns observed in the created lines leaves much to be desired. A Table with all the observations must be included and can replace the tedious (and often wrong) descriptions of the observations with the different lines. It would be too much to point out every mistaken expectation of protein expression. Two examples include:

      The expectation that ACDH-10 is enriched in the intestine and epidermal tissues (hypodermis) is naïve - there are multiple paralogs of this protein (look at WormPaths or WormFlux) that may share functions in different tissues. There is also no reason to assume that fatty acid metabolism does not occur in other tissues (including the germline). Finally, there are no published studies about this enzyme, so we really don't know for sure what it's doing.

      The expectation that HXK-1 is ubiquitously expressed is similarly naïve. There are three paralogous enzymes that are all associated with the same reaction, and we have shown that these three function redundantly in vivo, perhaps in different tissues (PMID: 40011787). Moreover, single cell RNA-seq data (PMID: 38816550) also shows enrichment of hxk-1 in gonadal sheath cells.

      The table should have at least the following information: gene/protein name - Wormbase ID - TPM levels of single cell data assigned to tissues for L2, L4 and adult (all published) - tissues in which expression is observed in the lines presented by the authors.

      Other points:

      (1) We would encourage the authors to provide systematic validation of the reported insertions. The manuscript reports that 24 of 30 tags were isolated and visible but does not clearly state whether each isolated line was confirmed by sequence‑level validation to be correctly in‑frame and free of unintended mutations at the target locus.

      (2) The manuscript presents aggregated success counts (e.g., 8/10 mTagBFP2 tags, 9/10 mStayGold, 7/10 mScarlet3) and useful narrative descriptions of injection outcomes. We suggest also to include per‑locus success rates.

      (3) For pools that required re‑injection after initial failures, we would like to see a description of the specific changes that were made to the injection mixes or procedures (e.g., new repair template prep, different Cas9 reagent lot, guide redesign). This will be useful troubleshooting information for others.

      (4) The authors states that the fluorophore sequences are codon-optimized for C. elegans. We suggest they provide the exact donor/tag sequences used specifically state whether the fluorophore sequences contain any synthetic/artificial introns or other sequence modifications (e.g., silent PAM‑disrupting mutations) were included in the donor templates.

      (5) Page 3: Include a reference for "The C. elegans genome encodes around 20,000 genes"

      We hope these comments are useful.

      Comments on Revised Version:

      Overall, we found the responses to be quite recalcitrant.

      We have one remaining composite concern about the comparison between observed expression patterns with the new strains versus published data.

      First, the authors only report patterns for one stage while it should be not too much effort to image the different life stages. However, since this is a revision, we are not formally requesting they do this.

      Second, in the now provided Table (thank you) 'observed expression' (last column) is lacking for 9 of the 30 proteins, and for 6 of these the procedure was not successful. Why not report patterns for the other three? It is confusing also because on page 5, the authors say that "overall, 24 of 30 tags ...all of which were visible with fluorescence stereomicroscopy" - are we missing something? Also, they then said that they "obtained 6/9 of the originally failed tags"; why are the corresponding patterns not included in table 1, and are 9 proteins still labeled as "no" in the "success?" Column?

      Third, we strongly feel that the response to our comments about expression patterns is not adequate. On page 5 the authors say that "all proteins were expected to be ubiquitously expressed" and that "scRNA-seq indicated that transcript abundance was ubiquitous and without strong tissue-specific enrichment with few exceptions". However, in their rebuttal, the authors now argue for tissue-specific expression for proteins with paralogs, turning around their own argument! Moreover, their Table indicates that many genes show tissue-enriched expression by RNA-seq while many of their tagged proteins exhibit ubiquitous expression.

      Overall, this indicates that both the overall accomplishment of generating tagged protein strains and analyzing their expression is oversold.

    3. Reviewer #4 (Public review):

      Summary:

      Tagging the entire proteome of a metazoan would be a landmark achievement, providing a powerful complement and extension to existing "omic" catalogs in model systems. Here, Eroglu and Hobert argue that efficiently tagging multiple loci in a single "batch" would make the community-based achievement of this goal realistic. They provide rigorous evidence that such an approach is indeed feasible, exploring issues related to efficiency, design and screening strategies, disruption of gene function, and the potential for endogenously tagged alleles to reveal unexpected aspects of protein expression and localization. While the work has some minor gaps that are important to rigorously assess the feasibility of the proposed effort, the detailed and valuable insights that emerge should provide impetus to the community to coordinate efforts to make this ambitious goal a reality.

      Strengths:

      The work has numerous strengths. The authors provide compelling evidence that:

      - three distinct loci can be efficiently targeted with three distinct fluorescent tags in a single injection.

      - thoughtful targeting design can reduce the likelihood of disruption of function by the tag.

      - systematic design principles based on expression level and predicted localization/function can be used to optimize tagging strategies.

      - the resulting tags can provide unexpected insight into patterns of protein production and subcellular localization.

      Not all of these advances are novel in themselves, but taken together, they represent an important technical and conceptual advance. The most important strength comes from the exceptionally high value of the goal itself, in that the work is that it has the potential to spur a community-wide effort toward achieving the ambitious goal of proteome-wide tagging.

      Weaknesses:

      The work's shortcomings are minor.

      - One concern has to do with the feasibility of the proposed screening strategies. The experimental design cleverly coinjects tags for three loci in different gene expression 'zones'; this expression level determines which tag will be used. As the authors allude to, there is an important distinction between genes with the same overall FKPM value between those that are expressed broadly and those focally expressed in a specific tissue. The proposed strategy claims that there are a sufficient number of highly expressed genes "to be used as visible markers" for recovering successfully edited animals. It would be useful for the authors to discuss the issue of broad vs focused expression among this set of genes a bit more thoroughly, with an eye toward the issue of how likely it is that these genes could indeed consistently be used as visible markers, particularly for those at the low end of this limit.

      - What fraction of the proteome (on a per-gene basis) is secreted proteins? How difficult will it be to screen these for successful tags? Are there specific tags that would be more optimal for secreted proteins? (The authors mention the use of an SL2 or T2A cassette to label the cells in which these proteins are expressed but note that there are technical challenges associated with doing this at scale.)

      - For secreted and/or weakly expressed genes, it would be useful for the authors to estimate for what fraction of these would successful insertions need to be screened by PCR, and what resources (time and money) this would likely entail.

      - For how many genes would a single tag not capture all predicted isoforms?

      - Finally, some readers might object to the authors' assertion in the abstract that this work is "a first step in this direction" (presumably referring to designing a strategy for whole-proteome tagging). There is no concern that the authors are disregarding the extensive work of other groups, as they explicitly mention the contributions of other groups to the foundation that enables the present work. However, the spirit of the abstract could be misinterpreted by a well-intentioned reader.

    4. Author response:

      The following is the authors’ response to the original reviews.

      eLife Assessment

      The nematode C. elegans is an ideal model in which to achieve the ambitious goal of a genome-wide atlas of protein expression and localization. In this paper, the authors explore the utility of a new and efficient method for labeling proteins with fluorescent tags, evaluating its potential to be the basis for a larger, genome-wide effort that is likely to be very useful for the community. While the evidence for the method itself is solid, carrying out this project at a large scale will require significant additional feasibility studies.

      We appreciate the editor’s recognition that the evidence for our method is solid and that a genome-wide protein atlas in C. elegans would be highly valuable to the community. However, we respectfully disagree that “significant additional feasibility studies” are required. Take the yeast proteome-wide GFP tagging project (Huh et al., Nature 2003). It achieved ~75% coverage of ~6,000 proteins directly from an established protocol without any prior significant feasibility studies, at least to our knowledge. While the C. elegans genome is 3 times in size, we would argue that our tagging protocol may even be less labor intensive as it does not involve any cloning and the screening is visual, requiring no molecular biology skills. Reviewer 3 notes: ‘They also provide convincing evidence that labelling the whole proteome is an achievable goal with relatively limited resources and time.’

      Our pilot study validates all key parameters for genome-wide scaling: editing efficiency at novel loci with untested reagents, viability of tagged worms, and detectability of multiple spectrally separated fluorophores across expression ranges. These address the core technical, biological, and practical challenges of large-scale endogenous tagging in a multicellular organism, leaving no fundamental barriers in our view.

      The proposed cost and timeline align quite favorably with established large-scale consortium projects: e.g., ENCODE pilot analyzed 1% of the human genome at ~$55 million over 4 years; Mouse Knockout Consortium scaled to ~20,000 genes over 20 years (ongoing) with ~$100 million; Human Protein Atlas mapped ~87% of proteins with antibodies in fixed cells (through much more labor intensive methods) over 20+ years at >$100 million. With ~8% of C. elegans genes already tagged (WormTagDB) and labs already tagging entire gene classes (PMID: 40463100), scaling our protocol to the proteome is feasible, potentially covering the genome in 5-6 years by a single lab or faster with distributed effort at a reagent cost of merely $2.2 million. The main barriers now are funding commitment and assembling collaborators, not further feasibility testing.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      Eroglu and Hobert demonstrate that injecting CRISPR guides and repair constructs to target three genes at a time, tagging each with a different fluorescent protein, and selecting which gene to tag with which fluorophore based on genes' expression levels, can improve the efficiency of gene tagging.

      Strengths:

      This manuscript demonstrates that three genes can be targeted efficiently with three different fluorophores. It also presents some practical considerations, like using the fluorophore least complicated by agar/worm autofluorescence for genes with low expression levels, and cost calculations if the same methods were used on all genes.

      Weaknesses:

      Eroglu has demonstrated in a previous publication that single-stranded DNA injection can increase the efficiency of CRISPR in C. elegans while inserting two fluorescent proteins and a co-CRISPR marker into three loci. The current work is, therefore, an incremental advance. In general, I applaud the authors' willingness to think ahead to how whole proteome tagging might be accomplished, but I predict that the advance here will be one of many small advances that will get the field to that goal.

      Our manuscript indeed builds on prior multiplex editing (including our own co-CRISPR work), but the manuscript's primary contribution is not a novel technical breakthrough per se. Instead, our main goal was to pilot and strategize a feasible path to whole-proteome tagging in C. elegans and, most critically, test the following key parameters: (1) success rate of triple pools with prior untested reagents at novel targets; (2) utility of fluorophores across expression levels; (3) major effects on tagged protein function. In prior multiplexing, we used two targets which we already knew could be edited quite efficiently, with the 3rd target a point mutation with nearly 100% efficiency. Thus, it was not at all clear that picking 3 random genes and replacing the 3rd highly efficient locus with another less efficient large insertion would work or be sufficiently scalable for thousands of novel genes with unvalidated reagents at first pass.

      The title vastly oversells the advance in my view, and the first sentence of the Discussion seems a more apt summary of the key advance here.

      Some injections target genes on the same chromosome together, which will create unnecessary issues when doing necessary backcrossing, especially if the mutation rate is increased by CRISPR.

      We disagree with the reviewer’s assessment of the need for backcrossing, for two reasons: (1) Prior studies have shown that off-target mutations are not a serious concern in C. elegans (reviewed in PMID: 26336798). For instance, WGS of strains after CRISPR/Cas9 found negligible off-target effects (PMID: 25249454, PMID: 30420468 – using similar RNP/ssDNA method and multiple guides; PMID: 23979577, PMID: 27650892 using other methods). Targeted sequencing studies have reported similar findings, using various CRISPR/Cas9 methods, with essentially no mutations at sites other than the intended target (PMID: 23995389; PMID: 23817069). (2) If the goal is to tag the entire genome, the introduction of backcrossing should not reasonably be a routine part of the initial tagging.

      Lastly, if one really does want to backcross, the existence of tags on the same chromosome is actually an advantage because it permits selection for recombinants with wild-type chromosomes.

      Also, the need for backcrossing and perhaps sequencing made me wonder if injecting 3 together really is helpful vs targeting each gene separately, since only 5 worms need to be injected.

      Apart from our disagreement regarding backcrossing, we are puzzled by the reviewer’s comment. Why would one do single tagging at a time, rather than triple tagging if the whole point is to scale up tagging? It is important to keep in mind that the rate limiting step for tagging the whole genome is the number of injections that can be done per day. Since there is no cloning to generate the repair templates/guides and all other reagents are commercially available and not sample specific, these can be prepared quite rapidly. Being able to isolate multiple lines (together or independently) from the same injection increases throughput 3-fold and in our view does not provide any disadvantages as individual tags can be isolated independently if desired.

      Beyond the numerous technical advantages pooling provides (also lower cost and throughput for making injection mixes as well as imaging), our results show that it yields epistemic benefits as well: we would never have noted the subcellular pattern in Fig. 6B, C with different sets of mitochondria being marked by different mitochondrial proteins had we imaged them separately or even aligned to a pan-mitochondrial landmark. As we mentioned in the discussion, grouping proteins predicted to localize to the same compartment together can simultaneously test how uniform or differentiated such compartments are during the screen.

      The limited utility of current blue fluorescent proteins makes me wonder if it's worth using at all at this stage, before there are better blue (or far red) fluorescent proteins.

      We do not think that the utility of current BFPs is that limiting. At least the theoretical brightness of mTagBFP2 is comparable to that of EGFP (PMID: 30886412), which was useful for the bulk of currently tagged proteins. Due to modestly higher autofluorescence in the blue spectrum, the practical brightness is somewhat less ideal, but we have shown that many proteins are expressed high enough to be detected quite well with mTagBFP2 by eye at low magnification. We also note that many tags that are not visible by eye under a dissection scope become visible with long exposure cameras of widefield microscopes or modern confocal (GaAsP) detectors, so the list of genes detectable with mTagBFP2 is likely to be much higher. We routinely use mTagBFP2 to super-resolve subnuclear structures with endogenous tags (e.g., in the nucleolus), with some tags having lower annotated FPKMs than the genes tested here.

      Some literature reviews, particularly in the Introduction and Abstract, rely too much on recent examples from the authors' laboratory instead of presenting the state of the field. I'd like to have known what exactly has been done with simultaneous injection targeting multiple loci more thoroughly, comparing what has been accomplished to date by various laboratories' advances to date.

      We are not sure what the reviewer is referring to. In the Abstract, we do not refer to any literature. In the Introduction, we cite 28 papers, 6 of those from our lab (4 of which providing examples of protein tags). We do not believe that this can be fairly called an unbalanced presentation of the state of the field.

      This being said, we have gladly expanded our Introduction to provide more background on co-CRISPRing. Labs have routinely used co-conversion (“coCRISPR”) markers for picking out their intended edits (e.g., point mutations or insertions), as it has been shown by multiple groups that a CRISPR/Cas9 edit at one locus correlates with efficiency at other simultaneous targets (PMID: 25161212). Generally, making point mutations with the Cas9/RNP protocol is highly efficient, especially at specific loci such as dpy-10. However, multiple FP-sized insertions have not been routinely attempted. We and only one other group have successfully attempted it using previously working targets and reagents (e.g., 28% in PMID: 26187122). Importantly, the efficiency of such multiple insertions has never been assessed at scale and using entirely untested reagents at novel sites – critical parameters to determine for a whole genome approach. So, we test here (1) the efficiency of triple insertions and (2) the chance of getting them with new and untested guides and reagents.

      In our view, since we have to use some injection/coCRISPR marker anyway for those genes which are not expressed at dissecting-scope visible levels (likely most genes), using highly expressed intended targets as improvised markers in a pooled approach makes our approach much more efficient. It allows us to find the worms with the highest chance of yielding CRISPR insertions, which we can screen with higher power methods for the dimmer targets, while enabling us to co-isolate other intended targets. Insertions, being often heterozygous in F1, can be segregated independently if desired, or homozygosed together to facilitate maintenance then outcrossed individually by those interested in studying specific genes in more detail.

      In the revised version of this manuscript, we now discuss some of these points in the introduction section:

      “Currently, around 1554 proteins representing 8% of the proteome are estimated to have been endogenously tagged (Leyhr et al., 2025). However, at current rates, tagging the proteome is projected to take around 100 years and likely involve numerous duplicate attempts on a small number of commonly studied proteins (Leyhr et al., 2025). It will thus be crucial for the field to coordinate tagging efforts and scale up tagging protocols to enable coverage of the entire genome at a reasonable timescale and cost. Given the number of injections is a major time-limiting factor, pooling multiple injections into one would at minimum cut tagging time by a factor of 3. In C. elegans, screening for novel CRISPR/Cas9-induced genomic edits is already facilitated either by use of co-injection markers (i.e., plasmids that form extrachromosomal arrays) that yield phenotypes or fluorescence in progeny of successfully injected worms, or co-editing well characterized loci using established and highly efficient reagents which likewise yield visible phenotypes. In the latter approach, termed “co-CRISPR”, worms edited at the marker locus are most likely to also carry the intended edit (Arribere et al., 2014). Recent methods for CRISPR/Cas9 mediated genomic insertions have pushed efficiencies to sufficient levels to simultaneously insert multiple fluorophores (e.g., mNeonGreen and mScarlet) as well as a co-CRISPR marker (dpy-10) at three independent loci in a single injection (Eroglu et al., 2023; Paix et al., 2015). These attempts pooled reagents previously established to work efficiently and targeted genes that were known to yield functional fusion proteins when tagged. Thus, while in principle current methods could allow tagging of at least 3 independent loci in one injection if a co-CRISPR marker is omitted, it is not known to what extent such an approach could be generalized across the genome with previously unvalidated reagents (i.e., guides and repair template homology arms) at novel loci to yield functional tags”

      Reviewer #2 (Public review):

      The manuscript by Eroglu and Hobert presents a set of strains each harboring up to three fluorescently tagged endogenous proteins. While there is technically nothing wrong with the method and the images are beautiful, we struggled to appreciate the advance of this work - who is this paper for?

      We consider this paper to have two purposes: (1) motivate the community to come together to consider such genome-wide tagging approach; (2) provide a reference point for funding agencies that such an aim is not unreasonable and will provide novel interesting insights.

      As a technical method, the advance is minimal since the first author had already demonstrated that three mutations (fluorophore insertion and co-CRISPR marker) could be introduced simultaneously.

      We agree that the basic principle is similar. However, it was not clear that triple pooling three novel large edits would work, given the numbers in our original paper or that it would be scalable.

      The dpy-10 coCRISPR marker previously used is a highly efficient single site, with close to 100% hit rate. We also knew in the earlier study that the two pooled insertions already worked quite efficiently and did not disrupt the function of targeted proteins. Exchanging these plus dpy-10 for three novel tags was not guaranteed to succeed for many potential reasons, including both biological and technical. For instance, such a “marker free” approach necessitates that a significant number of targets in the genome should be expressed highly enough to be visible by fluorescence stereomicroscopy when tagged with current best fluorophores. The chance of disrupting gene function by tagging was also not explored in detail in C. elegans, nor whether one untested guide is generally sufficient. We think that establishing these parameters was meaningful and necessary for the goal of whole genome tagging. We have clarified some of these points in the text.

      As a pilot for creating genome-scale resources, it is not clear whether three different fluorophores in one animal, while elegantly designed and implemented, will be desired by the broader community. 

      The usage of three different fluorophores is largely driven by the ability to co-inject and therefore cut injection effort by a factor of three. Moreover, having all three fluorophores together facilitates imaging and maintenance. Lastly, co-labeling has the potential to reveal unexpected patterns of co-localization or lack thereof (example: two mitochondrial proteins that we found to not have overlapping distribution). We clarified this point in the revised text in both the results and discussion.

      Finally, the interpretation of the patterns observed in the created lines is somewhat lacking. A Table with all the observations must be included. This can replace the descriptions of the observations with the different lines, which could be somewhat laborious for the reader, and are often wrong. There are numerous mistaken expectations of protein expression here, but two examples include:

      We are not convinced that our expectations are mistaken. Below we respond to the reviewer’s specific examples, and we are open to hear from the reviewer about additional cases.

      (1) The expectation that ACDH-10 is enriched in the intestine and epidermal tissues (hypodermis).

      There are multiple paralogs of this protein (see WormPaths or WormFlux) that may share functions in different tissues. There is also no reason to assume that fatty acid metabolism does not occur in other tissues (including the germline). Finally, there are no published studies about this enzyme, so we really don't know for sure what it's doing.

      The expression of acdh-10 is annotated in multiple scRNA datasets as intestine and epidermal enriched (CeNGEN/Taylor et al. 2021, highest in epidermis; Ghaddar et al 2023 highest in intestine). We did not mean to imply that fatty acid metabolism does not occur in the gonad, nor that a paralog of acdh-10 could not be performing the same function in tissues where acdh-10 is not expressed.

      However, this raises an important question: why have different paralogs doing the same thing? Duplicate genes with the same function are generally not evolutionarily stable (PMID: 11073452, PMID: 24659815). That there are such striking tissue specific expression patterns of an essential or widely expressed protein class suggests that paralogs of the gene likely differ in some meaningful parameter that might align with tissue-specific functional needs or regulation. The reviewer’s statement that ‘there are no published studies about this enzyme, so we really don't know for sure what it's doing’ is in fact an excellent demonstration of our point; finding out where the duplicates are expressed can provide a starting point to uncover potential differences between the paralogs. At the very least it can delineate to what degree paralogs diverge in their expression across the proteome and identify which such cases merit further study. In a more ideal scenario, prior information of protein function could indicate that the involved pathway requires tissue specific regulation.

      (2) The expectation that HXK-1 is ubiquitously expressed.

      Three paralogous enzymes are all associated with the same reaction, and we have shown that these three function redundantly in vivo, perhaps in different tissues (PMID: 40011787).

      The cited paper (PMID: 40011787) does not show where they are expressed. We discussed redundancy/paralogs above in point 1, and in our view the same applies here. They may perform the same reaction but are likely to differ in some meaningful way, be it regulation or rate of activity, for them to be stably maintained as functional genes over evolution.

      Moreover, single-cell RNA-seq data (PMID: 38816550) also show enrichment of hxk-1 in gonadal sheath cells.

      The Ghaddar et al. and CeNGEN/Taylor et al. datasets do not show this. The scRNA paper cited (PMID: 38816550) also shows enrichment in neurons, pharynx, coelomocyte and germ cells which we did not note. In our view, these in fact further support our goals: often, transcript datasets alone (frequently used to infer tissue function) do not sufficiently predict protein expression. One can post hoc find an scRNA-seq dataset that aligns somewhat with our protein observations, but how does one know which to trust a priori? Disagreements between transcript datasets will ultimately require resolution at the protein level, in our view.

      To clarify these points, we added the following to the discussion section:

      “We also noted unexpected cell type dependent distributions of proteins involved in broadly important metabolic processes such as ACDH-10, which was depleted from the germline compared to other tissues, and HXK-1, which was highly enriched in the gonadal sheath. Notably, for these as well as other cases, scRNA-seq datasets were not sufficient to deduce a priori the observed cell type specific differences at the protein level. Importantly, many genes encoding metabolic enzymes including acdh-10 and hxk-1 have paralogs that likely perform similar catalytic functions. Yet, duplicate genes with identical functions are generally not evolutionarily stable (Adler et al., 2014; Lynch and Conery, 2000); thus such genes are likely to differ in some meaningful parameter (e.g., regulation or activity) that might align with tissue-specific functional needs. Fully annotating the expression patterns of paralogs at the protein level could indicate which tissues require unique metabolic needs and indicate which paralogous genes have undergone sub- versus neo-functionalization. For those proteins that are less functionally understood, unexpected distributions might indicate which merit further study.”

      The table should have at least the following information: gene/protein name - Wormbase ID - TPM levels of single cell data assigned to tissues for L2, L4, and adult (all published) - tissues in which expression is observed in the lines presented by the authors.

      We added some of this information such as annotated expression levels in young adults from various scRNA datasets (but not larval datasets as we did not image these). We note that each of these studies use different pipelines and report different metrics (scaled TPM/Z-score versus Seurat average expression versus TPM), so comparisons between them are not informative unless they are integrated and analyzed together.

      Reviewer #3 (Public review):

      Summary:

      The authors argue that establishing the expression pattern and subcellular localisation of an animal's proteome will highlight many hypotheses for further study. To make this point and show feasibility, they developed a pipeline to knock in DNA encoding fluorescent tags into C. elegans genes.

      Strengths:

      The authors effectively make the points above. For example, they provide evidence of two populations of mitochondria in the C. elegans germline that differ qualitatively in the proteins they express. They also provide convincing evidence that labelling the whole proteome is an achievable goal with relatively limited resources and time.

      We appreciate the referee’s recognition that whole proteome tagging is feasible.

      Weaknesses:

      Cell biology in C. elegans is challenging because of the small size of many of its cells, notably neurons. This can make establishing the sub-cellular localisation of a fluorescently tagged protein, or co-localizing it with another protein, tricky. The authors point out in their introduction that advances in light microscopy, such as diSPIM, STED, and ISM (a close relative of SIM), have increased the resolution of light microscopy. They also point out that recent advances in expansion microscopy can similarly help overcome the resolution limit.

      (1) Have the authors investigated if the three fluorescent tags they use are appropriate for super-resolution microscopy of C. elegans, e.g., STED or SIM? Would Elektra be better than mTAGBFP2? How does mScarlet3-S2 compare to mScarlet 3?

      All three tags work for ISM (i.e., Airyscan). We previously tried Electra (not for the genes tested here) but could not isolate positive tags. Given Electra is not that much brighter on paper than mTagBFP2 we did not pursue it further, though we recognize that these may simply have been unlucky injections. mScarlet3-S2 is quite a bit dimmer than mScarlet3 on paper – the advantage is that it has higher photostability. In our view, the limiting factor will be having FPs that are bright enough to screen, image and scale to the whole genome, so brightness will likely provide an advantage over photostability at this stage.

      (2) Have the authors investigated what tags could be used in expansion microscopy - that is, which retain antigenicity or even fluorescence after the protocol is applied? It may be useful to add different epitope tags to the knock-in cassettes for this purpose.

      mSG and mSc3 retain fluorescence after fixing with formaldehyde. We have not tested mTagBFP2 fluorescence in fixed worms. We agree that adding different epitope tags would be useful.

      The paper is fine as it stands. The experiments above could add value to it and future-proof it, but are not essential. If the experiments are not attempted, the authors could refer to the points above in the discussion.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) Merged figures appear saturated, and use colors that won't work for red-green colorblind viewers. 

      For all figures, we also show individual channels separately, which is common practice for making fluorescence images accessible to colorblind readers (PMID: 33788834). Figures highlighting non-overlap like 6B and C are already in accessible colors when merged (blue/green) and include a numerical quantification. 3-color RGB images preserve the greatest information for the highest number of individuals.

      (2) Targeting ubiquitously expressed genes as a proof of concept gives me some concern that this might underestimate the challenges that may be experienced with less widely expressed genes.

      While the genes were predicted to be ubiquitously expressed, many were not in practice, like HXK-1 and F54C8.1, which were also among the lower expressed genes on our list and highly cell type restricted. As discussed, the more tissue restricted a gene, the likelier that bulk RNA levels underestimate expression. Such genes are therefore more likely to be detected in a specific tissue. We routinely isolate tissue restricted endogenous tags, including those expressed in only a few neurons, with bulk FPKMs lower than the ranges tested in this manuscript.

      (3) Some results are not shown or referenced (autofluorescence, for example, is shown using a schematic in Figure 1C).

      We now provide representative images alongside what would be expected to be observed by eye during screening.

      (4) It would be useful to describe how to recover worms from what is shown in Figure 1A. 

      In the revised version, we added the following in the caption for Fig. 1A:

      “Selected worms expressing the brighter tag can be screened for dimmer tags by higher magnification and long exposure imaging. Worms can be recovered directly from slides if immobilized by levamisole as described (Ghanta et al., 2021). Alternatively, single hermaphrodite worms can be isolated, allowed to lay eggs, then screened.”

      (5) A blue bar of data must be missing from Figure 3B injection pool 5.

      As stated in the text, “All but one tag (cox-6B::mTagBFP2) was visible in the F1 generation of injected P0 animals, and these were subsequently isolated among F2 worms positive for the other tags in the pool.”

      To clarify that data points are not unintentionally omitted, we added the following text to the caption of Fig. 3B:

      “For group 5 including cox-6B::mTagBFP2, worms with detectable levels of mTagBFP2 fluorescence were not recovered in the F1 generation but were isolated among progeny of F1s positive for mStayGold and mScarlet3; we were thus unable to quantify efficiency for this locus at F1.”

      (6) Some expression or localization patterns were unexpected, but complications like germline silencing and protein mislocalization, with a small fraction localizing normally and rescuing function, were not presented as possibilities. Viability is used to confirm function, but without presenting whether this means 100% viability, less, or just the ability to maintain a strain.

      We already do discuss mislocalization and functionality issues in the Discussion, as well as tradeoffs of alternate methods. Any existing method to observe biological molecules, be it protein, RNA or DNA, has multiple drawbacks and sources of artifacts, which are unlikely to be fully eliminated in the foreseeable future.

      In regard to germline silencing of endogenously tagged genes in C. elegans, there is actually very little evidence for this. Collectively, various labs have now generated over 200 reporter alleles of germline-expressed genes (WormTagDB), with robust expression throughout the germline and retention of function. Likewise, numerous of our tags across fluorophores showed robust germline expressions including EEF-1A.1::mTagBFP2, Y22D7AL.10::mStayGold, and HAT-1::mScarlet3. In fact, overall transcript levels generally tended to underestimate germline enrichment at the protein level. We note that single-copy transgenes driven by eef-1A.1/eft-3 promoter by itself are frequently not expressed in the germline (PMID: 31064766); that we could detect EEF-1A.1 robustly in the germline when tagged endogenously is evidence that silencing is unlikely to be a widespread concern, and at the least less of a concern than single copy transgenes. We appreciate that for a transgene, presence/absence of specific sequence elements and genomic loci play a role in expression, but an endogenous tag captures all such information at a given locus.

      Indeed, we found only two reports of endogenous tags being silenced in the germline, the first being a novel tag (not fluorophore) which initially prevented expression at the tagged locus (PMID: 30109984), but after making changes to the sequence to avoid silencing signals the authors could rescue expression and thereafter saw robust expression in various novel contexts with this tag. The second example (PMID: 34547227) leaves open the possibility that germline repression of that particular gene might be a part of its endogenous regulation.

      Nevertheless, given it is probably rare if occurs at all, it will likely take a large scale tagging effort to uncover such cases at sufficient numbers to study. In our view, this further justifies tagging at large, ideally genomic, scales. If we do discover that there are numerous annotated germline proteins which we don’t observe by tagging, that would be interesting to study on its own.

      (7) Halotag is presented in the Discussion as a small tag, but it is bigger than GFP.

      Thank you for catching this. We have removed the discussion of Halotag. Given the comparable size to FPs, it would be unlikely to alleviate issues of tag functionality.

      (8) It would be useful to include FPKMs and viability percentages in Table 1.

      FPKM is included in column 6, but the title for this column is cut off. In the revised table FPKM values are now shown more clearly across stages.

      We did not quantify viability percentage. In our view it does not yield an informative metric when there is little information about the protein’s required dosage for function, which was the case for most proteins here. A haplosufficient gene might yield a full brood size even if 50% of protein function is lost; conversely, a highly dose sensitive protein could yield penetrant and severe inviability with mild perturbation of function. It also is not actionable information at this stage if there is no alternate tagging strategy as a baseline of comparison. The worms we picked to image all have viable embryos as adults, so in those individuals the genes were likely to be sufficiently expressed and functional.

      (9) Because establishing that a guide works well is a limiting step for many CRISPR experiments (once a guide works well, it's easy to inject 5 worms and get lines), I wondered if testing that for many genes is what is really needed in the field at this stage. 

      Guide quality is rarely an issue in C. elegans, as for all the genes here we tried only one guide, all of which were previously untested. We now clarified this in the discussion section:

      “Notably, we find that previously untested guide RNAs and homology arms perform exceptionally well at novel loci, as we only tested one set of reagents for each locus which yielded satisfactory tagging rates.”

      (10) For a manuscript where the injection is so central to what was done, I was surprised to read in the Acknowledgments that all of the injections were done by someone who is not included as an author.

      We are likewise surprised by such a comment but gladly clarify: Chi Chen has been with us as an expert microinjection specialist for more than 25 years and her very important technical contributions have been acknowledged in many dozen papers. Multiple authorship guidelines, including COPE’s and ICMJE’s, state that technical contributions alone do not qualify for authorship.

      Reviewer #2 (Recommendations for the authors):

      (1) We would encourage the authors to provide systematic validation of the reported insertions. The manuscript reports that 24 of 30 tags were isolated and visible, but does not clearly state whether each isolated line was confirmed by sequence‑level validation to be correctly in‑frame and free of unintended mutations at the target locus.

      We appreciate the reviewer’s concerns on fidelity. These parameters have been assessed in prior published work (e.g., PMID: 30504364, PMID: 34748534) and in our hands are in the range of 80% whenever we sequence non-fluorescent tags of similar sizes. The efficiencies we observed are high enough that one can expect to recover numerous worms with the exact intended sequence for each target, though we would argue mutations within the FP reporter are less likely to matter if it retains high fluorescence.

      (2) The manuscript presents aggregated success counts (e.g., 8/10 mTagBFP2 tags, 9/10 mStayGold, 7/10 mScarlet3) and useful narrative descriptions of injection outcomes. We also suggest including per‑locus success rates.

      Figure 3B shows per locus success rate and source data is provided for this figure. Each dot is an individual injection and the Y axis is per locus rate. We now worded this more clearly in the figure’s caption.

      “Total insertion efficiencies per locus for the indicated targets across injection pools.”

      (3) For pools that required re‑injection after initial failures, we would like to see a description of the specific changes that were made to the injection mixes or procedures (e.g., new repair template prep, different Cas9 reagent lot, guide redesign). This will be useful troubleshooting information for others.

      We re-made the exact same injection mix but with nanodrop to ensure the purity of the repair templates as assessed by absorbance ratios (A260/230 and A260/280) were sufficient after each purification step. No other changes were made. This is now specified in the methods section in the following way:

      “For re-runs of pools 4, 6 and 10 which failed initially, we regenerated the repair templates and ensured that after each column purification, the A260/230 ratio of the purified DNA was ≥2.2 and A260/280 was 1.8 ± 0.05 when measured with a Nanodrop spectrophotometer.”

      (4) The authors state that the fluorophore sequences are codon-optimized for C. elegans. We suggest they provide the exact donor/tag sequences, specifically state whether the fluorophore sequences contain any synthetic/artificial introns, or whether other sequence modifications (e.g., silent PAM‑disrupting mutations) were included in the donor templates. 

      This information is provided in Supplementary Table 1.

      (5) Page 3: Include a reference for "The C. elegans genome encodes around 20,000 genes" 

      We added a reference to the most recent release of the genome (WS237, May 2013). Spieth et al., 2014.

    1. /apps/DefaultApp/DataStatusEvent

      диаграмма:

      Речь идет об отправке данных с одного клиента многим клиентам https://flashphoner.com/docs/api/WCS5/rest_api/latest/v3/#tag/Data/operation/sendData

      1. От клиента к серверу POST /data/send
      2. Рисуем второго клиента, к нему OnDataEvent
      3. Дальше POST /apps/DefaultApp/DataStatusEvent на бэкенд и т.д.
    1. reply to u/deleted at https://old.reddit.com/r/typewriters/comments/1te4u1i/state_of_the_typosphere/

      Two or three typewriter repair shops have opened up in the past couple of years, though probably not enough to offset the retirements or deaths which include Tom Furrier (Cambridge Typewriter) and Duane Jensen (Phoenix Typewriter) respectively. Lucas Dul opened up a brick-and-mortar typewriter shop in Chicago.

      Philly Typewriter and Bremerton Typewriter Company have started up typewriter repair schools/apprenticeships to expand on the trade.

      Tom Hanks has continued donating typewriters to typewriter repair shops over the past few years, ostensibly to encourage the space as well as to slim down his own collection.

      Richard Polt recently downsized his collection significantly. (His blog is generally a good source of the news of what's new in the past few years.)

      Prices are up somewhat in general, but especially for Hermes 3000s, Olympias, Smith-Corona Silent Supers, and Olivetti Letteras even in poor condition.

      Historical updates: https://typewriterdatabase.com/twdb.0.news-media

      Type Pals has started up monthly meetups again: https://www.typepals.com/events

      Lou Spirito designed a baseball scorecard for typewriters which was unveiled by Tom Hanks on March 29, 2025.

      Qwertyfest seems to be going strong: https://www.qwertyfest.com/

      Atlanta, Albuquerque, and Los Angeles have bee hosting type-ins a few times a year.

      I've fleshed out some details and examples on typecasting for those interested in trying it out: https://indieweb.org/typecast

    1. best match.

      Circulation v. Reserve

      1. A Tascam Recorder with a green tag (circulation)
      2. A hig-end lighting kit with a blue tag (reserve)
      3. 3D printing pass that requires prior training (reserve)
      4. A PA system that you can book in advance (reserve)
      5. A USB to USB-C adapter that a student checked out at the desk without booking in advance (circulation)
      6. A SM58 microphone, circulated though Workflows (LibCal)
      7. A Canon RP camera, circulated through LibCal (reserve)
      8. A Canon Vixia camera, with a UVA barcode and green tag (circulation)
    2. Although UVA owns a lot of material, we don't have copies of every resource UVA library users might request.  Our library has an Interlibrary Loan services department to help fill the gap by borrowing materials from libraries elsewhere when library users request items UVA library does not own.Interlibrary Loan (ILL) items are distinguished by an orange flap with the words "UVA Library Interlibrary Loan" that is secured to the cover of the item, and a purple slip with the borrower's name that will be sticking out of the item itself.  The ILL barcode for ILL items is on the purple slip. It starts with the letters TN.ILL items are tracked and circulated in ILLiad WebCirc, they will not appear in our UVA catalog or in Workflows!ILLiad WebCirc is an online system used to track and circulate Interlibrary Loan materials.

      Reserve Equipment

      Reserve equipment are all the pieces in the vault with a BLUE tag. These items rarely have a UVA barcode, and tend to be higher-end.

      The library information system we use to circulate reserve equipment is LibCal

    3. UVA owns an abundance of books, manuscripts, DVDs, musical scores, and much more.All of these items will have a UVA barcode that is found on the item's cover.  That's it! That's the neat trick for identifying UVA items. UVA items have a UVA barcode.And, (is this obvious?) all UVA materials are listed in our online library catalog, Virgo, and in the library information system we use for circulation, Workflows.

      Circulation Equipment Circulation equipment are all the pieces in the vault with a GREEN tag. All of these items have a UVA barcode that is found in the equipment's case or on the largest piece of the equipment. That's it! That's the neat trick for identifying Circulation equipment.

      Circulation equipment is labeled in GREEN and has a UVA BARCODE.

      The library information system we use for circulation equipment is Workflows

    1. Author response:

      The following is the authors’ response to the original reviews.

      We would like to express our deep appreciation to the editor and reviewers for their constructive comments and suggestions, which have significantly improved the quality of our manuscript. In response, we have carefully revised the manuscript, addressed all comments, and performed additional experiments and analyses to strengthen our findings.

      (1) We repeated retrograde tracing using CTB-647 to verify precise targeting of SPN and DGC neurons, as shown in the new Figure 7.

      (2) We performed dual retrograde tracing combined with fiber photometry or optogenetic activation to investigate the role of PMC dual-projecting neurons in the control of urination, as shown in Figure supplements 11 and 12.

      (3) We conducted new experiments activating PMC<sup>ESR1+</sup> neurons after PDNx to assess their role in urination, as shown in new Figure 6.

      (4) We added a more detailed analysis of the dynamics of neural responses in PMC<sup>ESR1+</sup> neurons in Figure supplements 3F-3G.

      (5) We analyzed peak Ca<sup>2+</sup> signals in the PMC during and after the onset of EMG bursting, as shown in Figure supplement 4F.

      (6) We added a comparison of spontaneous and light-induced spikes in PMC<sup>ESR1+</sup> neurons, as shown in Figure supplements 3B–3C.

      (7) We expanded the Discussion to address how PMC<sup>ESR1+</sup> neurons coordinate bladder contraction and sphincter relaxation to control both the initiation and suspension of urination.

      We hope these revisions meet the reviewers' expectations and contribute to the improvement of our manuscript.

      Reviewer #1 (Public review):

      Summary:

      Urination requires precise coordination between the bladder and external urethral sphincter (EUS), while the neural substrates controlling this coordination remain poorly understood. In this study, Li et al. identify estrogen receptor 1-expressing neurons (ESR1+) in Barrington's nucleus as key regulators that faithfully initiate or suspend urination. Results from peripheral nerve lesions suggest that BarEsr1 neurons play independent roles in controlling bladder contraction and relaxation of the EUS. Finally, the authors performed region-specific retrograde tracing, claiming that distinct populations of BarEsr1 neurons target specific spinal nuclei involved in regulating the bladder and EUS, respectively.

      Strengths:

      Overall, the work is of high quality. The authors integrate several cutting-edge technologies and sophisticated, thorough analyses, including opto-tagged single unit recordings, combined optogenetics, and urodynamics, particularly those following distinct peripheral nerve lesions.

      We are grateful for your insightful and constructive comments, which affirmed the importance and technical depth of our work. Thank you for dedicating your expertise and time to reviewing our manuscript. Guided by your suggestions, we have revised the paper as detailed below.

      Weaknesses:

      (1) My major concern is the novelty of this study. Keller et al. 2018 have shown that BarEsr1 neurons are active during urination and play an essential role in relaxing the external urethral sphincter (EUS). Minimally, substantial content that merely confirms previous findings (e.g. Figures 1A-E; Figures 3A-E) should be move to the supplementary datasets.

      Thank you for this valuable and constructive comment. We fully agree that the novelty of our study relative to Keller et al., 2018 must be made explicit. Keller et al. established that PMC<sup>ESR1+</sup> neurons are active during socially evoked urine-marking behavior (voluntary urination) and demonstrated their essential role in relaxing the EUS. Their study mainly focused on behavioral context and EUS relaxation. In contrast, our work addresses a distinct, mechanistic question: how these same neurons participate in reflexive, physiological urination and coordinate both bladder detrusor contraction and EUS relaxation.

      Novel aspects of the present study:

      (1) Temporal dynamics of PMC<sup>ESR1+</sup> neurons during reflexive micturition.

      Using opto-tagging and single-unit recordings, we reveal the precise firing pattern of PMC<sup>ESR1+</sup> neurons during reflexive voiding. Simultaneous fiber photometry, cystometry, and EUS-EMG recordings demonstrate that population-level activity of PMC<sup>ESR1+</sup> neurons precedes and tightly correlates with both bladder contraction and EUS relaxation a coordination not previously demonstrated.

      (2) Causal role in reflexive urination.

      Manual closed-loop optogenetic inhibition at the onset of reflexive voiding acutely terminates EUS bursting and bladder contraction, immediately halting urine release.

      (3) Dual control of bladder and EUS.

      Optogenetic activation combined with selective pelvic or pudendal nerve transection shows that PMC<sup>ESR1+</sup> neurons drive both bladder contraction and EUS relaxation, revealing a coordinating role beyond EUS relaxation alone.

      (4) Anatomical substrate for coordinated control of bladder contraction and EUS relaxation in reflexive urination.

      Retrograde tracing identifies three spinal-projecting sub-populations: SPN-only, DGC-only, and dual-targeting neurons, providing a circuit-level explanation for the simultaneous control of bladder and EUS.

      Following your suggestion, panels that merely replicate Keller et al. (former Figures 1A–1E and Figures 3A–3E) have been moved to new Figure Supplements 1 and 7, respectively, so that the main figures now emphasize the new mechanistic findings.

      (2) I also have concerns regarding the results showing that the inactivation of BarEsr1 neurons led to the cessation of EUS muscle firing (Figures 2G and S5C). As shown in the cartoon illustration of Figure 8, spinal projections of BarEsr1 neurons contact interneurons (presumably inhibitory) that innervate motor neurons, which in turn excite the EUS. I would therefore expect that the inactivation of BarEsr1 should shift the EUS firing pattern from phasic (as relaxation) to tonic (removal of relaxation), rather than stopping their firing entirely. Could the authors comment on this and provide potential reasons or mechanisms for this finding?

      Thank you for this crucial comment. We apologize that the representative EUS-EMG traces in Figures 2G and S5C were too small to be clearly seen and that the corresponding results description was not sufficiently accurate. We have now replaced these EMG traces with enlarged versions (revised Figures 2G and S5C) and revised the corresponding Results section (lines 184, 197, 340-341). Based on the enlarged traces, we found that acute photoinhibition of PMC<sup>ESR1+</sup> neurons at the onset of phasic EUS-EMG bursting shifted the EUS firing pattern from large-amplitude phasic bursts to low-amplitude tonic firing. This suggests that ongoing activity of PMC<sup>ESR1+</sup> neurons is required to maintain phasic EUS bursting. A similar shift from phasic to tonic EUS-EMG activity during optogenetic silencing of PMC<sup>ESR1+</sup> neurons was reported by Keller et al., 2018 (Figure supplement 8C), confirming the reproducibility of the phenotype. We propose that the potential mechanism of this low-amplitude tonic activity may be mediated in part by a spinal reflex pathway (the guarding reflex) for preventing urination, whereby the loss of PMC<sup>ESR1+</sup> neurons-mediated supraspinal facilitation reduces inhibition of spinal interneurons, leading to enhanced baseline excitability of EUS motor neurons in response to bladder afferent input during bladder distension (William C. de Groat et al., Comprehensive Physiology. 2015, PMID: 25589273).

      (3) Current evidence is insufficient to support the claim that the majority of BarEsr1 neurons innervate the SPN but not DGC. The current spinal images are uninformative, as the fluorescence reflects the distribution of Esr1- or Crh-expressing neurons in the spinal cord, along with descending BarEsr1 or BarCrh axons. Given the close anatomical proximity of these two nuclei, a more thorough histological analysis is required to demonstrate that the spinal injections were accurately confined to either the SPN or the DGC.

      Thank you for raising this important concern. To rigorously verify that our spinal injections were confined to either the SPN or the DGC, we performed new retrograde-tracing experiments in ESR1-Cre and CRH-Cre mice. We injected a mixture of AAV-Retro-DIO-mCherry or AAV-Retro-DIO-EGFP with the retrograde tracer CTB-647 specifically into the SPN or DGC (Methods, lines 465-466). Only animals in which CTB-647 fluorescence was strictly limited to the target nucleus, without detectable spread to the adjacent region, were included in the analysis (new Figures 7A and 7E). These results confirm our original observation that PMC<sup>ESR1+</sup> neurons comprise three distinct spinal-projection subpopulations: one (19.0%) targeting the SPN, one (52.2%) innervating the DGC, and a third (28.8%) projecting to both regions (Results, lines 304–306; new Figures 7F–7H). In addition, the majority of PMC<sup>CRH+</sup> neurons project to the SPN but not the DGC (new Figures 7B–7D; Results, lines 297–301). We have assembled new Figure 7 using the newly acquired spinal images and the validated data.

      Reviewer #1 (Recommendations for the authors):

      From the abstract: "Anatomically, PMCESR1+ cells possess two subpopulations projecting to either the pelvic or pudendal nerve". I don't think these neurons directly project to either nerve.

      Thank you for this precise comment. We apologize for incorrectly stating that PMC<sup>ESR1+</sup> cells project directly to the pelvic or pudendal nerves. In the revised Abstract (lines 32–36) we have rephrased the sentence to clarify the actual anatomy: “Anatomically, PMC<sup>ESR1+</sup> neurons consist of three distinct spinal-projection-based subpopulations: one targeting the sacral parasympathetic nucleus (SPN), one innervating the dorsal gray commissure (DGC), and a third that projects to both regions, thereby enforcing the coordination of bladder contraction and sphincter relaxation in a rigid temporal sequence.”. We trust this revision now accurately reflects the anatomical findings.

      Reviewer #2 (Public review):

      Summary:

      The authors have performed a rigorous study to assess the role of ESR1+ neurons in the PMC to control the coordination of bladder and sphincter muscles during urination. This is an important extension of previous work defining the role of these brainstem neurons, and convincingly adds to the understanding of their role as master regulators of urination. This is a thorough, well-done study that clarifies how the Pontine micturition center coordinates different muscle groups for efficient urination, but there are some questions and considerations that remain.

      Strengths:

      These data are thorough and convincing in showing that ESR1+PMC neurons exert coordinated control over both the bladder and sphincter activity, which is essential for efficient urination. The anatomical distinctions in pelvic versus pudendal control are clear, and it's an advance to understand how this coordination occurs. This work offers a clearer picture of how micturition is driven.

      We sincerely thank you for highlighting the rigor of our study and for recognizing the advance in understanding how PMC<sup>ESR1+</sup> neurons exert coordinated, anatomically segregated control over bladder and sphincter. We also appreciate the constructive suggestions that helped us further improve clarity, which we address point-by-point below.

      Weaknesses:

      The dynamics of how this population of ESR1+ neurons is engaged in natural urination events remains unclear. Not all ESR1+ neurons are always engaged, and it is not measured whether this is simply variation in population activity, or if more neurons are engaged during more intense starting bladder pressures, for instance. In particular, the response dynamics of single and doubly-projecting neurons are not defined. Additionally, the model for how these neurons coordinate with CRH+ neuron activity in the PMC is not addressed, although these cell types seem to be engaged at the same time. Lastly, it would be interesting to know how sensory input can likely modulate the activity of these neurons, but this is perhaps a future direction.

      Thank you for this insightful comment. First, we agree that not all ESR1+ neurons are consistently engaged during urination (Figure 1B). Because bladder pressure was not measured during the opto-tagging experiments, we cannot determine whether this reflects trial-to-trial variability in population activity or pressure-dependent recruitment of additional neurons. We speculate that stronger starting bladder pressures may recruit a larger subset of ESR1+ neurons, analogous to graded, pressure-dependent recruitment observed in peripheral sensory neurons (Bruns et al., J Neural Eng. 2011, PMID: 21878706; Marshall et al., Nature. 2020, PMID: 33057202).

      Second, using fiber photometry recording and optogenetic activation, we examined the dynamics of dual-projecting neurons in the PMC that were retrogradely labeled from the SPN and DGC. Their activity correlated with bladder contraction and sphincter relaxation, and optogenetic activation sequentially induced these events to trigger urination (see Recommendation #8). Although retrograde labeling captured only a subset of dual-projecting neurons, the results indicate that they coordinate bladder and sphincter activity.

      Third, previous studies suggest that PMC<sup>CRH+</sup> cells are associated with bladder contraction and likely serve as an integration center for context-dependent micturition behavior (Hou et al., Cell. 2016, PMID: 27662084; Ito et al., Elife. 2020, PMID: 32347794). We therefore propose that PMC<sup>CRH+</sup> cells establish the baseline conditions and contextual readiness for voiding, whereas PMC<sup>ESR1+</sup> cells act as the executive command to reliably initiate and execute the event.

      Finally, we agree that sensory inputs likely modulate PMC<sup>ESR1+</sup> neuron activity. Although this falls beyond the scope of the present study, it represents an important avenue for future investigation.

      Reviewer #2 (Recommendations for the authors):

      (1) In the introduction, the authors write that Keller 2018 only showed this ESR1 population to induce EUS relaxation, but those results also do show bladder contraction with photostimulation of this population. While the authors' work extends this finding in important ways, this should be acknowledged (line 60).

      Thank you for this important correction. We have now revised the Introduction to explicitly acknowledge that stimulation of neurons expressing estrogen receptor 1 (ESR1) in the PMC (PMC<sup>ESR1+</sup>) contributes to sphincter relaxation and increased bladder pressure (Introduction, lines 60-62), as originally reported by Keller et al., 2018.

      (2) I think a more detailed analysis of the dynamics of neural responses in the PMC ESR1 neurons would be valuable. For example: are the same cells always engaged before micturition, or do different populations activate on different trials? Can the authors comment on the half of the opto-tagged ESR1 population that is not firing during urination? Do they ever fire? A cell-by-cell analysis of which neurons are engaged over multiple trials would be very valuable to understand the dynamics of population activity. Figure 1H shows cumulative sessions, but what do single sessions look like?

      Thank you for these valuable comments. In response, we have performed refined single-trial analyses of neuronal activity, as detailed in the point-by-point replies below.

      For example: are the same cells always engaged before micturition, or do different populations activate on different trials?

      Among 11 PMC<sup>ESR1+</sup> units that showed urination-related excitation, 8 units exhibited a consistent firing increase in every voiding trial, whereas the remaining 3 increased their discharge in >78 % of trials (Figure 1B; new Figure supplement 3F). Thus, the same PMC<sup>ESR1+</sup> cells are recruited repeatedly, rather than distinct populations being activated on different trials. We have added this clarification to Results (lines 106–108).

      Can the authors comment on the half of the opto-tagged ESR1 population that is not firing during urination? Do they ever fire? A cell-by-cell analysis of which neurons are engaged over multiple trials would be very valuable to understand the dynamics of population activity.

      Approximately half of the opto-tagged PMC<sup>ESR1+</sup> cells showed no increase in firing rate during urination, yet exhibited spontaneous spikes at other times (new Figure supplement 3G), confirming their electrical competence. Because the PMC also participates in defecation, uterine activity, and other pelvic functions (Rouzade-Dominguez et al., Eur J Neurosci. 2003, PMID: 14686905; Schellino et al., Frontiers in Neuroanatomy. 2020, PMID: 33013330; Quaghebeur et al., Auton Neurosci. 2021, PMID: 34391125), these ESR1+ neurons may serve functions other than urination. We have now added this cell-by-cell analysis and discussion to the manuscript (Results, lines 108-112).

      Figure 1 H shows cumulative sessions, but what do single sessions look like?

      As shown in new Figure supplements 3F–3G, single-session raster plots reveal that PMC<sup>ESR1+</sup> neurons display consistent firing patterns across individual trials. Neurons whose firing rate increased during urination did so in most trials (Figure supplement 3F), whereas neurons unrelated to voiding remained silent or showed no discernible rate change during voiding across trials (Figure supplement 3G). These single-session observations are consistent with the cumulative population analysis shown in Figure 1H (new Figure 1B).

      (3) Supplemental Figure 4: It seems clear from this figure that NVCs are only occurring when the sphincter fails to engage. Can the authors quantify how often this is the case?

      Thank you for this important point. We have now quantified the occurrence of non-voiding contractions (NVCs) across all 229 bladder contraction events from 3 mice shown in Supplemental Figure 4. NVCs were observed exclusively when the external urethral sphincter failed to relax, accounting for 62/229 events (27.1 %), whereas coordinated voiding contractions (VCs) occurred in the remaining 167 events (72.9 %). These new data are presented in Figure supplement 4C.

      (4) Continuing from the above point: the authors say that the insufficient top-down drive or strength of activity from PMC ESR1 neurons is why NVCs occur. In looking closely, it also seems there is a small hump and subsequent increase in the calcium signal when the EUS bursting begins (particularly clear in Supplementary Figure 4). Could this instead mean that the bursting/urethral activity itself is feeding back onto the PMC to continue/enhance its activity, and it is instead the lack of sphincter bursting that results in the NVC? Could the authors analyze the signal during and after bursting starts? This model is consistent with one of the classic reflexes defined by Barrington, in which urethral fluid flow/activation enhances bladder contraction. The Figure 4 transection experiments do not fully answer this, as the authors are driving activity in the PMC at this time, but they could test this using PDN transection with fiber photometry recording.

      Thank you for this important point. We fully agree that EUS bursting may provide excitatory feedback to the PMC that sustains or even amplifies its activity, and that the absence of such feedback could underlie NVCs. To test this possibility, we re-analyzed the fiber-photometry traces aligned to the onset and offset of each EUS bursting (new Figure supplement 4). A small but consistent hump in the Ca<sup>2+</sup> signal appeared before bursting onset and the Ca<sup>2+</sup> signal continued to rise throughout the bursting (Figure supplement 4B, yellow arrow). The amplitude at bursting offset was significantly higher than both the NVC peak and the level recorded at bursting onset. These observations support the interpretation that urethral fluid flow/activation supplies excitatory feedback that reinforces PMC activity and bladder contraction, consistent with Barrington’s classic reflex. We have incorporated these new analyses into the revised manuscript (lines 145–155 and Figure supplement 4F).

      We agree that the positive-feedback loop described by Barrington’s classic urethra-to-bladder reflex is an intriguing mechanism. However, the PDN-transection experiment in Figure 4 was designed to determine if bladder contractions triggered by PMC<sup>ESR1+</sup> cells can proceed in the absence of sphincter bursting, not to evaluate this reflex. Incorporating simultaneous fiber-photometry recording into the PDN-transection experiment would therefore go beyond the scope of the present study. In future work we are keen to combine PDN transection with fiber photometry to further determine whether the urethra-to-bladder reflex contributes to the sustained PMC activity observed in our paradigm.

      (5) In Figure 4, is the timing of sphincter engagement different with ChR2 stimulation from what normally occurs? It appears that the bursting happens immediately upon activation whereas bladder contraction is a bit delayed.

      Thank you for this important observation. We have carefully re-examined the EMG traces from all animals shown in Figure 4. We confirm that the onset of sphincter bursting activity during ChR2 stimulation is indeed more rapid than during natural reflex voiding; nevertheless, the onset of phasic sphincter bursting during ChR2 stimulation remained delayed relative to the intravesical pressure rise (see Figure 8B).

      The immediate sphincter discharge visible in some trials was tonic EUS discharge or rare irregular bursting, not the typical EUS bursting. This tonic pattern corresponds to the spinal guarding reflex that suppresses urine leakage (Fowler et al., Nature Reviews Neuroscience. 2008, PMID: 18490916; Keller et al., Nature Neuroscience. 2018, PMID: 30104734). These segments were identified by their amplitude and spectral content and excluded from burst-onset analysis. Our analysis protocol therefore distinguishes tonic guarding activity from true phasic bursting, ensuring that only the latter was used to determine burst timing.

      (6) The explanation on line 299 about how spinal reflexes are impinging on this circuit is confusing. I agree that the bladder contraction stopping later than the EUS signal likely has something to do with spinal reflexes, but it seems this could instead be feedback from the urethral fluid flow, which continues bladder contractions (urethra-destrusor facilitative reflex). Could the authors clarify their thoughts here?

      Thank you for highlighting this ambiguity. We agree that the delayed cessation of bladder contraction could equally reflect either (1) the urethra-to-bladder facilitative reflex driven by ongoing urethral fluid flow or (2) spinal reflexes that we described. In the revised manuscript (Results, lines 343–349), we have re-worded the paragraph to make this dual possibility explicit, thereby avoiding an overly strong emphasis on spinal mechanisms alone.

      (7) A note on phrasing: the authors frequently say PMCESR1 cells drive sphincter relaxation, but then show an effect on sphincter bursting. Experienced readers might realize that relaxation and bursting are connected, but this might be confusing for readers and should be clarified in the text.

      Thank you for highlighting the potential ambiguity. We agree that the sentence “PMC<sup>ESR1</sup> cells drive sphincter relaxation” can seem paradoxical when our data show increased EUS bursting. In adult mice, the EUS does not remain continuously relaxed during voiding; instead, it generates rhythmic bursting composed of high-frequency spike clusters (active periods) alternating with low tonic activity (silent periods), resulting in rhythmic contractions and relaxations of EUS. This phasic activity acts as a pump that facilitates urine flow through the narrow rodent urethra (Kadekawa et al., Am J Physiol Regul Integr Comp Physiol, 2016, PMID: 26818058). The EUS bursting activity we recorded is consistent with the results reported in previous studies (Keller et al., Nat Neurosci, 2018, PMID:30104734; Ito et al., Elife, 2020, PMID:32347794).

      Consequently, when PMC<sup>ESR1</sup> neurons initiate bursting, they simultaneously generate the relaxation phases that separate the spikes. To make this explicit we have replaced the phrase “PMC<sup>ESR1+</sup> cells drive sphincter relaxation” with “PMC<sup>ESR1</sup> neurons trigger EUS bursting, which generates rhythmic sphincter contractions and relaxations.” (Results, page 7, lines 219-221). We have applied similar clarifications throughout the revised manuscript (Results, lines 125-129). We hope this revision eliminates any apparent contradiction.

      (8) The question remains as to which neurons (dual projecting, single projecting, or all?) are active in natural urination. This is possible to do through dual injection of retrograde virus in SPN and DGC that could coordinately turn on Gcamp, but this challenging experiment is perhaps beyond the scope of this paper. Even still, the authors could discuss their model for whether the dual- and single-projecting neurons are all engaged at once in a natural urination event. Do the authors have any data that could provide insight as to when these sub-populations are active? Results from the opto-tagging in Figure 1 (and comment #2 about single neuron firing properties) might provide a foundation for hypotheses or insights.

      Thank you for this valuable suggestion. We have now performed the experiment you proposed: dual injection of retrograde virus (AAV-Retro-Cre and AAV-Retro-DIO-GCaMP6s) in SPN and DGC were used to selectively label PMC dual-projecting neurons, and a 200-µm optic fiber was implanted above the PMC to record their Ca<sup>2+</sup> dynamics during natural urination (Figure supplement 11A and Methods, lines 470–474, 652-655). Dual-projecting neurons exhibited robust activation throughout the entire voiding phase that was tightly correlated with intravesical pressure rise and EUS bursting (Figure supplements 11A–11H). However, technical limits of current retrograde tools preclude selective isolation of single-projecting (SPN-only or DGC-only) subsets for independent fiber-photometry recordings and injection restricted to one target unavoidably labels both single- and dual-projecting cells. We now state this technical limitation explicitly (Discussion, lines 426-430).

      Accordingly, in the revised Discussion (lines 389-406), we integrate fiber-photometry Ca<sup>2+</sup> signals with single-unit data from opto-tagged recordings to propose several testable, non-mutually-exclusive models for how dual- and single-projecting PMC<sup>ESR1+</sup> neurons are engaged during natural urination: “Based on population dynamics obtained by fiber photometry (Figures 1D-1H, Figure supplements 1A-1F, and Figure supplements 11A-11H) and single-neuron firing properties recorded via optrode (Figures 1A-1C), we propose several mechanistic models for the engagement of dual- and single-projecting PMC<sup>ESR1+</sup> neurons during natural micturition. One possibility is that all three populations (dual-projecting, SPN-projecting and DGC-projecting neurons) are co-activated, with the dual-projecting subset acting as a “bridging amplifier” that sustains rising bladder pressure while coordinating EUS relaxation. Alternatively, SPN-projecting neurons may be recruited first to initiate bladder contraction, followed by DGC-projecting neurons that evoke EUS bursting and facilitate urine entry into the urethra; once flow begins, the urethro-detrusor facilitative reflex could recruit dual-projecting neurons to further enhance voiding efficiency. In addition, contextual or state-dependent urination—such as scent-marking behavior characterized by multiple voiding events with smaller volumes than reflexive urination—may predominantly rely on sequential and cooperative activation of single-projecting neurons. Other recruitment sequences remain conceivable. Future studies combining diverse urination-related behavioral paradigms with simultaneous recordings from projection-specifically labeled PMC neurons will be required to validate and refine these models.”

      Reviewer #3 (Public review):

      Summary:

      The paper by Li et al explored the role of Estrogen receptor 1 (Esr1) expressing neurons in the pontine micturition center (PMC), a brainstem region also known as Barrington's nucleus (Hou et al 2016, Keller et al 2018). First, the author conducted bulk Ca2+ imaging/unit recording from PMCESR1 to investigate the correlations of PMCESR1 neural activity to voiding behavior in conscious mice and bladder pressure/external urethral muscle activity in urethane anesthetized mice. Next, the authors conducted optogenetics inactivation/activation of PMCESR1 to confirm the contribution to the voiding behavior also conducted peripheral nerve transection together with optogenetics activation to confirm the independent control of bladder pressure and urethral sphincter muscle.

      We sincerely thank you for providing a thoughtful summary and insightful comments on our study.

      Weaknesses:

      (1) The study demonstrates that pelvic nerve transection reduces urinary volume triggered by PMC ESR1+ cell photoactivation in freely moving mice. Could the role of pudendal nerve transection also be examined in awake mice to provide a more comprehensive understanding of neural involvement?

      Thank you for this valuable suggestion. We conducted an additional experiment to determine the contribution of the pudendal nerve to PMC<sup>ESR1+</sup> neuron-driven voiding in awake mice. Bilateral pudendal nerve transection (PDNx) reduced the optogenetically evoked urine volume compared with sham-operated controls, yet photoactivation of PMC<sup>ESR1+</sup> neurons still reliably induced urination after PDNx (new Figure 6). Thus, bilateral integrity of the pudendal nerve is required for efficient PMC<sup>ESR1+</sup> neuron-driven voiding, most likely by transmitting the signals that entrain rhythmic EUS bursting. These data and experimental details have been incorporated into Figure 6, Results (lines 272–276), and Methods (lines 542–545).

      (2) While the paper primarily focuses on PMCESR1+ cells in bladder-sphincter coordination, the analysis of PMCESR1+-DGC/SPN neural circuits - given their distinct anatomical projections in the sacral spinal cord - feels underexplored. How do these circuits influence bladder and sphincter function when activated or inhibited? Also, do you have any tracing data to confirm whether bladder-sphincter innervation comes from distinct spinal nuclei?

      Thank you for this critical comment. To determine how PMC<sup>ESR1+</sup> neurons that target distinct sacral nuclei influence bladder–sphincter coordination, we first focused on the dual-projecting subset in a new experiment (Figures supplement 11 and Methods, lines 470–477, 652-655, 669-673). Dual retrograde virus injections into SPN and DGC selectively labelled PMC dual-projecting neurons, a subset of which are ESR1+. Fiber-photometry recordings showed that these cells were active during bladder contraction and sphincter relaxation (Figure supplements 11E-11H), whereas optogenetic activation reliably initiated urination: bladder pressure rose immediately and was followed by rhythmic EUS bursting (Figure supplements 11I-11N and 12B; Results, lines 309-313, 332-335). Thus, the dual-projecting sub-population is sufficient to coordinate bladder contraction with sphincter relaxation. Current retrograde tools do not allow selective isolation of single-projecting (SPN-only or DGC-only) subsets; injecting only one target unavoidably labels both single- and dual-projecting cells. Consequently, we cannot yet compare the functional impact of pure SPN-only versus DGC-only PMC populations. This limitation is now stated explicitly in the revised Discussion (lines 426–430).

      In our 2025 paper (Yan et al., Commun Biol, 2025, PMID: 40259086), we used PRV-based retrograde tracing to show that SPN and DGC constitute two separate spinal nuclei controlling the bladder and the EUS, respectively. Classic studies have reached the same conclusion (Yao et al., Nat Neurosci, 2018, PMID: 30361547; Karnup & De Groat, IBRO Reports, 2020, PMID: 32775758; Karnup, Auton Neurosci, 2021, PMID: 34391124). These citations and a concise summary have been added to the Results (lines 289–294).

      (3) Although the paper successfully identifies the physiological role of PMCESR1+ cells in bladder-sphincter coordination, the study falls short in examining the electrophysiological properties of PMC ESR1+-DGC/SPN cells. A deeper investigation here would strengthen the findings.

      Thank you for this thoughtful suggestion. While a detailed electrophysiological characterization of PMC<sup>ESR1+-DGC/SPN</sup> neurons would provide complementary information, the primary goal of the present study was to define the in vivo functional dynamics and behavioral role of these neurons during natural urination. As you suggested, further electrophysiological analysis of PMC<sup>ESR1+-DGC/SPN</sup> neurons will be an important direction for our future work.

      (4) The parameters for photoactivation (blue light pulses delivered at 25 Hz for 15 ms, every 30 s) and photoinhibition (pulses at 50 Hz for 20 ms) vary. What drove the selection of these specific parameters? Moreover, for photoactivation experiments, the change in pressure (ΔP = P5 sec - P0 sec) is calculated differently from photoinhibition (Δpressure = Ppeak - Pmin). Can you clarify the reasoning behind these differing approaches?

      Thank you for this opportunity to clarify our experimental design. The photoactivation protocol (25 Hz, 15 ms pulses) was chosen because PMC<sup>ESR1+</sup> neurons faithfully follow this frequency without depolarisation block and it reliably triggers voiding (Keller et al., Nat Neurosci, 2018, PMID:30104734). For photoinhibition we originally stated “50 Hz, 20 ms pulses”, but this was an error. Consistent with the same study (Keller et al., Nat Neurosci, 2018, PMID:30104734), we used continuous light (constant illumination) to maintain sustained suppression. The Methods section has been corrected (lines 659-661, 690-691).

      The ΔP formula was tailored to the temporal profile of each manipulation. For activation, ΔP (P<sub>5 sec</sub> - P<sub>0 sec</sub>) captures the rapid pressure rise after light onset; the same window was used in (Hou et al., Cell. 2016, PMID: 27662084). For inhibition, because saline infusion produces rhythmic reflex voiding, we delivered light at the onset of EUS bursting (i.e. when pressure was already at ~peak). Inhibition abruptly stops the bladder contraction, so the bladder cannot return to its pre-void baseline. The Δpressure (P<sub>peak</sub> – P<sub>min</sub>) was therefore used to quantify the extent to which the ongoing pressure wave was aborted by photoinhibition. P<sub>min</sub> is the lowest value reached before the next infusion-driven upswing, making the metric insensitive to the slow baseline drift produced by continuous infusion. These clarifications have been added to the Methods (Methods, lines 676-677, 679-680, 692-693).

      (5) The discussion could further emphasize how PMCESR1+ cells coordinate bladder contraction and sphincter relaxation to control urination, highlighting their central role in the initiation and suspension of this process.

      Thank you for this valuable comment. We have revised the Discussion to emphasize that PMC<sup>ESR1+</sup> neurons coordinate urination by sequentially driving bladder contraction followed by sphincter relaxation through their dual projections to the SPN and DGC. We also emphasized that this coordination is essential for the initiation and effective execution of voiding (Discussion, lines 369-388). In addition, in the revised Discussion (Discussion, lines 389-406), we integrate fiber-photometry Ca<sup>2+</sup> signals with single-unit data from opto-tagged recordings to propose several testable, non-mutually-exclusive models for how PMC<sup>ESR1+</sup> cells are engaged during natural urination.

      (6) In Figure 8, The authors analyze the temporal sequence of bladder pressure and EUS bursting during natural voiding and PMC activation-induced voiding. It would be acceptable to consider the existence of a lower spinal reflex circuit, however, the interpretation of the data contains speculation. Bladder pressure measurement is hard to say reflecting efferent pelvic nerve activity in real time. (As a biological system, bladder contraction is mediated by smooth muscle, and does not reflect real-time efferent pelvic nerve activity. As an experimental set-up, bladder pressure measurement has some delays to reflect bladder pressure because of tubing, but EUS bursting has no delay.) Especially for the inactivation experiment, these factors would contribute to the interpretation of data. This reviewer recommends a rewrite of the section considering these limitations. Most of the section is suitable for the results.

      We agree with the reviewer that bladder pressure, mediated by smooth muscle contraction, provides an indirect measure of efferent pelvic nerve activity and is subject to both physiological and experimental delays. Regarding potential delay from the tubing system, pressure propagates in fluid at approximately 1000 m/s (Kela & Pekka, Proceedings of World Academy of Science Engineering & Technology, 2009, DOI: 10.5281/zenodo.1080526). Given that the total tubing length in our setup is 0.5-1 meter, this gives an estimated transmission delay of only 0.5-1 ms. However, this delay is negligible compared with the observed time difference (~700 ms) between the cessation of EUS bursting and the termination of bladder contraction. Theoretically, pressure transmission is not expected to introduce a temporal delay. However, we cannot exclude the possibility that the pressure measurement itself may impose such a delay, because bladder pressure does not necessarily reflect efferent pelvic nerve activity in real time. Future studies using simultaneous recordings of bladder pressure and pelvic nerve discharges will help clarify whether a true temporal delay exists. Nevertheless, we agree that additional physiological or peripheral factors may also contribute to this difference in timing. As suggested by the reviewer, we have revised the discussion to consider the potential influence of other factors, such as urethra-detrusor facilitative reflex (Results, lines 343-349).

      Reviewer #3 (Recommendations for the authors):

      (1) In opto-tag experiments, a comparison of average AP waveform during behavior and during light stimulation should be included as criteria. It should be mostly the same waveform.

      Thank you for bringing this to our attention. We have now added this comparison as an inclusion criterion in the revised manuscript. Figure supplement 3B shows representative examples of the average waveforms, and Figure supplement 3C displays the distribution of correlation coefficients between spontaneous and light-evoked spikes for all recorded PMC<sup>ESR1+</sup> units, all of which exhibited r > 0.8.

      (2) Optical fiber implantation seems to be done in two different methods. In Figure 1 and Figure 2, the fiber tip is positioned just above PMC but in Figure 3 it seems to be angled. The information should be included in the Methods section.

      Thank you for this important comment. We have now clarified in the Methods that for Figures 1 and 2, the optical fibers were implanted vertically above the PMC, whereas for Figure 3, the left optical fiber was implanted at a 33° lateral angle targeting the PMC (Methods, lines 499-503).

      (3) In the closed-loop inhibition experiments of Figure 2, the parameters to start closed-loop photo-inactivation were not described in the method. If it is a manual closed loop, it should be described clearly.

      Thank you for raising this important point. We apologize for omitting these details in the original Methods. We have now added a complete description of the manual closed-loop photo-inhibition protocol, including the triggering criteria and operator-controlled timing, in the revised Methods section (lines 602–605).

      (4) In Figure 7A/E the authors provide a spinal cord image to show the injection site, but the image is misleading. The figure only shows AAV-infected CRH/ESR1 neurons in the spinal cord section. It does not indicate the AAV injection site or the terminal distribution.

      Thank you for your important comment. We apologize for providing a spinal cord image that did not accurately depict the injection site. To rigorously verify that our spinal injections were confined to SPN or DGC, we performed new retrograde-tracing experiments in ESR1-Cre and CRH-Cre mice. A mixture of AAV-Retro-DIO-mCherry or AAV-Retro-DIO-EGFP with the retrograde tracer CTB-647 was injected specifically into SPN or DGC. Only animals in which CTB-647 fluorescence was strictly limited to the target nucleus, without spread to the adjacent region, were included (new Figures 7A and 7E). These data confirmed our original observations and have been pooled in Figure 7. The manuscript and figure have been updated accordingly (Results, lines 297-301, 304-306; Methods, lines 465–466).

    1. Author response:

      The following is the authors’ response to the original reviews.

      eLife Assessment

      This is a useful study presenting solid data indicating that the bacterial GTPases EngA and ObgE enable single-step reconstitution of functional 50S ribosomal subunits under near-physiological conditions. The study elegantly bridges the gap between the non-physiological aspects of the previous two-step reconstitution method and the extract-dependent iSAT system to enable ribosome assembly under translation-compatible conditions; however, it is limited by reliance on rRNA and proteins extracted from native ribosomes and does not achieve a true bottom-up reconstruction from all synthetic components. The evidence is incomplete in not characterizing the spectrum of reporter polypeptides produced and not comparing their rate and yield of synthesis from reconstituted ribosomes to that obtained with pure native ribosomes; and the impact of the study is limited by not including reporters to examine the fidelity of initiation, elongation or termination achieved with the reconstituted ribosomes.

      As described below, based on the comments from the public reviewers, we have summarized at the end of the Discussion how this study contributes toward true bottom-up reconstruction from fully synthetic components, as well as the aspects that will require further development. In addition, we have newly provided data characterizing the reporter polypeptides from multiple perspectives, demonstrating that the assembled ribosomes do not exhibit issues such as reduced fidelity (Fig. 6, 7, Supplementary Data 2, 3). We believe that these data adequately address the limitations that were pointed out in the eLife Assessment.

      Public Reviews:

      Reviewer #1 (Public review):

      This study presents evidence that the addition of the two GTPases EngA and ObgE to reactions comprised of rRNAs and total ribosomal proteins purified from native bacterial ribosomes can bypass the requirements for non-physiological temperature shifts and Mg+2 ion concentrations for in vitro reconstitution of functional E. coli ribosomes.

      Strengths:

      This advance allows ribosome reconstitution in a fully reconstituted protein synthesis system containing individually purified recombinant translation factors, with the reconstituted ribosomes substituting for native purified ribosomes to support protein synthesis. This work potentially represents an important development in the long-term effort to produce synthetic cells.

      Weaknesses:

      While much of the evidence is solid, the analysis is incomplete in certain respects that detract from the scientific quality and significance of the findings:

      (1) The authors do not describe how the native ribosomal proteins (RPs) were purified, and it is unclear whether all subassemblies of RPs have been disrupted in the purification procedure. If not, additional chaperones might be required beyond the two GTPases described here for functional ribosome assembly from individual RPs.

      Native ribosomal proteins (RPs) were prepared from native ribosomes, according to the well-established protocol described by Dr. Knud H. Nierhaus [Nierhaus, K. H. Reconstitution of ribosomes in Ribosomes and protein synthesis: A Practical Approach (Spedding G. eds.) 161-189, IRL Press at Oxford University Press, New York (1990)]. In this method, ribosome proteins are subjected to dialysis in 6 M urea buffer, a strong denaturing condition that may completely disrupt ribosomal structure and dissociate all ribosomal protein subassemblies. To make this point clear, we described the detailed ribosomal protein (RP) preparation procedure in the manuscript, rather than merely referring to the book.

      In addition, we would like to clarify one point related to this comment. The focus of the present study is to show that the presence of two factors is required for single-step ribosome reconstitution under translation-compatible, cell-free conditions. We do not intend to claim that these two factors are absolutely sufficient for ribosome reconstitution. Hence, we have revised the manuscript to more explicitly state what this work does and does not conclude.

      (2) Reconstitution studies in the past have succeeded by using all recombinant, individually purified RPs, which would clearly address the issue in the preceding comment and also eliminate the possibility that an unknown ribosome assembly factor that co-purifies with native ribosomes has been added to the reconstitution reactions along with the RPs.

      As noted in the response to the Comment (1), the focus of the present study is the requirement of the two factors for functional ribosome assembly. Therefore, we consider that it is not necessary to completely exclude the possibility that unknown ribosome assembly factors are present in the RP preparation. Nevertheless, we agree that it is important to clarify what factors, if any, are co-present in the RP fraction. To address this, we performed proteomic analysis of the TP70 preparation (Supplementary Data 3) and stated the possibility of other factors’ inclusion.

      We also agree that additional, as-yet-unidentified components, including factors involved in rRNA modification, could plausibly further improve assembly efficiency. We also consider that such studies may contribute to extending the system to the use of in vitro-transcribed rRNA and fully recombinant ribosomal proteins, which could be essentially a next step of this study. We noted the possibility of as-yet-unidentified components and the future perspectives in the Discussion.

      (3) They never compared the efficiency of the reconstituted ribosomes to native ribosomes added to the "PURE" in vitro protein synthesis system, making it unclear what proportion of the reconstituted ribosomes are functional, and how protein yield per mRNA molecule compares to that given by the PURE system programmed with purified native ribosomes.

      According to this suggestion, we measured the sfGFP synthesis rate from the increase in fluorescence over time under conditions where the template mRNA is in excess, and compared this rate directly between reconstituted and native ribosomes. We consider that this comparison provides insight into what fraction of ribosomes reconstituted in our system are functionally active (Fig. 6).

      As noted in the provisional responses, quantifying protein yield per mRNA molecule is substantially more challenging. The translation system is complex, and the apparent yield per mRNA can vary depending on factors such as differences in polysome formation efficiency. In addition, the PURE system is a coupled transcription–translation setup that starts from DNA templates, which further complicates rigorous normalization on a per-mRNA basis. Because the main focus of this study is to determine how many functionally active ribosomes can be reconstituted under translation-compatible conditions, we addressed this comment by just carrying out the experiment comparing sfGFP synthesis rate.

      (4) They also have not examined the synthesized GFP protein by SDS-PAGE to determine what proportion is full-length.

      We have added an affinity tag to the sfGFP reporter, and then, purified the synthesized products from the reaction mixture and analyzed it by SDS–PAGE (Fig. 7a).

      (5) The previous development of the PURE system included examinations of the synthesis of multiple proteins, one of which was an enzyme whose specific activity could be compared to that of the native enzyme. This would be a significant improvement to the current study. They could also have programmed the translation reactions containing reconstituted ribosomes with (i) total native mRNA and compared the products in SDS-PAGE to those obtained with the control PURE system containing native ribosomes; (ii) with specifc reporter mRNAs designed to examine dependence on a Shine-Dalgarno sequence and the impact of an in-frame stop codon in prematurely terminating translation to assess the fidelity of initiation and termination events; and (iii) an mRNA with a programmed frameshift site to assess elongation fidelity displayed by their reconstituted ribosomes.

      Following the recommendation, we selected DHFR as an enzymatically active protein and used it as a reporter, confirming that it exhibited enzymatic activity comparable to that observed when synthesized by native ribosomes (Fig. 7c). In addition, MS analysis of the purified sfGFP used for SDS-PAGE analysis showed that nearly all peptide fragments were detected, covering almost the entire sequence from the initiator amino acid to the amino acid immediately preceding the stop codon (Fig. 7b, Supplementary Data 2. These results suggest that protein synthesis by the newly assembled ribosomes proceeds smoothly from initiation to termination, with no apparent problem in fidelity, and therefore indicate that functional ribosomes were successfully reconstituted.

      Reviewer #2 (Public review):

      This study presents a significant advance in the field of in vitro ribosome assembly by demonstrating that the bacterial GTPases EngA and ObgE enable single-step reconstitution of functional 50S ribosomal subunits under near-physiological conditions-specifically at 37 {degree sign}C and with total Mg<sup>2+</sup> concentrations below 10 mM.

      This achievement directly addresses a long-standing limitation of the traditional two-step in vitro assembly protocol (Nierhaus & Dohme, PNAS 1974), which requires non-physiological temperatures (44-50 {degree sign}C), and high Mg<sup>2+</sup> concentrations (~20 mM). Inspired by the integrated Synthesis, Assembly, and Translation (iSAT) platform (Jewett et al., Mol Syst Biol 2013), leveraging E. coli S150 crude extract, which supplies essential assembly factors, the authors hypothesize that specific ribosome biogenesis factors-particularly GTPases present in such extracts-may be responsible for enabling assembly under mild conditions. Through systematic screening, they identify EngA and ObgE as the minimal pair sufficient to replace the need for temperature and Mg<sup>2+</sup> shifts when using phenol-extracted (i.e., mature, modified) rRNA and purified TP70 proteins.

      However, several important concerns remain:

      (1) Dependence on Native rRNA Limits Generalizability

      The current system relies on rRNA extracted from native ribosomes via phenol, which retains natural post-transcriptional modifications. As the authors note (lines 302-304), attempts to assemble active 50S subunits using in vitro transcribed rRNA, even in the presence of EngA and ObgE, failed. This contrasts with iSAT, where in vitro transcribed rRNA can yield functional (though reduced-activity, ~20% of native) ribosomes, presumably due to the presence of rRNA modification enzymes and additional chaperones in the S150 extract. Thus, while this study successfully isolates two key GTPase factors that mimic part of iSAT's functionality, it does not fully recapitulate iSAT's capacity for de novo assembly from unmodified RNA. The manuscript should clarify that the in vitro assembly demonstrated here is contingent on using native rRNA and does not yet achieve true bottom-up reconstruction from synthetic parts. Moreover, given iSAT's success with transcribed rRNA, could a similar systematic omission approach (e.g., adding individual factors) help identify the additional components required to support unmodified rRNA folding?

      We fully recognize the reviewer’s point that our current system has not yet achieved a true bottom-up reconstruction. Although we intended to state this clearly in the manuscript, the fact that this concern remains indicates that our description was not sufficiently explicit. We therefore added the paragraph to ensure that this limitation is clearly communicated to readers.

      (2) Imprecise Use of "Physiological Mg<sup>2+</sup> Concentration"

      The abstract states that assembly occurs at "physiological Mg<sup>2+</sup> concentration" (<10 mM). However, while this total Mg<sup>2+</sup> level aligns with optimized in vitro translation buffers (e.g., in PURE or iSAT systems), it exceeds estimates of free cytosolic [Mg<sup>2+</sup>] in E. coli (~1-2 mM). The authors should clarify that they refer to total Mg<sup>2+</sup> concentrations compatible with cell-free protein synthesis, not necessarily intracellular free ion levels, to avoid misleading readers about true physiological relevance.

      We agree that this is a very reasonable point and revised the manuscript to clarify that we are referring to the total Mg<sup>2+</sup> concentration compatible with cell-free protein synthesis, rather than the intracellular free Mg<sup>2+</sup> level under physiological conditions. We also changed the term “physiological” to “near-physiological” to avoid the misunderstanding.

      In summary, this work elegantly bridges the gap between the two-step method and the extract-dependent iSAT system by identifying two defined GTPases that capture a core functionality of cellular extracts: enabling ribosome assembly under translation-compatible conditions. However, the reliance on native rRNA underscores that additional factors - likely present in iSAT's S150 extract - are still needed for full de novo reconstitution from unmodified transcripts. Future work combining the precision of this defined system with the completeness of iSAT may ultimately realize truly autonomous synthetic ribosome biogenesis.

      Recommendations for the authors:

      Reviewing Editor Comments:

      Recommendations for improvement:

      (1) Assess the length distribution of GFP polypeptides being produced using SDS-PAGE.

      SDS-PAGE was performed according to the comment 4 of the Reviewer #1 (Fig. 7b). Please refer to our response addressing the comment.

      (2) Compare the rate and yield of GFP synthesized per mRNA using their reconstituted ribosomes to that obtained with pure native ribosomes.

      The efficiency of the reconstituted ribosomes was compared to native ribosomes according to the comment 3 of the Reviewer #1 (Fig. 6). Please refer to our response addressing the comment.

      (3) Expand the panel of reporter mRNAs being examined to compare the fidelity of initiation, elongation or termination achieved with reconstituted ribosomes to that obtained using native ribosomes.

      DHFR synthesis was addressed and also MS analysis of synthesized sfGFP was performed according to the comment 5 of the Reviewer #1 (Fig. 7b, c). Please refer to our response addressing the comment.

      (4) Revise the manuscript to clarify that the in vitro assembly demonstrated here is contingent on using native rRNA and thus does not achieve a true bottom-up reconstruction from synthetic parts.

      We added to the Discussion a paragraph summarizing the findings of this study, limitations, and future perspectives according to the comment 1 and 2 of the Reviewer #1 and the comment 1 of the Reviewer #2. Please refer to our responses addressing these comments.

      (5) Revise the manuscript to clarify that they are referring to total Mg2+ concentrations compatible with cell-free protein synthesis, not necessarily intracellular free ion levels, to avoid misleading readers about the physiological relevance of the reconstitution.

      We revised the manuscript to clarify this point according to the comment 2 of the Reviewer #2. Please refer to our response addressing the comment.

      (6) Revise the text to fully describe how the native ribosomal proteins (RPs) were purified and indicate whether all subassemblies of RPs were disrupted in the purification procedure.

      We revised the Methods section to clarify how the native RPs were purified and that all subassemblies of RPs were disrupted according to the comment 1 of the Reviewer #1.

      (7) Revise the text to indicate that achieving ribosome reconstitutions using all recombinant, individually purified RPs is required to achieve a true bottom-up reconstruction from all synthetic components.

      As with our response to the comment 4, we have added the point at the end of the Discussion as a future perspective toward true bottom-up reconstruction from all synthetic components.

      (8) Consider conducting a similar systematic omission approach (e.g., adding individual factors) to help identify the additional components required to support unmodified rRNA folding.

      As with our response to the comment 4 and 7, we have added the point at the end of the Discussion as a future perspective toward identification of additional essential factors for true bottom-up reconstruction.

      Reviewer #1 (Recommendations for the authors):

      (1) Assessing the spectrum of GFP polypeptides being produced by SDS-PAGE and comparing the rate and yield of GFP produced to that obtained with pure native ribosomes would seem to be essential additional measurements needed to bolster the evidence supporting the main conclusions of the work.

      SDS-PAGE and MS analysis of the synthesized sfGFP were performed (Fig. 7a, b). Comparison of the assembled ribosomes and native ones were also performed (Fig. 6).

      (2) Examining translation of other reporter mRNAs designed to compare the fidelity of initiation, elongation or termination achieved with reconstituted ribosomes to that produced by native ribosomes in the PURE system would be required to elevate the scientific quality of the work and its significance to the field.

      DHFR synthesis and its activity measurement were performed (Fig. 7c). Also, MS analysis of the purified sfGFP showed that nearly all peptide fragments were detected, covering almost the entire sequence from the initiator amino acid to the amino acid immediately preceding the stop codon (Fig. 7b). We consider that these findings indicate that there is no apparent problem with fidelity.

    1. Reviewer #2 (Public review):

      Summary:

      Chapman, Determan et al. investigate how pathogenic mutations in DNMT3A, which cause Tatton-Brown-Rahman Syndrome (TBRS), disrupt human cortical developmental processes using a comprehensive panel of human pluripotent stem cell models spanning DNMT3A loss-of-function severity. The authors aim to identify the cellular and molecular mechanisms underlying TBRS-associated brain overgrowth and intellectual disability, and to test whether mechanistic convergence exists between TBRS and other overgrowth-intellectual disability disorders (OGIDs) caused by mutations in EZH2 (Weaver syndrome) or PIK3CA pathway components. Their central conclusion is that GABAergic interneuron development is selectively vulnerable to DNMT3A mutation, where reduced DNA methylation causes premature de-repression of neuronal and synaptic genes, driving precocious neuronal maturation and hyperactivity sufficient to disrupt neuronal network synchrony. This report adds to a growing literature supporting the vulnerability of GABAergic interneurons in NDDs and further provides a mechanistic view of this vulnerability, potentially convergent across OGIDs. The mechanistic claims around H3K27me3 compensation and mTOR-based therapeutic convergence, while promising, rest on more preliminary evidence and would benefit from the distinction between correlation and mechanism being made more explicit in the text. Overall, this is a compelling study with a rigorous experimental design and novel findings with a potential impact on a better understanding of the OGID pathophysiology.

      Strengths:

      (1) A major strength of this work is the breadth and rigor of the disease modeling approach. Four independent TBRS model systems are used in tandem: a patient-derived iPSC line with isogenic CRISPR-corrected control (R882H), a knock-in hESC model (P904L) with its wild-type isogenic, patient deletion iPSC lines (Del1/2), and CRISPRi knockdown models (G1/G2), collectively spanning a range of DNMT3A loss-of-function that correlates with phenotypic severity. This allelic series design substantially strengthens causal inference beyond what any single isogenic pair could provide.

      (2) The multi-omic integration across matched developmental stages provides a strong mechanistic foundation for the cellular phenotyping and provides significantly enhanced novelty. RNA-seq, whole-genome bisulfite sequencing, and H3K27me3 CUT&Tag are combined in the same cell types, and timepoints show that DNMT3A loss reduces CG methylation at neuronal and synaptic gene loci, leading to premature transcriptional activation.

      (3) The selective vulnerability of ventral (GABAergic) versus dorsal (glutamatergic) progenitors is one of the study's most important findings. This lineage specificity is consistently observed across all model systems and in both 2D and organoid formats, where ventral NPCs show increased proliferation, premature neuronal gene expression, and increased neurogenesis, while dorsal NPCs are largely unaffected at the transcriptomic and cellular level despite exhibiting comparable DNA methylation changes. This adds to a body of emerging work showing GABAergic interneuron vulnerability in NDDs where ubiquitously expressed genes such as chromatin modifiers are perturbed, and provides additional molecular insights into potential mechanisms of "resilience" of dorsal populations.

      (4) The functional characterization follows a logical progression from single-neuron electrophysiology (demonstrating GABAergic hyperactivity with increased action potential amplitude and firing rate) to network-level analysis using high-density multi-electrode arrays. The HD-MEA experimental design - pairing TBRS or control GABAergic neurons with a constant background of control iGlut neurons - cleanly isolates GABAergic dysfunction as the driver of network hypersynchrony.

      Weaknesses:

      (1) The concomitant induction of proliferation and differentiation in TBRS V-NPCs is conceptually striking, since these are generally considered antagonistic developmental programs. The authors partially address this tension by noting that DNMT3A LOF alone is insufficient to initiate neuronal differentiation, i.e., V-NPCs upregulate neuronal and synaptic genes while retaining progenitor identity, implying that transcriptomic priming and commitment to differentiation are decoupled. However, the relationship between the proliferative phenotype and the epigenetic priming phenotype remains mechanistically unresolved. The manuscript documents mTOR pathway upregulation at the protein level and identifies shared DEGs that include proliferative regulators, but it does not establish whether mTOR-driven proliferation and mCG-loss-driven neuronal gene de-repression/enhanced differentiation are causally linked or represent two independent consequences of DNMT3A LOF.

      (2) Relatedly, the rapamycin rescue experiment is a valuable proof-of-concept for the PIK3/AKT/mTOR convergence but is limited to a single dose in a single model (882) with a single readout (Ki67+ proliferation). Given the prominence of mTOR pathway convergence in the manuscript as a potential shared therapeutic avenue across OGIDs, the data supporting this claim are somewhat preliminary. It remains unknown whether mTOR inhibition rescues downstream phenotypes (neurogenesis, gene expression, neuronal maturation) or whether less severe TBRS models respond similarly. This might also help tackle the first comment above. e.g., if mTOR inhibition rescued proliferation but not the transcriptomic priming, that would support two independent mechanisms.

      (3) The claim that H3K27me3 compensates for mCG loss is an important mechanistic point, but the current data do not distinguish between active compensation, in which EZH2 is recruited in response to methylation loss, and functional redundancy, in which H3K27me3 is independently established and becomes the dominant repressive mark once DNA methylation is reduced. The EZH2 knockdown/inhibition experiments show that H3K27me3 is sufficient to maintain repression at hypo-DMR sites, but they do not establish that H3K27me3 gain is itself a response to methylation loss. Because H3K27me3 profiling was performed only in the severe 882 model, it is also unclear whether H3K27me3 gain scales with DNMT3A LOF severity, as a compensatory model would predict. Finally, the EZH2 overexpression rescue is performed in V-NPCs, whereas the compensation model is developed primarily in D-NPCs, making it difficult to assess whether the same mechanism operates in the lineage where it was originally inferred.

      (4) The narrative framing of dorsal neuron development as unaffected by DNMT3A LOF is somewhat at odds with the data presented. The 882 D-NPCs show substantial DNA methylation changes, and TBRS D-INs exhibit what the authors describe as "substantive transcriptomic differences" involving persistent expression of pluripotency and progenitor genes, which seems to be a distinct but potentially significant phenotype. The impact of DNMT3A loss between ventral and dorsal lineages might be more accurately framed as divergent in nature rather than specific to a certain population.

      (5) SST stainings are not entirely convincing. They appear mostly nuclear, and some instances localized to rosettes in organoids, whereas the protein is largely confined to processes and is expected to be found outside progenitor-rich zones like rosettes.

    2. Author response:

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      This is an important study that describes the consequences of the DNMT3A mutation in human neuronal development for the first time. The selective impact of DNMT3A function on GABAergic interneurons is interesting and an important feature of future therapeutics. The claims made in that manuscript are supported by strong evidence for the most part. And the data are of high quality in general and presented well.

      Strengths:

      The strengths of the work include: Characterization of multiple DNMT3A loss-of-function alleles, including two misense variants, R882H, P904L, and a deletion allele. The missense mutation lines both include an ideal control with the same genetic background. The CRISPRi-mediated DNMT3A knockdown has also been included. The study identifies the mTOR-PI3K pathway as a factor of overgrowth issues found in the mutant organoid. In bulk mRNA sequencing and whole-genome bisulfite sequencing, identify hypomethylated genomic regions associated with gene expression repression. Again, this is more pronounced in the ventral organoid compared to the dorsal organoid. In addition, the extensive electrophysiological characterizations with a high-density microelectrode array support the more mature status of mutant interneurons.

      Weaknesses:

      Although a strong study overall, some weaknesses are noted. These include:

      (1) The lack of validation data for the generated iPSCs and hESCs, such as the chromosomal contents, ploidy, and pluripotency states.

      We thank the reviewer for their constructive feedback. We previously validated our 882 models with whole genome sequencing and teratoma formation upon mouse fat pad injection, while the parental human embryonic stem cell line (WA01 hESCs) used for P904L variant knock-in was validated by our Genome Engineering Stem Cell (GESC) core upon derivation of that variant knock-in model. We have now added both karyotyping and pluripotency staining (SOX2/OCT4) for all other hPSC lines as (new) Supplementary Figure S17 and included further description in our Methods section under “hPSC Model Generation and Culture”.

      New Data: Supplemental Figure S17 (SOX2/OCT4 staining in hPSCs and karyotyping of all lines used)

      Text edits: Additional language confirming hPSC line validation will be added to the Methods section under “hPSC Model Generation and Culture” on page 18.

      (2) Other weaknesses relate to data interpretation and insufficient discussion of related matters, as detailed in the recommendations to the authors.

      We thank the reviewer for their insightful suggestions and have detailed our responses in the “recommendations to the authors” section.

      (3) Also, some errors are noted and detailed in the recommendation section.

      We thank the reviewer for catching these errors and have since corrected them, with detailed responses below.

      Reviewer #2 (Public review):

      Summary:

      Chapman, Determan et al. investigate how pathogenic mutations in DNMT3A, which cause Tatton-Brown-Rahman Syndrome (TBRS), disrupt human cortical developmental processes using a comprehensive panel of human pluripotent stem cell models spanning DNMT3A loss-of-function severity. The authors aim to identify the cellular and molecular mechanisms underlying TBRS-associated brain overgrowth and intellectual disability, and to test whether mechanistic convergence exists between TBRS and other overgrowth-intellectual disability disorders (OGIDs) caused by mutations in EZH2 (Weaver syndrome) or PIK3CA pathway components. Their central conclusion is that GABAergic interneuron development is selectively vulnerable to DNMT3A mutation, where reduced DNA methylation causes premature de-repression of neuronal and synaptic genes, driving precocious neuronal maturation and hyperactivity sufficient to disrupt neuronal network synchrony. This report adds to a growing literature supporting the vulnerability of GABAergic interneurons in NDDs and further provides a mechanistic view of this vulnerability, potentially convergent across OGIDs. The mechanistic claims around H3K27me3 compensation and mTOR-based therapeutic convergence, while promising, rest on more preliminary evidence and would benefit from the distinction between correlation and mechanism being made more explicit in the text. Overall, this is a compelling study with a rigorous experimental design and novel findings with a potential impact on a better understanding of the OGID pathophysiology.

      Strengths:

      (1) A major strength of this work is the breadth and rigor of the disease modeling approach. Four independent TBRS model systems are used in tandem: a patient-derived iPSC line with isogenic CRISPR-corrected control (R882H), a knock-in hESC model (P904L) with its wild-type isogenic, patient deletion iPSC lines (Del1/2), and CRISPRi knockdown models (G1/G2), collectively spanning a range of DNMT3A loss-of-function that correlates with phenotypic severity. This allelic series design substantially strengthens causal inference beyond what any single isogenic pair could provide.

      (2) The multi-omic integration across matched developmental stages provides a strong mechanistic foundation for the cellular phenotyping and provides significantly enhanced novelty. RNA-seq, whole-genome bisulfite sequencing, and H3K27me3 CUT&Tag are combined in the same cell types, and timepoints show that DNMT3A loss reduces CG methylation at neuronal and synaptic gene loci, leading to premature transcriptional activation.

      (3) The selective vulnerability of ventral (GABAergic) versus dorsal (glutamatergic) progenitors is one of the study's most important findings. This lineage specificity is consistently observed across all model systems and in both 2D and organoid formats, where ventral NPCs show increased proliferation, premature neuronal gene expression, and increased neurogenesis, while dorsal NPCs are largely unaffected at the transcriptomic and cellular level despite exhibiting comparable DNA methylation changes. This adds to a body of emerging work showing GABAergic interneuron vulnerability in NDDs where ubiquitously expressed genes such as chromatin modifiers are perturbed, and provides additional molecular insights into potential mechanisms of "resilience" of dorsal populations.

      (4) The functional characterization follows a logical progression from single-neuron electrophysiology (demonstrating GABAergic hyperactivity with increased action potential amplitude and firing rate) to network-level analysis using high-density multi-electrode arrays. The HD-MEA experimental design - pairing TBRS or control GABAergic neurons with a constant background of control iGlut neurons - cleanly isolates GABAergic dysfunction as the driver of network hypersynchrony.

      Weaknesses:

      (1) The concomitant induction of proliferation and differentiation in TBRS V-NPCs is conceptually striking, since these are generally considered antagonistic developmental programs. The authors partially address this tension by noting that DNMT3A LOF alone is insufficient to initiate neuronal differentiation, i.e., V-NPCs upregulate neuronal and synaptic genes while retaining progenitor identity, implying that transcriptomic priming and commitment to differentiation are decoupled. However, the relationship between the proliferative phenotype and the epigenetic priming phenotype remains mechanistically unresolved. The manuscript documents mTOR pathway upregulation at the protein level and identifies shared DEGs that include proliferative regulators, but it does not establish whether mTOR-driven proliferation and mCG-loss-driven neuronal gene de-repression/enhanced differentiation are causally linked or represent two independent consequences of DNMT3A LOF.

      We thank the reviewer for their comment and agree that this phenotype, whereby progenitors exhibited both increased proliferation and hallmarks of gene expression associated with neuronal differentiation is striking and interesting, given that these are typically antagonistic paradigms during normal development.

      We documented that these phenotypes involve upregulated expression of both neuronal/synaptic and proliferative genes in V-NPCs (Figure 2d), with concomitant loss of repressive DNA methylation at regulatory elements associated with these genes (Figure 2f, Supplemental Data 5). In this work, DNMT3A mutation had a more prominent role in de-repressing neuronal and synaptic gene expression to promote hallmarks of neuron differentiation, while playing a relatively less central role in direct regulation of proliferation genes, as seen from the relative prominence of neuronal/synaptic- versus proliferation-related GO terms in our Supplemental Data 5 table.

      To examine the mechanisms underlying increased V-NPC proliferation in our TBRS models, we assessed a potential relationship with the PIK3/AKT/mTOR pathway, as this is implicated in increased proliferation resulting from DNMT3A-associated mutation in myeloid leukemia (Dai et al., 2017, PMID: 28461508). In our work, DNMT3A mutation increased the expression and/or phosphorylation of mTOR signaling pathway targets specifically in V-NPCs (Figure 1q-r, Supplemental Figure S3a-d). However, while TBRS mutation directly affected repressive DNA methylation at a suite of cell proliferation-related genes, these did not include the PIK3/AKT/mTOR pathway genes themselves, suggesting an indirect relationship between altered DNA methylation and increased mTOR signaling.

      Text Edits: We will incorporate further discussion of how DNMT3A-mediated gene repression and levels of PIK3/AKT/mTOR pathway signaling may be interacting, providing a framework for future studies to identify how these related OGID gene mutations may converge mechanistically.

      (2) Relatedly, the rapamycin rescue experiment is a valuable proof-of-concept for the PIK3/AKT/mTOR convergence but is limited to a single dose in a single model (882) with a single readout (Ki67+ proliferation). Given the prominence of mTOR pathway convergence in the manuscript as a potential shared therapeutic avenue across OGIDs, the data supporting this claim are somewhat preliminary. It remains unknown whether mTOR inhibition rescues downstream phenotypes (neurogenesis, gene expression, neuronal maturation) or whether less severe TBRS models respond similarly. This might also help tackle the first comment above. e.g., if mTOR inhibition rescued proliferation but not the transcriptomic priming, that would support two independent mechanisms.

      We thank the reviewer for their comment. We explored both the overall levels and phosphorylation of proteins involved in PIK3/AKT/mTOR signaling in the 882, 904, Del1, Del2, and KO V-NPC models (Figure 1q-r, Supplementary Figure S3a-d), finding specific increases of all proteins. We showed that rapamycin addition reversed the increased proportion of KI67+ proliferating cell nuclei resulting from 882 mutation in V-NPCs in main Figure 1s, while demonstrating that rapamycin also reduced the proportion of KI67+ nuclei observed in both less severe 904 and Del1 V-NPC models (Supplementary Figure S3e-f).

      We agree that understanding whether rapamycin treatment can rescue TBRS neuronal phenotypes would be very interesting, as previous work on Tuberous Sclerosis Complex has utilized rapamycin and other mTOR inhibitors to effectively reverse TSC-related alterations of neuronal morphology and neuronal hyperexcitability (Buttermore et al., 2025, PMID: 40792287). Future studies examining convergent mechanisms and therapeutics for OGIDs should examine how similarly targeting this and related pathways rescues altered neuronal morphology, maturation, and function, as we have demonstrated that TBRS mutation has subsequent consequences for V-IN differentiation, maturation, and function. This point has been detailed in the discussion section on pages 15-16.

      (3) The claim that H3K27me3 compensates for mCG loss is an important mechanistic point, but the current data do not distinguish between active compensation, in which EZH2 is recruited in response to methylation loss, and functional redundancy, in which H3K27me3 is independently established and becomes the dominant repressive mark once DNA methylation is reduced. The EZH2 knockdown/inhibition experiments show that H3K27me3 is sufficient to maintain repression at hypo-DMR sites, but they do not establish that H3K27me3 gain is itself a response to methylation loss. Because H3K27me3 profiling was performed only in the severe 882 model, it is also unclear whether H3K27me3 gain scales with DNMT3A LOF severity, as a compensatory model would predict. Finally, the EZH2 overexpression rescue is performed in V-NPCs, whereas the compensation model is developed primarily in D-NPCs, making it difficult to assess whether the same mechanism operates in the lineage where it was originally inferred.

      We thank the reviewer for the opportunity to clarify our findings and experimental reasoning. A previous study using a conditional Dnmt3a knockout mouse model (Li et al., 2022, PMID: 35604009) demonstrated increased expression of multiple PRC2 components following the loss of Dnmt3a. This study demonstrated that sites which lost DNA methylation gained H3K27me3 in postnatal neurons upon Dnmt3a loss. Therefore, we hypothesize that the gain of H3K27me3 likely occurs in response to loss of DNMT3A methylation.

      While we did not perform CUT&Tag for H3K27me3 in our less severe models, we did validate gene expression changes following EZH2 knockdown and inhibition in both the R882H (Figure 4g-h) and P904L (Supplementary Figure S8b) models, finding that gene expression was unchanged in the model with the less severe DNMT3A mutation (P904L). Based upon these findings, we hypothesized that compensatory H3K27me3 may occur only upon severe DNMT3A loss, as seen in the dominant-negative R882H model. Furthermore, as H3K27me3 compensation was more prominent in D-NPCs, we hypothesized that this might be sufficient to prevent de-repression and aberrant neuronal gene repression upon loss of DNMT3A-mediated repression in D-NPCs. However, since TBRS mutation caused the most prominent de-repression of neuronal gene expression in V-NPCs, we also tested whether EZH2 overexpression could reverse this, finding that it partially suppressed this dysregulated neuronal gene expression. To better clarify this logic and the findings, we will make text edits to this results section.

      Text edits: We will clarify the reasoning for performing the EZH2 overexpression experiments in V-NPCs and reference Li et al., 2022 in both the results (pg. 9-10) and discussion.

      (4) The narrative framing of dorsal neuron development as unaffected by DNMT3A LOF is somewhat at odds with the data presented. The 882 D-NPCs show substantial DNA methylation changes, and TBRS D-INs exhibit what the authors describe as "substantive transcriptomic differences" involving persistent expression of pluripotency and progenitor genes, which seems to be a distinct but potentially significant phenotype. The impact of DNMT3A loss between ventral and dorsal lineages might be more accurately framed as divergent in nature rather than specific to a certain population.

      We thank the reviewer for their comment. While TBRS mutations appear to have a significantly stronger effect on V-NPCs and subsequently V-INs, both transcriptomic and methylation alterations do also occur upon TBRS mutation in D-NPCs and D-INs, as noted in Supplemental Figure S4d, S11, and Supplemental Data 2. However, we observed substantially greater molecular alterations in V-NPCs/V-INs, a lack of overt cellular phenotypes in D-NPCs where assayed, and a lack of functional consequences in matured D-INs, suggesting a more significant requirement for DNMT3A in regulating the differentiation and subsequent maturation of cortical inhibitory interneurons during embryonic and early pre-natal development, the developmental periods that we can readily model in hPSC-derived neurons.

      It should also be noted that these hPSC differentiation models do not recapitulate post-natal deposition of non-CpG (mCA) DNA methylation, a mechanism disrupted postnatally by TBRS-associated mutations in our prior work in murine models (Harrison Gabel; e.g. Beard et al., 2023, PMID: 37952155). Therefore, we hypothesize that if we could sufficiently mature D-INs to a state that modeled postnatal development and recapitulated this non-CpG methylation, we might be able to detect cellular and functional phenotypes in later stage D-INs. To avoid misinterpretation, we will alter the language in the results section to confirm that there are both transcriptomic and methylation changes in our D-NPCs/D-INs, but that these are not accompanied by cellular phenotypes or neuronal dysfunction.

      Text edits: We will better clarify that there are transcriptomic and methylation changes in D-NPCs/D-INs, but that these changes are minimal compared to those in V-NPCs/V-INs, as supported by the lack of cellular and functional phenotypes seen in D-NPCs/D-INs.

      (5) SST stainings are not entirely convincing. They appear mostly nuclear, and some instances localized to rosettes in organoids, whereas the protein is largely confined to processes and is expected to be found outside progenitor-rich zones like rosettes.

      We agree that the perinuclear SST staining detected in these young ventral telencephalic-patterned organoids at day 30 differs somewhat from the more process-localized and cytosolic signal seen in later stage organoids in other studies. This may be related to the use of different commercial SST antibodies across studies but also likely reflects SST immunoreactivity in newborn neurons near the onset of SST expression. For example, immature SST-immunoreactive neurons in the early postnatal rat cortex exhibit predominant SST staining in perinuclear cytoplasm and short processes (e.g. Fig. 3 in Lee et al, PMID: 9664223) while acquiring more cytosolic and process-localized staining as postnatal neuron maturation occurs. Evaluation of immunopositivity for other markers of neurogenesis (ASCL1) and immature neurons (TUJ1) is also congruent with these findings for SST, with TBRS-associated mutations increasing in the fraction of cells in V-NPCs/V-ORGs that express these three markers.

      Reviewer #3 (Public review):

      Summary:

      In this manuscript, the authors investigated TBRS etiology by using new human pluripotent stem cell models, modeling varying levels of TBRS-associated loss of DNMT3A function. They identified increased lineage-specific proliferation of precursors in TBRS ventral MGE-like progenitors, which they propose was related to increased signaling through the PIK3/AKT/mTOR pathway. Furthermore, they show that reduced DNA methylation during MGE-like progenitor differentiation into GABAergic interneurons can cause a premature expression of neuronal and synaptic genes, triggering precocious neuronal maturation. In conclusion, they propose that TBRS-derived GABAergic neurons exhibit hyperactivity that can alters the development and structure of neuronal networks.

      Strengths:

      Overall, the data presented is convincing, from an early developmental point of view, given that the iPSC-derived 2D cultures or organoids used do not get to reach a mature state. Nonetheless, the data clearly show the effects that deleterious mutations in TBRS can cause during the period of neurogenesis, which was missing in the field.

      Weaknesses:

      (1) Li et al., 2022 (referred to in the manuscript) seems to already show the interplay between H3K27me3 and Dnmt3a discussed in this study i.e., that in the absence of DNA methylation, there is an expansion of polycomb-like repression. These data should be better acknowledged in the paragraph 'Repressive H3K27me3 compensates for severe loss of DNA methylation' (page 9), given it supports the data presented in this manuscript and suggests this as a common mechanism in the interplay between these two repressive marks, as it is well established in the literature.

      We thank the reviewer for this suggestion and will incorporate this reference into both the results and the discussion when discussing the respective roles of DNMT3A and PCR2-mediated repression.

      Text edits: We will add Li et al., 2022 to both the results section (pg. 9-10) and our discussion section.

      (2) The authors should acknowledge that the omics data come from a mixed population of cells.

      We thank the reviewer for their comment. We have validated that the established 2-D differentiation methods we used in this study generate cell populations with >85-90% enrichment for the desired progenitor and neuronal cell type, based upon marker expression, but acknowledge that these are bulk -omics data obtained from cells that may represent a mixed population and have now detailed this in the methods section under “Sequencing”.

      Text edits: we will add language acknowledging that our omics data (bulk) was generated from mixed populations of cells.

      (3) The authors are encouraged to further discuss whether the overgrowth observed in ventral GABAergic cultures or organoids compares to the overgrowth observed in diseased patients. One expects MRIs to have been performed in patients and that these could be harnessed to discern if overgrowth occurs in the cortex or ventral regions of the brain.

      We thank the reviewer for their suggestion and do note that at least one published study documents increased cortical thickness in the MRIs of TBRS patients (Jiménez de la Peña et al., 2024, PMID: 37795572); however, to our knowledge studies have not examined regional or cell type-selective overgrowth of cortical tissue in TBRS patients. Future clinical studies examining the nature of the neuronal progenitor overgrowth and resulting consequences for patient brain imaging would be of interest to better understand TBRS-associated etiology of brain overgrowth and its manifestations.

    1. Author response:

      [Editors' note: The authors included an author response to reviews from another journal]

      Reviewer #1 (Comments to the Authors):

      In this manuscript the authors describe that cells in collective movements adopt a superdiffusive behavior to out pace individual cells. This behavior is regulated by cell-cell junctional stability and force transmission. The authors state that speed is regulated by vinculin through mechanosensitivity.

      While is makes intuitive sense that cells may move more efficiently collectively as it reduces their exploratory space and therefore increases their efficiency of movement,

      We agree that this is an intuitive explanation. However, previous literature had shown that confluent cells may or may not migrate depending on conditions that do not solely depend on the space available per cell, but also involve the intrinsic activity of the cell, its cortical tension, and its adhesion with its neighbors, with sometimes counterintuitive effects (doi: 10.1016/J.CEB.2021.07.011). This was the reason that motivated us to investigate how these various ingredients affected space exploration efficiency on different time scales.

      Our results indeed refute the intuition that cells move more efficiently when their exploratory space is reduced by showing that the outcome depends on the time scale considered (Fig. S3B). Specifically, on short time scales (less than 3 hours), the area explored by individual MDCK cells is larger than that explored by MDCK cells at confluence. On a longer time scale (greater than 3 hours), however, the area explored by confluent MDCK cells is larger. This switch is a direct consequence of the change in migratory behavior from persistent random walk to superdiffusion, Moreover, its position in time depends on the cell line: extrapolation of our results on RPE-1 cells suggests that it should theoretically occur after approximately 300hrs, if this time scale was experimentally accessible (Fig. S3F).

      …the role of junctions specifically is less clear.

      We are sorry that we were not able to clearly convey the roles of junctions. We have substantially rewritten our text to address this and all the changes are highlighted in orange. As summarized in Fig. 6F, junctions have three roles. The first role is on persistence, through velocity coordination between neighbors, the second is on speed, through the stability of junctions, and the third role is on directionality, through the sensitivity of the monolayer to the wound edge.

      The first role is evidenced thanks to the comparison of the MSD between single cell and confluent migration assays and the use of the alpha-catenin KD cell line. Alpha-catenin depletion is known to be the most potent disruptor of adherens junctions (DOI:10.1091/mbc.e06-05-0471, , DOI:10.1126/science.aaf7119, (DOI:10.1073/pnas.1002662107, DOI:10.1073/pnas.1119313109), and we show that it significantly alters the superdiffusive behavior that emerges in the confluent migration assay (Fig. 3E,F, 5C). Therefore, junction integrity is critical for the control of cell persistence.

      Moreover, alpha-catenin depletion induces a loss of velocity coordination between neighbors (Fig. S3E), which we show through numerical simulations to induce superdiffusion (Fig. 3G). By contrast, E-cadherin KO and vinculin mutants have no effect on the superdiffusion of confluent cells (Fig. 3E, 4A). Therefore, the critical molecular ingredient is the link provided by alpha-catenin to the cytoskeleton that provides junction integrity.

      The second role of junctions is evidenced thanks to the comparison of cell speeds between single and confluent migration assays with the vinculin mutants (Fig. S4A). Results show that cell speed is reduced of about 10µm/h by confluence, regardless of the mutant except for YE, whose only difference with other mutants is its lower stability (Fig. 4F). This supports that junction stability, and not the other effects of mutants, controls cell speed (we provide a detailed demonstration in the response to the following question). As expected, junction integrity is required as well, as seen from the higher cell speed of the alpha-catenin KD cell line compared to WT (first MSD point in Fig. 3B, E).

      The third role of junctions is evidenced thanks to the comparison between confluent and directed migration assays (Fig. 6A). Results show that the wound healing rate is proportional to cell speed at confluence, regardless of the mutant except for YE, which displays no tension gradient in junctions from front to back cells (Fig. 6C). This supports that such gradient is required for cells to identify on which side is the wound edge. As expected, junction integrity is required as well, as seen from the loss of directional bias of the alpha-catenin KD cell line (Fig. 5F).

      The authors chose vinculin as the basis by which to manipulate tensions at cell-cell junctions, but this comes with considerable drawbacks. Namely, since vinculin appears at both cell-cell and cell-matrix junctions, its role and the role of its mutations is not clear here. The authors state that the collective migration speed is related to junctional stability, but because vinculin is also at FA, how can this be concluded?

      We apologize for the lack of clarity. We hope that the highlighted changes in the revised manuscript will improve this point. As exemplified above, comparing cell migration between isolated cells and confluent cells is essential to enable us to distinguish between the contributions of AJs and FAs. Indeed, since isolated cells lack AJs, the impact of vinculin mutants on single cell migration can only be explained by their effects on FAs. This is how we first determine the effects of vinculin mutants on migration that depend on FAs. Because confluent cells also have FAs, we expect that the effects of vinculin mutants on the migration of isolated cells will still be present in confluent cells, to which will be added the effects of these mutants on AJs and their consequences on migration, if any.

      Therefore, when compared to WT cells, if a given mutant decreases or increases migration speed in individual cells, and does so in confluent cells in the same proportion, then its effects at confluence can be entirely explained by its effects in individual cells, and there are no additional effects of that mutant from AJs. This is indeed what we observe for all mutants except the YE mutant (Fig. S4C), leading us to conclude that none of the vinculin mutants, except the YE mutant, have an effect on migration at confluence that results from AJs. In contrast, the YE mutant has effects on migration at confluence that cannot be explained by its effect on individual cell migration. Therefore, the effects of YE at confluence depend on AJs, whether they result from alterations in AJs, FAs, or both. To distinguish between these scenarios, we proceed by elimination, comparing the effects of YE to those of other mutants on force transmission and adhesion stability, and how these two factors associate with migration speed, as explained below. In FAs, YE alters force transmission differently in individual cells and at confluence, but we already know from Fig. 2 that force transmission in FAs cannot alone explain the speed of migration. This result rules out an indirect effect of AJs on cell migration at confluence through FAs. Furthermore, in AJs, YE affects stability and force transmission, but TL has the same effect on force transmission as YE and we already know that none of the effects of TL on migration depend on AJs (Fig. 3, S4C). This result rules out an effect of force transmission in AJs on migration speed at confluence. We conclude that stability at the AJ level, which is the remaining property specifically impaired by YE, is what regulates migration speed at confluence.

      The manuscript's logic and flow are not clear in some places, making the story hard to follow. As one example, the FRAP data, which the authors suggest is used to investigate vinculin's combined role does not help in this capacity as the interpretation and its connection to the bigger story are not clear.

      We are sorry again for the lack of clarity. We used FRAP data to evaluate the effects of vinculin mutants on adhesion stability. Indeed, mutants have different effects on adhesion stability (Fig. 2E, 4F). In addition, they also have different effects on force transmission (Fig. 2D, 4D,E). The partial overlap in functional alterations caused by the mutants allows us to test the involvement of the overlapping function (here stability) in the overall migration outcome. For example, if two mutants have a similar effect on adhesion stability but different effects on migration speed (such as TL and T12), we can then rule out that speed results from adhesion stability. Similarly, if two mutants have different effects on stability but a similar effect on speed (such as TL and YE), we can also rule out that speed results from stability. We applied the same reasoning to force transmission to conclude that neither adhesion stability nor force transmission alone is sufficient for cells to migrate rapidly. However, the combination of the two enables rapid migration.

      As another example, the information derived from the use of the mutants is not clear in the context of the message in the manuscript since they affect cell-cell and cell-matrix junctions and in some places show results that are counter intuitive and not well-explained, to which the authors admit they are surprising but then do not explain their meaning.

      As such, it is very hard to follow the logic with regard to the information resulting from the mutant experiments.

      We provide above a detailed break-down of our strategy to analyze the results. We regret that our manuscript did not adequately convey our conclusions and we hope that the new version of the manuscript improves this point.

      Proliferation has been shown to play a role in wound healing. Does proliferation change in the various conditions?

      This is an important point. The average speed of cells at confluence is approximately 20 µm/h (Fig. 4B), which means that each cell moves approximately its own size in one hour. During this time, assuming a 16-hour cell cycle, 6% of the cells would have divided, each of them likely pushing one of its neighbors a distance equivalent to the size of a cell. Therefore, cell proliferation accounts for at most a few percent of the total cell movement. For this reason, we can assume that growth does not account for a large part of the movement we observe. This is consistent with previous work showing that proliferation does not contribute significantly to wound healing (DOI: 10.1073/pnas.0705062104, DOI: 10.1083/jcb.201207148).

      Minor comments:

      The authors should provide a better description of the mutants: what does a tailless mutant not bind, or bind differently? More context is needed to help interpret the results. While the mutants have all been published on before, it would be helpful to have more information here so that the manuscript is easier to follow.

      We are sorry that the information we provided was insufficient. We have now detailed the mutations to help the reader understand how interactions are altered.

      Figure 1A is not necessary. Figure 1 overall is fairly predictable as there have been many papers using the persistent random walk as the best model to single cell migration (dating back to the early 1990's). The authors define a new term, angular memory, which they show decreases with increasing delta t as one would predict.

      We acknowledge that persistent random walks have already been observed for individual cells, as in references 3-4 cited in the introduction. Nevertheless, we believe that Figure 1 is important because not all cells migrate as persistent random walkers when isolated. Some migrate in a more exotic manner, resulting in superdiffusive behavior, as in references 5-8 cited in the introduction. Since we observe superdiffusive behavior at confluence (Figure 2), it was therefore necessary to show whether or not single cells were superdiffusive too. We also use this figure to introduce angular memory, a measure that, to our knowledge, has never been used before. According to intuition, it decreases to 0 for persistent random walkers, just as another resembling measure, velocity autocorrelation, would do. However, the angular memory of fractional Brownian walkers does not vanish with increasing delta t (Fig. 3D), while velocity correlation would, just as that of persistent random walkers. This difference makes angular memory much more appropriate for distinguishing between the two migration behaviors, and prompted us to introduce it in the first figure as a reference.

      In the wound healing assay, which cells were measured? Leading edge or interior, and does it matter?

      Figure 5A shows that cells behave differently depending on their distance from the wound. This is because the traces shown correspond to the first few hours of the movie, during which the cells at the front begin to move first. Figure S5A shows the speed of the cells over time after the wound and indicates that the cells reach a stable speed after approximately 3 to 4 hours. Figure S5B shows the speed of the cells as a function of distance from the wound at steady state. These results show that the speed of the cells no longer depends on the distance from the wound at this stage. As indicated in the “Materials and Methods” section, we only considered time points beyond this stage for subsequent analyses of population-averaged MSD and velocity presented in Figure 5, so the location of cells at the front or rear was irrelevant.

      Reviewer #2 (Comments to the Authors):

      To migrate cells must spatially explore their environments, a process that is guided by intrinsic signals (adhesive and mechanical properties, etc) and extrinsic (gradient cues) signals. This exploration can occur on the single or multicellular level. In this study, the authors examine the effect of cell-cell interactions, guidance cues, and cell mechanics in the exploratory capacity of MDCK cells. The authors show that cell-cell adhesion provides a "infinite directional memory for migration" and cell speed is dependent upon the focal adhesion stability, cell mechanics, and the mobility of adherens junctions-these processes are modulated by vinculin.

      My three major concerns with the manuscript are as follows:

      (1) While there is potential new information about the role cell-cell junctions and guidance cues play in cell migration, there is not enough NEW insight presented. Rather the role of vinculin in these processes is expected given what is already known about its ability to control focal adhesion stability, mechanics, and adherens junctions.

      We agree that our cell migration results make sense based on the effects of vinculin mutants on the stability and force transmission of adhesions. Nevertheless, we argue that this was not the only possible scenario. Indeed, we find that none of the effects of vinculin mutants on AJs (except YE) have an impact on cell migration (Fig. S4C). One might have expected that the increased stability provided by the TL and T12 mutants would reduce the speed of collective cell migration, just as the YE mutant increased cell speed due to its altered stability. This is not what we found, and this reveals a nonlinear relationship between AJ stability and migration speed that could be investigated more thoroughly in future studies. Another example is that the effects of the mutants on force transmission in AJs do not impact migration speed at confluence but do impact directed collective migration (Fig. 6). One might have expected that vinculin-mediated force transmission in AJs would impact collective migration, whether directed or not.

      More importantly, we show that the role of intercellular adhesion in cell migration is more complex than expected. Indeed, it depends on the timescale considered: intercellular adhesion is detrimental to short-term spatial exploration and beneficial in the long term (Fig. S3B). Such a timescale-dependent behavior is impossible to predict from previously known effects of the mutants or other molecular considerations. Furthermore, we show that this behavior can be fully explained by the coordination of velocities between neighbors, which depends on intact connections between AJs and the cytoskeleton via alpha-catenin, but is independent of vinculin mutants that connect AJs to the cytoskeleton in parallel with alpha-catenin. One might have expected these connections to also have an impact on velocity coordination, and thus on spatial exploration, but we show that this is not the case (Fig. 3). Finally, we show that directed collective migration has a negligible impact on cell exploration at our experimental timescale (Fig. 5), whereas we initially expected the wound to make migration more ballistic. This reveals that such a directional signal affects spatial exploration at much longer timescales than expected.

      Overall, our results quantify the outcome of competing effects and provide timescales at which one effect outweighs the other in influencing cell migration. We believe this is an original approach that provides substantial new insights into collective cell migration.

      (2) The phenotypes of the cells expressing the mutant vinculins varying greatly. These phenotypes are not addressed despite the fact that they could potentially complicate the analyses. For example, there are dramatic differences between focal adhesion numbers and sizes in the cells expressing the different vinculin mutants; cell spreading is also dramatically altered. Likewise, the T12 mutant vinculin has previously been reported to have increased adhesive strength, increased traction forces, and cell spreading. How does this knowledge change the interpretation?

      We agree that vinculin mutants may have effects on the size and number of FAs, cell spreading, and traction forces that we do not examine here. These consequences can be explained by the effects of these mutants on force transmission in FAs and on their stability, which we report in our work. They do not affect our interpretations. Here, we provide a predictive model of migration speed based on the combination of two consequences of vinculin function, namely stability and force transmission. An interesting avenue for future research would be to assess whether these combinations can be reduced to a single higherlevel effect of vinculin on the cellular phenotype that would be sufficient to predict migration speed. This work remains to be done, as neither FA size and number, cell spreading, adhesion force, nor traction forces alone are sufficient to predict migration speed.

      Along the same lines, it has previously been established that tagged version of vinculin do not efficiently integrate into adherens junctions. Published work from the Nelson laboratory suggests that GFP-vinculins do not localize to cell-cell junctions and work from other laboratories suggests localization occurs only when the endogenous vinculin is silenced.

      We are aware that some GFP-vinculin constructs may not localize as well as the endogenous protein at AJs. This is due to the localization of the GFP tag on the head of vinculin and depends on the length of the linker between GFP and the head of vinculin. The longer the linker, the easier the interaction with AJ partners. Unlike these constructs, the vinculinTSMod sensors we use in our work do not carry a GFP on the head and do not suffer from the same limitations.

      Furthermore, vinculin recruitment to AJs depends on force, with little or no recruitment when tension on the AJs is relaxed (DOI: 10.1038/ncb2055). Vinculin recruitment has in fact already been used as an indicator of AJ tension in Drosophila (DOI: 10.1038/s41467-01807448-8). Consequently, the amount of vinculin visible at the AJs varies depending on the tension exerted on the AJs, which our results confirm: vinculin is more difficult to detect at the AJs in cells located at the front of a wound than in those located at the back (Fig. 6B), which is consistent with the difference in vinculin tension between front and back cells (Fig. 6C) and to the E-cadherin tension gradient between front and back cells (DOI: 10.1083/jcb.201706013). Overall, these results show that vinculin is not always easy to detect at AJs, but this is due to the properties of vinculin, which the constructs we use reproduce better than previous constructs (see also below).

      The images in figure S2 and the prebleach images in figure S4 do not show convincing localization of the mutant vinculins to cell-cell adhesions. This is of special concern given that YE mutant protein hardly has any discernable localization to cell-cell junctions; additionally, none of the mutant proteins were tested for their ability to co-localize with adherens junction components. This raises the question if the parameters being examined and the conclusions drawn from them are affected by a difference in localization.

      We agree that the recruitment of vinculin at intercellular contacts may be difficult to see.

      Besides force-dependent effects mentioned above, other factors are involved. The images shown in Figures S2 and S4 are from live cells in which cytoplasmic vinculin is still present, and its level proportional to the mobility of vinculin. Indeed, the TL and T12 mutants show a more marked contrast between intercellular contacts and the cytoplasm, which is consistent with their greater stability at AJs (Fig. 4F). Conversely, YE shows lower contrast, which is consistent with the lower stability of this construct at AJs (Fig. 4F). The FL construct lies between the two. As a result, the cytoplasmic content can variably mask vinculin recruitment at the AJs depending on the mutant.

      We have now performed additional quantifications of mutant recruitment at intercellular contacts as a function of distance from the basal surface of the cells and relative to their recruitment in FAs, in live cells. Results are shown in the new Fig. S4F. We find that all the constructs are recruited to intercellular contacts with a density that is at most half of that in FAs and that varies along the height. FL shows the highest density, localized more apically, consistent with the localization of an AJ-bound actin belt. The mutants appear to be more homogenously distributed along the height of the lateral surface, which may be explained by their impaired autoinhibition (TL, T12), or mechanosensitivity (YE). This variability also contributes to the difficulty in seeing vinculin recruitment in all cells in a single z-slice.

      To confirm the proper recruitment of vinculin constructs to AJs we have performed immunofluorescence against alpha-catenin and phalloidin on each of the stable cell lines. Results are shown in the new Fig. S4D and E. In these experiments, cell permeabilization allows for the release of some of the cytoplasmic pool of vinculin, which highlights the recruitment of all vinculin constructs to intercellular contacts. There, all vinculin constructs colocalize with alpha-catenin and F-actin, as expected. Additionally, images displayed are maximum intensity projections to mitigate recruitment variability along the height.

      Overall, our results clearly support the localization of vinculin at intercellular contacts, and the differences between the constructs are consistent with the effects of their mutations.

      (3) There is a lack of new mechanistic insight. Conclusions are made about a role of vinculin dimerization. This conclusion appears to be based upon the usage of the mutant version of vinculin Y1065. Did the authors directly measure the ability of this mutant protein to dimerize? Is actin binding also affected.

      The binding properties of the Y1065E mutant, including its dimerization and binding to actin, have already been characterized by other researchers (ref. 40 in our manuscript, as well as DOI:10.1111/j.1432-1033. 1997.01136.x or DOI: 10.1016/j.febslet.2013.02.042). We assumed that these properties are now well established and can be used to explain higher-level phenotypes that we show for the first time, to our knowledge.

      Reviewer #3 (Comments to the Authors):

      Canever et al. tracked two epithelial cell lines on collagen coated glass and showed that isolated cells (non confluent) move as persistent random walkers, whereas confluent monolayers migrate super diffusive, with long range directional memory. By systematically perturbing adhesion machinery they found that focal adhesion mutations mainly tune the speed of single cell tracks, but cannot create long range memory, while force bearing adherens junctions are essential for the super diffusive regime-genetically perturbing them collapses collective memory. These interesting results identify junctional tension as important to switch epithelial cells/sheets between individual and collective search modes - an important quantitative insight that is of clear relevance to cell biologists.

      - The presented data is nicely quantitative and convincing, but I have subtle concerns about the generality of the findings. While the authors show that the differential behavior, they describe is not cell-line specific (MDCK, RPE), there are no experiments evaluating the generality of their conclusions across different matrix conditions. How are the measured migration parameters affected by matrix stiffness? Cell migration on collagen coated glass coverslips is a relatively narrow and artificial condition. How is the collective directional memory expected to behave on softer substrates? The generality of the conclusions could be strengthened by repeating measurements using hydrogels of varying stiffness. Further, it should be discussed to which tissues in the body the selected matrix conditions and migration modes plausibly apply.

      We agree that the generality of our results and the relevance of glass-rigid substrates is an important point. In vivo, epithelial cells rest on a basement membrane with a typical stiffness of approximately 10 MPa, as demonstrated by experimental evaluations on various tissue explants, including renal glomeruli and Bruch's membrane, which are relevant to MDCK and RPE-1 cells (DOI: 10.1111/j.1742-4658.2007.05823.x, DOI: 10.1172/JCI106898, DOI:10.1038/eye.1987.35), we have added these references in the manuscript to support our experimental strategy. In vitro, the most significant effects of substrate stiffness on FAs and cell migration generally occur at much lower stiffnesses, between 0.2 and 100 kPa, and cell phenotypes generally plateau at levels comparable to those observed on glass, even below 100 kPa (DOI: 10.1242/jcs.133645, DOI: 10.1038/ncb3268, DOI:10.1039/c5ib00307e, DOI: 10.1039/c9sm01893j). Furthermore, substrate stiffness has much more moderate effects on confluent cells than on isolated cells. For example, it has been previously demonstrated that confluent layers of MCF10A epithelium showed no change in velocity coordination in the range of 3 to 65 kPa (DOI: 10.1083/jcb.201207148). Therefore, collagen-coated glass appears to be a reasonable model for the basement membrane. Overall, we believe that we have conducted our experiments under physiological conditions, and that our results apply to a wide range of substrate stiffnesses.

      - It would be nice to see how long it takes confluent cell layers to close rectangular wounds of defined size when cells migrate as individual (adherens junctions perturbation) versus collective (wt) (on substrates of different stiffness). Presumably, there should be faster wound closure under the collective regime, at least for simple shaped wounds.

      This is an interesting question, which our results indirectly address. In our study, we measured the wound healing speed of the WT MDCK cell line as well as lines expressing mutant vinculin constructs (Fig. 6A). These results show that this speed ranges from 5 to 15 µm/h depending on the construct expressed (and for reasons that we explain in the manuscript). These values make it easy to estimate the time required to close a wound based on its width. For example, it would take 5 hours to close a 100 µm wide wound for the WT cell line, which has a rate of 10 µm/h (on both sides of the wound).

      Wound closure for cells with disrupted adhesive junctions has already been documented (DOI: 10.1083/jcb.200910041). The results show that wound closure is indeed slower than with WT cells. Although this previous study does not reveal the underlying causes, our work now shows that there are two factors: weaker directional memory due to impaired intercellular coordination and, in the longer term, an additional lack of sensitivity to the guidance signal provided by the wound.

      - Akin to substrate stiffness variation, I am missing experiments that test the effect of cytoskeletal tension on these migration modes. Experiments with Rho kinase or myosin inhibitors could meaningfully broaden the scope of this study.

      Rho kinase or myosin inhibitors applied to cells during the time required to assess migration patterns (a movie recorded overnight is necessary to obtain a statistically reliable calculation of MSD over 3 to 4 hours) are likely to affect many other cellular processes in addition to the cytoskeletal tension directly involved in migration. We believe that the accumulation of these effects will make interpretation of the results very difficult. For example, it has been shown that inhibition of ROCK by Y27 promotes healing of corneal endothelial lesions by affecting proliferation through cyclin D and p27 (DOI: 10.1167/iovs.13-12225), or by improving respiration, which would provide the energy necessary for migration (DOI: 10.1096/fj.202101442RR). Consistently, another study on HaCaT epidermal cells confirms that myosin phosphatase accelerates wound healing through proliferation (DOI: 10.1016/j.bbadis.2018.07.013). In contrast, in HUVEC cells, ROCK inhibition significantly impaired the proliferation and migration of vascular endothelial cells in vitro in a dose-dependent manner (DOI: 10.1097/ICO.0000000000000493).

      Furthermore, previous studies have highlighted that differential contractility at the subcellular level is important for collective migration (DOI: 10.1038/ncb2133, DOI: 10.1083/jcb.201706013), which is not possible to examine with global activation or inhibition of contractility. This prompts the development of more refined and specific measurement and disruption strategies to assess the respective impact of cytoskeletal tension on cell-cell and cell-matrix adhesion mechanisms. Our work, which uses biosensors to assess how this tension differentially affects cell-cell and cell-matrix adhesions, is a step in this direction. The localized spatio-temporal activation or inhibition of myosin subtypes or Rho GTPase regulators specific to these adhesion structures will likely answer these questions in the future, but we believe that the development and application of these approaches will require a substantial amount of work that goes beyond the scope of our study.

    1. Wear a Library Student Worker tag while working.  You'll appear more professional and it will set you apart from student patrons.

      Take this out - we don't have worker tags on the 3rd floor anymore

    2. Wear a Library Student Worker tag while working.  You'll appear more professional and it will set you apart from student patrons. Please don't wear brimmed hats or sunglasses as they can impede eye contact.

      This is not RMC policy but we can discuss.

    1. Cotton from BCI farms may be mixed with conventional cotton along the way, that's why we can't put a BCI-tag on our clothes.

      This statement raises transparency issues because consumers may assume the cotton products are fully sustainable, even though the material can still be mixed with conventional cotton. Companies should clearly explain the limitations of sustainability claims to avoid confusion and misleading marketing.

    1. Wenn Sie den Arzt, der Sie während der Geburt betreuen soll, gerne vorher kennen möchten und Ihnen die Wolfartklinik in Gräfelfing gut gefällt, dann steht ihnen Herr PD Dr. Raab jederzeit bei Tag oder Nacht zur Verfügung.

      Streichen

    1. find that we can split the users into a small group of power users who do the majority of the contributions, and a very large group of lurkers who contribute little to nothing. Fo

      I find it interesting how we use the terms power users and lurkers for crowdsourcing sectors specfically. When raising money, you would think that you would not want to tag any donor, of any kind, of any donation, with any negative label. The term lurker makes it seem like a negative term to the person who is a lurker- like someone who didn't do all that they could to support. Meanwhile power users have that positive connotation, which makes sense, but its the dicotomy between the two labels that I find interesting. Not all donors are equal, but any donor is surely one you would want to tag with a good label? I understand for social media posts etc, this concept changes, but for crowdsourcing specifically I find this interesting.

    1. Popular products in Wireless internationally
      1. Many of the alt tag descriptions for these products exceed 125 characters. Also, if you were to click on one of these items, you would see that the normal descriptions are also extremely long.
    1. A signal phrase, also known as an attributive tag, is a device used to smoothly integrate quotations and paraphrases into your essay. It is important to use signal phrases to clearly attribute supporting evidence to its author or authors and to avoid interrupting the flow of an essay. Signal phrases can also be used as meaningful transitions, moving your readers between your ideas and those of your sources.

      The use of signal phrases is often taught merely as citation tools, ignoring their role in creating a cohesive writing structure. These examples demonstrate how signal phrases can enhance the flow and readability of academic writing.

    1. Author response:

      Reviewer #1 (Evidence, reproducibility and clarity):

      Summary:

      This manuscript reports the identification of putative orthologues of mitochondrial contact site and cristae organizing system (MICOS) proteins in Plasmodium falciparum - an organism that unusually shows an acristate mitochondrion during the asexual part of its life cycle and then this develops cristae as it enters the sexual stage of its life cycle and beyond into the mosquito. The authors identify PfMIC60 and PfMIC19 as putative members and study these in detail. The authors at HA tags to both proteins and look for timing of expression during the parasite life cycle and attempt (unsuccessfully) to localise them within the parasite. They also genetically deleted both gene singly and in parallel and phenotyped the effect on parasite development. They show that both proteins are expressed in gametocytes and not asexuals, suggesting they are present at the same time as cristae development. They also show that the proteins are dispensible for the entire parasite life cycle investigated (asexuals through to sporozoites), however there is some reduction in mosquito transmission. Using EM techniques they show that the morphology of gametocyte mitochondria is abnormal in the knockout lines, although there is great variation.

      Major comments:

      The manuscript is interesting and is an intriguing use of a well studied organism of medical importance to answer fundamental biological questions. My main comments are that there should be greater detail in areas around methodology and statistical tests used. Also, the mosquito transmission assays (which are notoriously difficult to perform) show substantial variation between replicates and the statistical tests and data presentation are not clear enough to conclude the reduction in transmission that is claimed. Perhaps this could be improved with clearer text?

      We would like to thank the reviewer for taking the time to review our manuscript. We are happy to hear the reviewer thinks the manuscript is interesting and thank the reviewer for their constructive feedback.

      To clarify the statistical analyses used, we included a new supplementary dataset with all statistical analyses and p-values indicated per graph. Furthermore, figure legends now include the information on the exact statistical test used in each case.

      Regarding mosquito experiments, while we indeed reported a reduction in transmission and oocysts numbers, we are aware that this effect might be due to the high variability in mosquito feeding assays. To highlight this point, we deleted the sentence “with the transmission reduction of [numbers]….” and we included the sentence “The high variability encountered in the standard membrane feeding assays, though, partially obstructs a clear conclusion on the biological relevance of the observed reduction in oocyst numbers“

      More specific comments to address:

      Line 101/Fig1E (and figure legend) - What is this heatmap showing. It would be helpful to have a sentence or two linking it to a specific methodology. I could not find details in the M+M section and "specialized, high molecular mass gels" does not adequately explain what experiments were performed. The reference to Supplementary Information 1 also did not provide information.

      We added the information “high molecular mass gels with lower acrylamide percentage” to clarify methodology in the text. Furthermore, we extended the figure legend to include all relevant information. Further experimental details can be found in the study cited in this context, where the dataset originates from (Evers et al., 2021).

      Line 115 and Supplementary Figure 2C + D - The main text says that the transgenic parasites contained a mitochondrially localized mScarlet for visualization and localization, but in the supplementary figure 2 it shows mitotracker labelling rather than mScarlet. This is very confusing. The figure legend also mentions both mScarlet and MitoTracker. I assume that mScarlet was used to view in regular IFAs (Fig S2C) and the MitoTracker was used for the expansion microscopy (Fig S2D)?

      Please clarify.

      We thank the reviewer for pointing this out – this was indeed incorrectly annotated. We used the endogenous mito-mScarlet signal in IFA and mitoTracker in U-ExM. The figure annotation has now been corrected.

      Figure 2C - what is the statistical test being used (the methods say "Mean oocysts per midgut and statistical significance were calculated using a generalized linear mixed effect model with a random experiment effect under a negative binomial distribution." but what test is this?)?

      The statistic test is now included in the material and method section with the sentence “The fitted model was used to obtain estimated means and contrasts and were evaluated using Wald Statistics”. The test is now also mentioned in the figure legend.

      Also the choice of a log10 scale for oocyst intensity is an unusual choice - how are the mosquitoes with 0 oocysts being represented on this graph? It looks like they are being plotted at 10^-1 (which would be 0.1 oocysts in a mosquito which would be impossible).

      As the data spans three orders of magnitude with low values being biologically meaningful, we decided that a log scale would best facilitate readability of the graph. As the 0 values are also important to show, we went with a standard approach to handle 0s in log transformed data and substituted the 0s with a small value (0.001). We apologize for not mentioning this transformation in the manuscript. To make this transformation transparent, we added a break at the lower end of the log-scaled y-axis and relabelled the lowest tick as ‘0’. This ensures that mosquitoes with zero oocysts are shown along the x-axis without being assigned an artificial value on the log scale. We would furthermore like to highlight that for statistics we used the true value 0 and not 0.001.

      Figure 2D - it is great that the data from all feeding replicates has been shared, however it is difficult to conclude any meaningful impact in transmission with the knock-out lines when there is so much variation and so few mosquitoes dissected for some datapoints (10 mosquitoes are very small sample sizes). For example, Exp1 shows a clear decrease in mic19- transmission, but then Exp2 does not really show as great effect. Similarly, why does the double knock out have better transmission than the single knockouts? Sure there would be a greater effect?

      We agree with the reviewer and with the new sentence added, as per major point, we hope we clarified the concept. Note that original Figure 2D has been moved to the supplementary information, as per minor comment of another reviewer.

      Figure 3 legend - Please add which statistical test was used and the number of replicates.

      Done

      Figure 4 legend - Please add which statistical test was used and the number of replicates.

      Done. Regarding replicates, note that while we measured over 100 cristae from over 30 mitochondria, these all stem from the same parasite culture.

      Figure 5C - the 3D reconstructions are very nice, but what does the red and yellow coloring show?

      Indeed, the information was missing. We added it to the figure legend.

      Line 352 - "Still, it is striking that, despite the pronounced morphological phenotype, and the possibly high mitochondrial stress levels, the parasites appeared mostly unaffected in life cycle propagation, raising questions about the functional relevance of mitochondria at these stages."

      How do the authors reconcile this statement with the proven fact that mitochondria-targeted antimalarials (such as atovaquone) are very potent inhibitors of parasite mosquito transmission?

      Our original sentence was reductive. What we wanted to state was related to the functional relevance of crista architecture and overall mitochondrial morphology rather than the general functional relevance of the mitochondria. We changed the sentence accordingly.

      Furthermore, even though we do not discuss this in the article, we are aware of mitochondria targeting drugs that are known to block mosquito transmission. We want to point out that it is difficult to discern the disruption of ETC and therefore an impact on energy conversion with the impact on the essential pathway of pyrimidine synthesis, highly relevant in microgamete formation. Still, a recent paper from Sparkes et al. 2024 showed the essentiality of mitochondrial ATP synthesis during gametogenesis so it is very likely that the mitochondrial energy conversion is highly relevant for transmission to the mosquito.

      Reviewer #1 (Significance):

      This manuscript is a novel approach to studying mitochondrial biology and does open a lot of unanswered questions for further research directions. Currently there are limitations in the use of statistical tests and detail of methodology, but these could be easily be addressed with a bit more analysis/better explanation in the text.

      This manuscript could be of interest to readers with a general interest in mitochondrial cell biology and those within the specific field of Plasmodium research.

      My expertise is in Plasmodium cell biology.

      We thank the reviewer for the praise.

      Reviewer #2 (Evidence, reproducibility and clarity):

      Major comments:

      (1) In my opinion, the authors tend to sensationalize or overinterpret their results. The title of the manuscript is very misleading. While MICOS is certainly important for crista formation, it is not the only factor, as ATP synthase dimer rows make a highly significant contribution to crista morphology. Thus, one can argue with equal validity that ATP synthase should be considered the 'architect', as it's the conformation of the dimers and rows modulate positive curvature. Secondly, while cristae are still formed upon mic60/mic19 gene knockout (KO), they are severely deformed, and likely dysfunctional (see below). Thus, I do not agree with the title that MICOS is dispensable for crista formation, because the authors results show that it clearly is essential. So, the title should be changed.

      We thank the reviewer for taking the time to review our manuscript.

      Based on the reviewers’ interpretation we conclude the title does not come across as intended. We have changed the title to: “The role of MICOS in organizing mitochondrial cristae in malaria parasites”

      The Discussion section starting from line 373 also suffers from overinterpretation as well as being repetitive and hard to understand. The authors infer that MICOS stability is compromised less in the single KOs (sKO) in compared to the mic60/mic19 double KO (dKO). MICOS stability was never directly addressed here and the composition of the MICOS complex is unaddressed, so it does not make sense to speculate by such tenuous connections. The data suggest to me that mic60 and mic19 are equally important for crista formation and crista junction (CJ) stabilization, and the dKO has a more severe phenotype than either KO, further demonstrating neither is epistatic.

      We do agree with the reviewer’s notion that we did not address complex stability, and our wording did not make this sufficiently clear. We shortened and rephrased the paragraph in question.

      The following paragraphs (line 387 to 422) continues with such unnecessary overinterpretation to the point that it is confusing and contradictory. Line 387 mentions an 'almost complete loss of CJs' and then line 411 mentions an increase in CJ diameter, both upon Mic60 ablation. I do not think this discussion brings any added value to the manuscript and should be shortened. Yes, maybe there are other putative MICOS subunits that may linger in the KOS that are further destabilized in the dKO, or maybe Mic60 remains in the mic19 KO (and vice versa) to somehow salvage more CJs, which is not possible in the dKO. It is impossible to say with confidence how ATP synthase behaves in the KOs with the current data.

      We shortened this paragraph.

      (2) While the authors went through impressive lengths to detect any effect on lifecycle progression, none was found except for a reduction in oocyte count. However, the authors did not address any direct effect on mitochondria, such as OXPHOS complex assembly, respiration, membrane potential. This seems like a missed opportunity, given the team's previous and very nice work mapping these complexes by complexome profiling. However, I think there are some experiments the authors can still do to address any mitochondrial defects using what they have and not resorting to complexome profiling (although this would be definitive if it is feasible):

      i) Quantification of MitoTracker Red staining in WT and KOs. The authors used this dye to visualize mitochondria to assay their gross morphology, but unfortunately not to assay membrane potential in the mutants. The authors can compare relative intensities of the different mitochondria types they categorized in Fig. 3A in 20-30 cells to determine if membrane potential is affected when the cristae are deformed in the mutants. One would predict they are affected.

      Interesting suggestion. As our staining and imaging conditions are suitable for such analysis (as demonstrated by Sarazin et al., 2025, https://www.biorxiv.org/content/10.1101/2025.11.27.690934v1), we performed the measurements on the same dataset which we collected for Figure 3. We did, however, not detect any difference in mitotracker intensity between the different lines. The result of this analysis is included in the new version of Supplementary figure S6.

      ii) Sporozoites are shown in Fig S5. The authors can use the same set up to track their motion, with the hypothesis that they will be slower in the mutants compared to WT due to less ATP. This assumes that sporozoite mitochondria are active as in gametocytes.

      While theoretically plausible and informative, we currently do not know the relevance of mitochondrial energy conversion for general sporozoite biology or specifically features of sporozoite movement. Given the required resources and time to set this experiment up and the uncertainty whether it is a relevant proxy for mitochondrial functioning, we argue it is out of scope for this manuscript.

      iii) Shotgun proteomics to compare protein levels in mutants compared to WT, with the hypothesis that OXPHOS complex subunits will be destabilized in the mutants with deformed cristae. This could be indirect evidence that OXPHOS assembly is affected, resulting in destabilized subunits that fail to incorporate into their respective complexes.

      While this experiment could potentially further our understanding of the interaction between MICOS and levels of OXPHOS complex subunits we argue that the indirect nature of the evidence does not justify the required investments.

      To expedite resubmission, the authors can restrict the cell lines to WT and the dKO, as the latter has a stronger phenotype that the individual KOs and conclusions from this cell line are valid for overall conclusions about Plasmodium MICOS.

      I will also conclude that complexome/shotgun proteomics may be a useful tool also for identifying other putative MICOS subunits by determining if proteins sharing the same complexome profile as PfMic60 and Mic19 are affected. This would address the overinterpretation problem of point 1.

      (3) I am aware of the authors previous work in which they were not able to detect cristae in ABS, and thus have concluded that these are truly acristate. This can very well be true, or there can be immature cristae forms that evaded detection at the resolution they used in their volumetric EM acquisitions. The mitochondria and gametocyte cristae are pretty small anyway, so it not unreasonable to assume that putative rudimentary cristae in ABS may be even smaller still. Minute levels of sampled complex III and IV plus complex V dimers in ABS that were detected previously by the authors by complexome profiling would argue for the presence of miniscule and/or very few cristae.

      I think that authors should hedge their claim that ABS is acristate by briefly stating that there still is a possibility that miniscule cristae may have been overlooked previously.

      We acknowledge that we cannot demonstrate the absolute absence of any membrane irregularities along the inner mitochondrial membrane. At the same time, if such structures were present, they would be extremely small and unlikely to contain the full set of proteins characteristic of mature cristae. For this reason, we consider it appropriate to classify ABS mitochondria as acristate. To reflect the reviewer’s point while maintaining clarity for readers, we have slightly adjusted our wording in the manuscript, changing ‘fully acristate’ to ‘acristate’.

      This brings me to the claim that Mic19 and Mic60 proteins are not expressed in ABS. This is based on the lack of signal from the epitope tag; a weak signal is detected in gametocytes. Thus, one can counter that Mic19 and Mic60 are also expressed, but below the expression limits of the assay, as the protein exhibits low expression levels when mitochondrial activity is upregulated.

      We agree with the reviewer that the absence of a detectable epitope-tag signal does not definitively exclude low-level expression, and we have therefore replaced the term ‘absent’ with ‘undetectable’ throughout the manuscript. In context with previous findings of low-level transcripts of the proteins in a study by Lopez-Berragan et al. and Otto et al., we also added the sentence “The apparent absence could indicate that transcripts are not translated in ABS or that the proteins’ expression was below detection limits of western blot analysis.” to the discussion. At the same time, we would like to clarify that transcript levels for both genes fall within the <25th percentile, suggesting that these low values likely represent background signal rather than biologically meaningful expression. This interpretation is further supported by proteomic datasets in PlasmoDB, which report PfMIC19 and PfMIC60 expression in gametocyte and mosquito stages, but not in asexual blood stages.”

      To address this point, the authors should determine of mature mic60 and mic19 mRNAs are detected in ABS in comparison to the dKO, which will lack either transcript. RT-qPCR using polyT primers can be employed to detect these transcripts. If the level of these mRNAs are equivalent to dKO in WT ABS, the authors can make a pretty strong case for the absence of cristae in ABS.

      We appreciate the reviewer’s suggestion. As noted in the Discussion, existing transcriptomic datasets already show detectable MIC19 and MIC60 mRNAs in ABS. For this reason, we expect RT-qPCR to reveal low (but not absent) levels of both transcripts, unlike the true loss expected to be observed in the dKO. Because such residual signals have been reported previously and their biological relevance remains uncertain, we do not believe transcript levels alone can serve as a definitive indicator of cristae absence in ABS.

      They should highlight the twin CX9C motifs that are a hallmark of Mic19 and other proteins that undergo oxidative folding via the MIA pathway. Interestingly, the Mia40 oxidoreductase that is central to MIA in yeast and animals, is absent in apicomplexans (DOI: 10.1080/19420889.2015.1094593).

      Searching for the CX9C motifs is a valuable suggestion. In response to the reviewer´s suggestion we analysed the conservation of the motif in PfMIC19 and included this in a new figure panel (Figure 1 F).

      Did the authors try to align Plasmodium Mic19 orthologs with conventional Mic19s? This may reveal some conserved residues within and outside of the CHCH domain.

      In response to this comment we made Figure 1 F, where we show conserved residues within the CHCH domains of a broad range of MIC19 annotated sequences across the opisthokonts, and show that the Cx9C motifs are conserved also in PfMIC19. Outside the CHCH domain, we did not find any meaningful conservation, as PfMIC19 heavily diverges from opisthokont MIC19.

      (5) Statistical significance. Sometimes my eyes see population differences that are considered insignificant by the statistical methods employed by the authors, eg Fig. 4E, mutants compared to WT, especially the dKO. Have the authors considered using other methods such as student t-test for pairwise comparisons?

      The graphs in figures 3, 4 and 5 got a makeover, such that they now are in linear scale and violin plots (also following a suggestion from further down in the reviewer’s comments). We believe that this improves interpretability. ANOVA was kept as statistical testing to assure the correction for multiple comparisons that cannot be performed with standard t-test. A full overview of statistics and exact pvalues can also be found in the newly added supplementary information 2.

      Minor comments:

      Line 33. Anaerobes (eg Giardia) have mitochondria that do produce ATP, unlike aerobic mitochondria

      We acknowledge that producing ATP via OXPHOS is not a characteristic of all mitochondria-like organelles (e.g. mitosomes), which is why these are typically classified separately from canonical mitochondria. When not considering mitochondria-like organelles, energy conversion is the function that the mitochondrion is most well-known for and the one associated with cristae.

      Line 56: Unclear what authors mean by "canonical model of mitochondria"

      To clarify we changed this to “yeast or human” model of mitochondria.

      Lines 75-76: This applies to Mic10 only

      We removed the “high degree of conservation in other cristate eukaryotes” statement.

      Line 80: Cite DOI: 10.1016/j.cub.2020.02.053

      Done

      Fig 2D: I find this table difficult to read. If authors keep table format, at least get rid of 'mean' column' as this data is better depicted in 2C. I suggest depicted this data either like in 3B depicting portion of infected vs unaffected flies in all experiments, then move modified Table to supplement. Important to point out experiment 5 appears to be an outlier with reduced infectivity across all cell lines, including WT.

      To clarify: the mean reported in the table indicates the mean per replicate while the mean reported in figure 2C is the overall mean for a given genotype that corrects for variability within experiments. We agree that moving the table to the supplementary data is a good idea. We decided to not include a graph for infected and non-infected mosquitoes as this information would be partially misleading, highlighting a phenotype we argue to be influenced by the strong variability.

      Fig. 3C-G: I feel like these data repeatedly lead to same conclusions. These are all different ways of showing what is depicted in Fig 2B: mitochondria gross morphology is affected upon ablation of MICOS. I suggest that these graphs be moved to supplement and replaced by the beautiful images.

      Thank you for the nice comment on our images. We have now moved part of the graphs to supplementary figure 6 and only kept the Relative Frequency, Sphericity and total mitochondria volume per cell in the main figure.

      Line 180: Be more specific with which tubulin isoform is used as a male marker and state why this marker was used in supplemental Fig S6.

      We have now specified the exact tubulin isoform used as the male gametocyte marker, both in the main text and in Supplementary Fig. S6. This is a commercial antibody previously known to work as an effective male marker, which is why we selected it for this experiment. This is now clearly stated in the manuscript.

      Line 196 and Fig 3C: the word 'intensities' in this context is very ambiguous. Please choose a different term (puncta, elements, parts?). This is related to major point 2i above.

      To clarify the biological effect that we can conclude form the measurement, we added an explanation about it in the respective section of the results, and we decided to replace the raw results of the plug-in readout with the deduced relative dispersion.

      Line 222: Report male/female crista measurements

      We added Supplementary information 2, which contains exact statistical test and outcomes on all presented quantifications as well as a per-sex statistical analysis of the data from figure 4. Correspondingly, we extended supplementary information 2 by a per-sex colour code for the thin section TEM data.

      Fig. 4B-E: depict data as violin plots or scatter plots like Fig. 2C to get a better grasp of how the crista coverage is distributed. It seems like the data spread is wider in the double KO. This would also solve the problem with the standard deviation extending beyond 0%.

      We changed this accordingly.

      Lines 331-333: Please clarify that this applies for some, but not all MICOS subunits. Please also see major point 1 above. Also, the authors should point out that despite their structural divergence, trypanosomal cryptic mitofilins Mic34 and Mic40 are essential for parasite growth, in contrast to their findings with PfMic60 (DOI: https://doi.org/10.1101/2025.01.31.635831).

      This has been changed accordingly.

      Line 320: incorrect citation. Related to point 1above.

      Correct citation is now included in the text.

      Lines 333-335. This is related to the above. Again, some subunits appear to affect cell growth under lab conditions, and some do not. This and the previous sentence should be rewritten to reflect this.

      This has been changed accordingly.

      Line 343-345: The sentence and citation 45 are strange. Regarding the former, it is about CHCHD10, whose status as a bona fide MICOS subunit is very tenuous, so I would omit this. About the phenomenon observed, I think it makes more sense to write that Mic60 ablation results in partially fragmented mitochondria in yeast (Rabl et al., 2009 J Cell Biol. 185: 1047-63). A fragmented mitochondria is often a physiological response to stress. I would just rewrite as not to imply that mitochondrial fission (or fusion) is impaired in these KOs, or at least this could be one of several possibilities.

      The sentence has been substituted following the indication of the reviewer. Though we still include the data of the human cells as this has also been shown in Stephens et al. 2020.

      Line 373: 'This indicates' is too strong. I would say 'may suggest' as you have no proof that any of the KOs disrupts MICOS. This hypothesis can be tested by other means, but not by penetrance of a phenotype.

      Done

      Line 376-377; 'deplete functionality' does not make sense, especially in the context of talking about MICOS subunit stability. In my opinion, this paragraph overinterprets the KO effects on MICOS stability. None of the experiments address this phenomenon, and thus the authors should not try to interpret their results in this context. See major point 1.

      We removed the sentence. Also, the entire paragraph has been shortened, restructured and wording was changed to address major point 1.

      Other suggestions for added value

      (1) Does Plasmodium Sam50 co-fractionate with Mic60 and Mic19 in BN PAGE (Fig. 1E)

      While we did identify SAMM50 in our BN PAGE, the protein does not co-migrate with the MICOS components but instead comigrates with other components of a putative sorting and assembly machinery (SAM) complex. As SAMM50, the SAM complex and the overarching putative mitochondrial membrane space bridging (MIB) complex are not mentioned in the manuscript, we decided to not include the information in Author response image 1.

      Author response image 1.

      Reviewer #2 (Significance):

      The manuscript by Tassan-Lugrezin is predicated on the idea that Plasmodium represents the only system in which de novo crista formation can be studied. They leverage this system to ask the question whether MICOS is essential for this process. They conclude based on their data that the answer is no, which the authors consider unprecedented. But even if their claim is true that ABS is acristate, this supposed advantage does not really bring any meaningful insight into how MICOS works in Plasmodium.

      First the positives of this manuscript. As has been the case with this research team, the manuscript is very sophisticated in the experimental approaches that are made. The highlights are the beautiful and often conclusive microscopy performed by the authors. Only the localization of Mic60 and Mic19 was inconclusive due to their very low expression unfortunately.

      The examination of the MICOS mutants during in vitro life cycle of Plasmodium falciparum is extremely impressive and yields convincing results. Mitochondrial deformation is tolerated by life cycle stage differentiation, with a modest but significant reduction of oocyte production, being observed.

      However, despite the herculean efforts of the authors, the manuscript as it currently stands represents only a minor advance in our understanding of the evolution of MICOS, which from the title and focus of the manuscript, is the main goal of the authors.

      In its current form, the manuscript reports some potentially important findings:

      (1) Mic60 is verified to play a role in crista formation, as is predicted by its orthology to other characterized Mic60 orthologs.

      (2) The discovery of a novel Mic19 analog (since the authors maintain there is no significant sequence homology), which exhibits a similar (or the same?) complexome profile with Mic60. This protein was upregulated in gametocytes like Mic60 and phenocopies Mic60 KO.

      (3) Both of these MICOS subunits are essential (not dispensable) for proper crista formation

      (4) Surprisingly, neither MICOS subunit is essential for in vitro growth or differentiation from ABS to sexual stages, and from the latter to sporozoites. This says more about the biology of plasmodium itself than anything about the essentiality of Mic60, i.e. plasmodium life cycle progression tolerates defects to mitochondrial morphology. But yes, I agree with the authors that Mic60's apparent insignificance for cell growth in examined conditions does differ with its essentiality in other eukaryotes. But fitness costs were not assayed (e.g. by competition between mutants and WT in infection of mosquitoes)

      (5) Decreased fitness of the mutants is implied by a reduction of oocyte formation.

      While interesting in their own way, collectively they do not represent a major advance in our understanding of MICOS evolution. Furthermore, the findings bifurcate into categories informing MICOS or Plasmodium biology. Both aspects are somewhat underdeveloped in their current form.

      This is unfortunate because there seem to be many missed opportunities in the manuscript that could, with additional experiments, lead to a manuscript with much wider impact. For me, what is remarkable about Plasmodium MICOS that sets it apart from other iterations is the apparent absence of the Mic10 subunit. Purification of plasmodium MICOS via the epitope tagged Mic60 and Mic19 could have verified that MICOS is assembled without this core subunit. Perhaps Mic60 and Mic19 are the vestiges of the complex, and thus operate alone in shaping cristae. Such a reduction may also suggest the declining importance of mitochondria in plasmodium.

      Another missed opportunity was to assay the impact of MICOS-depletion of OXPHOS in plasmodium.

      This is a salient issue as maybe crista morphology is decoupled from OXPHOS capacity in Plasmodium, which links to the apparent tolerance of mitochondrial morphology in cell growth and differentiation. I suggested in section A experiments to address this deficit.

      Finally, the authors could assay fitness costs of MICOS-ablation and associated phenotypes by assaying whether mosquito infectivity is reduced in the mutants when they are directly competing with WT plasmodium. Like the authors, I am also surprised that MICOS mutants can pass population bottlenecks represented by differentiation events. Perhaps the apparent robustness of differentiation may contribute plasmodium's remarkable ability to adapt.

      I realize that the authors put a lot of efforts into their study and again, I am very impressed by the sophistication of the methods employed. Nevertheless, I think there is still better ways to increase the impact of the study aside from overinterpreting the conclusions from the data. But this would require more experiments along the lines I suggest in Section A and here.

      We thank the reviewer for their extensive analysis of the significance of our findings, including the compliments on our microscopy images and the sophisticated experimental approaches. We hope we have convincingly argued why we could or could not include some of the additional analyses suggested by the reviewer in section 1 above.

      With regard to the significance statement, we want to point out that our finding that PfMICOS is not needed for initial formation of cristae (as opposed to organization thereof), is a confirmation of something that has been assumed by the field, without being the actual focus of studies. We argue that the distinction between formation and organization of cristae is important and deserves some attention within the manuscript. The result of MICOS not being involved in the initial formation of cristae, we argue to be relevant in Plasmodium biology and beyond. As for the insights into how MICOS works in Plasmodium we have confirmed that the previously annotated PfMIC60 is indeed involved in the organization of cristae. Furthermore, we have identified and characterized PfMIC19. These findings, we argue, are indeed meaningful insights into PfMICOS.

      Reviewer #3 (Evidence, reproducibility and clarity):

      Summary:

      MICOS is a conserved mitochondrial protein complex responsible for organising the mitochondrial inner membrane and the maintenance of cristae junctions. This study sheds first light on the role of two MICOS subunits (Mic60 and the newly annotated Mic19) in the malaria parasite Plasmodium falciparum, which forms cristae de novo during sexual development, as demonstrated by EM of thin section and electron tomography. By generating knockout lines (including a double knockout), the authors demonstrate that knockout of both MICOS subunits leads to defects in cristae morphology and a partial loss of cristae junctions. With a formidable set of parasitological assays, the authors show that despite the metabolically important role of mitochondria for gametocytes, the knockout lines can progress through the life stages and form sporozoites, albeit with diminished infection efficiency.

      We thank the reviewer for their time and compliment.

      Major comments:

      (1) The authors should improve to present their findings in the right context, in particular by:

      i) giving a clearer description in the introduction of what is already known about the role of MICOS. This starts in the introduction, where one main finding is missing: loss of MICOS leads to loss of cristae junctions and the detachment of cristae membranes, which are nevertheless formed, but become membrane vesicles. This needs to be clearly stated in the introduction to allow the reader to understand the consistency of the authors' findings in P. falciparum with previous reports in the literature.

      We extended the introduction to include this information.

      iii) at the end to the introduction, the motivating hypothesis is formulated ad hoc "conclusive evidence about its involvement in the initial formation of cristae is still lacking" (line 83). If there is evidence in the literature that MICOS is strictly required for cristae formation in any organism, then this should be explained, because the bona fide role of MICOS is maintenance of cristae junctions (the hypothesis is still plausible and its testing important).

      To clarify we rephrased the sentence to: “Although MICOS has been described as an organizer of crista junctions, its role during the initial formation of nascent cristae has not been investigated.”

      (2) Line 96-97: "Interestingly, PfMIC60 is much larger than the human MICOS counterpart, with a large, poorly predicted N-terminal extension." This statement is lacking a reference and presumably refers to annotated ORFs. The authors should clarify if the true N-terminus is definitely known - a 120kDa size is shown for the P. falciparum but this is not compared to the expected length or the size in S. cerevisiae.

      To solve the reference issue, we added the uniprot IDs we compared to see that the annotated ORF is bigger in Plasmodium. We also changed the comparison to yeast instead of human, because we realized it is confusing to compare to yeast all throughout the figure, but then talk about human in this specific sentence.

      Regarding whether the true N-terminus is known. Short answer: No, not exactly.

      However, we do know that the Pf version is about double the size of the yeast protein.

      As the reviewer correctly states, we show the size of 120kDa for the tagged protein in Figure 1G. Considering that we tagged the protein C-terminally, and observed a 120kDa product on western blot, it is safe to conclude that the true N-terminus does not deviate massively from the annotated ORF, and hence, that there is a considerable extension of the protein beyond a 60kDa protein. We do not directly compare to yeast MIC60 on our western blots, however, that comparison can be drawn from literature: Tarasenko et al., 2017 showed that purified MIC60 running at ~60kDa on SDS-PAGE actively bends membranes, suggesting that in its active form, the monomer of yeast MIC60 is indeed 60kDa in size.

      To clarify, we now emphasize that we ran the Alphafold prediction on the annotated open reading frame (annotated and sequenced by Bohme et al. and Chapell et al. now cited in the manuscript), and revised the wording to make clear what we are comparing in which sentence.

      (3) lines 244-245: "Furthermore, our data indicates the effect size increases with simultaneous ablation of both proteins?". The authors should explain which data they are referring to, as some of the data in Fig 3 and 4 look similar and all significance tests relate to the wild type, not between the different mutants, so it is not clear if any overserved differences are significant. The authors repeat this claim in the discussion in lines 368-369 without referring to a specific significance test. This needs to be clarified.

      As a reply to this and other comments from the reviewers we added the multiple testing within all samples. In addition, to clarify statistics used we included a supplementary dataset with all p-values and statistical tests used.

      (4) lines 304-306: "Though well established as the cristae organizing system, the role of MICOS in initial formation of cristae remains hidden in model organisms that constitutively display cristae.". This sentence is misleading since even in organisms that display numerous cristae throughout their life cycle, new cristae are being formed as the cells proliferate. Thus, failure to produce cristae in MICOS knockout lines would have been observable but has apparently not been reported in the literature. Thus, the concerted process in P. falciparum makes it a great model organism, but not fundamentally different to what has been studied before in other organisms.

      We deleted this statement.

      (5) lines 373-378. "where ablation of just MIC60 is sufficient to deplete functionality of the entire MICOS (11, 15),". The authors' claim appears to be contrary to what is actually stated in ref 15, which they cite:

      "MICOS subunits have non-redundant functions as the absence of both MICOS subcomplexes results in more severe morphological and respiratory growth defects than deletion of single MICOS subunits or subcomplexes."

      This seems in line with what the authors show, rather than "different".

      This sentence has been removed.

      (6) lines 380-385: "... thus suggesting that membrane invaginations still arise, but are not properly arranged in these knockout lines. This suggests that MICOS either isn't fully depleted,...". These conclusions are incompatible with findings from ref. 15, which the authors cite. In that study, the authors generated a ∆MICOS line which still forms membrane invaginations, showing that MICOS is not required at all for this process in yeast. Hence the authors' implication that MICOS needs to be fully depleted before membrane invaginations cease to occur is not supported by the literature.

      This sentence has been deleted in the revised version of the manuscript.

      Minor comments:

      (1) The authors should consider if the first part of their title could be seen as misleading: It suggests that MICOS is "the architect" in cristae formation, but this is not consistent with the literature nor their own findings.

      Title is changed accordingly

      - Line 43, of the three seminal papers describing the discovery of MICOS in 2011, the authors only cite two (refs 6 and 7), but miss the third paper, Hoppins et al, PMID: 21987634, which should probably be corrected.

      Done, the paper is now cited

      - Page 2, line 58: for a more complete picture the authors should also cite the work of others here which shows that although at very low levels, e.g. complex III (a drug target) and ATP synthase do assemble (Nina et al, 2011, JBC).

      Done

      - Page 3, line 80: "Irrespective of the shape of an organism's cristae, the crista junctions have been described as tubular channels that connect the cristae membrane to the inner boundary membrane (22, 24)." This omits the slit-shaped cristae junctions found in yeast (Davies et al, 2011, PNAS), which the authors should include.

      The paper and concept have been added to the manuscript, though the sentence has been moved up in the introduction, when crista junctions are first introduced.

      - Line 97: "poorly predicted N-terminal extension", as there is no experimental structure, we don't know if the prediction is poor. Presumably the authors mean either poorly ordered or the absence of secondary structure elements, or the poor confidence score for that region in the prediction? This should be clarified or corrected.

      We were referring to the poor confidence score. To address this comment as well as major point 2, we rewrote the respective paragraph. It now clearly states that confidence of the prediction is low, and we mention the tool that was used to identify conserved domains (Topology-based Evolutionary Domains).

      - Line 98: "an antiparallel array of ten β-sheets". They are actually two parallel beta-sheets stacked together. The authors could find out the name of this fold, but the confidence of the prediction is marked a low/very low. So, its existence is unknown, not just its "function".

      We adapted the domain description to “a stack of two parallel beta-sheets" and replaced the statement on unknown function by the statement “Because this domain is predicted solely from computational analysis, both its actual existence in the native protein and its biological function remain unknown.”

      - Fig 1B: The authors show two alphafold predictions of S. cerevisiae and P. falciparum Mic60 structures. There is however an experimental Mic60/19 (fragment) structure from the former organism (PMID: 36044574), which should be included if possible.

      We appreciate the reviewer’s suggestion and note that the available structural data indeed provides valuable insight into how MIC60 and MIC19 interact. However, these structures represent fusion constructs of limited protein fragments and therefore capture only a small portion of each protein, specifically the interaction interface. Because our aim in Fig. 1B is to compare the overall domain architecture of the full-length proteins, we believe that including fragment-based structures would be less informative in this context.

      - Line: 318-321: "The same trend was observed for PfMIC19 and PfMIC60. Although transcriptomic data suggested that low-level transcripts of PfMIC19 and PfMIC60 are present in ABS (38), we did not detect either of the proteins in ABS by western blot analysis. While this statement is true, the authors should comment on the sensitivity of the respective methods - how well was the antibody working in their hands and how do they interpret the absence of a WB band compared to transcriptomics data?

      The HA antibody used in our experiments is a standard commercial reagent that performs reliably in both WB and IFA, although it shows a low background signal in gametocytes. We agree that the sensitivity of the method and the interpretation of weak or absent bands should be addressed explicitly. Transcript levels for both PfMIC19 and PfMIC60 in asexual blood stages fall within the <25 percentile, suggesting that these signals likely represent background. Nevertheless, we acknowledge that low-level protein expression below the detection limit of western blot analysis cannot be excluded. To reflect these considerations, we added the sentence: ‘The apparent absence could indicate that transcripts are not translated in ABS or that the proteins’ expression was below detection limits of western blot analysis.

      - Lines 322-323: would the authors not typically have expected an IFA signal given the strength of the band in Western blot? If possible, the authors should comment if the negative fluorescence outcome can indeed be explained with the low abundance or if technical challenges are an equally good explanation.

      Considering the nature of the investigated proteins (embedded in the IMM and spread throughout the mitochondria) difficulties in achieving a clear signal in IFA or U-ExM are not very surprizing. While epitopes may remain buried in IFA, U-ExM usually increases accessibility for the antibodies. However, U-ExM comes at the cost of being prone to dotty background signals, therefore potentially hiding low abundance, naturally dotty signals such as the signal of MICOS proteins that localize to distinct foci (at the CJ) along the mitochondrion. Current literature suggests that, in both human and yeast, STED is the preferred method for accurate spatial resolution of MICOS proteins (https://www.ncbi.nlm.nih.gov/pubmed/32567732,https://www.ncbi.nlm.nih.gov/pubmed/3206734 4). Unfortunately, we do not have experience with, nor access to, this particular technique/method.

      - Lines 357-365: the authors describe limitations of the applied methods adequately. Perhaps it would be helpful to make a similar statement about the analysis of 3D objects like mitochondria and cristae from 2D sections. E.g. the apparent cristae length depends on whether cristae are straight (e.g. coiled structures do not display long cross sections despite their true length in 3D).

      The limitations of other methods are described in the respective results section.

      We added a clarifying sentence in the results section of Figure 4:

      “Note that such measurements do not indicate the true total length or width of cristae, as the data is two-dimensional. The recorded values are to be considered indicative of possible trends, rather than absolute dimensions of cristae.“

      This statement refers to the length/width measurements of cristae.

      In the context of Figure 4D we mention the following (see preprint lines 229 – 230): “We expect this effect to translate into the third dimension and thus conclude that the mean crista volume increases with the loss of either PfMIC19, PfMIC60, or both.”

      For Figure 5, we included a clarifying statement in the results section of the preprint (lines 269 – 273): “Note that these mitochondrial volumes are not full mitochondria, but large segments thereof. As a result of the incompleteness of the mitochondria within the section, and the tomography specific artefact of the missing wedge, we were unable to confirm whether cristae were in fact fully detached from the boundary membrane, or just too long to fit within the observable z-range.”

      - Line 404: perhaps undetected or similar would be a better description than "hidden"?

      The sentence does not exist in the revised manuscript.

      Reviewer #3 (Significance):

      The main strength of the study is that it provides the first characterisation of the MICOS complex in P. falciparum, a human parasite in which the mitochondrion has been shown to be a drug target. Mic60 and the newly annotated Mic19 are confirmed to be essential for proper cristae formation and morphology, as well as overall mitochondrial morphology. Furthermore, the mutant lines are characterised for their ability to complete the parasite life cycle and defects in infection effectivity are observed. This work is an important first step for deciphering the role of MICOS in the malaria parasite and the composition and function of this complex in this organism. The limitation of the study stems from what is already known about MICOS and its subunits in great detail in yeast and humans with similar findings regarding loss of cristae and cristae defects. The findings of this study do not provide dramatic new insight on MICOS function or go substantially beyond the vast existing literature in terms of the extent of the study, which focuses on parasitological assays and morphological analysis. Exploring the role of MICOS in an early-divergent organism and human parasite is however important given the divergence found in mitochondrial biology and P. falciparum is a uniquely suited model system. One aspect that would increase the impact of the paper would be if the authors could mechanistically link the observed morphological defects to the decreased infection efficiency, e.g. by probing effects on mitochondrial function. This will likely be challenging as the morphological defects are diverse and the fitness defects appear moderate/mild.

      As suggested by Reviewer 2, we examined mitochondrial membrane potential in gametocytes using MitoTracker staining and did not observe any obvious differences associated with the morphological defects. At present, additional assays to probe mitochondrial function in P. falciparum gametocytes are not sufficiently established, and developing and validating such methods would require substantial work before they could be applied to our mutant lines. For these reasons, a more detailed mechanistic link between the observed morphological changes and the reduced infection efficiency is currently beyond reach.

      The advance presented in this study is to pioneer the study of MICOS in P. falciparum, thus widening our understanding of the role of this complex to different model organism. This study will likely be mainly of interest for specialised audiences such as basic research parasitologists and mitochondrial biologists. My own field of expertise is mitochondrial biology and structural biology.

    1. I would need eleven additional tokens for digits 0 to 9 and PERIOD.

      Nope. You could just use the traditional approach where most tokenizers only have a generic tag/discriminant for all number tokens. The every-non-text-token-is-one-character constraint is arbitrary and unnecessary.

    1. Show some love for the moms in your life

      (Perceivable Principle) I noticed this big promotional banner right away, but it made me wonder how it translates for someone using a screen reader. According to the Perceivable principle, the image next to this text needs a concise <alt> tag of 125 characters or less so visually impaired users don't miss out on the information. If it is just named something random like "IMG_098.jpg" in the code, the site is failing to make this content truly presentable to everyone.

    1. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      This study investigates the roles of Rab32 and Rab38 in hepatic lipid droplet metabolism. The authors propose that Rab32/38-positive lysosome-related organelles (LROs) mediate lipid droplet degradation through a mechanism independent of conventional macroautophagy. While the study addresses an interesting question, several conceptual and technical issues need to be addressed before the conclusions can be fully supported.

      Major Concerns

      1.The authors primarily define the Rab32/38-positive ring-like structures as "lysosome-related organelles (LROs)" based on their morphological characteristics and co-localization with LAMP1. However, this classification lacks biochemical validation. Would it be more appropriate to include a Lyso-IP assay to provide additional supporting evidence? 2.In hepatocytes, what is the operational definition of LROs? Beyond being "larger in size," how are these structures functionally distinguished from conventional lysosomes? If Rab32/38 defines LRO identity, why does GFP-Rab32/38 not co-localize with all LAMP1-positive structures (Figure S1A)? 3.In Figure 2A, the dextran pulse-chase experiment shows fluid-phase uptake into large vacuoles; however, dextran can enter any endocytic compartment after prolonged chase periods. What evidence supports that these structures are bona fide LROs rather than enlarged late endosomes or lysosomes resulting from long-term culture? What determines why only certain lysosomes become Rab32/38-positive? This heterogeneity is not explained. Does it imply that pre-existing lysosomes convert into LROs, or that LROs are newly formed under high-density stress? The developmental trajectory of these structures has not been explored. 4.The authors propose a microautophagy mechanism based on the "invagination-like" structures observed by light microscopy (Figure 3A). However, the resolution of light microscopy is insufficient to distinguish true membrane invaginations from lipid droplets that are closely apposed to, or partially wrapped by, the outer membrane of LROs in three-dimensional space. Would a CLEM experiment be necessary to confirm that lipid droplets are indeed located within the lumen of LROs, rather than in deep invaginations that remain connected to the cytosol? In addition, multilamellar membrane structures were observed after Bafilomycin A1 treatment (Figure 3A). Have these structures been validated by electron microscopy, or could they simply represent complex membrane infoldings within swollen lysosomes? The conclusions drawn from light microscopy alone appear somewhat insufficient. 5.The authors use ATG4B C74A overexpression to claim macroautophagy independence. However, while this mutant blocks LC3 lipidation, the study still lacks genetic evidence, such as ATG knockouts. In Figure S2B, the authors state that the "majority" of Rab38-positive LRO-associated lipid droplets are LC3-negative, but no quantitative data are provided. 6.The manuscript does not clearly distinguish the functions of Rab32 and Rab38. Although the authors describe these proteins as paralogs with overlapping roles, multiple data points indicate that they have differential effects on lipid droplet (LD) metabolism. Notably, Rab38-but not Rab32-significantly affects LD delivery to acidic compartments, exerts a stronger influence on LRO size, and responds more robustly to VPS4B perturbation. These observations suggest that Rab32 and Rab38 regulate distinct steps of LD metabolism rather than functioning redundantly. However, the manuscript does not clearly highlight these functional differences and lacks mechanistic validation. 7.Figure 5A shows that the PI3P probe (2×FYVE) forms ring-like structures inside or near the LRO membrane. However, LROs themselves are Rab5-negative (Figures 1C-E), and PI3P is typically generated by Vps34 on early endosomes. Where do these PI3P signals originate? Are they transported from other organelles, or is there a local PI3P-generating mechanism on the LRO membrane? If the latter, which kinase is responsible, and is Vps34 recruited to the LRO membrane? This issue is not discussed. If PI3P is indeed locally generated on LROs, it could represent a key feature distinguishing LROs from classical lysosomes.

      Minor Concerns

      1.The double-knockout mice exhibit obesity and fatty liver; however, Rab32 and Rab38 are expressed in multiple tissues. A whole-body knockout model cannot distinguish whether these effects are hepatocyte-autonomous or arise from contributions by adipose tissue or macrophages, emphasizing the need for liver-specific knockout animals or cell models. Serum TAG levels were unchanged, and the authors speculate that VLDL secretion may be impaired, but this was not directly tested. Furthermore, the authors do not address the observed sex-specific effects, which appear to be male-specific. 2.The concentration of Orlistat used is relatively high (50-200 μM) and may cause non-specific effects. Have dose-response experiments been performed, or have other LAL inhibitors (e.g., Lalistat) been tested? 3.LysoTracker reflects acidity rather than lysosome identity, and reduced acidification in DKD cells may affect co-localization analysis.

      Significance

      Assessment of Significance Overall Assessment

      Strengths:

      Conceptual novelty: Introduces lysosome-related organelles (LROs) into hepatic lipid metabolism, expanding the functional repertoire of Rab32/38 beyond pigment cells and macrophages.

      Mechanistic exploration: Links LD uptake to PI3P/PI(3,5)P2 signaling and VPS4B, providing molecular handles for future studies.

      In vivo validation: DKO mice show age-dependent obesity and HFD sensitivity, establishing physiological relevance.

      Weaknesses:

      Rab32 vs. Rab38 functions remain blurred: Data suggest differential roles (Rab38 in LD delivery, Rab32 in LD size regulation), but authors default to "redundancy" narrative.

      Microautophagy evidence incomplete: Relies on light microscopy; EM/CLEM needed to confirm true internalization.

      Model relevance unclear: High-confluence AML12 vacuoles lack clear physiological correlate in healthy liver.

      Audience

      Primary:

      Lysosome biologists

      Autophagy researchers

      Lipid metabolism researchers

      Secondary:

      Cell biologists

      Metabolic disease researchers

      Geneticists

    1. The price tag of the AI gold rush: $725 billion. Will it pay off?

      这个7250亿美元的AI投资规模数据表明AI领域正在经历前所未有的资本投入。这一数字相当于许多中等规模国家的GDP,反映了市场对AI技术的极高期望。然而,文章质疑这种巨额投资是否能获得相应回报,暗示可能存在AI泡沫风险。

    1. reply to https://www.facebook.com/groups/TypewriterCollectors/posts/10161712887224678/

      to Steve Clancy Zach Hubbird Jean Brunet

      I'm curious what the sourcing is on your differentiation of the two models? Are there manuals, advertising, or other details to back up the differences? From what I can see, the phrase "Rhythm Touch" seems to have been an advertising tag for the Underwood SS which started a few months after production of the SS began and there wasn't any difference in them other than the advertising tag.

      Robert Messenger has some scant history on the machine and the differences, primarily due to a redesign at the time, at https://oztypewriter.blogspot.com/2012/11/on-this-day-in-typewriter-history_25.html. The primary change from the S to the SS seems to have been a move from a carriage shift to a basket shift and so it seems somewhat fitting that Underwood uses the phrase "Rhythm Touch" as an advertising gimmick much like Smith-Corona were doing with their "Floating Shift" marketing.

      Generally standards at the time were not differentiated by different trim lines as standards had all the bells and whistles for office use (potentially aside from custom use cases like decimal tabulators or extra wide carriage). Meanwhile all the trim variations were generally seen in the portable market geared toward home use rather than office. This would seem to support the idea that there's only the SS and "Rhythm Touch" is only an advertising tag line as the SS was newly introduced in January of '46 and "Rhythm Touch" appears around July '46.

      There's also some discussion on the TWdB in the commentary at https://typewriterdatabase.com/1950-underwood-ss.23202.typewriter which may add to the question.

      I'm curious to hear everyone's thoughts on the idea/thesis that the only model is the Underwood SS which is being marketed as the "Rhythm Touch" or evidence to the contrary to refute the claim.

    1. four commercial markers: Anzeige, Werbung, Advertorial meta tag, and “Verantwortlich für den Inhalt”.

      Is it just me or are there only two of them visible on the picture?

    1. Differentiating between an Underwood SS and the Underwood Rhythm Touch:

      comment to James Grooms at https://typewriterdatabase.com/show.23202.typewriter

      James, perhaps it's hiding somewhere else in the comments on the database, but I'm curious if you've come across definitive differences between the Underwood SS and the Underwood Rhythm Touch models which have separate pages within the database:<br /> - SS https://typewriterdatabase.com/Underwood.SS.4.bmys - Rhythm Touch https://typewriterdatabase.com/Underwood.Rhythm+Touch.4.bmys

      Most of my Google searches don't return anything definitive or with actual sourcing of any sort.

      The main page has the SS starting in May 1946 and the Rhythm Touch beginning in July of that year, but doesn't seem to specify between the two in any substantive way. Neither of the two models seems to have had a name printed on it.

      Your description here uses both designators, but knowing your penchant for newspaper and magazine advertisements, I would suspect you may have seen specific differentiators.

      This Facebook post has some handwaving differentiators: https://www.facebook.com/groups/TypewriterCollectors/posts/10161712887224678/ but none seem definitive or sourced. It also uses the phrase carriage shift, though presumably with these models Underwood had moved to a segment/basket shift on their standards.

      Other than the chrome side detailing moving from 3 strips to 5 as you've noted, one of the few differentiators I can see in this era is the shift from the shorter carriage return lever to the longer armed version around 1948 which Robert Messenger notes in https://oztypewriter.blogspot.com/2012/11/on-this-day-in-typewriter-history_25.html. However that same page also has an advertisement on it with the words Rhythm Touch featuring a short armed (older style) carriage return.

      Is there really a difference between the SS and the Rhythm Touch or are they the same model with the phrase "Rhythm Touch" used as a marketing tag to compete potentially with Smith-Corona's "Floating Shift"?

      Thanks!

    1. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      Zacharia and colleagues investigate the role of the C-terminus of IFT172 (IFT172c), a component of the IFT-B subcomplex. IFT172 is required for proper ciliary trafficking and mutations in its C-terminus are associated with skeletal ciliopathies. The authors begin by performing a pull-down to identify binding partners of His-tagged CrIFT172968-C in Chlamydomonas reinhardtii flagella. Interactions with three candidates (IFT140, IFT144, and a UBX-domain containing protein) are validated by AlphaFold Multimer with the IFT140 and IFT144 predictions in agreement with published cryo-ET structures of anterograde and retrograde IFT trains. They present a crystal structure of IFT172c and find that a part of the C-terminal domain of IFT172 resembles the fold of a non-canonical U-box domain. As U-box domains typically function to bind ubiquitin-loaded E2 enzymes, this discovery stimulates the authors to investigate the ubiquitin-binding and ubiquitination properties of IFT172c. Using in vitro ubiquitination assays with truncated IFT172c constructs, the authors demonstrate partial ubiquitination of IFT172c in the presence of the E2 enzyme UBCH5A. The authors also show a direct interaction of IFT172c with ubiquitin chains in vitro. Finally, the authors demonstrate that deletion of the U-box-like subdomain of IFT172 impairs ciliogenesis and TGFbeta signaling in RPE1 cells.

      However, some of the conclusions of this paper are only partially supported by the data, and presented analyses are potentially governed by in vitro artifacts. In particular, the data supporting autoubiquitination and ubiquitin-binding are inconclusive. Without further evidence supporting a ubiquitin-binding role for the C-terminus, the title is potentially misleading.

      Strengths:

      (1) The pull-down with IFT172 C-terminus from C. reinhardtii cilia lysates is well performed and provides valuable insights into its potential roles.

      (2) The crystal structure of the IFT172 C-terminus is of high quality.

      (3) The presented AlphaFold-multimer predictions of IFT172c:IFT140 and IFT172c:IFT144 are convincing and agree with experimental cryo-ET data.

      Weaknesses:

      (1) The crystal structure of HsIFT172c reveals a single globular domain formed by the last three TPR repeats and C-terminal residues of IFT172. However, the authors subdivide this globular domain into TPR, linker, and U-box-like regions that they treat as separate entities throughout the manuscript. This is potentially misleading as the U-box surface that is proposed to bind ubiquitin or E2 is not surface accessible but instead interacts with the TPR motifs. They justify this approach by speculating that the presented IFT172c structure represents an autoinhibited state and that the U-box-like domain can become accessible following phosphorylation. However, additional evidence supporting the proposed autoinhibited state and the potential accessibility of the U-box surface following phosphorylation is needed, as it is not tested or supported by the current data.

      We thank the reviewer for this comment. IFT172C contains TPR region and Ubox-like region, which are admittedly tightly bound to each other. While there is a possibility that this region functions and exists as one domain, below are the reasons why we chose to classify these regions as two different domains.

      (1) TPR and Ubox-like regions are two different structural classes

      (2) TPR region is linked to Ubox-like region via a long linker which seems poised to regulate the relative movement between these regions.

      (3) Many ciliopathy mutations are mapped to the interface of TPR region and the Ubox region hinting at a regulatory mechanism governed by this interface.

      That said, we agree that the proposed autoinhibited state and its potential relief by phosphorylation remains a hypothesis that requires experimental validation. We have revised the manuscript to present this more clearly as a speculative model rather than an established mechanism. We clearly acknowledge this limitation on pg. 16-17 of the revised discussion: ‘The IFT172 U-box domain appears to be in an auto-inhibited state in our crystal structure of HsIFT172C2 (Fig. 2E), potentially explaining the absence of a robust auto-ubiquitination activity in-vitro. This structural inhibition is reminiscent of the RING ubiquitin ligase CBL [59], where phosphorylation and substrate binding trigger a conformational change that activates ligase activity [59,75]. Intriguingly, the phosphosite database [76] lists four residues (T1533, S1549, T1689, Y1691) at the U-box/TPR interface as phosphorylation sites (Fig. S2D). Phosphorylation of these residues could potentially alleviate the auto-inhibited state, suggesting a possible regulatory mechanism. Furthermore, a 30-residue linker connects the U-box domain to the last TPR of IFT172, likely providing significant conformational flexibility (Fig. 2A-B). This flexibility may be functionally crucial for the U-box domain, allowing it to adopt different conformations as needed for its various roles. However, we note that the proposed autoinhibition model and its potential regulation by phosphorylation remain hypothetical and require future experimental validation.

      (2) While in vitro ubiquitination of IFT172 has been demonstrated, in vivo evidence of this process is necessary to support its physiological relevance.

      We thank the reviewer for this important point. We agree that in vivo evidence of IFT172 ubiquitination would strengthen the physiological relevance of our findings. While our current study focuses on the in vitro characterization of this activity, we have revised the manuscript to more clearly state that demonstration of IFT172 ubiquitination activity in cells, including identification of bona fide substrates, is required to establish its physiological significance (p. 16). We consider this an important direction for future studies.

      (3) The authors describe IFT172 as being autoubiquitinated. However, the identified E2 enzymes UBCH5A and UBCH5B can both function in E3-independent ubiquitination (as pointed out by the authors) and mediate ubiquitin chain formation in an E3-independent manner in vitro (see ubiquitin chain ladder formation in Figure 3A). In addition, point mutation of known E3-binding sites in UBCH5A or TPR/U-box interface residues in IFT172 has no effect on the mono-ubiquitination of IFT172c1. Together, these data suggest that IFT172 is an E3-independent substrate of UBCH5A in vitro. The authors should state this possibility more clearly and avoid terminology such as "autoubiquitination" as it implies that IFT172 is an E3 ligase, which is misleading. Similarly, statements on page 10 and elsewhere are not supported by the data (e.g. "the low in vitro ubiquitination activity exhibited by IFT172" and "ubiquitin conjugation occurring on HsIFT172C1 in the presence of UBCH5A, possibly in coordination with the IFT172 U-box domain").

      We now consider this possibility and tone down our statements about the autoubiquitination activity of IFT172 in both the abstract and results/discussion parts of the revised version of the manuscript. We no longer refer to IFT172 as having auto-ubiquitination activity in the manuscript.

      (4) Related to the above point, the conclusion on page 11, that mono-ubiquitination of IFT172 is U-box-independent while polyubiquitination of IFT172 is U-box-dependent appears implausible. The authors should consider that UBCH5A is known to form free ubiquitin chains in vitro and structural rearrangements in F1715A/C1725R variants could render additional ubiquitination sites or the monoubiquitinated form of IFT172 inaccessible/unfavorable for further processing by UBCH5A.

      We agree and the conclusion on pg. 11 has now been changed to: Therefore, while mutations in the IFT172 U-box domain affect the formation of higher molecular weight ubiquitin conjugates, the prominent mono-ubiquitination of IFT172 is likely attributable to the E3-independent activity of UbcH5a, as this event is not impacted by these U-box mutations, rather than indicating an intrinsic auto-ubiquitination capacity of IFT172 itself.

      (5) Identification of the specific ubiquitination site(s) within IFT172 would be valuable as it would allow targeted mutation to determine whether the ubiquitination of IFT172 is physiologically relevant. Ubiquitination of the C1 but not the C2 or C3 constructs suggests that the ubiquitination site is located in TPRs ranging from residues 969-1470. Could this region of TPR repeats (lacking the IFT172C3 part) suffice as a substrate for UBCH5A in ubiquitination assays?

      We thank the reviewer for raising this important point about ubiquitination site identification. While not included in our manuscript, we did perform mass spectrometry analysis of ubiquitination sites using wild-type IFT172 and several mutants (P1725A, C1727R, and F1715A). As shown in Author response image 1, we detected multiple ubiquitination sites across these constructs. The wild-type protein showed ubiquitination at positions K1022, K1237, K1271, and K1551, while the mutants displayed slightly different patterns of modification. However, we should note that the MS intensity signals for these ubiquitinated peptides were relatively low compared to unmodified peptides, making it difficult to draw strong conclusions about site specificity or physiological relevance.

      Author response image 1.

      Consistent with the reviewer's suggestion, all detected ubiquitination sites fall within the TPR-containing region (residues 1022-1551), which is present in the C1 construct but absent from C2 and C3, explaining the construct-dependent ubiquitination pattern. We did not test the TPR region alone as a UBCH5A substrate, but this would be an informative experiment for future studies.

      (6) The discrepancy between the molecular weight shifts observed in anti-ubiquitin Western blots and Coomassie-stained gels is noteworthy. The authors show the appearance of a mono-ubiquitinated protein of ~108 kDa in anti-ubiquitin Western blots. However, this molecular weight shift is not observed for total IFT172 in the corresponding Coomassie-stained gels (Figures 3B, D, F). Surprisingly, this MW shift is visible in an anti-His Western blot of a ubiquitination assay (Fig 3C). Together, this raises the concern that only a small fraction of IFT172 is being modified with ubiquitin. Quantification of the percentage of ubiquitinated IFT172 in the in vitro experiments could provide helpful context.

      We acknowledge that the ubiquitin conjugation of IFT172 in vitro is weak, as stated in the manuscript (p. 16). The discrepancy between anti-ubiquitin Western blots and Coomassie-stained gels is consistent with only a small fraction of IFT172 being modified, which is expected given that the reaction likely reflects E3-independent ubiquitination by UBCH5A rather than a robust enzymatic activity of IFT172 itself. The anti-His Western blot (Fig. 3C) is more sensitive than Coomassie staining, explaining why the shift is visible there but not on Coomassie. We have not performed formal quantification of the ubiquitinated fraction, but based on the Coomassie data, we estimate it to be a minor proportion of total IFT172, consistent with the toned-down conclusions in our revised manuscript. The identification of physiological substrates and in vivo validation will be important future directions to establish the biological relevance of these observations.

      (7) The authors propose that IFT172 binds ubiquitin and demonstrate that GST-tagged HsIFT172C2 or HsIFT172C3 can pull down tetra-ubiquitin chains. However, ubiquitin is known to be "sticky" and to have a tendency for weak, nonspecific interactions with exposed hydrophobic surfaces. Given that only a small proportion of the ubiquitin chains bind in the pull-down, specific point mutations that identify the ubiquitin-binding site are required to convincingly show the ubiquitin binding of IFT172.

      We appreciate the reviewer's point regarding the potential for non-specific ubiquitin interactions and the value of mutational analysis for confirming specificity. While further mutagenesis of the predicted ubiquitin-binding interface was not performed for this revision, we note that our data show comparable tetra-ubiquitin pull-down by both the larger HsIFT172C2 construct and, importantly, the isolated HsIFT172C3 U-box domain itself (Fig. 4D). This localization of binding to the smaller U-box domain, coupled with our AlphaFold model predicting a specific interface with ubiquitin (Fig. 4E-F) and the observation that a mutation elsewhere (D1605R, Fig. 4C) does not abrogate this binding, collectively suggest a degree of specificity. We have revised the manuscript to more cautiously present these findings and acknowledge the need for future studies to definitively map the binding site. Specifically, we have now toned down the conclusion in the section on pg. 12-13 of the revised manuscript including a toned down heading: “IFT172 U-box domain pulls down ubiquitin in vitro”.

      (8) The authors generated structure-guided mutations based on the predicted Ub-interface and on the TPR/U-box interface and used these for the ubiquitination assays in Fig 3. These same mutations could provide valuable insights into ubiquitin binding assays as they may disrupt or enhance ubiquitin binding (by relieving "autoinhibition"), respectively. Surprisingly, two of these sites are highlighted in the predicted ubiquitin-binding interface (F1715, I1688; Figure 4E) but not analyzed in the accompanying ubiquitin-binding assays in Figure 4.

      We thank the reviewer for emphasizing the importance of mutational analysis to confirm the specificity of ubiquitin binding and for specifically inquiring about residues like F1715 and I1688 at the predicted ubiquitin interface. We tested purified HsIFT172C1 constructs containing the F1715A mutation (along with P1725A and C1727R variants) in pull-down assays with GST-Ubiquitin, see Author response image 2.

      Author response image 2.

      However, these experiments did not reveal a conclusive difference in ubiquitin binding for any of the tested variants compared to wild-type IFT172. The I1688A mutant, unfortunately, yielded insoluble protein and could not be evaluated. It is conceivable that the F1715A mutation was not disruptive enough to significantly alter binding, and future studies with different substitutions might be more informative. Nevertheless, our observations that the isolated HsIFT172C3 U-box domain itself pulls down tetra-ubiquitin (Fig. 4D), that our AlphaFold model predicts a specific interface (Fig. 4E-F), and that a mutation elsewhere (D1605R, Fig. 4C) does not abrogate this binding, collectively suggest a degree of specificity. We have revised the manuscript to present these ubiquitin binding findings cautiously, acknowledging the need for further investigation to definitively map the binding site and its functional relevance.

      (9) If IFT172 is a ubiquitin-binding protein, it might be expected that the pull-down experiments in Figure S1 would identify ubiquitin, ubiquitinated proteins, or E2 enzymes. These were not observed, raising doubt that IFT172 is a ubiquitin-binding protein.

      We acknowledge that the absence of ubiquitin or ubiquitinated proteins in our pull-down/MS experiment (Fig. S1) could raise questions about the ubiquitin-binding capacity of IFT172. However, several technical factors likely explain this. First, IFT172 appears to bind ubiquitin with low affinity, as indicated by our in vitro pull-downs and the AF-predicted interface. Second, we used extensive washes to remove non-specific interactors, which would also remove weak but potentially genuine ubiquitin interactions. Third, we did not include ubiquitination-preserving reagents such as NEM in our pull-down buffers, exposing ubiquitinated proteins to DUB-mediated deubiquitination during the experiment. These factors combined would strongly select against the detection of ubiquitin-related interactors under our experimental conditions.

      (10) The cell-based experiments demonstrate that the U-box-like region is important for the stability of IFT172 but does not demonstrate that the effect on the TGFb pathway is due to the loss of ubiquitin-binding or ubiquitination activity of IFT172.

      We acknowledge that our current data cannot definitively distinguish whether the TGFβ pathway defects arise from reduced IFT172 protein stability or from specific loss of ubiquitin-related functions of the U-box domain. Our experiments demonstrate that the U-box region is required for both IFT172 stability and proper TGFβ signaling, but we agree that establishing a direct mechanistic link between ubiquitin-binding/conjugation and signaling would require additional experiments such as point mutations that selectively disrupt ubiquitin-related activity without affecting protein stability. We have revised the discussion (p. 18-19) to more clearly acknowledge this limitation. Addition to text: “However, we note that our current experiments cannot distinguish whether these signaling effects result specifically from loss of ubiquitin-related functions of the U-box domain or from the reduced levels of functional IFT172 protein in the heterozygous U-box deleted cells. Targeted point mutations that selectively disrupt ubiquitin binding without affecting protein stability would be required to resolve this question.”

      (11) The challenges in experimentally validating the interaction between IFT172 and the UBX-domain-containing protein are understandable. Alternative approaches, such as using single domains from the UBX protein, implementing solubilizing tags, or disrupting the predicted binding interface in Chlamydomonas flagella pull-downs, could be considered. In this context, the conclusion on page 7 that "The uncharacterized UBX-domain-containing protein was validated by AF-M as a direct IFT172 interactor" is incorrect as a prediction of an interaction interface with AF-M does not validate a direct interaction per se.

      We agree with the reviewer that our AlphaFold-Multimer (AF-M) predictions alone do not constitute experimental validation of a direct interaction. We appreciate the reviewer's understanding of the technical challenges in validating this interaction experimentally. We have revised our text (p. 7) to state that "The uncharacterized UBX-domain-containing protein was predicted by AF-M as a potential direct IFT172 interactor" and discuss the AF-M predictions as computational evidence that suggests, but does not prove, a direct interaction.

      Reviewer #2 (Public review):

      Summary:

      Cilia are antenna-like extensions projecting from the surface of most vertebrate cells. Protein transport along the ciliary axoneme is enabled by motor protein complexes with multimeric so-called IFT-A and IFT-B complexes attached. While the components of these IFT complexes have been known for a while, precise interactions between different complex members, especially how IFT-A and IFT-B subcomplexes interact, are still not entirely clear. Likewise, the precise underlying molecular mechanism in human ciliopathies resulting from IFT dysfunction has remained elusive.

      Here, the authors investigated the structure and putative function of the to-date poorly characterised C-terminus of IFT-B complex member IFT172 using alpha-fold predictions, crystallography and biochemical analyses including proteomics analyses followed by mass spectrometry, pull-down assays, and TGFbeta signalling analyses using chlamydomonas flagellae and RPE cells. The authors hereby provide novel insights into the crystal structure of IFT172 and identify novel interaction sites between IFT172 and the IFT-A complex members IFT140/IFT144. They suggest a U-box-like domain within the IFT172 C-terminus could play a role in IFT172 auto-ubiquitination as well as for TGFbeta signalling regulation.

      As a number of disease-causing IFT72 sequence variants resulting in mammalian ciliopathy phenotypes in IFT172 have been previously identified in the IFT172 C-terminus, the authors also investigate the effects of such variants on auto-ubiquitination. This revealed no mutational effect on mono-ubiquitination which the authors suggest could be independent of the U-box-like domain but reduced overall IFT172 ubiquitination.

      Strengths:

      The manuscript is clear and well written and experimental data is of high quality. The findings provide novel insights into IFT172 function, IFT complex-A and B interactions, and they offer novel potential mechanisms that could contribute to the phenotypes associated with IFT172 C-terminal ciliopathy variants.

      Weaknesses:

      Some suggestions/questions are included in the comments to the authors below.

      Reviewer #3 (Public review):

      Summary:

      Zacharia et al report on the molecular function of the C-terminal domain of the intraflagellar transport IFT-B complex component IFT172 by structure determination and biochemical in vitro and cell culture-based assays. The authors identify an IFT-A binding site that mediates a mutually exclusive interaction to two different IFT-A subunits, IFT144 and IFT140, consistent with interactions suggested in anterograde and retrograde IFT trains by previous cryo-electron tomography studies. Additionally, the authors identify a U-box-like domain that binds ubiquitin and conveys ubiquitin conjugation activity in the presence of the UbcH5a E2 enzyme in vitro. RPE1 cell lines that lack the U-box domain show a reduction in ciliation rate with shorter cilia, and heterozygous cells manifest TGF-beta signaling defects, suggesting an involvement of the U-box domain in cilium-dependent signaling.

      Strengths:

      (1) The structural analyses of the C-terminal domain of IFT172 combine crystallography with structure prediction using state-of-the-art algorithms, which gives high confidence in the presented protein structures. The structure-based predictions of protein interactions are validated by further biochemical experiments to assess the specific binding of the IFT172 C-terminal domains with other proteins.

      (2) The finding that the IFT172 C-terminus interactions with the IFT-A components IFT140 and IFT144 appear mutually exclusive confirm a suggested role in mediating the binding of IFT-B to IFT-A in anterograde and retrograde IFT trains, which is of very high scientific value.

      (3) The suggested molecular mechanism of IFT train coordination explains previous findings in Chlamydomonas IFT172 mutants, in particular an IFT172 mutant that appeared defective in retrograde IFT, as well as mutations identified in ciliopathy patients.

      (4) The identification of other IFT172 interactors by unbiased mass spectrometry-based proteomics is very exciting. Analysis of stoichiometries between IFT components suggests that these interactors could be part of IFT trains, either as cargos or additional components that may fulfill interesting functions in cilia and flagella.

      (5) The authors unexpectedly identify a U-box-like fold in the IFT172 C-terminus and thoroughly dissect it by sequence and mutational analyses to reveal unexpected ubiquitin binding and potential intrinsic ubiquitination activity.

      (6) The overall data quality is very high. The use of IFT172 proteins from different organisms suggests a conserved function.

      Weaknesses:

      (1) Interaction studies were carried out by pulldown experiments, which identified more IFT172 interaction partners. Whether these interactions can be seen in living cells remains to be elucidated in subsequent studies.

      We agree with the reviewer that validation of protein-protein interactions in living cells provides important physiological context. While our pulldown experiments have identified several promising interaction partners and the AF-M predictions provide computational support for these interactions, we acknowledge that demonstrating these interactions in vivo would strengthen our findings. However, we believe our current biochemical and structural analyses provide valuable insights into the molecular basis of IFT172's interactions, laying important groundwork for future cell-based studies.

      (2) The cell culture-based experiments in the IFT172 mutants are exciting and show that the U-box domain is important for protein stability and point towards involvement of the U-box domain in cellular signaling processes. However, the characterization of the generated cell lines falls behind the very rigorous analysis of other aspects of this work.

      We thank the reviewer for noting that the characterization of our cell lines could be more rigorous. In the revised version of the manuscript, we have addressed this by providing additional validation data for all four engineered RPE1 cell lines. First, we performed Sanger sequencing to confirm precise in-frame integration of the GFP tag at the targeted loci and to exclude unintended insertions or deletions (indels), both for the full-length IFT172-eGFP lines (Fig. S6) and for the IFT172∆U-box-eGFP lines (Fig. S7). Second, we performed anti-IFT172 immunoblotting on all four cell lines alongside parental RPE1 cells, confirming expression of both the full-length and U-box-truncated IFT172 proteins (Fig. S8). Notably, the immunoblot revealed reduced steady-state levels of the IFT172∆U-box protein compared to full-length IFT172, providing direct biochemical evidence that loss of the U-box domain compromises IFT172 protein stability consistent with the ciliogenesis phenotype described in the main text. Together, these data verify the integrity of the edited loci at both the genomic and protein levels, and strengthen the validation of the cellular models used in this study.

      Overall, the authors achieved to characterize an understudied protein domain of the ciliary intraflagellar transport machinery and gained important molecular insights into its role in primary cilia biology, beyond IFT. By identifying an unexpected functional protein domain and novel interaction partners the work makes an important contribution to further our understanding of how ciliary processes might be regulated by ubiquitination on a molecular level. Based on this work it will be important for future studies in the cilia community to consider direct ubiquitin binding by IFT complexes.

      Conceptually, the study highlights that protein transport complexes can exhibit additional intrinsic structural features for potential auto-regulatory processes. Moreover, the study adds to the functional diversity of small U-box and ubiquitin-binding domains, which will be of interest to a broader cell biology and structural biology audience.

      Additional comments:

      The authors investigate the consequences of the U-box deletion on ciliary TGF-beta signaling. While a cilium-dependent effect of TGF-beta signaling on the phosphorylation of SMAD2 has been demonstrated, the precise function of cilia in AKT signaling has not been fully established in the field. Therefore, the relevance of this finding is somewhat unclear. It may help to discuss relevant literature on the topic, such as Shim et al., PNAS, 2020.

      We appreciate the reviewer's comment highlighting that the role of primary cilia in AKT signaling is not as well established as for SMAD2/3. However, we note that a direct functional link between AKT signaling and ciliogenesis has been demonstrated, showing that AKT regulates ciliogenesis initiation through a Rab11-effector switch mechanism (Walia et al., 2019; PMID: 31204173, co-authored by the corresponding author of this study). Furthermore, Shim et al. (PMID: 33753495) demonstrated a cilia-dependent reciprocal activation of AKT1 and SMAD2/3. In the revised manuscript (p. 19, ref. 97), we have expanded the discussion to cite these studies and provide a clearer literature context for the cilia-AKT connection, while acknowledging that the precise mechanism by which the IFT172 U-box domain influences AKT activation requires further investigation.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      Points for the discussion:

      (1) The discussion should mention that IFT-A subunits IFT121, IFT122 and IFT144 share a similar domain organization to IFT172 (TPRs terminating in Zn-finger-like domains). Do the authors consider these as potential ubiquitin-binding proteins with E3 ligase activity? The possibility that these Zn-finger-like regions share a common origin, and function to stabilize the proteins or mediate IFT subunit interactions without a role in ubiquitin biology should be considered.

      We appreciate this important point. We agree that the shared domain architecture across IFT121, IFT122, IFT144, and IFT172 raises the question of whether these C-terminal domains primarily serve structural rather than ubiquitin-related roles. We have added a discussion paragraph (p. 16) acknowledging that a structural/stabilizing function is the more parsimonious explanation, while noting that whether IFT172's U-box-like domain has additionally acquired ubiquitin-related activity remains an open question.

      (2) From their modeling data, do the authors have an explanation for why a substitution as conservative as D1605E would cause disease?

      The D1605E substitution maps to the IFT172-IFT-A interaction interface (Fig. 1F). While this is a conservative change, D1605 is located at a tightly packed protein-protein interface where even the addition of a single methylene group (the difference between aspartate and glutamate) could introduce steric clashes with residues of IFT140 or IFT144, or alter the precise geometry of hydrogen bonds or salt bridges critical for the interaction. Unfortunately, this level of detail is beyond the resolution of AlphaFold models. However, the fact that this residue is positioned directly at the binding interface provides a plausible structural rationale for its pathogenicity.

      (3) The authors speculate that the L1615P mutation in the Chlamydomonas fla11 strain causes a faulty switch to retrograde IFT and this provides a molecular basis for the retrograde IFT phenotype. However, because the mutation is also within the IFT144 binding site, why is anterograde IFT also not affected?

      The fla11 L1615P mutation resides in helix αA, which participates in both IFT144 (anterograde) and IFT140 (retrograde) interactions. The predominantly retrograde phenotype can be rationalized by the fundamentally different structural roles of the IFT172 C-terminus in anterograde versus retrograde trains. In anterograde trains, the IFT172 C-terminus acts as a flexible tether in stoichiometric excess (2:1 IFT-B:IFT-A ratio), providing an avidity effect that likely compensates for reduced binding affinity caused by L1615P (Lacey et al., 2023). Additional lateral interactions between IFT-B subunits further stabilize the anterograde polymer independently of the IFT172-IFT144 link. In contrast, the retrograde train requires the IFT172 C-terminus to adopt a rigid, resolved conformation that is integral to the IFT-A dimeric interface, with no redundant lateral interactions to compensate (Lacey et al., 2024). The helix-breaking L1615P mutation would specifically disrupt this precise structural requirement, explaining the selective retrograde IFT defect in fla11. We have added this discussion to the revised manuscript (p. 16).

      Minor:

      (1) On page 5, the authors describe the fla11 phenotypes including accumulation of IFT particles at the tip and accumulation of ubiquitinated proteins in the cilium. Could the authors please expand on how this suggests that IFT172 could be involved in ciliary ubiquitination events and discuss an alternative scenario of impaired assembly of functional retrograde IFT in this strain leading to accumulation of ubiquitinated proteins?

      In the revised manuscript (p. 16), we have expanded the discussion of the fla11 phenotype to address this point. We now discuss how the distinct structural roles of the IFT172 C-terminus in anterograde versus retrograde trains explain the selective retrograde IFT defect in fla11, and explicitly note that the accumulation of ubiquitinated proteins in fla11 cilia may reflect impaired retrograde IFT-mediated clearance rather than a direct role of IFT172 in ciliary ubiquitination.

      (2) The authors should also expand on the literature of known UBX-IFT interactions in their manuscript (e.g. Raman et al. PMID 26389662).

      We have expanded the discussion of UBX-IFT interactions in the revised manuscript (p. 7) by citing the work of Raman et al. (PMID 26389662), who identified a direct interaction between the UBX-domain protein UBXN10 and IFT-B via CLUAP1/IFT38 for VCP-mediated regulation of IFT complex integrity. This provides important context for our identification of a UBX-domain protein as an IFT172 interactor.

      (3) On page 11, I1688 is incorrectly referred to as I688.

      Fixed.

      Reviewer #2 (Recommendations for the authors):

      (1) The finding that the interaction with IFT140/144 is mutually exclusive is very interesting. Could you speculate on or do you have any data regarding the effects to the overall IFT-complex conformation and downstream biological effects depending on which partner is bound?

      I am not a structural biologist so this may be an irrelevant/impossible-to-answer question: I was also wondering as Ref 46 has shown that the dynein-2 motor complex binds to the edge of IFT-B2 (for assembled trains): Could the IFT172 C-terminus be involved here or somehow influence this interaction? In your mass spec data from Cr cilia using CrIFT172_968-C you don`t mention pulling down dynein-2 components so there doesn`t seem to be a direct interaction, but could the IFT-B2 conformation depend on if IFT172 has bound IFT-140 or IFT144 and hence this interaction influence the dynein-2 binding?

      We thank the reviewer for this insightful question. Based on recent cryo-ET structures of anterograde and retrograde IFT trains (Lacey et al., 2023; 2024), the switch from IFT144 to IFT140 binding fundamentally changes IFT172's structural role. In anterograde trains, the IFT172 C-terminus acts as a flexible tether tolerating the 2:1 IFT-B:IFT-A stoichiometry and permitting long polymer formation. In retrograde trains, it adopts a rigid conformation integral to the IFT-A dimeric interface, driving the formation of discrete retrograde units with distinct architecture.

      Regarding Dynein-2: while IFT172 does not directly bind Dynein-2 (consistent with our MS data), the reviewer's intuition is correct that IFT172's binding partner influences Dynein-2 association. In anterograde trains, autoinhibited Dynein-2 binds a composite surface formed between adjacent IFT-B2 repeats. When IFT172 switches to IFT140 at the ciliary tip, the resulting train depolymerization destroys this composite binding site, releasing Dynein-2 from its cargo mode to function as an active retrograde motor. The IFT172 binding switch may thus indirectly acts as a structural checkpoint for Dynein-2 activation.

      (2) The data provided regarding TGFbeta signalling effects in cells with heterozygous U-box-like domain deletions is interesting. While secondary effects of impaired ciliogenesis due to homozygous deletion of the U-box-like domain can cause difficulties to analysing cell signalling effects, it would still be interesting to check the effects of bi-allelic human IFT172 disease variants in this region as well (the human disease phenotype is recessive and human mutations are likely hypomorphic variants still allowing for ciliogenesis).

      Also, while there may be secondary effects, it would still be interesting to check homozygous U-box deleted cells as an aggravated effect would further support the data from the het cells.

      We agree that testing bi-allelic human disease variants would strengthen the physiological relevance of our findings. While generating knock-in RPE1 lines was beyond the scope of this revision, we have obtained preliminary data from patient-derived fibroblasts carrying bi-allelic IFT172 missense variants in the U-box region (NPH2161). TGF-β1 stimulation time courses in these fibroblasts show altered p-SMAD2 kinetics compared to control fibroblasts, consistent with the phenotype observed in our heterozygous U-box deleted RPE1 cells (see Author response image 3).

      Author response image 3.

      While these results are preliminary and require further replication, they support the involvement of the IFT172 U-box domain in TGF-β signaling regulation in a disease-relevant context. Regarding homozygous U-box deleted cells, the severe reduction in IFT172 protein levels and ciliogenesis defects (Fig. 5B,D) make it difficult to separate U-box-specific effects from secondary consequences of impaired cilia formation, as the reviewer notes. We consider this an important direction for future studies using targeted point mutations rather than domain deletions.

      (3) Figure 5 E-G: Overall, the effects upon TGFB1 addition are rather small compared to previously published data eg Clement et al Cell reports 2013 where one of the authors is the senior. Are RPE cells less responsive or do you have another theory? Did you check TGFB receptor levels to ensure the differences are not due to different levels of receptor expression? I feel it could be interesting to also check ciliary phopsho-SMAD localisation by IF. In Clement et al, loss of IFT88 results in reduced phospho-SMAD2 levels, do you have any theory why these opposite effects compared to the IFT172 loss of function could occur?

      We thank the reviewer for this insightful comment. The Tg737orpk fibroblasts used in Clement et al. (2013), which harbor a hypomorphic mutation in IFT88, exhibit severely stunted cilia. This defect broadly disrupts cilium-dependent signaling pathways, including R-SMAD activation, and is therefore expected to produce more pronounced signaling phenotypes. In contrast, our study utilizes RPE-1 cells with structurally intact cilia, enabling us to investigate more specific alterations in ciliary signaling associated with IFT172 function rather than the global effects of cilia loss. Consequently, the more modest effects observed in our system are consistent with the less severe structural and functional perturbation. Both fibroblasts and RPE-1 cells are known to express TGF-β receptors and to respond robustly to TGF-β stimulation, making it unlikely that differences in receptor abundance alone account for the observed discrepancies. We also note that increasing evidence supports a role for the primary cilium in fine-tuning TGF-β signaling output by coordinating both canonical (R-SMAD-mediated) and non-canonical (e.g., AKT/ERK-mediated) pathways. Our data raise the possibility that loss of the IFT172 U-box domain, or reduced IFT172 levels, may differentially affect this balance, rather than simply attenuating signaling uniformly, as seen with more severe ciliary defects such as IFT88 disruption in Tg737orpk cells. We agree that the current dataset does not fully resolve the underlying mechanism. We therefore consider it an important direction for future work to examine, in greater detail, the localization and phosphorylation status of key canonical and non-canonical signaling components in context of the primary cilium by IF analyses.

      (4) In the summary conclusion at the end of the discussions, the authors propose that IFT72 could directly influence the fate of ubiquitinated TGFB receptors. Do you have any data supporting the theory that TGFB ubiquitination is influenced by IFT172 ?

      We acknowledge that our current data are insufficient to establish a direct link between IFT172-dependent ubiquitination events and TGF-β receptor regulation. Accordingly, we have revised the Discussion (page 19) to remove our previous hypothesis proposing a role for IFT172 in modulating TGF-β receptor ubiquitination.

      While our experiments demonstrate that the U-box region is required for both IFT172 stability and proper TGF-β signaling, we agree that establishing a direct mechanistic connection between ubiquitin-related activity of IFT172 and signaling outcomes would require additional approaches such as targeted point mutations that selectively disrupt ubiquitin-binding or conjugation functions.

      Furthermore, we note that our current data do not allow us to distinguish whether the observed signaling phenotypes arise specifically from the loss of ubiquitin-related functions of the U-box domain or from reduced levels of functional IFT172 protein in the heterozygous U-box–deleted cells.

      (5) Wording:

      Abstract

      "IFT72..is associated with several disease variants causing ciliopathies". I would change this to "..and several disease-causing IFT172 variants have been identified in ciliopathy patients".

      Corrected.

      Introduction

      "Another cohort of patients with milder ciliopathy resembling BBS also presented with ...". I would reword this to "Another cohort of patients with phenotypically slightly different ciliopathy features resembling BBS also presented with ...". It`s not necessarily less severe (they may die of cardiovascular complications in their early thirties for example due to metabolic syndrome, they are intellectually impaired, become blind...), but rather different.

      Changed according to the reviewer’s recommendations.

      Reviewer #3 (Recommendations for the authors):

      (1) Recommended modifications:

      (a) The RPE lines generated should be described better, i.e. sequencing information should be provided, or some kind of evidence that the lines are what they are supposed to be.

      As also noted above, we acknowledge that the characterization presented for the RPE cell lines was insufficient in the initial version of the manuscript. In the revised version, we have addressed this limitation by including detailed sequencing analyses to validate the modifications introduced. Specifically, we provide sequencing data confirming both the integration of the GFP tag and the successful deletion of the U-box domain in all four engineered RPE cell lines. These data verify the integrity of the edited loci and exclude the presence of unintended insertions or deletions at the targeted regions. The corresponding results are presented in Figures S6 and S7 of the revised manuscript, thereby strengthening the validation of the cellular models used in this study.

      (b) It would be more convincing if more than one clone of the RPE lines were presented, as this could rule out possible clonal effects.

      We acknowledge that only a single clone was characterized for each of the four genotypes (IFT172-FL homozygous, IFT172-FL heterozygous, IFT172∆U-box homozygous, IFT172∆U-box heterozygous), and we agree that independent clones would provide stronger protection against clonal artifacts. Generating and validating additional clones was not feasible within the scope of this revision. However, several features of our data mitigate this concern. First, the phenotypes scale with allele dosage: the homozygous ∆U-box line shows the strongest reduction in IFT172 protein level, ciliation, and cilium length, while the heterozygous line shows intermediate defects (Fig. 5B, D and Fig. S8). A clonal off-target effect would not be expected to produce this dose-dependent pattern across two independently isolated lines. Second, the reduced steady-state IFT172 level in the ∆U-box lines (Fig. S8) is consistent with our in vitro observation that the U-box/TPR interface is required for protein stability, providing an independent biochemical rationale for the cellular phenotype. Third, Sanger sequencing of all four lines confirmed precise in-frame integration with no indels at the targeted locus (Figs. S6, S7). We have added a sentence to the Discussion (p. 20) acknowledging that confirmation in additional independent clones remains an important goal for follow-up work.

      (c) Figure 5C: distribution of the GFP-tagged IFT172∆U-box protein could be quantified to support the statement.

      In the revised version of the manuscript, we have included additional quantification of GFP fluorescence across all four cell lines to support our conclusions regarding IFT172 ciliary localization. The corresponding data for each cell line are presented in Figure S5C–F.

      (d) The final sentences include quite bold statements about a general function of IFT172 in signal regulation. Yet, the evidence is the weakest part of the work. It is only shown in i) one cell line, ii) in one cell clone that is not extensively characterized, and iii) for one signaling pathway that is not the best-studied cilia signaling pathway. Therefore, I recommend a more moderate statement.

      Abstract last sentence has now been toned down and reads: Our findings suggest that IFT172, beyond its structural role in bridging IFT-A and IFT-B complexes within IFT trains, harbors a conserved U-box-like domain with potential involvement in ciliary ubiquitination processes and signaling, providing new insights into the molecular mechanisms underlying IFT172-related ciliopathies.

      (e) The order of the figures is not followed in the main text, which is distracting.

      The order of figures is now consecutive in the revised manuscript.

      (2) Questions and comments to consider:

      (a) It is unclear why tetra-ubiquitin chains have been used.

      We thank the reviewer for this question. Recent evidence suggests that ubiquitin chains, rather than monomeric ubiquitin, act as sorting and signaling cues at the primary cilium (Shinde et al., 2020). To probe the ubiquitin-binding activity of IFT172, we therefore used a tetrameric ubiquitin chain as a model substrate, which better reflects the multivalent nature and binding avidity expected for physiological polyubiquitin signals than a ubiquitin monomer. Specifically, we used a recombinantly expressed linear (Met1-linked) tetra-ubiquitin chain, generated as a genetically encoded fusion. Linear ubiquitin chains are well-established non-degradative signaling chains recognized by a dedicated class of ubiquitin-binding domains, making them a suitable probe for detecting ubiquitin-binding activity outside the canonical proteasomal pathway. In addition, monomeric ubiquitin (~8 kDa) is poorly retained during membrane transfer in Western blotting, which further precluded its reliable use as a probe in our pull-down assays. Together, these considerations motivated the use of tetrameric ubiquitin as a biologically and technically appropriate substrate for assessing IFT172's ubiquitin-binding activity.

      (b) Figure 4D: described in the text as "pulldown tetraubiquitin at comparable levels", which is not obvious from the figure presented, it appears reduced by at least 30%.

      We thank the reviewer for this observation. As described on page 10 of the manuscript and evident from Figure 4D, the purified GST–HsIFT172C3 construct underwent substantial proteolytic cleavage during purification. This degradation limited our ability to include amounts of intact GST–HsIFT172C3 comparable to those of the full-length GST–HsIFT172C2 construct in the pull-down assays. Importantly, when accounting for the reduced proportion of full-length GST–HsIFT172C3 present in the assay, the observed differences in tetra-ubiquitin pull-down efficiency between the two constructs are expected to be comparable. This is supported by the Coomassie staining shown in Figure 4D, which reflects the relative abundance of the intact protein species used in the experiment.

      (c) With the proposed model, why would the fla11 mutant only affect retrograde IFT?

      We have revised our manuscript in page 16 of the discussion section providing a plausible explanation of why only retrograde IFT is affected in the fla11 mutant.

      (3) Minor copy-editing:

      (a) Page 3, first paragraph: led := leads.

      (b) Kinesin-2 and Dynein-2 should be hyphenated.

      (c) Page 4: wwp1 should be WWP1.

      (d) Bonafide should be italicized: bona fide.

      (e) Some abbreviations appear uncommon and therefore somewhat distracting: TGFB instead of TGF-beta, Cr in instances where specifically referred to the organism.

      (f) Unprecise lab jargon: "very C-terminal".

      (g) Lab jargon: "purified a C-terminal construct".

      (h) Lab jargon: "pull-downs".

      (i) Page 8: "DALI" only abbreviated.

      (j) Page 9: "Appearance ... were observed" should be "was".

      (k) Page 11: "I688" should be "I1688".

      (l) Page 12: "PDs" unclear.

      These minor points have been corrected.

      We have revised the text and figures to ensure using the widely accepted nomenclature, using TGF-β to refer to the signaling pathway and TGF-β1 specifically when referring to the ligand.

      We further revised the text to reflect the use “Chlamydomonas reinhardtii” in instances when referring to the organism and “Cr” when referring to the protein.

      We have removed the informal phrases "very C-terminal" and "purified a C-terminal construct" from the revised manuscript. We have retained the term "pull-down," as this is well-established and widely used terminology in the biochemistry literature to describe the affinity-based co-isolation assays used here. PD has been replaced with pull-down.

      The grammatical error on page 9 ("Appearance... “were observed") has been corrected to "was observed”.

    1. Reviewer #1 (Public review):

      Summary:

      The authors Hall et al. establish a purification method for snake venom metalloproteinases (SVMPs). By generating a generic approach to purify this divergent class of recombinant proteins, they enhance the field's accessibility to larger quantity SVMPs with confirmed activity and, for some, characterized kinetics. In some cases, the recombinant protein displayed comparable substrate specificity and substrate recognition compared to the native enzyme, providing convincing evidence of the authors' successful recombinant expression strategy. Beyond describing their route towards protein purification, they further provide evidence for self-activation upon Zn2+ incubation. They further provide initial insights on how to design high throughput screening (HTS) methods for drug discovery and outline future perspectives for the in-depth characterization of these enzyme classes to enable the development of novel biomedical applications.

      Strengths:

      The study is well presented and structured in a compelling way and the universal applicability of the approach is nicely presented.<br /> The purification strategy results in highly pure protein products, well characterized by size exclusion chromatography, SDS page as well as confirmed by mass spectrometry analysis. Further, a significant portion of the manuscript focuses on enzyme activity, thereby validating function. Particularly convincing is the comparability between recombinant vs. native enzymes; this is successfully exemplified by insulin B digestion. By testing the fluorogenic substrate, the authors provide evidence that their production method of recombinant protein can open up possibilities in HTS. Since their purification method can be applied to three structurally variable SVMP classes, this demonstrates the robust nature of the approach.

      Weakness

      The product obtained from the purification protocol appears to be a heterogenous mixture of self-activated and intact protein species. The protocol would benefit from improved control over the self-activation process. The authors explain well why they cannot deplete Zn2+ in cell culture or increase the pH to prevent autoactivation during the current purification steps. However, this leads me to the suggestion, if the His tag could be exchanged to a different tag that is less pH sensitive and not dependent on divalent ions (Strep-Tactin XT?) to allow for removal of divalent ions and low pH during purification steps. Another suggestion would be if they could replace the endogenous protease cleavage site in their expression construct design to a TEV protease recognition site, for example, to have more control over activation of the recombinant proteins.

      The graphic to explain the universal applicability of the approach, Figure S1, has some mistakes, like duplication of text, an arrow without a meaning and should be revised.

      Overall, the authors successfully purified active SVMP proteins of all three structurally diverse classes in high quality and provided convincing evidence throughout the manuscript to support their claims. The described method will be of use for a broader community working with self-activating and cytotoxic proteases.

      Comment on the revised version:

      I find that the clarity and overall structure of the manuscript have improved. However, the weakness I previously highlighted has neither been addressed experimentally nor convincingly explained. Therefore, the assessment stayed unchanged from my side.

    2. Author response:

      The following is the authors’ response to the original reviews.

      Reviewer #1 (Public review):

      Summary:

      The authors Hall et al. establish a purification method for snake venom metalloproteinases (SVMPs). By generating a generic approach to purify this divergent class of recombinant proteins, they enhance the field's accessibility to larger quantities of SVMPs with confirmed activity and, for some, characterized kinetics. In some cases, the recombinant protein displayed comparable substrate specificity and substrate recognition compared to the native enzyme, providing convincing evidence of the authors' successful recombinant expression strategy. Beyond describing their route towards protein purification, they further provide evidence for self-activation upon Zn2+ incubation. They further provide insights on how to design high-throughput screening (HTS) methods for drug discovery and outline future perspectives for the in-depth characterization of these enzyme classes to enable the development of novel biomedical applications.

      Strengths:

      The study is well-presented and structured in a compelling way. The purification strategy results in highly pure protein products, well characterized by size exclusion chromatography, SDS page as well as confirmed by mass spectrometry analysis. Further, a significant portion of the manuscript focuses on enzyme activity, thereby validating function. Particularly convincing is the comparability between recombinant vs. native enzymes; this is successfully exemplified by insulin B digestion. By testing the fluorogenic substrate, the authors provide evidence that their production method of recombinant protein can open up possibilities in HTS. Since their purification method can be applied to three structurally variable SVMP classes, this demonstrates the robust nature of the approach.

      We thank the reviewer for their positive assessment of our work.

      Weaknesses:

      The universal applicability of the approach could be emphasized more clearly. The potential for this generic protocol for recombinant SVMP zymogen production to be adapted to other SVMPs is somewhat obscured by the detailed optimization steps. A general schematic overview would strengthen the manuscript, presented as a final model, to illustrate how this strategy can be extended to other targets with similar features. Such a schematic might, for example, outline the propeptide fusion design, including its tags, relevant optimizations during expression, lysis, purification (e.g., strategies for metal ion removal and maintenance of protease inactivity), as well as the controllable auto-activation.

      In the revised version of the manuscript, we moved the detailed description of the optimisation of SVMP expression, including mature SVMP expression, Marimastat addition, active site mutations and fusion of propeptides, into the supplement as supplementary text. We hope this improves the clarity and flow. As suggested, we now include a new figure outlining the SVMP production strategy and optimisation steps in the revised manuscript (new Figure S1).

      The product obtained from the purification protocol appears to be a heterogeneous mixture of selfactivated and intact protein species. The protocol would benefit from improved control over the selfactivation process. The Methods section does not indicate whether residual metal ions were attempted to be removed during the purification, which could influence premature activation.

      We agree that improved control of self-activation would be desirable. However, there is an issue: Previous studies reported that (1) SVMP zymogens are processed within secretory cells of the venom gland (Portes-Junior et al., 2014), and (2) mature SVMPs accumulate in secretory vesicles during venom production (Carneiro et al., 2002). Accordingly, preventing the auto-processing of SVMP zymogens is difficult to achieve because this would require Zn<sup>2+</sup> depletion within the insect cells during production which would result in cytotoxicity. We have included this information in the updated Discussion section of the revised manuscript.

      Additionally, it has not been discussed whether the shift to pH 8 in the purification process is necessary from the initial steps onwards, given that a lower pH would be expected to maintain enzyme latency.

      The shift to pH 8 is required for the affinity purification of the SVMP zymogens from the medium, involving the poly-histidine-tag and immobilized metal affinity chromatography (IMAC). At lower pH, the histidines would become protonated, preventing binding of the His-tag to the column. Thus, with the His-tag the shift to pH 7.5 or pH 8 is necessary.

      The characterization of PIII activity using the fluorogenic peptide effectively links the project to its broader implications for drug design. However, the absence of comparable solutions for PI and PII classes limits the overall scope and impact of the finding.

      We agree that such assays would be extremely useful. However, the development of fluorescence based high-throughput assays to test for PI and PII SVMP activity is beyond the scope of this study. Here, our overarching objective is to report a broadly applicable production method for PI, PII and PIII SVMPs.

      Overall, the authors successfully purified active SVMP proteins of all three structurally diverse classes in high quality and provided convincing evidence throughout the manuscript to support their claims. The described method will be of use for a broader community working with self-activating and cytotoxic proteases.

      Thank you.

      Reviewer #2 (Public review):

      Summary:

      The aim of the study by Hall et al. was to establish a generic method for the production of Snake Venom Metalloproteases (SVMPs). These have been difficult to purify in the mg quantities required for mechanistic, biochemical, and structural studies.

      Strengths:

      The authors have successfully applied the MultiBac system and describe with a high level of detail the downstream purification methods applied to purify the SVMP PI, PII, and PIII. The paper carefully presents the non-successful approaches taken (such as expression of mature proteins, the use of protease inhibitors, prodomain segments, and co-expression of disulfide-isomerases) before establishing the construct and expression conditions required. The authors finally convincingly describe various activity assays to demonstrate the activity of the purified enzymes in a variety of established SVMP assays.

      We thank the reviewer for their positive assessment of our work.

      Weaknesses:

      The manuscript suffers from a lack of bottoming out and stringent scientific procedures in the methodology and the characterization of the generated enzymes.

      As an example, a further characterization of the generated protein fragments in Figure 3 by intact mass spectroscopy would have aided in accurate mass determination rather than relying on SEC elution volumes against a standard. Protein shape and charge can affect migration in SEC.

      We agree that intact MS would be useful to determine the mass of the produced SVMPs. In this manuscript, we performed SEC as a purification step, removing aggregates. Furthermore, SEC allowed determining if the SVMPs form monomers or dimers. MS characterisation of intact SVMPs (and their PTMs) is not trivial and beyond the scope of this manuscript (see below).

      Also, the analysis of N-linked glycosylation demonstrates some reactivity of PIII to PNGase F, but fails to conclude whether one or more sites are occupied, or whether other types of glycosylation is present. Again, intact mass experiments would have resolved such issues.

      We concur that glycosylation of SVMPs is an important question. However, analysing the glycosylation of the SVMPs is beyond the scope of this manuscript; it is actually a project on its own: Intact MS can indeed provide information on glycosylation but is not very precise. Unambiguous assignment of the number and occupancy of glycosylation sites is more challenging, especially for large, glycosylated proteins such as our PIII SVMP zymogen. In practice, confident mapping of glycosylation sites would require peptide-level mass spectrometry following enzymatic digestion (Trypsin and Multi-Enzymatic Limited Digestion, ideally). Sample preparation, method optimization, MS acquisition, and data analysis together would require a significant investment. Moreover, we do not have access to the native PIII SVMP from Echis carinatus sochureki venom - this is the main point of our manuscript: we describe a protocol to produce SVMPs which could not be purified from venom. Therefore, a comparison of the glycosylation of the recombinant SVMP and the native SVMP cannot be performed unfortunately (see below).

      The activity assays in Figure 4 are not performed consistently with kinetic assays and degradation assays performed for some, but not all, enzymes, and there is no Echis ocellatus comparison in Figure 4h.

      This is correct. The suggested control experiment is not possible for the PII SVMP and PIII SVMP because we cannot purify the native PII and PIII SVMPs from Echis venom. We have highlighted this information in the revised manuscript in the insulin B degradation section.

      Overall, whilst not affecting the main conclusion, this leaves the reader with an impression of preliminary data being presented. For consistency, application of the same assays to all enzymes (high-grade purified) would have provided the reader with a fuller picture.

      In the revised manuscript, we included new data showing the requested characterisations of all three SVMPs.

      We have included the respective assays in Figure 5 and Supplementary Figure S11. In the original manuscript, we had omitted these assays as the data show no enzymatic activity in the respective assays. Specifically, we show that (1) PII does not cause insulin B degradation (Fig. S11b), (2) that the PI and PII SVMPs do not degrade the fluorogenic peptide which is prototypic for PIII SVMPs and MMPs (Fig. S11a), (3) PI and PIII do not cause platelet aggregation because they lack the entire disintegrin domain (PI) or the RGD motif (PIII) (Fig. 5a), and (4) that the PI and PII SVMPs, like the PIII SVMP, are not pro-coagulant and do not cause blood clotting (Fig. 5d,5e and Fig. S11c). We also included this new information in the main text of our revised manuscript.

      Overall, the data presented demonstrates a very credible path for the production of active SVMP for further downstream characterization. The generality of the approach to all SVMP from different snakes remains to be demonstrated by the community, but if generally applicable, the method will enable numerous studies with the aim of either utilizing SVMPS as therapeutic agents or to enable the generation of specific anti-venom reagents, such as antibodies or small molecule inhibitors.

      Thank you.

      Reviewer #3 (Public review):

      Summary:

      The presented study describes the long journey towards the expression of members' SVMP toxins from snake venom, which are toxins of major importance in a snakebite scenario. As in the past, their functional analysis relied on challenging isolation; the toxins' heterologous expression offers a potential solution to some major obstacles hindering a better understanding of toxin pathophysiology. Through a series of laborious and elegantly crafted experiments, including the reporting of various failed attempts, the authors establish the expression of all three SVMP subtypes and prove their activity in bioassays. The expression is carried out as naturally occurring zymogens that autocleave upon exposure to zinc, which is a novel modus operandi for yielding fusion proteins and sheds also some new light on the potential mechanism that snakes use to activate enzymatic toxins from zymogenic preforms.

      Strengths:

      The manuscript draws from an extensive portfolio of well-reasoned and hypothesis-driven experiments that lead to a stepwise solution. The wetlands data generated is outstanding, although not all experiments along this rocky road to victory were successful. A major strength of the paper is that, translationally speaking, it opens up novel routes for biodiscovery since a first reliable platform for expression of an understudied, yet potent toxin class is established. The discovered strategy to pursue expression as zymogens could see broad application in venom biotechnology, where several toxin types are pending successful expression. The work further provides better insights into how snake toxins are processed.

      We thank the reviewer for their positive assessment of our work.

      Weaknesses:

      The manuscript contains several chapters reporting failed experiments, which makes it difficult to follow in places.

      Based on a similar comment of Reviewer 1, we now moved the ‘failed’ experiments reporting on SVMP expression optimisation to the supplement as new supplementary text. We hope that the revisions have improved the clarity and overall readability of our manuscript.

      The reporting of experimental details, especially sample sizes and replicates, could be optimised.

      The number of replicates has now been added to the figure legends in the revised manuscript. Detailed experimental information is found in the revised Methods part.

      At the time of writing, it remains unclear whether the glycosilations detected at a pIII SVMP could have an impact on the bioactivities measured, which is a major aspect, and future follow-ups should clarify this.

      A detailed analysis of glycosylation of the PIII SVMP is beyond the scope of our manuscript (see above, response to Reviewer 2). Our manuscript describes a generic protocol to produce active SVMPs. Importantly, we cannot purify the native PIII SVMP from Echis carinatus sochureki venom. Therefore, it is not possible to compare our PIII SVMP with the native PIII SVMP.

      We agree that this is an important question, and we will aim in the future to perform such a comparison of a different insect cell-produced PIII with a native PIII SVMP that can be readily purified from venom.

      Finally, the work, albeit of critical importance, would benefit from a more down-to-earth evaluation of its findings, as still various persistent obstacles that need to be overcome.

      We consider cytotoxicity to be the principal bottleneck in SVMP production. In this study, we present a strategy to overcome this bottleneck.

      Major comments to the manuscript:

      (1) Lines 148-149: "indicating that expressing inactivated SVMPs could be a viable, although inefficient, approach". I think this text serves a good purpose to express some thoughts on the nature of how the current draft is set up. It is quite established that various proteases cause extreme viability losses to their expression host (whether due to toxicity, but surely also because of metabolic burden), which is why their expression as inactive fusion proteins is the default strategy in all cases I have thus far seen. I believe that, especially in venom studies, this is of importance given the increased toxicity often targeting cellular integrity, and especially here, because Echis are known to feed on arthropods at younger life history stages, making it very likely that some venom components are especially active against insects and other invertebrates. With that in mind, I would argue that exploring their production in inactive form is the obvious strategy one would come up with and not really the conclusion of a series of (well-conducted and scientifically sound!) experiments. For me, the insight of inactive expression is largely confirmatory of what is established, unless I miss something in the authors' rationale. If yes, it would be important to clarify that in the online version.

      We agree that producing zymogens represents a straightforward strategy and now, in hindsight, would have wished we had tested this first thing, it would have saved us and apparently many others significant effort. However, realising this, and implementing this approach took us considerable time and insight as we described in this manuscript. The alternative strategies we describe in the manuscript, in particular the use of inhibitors and active-site mutation, have been successfully applied for recombinant production of diverse enzymes before, including enzymes that are toxic to host cells.

      We have revised the manuscript as requested and moved the optimisation of SVMP expression to the Supplement. We hope this improved the clarity, overall readability of the text and thus addressed the reviewer’s comment.

      (2) Line 173: Here, Alphafold 3 was used, whereas in previous sections (e.g., line 153, line 210), it was Alphafold 2. I suggest using one release across the manuscript.

      Thank you for bringing this to our attention. In the revised version of the manuscript, we clarified that all models were generated using AlphaFold 3.

      (3) Line 252-254: I fully agree, the PIII SVMP is glycosylated. Glycosylation is an important mediator of snake venom activity, and several works have described their importance in the field. This raises the question, which glycosylations have been introduced here in the SVMP, and to verify that these are glycosylations that belong to those found in snakes. This is important as insects facilitate thousands of N- and O- O-glycosylations to modulate the activity of their proteome, of which many are specific to insects. If some of these were integrated into the SVMP, this could have an impact on downstream produced bioassays and also antigenicity (the surface would be somewhat different from natural toxins, causing different selection).

      We agree that glycosylation is important and warrants a follow-up in the future.

      However, most publications we found reported that de-glycosylation has a negative effect on stability and solubility of SVMPs, which is expected to have a knock-on effect on toxin activity (e.g. AndradeSilva et al., 2025; DOI: 10.1021/acs.jproteome.5c00249). It will be difficult to separate the two effects from each other. We found only a few examples where SVMP glycosylation (sialylation and Nglycosylation) modulated proteolytic and haemorrhagic functions, including interaction with substrates such as e.g. fibrinogen (Schluga et al., 2024; https://doi.org/10.3390/toxins16110486; Chen et al., 2008; 10.1111/j.1742-4658.2008.06540.x; Nikai et al., 2000; DOI: 10.1006/abbi.2000.1795. PMID: 10871038). In our manuscript, we show that our PIII SVMP is very cytotoxic and highly active in casein, fibrinogen and ESO10 degradation assays, with a K<sub>M</sub> and k<sub>cat</sub>/K<sub>M</sub> comparing favourably with other SVMPs and MMPs. We are not aware of a specific substrate for this particular PIII SVMP that depends on a distinct glycosylation pattern. Recombinant production of such SVMPs with specific glycosylation pattern requirement would be a challenge in all commonly used expression systems (yeast, plant, insect cells and mammalian cells). In fact, insect cell expression systems could be advantageous in this respect because the Sf21 and High Five (Hi5) lepidopteran cell lines we utilised are well-characterized for their ability to perform posttranslational modifications on complex secreted proteins:

      (1) N-Glycan conservation: Both Sf21 and Hi5 cells typically produce N-glycans that are trimmed to a core 'paucimannose' structure (Man3GlcNAc2), often with an alpha1,6-fucosylation. While snakes can produce more complex, sialylated N-glycans, glycomic studies of native venoms (e.g., Bothrops venom) have demonstrated that high-mannose and paucimannose structures are also prevalent in native SVMPs. Therefore, the recombinant glycoforms produced in our system are not 'unnatural' in the snake venom context but rather represent a subset of the native glycan microheterogeneity.

      (2) Occupancy vs structure: The critical function of glycosylation in PIII SVMPs is thought to be often structural, facilitating correct folding and protecting the large metalloprotease and disintegrin-like domains from proteolytic degradation. Because Sf21 and Hi5 cells recognize the same Nglycosylation sequon (Asn-X-Ser/Thr) as reptilian cells, the site-occupancy remains consistent with the native protein, preserving the overall topography of the toxin.

      (3) Activity and authentic self-processing: We acknowledge that insect-specific alpha1,3-fucosylation can occur in Hi5 cells and is potentially antigenic. As the recombinant SVMPs will be used for binder selections and for testing in silico designed binders, useful binders will be selected based on neutralising activity against venom toxins. Here, our assays focused on auto-activation and proteolytic activity, which is primarily driven by the catalytic Zn<sup>2+</sup>-site and the protein backbone.

      As stated above, analysis of glycosylation pattern of the PIII SVMP is a project on its own and beyond the scope of this manuscript.

      We have incorporated some of the above information into the discussion section of the revised manuscript to clarify that insect cell glycosylation does not recapitulate the full diversity of SVMP glycosylation observed in native venoms.

      (4) General comment for the bioassays: It would be good to specify the replicates again and report the data, including standard deviations.

      We included this information in the figure legends.

      Discussion:

      I think the data generated in the study is very valuable and will be instrumental for pushing the frontiers in SVMP research, but still I would like to see a bit of modesty in their discussion. As I have pointed out above, it is unclear which effect the glycosilations may have (i.e., are the glycosilations found reminiscent of natural ones?), despite their being functionally important. Also, yes, isolation of SVMPs is challenging, but the reality is that their expression is equally challenging, as evidenced by the heaps of presented negative data (with which I have no problems, I think reporting such is actually important). So far, the "generic" protocol has been used to express one member per structural class of Echis SVMP, but no evidence is provided that it would work equally well on other members from taxonomically more distant snakes (e.g., the pIII known from Naja oxiana). It is very likely, but at the time of writing, purely speculative.

      We have expressed additional PIII SVMPs from Echis and Daboia species and will report their production and characterisation in due course.

      Lastly, the reality is also that the expression in insect cells can only be carried out by highly specialized labs (even in the expression world, as most laboratories work with bacterial or fungal hosts), whereas the isolation can be attempted in most venom labs. That said, production in insect cells also has economic repercussions as it will be very challenging to generate yields that are economically viable versus other systems, which is pivotal because the authors talk about bioprospecting and the toxins used in snakebite agent research.

      We thank the reviewer for this perspective on the practicalities of protein expression. However, we respectfully disagree with the characterization of insect cell expression as an inaccessible or economically non-viable platform for toxin research. We offer the following points:

      (1) Prevalence and accessibility: Contrary to the suggestion that insect cell expression is restricted to highly specialized labs, the Baculovirus Expression Vector System (BEVS) has become a cornerstone of modern biologics production, structural biology and biochemistry. For instance, our MultiBac system (which is but one of several systems currently widely in use) is utilised by over 1,000 laboratories and institutions, academic and pharma/biotech, worldwide. The maturation of commercially available kits, automated platforms, and standardized protocols has moved this technology into the mainstream, making it a standard tool for any lab requiring high-quality eukaryotic proteins.

      (2) Biological necessity: Bacterial (E. coli) and fungal (P. pastoris) systems are widely accessible, however, they appear to be fundamentally incapable of producing functional SVMPs. SVMPs require complex disulfide-bond formation, intricate folding, and N-glycosylation for stability and solubility. Bacterial systems have been widely tried by us and others but typically result in very low expression or misfolded inclusion bodies. Of note, originally, we had invested significant effort to adapt P. pastoris to the production of eukaryotic proteins we are interested in, without success, before moving on to the MultiBac system. The SVMPs that we analysed here are highly cytotoxic, rendering the baculovirus/insect cell system in a way a logical choice given that the cells are no longer 'living' after infection with the baculovirus (but more akin membrane-enveloped bioreactors). Thus, one can make the argument that insect cells represent the most accessible middle ground that provides folding apparatus and necessary post-translational modifications (PTMs) required for biological relevance, and it is possible to produce mg amounts of SVMP proteins per litre cell culture as reported here in our manuscript.

      (3) Economic viability and bioprospecting: Regarding the economic argument, we contend that viability in bioprospecting is defined by functional yield rather than simple volume. Producing large quantities of non-functional or misfolded protein in a cheaper system is economically inefficient. Furthermore, for snakebite research, the ability to produce specific, pure isoforms recombinantly without the contamination of other toxic venom components found in native isolations is essential for high-throughput screening and drug design.

      (4) Scalability: Historically, insect cell production was seen as expensive, but current bioreactor technology and reduction in consumables and media costs allow for significant scaling. Many therapeutic reagents (vaccines, viral vectors, protein biologics) are produced routinely in baculovirus/insect cells. For the purposes of bioprospecting and lead identification, the yields provided by our Hi5/Sf21 system are sufficient for rigorous downstream bioassays and structural characterization.

      Again, I believe the paper is highly important and excellently crafted, but I think especially the discussion should see some refinement to address the drawbacks and to evaluate the paper's findings with more modesty.

      Thank you. We included the discussion about glycosylation patterns.

      Recommendations for the authors:

      Reviewer #1 (Recommendations for the authors):

      (1) It is not entirely clear to me if the final constructs are indeed "fusion-proteins" (line 172, 974), in the sense of chimeric proteins. From the current description, it appears that the prodomain is encoded in the same gene rather than fused as a separate domain. Thus, referring to these constructs as fusion proteins may overstate the degree of protein engineering involved in the study.

      This is correct. In the revised manuscript, ‘fusion protein’ is only used in the context of the propeptide SVMP fusion construct to avoid confusion.

      (2) Figure 2J: It is difficult to assess how much protein is secreted relative to the intracellular amounts. The blot is surely misleading, as the effective protein dilution differs substantially between intracellularly vs. extracellularly. Providing an estimate of the relative dilution of extracellular protein would help clarify the extent of secretion.

      We estimate that the SNP and SN fractions are at least 10-times more concentrated than the media fraction. The blot is analytical and not quantitative.

      (3) The manuscript appears to use both alphafold 2 and alphafold 3 for structural predictions. Clarification on the choice of the version and its impact on results would improve consistency.

      In the revised version of the manuscript, we clarify that all structural models were generated using AlphaFold 3.

      (4) Figure S3b and others: a clear description of the antibodies used in the Western blots would be appreciated (including in the methods).

      We included this information in the figure legends and a paragraph in the methods section for Western blots in the revised manuscript.

      (5) MTT cytotoxicity testing would be more convincing if done in a concentration-dependent manner.

      We repeated this assay using different concentrations of SVMPs and show the results as a new Figure 5f in the revised manuscript.

      (6) Figure S3c: It could be interesting to show the sequence coverage to get an impression of what part of the protein is there.

      We have included this information as Supplementary Figure S4d in the revised manuscript.

      Reviewer #2 (Recommendations for the authors):

      Overall, the study is presented in a step-by-step manner, and its conclusions are valid.

      (1) As suggested in the public review, further characterization of the purified material would be good, for example, by intact mass-spectroscopy to characterize the enzymes in further detail.

      Preliminary MALDI-MS analysis (performed in Loic Quinton’s laboratory) of our PIII SVMP revealed a broad and heterogeneous mass distribution, consistent with heterogeneity caused by the presence of multiple glycoforms (which is not unlike the microheterogeneity in native snake venom). However, owing to the inherent limitations of MALDI-MS for the analysis of glycoproteins, our data do not allow determination of the number of occupied N-glycosylation sites or the identification of additional types of glycosylation.

      Moreover, the relatively large molecular mass of these proteins (zymogen 70.2 kDa protein only, mature PIII 50.6 kDa protein only) makes analysis by electrospray ionisation mass spectrometry technically challenging.

      An MS-based deep analysis of the glycosylation patterns would therefore be a project on its own, and beyond the scope of the present manuscript.

      (2) The studies involving PII appear challenging due to low yields and stability of the enzyme and the mentioned self-degradation. Some studies, such as the casein-degradation, would benefit from working with a well-characterized batch of enzymes to ensure, it is not auto-degrading during the experiment.

      We believe that the finding that the PII SVMP degrades itself after incubation with Zn<sup>2+</sup> is an important observation. It is novel to the best of our knowledge. Moreover, the key message of our manuscript is that we can produce and characterise novel SVMPs that cannot be readily purified from venom (and thus are not well characterised).

      Besides, there are very few intact PII SVMPs in venom (e.g. Suntravat et al. BMC Molecular Biol 2016); the vast majority cleaves itself into a PI and a disintegrin.

      (3) Figure 4h. Degradation of insulin is only shown for recombinant PIII, not the native enzyme, and therefore doesn't convey any information with respect to how well they compare.

      We do not have available any native PII and PIII SVMPs for a comparison with the recombinant SVMPs (in our manuscript we show expression of new, uncharacterised SVMPs). We have included the PIII SVMP in the original manuscript to show that the enzyme is active and has a different specificity compared to PI SVMP. In the revised manuscript, we also included the PII SVMP insulin B degradation assay in Supplementary Figure S11b.

      (4) Figure 5a. Inconsistent use of enzymes - data for PII is presented (both as mature protein and Zymogen) and compared to PIII, but not PI, as both zymogen and mature protein. The current data presentation is confusing and gives the idea of the manuscript assembled with figures produced during the exploratory phase of the study, and not from subsequent experiments systematically conducted for the purposes of clarity and completeness.

      In the revised manuscript, we included the missing enzymatic characterisations in Figure 5 (panel a and e) and Supplementary Figure S11a-c. These data were initially not included because the respective enzymes are inactive in these assays.

      (5) The manuscript would benefit from editing to make it more concise. For an early-career reader, it is of interest and utility to follow the thought and experimental processes that led to the successful solution, but there is a risk of losing the reader's interest along the way by going through expression experiments that did not "work" in the typical sense of the word. To this reviewer, there is no added value in a full paragraph around co-expression with disulfide isomerase, as it did not improve the protein yield. A single sentence, "co-expression with PDI did not improve yields," with a reference to a supplemental figure would convey that message.

      We have moved the optimisation of SVMP expression to the Supplementary Information, which we hope has improved the clarity and flow of the main text.

      We note that the hypothesis that co-expression of protein disulfide isomerases (PDIs) enhances yields of functional SVMPs, given the high expression of PDIs in snake venom gland cells, is well established in the field. While we consider PDIs (and other chaperones) likely to play an important role in SVMP expression, we were unable to demonstrate this effect using the baculovirus-insect cell expression system and hypothesize that efficient insect and/or baculoviral PDIs are already present.

      (6) Similarly with N-linked glycosylation, the section needs a headline (line 241) and firming up of a sentence like "and possibly not all of the glycosylation..." which is vague and appears to state that it was not really of interest to pursue this further. My view is that either an experiment is done properly with a stated aim and purpose, interpreted, and then, based on whether the results are of interest to the main story or not, they are included. If N-linked glycosylation is to be included in the manuscript, it should be with a purpose (e.g., N-linked glycosylation affects enzyme activity). As it stands, the message is "there is some N-linked glycosylation" without further explanation, and this generates information without justifying the inclusion hereof.

      Please see our reply above regarding an in-depth characterisation of insect cell glycosylation of the recombinant PIII SVMP without access to the native enzyme for comparison. In our revised manuscript, we confirm that the PIII SVMP is glycosylated and that this at least partly accounts for the apparent discrepancy in molecular weight observed in SEC and SDS PAGE. We have modified the text to clarify the purpose of the PNGase deglycosylation experiment.

      (7) The manuscript, in its current form, appears to have been copied from a Thesis with very detailed step-by-step logic and description. While this is useful in a scholarly context, a scientific manuscript should be presented more compactly, assuming the readers know basic biochemistry.

      We trust that this Reviewer finds the revised version of our manuscript more compact and concise. 

      Reviewer #3 (Recommendations for the authors):

      (1) Material and Methods plus Figures:

      Please report the number of replicates per experiment and how data is presented (means/ medians/ standard deviation/ others), and add error bars to the plots where needed.

      In the revised manuscript we have included the number of repeats in the figure legends.

      (2) Abstract

      Line 4: I would not say that SVMPs are the most potent viper toxins. This place is probably taken by some of the highly neurotoxic PLA2, such as Crotoxin. Nevertheless, SVMPs are surely some of the most important toxins responsible for pathophysiological effects stemming from viper envenoming, but I would suggest rephrasing for accuracy.

      In the revised manuscript, we have modified this sentence.

      (3) Introduction

      Lines 27-31: I would like to see a reference supporting the existence of all SVMP types across vipers.

      We have included references supporting the existence of PI, PII and PIII SVMPs in viper venom. We also rewrote the sentence to state that “representatives of all three sub-classes are present in different viper venoms.” This clarifies that we do not say that all classes are present in all venoms.

      Lines 59-60: I am not sure if this should be considered such an important impediment. Essentially, many vipers yield double- to triple-digit mg amounts of crude venom per specimen from only a single milking.

      We have rewritten this text in the revised manuscript.

      Currently, it is not possible to purify any given SVMP of interest from venom; in particular for E. ocellatus SVMP isoform mixtures are typically purified rather than individual enzymes (see also introduction section of our manuscript line 57ff). Also, many SVMPs are not present in sufficient amounts in the venom. Here, we provide an approach to recombinantly produce any SVMP of interest, independent of its abundance in the venom.

      (4) Results

      Line 102: The army-fallworms name is Spodoptera, not Spotoptera. Please correct the typo.

      Done. Apologies for our oversight.

      Line 311: Please provide the data at least as a supplement.

      In the revised manuscript, we have included this experiment in Supplementary Figure S6c.

      Line 432- 433: It would be useful to clarify whether the protein should have a pro-coagulant activity (or not).

      We have changed this sentence as follows in the revised manuscript: This shows that our recombinantly produced SVMPs have no pro-coagulant activity, which was unknown before.

    1. Author response:

      The following is the authors’ response to the original reviews.

      Public Reviews:

      Reviewer #1 (Public review):

      (1) The pathogenic mechanism of the E182STOP variant is unclear. The mutant protein does not appear to affect WT protein localization, arguing against a dominant-negative effect. Yet, overexpression of HSD17B7-E182* alone causes toxicity in zebrafish and mislocalizes cholesterol in HEI-OC1 cells, suggesting a gain-of-function or toxic effect. In addition, the variant mRNA is expressed at a low level, consistent with nonsense-mediated decay. This apparent complexity and inconsistency need clearer explanation.

      We appreciate the reviewer’s careful evaluation of this mechanistic complexity. Based on our combined molecular, cellular, and in vivo data, we propose that the pathogenic effect of the HSD17B7-E182* variant reflects a composite mechanism, rather than a classical dominant-negative effect.

      At the transcript level, the E182* variant introduces a premature termination codon and shows markedly reduced mRNA abundance, consistent with partial degradation by nonsense-mediated mRNA decay. This reduction is expected to decrease overall HSD17B7 dosage, contributing a loss-of-function component. Unlike HSD17B7, the truncated HSD17B7<sup>E182*</sup> mislocalizes cholesterol in HEI-OC1 cells, and overexpression alone reduces hair cell MET function and startle response in zebrafish embryos. We therefore propose that the truncated protein disturbing local cholesterol homeostasis, thereby exerts a toxic or ectopic gain-of-function.

      We have revised the manuscript to clarify the dual-mechanism model.

      (2) The link to human deafness is based on a single heterozygous patient with no syndromic features. Given that nearly all known cholesterol metabolism disorders are syndromic, this raises concerns about causality or specificity. The term "novel deafness gene" is premature without additional cases or segregation data.

      We thank the reviewer for this important point. We fully agree that, based on a single heterozygous case without segregation data, it is premature to designate HSD17B7 as a novel deafness gene. Therefore, we have revised the manuscript to use the description of "candidate deafness genes".

      (3) The localization of HSD17B7 should be clarified better: In HEI-OC1 cells, HSD17B7 localizes to the ER, as expected. In mouse hair cells, the staining pattern is cytosolic and almost perfectly overlaps with the hair cell marker used, Myo7a. This needs to be discussed. Without KO tissue, HSD17B7 antibody specificity remains uncertain.

      We thank the reviewer for the constructive comments regarding HSD17B7 localization and antibody specificity.

      Regarding subcellular localization, the original Figure 1K was intended to demonstrate the expression of HSD17B7 in mouse hair cells. To address this concern, we performed additional immunostaining on dissected organ of Corti sections at P1, P4, and P7 using higher magnification. Using parvalbumin as a hair cell marker, HSD17B7 displayed a partially punctate intracellular pattern in hair cells (revised Figure 1K). This pattern is consistent with localization to membrane-associated compartments, including the endoplasmic reticulum, and agrees with the ER-associated localization observed in HEI-OC1 cells and zebrafish hair cells. In mature hair cells, ER-associated signals may appear cytosolic and overlap with general hair cell markers such as Myo7a.

      Regarding antibody specificity, although HSD17B7 knockout tissue was not available, we performed complementary validation experiments in HEI-OC1 cells. Cells were transfected with pCMV-Flag, pCMV-Flag-hHSD17B7WT, or pCMV-hHSD17B7WT-EGFP constructs and stained with anti-Flag, anti-EGFP, and anti-HSD17B7 antibodies. The HSD17B7 antibody signal showed strong co-localization with both FLAG- and EGFP-tagged HSD17B7 (revised Figure S1A and B), supporting its specificity.

      Reviewer #2 (Public review):

      (1) The statement that HSD17B7 is "highly" expressed in sensory hair cells in mice and zebrafish seems incorrect for zebrafish:

      (a) The data do not support the notion that HSB17B7 is "highly expressed" in zebrafish. Compared to other genes (TMC1, TMIE, and others), the HSB17B7 level of expression in neuromast hair cells is low (Figure 1F), and by extension (Figure 1C), also in all hair cells. This interpretation is in line with the weak detection of an mRNA signal by ISH (Figure 1G I"). On this note, the staining reported in I" does not seem to label the cytoplasm of neuromast hair cells. An antisense probe control, along with a positive control (such as TMC1 or another), is necessary to interpret the ISH signal in the neuromast.

      We thank the reviewer for this detailed evaluation and agree that the description of HSD17B7 expression in zebrafish hair cells requires clarification.

      To address this, we performed a quantitative comparison of average expression levels within neuromast hair cells using log-normalized single-cell RNA-seq data. This analysis shows that hsd17b7 is expressed at a level comparable to several known MET-associated genes (e.g., tmc1 and lhfpl5a) (revised Figure 1D). Regarding the pseudotime heatmap (Figure 1F), we now state that this analysis illustrates temporal expression dynamics within neuromast hair cell development.

      In addition, we have clarified the interpretation of the whole-mount in situ hybridization data by emphasizing that the signal indicates spatial enrichment rather than high transcript abundance.

      We have updated the figure panels, legends, and corresponding text in the Results section to reflect these changes.

      (b) However, this is correct for mouse cochlear hair cells, based on single-cell RNA-seq published databases and immunostaining performed in the study. However, the specificity of the anti-HSD17B7 antibody used in the study (in immunostaining and western blot) is not demonstrated. Additionally, it stains some supporting cells or nerve terminals. Was that expression expected?

      To assess antibody specificity, we performed validation experiments using distinct epitopes. In HEI-OC1 cells transfected with pCMV-Flag-HSD17B7, or pCMV-HSD17B7-EGFP constructs, immunostaining with anti-HSD17B7 showed strong co-localization with both FLAG- and EGFP-tag (revised Figure S1B). In addition, western blot analyses using the same constructs confirmed the specific detection of HSD17B7 protein (revised Figure S1B). These validation data have now been included as supplementary figures in the revised manuscript and provide independent supporting evidence for the specificity of the anti-HSD17B7 antibody.

      (2) A previous report showed that HSD17B7 is expressed in mouse vestibular hair cells by single-cell RNAseq and immunostaining in mice, but it is not cited: Spatiotemporal dynamics of inner ear sensory and non-sensory cells revealed by single-cell transcriptomics. Jan TA, Eltawil Y, Ling AH, Chen L, Ellwanger DC, Heller S, Cheng AG. Cell Rep. 2021 Jul 13;36(2):109358. doi: 10.1016/j.celrep.2021.109358.

      We have now cited this reference in the revised manuscript.

      (3) Overexpressed HSD17B7-EGFP C-terminal fusion in zebrafish hair cells shows a punctiform signal in the soma but apparently does not stain the hair bundles. One limitation is the consequence of the C-terminal EGFP fusion to HSD17B7 on its function, which is not discussed.

      We thank the reviewer for raising this important technical point. The apparent absence of an HSD17B7-EGFP signal in hair bundles is primarily due to the imaging strategy and the selection of representative images. In zebrafish hair cells, the EGFP signal within hair bundles is extremely strong. To better visualize the intracellular distribution of HSD17B7 within the hair cell soma, we selected representative confocal optical sections that were focused on the cell body rather than on the apical hair bundle plane. As a result, the hair bundle signal is not visible in the images shown.

      Importantly, we agree that C-terminal EGFP fusion may potentially influence protein localization or function. We have therefore revised the Discussion to discuss this limitation and to clarify that our central conclusions regarding HSD17B7 function are primarily supported by loss-of-function analyses, rescue experiments using untagged mRNA, and cholesterol perturbation phenotypes, rather than relying solely on EGFP-tagged overexpression constructs.

      (4) A mutant Zebrafish CRISPR was generated, leading to a truncation after the first 96 aa out of the 340 aa total. It is unclear why the gene editing was not done closer to the ATG. This allele may conserve some function, which is not discussed.

      Targeting regions close to the ATG is indeed a commonly used strategy for CRISPR-mediated gene disruption. In this study, sgRNA selection was guided by online CRISPR design tools (CRISPRscan), prioritizing predicted cutting efficiency and specificity. This strategy resulted in a frameshift mutation introducing a premature stop codon after amino acid 96 of the 340-aa Hsd17b7 protein.

      Importantly, this truncation removes most of the conserved catalytic core required for 17β-hydroxysteroid dehydrogenase activity, including key motifs involved in NAD(P)-binding and substrate recognition. Therefore, although the mutation does not occur immediately adjacent to the ATG, the resulting allele is predicted to lack enzymatic function. We have clarified this rationale and discussed the functional consequences of the truncation in the revised manuscript.

      (5) The hsd17b7 mutant allele has a slightly reduced number of genetically labeled hair cells (quantified as a 16% reduction, estimated at 1-2 HC of the 9 HC present per neuromast). On a note, it is unclear what criteria were used to select HC in the picture. Some Brn3C:mGFP positive cells are apparently not included in the quantifications (Figure 2F, Figure 5A).

      Upon re-evaluation, we recognized that the original figure annotations were not sufficiently clear and may have led to confusion regarding hair cell selection. In the original images, the absence of dashed outlines around some Brn3c:mGFP<sup>+</sup> cells may have been misinterpreted as their exclusion from analysis. To address this issue, we have revised Figures 2F and 5A by updating the annotations to ensure that all Brn3c:mGFP<sup>+</sup> hair cells within each neuromast are clearly visible and unambiguously included (revised Figures 2F and 6A). Corresponding figure legends have also been revised to clarify the criteria used for hair cell identification and quantification.

      (6) The authors used FM4-64 staining to evaluate the hair cell mechanotransduction activity indirectly. They found a 40% reduction in labeling intensity in the HCs of the lateral line neuromast. Because the reduction of hair cell number (16%) is inferior to the reduction of FM4-64 staining, the authors argue that it indicates that the defect is primarily affecting the mechanotransduction function rather than the number of HCs. This argument is insufficient. Indeed, a scenario could be that some HC cells died and have been eliminated, while others are also engaged in this path and no longer perform the MET function. The numbers would then match. If single-cell staining can be resolved, one could determine the FM4-64 intensity per cell. It would also be informative to evaluate the potential occurrence of cell death in this mutant. On another note, the current quantification of the FM4-64 fluorescence intensity and its normalization are not described in the methods. More importantly, an independent and more direct experimental assay is needed to confirm this point. For example, using a GCaMP6-T2A-RFP allele for Ca2+ imaging and signal normalization. 

      We have revised the FM4-64 quantification strategy. Instead of measuring fluorescence intensity at the neuromast level, FM4-64 uptake was re-quantified at the single hair cell level. Hair cells within each neuromast were identified based on mGFP labeling, and the mean FM4-64 fluorescence intensity was measured for each individual hair cell. The average FM4-64 intensity per hair cell was then calculated for each neuromast and used for group comparisons (revised Figures 2F, 6B, and 8B, Figure S5B). The updated quantification method, normalization procedure, and analysis pipeline have now been described in the revised Methods section.

      As supportive evidence, we further analyzed single-cell RNA-seq data from control and hsd17b7 mutant hair cells (revised Figure 3). This analysis revealed dysregulation of multiple genes involved in the MET machinery, including reduced expression of tip-link–associated components and altered expression of other MET-related genes. While these transcriptional changes do not constitute a direct functional assay, they are consistent with perturbation of MET-associated pathways and complement the FM4-64 findings.

      (7) The authors used an acoustic startle response to elicit a behavioral response from the larvae and evaluate the "auditory response". They found a significative decrease in the response (movement trajectory, swimming velocity, distance) in the hsd17b7 mutant. The authors conclude that this gene is crucial for the "auditory function in zebrafish".

      This is an overstatement:

      (a) First, this test is adequate as a screening tool to identify animals that have lost completely the behavioral response to this acoustic and vibrational stimulation, which also involves a motor response. However, additional tests are required to confirm an auditory origin of the defect, such as Auditory Evoked Potential recordings, or for the vestibular function, the Vestibulo-Ocular Reflex. 

      We thank the reviewer for highlighting the limitations in interpreting the acoustic startle assay. We have revised the manuscript to avoid overstatement and now describe the observed phenotype as a reduction in the behavioral response to acoustic and vibrational stimulation, rather than concluding a specific impairment of auditory function.

      (b) Secondly, the behavioral defects observed in the mutant compared to the control are significantly different, but the differences are slight, contained within the Standard Deviation (20% for velocity, 25% for distance). To this point, the Figure 2 B and C plots are misleading because their y-axis do not start at 0.

      We have corrected Figures 2B and 2C so that the y-axes start at zero, thereby providing a more transparent visualization of the behavioral differences. The figure legends have also been revised to clarify the presentation of the data.

      (8) Overexpression of HSD17B7 in cell line HEI-OC1 apparently "significantly increases" the intensity of cholesterol-related signal using a genetically encoded fluorescent sensor (D4H-mCherry). However, the description of this quantification (per cell or per surface area) and the normalization of the fluorescent signal are not provided. 

      The quantification of the D4H-mCherry signal in HEI-OC1 cells was performed at the single-cell level. Specifically, individual cells were segmented based on morphology, and the mean fluorescence intensity of D4H-mCherry per cell was measured. To account for variability in cell size and imaging conditions, fluorescence intensity was normalized to the background signal measured from cell-free regions in the same field of view. We have now clarified the quantification strategy and normalization procedure in the revised Methods and Results sections.

      (9) When this experiment is conducted in vivo in zebrafish, a reduction in the "DH4 relative intensity" is detected (same issue with the absence of a detailed method description). However, as the difference is smaller than the standard deviation, this raises questions about the biological relevance of this result.

      We have now clarified the quantification strategy and normalization procedure in the revised Methods and Results sections.

      (10) The authors identified a deaf child as a carrier of a nonsense mutation in HSB17B7, which is predicted to terminate the HSB17B7 protein before the transmembrane domain. However, as no genetic linkage is possible, the causality is not demonstrated.

      We thank the reviewer for raising this important point. Unfortunately, we were unable to obtain the parents' genetic testing data to perform formal genetic and linkage analysis. To address this limitation, we have revised the manuscript to avoid causal overstatement and now describe the HSD17B7 E182* variant as a candidate pathogenic variant associated with hearing loss. Importantly, our functional analyses in zebrafish and cell-based systems demonstrate that the E182* truncation abolishes key biological activities of HSD17B7, including subcellular localization, cholesterol regulation, mechanotransduction-related activity, and behavioral responses. These convergent functional data provide biological support for the potential pathogenic relevance of this variant.

      (11) Previous results obtained from mouse HSD17B7-KO (citation below) are not described in sufficient detail. This is critical because, in this paper, the mouse loss-of-function of HSD17B7 is embryonically lethal, whereas no apparent phenotype was reported in heterozygotes, which are viable and fertile. Therefore, it seems unlikely that heterozygous mice exhibit hearing loss or vestibular defects; however, it would be essential to verify this to support the notion that the truncated allele found in one patient is causal.

      Hydroxysteroid (17beta) dehydrogenase 7 activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal survival and cardiovascular differentiation in early mouse embryos.

      Jokela H, Rantakari P, Lamminen T, Strauss L, Ola R, Mutka AL, Gylling H, Miettinen T,

      Pakarinen P, Sainio K, Poutanen M. Endocrinology. 2010 Apr;151(4):1884-92. doi: 10.1210/en.2009-0928. Epub 2010 Feb 25.

      We thank the reviewer for raising this important point. We acknowledge that previous work has shown that complete loss of Hsd17b7 in mice is embryonically lethal, whereas heterozygous animals are viable and fertile (Jokela et al., 2010). Notably, this study primarily focused on embryonic development, cholesterol metabolism, and cardiovascular and neuroectodermal survival, and auditory or vestibular functions were not specifically examined. Therefore, subtle or sensory organ–specific phenotypes in heterozygous mice cannot be excluded.

      The human variant identified in this study (E182*) is a nonsense mutation predicted to truncate the HSD17B7 protein prior to the transmembrane and cytoplasmic domains. We therefore present it as a candidate loss-of-function variant, providing supportive human genetic evidence that is consistent with our functional analyses in zebrafish hair cells, rather than as definitive proof of causality. We have revised the manuscript to clarify these points and to acknowledge this limitation.

      (12) The authors used this truncated protein in their startle response and FM4-64 assays. First, they show that contrary to the WT version, this truncated form cannot rescue their phenotypes when overexpressed. Secondly, they tested whether this truncated protein could recapitulate the startle reflex and FM4-64 phenotypes of the mutant allele. At the homozygous level (not mentioned by the way), it can apparently do so to a lesser degree than the previous mutant. Again, the differences are within the Standard Deviation of the averages. The authors conclude that this mutation found in humans has a "negative effect" on hearing, which is again not supported by the data. 

      We thank the reviewer for this important comment. We agree that the overexpression strategy employed in this study does not fully replicate the endogenous heterozygous state observed in patients, and that the magnitude of the observed effects varies across samples. Accordingly, our experiments were not intended to demonstrate a definitive causal role of the HSD17B7 <sup>E182*</sup> variant in hearing loss.

      Instead, the overexpression assays were designed to assess whether the truncated HSD17B7 protein displays abnormal cellular properties and whether its presence can interfere with processes relevant to hair cell function. Under these conditions, HSD17B7<sup>E182*</sup> exhibited aberrant subcellular localization, altered intracellular cholesterol distribution, and was associated with reduced FM4-64 uptake and changes in startle-associated behaviors, whereas the wild-type protein did not.

      We revised the manuscript to moderate our conclusions. Rather than claim that the E182* mutation has a definitive “negative effect on auditory function,” we now describe it as a functionally compromised allele that disrupts cholesterol distribution and MET-related activity under overexpression conditions, providing mechanistic support consistent with our zebrafish loss-of-function data and the identification of this variant in a patient with hearing loss. In addition, the "negative effect" statement was based on the result that overexpression of the E182* mutation in wild-type embryos caused the compromised MET function and startle response defect.

      (13) The authors looked at the distribution of the HSB17B7 in a cell line. The WT version goes to the ER, while the truncated one forms aggregates. An interesting experiment consisted of co-expressing both constructs (Figure S6) to see whether the truncated version would mislocalize the WT version, which could be a mechanism for a dominant phenotype. However, this is not the case.

      We thank the reviewer for raising this important point regarding a potential dominant-negative mechanism. Consistent with the reviewer’s interpretation, we found that HSD17B7<sup>WT</sup> predominantly localizes to the endoplasmic reticulum, whereas the truncated HSD17B7<sup>E182*</sup> protein forms intracellular aggregates. Importantly, we further observed that the E182* mutation markedly reduces the stability of both HSD17B7 mRNA and protein, resulting in substantially decreased abundance of the truncated protein (Figure S6B–E). As a consequence, the cellular levels of HSD17B7^E182* are abnormally low.

      Based on these findings, we consider it unlikely that the E182* variant exerts its effect through interference with the wild-type protein. Our results suggest that the heterozygous c.544G>T (p.E182*) variant contributes to auditory dysfunction through potential pathogenic mechanisms: 1, haploinsufficiency caused by reduced HSD17B7 expression, 2, functional impairment due to altered protein subcellular localization and cholesterol distribution.

      We have revised the Results and Discussion sections. Our conclusions now emphasize that the functional impact of this variant is attributable to decreased effective HSD17B7 dosage, consistent with the observed defects in cholesterol synthesis, MET-related activity, and auditory-associated phenotypes in our model.

      (14) Through mass spectrometry of HSB17B7 proteins in the cell line, they identified a protein involved in ER retention, RER1. By biochemistry and in a cell line, they show that truncated HSB17B7 prevents the interaction with RER1, which would explain the subcellular localization.

      Consistent with the reviewer’s interpretation, wild-type HSD17B7 interacts with RER1, a protein known to participate in ER retention, whereas this interaction is lost in the truncated HSD17B7 variant. We propose that RER1 is an interacting partner of HSD17B7, providing a mechanistic explanation for the protein's subcellular localization.

      (15) Information and specificity validation of the HSB17B7 antibody are not presented. It seems that it is the same used on mice by IF and on zebrafish by Western. If so, the antibody could be used on zebrafish by IF to localize the endogenous protein (not overexpression as done here). Secondly, the specificity of the antibody should be verified on the mutant allele. That would bring confidence that the staining on the mouse is likely specific.

      We thank the reviewer for raising this important point regarding antibody specificity and validation. Information on the HSD17B7 antibody and its validation has been provided in our response to comment 1, where we described the use of antibodies recognizing different epitopes and the experimental strategies employed to assess specificity (revised Figure S1A and B).

      Although the same antibody was used for Western blot analysis in zebrafish samples, its performance in immunofluorescence staining of zebrafish tissues was suboptimal, with relatively high background. For this reason, we did not rely on this antibody for endogenous Hsd17b7 localization in zebrafish by immunofluorescence and instead employed tagged constructs for subcellular localization analyses. This approach provides more reliable and interpretable localization information under the current experimental conditions.

      Recommendations for the authors:

      Reviewing Editor Comments:

      Suggested revisions to help improve the study and the eLife Assessment:

      (1) FM4-64 uptake: Isolate the effect of hair cell loss and MET reduction.

      (2) Clarify the mechanistic model: Is the mutant protein pathogenic due to toxicity, lack of expression or function, or both? Come up with a clearer causal chain of events.

      (3) Mouse immunostaining: Validate the HSD17B7 antibody, and since mouse RNAseq data (gEAR database) suggest that HSD17B7 expression increases dramatically between P0-P5, show this developmental progression by immunostaining of the mouse organ of Corti at P0, P3, and P5.

      (4) The HSD17B7-E182* expression disrupts cholesterol (D4H staining) in OC1 cells. This should also be demonstrated in the mutant zebrafish.

      (5) Structural modeling of E182* is uninformative; half the protein is absent. This kind of analysis is better suited for missense variants. Suggest removing this analysis.

      We thank the Reviewing Editor for these constructive suggestions. The major points raised here substantially overlap with the concerns raised in the public reviews. In response, we have:

      (1) revised FM4-64 quantification and interpretation to better distinguish hair cell loss from MET impairment;

      (2) Clarify the mechanistic mode. Mechanistically, the mutation decreases mRNA abundance and significantly reduces protein levels. Moreover, expression of the p.E182* mutation disrupted the interaction between HSD17B7 and the ER retention receptor RER1, leading to aberrant subcellular localization and altered cholesterol distribution, thereby exacerbating HC dysfunction.

      (3) provided additional validation of the HSD17B7 antibody using antibodies targeting distinct epitopes, and extended mouse organ of Corti immunostaining to postnatal stages P1, P4, and P7 to demonstrate the developmental upregulation of HSD17B7 expression;

      (4) added in vivo zebrafish experiments demonstrating that expression of HSD17B7<sup>E182*</sup> disrupts cholesterol distribution in hair cells, consistent with the effects observed in HEI-OC1 cells using D4H staining;

      (5) removed the structural modeling of the E182* variant.

      Recommendations for the authors:

      The recommendations from Reviewer #1 and Reviewer #2 were carefully considered and addressed. Most of these points overlap with the public reviews and the Reviewing Editor's comments and have been addressed through a revised mechanistic interpretation, additional clarifications in the Methods, more moderate claims regarding auditory function and human genetics, and the removal or revision of potentially misleading analyses. In addition, a number of minor issues were corrected, including missing or incorrect references, repetitive or unclear statements in the Introduction, insufficient methodological details, imprecise terminology, and typographical or formatting errors. Collectively, these revisions improve the clarity, rigor, and transparency of the study without altering its central conclusions.

    1. What strategies do you think might work to improve how social media platforms use recommendations?

      Often, many social media sites have a "tag" system when it comes to posts and other content (these sites include YouTube). One way to improve recommendations would be if media sites allowed for users to essentially designate some tags with "not-interested" so that content with those tags are less likely to be recommended. This could help users avoid seeing upsetting content.

    1. Reviewer #1 (Public review):

      Summary:

      This study examines the role of the long non-coding RNA Dreg1 in regulating Gata3 expression and ILC2 development. Using Dreg1 deficient mice, the authors show a selective loss of ILC2s but not T or NK cells, suggesting a lineage-specific requirement for Dreg1. By integrating public chromatin and TF-binding datasets, they propose a Tcf1-Dreg1-Gata3 regulatory axis. The topic is relevant for understanding epigenetic regulation of ILC differentiation.

      Strengths:

      (1) Clear in vivo evidence for a lineage-specific role of Dreg1.

      (2) Comprehensive integration of genomic datasets.

      (3) Cross-species comparison linking mouse and human regulatory regions.

      Weaknesses:

      (1) Mechanistic conclusions remain correlative, relying on public data.

      (2) Lack of direct chromatin or transcriptional validation of Tcf1-mediated regulation.

      (3) Human enhancer function is not experimentally confirmed.

      (4) Insufficient methodological detail and limited mechanistic discussion.

      Comments on revisions:

      The authors have provided clear evidence that Dreg1 is necessary for ILC2 development, but their refusal to perform any mechanistic experiment remains a significant weakness. While their appeal to the 3Rs and the use of public datasets is noted, re-analyzing external data from heterogeneous sources cannot substitute for direct, internal validation of the Tcf1-Dreg1-Gata3 axis in their specific knockout model. This is particularly problematic because ILC2 progenitors, though rare, can be isolated from bone marrow, especially since assays like CUT&Tag and others are specifically designed for low cell numbers. By relying on public T-cell CRISPR screens to justify human ILC2 functions, the authors are substituting cross-cell-type correlation for definitive functional proof. Consequently, the manuscript currently describes a discovery of necessity without providing a verified molecular mechanism, which should be more explicitly reflected in the title and conclusions.

    2. Author response:

      The following is the authors’ response to the original reviews

      Public Reviews:

      Reviewer #1 (Public review):

      Summary:

      This study examines the role of the long non-coding RNA Dreg1 in regulating Gata3 expression and ILC2 development. Using Dreg1-deficient mice, the authors show a selective loss of ILC2s but not T or NK cells, suggesting a lineage-specific requirement for Dreg1. By integrating public chromatin and TF-binding datasets, they propose a Tcf1-Dreg1-Gata3 regulatory axis. The topic is relevant for understanding epigenetic regulation of ILC differentiation.

      Strengths:

      (1) Clear in vivo evidence for a lineage-specific role of Dreg1.

      (2) Comprehensive integration of genomic datasets.

      (3) Cross-species comparison linking mouse and human regulatory regions.

      Weaknesses:

      (1) Mechanistic conclusions remain correlative, relying on public data.

      We agree that the mechanistic conclusions are of our study are indeed correlative and we mention this in the discussion. The primary work of the study is the discovery of Dreg1's necessity for ILC2 development via the new knockout mouse model. Re-analysing good quality publicly available data on rare cell populations is an appropriate approach and in line with DORA guidelines for ethical research.

      (2) Lack of direct chromatin or transcriptional validation of Tcf1-mediated regulation.

      The most appropriate way to examine direct Tcf1 target genes in primary cells is to examine the association of Tcf1 binding with the changes that occur in Tcf1-bound genes after Tcf7 knockout. By analysing publicly available data on ILC progenitors we indeed did this. We revealed that Tcf1 bound to Dreg1 and that Dreg1 was not expressed when Tcf1 was knocked out in ILC progenitors. In addition we examined H3K27ac at the Dreg1 locus in the same ILC progenitors to demonstrate that Tcf1 appears to be important for decorating the Dreg1 gene with this histone modification. We believe that this analysis is sufficient to conclude that Tcf1 is required for the expression of Dreg1 in ILC progenitors.

      (3) Human enhancer function is not experimentally confirmed.

      We agree that the potential human enhancer of GATA3 we identified has not been confirmed in human ILC. However, a previous study showed clear evidence that this region has GATA3 enhancer activity in human T cells. Therefore, while not specific to ILC2s the region where the DREG1 homologues lie does indeed harbour enhancer activity.

      (4) Insufficient methodological detail and limited mechanistic discussion.

      We have now made the changes suggested by the reviewer to both the methods/figure legends and also the discussion.

      Reviewer #1 (Recommendations for the authors):

      The authors generated Dreg1-deficient mice and demonstrated that loss of this locus selectively reduces ILC2s but not T or NK cells, indicating a lineage-specific requirement for Dreg1 in ILC development. By analyzing publicly available chromatin accessibility and transcription factor-binding datasets, they link Dreg1 expression to Tcf1-dependent chromatin activation and extend their findings to human data by identifying a syntenic GATA3 enhancer that produces homologous Dreg lncRNAs in ILC2s. While the study addresses an interesting question, most of the mechanistic interpretations rely heavily on publicly available datasets rather than the authors' own functional evidence. To establish causality and reinforce the overall conclusions, I provide below some comments and suggestions for additional experiments and clarifications that would considerably strengthen the manuscript.

      (1) In Figure 3, the authors use public datasets to argue that Tcf1 regulates Dreg1 expression by modulating chromatin accessibility and H3K27ac at its locus. However, since these data are derived from heterogeneous external sources, the conclusions remain associative. To better support causality, the authors should generate matched datasets from their own sorted progenitor populations and perform CUT&Tag for Tcf1 and H3K27ac in wild-type and Tcf7 knockout progenitors to directly test whether Tcf1 binding establishes an active chromatin state at Dreg1. Also, complementing this with nascent RNA or pre-mRNA quantification would link chromatin activation to transcriptional output. These experiments are technically feasible in progenitors and would substantially strengthen the claim that Tcf1 directly drives Dreg1 activation during ILC development.

      We believe that utilising publicly available data sufficiently answers this question while also adhering to ethical considerations. The ILC populations used to produce the publicly available data were akin to those we examined in our analyses, and the data was of sufficient quality. Moreover, they enable us to access data from Tcf1-deficient mice. Redoing large-scale chromatin profiling on rare cell types would require hundreds of mice to achieve sufficient cell numbers. Repeating this solely for “originality” contradicts the 3Rs principles (replacement, reduction, refinement) if high quality public data already exists and we feel will require years of redundant work. In addition, we believe the fact that the data derive from heterogenous external sources, yet align well, only strengthen our conclusions. We have now added mention to our use of publicly available data in the discussion.

      (2) In Figure 4, the authors provide correlative evidence from public datasets suggesting that the human region syntenic to the murine Dreg1 locus acts as a distal enhancer of GATA3 and gives rise to two ILC2-specific lncRNAs. To substantiate this claim, the authors should perform CUT&Tag for H3K27ac in human ILC2s to confirm enhancer activation and use 3C or HiChIP to demonstrate physical interaction with the GATA3 promoter. These experiments should be doable by fusing pooled ILC2 samples and would provide more direct evidence that this region actively regulates GATA3 expression.

      Assessing the activity of a distal enhancer region on its target gene in primary human cells is extremely difficult, due to a number of technical and biological complications such as enhancer redundancy. This is why we chose to reanalyse an extensive enhancer deletion screen performed in human T cells by Chen et al., AJHG 2023. This analysis clearly showed deletion of the region we identified as harbouring Dreg1 homologues affected GATA3 expression, thus confirming its enhancer activity. While we agree with the reviewer that specific profiling of human ILC populations for H3K27ac and 3D genome architecture would provide further correlative evidence this will be a time-consuming and costly endevour with human material and ultimately the definitive proof in ILCs would require specific deletion of this region in ILC2s. We have mentioned this caveat in the discussion.

      (3) Several figure legends lack essential methodological details. Figure 1 should specify how NK and ILC populations were gated, including intermediate steps and markers used. The same applies to Supplementary Figure 1, and particularly to Supplementary Figure 2, where gating strategies for progenitors are shown but not explained. Figure 2 should also indicate that these analyses were performed in bone marrow. Clearer legends are crucial for interpreting and reproducing the data.

      We have made the suggested changes.

      (4) It is also unclear throughout the manuscript whether the authors performed any ATACseq experiments themselves or relied entirely on public datasets. This information should be stated explicitly in the main text and figure legends, not only in the Methods section. Similarly, the source of the ChIPseq or CUT&Run datasets should be clearly indicated alongside the relevant figures.

      We apologise for not making this clearer and have now clearly articulated if the data was public in the text.

      (5) As the authors themselves suggest, performing experiments that selectively suppress Dreg1 transcription using antisense oligonucleotides or CRISPR interference at the Dreg1 promoter would provide more valuable mechanistic insights. Conducting these experiments in their own system would allow them to determine whether Dreg1 functions through its RNA product or as a DNA enhancer element, thereby strengthening the causal link between Dreg1 activity and Gata3 regulation.

      We agree with the reviewer, however, this, in our opinion is beyond the scope of this manuscript. The strength of this manuscript lies in the findings from the novel Dreg1 knockout mouse strain. Future studies will focus on understanding how Dreg1 influences Gata3 expression.

      (6) The discussion would benefit from a clearer and more integrated explanation of how Dreg1 fits into the transcriptional network that controls ILC2 differentiation. The authors could elaborate on whether Dreg1 fine-tunes Gata3 expression or functions as part of a regulatory loop with Tcf1, and better explain how this mechanism might be conserved in humans. In addition, the authors should explicitly acknowledge the limitations of relying on publicly available datasets and emphasize the need for direct experimental validation to support their mechanistic interpretation.

      We have now made these suggested inclusions.

      Reviewer #2 (Public review):

      The authors investigate the role of the long non-coding RNA Dreg1 for the development, differentiation, or maintenance of group 2 ILC (ILC2). Dreg1 is encoded close to the Gata3 locus, a transcription factor implicated in the differentiation of T cells and ILC, and in particular of type 2 immune cells (i.e., Th2 cells and ILC2). The center of the paper is the generation of a Dreg1-deficient mouse. While Dreg1-/- mice did not show any profound ab T or gd T cell, ILC1, ILC3, and NK cell phenotypes, ILC2 frequencies were reduced in various organs tested (small intestine, lung, visceral adipose tissue). In the bone marrow, immature ILC2 or ILC2 progenitors were reduced, whereas a common ILC progenitor was overrepresented, suggesting a differentiation block. Using ATAC-seq, the authors find that the promoter of Dreg1 is open in early lymphoid progenitors, and the acquisition of chromatin accessibility downstream correlates with increased Dreg1 expression in ILC2 progenitors. Examining publicly available Tcf1 CUT&Run data, they find that Tcf1 was specifically bound to the accessible sites of the Dreg1 locus in early innate lymphoid progenitors. Finally, the syntenic region in the human genome contains two non-coding RNA genes with an expression pattern resembling mouse Dreg1.

      The topic of the manuscript is interesting. However, there are various limitations that are summarized below.

      (1) The authors generated a new mouse model. The strategy should be better described, including the genetic background of the initially microinjected material. How many generations was the targeted offspring backcrossed to C57BL/6J?

      The mice were backcrossed for at least 2 generations to C57BL/6. This information is now included in the methods section.

      (2) The data is obtained from mice in which the Dreg1 gene is deleted in all cells. A cell-intrinsic role of Dreg1 in ILC2 has not been demonstrated. It should be shown that Dreg1 is required in ILC2 and their progenitors.

      We now provide new mixed bone marrow irradiation chimera data that shows that the effect is intrinsic to Dreg1-deficient ILC2 cells (Figure 1F and Supplementary Figure 1E-G).

      (3) The data on how Dreg1 contributes to the differentiation and or maintenance of ILC2 is not addressed at a very definitive level. Does Dreg1 affect Gata3 expression, mRNA stability, or turnover in ILC2? Previous work of the authors indicated that knockdown of Dreg1 does not affect Gata3 expression (PMID: 32970351).

      We have indeed shown that Dreg1-deficient ILC2P have reduced levels of Gata3 (Figure 2H) however we have not determined the exact mechanisms by which Dreg1 controls ILC2 development.

      (4) How Dreg1 exactly affects ILC2 differentiation remains unclear.

      We agree with the reviewer, however, this article is focused on the first description of the Dreg1 knockout mice and the surprisingly specific effect on ILC2 development.

      Reviewer #2 (Recommendations for the authors):

      (1) Relating to point 2 of public review:

      It should be shown that Dreg1 is required in ILC2 and their progenitors. Mixed bone marrow chimeras would be an adequate strategy.

      We have now done this and clearly showed that the effect is intrinsic to Dreg1-deficient ILC2s.

      (2) Relating to point 3 of public review:

      Minimally, Gata3 expression should be analyzed in ILC2, ILC2P, and the ILC progenitors by qRT-PCR and antibody stain.

      We have indeed shown reduced Gata3 levels by antibody stain in Figure 2H.

      (3) Relating to point 4 of public review:

      The manuscript would benefit from additional data studying ILC2 differentiation in (competitive) adoptive transfer experiments or using in vitro differentiation assays.

      We have performed the mixed bone marrow chimera experiments which are testing the competitiveness of Dreg1-deficient bone barrow with control wildtype. In this case the WT ILC2s outcompeted the Dreg1-deficient ILC2s for the same niche.

  7. Apr 2026
    1. Author response:

      [These author responses are to reviews from another journal.]

      Reviewer #1:

      This manuscript investigates the behaviour of a variety of clock proteins in cultured cells when epitope tagged and transiently expressed and try to draw general implications for endogenous function of circadian clock proteins.

      Clock proteins are expressed at low levels in most cells, and so the clock interacting proteins (other kinases, phosphatases, ubiquitin-conjugated enzymes, etc.) are likewise probably at low abundance. Over-expression of one or two or even three components of a multicomponent system is going to produce odd and obscure non-physiological imbalances. The authors do not extend detailed study of these imbalances to more physiologic levels so the importance of their observations to clock function is not clear, and importantly, they are not tested in more biologically relevant models.

      To study the function of components within a system, the steady state must be perturbed in one way or another. This can be achieved through pharmacological treatment, mutagenesis, downregulation, or overexpression. Such interventions are inherently non-physiological, and the relevance of the resulting observations must therefore be carefully validated.

      In our study, the purpose of PER2 overexpression was to investigate its subcellular dynamics in the absence and presence of CRYs, specifically CRY1. This is far less trivial than it might appear at first glance, because our data clearly show that PER2 overexpression triggers, within 24 h, the accumulation of endogenous CRY1 (Fig. 1A), due to PER2-mediated stabilization of CRY1 (Fig. 4). PER2 overexpression also induces the accumulation of endogenous PER1, CK1, and BMAL1 (Fig. 2).

      This effect was not considered in previous studies, such as Yagita et al. (2002), in which PER2 subcellular localization was assessed at a single time point following transient transfection. Yagita et al. found roughly equal proportions of cells with PER2 exclusively in the nucleus, exclusively in the cytoplasm, or distributed between both compartments. Such extreme cell-to-cell variability cannot be explained solely by PER2’s shuttling dynamics, as that would imply synchronous export in one cell and synchronous import in another.

      Our time-resolved analysis of DOX-induced PER2 expression strongly suggests that the variability reported by Yagita et al. reflects a heterogeneous population of unsynchronized cells at different temporal stages along a trajectory from cytoplasmic PER2 (unbound) to nuclear PER2 fully saturated with CRYs (bound), owing to stabilization of endogenous CRYs. Similarly, Öllinger et al. (2014) analyzed PER2 nuclear export in cells constitutively expressing PER2-Dendra. Under such steady-state conditions, PER2-Dendra is already in complex with endogenous CRYs. The slow export rate and lack of dependence on additional CRY1 expression therefore likely reflect export of the complex, which is intrinsically slow.

      Thus, prior to our work, no data on the true shuttling dynamics of PER2 were available.

      Importantly, our results show not only that CRY1 promotes nuclear accumulation of PER2 (as reported by Öllinger et al.) but also that, conversely, PER2 promotes cytosolic accumulation of CRY1, depending on their expression ratio. Since CRY1 is predominantly nuclear and PER2 predominantly cytosolic, and because a PER2 dimer can bind one or two CRY1 molecules, our data suggest that the shuttling equilibrium depends on PER2 saturation state: a PER2 dimer bound to one CRY1 remains cytosolic, whereas a dimer bound to two CRY1 is nuclear.

      These observations are novel and have not been reported previously. They were only possible through time-resolved analysis of overexpressed proteins.

      A number of the findings are confirmatory rather than novel - the phosphorylation-regulated nuclear-cytoplasmic shuttling of CK1 and PER proteins is long known, and it's not clearly stated what is novel here. 

      We acknowledge prior work by Milne et al. (2001), who showed that kinase-dead CK1 is predominantly nuclear and that prolonged treatment with leptomycin B (16 h) enhances its nuclear localization. We cite this study at the beginning of the relevant paragraph. While we confirm these earlier observations, our work extends them in several important and novel ways:

      (1) Rapid dynamics of CK1 localization – We show that pharmacological inhibition of CK1 with PF670 induces rapid (within 1 h) depletion of CK1δ from the centrosome, accompanied by nuclear accumulation and elevated CK1δ levels. These kinetics have not previously been reported. We also show that proteasome inhibition with MG132 enhance centrosomal staining, indicating that centrosomal binding sites are not saturated. Together, the data show that CK1δ equilibrates rapidly between its binding partners. 

      (2) Integration of localization with protein stability – We relate the known localization patterns of WT CK1 and the kinase-dead mutant K38R to CK1 degradation dynamics and further compare them to the tau-like kinase mutant CK1δ-R1178Q. This integration of subcellular localization data with turnover mechanisms provides new mechanistic insight.

      (3) Comprehensive regulatory model – In the revised manuscript, we now include a schematic summarizing how CK1δ is posttranslationally regulated via subcellular shuttling, nuclear degradation, and dynamic interactions with binding partners (Figure EV5C). To our knowledge, such a comprehensive view of CK1δ regulation, linking localization, stability, and partner association, has not been presented before.

      We believe these additions clearly distinguish our findings from prior reports and highlight the novel aspects of our study.

      The formation of PER and CRY and CK1 complexes likewise is well established. The finding that formation of multiprotein complexes stabilize otherwise unstable over-expressed proteins is interesting but not novel.

      We fully agree that the existence of PER–CRY–CK1 complexes is well established. It is also known that PER2 stabilizes CRY1 by occupying the FBXL3 binding site and that CRY1 promotes the nuclear accumulation of PER2. We do not present these established interactions as novel findings.

      Our novel contribution, as outlined above, is the discovery that the shuttling and subcellular localization of PER2 and CRY1 are mutually dependent on their expression ratio. Specifically, we show for the first time that the steady-state shuttling distribution PER2 alone is cytosolic due to its rapid nuclear export wherease CRY1 is predominantly nuclear (known). Given that CRY1 facilitates the nuclear import of PER2 (known) and that a PER2 dimer can bind either one or two CRY1 molecules, our data showing that cytoplasmic PER2-CRY1 foci contain less CRY1 than nuclear foci lead us to conclude that cytoplasmic PER2 complexes contain one CRY1 molecule, while nuclear complexes contain two.

      This model provides a mechanistic explanation for the distribution of PER2 between the cytosol and nucleus and for the relatively lower cytosolic CRY1 levels. Moost importantly, we further show (for the first time) that CK1-mediated phosphorylation of PER2 displaces CRY1. This phosphorylation event would produce PER2 dimers with one or no CRY1 bound, promoting their export to the cytosol. We believe this represents a novel and potentially important mechanism for regulating circadian clock function.

      The results from many of the imaging assays are not quantitated, and the figures often show single cells. It's hard to draw statistical significance from these.

      The phenotypes we report here are result of multiple technical and biological replicates (n >3). Image analysis and statistical analysis was performed when required. We show additional examples in the EVs.

      There are a number of phenomena seen whose physiological relevance is unclear. In figure 1, forced over-expression of CRY1 and PER2 leads to formation of nuclear foci. It is unlikely these foci form at non-overexpressed levels, and so the general interest and relevance is not high nor investigated. This reduces the impact of the finding.

      It has been shown that PERs and CRYs do not form thermodynamically stable, large (detectable) foci under physiological conditions, as we have stated in the manuscript. Whether these proteins have the propensity to form smaller, more dynamic structures of physiological relevance is an interesting question that could be explored elsewhere, but it is not relevant to our study. In our work, these foci are simply convenient markers for analyzing the interaction and subcellular (co)localization of clock proteins under investigation. In the revised version, we have kept the analysis of these foci and the discussion of their potential relevance to a minimum in order to avoid confusion and unnecessary discussions.

      The finding that CK1δ is keep in the dephosphorylated state by binding to PER has been established previously by Johnson and colleagues and should perhaps be mentioned (Qin JBR 2015 (doi: 10.1177/0748730415582127).

      There is clearly a misunderstanding here. Qin et al.’s data show that, in a cell-free system, CK1ε phosphorylates PER2 and also autophosphorylates its C-terminal tail (autoradiograph, Fig. 1E).  

      However, because PER2 phosphorylation is carried out by CK1ε that is tightly anchored to PER2, there is competition between PER2 phosphorylation and tail autophosphorylation. As a result, the kinetics of tail phosphorylation are slower (Fig. 3B and quantification in C) than those observed with free CK1ε (as seen in the presence of the p53 substrate, Fig. 3A,C). We believe that his is also happening in the cell.

      Author response image 1.

      Our data, in contrast, address a different point. It has been known from the Virshup lab for decades that CK1δ/ε undergo futile cycles of (auto)phosphorylation and dephosphorylation, resulting in an active, dephosphorylated kinase in cells because cellular phosphatases are more efficient than CK1 autophosphorylation. We now show that CK1δ is also efficiently dephosphorylated when bound to PER2 (Fig. 3). Nevertheless, despite dephosphorylation of PER2-bound CK1δ, PER2 itself becomes hyperphosphorylated, indicating that cellular phosphatases act differently on these two substrates. To clarify this point, we inhibited phosphatases with calyculin A (CalA). Under these conditions, both PER2 and PER2-bound CK1δ became efficiently hyperphosphorylated (new Fig. 3).

      The degradation of kinase-active but not inactive CK1 is only shown here with 50-fold overexpressed protein so it's interesting, but the relevance to circadian biology is not made clear. The fact that over-expressed CK1 is degraded primarily in the nucleus is interesting, but needs further characterization - is this affected by the epitope tag? Is it true of endogenous CK1 or only over-expressed CK1? Is this not seen with e.g. other forms of CK1, e.g. lacking the C-terminus?

      The observation that unassembled kinase is rapidly degraded is most clearly demonstrated by overexpression experiments. However, Fig. 3 shows that overexpression of CRY1 and PER2 leads to the accumulation of elevated levels of endogenous CK1δ (untagged), indicating that endogenous kinase is likewise degraded in the absence of a stabilizing binding partner. In addition, we present data showing that overexpression of tagged CK1δ reduces the levels of endogenous, untagged CK1δ, further supporting the conclusion that unassembled endogenous CK1δ is unstable and subject to degradation.

      Further characterization of the CK1 degradation pathway is of considerable interest and could form the basis of a separate study, particularly to identify the components that mediate activity-dependent nuclear export and activity-dependent nuclear degradation. The Δ-tail kinase is expressed at very low levels, although interpretation is complicated by the possibility that this reflects pleiotropic effects.

      The final figure, showing that nuclear CK1 is the form responsible for shortening rhythms, is interesting. Is this because massive increases in nuclear CK1 alter PER, or BMAL/CLOCK, or proteasome activity?  

      Our data show that cells expressing either nuclear or cytosolic CK1 are viable, proliferate normally, and maintain a functional circadian clock. Therefore, overexpression of the kinase does not produce pleiotropic effects.

      To assume it's due to PER phosphorylation is in disagreement with the studies of Meng et al. Neuron 2008 DOI 10.1016/j.neuron.2008.01.019.

      The data are not in disagreement with Meng et al.; in fact, they align quite well. Meng et al. showed that CK1ε-tau shortens the circadian period, which we had also previously reported for CK1δ-tau-like (Marzoll et al., 2022). We now demonstrate that CK1δtau-like is enriched in the nucleus, contributing to its period-shortening phenotype. Furthermore, we show that active CK1δ (but not CK1δ-K38R) promotes cytoplasmic accumulation of PER:CRY complexes, consistent with PER2 degradation in the cytosol as described by Meng et al.

      Taken together, these findings suggest that PER proteins acquire their CK1 in the nucleus, and this interaction determines the circadian period length. Following a time delay—set by the kinetics of PER2 phosphorylation—PER2:CRY complexes are exported to the cytosol along with their bound CK1, where they are subsequently degraded.

      Reviewer #2:

      Interactions between the circadian clock proteins PER1/2 with CK1d/e and CRY1/2 influence each of their stability, subcellular localization, and activity, as countless studies over the last two decades have shown. However, many questions still remain, especially in light of newer models of the transcription-translation feedback loop (TTFL) in which the repression phase relies on two distinct mechanisms, a phosphorylation-dependent displacement of the transcription factor by CK1-PER-CRY complexes from DNA early in repression, and a CRY1dependent sequestration of the transcription factor activation domain later in repression. In particular, questions remain about mechanisms triggering nuclear entry/export and activity of these proteins in the cytoplasm and nucleus. 

      Here, the authors utilize a system of induced and/or transient overexpression of proteins with or without with fluorophores to track subcellular localization, stability, and interactions. As the authors point out throughout the manuscript, the overexpression of these clock proteins often causes them to behave differently from the endogenous proteins. It looks as though the authors have done their best to account for these changes, and they have certainly been rigorous in pointing them out, but there is concern that some of the conclusions may be influenced by this overexpression. For example, the relevance of work related to the overexpression-dependent foci is unclear. 

      Same answer as to Reviewer 1: It has been shown that PERs and CRYs do not form thermodynamically stable, large (detectable) foci under physiological conditions, as we have stated in the manuscript. Whether these proteins have the propensity to form smaller, more dynamic structures of physiological relevance is an interesting question that could be explored elsewhere, but it is not relevant to our study. In our work, these foci are simply convenient markers for analyzing the interaction and subcellular (co)localization of the clock proteins under investigation. In the revised version, we have kept the analysis of these foci and the discussion of their potential relevance to a minimum in order to avoid confusion.

      The findings that the stability of the kinase depend on localization, its intrinsic activity, and interaction with PER2 are interesting and important. Use of the CKBD deletion to show that CK1 stabilization depends on its anchoring interaction with PER2 is a nice touch. The authors bring up an excellent point that most of the potential phosphorylation sites on PER1 and PER2 have not been functionally characterized aside from the phosphoswitch mechanism. Their observation that CK1 eventually induces cytoplasmic localization of the CK1-PER-CRY1 complex and the release of CRY1 is intriguing. In particular, the finding that pretreatment of PER2 with CK1 in vitro blocked its ability to interact with CRY1 is very interesting. However, the absence of mechanistic data to explore this in more detail limits the impact of this conclusion. Using the system they have established here to identify the site(s) on PER2 and/or CRY1 that lead to this would help to solidify this work and increase the impact of this work. Overall, there are some interesting findings here but the inclusion of some competing viewpoints and mechanistic data would strengthen the impact of the work.

      Major

      (1) The characterization of the tau-like CK1 mutant R178C as less active than the wild type enzyme is not entirely correct-it is less active on the FASP region as described, but it has increased activity on S478 in the phosphodegron that is independent of inhibition from the FASP region (Gallego et al. PNAS, 2007 and Philpott et al. eLife, 2020). It is still possible that some of the period shortening effects of the mutant could arise from enhanced nuclear accumulation, but the oversimplified description of the mutant as less active should be corrected.  

      In the revised version, we discuss that the enhanced nuclear localization of the Tau-like kinase may contribute, at least in part, to period shortening, similar to how forced nuclear overexpression of wild-type kinase also shortens the period. We emphasize, however, that CK1 Tau is compromised in its priming-dependent activity, whereas its priming-independent activity is context-specific and enhanced toward the β-TrCP site.

      (2) One of main conclusions from the paper, that CK1 induces cytoplasmic localization of the CK1-PER2-CRY1 complex and subsequent release of CRY1 would be strengthened significantly by identifying the phosphorylation site(s) responsible for the cytoplasmic localization of the complex and the release of CRY1. The system they have developed here seems ideal to identify these sites.

      We fully agree with the reviewer. We substituted the known phosphorylation sites in PER2 surrounding the CRY-binding domain, but this had no effect on the phosphorylationdependent release of CRY1. Therefore, a more systematic analysis will be required, including the possibility that phosphorylations in CRY1 itself may contribute. To this end, we are generating PER2 and CRY1 variants in which all Ser/Thr residues are replaced by Ala. Using these constructs alongside the wild-type versions, we will by PCR systematically create hybrids in which specific regions containing phosphorylation sites are exchanged.

      Nevertheless, this will require considerable time and effort, and we believe this investigation exceeds the scope of the present manuscript and will address it in future work.

      (3) The concept of delayed release of CRY1 presented here is an interesting one. It's unclear why the authors have also not incorporated prior findings (Ukai-Tadenuma et al. Cell, 2012, Koike et al. Science, 2012) that peak levels of CRY1 are expressed in a later phase than CRY2, PER1, and PER2. It seems like figure EV6 should reflect the observation that CRY2 is the predominant cryptochrome present during early repression (Koike et al. Science, 2012).

      The reviewer is absolutely right: the expression phases of CRY1, CRY2, PER1, and PER2 are important. I have recently discussed these issues in detail in a News & Views article in The EMBO Journal, commenting on a paper by Smyllie et al. In this News & Views article, I discuss that the presently available data suggest that CRY1 is always present throughout the circadian cycle and keeps circadian transcription partially repressed even at peak phases of expression. In the revised version, I refer to these publications, including those mentioned by the reviewer. However, I would like to keep the model presented in the supplementary figure as simple as possible and specifically focused on the work presented in this manuscript, rather than presenting a comprehensive conceptual model of the circadian clock.

      (4) The model presented in figure EV6 and described throughout the text shows that PER-CRY complexes interact with CK1 in the nucleus, and not in the cytoplasm prior to nuclear entry. Prior work on endogenous protein complexes has shown that CK1-PER-CRY complexes exist in the cytoplasm very early on in the repression phase (Aryal et al. Mol Cell, 2017-ref. 14 in the manuscript). Work by Sancar and colleagues (Cao et al. PNAS, 2020) also shows with endogenous proteins that CK1d has a circadian pattern of nuclear entry (or possibly retention) concomitant with PER2 that is dependent on the presence of PERs and CRYs. Together, these data seem to be inconsistent with your model. 

      We think the data are not inconsistent. The recent Smyllie et al. paper in EMBO Journal shows that PER2 is present in both the cytosol and the nucleus at all times when it is expressed, but cytosolic PER2 is not saturated with CRY, which is more nuclear. Our data demonstrate that PER2 shuttles between the cytosol and the nucleus depending on its occupancy with CRYs (see schematic Fig. 1). Occupancy, in turn, depends on expression levels and binding affinities, including those of CRY2 and PER1. Consequently, PER2 complexes could shuttle continuously throughout the circadian cycle—either because they are not saturated with CRYs due to the balance between expression levels, freely available CRY, and binding affinity, or later in the cycle because CRYs are displaced by phosphorylation. If PER2 acquires casein kinase in the nucleus early in the cycle, it will shuttle out to the cytosol together with the bound CK1. We believe this does occur, but early in the circadian cycle the saturation of PER2 with casein kinase is likely to be very low due to the limited availability of CK1 in the nucleus. I am aware that not everyone will share this interpretation point by point, but discussing it in greater length and detail exceeds the scope of the present manuscript.

      Reviewer #3:

      This manuscript by Serrano and co-workers is a tight body of work that provides much needed insights into the regulation of clock proteins by CK1D, and into the regulation of CK1D itself. While the whole paper relies on artificial overexpression of chimeric/tagged proteins that may have significant differences in the function, the stability and subcellular distribution of the endogenous proteins they are suppose to model, this limitation was been clearly stated by the authors, and nevertheless their study still provides important insights. 

      While the authors have specified which Ck1d isoform (Ck1d1) they are overexpressing in their model cell lines, they may have thought to consider that the overexpression of one Ck1 homologue may affect the endogenous expression of the other homologues and their isoforms, e.g. ck1d1 overexpression may cause an increase in Ck1d2 or Ck1e, which would in turn affect the conclusions. 

      We show in revised Fig. 3 that overexpression of CK1δ1 reduces the expression of endogenous CK1δ1/2. This is consistent with our prediction that overexpressed and endogenous CK1 (including CK1ε) compete for the same stabilizing binding partners, leading to rapid degradation of unassembled kinases.

      Moreover, the antibody they used for endogenous Ck1d (which is ab85320, also mentioned as AF12G4 but that is the clone number, not the catalogue number) is discontinued and its specificity against Ck1d1, Ck1d2 or even the highly identical Ck1e, has not been clearly demonstrated. We know from Fig 3 that it can detect Ck1d1 but it would be great if the authors would provide additional evidence for the specificity of this antibody, for example by overexpressing Ck1d1/Ck1d2/Ck1e to see really which "endogenous" Ck1 we are seeing.

      Are the three bands for example seen in Fig 4A corresponding to the different isoforms? This simple experiment would reinforce the conclusions. 

      We show in the revised figure that the antibody recognizes CK1δ1 and CK1δ2, but not CK1ε. In U2OS cells, the antibody detects a single band (Figure); we do not know whether this represents predominantly one splice isoform or both, which are not resolved. However, this distinction is not relevant for our interpretation, because overexpression of tagged CK1δ1 reduces the expression of whichever endogenous kinase is present.

      There are no minor comments, as the figures, the figure legends and main text are all of good quality and ready for publication.

      Reviewers’ Responses to Point-by-Point Response to Peer Review 

      Referee #1:

      I appreciated the additional efforts by the authors to improve the manuscript. Unfortunately, the underlying approach of forced over-expression remains artifact-prone, and has been largely supplanted by readily available knockin and targeted mutagenesis methods. Over-expression may give clues, but I think more rigorous mechanistic validation is needed to make this compelling. I cannot support publication of this manuscript.

      Referee #2:

      In their response to reviewers, the authors make the valid point that the steady state of a system is usually perturbed to study it. In this study, they have used overexpression of the clock proteins PER2, CRY1 and CK1 to study their effects on subcellular dynamics and stability. In justifying this choice, they refer to several papers that similarly overexpressed at least one of these components, stating that their time-resolved approach brings novel insights. However, there is a missed opportunity here to translate any lessons learned from overexpression studies to a system where the proteins are expressed at physiological levels and stoichiometry.

      The authors reply to reviewer 1 stating that they conclude PER proteins acquire CK1 in the nucleus, but this does not account for other studies showing an apparent PER-CK1 complex in the cytoplasm during the early phases of repression and/or a pattern of PER-dependent nuclear entry of CK1 (Lee et al. 2001, Cell; Aryal et al. 2017 Mol Cell; Cao et al. 2021 PNAS). Given that all 3 of these studies were done with native expression levels, it seems incumbent upon the authors to demonstrate that their conclusions from the overexpression study are physiologically relevant by translating them in some way to a more native system. This also addresses a point made by reviewer 2, major concern 4 that was not satisfactorily addressed by the authors. Perhaps they could validate their hypothesis of PER shuttling and interactions with CK1 or CRY1 that alter this in a native system similar to Aryal or Cao et al. with the use of nuclear export inhibitors?

      The response to reviewer 2, major concern 1 is thoughtful and much appreciated. However, simplifying the effects of the tau mutation on CK1 as having a decreased rate on priming-dependent phosphorylation but not priming-independent is not quite true-the tau mutation also decreases the rate of priming-independent phosphorylation of S662 (in humans) (Philpott et al. 2020, eLife).

      Other papers appearing in this journal seem to all include at least one major new mechanistic insight. Although the authors do a diligent job in characterizing the overexpressed proteins in this system, some of their conclusions are at odds with prior studies of the system in more native conditions, so the potential impact of this work is unclear. To verify these conclusions or test new ones (ie, that CK1 disrupts PER-CRY1 interactions), they should use their insights to generate mutations or make perturbations in a native system and demonstrate that they still hold.

      Referee #3:

      The authors have adequately addressed the reviewers' comments, and it is my opinion that the manuscript is ready for publication. It is true, as previously mentioned by other reviewers, that the evidence presented rely on overexpression, which for the other reviewers seem to preclude publication. However, I find this to be a too strict opinion.

      If the authors had indeed provided evidence using crispr-cas9-mediated genetic manipulation and tagging/mutating endogenous genes for all their experiments, thereby providing more physiological evidence of how clock proteins interact, they would probably have submitted their manuscript to an alternative journal with a higher impact.

      As it stands, it is my opinion that, considering the evidence and limitations of the study, this manuscript is a good match for the journal.

      Author Rebuttal:

      Apologies for the delayed reply regarding our manuscript. In the meantime, we have added several new experiments which address the comments of the reviewers and more. These are now included as Figures 1C, EV3, 4D, 6E, 6F, EV6D, and EV7.

      Figure 1C reinforces our observations from Figure 1B showing that induction of stably-integrated PER2 also results in accumulation of endogenous CRY1 at a timescale that is compatible with the gradual localization of overexpressed PER2 into the nucleus.

      Figure EV3 addresses several technical comments from Reviewers #3 and #1, respectively: Figure EV3A shows that our CK1δ antibody recognizes CK1δ1 and CK1δ2, but not CK1ε. Figures EV 3B and C clearly show how overexpression of our transgenic CK1δ results in decreased endogenous CK1δ which further demonstrates the rapid turnover of active kinase.

      Figure 4D addresses the comment from Reviewer #2. We clearly show that CK1δ is not kept in a dephosphorylated state by binding to PER. In addition to our direct comment to this point, Figure 4D shows that CK1δ regardless if it is expressed alone or in complex with PER2 is phosphorylated to a similar extent when the cells are treated with the phosphatase inhibitor CalA. As indicated in our direct response, we are rather more interested in the observation that cellular phosphatases act differently on PER2 compared to CK1δ despite being in the same PER:CK1δ complex (as shown by the clear stabilization of overexpressed CK1δ by co-expression of PER2).

      Figures 6E, 6F, and EV6D demonstrate that our observations from overexpression systems are also observed in a more physiological context, addressing comments from Reviewers #1 and #2. Figure 6E shows that dephosphorylation of PER2 leads to its relocalization from the cytosol to the nucleus, while Figure 6F analyzes the subcellular localization of PER2 in the context of a functional circadian clock in U2OS cells. The latter demonstrates that PER2 is predominantly nuclear early in the circadian cycle, but redistributes to the cytosol at later time points. We included these experiments in response to the reviewer’s request for a more physiological context. Since we are not a mouse lab, this cell-based system represents the most physiological model we can provide. Figure 6F show the dynamics of endogenous PER2 from DEX-synchronized cells. At early timepoints, PER2 is predominantly nuclear likely due to the incorporation of CRY1 forming the PER:CRY complex. At later timepoints PER2 is redistributed between the cytoplasm and nucleus due to PER2 phosphorylation. Importantly, these results are consistent with and recontextualize the results from Liu et al. (Xie et al., PNAS, 2023) showing the hypophosphorylated PER2 at early timepoints post-DEX is predominantly nuclear and hyperphosphoryated PER2, that appear later post-DEX is predominantly cytoplasmic.

      Finally, Figure EV7 provides a model how the subcellular distribution of CK1δ affects its assembly into the PER:CRY complex emphasizing how nuclear kinase enacts its role in the circadian clock.

      Response to Reviewers:

      We were disappointed by the categorical rejection of overexpression experiments. Without a specific discussion of why they would be inappropriate or not sufficient in the context of the work presented here, the blanket assertion that overexpression inevitably produces artifacts functions more as a rhetorical device than as a substantiated scientific argument. The fact that the term ‘physiological’ generally carries a positive connotation, whereas ‘overexpression’ is often perceived negatively, does not in itself justify the categorical rejection of experiments.

      While we appreciate that some reviewers may personally prefer alternative strategies, we believe that the suitability of any approach must be evaluated in light of the specific biological questions being addressed. I cannot see a single specific point in the reviewers’ responses indicating that any of our experiments yielded artificial results. It is true that targeted knock-in and mutagenesis methods are available, however, these approaches are simply not suited to the questions raised in this manuscript. We also fully agree that, whenever possible, insights from overexpression studies should be validated in systems with a functional clock where proteins are expressed at physiological levels, which we did using U2OS cells, and noting the compatibility of our results with those in the literature using endogenously-tagged constructs. We have cited several recent studies that have investigated the subcellular distribution and circadian dynamics of endogenous or endogenously-tagged clock proteins in mice (Cao et al, 2021; Smyllie et al, 2022, 2016, 2025) and U2OS cells (Öllinger et al, 2014; Gabriel et al, 2021; Xie et al, 2023). While we cannot substantially expand on these previous observations, we confirm them in the revised version by demonstrating the nuclear-to-cytoplasmic relocalization of PER2 in U2OS cells over the course of a circadian cycle. In addition, we show that this process is, in principle, reversible: when CK1 is inhibited with PF670, overexpressed hyperphosphorylated cytosolic PER2 becomes dephosphorylated and accumulates in the nucleus.

      Overall, we consider our approach not only complementary but also essential, as it enables us to address two key questions that would otherwise be difficult or even impossible to resolve:

      (1) Mutual impact of PER2 and CRY1 on subcellular dynamics and the role of PER2 phosphorylation

      Evidence from mouse liver (Cao et al, 2021), mouse SCN (Smyllie et al, 2022, 2025), and U2OS cells (Xie et al, 2023) indicates that a substantial fraction of PER2 remains cytoplasmic throughout its expression cycle, even in the presence of CRY1, which promotes PER’s nuclear import. The mechanisms underlying this cytoplasmic retention remain unclear, and no circadian function has yet been attributed to the cytosolic PER2 pool. Our study addresses how PER2 abundance, phosphorylation state, and stoichiometry relative to CRY1 govern their interaction and subcellular dynamics. This is physiologically relevant because PER1/2 and CRY1/2 proteins oscillate in expression and degradation out of phase, such that their concentrations, stoichiometry, and phosphorylation state vary systematically over the circadian cycle. Transient transfection and inducible overexpression combined with time-lapse microscopy are essential here, as they uniquely allow modulation of protein ratios and CK1δ levels and to resolve their dynamics.

      Previous work established that CRY1 is nuclear and promotes PER2 nuclear accumulation (Smyllie et al, 2022). Our data extend this by showing that subcellular distribution is determined by the CRY1:PER2 ratio. While CRY1 alone is nuclear we show that PER2 alone is cytoplasmic due to rapid nuclear export. Mixed conditions reveal ratio-dependent shifts: at low CRY1-to-PER2 ratios, CRY1 relocalizes to the cytoplasm, whereas at high ratios, PER2 is retained in the nucleus. We explain this behavior by PER2 dimerization: dimers bound to two CRY1 molecules remain nuclear, while dimers bound to a single CRY1 localize to the cytosol. Such species can be expected to form in a physiological context depending on binding affinities and rhythmic expression levels and ratios across circadian time. Importantly, we show that CK1δ-mediated phosphorylation destabilizes PER2 and CRY1 interactions. From this, we infer that PER2 dimers with only a single bound CRY1 transiently form and accumulate in the cytosol, consistent with the lower CRY1-to-PER2 ratio we observe in the cytosol and that has also been reported in the SCN (Smyllie et al, 2025). With continued phosphorylation, PER2 dimers lose CRY1 altogether, while the released CRY1 accumulates in the nucleus. We suggest that this mechanism supports and extends the late repressive phase of the circadian cycle. Recent data show that hypophosphorylated PER2 is predominantly nuclear, whereas hyperphosphorylated PER2 is largely cytoplasmic in mouse liver (Cao et al, 2021; Xie et al, 2023), linking our data to a physiological context.

      Taken together, these findings suggest a mechanism whereby stoichiometry, subunit composition, and CK1δ phosphorylation determine PER:CRY complex composition and localization. Crucially, these complexes and their dynamic relocalization could only be observed using inducible overexpression; knock-in strategies at endogenous levels would not be able to capture such states.

      (2) Posttranslational regulation and subcellular homeostasis of CK1δ and impact on the clock

      Previous work has shown that nuclear export of CK1δ depends on its kinase activity (Milne et al, 2001). Here, we further demonstrate that unassembled CK1δ is subject to degradation, with nuclear turnover accelerated by its catalytic activity. Thus, when evaluating the impact of CK1δ mutants on the circadian clock, one must consider not only kinase activity but also protein stability and subcellular distribution. We find that CK1δ availability for PER2 differs between cytosol and nucleus. In particular, nuclear CK1δ is limiting, and its abundance directly determines circadian period length. This is significant because subcellular CK1δ availability and posttranslational regulation have not previously been examined or incorporated into circadian clock models, as the kinase has been assumed to be non-limiting given its constant expression throughout the circadian cycle. Complex formation between CK1δ and PER is a well-established determinant of circadian timing, with CK1δ overexpression known to shorten period length. Our data explain why: the binding equilibrium between CK1δ and PER must be finely tuned. Previous studies suggested that PER associates with CK1δ in the cytosol and enters the nucleus as a PER:CRY:CK1δ complex (Lee et al, 2001; Aryal et al, 2017). Our data suggest that nuclear PER is not saturated with CK1δ. This is because levels of free, active CK1δ in the nucleus are low, owing to its rapid export or degradation by the nuclear proteasome, which limits its availability for PER binding.

      Our overexpression studies support this mechanism. NES-tagged CK1δ overexpression does not alter circadian period length, because it fails to increase nuclear CK1δ levels: Each PER molecule can coimport only one kinase, a process already occurring in wild-type cells, and the few co-imported molecules rapidly equilibrate with the nuclear pool, where they are subject to export or degradation. In contrast, NLS-tagged CK1δ overexpression directly increases nuclear kinase abundance by antagonizing export, thereby enhancing PER binding and shortening circadian period. This multilayered regulation of CK1δ stability and localization and its consequences for PER2 availability would not have been revealed without targeted overexpression. Our findings therefore fill a key knowledge gap and remain fully consistent with previous studies (Lee et al, 2001; Aryal et al, 2017; Cao et al, 2021).

      Conclusion: In sum, our findings are novel and physiologically relevant, aligning with data from mouse liver and SCN. While studies at strictly endogenous protein levels are important and necessary, perturbation of steady state is a standard strategy to uncover and observe novel mechanisms. Endogenous-level experiments would demand technically unrealistic systems (for example, even the simplest case, analyzing the subcellular dynamics of PER2 alone, would require cells lacking PER1, CRY1/2, and CK1δ/ε). Moreover, adjustment of PER2-to-CRY1 ratios cannot be achieved with stably integrated genes and of course not at physiological expression levels. Thus, inducible overexpression is not merely practical but currently the most feasible approach to dissect these dynamics. We complement our findings with data from U2OS cells with a functional clock, showing that the availability of nuclear CK1δ directly determines circadian period length. Although specific aspects of our extended model require further experimental validation, no published evidence contradicts it to date. Mechanistic discussions of the circadian clock have so far focused primarily on PER protein degradation. Our model broadens this perspective by incorporating CK1δ homeostasis, PER:CRY complex composition, subcellular localization, and their regulation by phosphorylation. In doing so, it provides a detailed framework to be critically tested and refined in future studies.

    1. Author response:

      The following is the authors’ response to the previous reviews

      Public Reviews:

      Reviewer #1 (Public review):

      This manuscript investigates how dentate gyrus (DG) granule cell subregions, specifically suprapyramidal (SB) and infrapyramidal (IB) blades, are differentially recruited during a high cognitive demand pattern separation task. The authors combine TRAP2 activity labeling, touchscreen-based TUNL behavior, and chemogenetic inhibition of adult-born dentate granule cells (abDGCs) or mature granule cells (mGCs) to dissect circuit contributions.

      This manuscript presents an interesting and well-designed investigation into DG activity patterns under varying cognitive demands and the role of abDGCs in shaping mGC activity. The integration of TRAP2-based activity labeling, chemogenetic manipulation, and behavioral assays provides valuable insight into DG subregional organization and functional recruitment. However, several methodological and quantitative issues limit the interpretability of the findings. Addressing the concerns below will greatly strengthen the rigor and clarity of the study.

      Major points:

      (1) Quantification methods for TRAP+ cells are not applied consistently across panels in Figure 1, making interpretation difficult. Specifically, Figure 1F reports TRAP+ mGCs as density, whereas Figure 1G reports TRAP+ abDGCs as a percentage, hindering direct comparison. Additionally, Figure 1H presents reactivation analysis only for mGCs; a parallel analysis for abDGCs is needed for comparison across cell types.

      In Figure 1G and 1H we report TRAP+ abDGCs as a percentage rather than density because we are analyzing colocalization of the two markers, which are very sparse in this population. Given the very low number of double-labeled abDGCs, calculating density would not be practical. In the revised manuscript we have clarified the rationale for using these measures. As noted in the current text, we did not observe abDGCs co-expressing TRAP and c-Fos; we have made this point more explicit to guide interpretation of these data.

      (2) The anatomical distribution of TRAP+ cells is different between low- and high-cognitive demand conditions (Figure 2). Are these sections from dorsal or ventral DG? Is this specific to dorsal DG, as itis preferentially involved in cognitive function? What happens in ventral DG?

      The sections shown in Figure 2 were obtained from the dorsal dentate gyrus (see Methods, “Histology and imaging”: stereotaxic coordinates −1.20 to −2.30 mm relative to bregma, Paxinos atlas). From a feasibility standpoint, it is not possible to analyze the entire longitudinal extent of the hippocampus with these low-throughput histological approaches. We therefore focused on the dorsal DG, for which there is a strong functional rationale. A large body of work indicates that the dorsal hippocampus, and specifically the dorsal DG, is preferentially involved in spatial memory and in the fine contextual discrimination that underlies pattern separation. The dorsal hippocampus is critical for encoding and distinguishing similar spatial representations, a core component of the high-cognitive demand task used here. In contrast, the ventral DG is more strongly associated with emotional regulation and affective memory processing and is less implicated in high-resolution spatial encoding. For these reasons, the present study was designed to assess TRAP+ cell distributions specifically in the dorsal DG.

      (3) The activity manipulation using chemogenetic inhibition of abDGCs in AsclCreER; hM4 mice was performed; however, because tamoxifen chow was administered for 4 or 7 weeks, the labeled abDGC population was not properly birth-dated. Instead, it consisted of a heterogeneous cohort of cells ranging from 0 to 5-7 weeks old. Thus, caution should be taken when interpreting these results, and the limitations of this approach should be acknowledged.

      We agree that prolonged tamoxifen administration results in labeling a heterogeneous population of abDGCs spanning approximately 0 to 5–7 weeks of age, rather than a precisely birth-dated cohort. This is a limitation of this approach and we have included discussion of this in more detail in the revised manuscript.

      (4) There is a major issue related to the quantification of the DREADD experiments in Figure 4, Figure 5, Figure 6, and Figure 7. The hM4 mouse line used in this study should be quantified using HA, rather than mCitrine, to reliably identify cells derived from the Ascl lineage. mCitrine expression in this mouse line is not specific to adult-born neurons (off-targets), and its expression does not accurately reflect hM4 expression.

      We agree that mCitrine is not a marker that allows localization of hM4Di as it is well known that the mCitrine can be independently expressed in a Cre independent manner in this mouse. As suggested, we have removed the figure that showed the mCitrine and have performed immunohistochemical localization of the DREADD with an antibody against the HA tag. This is now shown in Figure 5.

      (5) Key markers needed to assess the maturation state of abDGCs are missing from the quantification. Incorporating DCX and NeuN into the analysis would provide essential information about the developmental stage of these cells.

      The goal of this study was to examine activity patterns of adult-born versus mature granule cells, rather than to assess maturation state. The adult-born neurons analyzed were 25–39 days old, an age at which point most cells have progressed beyond the DCX<sup>+</sup> stage and are expected to express NeuN based on prior work. We therefore do not think that including DCX or NeuN quantification would provide additional information relevant to the aims or interpretation of this study.

      Minor points:

      (1) The labeling (Distance from the hilus) in Figure 2B is misleading. Is that the same location as the subgranular zone (SGZ)? If so, it's better to use the term SGZ to avoid confusion.

      We have updated Figure 2B, the Methods, and the main text to more explicitly localize this which it the boundary between the subgranular zone (SGZ) and the hilus.

      (2) Cell number information is missing from Figures 2B and 2C; please include this data.

      We have now added the cell number information to the figure legends. In Figures 2B and 2C, each point corresponds to a single cell, with an equal number of mice per group. The total number of TRAP<sup>+</sup> cells per mouse is shown in Figure 1F, which reports TRAP<sup>+</sup> cell densities by group.

      (3) Sample DG images should clearly delineate the borders between the dentate gyrus and the hilus. In several images, this boundary is difficult to discern.

      We made the DG-hilus boundaries clearer in the sample images to improve visualization and interpretation.

      (4) In Figure 6, it is not clear how tamoxifen was administered to selectively inhibit the more mature 6-7-week-old abDGC population, nor how this paradigm differs from the chow-based approach. Please clarify the tamoxifen administration protocol and the rationale for its specificity.

      We apologize for the confusion here. The protocol used in Figure 6 is the same tamoxifen chow–based approach as in Figure 5, differing only in the duration of tamoxifen exposure. Mice in Figure 5 received tamoxifen chow for 7 weeks, whereas mice in Figure 6 received it for 4 weeks, restricting labeling to a younger and narrower cohort of adult-born DGCs. Thus, the population targeted in Figure 6 is younger than that in Figure 5 and does not correspond to mature 6–7-week-old neurons. By contrast, the experiment in Figure 4 targets a more mature population, consisting predominantly of ~5-week-old adult-born neurons as well as mature granule cells, which are Dock10-positive and express Cre endogenously, allowing selective manipulation of this later-stage population.

      We have corrected the paragraph accordingly and clarified the age range of the labeled populations in the revised manuscript.

      Comments on revisions:

      I appreciate the authors' careful and thorough revisions. They have addressed all of my previous concerns satisfactorily, and the manuscript is now significantly strengthened. I have no further concerns.

      Reviewer #2 (Public review):

      In this study, the authors investigate how increasing cognitive demand shapes activity patterns in the dorsal dentate gyrus (DG). Using a touchscreen-based TUNL task combined with TRAP/c-Fos tagging, birth-dating of adult-born granule cells (abDGCs), and chemogenetic inhibition, they show that higher task demand increases mature granule cell (mGC) recruitment and enhances suprapyramidal (SB) versus infrapyramidal (IB) blade bias. Functionally, mGC inhibition reduces overall activity and impairs performance without disrupting blade bias, whereas inhibition of {less than or equal to}7-week-old abDGCs increases mGC activity, abolishes blade bias, and impairs discrimination under high-demand conditions. These findings suggest that effective pattern separation depends not only on overall DG activity levels but also on the spatial organization of recruited ensembles.

      The integration of touchscreen TUNL with temporally controlled activity tagging and birth-dated cohorts is technically strong. Quantification of SB-IB bias and radial/apical distributions adds anatomical precision beyond bulk activity measures. The comparison between mGC and abDGC inhibition is conceptually compelling and supports dissociable functional roles. Overall, the data convincingly demonstrate that increasing cognitive demand amplifies blade-biased DG recruitment and that mGCs and abDGCs differentially contribute to both behavioral performance and network organization.

      However, how abDGCs are integrated into the mGC network under high cognitive demand remains unresolved. Additional experiments are needed to clarify how abDGCs shape spatial recruitment patterns and whether they directly inhibit or indirectly regulate mGC activity to maintain high performance.

      Furthermore, the authors frame "high cognitive demand" as a multidimensional construct encompassing broad behavioral challenge. It would strengthen the work to delineate how local abDGC-mGC circuit interactions regulate specific task components in real time. This will require higher temporal resolution approaches, as TRAP and c-Fos labeling integrate activity over prolonged windows and primarily reflect sustained engagement rather than moment-to-moment computations.

      The central conclusion that dentate function depends on coordinated spatial recruitment rather than total activity magnitude is supported by the data, although mechanistic interpretations should be tempered given methodological limitations.

      Overall, this work advances models of adult neurogenesis by emphasizing a critical-period modulatory role of abDGCs in organizing DG network activity during high-demand discrimination. The combined behavioral and circuit-level framework is likely to be influential in the field.

      Reviewer #3 (Public review):

      This study examines the role of dentate gyrus neuronal populations, reflecting neurogenesis and anatomical location (suprapyramidal vs infrapyramidal blade), in a mnemonic discrimination task that taxes the pattern separation functions of the dentate. The authors measure dentate gyrus activity resulting from cognitive training and test whether adult neurogenesis is required for both the anatomical patterns of activity and performance in the cognitive task. The authors find that more cognitively challenging variants of the task evoked more dentate activity, but also distinct patterns of activity (more activity in the suprapyramidal blade, less in the infdrapyramidal blade). Using chemogenetic approaches they silence mature vs immature dentate gyrus neurons and find that only mature neurons (either the general population or specifically mature adult-born neurons), and not immature adult-born neurons, are required for the difficult version of the task. Inhibition of mature adult-born neurons furthermore increased overall activity in the dentate and reduced the biased pattern of activity across the blades, consistent with evidence that adult-born neurons broadly regulate dentate gyrus activity.

      Comments on revisions:

      I appreciate the efforts the authors have taken to revise this manuscript. I have only minor concerns with this revised version of the manuscript:

      Methods state that significance is defined as P<0.05 but some results are interpreted as significant when P=0.05. Either the alpha value needs to change or the interpretation needs to change.

      We have corrected the statement in the Methods section to define statistical significance as P ≤ 0.05, which aligns with how significance was interpreted throughout the manuscript.

      I believe the statistical results for group and blade effects for the ANOVAs, in Figs 2,3 & 4, appear to be switched (blade should be significant, not group).

      We thank the reviewer for pointing out this mistake. We have corrected the reported statistical results for the group and blade effects in the manuscript accordingly.

      I appreciate that sometimes there is not a perfect overlap between immunohistochemical signals, but I continue to believe that the spatially-non-overlapping TRAP and EDU signals in Fig 3 is caused by these 2 markers being in different cells. A Z-stack or orthogonal projection could verify/disprove this concern.

      We agree that limited overlap in single optical sections can raise the possibility that TRAP and EdU signals originate from different cells. However, based on our imaging conditions and inspection across focal planes, the signals are consistent with being present within the same cells, with partial spatial separation likely reflecting subcellular localization and/or sectioning effects.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Response to the Reviewers

      We thank three anonymous Reviewers for their careful examination of our manuscript. Below, we provide a point-by-point response.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      1. EVIDENCE, REPRODUCIBILITY AND CLARITY Summary

      Hubbert and colleagues describe ExTaSy, a CRISPR-Cas9-based platform for the endogenous tagging of proteins in Drosophila melanogaster. The system combines several established molecular tools into a single-vector framework: homology-directed repair (HDR) for the insertion of a 3XHA tag at the endogenous locus, piggyBac transposase-mediated near-scarless removal of a transgenic selection marker, and φC31 integrase-mediated recombination-mediated cassette exchange (RMCE) for subsequent tag swapping. The authors demonstrate the system across a set of 65 genomic loci and provide a bioinformatic pipeline to automate guide RNA and homology arm design.

      Major Comments

      1. Validation of knock-in lines is inadequate and does not reflect current standards in the field. The authors state that correct insertions were confirmed using "two PCRs per inserted fragment done with primers binding to the 5' and 3' ends of the inserted DNA and corresponding gene-specific validation primers." This strategy is well known to produce false positives, as it cannot distinguish correctly targeted single-copy integrants from concatemeric insertions at the target locus (e.g. Skryabin et al., 2020). The current standard for validating CRISPR-mediated knock-ins requires PCR amplification using primers that anneal outside the homology arms and span the entire inserted cassette. These reactions must be performed under conditions that minimise the formation of PCR chimeras, specifically low cycle numbers and use of a high-processivity polymerase. The authors should either provide data from such experiments for their characterised lines, or clearly acknowledge this limitation and qualify their efficiency estimates accordingly (see related point 2 below).

      __Response: __We originally opted for using primers that span a fragment from the inserted DNA into the genomic locus for ease of amplification, which is currently standard in the field (e.g., Kanca et al. 2022). We usually run these PCRs in a heterozygous background (before homozygous stocks are established or because tagged lines remain balanced), and the unmodified locus preferentially amplifies in a whole-fragment PCR. However, we have recently started running whole-fragment PCRs and plan to repeat them for all loci and will report the results in a revised version of the manuscript. We are also revising the manuscript to reflect the necessity (or at least preference) to perform insert-spanning PCRs.

      Reported efficiency metrics do not adequately distinguish correctly targeted integrants from marker-positive flies.

      A related concern is that many of the efficiency parameters reported in the manuscript appear to be based solely on the detection of the marker cassette. The 63.1% overall success rate, for example, seemingly reflects the recovery of DsRed-positive flies rather than of sequence validated, single-copy, on-target integrants. These are fundamentally different quantities, with only the latter being of practical value for the users of the described technique. The authors should either provide data that properly accounts for correct integration, or more carefully define what each reported metric represents and explicitly acknowledge the limitations of using marker presence as a proxy for successful knock-in.

      __Response: __The reviewer is correct that the numbers we report are DsRed-positive flies. However, most have been confirmed with end-of-fragment/locus spanning PCRs, so are on-target (although not necessarily single-copy; see comment #1). While we cannot categorically exclude off-target insertions, we have not observed any cases where the DsRed segregates independently of the targeted chromosome, which at least makes off-target insertions on other chromosomes highly unlikely. We will clarify in the text that the 63.1 % success rate relates to DsRed marker expression and insertion site-spanning PCR and acknowledge the limitations as suggested by the reviewer.

      The characterisation of tag exchange requires expansion or more careful framing of its scope.

      The possibility of exchanging tags through fly crosses rather than repeated microinjections is, in the view of this reviewer, the most practically useful feature of ExTaSy and the aspect most likely to drive community adoption. It is therefore important that this feature is characterised with sufficient rigour to allow prospective users to assess its reliability. In the current manuscript, tag exchange has been demonstrated at only five loci using a single replacement tag (sfGFP). The dataset includes one outright failure (the Met C-terminus) and one instance of an unexpected 9 bp insertion at the recombination site, leaving the success rates and failure modes across a broader range of loci and tags uncharacterised. The authors should either expand the tag exchange experiments to cover a more representative set of conditions, or frame the current data explicitly as a proof of concept and limit their conclusions about the practical utility of tag exchange accordingly. In either case, the value of this work to the community would be substantially increased if a collection of donor lines carrying the most commonly used tags for different applications, as the authors themselves enumerate in the Discussion, were generated and deposited at a public stock centre such as the VDRC concurrent with publication. On this note, it is also worth flagging that at present the plasmids described in this study have not yet been deposited at Addgene or the European Plasmid Repository, and that fly lines are available only on request. For a methods paper aimed at community adoption, deposition of reagents in publicly accessible repositories at the time of publication is the expected standard.

      __Response: __We are in the process of increasing the number of fly stocks for which tags have been exchanged and will be able to provide a more rigorous characterization with an updated version of the manuscript. We are also working on additional swap lines (for example T2A-GAL4). Regarding submission of the materials to relevant databases, we are in the process of depositing the plasmids on Addgene. We plan to deposit the swap lines and other toolkit stocks (new hs-Flp, vas-int lines as well as pBac transposase lines) at the VDRC or BDSC. To make the tagged fly lines viable for distribution via the VDRC, we are working to increase their numbers, and we plan to publish them separately as a resource, where we also plan to characterize the expression of more transcription factors and their isoforms in greater detail.

      The Introduction should better reflect the current state of the field, including explicit comparison with MiMIC and CRIMIC.

      The introduction would benefit from a clearer distinction between transgene-based approaches that introduce additional gene copies and true CRISPR-mediated knock-ins at the endogenous locus. As it stands, the discussion of prior methods does not sufficiently acknowledge that CRISPR-based knock-in is already the standard approach in Drosophila, and that the individual techniques employed in ExTaSy are well established. Notably, the MiMIC and CRIMIC systems (Nagarkar-Jaiswal et al., 2015; Li-Kroeger et al., 2018), which also support RMCE-based tag exchange at endogenous loci and for which large collections of lines are already publicly available, are not adequately discussed. These are arguably the closest comparators to ExTaSy, and the authors should explicitly address how their approach differs from and offers advantages over this existing framework, particularly given that MiMIC/CRIMIC insertions can also tag internal sites and thus avoid some of the terminus-specific complications described here.

      __Response: __We will expand the introduction and the discussion to give more reference to other resources for endogenously and exogenously tagged genes in Drosophila and compare ExTaSy in greater detail with other methods, highlighting advantages and disadvantages of each and making clear that RMCE-based tag exchange and marker removal are not novel inventions.

      • *

      Minor Comment

      The labelling of sgRNA target sites in Figure 1 is inaccurate and should be corrected.

      In Figure 1, the sgRNA target sites are annotated with triangles labelled "PAM synth." The presence of a PAM is necessary but not sufficient to define a target site; the label should therefore be changed to "target site" or an equivalent term. Additionally, the Methods section incorrectly expands PAM as "primary adjacent motif"; the correct expansion is "protospacer adjacent motif."

      __Response: __The labelling in Figure 1 will be changed and the PAM abbreviation corrected.

      Could the fly crossing scheme in Figure S3 be simplified?

      In the scheme in Fig. S3 the second step seems to be intended to introduce the hs-Flp and vase-Int transgenes. Would it not be possible to already incorporate the Integrase into the swap fly line when it is made and the hs-Flp into the ExTaSy line, thereby saving one generation?

      __Response: __This would in principle be possible; however, we prefer to keep the lines “clean” in case a tag exchange is not desired, and so this would require an initial crossing step. We therefore prefer the crossing scheme as it is.

      Figure 1F has no call out in the main text.

      __Response: __This will be corrected.

      Line 155: What was the reason for the low survival rate? Is this likely to be indicative of a problem during marker removal, or a stochastic event as not all fly crosses are always productive (bad food, early death of flies, etc.)?

      __Response: __This was a stochastic event. The fly line we used for expression of piggyBac transposase (BDSC_8285) is generally not growing well, and we could only use one eighth of all offspring to ensure correct segregation. We will make this clear in the text.

      Line 160: What is the N number of "all cases"?

      __Response: __This will be changed to “We performed Sanger sequencing for one established line for each of the 17 loci and confirmed clean excision of the piggyBac sites in all cases.”

      Scale bars are missing in Fig. 3g,h.

      __Response: __These will be included.

      • *

      Line 219: The labeling of the panels got mixed up. Panel F does not show an immunostaining.

      __Response: __The labeling will be corrected.

      Line 226 and Fig. 3h: It is unclear what area is shown in the inlay. The overview image highlights three POIs, but none seem to fit the inlay.

      __Response: __The images were indeed misleading as the inlay did not show a magnification of the same focal plane. We will show the inlay together with the overview of the corresponding focal plane as part of Supplementary Figure 5 and will amend the text accordingly.

      Line 233: Why was the transgenic marker not removed? The authors want to highlight the easy and advantage of marker removal, so leaving in the marker is an odd choice.

      __Response: __In this case, we observed that flies become homozygous even with the marker, so we assumed that a marker removal would not be necessary. We are currently performing additional experiments to remove the marker and repeat the staining, which we will submit with a revised version of the manuscript.

      Line 250: Why was only one isoform of hth tagged? Without a rational this seems to be an odd choice, in particular since the authors seem to suggest in the introduction (Line 38) that a disadvantage of previous technologies is the tagging of only selected isoforms.

      __Response: __While expanding the introduction (see comment #4), we will also rephrase it to highlight that current CRISPR-based methods (MiMIC and CRIMIC) are designed to tag all isoforms simultaneously or select isoforms, whereas overexpression constructs are limited to one isoform. In contrast, ExTaSy allows tagging of all isoforms that share a terminus. We will emphasize advantages and disadvantages in the discussion. In the case of hth, three different C-termini are annotated, and we are currently performing experiments to also tag the other termini and co-stain them with Ubx. We will submit the results in a revised version of the manuscript.


      Reviewer #1 (Significance (Required)):

      SIGNIFICANCE

      ExTaSy assembles a set of well-established tools, namely CRISPR-mediated HDR, piggyBac-based marker excision, and φC31-mediated RMCE, into a unified, single-vector framework for endogenous protein tagging in Drosophila. The individual components have all been described and are in routine use in the field; the conceptual advance is therefore limited. Nevertheless, the integration of these features into a streamlined platform with accompanying automated design software represents a practical contribution that is likely to be of genuine utility to the Drosophila community, particularly for laboratories without specialist transgenesis infrastructure.

      The possibility of tag exchange by fly crossing is the most distinctive feature of the system. However, as discussed above, this is currently demonstrated at only five loci with a single replacement tag, which limits the conclusions that can be drawn about its generality. More broadly, ExTaSy employs well-proven strategies throughout, which is a source of reliability but also means that the study does not incorporate more recent developments in the field. For example, approaches based on single-strand annealing, such as the recently described Seed/Harvest system (Aguilar et al., 2024), can achieve entirely scarless marker removal and thus circumvent the TTAA scar left by piggyBac excision, a limitation the authors themselves acknowledge may reduce expression at modified N-terminal loci. Similarly, the current system is restricted to N- and C-terminal tagging. Given that the goal of endogenous tagging is to minimally perturb protein function, and given the now widespread availability of high-quality protein structure predictions for the Drosophila proteome, a modern tagging platform might be expected to use structural modelling to identify optimal insertion sites irrespective of their location. These are not oversights that diminish the practical value of the current work, but highlight that this study does not always operate at the cutting edge of method development in this area. A brief discussion of these more recent developments in the context of ExTaSy's design choices would usefully situate the work within the broader landscape and help readers understand both what the system offers today and where improvements are likely to come from.

      __Responses: __

      • As stated above, we are currently performing experiments to further validate the tag exchange.
      • Regarding the SEED/Harvest system, we have considered this; however, this would leave both flanking attP/attB sites at the genomic locus rather than only the site between the tag and the CDS. Both sites would have to be incorporated into the CDS or they would leave an even bigger scar. Additionally, since SEED/Harvest relies on micro-homology between two tag halves, it would require removal of the transgenesis marker before tagged lines become usable. Our system is advantageous in that C-terminally tagged lines can usually be used immediately. However, we will refer to the paper by Aguilar et al. and discuss how a similar system could be incorporated into ExTaSy.
      • Regarding structure-function predictions, these could be incorporated into the bioinformatic pipeline. It would then be possible to modify ExTaSy to introduce tags internally together with a SEED/Harvest-like modification. We will include this in the discussion.

        Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Summary

      Hubbert et al. describes ExTaSy (Exchangeable Tagging System), a method for endogenous protein tagging in fruitflies. The technique attempts to address some limitations of current tagging strategies, such as non-physiological expression from transgenes, disruption of the target gene, and limited usefulness of a single tag type. The basic approach is not novel, rather it effectively incorporates ideas from several previously published methods:

      • Crispr-based release of the HDR donor from the backbone in vivo (Kanca et al., 2019 and 2021).
      • PBac scarless tagging (flycrisprdesign)
      • In vivo RMCE to swap out tags (Nagarkar-Jaiswal et al., 2015) Although not novel, the authors show the completeness and effectiveness of the approach. They were able to tag genes across multiple chromosomes, with knock-in rates comparable to other approaches, and demonstrate tag swapping through RMCE. Overall, this work introduces a versatile and modular platform that combines several previous innovations into a single effective package.

      Major comments

      1.The manuscript would benefit from a more upfront discussion of how ExTaSy relates to existing methods. As currently written, the implies a higher degree of novelty than is warranted, since ExTaSy combine several previously established approaches, including, as already noted. While this is valuable, the authors should more clearly acknowledge in the abstract and introduction that the primary advance is the unification and streamlining of these existing technologies into a single platform, rather than the introduction of fundamentally new components.

      __Response: __While we did cite most of the publications mentioned by the reviewer, we will make clearer that our system combines several previously established Drosophila systems and is not per se a novel invention. We will expand the introduction and discussion to reflect this and cite additional publications.

      • *

      2.Comparison to prior systems. The manuscript should include a direct comparison to existing tagging pipelines. For example: What practical steps are eliminated relative to prior approaches? Does ExTaSy reduce the number of injections or constructs required? How does the workflow differ in terms of time, cost, or technical expertise? This is vaguely addressed in the discussion, but more specific and clear comparisons would improve things for the reader who is trying to decide which method to use. For example, how does this strategy directly compare with the protein trap alleles described in Kanca et al., 2022? This could be done as a supplemental table.

      __Response: __A similar concern has been raised by reviewer #1 (comment #4). We will expand the introduction and the discussion to compare ExTaSy in more detail with other methods, highlighting advantages and disadvantages of each.

      3.Only 4 successful RMCE swaps are presented. This is too few to make a confident conclusion about the efficiency. The authors should do at least 4 more and include negative data.

      __Response: __A similar point has been made by reviewer #1 (comment #3). We are in the process of expanding the number of fly stocks for which tags have been exchanged and will be able to provide a more rigorous characterization with an updated version of the manuscript.

      4.Some discussion of the potential limitations of the linker from the residual att sites is needed.

      __Response: __We will include this in the discussion.

      Minor comments

      1.It would be helpful to include a workflow overview figure summarizing the full pipeline.

      __Response: __We will include such a figure in the supplement.

      2.Line 124: Most genes we tagged at the C-terminus were homozygous viable, indicating limited detrimental effects. Need to include the numbers? What is "most genes."

      __Response: __We will include these numbers in the text.

      3.Briefly explain how the tested genes were selected (e.g., random, representative, biased toward certain classes), as this could affect interpretation of generalizability. If most of the genes are essential for viability, this makes the viability of tagged lines more impressive.

      __Response: __This is an excellent suggestion, and we thank the reviewer for pointing this out. We have mainly tagged genes that are relevant for work in our labs and for collaborators, focusing almost entirely on transcription factor-encoding genes that are largely essential for normal development. We will include a brief discussion of this.

      Reviewer #2 (Significance (Required)):

      Significance

      1.General assessment: This study presents ExTaSy, a practical and well-executed platform for endogenous protein tagging in Drosophila. Its main strength is the integration of multiple existing technologies into a streamlined workflow that enables tagging, marker removal, and tag swapping. The system is clearly functional and broadly applicable. However, the conceptual novelty is limited, and the manuscript should more explicitly frame the work as an engineering advance. Tagging and RMCE efficiencies are moderate.

      2.Advance: ExTaSy represents a technical advance that combines CRISPR HDR tagging, piggyBac scarless editing, and RMCE into a single platform. The biggest improvement is the ability to tag once and flexibly swap tags via crosses, reducing the need for repeated genome engineering. This extends existing methods by improving experimental flexibility.

      3.Audience: This work will primarily interest a specialized audience in Drosophila genetics, CRISPR technologies, and functional genomics, with broader relevance to researchers developing tagging systems in other model organisms.

      4.Field of expertise: CRISPR screening, Drosophila genetics, functional genomics. No limitations on my ability to evaluate.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      This methods paper is targeting the long-standing ambition of how to most efficiently tag proteins at the endogenous gene locus in Drosophila. Since the invention of CRISPR-Cas9 many genes have been successfully modified in Drosophila, but the community is still lacking a large collection of tagged proteins under endogenous control made with the same method.

      This manuscript is using a small tag, 3xHA, which supposedly is easier to integrate, and the design allows to then swap the tag with larger fluorescent tags, solely by fly crossing. Then, the dsRed or white markers, allowing identification, can be removed with a biggybac recombinase leaving only a small scar. However, attP/B/R scars do remain. Design and cloning appear straightforward. Overall, this is an interesting strategy.

      However, the manuscript falls short in really describing the resource, apart from the cloning design. A more rigorous analysis of a number of lines should be presented to better judge if the strategy practically works. It is quite disappointing to see that only 2 or 3 genes/proteins were analysed here in a bit more detail. This does not sound like a very straightforward resource that aims to go large scale.

      Major comments:

      1. The important novelty here is not only the design that allows high-throughput cloning but more importantly that the tagged lines are actually correct and functional. To present this better, I suggest to rearrange Figure 1 to show the flow: 65 constructs cloned, 41 "successfully" inserted. Of how many the dsRed marker was removed, of how many expression or function was tested? Hence the reader knows about the current state of the resource. These numbers would be informative to have in the abstract, too.

      __Response: __We will include these numbers in the abstract. Reviewer 2 asked for an overview figure of the workflow, which we will include as a supplementary figure, where we can also include numbers as suggested by this reviewer.

      The 41 tagged gene insertions need at least some basic characterisation to verify that they are at the correct place or make a functional protein. Which genes were chosen? I do not see 41 genes tagged in the table provided. I supposed the N-terminal tags should initially be loss of function. Are the N-term lines lethal when inserted in an essential gene? Again, this could be shown in an overview, instead by a non-quantitative statement in the text.

      __Response: __We have verified the insertion site of the lines with genotyping PCR. We will include a table to show in more detail which genes were tagged at which terminus, and which protein isoforms are captured by the respective tag.

      • *

      How many of the 41 tagged proteins are functional? The authors only provide information on Ubx-3xHA (functional) and Mef2-3xHA (non-functional), which I find weak.

      __Response: __We will include this information in the table mentioned in the above comment.

      Stainings are only shown for 2 proteins, Ubx-GFP and Exd-3xHA. How about the others?

      __Response: __We are currently in the process of using ExTaSy to establish a library of tagged fly lines, which we intend to characterize in more detail and publish separately. For the current manuscript, we prefer to focus on the methodology of the tagging system itself.

      I am not sure about how to calculate the transgenesis rates, but strictly speaking to ones that did not result in an insertion should also be counted for the statistics, I guess.

      __Response: __There is indeed no commonly agreed upon way to calculate these rates, and it is done differently in different publications. We felt that metrics that discriminate between the overall success rate (i.e., all those injections that lead to transgenics) and the success rate within successful injections would be most useful. We will try to make clear in the text where we refer to all attempts and where we exclusively refer to the successful ones.

      Minor comments:

      1. The introduction states that ExTaSy would tag all isoforms of genes. However, I find this an overstatement, as for complex genes tagging at the one place cannot always label all isoforms, see the Hth line generated here (Iso E).

      __Response: __This was indeed badly phrased and we will correct the wording also in response to reviewer #1 comment #14 to reflect that overexpression constructs are limited to a specific isoform, whereas ExTaSy enables simultaneous tagging of all isoforms that share a terminus.

      Why does it matter on which chromosome the target gene is? This can be moved to supplement. I would rather like to know what the genes are.

      __Response: __We presume that the reviewer refers to Figure 1, where we show the success rates for individual chromosomes. We felt that the lower success rate for injections targeting gene on chr3 (which is, as we describe, due to lower survival of the injection line) warranted this separation by chromosome. As stated above, we will include a list of tagged genes as a table.

      **Referees cross-commenting**

      I agree with the 2 other reviewer's points. In particular that the knock-in lines need better verifications. This was also my major point.

      __Response: __As also stated for reviewer #1 comment #1, we have now begun to run whole-fragment PCRs for all loci to investigate this further and will report the results in a revised version of the manuscript.

      Reviewer #3 (Significance (Required)):

      The methodology presented here is per se not really new. The 3xP3-dsRed eye marker is standard, its removal by biggbac transposase has been done before and RMCE to change the tagging cassettes with attP/B is done since many years. The latter has the disadvantage to not be seamless, as one attR site remains, which is translated, the other attR site remains in the 5'- or 3'-UTR, which can have an effect. U6-driven sgRNA expression is also standard.

      __Response: __We will make clearer that our system combines several previously established Drosophila systems and is not per se a novel invention. We will expand the introduction and discussion to reflect this and cite additional publications.

      The design includes the sgRNA and the HDR template cassette in a single vector, which is smart and makes cloning straight forward. Again, the paper would be stronger if the list of all cloned clones would be listed (are 65 all that were clones or all that were injected?

      __Response: __We will include this as a table.

      As the authors do not rigorously test the function of the tagged genes, it is hard to judge how valuable the pipeline is. This can be easily solved by providing more data that support the easy, high-throughput exchange tagging pipeline that produces tagged Drosophila lines that are useful to the community.

      __Response: __As stated above, we plan to publish a more detailed analysis of tagged lines as a separate resource paper. We will state in the manuscript which lines were homozygous viable before and after marker removal, which gives at least an indication of whether the tagged protein is functional.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      This methods paper is targeting the long-standing ambition of how to most efficiently tag proteins at the endogenous gene locus in Drosophila. Since the invention of CRISPR-Cas9 many genes have been successfully modified in Drosophila, but the community is still lacking a large collection of tagged proteins under endogenous control made with the same method. This manuscript is using a small tag, 3xHA, which supposedly is easier to integrate, and the design allows to then swap the tag with larger fluorescent tags, solely by fly crossing. Then, the dsRed or white markers, allowing identification, can be removed with a biggybac recombinase leaving only a small scar. However, attP/B/R scars do remain. Design and cloning appear straightforward. Overall, this is an interesting strategy. However, the manuscript falls short in really describing the resource, apart from the cloning design. A more rigorous analysis of a number of lines should be presented to better judge if the strategy practically works. It is quite disappointing to see that only 2 or 3 genes/proteins were analysed here in a bit more detail. This does not sound like a very straightforward resource that aims to go large scale.

      Major comments:

      1. The important novelty here is not only the design that allows high-throughput cloning but more importantly that the tagged lines are actually correct and functional. To present this better, I suggest to rearrange Figure 1 to show the flow: 65 constructs cloned, 41 "successfully" inserted. Of how many the dsRed marker was removed, of how many expression or function was tested? Hence the reader knows about the current state of the resource. These numbers would be informative to have in the abstract, too.
      2. The 41 tagged gene insertions need at least some basic characterisation to verify that they are at the correct place or make a functional protein. Which genes were chosen? I do not see 41 genes tagged in the table provided. I supposed the N-terminal tags should initially be loss of function. Are the N-term lines lethal when inserted in an essential gene? Again, this could be shown in an overview, instead by a non-quantitative statement in the text.
      3. How many of the 41 tagged proteins are functional? The authors only provide information on Ubx-3xHA (functional) and Mef2-3xHA (non-functional), which I find weak.
      4. Stainings are only shown for 2 proteins, Ubx-GFP and Exd-3xHA. How about the others?
      5. I am not sure about how to calculate the transgenesis rates, but strictly speaking to ones that did not result in an insertion should also be counted for the statistics, I guess.

      Minor comments:

      1. The introduction states that ExTaSy would tag all isoforms of genes. However, I find this an overstatement, as for complex genes tagging at the one place cannot always label all isoforms, see the Hth line generated here (Iso E).
      2. Why does it matter on which chromosome the target gene is? This can be moved to supplement. I would rather like to know what the genes are.

      Referees cross-commenting

      I agree with the 2 other reviewer's points. In particular that the knock-in lines need better verifications. This was also my major point.

      Significance

      The methodology presented here is per se not really new. The 3xP3-dsRed eye marker is standard, its removal by biggbac transposase has been done before and RMCE to change the tagging cassettes with attP/B is done since many years. The latter has the disadvantage to not be seamless, as one attR site remains, which is translated, the other attR site remains in the 5'- or 3'-UTR, which can have an effect. U6-driven sgRNA expression is also standard. The design includes the sgRNA and the HDR template cassette in a single vector, which is smart and makes cloning straight forward. Again, the paper would be stronger if the list of all cloned clones would be listed (are 65 all that were clones or all that were injected?

      As the authors do not rigorously test the function of the tagged genes, it is hard to judge how valuable the pipeline is. This can be easily solved by providing more data that support the easy, high-throughput exchange tagging pipeline that produces tagged Drosophila lines that are useful to the community.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary

      Hubbert et al. describes ExTaSy (Exchangeable Tagging System), a method for endogenous protein tagging in fruitflies. The technique attempts to address some limitations of current tagging strategies, such as non-physiological expression from transgenes, disruption of the target gene, and limited usefulness of a single tag type. The basic approach is not novel, rather it effectively incorporates ideas from several previously published methods:

      • Crispr-based release of the HDR donor from the backbone in vivo (Kanca et al., 2019 and 2021).
      • PBac scarless tagging (flycrisprdesign)
      • In vivo RMCE to swap out tags (Nagarkar-Jaiswal et al., 2015) Although not novel, the authors show the completeness and effectiveness of the approach. They were able to tag genes across multiple chromosomes, with knock-in rates comparable to other approaches, and demonstrate tag swapping through RMCE. Overall, this work introduces a versatile and modular platform that combines several previous innovations into a single effective package.

      Major comments

      1.The manuscript would benefit from a more upfront discussion of how ExTaSy relates to existing methods. As currently written, the implies a higher degree of novelty than is warranted, since ExTaSy combine several previously established approaches, including, as already noted. While this is valuable, the authors should more clearly acknowledge in the abstract and introduction that the primary advance is the unification and streamlining of these existing technologies into a single platform, rather than the introduction of fundamentally new components. 2.Comparison to prior systems. The manuscript should include a direct comparison to existing tagging pipelines. For example: What practical steps are eliminated relative to prior approaches? Does ExTaSy reduce the number of injections or constructs required? How does the workflow differ in terms of time, cost, or technical expertise? This is vaguely addressed in the discussion, but more specific and clear comparisons would improve things for the reader who is trying to decide which method to use. For example, how does this strategy directly compare with the protein trap alleles described in Kanca et al., 2022? This could be done as a supplemental table. 3.Only 4 successful RMCE swaps are presented. This is too few to make a confident conclusion about the efficiency. The authors should do at least 4 more and include negative data. 4.Some discussion of the potential limitations of the linker from the residual att sites is needed.

      Minor comments

      1.It would be helpful to include a workflow overview figure summarizing the full pipeline. 2.Line 124: Most genes we tagged at the C-terminus were homozygous viable, indicating limited detrimental effects. Need to include the numbers? What is "most genes." 3.Briefly explain how the tested genes were selected (e.g., random, representative, biased toward certain classes), as this could affect interpretation of generalizability. If most of the genes are essential for viability, this makes the viability of tagged lines more impressive.

      Significance

      1.General assessment: This study presents ExTaSy, a practical and well-executed platform for endogenous protein tagging in Drosophila. Its main strength is the integration of multiple existing technologies into a streamlined workflow that enables tagging, marker removal, and tag swapping. The system is clearly functional and broadly applicable. However, the conceptual novelty is limited, and the manuscript should more explicitly frame the work as an engineering advance. Tagging and RMCE efficiencies are moderate. 2.Advance: ExTaSy represents a technical advance that combines CRISPR HDR tagging, piggyBac scarless editing, and RMCE into a single platform. The biggest improvement is the ability to tag once and flexibly swap tags via crosses, reducing the need for repeated genome engineering. This extends existing methods by improving experimental flexibility. 3.Audience: This work will primarily interest a specialized audience in Drosophila genetics, CRISPR technologies, and functional genomics, with broader relevance to researchers developing tagging systems in other model organisms. 4.Field of expertise: CRISPR screening, Drosophila genetics, functional genomics. No limitations on my ability to evaluate.

    4. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary

      Hubbert and colleagues describe ExTaSy, a CRISPR-Cas9-based platform for the endogenous tagging of proteins in Drosophila melanogaster. The system combines several established molecular tools into a single-vector framework: homology-directed repair (HDR) for the insertion of a 3XHA tag at the endogenous locus, piggyBac transposase-mediated near-scarless removal of a transgenic selection marker, and φC31 integrase-mediated recombination-mediated cassette exchange (RMCE) for subsequent tag swapping. The authors demonstrate the system across a set of 65 genomic loci and provide a bioinformatic pipeline to automate guide RNA and homology arm design.

      Major Comments

      1. Validation of knock-in lines is inadequate and does not reflect current standards in the field.

      The authors state that correct insertions were confirmed using "two PCRs per inserted fragment done with primers binding to the 5' and 3' ends of the inserted DNA and corresponding gene-specific validation primers." This strategy is well known to produce false positives, as it cannot distinguish correctly targeted single-copy integrants from concatemeric insertions at the target locus (e.g. Skryabin et al., 2020). The current standard for validating CRISPR-mediated knock-ins requires PCR amplification using primers that anneal outside the homology arms and span the entire inserted cassette. These reactions must be performed under conditions that minimise the formation of PCR chimeras, specifically low cycle numbers and use of a high-processivity polymerase. The authors should either provide data from such experiments for their characterised lines, or clearly acknowledge this limitation and qualify their efficiency estimates accordingly (see related point 2 below). 2. Reported efficiency metrics do not adequately distinguish correctly targeted integrants from marker-positive flies.

      A related concern is that many of the efficiency parameters reported in the manuscript appear to be based solely on the detection of the marker cassette. The 63.1% overall success rate, for example, seemingly reflects the recovery of DsRed-positive flies rather than of sequence validated, single-copy, on-target integrants. These are fundamentally different quantities, with only the latter being of practical value for the users of the described technique. The authors should either provide data that properly accounts for correct integration, or more carefully define what each reported metric represents and explicitly acknowledge the limitations of using marker presence as a proxy for successful knock-in. 3. The characterisation of tag exchange requires expansion or more careful framing of its scope.

      The possibility of exchanging tags through fly crosses rather than repeated microinjections is, in the view of this reviewer, the most practically useful feature of ExTaSy and the aspect most likely to drive community adoption. It is therefore important that this feature is characterised with sufficient rigour to allow prospective users to assess its reliability. In the current manuscript, tag exchange has been demonstrated at only five loci using a single replacement tag (sfGFP). The dataset includes one outright failure (the Met C-terminus) and one instance of an unexpected 9 bp insertion at the recombination site, leaving the success rates and failure modes across a broader range of loci and tags uncharacterised. The authors should either expand the tag exchange experiments to cover a more representative set of conditions, or frame the current data explicitly as a proof of concept and limit their conclusions about the practical utility of tag exchange accordingly. In either case, the value of this work to the community would be substantially increased if a collection of donor lines carrying the most commonly used tags for different applications, as the authors themselves enumerate in the Discussion, were generated and deposited at a public stock centre such as the VDRC concurrent with publication. On this note, it is also worth flagging that at present the plasmids described in this study have not yet been deposited at Addgene or the European Plasmid Repository, and that fly lines are available only on request. For a methods paper aimed at community adoption, deposition of reagents in publicly accessible repositories at the time of publication is the expected standard. 4. The Introduction should better reflect the current state of the field, including explicit comparison with MiMIC and CRIMIC.

      The introduction would benefit from a clearer distinction between transgene-based approaches that introduce additional gene copies and true CRISPR-mediated knock-ins at the endogenous locus. As it stands, the discussion of prior methods does not sufficiently acknowledge that CRISPR-based knock-in is already the standard approach in Drosophila, and that the individual techniques employed in ExTaSy are well established. Notably, the MiMIC and CRIMIC systems (Nagarkar-Jaiswal et al., 2015; Li-Kroeger et al., 2018), which also support RMCE-based tag exchange at endogenous loci and for which large collections of lines are already publicly available, are not adequately discussed. These are arguably the closest comparators to ExTaSy, and the authors should explicitly address how their approach differs from and offers advantages over this existing framework, particularly given that MiMIC/CRIMIC insertions can also tag internal sites and thus avoid some of the terminus-specific complications described here.

      Minor Comment

      1. The labelling of sgRNA target sites in Figure 1 is inaccurate and should be corrected.

      In Figure 1, the sgRNA target sites are annotated with triangles labelled "PAM synth." The presence of a PAM is necessary but not sufficient to define a target site; the label should therefore be changed to "target site" or an equivalent term. Additionally, the Methods section incorrectly expands PAM as "primary adjacent motif"; the correct expansion is "protospacer adjacent motif." 6. Could the fly crossing scheme in Figure S3 be simplified?

      In the scheme in Fig. S3 the second step seems to be intended to introduce the hs-Flp and vase-Int transgenes. Would it not be possible to already incorporate the Integrase into the swap fly line when it is made and the hs-Flp into the ExTaSy line, thereby saving one generation? 7. Figure 1F has no call out in the main text. 8. Line 155: What was the reason for the low survival rate? Is this likely to be indicative of a problem during marker removal, or a stochastic event as not all fly crosses are always productive (bad food, early death of flies, etc.)? 9. Line 160: What is the N number of "all cases"? 10. Scale bars are missing in Fig. 3g,h. 11. Line 219: The labeling of the panels got mixed up. Panel F does not show an immunostaining. 12. Line 226 and Fig. 3h: It is unclear what area is shown in the inlay. The overview image highlights three POIs, but none seem to fit the inlay. 13. Line 233: Why was the transgenic marker not removed? The authors want to highlight the easy and advantage of marker removal, so leaving in the marker is an odd choice. 14. Line 250: Why was only one isoform of hth tagged? Without a rational this seems to be an odd choice, in particular since the authors seem to suggest in the introduction (Line 38) that a disadvantage of previous technologies is the tagging of only selected isoforms.


      Significance

      ExTaSy assembles a set of well-established tools, namely CRISPR-mediated HDR, piggyBac-based marker excision, and φC31-mediated RMCE, into a unified, single-vector framework for endogenous protein tagging in Drosophila. The individual components have all been described and are in routine use in the field; the conceptual advance is therefore limited. Nevertheless, the integration of these features into a streamlined platform with accompanying automated design software represents a practical contribution that is likely to be of genuine utility to the Drosophila community, particularly for laboratories without specialist transgenesis infrastructure.

      The possibility of tag exchange by fly crossing is the most distinctive feature of the system. However, as discussed above, this is currently demonstrated at only five loci with a single replacement tag, which limits the conclusions that can be drawn about its generality. More broadly, ExTaSy employs well-proven strategies throughout, which is a source of reliability but also means that the study does not incorporate more recent developments in the field. For example, approaches based on single-strand annealing, such as the recently described Seed/Harvest system (Aguilar et al., 2024), can achieve entirely scarless marker removal and thus circumvent the TTAA scar left by piggyBac excision, a limitation the authors themselves acknowledge may reduce expression at modified N-terminal loci. Similarly, the current system is restricted to N- and C-terminal tagging. Given that the goal of endogenous tagging is to minimally perturb protein function, and given the now widespread availability of high-quality protein structure predictions for the Drosophila proteome, a modern tagging platform might be expected to use structural modelling to identify optimal insertion sites irrespective of their location. These are not oversights that diminish the practical value of the current work, but highlight that this study does not always operate at the cutting edge of method development in this area. A brief discussion of these more recent developments in the context of ExTaSy's design choices would usefully situate the work within the broader landscape and help readers understand both what the system offers today and where improvements are likely to come from.

    1. Note: This response was posted by the corresponding author to Review Commons. The content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      This paper describes the localisation of DNA repair proteins, which carry out their DNA repair function in the nucleus, to the cytoplasmic Golgi apparatus. Using the Human Protein Atlas to identify candidates, the authors use antibody localisation to show that a significant number of DNA repair proteins also localise at the Golgi. It appears that proteins involved in common DNA repair pathways localise to common regions of the Golgi. The Golgi-nucleus distribution of the DNA repairs proteins changes upon DNA damage, indicating a dynamic relationship. The authors focus on the DNA repair protein RAD51C and show that its loss from the Golgi and translocation to the nucleus upon DNA damage is mediated by the ATM kinase. Anchoring at the Golgi is shown to be mediated by the golgin giantin. A functional role for giantin in DNA repair is shown in knockdown studies, supporting a mechanism whereby Golgi anchoring of RAD51C, and possibly other DNA repair proteins, by giantin, is required to maintain proper control of DNA repair. The data are clear and support the authors' conclusions. The data are carefully quantified throughout. I found the text easy to read.

      • Major points:*

      • 1.) To validate the Golgi localisation, KD using siRNA was used. It was deemed that a signal reduction of 25% was enough to indicate specific antibody labelling. This seems like a low number, and not very stringent. For some of the hits, expressing tagged versions of the proteins would greatly strengthen the Golgi assignment. This may not be possible for all, but for RAD51C would seem an important experiment. *

      Response: We thank the reviewer for raising the important issue of antibody validation stringency. We agree that for a single-candidate study, a larger reduction after knockdown would generally be preferable. In our case, the 25% cutoff was used only in the primary high-content screening step as part of an intentionally inclusive two-stage workflow, for the following reasons:

      First, because this dataset is generated in a screening format across hundreds of targets, knockdown-efficiency, protein turnover, and the relative size of the Golgi associated pool are unknown and highly variable between genes. For many proteins the Golgi pool represents a small fraction of total cellular signal, and a modest change in total abundance can translate into a smaller absolute change in the Golgi ROI after segmentation, background subtraction, and imaging noise. We therefore selected a permissive cutoff to reduce false negatives and ensure we did not systematically miss candidates with slower turnover, partial knockdown, or small Golgi pools. This strategy is consistent with large scale subcellular mapping efforts, including the Human Protein Atlas, where genetic depletion by siRNA is used as a key validation pillar for immunofluorescence localization and is combined with additional validation strategies when deeper confidence is required (Stadler et al, 2012). Furthermore, it is important to note that this validation was performed in a high-content screening format in which fixation, permeabilisation, antibody concentration, and blocking conditions were kept uniform across all candidates rather than optimised for each individual antibody. In standard single-target immunofluorescence experiments, these parameters would be titrated to maximise signal-to-noise for the specific antibody and antigen in question. Under non-optimised screening conditions, the absolute magnitude of signal change upon knockdown is inherently attenuated compared to what would be expected from a purpose-optimised assay. We therefore consider a 25% reduction threshold under these uniform, non-optimised screening conditions to be a meaningful and appropriately calibrated criterion.

      Second, we wish to clarify that the primary intent of our screen was not to validate the Golgi-nuclear localisation of any single protein in isolation, but rather to identify whether entire functional pathways are represented at the two organelles. This is precisely why the bioinformatic network analysis was performed as an integral part of the workflow, and not as an afterthought. The finding that the validated hit list is significantly enriched for coherent functional clusters, most notably a network spanning multiple core DNA repair pathways (HR, MMR, BER, MMEJ) serves as an in silico validation of the dataset as a whole. The emergence of pathway-level organisation, with proteins from the same repair pathways co-associating, localising to the same Golgi sub-compartments, and redistributing in the same direction upon genotoxic stimuli, provides biological coherence that goes beyond what individual antibody validation can offer, and substantially reduces the likelihood that the Golgi signal represents a collection of unrelated false positives.

      Third, our mechanistic conclusions do not rely on the 25% screening threshold. For RAD51C, we used multiple orthogonal validation approaches, including independent antibodies recognizing distinct RAD51C epitopes and genetic depletion, supported by biochemical evidence.

      In response to this comment, we have provided the full screening validation dataset as source data (Supplementary____Table S1), including intensity changes for the candidates, so that readers can inspect the distributions and apply their own thresholds. We have also clarified in the Results section the rationale behind our screening strategy (lines 128-139) and the role of the bioinformatic network analysis as an integral validation step (lines 141-156).

      Turning to the specific suggestion of tagged RAD51C, we fully agree that tagged proteins can provide valuable orthogonal validation. We attempted endogenous tagging using CRISPR-mediated homologous recombination but were unable to obtain viable colonies following editing, consistent with the essential role of RAD51C in homologous recombination. We also attempted ectopic expression of tagged RAD51C but were unable to obtain constructs that preserved physiological expression levels, maintained robust cell viability or produced interpretable localization. This difficulty is not unique to our laboratory: colleagues working on RAD51 paralog complexes have reported that tagging or overexpression of RAD51C perturbs both its localisation and its ability to form functional paralog complexes (Greenhough et al, 2023; Rawal et al, 2023; Somyajit et al, 2015; Berti et al, 2020) all use purified complexes or untagged proteins for functional assays. We discussed these challenges extensively with experts in the DNA damage repair field at several international meetings (EMBO Sounio, Keystone Symposia, German DNA Repair Society). For these reasons, we relied on orthogonal approaches that do not require tagging (genetic depletion plus independent antibodies, and biochemical fractionation) to support the Golgi localization claim. We agree with the reviewer that this represents a limitation of this study, and we addressed these concerns in the discussion of our revised manuscript (lines 630-641).

      *2.) The total signal should be quantified for each DNA repair protein upon genotoxic stress, in addition to the Golgi to nucleus ratio. For many of the proteins it looks like the total signal goes down, which could influence interpretation. *

      Response: __We thank the reviewer for this important point. We wish to clarify that our imaging pipeline uses marker-based segmentation throughout, the Golgi compartment is segmented using GM130 and the nucleus using Hoechst, as unsegmented whole-cell masks without organelle markers yield unreliable intensity measurements in this experimental setup. True total cellular signal is therefore not directly accessible in this dataset. In the revised manuscript we provide the absolute fluorescence intensities for both the Golgi and nuclear compartments separately. In addition, we now include total (Golgi + nuclear) intensity measurements for each protein (__Supplementary Figures 3D, 4D, __and 5E__) as the most reliable proxy for overall protein distribution. These data are presented alongside the redistribution ratio to enable comprehensive interpretation.

      As the reviewer correctly notes, a subset of proteins shows a reduction in total signal after treatment, particularly with doxorubicin. This is consistent with known effects of doxorubicin-induced DNA damage on cellular proteostasis, including widespread ubiquitination and suppression of protein translation (Halim et al, 2018). Several DDR regulators are subject to ubiquitin-dependent turnover following genotoxic stress, such as CHK1 (Zhang et al, 2005). More broadly, ubiquitin and proteasome mediated regulation is an integral component of the DNA damage response and can affect the abundance and detectability of DDR factors (Brinkmann et al, 2015). Changes in abundance are therefore an expected biological feature of the response. For this reason, we used the Golgi-to-nucleus ratio as the primary redistribution readout, as it captures relative compartmental partitioning independently of changes in total protein levels.

      *3.) The study would benefit from live imaging of the Golgi to nucleus translocation of RAD51C. This would give a better indication of dynamics. *

      __Response: __We agree that live imaging would directly visualize the dynamics of RAD51C redistribution between the Golgi and the nucleus. This was indeed one of our initial goals following the identification of the Golgi-associated RAD51C pool. However, as described above in our response to Major Comment 1, live imaging requires a fluorescently tagged RAD51C construct, and all tagging strategies we attempted, both endogenous CRISPR-mediated tagging and ectopic expression, failed to yield cell lines with robust signal while preserving physiological behaviour. This appears to be a broader challenge for highly conserved and functionally constrained DNA repair proteins, and is not unique to our laboratory.

      Given these constraints, we focused on tag-independent approaches: multiple independent RAD51C antibodies combined with genetic depletion controls, quantitative fixed-cell time courses, and biochemical fractionation. These orthogonal datasets together support compartment-specific changes over time in a manner consistent with redistribution. We have clarified this limitation explicitly in the manuscript and avoided any wording that could be interpreted as implying direct single-molecule tracking in live cells. We present this as an important avenue for future work, contingent on the development of viable RAD51C-expressing cell lines (lines 630-641).

      *4.) The double depletion experiments suggest a functional relationship between giantin and RAD51C. But they do not formally show it. Experiments to more directly address the functional role of the interaction between these two proteins would strengthen the study. *

      Response: We agree with the reviewer that double depletion alone cannot formally prove that the physical Giantin-RAD51C interaction is the sole determinant of the observed DDR phenotypes. However, we would like to highlight the breadth of evidence we have assembled in support of this functional relationship:

      • Physical interaction between endogenous Giantin and RAD51C demonstrated by colocalisation (Figure 4F-G) and co-immunoprecipitation (Figure 4H-I).
      • Damage-induced dissociation of the Giantin-RAD51C complex that is prevented by ATM inhibition or Importazole treatment, directly linking the interaction to the DDR signalling axis (Figure 3K-P)
      • Premature nuclear accumulation of RAD51C upon Giantin depletion, producing aberrant nuclear foci lacking canonical HR markers and impaired ATM signalling (Figure 4B-E & J-M)
      • DR-GFP reporter assay confirming that Giantin depletion reduces HR efficiency to approximately 60% of control, consistent with the reduction previously reported in the genome-wide HR screen (Adamson et al. 2012) and validating the functional significance of Giantin in HR (Figure 5L).
      • Partial rescue of ATM phosphorylation, genomic instability and proliferation phenotypes by RAD51C co-depletion, arguing for RAD51C as a functionally relevant conduit of the Giantin-dependent phenotype (Figures 5M-5P). These observations are further supported by the established literature on RAD51C function, its roles in CHK2 phosphorylation, replication fork stabilisation, and RAD51 filament formation (Badie et al, 2009; Somyajit et al, 2015; Prakash et al, 2022) providing a mechanistically coherent framework in which mislocalisation of RAD51C, whether directly or indirectly through Giantin, leads to dysregulation of DDR signalling and repair capacity, as we directly demonstrate with the HR efficiency assay.

      Nonetheless, we fully agree that the most direct proof of the functional relevance of the physical Giantin-RAD51C interaction would come from separation-of-function experiments, ideally using an interaction-deficient Giantin mutant or an RAD51C variant unable to bind Giantin. We wish to be transparent that both approaches face substantial technical barriers in this system. RAD51C tagging consistently compromised cell viability and protein function, precluding the generation of interaction-deficient variants at physiological expression levels. Engineering an interaction-deficient Giantin mutant presents an independent challenge: Giantin is one of the largest Golgi matrix proteins (~376 kDa), composed almost entirely of extended coiled-coil domains that are resistant to structural prediction, and identifying a discrete RAD51C interaction interface without disrupting broader scaffolding function would require a dedicated structural and biochemical programme. We have framed these explicitly as the most important future priorities in the Discussion (lines 555-564), rather than over-interpreting the current data.

      *5.) The Kaplan-Meier plots in Fig S9 seems to be quite selective in that only breast cancer is shown. Does giantin reduction correlate with poor prognosis in other cancers? *

      __Response: __We thank the reviewer for this suggestion. We initially focused on breast cancer because RAD51C is a clinically established hereditary breast and ovarian cancer susceptibility gene (Meindl et al, 2010; Ghannoum et al, 2023), providing direct clinical context for a study centred on RAD51C dynamics and genome stability. We agree however that restricting the survival analysis to a single cancer type can appear selective.

      To address this directly, we expanded the in-silico survival analysis of Giantin (GOLGB1) using GEPIA2 (Tang et al, 2019) across all available TCGA cohorts (overall survival, median cutoff, FDR correction). In the pooled pan-cancer analysis, higher GOLGB1 expression is significantly associated with improved overall survival (HR(high) = 0.75, p = 6.6 × 10⁻¹⁵). When stratified by tumour type, the majority of individual associations do not reach statistical significance. The two most robust statistically significant associations are kidney renal clear cell carcinoma (KIRC; HR(high) = 0.57, p = 3.4 × 10⁻⁴), where high GOLGB1 expression is associated with improved survival, and lower-grade glioma (LGG; HR(high) = 1.5, p = 0.036), where the association is in the opposite direction. A significant association is also observed in thymoma (THYM; HR(high) = 7.3, p = 0.031), though this should be interpreted with caution given the small cohort size (n = 59). Notably, the breast cancer association observed in the KM Plotter analysis (HR = 0.71, p = 1.8 × 10⁻¹¹; n = 4,929) does not reach significance in the TCGA BRCA cohort (HR = 1.1, p = 0.68; n = 1,070), most likely reflecting the substantially smaller sample size of the TCGA cohort, which is approximately 4.6-fold smaller and therefore underpowered to detect a modest effect. These context-dependent associations are consistent with the tumour-type-specific roles of Golgi scaffolding proteins and are discussed accordingly in the revised manuscript.

      In the revised manuscript we have retained the original breast cancer Kaplan-Meier plots and supplemented them with a pan-cancer survival map across all TCGA cohorts (lines 611-625; Figure S9G) and a summary table (Supplementary Table 3) reporting hazard ratios, sample sizes, and p-values for each tumour type, allowing readers to assess the clinical relevance of GOLGB1 expression.

      *Minor points: There are a few grammatical errors here and there. The figures do not appear in the correct order in the text, which makes the early parts of the paper a bit difficult to follow. Some of the figures don't seem to clearly match the text. For example, it is mentioned that RAD51C labelling was done with 3 different antibodies. I could not find this data. *

      Response: __We thank the reviewer for these helpful observations. In the revised manuscript we have (i) carefully proofread the text and corrected grammatical errors throughout; (ii) revised the Results section to ensure that figures and supplementary figures are cited in sequential order and that each panel is explicitly introduced before being discussed, improving readability in the early sections. and (iii) corrected figure callouts to ensure they match the text. In particular, the statement that RAD51C labeling was performed with three different antibodies has been linked to the corresponding figure panels in the Results section. Antibody identifiers, sources, and dilutions are clearly reported in the Methods and in the table in __Supplementary Table S1.

      __ Reviewer #1 (Significance (Required)):__

      *This paper is novel and should be of significant interest to the field. It has important implications for how we think about the Golgi apparatus, and for how DNA repair pathways may be controlled. The pattern is clearly complex, with many DNA repair proteins localising to the Golgi, and some showing opposite dynamics. However, by focussing on RAD51C and giantin, the paper nicely demonstrates a novel mechanism for controlling DNA repair by these proteins. *

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      Background - Eukaryotic cells rely on tightly regulated DNA repair pathways to preserve genome stability under the constant threat of both endogenous and exogenous genotoxic stress. While the nucleus, and to a lesser extent the mitochondria, is the primary site where DNA damage is detected and repaired, accumulating evidence indicates that extranuclear organelles, particularly the Golgi apparatus, play a surprisingly important role in modulating stress signaling, proteostasis, and the trafficking/activation of key DNA repair factors.

      • Emerging evidence has shown that genotoxic stress can result in a major remodeling of the Golgi apparatus; however, the crosstalk between the Golgi and the nucleus, and its contribution to the DNA damage response, remains poorly defined. The present study offers timely insight by examining the spatiotemporal behavior of DNA repair proteins that shuttle between the Golgi and the nucleus, and how this trafficking contributes to the maintenance of genomic stability.*

      Main findings - The authors employed the Human Protein Atlas (HPA) project to shortlist proteins that might link Golgi-nuclear function and validated each candidate using an siRNA-mediated antibody-validation pipeline, thereby identifying 163 proteins that localize to both the Golgi and the nucleus. Bioinformatic analysis of these candidates revealed a significant enrichment for DNA damage response (DDR) regulators, including multiple factors from core DNA repair pathways, suggesting that a portion of the DDR machinery may reside in the Golgi at steady state. Interestingly, the authors observed that dual-localizing DDR proteins undergo lesion-specific redistribution between the Golgi and the nucleus in response to specific types of DNA injuries. For instance, BER and MMEJ proteins shifted from nucleus to Golgi in response to doxorubicin, whereas MMR and HR proteins redistributed from Golgi to nucleus. This trend was reversed with H2O2 or KBrO3 treatments.

      • To gain further insight into the link between the DDR and Golgi-nuclear communication, the authors focused on the HR factor RAD51C, which also plays a key role during the replicative stress response. The authors noticed that RAD51 is significantly associated with the Golgi, in addition to its known nuclear pool. Interestingly, they demonstrated that doxorubicin triggers the ATM-dependent release of this Golgi-tethered RAD51C pool and its Importin-β-mediated import into the nucleus, where it forms repair-associated foci. They further identified Giantin as the Golgi scaffold that anchors RAD51C at steady state in this subcellular compartment and showed that its depletion leads to premature nuclear accumulation of RAD51C, formation of aberrant RAD51C foci lacking canonical HR markers, reduced ATM activation, elevated genomic instability, and increased cell proliferation. *

      Together, this study revealed an underappreciated and functionally meaningful spatiotemporal level of regulation within the DDR, suggesting that the Golgi, rather than functioning solely as a trafficking organelle, acts as a platform that anchors, releases, and temporally controls the availability of key DNA repair factors in response to genotoxic stress. In particular, the authors demonstrated that the timely and regulated release of RAD51C from the Golgi is essential for maintaining genome stability and is dependent on canonical DDR signaling pathways, including ATM activation and Importin-β-mediated nuclear import.

      • Overall Critique - This manuscript offers a novel and compelling perspective on the regulation of the DDR by positioning the Golgi as an active participant in the spatiotemporal control of DNA repair factors. By integrating multiple experimental layers, including a systematic localization screening, a sub-Golgi mapping, several dynamic redistribution assays, and functional perturbation read-outs, the authors built a strong and coherent case for a biologically meaningful Golgi-nucleus communication axis during the DDR. Therefore, the study is timely and highly relevant for the DNA repair field, with broader implications for our understanding of how subcellular organelles coordinate genome maintenance and cellular homeostasis.

      While the manuscript is clearly written and the figures are coherent and supportive of the main findings of the study, several issues should be addressed to ensure full interpretability and reproducibility.

      Major Comments*

      *1. Limited use of agents causing genotoxic stress - The authors report intriguing lesion-specific shifts in Golgi-nuclear redistribution, yet much of the mechanistic work relies heavily on doxorubicin, a pleiotropic drug that induces diverse forms of DNA damage beyond DSBs. Expanding the core analysis of the study to include a broader panel of mechanistically defined genotoxins (e.g., etoposide, camptothecin, neocarzinostatin, or ionizing radiation) would substantially strengthen the conclusion that the trafficking patterns reflect damage-type specificity rather than drug-specific off-target effects. Such broader analysis would also clarify whether Golgi-nucleus communication responds differentially to replication-associated breaks, Topo II-dependent lesions, oxidative stress, or crosslinks. *

      __Response: __We thank the reviewer for this important point. We would first note that while doxorubicin is indeed pleiotropic, its primary and best-established mechanism of action is the poisoning of Topoisomerase II, leading to DNA double-strand breaks, a mechanism it shares with etoposide (van der Zanden et al, 2021; Thorn et al, 2011). The additional effects of doxorubicin, including reactive oxygen species generation and chromatin remodelling, are well-documented but secondary to this DSB-inducing activity, as we note in the revised manuscript. Nonetheless the goal of this study was not to comprehensively map lesion-specific trafficking for every DDR protein, but rather to establish the existence of a dynamic Golgi-nucleus redistribution axis and then focus mechanistically on the validated targets, in this case RAD51C. The lesion-dependent redistribution patterns are therefore presented as an initial, hypothesis-generating observation emerging from our screening and characterisation framework. A systematic, lesion-by-lesion dissection of redistribution kinetics across the broader DDR network would represent a substantial additional study and is beyond the scope of the present work.

      Importantly, our key mechanistic observations for RAD51C are not restricted to doxorubicin. We tested a panel of genotoxic agents covering mechanistically distinct lesion classes: camptothecin (CPT; Topoisomerase I-associated replication breaks), etoposide (ETO; Topoisomerase II-dependent DSBs), and mitomycin C (MMC; interstrand crosslinks) (Figures S8A-S8I). Across all DSB-inducing agents, RAD51C consistently redistributed from the Golgi to the nucleus, demonstrating that this response is not a doxorubicin-specific off-target effect. Notably, RAD51C did not redistribute in response to oxidative lesions induced by hydrogen peroxide or potassium bromate, consistent with its established role in homologous recombination and DSB repair rather than oxidative damage pathways, as discussed in the manuscript. This lesion-type selectivity provides additional evidence that the Golgi-nuclear redistribution we observe is a biologically specific response rather than a non-selective stress effect.

      *2. Functional implications of RAD51C redistribution for HR efficiency - Although the study convincingly demonstrates a release of RAD51C from the Golgi and its subsequent nuclear foci formation, it remains unclear how this redistribution influences HR efficiency. Incorporating a functional HR assay (e.g., DR-GFP reporter, RAD51 filament assembly, or fork protection assays) would help determine whether Golgi-anchored RAD51C release is directly required for HR or instead primarily modulates upstream DDR signaling. *

      Response: __We thank the reviewer for this important suggestion. We have performed DR-GFP reporter assays to directly assess HR efficiency following Giantin and RAD51C depletion. Depletion of Giantin reduced HR efficiency to approximately 60% of control levels, and RAD51C depletion to approximately 40%, consistent with the HR reduction previously reported in the genome-wide HR screen (Adamson et al, 2012). Co-depletion of Giantin and RAD51C reduced HR to levels comparable to RAD51C depletion alone, suggesting that the effect of Giantin on HR is mediated primarily through RAD51C, consistent with RAD51C being the key effector of the Giantin-dependent spatial regulatory mechanism we describe. These data are included in the revised manuscript (__lines 455-465; Figure 5L).

      *In addition, the manuscript does not fully reconcile how Golgi-tethering of RAD51C fits with its well-established nuclear roles during replication stress, where timely availability of RAD51C is essential for fork stabilization and restart. *

      Response: __We agree that the nuclear function of RAD51C during replication stress is well established and important to reconcile with our findings. Our imaging data consistently show a detectable nuclear RAD51C population at steady state across all cell lines examined, and we do not propose that RAD51C is exclusively Golgi-localised. We suggest that the two pools serve distinct functional purposes: the constitutive nuclear pool supports ongoing replication fork stabilisation and restart, processes that require RAD51C availability independently of acute DNA damage, while the Golgi-tethered fraction represents a damage-responsive reserve that is released acutely upon DSB induction in an ATM-dependent manner. We wish to be transparent that this two-pool model is speculative at present, formally distinguishing the contributions of each pool would require direct labelling of the Golgi-anchored fraction, which was not technically feasible in this system as discussed above. Nonetheless, this model is consistent with established principles of signal-responsive protein sequestration in cell biology, and is directly supported by our Giantin depletion data: premature release of the Golgi pool leads to aberrant nuclear RAD51C foci lacking canonical HR markers and impaired ATM signalling, demonstrating that unscheduled nuclear accumulation is actively detrimental rather than simply redundant. We have added a paragraph to the revised Discussion explicitly framing the two-pool distinction as a working model and identifying direct pool-identity tracking as an important future direction (__lines 566-587).

      *3. Specificity of Giantin-related phenotypes - The phenotypes observed upon Giantin depletion (e.g., increased micronuclei, comet tail moments, impaired ATM signaling, and elevated proliferation) could partially reflect a global dysfunction of the Golgi rather than RAD51C-specific tethering defects. Although co-depletion of RAD51C provides partial rescue, additional controls examining Golgi integrity, trafficking competence, or rescue with siRNA-resistant Giantin would help confirm specificity and distinguish direct from indirect effects. *

      __Response: __We thank the reviewer for raising this important concern, which was a central consideration throughout our investigation. We address it through three complementary lines of evidence.

      First, regarding Golgi structural integrity and trafficking competence: as previously reported, Giantin depletion has not been associated with strong Golgi fragmentation or major morphological alterations (Koreishi et al, 2013; Bergen et al, 2017; Stevenson et al, 2021), and we observed no significant Golgi fragmentation upon Giantin knockdown in our system. Consistent with the literature, Giantin has been implicated in specific cargo trafficking, most notably collagen secretion, rather than general secretory pathway function (Stevenson et al, 2021). To directly confirm that general Golgi trafficking competence was preserved in our experimental system, we performed the VSV-G-YFP trafficking assay (Presley et al, 1997), a well-established functional readout of general secretory trafficking. Giantin depletion did not result in a significant change in trafficking efficiency compared to control siRNA (Rebuttal Figure 1), consistent with the literature and arguing against a general collapse of Golgi function as the basis for the phenotypes observed.

      Rebuttal ____Figure 1. VSV-G-YFP trafficking assay.

      (A) Representative images of cells treated with control siRNA or giantin siRNA. Nuclei are stained with Hoechst. Total VSV-G-YFP (YFP-tsO45G) signal is shown together with antibody staining against VSV-G in non-permeabilized cells to assess cell surface levels. Scale bars, 10 μm.

      (B) Quantification of VSV-G trafficking from two independent biological replicates.

      Second, the phenotypes are RAD51C-dependent and not a generic Golgi dysfunction: the genomic instability and DDR signalling defects we observe upon Giantin depletion are not phenocopied by GMAP210 depletion, another Golgin family member, indicating that the phenotypes are not a generic consequence of Golgin loss. Critically, we now directly demonstrate using the DR-GFP reporter assay that Giantin depletion reduces HR efficiency to approximately 60% of control, and that co-depletion of RAD51C produces no further reduction beyond RAD51C depletion alone, consistent with RAD51C epistasis over Giantin for HR capacity (Figure 5L). This functional epistasis, together with the physical interaction between Giantin and RAD51C by co-immunoprecipitation, their co-localisation within the same Golgi sub-compartment, and the partial rescue of ATM phosphorylation, micronuclei formation and proliferation phenotypes upon RAD51C co-depletion, provides a coherent mechanistic chain linking Giantin specifically to RAD51C-dependent DDR outcomes. While we cannot formally exclude indirect contributions from other Giantin-associated factors, none of our observations are consistent with the phenotype arising from non-specific Golgi perturbation.

      Third, Giantin may play a broader role in connecting DDR signalling to cytoplasmic and Golgi-resident processes, beyond RAD51C tethering alone: we consider this a feature of the biology rather than a confound. Golgins are well established as multi-cargo scaffolding platforms, and Giantin in particular occupies a strategic position where several processes converge: the tethering of DDR factors, the regulation of damage-induced signalling cascades, and the directional trafficking of repair factors between compartments. This would explain why Giantin depletion produces a phenotype that extends beyond what RAD51C co-depletion alone can fully rescue, and is consistent with the pathway-level coherence we observe across our screen. Understanding the full complement of Giantin-associated DDR interactions represents one of the most compelling directions emerging from this work.

      In response to this comment, we have expanded the Discussion (lines 545-565) to explicitly propose that Giantin functions as a broader organisational node coordinating multiple DDR factors, while our data specifically and consistently implicate RAD51C as a primary conduit.

      *4. Positioning of ATM in the Golgi-nuclear signaling - While ATM inhibition prevents RAD51C release, its spatial and mechanistic basis of this regulation remains obscure. It is not clear whether ATM acts locally at the Golgi, through cytoplasmic pools, or indirectly via nuclear feedback signaling. Clarifying or discussing this point in more depth would improve the mechanistic coherence of the proposed model. *

      __Response: __We thank the reviewer for raising this important mechanistic question. The spatial basis of ATM action at the Golgi is indeed an emerging and exciting area of cell biology. A growing body of evidence demonstrates that ATM associates with the Golgi membrane through binding to phosphatidylinositol-4-phosphate (PI4P), and that this Golgi-resident pool modulates the magnitude and kinetics of the nuclear DDR (Ovejero et al, 2023). Importantly, the most recent work in this area demonstrates that Golgi-associated ATM is not merely a passive reservoir but is enzymatically active and capable of phosphorylating Golgi-resident substrates (Soulet et al, 2026), providing a compelling mechanistic basis for how damage-induced ATM signalling could reach the Golgi to license RAD51C release.

      To directly examine whether ATM localises to the Golgi in our system and whether its activation state changes upon DNA damage, we performed a biochemical Golgi enrichment assay using the Minute{trade mark, serif} Golgi Apparatus EnrichmentKit (Cat #: GO-037) to examine ATM distribution across cis- and trans-Golgi fractions. Fraction purity was validated using GM130 (cis-Golgi), TGN46 (trans-Golgi), and HSP60 (membrane fraction) (Rebuttal Figure 2A). This analysis revealed that ATM is detectable in the total membrane fraction and enriched in the cis-Golgi fraction under basal conditions (Rebuttal Figure 2A). Under normal physiological conditions, activated ATM (pATM) was absent from Golgi-enriched fractions (Rebuttal Figure 2B), but was detectable in the cis-Golgi fraction following doxorubicin-induced genotoxic stress (Rebuttal Figure 2C). While these observations are preliminary and require further validation, they are consistent with the emerging literature and raise the intriguing possibility that ATM is recruited to and activated at the Golgi in a damage-dependent manner, where it could act locally to license RAD51C release.

      Rebuttal Figure 2. Biochemical Golgi fractionation confirms ATM enrichment in cis-Golgi compartments.

      *Western blot of HeLa-K fractions enriched for cis- and trans-Golgi membranes, probing for (A) ATM under basal conditions, and (B and C) pATM under basal conditions and (B) pATM (C) after treatment with DOX (40 μM) (markers: GM130 for cis-Golgi, TGN46 for trans-Golgi, HSP60 for membrane fraction (MEM). *

      We consider the precise spatial and mechanistic dissection of ATM signalling at the Golgi and its relationship to nuclear feedback, one of the most exciting directions to emerge from this work, and one that we hope our study has helped to open. We have expanded the Discussion (lines 525-543) accordingly to place our findings in the context of the emerging Golgi-ATM literature and to frame this as an important unresolved question for future investigation.

      *5. RAD51C is examined in silo, without consideration for the BCDX2 complex - RAD51C is exclusively analyzed in isolation, despite its well-established function as part of the BCDX2 paralog complex (RAD51B-RAD51C-RAD51D-XRCC2). Because RAD51C does not normally operate as a standalone factor, it is unclear why only RAD51C, among all paralogs, would be subjected to Golgi tethering, ATM-dependent release, and Importin-β-driven nuclear import. This raises important mechanistic questions: Are other BCDX2 members also Golgi-associated? Do they undergo similar trafficking dynamics? Does Golgi tethering selectively regulate RAD51C, or does the complex translocate together? Addressing these points would greatly strengthen the biological plausibility and mechanistic coherence of the proposed model. *

      Response: We thank the reviewer for raising this important point. We fully agree that RAD51C functions as a core component of the BCDX2 (RAD51B-RAD51C-RAD51D-XRCC2) and CX3 (RAD51C-XRCC3) paralog complexes, and that its canonical roles in HR and replication fork protection occur within these assemblies. Our decision to focus on RAD51C was driven by the screening data: of the DDR proteins identified, RAD51C displayed the most robust Golgi-associated pool, the clearest damage-induced redistribution dynamics, and a tractable anchoring interaction with Giantin that could be interrogated biochemically.

      We would also note that extending this analysis to other RAD51 paralogs is not straightforward with current tools. The available commercial antibodies against RAD51B, RAD51D and XRCC2 perform poorly in immunofluorescence applications, and most localisation studies for these proteins have relied on overexpression of tagged constructs, a strategy that, as discussed above, risks perturbing both localisation and complex assembly. The lack of reliable antibodies for endogenous paralog detection at the resolution required for Golgi localisation analysis represents a genuine technical barrier that we encountered directly during this study.

      Whether Golgi association and ATM-dependent release involve RAD51C alone or extend to other BCDX2 or CX3 members is therefore a genuinely open and important question. We note that our co-immunoprecipitation data were performed on total cell lysate and cannot distinguish whether the Golgi-associated RAD51C is complexed with other paralogs or represents a monomeric subpopulation. Golgins are well established as multi-cargo scaffolding platforms, and it is entirely plausible that Giantin organises a broader paralog module rather than tethering RAD51C as an isolated subunit. A systematic analysis of RAD51 paralogs for Golgi localisation and lesion-dependent trafficking enabled by improved reagents such as proximity labelling or endogenous tagging approaches compatible with essential proteins would determine whether the BCDX2 complex translocates as a unit or whether individual subunits are differentially regulated, with potentially distinct consequences for HR fidelity. We have revised the manuscript accordingly and identify this as an explicit priority for future work in the revised Discussion (lines 583-602).

      Minor Comments

      1. Pathway-specific sub-Golgi localization patterns - The finding that DDR proteins map to distinct cis/trans Golgi subdomains is an interesting and potentially important observation. However, the dataset is limited to 15 proteins, making the proposed pathway-level trends (e.g., HR factors enriched in cis-Golgi; BER/MMEJ factors enriched in trans-Golgi) preliminary. Strengthening this conclusion by increasing the number of DDR proteins analyzed would help determine whether sub-Golgi compartmentalization contributes meaningfully to DNA repair pathway regulation.

      Response: We thank the reviewer for this constructive suggestion. We agree that extending sub-Golgi mapping to a larger number of DDR proteins would be valuable, and we present the current dataset explicitly as a first, hypothesis-generating map rather than a definitive pathway atlas.

      We would like to highlight, however, that the value of this observation lies not simply in the number of proteins mapped, but in the biological coherence of the patterns that emerge. The finding that proteins from the same repair pathway tend to occupy the same Golgi sub-compartment: BER and MMEJ factors enriching in the trans-Golgi, HR factors in the medial/cis-Golgi, and that this sub-compartmental positioning correlates with the direction of their redistribution upon genotoxic stress, is a pattern that would be unlikely to arise by chance across 15 independently validated proteins. This internal consistency argues that the sub-Golgi organisation reflects genuine pathway-level biology rather than noise, even if the dataset is not yet exhaustive. Together with the bioinformatic network analysis, which independently supports pathway-level clustering across the broader validated hit list, these observations reinforce each other as complementary layers of evidence.

      2. Is the Golgi-released RAD51C indeed the pool that enters the nucleus? The major assumption of the study is that the RAD51C population released from the Golgi upon DNA damage is the same pool that subsequently accumulates in the nucleus to form repair foci. While the imaging and fractionation data are consistent with this model, the study does not directly track or distinguish Golgi-derived RAD51C from cytoplasmic or pre-existing nuclear pools. Without a method to specifically label, pulse-chase, or track the Golgi-anchored fraction, it remains formally possible that nuclear RAD51C originates from other subcellular reservoirs.

      __Response: __We thank the reviewer for highlighting this important mechanistic point, which we agree cannot be fully resolved with the current dataset. Several independent lines of evidence are nonetheless consistent with a model in which the Golgi-associated pool contributes directly to damage-induced nuclear accumulation.

      • Our time-resolved imaging demonstrates a reciprocal decrease at the Golgi and a concurrent increase in the nucleus following genotoxic stress, consistent with redistribution rather than independent compartment-specific changes (Figures 3E-3I).
      • Biochemical fractionation provides an orthogonal readout of the same reciprocal shift under identical conditions (Figures 3J and S6D).
      • ATM inhibition simultaneously prevents Golgi loss and blunts nuclear accumulation, while Importin-β perturbation blocks nuclear entry, together supporting an active and regulated translocation route (Figures 3K-3P).
      • Giantin depletion, which releases the Golgi-tethered RAD51C pool prematurely, leads to aberrant nuclear RAD51C foci lacking canonical HR markers and impaired ATM signalling, strongly supporting that the Golgi-tethered fraction has functional consequences in the nucleus consistent with it being the relevant pool (Figures 4B-4E and 4J-4M).
      • In the revised manuscript we have included cytoplasmic RAD51C signal quantification across the doxorubicin time course (Figure 3H). The cytoplasmic signal shows only a moderate and gradual reduction that is kinetically distinct from the sharp Golgi decrease and does not precede the nuclear increase. This pattern is inconsistent with a large pre-existing cytoplasmic reservoir driving the nuclear accumulation; if the cytoplasmic pool were the primary source, one would expect a rapid and prominent cytoplasmic decrease coinciding with or preceding nuclear accumulation, which we do not observe. Instead, the data are more consistent with rapid transit of Golgi-released RAD51C through the cytoplasm rather than stable cytoplasmic accumulation prior to nuclear entry. We acknowledge that definitive pool-identity tracking would require spatially restricted labelling approaches such as Giantin-proximal TurboID or photoactivatable tagging strategies, which are precluded by the technical constraints on RAD51C tagging described above. We have revised the manuscript to avoid overstatement on this point and identify these approaches as important future directions (lines 297-305 & lines 715-719).

      Reviewer #2 (Significance (Required)):

      General assessment - This study presents a novel and conceptually compelling view of the DNA damage response (DDR) by positioning the Golgi apparatus as an active regulator of the spatiotemporal availability of DNA repair factors. The strongest aspects of the work include its integration of a systematic immune-localization screening, a sub-Golgi compartment mapping, dynamic redistribution assays, and functional perturbations to build a coherent model of Golgi-nucleus communication during genotoxic stress. The mechanistic focus on RAD51C provides a clear case study linking organelle-level regulation to genome stability.

      • Advance - To my knowledge, this is the first comprehensive demonstration that the Golgi can serve as a spatiotemporal coordination node for DDR proteins, including those involved in HR. The identification of a substantial pool of RAD51C, and reportedly other DDR factors, anchored within specific Golgi subdomains represents a significant conceptual advance. The demonstration that Golgi-tethered RAD51C is released in an ATM-dependent manner and subsequently participates in nuclear foci formation suggests a previously unrecognized organelle-level regulatory checkpoint in genome maintenance. This work therefore extends current models of the DDR by revealing a layer of intracellular coordination that bridges classical nuclear pathways with cytoplasmic organelle function.*

      • Audience - This study will be of strong interest to a specialized audience in the fields of DNA repair, genome stability, and cell biology, particularly those studying the spatial organization of repair pathways and intracellular stress signaling. It will also appeal to researchers investigating organelle biology, intracellular trafficking, and the broader coordination of cytoplasmic and nuclear responses to stress. Beyond these communities, the work may be relevant to cancer, as it suggests new mechanisms by which organelle perturbations or Golgi-associated scaffolding proteins could influence therapeutic responses or genomic instability.

      Reviewer expertise - Field of expertise: DNA repair, genome stability, organelle biology, cancer cell biology.*

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      *This study investigates the communication between the Golgi complex and the nucleus of the cell, which remains a largely unexplored field. The authors used publicly available siRNA and antibody data from the Human Protein Atlas as a basis for finding overlap between the proteomes of the two cellular compartments. In validating the data from the HPA, the study finds a novel cluster of DNA repair proteins present in the Golgi, which they validate and resolve to sub-compartmental localization. To do so they use immunofluorescence (IF) localization on ¬cis- and trans-Golgi cisternae marked by GM130 and TGN46, respectively. The authors find that many of the fully validated proteins present in both the nucleus and Golgi redistribute between the Golgi and the nucleus dependent on the protein and the type of DNA lesion. They focused on RAD51C, a recombination factor. They show that RAD51C resides in both the ¬cis- and trans- subsections prior to damage and responds to DNA damage in an ATM-dependent manner via release of a Golgi-based pool bound to Giantin, which is then imported into the nucleus via Importin-β. Knockdown experiments showed that Giantin regulates RAD51C spatially and temporally. The work reveals a dynamic interchange of proteins between the Golgi and nucleus that controls cell functions beyond the classic secretory, membrane trafficking, and PTM roles of the Golgi. The authors build on prior work on Golgi impacts on DDR, offering an alternative cellular compartment for storage of DDR factors prior to damage. Overall, the data is timely and relevant, as it finds new roles for the Golgi in DNA damage response (DDR) regulation. The data is largely convincing and well controlled. The IF data is presented in black and white single channels and merged in color, which allows good comparison of the different protein stains. The scope of the initial screen of HPA antibodies and Golgi/Nuclear dual proteomes is impressive, and the overlap of DDR proteins is characterized for fifteen different proteins at a sub-compartmental level. The focus on RAD51C as a member of the HR pathway was a strong choice, and the study presents interesting information on its regulation by Golgi complex members, as well as a feedback look with pATM. The possibility of the Golgi storing specific DDR factors in specific compartments is well-supported and intriguing. There are a few major and minor points that should strengthen the paper and improve clarity prior to publication. *

      Major Comments:

      *1. Much of the strength of the IF data is lost in the choice of scale for presentation of the data. In almost all cases, enlarged sections should be shown of the areas currently indicated by arrow, in all channels. This is done well in Figure 3A, where an area of the Golgi is enlarged and the overlap of RAD51C in the GM130-marked Golgi is clearly visible in the merged channel, even when printed out. I would highly recommend including the white box and enlarged in all images and channels, while keeping the representative fields as is (e.g. if the image is 40mm, draw a 7mm box around representative cells/Golgi, and enlarge to 15mm in the bottom left). This change should be made to F1E, F2F, F3E, F3J, and F3M, as well as having enlarged figures in the corners in all supplementary data IF figures. Where possible, a fully enlarged image of the bounding box could also be included. Some of the IF data would be strengthened by using the nuclei stain to draw a masking outline to include in the black and white channels, to clearly delaminate what is Golgi-localized and what is nuclear. *

      Response: We thank the reviewer for this helpful suggestion and fully agree that enlarged insets substantially improve the visibility of Golgi-localised signal, particularly when figures are printed. We share the reviewer's view that alternative display formats with larger insets would be preferable, and we have implemented enlarged boxed regions wherever space constraints permitted.

      Specifically, we have added boxed regions with enlarged insets to Figure 1E, all panels of Figure 3. For Figure 2, the number of conditions and proteins displayed simultaneously within the constraints of standard journal figure dimensions made it impractical to include enlarged insets for all panels without reducing the overall field size to the point of losing contextual information. We have nonetheless improved the visibility of the Golgi signal in Figure 2 as much as possible within these constraints, and note that the final figure layout will be further optimised in line with the journal's specific formatting guidelines. In addition, all figures have been provided as high-resolution image files to allow electronic magnification, enabling readers to inspect the Golgi-localised signal in detail beyond what is visible in the printed version.

      Regarding the use of nuclear outline masks in single-channel images, we tested this approach but found that given the number of structures present within each field, including Golgi stacks, nuclear foci, and cytoplasmic signal, overlaying nuclear outlines on individual channels added visual complexity that made the images harder rather than easier to interpret. As an alternative, we have included a full-colour merged panel, when possible, which we consider a cleaner way to delineate nuclear versus Golgi-localised signal and allows the reader to directly compare compartment-specific distributions across channels.

        1. *There is a lack of consistency in the representative images shown by IF. For example, Figure 1 gives the impression of very little RAD51C in the nucleus but this is rightly shown to not be the case in Supp. Fig 2A. The same is true of the various images of LIG1. The authors should use representative data that better reflects the distribution of the proteins being studied and maintain consistency across images. If there is a lot of variation in staining patterns, the authors should show images and percentages corresponding to the variations especially for the key gene studied, RAD51C.

      Response: We agree and have replaced the representative IF panels for RAD51C and LIG1 with images that better reflect the quantified distributions across biological replicates. The revised panels were selected to match the quantified compartment intensities shown in the accompanying graphs rather than representing outlier cells. We would also note that the apparent discrepancy between Figure 1E and Supplementary Figure S2A partly reflects a difference in imaging conditions: Supplementary Figure S2A __and __Figure 2F were acquired directly from the high-content screening pipeline under uniform, non-optimised antibody and fixation conditions at widefield resolution, whereas Figure 1E shows representative single optical section confocal images acquired after candidate identification with antibody conditions optimised for each individual protein. The improved signal-to-noise in the optimised confocal images more faithfully captures the dual Golgi and nuclear localisation of RAD51C, and the apparent difference between the two image sets is therefore expected rather than inconsistent. We have updated the figure legends to clarify the imaging modality and conditions for each panel. Furthermore, the quantified distribution of RAD51C across Golgi, nuclear and cytoplasmic compartments across multiple cell lines is shown in Figure 3B and 3D, providing a population-level representation of the dual localisation that complements the representative images shown in Figure 1E.

        1. *The initial screening by siRNA-mediated knockdown pipeline that validated and confirmed dual Golgi and nuclear localization of 163 of the 329 dual-localization HPA proteins does not have any data included. This seems like a very large amount of data to gloss over and not include even as supplementary data. This should be included as source data, and discussion of the in-text information should be strengthened. The data included with the networking of these validated proteins is strong, but the process of elimination and validation has not been shown. In addition, the antibody information included in the supplementary data does not include dilution factors or blocking factors is not included, which would be beneficial to future studies to include.

      Response: We agree and have addressed this in full. We note that the HPA antibody validation data, including immunofluorescence images and siRNA knockdown results, are publicly available for inspection on the Human Protein Atlas website (www.proteinatlas.org) for the majority of candidates, providing an independent layer of verification. In the revised submission, we additionally provide the complete siRNA-mediated validation dataset generated in our laboratory as source data (Table S1; lines 1025-1041), including for each candidate the HPA antibody identifier, gene symbol, Ensembl ID, antibody staining pattern, siRNA identifier, cell number per replicate, and normalised Golgi and nuclear signal ratios for both experimental replicates. This allows readers to inspect the validation metrics directly and apply alternative thresholds if desired. We have also expanded the antibody information to include diluent conditions (4% FBS in 0.1% Triton-X100 for all HPA antibodies used at 2 μg/ml in the screening pipeline), enabling reproducibility and reuse of the dataset by the community.

        1. *The authors should expand upon the paragraph lines 155-162 to include more discussion on Figure S2A and S2B. The expanse of this data is some of the strongest in the paper, and it should be further discussed in-text. Also, the rationale behind the choice in the specific proteins that are included in these analysis / figures is not always clear in -text, and more attention should be spent on the narrowing down of the analysis to the final proteins. This is also especially important as many of the DDR proteins chosen are not the most common DDR proteins. Also note in text that the Golgi marker GM130 (presumably) was used for the screening, which means that some proteins which are only localizing to the TGN46 trans Golgi might have been lost in the validation step (or, explain why this is not the case).

      Response: __We expanded the Results text (__lines 141-163) to discuss Figures S2A and S2B in more depth and clarified the rationale for selecting the final set of DDR proteins taken forward, including considerations of pathway representation, bioinformatic annotations, literature-described roles in DNA repair. We would also note that the identity of the DDR proteins identified in this screen was determined by the HPA dataset and the unbiased validation pipeline rather than by prior assumptions about which repair factors would be present at the Golgi. The presence of less commonly studied DDR factors is therefore a direct reflection of the screen output, and we consider this one of the strengths of the approach.

      We would also like to address the reviewer's concern about potential GM130-based bias directly: at the widefield or confocal resolution used in the high-content screening pipeline, the Golgi apparatus appears as a single perinuclear structure and cis- and trans-Golgi subdomains cannot be resolved. GM130 was therefore used purely as a segmentation marker to define the Golgi compartment as a whole rather than to selectively label the cis-Golgi cisternae. The resulting Golgi mask captures signals from the entire Golgi ribbon, including trans-Golgi regions, meaning that proteins with exclusively trans-Golgi localisation would not have been systematically excluded at the screening stage. Sub-compartmental resolution of cis versus trans localisation was only possible in subsequent analyses using nocodazole-dispersed mini-stacks imaged by confocal microscopy with co-staining for both GM130 and TGN46.

      *5. The relationship between Giantin loss, increased cell proliferation, and elevated endogenous DNA damage as it relates to RAD51C remains insufficiently resolved and requires further clarification. Several of the proliferation assays used are not optimal for addressing changes in cell growth. For example, Figure 5O appears to quantify cell numbers by counting fields from IF images, which is an unconventional approach. This should be done by growth curves, luminescent viability or colony formation assays. In addition, this point will be greatly strengthened by performing rescue experiments for Giantin directly (instead of co-depletion as a means of rescue) and/or using a mutant of RAD51C that does not bind to Giantin. If these additional experiments are beyond the current scope, the conclusions should be softened in the discussion. *

      Response: We thank the reviewer for raising these important points, which we address in turn:

      Giantin-RAD51C relationship and mechanistic interpretation. __We acknowledge that establishing the full causal chain between Giantin loss, RAD51C mislocalisation, elevated endogenous DNA damage and increased cell proliferation is challenging within the scope of a single study, and we discuss this openly in the Discussion (__lines 555-564). Our evidence collectively includes: physical interaction between endogenous Giantin and RAD51C by co-immunoprecipitation (Figures 4H and 4I), premature nuclear accumulation of RAD51C upon Giantin depletion (Figures 4B-4E and 4J-4M), new additional experiment showing direct reduction of HR efficiency in the DR-GFP assay (Figure 5L), impaired ATM signalling (Figures 5J and 5M), elevated genomic instability (Figures 5A-5E), and epistatic rescue by RAD51C co-depletion (Figures 5M-5P). These observations are further contextualised by the established literature on RAD51C function: RAD51C is known to regulate CHK2 phosphorylation and cell cycle checkpoint signalling (Badie et al, 2009), stabilise replication forks (Somyajit et al, 2015), and promote RAD51 filament formation required for DSB repair (Prakash et al, 2015). Dysregulation of these functions through Giantin-dependent mislocalisation provides a mechanistically coherent explanation for the elevated genomic instability and altered proliferation we observe, and is entirely consistent with our model. Together, the experimental evidence and the published biology of RAD51C support a model in which Giantin spatially regulates RAD51C to maintain proper DDR signalling and HR capacity.

      We agree that separation-of-function tools would further strengthen this model and identify these as important future priorities. We wish to note however that both approaches face substantial technical barriers in this system. As described in our response to Reviewer 1 Major Comment 1, RAD51C tagging, whether by CRISPR-mediated endogenous editing or ectopic expression, consistently compromised cell viability and protein function, precluding the generation of interaction-deficient variants at physiological expression levels. Engineering an interaction-deficient Giantin mutant presents an independent and considerable challenge: Giantin is one of the largest Golgi matrix proteins (~376 kDa), composed almost entirely of extended coiled-coil domains that are intrinsically difficult to model structurally, and identifying a discrete interaction interface with RAD51C without disrupting the broader scaffolding function of the protein would require a dedicated structural and biochemical programme. We therefore consider these important but substantial future directions rather than straightforward experimental additions to the current study.

      Proliferation assays. Colony formation assays provide a rigorous readout of long-term proliferative capacity, and these data are presented for single knockdown conditions in Figures 5F-5I. The cell number quantification in Figure 5P was specifically included to assess the double knockdown of Giantin and RAD51C simultaneously, a condition not covered by the colony formation assay. We respectfully note that automated fluorescence microscopy-based nuclear counting is a well-established approach for measuring cell proliferation in siRNA screening contexts. Nuclear counting from high-content imaging has been used as a direct readout of cell growth and proliferation in RNAi screens (Boutros et al, 2004; Martin et al, 2014; Garvey et al, 2016; Mikheeva et al, 2024), and has been shown to produce results comparable to or superior to conventional viability assays including MTT and flow cytometry-based methods (Mikheeva et al, 2024). We have nonetheless clarified in the revised figure legend that Figure 5P reports relative cell number quantified by automated nuclear counting from high-content imaging fields as a secondary concordant measure alongside the colony formation data, rather than a standalone proliferation assay.

      *6. It is unclear from the discussion and from presented data whether proteins are directly transported between the Golgi and the nucleus, or whether they go into the cytoplasm for a transient period, presumably when they could interact with Importin β. There is also some data where cytoplasm signal could be quantified to address this (Figure 3E-I). *

      Response: We thank the reviewer for this mechanistic point. In the revised manuscript we have included cytoplasmic RAD51C signal quantification alongside Golgi and nuclear measurements for the doxorubicin time course (lines 297-305; Figure 3H). The cytoplasmic signal shows a moderate and gradual reduction distinct in both magnitude and kinetics from the sharp Golgi decrease, consistent with a transient cytoplasmic intermediate rather than a stable pool. Regarding the identity of the translocating pool, two observations directly support a Golgi origin. First, Importazole treatment prevents RAD51C release from the Golgi following genotoxic stress and simultaneously reduces nuclear RAD51C foci formation, demonstrating that Importin-β-mediated import is required both for Golgi clearance and for productive nuclear accumulation. Second, Giantin depletion which prematurely releases the Golgi-tethered pool, leads to aberrant nuclear RAD51C foci, directly linking the Golgi-anchored fraction to nuclear accumulation. Together these data support a model in which Golgi-resident RAD51C transits through the cytoplasm for Importin-β-mediated nuclear import. We acknowledge that without direct labelling of the Golgi-anchored fraction, the precise contribution of each subcellular pool to the nuclear accumulation cannot be fully resolved with the current dataset. We discuss the development of appropriate tagging strategies as an important future direction to dissect the dynamics of this process in further detail.

      *7. Statistical analysis on experiments with more than two samples need to be performed with ANOVA and a follow up post-hoc test, not with two-tailed unpaired Student's t-test, which only compares the control and each individual sample. This type of analysis inflates the Type 1 error rates (false positives) in your datasets. For example, the two-tailed unpaired Student's t-test is appropriate in Figure 2F-H, but not in Figure 3 when the samples are timepoints. In this case, a One-way ANOVA with Tukey's post-hoc test (if you want to show all coparisons), or Bonferroni/Sidak if you only need to compare several samples). *

      Response: We agree with the reviewer and thank them for highlighting this important statistical issue. We have revised the statistical analysis for all experiments involving more than two groups to avoid inflation of Type I error rates caused by multiple pairwise Student's t tests. Specifically, for Figures 3F-I, 4C-E, and Figure 5, the data were reanalysed using one way ANOVA followed by the appropriate multiple comparisons post hoc test. The Methods section and corresponding figure legends have been updated to clearly state the statistical tests used for each dataset.

      Minor Comments: General 1. Throughout the text, the reference to many figures and supplementary figures in the same sentence, with little discussion of the data therein makes it hard to follow. In-text referencing is particularly confusing in the section "Dual-localising DDR proteins dynamically redistribute between the Golgi and nucleus in response to specific types of DNA injuries," where the reader is switching between multiple figures and supplementary figures.

      __Response: __We thank the reviewer for this helpful comment. In the revised manuscript, we have improved the readability of the text and revised the figure references to make them clearer. We hope these revisions make the manuscript easier to follow and allow readers to better inspect the figures.

      1. In figures that display technical replicates as individual data points, consider distinguishing each replicate by using different marker shapes (e.g., repeat 1 = upright triangle; repeat 2 = inverted triangle; repeat 3 = diamond). This would provide additional clarity regarding the consistency and repeatability of each technical repeat.

      __Response: __We thank the reviewer for this suggestion. We have updated the data presentation to distinguish biological replicates using different marker shapes in datasets where replicate tracking is of particular relevance to the interpretation. For datasets where individual replicate values are already clearly separable, we have maintained the existing presentation to avoid unnecessary visual complexity.

      1. Make sure all western blot data includes the marker size (F3C and F5L has none, F4H/I have size of proteins not size of markers).

      __Response: __We added missing marker sizes to our western blot data in the revised manuscript.

      1. Be consistent with use of capitalization in figure legends and graph/figure labels.

      __Response: __We made sure that the capitalisation is consistent in figure legends, graph and figure legends in the revised manuscript.

      Figure 2

      In Figure 2A, please include in the figure itself that GM130 is the cis Golgi, and TGN46 is the trans Golgi (Figures should not be dependent on the text for full understanding).

      __Response: __We revised Figure 2A and 2C to label GM130 as cis-Golgi and TGN46 as trans-Golgi within the figure, making it self-explanatory.

      1. Why are LRIG2 and LRRIQ3 not included in the 2E cis vs trans Golgi data, when all other proteins from F1D are included? Include, or comment on in-text.

      __Response: __Both LRIG2 and LRRIQ3 are included in 2E in both the original and revised manuscript.

      1. Be sure to include scale bar data in each figure legend (F2A-E is currently missing it), and include updated scales included in the enlarged data.

      __Response: __Scale bar data is now included in each figure legend in the revised manuscript.

      1. In Figure 2F, make sure that the merged green channel is presented at the same intensity as it is in the single black and white channel, as the green looks very overexposed in several of the merged (CCAR1 DMSO merged is the most noticeable).

      __Response: __We agree and thank you for pointing this out. We have now revised the images and corrected the issue by updating all image panels in the figure.

      1. In Figure 2G, include the grey label in the figure legend.

      __Response: __We thank the reviewer for this comment. The grey label has now been included in the figure legend in the revised manuscript.

      1. In Figure 2G-H, the method of data presentation in the graphs coupled with the statistical analysis is confusing and should be expanded upon in the legend.

      __Response: __We agree that the amount of data presented may appear overwhelming. In the revised figure, we have adjusted the placement of the statistical annotations to improve clarity. Also, we improved the figure legend, to make the figure easier to read and interpret.

      Figure 3

      Figure E/F/G: Is there cytoplasmic quantification as well? Your rationale is that the Golgi RAD51C goes into the nucleus, but via the cytoplasm (due to Importin β import); do you see the cytoplasmic levels increase? Or is it too dilute to notice a difference? At least, this omission needs to be mentioned in-text.

      Figure H/I also include the quantification of the cytoplasmic fraction. It is mentioned in-text on line 272, but not quantified. This comes up as a big question: Do the proteins go directly between the Golgi and nucleus, or do they go through the cytoplasm?

      __Response: __We thank the reviewer for both of these related points. As described in our response to Major Comment 6 above, we have added cytoplasmic RAD51C signal quantification to the doxorubicin time course in the revised manuscript (Figure 3H) and discuss the implications for the proposed translocation route.

      Figure 3A, 3E, and if the data is present for 3J and 3M, could all benefit from using the nuclei staining as a mask to draw an outline around the nucleus in the other channels, and then show a merge in full color instead of a nuclei-only channel. Also note from the major comments, that this data especially is so small to see without enlarged images.

      __Response: __We thank the reviewer for this suggestion. Regarding nuclear outline masks, we tested this approach but found that the number of structures present in each field, including Golgi stacks, nuclear foci and cytoplasmic signal, made overlaid outlines visually confusing rather than clarifying. We have instead included a full-colour merged panel in Figure 3E, which we consider a cleaner way to distinguish nuclear from Golgi-localised signal while preserving the spatial context of the data.

      Regarding image size, we have added enlarged insets to Figures 3E, 3J and 3M in the revised manuscript. We have chosen to display multiple cells per panel rather than a single enlarged cell in order to capture the heterogeneity of the cell population, which we consider important for an accurate representation of the data. All figures have been provided as high-resolution image files to allow electronic magnification, enabling detailed inspection of the signal beyond what is visible in the printed version. We acknowledge that the constraints of standard journal figure dimensions limit how large individual panels can be, and the final layout will be optimised in line with the journal's formatting guidelines.

      *In-text discussion of the results from Figure 3 has an in-depth discussion of the NLS and NES in RAD51C, but this is not followed up on with site-directed mutagenesis or any data; perhaps move this to the discussion instead of results section. *

      __Response: __We have removed the discussion of the NLS and NES from the Results section.

      Figure 4

      Comments from earlier figures hold, with size of enlarged events and using the nuclei as an outline in the single channels. E.g. Figure 4F arrows appear to point to nothing at the chosen scale. The zoom in 4G is insufficient, as the chosen feature is so small it is not even visible in full fields.

      __Response: __We thank the reviewer for this comment. The arrows in Figure 4F indicate individual nocodazole-dispersed Golgi mini-stacks, which are displayed at higher magnification in Figure 4G. The full field in Figure 4F is intentionally shown to illustrate the degree of Golgi dispersion achieved by nocodazole treatment, a context that may be unfamiliar to readers outside the Golgi field, before zooming into a single representative mini-stack in Figure 4G for the cisternal localisation analysis.

      • Figure 4H and 4I need to show the size of the markers *

      __Response: __The size of the markers are now included in the revised manuscript.

      *The representative image in 4L for siGiantin pATM has no pATM foci, while the quantification in 4M has a reduction from ~50% to ~25%, so this image is not representative of this data, or the data quantification is not as strong as the actual data. *

      __Response: __We thank the reviewer for this observation. We wish to clarify that the quantification in Figure 4M reports the mean percentage of RAD51C foci co-localising with pATM across the entire cell population from three independent biological replicates. A reduction from ~50% to ~25% therefore reflects a population-level shift in co-localisation frequency, not that every individual cell shows exactly 25% co-localisation. Given the inherent cell-to-cell variability in foci number and co-localisation, individual cells will span a range of values around this mean, and the representative image shown in Figure 4L reflects one such cell.

      Figure 5

      *Figure 5A has overexposure of the nuclei stain in order to visualize micronuclei. Readjust the levels, and enlarge the images for better visualization. (is this DAPI-stained? Please label). *

      __Response: __The display levels of the nuclear stain in Figure 5A are intentionally set to allow visualisation of micronuclei, which are significantly dimmer than the main nucleus and would not be detectable at display settings optimised for the primary nuclear signal. This is standard practice in micronuclei quantification studies and is necessary to accurately identify and score these structures. The nuclear stain is Hoechst 33342, and this has been explicitly labelled in the revised figure legend.

      *Figure 5A-C: Figure 5A does not show siRAD51, but it is included in the DMSO only graph. Please either show RAD51 data in 5A and 5C, or do not include in 5B. If the DMSO and ETO experiments were performed separately and that accounts for this discrepancy, then show separately. *

      __Response: __We thank the reviewer for this observation. The siRAD51C condition is included in Figure 5B as an internal positive control, consistent with its well-established role in genome stability. RAD51C depletion combined with etoposide treatment resulted in severe cellular toxicity and insufficient cell numbers for reliable quantification, and this condition was therefore excluded from Figure 5C. This has been clarified in the revised figure legend.

      *Figure 5M the white label is difficult to see in the green box. *

      __Response: __We have updated the label colour in Figure 5M to improve visibility against the green background in the revised manuscript.

      * Supplementary Figures*

      Consider reordering/ subdividing supplementary figures for ease of reference during reading.

      Response: We thank the reviewer for this suggestion. The current supplementary figure structure was intentionally designed to minimise the total number of supplementary figures and maintain a logical correspondence with the main figures, avoiding a situation where readers need to navigate an extensive supplementary section, a concern the reviewer raised regarding figure presentation. We believe the current organisation achieves a reasonable balance between completeness and accessibility.

      SF1 and SF2A: Include enlarged boxes or full images so that data is visible.

      __Response: __As described in our response to Major Comment 1, all figures have been provided as high-resolution image files to allow electronic magnification. Space constraints within standard journal figure dimensions preclude the addition of enlarged insets to all supplementary panels without substantially reducing the contextual field of view.

      *SF3A, SF4A, and SF5A: Include enlarged images, include nuclei marker if possible (otherwise, the nuclear intensity is not proven nuclear). *

      Response: We appreciate the suggestion, but adding enlarged insets and nuclei markers to all panels in Figures S3A, S4A and S5A would disproportionately increase the length and complexity of the supplementary section, making it harder rather than easier to navigate. The nuclear intensity measurements are derived from automated segmentation of the Hoechst channel using CellProfiler, which reliably defines nuclear boundaries independently of the antibody channel, and are therefore not dependent on visual confirmation of nuclear localisation in each representative image.

      *SF3B-C, SF4B-C, and SF5 B-D: Change the data presentation in the same method as changed for F2G-H. *

      Response: We have updated the figure legends for Figures S3B-C, S4B-C and S5B-D to improve readability.

      SF3D: List proteins in the same order as in B and C.

      Response: The proteins in Figure S3D are listed in the same order as in Figures S3B and S3C.

      SF6D: Label M N and C more clearly. Include size labels.

      Response: We have added clearer labels for the membrane (M), nuclear (N) and cytoplasmic (C) fractions and included molecular weight size markers in the revised Figure S6D.

      *SF7A-B: Include enlarged. *

      Response: We respectfully note that the purpose of Figures S7A-B is to display the overall cellular response to inhibitor treatments across the cell population, rather than to highlight specific subcellular structures. Enlarged insets would reduce the number of cells visible per panel and would not add scientific value in this context. The Golgi and nuclear signals are clearly visible at the chosen magnification.

      *SF8: Include arrows as in previous experiments, include enlarge. *

      Response: Arrows have been added to Figure S8 to indicate Golgi and nuclear RAD51C signal, consistent with the annotation style used in the main figures. The images already show two representative cells per condition to maximise the visible detail at the chosen scale.

      *SF9G: G is labelled, but not included. *

      Response: Figure S9G has been added in the revised manuscript, showing the pan-cancer overall survival map for GOLGB1 expression across all TCGA cohorts generated using GEPIA2. The figure legend has been updated accordingly.

      *Reviewer #3 (Significance (Required)): *

      * The work finds new roles for the Golgi in regulation of DNA damage responses and the screen could be an important dataset (but results need to be made available) for the DNA repair community. The scope of the initial screen of HPA antibodies and Golgi/Nuclear dual proteomes is impressive, and the overlap of DDR proteins is characterized for fifteen different proteins at a sub-compartmental level. The work provides important insights into RAD51C regulation, however, there are key mechanistic insights and control experiments missing from the studies involving RAD51C and Giantin, dampening its impact. The idea of an alternative cellular compartment for storage of DDR factors prior to damage is interesting, and suggests the spatial regulation of specific lesion responses are stored in specific sub-compartments of the Golgi, which could contribute to repair regulation.*

      References:

      Adamson B, Smogorzewska A, Sigoillot FD, King RW & Elledge SJ (2012) A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat Cell Biol 14: 318-328

      Badie S, Liao C, Thanasoula M, Barber P, Hill MA & Tarsounas M (2009) RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. J Cell Biol 185: 587-600

      Bergen DJM, Stevenson NL, Skinner REH, Stephens DJ & Hammond CL (2017) The Golgi matrix protein giantin is required for normal cilia function in zebrafish. Biol Open 6: 1180-1189

      Berti M, Teloni F, Mijic S, Ursich S, Fuchs J, Palumbieri MD, Krietsch J, Schmid JA, Garcin EB, Gon S, et al (2020) Sequential role of RAD51 paralog complexes in replication fork remodeling and restart. Nat Commun 11: 3531

      Boutros M, Kiger AA, Armknecht S, Kerr K, Hild M, Koch B, Haas SA, Paro R, Perrimon N & Heidelberg Fly Array Consortium (2004) Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303: 832-835

      Brinkmann K, Schell M, Hoppe T & Kashkar H (2015) Regulation of the DNA damage response by ubiquitin conjugation. Front Genet 6: 98

      Garvey CM, Spiller E, Lindsay D, Chiang C-T, Choi NC, Agus DB, Mallick P, Foo J & Mumenthaler SM (2016) A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep 6: 29752

      Ghannoum S, Fantini D, Zahoor M, Reiterer V, Phuyal S, Leoncio Netto W, Sørensen Ø, Iyer A, Sengupta D, Prasmickaite L, et al (2023) A combined experimental-computational approach uncovers a role for the Golgi matrix protein Giantin in breast cancer progression. PLoS Comput Biol 19: e1010995

      Greenhough LA, Liang C-C, Belan O, Kunzelmann S, Maslen S, Rodrigo-Brenni MC, Anand R, Skehel M, Boulton SJ & West SC (2023) Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor. Nature619: 650-657

      Halim VA, García-Santisteban I, Warmerdam DO, van den Broek B, Heck AJR, Mohammed S & Medema RH (2018) Doxorubicin-induced DNA damage causes extensive ubiquitination of ribosomal proteins associated with a decrease in protein translation. Mol Cell Proteomics 17: 2297-2308

      Koreishi M, Gniadek TJ, Yu S, Masuda J, Honjo Y & Satoh A (2013) The golgin tether giantin regulates the secretory pathway by controlling stack organization within Golgi apparatus. PLoS One 8: e59821

      Martin HL, Adams M, Higgins J, Bond J, Morrison EE, Bell SM, Warriner S, Nelson A & Tomlinson DC (2014) High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers. PLoS One 9: e88338

      Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, et al (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410-414

      Mikheeva AM, Bogomolov MA, Gasca VA, Sementsov MV, Spirin PV, Prassolov VS & Lebedev TD (2024) Improving the power of drug toxicity measurements by quantitative nuclei imaging. Cell Death Discov 10: 181

      Ovejero S, Kumanski S, Soulet C, Azarli J, Pardo B, Santt O, Constantinou A, Pasero P & Moriel-Carretero M (2023) A sterol-PI(4)P exchanger modulates the Tel1/ATM axis of the DNA damage response. EMBO J 42: e112684

      Prakash R, Rawal Y, Sullivan MR, Grundy MK, Bret H, Mihalevic MJ, Rein HL, Baird JM, Darrah K, Zhang F, et al(2022) Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants. Proc Natl Acad Sci U S A 119: e2202727119

      Prakash R, Zhang Y, Feng W & Jasin M (2015) Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol 7: a016600

      Presley JF, Cole NB, Schroer TA, Hirschberg K, Zaal KJM & Lippincott-Schwartz J (1997) ER-to-Golgi transport visualized in living cells. Nature 389: 81-85

      Rawal Y, Jia L, Meir A, Zhou S, Kaur H, Ruben EA, Kwon Y, Bernstein KA, Jasin M, Taylor AB, et al (2023) Structural insights into BCDX2 complex function in homologous recombination. Nature 619: 640-649

      Somyajit K, Saxena S, Babu S, Mishra A & Nagaraju G (2015) Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart. Nucleic Acids Res 43: 9835-9855

      Soulet C, Catalan J & Moriel-Carretero M (2026) The DNA Damage Response kinase ATM restricts Golgi extension. bioRxiv

      Stadler C, Hjelmare M, Neumann B, Jonasson K, Pepperkok R, Uhlén M & Lundberg E (2012) Systematic validation of antibody binding and protein subcellular localization using siRNA and confocal microscopy. J Proteomics 75: 2236-2251

      Stevenson NL, Bergen DJM, Lu Y, Prada-Sanchez ME, Kadler KE, Hammond CL & Stephens DJ (2021) Correction: Giantin is required for intracellular N-terminal processing of type I procollagen. J Cell Biol 220

      Tang Z, Kang B, Li C, Chen T & Zhang Z (2019) GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 47: W556-W560

      Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE & Altman RB (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21: 440-446

      van der Zanden SY, Qiao X & Neefjes J (2021) New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J 288: 6095-6111

      Zhang Y-W, Otterness DM, Chiang GG, Xie W, Liu Y-C, Mercurio F & Abraham RT (2005) Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 19: 607-618

    1. Author response:

      The following is the authors’ response to the original reviews.

      Reviewer #1 (Public review):

      Summary:

      This work demonstrates that MORC2 undergoes phase separation (PS) in cells to form nuclear condensates, and the authors demonstrate convincingly the interactions responsible for this phase separation. Specifically, the authors make good use of crystallography and NMR to identify multiple protein: protein interactions and use EMSA to confirm protein: DNA interactions. These interactions work together to promote in vitro and in cell phase separation and boost ATPase activity by the catalytic domain of MORC2.

      However, the authors have very weak evidence supporting their potentially valuable claim that MORC2 PS is important for the appropriate gene regulatory role of MORC2 in cells. Exploring causal links between PS and function is an important need in the phase separation field, particularly as regards the role of condensates in gene regulation, and is a non-trivial matter. Any study with convincing data on this matter will be very important. For this reason, it is crucial to properly explore the alternative possibility that soluble complexes, existing in the same conditions as phase-separated condensates, are the functional species. It is also critical to keep in mind that, while a specific protein domain may be essential for PS, this does not mean its only important function pertains to PS.

      In this study, the authors do not sufficiently explore the role that soluble MORC2 complexes may play alongside MORC2 condensates. Neither do they include enough data to solidly show that domain deletion leads to phenotypes via a loss of phase separation per se, rather than the loss of phase separation being a microscopically visible result, not cause, of an underlying shift in protein function. For these reasons, the authors' conclusions regarding the functional role of MORC2 condensates are based on incomplete data. This also dampens the utility of this work as a whole, since the very nice work detailing the mechanism of MORC2 PS is not paired with strong data showing the importance of this observation.

      We thank the reviewer for this thoughtful and constructive critique. We agree that establishing a causal link between phase separation (PS) and biological function—particularly in transcriptional regulation—is a central and non-trivial challenge in the condensate field. We also appreciate the reviewer’s emphasis on two critical alternative interpretations: (i) that soluble MORC2 complexes, rather than condensates, may represent the primary functional species, and (ii) that loss of phase separation upon domain deletion could reflect a downstream consequence of altered protein function rather than its cause.

      To address these concerns, we have performed a series of new experiments specifically designed to decouple condensate formation, and condensate dynamics, thereby allowing us to more rigorously interrogate the functional relevance of MORC2 condensates.

      First, to overcome the limitation of domain deletions which may affect MORC2 function beyond phase separation we introduced a micropeptide-based kill switch (KS) to the C terminus of MORC2. This strategy has recently emerged as a powerful approach to selectively reduce condensate dynamics without disrupting protein expression, folding, or domain architecture [1]. Importantly, unlike CC3 or IDRa deletions, MORC2+KS robustly form nuclear condensates but exhibits markedly reduced internal dynamics, as demonstrated by FRAP analyses showing minimal fluorescence recovery after photo bleaching (Fig. 6a-c). This strategy therefore allows us to perturb condensate material properties independently of MORC2 domain integrity.

      Second, we systematically compared the transcriptional consequences of rescuing MORC2-knockout HeLa cells with MORC2FL, condensation-deficient mutants (ΔCC3 and ΔIDRa), and the dynamics-defective MORC2+KS (Fig. 6d). Despite being expressed at substantially higher levels than MORC2FL (Fig. 6e), all three mutants showed a striking and consistent failure to restore MORC2-dependent transcriptional regulation (Fig. 6f-h). This effect was particularly pronounced for transcriptionally repressed genes, including two sets of high-confidence MORC2 targets reported in prior studies (Fig. 6i and Fig.S10). These findings demonstrate that neither increased protein abundance nor the mere presence of condensate-like structures alone is sufficient to restore MORC2 function.

      Third, our data instead support a model in which both soluble MORC2 complexes and dynamic MORC2 condensates are required for full transcriptional regulation activity. While soluble MORC2 is likely involved in target recognition and complex assembly, our results indicate that proper condensate formation—and critically, condensate dynamics—are essential for effective transcriptional repression and activation. The inability of the MORC2+KS mutant to rescue transcriptional defects, despite intact condensate formation, points away from a model in which MORC2 condensates represent only microscopically visible byproducts of MORC2 activity.

      We believe these new data strengthen the manuscript by pairing the detailed mechanistic dissection of MORC2 phase separation with direct functional evidence, enhancing the conceptual impact and biological significance of the study.

      Strengths:

      Static light scattering and crystallography are nicely used to demonstrate the dimerization of MORC2FL and to discover the structure of the CC3 domain dimer, presumably responsible for the dimerization of MORC2FL (Figure 1).

      Extensive use of deletion mutants in multiple cell lines is used to identify regions of MORC2 that are important for forming condensates in the nucleus: the IBD, IDR, and CC3 domains are found to be essential for condensate formation, while the CW domain plays an unknown role in condensate morphology (Figure 3). The authors use NMR to further identify that the IBD domain seems to interact with the first third of the centrally located IDR, termed IDRa, but not with the latter two-thirds of the IDR domain (Figure 4). This leads them to propose that phase separation is the product of IDB:IDRa interaction, CC3 dimerization, and an unknown but important role for the CW domain.

      Based on the observation that removal of the NLS resulted in diffuse cytoplasmic localization, they hypothesized that DNA may play an important role in MORC2 PS. EMSA was used to demonstrate interaction between DNA and several MORC2 domains: CC1, CC2, IDR, and TCD-CC3-IBD. Further in vitro microscopy with purified MORC2 showed that DNA addition significantly reduces MORC2 saturation concentration (Figure 5).

      These assays convincingly demonstrate that MORC2 phase separates in cells, and identify the protein domains and interactions responsible for this phenomenon, with the notable caveat that the role of the CW domain here is left unexplored.

      We appreciate the reviewer for their positive and detailed assessment of the strengths of our study. Our understanding of the CW domain’s function remains preliminary. Although we observed that the CW domain can influence condensate size, the IDR, IBD, and CC3 domains constitute the core structural elements driving phase separation. Consequently, the CW domain was not a primary focus of the current study. Nonetheless, investigating its functional contributions represents an interesting avenue for future work.

      Weaknesses:

      Although the authors demonstrated phase separation of MORC2FL, their evidence that this plays a functional role in the cell is incomplete.

      Firstly, looking at differentially upregulated genes under MORC2FL overexpression, the authors acknowledge that only 10% are shared with differentially regulated genes identified in other MORC2FL overexpression studies (Figure 6c, d). No explanation is given for why this overlap is so low, making it difficult to trust conclusions from this data set.

      We thank the reviewer for raising this important concern. In response, we have improved the quality and robustness of our RNA-seq analysis by repeating the experiments with optimized sample handling and increased sequencing depth. Using this updated dataset, we identified a considerably higher overlap between MORC2-regulated genes in our study and those reported previously.

      Specifically, we observed 84 overlapping genes with the study by Nikole L. Fendler et al. [2], corresponding to approximately 32% of the MORC2-regulated genes reported in that work (Fig. 6i). In addition, we identified 102 overlapping genes with the dataset reported by Iva A. Tchasovnikarova et al. [3], representing approximately 22% of the genes identified in that study (Fig. S10b).

      We note that complete concordance with previous reports is not expected, given substantial differences in experimental design. For example, Fendler et al. employed a doxycycline-inducible MORC2 expression system [2], whereas our study relies on transient overexpression in MORC2-knockout HeLa cells. In contrast, Tchasovnikarova et al. compared transcriptomes between MORC2 knockout and wild-type cells [3], rather than MORC2 rescue conditions. Moreover, RNA-seq results are inherently influenced by cell line batch variability, sequencing depth, and analysis pipelines, all of which differ across studies.

      Taken together, we consider an overlap in the range of ~20–30% to be reasonable and biologically meaningful in the context of these experimental differences, and we believe that the revised RNA-seq data provide a more reliable foundation for our conclusions regarding MORC2-dependent transcriptional regulation.

      Secondly, of the 21 genes shared in this study and in earlier studies, the authors note that the differential regulation is less pronounced when a phase-separation-deficient MORC2 mutant is overexpressed, rather than MORC2FL (Figure 6e). This is taken as evidence that phase separation is important for the proper function of MORC2. However, no consideration is made for the alternative possibility that the mutant, lacking the CC3 dimerization domain, may result in non-functional complexes involving MORC2, eliminating the need for a PS-centric conclusion. To take the overexpression data as solid evidence for a functional role of MORC2 PS, the authors would need to test the alternative, soluble complex hypothesis. Furthermore, there seems to be low replicate consistency for the MORC2 mutant condition (Figure S6a), with replicate 3 being markedly upregulated when compared to replicates 1 and 2.

      We thank the reviewer for raising these important concerns. In the revised manuscript, we have substantially strengthened both the experimental evidence and the data presentation to directly address the alternative “soluble complex” interpretation as well as the issue of replicate consistency. Specifically, we now provide data that clarify the functional impact of phase-separation-deficient MORC2 mutants and explicitly show replicate-level RNA-seq analyses. The Fig. 6 and Fig. S10support these improvements and enhance both the robustness and transparency of our transcriptional analyses. Collectively, these revisions directly address the reviewer’s concerns regarding the functional interpretation of MORC2 phase separation.

      Thirdly, the authors close by examining the in-cell PS capabilities and ATPase activity of several disease-associated mutants of MORC2 (Figure 7). However, the relevance of these mutants to the past 6 figures is unclear. None of these mutations is in regions identified as important for PS. Two of the mutations result in a higher percentage of the cell population being condensate-positive, but this is not seemingly connected to ATPase activity, as only one of these two mutants has increased ATPase activity. Figure 7 does not add any support to the main hypotheses in the paper, and nowhere in the paper do the authors investigate the protein regions where the mutations in Figure 7 are found.

      We thank the reviewer for raising this point regarding Fig. 7. At the current stage, the results for disease-associated mutations are primarily descriptive. While we observed that certain mutations clustered at the N-terminus can affect MORC2 condensate formation, ATPase activity, and DNA binding, we did not identify a mechanistic explanation for these correlations. Notably, the T424R mutation, previously reported to significantly enhance ATPase activity [4], also increased both intracellular condensate formation and in vitro DNA binding in our experiments. In contrast, other mutations did not show such consistent effects. Previous studies have established that MORC2’s ATP-binding and DNA-binding activities are independent [4]. Our results further suggest that MORC2’s phase separation behavior is independent of both ATP and DNA binding affinity, although existing evidence hints at potential cross-regulatory interactions among these three functions.

      We would also like to emphasize an additional observation that may help contextualize the relevance of N-terminal mutations. Although deletion of the MORC2 N-terminus does not prevent the remaining C-terminal region from forming nuclear condensates, these C-terminal condensates exhibit a marked loss of fluorescence recovery in FRAP assays (Fig. S11). This finding suggests that while the N-terminus is not strictly required for condensate assembly, it plays an important role in regulating condensate fluidity. Accordingly, disease-associated mutations distributed across the N-terminal region may influence MORC2 function by modulating condensate material properties rather than condensate formation per se. Based on this hypothesis, we evaluated the fluidity of condensates formed by the E236G and T424R mutants. FRAP measurements indicated substantially reduced fluorescence recovery in E236G, whereas T424R exerted minimal effects (Fig. 7e, f).

      Overall, our interpretation of the results in Fig. 7 is still at a preliminary stage. Nevertheless, the role of the MORC2 N-terminus in modulating condensate fluidity, together with the observed impairment caused by the E236G mutation, appears to be robust, although the underlying mechanism remains to be elucidated. We have incorporated additional discussion on this point and consider it an important direction for future study.

      Reviewer #1 (Recommendations for the authors):

      (1) Why does MORC2 overexpression lead to changes in gene regulation that are so different from past MORC2 overexpression studies? This is unsettling to me.

      (2) Likewise, why is replicate 3 for the MORC2ΔCC3 variant so different from replicates 1 and 2? Perhaps repeating this experiment would be helpful, both for showing better repeatability and perhaps as regards pulling out a stronger phenotype.

      We have repeated the experiments and obtained improved data quality.

      (3) A better explanation of the relevance of Figure 7 to the story of the rest of the paper, especially the phase-separation of MORC2, would be important to improving this paper.

      We thank the reviewer for this suggestion. We have performed additional experiments and expanded the discussion.

      (4) Are expression levels of mutant proteins in Figure 7 uniform between mutants? If not, is it possible that expression levels might account for the difference in condensate-positive cells between mutants?

      We cannot fully exclude the possibility that differences in expression levels may contribute to the observed differences among mutants. In our experiments, equal amounts of plasmid DNA were used for transfection across all conditions. Although we did not directly quantify post-transfection protein expression levels by immunoblotting or similar approaches, even if certain mutations were to affect protein expression, it would be technically challenging to further optimize the strategy to fully normalize expression levels across mutants.

      Importantly, we note that MORC2 does not form condensates in all transfected cells, even when EGFP fluorescence indicates robust expression levels that are comparable to, or even exceed, those observed in condensate-positive cells. This observation suggests that high expression alone is not sufficient to drive MORC2 phase separation in cells. Therefore, we do not favor the interpretation that the E236K and T424R mutations enhance MORC2 condensation simply by increasing MORC2 protein expression levels.

      Minor:

      (1) I would suggest considering using the term "dynamic" rather than "liquid-like", as FRAP is technically a measurement of the dynamicity of a protein within a volume, rather than a measurement of the actual fluidity of that volume.

      We thank the reviewer for this helpful suggestion. We agree that FRAP measurements primarily report protein mobility and condensate dynamics rather than the physical fluidity of the condensates. We have therefore revised the manuscript to replace “liquid-like” with “dynamic” where conclusions are based on FRAP analyses.

      (2) A further investigation of the role of the CW domain would be very interesting, since it clearly has a major role in condensate morphology. Perhaps CW confers important heterotypic interactions which contribute to compositional control of the MORC2 condensates, and thus function and morphology? However, due to the complexity of this specific question and the potentially marginal improvement offered by this paper, I do not think this is a critical addition.

      We thank the reviewer for this insightful suggestion. We have noted this possibility in the Discussion as an important avenue for future investigation.

      (3) Why is TCD not tested alone by EMSA for affinity to DNA in Figure 5?

      Our inference regarding the DNA-binding capacity of the TCD domain was based on comparative EMSA analyses. Specifically, we found that the TCD–CC3–IBD fragment was able to bind DNA, whereas the CC3–IBD fragment alone showed no detectable DNA binding. From this comparison, we inferred that the TCD domain is responsible for the observed DNA-binding activity.

      Because the TCD domain does not affect MORC2 condensate formation, it was not a central focus of the present study, which primarily aims to elucidate the mechanisms underlying MORC2 phase separation and its functional relevance. For this reason, we did not further test TCD alone by EMSA in Figure 5.

      Reviewer #2 (Public review):

      Summary:

      The study by Zhang et al. focuses on how phase separation of a chromatin-associated protein MORC2, could regulate gene expression. Their study shows that MORC2 forms dynamic nuclear condensates in cells. In vitro, MORC2 phase separation is driven by dimerization and multivalent interactions involving the C-terminal domain. A key finding is that the intrinsically disordered region (IDR) of MORC2 exhibits strong DNA binding. They report that DNA binding enhances MORC2's phase separation and its ATPase activity, offering new insights into how MORC2 contributes to chromatin organization and gene regulation. The authors try to correlate MORC2's condensate-forming ability with its gene silencing function, but this warrants additional controls and validation. Moreover, they investigate the effect of disease-linked mutations in the N-terminal domain of MORC2 on its ability to form cellular condensates, ATPase activity, and DNA-binding, though the findings appear inconclusive in the manuscript's current form.

      Thank you for your thorough and constructive review of our manuscript. In response to the concerns raised regarding the functional relevance of MORC2 condensate formation, we have redesigned and expanded the experiments presented in Fig. 6 and Fig. S6 to directly link MORC2’s condensate-forming capacity with its transcriptional regulatory function. These new experiments provide additional controls and validation, strengthening the causal relationship between MORC2 condensate dynamics and gene regulation.

      At the current stage, the results for disease-associated mutations are descriptive. While we observed that certain mutations clustered at the N-terminus can affect MORC2 condensate formation, ATPase activity, and DNA binding, we did not identify a mechanistic explanation for these correlations. Notably, the T424R mutation, previously reported to significantly enhance ATPase activity [4], also increased both intracellular condensate formation and in vitro DNA binding in our experiments. In contrast, other mutations did not show such consistent effects. Previous studies have established that MORC2’s ATP-binding and DNA-binding activities are independent [4]. Our results further suggest that MORC2’s phase separation behavior is also independent of both ATP and DNA binding, although existing evidence hints at potential cross-regulatory interactions among these three functions.

      Strengths:

      The authors determined a 3.1 Å resolution crystal structure of the dimeric coiled-coil 3 (CC3) domain of MORC2, revealing a hydrophobic interface that stabilizes dimer formation. They present extensive evidence that MORC2 undergoes liquid-liquid phase separation (LLPS) across multiple contexts, including in vitro, in cellulo, and in vivo. Through systematic cellular screening, they identified the C-terminal domain of MORC2 as a key driver of condensate formation. Biophysical and biochemical analyses further show that the IDR within the C-terminal domain interacts with the C-terminal end region (IBD) and also exhibits strong DNA-binding capacity, both of which promote MORC2 phase separation. Together, this study emphasizes that interactions mediated by multiple domains-CC3, IDR, and IBD- drives MORC2 phase separation. Finally, the authors quantified the effect of removing the CC3 on the upregulation and downregulation of target gene expression.

      We thank the reviewer for their appreciation of the key findings presented in this manuscript.

      Weaknesses:

      Though the findings appear compelling in isolation, the study lacks discussion on how its findings compare with previous studies. Particularly in the context of MORC2-DNA binding, there are previous studies extensively exploring MORC2-DNA binding (Tan, W., Park, J., Venugopal, H. et al. Nat Commun 2025), and its effect on ATPase activity (ref 22). The contradictory results in ref 22 about the impact of DNA-binding on ATPase activity, and ATPase activity on transcriptional repression, warrant proper discussion. The authors performed extensive in-cellulo screening for the investigation of domain contribution in MORC2 condensate formation, but the study does not consider/discuss the possibility of some indirect contributions from the complex cellular environment. Alternatively, the domain-specific contributions could be quantified in vitro by comparing phase diagrams for their variants. While the basis of this study is to investigate the mechanism of MORC2 condensate-mediated gene silencing, the findings in Figure 6 appear incomplete because the CC3 deletion not only affects phase separation of MORC2 but also dimerization. Furthermore, their investigation on disease-linked MORC2 mutations appears very preliminary and inconclusive because there are no obvious trends from the data. Overall, the discussion appears weak as it is missing references to previous studies and, most importantly, how their findings compare to others'.

      We thank the reviewer for their careful assessment of MORC2’s DNA-binding properties and its relationship with ATPase and transcriptional activities. We would like to offer the following clarifications to address these concerns, which will also be incorporated into the Discussion section of the revised manuscript.

      First, recent work by Tan et al. [5] similarly identified multiple DNA-binding sites in MORC2, consistent with our findings, though there are discrepancies in the precise binding regions. In particular, they reported that isolated CC1 and CC2 domains do not bind 60 bp dsDNA, which contrasts with our observations. We attribute this difference to the types of DNA used in the assays. In our study, we employed 601 DNA, a defined nucleosome-positioning sequence, which differs substantially from randomly designed short dsDNA. For instance, prior work by Christopher H. Douse et al. [54] also confirmed that MORC2’s CC1 domain can bind 601 DNA.

      Second, in the study by Fendler et al. [2], DNA binding was reported to reduce MORC2’s ATPase activity—an observation that appears inconsistent with the results presented in our Fig. 5j. A critical distinction between the two studies lies in the experimental systems used: Fendler et al. [2] employed MORC2 constructs and 35 bp double-stranded DNA (dsDNA), whereas our experiments utilized full-length MORC2 and 601 bp DNA (a sequence with high nucleosome assembly potential). These differences including the absence of potentially regulatory C-terminal regions in the truncated construct and the varying length/structural properties of the DNA substrates introduce variables that substantially complicate direct comparative analysis of ATPase activity outcomes.

      Separately, Douse et al. [4] demonstrated that the efficiency of HUSH complex-dependent epigenetic silencing decreases as MORC2’s ATP hydrolysis rate increases, implying an inverse relationship between ATPase activity and silencing function. Notably, our current work has not established a direct mechanistic link between MORC2 phase separation and its ATPase activity. Thus, we refrain from inferring that the effect of MORC2 phase separation on transcriptional repression is mediated through modulation of its ATPase function this remains an important question to address in future studies.

      Finally, we have redesigned and expanded the experiments presented in Fig. 6 and Fig. S6 to directly link MORC2’s condensate-forming capacity with its transcriptional regulatory function.

      Reviewer #2 (Recommendations for the authors):

      Major concerns:

      (1) Unaddressed discrepancies with the previous study:

      (a) Inadequate discussion of Reference 22 and apparent contradictions. Notably, Reference 22 provides evidence for reduced ATPase activity upon DNA binding, in contrast to the current study's observations. Moreover, Reference 22 demonstrates that ATP hydrolysis (ATPase activity) is inversely associated with MORC2-mediated gene silencing, whereas this study concludes that 'the silencing function of MORC2 requires its ATPase activity'. These apparent contradictions warrant a more thorough discussion to reconcile the differences, including potential mechanistic explanations and experimental context that could account for the discrepancies. Additionally, the authors should discuss potential reasons why Ref. 22 may not have observed phase separation during MORC2 biophysical analysis. For instance, in Ref. 22, SEC-MALS was performed at 2 mg/mL (~16 µM) MORC2 FL in the presence of 150 mM NaCl, conditions that could influence phase behavior based on the current manuscript's results. Addressing whether differences in protein construct, buffer composition, or experimental design might account for this discrepancy would strengthen the discussion.

      We thank the reviewer for pointing out the apparent discrepancies between our results and those reported in Ref. 22. We agree that these differences warrant explicit discussion, and we have revised the Discussion accordingly to clarify the experimental and conceptual distinctions between the two studies.

      First, regarding the effect of DNA binding on ATPase activity, Ref. 22 examined MORC2 ATPase activity under conditions where MORC2 does not undergo detectable phase separation, whereas our ATPase assays were performed under conditions in which MORC2 readily forms condensates in the presence of DNA. We therefore propose that the observed increase in ATPase activity in our study may reflect a distinct biochemical regime in which phase separation and/or high local protein concentration modulates enzymatic activity. Importantly, our data do not exclude the possibility that DNA binding per se can inhibit ATPase activity under non-condensing conditions, as reported in Ref. 22.

      Second, with respect to transcriptional repression, Ref. 22 reported an inverse correlation between ATP hydrolysis and MORC2-mediated silencing, whereas our study finds that ATPase activity is required for efficient repression. We suggest that these observations are not necessarily contradictory but may reflect different regulatory layers of MORC2 function. Specifically, ATP binding and hydrolysis may be required for MORC2 structural remodeling and chromatin engagement, while excessive or dysregulated ATP hydrolysis could impair stable silencing complexes, as suggested previously [4]. We now explicitly discuss this possibility in the revised manuscript.

      Finally, we appreciate the reviewer’s suggestion regarding the absence of phase separation in Ref. 22. Indeed, SEC-MALS experiments in Ref. 22 were conducted at ~16 µM MORC2 in the presence of 150 mM NaCl (the purification condition is 500 mM NaCl, 10% glycerol), conditions that based on our phase diagrams—are close to or above the saturation concentration but also strongly influenced by ionic strength. This combination of factors explains why the UV peak from SEC-MALS is not indicative of a homogeneous sample [3].

      (b) The DNA binding capacity of individual MORC2 domains was tested in Fig. 5. IDR appears to be the strongest DNA binder among others. Is this the effect of IDR being isolated from the rest of the protein? A recent paper (Tan, W., Park, J., Venugopal, H. et al. Nat Commun 2025) also investigated DNA binding capacity of different regions of MORC2 using hydrogen-deuterium exchange experiments and EMSA. Interestingly, it can be seen in Figure S9 that the DNA binding capacity of different regions changes when compared together to when in isolation (MORC2 1-603 vs 1-265; 1-495; 496-603). In line with the above, MORC2 IDR's interaction with DNA warrants additional investigation, taking the system as a whole to avoid misinterpretation arising from non-specific interactions.

      We appreciate the reviewer’s insightful comments regarding domain-specific DNA binding and the potential caveats of studying isolated regions. In Figure 5, our EMSA analyses show that the isolated IDR exhibits the strongest DNA-binding signal among the tested fragments. We agree that this observation may, at least in part, reflect the removal of structural or regulatory constraints imposed by the full-length protein.

      Consistent with the reviewer’s point, Tan et al. [5] demonstrated that DNA-binding behavior of MORC2 regions differs when analyzed in isolation versus in the context of larger constructs. We have now incorporated this comparison into the Discussion and explicitly note that DNA binding by the IDR should be interpreted as a contextual and potentially cooperative property rather than an autonomous function.

      Importantly, our conclusions do not rely on the IDR acting as an independent DNA-binding module in vivo. Rather, we propose that the IDR contributes to DNA engagement and phase behavior within the architectural framework of full-length MORC2. We now emphasize this limitation and highlight the need for future studies that probe DNA binding in the context of intact MORC2 or minimally perturbed constructs.

      (2) MORC2 DNA binding impacting phase separation and ATPase activity:

      While it is clear that MORC2: DNA interaction facilitates MORC2 phase separation, the impact on ATPase activity is not conclusive. First, they observe an opposite trend (compared to ref. 22) for DNA binding on MORC2's ATPase activity. Secondly, it is not clear if the increase in ATPase activity is mediated by DNA binding or phase separation. The ATPase activity was measured at 1 µM MORC2 protein concentration in the presence of DNA, where MORC2 appears to phase separate. To draw more definitive conclusions, additional controls are necessary. Specifically, a phase separation-deficient mutant (from this study) and a DNA-binding-deficient mutant (see ref. 22) should be included to disentangle the contributions of DNA binding and phase separation to ATPase activity. The choice of ATP-binding-deficient mutant N39A as a negative control seems inconclusive in this regard. Additionally, why is there an increase in ATP hydrolysis rate for the ATP-binding-deficient mutant in the presence of DNA, resulting in ATP hydrolysis rates similar to WT MORC2? This raises further questions about the underlying mechanism.

      We agree with the reviewer that disentangling the contributions of DNA binding and phase separation to ATPase activity is challenging and that our current data do not fully resolve this issue. As noted, ATPase assays were performed at protein concentrations (1 µM) where MORC2 undergoes DNA-induced phase separation, making it difficult to distinguish whether enhanced ATP hydrolysis arises directly from DNA binding or indirectly from condensate formation.

      We acknowledge that inclusion of additional mutants such as phase separation deficient or DNA-binding deficient variants would provide a more definitive mechanistic separation of these effects. However, generating and validating such mutants in a manner that preserves overall protein integrity is beyond the scope of the current study. Accordingly, we have revised the text to present our findings more cautiously and to frame the observed ATPase enhancement as a correlation rather than a causal mechanism.

      Regarding the ATP-binding–deficient N39A mutant, we agree that its behavior in the presence of DNA raises interesting mechanistic questions. We now explicitly note this unexpected observation and discuss possible explanations, including partial ATP binding, altered oligomeric states, or indirect effects mediated by condensate formation.

      (3) Dissecting the domain-specific contribution in MORC2 phase separation:

      (a) While in cellulo data indicate that the presence of IDR, NLS, CC3, and IBD is all essential for MORC2 condensate formation, it is not clear if this is the effect of the complex cellular environment or whether it is intrinsic for MORC2 phase separation ability. In lines 256-259, the authors suggest IDRa interaction with IBD may serve as a nucleation mechanism for LLPS. In other places, it has been mentioned that CC3 dimerization acts as a scaffold for condensate formation. It is not clear if all of these are essential for MORC2 phase separation, or one of them is essential while the other domain(s) facilitates the phase separation. Though Figure 3 provides a qualitative overview of the contribution of different regions in MORC2 phase separation in cellulo-influenced by the complex cellular environment and substrate interactions, the absolute domain contribution in phase separation would be better studied in vitro by quantitatively comparing phase diagrams (for example, c-sat vs temperature) of different domain deletion constructs.

      We thank the reviewer for highlighting the distinction between intrinsic phase separation propensity and cellular context dependent effects. Our in cellular screening was designed to identify regions required for condensate formation under physiological conditions, where chromatin, binding partners, and macromolecular crowding are present. We agree that this approach does not directly quantify the intrinsic phase separation contribution of individual domains.

      While CC3 dimerization, IDR–IBD interactions, and nuclear localization all contribute to condensate formation, our data do not imply that these elements are mechanistically equivalent. Rather, we propose that CC3 provides a structural scaffold, while IDR-mediated interactions lower the energetic barrier for condensation. We have revised the manuscript to clarify this hierarchical model and to avoid implying that all domains contribute equally or independently.

      We agree that quantitative in vitro phase diagrams would provide valuable insight into intrinsic domain contributions. Whereas the MORC2ΔCC3-IBD (1–900) and CC3-IBD (900-1032) fragment fails to induce phase separation, the IDR mix CC3–IBD fragment drives robust phase separation; additionally, phase separation is entirely abrogated in the absence of domain–domain interactions. These observations collectively verify that phase separation is contingent on specific domain combinations and their interactions.

      (b) Similarly, for line 228-231: 'Notably, condensates formed exclusively in the nucleus and not in the cytoplasm of transfected HeLa cells, suggesting that chromatin-associated nuclear factors, such as DNA, may contribute to the nucleation or stabilization of MORC2 condensates.' This is an important observation made by the authors. Since MORC2 readily phase separates in vitro under physiological conditions, it is important to discuss why MORC2 does not make condensates in the cytoplasm (in the case of MORC2deltaNLS). In this regard, how does the concentration of overexpressed EGFP-MORC2 constructs compare with in vitro tested droplets of MORC2?

      We thank the reviewer for highlighting this important conceptual point. Although MORC2 readily undergoes phase separation in vitro under physiological buffer conditions, the absence of condensate formation in the cytoplasm of cells expressing MORC2ΔNLS underscores the importance of the nuclear environment in promoting MORC2 assembly.

      The cytoplasm differs fundamentally from the nucleus not only in overall molecular composition but also in the availability of high-valency scaffolds such as chromatin. We propose that chromatin-associated components, particularly DNA, provide a platform that locally concentrates MORC2 and increases its effective valency, thereby facilitating nucleation or stabilization of condensates in the nucleus. In contrast, the cytoplasm lacks such scaffolds, even when MORC2 is expressed at appreciable levels. In cultured cells, MORC2 is seldom observed in the cytoplasm. While specific experimental contexts may facilitate its cytoplasmic localization, such observations are rarely reported [6]. In transfection-based systems, MORC2 predominantly displays droplet-like behavior in the nucleus. Notably, in endogenous EGFP–MORC2 chimeric mice, we detected punctate MORC2 structures in the neuronal cytoplasm of the brain and spinal cord. The functional significance and biophysical state of cytoplasmic MORC2 remain largely unexplored.

      With respect to protein concentration, while EGFP-MORC2 is robustly expressed in cells, direct comparison between cellular expression levels and the protein concentrations used in vitro is inherently challenging. Importantly, in vitro phase separation is driven by bulk protein concentration under defined conditions, whereas in cells, effective local concentration and interaction valency are strongly shaped by spatial confinement and chromatin association. We have revised the manuscript text to emphasize this distinction and to avoid interpreting nuclear specificity as a purely concentration-dependent phenomenon.

      (c) Lines 227-228: '... CW domain restricts condensate overgrowth or fusion', this inference is based on CTDdeltaCW puncta being larger in size (Figure 3a). However, in Figure 4h MORC2deltaIDRb and MORC2deltaIDRc also result in larger puncta. Making a final conclusion that the CW domain restricts condensate overgrowth or fusion warrants additional investigation.

      We thank the reviewer for pointing out the limitation of our original conclusion. We agree that the enlarged puncta in both CTDΔCW (Figure 3a) indicate that condensate size regulation involves the CW domain was insufficiently rigorous.

      Re-analysis of existing data identifies clear phenotypic disparities between the mutants: MORC2ΔIDRb/ΔIDRc mutants show two distinct phenotypes (reduced puncta number with enlarged size, or unchanged puncta number with uniform enlargement), and their total puncta area per cell is comparable to the WT. By contrast, CTDΔCW mutants display markedly larger puncta relative to the WT. Based on this distinction, we have revised our conclusion to a more cautious formulation: "These observations suggest that the CW domain may participate in regulating initial nucleation size and the exact molecular mechanisms require further investigation."

      (4) MORC2 condensate-mediated gene silencing:

      This is one of the key investigations of this study where the authors evaluate the ability of MORC2 condensates to regulate gene silencing (transcriptional repression). The major concern here is that the authors are drawing their conclusion based on a CC3 domain deletion mutant of MORC2 and comparing it with wild-type MORC2. Notably, the CC3 domain is responsible for MORC2 dimerization, and as the authors quote, 'The dimeric assembly of CC3 is essential for maintaining the structural integrity of the protein', the absence of CC3 would have a direct impact on its function (such as ATPase activity). With these considerations, it is not clear whether the effect of CC3 domain deletion on gene regulation is an effect of no phase separation or a consequence of loss of function. This necessitates additional validation by including other controls, such as IBD domain deletion mutant, IDRa domain deletion mutant, where the phase separation is impeded without affecting dimerization.

      We appreciate the reviewer’s concern regarding the interpretation of CC3 deletion experiments. We agree that CC3 deletion affects both dimerization and phase separation, complicating attribution of gene regulatory effects solely to condensate formation. Our intention was not to claim that loss of repression arises exclusively from impaired phase separation, but rather to demonstrate that disrupting condensate-dynamic capacity correlates with impaired silencing.

      To directly address these concerns, we have performed a series of new experiments specifically designed to decouple condensate formation, condensate dynamics, and protein abundance, thereby allowing us to more rigorously interrogate the functional relevance of MORC2 condensates.

      First, to overcome the limitation of domain deletions which may affect MORC2 function beyond phase separation we introduced a micropeptide-based kill switch (KS) to the C terminus of MORC2. This strategy has recently emerged as a powerful approach to selectively reduce condensate dynamics without disrupting protein expression, folding, or domain architecture [1]. Importantly, unlike CC3 or IDRa deletions, MORC2+KS robustly form nuclear condensates but exhibits markedly reduced internal dynamics, as demonstrated by FRAP analyses showing minimal fluorescence recovery after photo bleaching (Fig. 6a-c). This strategy therefore allows us to perturb condensate material properties independently of MORC2 domain integrity.

      Second, we systematically compared the transcriptional consequences of rescuing MORC2-knockout HeLa cells with MORC2FL, condensation-deficient mutants (ΔCC3 and ΔIDRa), and the dynamics-defective MORC2+KS (Fig. 6d). Despite being expressed at substantially higher levels than MORC2FL (Fig. 6e), all three mutants showed a striking and consistent failure to restore MORC2-dependent transcriptional regulation (Fig. 6f-h). This effect was particularly pronounced for transcriptionally repressed genes, including two sets of high-confidence MORC2 targets reported in prior studies (Fig. 6i and Fig. S10). These findings demonstrate that neither increased protein abundance nor the mere presence of condensate-like structures alone is sufficient to restore MORC2 function.

      Third, our data instead support a model in which both soluble MORC2 complexes and dynamic MORC2 condensates are required for full transcriptional activity. While soluble MORC2 is likely involved in target recognition and complex assembly, our results indicate that proper condensate formation and critically, condensate dynamics are essential for effective transcriptional repression and activation. The inability of the MORC2+KS mutant to rescue transcriptional defects, despite intact condensate formation, points away from a model in which MORC2 condensates represent only microscopically visible byproducts of MORC2 activity.

      We believe these new data strengthen the manuscript by pairing the detailed mechanistic dissection of MORC2 phase separation with direct functional evidence, enhancing the conceptual impact and biological significance of the study.

      (5) Uncertain impact of pathogenic MORC2 mutations:

      Line 356-365: While the statements such as "disease-associated mutations primarily affect enzymatic and phase behaviors rather than DNA affinity" and "these findings provide mechanistic insight into how specific mutations may contribute to distinct pathological outcomes" are conceptually compelling, the data presented in Figure 7b-d do not appear to fully support these conclusions. For many of the mutants, the differences from WT across key parameters-condensation, ATPase activity, and DNA binding-are either modest or statistically insignificant. As such, drawing a unified mechanistic conclusion from these datasets may overstate what the data actually support.

      We agree that the effects of disease-associated MORC2 mutations described in Fig. 7 are modest and, in some cases, statistically insignificant. Our intention was to document observable trends rather than to propose a unified mechanistic framework. We have revised the manuscript to temper these conclusions and to emphasize the descriptive nature of these data.

      (6) Important conceptual clarifications:

      (a) Intrinsically disordered regions (IDRs) are not synonymous with phase separation. As the authors show, it is a combination of IDR-mediated interactions and CC3 dimerization that contributes towards the phase separation of MORC2. While IDRs can act as scaffolds for multivalent weak interactions that may promote biomolecular condensate formation, many IDRs serve other roles-such as mediating transient interactions, signaling, or regulatory functions-without undergoing phase separation. Researchers should avoid generalizing the assumption that the mere presence of IDRs in a protein implies its ability for phase separation. In this regard, authors should consider restructuring some of their generalized statements: Line 87-88: 'Recent studies suggest that intrinsically disordered regions (IDRs) can drive liquid-liquid phase separation (LLPS)' and Line 159-161: 'we noticed a long unstructured region at its C-terminus (Fig. S1b), a characteristic often associated with proteins capable of phase separation'.

      We agree that IDRs are not synonymous with phase separation and have revised the Introduction to avoid generalized statements. The revised text now emphasizes that IDRs can contribute to phase separation in a context-dependent manner and act in concert with structured oligomerization domains such as CC3-IBD.

      (b) Liquid-liquid phase separation: I would suggest switching the phrase to just phase separation. The rationale is that the in vitro studies of MORC2 (FRAP, droplet imaging) do not show liquid-like behavior, but perhaps liquid-solid. The FRAP studies suggest liquid-like behavior for some of the constructs. Given the differences in viscoelastic properties across the in vitro and in cellulo studies, it is better to generalize to "phase separation". Movies for droplet fusion and FRAP, wherever applicable, would be much appreciated. As the nature of in vitro MORC2 droplets appears different than in cells, movie representations of the above would enable readers to better assess the viscoelastic nature of the droplets (whether liquid, gel, etc).

      We appreciate the reviewer’s insight regarding the viscoelastic properties of MORC2. Our experimental data indeed show a disparity in dynamics between the two environments: while in vitro MORC2-FL condensates exhibit relatively low internal mobility, the in cellulo MORC2-FL puncta display high dynamics, characterized by rapid internal recovery in FRAP assays and droplet fusion events (Fig. S2f).

      This contrast suggests that the intracellular microenvironment plays a critical role in regulating the material state of MORC2 condensates. Consequently, we have focused on providing in vivo fusion data, as we believe in vitro characterizations (such as fusion or FRAP under various artificial conditions) may not faithfully represent the physiological behavior of MORC2. We have revised the manuscript to use the more general term “phase separation” or “condensation” and have added a discussion on these limitations to avoid overinterpreting the material properties observed in vitro.

      (7) Methods:

      (a) Figure 6 S2b: If phase separation occurs at, say, 1.8 µM protein concentration, this indicates that the protein has reached its saturation concentration (c-sat). Beyond c-sat, any additional protein should partition into the dense phase, while the concentration of the dilute phase remains constant. However, in this figure, the dilute phase concentration appears to increase with increasing total protein concentration, which is inconsistent with expected phase separation behavior. As the methods section does not have any sub-section for the sedimentation assay, it becomes difficult to understand how this experiment was performed, whether there is any technical discrepancy in the way soluble and pellet fractions were handled and processed for loading onto the gels. This is also the case with Figure 3d.

      We thank the reviewer for carefully examining the sedimentation assay and for raising this important conceptual point. We agree that, for an ideal two-phase system at thermodynamic equilibrium, the concentration of the dilute phase is expected to remain constant once the saturation concentration (c-sat) is reached.

      In our study, the sedimentation assay was used as an operational readout to assess concentration-dependent partitioning rather than to quantitatively define equilibrium phase boundaries. The assay involves centrifugation-based separation of supernatant and pellet fractions followed by SDS–PAGE analysis, and therefore does not necessarily report the equilibrium concentrations of coexisting dilute and dense phases. In particular, this approach can be influenced by incomplete physical separation of phases, kinetic trapping, and redistribution of material during handling, especially in systems where condensate maturation or internal reorganization occurs on longer timescales.

      Consequently, the apparent increase in the supernatant fraction with increasing total protein concentration likely stems from kinetic limitations and inherent technical constraints of the sedimentation assay, rather than a genuine deviation from classical phase separation behavior. These caveats are now explicitly clarified in the Methods section, with similar limitations of centrifugation-based assays for defining equilibrium phase behavior of biomolecular condensates reported previously.

      (b) Figure 4: The NMR comparisons appear to be primarily qualitative, lacking quantitative analyses such as chemical shift perturbation (CSP) and intensity ratio plots, which would offer deeper mechanistic insights. The NMR spectra detailing interactions among the IDR domains need to be quantified.

      We thank the reviewer for the suggestion. We have now performed quantitative CSP analyses for the NMR data shown in Fig. 4, and the corresponding CSP plots have been added to the revised manuscript (Fig. S7).

      As expected for interactions mediated by intrinsically disordered regions involved in phase separation, the observed CSPs are generally small. Notably, the CSP profile of IDRa closely matches that observed for the full-length IDR, whereas IDRb and IDRc show minimal perturbations. These results indicate that the interaction is primarily mediated by IDRa, with little contribution from the remaining regions.

      Peak intensity analyses were also examined but did not reveal additional residue-specific trends. Together, the quantitative CSP data support our conclusion that the interaction is weak, dynamic, and region-specific, consistent with an IDR-driven, phase-separation-related mechanism. We add this statement in method: CSPs were calculated in Hz at 600 MHz using the following equation:

      Minor comments:

      (1) Line 59-60: The Authors mention the HUSH-complex and then the MORC protein family, but do not discuss the relation between the two.

      We thank the reviewer for this comment. We have revised the Introduction to explicitly state that MORC2 may serve as a component of the HUSH complex and to clarify the functional relationship between MORC family proteins and HUSH-mediated transcriptional repression.

      (2) Line 74: 'Despite their structural similarities...', similarities between what all?

      We agree that this statement was ambiguous. We have revised the text to explicitly specify that the comparison refers to structural similarities among MORC family members.

      (3) Line 75: 'MORC-mediated repression remains...', this is the first time the word 'repression' is mentioned in the text and directly as an outstanding question.

      We have revised the Introduction to introduce the concept of transcriptional repression earlier and to provide appropriate context before posing it as an outstanding question.

      (4) The third paragraph does address issues in comments 1 and 3 to some extent, but the introduction needs some restructuring to provide a proper flow of information.

      We agree that the Introduction required restructuring. We have revised this section to improve logical flow, better integrate prior studies, and more clearly articulate the motivation and scope of the present work.

      (5) Line 83-85: How does the presence of IDRs suggest potential regulatory mechanisms?

      We have revised this sentence to clarify that IDRs may contribute to regulatory mechanisms by enabling multivalent and dynamic interactions, rather than implying that IDRs inherently confer regulatory function or phase separation capability.

      (6) Line 106-107: 'To determine whether MORC2 has N- and C-terminal dimerization interfaces similar to those...', reference 14 has already established that CC3 (denoted as CC4 in ref 14) is responsible for dimerization. Consider acknowledging their work in this regard?

      We thank the reviewer for this reminder. We have now explicitly acknowledged Ref. 14, which previously established the role of CC3 (denoted CC4 in that study) in MORC2 dimerization.

      (7) Lines 117-122: Are the authors comparing morphology from negative stain EM with AlphaFold predicted structure (Figure S1a and S1b)? If so, providing a zoomed-in inset from Figure S1a would be helpful.

      Yes, the comparison was intended to relate the negative-stain EM morphology to the AlphaFold-predicted architecture. We have added a zoomed-in inset in Fig. S1a to facilitate clearer comparison.

      (8) Line 152-153: '...even under varying physiological conditions', what are these varying conditions? Are the authors trying to point towards any of their specific results?

      We have revised this phrase to explicitly refer to variations in salt concentration and protein concentration tested in our in vitro assays.

      (9) Line 154-155: 'The dimeric assembly of CC3 is essential for maintaining the structural integrity of the protein', if it has been established, then please provide a reference.

      We thank the reviewer for this suggestion. For MORC family proteins, C-terminal coiled-coil–mediated dimerization is necessary for correct homodimer formation and functional stability (Xie et al., 2019, Cell Commun Signal. 17:160, Ref 14 in the revised manuscript).

      (10) Line 159-161: 'we noticed a long unstructured region at its C-terminus (Figure S1b), a characteristic often associated with proteins capable of phase separation25.', again authors are generalizing a statement which is, in most cases, context-dependent. For example, ref 25 mentions that unstructured regions or IDRs serve as a scaffold for multivalent interactions.

      We agree with the reviewer and have revised this sentence to avoid generalization. The revised text now emphasizes that IDRs may facilitate multivalent interactions in a context-dependent manner, rather than being intrinsically indicative of phase separation. Additionally, we have explicitly cited the mechanistic insight from Reference 25 that IDRs serve as scaffolds for multivalent interactions, to strengthen the logical link between the structural feature and its potential functional relevance.

      (11) Methods section for NMR (Line 665-667) mentions that nucleotides were added to a final concentration of 10 mM. There is no figure or section for MORC2 NMR with added nucleotides/DNA.

      We thank the reviewer for pointing this out. The nucleotide (ATP) addition was part of preliminary NMR trials and is not directly associated with the figures presented. We have deleted this in the Methods section to avoid confusion.

      (12) Line 285-294: Authors compare the effect of DNA binding on the phase separation of both MORC2FL and MORC2 CTDdeltaCW and conclude that DNA-induced condensation is primarily mediated through interactions with the IDR-NLS region. This appears not to be backed by proper control experiments. The authors do not show whether DNA binding mediates any phase separation for the isolated NTD or not? Similarly, what is the effect of DNA binding on MORC2 deltaIDR?

      We thank the reviewer for this insightful comment and agree that additional controls are essential for rigorously dissecting the contribution of DNA binding to MORC2 phase separation. Our interpretation that DNA-enhanced condensation is primarily mediated through the IDR–NLS region was based on comparative analyses of MORC2FL and MORC2 CTDΔCW, together with EMSA results demonstrating that DNA binding activity is conferred by the IDR–NLS–containing region. We acknowledge, however, that DNA binding alone is not sufficient to infer phase separation behavior.

      To address this point, we have performed additional analyses using the isolated NTD’ (residues 1–536) and MORC2 ΔIDR–NLS mutants (Fig. S6). The isolated NTD’ exhibited detectable DNA binding [4] but did not undergo DNA-induced condensation under conditions while MORC2FL or MORC2 CTDΔCW (residues 537-1032) readily formed condensates, indicating that DNA binding by itself is insufficient to drive phase separation. In parallel, MORC2 ΔIDR–NLS mutants showed severely compromised solubility and stability in vitro, which limited their quantitative characterization in phase separation assays. Nevertheless, under the conditions tested, these mutants did not display DNA-enhanced condensation comparable to MORC2FL.

      Taken together, these observations support a model in which the IDR–NLS region plays a critical role in coupling DNA binding to condensation, while additional domains are required to sustain robust phase separation. We have revised the manuscript text to clarify the experimental scope and to avoid overinterpreting the contribution of DNA binding in the absence of fully reconstituted control systems.

      (13) How did the authors assign the backbone amide NMR chemical shifts for MORC2?

      Backbone assignments of MORC2 IBD (1004-1032) were obtained using SOFAST versions of standard triple-resonance experiments, including HNCACB and CBCACONH, recorded at 298 K. Residual assignment ambiguities were resolved using [15] N-edited HMQC-NOESY-HMQC spectra.

      (14) Line 256: 'The partial compaction of IDRa...', what does the author mean here with 'partial compaction'? How did they measure compaction here?

      Regarding the term “partial compaction” mentioned previously, we apologize for the typographical error this phrase was erroneously used in place of “key component”.

      (15) Line 312-315: Why is there even a MORC2 readout for MORC2 KO cells with only EGFP? Also, the authors suggest that IDR deletion may impair mRNA stability or transcription; however, the expression levels of MORC2 deltaIDR and MORC2 deltaCC3 do not appear drastically different in Figure 3a.

      We thank the reviewer for raising these points. The apparent MORC2 signal in MORC2 knockout cells transfected with EGFP alone is due to the presence of residual MORC2 mRNA. Although CRISPR–Cas9–mediated knockout introduces a frameshift that prevents MORC2 protein expression, the mRNA can still be detected by RNA-seq. This is because nonsense-mediated decay (NMD), which targets transcripts with premature stop codons for degradation, is not always 100% efficient. Therefore, some MORC2 transcripts remain and produce detectable RNA-seq reads, even though no functional protein is expressed.

      Regarding the apparent discrepancy in expression levels, Fig. 3a displays only EGFP-positive cells, within which the fluorescence intensity of MORC2ΔIDR and MORC2ΔCC3 appears comparable to that of WT MORC2. However, the overall fraction of EGFP-positive cells is markedly reduced for these mutants compared to WT. Thus, while expression levels among successfully transfected cells are similar, fewer cells express detectable levels of the ΔIDR or ΔCC3 constructs across the total population. We therefore interpret this reduction in EGFP-positive cell fraction as reflecting impaired expression efficiency of these mutants, potentially arising from altered transcriptional output, mRNA stability, or protein stability. We have revised the manuscript text to clarify this distinction and to avoid overinterpreting the underlying mechanism in the absence of direct measurements.

      Author response image 1.

      EGFP, EGFP–MORC2 (FL), EGFP–MORC2 (ΔCC3), and EGFP–MORC2 (ΔIDR) were re-expressed in MORC2-knockout HeLa cells. Confocal imaging revealed that full-length MORC2 formed condensates in the nucleus, whereas mutants lacking either the CC3 or IDR domain failed to exhibit such behavior. Notably, under identical experimental conditions, we observed a marked reduction in the transfection efficiency of the EGFP-MORC2 (ΔIDR) construct. In contrast to the other variants, EGFP signals for ΔIDR were detectable in only a small fraction of the total cell population, despite consistent DNA loading and protocol synchronization. This observation suggests that the IDR might be required not only for biomolecular condensation but also for maintaining the steady-state levels of the MORC2 mRNA/protein or overall cellular fitness.

      (16) Line 330: 'MORC2 deltaCC3 failed to repress any of the 18 downregulated targets...'. This does not appear to be entirely true as repression of some targets (LBH, TGFB2, GADD45A) are closer to MORC2 FL than the EGFP control.

      We thank the reviewer for pointing out this inconsistency and for highlighting the need for precise wording. We have updated the dataset and revised the text to describe the results more accurately. We now describe that the mutants impair MORC2FL-mediated transcriptional regulation, consistent with the overall trend observed across these target genes.

      (17) Line 347-350: Based on the percent of cells with condensates, the authors conclude that CMT2Z-linked E236G and SMA-linked T424R mutants promote MORC2 phase separation. Again, the effect of these mutations on MORC2 condensation in cells may be direct or indirect. This can be investigated by comparing the in vitro effect of these mutations on MORC2 phase separation.

      We thank the reviewer for raising this important point and fully agree that the effects of disease-associated MORC2 mutations on condensate formation in cells may arise from either direct alteration in intrinsic phase separation propensity or indirect influences mediated by the cellular environment.

      In our study, disease-associated MORC2 mutants were assessed for condensate formation in HEK293F cells. Attempts were made to characterize these mutants in vitro; however, the E236G mutant exhibited markedly reduced solubility and stability upon purification, which precluded reliable in vitro phase separation analysis. We therefore evaluated the impact of E236G in cells and found that this mutation significantly impaired the dynamics of nuclear MORC2 condensates. For the T424R mutant, we note that its intracellular condensates displayed FRAP recovery kinetics comparable to those of WT MORC2, suggesting broadly similar dynamic properties of the assemblies formed in cells, but not necessarily implying a direct enhancement of intrinsic phase separation.

      In light of these considerations, we have revised the text in Lines 347–350 to avoid attributing a direct causal role of these mutations in promoting MORC2 phase separation. Instead, we now describe the observed increase in the fraction of cells containing condensates as a descriptive cellular correlation. We further emphasize that systematic in vitro characterization of disease-associated MORC2 mutants will be required to distinguish direct from indirect effects and represents an important direction for future investigation.

      (18) The discussion section lacks referencing to individual figures in the results section as well as previous literature.

      We agree with the reviewer that the Discussion would benefit from clearer integration with both the Results figures and prior literature. In the revised manuscript, we have substantially restructured the Discussion to explicitly reference key figures when interpreting experimental findings and to more clearly distinguish conclusions drawn from specific datasets. In addition, we have expanded citations to previous studies where relevant, particularly in the context of MORC2 DNA binding, ATPase regulation, chromatin association, and disease-linked mutations. These revisions aim to better situate our findings within the existing literature and to guide readers more clearly between experimental observations and their interpretation.

      Reviewer #3 (Public review):

      Summary:

      The manuscript by Zhang et al. demonstrates that MORC2 undergoes liquid-liquid phase separation (LLPS) to form nuclear condensates critical for transcriptional repression. Using a combination of in vitro LLPS assays, cellular studies, NMR spectroscopy, and crystallography, the authors show that a dimeric scaffold formed by CC3 drives phase separation, while multivalent interactions between an intrinsically disordered region (IDR) and a newly defined IDR-binding domain (IBD) further promote condensate formation. Notably, LLPS enhances MORC2 ATPase activity in a DNA-dependent manner and contributes to transcriptional regulation, establishing a functional link between phase separation, DNA binding, and transcriptional control. Overall, the manuscript is well-organized and logically structured, offering mechanistic insights into MORC2 function, and most conclusions are supported by the presented data. Nevertheless, some of the claims are not sufficiently supported by the current data and would benefit from additional evidence to strengthen the conclusions.

      Thank you for your insightful review and constructive suggestions, which have been invaluable in refining our manuscript.

      The following suggestions may help strengthen the manuscript:

      Major comments:

      (1) The central model proposes that multivalent interactions between the IDR and IBD promote MORC2 LLPS. However, the characterization of these interactions is currently limited. It is recommended that the authors perform more systematic analyses to investigate the contribution of these interactions to LLPS, for example, by in vitro assays assessing how the IDR or IBD individually influence MORC2 phase separation.

      We appreciate the reviewer’s insightful comment regarding the characterization of IDR–IBD interactions. In this study, we combined NMR spectroscopy, domain deletion analysis (in vivo), and in vitro phase separation assays to demonstrate that interactions between the IDR and IBD contribute to MORC2 condensate formation. To systematically assess the individual contributions of the IDR and IBD to MORC2 phase separation, we performed in vitro reconstitution assays using purified domain constructs (Fig. S6). Neither the isolated IDR nor the IBD alone exhibited phase separation under buffer conditions approximating the physiological environment, indicating that each domain is individually insufficient to drive condensation. Upon the addition of 10% PEG8000, phase separation was selectively observed for the IDR but not for the IBD, suggesting that the IDR possesses an intrinsic propensity for phase separation that can be enhanced by crowding molecular. Importantly, when the IDR and IBD were mixed, phase separation was robustly induced, supporting a model in which cooperative inter-domain interactions between the IDR and IBD promote MORC2 condensation. In the absence of PEG, no phase separation was observed for the IDR–IBD mixture. These observations imply that IDR–IBD interactions cannot drive phase separation on their own, but require cooperation with CC3-mediated dimerization to achieve this process, which is the central point we wish to emphasize.

      (2) The authors mention that DNA binding can promote MORC2 LLPS. It is recommended that they generate a phase diagram to systematically assess how DNA influences phase separation.

      We agree that constructing a full phase diagram would provide a more systematic evaluation of the effect of DNA on MORC2 phase separation. In the current study, we assessed DNA-dependent condensation across multiple protein and DNA concentrations, which consistently showed that DNA enhances MORC2 phase separation. At low protein concentration (0.5 µM), phase separation requires sufficient DNA, whereas increasing either DNA or protein concentration promotes liquid droplet formation. At high DNA and protein concentrations, amorphous structures dominate, indicating a transition away from dynamic assemblies. We have clarified this point in the Results and Discussion sections and now note that a comprehensive phase diagram analysis represents an important direction for future work.

      (3) The authors use the N39A mutant as a negative control to study the effect of DNA binding on ATP hydrolysis. Given that N39A is defective in DNA binding, it could also be employed to directly test whether DNA binding influences MORC2 phase separation.

      We thank you for your constructive suggestions. The purified wild-type MORC2(1–603) exhibited weak but detectable ATPase activity, whereas the N39A mutant was completely inactive [5]. Based on this characteristic, the N39A mutant was used as a negative control for the ATP-binding-deficient mutant in this study [3]. However, no evidence has been provided to demonstrate that the N39A mutant is defective in DNA binding. Importantly, both our results and previous studies [5-6] indicate that MORC2 engages DNA via multiple domains, suggesting that a single-point mutation is unlikely to significantly compromise its overall DNA-binding capacity.

      (4) Many of the cellular and in vitro LLPS experiments employ EGFP fusions. The authors should evaluate whether the EGFP tag influences MORC2 phase separation behavior.

      We appreciate the reviewer’s concern regarding the potential influence of the EGFP tag. The use of EGFP fusions in our study was primarily to maintain consistency with the in-cell experiments. Importantly, we confirmed that EGFP alone does not undergo phase separation in cells, and this observation is consistent with previous studies [7]. Additionally, in vitro phase separation of MORC2 was independently validated using Cy3–labeled CTD (Fig. S5), which recapitulated the condensate formation seen with EGFP-fused protein. Together, these results indicate that the EGFP tag does not significantly influence MORC2 phase separation, supporting the validity of our conclusions.

      Reviewer #3 (Recommendations for the authors):

      (1) The authors claim to have obtained nucleic acid-free protein, but no data are provided to support this assertion. It is recommended that they include appropriate validation to confirm the absence of nucleic acids.

      We thank the reviewer for highlighting this point. To validate that the purified MORC2 protein is indeed free of nucleic acid contamination, we have additional experimental evidence (e.g., A260/280 measurements, agarose gel analysis, or EMSA in Fig. 5), which has been added to the Methods section and Table S2.

      Note: Agarose gel analysis for MORC2 constructs to confirm the absence of nucleic acids. The pET32 vector as the positive control, the protein preparation for analysis is 0.05 mg. E means E. coli and H means HEK293F.

      (2) The FRAP recovery curves are not normalized to 0, making comparison difficult. The authors should normalize the post-bleach intensity to 0 and re-plot the curves to allow a more standard interpretation of mobile fractions.

      We agree with the reviewer and have now normalized the FRAP recovery curves by setting the post-bleach intensity to 0. The revised plots are presented in the Figures (2f, j, l; 6c, 7f), allowing for more direct comparison of mobile fractions across different conditions.

      (3) The HSQC spectra for IBD appear inconsistent: the peak positions in Fig. 4C do not align with those shown in panels D-F. The authors should verify the spectral assignments and ensure consistency across figures.

      We thank the reviewer for pointing this out. The apparent inconsistency arose from the fact that different spectral regions were displayed in Fig. 4c versus Fig. 4d-f for visualization purposes, which may have given the impression of mismatched peak positions. The spectral assignments themselves are consistent across all panels.

      To avoid confusion, we have now adjusted the spectral window shown in Fig. 4c to match that used in Fig. 4d-f. The revised figure ensures consistent presentation of the same spectral region across all panels.

      Reference:

      (1) Zhang, Y., Stöppelkamp, I., Fernandez-Pernas, P. et al. Probing condensate microenvironments with a micropeptide killswitch. Nature 643, 1107–1116 (2025).

      (2) Fendler NL, Ly J, Welp L, et al. Identification and characterization of a human MORC2 DNA binding region that is required for gene silencing. Nucleic Acids Res.53(4):gkae1273 (2025).

      (3) Tchasovnikarova, I., Timms, R., Douse, C. et al. Hyperactivation of HUSH complex function by Charcot–Marie–Tooth disease mutation in MORC2. Nat Genet 49, 1035–1044 (2017).

      (4) Douse, C. H. et al. Neuropathic MORC2 mutations perturb GHKL ATPase dimerization dynamics and epigenetic silencing by multiple structural mechanisms. Nat Commun 9, 651 (2018).

      (5) Tan, W., Park, J., Venugopal, H. et al. MORC2 is a phosphorylation-dependent DNA compaction machine. Nat Commun 16, 5606 (2025).

      (6) Sánchez-Solana B, Li DQ, Kumar R. Cytosolic functions of MORC2 in lipogenesis and adipogenesis. Biochim Biophys Acta. 1843(2):316-326 (2014).

      (7) Li, C.H., Coffey, E.L., Dall’Agnese, A. et al. MeCP2 links heterochromatin condensates and neurodevelopmental disease. Nature 586, 440–444 (2020).

    1. AbstractBackground Downloading and reanalyzing the existing single-cell RNA sequencing (scRNA-seq) data provides an efficient choice to gain clues and new insights. However, no tool can fetch the diverse scRNA-seq data types (raw data, count matrix, and processed object) distributed in various repositories, process and load the downloaded data to R, convert formats between scRNA-seq objects, and benchmark the format conversion tools.Findings Here, we present GEfetch2R, an R package with Docker image to (i) download diverse scRNA-seq data types, including raw data (SRA and ENA), count matrices (GEO, UCSC Cell Browser, and PanglaoDB), and processed objects (Zenodo, CELLxGENE, and HCA); (ii) process the downloaded data, load output/downloaded count matrices and annotations to R (SeuratObject/DESeqDataSet), filter the SeuratObject based on cell metadata and genes, and merge multiple SeuratObjects if applicable; (iii) convert formats between the widely used scRNA-seq objects, including SeuratObject, AnnData, SingleCellExperiment, CellDataSet/cell_data_set, and loom, and benchmark format conversion tools in terms of information kept, usability, running time, and scalability to guide the tool selection. Furthermore, GEfetch2R can also download, process, and load bulk RNA-seq raw data (SRA and ENA) and count matrices (GEO) to R (DESeqDataSet).Conclusions GEfetch2R is an R package dedicated to facilitating researchers to access and explore the existing gene expression data from various public repositories. It can function as a data downloader (supports all three scRNA-seq and two bulk RNA-seq data types), a data processor (processes and loads the output/downloaded count matrices and annotations to R), and an object format converter (between the widely used scRNA-seq objects).

      This work has been peer reviewed in GigaScience (see https://doi.org/10.1093/gigascience/giag039), which carries out open, named peer-review. These reviews are published under a CC-BY 4.0 license and were as follows:

      Reviewer 2:

      General Comments This manuscript introduces a tool named HVRLocator, designed to address the issue of missing or non-standard metadata in 16S rRNA sequencing data found in public databases such as the SRA. The tool identifies amplicon regions by aligning sequences to a reference genome and attempts to detect the presence of primers using a machine learning model. This is a subject with significant practical value, particularly for conducting large-scale meta-analyses. However, there are still many issues regarding methodological rigor, the depth of validation, and comparisons with existing tools that require further clarification by the authors. Major Comments 1. Concerns regarding the singularity of the reference sequence The authors mention aligning sequences to a single Escherichia coli (J01859.1) reference genome to determine start and end positions. Is a single E. coli reference sufficient to cover Archaea or bacterial phyla that are distantly related to Proteobacteria, which may be present in environmental samples (e.g., soil, ocean)? For taxa with significant length variations or insertions/deletions (Indels), could forced alignment to the E. coli reference lead to misjudgment of start/end positions? Have the authors evaluated the impact on accuracy if a more universal reference database (such as representative sequences from SILVA or Greengenes) were used? 2. Rationality of the primer detection model (Random Forest based on Quality Scores) The authors developed a Random Forest model to predict primer presence by analyzing the quality score distribution of the first 1,000 reads. Primer detection is typically based on the sequence itself rather than quality scores. Can the authors explain why quality scores were chosen as features? Sequencing quality scores are influenced by technical factors such as sequencer status, reagent batches, and run cycles, which have no direct biological correlation with the presence of primers. Is there a risk that this model is "overfitting" specific sequencing platforms or datasets? Since the reads are already downloaded, why not directly use degenerate primer sequence matching (e.g., using Cutadapt or SeqKit logic) to determine primer presence? This seems to be a more direct and accurate method. 3. Verification of accuracy claims In the validation section, the authors claim to achieve 100% accuracy on certain datasets. In bioinformatics tool development, a claim of 100% accuracy is often a red flag. Have the authors manually checked those samples marked as "correct" by the model that might suffer from edge effects or borderline cases? 4. Dataset imbalance in the Random Forest model For the Random Forest model, the authors used 882 samples with primers and 8,940 samples without primers for training. Such an extremely imbalanced dataset, even with stratified sampling, may cause the model to be biased towards the majority class. 5. Comparison with existing tools The manuscript mentions that no tool has been designed for this specific purpose, but this may overlook some existing general-purpose tools or scripts. Many pipelines (such as certain plugins in QIIME 2, USEARCH, etc.) possess functionalities to identify primers or evaluate amplicon regions. The authors should discuss how their tool compares to these existing workflows. Minor Comments 1. Confusion regarding processing speed metrics The abstract mentions a processing speed of "0.147 samples per minute", but later the text mentions "6.5 samples per minute" and "one sample every 0.147 minutes". There is confusion regarding units and values in these three descriptions (is it samples per minute or minutes per sample?). Please unify and correct these data to ensure consistency. 2. Usage of fastq-dump The use of fastq-dump is mentioned. The SRA Toolkit's fastq-dump is relatively slow and has largely been superseded by fasterq-dump for efficiency. Why did the authors not use the more efficient fasterq-dump? 3. Definition of "Standardized metadata" The term "standardized metadata" is used frequently. Please explicitly define what constitutes "standard" metadata in the context of this tool within the text. 4. Robustness and error handling The results section mentions that some samples failed due to "NCBI portal-related issues". Does this imply the tool lacks breakpoint resumption or retry mechanisms? Given that network fluctuations are common during large-scale downloads, how is the tool's robustness demonstrated? 5. Output confidence intervals The output file contains "TRUE/FALSE" and a probability score. For samples where the probability score is at a critical threshold (e.g., around 0.5), does the tool provide an "uncertain" tag, or does it force a classification? It is suggested to add an indicator for ambiguous ranges.

    1. AbstractBackground Amplicon sequencing of the 16S rRNA gene is widely used to assess microbial diversity due to its cost-effectiveness and efficiency. However, public 16S rRNA datasets often lack standardized metadata, particularly information on the sequenced hypervariable regions or primers used, which are critical for accurate analysis and data reuse. To address this, we present the HVRLocator, a computational tool that reliably identifies sequenced hypervariable regions, enhancing metadata quality and enabling more robust large-scale microbiome studies.Results The HVRLocator tool processed samples at an average rate of 0.147 per minute. Validation confirmed 100% accuracy in predicting alignment positions, correctly matching sequences to the expected primer regions based on literature. We demonstrated how to use the tool to select appropriate and comparable sequences for building a global bacterial database from V4 region amplicons of the 16S rRNA gene. Using HVRLocator, we selected 36,217 valid samples out of 45,882 runs, enabling us to identify cases where metadata incorrectly labeled sequences as targeting the V4 region.Conclusion Even when metadata is available, it can be inaccurate or misleading. HVRLocator offers a reliable and efficient method to identify the exact hypervariable sequenced region, ensuring accurate processing of large-scale 16S rRNA amplicon data. By bypassing inconsistent metadata and literature, it streamlines data curation and enhances the reliability of microbial studies, syntheses, and meta-analyses. Its use is essential for critically evaluating published data and enabling accurate and reproducible research in microbial ecology.

      This work has been peer reviewed in GigaScience (see https://doi.org/10.1093/gigascience/giag040), which carries out open, named peer-review. These reviews are published under a CC-BY 4.0 license and were as follows:

      Reviewer 2:

      General Comments This manuscript introduces a tool named HVRLocator, designed to address the issue of missing or non-standard metadata in 16S rRNA sequencing data found in public databases such as the SRA. The tool identifies amplicon regions by aligning sequences to a reference genome and attempts to detect the presence of primers using a machine learning model. This is a subject with significant practical value, particularly for conducting large-scale meta-analyses. However, there are still many issues regarding methodological rigor, the depth of validation, and comparisons with existing tools that require further clarification by the authors. Major Comments 1. Concerns regarding the singularity of the reference sequence The authors mention aligning sequences to a single Escherichia coli (J01859.1) reference genome to determine start and end positions. Is a single E. coli reference sufficient to cover Archaea or bacterial phyla that are distantly related to Proteobacteria, which may be present in environmental samples (e.g., soil, ocean)? For taxa with significant length variations or insertions/deletions (Indels), could forced alignment to the E. coli reference lead to misjudgment of start/end positions? Have the authors evaluated the impact on accuracy if a more universal reference database (such as representative sequences from SILVA or Greengenes) were used? 2. Rationality of the primer detection model (Random Forest based on Quality Scores) The authors developed a Random Forest model to predict primer presence by analyzing the quality score distribution of the first 1,000 reads. Primer detection is typically based on the sequence itself rather than quality scores. Can the authors explain why quality scores were chosen as features? Sequencing quality scores are influenced by technical factors such as sequencer status, reagent batches, and run cycles, which have no direct biological correlation with the presence of primers. Is there a risk that this model is "overfitting" specific sequencing platforms or datasets? Since the reads are already downloaded, why not directly use degenerate primer sequence matching (e.g., using Cutadapt or SeqKit logic) to determine primer presence? This seems to be a more direct and accurate method. 3. Verification of accuracy claims In the validation section, the authors claim to achieve 100% accuracy on certain datasets. In bioinformatics tool development, a claim of 100% accuracy is often a red flag. Have the authors manually checked those samples marked as "correct" by the model that might suffer from edge effects or borderline cases? 4. Dataset imbalance in the Random Forest model For the Random Forest model, the authors used 882 samples with primers and 8,940 samples without primers for training. Such an extremely imbalanced dataset, even with stratified sampling, may cause the model to be biased towards the majority class. 5. Comparison with existing tools The manuscript mentions that no tool has been designed for this specific purpose, but this may overlook some existing general-purpose tools or scripts. Many pipelines (such as certain plugins in QIIME 2, USEARCH, etc.) possess functionalities to identify primers or evaluate amplicon regions. The authors should discuss how their tool compares to these existing workflows. Minor Comments 1. Confusion regarding processing speed metrics The abstract mentions a processing speed of "0.147 samples per minute", but later the text mentions "6.5 samples per minute" and "one sample every 0.147 minutes". There is confusion regarding units and values in these three descriptions (is it samples per minute or minutes per sample?). Please unify and correct these data to ensure consistency. 2. Usage of fastq-dump The use of fastq-dump is mentioned. The SRA Toolkit's fastq-dump is relatively slow and has largely been superseded by fasterq-dump for efficiency. Why did the authors not use the more efficient fasterq-dump? 3. Definition of "Standardized metadata" The term "standardized metadata" is used frequently. Please explicitly define what constitutes "standard" metadata in the context of this tool within the text. 4. Robustness and error handling The results section mentions that some samples failed due to "NCBI portal-related issues". Does this imply the tool lacks breakpoint resumption or retry mechanisms? Given that network fluctuations are common during large-scale downloads, how is the tool's robustness demonstrated? 5. Output confidence intervals The output file contains "TRUE/FALSE" and a probability score. For samples where the probability score is at a critical threshold (e.g., around 0.5), does the tool provide an "uncertain" tag, or does it force a classification? It is suggested to add an indicator for ambiguous ranges.

    1. On 2026-04-09 21:38:21, user Alizée Malnoë wrote:

      The manuscript by Fridman et al. explores the unexpected finding that Aeromonas jandaei antagonistically employs a Type VI secretion system (T6SS) in a liquid environment. While researching the effector protein Awe1, which forms part of the T6SS apparatus, the authors observed T6SS-dependent intoxication of susceptible bacteria. Using a novel fluorescence-based screening method (named LiQuoR for liquid quantification of rivalry), the authors further determine that this intoxication is contact-dependent, and that contact between kin and non-kin Aeromonas bacteria in liquid is mediated by specific adhesins. Fridman et al. also identify additional marine bacteria capable of inflicting T6SS-mediated intoxication in liquid media, suggesting a mechanism for specific and contact-dependent bacterial competition and positing that such competition in liquid media may be more common in marine bacteria than previously documented. These findings have exciting implications for bacterial antagonism, potentially shifting the paradigm of how we view bacterial interactions in marine environments. We found this study to be well-written, containing high-quality data. Overall, the data presented in this manuscript are done well and support the claims made by the authors. We outline some major and minor adjustments aimed at aiding the clarity of reporting and presentation, strengthening the findings, as well as providing additional context for a broader audience.

      Major Comments<br /> - We are interested in the broader implications of the LiQuoR assay, particularly pertaining to this workflow’s application to different bacteria. The observation that the amount of prey luminescence in WT on solid media grew/increased after 4 h seemed counterintuitive to us (Figure 1E). It seems as if this result could make the workflow less sensitive for experiments done solely on solid media, further explanation of this finding would clarify on the workflows applicability to other solid surface experiments. Is this related to surface area? While this does not change the findings that inhibition is occurring in both liquid and in solid, it would enhance the clarity of these results to provide speculation on why this was seen.<br /> - We are curious about your perspective on the observation that kin-kin aggregation facilitated by CaCl2 supplementation does not increase kin intoxication but does increase non-kin intoxication (Figure 2A). Please speculate on this result in the discussion. Is the concentration used physiological? <br /> - While the images shown in Figure 2B make it clear that aggregates are forming in liquid media, we have a suggestion to improve the strength of these results and account for the images not shown. For instance, quantification of the % of prey cells displaying Sytox staining would more strongly demonstrate the presence of permeabilized E. coli in multiple aggregates. This quantification could substitute Figure 2C (which can be moved into the supplemental): it was not totally clear to us why an orthogonal view was included here. If this is significant for the findings, it would increase clarity to include an explanation for an audience less familiar with this system.<br /> -Lines 192-214: From a genomics perspective, we think further explaining how potential adhesins were identified would be helpful to increase the clarity and reproducibility of the experimental design. Please explain how you narrowed down these adhesins and located them in the genome, and why adhesins were targeted for this analysis over other proteins that could facilitate a physical interaction between predator and prey species. Define the acronyms and provide rationale for naming. <br /> -Figure 6B nicely demonstrates that intoxication takes place in liquid between certain marine bacteria but not in Vpara. However, please include a control showing that V. para does intoxicate prey in solid media to strengthen these findings and confirm that this strain of V. para is capable of intoxicating prey under typical conditions.<br /> -Given the significance of the TssB deletion for the core message of this work that type VI intoxication occurs in liquid media, please consider including data that confirm the TssB deletion e.g. sanger sequencing in supplemental or as source data. A complementation assay of TssB to show that regaining TssB restores the awe1 toxicity would be valuable.<br /> - Lines 224-225/Figure 5: We are curious and excited about the implications of the balance between kin-aggregation and non-kin aggregation and how this may aid our understanding of bacterial interactions in marine environments. Based on our understanding of these results, the observation that deletion of CraAj (responsible for kin-kin aggregation) increased non-kin intoxication (mediated by LapAj) could suggest that aggregation between two kin cells, who both contain the needed immunity proteins, could dampen the intoxication of nearby non-kin cells. This result is implied by the data but not specifically speculated on or addressed. Though it may not be within the scope of this experimental design, our group was intrigued by these findings. Given your expertise in this area, consider discussing how these bacterial interactions may play out and/or include these observations as part of Figure 5.

      Minor Comments<br /> -All figures: In the legends, it is stated “these experiments were repeated three times with similar results”. Please define what is meant by an experiment e.g. technical or biological replicate.<br /> -All figures: We felt that having the exact p-values indicating statistical significance is not necessary. For instance, in Figure 3B and 3D, we found it distracting that all of the values were significant by a factor of <1E-4, even when they appear different from each other. If this is simply a cutoff value, it would be helpful to keep that consistent between figures. Also, Figure 6A/B: The p-values presented, specifically the comparison between WT and T6SS – supplemented with 1 mM CaCl2 (6A) and the two left hand panels of 6B, do not appear to match the differences shown between the experimental groups. By eye, these groups do not appear different from one another but are shown to be either highly statistically significant or not statistically significant at all.<br /> - Figure 1A: To increase readability, we suggest that the colors could be more intuitive here- put WT in grey and then mix colors for double mutants. Bringing the light pink line (Δawei1 ΔtssB + pAwe1) to the front of the graph would further increase clarity.<br /> -Figure 1B/F: Making color scheme consistent between 1B and 1F would increase clarity.<br /> -LiQuoR assay: As there is often some level of variation in expression levels when working with a transformed population, confirmation that all prey strains luminesce to a similar level would provide further validation of this novel assay (similarly to what is done in FigS3B). <br /> -Figure 2A: The colored box legends showing whether CaCl2 is present or absent are inverted relative to one another, which we found to be confusing. To increase readability, please make them on the same side.<br /> -Figure 3B,C,D,E: To help guide the eye on the graphs, we suggest adding dashed lines between each new mutation group (+/- TssB).<br /> - Figure S1: Please include a loading control to verify assay input. <br /> - Table S1: Clarify the gene and strain for each mutation.<br /> - Line 112-113: It serves as an excellent control that the action of the T6SS apparatus is required for intoxication, however, since the T6SS apparatus is contained within the bacterium, would spent media contain free-floating T6SS proteins, or are these proteins only ejected from the bacterium in the presence of prey species? Please clarify. Direct evidence, such as immunoblotting, that effectors are present in the spent media from WT would make this claim more compelling.<br /> - Line 35: While this part of the introduction provides excellent background regarding the role of T6SS in interactions with eukaryotic cells, it would be helpful to also specifically mention the role of T6SS in prokaryotic communities, as much of the later work focuses on competition between bacteria.<br /> -Lines 70-71: A more thorough background on Aeromonas (lifestyle, importance, etc) is warranted.<br /> -Line 84: Please provide the exact genotype when first introducing this mutant, it would improve clarity for the reader to explicitly state that this is a double mutant.<br /> -Line 97: Clarify here that “Aj prey” in this paragraph refers to Aj which do not possess the cognate immunity protein, as the current phrasing could be interpreted to mean “prey of Aj”.<br /> -Line 138: “Desired conditions for competition” is vague. Is solid media also incubated with shaking or is it static?<br /> -Lines 156-157: The statement that all three effectors are injected into prey cells is broad and not necessarily supported within these findings. The injection of one effector could be favored, but other effectors could compensate in its absence.<br /> -Line 189: Describes Aj as stably binding to other competing bacteria. To this point, imaged aggregates have been fixed so stability of aggregates may not be known.<br /> -Line 248: Here, it is mentioned that there was a switch from using the Lux operon to using the RFP mCherry for improved cell detection. It might be helpful to clarify which fluorescent tag was used for each assay, as multiple different fluorescent tags are used.<br /> -Line 317: As the choice to test CaCl2 and the biological relevance of calcium for Aeromonas hosts is explained earlier in the manuscript, it would be interesting to include a brief explanation about the choice to include sodium chloride when assessing Vibrio intoxication rates. Presumably, sodium chloride was picked because Vibrio is commonly found in brackish water, but someone from outside the field may not be familiar with this biology. Additionally, since Aeromonas can be found in both fresh and brackish water, an interesting follow-up experiment would be to test the Aeromonas strains under different salinities.<br /> -Line 375-377: Needs citation.<br /> -Line 385: Clarify “under specific conditions not addressed within the scope of this study”.

      Carter Collins and Lily Pumphrey (Indiana University Bloomington) - not prompted by a journal; this review was written within a Peer Review in Life Sciences graduate course led by Alizée Malnoë with input from group discussion including Camy Guenther, Josy Joseph and Tahreem Zaheer. We are part of the Dept. of Biology where Julia Van Kessel’s group is located, Julia is a collaborator of the corresponding author and did not influence the choice of this preprint for our class.

    1. On 2026-04-07 08:39:09, user Guest wrote:

      I must confess, on first reading I found the manuscript quite exciting, but having gone through the earlier comments, I now see rather more clearly the gulf between what the data actually show and what the authors claim.

      One thing I would add to what has already been said: there is, quite remarkably, no protein localisation of KCNT1: not by GFP tag, not by antibody, in the multiciliated epidermis of Xenopus, mouse, or indeed human tissue. That is a rather glaring omission, to put it mildly. I would also agree that the proposed connection between KCNT1 and Piezo is tenuous at best.

    1. On 2025-11-19 21:19:50, user Daniel Vásquez-Restrepo wrote:

      This preprint already received a “major revision” decision. Unfortunately, the original reviewers were not available to evaluate it again, and the process stalled. Despite sending 15 additional peer-review invitations, no one agreed to take it on. Although the manuscript has now entered a new review process, I am attaching the previous reviewers’ comments.


      Reviewer 1

      This isn’t a finding as not only is it already available information, the use of the available IUCN maps and statuses was part of the methodology.

      R/ We rephrased the sentence to clarify that it refers to the underlying data itself and not to our results.

      I like the approach they’ve taken, but none of this is novel information or unexpected.

      R/ Although it is well known that mountains promote diversity and endemism at a global macroevolutionary scale, this information has not been explicitly tested in Colombian squamates in conjunction with threat categories. We consider that clearly stating the result of hotspots of diversity and endemism in Colombian squamates can help local environmental policies. Therefore, while our results are consistent with theoretical expectations, this alignment does not diminish the novelty of our findings, as we provide the first quantitative analysis supporting these patterns in the local context.

      This is the main novel finding of the work and I’d recommend reorganising the text to stress this.

      R/ We modified several sections of the text to emphasize the finding highlighted by the reviewer, also in accordance with comments made by the other reviewer.

      Unclear what this means in the context of this paper.<br /> R/ We rephrased the section for clarity.

      This is just the existing EDGE list, so I’m not sure it warrants mentioning as an output here.

      R/ In accordance with a comment from Reviewer 2, we acknowledge that this is a local rather than a global list, and that species rankings may differ between the two. Therefore, we believe it is an output worth highlighting. Nevertheless, we have clarified in the text the differences between the local and global scores and their implications.

      This entire paragraph seems superfluous, and this work has nothing to do with the latitudinal gradient so it’s a strange thing to focus discussion on.

      R/ While we briefly mention the latitudinal gradient, the main purpose of this introductory paragraph is to provide general context on biodiversity, leading into the key argument of the subsequent sections: the need to understand biodiversity and extinction risk as multidimensional phenomena. We have made minor adjustments to better integrate the role of the latitudinal gradient in promoting tropical diversity, thereby reinforcing the importance of prioritizing conservation efforts in regions of exceptionally high biodiversity.

      Suggested added context as this was unclear as worded.

      R/ We accepted the reviewer’s suggestion and revised the text accordingly.

      I’m not sure this follows - more that, as the paragraph goes onto say, it results in a lack of understanding of the impacts and vulnerability of the species.

      R/ We rephrased the idea to make it clearer.

      This seems to be an inappropriate reference, as Paez et al. 2006 focused on turtles rather than squamates. Please check and reword as needed.

      R/ We double-checked the reference and confirmed that it is correct, as it covers not only turtles but all Colombian reptiles (including squamates, crocodiles, and turtles).

      This seems inconsistent with the earlier statement that “a local assessment is lacking” - should this rather say a recent local assessment? Though as the paper goes on to reference a 2015 ‘local assessment’, it’s unclear what this section means.

      R/ We agree with the reviewer and revised the text to clarify that we refer to a recent assessment that also considers different facets of biodiversity, not just species richness (i.e., taxonomic diversity).

      The figure given later is 597, and that was used as the basis for the analysis. This may be a discrepancy due to a later update, but the same Reptile Database update should be cited throughout the paper for consistency.<br /> R/ In the Introduction, we refer to the most recent estimate of 620 reptile species for Colombia, based on the latest update of the Reptile Database (2024). However, the analyses in this study were based on the 2023 version of the database, which listed 597 species at that time. Given that the analyses were conducted using the 2023 data, and a complete reanalysis would be required to incorporate the updated figures, we chose to retain the original dataset to ensure consistency and reproducibility. We have clarified this point in the text to avoid confusion.

      Better to use the term ‘squamates’ rather than ‘reptiles’ if crocs and turtles are to be excluded.

      R/ Done, we have consistently replaced "reptiles" with "squamates" throughout the text where appropriate.

      Once again, this could benefit from clarity. The data in the Reptile Database should be reviewed with reference to available material and literature to be used as a formal checklist, but it should be ‘complete’ - it’s more likely to erroneously list species from a country than to miss ones that actually occur there.

      R/ We agree with the reviewer and rephrased the sentence to make the idea clearer.

      Are the authors able to explain the discrepancy between this figure and the maps (which represented 81% of the dataset)? Most IUCN assessments will have maps, but no IUCN maps will be associated with species that don’t have assessments.

      R/ The figures were validated against the information provided in Table S1. As the reviewer correctly points out, there are more assessments than polygons, consistent with the supplementary material. The figure of 77% corresponds to 461 species (excluding DD and NE categories) out of 597 species in our dataset (461/597 = 0.77). Meanwhile, the figure of 81% refers to 481 species with available geographic information, including species categorized as DD (481/597 = 0.81). The discrepancy arises because DD species were included when considering geographic data but excluded from threat category analyses. We have revised the Methods and Results sections to clarify this distinction explicitly. Also, we updated the previous 77% figure to include DD species too, increasing it to 92%.

      This is not a sufficient way to evaluate whether the assessments are likely to need updating - the Criteria take account of the distribution and extent of threats to each species, not simply its distribution. The ‘needs update’ tag is applied by the Red List only to assessments more than 10 years old, which is all that should be mentioned here.

      R/ We understand the reviewer’s concern and acknowledge that a mismatch between EOO and threat classification is not sufficient by itself to determine if an update is needed. We have separated these ideas in the text: first, we highlight species whose assessments are formally tagged as “needs update” after 10 years; second, we discuss species whose EOO does not align with their current threat classification. We moved the second point to the 3.2 Geographic patterns section, and expanded the Discussion to better explain these observations.

      See above. The authors didn’t ‘show’ this, they interpreted the Criteria incorrectly.

      R/ See previous answer. We further expanded the Discussion section to better frame this point.

      I would consider it suitable for the manuscript to be more fully revised as a shorter paper, as the region-scale analysis within Colombia and the phylogenetic results are of more interest than the well-trodden path of identifying the Andes as an area of greater endemism than Amazonia and the additional analyses included in the paper render its main findings somewhat opaque in places.

      R/ We consider that highlighting the Andes as an area of high endemism is necessary to provide context for interpreting the patterns of phylogenetic diversity. While it may be a well-known topic, not all readers will have the same background. Although the manuscript is extensive because it covers taxonomic, geographic, and phylogenetic patterns, its current length (ca. 6,300 words, excluding references) is well within the 9,000-word limit for Original Research articles in Biodiversity and Conservation and only slightly above the typical 5,000-word range. Nevertheless, we made an effort to shorten unnecessary sections to improve focus and clarity. For example, we removed some analysis related to diversification rates and extinction risk, since as the Reviewer 2 pointed out, some metrics depending on branch lengths may be biased.<br /> <br /> Reviewer 2

      L393-405: it is important to acknowledge the phylogenetic incompleteness of a national-level analysis, and how that might be affecting these results – divergence times are influenced by phylogenetic coverage and structure, removing >90% of squamate species from the phylogeny will give you divergence times between Colombian species, not true lineage age/divergence time information. This could be addressed with sensitivity analyses to explore how lineage age varies between pruned and complete trees, or with stronger discussion of the pitfalls of this approach in the methods and discussion, with clearer wording in the results.

      R/ We appreciate the reviewer’s insightful comment and fully agree. We performed additional calculations to assess sensitivity, and indeed, the age of some lineages can be severely affected, while others remain largely unchanged. Following the reviewer’s recommendation, we revised the Methods and Discussion sections to place greater emphasis on the limitations of using evolutionary metrics derived from pruned trees and on the considerations needed when interpreting these results. As the reviewer also notes, these results are not necessarily incorrect, since global conservation priorities do not always align with local ones. Additionally, we introduced local and global subscripts to our metrics to explicitly distinguish between them.

      407-418: Distinction is needed between EDGE scores and national EDGE scores (literally just saying ‘national EDGE scores’ would suffice). It may also be useful to identify national-specific priorities – i.e. high ranking national EDGE species that are not highly ranked in global context. There are EDGE scores available for all vertebrates at the global level here ( https://www.nature.com/articles/s41467-024-45119-z) . There are endemic Colombian squamates that are high EDGE in this study and also high EDGE at the global scale (e.g. Lepidoblepharis miyatai) but also species that are high EDGE nationally because of the phylogenetic diversity they are solely responsible for in Colombia, but the responsibility for which is shared beyond Colombia’s borders. These key cases can be instrumental in ensuring species that are globally ‘safe’ but locally important do not fall through the cracks.

      R/ Please refer to the previous response. We now explicitly distinguish between national EDGE scores and global EDGE scores throughout the text and highlight cases where species are locally important but not necessarily globally prioritized.

      L41 and throughout: “threatenedness” = “extinction risk” or “level of threat”.

      R/ Done.

      Throughout: It’s the IUCN Red List, not IUCN, particularly when referring to versions of the Red List database.

      R/ Done.

      L145: make it clear you’re referring to national endemics.

      R/ The Resolución 0126/2024 from Colombia’s Ministry of Environment (MADS) covers not only national endemics but all species occurring within the country’s administrative boundaries.

      L167: ensure it’s clear that its imputation based on taxonomy alone.

      R/ Done.

      L182: check references.

      R/ We reviewed the references cited at this point and confirm they are correct.

      L222-224 and throughout: phylogenetic diversity == Faith’s PD – the other measures are indices of phylogenetic distance/relatedness that are calculated in same units as PD, but are not phylogenetic diversity – that should be clarified.

      R/ Done. We clarified that Faith’s PD refers specifically to phylogenetic diversity, while the other metrics represent measures of phylogenetic relatedness or distance.

      L393: extinction risk should not be though of as a trait evolving but as the manifestation of extrinsic and intrinsic factors.

      R/ Agreed. We rewrote the sentence.<br /> L393-397: unclear what the relationships discussed are, and what they infer.

      R/ We have removed this section from both the Methods and Results. Given that the correlations discussed involved metrics dependent on branch length — and, as the reviewer previously pointed out, branch lengths can be affected by pruning the phylogenetic trees — we decided to eliminate this section. Overall, it did not substantially contribute to the text or to the discussion.

      L428-429: This is higher than, or at least comparable to, the global % of DD/NE squamates I think, so might not be considered relatively low for squamates.

      R/ We rewrote the sentence to clarify that it is comparable to or higher than the global percentage, as the reviewer correctly pointed out.

      L429-432: it might be worth highlighting how taxonomists and others can contribute to rapid reassessment of species with basic information in ecological publications see: https://doi.org/10.1016/j.biocon.2018.01.022

      R/ Done. We incorporated the reviewer’s suggestion.

      L442-444: Unclear what is meant here? A species can be assessed as CR with a wide range if its under population decline criteria, and a small-ranged species can be assessed as not-threatened if there is no evidence of decline/ongoing degradation.

      R/ This comment was also raised by Reviewer 1. We addressed it accordingly by revising the text to clarify that species can indeed have wide distributions and still qualify as Critically Endangered if facing significant threats, and vice versa. Please refer to our responses to Reviewer 1.

    1. On 2025-07-23 15:35:02, user Kate Nyhan wrote:

      Interesting analysis. <br /> In light of the reliance on MeSH subject indexing, I draw your attention to NLM's own data on the performance of machine indexing approaches in different categories, documented in the NLM Technical Bulletin: https://www.nlm.nih.gov/pubs/techbull/ma24/ma24_mtix.html . The check tag category (which includes the species labels on which the OPA iCite tool relies) F1 score (combining precision and recall) for MTIX (introduced in 2024) was 87% versus the original (human) indexing approach -- that is, significantly lower performance. And for a period of time before the introduction of MTIX, NLM was using a different machine indexing system, MTIA, whose F1 score for the check tag category was only 62% compared with human indexing. So, depending on when MTIA started to be used, and the proportion of records that were indexed with MTIA versus human indexers, I wonder how confident we can be that the relative proportions of different categories of MeSH terms truly reflect the prevalence of different categories of research over time. <br /> I also note, in the same source, that the performance of MTIA and MTIX at appropriately labeling Medline articles with supplementary concept terms was even worse than their performance with check tags: 39% and 71% versus human indexing. Supplementary concept terms are especially relevant to innovative, novel science (including basic science) -- terms that may in the future become MeSH terms. It's perhaps not surprising that tools trained on historical data are not great at handling novel concepts, but poor performance by machine indexing tools at applying appropriate supplementary concept records may be another factor in the apparent decline in basic science research. <br /> I'd also like to comment on the iCite Translation Module (of which the Human/Animal/MCB category assignment is part). I'm not really clear on how many PubMed records get such category labels. On the one hand, iCite includes all PubMed records. On the other hand, presumably only articles with MeSH terms can be assigned in the Triangle of Biomedicine -- that is, articles in journals that are indexed in PMC but not Medline are not included in the human/animal/MCB analysis. I assume that the proportion of PubMed records with Medline indexing has gone down, as NIH-funded authors publish more papers in journals that aren't indexed in Medline (many of which didn't exist at the start of this longitudinal analysis). Indeed, thanks to Ed Sperr's handy tool PubMed-By-Year, we can see that Medline records (ie, records with MeSH terms that can be analyzed by the human/animal/MCB categories in iCite) as a proportion of PubMed records was above 90% until (I am eyeballing the figure at https://esperr.github.io/pubmed-by-year/?q1=medline [sb]&startyear=1990) around 2011, at which point Medline coverage started declining quite precipitously. So, any analysis that relies so heavily on MeSH indexing is going to be leaving out a large number (and an increasing proportion) of recent papers.

    1. On 2025-05-17 03:57:12, user thegradstudent wrote:

      Summary<br /> This study introduces a novel computational pipeline for the de novo design of peptides that localize preferentially at the interface of biomolecular condensates. These condensates are membrane-less compartments created by protein and RNA molecules that form ‘dense’ and ‘dilute’ phases. The interface between these phases has been shown to promote the aggregation of the proteins that are part of the condensates and the formation of disease-associated fibrils of hnRPNA1. Previous literature has demonstrated preferential interfacial partitioning of a few proteins, but not of small molecules or peptides.

      This technique combines coarse-grained molecular simulations, mixed-integer linear programming (MILP), and machine learning. The authors use this workflow to design peptides that localize at the interface of biological condensates, hnRNPA1, LAX-1, and DDX4, which are formed by intrinsically disordered proteins. They test these designed peptides in vitro and show that they exhibit their intended surfactant-like activities using confocal microscopy. They also identify how the charge of these peptides is a crucial element of their physicochemical features.

      Overall, this study successfully shows that these short peptides preferentially distribute between the interface of the biomolecule condensate and the surrounding environment, showing surfactant-like properties. They also show that the net charge and the amino acid composition of these peptides in relation to their biomolecular condensate are crucial to determining whether they will preferentially partition at the interface.

      The authors have opened the potential to study more complex condensates using this rigorous strategy. This paper is exceptionally well written and thorough. I recommend this paper for publication with minor revisions.

      Major Point<br /> To experimentally validate this computational pipeline, you fluorescently label the selected peptides. This may show my lack of knowledge on this subject, but my one concern is regarding the potential effects of the fluorescent tag on the condensate system. This JBC paper from 2023 shows that fluorescently tagging a protein can promote phase separation , in this paper specifically huntingtin exon-1 with red fluorescent protein ( https://pmc.ncbi.nlm.nih.gov/articles/PMC10825056/ ). So, what is to say that the Cy5- fluorophore isn’t playing a role in creating these surfactant-like properties of the designed peptide?

      Minor Points<br /> - Figure 1: Placing the label descriptors of the figure in front of the written text makes it clearer when reading, instead of having them at the end.<br /> - Figure 1C: The grey color used for the box is a little dark, making it slightly hard to read the words and it is very close to the grey coloring within the figure. Maybe switch this box into an outline or go with a lighter shade of grey.<br /> - Figure 1A and the figure in the abstract: The question marks are a little confusing to me. There may be a better way to describe what you mean without them.<br /> - Figure 5C & D: There is green text next to red text, which can be confusing to the color impaired.

    1. On 2025-05-16 23:27:04, user Andie Souder wrote:

      Summary: <br /> The major goal of this paper was to understand FAD binding to Cry4b isoform in vitro. This was done by in vitro binding assays, simulations of FAD binding to Cry4b and solvent accessibility, and mRNA transcription levels of in vivo and immunoprecipitation. The major success of this paper is establishing protocols for optimization and finding new methods to work with the Cry4b isoform. The major weaknesses stem from a lack of reliable experimental data. But this paper brings to attention the need for thorough and rigorous protocols. It also highlights how little is known about these proteins and sheds light on areas that need to be explored.

      Major Issues:<br /> Perhaps I am misunderstanding the conclusion of this paper, but it seems like the results of your experiments do not support your conclusion. In the introduction, it states that genome analysis of Cry4b exon has stop codons in the intrinsic region and asks if the mRNA is translated into function protein in vivo. How do we know that the samples collected didn’t have a nonfunctioning version of mRNA being translated?

      https://pubmed.ncbi.nlm.nih.gov/32978454/ This paper states that the Cry4b is expressed only at night, were the specimens harvested during the day vs night to compare Cry4 isoform expression? Could that be the reason for the discrepancy in the MS results? As stated in the paper: “...the latest avian genome analyses showed that the CRY4b-specific exon carries loss-of-function mutations (e.g., stop codons), a pattern characteristic for intronic regions [29]This poses the question whether the ErCRY4b mRNA isoform is translated into a functional protein product in vivo.” Is this a factor that impacts the results of the experiments done?

      Considering that the major goal of this paper is to understand FAD binding in vitro, why weren’t those experiments thought out more carefully? It seems as if the inclusion of the vivo studies as well as the simulations were done in an attempt to reinforce the weak results of the experimental data. But the experimental data is hard to draw concrete conclusions from. In the paper, it states that the Cry4b might be misfolded, is there an experiment that verifies the fold of the protein? That is an important thing to consider, especially because these experiments are the basis of the paper. Does the solubility tag block FAD binding? What about the chaperone?

      Minor Issues:<br /> Resolution quality of figure 1 does not match the other figures<br /> Please add the confidence of the alpha fold generated structure<br /> Add to the figure 1 caption that the structures were generated using alpha fold<br /> Please clarify if there are competing interests as the bioRXIV webpage states that there is not but paper states that competing interest is present

    1. On 2024-07-21 00:09:37, user Meet Zandawala wrote:

      Manuscript title: TRPγ regulates lipid metabolism through Dh44 neuroendocrine cells

      Summary: This manuscript from Youngseok Lee lab examines the role of TRP gamma channel in regulating metabolic physiology. Specifically, it focuses on the regulation of lipid metabolism via DH44 neuroendocrine cells. It is a follow-up on the work from the same lab where they showcased the importance of TRP gamma in DH44 cells in regulating post-ingestive food selection (Dhakal et al 2022: https://doi.org/10.7554/eLife.56726 ). Overall, this work adds to the growing body of work on DH44 neuroendocrine cells which appear to be crucial internal metabolic sensors. We have a few major comments and suggestions on the preprint which could help clarify the mechanisms by which TRP gamma regulates lipid metabolism.

      1. TRP gamma mutants exhibit higher TAG and protein levels compared to controls. Inhibition of DH44 neurons using Kir2.1 recaptiulates the phenotype of increased TAG however protein levels are unaffected. Since these manipulations are not restricted to the adult stage, it is not possible to rule out developmental defects. It would be beneficial to also include the fly weight for these manipulations to see if their size is altered by these manipulations. Also, is there any impact on developmental timing?
      2. The experiments implicating the role of AMPK in DH44 neurons are quite interesting. However, the link between TRP gamma activation, AMPK and DH44 signaling is missing. How is DH44 release altered when TRP gamma is knocked down specifically in DH44 neurons?
      3. The author rescue the increased TAG levels in TRP gamma mutants by driving UAS-TRP expression using DH44-GAL4. However, they also able to rescue the phenotype by expressing UAS-TRP in DH44-R2 expressing cells. As far as we are aware, DH44 and DH44-R2 represent two independent populations. This raises some questions. What is the identity of the DH44-R2 cells which normally express TRP? What is the importance of having TRP gamma in both the source (DH44 cells) and the target (DH44-R2 cells) to regulate lipid homeostasis? Wouldn’t modulation of DH44 release alone be sufficient to regulate lipid homeostasis?
      4. DH44 is released as a hormone from both the PI neurons in the brain and endocrine cells in the VNC ( https://link.springer.com/article/10.1007/s00018-017-2682-y ). Neither this or the previous study on TRP gamma in DH44 neurons examined the presence or absence of TRP gamma in DH44 neurons the VNC. It is not clear if the DH44-GAL4 used in this study targets the DH44 neurons in the VNC.
      5. General comment about structure: The manuscript could benefit if additional context was provided for some of the experiments. The experiments using metformin are interesting and a valuable addition. However, since the link between metformin and DH44 signaling was not explored, the rationale for conducting these experiments is not quite clear. Is the rescue of TAG levels with metformin in TRP gamma mutants DH44-dependent or is metformin directly acting on the fat body? Metformin treatment in DH44 > TRP RNAi flies can clarify this.
      6. The manuscript would benefit from having a model which includes all the components in this inter-organ pathway (TRP gamma, DH44 neurons, gut etc).

      Minor comment:<br /> 1. Stock numbers for fly strains have not been provided.

      Signed by,<br /> Meet Zandawala <br /> Jayati Gera<br /> (Zandawala lab members)

    1. On 2022-11-28 00:06:07, user Shyam Bhakta wrote:

      Rather than predict the folding energy of the entire mRNA, it makes more sense to predict the folding energy of just the 5' UTR through first 10 codons, with and without the SKIK tag, as it is only this region that primarily controls the translation initiation rate by RNA structure. Even better would be to predict the translation initiation rates by inputting the mRNA sequence into the Salis Lab RBS Calculator (denovodna.com). This would better show how much the SKIK codon sequence alone can be expected to affect the protein production rates.

    1. On 2022-10-29 08:23:12, user Karen Lange wrote:

      This study investigates the autoproteolytic cleavage of polycystin1/PC1 in the C. elegans ortholog LOV-1. Walsh et al used CRISPR genome editing to tag the endogenous LOV-1 protein at both the N-terminus (mScarlet) and C-terminus (mNeonGreen).

      Figure 1 clearly shows that the N and C tagged fragments have different localisation patterns. The N and C terminal tagged fragments also displayed different transport dynamics (Figure 4). When a point mutation that is predicted to prevent cleavage (C2181S) was introduced in the mScarlet::LOV-1::mNeonGreen strain the localisation of LOV-1 was severely disrupted. Interestingly the the N-termini of LOV-1 was enriched in the cilia of three ray neurons suggesting that some cleavage can still occur in this mutant. Taken together this body of work presents strong evidence that LOV-1 is processed in C. elegans.

      The mScarlet::LOV-1::mNeonGreen strain will be a very useful tool for use in future studies to model conserved ciliopathy variants. I would predict that missense variants in the N or C terminal fragment do not affect the function of the other. Modelling these variants will help to elucidate disease mechanisms.

      One concern I have is whether or not the double tagged LOV-1 protein is fully functional. I can see in Figure 3D/F that the mating efficiency with unc-52 and the response behaviour is not significantly different from wild-type. However, I do not see the comparison to wild-type in the dpy-17 mating efficiency assay (Figure 3E). I would have appreciated a supplemental figure when the double tagged LOV-1 allele is first introduced to immediately address whether or not it is functional.

    1. On 2022-10-17 09:00:34, user Iratxe Puebla wrote:

      Review coordinated via ASAPbio’s crowd preprint review

      This review reflects comments and contributions by Ruchika Bajaj, Sree Rama Chaitanya Sridhara and Sara El Zahed. Review synthesized by Ruchika Bajaj.

      This study has developed a novel one-step methodology for the incorporation of membrane proteins from cells to lipid Salipro nanoparticles for structure-function studies using surface plasmon resonance (SPR) and single-particle cryoelectron microscopy (cryo-EM), which is a profound technology in the field of membrane protein structural biology. We raise some points that may strengthen the manuscript below:

      Main section, 4th paragraph “resuspended in digitoxin-containing buffer”- Does the sentence mean that membrane proteins were solubilized by detergent before reconstitution into salipro particles? Are salipro and digitoxin added at the same step? If this is the case, it is unclear how one can distinguish between the step wise solubilization and reconstitution or direct reconstitution into salipro particles. Further discussion on the mechanism of reconstitution would be helpful. In the same paragraph, the fragment “to increase membrane fluidity and render lipids” raises the question of whether the concentration of digitonin was optimized to balance the increase in membrane fluidity but not rendering the solubilization of membrane proteins.

      Main section, 4th paragraph, “the formation of saponin-containing mPANX1-GFP particles was assessed by analytical size exclusion chromatography using fluorescence detector” - It is assumed that fluorescence is detected from GFP. As the construct expressed is PANX1-GFP, GFP fluorescence signal will be received from reconstituted as well as not reconstituted PANX1. Is saponin specific signal being used as a signal for measuring the reconstitution of PANX1-GFP? In the same paragraph, “PreScission protease for on-column cleavage” is mentioned. Is GFP still intact in the expressed PANX-1 or is it cleaved? A diagram of these procedures showing the various steps will be helpful for readers.

      Main section, 4th paragraph “SDS-PAGE revealed the formation of pure and homogeneous Salipro-mPANX1 nanoparticles”- However, extra bands are present above the major band in Figure 1E, can some comment be provided on this point. Possible explanations for the additional bands could be post translational modifications or degradation of mPANX1.

      Methodology section, “membrane protein reconstitution screening using fluorescence-detection size exclusion chromatography (FSEC)” -The amount of salipro is given in ug. A comment on the ratio of protein to salipro particles would be important to decide the concentration of salipro with respect to the mass of the cell pellet.

      Figure 1G: The molecular weight of Salipro-mPANX1 particles is mentioned to be approximately 466kD. mPANX1 weighs about 48kD and heptamer will be 336kDa. A discussion on comparison of experimental and actual molecular weight would be interesting.

      hPANX1 was expressed in sf9 insect cells. A description regarding trials of expression of this construct in expi293 cells would be informative.

      Supplemental Figure 1B: The gel is overloaded and shows multiple bands for hPANX1, recommend selecting an alternative image for hPANX.

      Paragraph 6A phrase, “challenged with bezoylbenzoyl-ATP(bzATP), spironolactone and cabenoxolone” - Please explain the meaning of ‘challenged’ here.

      Supplementary Figure 2: Paragraph 6 mentions “binding constant could not be determined”. Please provide an explanation for this. Is it about the saturation phase not being approachable because of the feasibility of the binding experiment at higher concentration of cabenoxolone?

      The last summary sentence in Paragraph 6 is not clear, recommend rephrasing it.

      Figure 2A shows that Salipro particles have His tag. This suggests that an additional step of affinity purification with His tag could have been used to distinguish or separate reconstituted and un-reconstituted PANX1.

      Supplementary figure 4: Please explain whether the datasets for samples in the presence and absence of fluorinated lipids were combined together.

      Paragraph 8, “intracellular helices were not well resolved” - Please comment on a possible explanation. Does the Salipro scaffold contribute to the resolution? Please mention any future possibilities regarding improving the resolution by modifying the salipro scaffold or alternative scaffold. In the same paragraph, rmsd is mentioned at promoter level, please comment on how this value changes at heptamer level and why is it important to report the rmdd value to appreciate the direct reconstitution methodology.

      Last paragraph 10, “future membrane protein research” - Please comment on the utility of this methodology on prokaryotic membrane proteins, bacterial outer or inner membrane proteins or eukaryotic membrane proteins. Some more examples of reconstitution with the same method will support the applicability of this methodology on diverse kinds of membrane proteins. A discussion section comparing this methodology to other methods would also be useful for readers.

    1. On 2022-10-13 19:16:01, user BacillusBaRosh wrote:

      Author responses to feedback posted on hypothes.is - cut and paste because could not figure out how to respond there https://hypothes.is/a/5fVcAEaSEe2k4CPVTDZz7Q

      AtanasRadkov<br /> Oct 7<br /> on "Magnesium modulates Bacillus s…"<br /> (www.biorxiv.org)<br /> General comments:

      This study carefully delineates the role of magnesium in cell division versus cell elongation. The results are really important specifically for rod-shaped bacteria and also an important contribution to the broader field of understanding cell shape. Specifically, I love that they are distinguishing between labile and non-labile intracellular magnesium pools, as well as extracellular magnesium! These three pools are really challenging to separate but I commend them on engaging with this topic and using it to provide alternative explanations for their observations!

      A major contribution to prior findings on the effects of magnesium is the author’s ability to visualize the number of septa in the elongating cells in the absence of magnesium. This is novel information and I think the field will benefit from the microscopy data shown here.

      I completely agree with the authors that we need to be more careful when using rich media such as LB. It is particularly sad that we may be missing really interesting biology because of that! It’s worth moving away from such media or at least being more careful about batch to batch variability. Batch to batch variability is not as well appreciated in microbiology as it is for growing other cell types (for example, mammalian cells and insect cells).

      For me, the most exciting finding was that a large part of the cell length changes within the first 10min after adding magnesium. The authors do speculate in the discussion that this is likely happening because of biophysical or enzymatic effects, and I hope they explore this further in the future!

      I love how the paper reads like a novel! Congratulations on a very well-written paper!

      Kudos to the authors for providing many alternative explanations for their results. It demonstrates critical thinking and an open-mind to finding the truth.

      Comment<br /> Figure 2C → please include indication of statistical significance<br /> Figure 3C → please include indication of statistical significance<br /> Figure 6A → please include indication of statistical significance<br /> Figure 8B → please include indication of statistical significance<br /> Figure S1B → please include indication of statistical significance<br /> Figure S3B → please include indication of statistical significance

      Response<br /> Easy to add

      Comment<br /> For your overexpression experiments, do the overexpressed proteins have a tag? It would be helpful to have Western blot data showing that the particular proteins are actually being overexpressed. I think the phenotypes that you observe are very compelling, so I don’t doubt the conclusions. Western blot data would just provide some additional confirmation that you are actually achieving overexpression of UppS, MraY, and BcrC.

      Response<br /> The proteins are untagged. For the UppS and BcrC the cell shortening occurs with addition of inducer, , so strong indication expression is occurring. A western would provide information about degree of overexpression, but we don’t think is necessary to support conclusion drawn. Do you think there is an alternative possibility that needs to be excluded? We note that in another preprint (https://www.biorxiv.org/con... the authors delete the native uppS in their inducible Phy-uppS strain (Fig S4) and at 100 uM IPTG (10X less than what we used in experiment) the cells have wt growth on LB plates, so we at least know the Phy-uppS is functional and made (or they would die!). We are introducing the uppS deletion into our strain to see if we can identify a concentration of IPTG that doesn’t affect cell growth but still induces shortening.

      For MraY, the result is negative, so you are spot on – it is impossible to tell if due to lack of overexpression from data shown. We only know the strain is correctly made from sequencing. We will investigate if there is an antibody or functional fusion available. The reason we were not sure was worth doing is because the MraY reaction is reversible (15131133). This means that without a phenotype, there is no simple way to know the reaction can even be pushed forward even if the overexpression is confirmed (more negative data). We actually overexpressed some other proteins that act downstream (MraY, MurJ, AmJ) and they were also negative for shortening. Probably we should remove the negative data or reword to make the caveats of the negative result clear.

      Question<br /> Based on your data, there are definitely differences in gene expression when you compare cells grown in media with and without magnesium. Because the majority in cell length increase occurs in such a short time though (the first 10min), I was wondering if you think that some or most of it is not due to gene expression?

      Response<br /> The shortening is even faster than 10 min (not only statistically significant, but also obvious qualitatively if we mount immediately after adding Mg2+ ). We did not include the first timepoint because original purpose was to check everything was ready with microscope – did not expect shortening so fast! We can definitely add that data in. When we saw, we tried to capture the transition on pads, but going from culture to pad seems to stress the cells too much in the small window where the cool stuff happens. Since growth rate doesn’t appear to be a big factor in those initial divisions, we might be able to grow at lower temp and shift to pads for adjustment period before adding Mg2+. Did not play with it much due to lack of resources atm, but a flowcell setup would probably be best.<br /> In short, we think rapid divisions right after transition do not require transcription or translation. It really “smells” more like a biophysical thing.

      Question<br /> Do you have any hypotheses what is most likely to be affected by magnesium? Do you think if the membrane may be affected?

      Response<br /> We have a lot of hypotheses – all of which are speculative. There could be an extracytoplasmic enzyme involved in envelope synthesis is sensitive to Mg2+ availability, and that at lower concentrations, it’s activity is affected. There is some old literature with membrane preps that suggests PG synthesis requires higher Mg2+ than teichoic acid synthesis. If Und-P is limiting, higher Mg2+ may shift make the pool more available to make the septum. Tingfeng initially hypothesized there might be a receptor/signal mechanism but has not been able to identify one. Und-P seems to be important, but “availability” is not just pool, but how fast (and where!) the flipping across the membrane occurs. If Und-PP needs to be dephosphorylated to Und-P before being flipped back to cytoplasmic side, anything that effects the PPi equilibrium would be predicted to affect the reaction rate, with lower Pi (in periplasm or pseudoperiplasm in case of G+) favoring the dephosphorylation. Cell wall associated Mg2+ could shift equilibrium to be more favorable for a Und-PP phosphatase more closely associated with the divisome. I could go all day… In short, we don’t know enough!

      Question<br /> Why do you think less magnesium activates this program of less division and more elongation? Additionally why is abundant magnesium activating a program of increased cell division and less elongation? Do you think there is some evolutionary advantage, especially considering how important magnesium is for ATP production?

      Response<br /> In the window we looked at, the elongation rate is constant (not less or more) and only the division frequency changes. Some bacteria (like Caulobacter and to lesser extent E. coli) clearly elongate and divide simultaneously, so there is some competition for substrate (like Lipid II). Septators like Bacillus seem to delineate the two processes more, but we have found conditions where even Bacillus invaginates during division, so it’s not absolute. Like eukaryotic cells, bacterial undoubtedly have mechanisms not only commit to a round of DNA replication when there is some signal that resources are sufficient. Clearly with some bugs, this is not the case with cell division. The alternative possibility is that every cell cycle there is an opportunity to divide if some threshold of *something(s)* is reached. There is a hypothesis from Mtb literature that it may be GTP, but it’s not at all clear that is sufficient. In yeast, size at cell division is affected by perturbing 1-C pool.

      Question<br /> Related to this previous question, I also wonder if this magnesium-dependent phenotype would extend to other unicellular organisms, may be protists or algae? That would be a really exciting direction to explore!

      Response<br /> It’s a great question – lots to do! We didn’t even look at another Gram-positive, but we plan to. It’s trickier to limit Mg2+ in Gram-negatives (see 27471053 – we tried Bsub homolog for those wondering – it’s not responsible for phenotype we see).

      Question<br /> Regarding the zinc and manganese experiments, why do you think they lead to additional phenotypes compared to magnesium? Do you have any hypotheses?

      Response<br /> We have hypotheses, but if my (Jen’s) twitter engagement is any indication, way too speculative for public consumption at present. Need grant to acquire preliminary data to write grant.

      Question<br /> Regarding your results that Lipid I availability may be a major a problem for the cell division in the absence of magnesium, do you think that is due to effects magnesium has on the enzymes directly, or do you think magnesium affects the substrate availability/conformation by coordinating the phosphate groups? Or something else, may be membrane conformation?

      Response<br /> Several proteins involved in envelope synthesis (like UppS) are Mg2+ dependent enzymes. But at least for any intracellular players, levels of Mg2+ should be more than high enough to support enzyme activity even when levels are low (0.8 – 3.0 mM is Bsub range I recall off top of head). Could have impact extracytoplasmically by lowering pool sponged into the cell wall, but intuition (for what that is worth) is that it is not the coordination of an enzyme with a metal that is impacted rather the equilibrium with other ions like Pi and H+ and that this impacts net ATP synthesis. Lots to think about and do, and no simple answers. When Tingfeng started project idea was to find mechanism – didn’t realize we were asking “how does the cell work?” Turned out to be a bit much for a dissertation project :)

      -Jen Herman and Tingfeng Guo

    1. On 2022-10-07 09:04:58, user Iratxe Puebla wrote:

      Review coordinated via ASAPbio’s crowd preprint review

      This review reflects comments and contributions by Ruchika Bajaj, Gary McDowell, Sree Rama Chaitanya Sridhara. Review synthesized by Iratxe Puebla.

      The preprint studies the process for mitochondrial targeting of mitochondrial precursor proteins. Using a yeast model, experiments show that the cytosol transiently stores matrix-destined precursors in dedicated granules which the authors name MitoStores. The formation of MitoStores is controlled by the heat shock proteins Hsp42 and Hsp104, and suppresses the toxicity arising from non-imported accumulated mitochondrial precursor proteins.

      The manuscript is clear and well-written. The reviewers raised a few comments and suggestions as outlined below:

      The introduction was extremely clear and provides a good summary of the protein homeostasis dimension of the problem in question. However, there could be a clearer discussion of the processes of import, in particular with respect to the results discussing “clogging”. It is suggested to add a penultimate transitional paragraph in the introduction that facilitates this transition e.g. this could be expansion of the first paragraph in the Results section, moved into the introduction to provide more context about the cloggers, PACE, and the Rpn4-mediated proteasomal regulation.

      Figure 2E and Figure S2 - Can some further explanation be provided about what data belongs to delta-rpn otr WT, or whether the associated fold change is reported - delta-rpn/WT.

      Results ‘while the levels of most chaperones were unaffected or even reduced in Δrpn4 cells, the disaggregase Hsp104 and the small heat shock protein Hsp42 were considerably upregulated (Fig. 2F, G)’ - Suggest adding some further clarification as to why Hsp104 and Hsp42 are selected despite perturbations in other protein partners. Are there other proteins than proteosomes and chaperones which are significantly up- or down-regulated? STRING or cytoscape tools may help with the interactome analysis.

      Figure 3

      • Figure 3A - It seems Δrpn4 cells are bigger in size than control cells, suggest commenting on this point.
      • Figure 3B ‘Hsp104-GFP was purified on nanotrap sepharose’ - Please clarify on which tag the purification was based.
      • ‘grown at the indicated temperatures’ - Please clarify the rationale for using 30 or 40C.
      • ‘SN, supernatant representing the non-bound fraction’ - Please report what is total, wash and elute etc.

      Results ‘protein accumulated at similar levels as Hsp104-GFP in the yeast cytosol (Fig. S4B)’ - Please clarify whether the image reports qualitative or quantitative data, and how the levels of DHFR-GFP and Hsp104-GFP are compared based on S4B.

      ‘Owing to the striking acquisition of nuclear encoded mitochondrial proteins in these structures, we termed them MitoStores’ - Suggest providing some discussion about the fraction of Hsp104 that is part of the MitoStores? Does a major portion of Hsp104 in the absence of Rpn4 form MitoStore structures?

      Figure S5 C ‘Quantification of the colocalization of Hsp104-GFP with Pdb1-RFP after clogger expression for 4.5 h.’ - Suggest normalizing the intensity with one another.

      Results ‘Upon clogger induction, the RFP signal formed defined punctae that colocalized with Hsp104-GFP’ - The Hsp104-GFP pattern seems different between Fig 3A, 5, and S5. In some cases, clear punctae are seen and in others, a diffused pattern. Can some comment be provided on this? This might be important to score the colocalization between Hsp104-GFP and other protein partners tagged with RFP. If different conditions were used in the figures, recommend specifying this in the figure legends.

      Discussion ‘We observed that MitoStores are transient in nature and dissolve…’ - Suggest adding some discussion about the half-life of MitoStores, and about what the different stressors that can trigger MitoStores may be.

    1. On 2022-10-03 09:55:42, user Iratxe Puebla wrote:

      Review coordinated via ASAPbio’s crowd preprint review

      This review reflects comments and contributions by Luciana Gallo, Claudia Molina Pelayo, Sónia Gomes Pereira, Asli Sadli. Review synthesized by Iratxe Puebla.

      The preprint examines the meiotic recombination co-factor MND1 and its role in the repair of double-strand breaks (DSBs) in somatic cells. The paper reports that MND1 stimulates DNA repair through homologous recombination (HR) but is not involved in the response to replication-associated DSBs. MND1 localization to DSBs occurs through direct binding to RAD51-coated ssDNA. MND1 loss potentiates the G2 DNA damage checkpoint and the toxicity of IR-induced damage, opening avenues for therapeutic intervention, particularly in HR-proficient tumors.

      The reviewers raised some minor comments and suggestions on the work:

      Results ‘Therefore, we conclude that MND1-HOP2 are ubiquitously expressed proteins’ - we understand that the study looked at the transcript's expression level and not protein levels, consider revising this sentence.

      Figure 1F - Due to the differences in intensity for the loading control, recommend quantifying the normalized level of MND1.

      ‘we used live-cell imaging of RPE1 cells’ - Are these cells p53 KO? In Suppl. Figure 1K, RPE Delpta-p53 cells are used , but the HALO tag was introduced in the normal (WT) RPE cells. Could some clarification be provided for this difference, and report what's the level of MND1 and the effects of its loss in WT RPE cells?

      ‘Analysis of 53BP1 foci formation and resolution in asynchronously growing RPE1 cells revealed that MND1 depletion leads to slower repair and retention of DSBs after IR (Figure 2A, Suppl. Figure 2F&G)’ - While the quantification shown in Figure 2A is explicit, the foci in the raw images displayed in Suppl. Figure 2G appears to be more frequent in the siNT, especially in the last 2 time points. It may be worth making the images bigger and maybe clearer?

      ‘our data show that the role of MND1 in DNA repair is most prominent in G2 phase cells and restricted to repair of two-ended DSBs’ - Can some further context be provided for the last part of this claim. Is this due to the different modes of action of the different drugs used? If so, it would be nice to clarify in the text which drugs induce the two-ended DSBs.

      ‘These data show that MND1 is recruited to sites of DSBs’ - The data shows that there is an increase in MND1 foci, but whether these are or not the sites of DSBs is not clear. Recommend co-staining with a known DSBs marker.

      Methods

      • Haploid genetic screen - Please describe how cells were fixed.
      • Please detail if/what software was used for the Fisher’s exact test.
      • ‘Cells were fixed after 7 days of growth in 80% methanol and stained with 0.2% crystal violet’ - Please report at which temperature and for how long the steps were completed, and provide a reference for the crystal violet reagent.
      • ‘Membranes were blocked in 5% BSA’ - Please report the temperature and duration for this step.
      • Please describe how the propidium iodide staining was performed.
    1. On 2022-08-28 09:00:20, user Iratxe Puebla wrote:

      Review coordinated via ASAPbio’s crowd preprint review

      This review reflects comments and contributions by Ruchika Bajaj and Gary McDowell. Review synthesized by Bianca Melo Trovò.

      This study demonstrates the utility of an L-Methionine analog - ProSeMet - to tag and enrich proteins which have residues that are methylated in vivo, ex vivo and in vitro. Furthermore, the study demonstrates that this can be used in combination with mass spectrometry to identify these sites. Overall this is a useful, well-verified and well-described approach that will be helpful for future identification and investigation of methylation sites.

      Major comments

      It would be helpful if the manuscript could additionally discuss the reversibility of methylation generally, and the reversibility of the modification of protein residues by the alkyne group specifically, in the discussion, and whether that has any implications for their results. It may be that the dynamics of methylation and demethylation vary between the two; or it may be that they are the same - either way, that may affect how they suggest others use this method and interpret its results.

      Perhaps related to the question of reversibility, it would be helpful if the manuscript would comment on whether these are “true” methylation sites or not; i.e. whether they consider all these methylation sites to be functional. Trying to determine this would be an interesting direction for future work, but for this study a reflection on whether these novel functional methylation sites are simply capable of being methylated, or are likely to be methylation sites that are meaningful biologically, would be helpful.

      Results, ProSeMet competes with L-Met to pseudo methylate protein in the cytoplasm and nucleus: the manuscript claims that ProSeMet is not incorporated into newly synthesized proteins but rather converted to ProSeAM and used by native methyltransferases. There does appear to be some reduction in the labeling with ProSeMet on cycloheximide treatment in Figure 2D - could this suggest that it is incorporated into newly synthesized proteins as well as being converted to ProSeAM? If not, could the manuscript explain why not? This experiment clearly shows that in contrast to AHA labeling, there is still use of ProSeMet as a substrate when translation is inhibited; however, it is not clear how this demonstrates that it is not incorporated at all into newly synthesized proteins. If methyl has been incorporated in previously present proteins, perhaps this can be clarified in the text.

      Results, ProSeMet competes with L-Met to pseudomethylate protein in the cytoplasm and nucleus: the conclusion that “Cell fractionation of the cytosolic and nuclear compartments followed by SDS-PAGE fluorescent analysis revealed no fluorescent labeling of the L-Met control” is correct but may be overstated as there appears to be some background in the cytosolic fraction.

      Minor comments

      Introduction: Recommend including a mention to ProSeMet's permeability.

      Introduction, Figure 1: the last step with CuAAC and N3 labeling in the description of the Chemoenzymatic approach for metabolic MTase labeling is not clear. Please, add the description in the legend.

      Results, Figure 2D: the image suggests an overloaded gel, consider using an alternative gel image.

      Supplementary Material, Fig. S1: the data with L-met is only shown with T47D stacks.

      Supplementary Material, Fig. S3: please add the control for the no treatment condition.

      Results, Fig. 2A ‘ incubating for 30 m in L-Met free media’: Please confirm that the length of incubation was 30 minutes.

      Results, Enrichment of pseudo methylated proteins used to determine breadth of methyl proteome: Please provide some description for the SMARB1-deficient G401 cell line. Why smarb1 deficient?

      Results, Figure 3: Please define BP, MF, HP, NES, and label the x and y axes in panel D.

      Results, ProSeMet-directed pseudo methylation is detectable in vivo: Please, clarify if the administration was oral.

      Comments on reporting

      Results, ProSeMet competes with L-Met to pseudo methylate protein in the cytoplasm and nucleus: Please verify the quantity reported: 5µg on SDS-PAGE gel seems low.

      Results, ProSeMet-directed pseudo methylation is detectable in vivo: the manuscript reports that “mice starved prior to ProSeMet injection had increased ProSeMet labeling in the heart, whereas mice fed prior to ProSeMet administration had increased labeling in the brain and lungs”. The error bars are large, it would be helpful to show the individual real data points for the graphs in Figure 4.

      Results, Figure 4C: please report the mathematical expression used to calculate the relative fluorescence.

      Supplementary Material, Fig. S7: please provide more details on the antibody employed.

      Suggestions for future studies

      Future studies could investigate the biological functionality of the novel methylation sites - but this is a great proof of principle.

    1. On 2022-07-13 13:46:46, user Iratxe Puebla wrote:

      Review coordinated via ASAPbio’s crowd preprint review

      This review reflects comments and contributions by Oana Nicoleta Antonescu, Ruchika Bajaj, Sree Rama Chaitanya and Akihito Inoue. Review synthesized by Ruchika Bajaj.

      This study has characterized the function of Hero proteins in improving the recombinant expression of TAR DNA-binding protein in E. coli and restoration of enzymatic activity of firefly luciferase during heat and stress conditions. This study may be useful for future applications of Hero proteins in life sciences research. Please see below a few points offered as suggestions to help improve the study.

      • In introduction, 3rd paragraph, in context with “amino acid composition and length of Hero proteins”, please elaborate on the effect of these two factors on the function and stability of hero proteins.
      • The manuscript refers to “cis and trans” terms on several occassions. Please explain these terms in context with the association of Hero protein with the target proteins.
      • Introduction - A paragraph describing the origin of Hero proteins and the differences between the types of Hero proteins in the introduction section would be helpful for readers to understand the background on these proteins. For example, please explain the background on naming these proteins as Hero 7, 9, 11 etc. The genes SERF2, C9orf16, C19orf53, etc are mentioned in the plasmid construction section in the Material and methods. Please provide a brief explanation for the relationship between these genes and Hero proteins.

      • Please add more details in the Material and methods section, especifically in western blotting and the luciferase assay, to support the reproducibility of these experiments.

      • Figure 1A. Please explain the role of each component (for example factorXa) either in the text or the legend.
      • Figure 1B: Please add clarification regarding the normalization of lanes by total protein concentration.
      • Fig 1C. Please provide an explanation for the higher order bands in the western blot. The western blot using anti-FLAG antibodies shows non-specific bands. Alternative tags or antibodies or detection methods may be used, for example, GFP tag and in-gel fluorescence can be used to check the expression.
      • Figure 1D and 1E, the error bars are high. Suggest checking the data and providing the mathematical expressions used to calculate relative yields.
      • Figure 2D and E, the error bars are high, access to the raw data behind the graphs may aid interpretation. An explanation for the choice of temperatures 33 C and 37 C would be helpful. Is there any relation between the choice of temperature and the Tm of the protein? The protein is directly being treated at high temperature, similar experiments with cell-based assays would be helpful to understand the effect of the Hero proteins on the stability of Fluc. Would it be possible to report the mathematical expressions used to calculate “Remaining Fluc activity”. Recommend indicating n if these activities are calculated per mg of the protein. Please explain if the reduction in activity is due to loss of protein or loss of luminescence activity from each molecule of the protein.
      • Figure S1, access to the raw data would be helpful to understand the signal to noise ratio for activity.
      • Figure 2 and 3 show similar experiments with wild type and mutants, it may be possible to combine the figures (for example, to avoid the redundancy in Figure 2C and 3A).
      • Figure 3D and G, access to the raw data would be helpful to interpret the signal and noise ratio especially given the low values.
      • Figure 4, Can some further discussion be provided for the reason for higher residual activity for SM and DM than wild type? Tm experiments during stress conditions (heat shock and freeze thaw cycles) may be helpful to define the stability of Fluc and Fluc mutants.
      • Figure 5: Suggest including an explanation for choosing Proteinase K -among other proteases- for these experiments.
      • The residual activity is different in Figure 4 and 5, which could be due to different stress conditions. Please include some discussion about possible explanations.
      • In section “Hero proteins protect Fluc activity better in cis than in trans”, ‘When the molarity of recombinant GST, Hero9, and Hero11 proteins was increased by 10-fold...’ does molarity refer to the concentration of protein ?
      • In the first paragraph of the discussion, “physical shield that prevents collisions of molecules leading to denaturation” and “maintaining the proper folding” is mentioned. Is it the hypothesis for the mechanism behind the stability provided by Hero proteins? Can further discussion on this be provided, along with a relevant reference.
      • In the discussion section, it is mentioned that “Hero may be reminiscent of polyethylene glycol (PEG)”. Please provide further explanation for why hero proteins are correlated with PEG in this fragment.
      • A discussion on why specific Hero proteins may be better for specific target proteins may be helpful.
      • In the second paragraph, of the Discussion “Hero protein can behave differently depending on the client protein and condition” and “important to test multiple Hero proteins to identify one that best protects the protein of interest” are mentioned. Suggest adding further discussion of these points, for example around any alternatives or computational predictions or simulations to test individual Hero proteins for specific client proteins.
    1. On 2021-11-02 09:56:52, user David Bhella wrote:

      To help readers understand the path to publication, I am adding an account of the peer review process to each preprint.

      This article was initially rejected without peer-review by PLOS Pathogens. We then submitted to Scientific Reports, where the paper was accepted following review:

      Reviewer comments:

      Reviewer #1 (Technical Comments to the Author):

      In this manuscript, Ho et al. reported a 7-Å resolution cryoEM reconstruction model of MrNV VLP expressed in insect cells. MrNV could cause white tail disease in the giant freshwater prawn with high mortality rate, therefore is a serious threat to aquaculture. Together with PvNV infecting marine shrimp, MrNV may represent a new genus in the Nodaviridae family. The structure presented here shows a different arrangement of protruding spikes on the icosahedral capsid surface, compared to other nodaviruses, supporting this classification. The most significant difference is that the protrusions are dimeric, instead of trimeric as in other nodaviruses.

      This manuscript is well written. The methodology from VLP expression, purification, to imaging and 3D reconstruction is standard and clearly explained. The conclusions are logical based on the results. Some discussions could be better elaborated:

      1.The authors devoted a lot of space (especially figures) to the homology modeling which did not provide much information besides that the P domain of MrNV capsid protein is different from the input homologous models. It would be more helpful to instead show figures of the models fitted in the MrNV map, to directly show the discrepancies and suggest possible location of the MrNV P domain.

      2.Given the current information, there is not sufficient evidence to say whether the fuzzy density beneath 5-fold symmetry axis is RNA. The authors could discuss the possibility of it being protein, such as the N-terminal region of capsid, which is usually disordered in other nodaviral structures.

      3.Literature (ref. 14 &15) has shown two different assembly states of MrNV VLP expressed in E. coli and sf9 cells respectively. Could the structural information reported here help to explain the differences?

      4.Structural characterization of MrNV is in need due to the threat from white tail disease. Now with the 7-Å resolution available, the authors could discuss more about followup studies and/or downstream applications leading to potential intervention against white tail disease.

      Some minor points:

      1.Has the final map been deposited to the EMDataBank?

      2.With the current figures, the comparison between AB and CC dimers is a little hard to follow. It would help to label the A, B, C subunits. It is fine to label the dimers with colored arrows, but it would be more clear if the coloring is consistent between Figures 2 and 3. Please also consider including the measurements of angles and lengths in the figures, and labeling the supporting legs of CC dimer with an arrow or asterisk.

      Reviewer #2 (Technical Comments to the Author):

      The authors present work showing a cryo-EM 3D reconstruction of MrNV virus-like particles with the finding that “pronounced dimeric blade-shaped spikes" protruding above the surface of the particle are arranged differently than canonical structures of Alphanodaviruses. Thus the authors believe the new structure supports the prior assertion that MrNV belongs to a new genus of Nodaviridae designated Gammanadovirus.

      The authors use a generally accepted approach during the reconstruction process although the use of a crystal structure as an initial model rather than using an initial model generated from their experimental 2D class averages could possibly confound the interpretation. Whenever a known structure is used it can lead to potential model bias. It is this reviewer’s assumption that the authors used FHV for the initial model since FHV doesn’t have significant spikes on the surface. The authors also used a low-pass filter of 60 angstroms to the FHV initial model to partially mitigate model bias. In both of these cases this is typically an ok approach if significant homology exists. However the authors force icosahedral symmetry during reconstruction and they themselves highlight the fact that MrNV and FHV share only 20% homology. The manuscript could therefore be greatly strengthened by a reference-free 3D reconstruction where the initial model is created from the experimental 2D class averages rather than the FHV crystal structure. If the final reconstruction for the reference-free approach remains similar/identical to the current reconstruction, then the authors will have demonstrated conclusively that the interpretation is sound. Therefore it is suggested that the authors incorporate the results of a reference-free reconstruction into the manuscript (a supplemental figure will be fine). As this requires a rerun of only the 3D refinement image processing step and not new data acquisition, this should not be considered a major modification and if this is successfully implemented then this reviewer recommends publication.

      A few other minor comments to be addressed:

      According to Reference #9 (NaveenKumar et al. 2013) the capsid protein of MrNV and PvNV only share 44.6% homology but that drops to 22% for the last 115 amino acids at the C-terminus which is the region the author attribute to forming the protruding spikes. Thus, it seems possible that the structure of PvNV may be different. It is this reviewer’s suggestion that the authors refrain from extending their interpretation towards PvNV and simply focus on MrNV throughout the manuscript.

      Please define “VLPs” as “virus-like particles” in the abstract rather than just using the acronym.

      There appears to be a 6xHis-tag on the capsid protein but it is not used for purification scheme. A sentence should be added to describe why it is included and whether the additional amino acids are anticipated to be present within the dimeric spikes or otherwise impact the interpretation.

      During the post-processing steps, a b-factor of -890 square angstroms was applied. Was this calculated automatically using Relion or was it manually chosen?

      Figure 1, it would be helpful to see a sampling of the refined 2D class averages in addition to the central slice of the reconstruction.

      On line 120, suggest deleting “sharply resolved” to leave sentence as “Inspection of figure 1(b) reveals a capsid shell measuring between 2 and…” since “sharply resolved” is a qualitative term that others may feel is only appropriate for truly atomic resolution structures.

      Finally, the homology modelling is an interesting addition to the paper. However, since no conclusive results can really be drawn from the models at this time, it seems more appropriate for figure 4 to move to a supplemental figure.

    1. On 2021-10-26 23:22:30, user Xin Chen wrote:

      We appreciate that the authors tested our previous results using new reagents and methods. However, we have to point out that there is a big misunderstanding of our published work. First of all, asymmetric histones do NOT imply the existence of “immortal histones” as the authors hypothesized and used to make predictions in their experimental design. In fact, distinguishing old versus new canonical histone must be in the context of cell cycle progression: Old refers to the pre-existing histones before S phase and new refers to newly incorporated ones during S phase. These two populations can be distinguished by the tag-switch or photoconversion methods only after the switched or converted cell goes through one complete S phase and enters the subsequent M phase. Moreover, the new histones with switched or converted labels will mature over time during cell cycle and gain old histone features, and thus there are no “immortal” histones. However, we are not seeing any labels in this work that indicate active cell cycle progression, which is very concerning given these tissues are ex vivo for more than 40 hours.<br /> Second, it would be highly appreciated if the authors include germline versus somatic cell markers in their figures. As of now, it is impossible to tell whether the weak H3 signals in Figure 1C and 1E come from germ cells or somatic gonadal cells. The bright spot in Figure 3E was interpreted as hub cells, which are quiescent somatic cells. If this is the case, it would be very strange that such a quick old to new H3 turn-over occurs in these cells, as indicated in Figure 3E legend.<br /> Finally, we have to point out that our previous results were entirely misinterpreted in the “Alternative Hypothesis 2” in Figure 2, because we are not assigning random stem cells (GSC) and progenitor cells (SG) together as pairs — all GSC-GB pairs we analyzed are still connected by the spectrosome structure (Tran et al., 2012; Xie et al., 2015; Wooten et al., 2019), indicating that they are daughter cells derived from one GSC division. Furthermore, our previous conclusions were not solely based on the post-mitotic GSC-GB pairs, but also on stem cells undergoing asymmetric cell divisions, based on fixed and live cell imaging.<br /> In summary, this work is based on both misunderstanding and misinterpretation of our work, leading to an incorrect hypothesis. Additionally, there is no single dividing stem cell or a pair of daughter cells derived from stem cell division shown in this work that can lead to the conclusion of “Symmetric Inheritance of Histones H3 in Drosophila Male Germline Stem Cell Divisions”. We hope these comments clarify several critical points for both the authors and the readers of this preprint. Thank you for your attention!<br /> Xin Chen<br /> Johns Hopkins University

    1. On 2021-08-19 14:35:18, user Meng Wang wrote:

      We have recently reported that the Tn5-based epigenomic profiling methods, especially Stacc-seq and CoBATCH, are prone to open chromatin bias (https://www.biorxiv.org/content/10.1101/2021.07.09.451758v1). Rather than directly address this bias issue, the authors of Stacc-seq argued in this preprint that FC-I normalization (normalizing by input/IgG control) was better than FC-C (normalizing by background) for Stacc-seq etc. data analysis. Based on this, they claimed that our results had “a major analysis issue”. However, the truth is that we had already used both FC-I and FC-C normalization methods and both showed clear open chromatin bias for Stacc-seq and CoBATCH. The fact that our analyses demonstrating that CUT&Tag (5% FPR) showed much lower FPR than Stacc-seq (30% FPR) or CoBATCH (50% FPR) indicated that the high FPRs were not due to “artificially enhanced the relative enrichment of potential open chromatin bias”, but an intrinsic problem of Stacc-seq and CoBATCH. In our opinion, the preprint has several problems, which are detailed below.

      1. The preprint ignored the fact that we had already used both FC-I and FC-C normalization methods. The authors assumed that we only used FC-C for Stacc-seq etc. (Fig. 1A in Liu et al.). However, in fact we used both FC-C and FC-I in our analyses. In Fig. 1c, d and Fig. S2 of our manuscript (Wang et al.), methods labeled with “with IgG” were results from FC-I normalization, and methods without such label were results from FC-C normalization. Importantly, results from both normalizing methods showed clear open chromatin bias for Stacc-seq and CoBATCH (Fig. 1c,d and Fig. S2 in Wang et al.).

      2. The results of global H3K27me3 enrichment at the Polycomb targets in this preprint (Fig. 1C) was contradictory to their claim that using FC-C would cause “complete loss or dramatic reduction of enrichment at true targets for datasets generated by Tn5-based methods”. Fig. 1C of this preprint showed a clear H3K27me3 enrichment around the TSS of Polycomb targets compared to adjacent regions when using FC-C. The difference between results from FC-I and FC-C is caused by the y-scale. The fold change is a relative measurement, so the y-scale of different normalization methods is not directly comparable. If they set the y-scale of FC-C to 0~2, the enrichment pattern would be highly similar to that using FC-I.

      3. The genome browser snapshots of several loci in a large scale (low resolution) could not demonstrate that the results from FC-I and FC-C normalization are globally different. This preprint provided several example loci (Fig. 1B and Fig. 2 in Liu et al.) to show that using FC-C would cause “complete loss or dramatic reduction of enrichment at true targets for datasets generated by Tn5-based methods”. However, showing browser view of very large regions are misleading as the resolution is too low. For genome browser display, the look of the signal track patterns depends on y-scale, x-scale and windowing and smoothing function. When viewing a very large region, the signals are sampled and aggregated by genome browser and are not the raw signals. Thus, the patterns may not reflect the real situation. Indeed, when zoomed-in to check these regions, we found the peak patterns from FC-I and FC-C normalization are highly similar. In addition, examples from several loci could not reflect the global pattern. The global enrichment shown in Fig. 1C of this preprint did not support their conclusion, as discussed in point 2.

      In summary, our original analysis has already included the normalization method suggested by the authors of this preprint. Results from both normalization methods supported that Stacc-seq and CoBATCH had high open chromatin bias. In fact, the results from this preprint also support our conclusions. In Fig. 2 of this preprint, regardless whether FC-I, FC-C or RPKM were used, the discrete peaks from Stacc-seq etc. were more similar to ATAC-seq peaks, but were totally different from ChIP-seq peaks.

      Meng Wang and Yi Zhang<br /> Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, Massachusetts 02115, USA

    1. On 2021-05-04 15:06:24, user AAAAAAAAAA wrote:

      I noticed that you did the high salt tagmentation (300mM NaCl) for PBMC mixing experiments, which I think is the "right" way to avoid the open chromatin bias but for other experiments, you did the tagmentation in 10X ATAC buffer (10mM NaCl). Is there a particular reason for this? I thought the low salt would have serious ATAC signals, which is demonstrated in the original CUT&Tag paper.....

    1. On 2020-11-16 23:18:09, user Fraser Lab wrote:

      This manuscript details the efforts of a team of structural biology computational experts to cross-validate the proliferating SARS-CoV-2 structures emerging during the COVID-19 pandemic. Over the past five months, as soon as each new SARS-CoV-2 structure is made publicly available, the authors have subjected it to a barrage of validation metrics as well as residue-by-residue manual inspection. When they were able to get a hold of the raw data, they analyzed that as well for several of the most commonly occurring pathologies. Re-refined structures were sent back to the structures' original authors for reupload to the PDB via the recently available versioning option that preserves the PDB code (although it would be nice to quantify how many authors were contacted and what the “re-versioning” rate is after contact). In this manner, the structural biology community has simultaneously benefitted from an increased number of experimentalists' single-minded focus on the coronavirus (even where these efforts fall partly outside their areas of expertise) and these experts' careful curation of the resulting structures.

      The manuscript represents an incredible effort. As the authors call attention to in a few places, the errors in data processing and modeling are not only inevitable (especially under the circumstances) but tolerable, as long as they can be identified and corrected in a timely manner — the goal is not to gatekeep so that only experts are permitted to do this work, but to tag-team as effectively and efficiently as possible. Furthermore, there is the separate issue of pathologies resulting from decisions during data collection that cannot be corrected after the fact. It is critical that fixable and unfixable issues are extremely clearly distinguished from each other. We suggest the authors rewrite some of these narratives with the deliberate aim of identifying the origins of pathologies that can be mitigated or corrected in full, again differentiating between these, and taking care that the wording is as charitable as possible toward the researchers responsible.

      There are a few cases of oversimplified concepts that we believe can be succinctly expressed more accurately. For example, where the authors describe data as being "incomplete due to radiation damage," they could instead take the time to explain the difference between incompleteness resulting from a poorly chosen collection strategy, incompleteness in higher resolution bins, and radiation-induced damage that renders some reflections (and some real-space features) self-consistent but inaccurate. The "lower quality" of datasets suffering from these pathologies could be separated into uniformly low resolution datasets, which are more easily recognizable, and seemingly high-resolution datasets with serious systematic errors.

      The authors could also be more clear with a couple choices of wording around concepts of correctness. They write, "While the deposited structures are often improved by PDB-REDO, they need to be checked and should not be viewed as 'more correct' purely on [the] basis of a lower R value." In this and several other instances, we challenge the authors to replace any terms assigning value (improved, correct, error, bad, misidentified) with descriptions of what metrics they are examining and what they mean for the model and data. This publication is an opportunity to instill readers with a stronger sense of how to use the existing validation tools, and what to do when they turn up serious issues. It would be highly useful to go into some explanation of what constitutes model bias and how this is detected in crystallographic and EM data, what metrics we traditionally use to detect it, what happens when we refine against those metrics (!), and how the tradeoff between agreement with priors (geometry, clashscore) and agreement with data (real space CC, FSC) should vary with map quality. If the authors are willing to go as deep as explaining how the available validation metrics were devised, the average reader might learn quite a bit!

      A separate but closely related issue is the identification of real features that conflict with prior knowledge. Under what circumstances do we accept "bad" geometry is actually the right way to model something? These are often information-rich and functionally relevant discoveries, such as Hoogsteen base pairing or very strained geometries at a catalytic site. This is worth calling attention to.

      We read the opening of the "manual evaluation" section as a framing of structure solution as tedium that should be automated as much as possible, but whose results nevertheless fall short in the absence of an expert's intervention. This is unfortunate. We would rather laud both the amazing efficiency (and thereby throughput) that automating routine steps has made possible and the important role of the researcher in guiding the process and interpreting the results.

      On the topic of data not deposited in the PDB, the authors describe a case of a severely radiation damaged dataset and how it was necessary to reprocess the raw data to improve it. We strongly agree that raw data should be made publicly available for exactly these sorts of reasons. Once again, separating this administrative barrier from the researchers' decisions during data collection would be helpful in setting a positive tone. The authors point out the amazing proteindiffraction.org resource and should call for more deposition there (or to SBGrid DataGrid). In EM, the EMPIAR database plays a similar role (with greater proportional adoption) and the reprocessing potential of datasets deposited there should be highlighted and celebrated.

      The "supplying context", "summary" and especially "outlook" sections bring up some extremely important points that could bear to be repeated at the beginning of the manuscript to help frame this work. The tradeoff necessary under the present circumstances in particular — the fact that imperfect "first draft" structures are still useful, and much more useful when they can be quickly updated with any corrections — deserves greater emphasis, and perhaps further discussion of how the field should go about addressing and documenting problems with models and data after the pandemic. We are overall very excited to see this work in print alongside the resources already publicly available at insidecorona.net. Collectively, that resource and this manuscript represent an exciting development in peer review away from gatekeeping and toward continuous improvement!

      Finally, we note a handful of points that we suggest would improve readability:<br /> SARS-CoV is now also known as SARS-CoV-1. We strongly suggest using this term throughout the manuscript to differentiate it from SARS-CoV-2.<br /> The phrase "not by experimentalists, but scientists from other fields" suggests a false dichotomy. We recommend rewording so as to recognize the existence of experimentalists in other fields. <br /> The rationale for annotating secondary structures with the Haruspex neural network is not yet clear.<br /> The COVID-19 pandemic is "unprecedented" in very recent history, but arguably not unique even in recorded history — we would favor a different term here.<br /> The abbreviation RdRp is not defined.<br /> "fulfil" is a typo.<br /> “Structures solved in a hurry to address a pressing medical and societal need _are_ even more prone to mistakes.” - suggest "may be"

      James Fraser and Iris Young (UCSF)

    1. On 2020-09-30 10:20:45, user Emilian Stoynov wrote:

      Interesting article. Can you provide information how long was kept in captivity the captive bred individual with the patagial tag prior to be released again with leg-mount tag replacing the patagial one? Frequently, captive bred birds perform better when re-released after sometime of refueling/rehabilitation following the original release. This fact may bias the data from switching between different type of tags. The best would have been if this result was obtained by marking wild experienced bird first tagged with patagial and afterwards switched to leg-mount tag.

    1. On 2020-09-18 02:09:42, user Maria Ingaramo wrote:

      Summary: for now, we recommend using the S11 tag at the N-terminus of target proteins.

      Details:<br /> We'd like to thank Dr. Abby Dernburg for pointing out that our S11 fragment, which ends in two glycines, might act as a C-terminal degron signal (doi.org/10.1016/j.cell.2018...:DdzbmEETvEUkkesPwEqFKBomMYw "doi.org/10.1016/j.cell.2018.04.028)"). We've successfully tagged proteins at both the N-terminus and the C-terminus, but we have not established that these yield similar expression levels. We take this concern very seriously, and we're checking this now. Results will be posted here and at andrewgyork.github.io/split_wrmscarlet. In the meantime, we recommend avoiding the potential issue by attaching the S11 fragment at the N-terminus. If C-terminus tagging is required, we suggest the alternative S11 sequence YTVVEQYEKSVARHCTGGMDELYK.

      -Maria Ingaramo

    1. On 2020-06-26 10:15:50, user Ersa Flavinkins wrote:

      Major issue with the article: the vector, the pcDNA3.1-N-myc/C-C9 vector, is not found nor availible from catalogue in anywhere. All the ACE2 proteins are stained with anti-C9 antibodies--indicating that the cloned part is not the entire mRNA.

      The original specification of the c-myc/c9 vector was stained by the anti-c-myc antibodies on the cell surface--so there is an additiona signal peptide in fromt of the c-myc tag in the vector.

      no pcDNA3.1 vector have an AgeI site and XM_017650263.1 is not cut by either AgeI or Acc65I. As the human, civet and rat ACE2 gene is specified to have their signal peptide removed before cloning into their vector, the vector must carry it's own signal peptide--which is before the c-myc tag as the original thesis at ref.55https://www.ncbi.nlm.nih.gov/pmc/ar... and ref.34 https://www.ncbi.nlm.nih.go...

      specified the staining of the cells via antibodies targeting the c-myc tag on the N terminii of the ACE2 receptors.

      This leave all the receptors--the Human,Civet and the Rat--with an N-terminal C-myc tag. and the Ferret badger, Rhesus, Raccoon dog, Hog badger, Free-tailed bat, Rabbit, cat and dog ACE2 receptors may potentially contain parts of the signal peptides themselves or even the entire signal peptide. The Rs bat and pangolin ACE2 receptors were cloned into an unknown vector and there is no way of telling whether the Signal peptide, c-myc tag or other AAs were retained or not. However, as these were all marked as C9 tagged on the C-terminus, the exact cloned part must not include the C-terminal stop codon or other parts of the mRNA since the natural Stop codon will prevent C9 tag expression.

      There is no indication of the N-terminal clone site for the 2 ACE2 proteins, but the Human, Civet and Rat ACE2 is specified to have the signal peptide sequence removed. and therefore an additional signal sequence must be included before the C-myc tag in the vector to enable cell surface display.

      As the article specifies that the ACE2 proteins expressed from such vectors have a "N-terminal c-myc tag and a c-terminal C9 tag", the tage expressed as specified have serious issue with steric clashing with the other S1 RBD monomer and therefore downplaying the Human, Rat and Civet ACE2--this may be even more severe with the other ACE2 and the exact N-terminal status of the Rs and pangolin ACE2 receptor is impossible to tell. Over all, this experiment is heavily contaminated and there is no way to actually deduce the results by just their method section alone. As no published vector available offers simultaneousy the N-myc and C-C9 tagging capability in the protein product, it may or may not be the same vector as specified before.

      At best, it may downplay the ability of hACE2 to mediate entry with the PP assay by steric clash with the Tag and potential AAs in front of them--indicating an intentional overplay of Rs bat and pangolin ACE2 receptor by handicapping the rest with a bulky protein tag and a potential antibody binding to the tag, all of which clashes with the rest of the S glycoprotein and significantly decreases the entry efficiency, at worst--if the specified N-myc/C-c9 vector is the same as the vector described before, it mean that none of the PP assays are trustable as actual, unbiased data.

      Notably, the PP assay result described here is in conflict with another paper https://www.biorxiv.org/con... using the exact same protocol but specified a different N-terminal tag--the HA tag, again on the N terminus of their ACE2 proteins. Notably, the Rs bat and Rat receptor affinities, as well as the Feline and pangolin receptor affinities, as by PP assay, were inverted in the 2 publications. As well as the Feline and Rabbit receptor affinities--despite the feline and rabbit are specified as being tagged using the same protocol in both publications--c-myc in this and HA in the other.

      Unless the exact cloning sequences of the vectors and the inserts are published, neither publications can be used as an exact indicator of the true affinities of the ACE2 to the S glycoprotein, and none of the publications may be used as a true indicator, in isolation or in tandem, of the true affinities of animal ACE2 to the SARS-CoV-2 Spike glycoprotein.

    1. On 2020-06-16 21:57:53, user Fraser Lab wrote:

      I am posting this review on behalf of a student from a class at UCSF on peer review: https://fraserlab.com/peer_... . The student wishes to remain anonymous. I will be happy to act as an intermediary for any correspondence.

      In this manuscript Moti et. al., propose a novel way of visualizing Wnt transport from the ER to the membrane using the Retention Using Selective Hook (RUSH) system. Through use of this system, they also provide insight on the involvement of filopodia used for signaling by Wnt3A.

      Overall, the authors provide a very promising system for live visualization of Wnt transport inside of a producing cell. Wnts are known to be particularly difficult to tag and visualize in a live model, and this lab was able to show that their tagged Wnt3A not only transports as expected but also is still capable of signaling.

      Aside from the tool they developed, the authors state that Wnt transfer between cells via actin-based filopodia. Though they do show that Wnt-positive vesicles are seen in projections, they make the strong claim that it is being transferred to a receiving cell. The images and videos show movement in the projections, but the experiments do not show that the projections are touching the neighboring cell or transferring the vesicles. In supplemental video 5B, the Wnt-positive vesicles appear to actually be migrating into the cell body as opposed to the neighboring cell, which was not discussed.

      The major success of this paper is the creation of a functional RUSH-Wnt3A construct that can be used to visualize Wnt transport in the producing cell. As Wnts are very difficult to tag or manipulate, this is a great achievement and its use will strongly help further our understanding of Wnt transport.

      Minor points:<br /> The authors switched between HeLa, 293T and RKO cells for different conditions. As the RKO cells were engineered with WLS knockouts, the WT RKO cells could serve as the cell line to test for RUSH-Wnt3A alone and with the Porcupine inhibitor. If this was done intentionally, the authors should state why this was done. Otherwise, using the same cells for each condition would eliminate other factors that could affect the transport of RUSH-Wnt3A. <br /> Transfection of reporter cells (STF reporter) cells with RUSH-Wnt3A for signaling assay. These results would show self-activation of Wnt signaling. Could the STF reporter cells be co-cultured with a different cell line transfected with RUSH-Wnt3A to see the activity levels of the receiving cell? This could further support filopodia, or at least cell contact, as a way of activating cell signaling.<br /> Figure 6a is missing a label for what I suspect is LGR5834DEL.<br /> Figure 6c – would like to see filopodia quantification for LGR5(FL) and a non-transfected cell.